,entities,start_tokens,end_tokens,start_chars,end_chars,text,pmid,lf_chemicals_distsv,lf_disease_distsv,olabel,orig_index,label,prob_0,prob_1
0,22-oxacalcitriol,0,1,0,16,22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.,10027919_0,-1,-1,-1,0,-1,0.99906164,0.00093840755
1,secondary hyperparathyroidism,2,4,28,57,22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.,10027919_0,-1,-1,-1,1,-1,0.0015255576,0.9984744
2,low bone turnover,6,9,75,92,22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.,10027919_0,-1,-1,-1,2,-1,0.0025664382,0.9974336
3,renal failure,12,14,106,119,22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.,10027919_0,-1,-1,-1,3,-1,0.0015200287,0.99848
4,Calcitriol,2,3,12,22,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,4,-1,0.9991666,0.00083338114
5,parathyroid hormone,8,10,58,77,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,5,-1,0.998206,0.0017939225
6,PTH,11,12,79,82,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,6,-1,0.99810314,0.0018968461
7,renal failure,16,18,101,114,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,7,-1,0.0016670757,0.9983329
9,suppression of bone turnover,27,31,180,208,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,9,-1,0.004231005,0.995769
10,lead,34,35,220,224,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,10,-1,0.010112782,0.9898872
11,adynamic bone disease,36,39,228,249,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,11,-1,0.0013253416,0.99867463
12,vitamin D,2,4,6,15,"A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.",10027919_2,-1,-1,-1,12,-1,0.99889696,0.0011030708
13,22-oxacalcitriol,6,7,26,42,"A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.",10027919_2,-1,-1,-1,13,-1,0.9989648,0.0010351825
14,OCT,8,9,44,47,"A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.",10027919_2,-1,-1,-1,14,-1,0.99867517,0.0013247484
15,OCT,9,10,54,57,This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.,10027919_3,-1,-1,-1,15,-1,0.997974,0.0020260562
16,turnover,16,17,87,95,This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.,10027919_3,-1,-1,-1,16,-1,0.02533846,0.9746616
17,impaired renal function,22,25,119,142,This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.,10027919_3,-1,-1,-1,17,-1,0.005763284,0.9942367
18,N,10,11,52,53,"METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22).",10027919_4,-1,-1,-1,18,-1,0.2553381,0.7446619
19,N,19,20,84,85,"METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22).",10027919_4,-1,-1,-1,19,-1,0.23702236,0.76297766
22,OCT,19,20,108,111,"Fourteen weeks after the start of phosphate supplementation, half of the Nx and Sham dogs received doses of OCT (three times per week); the other half were given vehicle for 60 weeks.",10027919_6,-1,-1,-1,22,-1,0.9987999,0.0012001022
24,OCT,26,27,156,159,"Biochemical and hormonal indices of calcium and bone metabolism were measured throughout the study, and bone biopsies were done at baseline, 60 weeks after OCT or vehicle treatment, and at the end of the crossover period.",10027919_8,-1,-1,-1,24,-1,0.9986029,0.0013970913
25,OCT,6,7,21,24,"RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency.",10027919_9,-1,-1,-1,25,-1,0.9944711,0.005528974
26,renal insufficiency,17,19,94,113,"RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency.",10027919_9,-1,-1,-1,26,-1,0.0015574339,0.9984426
27,secondary hyperparathyroidism,2,4,17,46,"In long-standing secondary hyperparathyroidism, OCT (0.03 microg/kg) stabilized serum PTH levels during the first months.",10027919_10,-1,-1,-1,27,-1,0.0015823963,0.9984176
28,OCT,5,6,48,51,"In long-standing secondary hyperparathyroidism, OCT (0.03 microg/kg) stabilized serum PTH levels during the first months.",10027919_10,-1,-1,-1,28,-1,0.99772173,0.0022782637
30,hyperphosphatemia,9,10,64,81,These effects were accompanied by episodes of hypercalcemia and hyperphosphatemia.,10027919_12,-1,-1,-1,30,-1,0.0022316873,0.9977683
31,OCT,7,8,39,42,"In animals with normal renal function, OCT induced a transient decrease in serum PTH levels at a dose of 0.1 microg/kg, which was not sustained with lowering of the doses.",10027919_13,-1,-1,-1,31,-1,0.9975394,0.0024606253
32,OCT,4,5,12,15,"In Nx dogs, OCT reversed abnormal bone formation, such as woven osteoid and fibrosis, but did not significantly alter the level of bone turnover.",10027919_14,-1,-1,-1,32,-1,0.9954211,0.0045789173
33,abnormal bone formation,6,9,25,48,"In Nx dogs, OCT reversed abnormal bone formation, such as woven osteoid and fibrosis, but did not significantly alter the level of bone turnover.",10027919_14,-1,-1,-1,33,-1,0.0022914892,0.99770844
34,osteoid,13,14,64,71,"In Nx dogs, OCT reversed abnormal bone formation, such as woven osteoid and fibrosis, but did not significantly alter the level of bone turnover.",10027919_14,-1,-1,-1,34,-1,0.002007367,0.99799263
36,bone turnover,25,27,131,144,"In Nx dogs, OCT reversed abnormal bone formation, such as woven osteoid and fibrosis, but did not significantly alter the level of bone turnover.",10027919_14,-1,-1,-1,36,-1,0.023819689,0.97618026
37,OCT,3,4,13,16,"In addition, OCT improved mineralization lag time, (that is, the rate at which osteoid mineralizes) in both Nx and Sham dogs.",10027919_15,-1,-1,-1,37,-1,0.99004525,0.009954702
38,OCT,8,9,53,56,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,-1,-1,38,-1,0.9974947,0.0025053693
40,renal insufficiency,21,23,143,162,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,-1,-1,40,-1,0.0014335056,0.99856657
41,secondary hyperparathyroidism,33,35,202,231,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,-1,-1,41,-1,0.0016166454,0.9983834
42,low bone turnover,40,43,259,276,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,-1,-1,42,-1,0.0042869095,0.9957131
43,adynamic bone disease,53,56,323,344,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,-1,-1,43,-1,0.0012483199,0.99875164
52,ischemic cardiac disease,5,8,23,47,There was a history of ischemic cardiac disease 9 years earlier.,10074612_2,-1,-1,-1,52,-1,0.001321486,0.9986785
53,hemoptysis,9,10,62,72,"The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.",10074612_3,-1,-1,-1,53,-1,0.0011231151,0.99887687
54,rapidly progressive renal failure,11,15,74,107,"The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.",10074612_3,-1,-1,-1,54,-1,0.0014804094,0.9985196
55,hypoxemia,17,18,113,122,"The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.",10074612_3,-1,-1,-1,55,-1,0.0011038065,0.9988961
56,ventricular arrhythmia,7,9,43,65,The ECG showed a junctional rhythm without ventricular arrhythmia.,10074612_5,-1,-1,-1,56,-1,0.0015439786,0.998456
57,sudden death,8,10,54,66,This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone (IVMP).,10074612_6,-1,-1,-1,57,-1,0.0014419649,0.998558
59,IVMP,18,19,120,124,This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone (IVMP).,10074612_6,-1,-1,-1,59,-1,0.9960657,0.003934355
60,cardiac disease,4,6,30,45,"Rapid infusion and underlying cardiac disease were important risk factors in the case reported here, and the authors discount ventricular arrhythmia as the main mechanism.",10074612_8,-1,-1,-1,60,-1,0.0016304037,0.99836963
61,ventricular arrhythmia,20,22,126,148,"Rapid infusion and underlying cardiac disease were important risk factors in the case reported here, and the authors discount ventricular arrhythmia as the main mechanism.",10074612_8,-1,-1,-1,61,-1,0.0014578284,0.9985422
63,Parkinson's disease,4,7,21,40,"Ten patients who had Parkinson's disease with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of apomorphine.",10091616_1,-1,-1,-1,63,-1,0.0018743495,0.9981256
68,p<0.05,25,26,142,148,"Compared with the score at rest (1.3+/-0.3), a significant aggravation of the dyskinesia score was observed during speaking aloud (5.2+/-1.1, p<0.05), movements of right (4.5+/-1.0, p<0.05) and left (3.7+/-0.8, p<0.05) fingers, movements of the neck (5.1+/-1.0, p<0.05), and mental calculation (3.1+/-1.0, p<0.05).",10091616_2,-1,-1,-1,68,-1,0.29605284,0.7039472
69,p<0.05,34,35,182,188,"Compared with the score at rest (1.3+/-0.3), a significant aggravation of the dyskinesia score was observed during speaking aloud (5.2+/-1.1, p<0.05), movements of right (4.5+/-1.0, p<0.05) and left (3.7+/-0.8, p<0.05) fingers, movements of the neck (5.1+/-1.0, p<0.05), and mental calculation (3.1+/-1.0, p<0.05).",10091616_2,-1,-1,-1,69,-1,0.28252852,0.7174715
70,p<0.05,41,42,211,217,"Compared with the score at rest (1.3+/-0.3), a significant aggravation of the dyskinesia score was observed during speaking aloud (5.2+/-1.1, p<0.05), movements of right (4.5+/-1.0, p<0.05) and left (3.7+/-0.8, p<0.05) fingers, movements of the neck (5.1+/-1.0, p<0.05), and mental calculation (3.1+/-1.0, p<0.05).",10091616_2,-1,-1,-1,70,-1,0.27049428,0.7295057
71,p<0.05,52,53,262,268,"Compared with the score at rest (1.3+/-0.3), a significant aggravation of the dyskinesia score was observed during speaking aloud (5.2+/-1.1, p<0.05), movements of right (4.5+/-1.0, p<0.05) and left (3.7+/-0.8, p<0.05) fingers, movements of the neck (5.1+/-1.0, p<0.05), and mental calculation (3.1+/-1.0, p<0.05).",10091616_2,-1,-1,-1,71,-1,0.2998538,0.70014614
73,postural hypotension,1,3,19,39,Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.,10091617_0,-1,-1,-1,73,-1,0.0011891566,0.9988109
74,Parkinson's disease,4,7,43,62,Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.,10091617_0,-1,-1,-1,74,-1,0.0019735168,0.99802643
75,Parkinson's Disease,5,8,31,50,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,-1,-1,-1,75,-1,0.0036677266,0.99633235
76,Parkinson's disease,21,24,127,146,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,-1,-1,-1,76,-1,0.0030587865,0.99694115
77,PD,25,26,148,150,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,-1,-1,-1,77,-1,0.0024101497,0.9975898
78,mg selegiline,31,33,177,190,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,-1,-1,-1,78,-1,0.99884367,0.0011563028
80,systolic orthostatic hypotension,14,17,89,121,"Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline.",10091617_2,-1,-1,-1,80,-1,0.0012638813,0.9987361
84,PD,14,15,94,96,METHODS: The cardiovascular responses to standing and head-up tilt were studied repeatedly in PD patients receiving selegiline and as the drug was withdrawn.,10091617_5,-1,-1,-1,84,-1,0.004086379,0.99591357
86,systolic orthostatic hypotension,5,8,29,61,"RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures.",10091617_6,-1,-1,-1,86,-1,0.0012591557,0.99874085
87,PD,15,16,92,94,"RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures.",10091617_6,-1,-1,-1,87,-1,0.003134751,0.9968652
93,systolic and diastolic blood pressures,7,12,58,96,Stopping selegiline also significantly reduced the supine systolic and diastolic blood pressures consistent with a previously undescribed supine pressor action.,10091617_9,-1,-1,-1,93,-1,0.014430942,0.98556906
96,monoamine oxidase,14,16,104,121,The possibilities that these cardiovascular findings might be the result of non-selective inhibition of monoamine oxidase or of amphetamine and metamphetamine are discussed.,10091617_11,-1,-1,-1,96,-1,0.9988018,0.0011981627
98,metamphetamine,20,21,144,158,The possibilities that these cardiovascular findings might be the result of non-selective inhibition of monoamine oxidase or of amphetamine and metamphetamine are discussed.,10091617_11,-1,-1,-1,98,-1,0.9992937,0.00070634804
101,Picloxydine,0,1,0,11,Picloxydine irrigations appeared to have a lower incidence of erosive cystitis but further studies would have to be performed before it could be recommended for use in urological procedures.,1009330_4,-1,-1,-1,101,-1,0.9991111,0.0008888193
103,tetrandrine,2,3,11,22,Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.,10193204_0,-1,-1,-1,103,-1,0.99910164,0.00089833507
104,fangchinoline,4,5,27,40,Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.,10193204_0,-1,-1,-1,104,-1,0.9990482,0.00095177133
107,Tetrandrine,0,1,0,11,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,-1,-1,-1,107,-1,0.9990313,0.0009687431
108,TET,2,3,13,16,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,-1,-1,-1,108,-1,0.9941041,0.0058959685
109,fangchinoline,5,6,22,35,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,-1,-1,-1,109,-1,0.9988367,0.0011633548
110,FAN,7,8,37,40,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,-1,-1,-1,110,-1,0.99374735,0.006252656
111,bisbenzylisoquinoline,16,17,87,108,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,-1,-1,-1,111,-1,0.998331,0.0016690532
112,TET,10,11,63,66,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,-1,-1,-1,112,-1,0.99211097,0.00788899
113,FAN,12,13,71,74,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,-1,-1,-1,113,-1,0.9958039,0.0041961805
116,EP,23,24,144,146,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,-1,-1,-1,116,-1,0.99707174,0.0029282419
119,TET,16,17,61,64,"In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.",10193204_3,-1,-1,-1,119,-1,0.98976153,0.010238517
120,FAN,18,19,69,72,"In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.",10193204_3,-1,-1,-1,120,-1,0.9959325,0.0040675276
123,ASA,39,40,175,178,"In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.",10193204_3,-1,-1,-1,123,-1,0.9988211,0.0011789111
124,platelet aggregations,4,6,19,40,"In the vitro human platelet aggregations induced by the agonists used in tests, TET and FAN showed the inhibitions dose dependently.",10193204_4,-1,-1,-1,124,-1,0.002915403,0.99708456
125,TET,14,15,80,83,"In the vitro human platelet aggregations induced by the agonists used in tests, TET and FAN showed the inhibitions dose dependently.",10193204_4,-1,-1,-1,125,-1,0.9938519,0.006148098
126,FAN,16,17,88,91,"In the vitro human platelet aggregations induced by the agonists used in tests, TET and FAN showed the inhibitions dose dependently.",10193204_4,-1,-1,-1,126,-1,0.9967667,0.0032333436
127,TET,4,5,21,24,"In addition, neither TET nor FAN showed any anticoagulation activities in the measurement of the activated partial thromboplastin time (APTT), prothrombin time (PT) and thrombin time (TT) using human-citrated plasma.",10193204_5,-1,-1,-1,127,-1,0.9174826,0.0825173
128,FAN,6,7,29,32,"In addition, neither TET nor FAN showed any anticoagulation activities in the measurement of the activated partial thromboplastin time (APTT), prothrombin time (PT) and thrombin time (TT) using human-citrated plasma.",10193204_5,-1,-1,-1,128,-1,0.96877676,0.031223178
129,TET,6,7,45,48,These results suggest that antithrombosis of TET and FAN in mice may be mainly related to the antiplatelet aggregation activities.,10193204_6,-1,-1,-1,129,-1,0.0021210297,0.997879
130,FAN,8,9,53,56,These results suggest that antithrombosis of TET and FAN in mice may be mainly related to the antiplatelet aggregation activities.,10193204_6,-1,-1,-1,130,-1,0.0038348765,0.99616516
131,tubular damage?BACKGROUND,6,8,51,76,"Urine N-acetyl-beta-D-glucosaminidase--a marker of tubular damage?BACKGROUND: Although an indicator of renal tubular dysfunction, an increased urinary N-acetyl-beta-D-glucosaminidase (NAG) activity might reflect increased lysosomal activity in renal tubular cells.",10193809_0,-1,-1,-1,131,-1,0.009046192,0.99095374
132,renal tubular dysfunction,13,16,103,128,"Urine N-acetyl-beta-D-glucosaminidase--a marker of tubular damage?BACKGROUND: Although an indicator of renal tubular dysfunction, an increased urinary N-acetyl-beta-D-glucosaminidase (NAG) activity might reflect increased lysosomal activity in renal tubular cells.",10193809_0,-1,-1,-1,132,-1,0.0021813835,0.9978186
133,Puromycin aminonucleoside,2,4,9,34,METHODS: Puromycin aminonucleoside (PAN) was administered to Sprague Dawley rats to induce proteinuria.,10193809_1,-1,-1,-1,133,-1,0.99906963,0.0009303675
134,PAN,5,6,36,39,METHODS: Puromycin aminonucleoside (PAN) was administered to Sprague Dawley rats to induce proteinuria.,10193809_1,-1,-1,-1,134,-1,0.99816716,0.0018327674
136,PAN,4,5,31,34,"RESULTS: Following intravenous PAN urine volume and urine NAG activity increased significantly by day two, but returned to normal by day four. After day four all treated animals exhibited a marked rise in urine albumin, total protein excretion and NAG activity.",10193809_4,-1,-1,-1,136,-1,0.9952265,0.004773446
138,Cauda equina syndrome,0,3,0,21,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,-1,-1,-1,138,-1,0.0018727481,0.9981273
140,cauda equina syndrome,18,21,103,124,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,-1,-1,-1,140,-1,0.0019478868,0.9980521
141,cauda equina syndrome,32,35,197,218,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,-1,-1,-1,141,-1,0.001889752,0.9981103
144,mg,13,14,72,74,The dose of hyperbaric 5% lignocaine administered ranged from 60 to 120 mg.,10225068_3,-1,-1,-1,144,-1,0.92139786,0.07860212
148,neurological deficits,4,6,30,51,All cases sustained permanent neurological deficits.,10225068_6,-1,-1,-1,148,-1,0.0016159446,0.9983841
150,mg,24,25,149,151,We recommend that hyperbaric lignocaine should be administered in concentrations not greater than 2% and at a total dose preferably not exceeding 60 mg.,10225068_7,-1,-1,-1,150,-1,0.9897154,0.010284627
155,capillary leak syndrome,15,18,107,130,Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.,10328196_0,-1,-1,-1,155,-1,0.0013119177,0.99868804
159,capillary leak syndrome,7,10,47,70,After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.,10328196_2,-1,-1,-1,159,-1,0.001437021,0.998563
161,capillary leak syndrome,11,14,77,100,OBSERVATIONS: A keratome skin specimen from 1 patient with sirolimus-induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected sirolimus-treated patient with psoriasis (21%).,10328196_3,-1,-1,-1,161,-1,0.001320906,0.9986791
168,capillary leak syndrome,13,16,76,99,"CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.",10328196_5,-1,-1,-1,168,-1,0.0012635527,0.99873644
170,capillary leak,7,9,51,65,"Because patients with severe psoriasis may develop capillary leak from various systemic therapies, clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators.",10328196_7,-1,-1,-1,170,-1,0.0014604826,0.99853957
171,inflammatory diseases,21,23,150,171,"Because patients with severe psoriasis may develop capillary leak from various systemic therapies, clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators.",10328196_7,-1,-1,-1,171,-1,0.001532129,0.99846786
173,ACE inhibitors,3,5,18,32,Angioedema due to ACE inhibitors: common and inadequately diagnosed.,10342929_0,-1,-1,-1,173,-1,0.99857426,0.0014257752
178,thyroid disease,30,32,160,175,"These were evaluated with respect to the duration of lithium therapy, age, sex, and family history (whether or not the patient had a first-degree relative with thyroid disease).",10354657_2,-1,-1,-1,178,-1,0.002233672,0.9977664
179,Affective Disorders,2,4,9,28,"SETTING: Affective Disorders Clinic at St. Mary's Hospital, Montreal.",10354657_4,-1,-1,-1,179,-1,0.0028237537,0.9971763
180,bipolar disorder,15,17,66,82,PATIENTS: One hundred and one patients (28 men and 73 women) with bipolar disorder receiving lithium maintenance therapy ranging from 1 year's to 32 years' duration.,10354657_5,-1,-1,-1,180,-1,0.0019055071,0.9980945
188,thyroid illness,7,9,55,70,All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).,10354657_9,-1,-1,-1,188,-1,0.0015437374,0.99845624
199,thyroid illness,3,5,22,37,CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy.,10354657_14,-1,-1,-1,199,-1,0.0015114004,0.99848855
203,mood disorder,1,3,16,29,Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.,10365197_0,-1,-1,-1,203,-1,0.0011814878,0.99881846
204,psychiatric symptoms,7,9,52,72,Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.,10365197_0,-1,-1,-1,204,-1,0.0015115531,0.9984884
205,mood disorders,17,19,116,130,This paper attempts to examine and compare prevalence rates and symptom patterns of DSM substance-induced and other mood disorders.,10365197_1,-1,-1,-1,205,-1,0.0014987519,0.9985013
206,mood disorder,5,7,55,68,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,-1,206,-1,0.0011951865,0.9988048
207,CIMD,8,9,70,74,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,-1,207,-1,0.0028253857,0.9971746
208,mood disorders,12,14,83,97,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,-1,208,-1,0.0013156403,0.99868435
209,mood disorder,17,19,105,118,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,-1,209,-1,0.0012744423,0.9987256
210,psychiatric symptoms,24,26,148,168,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,-1,210,-1,0.0015387522,0.99846125
211,CIMD,4,5,24,28,The prevalence rate for CIMD was 12% at baseline.,10365197_3,-1,-1,-1,211,-1,0.0029320966,0.99706787
212,CIMD,6,7,40,44,Introduction of the DSM-IV diagnosis of CIMD did not substantially affect rates of the other depressive disorders.,10365197_4,-1,-1,-1,212,-1,0.006717858,0.9932821
213,depressive disorders,15,17,93,113,Introduction of the DSM-IV diagnosis of CIMD did not substantially affect rates of the other depressive disorders.,10365197_4,-1,-1,-1,213,-1,0.0018389856,0.998161
214,CIMD,2,3,14,18,Patients with CIMD had symptom severity levels between those of patients with and without a mood disorder.,10365197_5,-1,-1,-1,214,-1,0.002930228,0.9970697
215,mood disorder,15,17,92,105,Patients with CIMD had symptom severity levels between those of patients with and without a mood disorder.,10365197_5,-1,-1,-1,215,-1,0.0015020831,0.99849796
216,CIMD,11,12,69,73,"These findings suggest some validity for the new DSM-IV diagnosis of CIMD, but also suggest that it requires further specification and replication.",10365197_6,-1,-1,-1,216,-1,0.004126304,0.99587375
217,fucoidan,2,3,10,18,Effect of fucoidan treatment on collagenase-induced intracerebral hemorrhage in rats.,10406016_0,-1,-1,-1,217,-1,0.99854434,0.0014556977
218,intracerebral hemorrhage,6,8,52,76,Effect of fucoidan treatment on collagenase-induced intracerebral hemorrhage in rats.,10406016_0,-1,-1,-1,218,-1,0.0013907877,0.9986092
221,Intracerebral hemorrhage,0,2,0,24,Intracerebral hemorrhage is associated with more inflammation than ischemic stroke.,10406016_2,-1,-1,-1,221,-1,0.0013206834,0.99867934
224,fucoidan,5,6,38,46,"We tested the sulfated polysaccharide fucoidan, which has been reported to reduce inflammatory brain damage, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus.",10406016_3,-1,-1,-1,224,-1,0.99783856,0.0021614248
226,intracerebral hemorrhage,22,24,127,151,"We tested the sulfated polysaccharide fucoidan, which has been reported to reduce inflammatory brain damage, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus.",10406016_3,-1,-1,-1,226,-1,0.0012824256,0.99871755
227,fucoidan,9,10,57,65,Rats were treated with seven day intravenous infusion of fucoidan (30 micrograms h-1) or vehicle.,10406016_4,-1,-1,-1,227,-1,0.998439,0.0015609843
229,impaired blood clotting,5,8,44,67,"Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.",10406016_7,-1,-1,-1,229,-1,0.0020746577,0.9979253
230,hemodilution,9,10,72,84,"Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.",10406016_7,-1,-1,-1,230,-1,0.0012265777,0.9987734
231,hematomas,13,14,97,106,"Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.",10406016_7,-1,-1,-1,231,-1,0.0016242053,0.9983758
235,white matter edema,1,4,6,24,Acute white matter edema and eventual neuronal loss in the striatum adjacent to the hematoma did not differ between the two groups.,10406016_9,-1,-1,-1,235,-1,0.0018634372,0.9981365
236,neuronal loss,6,8,38,51,Acute white matter edema and eventual neuronal loss in the striatum adjacent to the hematoma did not differ between the two groups.,10406016_9,-1,-1,-1,236,-1,0.0016144749,0.99838555
238,intracerebral hemorrhage,12,14,97,121,Investigation of more specific anti-inflammatory agents and hemodiluting agents are warranted in intracerebral hemorrhage.,10406016_10,-1,-1,-1,238,-1,0.0013263399,0.9986737
240,cefotetan,9,10,67,76,Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures.,10411803_0,-1,-1,-1,240,-1,0.99904627,0.0009536989
242,cefotetan,6,7,56,65,"Second- and third-generation cephalosporins, especially cefotetan, are increasingly associated with severe, sometimes fatal immune hemolytic anemia.",10411803_1,-1,-1,-1,242,-1,0.9989761,0.0010239
244,hemolytic anemias,10,12,56,73,We noticed that 10 of our 35 cases of cefotetan-induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures.,10411803_2,-1,-1,-1,244,-1,0.0010922046,0.9989078
245,cefotetan,18,19,108,117,We noticed that 10 of our 35 cases of cefotetan-induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures.,10411803_2,-1,-1,-1,245,-1,0.99913627,0.0008638153
247,aneurysmal subarachnoid hemorrhage,10,13,79,113,Effects of nonsteroidal anti-inflammatory drugs on hemostasis in patients with aneurysmal subarachnoid hemorrhage.,10414674_0,-1,-1,-1,247,-1,0.0013939475,0.998606
248,NSAIDs,9,10,71,77,Platelet function is impaired by nonsteroidal anti-inflammatory drugs (NSAIDs) with prominent anti-inflammatory properties.,10414674_1,-1,-1,-1,248,-1,0.9975197,0.0024802608
249,aneurysmal subarachnoid hemorrhage,2,5,14,48,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,249,-1,0.0016524609,0.9983475
250,SAH,6,7,50,53,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,250,-1,0.0014008118,0.99859923
251,ketoprofen,13,14,89,99,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,251,-1,0.9993375,0.0006625332
252,mg,16,17,105,107,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,252,-1,0.99600816,0.0039918046
253,ketoprofen,23,24,128,138,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,253,-1,0.9993376,0.0006623438
254,n,26,27,146,147,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,254,-1,0.074108586,0.92589146
255,NSAID,33,34,163,168,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,255,-1,0.99899393,0.0010060391
258,n,48,49,230,231,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,258,-1,0.10866796,0.891332
259,aneurysmal SAH,58,60,281,295,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,259,-1,0.0015089357,0.99849105
261,adenosine diphosphate,8,10,52,73,Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen.,10414674_6,-1,-1,-1,261,-1,0.9991855,0.00081453554
262,ketoprofen,14,15,108,118,Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen.,10414674_6,-1,-1,-1,262,-1,0.9993216,0.0006784817
263,P,4,5,23,24,Aggregation was lower (P < .05) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day.,10414674_7,-1,-1,-1,263,-1,0.5324608,0.46753922
264,ketoprofen,10,11,39,49,Aggregation was lower (P < .05) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day.,10414674_7,-1,-1,-1,264,-1,0.9993055,0.000694508
266,contrast,1,2,3,11,"In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05).",10414674_8,-1,-1,-1,266,-1,0.2616609,0.7383391
270,P,25,26,174,175,"In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05).",10414674_8,-1,-1,-1,270,-1,0.52124935,0.47875065
271,ketoprofen,4,5,19,29,One patient in the ketoprofen group developed a postoperative intracranial hematoma.,10414674_9,-1,-1,-1,271,-1,0.99925536,0.0007446468
273,Coagulation,0,1,0,11,"Coagulation (prothrombin time [PT], activated partial thromboplastin time [APPT], fibrinogen concentration, and antithrombin III [AT III]) was comparable between the two groups.",10414674_10,-1,-1,-1,273,-1,0.004222051,0.99577796
274,antithrombin III,20,22,112,128,"Coagulation (prothrombin time [PT], activated partial thromboplastin time [APPT], fibrinogen concentration, and antithrombin III [AT III]) was comparable between the two groups.",10414674_10,-1,-1,-1,274,-1,0.9874171,0.012582852
275,AT III,23,25,130,136,"Coagulation (prothrombin time [PT], activated partial thromboplastin time [APPT], fibrinogen concentration, and antithrombin III [AT III]) was comparable between the two groups.",10414674_10,-1,-1,-1,275,-1,0.9467604,0.053239558
276,Ketoprofen,0,1,0,10,Ketoprofen but not acetaminophen impaired platelet function in patients with SAH.,10414674_11,-1,-1,-1,276,-1,0.9992575,0.0007424952
277,acetaminophen impaired platelet function,3,7,19,59,Ketoprofen but not acetaminophen impaired platelet function in patients with SAH.,10414674_11,-1,-1,-1,277,-1,0.629579,0.37042093
278,SAH,10,11,77,80,Ketoprofen but not acetaminophen impaired platelet function in patients with SAH.,10414674_11,-1,-1,-1,278,-1,0.0015632809,0.99843675
279,ketoprofen,1,2,3,13,"If ketoprofen is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for hemorrhage.",10414674_12,-1,-1,-1,279,-1,0.99926084,0.00073910475
280,cerebral artery aneurysms,7,10,40,65,"If ketoprofen is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for hemorrhage.",10414674_12,-1,-1,-1,280,-1,0.0021487714,0.99785125
282,atracurium,2,3,16,26,Accumulation of atracurium in the intravenous line led to recurarization after flushing the line in the recovery room.,10457883_2,-1,-1,-1,282,-1,0.9990382,0.00096182857
283,flushing,11,12,79,87,Accumulation of atracurium in the intravenous line led to recurarization after flushing the line in the recovery room.,10457883_2,-1,-1,-1,283,-1,0.007793955,0.99220604
284,respiratory arrest,1,3,2,20,A respiratory arrest with severe desaturation and bradycardia occurred.,10457883_3,-1,-1,-1,284,-1,0.0016249855,0.99837494
285,desaturation,5,6,33,45,A respiratory arrest with severe desaturation and bradycardia occurred.,10457883_3,-1,-1,-1,285,-1,0.0015327091,0.99846727
287,neuromuscular blockade,10,12,66,88,"Circumstances leading to this event and the mechanisms enabling a neuromuscular blockade to occur, following the administration of a small dose of relaxant, are discussed.",10457883_4,-1,-1,-1,287,-1,0.002551252,0.99744874
290,ASA,13,14,88,91,The haemodynamic effects of propofol in combination with ephedrine in elderly patients (ASA groups 3 and 4).The marked vasodilator and negative inotropic effects of propofol are disadvantages in frail elderly patients.,10520387_0,-1,-1,-1,290,-1,0.6204042,0.37959576
295,mg,10,11,48,50,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,-1,-1,-1,295,-1,0.9934115,0.0065885205
297,mg,15,16,71,73,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,-1,-1,-1,297,-1,0.99147815,0.008521847
299,ASA,24,25,117,120,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,-1,-1,-1,299,-1,0.9687056,0.03129441
308,myocardial ischemia,8,10,45,64,"Due to the risk of this tachycardia inducing myocardial ischemia, we would not recommend the use in elderly patients of any of the ephedrine/propofol/mixtures studied.",10520387_5,-1,-1,-1,308,-1,0.0013819812,0.998618
309,Nitric oxide,0,2,0,12,Nitric oxide synthase expression in the course of lead-induced hypertension.,10523326_0,-1,-1,-1,309,-1,0.9963427,0.0036572095
311,reactive oxygen species,4,7,28,51,"We recently showed elevated reactive oxygen species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.",10523326_1,-1,-1,-1,311,-1,0.816674,0.183326
312,nitrotyrosine,26,27,144,157,"We recently showed elevated reactive oxygen species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.",10523326_1,-1,-1,-1,312,-1,0.9989191,0.0010808624
317,drinking water,19,21,105,119,"Male Sprague-Dawley rats were randomly assigned to a lead-treated group (given lead acetate, 100 ppm, in drinking water and regular rat chow), a group given lead and vitamin E-fortified chow, or a normal control group given either regular food and water or vitamin E-fortified food for 12 weeks.",10523326_3,-1,-1,-1,317,-1,0.9879645,0.012035521
318,lead,30,31,157,161,"Male Sprague-Dawley rats were randomly assigned to a lead-treated group (given lead acetate, 100 ppm, in drinking water and regular rat chow), a group given lead and vitamin E-fortified chow, or a normal control group given either regular food and water or vitamin E-fortified food for 12 weeks.",10523326_3,-1,-1,-1,318,-1,0.99834013,0.0016598554
320,MDA,11,12,68,71,"Tail blood pressure, urinary NOx excretion, plasma malondialdehyde (MDA), and endothelial and inducible NOS (eNOS and iNOS) isotypes in the aorta and kidney were measured.",10523326_4,-1,-1,-1,320,-1,0.9969303,0.0030696765
321,MDA,11,12,69,72,"The lead-treated group exhibited a rise in blood pressure and plasma MDA concentration, a fall in urinary NOx excretion, and a paradoxical rise in vascular and renal tissue eNOS and iNOS expression.",10523326_5,-1,-1,-1,321,-1,0.9984053,0.0015947776
322,Vitamin E,0,2,0,9,"Vitamin E supplementation ameliorated hypertension, lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression.",10523326_6,-1,-1,-1,322,-1,0.9987613,0.0012387378
324,MDA,8,9,67,70,"Vitamin E supplementation ameliorated hypertension, lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression.",10523326_6,-1,-1,-1,324,-1,0.9975262,0.0024737925
325,Vitamin E,0,2,0,9,"Vitamin E supplementation had no effect on either blood pressure, plasma MDA, or NOS expression in the control group.",10523326_7,-1,-1,-1,325,-1,0.99884194,0.0011581145
326,MDA,12,13,73,76,"Vitamin E supplementation had no effect on either blood pressure, plasma MDA, or NOS expression in the control group.",10523326_7,-1,-1,-1,326,-1,0.97592133,0.02407864
327,lead,11,12,76,80,The study also revealed significant inhibition of NOS enzymatic activity by lead in cell-free preparations.,10523326_8,-1,-1,-1,327,-1,0.9984824,0.0015175526
330,Glyceryl trinitrate,0,2,0,19,Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.,10524660_0,-1,-1,-1,330,-1,0.99880815,0.0011918072
331,migraine without aura,5,8,39,60,Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.,10524660_0,-1,-1,-1,331,-1,0.0013097753,0.9986902
332,migraine with aura,11,14,77,95,Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.,10524660_0,-1,-1,-1,332,-1,0.0013684729,0.99863154
333,Migraine with aura,0,3,0,18,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,-1,-1,333,-1,0.0018309525,0.99816906
334,migraine without aura,4,7,23,44,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,-1,-1,334,-1,0.001800303,0.9981997
336,migraine with aura,16,19,92,110,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,-1,-1,336,-1,0.0017914788,0.9982085
337,migraine without aura,20,23,115,136,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,-1,-1,337,-1,0.0018012011,0.9981988
338,nitric oxide,12,14,79,91,"In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (NO) is involved in pain mechanisms of migraine without aura.",10524660_2,-1,-1,-1,338,-1,0.99798536,0.0020146777
340,migraine without aura,23,26,131,152,"In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (NO) is involved in pain mechanisms of migraine without aura.",10524660_2,-1,-1,-1,340,-1,0.0014089355,0.998591
341,migraine with aura,10,13,49,67,"In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.",10524660_3,-1,-1,-1,341,-1,0.0015100655,0.99848986
343,glyceryl trinitrate,27,29,151,170,"In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.",10524660_3,-1,-1,-1,343,-1,0.9990115,0.0009884527
344,GTN,30,31,172,175,"In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.",10524660_3,-1,-1,-1,344,-1,0.9984415,0.001558519
345,migraine with aura,43,46,227,245,"In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.",10524660_3,-1,-1,-1,345,-1,0.0014670995,0.9985329
346,migraine without aura,13,16,70,91,The specific aim was to elucidate whether an aura and/or an attack of migraine without aura could be induced.,10524660_4,-1,-1,-1,346,-1,0.0013897166,0.99861026
348,migraineurs,5,6,28,39,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,-1,-1,348,-1,0.0019058643,0.99809414
349,GTN,14,15,90,93,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,-1,-1,349,-1,0.99849534,0.0015046843
350,p=0.037,17,18,104,111,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,-1,-1,350,-1,0.34756607,0.65243393
351,h,26,27,148,149,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,-1,-1,351,-1,0.3977458,0.6022542
352,p,28,29,151,152,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,-1,-1,352,-1,0.35561326,0.64438677
354,migraineurs,12,13,76,87,"In the controls, the GTN-induced headache gradually disappeared, whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post-infusion.",10524660_8,-1,-1,-1,354,-1,0.0030312354,0.9969688
357,migraineurs,10,11,45,56,At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society.,10524660_9,-1,-1,-1,357,-1,0.0018899803,0.99811006
358,migraine without aura,16,19,95,116,At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society.,10524660_9,-1,-1,-1,358,-1,0.001431968,0.99856806
361,migraine with aura,13,16,76,94,The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura.,10524660_10,-1,-1,-1,361,-1,0.0014321499,0.9985678
365,migraine with aura,29,32,188,206,"Since cortical spreading depression has been shown to liberate NO in animals, this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura.",10524660_11,-1,-1,-1,365,-1,0.0015273177,0.99847263
368,nonsmall cell lung carcinoma,4,8,32,60,Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.,10526274_0,-1,-1,-1,368,-1,0.0038547704,0.99614525
370,nonsmall cell lung carcinoma,6,10,39,67,"BACKGROUND: Although the prevalence of nonsmall cell lung carcinoma (NSCLC) is high among elderly patients, few data are available regarding the efficacy and toxicity of chemotherapy in this group of patients.",10526274_2,-1,-1,-1,370,-1,0.00273846,0.9972615
371,NSCLC,11,12,69,74,"BACKGROUND: Although the prevalence of nonsmall cell lung carcinoma (NSCLC) is high among elderly patients, few data are available regarding the efficacy and toxicity of chemotherapy in this group of patients.",10526274_2,-1,-1,-1,371,-1,0.0016736782,0.99832636
374,VNB,10,11,68,71,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,-1,-1,-1,374,-1,0.99810827,0.0018917054
376,GEM,15,16,89,92,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,-1,-1,-1,376,-1,0.9981464,0.0018536116
379,GEM,12,13,69,72,In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.,10526274_4,-1,-1,-1,379,-1,0.9986091,0.0013908964
380,VNB,14,15,77,80,In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.,10526274_4,-1,-1,-1,380,-1,0.9984207,0.0015793106
381,NSCLC,20,21,115,120,In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.,10526274_4,-1,-1,-1,381,-1,0.0020167092,0.9979832
383,NSCLC,6,7,43,48,"METHODS: Forty-nine patients with advanced NSCLC were included, 38 of whom were age >/= 70 years and 11 were age < 70 years but who had some contraindication to receiving cisplatin.",10526274_5,-1,-1,-1,383,-1,0.0016760342,0.998324
386,VNB,4,5,27,30,"Treatment was comprised of VNB, 25 mg/m(2), plus GEM, 1000 mg/m(2), both on Days 1, 8, and 15 every 28 days.",10526274_7,-1,-1,-1,386,-1,0.99859804,0.0014019194
387,GEM,11,12,49,52,"Treatment was comprised of VNB, 25 mg/m(2), plus GEM, 1000 mg/m(2), both on Days 1, 8, and 15 every 28 days.",10526274_7,-1,-1,-1,387,-1,0.99886084,0.0011392263
395,P,28,29,151,152,The median age of those patients developing Grade 3-4 neutropenia was significantly higher than that of the remaining patients (75 years vs. 72 years; P = 0.047).,10526274_17,-1,-1,-1,395,-1,0.33385158,0.66614836
396,GEM,5,6,32,35,CONCLUSIONS: The combination of GEM and VNB is moderately active and well tolerated except in patients age >/= 75 years.,10526274_18,-1,-1,-1,396,-1,0.99820006,0.0017999627
397,VNB,7,8,40,43,CONCLUSIONS: The combination of GEM and VNB is moderately active and well tolerated except in patients age >/= 75 years.,10526274_18,-1,-1,-1,397,-1,0.9982247,0.0017753401
400,NSCLC,16,17,116,121,New chemotherapy combinations with higher activity and lower toxicity are needed for elderly patients with advanced NSCLC.,10526274_21,-1,-1,-1,400,-1,0.0020208305,0.9979792
402,calcium chloride,7,9,65,81,Rapid reversal of life-threatening diltiazem-induced tetany with calcium chloride.,10533019_0,-1,-1,-1,402,-1,0.9990514,0.00094864843
404,respiratory arrest,9,11,55,73,We describe a patient who developed tetany with sudden respiratory arrest after the infusion of intravenous diltiazem.,10533019_1,-1,-1,-1,404,-1,0.0011578581,0.9988422
406,calcium chloride,3,5,22,38,"The administration of calcium chloride rapidly resolved the patient's tetany with prompt recovery of respiratory function, averting the need for more aggressive airway management and ventilatory support.",10533019_2,-1,-1,-1,406,-1,0.99886584,0.0011341501
410,calcium chloride,18,20,136,152,The emergency physician should be aware that life-threatening tetany may accompany the administration of intravenous diltiazem and that calcium chloride may be a rapid and effective remedy.,10533019_3,-1,-1,-1,410,-1,0.999094,0.00090604165
411,decreased renal function,2,5,14,38,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,411,-1,0.003536185,0.99646384
412,heart failure,8,10,56,69,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,412,-1,0.0014952702,0.99850476
413,left ventricular dysfunction,21,24,154,182,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,413,-1,0.0021191484,0.9978809
414,congestive heart failure,37,40,300,324,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,414,-1,0.0015094947,0.99849045
415,CHF,41,42,326,329,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,415,-1,0.0014766122,0.9985234
416,decreased renal function,48,51,350,374,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,416,-1,0.004001154,0.99599886
417,reduction in renal function,8,12,55,82,OBJECTIVE: To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin-converting enzyme inhibitor therapy.,10539815_2,-1,-1,-1,417,-1,0.0039823134,0.99601763
418,CHF,15,16,100,103,OBJECTIVE: To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin-converting enzyme inhibitor therapy.,10539815_2,-1,-1,-1,418,-1,0.0015051041,0.99849486
419,Left Ventricular Dysfunction,9,12,45,73,"METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.",10539815_3,-1,-1,-1,419,-1,0.002083738,0.9979163
421,CHF,29,30,170,173,"METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.",10539815_3,-1,-1,-1,421,-1,0.0013600114,0.99864
423,Decreased renal function,0,3,0,24,Decreased renal function was defined as a rise in serum creatinine >/=0.5 mg/dL (44 micromol/L) from baseline.,10539815_5,-1,-1,-1,423,-1,0.003996556,0.99600345
425,in renal function,10,13,76,93,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,-1,-1,-1,425,-1,0.0075127357,0.9924873
427,low systolic blood pressure,23,27,158,185,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,-1,-1,-1,427,-1,0.01761259,0.9823874
428,mm Hg,30,32,192,197,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,-1,-1,-1,428,-1,0.059643473,0.9403565
431,diuretic,45,46,260,268,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,-1,-1,-1,431,-1,0.9979819,0.002018092
433,decreased renal function,14,17,81,105,RESULTS: Patients randomly assigned to enalapril had a 33% greater likelihood of decreased renal function than controls (P =.003).,10539815_7,-1,-1,-1,433,-1,0.0041336976,0.9958663
434,P,20,21,121,122,RESULTS: Patients randomly assigned to enalapril had a 33% greater likelihood of decreased renal function than controls (P =.003).,10539815_7,-1,-1,-1,434,-1,0.24888271,0.7511173
436,diuretic,14,15,78,86,"By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.",10539815_8,-1,-1,-1,436,-1,0.9990858,0.0009141837
438,decreased renal function,22,25,130,154,"By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.",10539815_8,-1,-1,-1,438,-1,0.0042726826,0.9957273
439,decreased renal function,10,13,59,83,"Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).",10539815_9,-1,-1,-1,439,-1,0.0035256876,0.9964743
443,Diuretic,0,1,0,8,"Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).",10539815_10,-1,-1,-1,443,-1,0.99894696,0.0010530801
444,decreased renal function,10,13,64,88,"Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).",10539815_10,-1,-1,-1,444,-1,0.003160152,0.9968399
448,renal impairment,4,6,16,32,"A lower risk of renal impairment was seen in both groups with beta-blocker therapy (RR 0.70, 95% CI 0.57-0.85) and higher baseline ejection fraction (RR 0.93 per 5% increment, 95% CI 0.91-0. 96).",10539815_12,-1,-1,-1,448,-1,0.0017340461,0.9982659
450,decreased renal function,13,16,64,88,CONCLUSIONS: Enalapril use caused a 33% increase in the risk of decreased renal function in patients with CHF.,10539815_13,-1,-1,-1,450,-1,0.002781462,0.9972185
451,CHF,19,20,106,109,CONCLUSIONS: Enalapril use caused a 33% increase in the risk of decreased renal function in patients with CHF.,10539815_13,-1,-1,-1,451,-1,0.0014676431,0.9985323
452,Diuretic,0,1,0,8,Diuretic use and advanced age increased this risk.,10539815_14,-1,-1,-1,452,-1,0.998028,0.0019720457
454,renal impairment,8,10,50,66,"Diabetes was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the enalapril group compared with the placebo group.",10539815_15,-1,-1,-1,454,-1,0.0014293003,0.9985707
455,CHF,14,15,88,91,"Diabetes was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the enalapril group compared with the placebo group.",10539815_15,-1,-1,-1,455,-1,0.0011633947,0.9988366
458,psychotic disorder,13,15,73,91,We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.,10565806_1,-1,-1,-1,458,-1,0.0015315979,0.99846834
459,hypomania,20,21,115,124,We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.,10565806_1,-1,-1,-1,459,-1,0.001415758,0.9985843
462,NRA0160,7,8,45,52,"A selective dopamine D4 receptor antagonist, NRA0160: a preclinical neuropharmacological profile.",10579464_0,-1,-1,-1,462,-1,0.99639434,0.0036056254
463,NRA0160,0,1,0,7,"NRA0160, 5 - [2- ( 4- ( 3 - fluorobenzylidene) piperidin-1-yl) ethyl] - 4 -(4-fluorophenyl) thiazole-2-carboxamide, has a high affinity for human cloned dopamine D4.2, D4.4 and D4.7 receptors, with Ki values of 0.5, 0.9 and 2.7 nM, respectively.",10579464_1,-1,-1,-1,463,-1,0.99362105,0.0063789575
466,NRA0160,0,1,0,7,"NRA0160 is over 20,000fold more potent at the dopamine D4.2 receptor compared with the human cloned dopamine D2L receptor.",10579464_2,-1,-1,-1,466,-1,0.997269,0.002731037
469,NRA0160,0,1,0,7,"NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM).",10579464_3,-1,-1,-1,469,-1,0.9967655,0.0032345303
472,(5-HT)2A,18,19,100,108,"NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM).",10579464_3,-1,-1,-1,472,-1,0.99759823,0.0024017182
473,NRA0160,0,1,0,7,NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.,10579464_4,-1,-1,-1,473,-1,0.99783057,0.0021693953
477,MAP,10,11,86,89,NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.,10579464_4,-1,-1,-1,477,-1,0.9981755,0.0018245531
478,NRA0160,0,1,0,7,"NRA0160 and clozapine antagonized MAP-induced stereotyped behavior in mice, although their effects did not exceed 50% inhibition, even at the highest dose given.",10579464_5,-1,-1,-1,478,-1,0.99825615,0.001743801
480,NRA0160,0,1,0,7,"NRA0160 and clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given.",10579464_6,-1,-1,-1,480,-1,0.9977075,0.0022925374
483,NRA0160,0,1,0,7,NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine.,10579464_7,-1,-1,-1,483,-1,0.9974541,0.0025459116
486,NRA0160,0,1,0,7,NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.,10579464_8,-1,-1,-1,486,-1,0.99723464,0.0027653885
488,phencyclidine,6,7,50,63,NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.,10579464_8,-1,-1,-1,488,-1,0.9993549,0.00064510986
489,NRA0160,4,5,28,35,These findings suggest that NRA0160 may have unique antipsychotic activities without the liability of motor side effects typical of classical antipsychotics.,10579464_9,-1,-1,-1,489,-1,0.9979609,0.0020390274
490,antipsychotics,20,21,142,156,These findings suggest that NRA0160 may have unique antipsychotic activities without the liability of motor side effects typical of classical antipsychotics.,10579464_9,-1,-1,-1,490,-1,0.99677676,0.003223258
492,vitamin D.The,8,10,67,80,"Warfarin-induced artery calcification is accelerated by growth and vitamin D.The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.",10669626_0,-1,-1,-1,492,-1,0.9466157,0.05338431
493,vitamin D,16,18,125,134,"Warfarin-induced artery calcification is accelerated by growth and vitamin D.The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.",10669626_0,-1,-1,-1,493,-1,0.99869955,0.0013004118
499,calcification of the artery media,9,14,57,90,Treatment for 2 weeks with Warfarin caused massive focal calcification of the artery media in 20-day-old rats and less extensive focal calcification in 42-day-old rats.,10669626_2,-1,-1,-1,499,-1,0.0036839237,0.99631613
501,contrast,1,2,3,11,"In contrast, no artery calcification could be detected in 10-month-old adult rats even after 4 weeks of Warfarin treatment.",10669626_3,-1,-1,-1,501,-1,0.12288611,0.87711394
506,calcification of the artery media,11,16,81,114,"Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet, growth-inhibited group.",10669626_5,-1,-1,-1,506,-1,0.0045844885,0.99541545
515,vitamin D,10,12,68,77,The second set of experiments examined the possible synergy between vitamin D and Warfarin in artery calcification.,10669626_8,-1,-1,-1,515,-1,0.9989655,0.0010344964
518,vitamin D,3,5,14,23,High doses of vitamin D are known to cause calcification of the artery media in as little as 3 to 4 days.,10669626_9,-1,-1,-1,518,-1,0.99890363,0.0010963116
519,calcification of the artery media,9,14,43,76,High doses of vitamin D are known to cause calcification of the artery media in as little as 3 to 4 days.,10669626_9,-1,-1,-1,519,-1,0.003438187,0.9965618
520,vitamin K,4,6,18,27,"High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week.",10669626_10,-1,-1,-1,520,-1,0.99876094,0.0012390504
522,calcification of the artery media,13,18,72,105,"High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week.",10669626_10,-1,-1,-1,522,-1,0.0031235772,0.99687636
525,vitamin D,9,11,49,58,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,-1,-1,-1,525,-1,0.99901843,0.0009815829
527,vitamin D,19,21,106,115,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,-1,-1,-1,527,-1,0.9989889,0.0010110119
529,vitamin D,32,34,176,185,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,-1,-1,-1,529,-1,0.9990435,0.0009564653
534,vitamin D,14,16,87,96,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,-1,-1,-1,534,-1,0.998906,0.0010939634
536,vitamin D,22,24,131,140,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,-1,-1,-1,536,-1,0.99891734,0.0010826617
540,vitamin D,17,19,98,107,"High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated.",10669626_14,-1,-1,-1,540,-1,0.99903643,0.00096353586
552,contrast,1,2,3,11,"By contrast, apomorphine-induced locomotion was more prominent in the novel exploratory box.",10683478_8,-1,-1,-1,552,-1,0.25754935,0.7424506
554,DOPAC,4,5,26,31,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,-1,-1,-1,554,-1,0.99887913,0.0011208085
555,DA,6,7,32,34,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,-1,-1,-1,555,-1,0.9985997,0.0014002615
556,HVA,8,9,39,42,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,-1,-1,-1,556,-1,0.9987845,0.0012155842
557,DA,10,11,43,45,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,-1,-1,-1,557,-1,0.9986958,0.0013041935
559,Gerstmann syndrome,1,3,22,40,Acetazolamide-induced Gerstmann syndrome.,10692744_0,-1,-1,-1,559,-1,0.0016311613,0.9983688
561,acetazolamide,4,5,27,40,Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.,10692744_1,-1,-1,-1,561,-1,0.9991387,0.0008613093
562,adverse drug reaction,9,12,57,78,Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.,10692744_1,-1,-1,-1,562,-1,0.0030682816,0.9969317
563,renal impairment,15,17,96,112,Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.,10692744_1,-1,-1,-1,563,-1,0.0017299264,0.99827003
564,Gerstmann syndrome,6,8,42,60,"We report a case of acetazolamide-induced Gerstmann syndrome in a patient with normal renal function, to highlight predisposing factors that are frequently overlooked.",10692744_2,-1,-1,-1,564,-1,0.0017291064,0.99827087
568,TAM,2,3,11,14,"Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.",10704919_1,-1,-1,-1,568,-1,0.9987503,0.0012496619
571,TAM,6,7,35,38,"This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms.",10704919_2,-1,-1,-1,571,-1,0.9988966,0.0011034113
573,TAM,0,1,0,3,TAM induces hemolysis of erythrocytes as a function of concentration.,10704919_3,-1,-1,-1,573,-1,0.9983444,0.0016555277
576,TAM,13,14,81,84,"The extension of hemolysis is variable with erythrocyte samples, but 12.5 microM TAM induces total hemolysis of all tested suspensions.",10704919_4,-1,-1,-1,576,-1,0.99850947,0.0014904985
578,TAM,6,7,46,49,"Despite inducing extensive erythrocyte lysis, TAM does not shift the osmotic fragility curves of erythrocytes.",10704919_5,-1,-1,-1,578,-1,0.99829465,0.00170541
579,hemolytic,1,2,4,13,The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.,10704919_6,-1,-1,-1,579,-1,0.0013021203,0.9986979
580,TAM,4,5,24,27,The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.,10704919_6,-1,-1,-1,580,-1,0.9990081,0.0009918602
581,hydroxyl,24,25,158,166,The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.,10704919_6,-1,-1,-1,581,-1,0.9720215,0.027978484
585,TAM,6,7,34,37,"Furthermore, it was observed that TAM inhibits the peroxidation of human erythrocytes induced by AAPH, thus ruling out TAM-induced cell oxidative stress.",10704919_8,-1,-1,-1,585,-1,0.9988133,0.00118678
586,AAPH,15,16,97,101,"Furthermore, it was observed that TAM inhibits the peroxidation of human erythrocytes induced by AAPH, thus ruling out TAM-induced cell oxidative stress.",10704919_8,-1,-1,-1,586,-1,0.5414577,0.45854232
588,TAM,3,4,20,23,"Hemolysis caused by TAM was not preceded by the leakage of K(+) from the cells, also excluding a colloid-osmotic type mechanism of hemolysis, according to the effects on osmotic fragility curves.",10704919_9,-1,-1,-1,588,-1,0.9986584,0.0013416231
590,TAM,2,3,9,12,"However, TAM induces release of peripheral proteins of membrane-cytoskeleton and cytosol proteins essentially bound to band 3.",10704919_10,-1,-1,-1,590,-1,0.99850357,0.0014964696
591,TAM,9,10,68,71,Either alpha-T or alpha-TAc increases membrane packing and prevents TAM partition into model membranes.,10704919_11,-1,-1,-1,591,-1,0.99814427,0.0018557161
593,tocopherols,9,10,60,71,These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided.,10704919_12,-1,-1,-1,593,-1,0.9992507,0.00074922934
594,TAM,15,16,98,101,These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided.,10704919_12,-1,-1,-1,594,-1,0.99893373,0.0010662153
596,TAM,13,14,100,103,"These defects explain the abnormal erythrocyte shape and decreased mechanical stability promoted by TAM, resulting in hemolytic anemia.",10704919_14,-1,-1,-1,596,-1,0.998042,0.0019580047
598,cytotoxicity,10,11,57,69,"Additionally, since membrane leakage is a final stage of cytotoxicity, the disruption of the structural characteristics of biomembranes by TAM may contribute to the multiple mechanisms of its anticancer action.",10704919_15,-1,-1,-1,598,-1,0.0016955554,0.99830437
599,TAM,21,22,139,142,"Additionally, since membrane leakage is a final stage of cytotoxicity, the disruption of the structural characteristics of biomembranes by TAM may contribute to the multiple mechanisms of its anticancer action.",10704919_15,-1,-1,-1,599,-1,0.9984118,0.0015882578
601,ATP,4,5,22,25,"Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.",10706004_0,-1,-1,-1,601,-1,0.99872905,0.0012709207
602,nitric oxide,15,17,83,95,"Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.",10706004_0,-1,-1,-1,602,-1,0.9987532,0.0012467941
608,ATP,9,10,53,56,"When activating the (Na,K)-ATPase with its substrate ATP, no changes in Km and Vmax values were observed in NO-deficient rats.",10706004_7,-1,-1,-1,608,-1,0.9986498,0.0013502241
610,ATP,30,31,165,168,"After recovery from hypertension, the activity of (Na,K)-ATPase increased, due to higher affinity of the ATP-binding site, as revealed from the lowered Km value for ATP.",10706004_9,-1,-1,-1,610,-1,0.99890006,0.0010999617
629,domperidone,0,1,0,11,domperidone (0.5 mg/kg).,10721819_6,-1,-1,-1,629,-1,0.99920386,0.0007961649
640,heart failure,9,11,72,85,Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.,10728962_0,-1,-1,-1,640,-1,0.0012289938,0.998771
641,phosphodiesterase,3,4,11,28,The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.,10728962_1,-1,-1,-1,641,-1,0.9972525,0.0027474337
642,inhibitors,4,5,29,39,The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.,10728962_1,-1,-1,-1,642,-1,0.9976052,0.0023947707
643,milrinone,7,8,48,57,The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.,10728962_1,-1,-1,-1,643,-1,0.99916065,0.0008393463
644,heart failure,13,15,85,98,The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.,10728962_1,-1,-1,-1,644,-1,0.001319014,0.998681
646,heart failure,4,6,31,44,"In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.",10728962_2,-1,-1,-1,646,-1,0.0013585789,0.99864143
648,milrinone,11,12,83,92,"In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.",10728962_2,-1,-1,-1,648,-1,0.99921644,0.0007835332
650,milrinone,26,27,186,195,"In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.",10728962_2,-1,-1,-1,650,-1,0.99925953,0.00074041984
661,venous thromboembolism,10,12,59,81,Recurrent use of newer oral contraceptives and the risk of venous thromboembolism.,10739826_0,-1,-1,-1,661,-1,0.0013820273,0.998618
662,venous thromboembolism,8,10,54,76,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,-1,-1,-1,662,-1,0.0014055825,0.99859446
663,VTE,11,12,78,81,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,-1,-1,-1,663,-1,0.0015347982,0.9984652
665,OC,19,20,126,128,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,-1,-1,-1,665,-1,0.99792385,0.0020761332
666,OC,27,28,170,172,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,-1,-1,-1,666,-1,0.99803406,0.0019659896
667,VTE,13,14,77,80,"Data from a Transnational case-control study were used to assess the risk of VTE for the latter patterns of use, while accounting for duration of use.",10739826_2,-1,-1,-1,667,-1,0.0016031085,0.99839693
668,VTE,10,11,40,43,"Over the period 1993-1996, 551 cases of VTE were identified in Germany and the UK along with 2066 controls.",10739826_3,-1,-1,-1,668,-1,0.0018237802,0.9981762
669,VTE,5,6,27,30,"The adjusted rate ratio of VTE for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills.",10739826_5,-1,-1,-1,669,-1,0.0020545411,0.9979455
670,OC,12,13,68,70,"The adjusted rate ratio of VTE for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills.",10739826_5,-1,-1,-1,670,-1,0.9925568,0.00744321
671,VTE,14,15,92,95,We conclude that second and third generation agents are associated with equivalent risks of VTE when the same agent is used repeatedly after interruption periods or when users are switched between the two generations of pills.,10739826_6,-1,-1,-1,671,-1,0.0016782864,0.9983217
672,OC,11,12,67,69,These analyses suggest that the higher risk observed for the newer OC in other studies may be the result of inadequate comparisons of pill users with different patterns of pill use.,10739826_7,-1,-1,-1,672,-1,0.9973041,0.0026958878
684,mg,6,7,32,34,"infusion of ketamine (bolus 0.1 mg kg-1 over 10 min followed by infusion of 7 micrograms kg-1 min-1), lidocaine 5 mg kg-1 or saline for 50 min.",10743446_4,-1,-1,-1,684,-1,0.99276936,0.0072306823
686,mg,23,24,114,116,"infusion of ketamine (bolus 0.1 mg kg-1 over 10 min followed by infusion of 7 micrograms kg-1 min-1), lidocaine 5 mg kg-1 or saline for 50 min.",10743446_4,-1,-1,-1,686,-1,0.995288,0.0047120005
704,CyA,14,15,113,116,"When tacrolimus side effects persist despite dose reduction, conversion to cyclosporine-based immunosuppression (CyA) is necessary.",10743694_1,-1,-1,-1,704,-1,0.0029250486,0.99707496
707,CyA.,15,16,104,108,"Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion.",10743694_3,-1,-1,-1,707,-1,0.39655498,0.603445
710,diabetes mellitus,13,15,78,95,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,710,-1,0.0012450544,0.998755
711,IDDM,16,17,97,101,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,711,-1,0.0015573546,0.9984427
713,gastrointestinal (GI) toxicity,27,32,128,158,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,713,-1,0.0016792062,0.99832076
716,IDDM,52,53,237,241,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,716,-1,0.0013163033,0.99868363
718,GI toxicity,62,64,268,279,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,718,-1,0.0015029544,0.998497
720,PTLD,77,78,347,351,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,720,-1,0.0018757276,0.9981243
725,CyA,12,13,79,82,"When tacrolimus side effects are unresponsive to dose reduction, conversion to CyA can be accomplished safely, with no increased risk of rejection and excellent long-term outcome.",10743694_10,-1,-1,-1,725,-1,0.008182014,0.99181795
733,juvenile rheumatoid arthritis,3,6,25,54,Ocular manifestations of juvenile rheumatoid arthritis.,1079693_0,-1,-1,-1,733,-1,0.0022008226,0.9977991
734,juvenile rheumatoid arthritis,5,8,25,54,We followed 210 cases of juvenile rheumatoid arthritis closely for eleven years.,1079693_1,-1,-1,-1,734,-1,0.0017819037,0.9982181
735,iridocyclitis,10,11,49,62,Thirty-six of the 210 patients (17.2%) developed iridocyclitis.,1079693_2,-1,-1,-1,735,-1,0.0015815031,0.99841845
736,Iridocyclitis,0,1,0,13,Iridocyclitis was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the arthritis.,1079693_3,-1,-1,-1,736,-1,0.0020659193,0.9979341
738,uveitis,8,9,39,46,"However, 30% of the patients developed uveitis after 16 years of age.",1079693_4,-1,-1,-1,738,-1,0.0013101683,0.99868983
739,uveitis,17,18,87,94,"Although 61% of patients had a noncontributory ocular history on entry, 42% had active uveitis on entry.",1079693_5,-1,-1,-1,739,-1,0.0013657497,0.9986343
740,uveitis,6,7,40,47,Our approach was effective in detecting uveitis in new cases and exacerbations of uveitis in established cases.,1079693_6,-1,-1,-1,740,-1,0.0012436794,0.9987563
741,uveitis,13,14,82,89,Our approach was effective in detecting uveitis in new cases and exacerbations of uveitis in established cases.,1079693_6,-1,-1,-1,741,-1,0.0012708815,0.99872917
742,uveitis,5,6,36,43,"Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.",1079693_7,-1,-1,-1,742,-1,0.0012081343,0.9987919
743,ocular pain,20,22,109,120,"Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.",1079693_7,-1,-1,-1,743,-1,0.0014440708,0.99855596
744,decreased visual acuity,23,26,122,145,"Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.",1079693_7,-1,-1,-1,744,-1,0.002784675,0.9972153
745,photophobia,28,29,150,161,"Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.",1079693_7,-1,-1,-1,745,-1,0.0013970615,0.9986029
746,uveitis,13,14,65,72,"Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.",1079693_8,-1,-1,-1,746,-1,0.0012706202,0.9987294
748,uveitis,17,18,94,101,"Despite this, there was a dramatic decrease in the 50% incidence of blinding complications of uveitis cited in earlier studies.",1079693_9,-1,-1,-1,748,-1,0.0012547082,0.9987453
750,band keratopathy,2,4,13,29,"Cataract and band keratopathy occurred in only 22 and 13% of our group, respectively.",1079693_10,-1,-1,-1,750,-1,0.0017980224,0.99820197
752,hydroxychloroquine,4,5,23,41,We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.,1079693_11,-1,-1,-1,752,-1,0.9992717,0.00072828704
753,chorioretinopathy,16,17,89,106,We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.,1079693_11,-1,-1,-1,753,-1,0.0020363126,0.99796367
756,keratoconjunctivitis sicca,1,3,8,34,Typical keratoconjunctivitis sicca developed in three of the uveitis cases.,1079693_13,-1,-1,-1,756,-1,0.0017809768,0.99821895
757,uveitis,8,9,61,68,Typical keratoconjunctivitis sicca developed in three of the uveitis cases.,1079693_13,-1,-1,-1,757,-1,0.0015084582,0.9984915
758,uveitis,3,4,22,29,This association with uveitis and JRA was not noted previously.,1079693_14,-1,-1,-1,758,-1,0.0012715864,0.99872845
759,JRA,5,6,34,37,This association with uveitis and JRA was not noted previously.,1079693_14,-1,-1,-1,759,-1,0.0014948352,0.99850523
761,band keratopathy,5,7,33,49,"Surgical treatment of cataracts, band keratopathy, and glaucoma achieved uniformly discouraging results.",1079693_15,-1,-1,-1,761,-1,0.0016174583,0.99838257
763,Intracranial aneurysms,0,2,0,22,Intracranial aneurysms and cocaine abuse: analysis of prognostic indicators.,10807237_0,-1,-1,-1,763,-1,0.0021068759,0.99789315
765,subarachnoid hemorrhage,5,7,26,49,OBJECTIVE: The outcome of subarachnoid hemorrhage associated with cocaine abuse is reportedly poor.,10807237_1,-1,-1,-1,765,-1,0.0015497517,0.9984503
768,ruptured aneurysms,12,14,66,84,This group was compared with a control group of 135 patients with ruptured aneurysms and no history of cocaine abuse.,10807237_4,-1,-1,-1,768,-1,0.0023822994,0.99761766
770,subarachnoid hemorrhage,15,17,78,101,"Age at presentation, time of ictus after intoxication, Hunt and Hess grade of subarachnoid hemorrhage, size of the aneurysm, location of the aneurysm, and the Glasgow Outcome Scale score were assessed and compared.",10807237_5,-1,-1,-1,770,-1,0.0017895569,0.99821043
773,P,19,20,108,109,RESULTS: The patients in the study group were significantly younger than the patients in the control group (P < 0.002).,10807237_6,-1,-1,-1,773,-1,0.34392077,0.65607923
776,mm,18,19,89,91,The majority of these aneurysms were smaller than those of the control group (8 +/- 6.08 mm versus 11 +/- 5.4 mm; P = 0.05).,10807237_8,-1,-1,-1,776,-1,0.010835904,0.9891641
777,mm,24,25,110,112,The majority of these aneurysms were smaller than those of the control group (8 +/- 6.08 mm versus 11 +/- 5.4 mm; P = 0.05).,10807237_8,-1,-1,-1,777,-1,0.010239716,0.9897602
778,P,26,27,114,115,The majority of these aneurysms were smaller than those of the control group (8 +/- 6.08 mm versus 11 +/- 5.4 mm; P = 0.05).,10807237_8,-1,-1,-1,778,-1,0.33945152,0.6605485
779,P,5,6,21,22,Hunt and Hess grade (P < 0.005) and age (P < 0.007) were significant predictors of outcome for the patients with cocaine-related aneurysms.,10807237_10,-1,-1,-1,779,-1,0.42419347,0.57580656
780,P,12,13,41,42,Hunt and Hess grade (P < 0.005) and age (P < 0.007) were significant predictors of outcome for the patients with cocaine-related aneurysms.,10807237_10,-1,-1,-1,780,-1,0.45566538,0.5443346
783,aneurysmal rupture,5,7,36,54,CONCLUSION: Cocaine use predisposed aneurysmal rupture at a significantly earlier age and in much smaller aneurysms.,10807237_11,-1,-1,-1,783,-1,0.0018769152,0.9981231
786,acute stroke,10,12,69,81,Effect of intravenous nimodipine on blood pressure and outcome after acute stroke.,10835440_0,-1,-1,-1,786,-1,0.0018247996,0.99817514
789,reduction in blood pressure,19,23,134,161,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,-1,-1,-1,789,-1,0.013422337,0.98657763
790,BP,24,25,163,165,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,-1,-1,-1,790,-1,0.013680318,0.9863196
791,acute stroke,31,33,197,209,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,-1,-1,-1,791,-1,0.0017355434,0.9982645
792,BP reduction,23,25,157,169,We sought to confirm this correlation with and without adjustment for prognostic variables and to investigate outcome in subgroups with increasing levels of BP reduction.,10835440_2,-1,-1,-1,792,-1,0.47709158,0.52290845
794,n=100,22,23,130,135,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,-1,-1,-1,794,-1,0.2448949,0.75510514
796,n=101,32,33,168,173,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,-1,-1,-1,796,-1,0.28688487,0.71311516
798,n=94,43,44,210,214,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,-1,-1,-1,798,-1,0.24815817,0.7518418
799,n=92,12,13,73,77,"RESULTS: Two hundred sixty-five patients were included in this analysis (n=92, 93, and 80 for placebo, low dose, and high dose, respectively).",10835440_5,-1,-1,-1,799,-1,0.09732474,0.9026753
801,reduction,7,8,61,70,Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.,10835440_6,-1,-1,-1,801,-1,0.016906232,0.98309374
802,systolic,9,10,74,82,Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.,10835440_6,-1,-1,-1,802,-1,0.026250858,0.9737491
803,diastolic BP,15,17,96,108,Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.,10835440_6,-1,-1,-1,803,-1,0.015045937,0.9849541
804,DBP reduction,8,10,60,73,"In multivariate analysis, a significant correlation between DBP reduction and worsening of the neurological score was found for the high-dose group (beta=0.49, P=0. 048).",10835440_7,-1,-1,-1,804,-1,0.27357757,0.7264224
805,P=0,25,26,160,163,"In multivariate analysis, a significant correlation between DBP reduction and worsening of the neurological score was found for the high-dose group (beta=0.49, P=0. 048).",10835440_7,-1,-1,-1,805,-1,0.29168454,0.70831543
808,neurological worsening,12,14,61,83,"CONCLUSIONS: DBP, but not SBP, reduction was associated with neurological worsening after the intravenous administration of high-dose nimodipine after acute stroke.",10835440_10,-1,-1,-1,808,-1,0.0010976116,0.9989023
810,acute stroke,22,24,151,163,"CONCLUSIONS: DBP, but not SBP, reduction was associated with neurological worsening after the intravenous administration of high-dose nimodipine after acute stroke.",10835440_10,-1,-1,-1,810,-1,0.0013547532,0.99864525
814,visceral pain,14,16,105,118,Cyclophosphamide-induced cystitis in freely-moving conscious rats: behavioral approach to a new model of visceral pain.,10840460_0,-1,-1,-1,814,-1,0.0013978819,0.9986021
815,visceral pain,7,9,31,44,PURPOSE: To develop a model of visceral pain in rats using a behavioral approach.,10840460_1,-1,-1,-1,815,-1,0.0017623738,0.9982376
817,CP,2,3,18,20,"Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.",10840460_2,-1,-1,-1,817,-1,0.99859816,0.0014019002
818,acrolein,22,23,129,137,"Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.",10840460_2,-1,-1,-1,818,-1,0.9990722,0.0009277968
820,CP,4,5,23,25,"MATERIALS AND METHODS: CP was administered at doses of 50, 100 and 200 mg./kg.",10840460_3,-1,-1,-1,820,-1,0.99830437,0.0016956701
823,CP,6,7,30,32,"In addition, 90 minutes after CP injection, that is, at the time of administration of morphine, the bladder was removed in some rats for histological examination.",10840460_8,-1,-1,-1,823,-1,0.99876404,0.0012360377
825,CP,19,20,118,120,"Finally, to show that the bladder is essential for the CP-induced behavioral modifications, female rats also received CP at doses of 200 mg./kg.",10840460_9,-1,-1,-1,825,-1,0.9988977,0.0011022618
826,mg,5,6,15,17,i.p. and of 20 mg.,10840460_10,-1,-1,-1,826,-1,0.9743561,0.025643898
827,acrolein,6,7,31,39,"by the intravesical route, and acrolein at doses of 0.5 mg.",10840460_11,-1,-1,-1,827,-1,0.9989058,0.001094226
828,mg,11,12,56,58,"by the intravesical route, and acrolein at doses of 0.5 mg.",10840460_11,-1,-1,-1,828,-1,0.9828856,0.017114418
829,CP,4,5,14,16,"i.v. RESULTS: CP dose-relatedly induced marked behavioral modifications in male rats: breathing rate decrease, closing of the eyes and occurrence of specific postures.",10840460_13,-1,-1,-1,829,-1,0.9983645,0.0016355306
831,behavioral disorders,4,6,41,61,Morphine dose-dependently reversed these behavioral disorders.,10840460_14,-1,-1,-1,831,-1,0.001684702,0.99831533
832,CP,19,20,92,94,A dose of 0.5 mg./kg. produced a reduction of almost 50% of the behavioral score induced by CP 200 mg./kg.,10840460_15,-1,-1,-1,832,-1,0.99871373,0.001286311
836,CP,4,5,16,18,"In female rats, CP 200 mg./kg.",10840460_18,-1,-1,-1,836,-1,0.99863064,0.0013694416
837,mg,6,7,31,33,Administered at the dose of 20 mg.,10840460_20,-1,-1,-1,837,-1,0.96062577,0.039374243
838,CP,2,3,16,18,"intravesically, CP did not produce any behavioral effects, whereas acrolein at 0.5 mg.",10840460_21,-1,-1,-1,838,-1,0.99856097,0.0014390306
839,acrolein,11,12,67,75,"intravesically, CP did not produce any behavioral effects, whereas acrolein at 0.5 mg.",10840460_21,-1,-1,-1,839,-1,0.9991295,0.0008705396
840,mg,14,15,83,85,"intravesically, CP did not produce any behavioral effects, whereas acrolein at 0.5 mg.",10840460_21,-1,-1,-1,840,-1,0.9860249,0.013975028
841,CP,8,9,73,75,intravesically induced behavioral modifications identical to those under CP 200 mg./kg.,10840460_22,-1,-1,-1,841,-1,0.99880135,0.0011986467
842,acrolein,2,3,12,20,"Conversely, acrolein 5 mg./kg.",10840460_24,-1,-1,-1,842,-1,0.9989993,0.0010006746
844,visceral pain,23,25,156,169,"CONCLUSIONS: Overall, these results indicate that this experimental model of CP-induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them.",10840460_26,-1,-1,-1,844,-1,0.0015134211,0.9984865
845,painful syndromes,32,34,212,229,"CONCLUSIONS: Overall, these results indicate that this experimental model of CP-induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them.",10840460_26,-1,-1,-1,845,-1,0.0016279566,0.998372
851,clonic fits,21,23,129,140,A 17-day-old infant on isoniazid therapy 13 mg/kg daily from birth because of maternal tuberculosis was admitted after 4 days of clonic fits.,1085609_1,-1,-1,-1,851,-1,0.0014937388,0.99850625
852,fits,1,2,4,8,"The fits ceased within 4 hours of administering intramuscular pyridoxine, suggesting an aetiology of pyridoxine deficiency secondary to isoniazid medication.",1085609_3,-1,-1,-1,852,-1,0.0014576578,0.9985423
858,emergency department,11,13,67,87,Ketamine sedation for the reduction of children's fractures in the emergency department.,10901305_0,-1,-1,-1,858,-1,0.0066207154,0.99337924
862,emergency department,26,28,145,165,The purpose of the present study was to examine the safety and efficacy of ketamine for sedation in the treatment of children's fractures in the emergency department.,10901305_2,-1,-1,-1,862,-1,0.010606112,0.9893939
863,fracture,32,33,164,172,"METHODS: One hundred and fourteen children (average age, 5.3 years; range, twelve months to ten years and ten months) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level-I trauma center were prospectively evaluated.",10901305_3,-1,-1,-1,863,-1,0.002733958,0.99726605
864,dislocation,34,35,176,187,"METHODS: One hundred and fourteen children (average age, 5.3 years; range, twelve months to ten years and ten months) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level-I trauma center were prospectively evaluated.",10901305_3,-1,-1,-1,864,-1,0.0022234335,0.99777657
865,emergency department,37,39,195,215,"METHODS: One hundred and fourteen children (average age, 5.3 years; range, twelve months to ten years and ten months) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level-I trauma center were prospectively evaluated.",10901305_3,-1,-1,-1,865,-1,0.011415056,0.98858494
866,trauma,42,43,229,235,"METHODS: One hundred and fourteen children (average age, 5.3 years; range, twelve months to ten years and ten months) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level-I trauma center were prospectively evaluated.",10901305_3,-1,-1,-1,866,-1,0.007913975,0.992086
867,Ketamine hydrochloride,0,2,0,22,Ketamine hydrochloride was administered intravenously (at a dose of two milligrams per kilogram of body weight) in ninety-nine of the patients and intramuscularly (at a dose of four milligrams per kilogram of body weight) in the other fifteen.,10901305_4,-1,-1,-1,867,-1,0.9989895,0.0010104188
868,body weight,15,17,99,110,Ketamine hydrochloride was administered intravenously (at a dose of two milligrams per kilogram of body weight) in ninety-nine of the patients and intramuscularly (at a dose of four milligrams per kilogram of body weight) in the other fifteen.,10901305_4,-1,-1,-1,868,-1,0.17656738,0.8234326
869,body weight,35,37,209,220,Ketamine hydrochloride was administered intravenously (at a dose of two milligrams per kilogram of body weight) in ninety-nine of the patients and intramuscularly (at a dose of four milligrams per kilogram of body weight) in the other fifteen.,10901305_4,-1,-1,-1,869,-1,0.18036324,0.8196368
873,fracture,14,15,93,101,"RESULTS: The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes).",10901305_7,-1,-1,-1,873,-1,0.0021282611,0.99787176
874,dislocation,16,17,105,116,"RESULTS: The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes).",10901305_7,-1,-1,-1,874,-1,0.0019679712,0.99803203
877,fracture,32,33,162,170,"The average score according to the Children's Hospital of Eastern Ontario Pain Scale was 6.4 points (range, 5 to 10 points), reflecting minimal or no pain during fracture reduction.",10901305_8,-1,-1,-1,877,-1,0.0041607344,0.99583924
878,fracture,1,2,9,17,Adequate fracture reduction was obtained in 111 of the children.,10901305_9,-1,-1,-1,878,-1,0.0047629443,0.995237
880,emesis,10,11,56,62,"Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient).",10901305_13,-1,-1,-1,880,-1,0.0012971035,0.9987029
882,clumsiness,21,22,109,119,"Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient).",10901305_13,-1,-1,-1,882,-1,0.0012971906,0.99870276
883,ataxic movements,25,27,132,148,"Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient).",10901305_13,-1,-1,-1,883,-1,0.0015426324,0.9984573
884,dysphoric reaction,33,35,171,189,"Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient).",10901305_13,-1,-1,-1,884,-1,0.0012662786,0.9987337
886,nightmares,12,13,72,82,"No long-term sequelae were noted, and no patients had hallucinations or nightmares.",10901305_14,-1,-1,-1,886,-1,0.0015559138,0.99844414
889,emergency department,23,25,150,170,"CONCLUSIONS: Ketamine reliably, safely, and quickly provided adequate sedation to effectively facilitate the reduction of children's fractures in the emergency department at our institution.",10901305_15,-1,-1,-1,889,-1,0.0056471596,0.9943528
891,emergency department,11,13,59,79,"Ketamine should only be used in an environment such as the emergency department, where proper one-on-one monitoring is used and board-certified physicians skilled in airway management are directly involved in the care of the patient.",10901305_16,-1,-1,-1,891,-1,0.0112888515,0.9887111
892,muscle dysfunction,1,3,21,39,Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression.,10910842_0,-1,-1,-1,892,-1,0.0022124453,0.9977876
895,glucocorticoids,3,4,15,30,Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood.,10910842_1,-1,-1,-1,895,-1,0.9989114,0.0010886671
900,twitch,7,8,32,38,"On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs.",10910842_5,-1,-1,-1,900,-1,0.0028044693,0.9971955
901,tetanic,10,11,49,56,"On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs.",10910842_5,-1,-1,-1,901,-1,0.0034796125,0.9965204
902,body weight gain,2,5,8,24,"Rate of body weight gain was depressed in the P100, FR, and P10 groups compared with the S group.",10910842_6,-1,-1,-1,902,-1,0.013931578,0.98606837
904,twitch,3,4,16,22,"The evoked peak twitch and tetanic tensions were less in the P100 group than in the P10 or S groups, however, tension per milligram of muscle mass was greater in the P100 group than in the S group.",10910842_8,-1,-1,-1,904,-1,0.0043859812,0.99561405
905,tetanic,5,6,27,34,"The evoked peak twitch and tetanic tensions were less in the P100 group than in the P10 or S groups, however, tension per milligram of muscle mass was greater in the P100 group than in the S group.",10910842_8,-1,-1,-1,905,-1,0.006293593,0.9937064
906,P,13,14,62,63,"The evoked tensions correlated with muscle mass (r(2) = 0.32, P < 0.001), however, not with expression of AChR. The 50% effective dose of d-tubocurarine did not correlate with muscle mass or AChR expression.",10910842_11,-1,-1,-1,906,-1,0.4626396,0.5373604
907,neuromuscular dysfunction,5,7,29,54,"Our results suggest that the neuromuscular dysfunction after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.",10910842_12,-1,-1,-1,907,-1,0.0015123535,0.9984876
909,muscle atrophy,16,18,120,134,"Our results suggest that the neuromuscular dysfunction after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.",10910842_12,-1,-1,-1,909,-1,0.0021847384,0.99781525
910,muscle atrophy,12,14,82,96,We suggest that the observed effects are dose-dependent and derive primarily from muscle atrophy and derive less from changes in acetylcholine receptor expression.,10910842_14,-1,-1,-1,910,-1,0.0023830647,0.997617
915,TMA,6,7,47,50,The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.,11007689_1,-1,-1,-1,915,-1,0.0013175815,0.99868244
918,immunoglobulin G,23,25,169,185,"Treatments have included discontinuation or reduction of cyclosporine dose with or without concurrent plasma exchange, plasma infusion, anticoagulation, and intravenous immunoglobulin G infusion.",11007689_2,-1,-1,-1,918,-1,0.99877685,0.0012231558
922,TMA,21,22,128,131,"As a result, switching to tacrolimus has been reported to be a viable therapeutic option in the setting of cyclosporine-induced TMA.",11007689_5,-1,-1,-1,922,-1,0.0017694918,0.9982305
924,TMA,12,13,99,102,"With the more widespread application of tacrolimus in organ transplantation, tacrolimus-associated TMA has also been recognized.",11007689_6,-1,-1,-1,924,-1,0.0019145246,0.9980855
925,TMA,10,11,65,68,"However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited.",11007689_7,-1,-1,-1,925,-1,0.0017021511,0.99829787
928,TMA,14,15,97,100,We report a case of a living donor renal transplant recipient who developed cyclosporine-induced TMA that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy.,11007689_8,-1,-1,-1,928,-1,0.0017228876,0.99827707
931,TMA,13,14,99,102,Introduction of tacrolimus as an alternative immunosuppressive agent resulted in the recurrence of TMA and the subsequent loss of the renal allograft.,11007689_9,-1,-1,-1,931,-1,0.0020275232,0.9979724
934,signs and symptoms,17,20,108,126,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,-1,-1,-1,934,-1,0.002210264,0.99778974
935,TMA,22,23,140,143,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,-1,-1,-1,935,-1,0.0018005815,0.99819934
937,Parkinson's disease,6,9,42,61,Apomorphine: an underutilized therapy for Parkinson's disease.,11009181_0,-1,-1,-1,937,-1,0.002228291,0.9977717
939,Parkinson's disease,12,15,75,94,Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease.,11009181_1,-1,-1,-1,939,-1,0.0019846926,0.9980153
940,Parkinson's disease,17,20,114,133,"While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study.",11009181_2,-1,-1,-1,940,-1,0.0018773798,0.99812263
951,psychiatric complications,18,20,129,154,"The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role.",11009181_7,-1,-1,-1,951,-1,0.0014297143,0.9985703
953,Parkinson's disease,12,15,89,108,"Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use.",11009181_8,-1,-1,-1,953,-1,0.0020036364,0.9979964
954,Alzheimer's disease,31,34,189,208,"OBJECTIVE: The pharmacological response to drugs that act on the cholinergic system of the iris has been used to predict deficits in central cholinergic functioning due to diseases such as Alzheimer's disease, yet correlations between central and peripheral responses have not been properly studied.",11022397_1,-1,-1,-1,954,-1,0.0028095478,0.9971904
957,tropicamide,4,5,14,25,"In 1 session, tropicamide (20 microL, 0.01%) was administered to one eye and placebo to the other.",11022397_8,-1,-1,-1,957,-1,0.99925405,0.0007458907
958,tropicamide,4,5,20,31,"In another session, tropicamide (20 microL, 0.01%) was administered to both eyes, followed 23 minutes later by the application of pilocarpine (20 microL, 0.1%) to one eye and placebo to the other.",11022397_9,-1,-1,-1,958,-1,0.99932456,0.00067551516
961,mg,12,13,58,60,"In 2 separate sessions, a single dose of scopolamine (0.5 mg, intravenously) or placebo was administered, and the effects on word recall were measured using the Buschke Selective Reminding Test over 2 hours.",11022397_11,-1,-1,-1,961,-1,0.98881626,0.011183757
962,tropicamide,11,12,68,79,OUTCOME MEASURES: Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.,11022397_12,-1,-1,-1,962,-1,0.9993457,0.0006543018
964,impairment in word recall,16,20,117,142,OUTCOME MEASURES: Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.,11022397_12,-1,-1,-1,964,-1,0.009913548,0.9900864
965,tropicamide,16,17,107,118,RESULTS: There was no significant difference between elderly and young volunteers in pupillary response to tropicamide at any time point (p > 0.05).,11022397_13,-1,-1,-1,965,-1,0.9992924,0.0007075978
966,p,22,23,138,139,RESULTS: There was no significant difference between elderly and young volunteers in pupillary response to tropicamide at any time point (p > 0.05).,11022397_13,-1,-1,-1,966,-1,0.2510402,0.7489598
967,p,30,31,175,176,"The elderly group had a significantly greater pilocarpine-induced net decrease in pupil size 85, 125, 165 and 215 minutes after administration, compared with the young group (p < 0.05).",11022397_14,-1,-1,-1,967,-1,0.43254855,0.5674514
968,impairment in word recall,12,16,81,106,"Compared with the young group, the elderly group had greater scopolamine-induced impairment in word recall 60, 90 and 120 minutes after administration (p < 0.05).",11022397_15,-1,-1,-1,968,-1,0.009548597,0.99045134
969,p,25,26,152,153,"Compared with the young group, the elderly group had greater scopolamine-induced impairment in word recall 60, 90 and 120 minutes after administration (p < 0.05).",11022397_15,-1,-1,-1,969,-1,0.41489866,0.58510137
971,tropicamide,15,16,93,104,CONCLUSION: There is an age-related pupillary response to pilocarpine that is not found with tropicamide.,11022397_16,-1,-1,-1,971,-1,0.9993389,0.0006610101
977,opioid,15,16,89,95,This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).,11027904_2,-1,-1,-1,977,-1,0.9962936,0.0037064147
978,MM,21,22,141,143,This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).,11027904_2,-1,-1,-1,978,-1,0.99649566,0.0035043126
979,n,25,26,156,157,This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).,11027904_2,-1,-1,-1,979,-1,0.09403799,0.90596205
980,n,37,38,220,221,This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).,11027904_2,-1,-1,-1,980,-1,0.106133975,0.893866
981,CP,13,14,84,86,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,-1,981,-1,0.00329027,0.9967097
983,hydromorphone,32,33,188,201,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,-1,983,-1,0.99936885,0.0006311593
984,mg,34,35,204,206,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,-1,984,-1,0.99233127,0.0076687187
985,ketorolac,40,41,244,253,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,-1,985,-1,0.99935156,0.0006484391
986,mg,42,43,257,259,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,-1,986,-1,0.9871997,0.012800301
987,MM,3,4,20,22,"Results showed that MM individuals were significantly less tolerant of CP pain than control subjects, replicating previous work.",11027904_4,-1,-1,-1,987,-1,0.009451496,0.99054855
988,CP pain,10,12,71,78,"Results showed that MM individuals were significantly less tolerant of CP pain than control subjects, replicating previous work.",11027904_4,-1,-1,-1,988,-1,0.002717972,0.997282
995,NMDA,9,10,70,74,"Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_2,-1,-1,-1,995,-1,0.9988865,0.0011134949
997,analgesia,23,24,144,153,"Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_2,-1,-1,-1,997,-1,0.0030807971,0.9969193
1005,nausea and vomiting,10,13,45,64,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,-1,-1,1005,-1,0.0018852144,0.9981148
1006,drowsiness,14,15,66,76,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,-1,-1,1006,-1,0.0016817845,0.9983182
1013,mg,9,10,63,65,These episodes reversed after the administration of diazepam 1 mg intravenously.,11027905_8,-1,-1,-1,1013,-1,0.99556184,0.0044381195
1014,drowsiness,3,4,25,35,Significant increases in drowsiness were reported in patients treated with ketamine in both groups and were more marked with ketamine 0.50 mg/kg.,11027905_9,-1,-1,-1,1014,-1,0.0014920584,0.9985079
1019,morphine analgesia,3,5,21,39,"Ketamine can improve morphine analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_11,-1,-1,-1,1019,-1,0.6846406,0.3153594
1024,spinal cord injury,7,10,50,68,High-dose methylprednisolone may do more harm for spinal cord injury.,11058428_0,-1,-1,-1,1024,-1,0.001556333,0.99844366
1025,Spinal Cord Injury,5,8,30,48,"Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose methylprednisolone became the standard of care for the acute spinal cord injury.",11058428_1,-1,-1,-1,1025,-1,0.001897431,0.9981026
1027,spinal cord injury,23,26,138,156,"Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose methylprednisolone became the standard of care for the acute spinal cord injury.",11058428_1,-1,-1,-1,1027,-1,0.0017562197,0.9982438
1028,corticosteroid myopathy,13,15,71,94,"In the NASCIS, there was no mention regarding the possibility of acute corticosteroid myopathy that high-dose methylprednisolone may cause.",11058428_2,-1,-1,-1,1028,-1,0.07938888,0.9206111
1032,damage to the muscle,7,11,38,58,We hypothesize that it may cause some damage to the muscle of spinal cord injury patients.,11058428_4,-1,-1,-1,1032,-1,0.004375861,0.9956241
1033,spinal cord injury,12,15,62,80,We hypothesize that it may cause some damage to the muscle of spinal cord injury patients.,11058428_4,-1,-1,-1,1033,-1,0.0020246415,0.9979754
1034,steroid myopathy,2,4,9,25,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,-1,-1,-1,1034,-1,0.09153116,0.90846884
1035,steroid myopathy,26,28,162,178,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,-1,-1,-1,1035,-1,0.08156442,0.91843563
1037,spinal cord injury,38,41,244,262,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,-1,-1,-1,1037,-1,0.0021146527,0.9978853
1039,corticosteroid myopathy,21,23,141,164,"To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy.",11058428_6,-1,-1,-1,1039,-1,0.07848904,0.92151093
1041,RAPA,13,14,64,68,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,-1,-1,-1,1041,-1,0.99469584,0.0053041633
1043,CsA,20,21,117,120,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,-1,-1,-1,1043,-1,0.9988122,0.0011878059
1045,Tac,25,26,137,140,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,-1,-1,-1,1045,-1,0.9984736,0.0015263959
1048,RAPA,13,14,83,87,METHODS: Twenty renal transplant recipients were switched to fixed dose rapamycin (RAPA) (5 mg/day) 0 to 204 months posttransplant.,11063349_2,-1,-1,-1,1048,-1,0.9988017,0.0011982596
1049,CsA,6,7,40,43,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1049,-1,0.9984092,0.0015907594
1050,Tac nephrotoxicity,8,10,47,65,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1050,-1,0.04232975,0.9576702
1051,CsA,15,16,78,81,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1051,-1,0.9983278,0.0016721912
1052,Tac toxicity,17,19,85,97,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1052,-1,0.13230985,0.86769015
1053,facial dysmorphism,24,26,110,128,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1053,-1,0.0013663858,0.99863356
1054,posttransplant lymphoproliferative disorder,30,33,134,177,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1054,-1,0.0019116529,0.9980883
1055,PTLD,34,35,179,183,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1055,-1,0.0014382682,0.9985618
1059,P<0.05,25,26,162,168,RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].,11063349_6,-1,-1,-1,1059,-1,0.40636697,0.593633
1060,Facial dysmorphism,0,2,0,18,Facial dysmorphism improved in two patients.,11063349_7,-1,-1,-1,1060,-1,0.0016622015,0.99833775
1061,PTLD,3,4,14,18,No relapse of PTLD was observed.,11063349_8,-1,-1,-1,1061,-1,0.0017879743,0.9982121
1062,pneumonia,3,4,24,33,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1062,-1,0.0011398421,0.9988601
1063,Pneumocystis,6,7,39,51,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1063,-1,0.0026491636,0.9973508
1064,pneumonia,8,9,60,69,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1064,-1,0.0013345897,0.99866545
1065,infectious mononucleosis,11,13,75,99,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1065,-1,0.0013872042,0.99861276
1066,PTLD,15,16,116,120,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1066,-1,0.0015460087,0.998454
1067,bronchiolitis obliterans,22,24,150,174,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1067,-1,0.0016609392,0.99833906
1069,RAPA,0,1,0,4,"RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.",11063349_11,-1,-1,-1,1069,-1,0.7190199,0.28098014
1070,pneumonia,9,10,51,60,"RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.",11063349_11,-1,-1,-1,1070,-1,0.0012245838,0.9987754
1071,PTLD,13,14,69,73,"RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.",11063349_11,-1,-1,-1,1071,-1,0.0012923663,0.99870765
1072,aphtous ulcers,19,21,91,105,"RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.",11063349_11,-1,-1,-1,1072,-1,0.0013336189,0.9986664
1073,RAPA,0,1,0,4,RAPA levels were high (>15 ng/ml) in 7 of 13 (54%) patients.,11063349_12,-1,-1,-1,1073,-1,0.9947383,0.0052617183
1074,RAPA,2,3,13,17,CONCLUSIONS: RAPA conversion provides adequate immunosuppression to enable CsA withdrawal.,11063349_13,-1,-1,-1,1074,-1,0.70355743,0.29644254
1075,CsA,9,10,75,78,CONCLUSIONS: RAPA conversion provides adequate immunosuppression to enable CsA withdrawal.,11063349_13,-1,-1,-1,1075,-1,0.9985116,0.0014884243
1076,RAPA,6,7,37,41,"However, when converting patients to RAPA drug levels should be monitored to avoid over-immunosuppression and adequate antiviral and Pneumocystis carinii pneumonia prophylaxis should be given.",11063349_14,-1,-1,-1,1076,-1,0.9780385,0.021961484
1077,Pneumocystis,19,20,133,145,"However, when converting patients to RAPA drug levels should be monitored to avoid over-immunosuppression and adequate antiviral and Pneumocystis carinii pneumonia prophylaxis should be given.",11063349_14,-1,-1,-1,1077,-1,0.010390903,0.9896091
1078,pneumonia,21,22,154,163,"However, when converting patients to RAPA drug levels should be monitored to avoid over-immunosuppression and adequate antiviral and Pneumocystis carinii pneumonia prophylaxis should be given.",11063349_14,-1,-1,-1,1078,-1,0.0019585337,0.9980414
1079,visual field constriction,15,18,142,167,"Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction.",11077455_0,-1,-1,-1,1079,-1,0.0027993799,0.9972006
1080,visual field constriction,3,6,21,46,PURPOSE: Symptomatic visual field constriction thought to be associated with vigabatrin has been reported.,11077455_1,-1,-1,-1,1080,-1,0.0030834826,0.99691653
1082,visual field loss,16,19,129,146,"The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin-attributed visual field loss, three of whom were reported previously.",11077455_2,-1,-1,-1,1082,-1,0.0033915075,0.9966085
1084,visual field constriction,6,9,38,63,RESULTS: Seven patients showed marked visual field constriction with some sparing of the temporal visual field.,11077455_6,-1,-1,-1,1084,-1,0.0038862925,0.99611366
1085,visual field constriction,3,6,19,44,CONCLUSION: Marked visual field constriction appears to be associated with vigabatrin therapy.,11077455_11,-1,-1,-1,1085,-1,0.0032644472,0.9967355
1088,Myocardial ischemia,0,2,0,19,Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography.,11078231_0,-1,-1,-1,1088,-1,0.0015445711,0.9984554
1089,coronary artery spasm,4,7,27,48,Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography.,11078231_0,-1,-1,-1,1089,-1,0.0016706748,0.99832934
1092,myocardial ischemia,14,16,83,102,Dobutamine stress echocardiography (DSE) is a useful and safe provocation test for myocardial ischemia.,11078231_1,-1,-1,-1,1092,-1,0.001626779,0.99837315
1093,coronary artery,15,17,71,86,"Until now, the test has been focused only on the organic lesion in the coronary artery, and positive DSE has indicated the presence of significant fixed coronary artery stenosis.",11078231_2,-1,-1,-1,1093,-1,0.004032949,0.99596703
1094,coronary artery stenosis,28,31,153,177,"Until now, the test has been focused only on the organic lesion in the coronary artery, and positive DSE has indicated the presence of significant fixed coronary artery stenosis.",11078231_2,-1,-1,-1,1094,-1,0.0023602445,0.9976398
1095,myocardial ischemia,10,12,51,70,The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine.,11078231_3,-1,-1,-1,1095,-1,0.0015787971,0.9984212
1098,coronary spastic angina,7,10,37,60,We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis.,11078231_4,-1,-1,-1,1098,-1,0.001600114,0.9983999
1099,coronary artery stenosis,14,17,91,115,We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis.,11078231_4,-1,-1,-1,1099,-1,0.0018746512,0.9981254
1100,anginal attacks,3,5,17,32,All patients had anginal attacks at rest with ST elevation on the electrocardiogram (variant angina).,11078231_5,-1,-1,-1,1100,-1,0.0014443123,0.9985557
1104,coronary artery stenosis,13,16,85,109,"Coronary spasm was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients.",11078231_6,-1,-1,-1,1104,-1,0.0023430835,0.99765694
1106,chest pain,8,10,27,37,"All 7 patients (13.7%) had chest pain during asynergy, and both chest pain and electrocardiographic changes were preceded by asynergy.",11078231_9,-1,-1,-1,1106,-1,0.0016010818,0.99839896
1107,chest pain,15,17,64,74,"All 7 patients (13.7%) had chest pain during asynergy, and both chest pain and electrocardiographic changes were preceded by asynergy.",11078231_9,-1,-1,-1,1107,-1,0.0016776052,0.9983224
1110,coronary spastic angina,13,16,89,112,These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina.,11078231_10,-1,-1,-1,1110,-1,0.0015589196,0.99844104
1111,coronary artery disease,6,9,34,57,"When DSE is performed to evaluate coronary artery disease, not only fixed coronary stenosis, but also coronary spasm should be considered as a genesis of asynergy.",11078231_11,-1,-1,-1,1111,-1,0.002129059,0.9978709
1112,coronary stenosis,13,15,74,91,"When DSE is performed to evaluate coronary artery disease, not only fixed coronary stenosis, but also coronary spasm should be considered as a genesis of asynergy.",11078231_11,-1,-1,-1,1112,-1,0.0019700017,0.99803
1116,myocardial ischemia,11,13,95,114,Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine-induced myocardial ischemia.,11079278_0,-1,-1,-1,1116,-1,0.0014630452,0.99853694
1119,technetium-99m sestamibi,14,17,89,113,"STUDY OBJECTIVE: To determine the effect of metoprolol on dobutamine stress testing with technetium-99m sestamibi single-photon emission computed tomography imaging and ST-segment monitoring, and to assess the impact of intravenous glucagon on metoprolol's effects.",11079278_1,-1,-1,-1,1119,-1,0.9990846,0.00091538264
1125,mg,29,30,176,178,"Before dobutamine was begun, no therapy was given during the first visit, and patients were randomized on subsequent visits to receive metoprolol or metoprolol plus glucagon 1 mg.",11079278_6,-1,-1,-1,1125,-1,0.99601483,0.003985155
1127,predobutamine,7,8,42,55,Metoprolol was dosed to achieve a resting predobutamine heart rate below 65 beats/minute or a total intravenous dose of 20 mg.,11079278_7,-1,-1,-1,1127,-1,0.99919885,0.0008011448
1128,mg,20,21,123,125,Metoprolol was dosed to achieve a resting predobutamine heart rate below 65 beats/minute or a total intravenous dose of 20 mg.,11079278_7,-1,-1,-1,1128,-1,0.99474794,0.005252001
1134,myocardial ischemia,13,15,94,113,"CONCLUSION: During dobutamine stress testing, metoprolol attenuates or eliminates evidence of myocardial ischemia.",11079278_12,-1,-1,-1,1134,-1,0.0016125299,0.99838746
1135,mg,2,3,11,13,"Glucagon 1 mg, although somewhat effective, does not correct this effect to the extent that it can be administered clinically.",11079278_13,-1,-1,-1,1135,-1,0.9955004,0.0044995933
1138,LID,36,37,216,219,The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and levodopa-induced dyskinesias (LID).,11099450_1,-1,-1,-1,1138,-1,0.0017079682,0.998292
1141,LID,52,53,360,363,"We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the levodopa responsiveness of scores in timed tests (Core Assessment Program for Intracerebral Transplantations) in the contralateral limbs and the improvement in these scores after surgery, whereas there was no correlation with the improvement in LID.",11099450_2,-1,-1,-1,1141,-1,0.0023342317,0.99766576
1142,P,8,9,48,49,"We also found a highly significant correlation (P: < 0.0001, r = 0.8) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs, whereas there was no correlation between the ventral volume and the improvement in parkinsonian 'off' signs.",11099450_3,-1,-1,-1,1142,-1,0.3251796,0.6748204
1143,LID,31,32,145,148,"We also found a highly significant correlation (P: < 0.0001, r = 0.8) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs, whereas there was no correlation between the ventral volume and the improvement in parkinsonian 'off' signs.",11099450_3,-1,-1,-1,1143,-1,0.0023315551,0.99766845
1149,LID,17,18,109,112,The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.,11099450_5,-1,-1,-1,1149,-1,0.001561863,0.9984382
1155,LID,26,27,137,140,"Whereas cells in a wider area of the GPi may be implicated in parkinsonism, the ventral GPi seems to be crucial for the manifestation of LID.",11099450_6,-1,-1,-1,1155,-1,0.0016496086,0.9983504
1161,nonsmall cell lung carcinoma,15,19,126,154,"Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.",11135224_0,-1,-1,-1,1161,-1,0.0031768929,0.9968231
1162,nonsmall cell lung carcinoma,13,17,103,131,BACKGROUND: Cisplatin-based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma (NSCLC).,11135224_1,-1,-1,-1,1162,-1,0.0033326752,0.9966673
1163,NSCLC,18,19,133,138,BACKGROUND: Cisplatin-based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma (NSCLC).,11135224_1,-1,-1,-1,1163,-1,0.0022026445,0.99779737
1168,NSCLC,30,31,175,180,"METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.",11135224_3,-1,-1,-1,1168,-1,0.0018801983,0.9981198
1169,NSCLC,7,8,66,71,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,-1,-1,-1,1169,-1,0.0019840715,0.9980159
1173,disease progression,17,19,149,168,"Although responding patients were scheduled to receive consolidation radiotherapy and 24 patients received preplanned second-line chemotherapy after disease progression, the response and toxicity rates reported refer only to the chemotherapy regimen given.",11135224_5,-1,-1,-1,1173,-1,0.0021965182,0.9978035
1186,NSCLC,20,21,127,132,"CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.",11135224_14,-1,-1,-1,1186,-1,0.0019053802,0.9980946
1187,Serotonergic antidepressants,0,2,0,28,Serotonergic antidepressants and urinary incontinence.,11147747_0,-1,-1,-1,1187,-1,0.9967855,0.0032145097
1188,urinary incontinence,3,5,33,53,Serotonergic antidepressants and urinary incontinence.,11147747_0,-1,-1,-1,1188,-1,0.0017243449,0.99827564
1189,serotonergic antidepressants,2,4,9,37,Many new serotonergic antidepressants have been introduced over the past decade.,11147747_1,-1,-1,-1,1189,-1,0.9959544,0.004045571
1190,urinary incontinence,1,3,9,29,Although urinary incontinence is listed as one side effect of these drugs in their package inserts there is only one report in the literature.,11147747_2,-1,-1,-1,1190,-1,0.0016200738,0.99837995
1195,reuptake,18,19,124,132,"In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.",11147747_4,-1,-1,-1,1195,-1,0.9983309,0.0016690848
1199,lithium carbonate,11,13,50,67,"In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.",11147747_5,-1,-1,-1,1199,-1,0.99898714,0.0010128678
1202,serotonergic antidepressants,7,9,54,82,Animal studies suggest that incontinence secondary to serotonergic antidepressants could be mediated by the 5HT4 receptors found on the bladder.,11147747_6,-1,-1,-1,1202,-1,0.99883777,0.0011622094
1212,emergency department seizure,6,9,37,65,Screening for stimulant use in adult emergency department seizure patients.,11185967_0,-1,-1,-1,1212,-1,0.0027801767,0.9972198
1215,emergency department seizure,23,26,141,169,OBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients.,11185967_1,-1,-1,-1,1215,-1,0.0030983887,0.99690163
1222,seizure disorder,9,11,68,84,"Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.",11185967_5,-1,-1,-1,1222,-1,0.0012039687,0.998796
1229,amphetamine abuse,19,21,110,127,Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005).,11185967_7,-1,-1,-1,1229,-1,0.88236165,0.11763836
1230,p,22,23,129,130,Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005).,11185967_7,-1,-1,-1,1230,-1,0.35422486,0.64577514
1232,amphetamines,13,14,80,92,"CONCLUSIONS: During this study period, routine plasma screening for cocaine and amphetamines in adult seizure patients had a low yield.",11185967_8,-1,-1,-1,1232,-1,0.99888986,0.0011100993
1235,sodium valproate,2,4,16,32,Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone.,11195262_0,-1,-1,-1,1235,-1,0.99915326,0.0008466996
1236,syndrome of inappropriate secretion of antidiuretic hormone,6,13,40,99,Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone.,11195262_0,-1,-1,-1,1236,-1,0.53175694,0.46824306
1237,sodium valproate,11,13,61,77,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,-1,-1,-1,1237,-1,0.9992906,0.0007093363
1238,VPA,14,15,79,82,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,-1,-1,-1,1238,-1,0.9989674,0.0010325916
1239,syndrome of inappropriate secretion of antidiuretic hormone,21,28,119,178,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,-1,-1,-1,1239,-1,0.52550983,0.4744902
1240,SIADH,29,30,180,185,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,-1,-1,-1,1240,-1,0.0019990487,0.9980009
1241,VPA,4,5,19,22,He had been taking VPA for treatment of idiopathic generalized tonic-clonic convulsions since he was 56 years old.,11195262_2,-1,-1,-1,1241,-1,0.9989335,0.001066452
1243,VPA,2,3,19,22,"After substituting VPA with zonisamide, the serum sodium level returned to normal.",11195262_3,-1,-1,-1,1243,-1,0.9991702,0.0008298425
1246,SIADH,5,6,28,33,We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA.,11195262_4,-1,-1,-1,1246,-1,0.0017181416,0.99828184
1247,weakness of the central nervous system,17,23,91,129,We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA.,11195262_4,-1,-1,-1,1247,-1,0.0030807692,0.9969193
1248,VPA,28,29,166,169,We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA.,11195262_4,-1,-1,-1,1248,-1,0.9990792,0.00092079915
1250,tizanidine,5,6,40,50,Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.,11198499_0,-1,-1,-1,1250,-1,0.99922085,0.0007790972
1252,adrenergic agonists,3,5,25,44,Centrally acting alpha-2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system.,11198499_1,-1,-1,-1,1252,-1,0.99764806,0.0023518975
1253,spasticity,16,17,110,120,Centrally acting alpha-2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system.,11198499_1,-1,-1,-1,1253,-1,0.0011767582,0.9988232
1254,disorders of the central nervous system,19,25,132,171,Centrally acting alpha-2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system.,11198499_1,-1,-1,-1,1254,-1,0.0028255738,0.9971744
1255,spasticity,6,7,32,42,"In addition to their effects on spasticity, certain adverse cardiorespiratory effects have been reported.",11198499_2,-1,-1,-1,1255,-1,0.0013270557,0.99867296
1256,angiotensin converting enzyme inhibitors,4,8,32,72,Adults chronically treated with angiotensin converting enzyme inhibitors may have a limited ability to respond to hypotension when the sympathetic response is simultaneously blocked.,11198499_3,-1,-1,-1,1256,-1,0.9985771,0.0014228387
1258,lisinopril,9,10,63,73,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,-1,-1,-1,1258,-1,0.99929035,0.0007095852
1261,tizanidine,27,28,195,205,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,-1,-1,-1,1261,-1,0.9993063,0.0006936824
1262,spasticity,37,38,248,258,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,-1,-1,-1,1262,-1,0.0011058337,0.99889416
1263,tizanidine,4,5,28,38,The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients.,11198499_5,-1,-1,-1,1263,-1,0.9992186,0.00078142615
1264,antihypertensive agents,7,9,49,72,The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients.,11198499_5,-1,-1,-1,1264,-1,0.99678314,0.0032168096
1266,spasticity,22,23,153,163,The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients.,11198499_5,-1,-1,-1,1266,-1,0.0012081768,0.9987919
1273,pentylenetetrazol,24,25,140,157,"Results presented here show that the differential sensitivities of BS and BR lines to beta-CCM can be extended to diazepam, picrotoxin, and pentylenetetrazol, suggesting a genetic selection of a general sensitivity and resistance to several ligands of the GABA(A) receptor.",11206082_5,-1,-1,-1,1273,-1,0.9993462,0.0006537682
1274,nitric oxide,2,4,15,27,Association of nitric oxide production and apoptosis in a model of experimental nephropathy.,11208990_0,-1,-1,-1,1274,-1,0.99792826,0.0020717229
1276,nitric oxide,8,10,51,63,BACKGROUND: In recent studies increased amounts of nitric oxide (NO) and apoptosis have been implicated in various pathological conditions in the kidney.,11208990_1,-1,-1,-1,1276,-1,0.9980167,0.0019833103
1277,nephrotic syndrome,17,19,94,112,We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin (ADR).,11208990_2,-1,-1,-1,1277,-1,0.0011372562,0.99886274
1279,ADR,27,28,158,161,We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin (ADR).,11208990_2,-1,-1,-1,1279,-1,0.99826425,0.0017357871
1280,nitrite,12,13,68,75,METHODS: The alteration in the NO pathway was assessed by measuring nitrite levels in serum/urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney (IPRK) system.,11208990_3,-1,-1,-1,1280,-1,0.9982651,0.0017349785
1282,aminoguanidine,21,22,107,121,"These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving aminoguanidine (AG) which is a specific inhibitor of inducible-NO synthase.",11208990_5,-1,-1,-1,1282,-1,0.9991756,0.00082433166
1283,AG,23,24,123,125,"These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving aminoguanidine (AG) which is a specific inhibitor of inducible-NO synthase.",11208990_5,-1,-1,-1,1283,-1,0.9983719,0.0016281139
1284,ADR,11,12,75,78,RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation.,11208990_7,-1,-1,-1,1284,-1,0.9948426,0.0051574307
1285,mesangial proliferation,16,18,103,126,RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation.,11208990_7,-1,-1,-1,1285,-1,0.0020724456,0.99792755
1286,tubulointerstitial inflammation,20,22,136,167,RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation.,11208990_7,-1,-1,-1,1286,-1,0.0022213145,0.9977787
1288,P,15,16,101,102,They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05).,11208990_8,-1,-1,-1,1288,-1,0.43368194,0.5663181
1289,nitrite,1,2,6,13,Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05).,11208990_9,-1,-1,-1,1289,-1,0.99774206,0.002257916
1290,P,11,12,80,81,Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05).,11208990_9,-1,-1,-1,1290,-1,0.49229115,0.50770885
1293,AG,2,3,15,17,Treatment with AG prevented the impairment of renal vascular bed responses and reduced both urine nitrite levels and apoptosis to control levels.,11208990_14,-1,-1,-1,1293,-1,0.99845743,0.0015425237
1294,nitrite,15,16,98,105,Treatment with AG prevented the impairment of renal vascular bed responses and reduced both urine nitrite levels and apoptosis to control levels.,11208990_14,-1,-1,-1,1294,-1,0.9983918,0.0016081741
1296,melatonin,3,4,16,25,Dual effects of melatonin on barbiturate-induced narcosis in rats.,11226639_0,-1,-1,-1,1296,-1,0.999084,0.0009160187
1297,narcosis,6,7,49,57,Dual effects of melatonin on barbiturate-induced narcosis in rats.,11226639_0,-1,-1,-1,1297,-1,0.0023228463,0.99767715
1298,Melatonin,0,1,0,9,"Melatonin affects the circadian sleep/wake cycle, but it is not clear whether it may influence drug-induced narcosis.",11226639_1,-1,-1,-1,1298,-1,0.99899787,0.0010021306
1299,narcosis,17,18,108,116,"Melatonin affects the circadian sleep/wake cycle, but it is not clear whether it may influence drug-induced narcosis.",11226639_1,-1,-1,-1,1299,-1,0.010403326,0.98959666
1300,Sodium thiopenthal,0,2,0,18,"Sodium thiopenthal was administered intraperitoneally into male rats pre-treated with melatonin (0.05, 0.5, 5 and 50 mg/kg).",11226639_2,-1,-1,-1,1300,-1,0.9992111,0.00078886066
1301,melatonin,10,11,86,95,"Sodium thiopenthal was administered intraperitoneally into male rats pre-treated with melatonin (0.05, 0.5, 5 and 50 mg/kg).",11226639_2,-1,-1,-1,1301,-1,0.99917173,0.00082828826
1302,Melatonin,0,1,0,9,"Melatonin pre-treatment affected in a dual manner barbiturate narcosis, however, no dose-effect correlation was found.",11226639_3,-1,-1,-1,1302,-1,0.99913824,0.00086174556
1303,barbiturate narcosis,7,9,50,70,"Melatonin pre-treatment affected in a dual manner barbiturate narcosis, however, no dose-effect correlation was found.",11226639_3,-1,-1,-1,1303,-1,0.60962355,0.39037648
1304,barbiturate narcosis,14,16,78,98,"In particular, low doses reduced the latency to and prolonged the duration of barbiturate narcosis.",11226639_4,-1,-1,-1,1304,-1,0.6085064,0.39149362
1305,contrast,1,2,3,11,"In contrast, the highest dose of melatonin (50 mg/kg) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis, and a reduction in mortality rate.",11226639_5,-1,-1,-1,1305,-1,0.6848379,0.31516215
1306,melatonin,7,8,33,42,"In contrast, the highest dose of melatonin (50 mg/kg) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis, and a reduction in mortality rate.",11226639_5,-1,-1,-1,1306,-1,0.999062,0.000938016
1307,narcosis,28,29,153,161,"In contrast, the highest dose of melatonin (50 mg/kg) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis, and a reduction in mortality rate.",11226639_5,-1,-1,-1,1307,-1,0.0023336522,0.99766636
1308,Melatonin,0,1,0,9,Melatonin 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-induced narcosis.,11226639_6,-1,-1,-1,1308,-1,0.9992217,0.0007783412
1309,narcosis,16,17,103,111,Melatonin 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-induced narcosis.,11226639_6,-1,-1,-1,1309,-1,0.021328878,0.97867113
1310,melatonin,6,7,25,34,"Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action.",11226639_7,-1,-1,-1,1310,-1,0.9991592,0.0008407427
1311,narcosis,9,10,54,62,"Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action.",11226639_7,-1,-1,-1,1311,-1,0.061609585,0.93839043
1312,barbiturate,16,17,92,103,"Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action.",11226639_7,-1,-1,-1,1312,-1,0.9992136,0.0007863494
1319,Myocet,5,6,30,36,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,-1,-1,-1,1319,-1,0.97960174,0.02039827
1322,doxorubicin cardiotoxicity,27,29,187,213,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,-1,-1,-1,1322,-1,0.06627486,0.9337251
1324,MBC,42,43,313,316,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,-1,-1,-1,1324,-1,0.0025757186,0.99742436
1325,MBC,9,10,61,64,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,-1,-1,-1,1325,-1,0.0015442953,0.99845564
1326,Myocet,26,27,162,168,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,-1,-1,-1,1326,-1,0.0016038221,0.9983962
1329,disease progression,53,55,283,302,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,-1,-1,-1,1329,-1,0.0013704095,0.99862957
1332,congestive heart failure,19,22,145,169,"Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).",11230490_3,-1,-1,-1,1332,-1,0.0012956167,0.9987043
1333,CHF,23,24,171,174,"Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).",11230490_3,-1,-1,-1,1333,-1,0.001385451,0.99861455
1335,CHF,15,16,72,75,RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).,11230490_5,-1,-1,-1,1335,-1,0.0012958605,0.9987041
1337,P,23,24,118,119,RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).,11230490_5,-1,-1,-1,1337,-1,0.15571286,0.8442871
1339,P,21,22,106,107,"Median cumulative doxorubicin dose at onset was more than 2,220 mg/m(2) for MC versus 480 mg/m(2) for AC (P =.0001, hazard ratio, 5.04).",11230490_6,-1,-1,-1,1339,-1,0.2633163,0.7366837
1341,Myocet,2,3,12,18,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,-1,-1,-1,1341,-1,0.45137566,0.54862434
1346,MBC,33,34,247,250,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,-1,-1,-1,1346,-1,0.002204451,0.9977956
1348,nitric oxide,9,11,58,70,"The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions.",11243580_1,-1,-1,-1,1348,-1,0.9977748,0.0022251646
1356,contrast,1,2,3,11,"In contrast, the L-arginine treatment increased the incidence of lidocaine (80 mg/kg, i.p.)-induced convulsions significantly.",11243580_6,-1,-1,-1,1356,-1,0.3436734,0.6563266
1360,cyclophosphamide cytotoxicity,6,8,56,85,Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors.,11245434_0,-1,-1,-1,1360,-1,0.6518297,0.34817022
1363,cytotoxicity,23,24,131,143,The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin (rHuEPO) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors.,11245434_1,-1,-1,-1,1363,-1,0.0017032122,0.9982968
1374,se,10,11,74,76,Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se.,11245434_6,-1,-1,-1,1374,-1,0.06149162,0.93850845
1381,cytotoxicity,7,8,63,75,"These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.",11245434_10,-1,-1,-1,1381,-1,0.0015202306,0.9984798
1396,Graves' disease,6,9,34,49,"RESULTS: A 25-year-old woman with Graves' disease had a febrile illness and evidence of pericarditis, which was confirmed by biopsy.",11250767_4,-1,-1,-1,1396,-1,0.0030153266,0.99698466
1397,febrile illness,11,13,56,71,"RESULTS: A 25-year-old woman with Graves' disease had a febrile illness and evidence of pericarditis, which was confirmed by biopsy.",11250767_4,-1,-1,-1,1397,-1,0.0012047704,0.99879515
1409,solitary kidney,11,13,80,95,Repeated transient anuria following losartan administration in a patient with a solitary kidney.,11256525_0,-1,-1,-1,1409,-1,0.0028751146,0.99712485
1411,solitary kidney,11,13,60,75,We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.,11256525_1,-1,-1,-1,1411,-1,0.0023149257,0.9976851
1412,chronic renal insufficiency,14,17,80,107,We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.,11256525_1,-1,-1,-1,1412,-1,0.0014778248,0.9985222
1415,myocardial infarction,5,7,26,47,"He was hospitalized for a myocardial infarction with pulmonary edema, treated with high-dose diuretics.",11256525_2,-1,-1,-1,1415,-1,0.0013053581,0.9986947
1416,pulmonary edema,8,10,53,68,"He was hospitalized for a myocardial infarction with pulmonary edema, treated with high-dose diuretics.",11256525_2,-1,-1,-1,1416,-1,0.0011790111,0.99882096
1417,systolic dysfunction losartan,3,6,14,43,Due to severe systolic dysfunction losartan was prescribed.,11256525_3,-1,-1,-1,1417,-1,0.65391225,0.34608775
1418,mg,7,8,35,37,"Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.",11256525_4,-1,-1,-1,1418,-1,0.9902047,0.009795311
1422,amine,24,25,137,142,"Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.",11256525_4,-1,-1,-1,1422,-1,0.9991548,0.00084514235
1424,mg,18,19,90,92,"One week later, by mistake, losartan was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient anuria lasting 10 hours.",11256525_5,-1,-1,-1,1424,-1,0.9946061,0.0053939144
1427,renal artery stenosis,10,13,45,66,"Ultimately, an arteriography showed a 70-80% renal artery stenosis.",11256525_7,-1,-1,-1,1427,-1,0.003713551,0.9962864
1428,renal artery stenosis,4,7,17,38,"In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS).",11256525_8,-1,-1,-1,1428,-1,0.0022629674,0.99773705
1429,heart failure,9,11,53,66,"In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS).",11256525_8,-1,-1,-1,1429,-1,0.0013923649,0.9986077
1430,diuretic,12,13,71,79,"In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS).",11256525_8,-1,-1,-1,1430,-1,0.9987594,0.0012406554
1434,renovascular disease,21,23,150,170,This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with renovascular disease and should be used with extreme caution in this setting.,11256525_10,-1,-1,-1,1434,-1,0.0013561796,0.9986438
1435,pain syndrome,2,4,30,43,Calcineurin-inhibitor induced pain syndrome (CIPS): a severe disabling complication after organ transplantation.,11263551_0,-1,-1,-1,1435,-1,0.0011561904,0.9988438
1436,CIPS,5,6,45,49,Calcineurin-inhibitor induced pain syndrome (CIPS): a severe disabling complication after organ transplantation.,11263551_0,-1,-1,-1,1436,-1,0.0014042633,0.9985958
1437,Bone pain,0,2,0,9,Bone pain after transplantation is a frequent complication that can be caused by several diseases.,11263551_1,-1,-1,-1,1437,-1,0.0020068637,0.9979931
1440,oedema,6,7,52,58,Magnetic resonance imaging demonstrated bone marrow oedema in the painful bones.,11263551_5,-1,-1,-1,1440,-1,0.0018764758,0.99812347
1441,painful,9,10,66,73,Magnetic resonance imaging demonstrated bone marrow oedema in the painful bones.,11263551_5,-1,-1,-1,1441,-1,0.0027728174,0.99722713
1443,foot pain,8,10,49,58,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1443,-1,0.0014507062,0.9985493
1444,reflex sympathetic dystrophy,12,15,65,93,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1444,-1,0.0014033662,0.9985966
1446,Morton's neuralgia,18,21,111,129,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1446,-1,0.0044837464,0.99551624
1447,gout,22,23,131,135,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1447,-1,0.0013259761,0.99867404
1449,avascular necrosis,26,28,151,169,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1449,-1,0.0013594034,0.9986406
1450,intermittent claudication,29,31,171,196,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1450,-1,0.0013851942,0.9986148
1451,foot deformities,33,35,210,226,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1451,-1,0.0013926275,0.99860746
1452,stress fractures,36,38,228,244,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1452,-1,0.0016836773,0.9983163
1453,hyperparathyroidism,40,41,250,269,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1453,-1,0.0018021247,0.99819785
1455,calcium channel blockers,12,15,85,109,The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.,11263551_7,-1,-1,-1,1455,-1,0.99905676,0.0009432998
1457,Pain Syndrome,3,5,34,47,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,-1,-1,-1,1457,-1,0.0011585795,0.99884146
1458,CIPS,6,7,49,53,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,-1,-1,-1,1458,-1,0.0013753126,0.9986247
1461,lead,6,7,41,45,Incorrect diagnosis of the syndrome will lead to a significant reduction of life quality in patients suffering from CIPS.,11263551_9,-1,-1,-1,1461,-1,0.028656611,0.9713434
1462,CIPS,18,19,116,120,Incorrect diagnosis of the syndrome will lead to a significant reduction of life quality in patients suffering from CIPS.,11263551_9,-1,-1,-1,1462,-1,0.001489394,0.99851054
1463,haemorrhagic myocarditis,1,3,6,30,Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy.,11271907_0,-1,-1,-1,1463,-1,0.0013769167,0.99862313
1465,Haemorrhagic myocarditis,0,2,0,24,Haemorrhagic myocarditis is a rare but important complication of cyclophosphamide therapy.,11271907_1,-1,-1,-1,1465,-1,0.0012462551,0.9987538
1468,Anthracyclines,0,1,0,14,"Anthracyclines are effective antineoplastic drugs, but they frequently cause dose-related cardiotoxicity.",11279304_1,-1,-1,-1,1468,-1,0.99792176,0.0020782007
1474,acute leukemia,29,31,191,205,We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.,11279304_3,-1,-1,-1,1474,-1,0.0013435378,0.9986564
1476,acute leukemia,3,5,23,37,Thirteen patients with acute leukemia were treated with a DNR-containing regimen.,11279304_4,-1,-1,-1,1476,-1,0.0014106231,0.99858934
1477,atrial natriuretic peptide,4,7,21,47,The plasma levels of atrial natriuretic peptide (ANP) and BNP were measured at the time of radionuclide angiography.,11279304_6,-1,-1,-1,1477,-1,0.99470204,0.005297928
1478,ANP,8,9,49,52,The plasma levels of atrial natriuretic peptide (ANP) and BNP were measured at the time of radionuclide angiography.,11279304_6,-1,-1,-1,1478,-1,0.996698,0.0033020568
1479,BNP,11,12,58,61,The plasma levels of atrial natriuretic peptide (ANP) and BNP were measured at the time of radionuclide angiography.,11279304_6,-1,-1,-1,1479,-1,0.99677026,0.003229714
1480,congestive heart failure,3,6,25,49,Three patients developed congestive heart failure after the completion of chemotherapy.,11279304_7,-1,-1,-1,1480,-1,0.001364881,0.9986351
1481,heart failure,7,9,51,64,Five patients were diagnosed as having subclinical heart failure after the completion of chemotherapy.,11279304_8,-1,-1,-1,1481,-1,0.001571835,0.9984282
1482,heart failure,13,15,75,88,The plasma levels of BNP in all the patients with clinical and subclinical heart failure increased above the normal limit (40 pg/ml) before the detection of clinical or subclinical heart failure by radionuclide angiography.,11279304_9,-1,-1,-1,1482,-1,0.0015049251,0.9984951
1483,heart failure,31,33,181,194,The plasma levels of BNP in all the patients with clinical and subclinical heart failure increased above the normal limit (40 pg/ml) before the detection of clinical or subclinical heart failure by radionuclide angiography.,11279304_9,-1,-1,-1,1483,-1,0.0015128108,0.9984871
1484,heart failure,13,15,64,77,"On the other hand, BNP did not increase in the patients without heart failure given DNR, even at more than 700 mg/m(2).",11279304_10,-1,-1,-1,1484,-1,0.0016418073,0.9983582
1485,DNR,16,17,84,87,"On the other hand, BNP did not increase in the patients without heart failure given DNR, even at more than 700 mg/m(2).",11279304_10,-1,-1,-1,1485,-1,0.99738604,0.0026139414
1486,ANP,4,5,20,23,The plasma level of ANP did not always increase in all the patients with clinical and subclinical heart failure.,11279304_11,-1,-1,-1,1486,-1,0.9983229,0.001677042
1487,heart failure,17,19,98,111,The plasma level of ANP did not always increase in all the patients with clinical and subclinical heart failure.,11279304_11,-1,-1,-1,1487,-1,0.0015556546,0.9984444
1490,atrial fibrillation,4,6,24,43,Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs.,11282081_0,-1,-1,-1,1490,-1,0.0017007226,0.9982993
1491,atrial fibrillation,11,13,93,112,BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.,11282081_1,-1,-1,-1,1491,-1,0.0017081609,0.9982918
1492,AF,14,15,114,116,BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.,11282081_1,-1,-1,-1,1492,-1,0.0014828544,0.9985171
1493,AF,15,16,89,91,"There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.",11282081_2,-1,-1,-1,1493,-1,0.0017824697,0.9982175
1494,AF,20,21,112,114,"There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.",11282081_2,-1,-1,-1,1494,-1,0.0023477303,0.99765223
1495,AF,8,9,49,51,"METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.",11282081_3,-1,-1,-1,1495,-1,0.002363306,0.9976367
1496,blockers,15,16,80,88,"METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.",11282081_3,-1,-1,-1,1496,-1,0.99758303,0.0024170133
1500,nadolol,13,14,81,88,Diltiazem was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments.,11282081_4,-1,-1,-1,1500,-1,0.9993099,0.0006901053
1501,AF,12,13,89,91,Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during AF.,11282081_5,-1,-1,-1,1501,-1,0.0022597613,0.99774027
1503,AF,4,5,26,28,"RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.",11282081_6,-1,-1,-1,1503,-1,0.0017204848,0.9982796
1504,AF,14,15,80,82,"RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.",11282081_6,-1,-1,-1,1504,-1,0.0019709216,0.99802905
1505,P<0.01,30,31,149,155,"RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.",11282081_6,-1,-1,-1,1505,-1,0.3690438,0.6309562
1506,P<0.0005,45,46,217,225,"RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.",11282081_6,-1,-1,-1,1506,-1,0.4871406,0.5128594
1509,ms,17,18,105,107,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,-1,1509,-1,0.04175037,0.95824957
1510,P<0.02,19,20,109,115,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,-1,1510,-1,0.44652978,0.5534702
1511,ms,27,28,142,144,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,-1,1511,-1,0.24909312,0.75090694
1512,P<0.05,39,40,199,205,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,-1,1512,-1,0.3702784,0.6297216
1513,AF,52,53,288,290,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,-1,1513,-1,0.002782576,0.9972174
1514,ms,57,58,309,311,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,-1,1514,-1,0.037086092,0.9629139
1515,P<0.005,59,60,313,320,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,-1,1515,-1,0.4714157,0.52858424
1517,AF,6,7,30,32,"Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).",11282081_9,-1,-1,-1,1517,-1,0.0043479474,0.995652
1518,AF,10,11,49,51,"Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).",11282081_9,-1,-1,-1,1518,-1,0.0041926233,0.9958074
1520,n=5,24,25,136,139,"Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).",11282081_9,-1,-1,-1,1520,-1,0.15427169,0.8457283
1522,AF,11,12,67,69,"In the presence of autonomic blockade, verapamil failed to promote AF and increased, rather than decreasing, refractoriness.",11282081_10,-1,-1,-1,1522,-1,0.001486384,0.99851364
1526,AF,6,7,53,55,Epicardial mapping suggested that verapamil promoted AF by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle.,11282081_12,-1,-1,-1,1526,-1,0.0021219754,0.9978781
1528,AF,4,5,32,34,"CONCLUSIONS: Verapamil promotes AF in normal dogs by promoting multiple circuit reentry, an effect dependent on intact autonomic tone and not shared by diltiazem.",11282081_13,-1,-1,-1,1528,-1,0.0022519073,0.9977481
1533,nitric oxide,5,7,26,38,It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).,11284996_1,-1,-1,-1,1533,-1,0.9981244,0.0018755561
1535,primary headaches,13,15,64,81,It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).,11284996_1,-1,-1,-1,1535,-1,0.0015691507,0.9984308
1537,CGRP,25,26,149,153,It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).,11284996_1,-1,-1,-1,1537,-1,0.99802184,0.001978143
1538,CGRP,11,12,62,66,In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.,11284996_2,-1,-1,-1,1538,-1,0.9983411,0.00165889
1540,glyceryl trinitrate,19,21,107,126,In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.,11284996_2,-1,-1,-1,1540,-1,0.99902976,0.00097026856
1541,GTN,22,23,128,131,In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.,11284996_2,-1,-1,-1,1541,-1,0.9986229,0.00137717
1543,GTN,9,10,66,69,The subjects were randomly allocated to receive 0.5 microg/kg/min GTN or placebo over 20 min on two headache-free days.,11284996_3,-1,-1,-1,1543,-1,0.99836093,0.0016390677
1545,GTN,11,12,86,89,Both patients and controls developed significantly stronger immediate headache on the GTN day than on the placebo day and the headache was significantly more pronounced in patients than in controls.,11284996_5,-1,-1,-1,1545,-1,0.9977047,0.0022953814
1547,CGRP,9,10,51,55,There was no difference between the area under the CGRP curve (AUCCGRP) on GTN vs. placebo day in either patients (P=0.65) or controls (P=0.48).,11284996_6,-1,-1,-1,1547,-1,0.9988311,0.0011689211
1548,GTN,15,16,75,78,There was no difference between the area under the CGRP curve (AUCCGRP) on GTN vs. placebo day in either patients (P=0.65) or controls (P=0.48).,11284996_6,-1,-1,-1,1548,-1,0.9970036,0.0029963208
1549,P=0.65,23,24,115,121,There was no difference between the area under the CGRP curve (AUCCGRP) on GTN vs. placebo day in either patients (P=0.65) or controls (P=0.48).,11284996_6,-1,-1,-1,1549,-1,0.11624956,0.88375044
1550,P=0.48,28,29,136,142,There was no difference between the area under the CGRP curve (AUCCGRP) on GTN vs. placebo day in either patients (P=0.65) or controls (P=0.48).,11284996_6,-1,-1,-1,1550,-1,0.12622008,0.87377995
1551,GTN,5,6,28,31,The AUCCGRP recorded on the GTN day did not differ between patients and controls (P=0.36).,11284996_7,-1,-1,-1,1551,-1,0.096408755,0.9035913
1552,P=0.36,15,16,82,88,The AUCCGRP recorded on the GTN day did not differ between patients and controls (P=0.36).,11284996_7,-1,-1,-1,1552,-1,0.15567392,0.844326
1553,CGRP,6,7,31,35,"Both in patients and controls, CGRP levels changed significantly over time, on both the GTN and placebo days (P < 0.05).",11284996_8,-1,-1,-1,1553,-1,0.9984407,0.0015593019
1554,GTN,16,17,88,91,"Both in patients and controls, CGRP levels changed significantly over time, on both the GTN and placebo days (P < 0.05).",11284996_8,-1,-1,-1,1554,-1,0.99764425,0.0023557688
1555,P,21,22,110,111,"Both in patients and controls, CGRP levels changed significantly over time, on both the GTN and placebo days (P < 0.05).",11284996_8,-1,-1,-1,1555,-1,0.4870749,0.5129251
1557,CGRP,14,15,97,101,The present study indicates that NO-induced immediate headache is not associated with release of CGRP.,11284996_9,-1,-1,-1,1557,-1,0.9981237,0.0018762901
1558,torsade de pointes,1,4,20,38,Fluconazole-induced torsade de pointes.,11302406_0,-1,-1,-1,1558,-1,0.0021997895,0.9978002
1559,torsade de pointes,8,11,55,73,OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.,11302406_1,-1,-1,-1,1559,-1,0.001678367,0.9983216
1560,TDP,12,13,75,78,OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.,11302406_1,-1,-1,-1,1560,-1,0.0021116855,0.99788827
1561,fluconazole,16,17,92,103,OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.,11302406_1,-1,-1,-1,1561,-1,0.9991685,0.0008315274
1562,TDP,21,22,122,125,OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.,11302406_1,-1,-1,-1,1562,-1,0.0020979133,0.99790204
1563,TDP,16,17,106,109,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1563,-1,0.0797691,0.9202309
1564,fluconazole,22,23,143,154,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1564,-1,0.9990864,0.00091358327
1565,TDP,31,32,197,200,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1565,-1,0.05674268,0.94325733
1566,coronary artery disease,34,37,212,235,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1566,-1,0.0018542213,0.9981458
1568,congestive heart failure,40,43,253,277,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1568,-1,0.001490911,0.9985091
1569,fluconazole,56,57,368,379,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1569,-1,0.9990932,0.00090681977
1570,TDP,58,59,384,387,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1570,-1,0.29156384,0.70843613
1571,TDP,1,2,4,7,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1571,-1,0.0018348972,0.9981651
1572,fluconazole,4,5,22,33,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1572,-1,0.9991416,0.0008584298
1573,premature ventricular contractions,15,18,91,125,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1573,-1,0.0014434734,0.99855655
1575,NSVT,23,24,168,172,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1575,-1,0.0014919605,0.99850804
1576,fluconazole,47,48,312,323,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1576,-1,0.99917114,0.0008289413
1577,TDP,52,53,347,350,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1577,-1,0.0020712763,0.99792874
1580,QT prolongation,13,15,74,89,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,-1,1580,-1,0.00906601,0.990934
1581,TDP,16,17,93,96,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,-1,1581,-1,0.0025381155,0.9974619
1582,NSVT,21,22,127,131,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,-1,1582,-1,0.0015374427,0.99846256
1583,premature ventricular contractions,23,26,136,170,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,-1,1583,-1,0.0015856677,0.9984143
1584,fluconazole,39,40,257,268,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,-1,1584,-1,0.99922156,0.00077842496
1585,fluconazole,7,8,45,56,"CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.",11302406_6,-1,-1,-1,1585,-1,0.9991359,0.0008641478
1586,prolongation of the QT interval,16,21,87,118,"CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.",11302406_6,-1,-1,-1,1586,-1,0.0062316484,0.99376833
1587,TDP,24,25,131,134,"CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.",11302406_6,-1,-1,-1,1587,-1,0.003407823,0.99659216
1588,fluconazole,7,8,62,73,Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for ventricular arrhythmias.,11302406_7,-1,-1,-1,1588,-1,0.99906784,0.00093222386
1592,renal failure,12,14,90,103,"Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.",1130930_1,-1,-1,-1,1592,-1,0.0013977268,0.99860233
1593,cephalothin sodium,22,24,148,166,"Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.",1130930_1,-1,-1,-1,1593,-1,0.99908876,0.00091128127
1594,gentamicin sulfate,25,27,171,189,"Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.",1130930_1,-1,-1,-1,1594,-1,0.9989759,0.0010241801
1596,renal insufficiency,2,4,14,33,Patients with renal insufficiency should not be given this regimen.,1130930_4,-1,-1,-1,1596,-1,0.0019412088,0.99805874
1599,lung toxicity,17,19,143,156,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,-1,-1,-1,1599,-1,0.0012942287,0.99870574
1601,grape seed proanthocyanidin,26,29,213,240,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,-1,-1,-1,1601,-1,0.9980258,0.0019742101
1602,Grape seed extract,0,3,0,18,"Grape seed extract, primarily a mixture of proanthocyanidins, has been shown to modulate a wide-range of biological, pharmacological and toxicological effects which are mainly cytoprotective.",11334364_1,-1,-1,-1,1602,-1,0.99739754,0.0026025071
1603,proanthocyanidins,8,9,43,60,"Grape seed extract, primarily a mixture of proanthocyanidins, has been shown to modulate a wide-range of biological, pharmacological and toxicological effects which are mainly cytoprotective.",11334364_1,-1,-1,-1,1603,-1,0.9966954,0.0033046296
1604,IH636 grape seed proanthocyanidin extract,6,11,35,76,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,-1,-1,-1,1604,-1,0.998135,0.0018649847
1605,GSPE,12,13,78,82,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,-1,-1,-1,1605,-1,0.99732083,0.0026791273
1609,lung toxicity,22,24,164,177,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,-1,-1,-1,1609,-1,0.0013469621,0.99865305
1612,GSPE,11,12,68,72,"For the cytoprotection study, animals were orally gavaged 100 mg/Kg GSPE for 7-10 days followed by i.p.",11334364_4,-1,-1,-1,1612,-1,0.99858403,0.0014160373
1613,AAP,7,8,42,45,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,-1,-1,-1,1613,-1,0.99863356,0.0013663606
1614,h,13,14,64,65,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,-1,-1,-1,1614,-1,0.29282898,0.707171
1615,AMI,15,16,67,70,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,-1,-1,-1,1615,-1,0.99842274,0.0015772969
1616,DOX,23,24,100,103,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,-1,-1,-1,1616,-1,0.9987716,0.0012283144
1617,h,29,30,121,122,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,-1,-1,-1,1617,-1,0.244388,0.755612
1618,PAS,39,40,247,250,"Parameters of study included analysis of serum chemistry (ALT, BUN and CPK), and orderly fragmentation of genomic DNA (both endonuclease-dependent and independent) in addition to microscopic evaluation of damage and/or protection in corresponding PAS stained tissues.",11334364_6,-1,-1,-1,1618,-1,0.99312675,0.006873266
1619,GSPE,3,4,22,26,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,-1,-1,-1,1619,-1,0.99885,0.0011499801
1620,AAP,7,8,48,51,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,-1,-1,-1,1620,-1,0.9988649,0.0011351915
1621,AMI,9,10,53,56,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,-1,-1,-1,1621,-1,0.9984798,0.0015202587
1622,DOX,11,12,61,64,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,-1,-1,-1,1622,-1,0.9988986,0.0011013309
1623,tissue damage,13,15,94,107,"Histopathological examination of kidney, heart and lung sections revealed moderate to massive tissue damage with a variety of morphological aberrations by all the three drugs in the absence of GSPE preexposure than in its presence.",11334364_8,-1,-1,-1,1623,-1,0.0021895608,0.9978104
1624,GSPE,30,31,193,197,"Histopathological examination of kidney, heart and lung sections revealed moderate to massive tissue damage with a variety of morphological aberrations by all the three drugs in the absence of GSPE preexposure than in its presence.",11334364_8,-1,-1,-1,1624,-1,0.9988876,0.0011124013
1625,AAP,9,10,39,42,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,-1,-1,-1,1625,-1,0.99893576,0.0010642031
1626,AMI,11,12,44,47,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,-1,-1,-1,1626,-1,0.99853766,0.0014623898
1627,DOX,13,14,52,55,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,-1,-1,-1,1627,-1,0.9987907,0.0012093108
1630,GSPE,31,32,167,171,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,-1,-1,-1,1630,-1,0.99893445,0.0010655397
1631,AAP,1,2,6,9,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,-1,-1,-1,1631,-1,0.9989567,0.0010432915
1632,AMI,3,4,11,14,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,-1,-1,-1,1632,-1,0.99858344,0.0014165329
1633,DOX,5,6,19,22,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,-1,-1,-1,1633,-1,0.9987649,0.0012351555
1634,GSPE,21,22,119,123,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,-1,-1,-1,1634,-1,0.9984693,0.001530678
1636,GSPE,7,8,51,55,"Taken together, these events undoubtedly establish GSPE's abundant bioavailability, and the power to defend multiple target organs from toxic assaults induced by structurally diverse and functionally different entities in vivo.",11334364_15,-1,-1,-1,1636,-1,0.9975236,0.0024763446
1637,leucocytoclastic vasculitis,1,3,10,37,Cutaneous leucocytoclastic vasculitis associated with oxacillin.,11337188_0,-1,-1,-1,1637,-1,0.0013546345,0.99864537
1638,oxacillin,5,6,54,63,Cutaneous leucocytoclastic vasculitis associated with oxacillin.,11337188_0,-1,-1,-1,1638,-1,0.99912363,0.0008763494
1639,oxacillin,7,8,39,48,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,-1,-1,-1,1639,-1,0.9990716,0.00092835433
1640,bacteremia,15,16,95,105,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,-1,-1,-1,1640,-1,0.0012447686,0.9987552
1641,renal failure,18,20,117,130,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,-1,-1,-1,1641,-1,0.0014475019,0.9985525
1642,purpuric lesions,26,28,164,180,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,-1,-1,-1,1642,-1,0.0016114701,0.9983885
1643,blisters,1,2,9,17,Necrotic blisters were noted on his fingers.,11337188_2,-1,-1,-1,1643,-1,0.0019429327,0.99805707
1644,leucocytoclastic vasculitis,6,8,44,71,Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis.,11337188_3,-1,-1,-1,1644,-1,0.0013397103,0.9986603
1645,Oxacillin,0,1,0,9,Oxacillin was discontinued and patient was treated with corticosteroids.,11337188_4,-1,-1,-1,1645,-1,0.99902964,0.0009703971
1648,Leucocytoclastic vasculitis,0,2,0,27,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,-1,-1,1648,-1,0.0012294515,0.99877053
1649,purpura,5,6,49,56,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,-1,-1,1649,-1,0.0012922894,0.99870765
1650,abdominal pain,13,15,103,117,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,-1,-1,1650,-1,0.0012306372,0.99876934
1651,arthralgia,16,17,119,129,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,-1,-1,1651,-1,0.0011321121,0.99886787
1652,renal involvement,19,21,135,152,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,-1,-1,1652,-1,0.0016290159,0.99837106
1654,collagen vascular disease,10,13,75,100,"Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia.",11337188_7,-1,-1,-1,1654,-1,0.0018557514,0.99814427
1655,neoplasia,14,15,105,114,"Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia.",11337188_7,-1,-1,-1,1655,-1,0.0013846073,0.9986154
1656,corticosteroid,8,9,43,57,"Usually it is a self-limited disorder, but corticosteroid therapy may be needed in life-threatening cases since early treatment with corticosteroids in severe cases can prevent complications.",11337188_9,-1,-1,-1,1656,-1,0.99871206,0.0012879745
1658,Oxacillin,0,1,0,9,Oxacillin should be included among the drugs that can cause leucocytoclastic vasculitis.,11337188_10,-1,-1,-1,1658,-1,0.9990709,0.00092910073
1659,leucocytoclastic vasculitis,10,12,60,87,Oxacillin should be included among the drugs that can cause leucocytoclastic vasculitis.,11337188_10,-1,-1,-1,1659,-1,0.0012072561,0.99879277
1660,mania,1,2,23,28,Antidepressant-induced mania in bipolar patients: identification of risk factors.,11379838_0,-1,-1,-1,1660,-1,0.00143471,0.99856526
1662,mania,9,10,58,63,BACKGROUND: Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression.,11379838_1,-1,-1,-1,1662,-1,0.0019132,0.9980868
1664,bipolar depression,25,27,178,196,BACKGROUND: Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression.,11379838_1,-1,-1,-1,1664,-1,0.0018959994,0.998104
1665,bipolar disorder,11,13,64,80,METHOD: The response of 44 patients meeting DSM-IV criteria for bipolar disorder to naturalistic treatment was assessed for at least 6 weeks using the Montgomery-Asberg Depression Rating Scale and the Bech-Rafaelson Mania Rating Scale.,11379838_2,-1,-1,-1,1665,-1,0.0022780122,0.99772197
1667,Mania,32,33,216,221,METHOD: The response of 44 patients meeting DSM-IV criteria for bipolar disorder to naturalistic treatment was assessed for at least 6 weeks using the Montgomery-Asberg Depression Rating Scale and the Bech-Rafaelson Mania Rating Scale.,11379838_2,-1,-1,-1,1667,-1,0.003377359,0.9966227
1669,hypomanic,6,7,36,45,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,-1,-1,1669,-1,0.0022857937,0.99771416
1670,bipolar I,26,28,149,158,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,-1,-1,1670,-1,0.009169991,0.99083006
1671,bipolar II,29,31,163,173,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,-1,-1,1671,-1,0.008278692,0.99172133
1675,serotonin reuptake inhibitors,56,59,333,362,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,-1,-1,1675,-1,0.9983182,0.001681859
1676,SSRIs,60,61,364,369,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,-1,-1,1676,-1,0.99799395,0.0020060579
1678,hypomania,4,5,21,30,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1678,-1,0.0014706664,0.9985293
1679,mania,6,7,34,39,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1679,-1,0.0015549096,0.9984451
1680,N,15,16,73,74,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1680,-1,0.04236673,0.95763326
1681,SSRIs,31,32,134,139,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1681,-1,0.9978472,0.0021528169
1682,N,40,41,154,155,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1682,-1,0.054811757,0.9451882
1684,N,52,53,198,199,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1684,-1,0.05256507,0.94743496
1685,hypomanic,57,58,217,226,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1685,-1,0.0016965485,0.9983034
1686,bipolar I,6,8,21,30,"Sex, age, diagnosis (bipolar I vs. bipolar II), and additional treatment did not affect the risk of switching.",11379838_5,-1,-1,-1,1686,-1,0.008446464,0.9915535
1687,bipolar II,9,11,35,45,"Sex, age, diagnosis (bipolar I vs. bipolar II), and additional treatment did not affect the risk of switching.",11379838_5,-1,-1,-1,1687,-1,0.0071595674,0.9928404
1688,contrast,1,2,3,11,"In contrast, mood switches were less frequent in patients receiving lithium (15%, 4/26) than in patients not treated with lithium (44%, 8/18; p = .04).",11379838_7,-1,-1,-1,1688,-1,0.13684466,0.86315536
1691,p,31,32,142,143,"In contrast, mood switches were less frequent in patients receiving lithium (15%, 4/26) than in patients not treated with lithium (44%, 8/18; p = .04).",11379838_7,-1,-1,-1,1691,-1,0.23970652,0.7602935
1693,p,37,38,236,237,"The number of previous manic episodes did not affect the probability of switching, whereas a high score on the hyperthymia component of the Semistructured Affective Temperament Interview was associated with a greater risk of switching (p = .008).",11379838_8,-1,-1,-1,1693,-1,0.27778623,0.7222138
1696,kidney disease,9,11,79,93,Peritubular capillary basement membrane reduplication in allografts and native kidney disease: a clinicopathologic study of 278 consecutive renal specimens.,11391224_0,-1,-1,-1,1696,-1,0.0021487735,0.99785125
1697,transplant glomerulopathy,8,10,50,75,BACKGROUND: An association has been found between transplant glomerulopathy (TG) and reduplication of peritubular capillary basement membranes (PTCR).,11391224_1,-1,-1,-1,1697,-1,0.0021035953,0.99789643
1698,TG,11,12,77,79,BACKGROUND: An association has been found between transplant glomerulopathy (TG) and reduplication of peritubular capillary basement membranes (PTCR).,11391224_1,-1,-1,-1,1698,-1,0.002107605,0.99789244
1699,TG,6,7,37,39,"In addition to renal allografts with TG, we also examined grafts with acute rejection, recurrent glomerulonephritis, chronic allograft nephropathy and stable grafts (""protocol biopsies"").",11391224_4,-1,-1,-1,1699,-1,0.0084221875,0.99157774
1701,chronic allograft nephropathy,19,22,117,146,"In addition to renal allografts with TG, we also examined grafts with acute rejection, recurrent glomerulonephritis, chronic allograft nephropathy and stable grafts (""protocol biopsies"").",11391224_4,-1,-1,-1,1701,-1,0.0016385809,0.9983614
1702,glomerulopathies,8,9,49,65,"Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis.",11391224_5,-1,-1,-1,1702,-1,0.0010958564,0.9989041
1704,malignant hypertension,17,19,114,136,"Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis.",11391224_5,-1,-1,-1,1704,-1,0.0012000056,0.99880004
1707,TG,11,12,44,46,"RESULTS: We found PTCR in 14 of 15 cases of TG, in 7 transplant biopsy specimens without TG, and in 13 of 143 native kidney biopsy specimens.",11391224_6,-1,-1,-1,1707,-1,0.0040606917,0.9959394
1708,TG,19,20,89,91,"RESULTS: We found PTCR in 14 of 15 cases of TG, in 7 transplant biopsy specimens without TG, and in 13 of 143 native kidney biopsy specimens.",11391224_6,-1,-1,-1,1708,-1,0.0052015283,0.9947984
1709,malignant hypertension,5,7,27,49,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,-1,-1,1709,-1,0.0011432568,0.9988568
1711,lupus nephritis,11,13,79,94,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,-1,-1,1711,-1,0.0010544574,0.99894553
1712,nephritis,15,16,113,122,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,-1,-1,1712,-1,0.0010949377,0.99890506
1714,acute renal failure,22,25,175,194,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,-1,-1,1714,-1,0.0010367428,0.99896324
1715,TG,5,6,32,34,Mild PTCR in allografts without TG did not predict renal failure or significant proteinuria after follow-up periods of between 3 months and 1 year.,11391224_8,-1,-1,-1,1715,-1,0.7500959,0.24990413
1716,renal failure,9,11,51,64,Mild PTCR in allografts without TG did not predict renal failure or significant proteinuria after follow-up periods of between 3 months and 1 year.,11391224_8,-1,-1,-1,1716,-1,0.0016323942,0.9983676
1718,TG,17,18,108,110,"CONCLUSIONS: We conclude that in transplants, there is a strong association between well-developed PTCR and TG, while the significance of mild PTCR and its predictive value in the absence of TG is unclear.",11391224_9,-1,-1,-1,1718,-1,0.03460783,0.9653921
1719,TG,33,34,191,193,"CONCLUSIONS: We conclude that in transplants, there is a strong association between well-developed PTCR and TG, while the significance of mild PTCR and its predictive value in the absence of TG is unclear.",11391224_9,-1,-1,-1,1719,-1,0.0074956533,0.99250436
1720,kidney diseases,6,8,35,50,"PTCR also occurs in certain native kidney diseases, though the association is not as strong as that for TG.",11391224_10,-1,-1,-1,1720,-1,0.0020256059,0.99797434
1721,TG,19,20,104,106,"PTCR also occurs in certain native kidney diseases, though the association is not as strong as that for TG.",11391224_10,-1,-1,-1,1721,-1,0.9792519,0.020748112
1722,endothelial injury,4,6,25,43,"We suggest that repeated endothelial injury, including immunologic injury, may be the cause of this lesion both in allografts and native kidneys.",11391224_11,-1,-1,-1,1722,-1,0.0021341902,0.99786586
1723,immunologic injury,8,10,55,73,"We suggest that repeated endothelial injury, including immunologic injury, may be the cause of this lesion both in allografts and native kidneys.",11391224_11,-1,-1,-1,1723,-1,0.0023148397,0.9976852
1724,renal,1,2,4,9,The renal pathology in a case of lithium-induced diabetes insipidus.,1141447_0,-1,-1,-1,1724,-1,0.002064846,0.9979352
1725,diabetes insipidus,8,10,49,67,The renal pathology in a case of lithium-induced diabetes insipidus.,1141447_0,-1,-1,-1,1725,-1,0.0014894842,0.99851054
1726,diabetes insipidus,4,6,26,44,A case of lithium-induced diabetes insipidus is reported.,1141447_1,-1,-1,-1,1726,-1,0.0015364449,0.99846363
1728,cardiac arrhythmia,1,3,17,35,Caffeine-induced cardiac arrhythmia: an unrecognised danger of healthfood products.,11419773_0,-1,-1,-1,1728,-1,0.0013411338,0.9986589
1729,mitral valve prolapse,7,10,50,71,"We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a ""natural energy"" guarana health drink containing a high concentration of caffeine.",11419773_1,-1,-1,-1,1729,-1,0.0032111332,0.99678886
1730,ventricular fibrillation,13,15,98,122,"We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a ""natural energy"" guarana health drink containing a high concentration of caffeine.",11419773_1,-1,-1,-1,1730,-1,0.0013590993,0.99864095
1732,BD1008,4,5,39,45,Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice.,11426838_0,-1,-1,-1,1732,-1,0.99905246,0.0009475509
1733,oligodeoxynucleotide,8,9,63,83,Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice.,11426838_0,-1,-1,-1,1733,-1,0.998125,0.001874976
1735,BD1018,17,18,109,115,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1735,-1,0.99884534,0.0011546754
1736,"3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane",19,20,117,181,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1736,-1,0.99717134,0.002828656
1737,BD1063,22,23,184,190,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1737,-1,0.9987068,0.0012931764
1739,LR132,28,29,249,254,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1739,-1,0.99896705,0.0010329541
1740,"1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine",30,31,256,335,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1740,-1,0.9969771,0.0030228903
1742,NMDA,22,23,134,138,"The three compounds vary in their affinities for sigma2 receptors and exhibit negligible affinities for dopamine, opioid, GABA(A) and NMDA receptors.",11426838_4,-1,-1,-1,1742,-1,0.9986583,0.001341655
1743,BD1018,8,9,50,56,"In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality.",11426838_5,-1,-1,-1,1743,-1,0.99883586,0.0011641852
1744,BD1063,10,11,58,64,"In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality.",11426838_5,-1,-1,-1,1744,-1,0.99861014,0.0013898676
1745,LR132,13,14,69,74,"In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality.",11426838_5,-1,-1,-1,1745,-1,0.9989742,0.0010258431
1747,LR132,4,5,30,35,"Moreover, post-treatment with LR132 prevented cocaine-induced lethality in a significant proportion of animals.",11426838_6,-1,-1,-1,1747,-1,0.9988776,0.0011223761
1748,contrast,1,2,3,11,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,-1,-1,-1,1748,-1,0.13701482,0.8629852
1749,DTG,18,19,135,138,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,-1,-1,-1,1749,-1,0.9987312,0.001268835
1750,BD1031,26,27,177,183,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,-1,-1,-1,1750,-1,0.99893886,0.0010611452
1751,"3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane",28,29,185,249,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,-1,-1,-1,1751,-1,0.9978642,0.0021358035
1752,behavioral toxicity,33,35,269,288,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,-1,-1,-1,1752,-1,0.0021150573,0.9978849
1754,BD1018,13,14,74,80,"At doses where alone, they produced no significant effects on locomotion, BD1018, BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine.",11426838_8,-1,-1,-1,1754,-1,0.9988901,0.0011099699
1755,BD1063,15,16,82,88,"At doses where alone, they produced no significant effects on locomotion, BD1018, BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine.",11426838_8,-1,-1,-1,1755,-1,0.998743,0.0012570245
1756,LR132,17,18,93,98,"At doses where alone, they produced no significant effects on locomotion, BD1018, BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine.",11426838_8,-1,-1,-1,1756,-1,0.9990013,0.0009987388
1758,oligodeoxynucleotide,21,22,139,159,"To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine.",11426838_9,-1,-1,-1,1758,-1,0.9987608,0.0012392323
1765,allograft dysfunction,20,22,136,157,We report a case of ranitidine-induced acute interstitial nephritis in a recipient of a cadaveric renal allograft presenting with acute allograft dysfunction within 48 hours of exposure to the drug.,11431197_4,-1,-1,-1,1765,-1,0.0017174672,0.99828255
1766,eosinophilic,8,9,61,73,"The biopsy specimen showed pathognomonic features, including eosinophilic infiltration of the interstitial compartment.",11431197_5,-1,-1,-1,1766,-1,0.0023661195,0.9976338
1767,Cholestatic jaundice,0,2,0,20,Cholestatic jaundice associated with the use of metformin.,11467664_0,-1,-1,-1,1767,-1,0.0013458476,0.9986541
1768,metformin,7,8,48,57,Cholestatic jaundice associated with the use of metformin.,11467664_0,-1,-1,-1,1768,-1,0.99885213,0.0011478323
1769,cholestatic jaundice,6,8,34,54,We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride.,11467664_1,-1,-1,-1,1769,-1,0.0013590797,0.99864095
1770,metformin hydrochloride,14,16,98,121,We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride.,11467664_1,-1,-1,-1,1770,-1,0.998987,0.0010130029
1774,Metformin hydrochloride,0,2,0,23,"Metformin hydrochloride was discontinued, and the patient's jaundice resolved slowly over a period of several months.",11467664_5,-1,-1,-1,1774,-1,0.99898034,0.0010195917
1777,metformin,12,13,61,70,"Given the onset of his jaundice 2 wk after the initiation of metformin, we believe that this case represents an example of metformin-associated hepatotoxicity, the first such case reported.",11467664_6,-1,-1,-1,1777,-1,0.99892646,0.0010735092
1783,chronic liver disease,17,20,86,107,This is an addition to the list of drugs that must be considered in the evaluation of chronic liver disease.,1147734_2,-1,-1,-1,1783,-1,0.0020538415,0.9979462
1787,levobupivacaine,8,9,50,65,"We compared the systemic toxicity of bupivacaine, levobupivacaine, and ropivacaine in anesthetized rats.",11524350_1,-1,-1,-1,1787,-1,0.9991972,0.0008028043
1788,ropivacaine,11,12,71,82,"We compared the systemic toxicity of bupivacaine, levobupivacaine, and ropivacaine in anesthetized rats.",11524350_1,-1,-1,-1,1788,-1,0.9993082,0.00069177715
1790,levobupivacaine,2,3,13,28,"Bupivacaine, levobupivacaine, or ropivacaine was infused at a rate of 2 mg.",11524350_3,-1,-1,-1,1790,-1,0.99914706,0.00085294165
1791,ropivacaine,5,6,33,44,"Bupivacaine, levobupivacaine, or ropivacaine was infused at a rate of 2 mg.",11524350_3,-1,-1,-1,1791,-1,0.9992551,0.0007448313
1792,mg,13,14,72,74,"Bupivacaine, levobupivacaine, or ropivacaine was infused at a rate of 2 mg.",11524350_3,-1,-1,-1,1792,-1,0.98762697,0.012373011
1795,mm Hg,13,15,84,89,Resuscitation was considered successful when a systolic arterial pressure > or =100 mm Hg was achieved within 5 min.,11524350_8,-1,-1,-1,1795,-1,0.03263128,0.9673688
1796,levobupivacaine,4,5,24,39,The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.,11524350_9,-1,-1,-1,1796,-1,0.9992132,0.0007867508
1797,ropivacaine,6,7,44,55,The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.,11524350_9,-1,-1,-1,1797,-1,0.999318,0.0006819703
1800,levobupivacaine,4,5,24,39,"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.",11524350_10,-1,-1,-1,1800,-1,0.9992532,0.00074675697
1801,dysrhythmias,7,8,54,66,"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.",11524350_10,-1,-1,-1,1801,-1,0.0013355452,0.9986645
1803,ropivacaine,17,18,125,136,"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.",11524350_10,-1,-1,-1,1803,-1,0.9993529,0.00064713176
1806,Ropivacaine,11,12,59,70,"However, a smaller dose of epinephrine was required in the Ropivacaine group than in the other groups.",11524350_12,-1,-1,-1,1806,-1,0.999329,0.0006710882
1808,levobupivacaine,7,8,42,57,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,-1,-1,-1,1808,-1,0.99924207,0.00075798214
1809,ropivacaine,13,14,90,101,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,-1,-1,-1,1809,-1,0.9993362,0.00066380994
1813,levobupivacaine,40,41,277,292,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,-1,-1,-1,1813,-1,0.9992281,0.00077192084
1814,rabbit syndrome,1,3,20,35,Withdrawal-emergent rabbit syndrome during dose reduction of risperidone.,11532387_0,-1,-1,-1,1814,-1,0.0017703689,0.9982297
1816,Rabbit syndrome,0,2,0,15,Rabbit syndrome (RS) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication.,11532387_1,-1,-1,-1,1816,-1,0.0017192642,0.99828076
1817,RS,3,4,17,19,Rabbit syndrome (RS) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication.,11532387_1,-1,-1,-1,1817,-1,0.0014975187,0.9985025
1818,neuroleptic,14,15,78,89,Rabbit syndrome (RS) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication.,11532387_1,-1,-1,-1,1818,-1,0.9986407,0.0013592765
1819,RS,7,8,46,48,"Here we present a case of withdrawal-emergent RS, which is the first of its kind to be reported.",11532387_2,-1,-1,-1,1819,-1,0.0018602215,0.99813974
1820,RS,3,4,22,24,The patient developed RS during dose reduction of risperidone.,11532387_3,-1,-1,-1,1820,-1,0.0020486095,0.99795145
1823,RS,5,6,48,50,"The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.",11532387_5,-1,-1,-1,1823,-1,0.001564639,0.9984353
1826,RS,37,38,261,263,"The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.",11532387_5,-1,-1,-1,1826,-1,0.0015291024,0.99847084
1827,E4031,6,7,61,66,"Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.1.",11569530_0,-1,-1,-1,1827,-1,0.9990139,0.0009860204
1831,Torsades de pointes,0,3,0,19,Torsades de pointes (TDP) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration (MAPD).,11569530_1,-1,-1,-1,1831,-1,0.0021006146,0.9978994
1832,TDP,4,5,21,24,Torsades de pointes (TDP) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration (MAPD).,11569530_1,-1,-1,-1,1832,-1,0.002215425,0.99778455
1834,TDP,0,1,0,3,TDP is a side-effect that has led to withdrawal of several drugs from the market (e.g. terfenadine and terodiline).,11569530_2,-1,-1,-1,1834,-1,0.005805941,0.9941941
1837,TDP,6,7,36,39,The potential of compounds to cause TDP was evaluated by monitoring their effects on MAPD in dog.,11569530_4,-1,-1,-1,1837,-1,0.005731383,0.99426866
1838,TDP,9,10,55,58,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,-1,-1,-1,1838,-1,0.002703362,0.99729663
1842,E4031,19,20,117,122,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,-1,-1,-1,1842,-1,0.99866307,0.0013369623
1846,E4031,28,29,117,122,"These data indicate that the free ED50 in plasma for terfenadine (1.9 nM), terodiline (76 nM), cisapride (11 nM) and E4031 (1.9 nM) closely correlate with the free concentration in man causing QT effects.",11569530_9,-1,-1,-1,1846,-1,0.9989697,0.001030381
1847,TDP,5,6,30,33,"For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.",11569530_10,-1,-1,-1,1847,-1,0.008774363,0.99122566
1851,TDP,13,14,80,83,These data underline the need to maximize the therapeutic ratio with respect to TDP in potential development candidates and the importance of using free drug concentrations in pharmacokinetic/pharmacodynamic studies.,11569530_11,-1,-1,-1,1851,-1,0.99810284,0.0018972055
1853,AIDS.OBJECTIVE,7,8,50,64,Amphotericin B-induced seizures in a patient with AIDS.OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.,11573852_0,-1,-1,-1,1853,-1,0.007286414,0.9927135
1855,AIDS,21,22,130,134,Amphotericin B-induced seizures in a patient with AIDS.OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.,11573852_0,-1,-1,-1,1855,-1,0.0024289547,0.99757105
1856,amphotericin B,24,26,152,166,Amphotericin B-induced seizures in a patient with AIDS.OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.,11573852_0,-1,-1,-1,1856,-1,0.9988759,0.0011240945
1857,grand mal seizures,9,12,71,89,"CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.",11573852_1,-1,-1,-1,1857,-1,0.002008205,0.9979918
1858,amphotericin B,16,18,121,135,"CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.",11573852_1,-1,-1,-1,1858,-1,0.99898964,0.0010104049
1859,petit mal seizures,20,23,142,160,"CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.",11573852_1,-1,-1,-1,1859,-1,0.0026479668,0.997352
1861,hydroxyzine,7,8,57,68,"The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine.",11573852_2,-1,-1,-1,1861,-1,0.99933773,0.0006622602
1862,promethazine,9,10,70,82,"The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine.",11573852_2,-1,-1,-1,1862,-1,0.9992793,0.00072066014
1866,lorazepam,5,6,40,49,"Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.",11573852_3,-1,-1,-1,1866,-1,0.99925345,0.0007465176
1868,amphotercin B,14,16,99,112,"Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.",11573852_3,-1,-1,-1,1868,-1,0.99913895,0.0008609867
1869,AIDS,2,3,12,16,"DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures.",11573852_4,-1,-1,-1,1869,-1,0.0016422699,0.9983577
1870,cryptococcal meningitis,4,6,21,44,"DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures.",11573852_4,-1,-1,-1,1870,-1,0.0018443579,0.99815565
1872,alcohol abuse,6,8,29,42,The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause seizures.,11573852_5,-1,-1,-1,1872,-1,0.40694427,0.5930557
1878,amphotericin B,7,9,41,55,The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.,11573852_8,-1,-1,-1,1878,-1,0.9987054,0.001294643
1880,AIDS,17,18,94,98,The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.,11573852_8,-1,-1,-1,1880,-1,0.0025702508,0.9974298
1881,Amphotericin B,2,4,13,27,CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.,11573852_9,-1,-1,-1,1881,-1,0.9986234,0.0013765974
1884,amphotericin B,10,12,54,68,"To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.",11573852_10,-1,-1,-1,1884,-1,0.9987791,0.0012209
1885,retention of urine,1,4,8,26,Bladder retention of urine as a result of continuous intravenous infusion of fentanyl: 2 case reports.,11581460_0,-1,-1,-1,1885,-1,0.0030128704,0.99698716
1890,chest wall rigidity,8,11,65,84,"Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.",11581460_3,-1,-1,-1,1890,-1,0.0019544258,0.99804556
1892,respiratory depression,14,16,99,121,"Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.",11581460_3,-1,-1,-1,1892,-1,0.0013247548,0.99867517
1894,urinary bladder retention,5,8,17,42,"Here, 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of fentanyl are reported.",11581460_4,-1,-1,-1,1894,-1,0.0014935796,0.99850637
1895,hydronephrosis,14,15,95,109,"Here, 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of fentanyl are reported.",11581460_4,-1,-1,-1,1895,-1,0.0012997393,0.99870026
1898,mycophenolate mofetil,2,4,14,35,Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.,11583940_0,-1,-1,-1,1898,-1,0.99908483,0.00091516285
1899,Calcineurin inhibitors,0,2,0,22,"Calcineurin inhibitors, such as cyclosporine and tacrolimus, have been available for almost 20 years.",11583940_1,-1,-1,-1,1899,-1,0.9984415,0.0015585369
1906,mycophenolate mofetil,6,8,49,70,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,-1,-1,-1,1906,-1,0.99909663,0.00090338226
1910,myeloencephalopathy,1,2,6,25,Fatal myeloencephalopathy due to accidental intrathecal vincristin administration: a report of two cases.,11587867_0,-1,-1,-1,1910,-1,0.0011960976,0.99880385
1911,vincristin,6,7,56,66,Fatal myeloencephalopathy due to accidental intrathecal vincristin administration: a report of two cases.,11587867_0,-1,-1,-1,1911,-1,0.99926823,0.00073176343
1913,acute lymphoblastic leucemia,18,21,116,144,We report on two fatal cases of accidental intrathecal vincristine instillation in a 5-year old girl with recurrent acute lymphoblastic leucemia and a 57-year old man with lymphoblastic lymphoma.,11587867_1,-1,-1,-1,1913,-1,0.0011783425,0.9988217
1914,lymphoblastic lymphoma,27,29,172,194,We report on two fatal cases of accidental intrathecal vincristine instillation in a 5-year old girl with recurrent acute lymphoblastic leucemia and a 57-year old man with lymphoblastic lymphoma.,11587867_1,-1,-1,-1,1914,-1,0.0014971766,0.99850285
1916,sensory and motor dysfunction,12,16,70,99,"Clinically, the onset was characterized by the signs of opistothonus, sensory and motor dysfunction and ascending paralysis.",11587867_3,-1,-1,-1,1916,-1,0.0018133828,0.99818665
1920,Palpebral twitching,0,2,0,19,Palpebral twitching in a depressed adolescent on citalopram.,11642480_0,-1,-1,-1,1920,-1,0.0024771693,0.9975228
1926,palpebral twitching,18,20,117,136,We report a favorable response to treatment with citalopram by a 15-year-old boy with major depression who exhibited palpebral twitching during his first 2 weeks of treatment.,11642480_2,-1,-1,-1,1926,-1,0.002820748,0.99717927
1935,lymphadenitis,12,13,84,97,"Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis, associated with erythrophagocytosis and prominent eosinophilic infiltrates, without viral inclusion bodies, suggestive of an adverse drug reaction.",11672959_2,-1,-1,-1,1935,-1,0.0011850541,0.99881494
1936,eosinophilic,19,20,149,161,"Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis, associated with erythrophagocytosis and prominent eosinophilic infiltrates, without viral inclusion bodies, suggestive of an adverse drug reaction.",11672959_2,-1,-1,-1,1936,-1,0.002463239,0.9975368
1937,adverse drug reaction,30,33,224,245,"Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis, associated with erythrophagocytosis and prominent eosinophilic infiltrates, without viral inclusion bodies, suggestive of an adverse drug reaction.",11672959_2,-1,-1,-1,1937,-1,0.0034378849,0.99656206
1939,autoimmunity,22,23,139,151,"A week later, fulminant drug-induced hepatitis, associated with the presence of anti-nuclear autoantibodies (but not with other markers of autoimmunity), and accompanied by multi-organ failure and sepsis, supervened.",11672959_3,-1,-1,-1,1939,-1,0.0014363267,0.9985637
1940,multi-organ,28,29,173,184,"A week later, fulminant drug-induced hepatitis, associated with the presence of anti-nuclear autoantibodies (but not with other markers of autoimmunity), and accompanied by multi-organ failure and sepsis, supervened.",11672959_3,-1,-1,-1,1940,-1,0.0031593272,0.9968407
1941,failure,29,30,185,192,"A week later, fulminant drug-induced hepatitis, associated with the presence of anti-nuclear autoantibodies (but not with other markers of autoimmunity), and accompanied by multi-organ failure and sepsis, supervened.",11672959_3,-1,-1,-1,1941,-1,0.0013924158,0.9986076
1943,massive hepatocellular necrosis,5,8,43,74,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,-1,-1,-1,1943,-1,0.0014477611,0.99855226
1944,hypersensitivity myocarditis,10,12,82,110,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,-1,-1,-1,1944,-1,0.0012065081,0.9987935
1945,nephritis,16,17,144,153,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,-1,-1,-1,1945,-1,0.0011311749,0.99886876
1946,bone marrow necrosis,19,22,168,188,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,-1,-1,-1,1946,-1,0.0023168097,0.99768317
1951,akathisia,16,17,124,133,"Intravenous administration of prochlorperazine by 15-minute infusion versus 2-minute bolus does not affect the incidence of akathisia: a prospective, randomized, controlled trial.",11679859_0,-1,-1,-1,1951,-1,0.001370048,0.9986299
1952,akathisia,10,11,50,59,STUDY OBJECTIVE: We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2-minute bolus or 15-minute infusion.,11679859_1,-1,-1,-1,1952,-1,0.0012587096,0.9987413
1954,emergency department,13,15,75,95,"METHODS: We conducted a prospective, randomized, double-blind study in the emergency department of a central-city teaching hospital.",11679859_2,-1,-1,-1,1954,-1,0.00750805,0.9924919
1959,mg,7,8,49,51,Study participants were randomized to receive 10 mg of prochlorperazine administered intravenously by means of 2-minute push (bolus group) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15-minute period (infusion group).,11679859_4,-1,-1,-1,1959,-1,0.99516726,0.004832773
1961,mg,23,24,145,147,Study participants were randomized to receive 10 mg of prochlorperazine administered intravenously by means of 2-minute push (bolus group) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15-minute period (infusion group).,11679859_4,-1,-1,-1,1961,-1,0.99364686,0.0063532223
1962,akathisia,10,11,67,76,The main outcome was the number of study participants experiencing akathisia within 60 minutes of administration.,11679859_5,-1,-1,-1,1962,-1,0.0013631715,0.9986368
1963,Akathisia,0,1,0,9,Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale.,11679859_6,-1,-1,-1,1963,-1,0.001277991,0.998722
1964,restlessness,9,10,56,68,Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale.,11679859_6,-1,-1,-1,1964,-1,0.0012993879,0.9987006
1966,akathisia,22,23,131,140,Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale.,11679859_6,-1,-1,-1,1966,-1,0.0014868446,0.99851316
1967,akathisia,35,36,210,219,Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale.,11679859_6,-1,-1,-1,1967,-1,0.0014274559,0.9985726
1972,akathisia,11,12,38,47,"In the bolus group, 26.0% (13/50) had akathisia compared with 32.7% (16/49) in the infusion group (Delta=-6.7%; 95% confidence interval [CI] -24.6% to 11.2%).",11679859_11,-1,-1,-1,1972,-1,0.0012225045,0.99877745
1975,akathisia,10,11,48,57,CONCLUSION: A 50% reduction in the incidence of akathisia when prochlorperazine was administered by means of 15-minute intravenous infusion versus a 2-minute intravenous push was not detected.,11679859_14,-1,-1,-1,1975,-1,0.0012706618,0.9987293
1980,nimesulide,2,3,16,26,Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.,11694026_0,-1,-1,-1,1980,-1,0.99913377,0.00086624094
1982,nimesulide,6,7,44,54,"Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous, respiratory and anaphylactoid reactions induced by nonsteroidal anti-inflammatory drugs (NSAIDs).",11694026_1,-1,-1,-1,1982,-1,0.99920976,0.00079023687
1984,NSAIDs,24,25,188,194,"Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous, respiratory and anaphylactoid reactions induced by nonsteroidal anti-inflammatory drugs (NSAIDs).",11694026_1,-1,-1,-1,1984,-1,0.99884087,0.0011591408
1985,nimesulide,9,10,62,72,In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/angioedema.,11694026_2,-1,-1,-1,1985,-1,0.99922,0.000779953
1988,nimesulide,19,20,118,128,"Furthermore, we evaluated whether some factors have the potential to increase the risk of reaction to paracetamol and nimesulide.",11694026_3,-1,-1,-1,1988,-1,0.99922705,0.0007729244
1989,nimesulide,6,7,58,68,A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/angioedema.,11694026_4,-1,-1,-1,1989,-1,0.99917275,0.000827231
1991,nimesulide,12,13,59,69,A total of 75/829 (9.4%) patients experienced reactions to nimesulide or paracetamol.,11694026_5,-1,-1,-1,1991,-1,0.99920326,0.0007967835
1993,nimesulide,6,7,32,42,"Of the 715 patients tested with nimesulide 62 (8.6%) showed a positive test, while of 114 subjects submitted to the challenge with paracetamol, 13 (9.6%) did not tolerate this drug.",11694026_6,-1,-1,-1,1993,-1,0.9991634,0.00083661947
1998,nimesulide,10,11,61,71,"Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.",11694026_8,-1,-1,-1,1998,-1,0.9991916,0.00080836896
2000,NSAIDs,20,21,147,153,"Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.",11694026_8,-1,-1,-1,2000,-1,0.9990069,0.000993151
2012,ocular hypertension,10,12,76,95,"METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).",11704023_4,-1,-1,-1,2012,-1,0.0014191207,0.99858093
2013,/-SD,17,18,110,114,"METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).",11704023_4,-1,-1,-1,2013,-1,0.23318385,0.76681614
2018,P,18,19,109,110,"RESULTS: Both timolol solution and timolol gellan reduced the mean 24-hour heart rate compared with placebo (P < or = .001), and this reduction was most pronounced during the daytime (-7.5% change in mean heart rate, -5.7 beats/min).",11704023_6,-1,-1,-1,2018,-1,0.4002259,0.59977406
2023,P,34,35,216,217,"During the night, the mean 12-hour heart rate on placebo and timolol gellan were both significantly less than on timolol solution; the difference between solution and gellan treatments was statistically significant (P = .01).",11704023_8,-1,-1,-1,2023,-1,0.3571579,0.6428421
2029,hepatitis C,10,12,81,92,Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications.,11705128_0,-1,-1,-1,2029,-1,0.0015483475,0.9984516
2030,interferon,15,16,127,137,OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).,11705128_1,-1,-1,-1,2030,-1,0.99908495,0.0009150461
2031,chronic hepatitis C,26,29,224,243,OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).,11705128_1,-1,-1,-1,2031,-1,0.002001779,0.9979982
2032,CHC,30,31,245,248,OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).,11705128_1,-1,-1,-1,2032,-1,0.00157152,0.99842846
2034,RIHA,15,16,114,118,Combination therapy is associated with a clinically important adverse effect: ribavirin-induced hemolytic anemia (RIHA).,11705128_2,-1,-1,-1,2034,-1,0.0014841445,0.9985159
2035,RIHA,15,16,91,95,The objective of this study was to evaluate the direct health-care costs and management of RIHA during treatment of CHC in a clinical trial setting.,11705128_3,-1,-1,-1,2035,-1,0.0069361613,0.99306387
2036,CHC,19,20,116,119,The objective of this study was to evaluate the direct health-care costs and management of RIHA during treatment of CHC in a clinical trial setting.,11705128_3,-1,-1,-1,2036,-1,0.0017049521,0.998295
2037,RIHA,17,18,115,119,METHODS: A systematic literature review was conducted to synthesize information on the incidence and management of RIHA.,11705128_4,-1,-1,-1,2037,-1,0.0026969546,0.997303
2038,RIHA,10,11,72,76,Decision-analytic techniques were used to estimate the cost of treating RIHA.,11705128_5,-1,-1,-1,2038,-1,0.003636372,0.9963637
2039,RIHA,2,3,9,13,"RESULTS: RIHA, defined as a reduction in hemoglobin to less than 100 g/L, occurs in approximately 7% to 9% of patients treated with combination therapy.",11705128_7,-1,-1,-1,2039,-1,0.0033785354,0.9966215
2040,RIHA,7,8,39,43,The standard of care for management of RIHA is reduction or discontinuation of the ribavirin dosage.,11705128_8,-1,-1,-1,2040,-1,0.0018299295,0.99817
2042,RIHA,9,10,64,68,We estimated the direct cost of treating clinically significant RIHA to be  170 per patient receiving combination therapy per 48-week treatment course (range  68- 692).,11705128_9,-1,-1,-1,2042,-1,0.002270348,0.9977297
2043,RIHA,24,25,135,139,"In comparison, the cost of 48 weeks of combination therapy is  16,459. CONCLUSIONS: The direct cost of treating clinically significant RIHA is 1% ( 170/ 16,459) of drug treatment costs.",11705128_11,-1,-1,-1,2043,-1,0.0027426553,0.9972574
2045,RIHA,12,13,74,78,Questions remain about the optimal dose of ribavirin and the incidence of RIHA in a real-world population.,11705128_12,-1,-1,-1,2045,-1,0.0019650215,0.998035
2046,RIHA,13,14,84,88,"Despite these uncertainties, this initial evaluation of the direct cost of treating RIHA provides an estimate of the cost and management implications of this clinically important adverse effect.",11705128_13,-1,-1,-1,2046,-1,0.0021066433,0.9978934
2048,lactate,8,9,74,81,Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice.,11706060_0,-1,-1,-1,2048,-1,0.9971686,0.0028313554
2049,AIDS,11,12,96,100,Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice.,11706060_0,-1,-1,-1,2049,-1,0.004268362,0.99573165
2051,CM,12,13,78,80,Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.,11706060_1,-1,-1,-1,2051,-1,0.0018261987,0.99817383
2052,lactate,18,19,105,112,Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.,11706060_1,-1,-1,-1,2052,-1,0.99796695,0.002032978
2053,LA,20,21,114,116,Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.,11706060_1,-1,-1,-1,2053,-1,0.9761431,0.023856817
2054,AIDS,23,24,121,125,Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.,11706060_1,-1,-1,-1,2054,-1,0.0016398311,0.9983602
2056,AIDS,12,13,87,91,"To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.",11706060_2,-1,-1,-1,2056,-1,0.0077088177,0.99229115
2060,atrial natriuretic factor,22,25,148,173,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,-1,-1,-1,2060,-1,0.9967571,0.0032429134
2061,ANF,26,27,175,178,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,-1,-1,-1,2061,-1,0.9981077,0.0018922888
2063,LA,41,42,251,253,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,-1,-1,-1,2063,-1,0.99583995,0.0041600405
2064,TG,5,6,21,23,"After 35 days in the TG + HAART cohort, left ventricular mass increased 160% by echocardiography.",11706060_5,-1,-1,-1,2064,-1,0.9940957,0.0059043397
2065,ANF,2,3,13,16,"Molecularly, ANF mRNA increased 250% and SERCA2 mRNA decreased 57%.",11706060_6,-1,-1,-1,2065,-1,0.99757916,0.002420811
2066,LA,2,3,15,17,"Biochemically, LA was elevated (8.5 +/- 2.0 mM).",11706060_7,-1,-1,-1,2066,-1,0.9875574,0.012442621
2067,mM,10,11,44,46,"Biochemically, LA was elevated (8.5 +/- 2.0 mM).",11706060_7,-1,-1,-1,2067,-1,0.19587159,0.8041284
2068,ANF,5,6,20,23,"After 10 days, only ANF was elevated, and only in the TG + HAART cohort.",11706060_11,-1,-1,-1,2068,-1,0.99320674,0.006793254
2069,TG,13,14,54,56,"After 10 days, only ANF was elevated, and only in the TG + HAART cohort.",11706060_11,-1,-1,-1,2069,-1,0.9938305,0.0061695534
2070,CM,7,8,56,58,Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice.,11706060_12,-1,-1,-1,2070,-1,0.002305597,0.99769443
2071,LA,10,11,73,75,Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice.,11706060_12,-1,-1,-1,2071,-1,0.9880922,0.011907862
2072,AIDS,12,13,79,83,Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice.,11706060_12,-1,-1,-1,2072,-1,0.003756356,0.9962437
2074,WR-2721,7,8,35,42,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,-1,-1,-1,2074,-1,0.9988236,0.0011763468
2087,WR-2721,0,1,0,7,WR-2721 or amifostine initially was developed to protect military personnel in the event of nuclear war.,11745184_3,-1,-1,-1,2087,-1,0.99872977,0.0012701965
2090,alkylating agents,13,15,86,103,Amifostine subsequently was shown to protect normal tissues from the toxic effects of alkylating agents and cisplatin without decreasing the antitumor effect of the chemotherapy.,11745184_4,-1,-1,-1,2090,-1,0.998458,0.0015420201
2105,disease progression,7,9,47,66,Treatment was administered every 3 weeks until disease progression.,11745184_10,-1,-1,-1,2105,-1,0.0027173853,0.9972826
2106,disease progression,10,12,49,68,Most patients (57%) stopped treatment because of disease progression.,11745184_14,-1,-1,-1,2106,-1,0.0019737526,0.9980262
2107,Neurologic toxicity,0,2,0,19,Neurologic toxicity was reported in 52% of patients.,11745184_15,-1,-1,-1,2107,-1,0.0012827654,0.9987173
2115,myocardial infarction,6,8,36,57,Oral contraceptives and the risk of myocardial infarction.,11752354_0,-1,-1,-1,2115,-1,0.0018546565,0.99814534
2117,myocardial infarction,14,16,82,103,"BACKGROUND: An association between the use of oral contraceptives and the risk of myocardial infarction has been found in some, but not all, studies.",11752354_1,-1,-1,-1,2117,-1,0.0017578864,0.99824214
2118,progestagen,10,11,59,70,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,-1,2118,-1,0.99910766,0.00089233706
2120,gestodene,19,20,122,131,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,-1,2120,-1,0.999273,0.0007270486
2121,levonorgestrel,26,27,162,176,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,-1,2121,-1,0.99916625,0.00083371473
2124,myocardial infarction,72,74,424,445,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,-1,2124,-1,0.0019819632,0.998018
2125,myocardial infarction,87,89,508,529,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,-1,2125,-1,0.0019577884,0.9980422
2126,factor V Leiden,3,6,16,31,"An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).",11752354_4,-1,-1,-1,2126,-1,0.020777846,0.9792221
2127,myocardial infarction,28,30,156,177,"An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).",11752354_4,-1,-1,-1,2127,-1,0.0015908745,0.9984092
2128,combined oral contraceptive,37,40,211,238,"An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).",11752354_4,-1,-1,-1,2128,-1,0.99764544,0.0023546012
2132,myocardial infarction,50,52,257,278,"Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of myocardial infarction was increased among women who used second-generation oral contraceptives.",11752354_6,-1,-1,-1,2132,-1,0.0015173778,0.99848264
2136,myocardial infarction,3,5,12,33,The risk of myocardial infarction was similar among women who used oral contraceptives whether or not they had a prothrombotic mutation.,11752354_8,-1,-1,-1,2136,-1,0.0014880494,0.99851197
2146,mg,38,39,242,244,"METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg.",11752998_3,-1,-1,-1,2146,-1,0.99069655,0.009303439
2148,mg,49,50,306,308,"METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg.",11752998_3,-1,-1,-1,2148,-1,0.99052936,0.009470672
2150,mechanical hyperalgesia,20,22,127,150,"Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.",11752998_4,-1,-1,-1,2150,-1,0.0014025324,0.99859744
2151,allodynia,23,24,155,164,"Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.",11752998_4,-1,-1,-1,2151,-1,0.0012301691,0.9987698
2156,allodynia,21,22,142,151,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,-1,-1,2156,-1,0.0013313536,0.9986687
2158,h.,30,31,205,207,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,-1,-1,2158,-1,0.13605733,0.8639426
2159,contrast,32,33,211,219,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,-1,-1,2159,-1,0.25366458,0.7463354
2161,h,46,47,287,288,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,-1,-1,2161,-1,0.21261248,0.78738755
2167,renal disease,1,3,10,23,End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.,11773892_0,-1,-1,-1,2167,-1,0.0014010126,0.998599
2168,ESRD,4,5,25,29,End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.,11773892_0,-1,-1,-1,2168,-1,0.0013140136,0.998686
2169,calcineurin inhibitors cyclosporine,3,6,16,51,BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic.,11773892_1,-1,-1,-1,2169,-1,0.99894816,0.0010518177
2172,renal disease,18,20,100,113,"Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD).",11773892_3,-1,-1,-1,2172,-1,0.001565367,0.9984346
2173,ESRD,21,22,115,119,"Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD).",11773892_3,-1,-1,-1,2173,-1,0.0014572248,0.9985428
2174,ESRD,9,10,65,69,This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients.,11773892_4,-1,-1,-1,2174,-1,0.0011601478,0.9988399
2176,CRF,15,16,97,100,This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients.,11773892_4,-1,-1,-1,2176,-1,0.0013918397,0.9986082
2177,n=834,22,23,133,138,METHODS: Patients receiving an OLTX only from June 1985 through December of 1994 who survived 6 months postoperatively were studied (n=834).,11773892_5,-1,-1,-1,2177,-1,0.2328152,0.7671848
2178,CRF,10,11,54,57,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2178,-1,0.0017289566,0.998271
2179,ESRD,12,13,61,65,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2179,-1,0.0016939759,0.99830604
2180,n=748,14,15,67,72,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2180,-1,0.11595991,0.8840401
2181,CRF,16,17,74,77,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2181,-1,0.002355689,0.99764425
2183,n=41,25,26,118,122,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2183,-1,0.06249905,0.937501
2184,ESRD,28,29,128,132,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2184,-1,0.0017151908,0.99828476
2185,n=45,30,31,134,138,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2185,-1,0.044866167,0.9551338
2186,ESRD,17,18,114,118,"Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD.",11773892_8,-1,-1,-1,2186,-1,0.0027189392,0.9972811
2187,ESRD,25,26,155,159,"Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD.",11773892_8,-1,-1,-1,2187,-1,0.0017797194,0.99822026
2189,CRF,18,19,86,89,"RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%).",11773892_9,-1,-1,-1,2189,-1,0.0014522217,0.99854773
2190,ESRD,22,23,99,103,"RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%).",11773892_9,-1,-1,-1,2190,-1,0.0014309441,0.998569
2191,CRF,5,6,32,35,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,-1,-1,-1,2191,-1,0.0018884096,0.9981116
2192,ESRD,7,8,40,44,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,-1,-1,-1,2192,-1,0.0016171935,0.9983828
2194,hepatorenal syndrome,22,24,141,161,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,-1,-1,-1,2194,-1,0.0012871554,0.9987129
2197,CRF,39,40,270,273,"Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.",11773892_11,-1,-1,-1,2197,-1,0.0019240626,0.99807596
2198,ESRD,41,42,277,281,"Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.",11773892_11,-1,-1,-1,2198,-1,0.0019185195,0.99808145
2199,ESRD,26,27,138,142,"Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group.",11773892_12,-1,-1,-1,2199,-1,0.0018050101,0.998195
2200,ESRD,2,3,20,24,Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants.,11773892_13,-1,-1,-1,2200,-1,0.0013069765,0.99869305
2201,ESRD,10,11,62,66,Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants.,11773892_13,-1,-1,-1,2201,-1,0.0013366884,0.9986633
2202,ESRD,26,27,155,159,Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants.,11773892_13,-1,-1,-1,2202,-1,0.0013083452,0.9986916
2203,CRF,11,12,64,67,CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate.,11773892_14,-1,-1,-1,2203,-1,0.0016564218,0.9983436
2204,ESRD,13,14,72,76,CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate.,11773892_14,-1,-1,-1,2204,-1,0.0015554952,0.9984445
2205,ESRD,3,4,19,23,"The development of ESRD decreases survival, particularly in those patients treated with dialysis only.",11773892_15,-1,-1,-1,2205,-1,0.0015271273,0.99847287
2206,ESRD,3,4,21,25,Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome.,11773892_16,-1,-1,-1,2206,-1,0.0013119247,0.99868804
2208,hepatorenal syndrome,18,20,109,129,Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome.,11773892_16,-1,-1,-1,2208,-1,0.0013228523,0.9986771
2210,CRF,18,19,115,118,"However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD.",11773892_17,-1,-1,-1,2210,-1,0.0015581896,0.9984419
2211,ESRD,20,21,122,126,"However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD.",11773892_17,-1,-1,-1,2211,-1,0.0014452843,0.99855477
2212,Epileptic seizures,0,2,0,18,Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats.,11807648_0,-1,-1,-1,2212,-1,0.0014660087,0.99853396
2213,tranexamic acid,9,11,80,95,Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats.,11807648_0,-1,-1,-1,2213,-1,0.99919266,0.00080735015
2214,fibrinolysis inhibitors,3,5,20,43,"Recently, synthetic fibrinolysis inhibitors such as tranexamic acid (tAMCA) have been considered as substitutes for aprotinin.",11807648_3,-1,-1,-1,2214,-1,0.3747065,0.6252935
2215,tranexamic acid,7,9,52,67,"Recently, synthetic fibrinolysis inhibitors such as tranexamic acid (tAMCA) have been considered as substitutes for aprotinin.",11807648_3,-1,-1,-1,2215,-1,0.9992053,0.00079470273
2216,tAMCA,10,11,69,74,"Recently, synthetic fibrinolysis inhibitors such as tranexamic acid (tAMCA) have been considered as substitutes for aprotinin.",11807648_3,-1,-1,-1,2216,-1,0.99881124,0.001188755
2217,tAMCA,2,3,9,14,"However, tAMCA has been shown to cause epileptic seizures.",11807648_4,-1,-1,-1,2217,-1,0.99612707,0.0038730062
2218,epileptic seizures,8,10,39,57,"However, tAMCA has been shown to cause epileptic seizures.",11807648_4,-1,-1,-1,2218,-1,0.0013647283,0.99863523
2219,tAMCA,5,6,27,32,We wanted to study whether tAMCA retains its convulsive action if incorporated into a FS.,11807648_5,-1,-1,-1,2219,-1,0.99872404,0.0012759562
2221,tAMCA,9,10,63,68,METHOD: FS containing aprotinin or different concentrations of tAMCA (0.5-47.5 mg/ml) were applied to the pial surface of the cortex of anaesthetized rats.,11807648_6,-1,-1,-1,2221,-1,0.99919826,0.0008017745
2222,tAMCA,4,5,24,29,FINDINGS: FS containing tAMCA caused paroxysmal brain activity which was associated with distinct convulsive behaviours.,11807648_8,-1,-1,-1,2222,-1,0.9988462,0.0011538282
2225,tAMCA,10,11,72,77,The degree of these seizures increased with increasing concentration of tAMCA.,11807648_9,-1,-1,-1,2225,-1,0.99887544,0.0011245743
2226,tAMCA,6,7,31,36,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,-1,-1,-1,2226,-1,0.9991345,0.0008654959
2227,generalized seizures,8,10,44,64,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,-1,-1,-1,2227,-1,0.0014975544,0.9985025
2228,n=6,15,16,85,88,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,-1,-1,-1,2228,-1,0.07825807,0.9217419
2229,tAMCA,22,23,124,129,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,-1,-1,-1,2229,-1,0.99918,0.0008199579
2231,contrast,1,2,3,11,"In contrast, FS containing aprotinin did not evoke any paroxysmal activity.",11807648_11,-1,-1,-1,2231,-1,0.334217,0.66578305
2232,Tranexamic acid,2,4,16,31,INTERPRETATION: Tranexamic acid retains its convulsive action within FS.,11807648_12,-1,-1,-1,2232,-1,0.99912935,0.00087071466
2234,tAMCA,6,7,27,32,"Thus, use of FS containing tAMCA for surgery within or close to the CNS may pose a substantial risk to the patient.",11807648_13,-1,-1,-1,2234,-1,0.9981249,0.0018750661
2238,thromboemboli,19,20,126,139,"BACKGROUND: Heparin-induced thrombocytopenia presents 5 to 12 days after heparin exposure, with or without arterial or venous thromboemboli.",11827497_1,-1,-1,-1,2238,-1,0.0011588434,0.9988412
2242,thromboembolic complications,19,21,134,162,PATIENTS: 14 patients seen over a 3-year period in whom heparin-induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications.,11827497_6,-1,-1,-1,2242,-1,0.0011725902,0.9988274
2243,thromboembolism,9,10,63,78,"MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.",11827497_7,-1,-1,-1,2243,-1,0.0011420693,0.998858
2244,platelet factor 4,14,17,107,124,"MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.",11827497_7,-1,-1,-1,2244,-1,0.96498233,0.035017654
2247,thromboembolic complications,35,37,192,220,"RESULTS: Patients went home after hospitalizations that had included heparin exposure--in most cases, with no thrombocytopenia recognized--only to return to the hospital (median, day 14) with thromboembolic complications.",11827497_8,-1,-1,-1,2247,-1,0.001346499,0.99865353
2248,Thromboemboli,0,1,0,13,"Thromboemboli were venous (12 patients, 7 with pulmonary emboli) or arterial (4 patients) or both.",11827497_9,-1,-1,-1,2248,-1,0.0014401211,0.9985599
2249,pulmonary emboli,9,11,47,63,"Thromboemboli were venous (12 patients, 7 with pulmonary emboli) or arterial (4 patients) or both.",11827497_9,-1,-1,-1,2249,-1,0.0016182764,0.99838173
2255,thromboembolism,17,18,142,157,"To avoid disastrous outcomes, physicians must consider heparin-induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism; therapy with alternative anticoagulants, not heparin, should be initiated.",11827497_16,-1,-1,-1,2255,-1,0.0011645961,0.9988354
2258,dopamine agonist,6,8,59,75,Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.,11838826_0,-1,-1,-1,2258,-1,0.9990343,0.0009657836
2261,prolactinomas,7,8,55,68,Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature.,11838826_2,-1,-1,-1,2261,-1,0.29902914,0.7009709
2262,arrested,12,13,92,100,Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature.,11838826_2,-1,-1,-1,2262,-1,0.0028902048,0.99710983
2263,delayed puberty,19,21,144,159,Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature.,11838826_2,-1,-1,-1,2263,-1,0.002595839,0.99740416
2264,short stature,22,24,163,176,Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature.,11838826_2,-1,-1,-1,2264,-1,0.0017332243,0.9982667
2267,cabergoline,9,10,82,93,We report the successful treatment of risperidone-induced hyperprolactinemia with cabergoline in youth.,11838826_4,-1,-1,-1,2267,-1,0.99930096,0.000698989
2269,cabergoline,16,17,124,135,METHODS: We undertook a retrospective case review of four children with risperidone-induced hyperprolactinemia treated with cabergoline.,11838826_5,-1,-1,-1,2269,-1,0.99930525,0.00069475395
2270,Mental Disorders,17,19,79,95,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,-1,-1,-1,2270,-1,0.002198715,0.99780124
2271,bipolar disorder,23,25,113,129,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,-1,-1,-1,2271,-1,0.0014524776,0.9985475
2272,psychoses,26,27,133,142,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,-1,-1,-1,2272,-1,0.0014666455,0.99853337
2273,cabergoline,51,52,261,272,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,-1,-1,-1,2273,-1,0.99931586,0.00068410416
2274,cabergoline,19,20,92,103,"When serum prolactin levels normalized in all four subjects (mean 11.2 +/- 10.9 ng/mL), the cabergoline dose was reduced to 1 mg/week in three of four subjects.",11838826_7,-1,-1,-1,2274,-1,0.99928266,0.00071736914
2275,cabergoline,6,7,34,45,"The mean duration of therapy with cabergoline was 523.5 +/- 129.7 days, and the mean duration of therapy with risperidone was 788.5 +/- 162.5 days.",11838826_8,-1,-1,-1,2275,-1,0.9993011,0.00069893146
2277,Cabergoline,0,1,0,11,Cabergoline was well tolerated without adverse effects.,11838826_9,-1,-1,-1,2277,-1,0.9991478,0.00085221254
2278,Cabergoline,2,3,13,24,"CONCLUSIONS: Cabergoline may be useful for the treatment of risperidone-induced hyperprolactinemia in youth; however, further research is needed.",11838826_10,-1,-1,-1,2278,-1,0.999257,0.0007429201
2280,cholestatic hepatitis,1,3,6,27,Acute cholestatic hepatitis after exposure to isoflurane.,11847945_0,-1,-1,-1,2280,-1,0.0014512975,0.9985487
2282,cholestatic hepatitis,8,10,37,58,OBJECTIVE: To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic isoflurane.,11847945_1,-1,-1,-1,2282,-1,0.0012247761,0.9987752
2284,cholestatic hepatitis,11,13,68,89,CASE SUMMARY: A 70-year-old healthy woman from Iraq developed acute cholestatic hepatitis 3 weeks following repair of the right rotator cuff under general anesthesia.,11847945_2,-1,-1,-1,2284,-1,0.0013150251,0.99868494
2286,dipyrone,7,8,46,54,No other medications were involved except for dipyrone for analgesia.,11847945_4,-1,-1,-1,2286,-1,0.9990821,0.00091784453
2287,analgesia,9,10,59,68,No other medications were involved except for dipyrone for analgesia.,11847945_4,-1,-1,-1,2287,-1,0.0027590075,0.997241
2290,dipyrone,6,7,40,48,Accidental reexposure by the patient to dipyrone was uneventful.,11847945_6,-1,-1,-1,2290,-1,0.99900645,0.0009935631
2291,halothane hepatitis,11,13,71,90,"DISCUSSION: The clinical and histologic picture of this case resembles halothane hepatitis, which has a significant mortality rate.",11847945_7,-1,-1,-1,2291,-1,0.7376434,0.26235652
2293,cholestatic hepatitis,12,14,69,90,"CONCLUSIONS: Isoflurane, a common anesthetic agent, can cause severe cholestatic hepatitis.",11847945_8,-1,-1,-1,2293,-1,0.001264735,0.99873525
2294,Torsade de pointes,0,3,0,18,Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.,11858397_0,-1,-1,-1,2294,-1,0.001857143,0.99814284
2296,left bundle branch block,13,17,91,115,Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.,11858397_0,-1,-1,-1,2296,-1,0.0053182854,0.99468166
2297,long QT syndrome,10,13,56,72,There is a growing list of drugs implicated in acquired long QT syndrome and torsade de pointes.,11858397_1,-1,-1,-1,2297,-1,0.0016928207,0.9983072
2298,torsade de pointes,14,17,77,95,There is a growing list of drugs implicated in acquired long QT syndrome and torsade de pointes.,11858397_1,-1,-1,-1,2298,-1,0.0018850368,0.99811494
2301,left bundle branch block,9,13,59,83,We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.,11858397_3,-1,-1,-1,2301,-1,0.0050775986,0.99492246
2302,torsade de pointes,15,18,98,116,We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.,11858397_3,-1,-1,-1,2302,-1,0.001961797,0.99803823
2304,torsade de pointes,4,7,28,46,This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously.,11858397_4,-1,-1,-1,2304,-1,0.0021020982,0.99789786
2306,erythromycin,10,11,66,78,This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously.,11858397_4,-1,-1,-1,2306,-1,0.9991881,0.00081187295
2308,torsade de pointes,8,11,61,79,This is the first documentation that metoclopramide provokes torsade de pointes clinically.,11858397_6,-1,-1,-1,2308,-1,0.0023126581,0.99768734
2310,torsade de pointes,11,14,68,86,Metoclopramide should be used cautiously in patients with a risk of torsade de pointes.,11858397_7,-1,-1,-1,2310,-1,0.0021608646,0.99783915
2312,cell death,6,8,49,59,Dopamine D2 receptor signaling controls neuronal cell death induced by muscarinic and glutamatergic drugs.,11860278_0,-1,-1,-1,2312,-1,0.0026845986,0.99731535
2314,DA,2,3,10,12,"Dopamine (DA), through D1/D2 receptor-mediated signaling, plays a major role in the control of epileptic seizures arising in the limbic system.",11860278_1,-1,-1,-1,2314,-1,0.99874866,0.0012513727
2315,epileptic seizures,18,20,95,113,"Dopamine (DA), through D1/D2 receptor-mediated signaling, plays a major role in the control of epileptic seizures arising in the limbic system.",11860278_1,-1,-1,-1,2315,-1,0.0013914144,0.99860865
2316,Excitotoxicity,0,1,0,14,Excitotoxicity leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level.,11860278_2,-1,-1,-1,2316,-1,0.0012719937,0.998728
2319,DA,11,12,51,53,"In this respect, little is known about the role of DA receptors in the occurrence of epilepsy-induced neuronal cell death.",11860278_3,-1,-1,-1,2319,-1,0.9988206,0.0011793672
2320,cell death,19,21,111,121,"In this respect, little is known about the role of DA receptors in the occurrence of epilepsy-induced neuronal cell death.",11860278_3,-1,-1,-1,2320,-1,0.002130432,0.9978695
2324,kainic acid,9,11,62,73,"We compared these results with those previously obtained with kainic acid (KA), a potent glutamate agonist.",11860278_5,-1,-1,-1,2324,-1,0.99912304,0.00087695714
2325,KA,12,13,75,77,"We compared these results with those previously obtained with kainic acid (KA), a potent glutamate agonist.",11860278_5,-1,-1,-1,2325,-1,0.998787,0.0012130315
2330,neuronal death,9,11,66,80,"However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.",11860278_7,-1,-1,-1,2330,-1,0.0013738,0.99862623
2331,KA,21,22,128,130,"However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.",11860278_7,-1,-1,-1,2331,-1,0.99866486,0.0013351566
2335,neurodegeneration,7,8,55,72,"Moreover, the dopaminergic control of epilepsy-induced neurodegeneration seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters.",11860278_9,-1,-1,-1,2335,-1,0.00115605,0.9988439
2337,pregnenolone sulphate,10,12,87,108,Steroid structure and pharmacological properties determine the anti-amnesic effects of pregnenolone sulphate in the passive avoidance task in rats.,11860495_0,-1,-1,-1,2337,-1,0.99907887,0.0009210913
2338,Pregnenolone sulphate,0,2,0,21,"Pregnenolone sulphate (PREGS) has generated interest as one of the most potent memory-enhancing neurosteroids to be examined in rodent learning studies, with particular importance in the ageing process.",11860495_1,-1,-1,-1,2338,-1,0.99873847,0.0012615385
2339,PREGS,3,4,23,28,"Pregnenolone sulphate (PREGS) has generated interest as one of the most potent memory-enhancing neurosteroids to be examined in rodent learning studies, with particular importance in the ageing process.",11860495_1,-1,-1,-1,2339,-1,0.99732375,0.0026762239
2341,PREGS,6,7,41,46,This hypothesis stems from findings that PREGS is a potent positive modulator of N-methyl-d-aspartate receptors (NMDARs) and a negative modulator of gamma-aminobutyric acid(A) receptors (GABA(A)Rs).,11860495_3,-1,-1,-1,2341,-1,0.99550974,0.0044902945
2342,PREGS,2,3,10,15,"Moreover, PREGS is able to reverse the amnesic-like effects of NMDAR and GABA(A)R ligands.",11860495_4,-1,-1,-1,2342,-1,0.99695337,0.003046564
2343,PREGS,18,19,122,127,"To investigate this hypothesis, the present study in rats examined the memory-altering abilities of structural analogs of PREGS, which differ in their modulation of NMDAR and/or GABA(A)R function.",11860495_5,-1,-1,-1,2343,-1,0.99818736,0.0018125888
2344,11-ketopregnenolone sulphate,5,7,25,53,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,-1,-1,-1,2344,-1,0.99844223,0.0015577727
2345,epipregnanolone,19,20,107,122,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,-1,-1,-1,2345,-1,0.99925166,0.00074829353
2346,PREGS,42,43,243,248,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,-1,-1,-1,2346,-1,0.9969079,0.0030921577
2347,PREGS,49,50,283,288,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,-1,-1,-1,2347,-1,0.99810433,0.0018956393
2348,PREGS,4,5,32,37,The memory-enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine-induced amnesia.,11860495_7,-1,-1,-1,2348,-1,0.9984658,0.0015342357
2350,PREGS,1,2,5,10,Both PREGS and its (-) enantiomer blocked the effects of scopolamine.,11860495_8,-1,-1,-1,2350,-1,0.9965668,0.0034331942
2352,PREGS,6,7,30,35,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,-1,-1,-1,2352,-1,0.995996,0.0040039825
2353,11-ketopregnenolone sulphate,8,10,37,65,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,-1,-1,-1,2353,-1,0.99865544,0.0013445279
2354,epipregnanolone sulphate,11,13,70,94,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,-1,-1,-1,2354,-1,0.9990742,0.0009257663
2356,NMDA,27,28,181,185,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,-1,-1,-1,2356,-1,0.99895537,0.0010446138
2357,PREGS,34,35,239,244,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,-1,-1,-1,2357,-1,0.99634004,0.0036599508
2358,PREGS,10,11,72,77,"Moreover, enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine-induced amnesia.",11860495_10,-1,-1,-1,2358,-1,0.99670464,0.0032953795
2361,heart failure,10,12,92,105,Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure.,11861791_0,-1,-1,-1,2361,-1,0.0013097677,0.9986902
2362,DNA damage,13,15,88,98,Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.,11861791_1,-1,-1,-1,2362,-1,0.14007422,0.8599258
2363,dysfunction,21,22,131,142,Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.,11861791_1,-1,-1,-1,2363,-1,0.001795349,0.9982046
2364,tissue injury,23,25,147,160,Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.,11861791_1,-1,-1,-1,2364,-1,0.00213718,0.9978629
2367,DOX,14,15,94,97,"Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.",11861791_2,-1,-1,-1,2367,-1,0.9987821,0.0012178929
2370,PJ34,19,20,136,140,"Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX.",11861791_4,-1,-1,-1,2370,-1,0.9988171,0.0011828854
2372,DOX,36,37,231,234,"Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX.",11861791_4,-1,-1,-1,2372,-1,0.9989398,0.0010601798
2373,DOX,9,10,60,63,PARP-1+/+ and PARP-1-/- mice received a single injection of DOX (25 mg/kg i.p).,11861791_5,-1,-1,-1,2373,-1,0.9989017,0.0010982283
2374,DOX,3,4,16,19,"Five days after DOX administration, left ventricular performance was significantly depressed in PARP-1+/+ mice, but only to a smaller extent in PARP-1-/- ones.",11861791_6,-1,-1,-1,2374,-1,0.998868,0.0011319994
2376,PJ34,9,10,63,67,Similar experiments were conducted in BALB/c mice treated with PJ34 or vehicle.,11861791_7,-1,-1,-1,2376,-1,0.99809545,0.001904555
2377,PJ34,3,4,17,21,Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals.,11861791_8,-1,-1,-1,2377,-1,0.995983,0.0040169647
2379,PJ34,2,3,12,16,In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.,11861791_9,-1,-1,-1,2379,-1,0.9984693,0.0015307261
2380,lactate,11,12,77,84,In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.,11861791_9,-1,-1,-1,2380,-1,0.99821436,0.0017856702
2381,creatine kinase,14,16,103,118,In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.,11861791_9,-1,-1,-1,2381,-1,0.9977731,0.0022269124
2383,DOX,9,10,59,62,"Thus, PARP activation contributes to the cardiotoxicity of DOX.",11861791_10,-1,-1,-1,2383,-1,0.99794024,0.002059686
2384,cardiac complications,11,13,79,100,PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment.,11861791_11,-1,-1,-1,2384,-1,0.0012363101,0.9987637
2385,DOX,16,17,121,124,PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment.,11861791_11,-1,-1,-1,2385,-1,0.9984604,0.0015395933
2387,hypokalemia,13,14,80,91,"Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.",11868798_0,-1,-1,-1,2387,-1,0.0011146532,0.99888533
2390,amphotericin B,25,27,168,182,"Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.",11868798_0,-1,-1,-1,2390,-1,0.9989705,0.0010295234
2391,AmB,28,29,184,187,"Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.",11868798_0,-1,-1,-1,2391,-1,0.9986185,0.0013815555
2392,epithelial toxicity,3,5,25,44,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2392,-1,0.0022780295,0.99772197
2393,potassium wasting,12,14,86,103,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2393,-1,0.15632078,0.84367925
2394,AmB.,24,25,159,163,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2394,-1,0.8951626,0.10483746
2396,tubular toxicity,30,32,205,221,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2396,-1,0.0020862254,0.9979138
2397,AmB.,33,34,225,229,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2397,-1,0.8893542,0.11064579
2400,hypokalemia,51,52,342,353,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2400,-1,0.0016559425,0.99834406
2401,neutropenic,53,54,357,368,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2401,-1,0.0017315248,0.9982685
2402,AmB,56,57,381,384,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2402,-1,0.99879515,0.0012047895
2403,hematological disorders,9,11,48,71,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,-1,-1,-1,2403,-1,0.0011674678,0.9988325
2404,AmB,17,18,118,121,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,-1,-1,-1,2404,-1,0.9984402,0.0015597482
2405,AmB,20,21,131,134,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,-1,-1,-1,2405,-1,0.9984548,0.0015452126
2407,mg,25,26,163,165,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,-1,-1,-1,2407,-1,0.99697447,0.0030254838
2408,fungal infection,34,36,216,232,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,-1,-1,-1,2408,-1,0.0014337492,0.9985663
2409,AmB,5,6,40,43,RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).,11868798_3,-1,-1,-1,2409,-1,0.998635,0.0013649844
2412,AmB,17,18,133,136,RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).,11868798_3,-1,-1,-1,2412,-1,0.99850684,0.0014931821
2413,P,20,21,144,145,RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).,11868798_3,-1,-1,-1,2413,-1,0.37452823,0.6254717
2414,AmB,3,4,25,28,Those patients receiving AmB and spironolactone required significantly less potassium supplementation to maintain their plasma potassium within the normal range (P = 0.022).,11868798_4,-1,-1,-1,2414,-1,0.99884605,0.0011539481
2418,P,21,22,162,163,Those patients receiving AmB and spironolactone required significantly less potassium supplementation to maintain their plasma potassium within the normal range (P = 0.022).,11868798_4,-1,-1,-1,2418,-1,0.4358231,0.5641769
2420,AmB,11,12,81,84,"Moreover, urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone (P = 0.040).",11868798_5,-1,-1,-1,2420,-1,0.99847,0.0015299801
2422,AmB,17,18,125,128,"Moreover, urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone (P = 0.040).",11868798_5,-1,-1,-1,2422,-1,0.998517,0.0014830155
2423,P,20,21,136,137,"Moreover, urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone (P = 0.040).",11868798_5,-1,-1,-1,2423,-1,0.2833959,0.7166041
2426,hypokalemia,13,14,96,107,CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.,11868798_6,-1,-1,-1,2426,-1,0.0014496151,0.99855036
2428,neutropenic,20,21,146,157,CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.,11868798_6,-1,-1,-1,2428,-1,0.0018660555,0.99813396
2429,AmB,23,24,170,173,CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.,11868798_6,-1,-1,-1,2429,-1,0.9987997,0.0012002839
2446,hemorrhaging,11,12,83,95,"Microscopic observation showed the configuration of exencephaly at E13.5, frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15.5, and multiple modes of reduction in the exencephalic tissue at E18.5.",11875660_8,-1,-1,-1,2446,-1,0.001509686,0.99849033
2451,peripheral circulatory failure,19,22,137,167,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,-1,-1,-1,2451,-1,0.0019344221,0.99806553
2452,hemorrhaging,23,24,175,187,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,-1,-1,-1,2452,-1,0.0014026379,0.9985973
2456,Erectile dysfunction,0,2,0,20,Erectile dysfunction occurs following substantia nigra lesions in the rat.,11890511_0,-1,-1,-1,2456,-1,0.0015255196,0.9984744
2457,nigra,5,6,49,54,Erectile dysfunction occurs following substantia nigra lesions in the rat.,11890511_0,-1,-1,-1,2457,-1,0.37246212,0.6275379
2459,penile erections,2,4,31,47,Behavioral apomorphine-induced penile erections were reduced (5/8) and increased (3/8) in uni- and bilateral lesioned animals.,11890511_2,-1,-1,-1,2459,-1,0.0018134734,0.9981865
2461,erectile dysfunction,9,11,62,82,Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson's disease.,11890511_6,-1,-1,-1,2461,-1,0.0014717929,0.99852824
2462,erectile dysfunction,21,23,125,145,Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson's disease.,11890511_6,-1,-1,-1,2462,-1,0.0015289504,0.9984711
2463,Parkinson's disease,24,27,149,168,Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson's disease.,11890511_6,-1,-1,-1,2463,-1,0.003153909,0.996846
2464,myocardial infarction,5,7,55,76,99mTc-glucarate for detection of isoproterenol-induced myocardial infarction in rats.,11897407_0,-1,-1,-1,2464,-1,0.0013445062,0.99865544
2468,glucaric acid,6,8,48,61,A new infarct-avid radiopharmaceutical based on glucaric acid was prepared in the hospital radiopharmacy of the INCMNSZ.,11897407_3,-1,-1,-1,2468,-1,0.99836,0.0016399637
2469,h,9,10,51,52,"99mTc-glucarate was easy to prepare, stable for 96 h and was used to study its biodistribution in rats with isoproterenol-induced acute myocardial infarction.",11897407_4,-1,-1,-1,2469,-1,0.124428146,0.87557185
2471,infarct,8,9,61,68,Histological studies demonstrated that the rats developed an infarct 18 h after isoproterenol administration.,11897407_5,-1,-1,-1,2471,-1,0.0015531931,0.9984469
2472,h,10,11,72,73,Histological studies demonstrated that the rats developed an infarct 18 h after isoproterenol administration.,11897407_5,-1,-1,-1,2472,-1,0.09534969,0.90465033
2474,contrast,7,8,42,50,"The high image quality suggests that high contrast images can be obtained in humans and the 96 h stability makes it an ideal agent to detect, in patients, early cardiac infarction.",11897407_9,-1,-1,-1,2474,-1,0.16629533,0.83370465
2475,h,17,18,95,96,"The high image quality suggests that high contrast images can be obtained in humans and the 96 h stability makes it an ideal agent to detect, in patients, early cardiac infarction.",11897407_9,-1,-1,-1,2475,-1,0.22825865,0.7717414
2476,cardiac infarction,31,33,161,179,"The high image quality suggests that high contrast images can be obtained in humans and the 96 h stability makes it an ideal agent to detect, in patients, early cardiac infarction.",11897407_9,-1,-1,-1,2476,-1,0.0014768258,0.9985232
2489,mecamylamine,7,8,54,66,"Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.",11900788_4,-1,-1,-1,2489,-1,0.99936193,0.0006381265
2503,morphine catalepsy,4,6,22,40,"It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors, and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms.",11900788_7,-1,-1,-1,2503,-1,0.11479665,0.8852033
2507,Parkinson's disease,6,9,51,70,Force overflow and levodopa-induced dyskinesias in Parkinson's disease.,11912119_0,-1,-1,-1,2507,-1,0.0021396216,0.9978604
2508,Parkinson's disease,8,11,46,65,"We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).",11912119_1,-1,-1,-1,2508,-1,0.0020213642,0.9979786
2511,LID,26,27,177,180,"We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).",11912119_1,-1,-1,-1,2511,-1,0.0014003883,0.9985996
2512,Parkinson's disease,5,8,25,44,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2512,-1,0.0026014561,0.9973985
2513,Parkinson's disease,11,14,60,79,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2513,-1,0.0024451974,0.99755484
2514,LID,15,16,82,85,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2514,-1,0.0016135727,0.9983864
2515,n,17,18,87,88,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2515,-1,0.01341646,0.98658353
2517,Parkinson's disease,26,29,137,156,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2517,-1,0.0027191122,0.99728084
2518,LID,30,31,159,162,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2518,-1,0.0016537714,0.9983462
2519,n,32,33,164,165,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2519,-1,0.009918394,0.9900816
2520,Parkinson's Disease,6,9,31,50,"The motor score of the Unified Parkinson's Disease Rating Scale, a dyskinesia score and force in a grip-lift paradigm were assessed ON and OFF levodopa.",11912119_3,-1,-1,-1,2520,-1,0.0035847384,0.99641526
2523,Parkinson's disease,10,13,58,77,A pathological increase of forces was seen in ON-state in Parkinson's disease + LID only.,11912119_4,-1,-1,-1,2523,-1,0.0028810466,0.99711895
2524,LID,14,15,80,83,A pathological increase of forces was seen in ON-state in Parkinson's disease + LID only.,11912119_4,-1,-1,-1,2524,-1,0.0020327342,0.9979672
2525,Parkinson's disease,1,4,3,22,"In Parkinson's disease + LID, the force involved in pressing down the object before lifting was significantly increased by levodopa (by 61%, P < 0.05).",11912119_5,-1,-1,-1,2525,-1,0.003328506,0.99667144
2526,LID,5,6,25,28,"In Parkinson's disease + LID, the force involved in pressing down the object before lifting was significantly increased by levodopa (by 61%, P < 0.05).",11912119_5,-1,-1,-1,2526,-1,0.002399811,0.99760014
2528,P,27,28,141,142,"In Parkinson's disease + LID, the force involved in pressing down the object before lifting was significantly increased by levodopa (by 61%, P < 0.05).",11912119_5,-1,-1,-1,2528,-1,0.5745112,0.42548886
2529,P,10,11,43,44,An overshooting of peak grip force by 51% (P < 0.05) and of static grip force by 45% (P < 0.01) was observed in the ON- compared with the OFF-drug condition.,11912119_6,-1,-1,-1,2529,-1,0.37875292,0.62124705
2530,P,23,24,86,87,An overshooting of peak grip force by 51% (P < 0.05) and of static grip force by 45% (P < 0.01) was observed in the ON- compared with the OFF-drug condition.,11912119_6,-1,-1,-1,2530,-1,0.39141354,0.60858643
2531,contrast,1,2,3,11,"In contrast, no excessive force was found in Parkinson's disease - LID.",11912119_7,-1,-1,-1,2531,-1,0.12403249,0.8759675
2532,Parkinson's disease,9,12,45,64,"In contrast, no excessive force was found in Parkinson's disease - LID.",11912119_7,-1,-1,-1,2532,-1,0.0035058965,0.9964941
2533,LID,13,14,67,70,"In contrast, no excessive force was found in Parkinson's disease - LID.",11912119_7,-1,-1,-1,2533,-1,0.0024016714,0.99759835
2534,P,9,10,38,39,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2534,-1,0.5124149,0.4875851
2535,Parkinson's disease,15,18,58,77,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2535,-1,0.0040777912,0.9959222
2536,LID,19,20,80,83,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2536,-1,0.0029702755,0.99702966
2537,Parkinson's disease,22,25,92,111,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2537,-1,0.0042598485,0.9957402
2538,LID,26,27,114,117,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2538,-1,0.0030606573,0.9969394
2539,P,38,39,166,167,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2539,-1,0.4533213,0.5466787
2541,P,20,21,113,114,"Severity of peak-dose dyskinesias was strongly correlated with grip force in ON-state (r = 0.79 with peak force, P < 0.01).",11912119_9,-1,-1,-1,2541,-1,0.46376833,0.53623164
2542,LID,8,9,48,51,Force excess was only observed in patients with LID and motor fluctuations.,11912119_11,-1,-1,-1,2542,-1,0.0016834851,0.9983165
2544,LID,4,5,23,26,We postulate that both LID and grip force excess share common pathophysiological mechanisms related to motor fluctuations.,11912119_13,-1,-1,-1,2544,-1,0.02360348,0.9763965
2546,Zyban,2,3,11,16,Bupropion (Zyban) toxicity.,11928786_0,-1,-1,-1,2546,-1,0.99878675,0.0012133019
2551,Zyban,0,1,0,5,"Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid.",11928786_2,-1,-1,-1,2551,-1,0.99902165,0.0009783916
2552,bupropion hydrochloride,6,8,42,65,"Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid.",11928786_2,-1,-1,-1,2552,-1,0.9991947,0.0008053013
2557,drowsiness,5,6,38,48,"Common features included tachycardia, drowsiness, hallucinations and convulsions.",11928786_5,-1,-1,-1,2557,-1,0.0013456732,0.99865425
2567,Zyban,0,1,0,5,Zyban caused significant neurological and cardiovascular toxicity in overdose.,11928786_10,-1,-1,-1,2567,-1,0.99816567,0.0018343367
2568,cardiovascular toxicity,5,7,42,65,Zyban caused significant neurological and cardiovascular toxicity in overdose.,11928786_10,-1,-1,-1,2568,-1,0.0012761494,0.9987238
2571,PAN nephrosis,9,11,52,65,GLEPP1 receptor tyrosine phosphatase (Ptpro) in rat PAN nephrosis.,11961407_0,-1,-1,-1,2571,-1,0.0016051022,0.9983949
2572,tyrosine phosphatase,13,15,81,101,Glomerular epithelial protein 1 (GLEPP1) is a podocyte receptor membrane protein tyrosine phosphatase located on the apical cell membrane of visceral glomerular epithelial cell and foot processes.,11961407_2,-1,-1,-1,2572,-1,0.9937959,0.0062041287
2573,glomerular injury,11,13,58,75,"To better understand the utility of GLEPP1 as a marker of glomerular injury, the amount and distribution of GLEPP1 protein and mRNA were examined by immunohistochemistry, Western blot and RNase protection assay in a model of podocyte injury in the rat.",11961407_4,-1,-1,-1,2573,-1,0.0017747621,0.9982253
2574,Puromycin aminonucleoside nephrosis,0,3,0,35,"Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).",11961407_5,-1,-1,-1,2574,-1,0.55129504,0.448705
2575,puromycin aminonucleoside,10,12,87,112,"Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).",11961407_5,-1,-1,-1,2575,-1,0.99916697,0.00083305006
2576,PAN,13,14,114,117,"Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).",11961407_5,-1,-1,-1,2576,-1,0.99838805,0.0016120019
2577,PAN,21,22,68,71,"Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126).",11961407_6,-1,-1,-1,2577,-1,0.9912151,0.008784932
2581,p,42,43,177,178,"At day 5, GLEPP1 protein and mRNA were reduced from the normal range (265.2 +/- 79.6 x 10(6) moles/glomerulus and 100%) to 15% of normal (41.8 +/- 4.8 x 10(6) moles/glomerulus, p < 0.005).",11961407_7,-1,-1,-1,2581,-1,0.3937831,0.6062169
2582,p,23,24,111,112,This occurred in association with an increase in urinary protein content from 1.8 +/- 1 to 99.0 +/- 61 mg/day (p < 0.001).,11961407_8,-1,-1,-1,2582,-1,0.40589058,0.5941094
2583,contrast,1,2,3,11,"In contrast, podocalyxin did not change significantly at this time.",11961407_9,-1,-1,-1,2583,-1,0.577361,0.42263907
2584,PAN,14,15,92,95,"We conclude that GLEPP1 expression, unlike podocalyxin, reflects podocyte injury induced by PAN.",11961407_12,-1,-1,-1,2584,-1,0.99276465,0.007235418
2585,MK-801,3,4,22,28,Behavioral effects of MK-801 on reserpine-treated mice.,11999899_0,-1,-1,-1,2585,-1,0.99902856,0.00097149063
2586,dizocilpine,3,4,15,26,"The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on dopamine-related behaviors induced by reserpine treatments.",11999899_1,-1,-1,-1,2586,-1,0.99928254,0.0007175215
2587,MK-801,5,6,28,34,"The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on dopamine-related behaviors induced by reserpine treatments.",11999899_1,-1,-1,-1,2587,-1,0.9990539,0.0009460597
2588,NMDA,12,13,76,80,"The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on dopamine-related behaviors induced by reserpine treatments.",11999899_1,-1,-1,-1,2588,-1,0.9990797,0.00092022377
2590,Parkinson's disease,12,15,71,90,"This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage.",11999899_2,-1,-1,-1,2590,-1,0.00170075,0.9982993
2591,tardive dyskinesia,17,19,95,113,"This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage.",11999899_2,-1,-1,-1,2591,-1,0.0011636224,0.99883634
2593,orofacial dyskinesia,18,20,89,109,"Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of tardive dyskinesia.",11999899_3,-1,-1,-1,2593,-1,0.0019307167,0.99806935
2594,tardive dyskinesia,34,36,188,206,"Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of tardive dyskinesia.",11999899_3,-1,-1,-1,2594,-1,0.0012638838,0.9987361
2598,Parkinson's disease,12,15,76,95,"Reserpine also produced tremor and catalepsy, which are signs suggestive of Parkinson's disease.",11999899_4,-1,-1,-1,2598,-1,0.0022479831,0.997752
2599,MK-801,0,1,0,6,"MK-801 (0.1 mg/kg), administered 30 min before the observation test, prevented the vacuous chewing movements, tongue protrusions and catalepsy induced by reserpine.",11999899_5,-1,-1,-1,2599,-1,0.9990693,0.00093069545
2602,MK-801,2,3,9,15,"However, MK-801 injection produced a significant increase of tremor in reserpine-treated mice.",11999899_6,-1,-1,-1,2602,-1,0.9989785,0.0010214768
2605,apomophine,15,16,73,83,"Reserpine (1 mg/kg), administered 90 min before the test and followed by apomophine injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice.",11999899_7,-1,-1,-1,2605,-1,0.99933124,0.00066875777
2610,MK-801,0,1,0,6,MK-801 (0.1 mg/kg) administration attenuated the catalepsy and tremor induced by reserpine.,11999899_9,-1,-1,-1,2610,-1,0.99905866,0.0009413146
2615,h,8,9,41,42,"Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.",11999899_10,-1,-1,-1,2615,-1,0.83384454,0.16615546
2618,MK-801,33,34,196,202,"Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.",11999899_10,-1,-1,-1,2618,-1,0.9991498,0.0008502104
2621,abnormal movements,8,10,57,75,"These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.",11999899_11,-1,-1,-1,2621,-1,0.0015428095,0.9984572
2622,tardive dsykinesia,26,28,172,190,"These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.",11999899_11,-1,-1,-1,2622,-1,0.002194476,0.99780554
2623,NMDA,5,6,39,43,"The glutamatergic blockage produced by NMDA can restore these signs, such as vacuous chewing movements, tongue protrusions, catalepsy and tremor according to the employed model.",11999899_12,-1,-1,-1,2623,-1,0.99889416,0.0011058167
2626,visual disturbances,4,6,41,60,"Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.",12013711_0,-1,-1,-1,2626,-1,0.0013205657,0.99867946
2628,LSD,14,15,110,113,"Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.",12013711_0,-1,-1,-1,2628,-1,0.99869746,0.0013025394
2630,LSD,10,11,55,58,"Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.",12013711_1,-1,-1,-1,2630,-1,0.99818146,0.0018185939
2631,EPS,17,18,98,101,"Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.",12013711_1,-1,-1,-1,2631,-1,0.0015351212,0.99846494
2632,antipsychotics,20,21,115,129,"Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.",12013711_1,-1,-1,-1,2632,-1,0.99865913,0.0013409059
2634,visual disturbances,7,9,47,66,"They both reported short episodes of transient visual disturbances, which appeared immediately after starting treatment with risperidone.",12013711_2,-1,-1,-1,2634,-1,0.0015186223,0.99848133
2636,visual disturbances,3,5,23,42,"This imagery resembled visual disturbances previously experienced as ""flashbacks"" related to prior LSD consumption.",12013711_3,-1,-1,-1,2636,-1,0.0019690928,0.99803084
2637,LSD,14,15,99,102,"This imagery resembled visual disturbances previously experienced as ""flashbacks"" related to prior LSD consumption.",12013711_3,-1,-1,-1,2637,-1,0.99846065,0.0015393118
2639,visual disturbances,6,8,49,68,Risperidone administration was continued and the visual disturbances gradually wore off.,12013711_4,-1,-1,-1,2639,-1,0.0016889201,0.99831104
2640,visual disturbances,11,13,64,83,"During a six-month follow-up period, there was no recurrence of visual disturbances.",12013711_5,-1,-1,-1,2640,-1,0.0017212565,0.99827874
2642,Antithymocyte globulin,0,2,0,22,Antithymocyte globulin in the treatment of D-penicillamine-induced aplastic anemia.,12041669_0,-1,-1,-1,2642,-1,0.5691871,0.43081293
2644,antithymocyte globulin,4,6,23,45,A patient who received antithymocyte globulin therapy for aplastic anemia due to D-penicillamine therapy is described.,12041669_1,-1,-1,-1,2644,-1,0.90497726,0.09502277
2646,antithymocyte globulin,2,4,7,29,Use of antithymocyte globulin may be the optimal treatment of D-penicillamine-induced aplastic anemia.,12041669_3,-1,-1,-1,2646,-1,0.76372975,0.23627025
2649,Topiramate,0,1,0,10,Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures.,12042105_1,-1,-1,-1,2649,-1,0.9992719,0.0007281309
2652,lead,23,24,138,142,"In addition, a distal tubular acidification defect may result, thus impairing the normal compensatory drop in urine pH. These factors can lead to the development of calcium phosphate nephrolithiasis.",12042105_3,-1,-1,-1,2652,-1,0.03509235,0.96490765
2653,calcium phosphate nephrolithiasis,28,31,165,198,"In addition, a distal tubular acidification defect may result, thus impairing the normal compensatory drop in urine pH. These factors can lead to the development of calcium phosphate nephrolithiasis.",12042105_3,-1,-1,-1,2653,-1,0.19827183,0.8017281
2655,Metamizol,0,1,0,9,Metamizol potentiates morphine antinociception but not constipation after chronic treatment.,12063090_0,-1,-1,-1,2655,-1,0.99920803,0.00079203525
2658,constipating,6,7,44,56,This work evaluates the antinociceptive and constipating effects of the combination of 3.2 mg/kg s.c.,12063090_1,-1,-1,-1,2658,-1,0.0032178378,0.9967822
2660,metamizol,0,1,0,9,metamizol in acutely and chronically treated (once a day for 12 days) rats.,12063090_3,-1,-1,-1,2660,-1,0.99921894,0.00078110374
2661,functional impairment,17,19,111,132,"On the 13th day, antinociceptive effects were assessed using a model of inflammatory nociception, pain-induced functional impairment model, and the charcoal meal test was used to evaluate the intestinal transit.",12063090_4,-1,-1,-1,2661,-1,0.0016978702,0.9983021
2662,charcoal,23,24,148,156,"On the 13th day, antinociceptive effects were assessed using a model of inflammatory nociception, pain-induced functional impairment model, and the charcoal meal test was used to evaluate the intestinal transit.",12063090_4,-1,-1,-1,2662,-1,0.9974275,0.0025724873
2664,metamizol,5,6,45,54,Simultaneous administration of morphine with metamizol resulted in a markedly antinociceptive potentiation and an increasing of the duration of action after a single (298+/-7 vs. 139+/-36 units area (ua); P<0.001) and repeated administration (280+/-17 vs. 131+/-22 ua; P<0.001).,12063090_5,-1,-1,-1,2664,-1,0.99925894,0.0007410404
2665,P<0.001,33,34,205,212,Simultaneous administration of morphine with metamizol resulted in a markedly antinociceptive potentiation and an increasing of the duration of action after a single (298+/-7 vs. 139+/-36 units area (ua); P<0.001) and repeated administration (280+/-17 vs. 131+/-22 ua; P<0.001).,12063090_5,-1,-1,-1,2665,-1,0.3652401,0.6347599
2666,P<0.001,44,45,269,276,Simultaneous administration of morphine with metamizol resulted in a markedly antinociceptive potentiation and an increasing of the duration of action after a single (298+/-7 vs. 139+/-36 units area (ua); P<0.001) and repeated administration (280+/-17 vs. 131+/-22 ua; P<0.001).,12063090_5,-1,-1,-1,2666,-1,0.33993006,0.6600699
2669,P<0.05,16,17,102,108,"Acute antinociceptive effects of the combination were partially prevented by 3.2 mg/kg naloxone s.c. (P<0.05), suggesting the partial involvement of the opioidergic system in the synergism observed.",12063090_7,-1,-1,-1,2669,-1,0.44211605,0.557884
2671,constipating,31,32,186,198,"In independent groups, morphine inhibited the intestinal transit in 48+/-4% and 38+/-4% after acute and chronic treatment, respectively, suggesting that tolerance did not develop to the constipating effects.",12063090_8,-1,-1,-1,2671,-1,0.0030481827,0.9969518
2673,metamizol,20,21,135,144,"The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that metamizol did not potentiate morphine-induced constipation.",12063090_9,-1,-1,-1,2673,-1,0.9993156,0.0006843366
2676,metamizol,9,10,67,76,"These findings show a significant interaction between morphine and metamizol in chronically treated rats, suggesting that this combination could be useful for the treatment of chronic pain.",12063090_10,-1,-1,-1,2676,-1,0.99928856,0.0007114656
2677,chronic pain,26,28,176,188,"These findings show a significant interaction between morphine and metamizol in chronically treated rats, suggesting that this combination could be useful for the treatment of chronic pain.",12063090_10,-1,-1,-1,2677,-1,0.0022066527,0.9977933
2678,Ifosfamide encephalopathy,0,2,0,25,Ifosfamide encephalopathy presenting with asterixis.,12084448_0,-1,-1,-1,2678,-1,0.6884901,0.3115099
2681,IFX,9,10,58,61,CNS toxic effects of the antineoplastic agent ifosfamide (IFX) are frequent and include a variety of neurological symptoms that can limit drug use.,12084448_1,-1,-1,-1,2681,-1,0.99798393,0.0020160107
2682,neurological symptoms,18,20,101,122,CNS toxic effects of the antineoplastic agent ifosfamide (IFX) are frequent and include a variety of neurological symptoms that can limit drug use.,12084448_1,-1,-1,-1,2682,-1,0.0012940881,0.99870586
2685,plasmacytoma,27,28,161,173,"We report a case of a 51-year-old man who developed severe, disabling negative myoclonus of the upper and lower extremities after the infusion of ifosfamide for plasmacytoma.",12084448_2,-1,-1,-1,2685,-1,0.002874789,0.9971252
2686,structural lesions of the brain,11,16,85,116,Cranial magnetic resonance imaging and extensive laboratory studies failed to reveal structural lesions of the brain and metabolic abnormalities.,12084448_4,-1,-1,-1,2686,-1,0.0039965045,0.99600345
2687,metabolic abnormalities,17,19,121,144,Cranial magnetic resonance imaging and extensive laboratory studies failed to reveal structural lesions of the brain and metabolic abnormalities.,12084448_4,-1,-1,-1,2687,-1,0.00386929,0.9961307
2690,h,9,10,64,65,The administration of ifosfamide was discontinued and within 12 h the asterixis resolved completely.,12084448_6,-1,-1,-1,2690,-1,0.18764055,0.81235945
2695,IFX,41,42,265,268,"In the patient described, the presence of asterixis during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX.",12084448_7,-1,-1,-1,2695,-1,0.9987581,0.0012419146
2699,thymidine,6,7,37,46,There was a significant reduction of thymidine incorporation into both erythroid and endothelial cells in cultures pre-treated with IGF-IL-3 and EPO.,12090760_5,-1,-1,-1,2699,-1,0.9981749,0.0018251264
2700,thymidine,18,19,150,159,Endothelial cell culture supernatants separated by ultrafiltration and ultracentrifugation from cells treated with EPO and IL-3 significantly reduced thymidine incorporation into erythroid cells as compared to identical fractions obtained from the media of cells cultured with EPO alone.,12090760_6,-1,-1,-1,2700,-1,0.99829227,0.001707678
2710,postoperative analgesia,10,12,71,94,Local anaesthetic blocks were useful in decreasing the requirement for postoperative analgesia.,12091028_5,-1,-1,-1,2710,-1,0.004801666,0.9951983
2711,h,11,12,70,71,"An antisialogue was usually unnecessary in operations lasting up to 2 h, glycopyrrolate being the best choice for its lowest psychotropic and chronotropic effects, especially in a hot climate.",12091028_6,-1,-1,-1,2711,-1,0.037216257,0.96278375
2714,adenovirus disease,5,7,43,61,Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children.,12093990_0,-1,-1,-1,2714,-1,0.0020736847,0.99792635
2715,adenovirus disease,4,6,24,42,"The incidence of severe adenovirus disease in pediatrics is increasing in association with growing numbers of immunocompromised children, where case fatality rates as high as 50% to 80% have been reported.",12093990_2,-1,-1,-1,2715,-1,0.01764924,0.9823507
2716,adenovirus disease,14,16,88,106,"There are no approved antiviral agents with proven efficacy for the treatment of severe adenovirus disease, nor are there any prospective randomized, controlled trials of potentially useful anti-adenovirus therapies.",12093990_3,-1,-1,-1,2716,-1,0.0034375794,0.9965624
2717,adenovirus disease,8,10,53,71,Apparent clinical success in the treatment of severe adenovirus disease is limited to a few case reports and small series.,12093990_4,-1,-1,-1,2717,-1,0.0024670921,0.99753284
2719,cidofovir,7,8,54,63,Experience is greatest with intravenous ribavirin and cidofovir.,12093990_5,-1,-1,-1,2719,-1,0.9990695,0.0009305488
2721,guanosine,3,4,13,22,"Ribavirin, a guanosine analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro.",12093990_6,-1,-1,-1,2721,-1,0.99906546,0.00093452266
2723,respiratory syncytial virus infection,10,14,59,96,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,-1,-1,-1,2723,-1,0.0015446441,0.9984554
2724,interferon,20,21,129,139,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,-1,-1,-1,2724,-1,0.99887866,0.0011212901
2725,hepatitis C.,23,25,149,161,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,-1,-1,-1,2725,-1,0.0100111,0.9899889
2728,hemorrhagic fever,35,37,230,247,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,-1,-1,-1,2728,-1,0.0012570802,0.998743
2731,cidofovir,3,4,11,20,"The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.",12093990_9,-1,-1,-1,2731,-1,0.99894696,0.001053059
2732,adenovirus infection,6,8,31,51,"The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.",12093990_9,-1,-1,-1,2732,-1,0.023520049,0.97647995
2735,adenovirus disease,12,14,82,100,OBJECTIVE: We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature.,12093990_10,-1,-1,-1,2735,-1,0.0020578445,0.99794215
2737,adenovirus disease,18,20,135,153,DESIGN/METHODS: We retrospectively reviewed the medical records of 5 children treated with intravenous ribavirin for documented severe adenovirus disease.,12093990_11,-1,-1,-1,2737,-1,0.002138504,0.99786144
2738,hemorrhagic cystitis,4,6,34,54,"Two patients developed adenovirus hemorrhagic cystitis after cardiac and bone marrow transplants, respectively.",12093990_12,-1,-1,-1,2738,-1,0.0012755492,0.9987244
2739,cidofovir,8,9,61,70,The bone marrow transplant patient also received intravenous cidofovir for progressive disseminated disease.,12093990_13,-1,-1,-1,2739,-1,0.998998,0.0010020804
2740,disseminated disease,11,13,87,107,The bone marrow transplant patient also received intravenous cidofovir for progressive disseminated disease.,12093990_13,-1,-1,-1,2740,-1,0.0016119182,0.99838805
2741,pneumonia,6,7,46,55,"An additional 3 children developed adenovirus pneumonia; 2 were neonates, 1 of whom had partial DiGeorge syndrome.",12093990_14,-1,-1,-1,2741,-1,0.001251923,0.99874806
2742,DiGeorge syndrome,17,19,96,113,"An additional 3 children developed adenovirus pneumonia; 2 were neonates, 1 of whom had partial DiGeorge syndrome.",12093990_14,-1,-1,-1,2742,-1,0.0016732255,0.9983267
2744,hemorrhagic cystitis,22,24,147,167,RESULTS: Complete clinical recovery followed later by viral clearance was observed in 2 children: the cardiac transplant recipient with adenovirus hemorrhagic cystitis and the immunocompetent neonate with adenovirus pneumonia.,12093990_17,-1,-1,-1,2744,-1,0.0011734907,0.99882644
2745,pneumonia,30,31,216,225,RESULTS: Complete clinical recovery followed later by viral clearance was observed in 2 children: the cardiac transplant recipient with adenovirus hemorrhagic cystitis and the immunocompetent neonate with adenovirus pneumonia.,12093990_17,-1,-1,-1,2745,-1,0.001276846,0.9987231
2746,adenovirus disease,6,8,33,51,The remaining 3 children died of adenovirus disease.,12093990_18,-1,-1,-1,2746,-1,0.005740002,0.99425995
2748,cidofovir,2,3,7,16,Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia.,12093990_20,-1,-1,-1,2748,-1,0.9987804,0.0012196028
2749,progressive renal failure,9,12,48,73,Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia.,12093990_20,-1,-1,-1,2749,-1,0.0012300079,0.99876994
2751,adenovirus disease,19,21,127,145,"DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with immunodeficiency.",12093990_21,-1,-1,-1,2751,-1,0.016098728,0.9839012
2752,immunodeficiency,35,36,233,249,"DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with immunodeficiency.",12093990_21,-1,-1,-1,2752,-1,0.0013899232,0.99861
2754,adenovirus disease,11,13,78,96,"Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the infection.",12093990_22,-1,-1,-1,2754,-1,0.0019625793,0.9980374
2756,adenovirus disease,15,17,96,114,"Early identification, eg by polymerase chain reaction of those patients at risk of disseminated adenovirus disease may permit earlier antiviral treatment and better evaluation of therapeutic response.",12093990_23,-1,-1,-1,2756,-1,0.0029471896,0.9970528
2757,adenovirus disease,8,10,43,61,CONCLUSIONS: Two of 5 children with severe adenovirus disease treated with intravenous ribavirin recovered.,12093990_24,-1,-1,-1,2757,-1,0.0016933994,0.99830663
2759,adenovirus infection,22,24,136,156,"The availability of newer rapid diagnostic techniques, such as polymerase chain reaction, may make earlier, more effective treatment of adenovirus infection possible.",12093990_25,-1,-1,-1,2759,-1,0.014463967,0.98553604
2760,adenovirus disease,7,9,51,69,"Given the seriousness and increasing prevalence of adenovirus disease in certain hosts, especially children, a large, multicenter clinical trial of potentially useful anti-adenoviral therapies, such as intravenous ribavirin, is clearly required to demonstrate the most effective and least toxic therapy.",12093990_26,-1,-1,-1,2760,-1,0.008259019,0.99174094
2762,asystolic cardiac arrest,1,4,8,32,Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.,12101159_0,-1,-1,-1,2762,-1,0.0014918504,0.99850816
2763,diltiazem overdose,5,7,39,57,Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.,12101159_0,-1,-1,-1,2763,-1,0.56773615,0.43226382
2769,isosorbide nitrate,21,23,96,114,"A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.",12101159_1,-1,-1,-1,2769,-1,0.9992555,0.0007445539
2772,charcoal,16,17,104,112,He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.,12101159_2,-1,-1,-1,2772,-1,0.99747294,0.0025270502
2776,asystolic,15,16,108,117,"The patient remained unresponsive with junctional bradycardia, unrecordable blood pressure, and then became asystolic.",12101159_4,-1,-1,-1,2776,-1,0.0022651472,0.9977348
2781,diltiazem overdose,16,18,98,116,"This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose, particularly with the onset of asystole.",12101159_7,-1,-1,-1,2781,-1,0.40959984,0.59040016
2784,diltiazem overdose,11,13,63,81,It should be considered early in cases of cardiac arrest after diltiazem overdose.,12101159_8,-1,-1,-1,2784,-1,0.57854766,0.4214523
2787,Unfractionated heparin,0,2,0,22,Unfractionated heparin (UH) is currently the substitute for selected patients.,12109865_2,-1,-1,-1,2787,-1,0.9957228,0.004277236
2788,UH,3,4,24,26,Unfractionated heparin (UH) is currently the substitute for selected patients.,12109865_2,-1,-1,-1,2788,-1,0.98319244,0.016807515
2790,LMWH,3,4,30,34,"Low-molecular-weight heparin (LMWH) offers theoretical advantages over UH, but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves.",12109865_3,-1,-1,-1,2790,-1,0.99748576,0.0025141959
2791,UH,9,10,71,73,"Low-molecular-weight heparin (LMWH) offers theoretical advantages over UH, but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves.",12109865_3,-1,-1,-1,2791,-1,0.15872528,0.84127474
2792,UH,23,24,151,153,"Low-molecular-weight heparin (LMWH) offers theoretical advantages over UH, but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves.",12109865_3,-1,-1,-1,2792,-1,0.29707724,0.70292276
2793,LMWH,20,21,97,101,HYPOTHESIS: The aim of the present study was to review the data accumulated so far on the use of LMWH in this patient population and to discuss its applicability in common practice.,12109865_4,-1,-1,-1,2793,-1,0.99798834,0.0020116179
2794,LMWH,11,12,59,63,"METHODS: For this paper, the current medical literature on LMWH in patients with mechanical heart valves was extensively reviewed.",12109865_5,-1,-1,-1,2794,-1,0.99609107,0.00390893
2796,n,21,22,123,124,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,-1,-1,-1,2796,-1,0.06961219,0.9303878
2797,n,34,35,192,193,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,-1,-1,-1,2797,-1,0.03857859,0.9614215
2798,n,50,51,244,245,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,-1,-1,-1,2798,-1,0.030724855,0.9692751
2799,n,63,64,282,283,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,-1,-1,-1,2799,-1,0.04903762,0.9509623
2800,thromboembolism,4,5,22,37,"The incidence rate of thromboembolism was 0.9% for all the studies and 0.5, 0, 20, and 0% in groups a, b, c, and d, respectively; for hemorrhage, the overall rate was 3.4% (3.8, 2.6, 10, and 0% for the respective groups).",12109865_10,-1,-1,-1,2800,-1,0.0014097086,0.9985903
2802,LMWH,10,11,66,70,"CONCLUSIONS: In patients with mechanical heart valves, short-term LMWH therapy compares favorably with UH.",12109865_11,-1,-1,-1,2802,-1,0.99876463,0.0012353442
2803,LMWH,5,6,27,31,Data on mid- and long-term LMWH administration in these patients are sparse.,12109865_12,-1,-1,-1,2803,-1,0.99856466,0.0014353319
2804,LMWH,16,17,99,103,Further randomized studies are needed to confirm the safety and precise indications for the use of LMWH in patients with mechanical heart valves.,12109865_13,-1,-1,-1,2804,-1,0.99857485,0.001425167
2812,mg,5,6,39,41,The patient received metoclopramide 10 mg i.v.,12139551_2,-1,-1,-1,2812,-1,0.99437076,0.005629272
2813,h.,4,5,21,23,"five times during 48 h. After interviewing the attending nurses and reviewing the written documentation, it is clear that every administration of metoclopramide was immediately (within s) followed by asystole.",12139551_3,-1,-1,-1,2813,-1,0.17718838,0.8228116
2818,mg,7,8,36,38,"The patient received atropine 0.5-1 mg and chest compressions, before sinus rhythm again took over.",12139551_5,-1,-1,-1,2818,-1,0.9952539,0.004746155
2822,adverse drug reaction,21,24,143,164,The rapid injection via the central venous route and the concomitant tapering of dopamine infusion might have contributed in precipitating the adverse drug reaction.,12139551_7,-1,-1,-1,2822,-1,0.0032316507,0.99676836
2823,nitric oxide,6,8,47,59,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,-1,-1,-1,2823,-1,0.99597496,0.0040250234
2824,arteritis,27,28,151,160,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,-1,-1,-1,2824,-1,0.0014268347,0.9985732
2825,fenoldopam,32,33,180,190,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,-1,-1,-1,2825,-1,0.99928075,0.00071929925
2827,Arteritis,0,1,0,9,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,-1,-1,-1,2827,-1,0.0012497524,0.9987502
2828,vasodilators,5,6,29,41,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,-1,-1,-1,2828,-1,0.57110375,0.4288963
2829,fenoldopam,7,8,43,53,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,-1,-1,-1,2829,-1,0.9992685,0.00073151174
2831,nitric oxide,20,22,144,156,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,-1,-1,-1,2831,-1,0.9959794,0.0040205014
2832,fenoldopam,3,4,23,33,Rats were administered fenoldopam for 24 hours by intravenous infusion with or without following repeated daily oral administrations of theophylline.,12180796_2,-1,-1,-1,2832,-1,0.99928313,0.0007168572
2835,arteritis,31,32,172,181,"These results suggest that the peak expression of iNOS antigen was followed by that of bFGF antigen, and bFGF may have a suppressive effect on iNOS expression in these rat arteritis models.",12180796_4,-1,-1,-1,2835,-1,0.0019178184,0.99808216
2842,neostigmine,8,9,50,61,"Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of tremor and clonus were recorded and converted to threshold dose.",12198388_4,-1,-1,-1,2842,-1,0.99931276,0.0006872231
2845,ACh,11,12,84,87,We also used microdialysis to measure basal and potassium-stimulated acetylcholine (ACh) release in the CA1 region of the hippocampus.,12198388_5,-1,-1,-1,2845,-1,0.99869186,0.0013081259
2847,ACh,1,2,12,15,Hippocampal ACh also was measured during testing for handling-induced convulsions.,12198388_7,-1,-1,-1,2847,-1,0.99792117,0.0020788517
2852,neostigmine,14,15,89,100,"RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.",12198388_8,-1,-1,-1,2852,-1,0.9993044,0.0006955757
2853,ACh,13,14,75,78,"In microdialysis experiments, the lines did not differ in basal release of ACh, and 50 mM KCl increased ACh output in both lines of mice.",12198388_9,-1,-1,-1,2853,-1,0.99832386,0.0016761075
2854,mM KCl,17,19,87,93,"In microdialysis experiments, the lines did not differ in basal release of ACh, and 50 mM KCl increased ACh output in both lines of mice.",12198388_9,-1,-1,-1,2854,-1,0.99772197,0.0022780427
2855,ACh,20,21,104,107,"In microdialysis experiments, the lines did not differ in basal release of ACh, and 50 mM KCl increased ACh output in both lines of mice.",12198388_9,-1,-1,-1,2855,-1,0.9984915,0.0015084429
2856,ACh,7,8,36,39,"However, the increase in release of ACh produced by the first application of KCl was 2-fold higher in WSP versus WSR mice.",12198388_10,-1,-1,-1,2856,-1,0.9982014,0.0017986431
2857,KCl,14,15,77,80,"However, the increase in release of ACh produced by the first application of KCl was 2-fold higher in WSP versus WSR mice.",12198388_10,-1,-1,-1,2857,-1,0.9987141,0.0012859717
2858,ACh,2,3,17,20,"When hippocampal ACh was measured during testing for handling-induced convulsions, extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.",12198388_11,-1,-1,-1,2858,-1,0.9987282,0.0012717254
2860,ACh,12,13,97,100,"When hippocampal ACh was measured during testing for handling-induced convulsions, extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.",12198388_11,-1,-1,-1,2860,-1,0.9987477,0.0012522897
2861,convulsants,15,16,120,131,CONCLUSIONS: These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic convulsants may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal.,12198388_12,-1,-1,-1,2861,-1,0.27249566,0.7275043
2864,convulsants,10,11,65,76,"Specifically, WSP mice may have lower sensitivity to cholinergic convulsants compared with WSR because of postsynaptic receptor desensitization brought on by higher activity of cholinergic neurons.",12198388_13,-1,-1,-1,2864,-1,0.17664757,0.82335246
2865,muscle pain,1,3,18,29,Capsaicin-induced muscle pain alters the excitability of the human jaw-stretch reflex.,12202650_0,-1,-1,-1,2865,-1,0.0018180773,0.99818194
2866,painful temporomandibular disorders,3,6,23,58,"The pathophysiology of painful temporomandibular disorders is not fully understood, but evidence suggests that muscle pain modulates motor function in characteristic ways.",12202650_1,-1,-1,-1,2866,-1,0.0017696628,0.9982304
2867,muscle pain,15,17,111,122,"The pathophysiology of painful temporomandibular disorders is not fully understood, but evidence suggests that muscle pain modulates motor function in characteristic ways.",12202650_1,-1,-1,-1,2867,-1,0.0023060741,0.99769396
2872,painful,17,18,106,113,"The normalized reflex amplitude was significantly higher during pain, but only at faster stretches in the painful muscle.",12202650_6,-1,-1,-1,2872,-1,0.0027058441,0.9972941
2873,muscle pain,8,10,59,70,Increased sensitivity of the fusimotor system during acute muscle pain could be one likely mechanism to explain the findings.,12202650_7,-1,-1,-1,2873,-1,0.0020888827,0.99791116
2876,muscle rigidity,8,10,51,66,"Haloperidol (1 mg/kg ip) induced parkinsonian-like muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint.",12231232_2,-1,-1,-1,2876,-1,0.0015518804,0.99844813
2877,AIDA,3,4,41,45,"(RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA; 0.5-15 microg/0.5 microl), a potent and selective mGluR1 antagonist, or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC; 7.5-15 microg/0.5 microl), a selective group II agonist, was injected bilaterally into the striatum of haloperidol-treated animals.",12231232_3,-1,-1,-1,2877,-1,0.9985728,0.0014271819
2878,AIDA,0,1,0,4,AIDA in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced muscle rigidity.,12231232_4,-1,-1,-1,2878,-1,0.99837685,0.0016231185
2879,muscle rigidity,12,14,77,92,AIDA in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced muscle rigidity.,12231232_4,-1,-1,-1,2879,-1,0.0017809056,0.9982191
2880,contrast,1,2,3,11,"In contrast, 2R,4R-APDC injections were ineffective.",12231232_5,-1,-1,-1,2880,-1,0.36617073,0.6338293
2881,parkinsonian muscle rigidity,23,26,129,157,"The present results may suggest that the blockade of striatal mGluR1, but not the stimulation of group II mGluRs, may ameliorate parkinsonian muscle rigidity.",12231232_6,-1,-1,-1,2881,-1,0.0015890533,0.99841094
2885,GR 55562,21,23,128,136,"Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core, and then were locally injected with GR 55562 (an antagonist of 5-HT1B receptors) or CP 93129 (an agonist of 5-HT1B receptors).",12369736_2,-1,-1,-1,2885,-1,0.9988343,0.0011657099
2886,CP 93129,31,33,176,184,"Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core, and then were locally injected with GR 55562 (an antagonist of 5-HT1B receptors) or CP 93129 (an agonist of 5-HT1B receptors).",12369736_2,-1,-1,-1,2886,-1,0.99884015,0.0011599069
2887,GR 55562,7,9,39,47,"Given alone to any accumbal subregion, GR 55562 (0.1-10 microg/side) or CP 93129 (0.1-10 microg/side) did not change basal locomotor activity.",12369736_3,-1,-1,-1,2887,-1,0.9987255,0.0012744743
2888,CP 93129,16,18,72,80,"Given alone to any accumbal subregion, GR 55562 (0.1-10 microg/side) or CP 93129 (0.1-10 microg/side) did not change basal locomotor activity.",12369736_3,-1,-1,-1,2888,-1,0.9987746,0.0012254098
2890,GR 55562,0,2,0,8,"GR 55562 (0.1-10 microg/side), administered intra-accumbens shell prior to cocaine, dose-dependently attenuated the psychostimulant-induced locomotor hyperactivity.",12369736_5,-1,-1,-1,2890,-1,0.99893504,0.0010649419
2893,GR 55562,12,14,71,79,Such attenuation was not found in animals which had been injected with GR 55562 into the accumbens core.,12369736_6,-1,-1,-1,2893,-1,0.99880993,0.0011901209
2895,CP 93129,15,17,74,82,"When injected into the accumbens shell (but not the core) before cocaine, CP 93129 (0.1-10 microg/side) enhanced the locomotor response to cocaine; the maximum effect being observed after 10 microg/side of the agonist.",12369736_7,-1,-1,-1,2895,-1,0.99902356,0.0009764076
2897,GR 55562,10,12,80,88,The later enhancement was attenuated after intra-accumbens shell treatment with GR 55562 (1 microg/side).,12369736_8,-1,-1,-1,2897,-1,0.9986981,0.001301915
2899,hyperlocomotion,6,7,43,58,"Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.",12369736_9,-1,-1,-1,2899,-1,0.0018007666,0.9981993
2900,GR 55562,37,39,255,263,"Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.",12369736_9,-1,-1,-1,2900,-1,0.99871683,0.0012831674
2901,CP 93129,43,45,278,286,"Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.",12369736_9,-1,-1,-1,2901,-1,0.9986507,0.0013493251
2903,chest pain,2,4,16,26,Cocaine related chest pain: are we seeing the tip of an iceberg?The recreational use of cocaine is on the increase.,12443032_0,-1,-1,-1,2903,-1,0.0015893453,0.9984106
2907,chest pain,9,11,50,60,"In particular, the tendency of cocaine to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk.",12443032_2,-1,-1,-1,2907,-1,0.0015902021,0.99840975
2908,chest pain,28,30,142,152,"In particular, the tendency of cocaine to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk.",12443032_2,-1,-1,-1,2908,-1,0.0016989707,0.9983011
2909,chest pain,3,5,17,27,The mechanism of chest pain related to cocaine use is discussed and treatment dilemmas are discussed.,12443032_3,-1,-1,-1,2909,-1,0.0016121279,0.99838793
2913,renal cell carcinoma,9,12,55,75,A phase II study of thalidomide in advanced metastatic renal cell carcinoma.,12448656_0,-1,-1,-1,2913,-1,0.0028076717,0.9971923
2916,renal cell cancer,15,18,102,119,"OBJECTIVES: To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165, with therapy.",12448656_1,-1,-1,-1,2916,-1,0.002751856,0.9972481
2919,metastases,23,24,137,147,"RESULTS: 24 patients were evaluable for response with one partial response of 11 months duration of a patient with hepatic and pulmonary metastases (4%), one minor response, and 2 patients stable for over 6 months.",12448656_6,-1,-1,-1,2919,-1,0.0016017985,0.99839824
2924,renal cell carcinoma,15,18,88,108,CONCLUSION: These results are consistent with a low level of activity of thalidomide in renal cell carcinoma.,12448656_9,-1,-1,-1,2924,-1,0.003114199,0.99688584
2926,renal cell carcinoma,10,13,59,79,"The dose-response relationship, if any, of thalidomide for renal cell carcinoma is unclear.",12448656_11,-1,-1,-1,2926,-1,0.0022042966,0.9977957
2929,postoperative myalgia?This,5,7,45,71,Can lidocaine reduce succinylcholine induced postoperative myalgia?This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery.,12452237_0,-1,-1,-1,2929,-1,0.010335002,0.989665
2933,mg,13,14,76,78,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2933,-1,0.9930662,0.0069337673
2935,mg,23,24,113,115,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2935,-1,0.9943613,0.0056386534
2937,mg,30,31,149,151,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2937,-1,0.99183285,0.008167165
2938,rocuronium,41,42,190,200,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2938,-1,0.9993319,0.0006680816
2939,mg,43,44,205,207,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2939,-1,0.99221355,0.007786428
2941,mg,2,3,13,15,"Morphine 0.1 mg x kg(-1) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor, ECG and pulse oximetry.",12452237_3,-1,-1,-1,2941,-1,0.9892231,0.010776883
2942,thiopental,7,8,40,50,"Anesthesia was induced with 5 mg.kg(-1) thiopental iv. followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation.",12452237_4,-1,-1,-1,2942,-1,0.99931407,0.0006858975
2944,rocuronium,20,21,101,111,"Anesthesia was induced with 5 mg.kg(-1) thiopental iv. followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation.",12452237_4,-1,-1,-1,2944,-1,0.9993507,0.0006492525
2947,muscle fasciculation,4,6,26,46,The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS (p < 0.001).,12452237_8,-1,-1,-1,2947,-1,0.0056402558,0.9943598
2948,muscle fasciculation,23,25,129,149,The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS (p < 0.001).,12452237_8,-1,-1,-1,2948,-1,0.0050529432,0.99494714
2949,p,31,32,174,175,The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS (p < 0.001).,12452237_8,-1,-1,-1,2949,-1,0.3488837,0.6511163
2950,h,2,3,6,7,"At 24 h, the incidence of myalgia was higher in Group PS than in Group LS and PR (p < 0.05).",12452237_9,-1,-1,-1,2950,-1,0.21943922,0.7805608
2952,PS,12,13,54,56,"At 24 h, the incidence of myalgia was higher in Group PS than in Group LS and PR (p < 0.05).",12452237_9,-1,-1,-1,2952,-1,0.026535051,0.9734649
2953,p,20,21,82,83,"At 24 h, the incidence of myalgia was higher in Group PS than in Group LS and PR (p < 0.05).",12452237_9,-1,-1,-1,2953,-1,0.45846763,0.54153234
2955,muscle fasciculation,14,16,83,103,A correlation was not found between the incidence of myalgia and the occurrence of muscle fasciculation.,12452237_10,-1,-1,-1,2955,-1,0.0027765867,0.9972234
2958,postoperative myalgia,21,23,123,144,"In conclusion, where succinylcholine is used, lidocaine is proven to be the useful pretreatment agent for the reduction of postoperative myalgia.",12452237_12,-1,-1,-1,2958,-1,0.0013549165,0.9986451
2960,mg,9,10,67,69,Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.,12464714_0,-1,-1,-1,2960,-1,0.9962205,0.0037794884
2965,mg,14,15,102,104,This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy.,12464714_2,-1,-1,-1,2965,-1,0.9934962,0.006503854
2967,mg,22,23,146,148,This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy.,12464714_2,-1,-1,-1,2967,-1,0.99086326,0.009136668
2970,p,25,26,131,132,"Of patients expressing a preference (89.1%), more than twice as many preferred rizatriptan to ergotamine/caffeine (69.9 vs. 30.1%, p < or = 0.001).",12464714_3,-1,-1,-1,2970,-1,0.4071617,0.5928383
2974,h,9,10,48,49,The co-primary endpoint of being pain free at 2 h was also in favor of rizatriptan.,12464714_5,-1,-1,-1,2974,-1,0.17601505,0.823985
2977,h,8,9,48,49,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,-1,-1,-1,2977,-1,0.12030653,0.87969345
2979,p,20,21,123,124,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,-1,-1,-1,2979,-1,0.47477472,0.5252253
2981,h,32,33,176,177,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,-1,-1,-1,2981,-1,0.17889972,0.8211003
2983,h,4,5,21,22,"Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p < or = 0.001), with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing.",12464714_7,-1,-1,-1,2983,-1,0.13698274,0.86301726
2985,p,16,17,84,85,"Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p < or = 0.001), with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing.",12464714_7,-1,-1,-1,2985,-1,0.49429518,0.5057049
2989,h,12,13,62,63,"Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).",12464714_8,-1,-1,-1,2989,-1,0.19762315,0.80237687
2990,h,24,25,130,131,"Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).",12464714_8,-1,-1,-1,2990,-1,0.12595138,0.8740486
2991,p,35,36,185,186,"Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).",12464714_8,-1,-1,-1,2991,-1,0.34017575,0.65982425
2995,phonophobia,17,18,110,121,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,-1,-1,-1,2995,-1,0.0017468352,0.99825317
2996,photophobia,19,20,125,136,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,-1,-1,-1,2996,-1,0.0015330915,0.9984669
2997,h,27,28,177,178,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,-1,-1,-1,2997,-1,0.19631027,0.8036897
2998,p,32,33,198,199,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,-1,-1,-1,2998,-1,0.5479328,0.45206717
2999,h,12,13,62,63,"More patients were (completely, very or somewhat) satisfied 2 h after treatment with rizatriptan (69.8%) than at 2 h after treatment with ergotamine/caffeine (38.6%, p < or = 0.001).",12464714_10,-1,-1,-1,2999,-1,0.30499223,0.6950078
3001,h,24,25,115,116,"More patients were (completely, very or somewhat) satisfied 2 h after treatment with rizatriptan (69.8%) than at 2 h after treatment with ergotamine/caffeine (38.6%, p < or = 0.001).",12464714_10,-1,-1,-1,3001,-1,0.36614865,0.63385135
3002,p,33,34,166,167,"More patients were (completely, very or somewhat) satisfied 2 h after treatment with rizatriptan (69.8%) than at 2 h after treatment with ergotamine/caffeine (38.6%, p < or = 0.001).",12464714_10,-1,-1,-1,3002,-1,0.4150018,0.58499825
3016,contrast,1,2,3,11,"In contrast, the conduction velocity, the number and size of axons in the optic nerve, and the specific localization of Na(v)1.6 channels in the nodes of Ranvier were unchanged.",12481039_6,-1,-1,-1,3016,-1,0.1904566,0.8095434
3022,glioblastomas,12,13,93,106,Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas.,12483326_0,-1,-1,-1,3022,-1,0.0014921153,0.9985079
3024,malignant tumor,5,7,30,45,BACKGROUND: Glioblastoma is a malignant tumor that occurs in the cerebrum during adulthood.,12483326_1,-1,-1,-1,3024,-1,0.0030085193,0.9969915
3032,glioblastomas,13,14,88,101,CASE: A 58-year-old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe.,12483326_6,-1,-1,-1,3032,-1,0.0016524333,0.9983475
3034,visual disturbance,5,7,26,44,He complained of pain and visual disturbance in the ipsilateral eye 30 h after the injection.,12483326_7,-1,-1,-1,3034,-1,0.0017734295,0.9982266
3035,h,12,13,71,72,He complained of pain and visual disturbance in the ipsilateral eye 30 h after the injection.,12483326_7,-1,-1,-1,3035,-1,0.10651414,0.89348584
3036,carboplatin toxicity,7,9,47,67,Various ocular symptoms and findings caused by carboplatin toxicity were seen.,12483326_8,-1,-1,-1,3036,-1,0.61164427,0.3883557
3038,glycerin,11,12,79,87,RESULTS: He was treated with intravenous administration of corticosteroids and glycerin for 6 days after the injection.,12483326_9,-1,-1,-1,3038,-1,0.99906343,0.00093662506
3040,ocular pain,13,15,107,118,"Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks.",12483326_10,-1,-1,-1,3040,-1,0.0014614459,0.9985386
3041,papilledema,18,19,142,153,"Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks.",12483326_10,-1,-1,-1,3041,-1,0.0013620016,0.998638
3042,retinal detachment,21,23,168,186,"Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks.",12483326_10,-1,-1,-1,3042,-1,0.0013512893,0.9986487
3043,chorioretinal atrophy,7,9,32,53,"Finally, 6 weeks later, diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost.",12483326_11,-1,-1,-1,3043,-1,0.0031262035,0.99687374
3044,optic atrophy,10,12,59,72,"Finally, 6 weeks later, diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost.",12483326_11,-1,-1,-1,3044,-1,0.0017643824,0.9982356
3046,ocular toxicity,17,19,112,127,"CONCLUSION: When performing intracarotid injection of carboplatin, we must be aware of its potentially blinding ocular toxicity.",12483326_12,-1,-1,-1,3046,-1,0.0014737296,0.9985262
3059,absence seizures,4,6,37,53,Anti-epileptic drugs-induced de novo absence seizures.,12536034_0,-1,-1,-1,3059,-1,0.0015342027,0.9984658
3060,absence epilepsy,8,10,48,64,The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin.,12536034_1,-1,-1,-1,3060,-1,0.0014897182,0.9985103
3063,absence seizure,11,13,72,87,"Despite the underlying diseases, the prognosis for drug-induced de novo absence seizure is good because it subsides rapidly after discontinuing the use of the offending drugs.",12536034_2,-1,-1,-1,3063,-1,0.0014720298,0.998528
3064,absence epilepsy,16,18,133,149,The gamma-aminobutyric acid-transmitted thalamocortical circuitry accounts for a major part of the underlying neurophysiology of the absence epilepsy.,12536034_3,-1,-1,-1,3064,-1,0.0019553243,0.9980446
3065,absence seizure,4,6,29,44,"Because drug-induced de novo absence seizure is rare, pro-absence drugs can only be considered a promoting factor.",12536034_4,-1,-1,-1,3065,-1,0.001561562,0.9984384
3066,absence seizure,21,23,136,151,The underlying epileptogenecity of the patients or the synergistic effects of the accompanying drugs is required to trigger the de novo absence seizure.,12536034_5,-1,-1,-1,3066,-1,0.0015881729,0.9984118
3069,absence epilepsy,6,8,45,61,"By understanding the underlying mechanism of absence epilepsy, we can avoid the inappropriate use of anticonvulsants in children with epilepsy and prevent drug-induced absence seizures.",12536034_7,-1,-1,-1,3069,-1,0.0013790415,0.998621
3071,absence seizures,24,26,168,184,"By understanding the underlying mechanism of absence epilepsy, we can avoid the inappropriate use of anticonvulsants in children with epilepsy and prevent drug-induced absence seizures.",12536034_7,-1,-1,-1,3071,-1,0.0013455964,0.99865437
3075,liver failure,8,10,37,50,OBJECTIVE: To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole.,12549952_1,-1,-1,-1,3075,-1,0.0013399337,0.9986601
3084,deterioration of renal function,7,11,44,75,He developed acute liver failure with rapid deterioration of renal function.,12549952_4,-1,-1,-1,3084,-1,0.0026414276,0.9973585
3085,acute liver injury,7,10,57,75,Liver biopsy showed evidence of nonspecific drug-induced acute liver injury.,12549952_5,-1,-1,-1,3085,-1,0.0012502678,0.99874973
3096,acute liver insult,10,13,62,80,CONCLUSIONS: Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs.,12549952_10,-1,-1,-1,3096,-1,0.0013330803,0.9986669
3099,pyeloureteritis cystica,3,5,16,39,The etiology of pyeloureteritis cystica has long been attributed to chronic infection and inflammation.,1255900_1,-1,-1,-1,3099,-1,0.0018785256,0.99812144
3104,pelvic thrombophlebitis,12,14,83,106,The disease occurred subsequent to the initiation of heparin therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation.,1255900_4,-1,-1,-1,3104,-1,0.0012036476,0.99879634
3105,pyeloureteritis cystica,15,17,98,121,The rate of resolution of the radiographic findings may be helpful in distinguishing between true pyeloureteritis cystica and submucosal hemorrhage.,1255900_5,-1,-1,-1,3105,-1,0.0018740705,0.998126
3106,submucosal hemorrhage,18,20,126,147,The rate of resolution of the radiographic findings may be helpful in distinguishing between true pyeloureteritis cystica and submucosal hemorrhage.,1255900_5,-1,-1,-1,3106,-1,0.0033566612,0.9966433
3108,contrast medium,6,8,33,48,BACKGROUND: The use of iodinated contrast medium can result in nephropathy.,12571256_1,-1,-1,-1,3108,-1,0.99614453,0.0038554384
3110,contrast medium,2,4,20,35,Whether iso-osmolar contrast medium is less nephrotoxic than low-osmolar contrast medium in high-risk patients is uncertain.,12571256_2,-1,-1,-1,3110,-1,0.99735165,0.0026483121
3112,contrast medium,9,11,73,88,Whether iso-osmolar contrast medium is less nephrotoxic than low-osmolar contrast medium in high-risk patients is uncertain.,12571256_2,-1,-1,-1,3112,-1,0.9972011,0.0027989608
3114,contrast medium,24,26,152,167,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,-1,-1,-1,3114,-1,0.99274445,0.007255558
3116,contrast medium,38,40,229,244,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,-1,-1,-1,3116,-1,0.9935409,0.0064590788
3117,iohexol,41,42,246,253,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,-1,-1,-1,3117,-1,0.9991742,0.0008257373
3120,mg,15,16,97,99,The study involved 129 patients with diabetes with serum creatinine concentrations of 1.5 to 3.5 mg per deciliter who underwent coronary or aortofemoral angiography.,12571256_4,-1,-1,-1,3120,-1,0.96532816,0.034671836
3123,mg,12,13,73,75,"Other end points were an increase in the creatinine concentration of 0.5 mg per deciliter or more, an increase of 1.0 mg per deciliter or more, and a change in the creatinine concentration from day 0 to day 7.",12571256_6,-1,-1,-1,3123,-1,0.9701601,0.02983986
3124,mg,22,23,118,120,"Other end points were an increase in the creatinine concentration of 0.5 mg per deciliter or more, an increase of 1.0 mg per deciliter or more, and a change in the creatinine concentration from day 0 to day 7.",12571256_6,-1,-1,-1,3124,-1,0.9625551,0.037444953
3129,mg,15,16,67,69,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3129,-1,0.9338264,0.066173635
3131,mg,24,25,116,118,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3131,-1,0.9300804,0.06991961
3132,iohexol,29,30,140,147,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3132,-1,0.99925905,0.000740898
3133,P=0.001,32,33,155,162,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3133,-1,0.35180876,0.6481913
3135,iohexol,42,43,216,223,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3135,-1,0.99924505,0.0007550156
3136,mg,45,46,231,233,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3136,-1,0.8951878,0.10481215
3139,mg,22,23,113,115,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,-1,-1,-1,3139,-1,0.95997554,0.04002441
3140,iohexol,38,39,185,192,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,-1,-1,-1,3140,-1,0.99924767,0.0007523595
3141,P=0.002,45,46,213,220,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,-1,-1,-1,3141,-1,0.38056853,0.6194315
3144,mg,9,10,54,56,"No patient receiving iodixanol had an increase of 1.0 mg per deciliter or more, but 10 patients in the iohexol group (15 percent) did.",12571256_10,-1,-1,-1,3144,-1,0.93142396,0.068576075
3145,iohexol,20,21,103,110,"No patient receiving iodixanol had an increase of 1.0 mg per deciliter or more, but 10 patients in the iohexol group (15 percent) did.",12571256_10,-1,-1,-1,3145,-1,0.99926573,0.000734302
3147,mg,15,16,77,79,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3147,-1,0.9580093,0.04199067
3149,mg,24,25,126,128,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3149,-1,0.954441,0.045559004
3150,iohexol,29,30,150,157,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3150,-1,0.99925405,0.0007459095
3151,P=0.003,32,33,165,172,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3151,-1,0.33872473,0.66127527
3153,iohexol,44,45,226,233,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3153,-1,0.9992379,0.0007620901
3154,mg,48,49,247,249,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3154,-1,0.9152639,0.08473611
3156,contrast medium,5,7,36,51,"CONCLUSIONS: Nephropathy induced by contrast medium may be less likely to develop in high-risk patients when iodixanol is used rather than a low-osmolar, nonionic contrast medium.",12571256_12,-1,-1,-1,3156,-1,0.9983115,0.0016885222
3158,contrast medium,26,28,163,178,"CONCLUSIONS: Nephropathy induced by contrast medium may be less likely to develop in high-risk patients when iodixanol is used rather than a low-osmolar, nonionic contrast medium.",12571256_12,-1,-1,-1,3158,-1,0.997983,0.0020170067
3164,increase in blood pressure,15,19,101,127,The purpose of the present study was to determine if prenatal dexamethasone programmed a progressive increase in blood pressure and renal injury in rats.,12574103_2,-1,-1,-1,3164,-1,0.007703538,0.9922964
3167,body weight,16,18,106,117,"Pregnant rats were given either vehicle or 2 daily intraperitoneal injections of dexamethasone (0.2 mg/kg body weight) on gestational days 11 and 12, 13 and 14, 15 and 16, 17 and 18, or 19 and 20.",12574103_3,-1,-1,-1,3167,-1,0.8412848,0.15871517
3169,in,16,17,93,95,"Offspring of rats administered dexamethasone on days 15 and 16 gestation had a 20% reduction in glomerular number compared with control at 6 to 9 months of age (22 527+/-509 versus 28 050+/-561, P<0.05), which was comparable to the percent reduction in glomeruli measured at 3 weeks of age.",12574103_4,-1,-1,-1,3169,-1,0.016612448,0.9833876
3170,P<0.05,36,37,195,201,"Offspring of rats administered dexamethasone on days 15 and 16 gestation had a 20% reduction in glomerular number compared with control at 6 to 9 months of age (22 527+/-509 versus 28 050+/-561, P<0.05), which was comparable to the percent reduction in glomeruli measured at 3 weeks of age.",12574103_4,-1,-1,-1,3170,-1,0.3578778,0.64212227
3171,glomeruli,47,48,253,262,"Offspring of rats administered dexamethasone on days 15 and 16 gestation had a 20% reduction in glomerular number compared with control at 6 to 9 months of age (22 527+/-509 versus 28 050+/-561, P<0.05), which was comparable to the percent reduction in glomeruli measured at 3 weeks of age.",12574103_4,-1,-1,-1,3171,-1,0.010426217,0.9895738
3173,P<0.05,31,32,165,171,Six- to 9-month old rats receiving prenatal dexamethasone on days 17 and 18 of gestation had a 17% reduction in glomeruli (23 380+/-587) compared with control rats (P<0.05).,12574103_5,-1,-1,-1,3173,-1,0.42772698,0.572273
3175,elevated blood pressures,23,26,108,132,"Male rats that received prenatal dexamethasone on days 15 and 16, 17 and 18, and 13 and 14 of gestation had elevated blood pressures at 6 months of age; the latter group did not have a reduction in glomerular number.",12574103_6,-1,-1,-1,3175,-1,0.011649305,0.98835075
3180,reduction in,11,13,66,78,"This study shows that prenatal dexamethasone in rats results in a reduction in glomerular number, glomerulosclerosis, and hypertension when administered at specific points during gestation.",12574103_8,-1,-1,-1,3180,-1,0.0050670854,0.99493295
3185,cyclosporine A,9,11,73,87,"Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.",12584269_0,-1,-1,-1,3185,-1,0.99920744,0.00079261925
3189,SRL,4,5,23,26,BACKGROUND: Sirolimus (SRL) may supplement calcineurin inhibitors in clinical organ transplantation.,12584269_1,-1,-1,-1,3189,-1,0.9986253,0.0013747194
3190,calcineurin inhibitors,8,10,43,65,BACKGROUND: Sirolimus (SRL) may supplement calcineurin inhibitors in clinical organ transplantation.,12584269_1,-1,-1,-1,3190,-1,0.99892944,0.0010705716
3192,SRL,5,6,27,30,"These are nephrotoxic, but SRL seems to act differently displaying only minor nephrotoxic effects, although this question is still open.",12584269_2,-1,-1,-1,3192,-1,0.99849653,0.0015034842
3194,SRL,7,8,41,44,In a number of treatment protocols where SRL was combined with a calcineurin inhibitor indications of a synergistic nephrotoxic effect were described.,12584269_3,-1,-1,-1,3194,-1,0.99835926,0.0016407039
3196,cyclosporine A,26,28,161,175,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,-1,-1,-1,3196,-1,0.9991731,0.0008269012
3197,CsA,29,30,177,180,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,-1,-1,-1,3197,-1,0.99900216,0.0009978866
3199,FK506,34,35,195,200,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,-1,-1,-1,3199,-1,0.99914515,0.00085484196
3200,SRL,37,38,205,208,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,-1,-1,-1,3200,-1,0.9989729,0.0010270928
3201,CsA,9,10,34,37,"METHODS: For a period of 2 weeks, CsA 15 mg/kg/day (given orally), FK506 3.0 mg/kg/day (given orally) or SRL 0.4 mg/kg/day (given intraperitoneally) was administered once a day as these doses have earlier been found to achieve a significant immunosuppressive effect in Sprague-Dawley rats.",12584269_5,-1,-1,-1,3201,-1,0.99911803,0.00088193966
3202,FK506,17,18,67,72,"METHODS: For a period of 2 weeks, CsA 15 mg/kg/day (given orally), FK506 3.0 mg/kg/day (given orally) or SRL 0.4 mg/kg/day (given intraperitoneally) was administered once a day as these doses have earlier been found to achieve a significant immunosuppressive effect in Sprague-Dawley rats.",12584269_5,-1,-1,-1,3202,-1,0.9992673,0.0007326796
3203,SRL,25,26,105,108,"METHODS: For a period of 2 weeks, CsA 15 mg/kg/day (given orally), FK506 3.0 mg/kg/day (given orally) or SRL 0.4 mg/kg/day (given intraperitoneally) was administered once a day as these doses have earlier been found to achieve a significant immunosuppressive effect in Sprague-Dawley rats.",12584269_5,-1,-1,-1,3203,-1,0.9991085,0.0008914312
3204,Cr(EDTA,22,23,113,120,"In the 'conscious catheterized rat' model, the glomerular filtration rate (GFR) was measured as the clearance of Cr(EDTA).",12584269_6,-1,-1,-1,3204,-1,0.99854445,0.0014555245
3208,CsA,2,3,9,12,"RESULTS: CsA, FK506 and SRL all significantly decreased the GFR.",12584269_8,-1,-1,-1,3208,-1,0.9989826,0.0010173145
3209,FK506,4,5,14,19,"RESULTS: CsA, FK506 and SRL all significantly decreased the GFR.",12584269_8,-1,-1,-1,3209,-1,0.99916244,0.0008376158
3210,SRL,6,7,24,27,"RESULTS: CsA, FK506 and SRL all significantly decreased the GFR.",12584269_8,-1,-1,-1,3210,-1,0.9987778,0.0012222218
3211,CsA,6,7,38,41,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,-1,-1,-1,3211,-1,0.9990953,0.0009047312
3212,FK506,11,12,67,72,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,-1,-1,-1,3212,-1,0.9991868,0.00081321865
3213,SRL,13,14,76,79,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,-1,-1,-1,3213,-1,0.9990096,0.0009904187
3214,FK506,25,26,142,147,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,-1,-1,-1,3214,-1,0.99920064,0.0007993475
3215,SRL,27,28,153,156,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,-1,-1,-1,3215,-1,0.99893767,0.0010623432
3216,CsA,11,12,80,83,The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).,12584269_11,-1,-1,-1,3216,-1,0.9990125,0.0009875087
3217,SRL,13,14,89,92,The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).,12584269_11,-1,-1,-1,3217,-1,0.9988134,0.0011866264
3218,P<0.001,15,16,94,101,The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).,12584269_11,-1,-1,-1,3218,-1,0.30854133,0.6914587
3220,P<0.02,45,46,274,280,The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).,12584269_11,-1,-1,-1,3220,-1,0.37988648,0.62011355
3221,FK506,1,2,4,9,The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls (P=0.05).,12584269_12,-1,-1,-1,3221,-1,0.99919575,0.00080423534
3222,SRL,3,4,15,18,The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls (P=0.05).,12584269_12,-1,-1,-1,3222,-1,0.99874556,0.0012544524
3224,P=0.05,18,19,109,115,The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls (P=0.05).,12584269_12,-1,-1,-1,3224,-1,0.2391292,0.76087075
3226,CsA,11,12,76,79,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,-1,-1,-1,3226,-1,0.9991197,0.0008802526
3227,SRL,13,14,85,88,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,-1,-1,-1,3227,-1,0.9990451,0.00095492636
3228,FK506,16,17,98,103,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,-1,-1,-1,3228,-1,0.99925476,0.0007452051
3229,SRL,18,19,109,112,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,-1,-1,-1,3229,-1,0.99902093,0.0009790709
3232,myocardial cell injury,24,27,115,137,BACKGROUND: Cardiac troponins I (cTnI) and T (cTnT) have been shown to be highly sensitive and specific markers of myocardial cell injury.,12589964_1,-1,-1,-1,3232,-1,0.0031505853,0.99684936
3236,cardiac disorders,38,40,239,256,"We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.",12589964_2,-1,-1,-1,3236,-1,0.0013363359,0.99866366
3237,DOX,9,10,54,57,"METHODS: Thirty-five Wistar rats were given 1.5 mg/kg DOX, i.v., weekly for up to 8 weeks for a total cumulative dose of 12 mg/kg BW.",12589964_3,-1,-1,-1,3237,-1,0.99859756,0.0014023829
3238,DOX,26,27,160,163,"By using transthoracic echocardiography, anterior and posterior wall thickness, LV diameters and LV fractional shortening (FS) were measured in all rats before DOX or saline, and at weeks 6 and 9 after treatment in all surviving rats.",12589964_6,-1,-1,-1,3238,-1,0.99879164,0.0012084392
3239,DOX,13,14,68,71,Histology was performed in DOX-rats at 6 and 9 weeks after the last DOX dose and in all controls.,12589964_7,-1,-1,-1,3239,-1,0.9987484,0.0012515271
3240,DOX,5,6,25,28,RESULTS: Eighteen of the DOX rats died prematurely of general toxicity during the 9-week period.,12589964_8,-1,-1,-1,3240,-1,0.9976884,0.0023116253
3242,DOX,24,25,131,134,"End-diastolic (ED) and end-systolic (ES) LV diameters/BW significantly increased, whereas LV FS was decreased after 9 weeks in the DOX group (p<0.001).",12589964_9,-1,-1,-1,3242,-1,0.9984394,0.0015605919
3243,p<0.001,27,28,142,149,"End-diastolic (ED) and end-systolic (ES) LV diameters/BW significantly increased, whereas LV FS was decreased after 9 weeks in the DOX group (p<0.001).",12589964_9,-1,-1,-1,3243,-1,0.35012218,0.6498778
3244,DOX,8,9,54,57,Histological evaluation of hearts from all rats given DOX revealed significant slight degrees of perivascular and interstitial fibrosis.,12589964_11,-1,-1,-1,3244,-1,0.9985422,0.0014577903
3247,DOX,8,9,40,43,A significant rise in cTnT was found in DOX rats after cumulative doses of 7.5 and 12 mg/kg in comparison with baseline (p<0.05).,12589964_14,-1,-1,-1,3247,-1,0.99857986,0.0014202029
3248,p<0.05,23,24,121,127,A significant rise in cTnT was found in DOX rats after cumulative doses of 7.5 and 12 mg/kg in comparison with baseline (p<0.05).,12589964_14,-1,-1,-1,3248,-1,0.38885745,0.6111426
3249,DOX,16,17,93,96,cTnT found in rats after 12 mg/kg were significantly greater than that found after 7.5 mg/kg DOX.,12589964_15,-1,-1,-1,3249,-1,0.9986405,0.0013595737
3250,DOX,12,13,69,72,"Maximal cTnI (pg/ml) and cTnT levels were significantly increased in DOX rats compared with controls (p=0.006, 0.007).",12589964_16,-1,-1,-1,3250,-1,0.9983321,0.0016679475
3251,p=0.006,18,19,102,109,"Maximal cTnI (pg/ml) and cTnT levels were significantly increased in DOX rats compared with controls (p=0.006, 0.007).",12589964_16,-1,-1,-1,3251,-1,0.47233278,0.5276672
3252,DOX,12,13,54,57,"cTnI (ng/ml), CK-MB mass and CK remained unchanged in DOX rats compared with controls.",12589964_17,-1,-1,-1,3252,-1,0.99835926,0.0016407595
3253,p<0.0001,21,22,121,129,Analysis of data revealed a significant correlation between maximal cTnT and ED and ES LV diameters/BW (r=0.81 and 0.65; p<0.0001).,12589964_19,-1,-1,-1,3253,-1,0.3913131,0.60868686
3254,ischemic injury,5,7,30,45,"CONCLUSIONS: Among markers of ischemic injury after DOX in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes.",12589964_21,-1,-1,-1,3254,-1,0.0016143181,0.99838567
3255,DOX,8,9,52,55,"CONCLUSIONS: Among markers of ischemic injury after DOX in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes.",12589964_21,-1,-1,-1,3255,-1,0.99853253,0.0014674083
3257,DOX,13,14,75,78,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,-1,-1,-1,3257,-1,0.998206,0.001793979
3258,DOX,38,39,209,212,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,-1,-1,-1,3258,-1,0.9981845,0.0018154769
3260,hypoxemia,1,2,19,28,Octreotide-induced hypoxemia and pulmonary hypertension in premature neonates.,12596116_0,-1,-1,-1,3260,-1,0.0010671137,0.9989329
3262,fistula,11,12,73,80,The authors report 2 cases of premature neonates who had enterocutaneous fistula complicating necrotizing enterocolitis.,12596116_1,-1,-1,-1,3262,-1,0.0012690998,0.99873084
3263,necrotizing enterocolitis,13,15,94,119,The authors report 2 cases of premature neonates who had enterocutaneous fistula complicating necrotizing enterocolitis.,12596116_1,-1,-1,-1,3263,-1,0.0011582519,0.9988418
3266,fistula,17,18,123,130,"Pulmonary hypertension developed after administration of a somatostatin analogue, octreotide, to enhance resolution of the fistula.",12596116_2,-1,-1,-1,3266,-1,0.0015148311,0.99848515
3267,edaravone,3,4,21,30,Protective effect of edaravone against streptomycin-induced vestibulotoxicity in the guinea pig.,12600698_0,-1,-1,-1,3267,-1,0.9991165,0.0008835256
3268,vestibulotoxicity,6,7,60,77,Protective effect of edaravone against streptomycin-induced vestibulotoxicity in the guinea pig.,12600698_0,-1,-1,-1,3268,-1,0.001517242,0.99848276
3269,vestibulotoxicity,6,7,60,77,This study investigated alleviation of streptomycin-induced vestibulotoxicity by edaravone in guinea pigs.,12600698_1,-1,-1,-1,3269,-1,0.0014620146,0.998538
3270,edaravone,8,9,81,90,This study investigated alleviation of streptomycin-induced vestibulotoxicity by edaravone in guinea pigs.,12600698_1,-1,-1,-1,3270,-1,0.9991192,0.0008807627
3271,Edaravone,0,1,0,9,"Edaravone, a free radical scavenger, has potent free radical quenching action and is used in clinical practice to treat cerebral infarction.",12600698_2,-1,-1,-1,3271,-1,0.9991084,0.0008916419
3272,cerebral infarction,21,23,120,139,"Edaravone, a free radical scavenger, has potent free radical quenching action and is used in clinical practice to treat cerebral infarction.",12600698_2,-1,-1,-1,3272,-1,0.0014221097,0.99857783
3274,h,12,13,70,71,"Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.",12600698_3,-1,-1,-1,3274,-1,0.5110747,0.48892528
3275,edaravone,15,16,77,86,"Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.",12600698_3,-1,-1,-1,3275,-1,0.9991001,0.0008999672
3276,n=8,17,18,88,91,"Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.",12600698_3,-1,-1,-1,3276,-1,0.5729742,0.42702585
3277,n=6,22,23,104,107,"Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.",12600698_3,-1,-1,-1,3277,-1,0.6137001,0.3862999
3278,edaravone,12,13,89,98,Animals injected with saline showed statistically smaller gains than those injected with edaravone.,12600698_5,-1,-1,-1,3278,-1,0.99909437,0.0009056247
3279,edaravone,4,5,27,36,These results suggest that edaravone suppresses streptomycin-induced vestibulotoxicity.,12600698_6,-1,-1,-1,3279,-1,0.9991036,0.0008963476
3280,vestibulotoxicity,7,8,69,86,These results suggest that edaravone suppresses streptomycin-induced vestibulotoxicity.,12600698_6,-1,-1,-1,3280,-1,0.0015413046,0.99845874
3281,venous thromboembolism,3,5,12,34,The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.,12615818_0,-1,-1,-1,3281,-1,0.0012779143,0.998722
3282,cyproterone acetate,8,10,55,74,The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.,12615818_0,-1,-1,-1,3282,-1,0.99926966,0.0007303084
3283,ethinyl estradiol,13,15,95,112,The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.,12615818_0,-1,-1,-1,3283,-1,0.9991642,0.000835751
3284,Cyproterone acetate,2,4,12,31,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,-1,-1,3284,-1,0.999265,0.0007349993
3285,ethinyl estradiol,6,8,46,63,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,-1,-1,3285,-1,0.99919504,0.0008049177
3287,hirsutism,24,25,136,145,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,-1,-1,3287,-1,0.0012643281,0.9987357
3288,polycystic ovary syndrome,32,35,181,206,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,-1,-1,3288,-1,0.0019804507,0.9980196
3289,PCOS,36,37,208,212,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,-1,-1,3289,-1,0.0015584566,0.9984415
3290,venous thromboembolism,8,10,56,78,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,-1,-1,-1,3290,-1,0.0013055793,0.9986945
3291,VTE,11,12,80,83,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,-1,-1,-1,3291,-1,0.0014083687,0.9985916
3292,combined oral contraceptives,19,22,135,163,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,-1,-1,-1,3292,-1,0.9974896,0.0025104794
3293,COCs,23,24,165,169,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,-1,-1,-1,3293,-1,0.9972805,0.0027194652
3295,hirsutism,31,32,184,193,"METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.",12615818_4,-1,-1,-1,3295,-1,0.0016345404,0.99836546
3296,PCOS,33,34,197,201,"METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.",12615818_4,-1,-1,-1,3296,-1,0.0015430063,0.99845695
3297,VTE,39,40,226,229,"METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.",12615818_4,-1,-1,-1,3297,-1,0.0014170591,0.99858296
3298,COCs,11,12,78,82,RESULTS: The age-adjusted incidence rate ratio for CPA/EE versus conventional COCs was 2.20 [95% confidence interval (CI) 1.35-3.58].,12615818_5,-1,-1,-1,3298,-1,0.94219893,0.0578011
3299,oral contraception,10,12,54,72,"Using as the reference group women who were not using oral contraception, had no recent pregnancy or menopausal symptoms, the case-control analysis gave an adjusted odds ratio (OR(adj)) of 7.44 (95% CI 3.67-15.08) for CPA/EE use compared with an OR(adj) of 2.58 (95% CI 1.60-4.18) for use of conventional COCs.",12615818_6,-1,-1,-1,3299,-1,0.99754685,0.0024531938
3300,menopausal symptoms,18,20,101,120,"Using as the reference group women who were not using oral contraception, had no recent pregnancy or menopausal symptoms, the case-control analysis gave an adjusted odds ratio (OR(adj)) of 7.44 (95% CI 3.67-15.08) for CPA/EE use compared with an OR(adj) of 2.58 (95% CI 1.60-4.18) for use of conventional COCs.",12615818_6,-1,-1,-1,3300,-1,0.002153955,0.997846
3301,COCs,65,66,305,309,"Using as the reference group women who were not using oral contraception, had no recent pregnancy or menopausal symptoms, the case-control analysis gave an adjusted odds ratio (OR(adj)) of 7.44 (95% CI 3.67-15.08) for CPA/EE use compared with an OR(adj) of 2.58 (95% CI 1.60-4.18) for use of conventional COCs.",12615818_6,-1,-1,-1,3301,-1,0.99683785,0.003162081
3302,VTE,9,10,55,58,"CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.",12615818_7,-1,-1,-1,3302,-1,0.0012880511,0.99871194
3304,hirsutism,21,22,113,122,"CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.",12615818_7,-1,-1,-1,3304,-1,0.0014021292,0.9985979
3305,PCOS,23,24,126,130,"CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.",12615818_7,-1,-1,-1,3305,-1,0.0014089664,0.998591
3306,gum Arabic,5,7,29,39,The effect of treatment with gum Arabic on gentamicin nephrotoxicity in rats: a preliminary study.,12617329_0,-1,-1,-1,3306,-1,0.9980064,0.0019936014
3307,gentamicin nephrotoxicity,8,10,43,68,The effect of treatment with gum Arabic on gentamicin nephrotoxicity in rats: a preliminary study.,12617329_0,-1,-1,-1,3307,-1,0.068595506,0.9314045
3308,gum Arabic,13,15,69,79,In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.,12617329_1,-1,-1,-1,3308,-1,0.99837166,0.0016284155
3309,acute renal failure,16,19,83,102,In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.,12617329_1,-1,-1,-1,3309,-1,0.001278338,0.99872166
3311,GM,23,24,126,128,In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.,12617329_1,-1,-1,-1,3311,-1,0.993005,0.0069950093
3313,gum Arabic,22,24,95,105,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,-1,-1,-1,3313,-1,0.99893993,0.0010601348
3314,gum Arabic,35,37,150,160,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,-1,-1,-1,3314,-1,0.9986487,0.001351274
3315,gum Arabic,46,48,193,203,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,-1,-1,-1,3315,-1,0.9989115,0.0010884528
3316,GM,50,51,223,225,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,-1,-1,-1,3316,-1,0.9981225,0.001877479
3320,reduced glutathione,15,17,101,120,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,-1,-1,-1,3320,-1,0.9985833,0.0014167029
3321,GSH,18,19,122,125,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,-1,-1,-1,3321,-1,0.9985158,0.0014842248
3322,gum Arabic,7,9,54,64,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3322,-1,0.99857414,0.0014258022
3323,GM,10,11,69,71,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3323,-1,0.99823856,0.001761485
3326,cellulose,38,39,214,223,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3326,-1,0.9983627,0.0016372793
3327,GM,40,41,228,230,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3327,-1,0.99838006,0.0016199813
3328,GSH,48,49,264,267,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3328,-1,0.99835074,0.001649253
3329,cellulose,59,60,299,308,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3329,-1,0.99824,0.0017599476
3330,GM,61,62,314,316,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3330,-1,0.9981012,0.0018988024
3331,proximal tubular necrosis,66,69,339,364,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3331,-1,0.004860858,0.9951391
3332,GM,78,79,415,417,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3332,-1,0.9983109,0.0016890268
3333,gum Arabic,81,83,432,442,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3333,-1,0.9987538,0.0012462345
3334,GM,87,88,463,465,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3334,-1,0.9983315,0.0016684929
3335,cellulose,89,90,470,479,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3335,-1,0.99862087,0.0013790944
3336,gum Arabic,5,7,26,36,It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of GM nephrotoxicity.,12617329_5,-1,-1,-1,3336,-1,0.9986401,0.0013598215
3337,GM nephrotoxicity,22,24,136,153,It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of GM nephrotoxicity.,12617329_5,-1,-1,-1,3337,-1,0.012926093,0.9870739
3339,venous thromboembolism,3,5,23,45,Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.,12627929_0,-1,-1,-1,3339,-1,0.0011543983,0.9988456
3343,venous thromboembolism,8,10,46,68,STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.,12627929_1,-1,-1,-1,3343,-1,0.0011789954,0.99882096
3344,VTE,11,12,70,73,STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.,12627929_1,-1,-1,-1,3344,-1,0.0012624472,0.9987375
3351,mg,29,30,182,184,"INTERVENTION: Each patient received either intravenous docetaxel 30 mg/m2/week for 3 consecutive weeks, followed by 1 week off, or the combination of continuous oral thalidomide 200 mg every evening plus the same docetaxel regimen.",12627929_5,-1,-1,-1,3351,-1,0.99659085,0.0034091626
3354,disease progression,13,15,81,100,This 4-week cycle was repeated until there was evidence of excessive toxicity or disease progression.,12627929_6,-1,-1,-1,3354,-1,0.0017386002,0.9982614
3356,VTE,14,15,90,93,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,-1,-1,-1,3356,-1,0.0014915926,0.9985084
3359,VTE,31,32,176,179,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,-1,-1,-1,3359,-1,0.0014854225,0.9985146
3360,p=0.025,33,34,181,188,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,-1,-1,-1,3360,-1,0.34313703,0.656863
3364,VTE,19,20,130,133,CONCLUSION: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE.,12627929_8,-1,-1,-1,3364,-1,0.0013325803,0.9986675
3366,cholestatic hepatitis,1,3,20,41,Ticlopidine-induced cholestatic hepatitis.,12639165_0,-1,-1,-1,3366,-1,0.0013387729,0.9986613
3367,cholestatic hepatitis,8,10,52,73,"OBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases.",12639165_1,-1,-1,-1,3367,-1,0.0012709021,0.99872905
3368,cholestatic hepatitis,7,9,49,70,"CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty, with complete remission during the follow-up period.",12639165_2,-1,-1,-1,3368,-1,0.0015754731,0.99842453
3371,Cholestatic hepatitis,2,4,12,33,DISCUSSION: Cholestatic hepatitis is a rare complication of the antiplatelet agent ticlopidine; several cases have been reported but few in the English literature.,12639165_4,-1,-1,-1,3371,-1,0.0013528605,0.99864715
3375,cholestatic hepatitis,16,18,127,148,"Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis, which resolved after discontinuation of the drug.",12639165_5,-1,-1,-1,3375,-1,0.0014391835,0.99856085
3377,adverse drug,7,9,52,64,An objective causality assessment revealed that the adverse drug event was probably related to the use of ticlopidine.,12639165_7,-1,-1,-1,3377,-1,0.014700616,0.98529935
3381,Cholestatic hepatitis,2,4,13,34,CONCLUSIONS: Cholestatic hepatitis is a rare adverse effect of ticlopidine that may be immune mediated.,12639165_10,-1,-1,-1,3381,-1,0.0012923958,0.99870765
3386,nephrotic syndrome,16,18,116,134,Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome.,12653683_0,-1,-1,-1,3386,-1,0.0011816726,0.99881834
3387,nephrotic syndrome,2,4,16,34,"In experimental nephrotic syndrome, urinary sodium excretion is decreased during the early phase of the disease.",12653683_1,-1,-1,-1,3387,-1,0.0014483699,0.99855167
3392,puromycin aminonucleoside,11,13,64,89,We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside (PAN)-induced nephrotic syndrome.,12653683_4,-1,-1,-1,3392,-1,0.99918,0.0008199152
3393,nephrotic syndrome,14,16,104,122,We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside (PAN)-induced nephrotic syndrome.,12653683_4,-1,-1,-1,3393,-1,0.0012016476,0.9987984
3397,PAN,26,27,173,176,"The time courses of urinary sodium excretion, plasma aldosterone concentration and proteinuria were studied in male Sprague-Dawley rats treated with a single dose of either PAN or vehicle.",12653683_5,-1,-1,-1,3397,-1,0.9986029,0.0013970295
3401,PAN,11,12,51,54,"Sodium retention occurred on days 2, 3 and 6 after PAN injection.",12653683_8,-1,-1,-1,3401,-1,0.9978916,0.0021083972
3406,nephrotic syndrome,23,25,137,155,"In conclusion, ENaC mRNA expression, especially alphaENaC, is increased in the very early phase of the experimental model of PAN-induced nephrotic syndrome in rats, but appears to escape from the regulation by aldosterone after day 3.",12653683_12,-1,-1,-1,3406,-1,0.0013287953,0.9986712
3408,GABA,4,5,33,37,Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine.,12684739_0,-1,-1,-1,3408,-1,0.9990546,0.0009453344
3411,GABA,3,4,23,27,RATIONALE: gamma-Vinyl GABA (GVG) irreversibly inhibits GABA-transaminase.,12684739_1,-1,-1,-1,3411,-1,0.99886835,0.0011316809
3412,GVG,5,6,29,32,RATIONALE: gamma-Vinyl GABA (GVG) irreversibly inhibits GABA-transaminase.,12684739_1,-1,-1,-1,3412,-1,0.9984383,0.0015616711
3413,GABA,12,13,95,99,This non-receptor mediated inhibition requires de novo synthesis for restoration of functional GABA catabolism.,12684739_2,-1,-1,-1,3413,-1,0.9981811,0.001818975
3414,substance abuse,8,10,55,70,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,-1,3414,-1,0.4572457,0.5427543
3416,VFD,19,20,119,122,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,-1,3416,-1,0.0017345548,0.99826545
3417,GVG,35,36,218,221,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,-1,3417,-1,0.99638295,0.0036170322
3419,DA,47,48,289,291,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,-1,3419,-1,0.9987558,0.0012442376
3420,GVG,3,4,21,24,"RESULTS: Sub-chronic GVG exposure inhibited the effect of cocaine for 3 days, which exceeded in magnitude and duration the identical acute dose.",12684739_6,-1,-1,-1,3420,-1,0.9975586,0.0024413525
3422,GVG,5,6,34,37,"CONCLUSIONS: Sub-chronic low dose GVG potentiates and extends the inhibition of cocaine-induced increases in dopamine, effectively reducing cumulative exposures and the risk for VFDS.",12684739_7,-1,-1,-1,3422,-1,0.9973605,0.0026394299
3424,VFDS,25,26,178,182,"CONCLUSIONS: Sub-chronic low dose GVG potentiates and extends the inhibition of cocaine-induced increases in dopamine, effectively reducing cumulative exposures and the risk for VFDS.",12684739_7,-1,-1,-1,3424,-1,0.0015504565,0.99844956
3425,oromandibular dystonia,1,3,17,39,Levodopa-induced oromandibular dystonia in progressive supranuclear palsy.,12691807_0,-1,-1,-1,3425,-1,0.0015343467,0.99846566
3426,progressive supranuclear palsy,4,7,43,73,Levodopa-induced oromandibular dystonia in progressive supranuclear palsy.,12691807_0,-1,-1,-1,3426,-1,0.0014712618,0.9985287
3428,Parkinson's disease,6,9,51,70,Levodopa-induced dyskinesias have been reported in Parkinson's disease and multiple system atrophy.,12691807_1,-1,-1,-1,3428,-1,0.0019469545,0.9980531
3429,multiple system atrophy,10,13,75,98,Levodopa-induced dyskinesias have been reported in Parkinson's disease and multiple system atrophy.,12691807_1,-1,-1,-1,3429,-1,0.0029708955,0.9970291
3430,Cranial dystonias,0,2,0,17,Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).,12691807_2,-1,-1,-1,3430,-1,0.001472435,0.9985275
3431,progressive supranuclear palsy,7,10,44,74,Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).,12691807_2,-1,-1,-1,3431,-1,0.0014536864,0.99854636
3432,PSP,11,12,76,79,Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).,12691807_2,-1,-1,-1,3432,-1,0.0013913799,0.99860865
3433,Oromandibular dystonia,11,13,74,96,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,-1,-1,3433,-1,0.0014791735,0.9985208
3434,OMD,14,15,98,101,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,-1,-1,3434,-1,0.0014336619,0.9985663
3435,PSP,18,19,108,111,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,-1,-1,3435,-1,0.0017178988,0.9982821
3436,PSP,34,35,215,218,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,-1,-1,3436,-1,0.0014291669,0.9985708
3438,MR,6,7,39,41,Our objective was to investigate brain MR imaging findings and the utility of diffusion-weighted (DW) imaging in organ transplant patients who developed neurologic symptoms during tacrolimus therapy.,12695819_1,-1,-1,-1,3438,-1,0.023598757,0.97640127
3439,neurologic symptoms,24,26,153,172,Our objective was to investigate brain MR imaging findings and the utility of diffusion-weighted (DW) imaging in organ transplant patients who developed neurologic symptoms during tacrolimus therapy.,12695819_1,-1,-1,-1,3439,-1,0.0012816051,0.9987184
3441,MR,1,2,6,8,"Brain MR studies, including DW imaging, were prospectively performed in 14 organ transplant patients receiving tacrolimus who developed neurologic complications.",12695819_2,-1,-1,-1,3441,-1,0.030985607,0.96901435
3443,neurologic complications,20,22,136,160,"Brain MR studies, including DW imaging, were prospectively performed in 14 organ transplant patients receiving tacrolimus who developed neurologic complications.",12695819_2,-1,-1,-1,3443,-1,0.0012327513,0.99876726
3444,MR,9,10,53,55,"In each patient who had abnormalities on the initial MR study, a follow-up MR study was performed 1 month later.",12695819_3,-1,-1,-1,3444,-1,0.031257242,0.9687427
3445,MR,14,15,75,77,"In each patient who had abnormalities on the initial MR study, a follow-up MR study was performed 1 month later.",12695819_3,-1,-1,-1,3445,-1,0.04576976,0.9542303
3446,MR,10,11,59,61,Apparent diffusion coefficient (ADC) values on the initial MR study were correlated with reversibility of the lesions.,12695819_4,-1,-1,-1,3446,-1,0.07185613,0.92814386
3447,white matter abnormalities,11,14,34,60,"Of the 14 patients, 5 (35.7%) had white matter abnormalities, 1 (7.1%) had putaminal hemorrhage, and 8 (57.1%) had normal findings on initial MR images.",12695819_5,-1,-1,-1,3447,-1,0.0033435966,0.9966564
3448,putaminal hemorrhage,21,23,75,95,"Of the 14 patients, 5 (35.7%) had white matter abnormalities, 1 (7.1%) had putaminal hemorrhage, and 8 (57.1%) had normal findings on initial MR images.",12695819_5,-1,-1,-1,3448,-1,0.015265042,0.984735
3449,MR,35,36,142,144,"Of the 14 patients, 5 (35.7%) had white matter abnormalities, 1 (7.1%) had putaminal hemorrhage, and 8 (57.1%) had normal findings on initial MR images.",12695819_5,-1,-1,-1,3449,-1,0.10658362,0.8934164
3450,white matter abnormalities,5,8,26,52,"Among the 5 patients with white matter abnormalities, 4 patients (80.0%) showed higher than normal ADC values on initial MR images, and all showed complete resolution on follow-up images.",12695819_6,-1,-1,-1,3450,-1,0.0029202725,0.9970797
3451,MR,23,24,121,123,"Among the 5 patients with white matter abnormalities, 4 patients (80.0%) showed higher than normal ADC values on initial MR images, and all showed complete resolution on follow-up images.",12695819_6,-1,-1,-1,3451,-1,0.1419455,0.8580545
3452,laminar necrosis,20,22,114,130,The remaining 1 patient (20.0%) showed lower than normal ADC value and showed incomplete resolution with cortical laminar necrosis.,12695819_7,-1,-1,-1,3452,-1,0.0028261316,0.9971739
3457,mg,4,5,27,29,Hydrocortisone acetate (50 mg) was given orally every 6 hours for 24 hours after a 5-day fixed-salt diet (150 mmol/d).,12707296_4,-1,-1,-1,3457,-1,0.987978,0.012021965
3459,P<0.05,16,17,113,119,"Plasma cortisol concentrations were significantly raised during the active phase (323+/-43 to 1082+/-245 mmol/L, P<0.05).",12707296_9,-1,-1,-1,3459,-1,0.51528513,0.48471487
3460,mm Hg,10,12,56,61,Systolic blood pressure was elevated by an average of 7 mm Hg.,12707296_10,-1,-1,-1,3460,-1,0.013407589,0.9865925
3463,increases in blood pressure,4,8,34,61,We conclude that cortisol-induced increases in blood pressure are not associated with abnormalities in the l-arginine transport system.,12707296_12,-1,-1,-1,3463,-1,0.006689349,0.9933107
3466,intracerebral hemorrhage,9,11,64,88,Amount of bleeding and hematoma size in the collagenase-induced intracerebral hemorrhage rat model.,12716030_0,-1,-1,-1,3466,-1,0.0012979866,0.99870205
3467,intracerebral hemorrhage,4,6,23,47,The aggravated risk on intracerebral hemorrhage (ICH) with drugs used for stroke patients should be estimated carefully.,12716030_1,-1,-1,-1,3467,-1,0.0013498926,0.99865013
3468,ICH,7,8,49,52,The aggravated risk on intracerebral hemorrhage (ICH) with drugs used for stroke patients should be estimated carefully.,12716030_1,-1,-1,-1,3468,-1,0.0014797527,0.9985203
3470,ICH,10,11,77,80,We therefore established sensitive quantification methods and provided a rat ICH model for detection of ICH deterioration.,12716030_2,-1,-1,-1,3470,-1,0.0014344082,0.9985656
3471,ICH deterioration,15,17,104,121,We therefore established sensitive quantification methods and provided a rat ICH model for detection of ICH deterioration.,12716030_2,-1,-1,-1,3471,-1,0.0013595459,0.9986405
3472,ICH,1,2,3,6,"In ICH intrastriatally induced by 0.014-unit, 0.070-unit, and 0.350-unit collagenase, the amount of bleeding was measured using a hemoglobin assay developed in the present study and was compared with the morphologically determined hematoma volume.",12716030_3,-1,-1,-1,3472,-1,0.0017286522,0.99827135
3477,ICH deterioration,21,23,144,161,"The blood amounts and hematoma volumes were significantly correlated, and the hematoma induced by 0.014-unit collagenase was adequate to detect ICH deterioration.",12716030_4,-1,-1,-1,3477,-1,0.0012441583,0.9987558
3478,ICH,1,2,3,6,"In ICH induction using 0.014-unit collagenase, heparin enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.",12716030_5,-1,-1,-1,3478,-1,0.0014654938,0.99853456
3481,ICH,18,19,119,122,"In ICH induction using 0.014-unit collagenase, heparin enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.",12716030_5,-1,-1,-1,3481,-1,0.0020951212,0.9979049
3483,ICH,10,11,64,67,"Data suggest that this sensitive hemoglobin assay is useful for ICH detection, and that a model with a small ICH induced with a low-dose collagenase should be used for evaluation of drugs that may affect ICH.",12716030_6,-1,-1,-1,3483,-1,0.0015383464,0.9984617
3484,ICH,20,21,109,112,"Data suggest that this sensitive hemoglobin assay is useful for ICH detection, and that a model with a small ICH induced with a low-dose collagenase should be used for evaluation of drugs that may affect ICH.",12716030_6,-1,-1,-1,3484,-1,0.0015095967,0.99849033
3485,ICH,36,37,204,207,"Data suggest that this sensitive hemoglobin assay is useful for ICH detection, and that a model with a small ICH induced with a low-dose collagenase should be used for evaluation of drugs that may affect ICH.",12716030_6,-1,-1,-1,3485,-1,0.0015095242,0.99849045
3486,Dexatrim,3,4,13,21,Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.,12734532_0,-1,-1,-1,3486,-1,0.99928087,0.000719181
3487,Phenylpropanolamine,5,6,23,42,Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.,12734532_0,-1,-1,-1,3487,-1,0.9992384,0.0007616102
3488,myocardial infarction,11,13,58,79,Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.,12734532_0,-1,-1,-1,3488,-1,0.0013720145,0.998628
3489,Phenylpropanolamine,0,1,0,19,Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.,12734532_1,-1,-1,-1,3489,-1,0.9991517,0.00084828405
3490,PPA,2,3,21,24,Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.,12734532_1,-1,-1,-1,3490,-1,0.9985097,0.0014902786
3491,amine,7,8,43,48,Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.,12734532_1,-1,-1,-1,3491,-1,0.9958262,0.0041737272
3493,hemorrhagic strokes,9,11,59,78,Its use has been associated with hypertensive episodes and hemorrhagic strokes in younger women.,12734532_2,-1,-1,-1,3493,-1,0.0010939571,0.998906
3494,PPA,7,8,41,44,"Several reports have linked the abuse of PPA with myocardial injury, especially when overdose is involved.",12734532_3,-1,-1,-1,3494,-1,0.91887605,0.08112398
3497,Dexatrim,7,8,33,41,We report here the first case of Dexatrim (PPA)-induced myocardial injury in a young woman who was using it at recommended doses for weight control.,12734532_4,-1,-1,-1,3497,-1,0.99930036,0.00069963787
3499,PPA,10,11,44,47,"In addition, we review the 7 other cases of PPA related myocardial injury that have been reported so far.",12734532_5,-1,-1,-1,3499,-1,0.004706804,0.9952932
3501,PPA,16,17,97,100,"Physicians and patients should be alert to the potential cardiac risk associated with the use of PPA, even at doses generally considered to be safe.",12734532_6,-1,-1,-1,3501,-1,0.996505,0.0034950036
3502,creatine kinase,5,7,37,52,Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus.,12739036_0,-1,-1,-1,3502,-1,0.99801576,0.0019842773
3503,systemic lupus erythematosus,9,12,63,91,Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus.,12739036_0,-1,-1,-1,3503,-1,0.001933131,0.99806684
3505,systemic lupus erythematosus,8,11,40,68,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,-1,-1,-1,3505,-1,0.0015067531,0.9984932
3506,SLE,12,13,70,73,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,-1,-1,-1,3506,-1,0.0014218714,0.9985781
3507,renal involvement,15,17,80,97,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,-1,-1,-1,3507,-1,0.0014464711,0.9985536
3511,CQ,5,6,37,39,Additional therapy with chloroquine (CQ) was started because of arthralgia.,12739036_3,-1,-1,-1,3511,-1,0.9984768,0.0015232292
3512,arthralgia,11,12,64,74,Additional therapy with chloroquine (CQ) was started because of arthralgia.,12739036_3,-1,-1,-1,3512,-1,0.0011526331,0.99884737
3513,creatine kinase,7,9,37,52,"At the same time, slightly increased creatine kinase (CK) levels were noted.",12739036_4,-1,-1,-1,3513,-1,0.9971307,0.0028693734
3514,Myositis,0,1,0,8,"Myositis was suspected, and the patient was treated with steroids.",12739036_5,-1,-1,-1,3514,-1,0.0013016919,0.99869823
3516,muscular weakness,11,13,66,83,"The CK increase persisted, however, and she developed progressive muscular weakness and muscular atrophy.",12739036_6,-1,-1,-1,3516,-1,0.00151244,0.9984876
3517,muscular atrophy,14,16,88,104,"The CK increase persisted, however, and she developed progressive muscular weakness and muscular atrophy.",12739036_6,-1,-1,-1,3517,-1,0.0016283209,0.99837166
3518,myositis,9,10,71,79,The neurological and electrophysiological findings were not typical of myositis.,12739036_8,-1,-1,-1,3518,-1,0.0013919816,0.99860805
3519,polymyositis,14,15,76,88,"Thus, muscle biopsy of the deltoid muscle was performed in order to exclude polymyositis or toxic myopathy.",12739036_9,-1,-1,-1,3519,-1,0.0013367783,0.9986632
3522,affection of the musculoskeletal system,4,9,43,82,Discriminating between primary SLE-induced affection of the musculoskeletal system and drug-induced side effects is important for appropriate treatment of SLE patients.,12739036_11,-1,-1,-1,3522,-1,0.0019020124,0.99809796
3523,SLE,19,20,155,158,Discriminating between primary SLE-induced affection of the musculoskeletal system and drug-induced side effects is important for appropriate treatment of SLE patients.,12739036_11,-1,-1,-1,3523,-1,0.0014124984,0.9985875
3525,sleep deprivation,3,5,24,41,Seizure associated with sleep deprivation and sustained-release bupropion.,12745515_0,-1,-1,-1,3525,-1,0.004711137,0.99528885
3529,sleep deprivation,13,15,101,118,This case report describes a generalized seizure associated with sustained-release bupropion use and sleep deprivation.,12745515_1,-1,-1,-1,3529,-1,0.004968731,0.99503124
3533,tonic clonic seizure,12,15,70,90,"After 5 weeks of bupropion use, the subject experienced a generalized tonic clonic seizure after staying up nearly all night packing and moving to a new residence.",12745515_3,-1,-1,-1,3533,-1,0.0014255911,0.9985744
3535,sleep deprivation,3,5,16,33,We suggest that sleep deprivation may add to the risk of bupropion-associated seizures.,12745515_5,-1,-1,-1,3535,-1,0.880318,0.119681984
3538,hippocampal injury,3,5,34,52,Estradiol reduces seizure-induced hippocampal injury in ovariectomized female but not in male rats.,12757899_0,-1,-1,-1,3538,-1,0.0021565864,0.9978434
3539,Estrogens,0,1,0,9,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,12757899_1,-1,-1,-1,3539,-1,0.99838996,0.0016100139
3540,hippocampal injury,5,7,43,61,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,12757899_1,-1,-1,-1,3540,-1,0.0024579768,0.997542
3541,status epilepticus,11,13,93,111,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,12757899_1,-1,-1,-1,3541,-1,0.001515225,0.9984848
3542,SE,14,15,113,115,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,12757899_1,-1,-1,-1,3542,-1,0.0017498019,0.9982502
3543,SE,16,17,130,132,We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to lithium-pilocarpine-induced SE.,12757899_2,-1,-1,-1,3543,-1,0.008984859,0.99101514
3544,oil,11,12,76,79,Rats received subcutaneous injections of 17beta-estradiol (2 microg/rat) or oil once daily for four consecutive days.,12757899_3,-1,-1,-1,3544,-1,0.9986304,0.001369617
3545,SE,0,1,0,2,SE was induced 20 h following the second injection and terminated 3 h later.,12757899_4,-1,-1,-1,3545,-1,0.013329237,0.9866708
3546,h,4,5,18,19,SE was induced 20 h following the second injection and terminated 3 h later.,12757899_4,-1,-1,-1,3546,-1,0.109108254,0.89089173
3547,h,12,13,68,69,SE was induced 20 h following the second injection and terminated 3 h later.,12757899_4,-1,-1,-1,3547,-1,0.0968218,0.9031782
3548,SE,14,15,88,90,The extent of silver-stained CA3 and CA1 hippocampal neurons was evaluated 2 days after SE.,12757899_5,-1,-1,-1,3548,-1,0.98848885,0.011511138
3552,Postoperative myalgia,0,2,0,21,Postoperative myalgia after succinylcholine: no evidence for an inflammatory origin.,12760988_0,-1,-1,-1,3552,-1,0.0014630941,0.99853694
3555,postoperative myalgia,8,10,56,77,A common side effect associated with succinylcholine is postoperative myalgia.,12760988_1,-1,-1,-1,3555,-1,0.0013292404,0.9986708
3562,n,20,21,159,160,The incidence and severity of succinylcholine-associated myalgia was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine (n = 32 for each).,12760988_4,-1,-1,-1,3562,-1,0.1281336,0.87186635
3567,h,2,3,6,7,"At 48 h after surgery, 12 patients in both groups still suffered from myalgia (not significant).",12760988_6,-1,-1,-1,3567,-1,0.122886345,0.87711364
3575,postoperative myalgia,19,21,158,179,IMPLICATIONS: Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine-induced postoperative myalgia.,12760988_10,-1,-1,-1,3575,-1,0.0012611613,0.9987388
3576,postoperative myalgia,8,10,59,80,"Furthermore, there was no significant relationship between postoperative myalgia and time course of interleukin-6 concentrations, a marker of inflammation.",12760988_11,-1,-1,-1,3576,-1,0.001520507,0.99847955
3579,postoperative myalgia,8,10,60,81,Pretreatment with dexamethasone is not justified to prevent postoperative myalgia after succinylcholine.,12760988_12,-1,-1,-1,3579,-1,0.0013137971,0.99868625
3581,Pseudoacromegaly,0,1,0,16,Pseudoacromegaly induced by the long-term use of minoxidil.,12789195_0,-1,-1,-1,3581,-1,0.0014590013,0.998541
3582,minoxidil,7,8,49,58,Pseudoacromegaly induced by the long-term use of minoxidil.,12789195_0,-1,-1,-1,3582,-1,0.99928635,0.0007137158
3583,Acromegaly,0,1,0,10,Acromegaly is an endocrine disorder caused by chronic excessive growth hormone secretion from the anterior pituitary gland.,12789195_1,-1,-1,-1,3583,-1,0.0015093066,0.9984907
3584,endocrine disorder,3,5,17,35,Acromegaly is an endocrine disorder caused by chronic excessive growth hormone secretion from the anterior pituitary gland.,12789195_1,-1,-1,-1,3584,-1,0.0016472449,0.99835277
3585,growth hormone,9,11,64,78,Acromegaly is an endocrine disorder caused by chronic excessive growth hormone secretion from the anterior pituitary gland.,12789195_1,-1,-1,-1,3585,-1,0.99290246,0.0070975204
3587,cutis verticis gyrata,30,33,172,193,"Significant disfiguring changes occur as a result of bone, cartilage, and soft tissue hypertrophy, including the thickening of the skin, coarsening of facial features, and cutis verticis gyrata.",12789195_2,-1,-1,-1,3587,-1,0.0031683217,0.9968317
3588,Pseudoacromegaly,0,1,0,16,"Pseudoacromegaly, on the other hand, is the presence of similar acromegaloid features in the absence of elevated growth hormone or insulin-like growth factor levels.",12789195_3,-1,-1,-1,3588,-1,0.0015083237,0.99849164
3589,growth hormone,19,21,113,127,"Pseudoacromegaly, on the other hand, is the presence of similar acromegaloid features in the absence of elevated growth hormone or insulin-like growth factor levels.",12789195_3,-1,-1,-1,3589,-1,0.9979132,0.002086824
3590,pseudoacromegaly,5,6,26,42,We present a patient with pseudoacromegaly that resulted from the long-term use of minoxidil at an unusually high dose.,12789195_4,-1,-1,-1,3590,-1,0.0014111242,0.99858886
3591,minoxidil,13,14,83,92,We present a patient with pseudoacromegaly that resulted from the long-term use of minoxidil at an unusually high dose.,12789195_4,-1,-1,-1,3591,-1,0.9993011,0.00069897145
3592,pseudoacromegaly,7,8,33,49,This is the first case report of pseudoacromegaly as a side effect of minoxidil use.,12789195_5,-1,-1,-1,3592,-1,0.0014538981,0.9985461
3593,minoxidil,13,14,70,79,This is the first case report of pseudoacromegaly as a side effect of minoxidil use.,12789195_5,-1,-1,-1,3593,-1,0.99930465,0.0006953905
3596,androgen,10,11,58,66,BACKGROUND: To determine the onset and extent of combined androgen blockade (CAB)-induced anemia in prostate cancer patients without bone involvement.,12820454_1,-1,-1,-1,3596,-1,0.99849665,0.001503315
3599,prostatic adenocarcinoma,8,10,60,84,PATIENTS AND METHODS: Forty-two patients with biopsy-proven prostatic adenocarcinoma [26 with stage C (T3N0M0) and 16 with stage D1 (T3N1M0)] were included in this study.,12820454_2,-1,-1,-1,3599,-1,0.0029007113,0.9970993
3600,leuprolide acetate,5,7,27,45,"All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).",12820454_3,-1,-1,-1,3600,-1,0.99916375,0.00083623134
3601,mg,11,12,60,62,"All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).",12820454_3,-1,-1,-1,3601,-1,0.9929894,0.007010614
3602,mg flutamide,20,22,104,116,"All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).",12820454_3,-1,-1,-1,3602,-1,0.9986565,0.001343517
3608,SE,24,25,100,102,"At six months post-CAB, patients with severe anemia had a Hb mean value of 10.2 +/- 0.1 g/dl (X +/- SE), whereas the other patients had mild anemia with Hb mean value of 13.2 +/- 0.17 (X +/- SE).",12820454_10,-1,-1,-1,3608,-1,0.10794462,0.8920554
3610,SE,47,48,191,193,"At six months post-CAB, patients with severe anemia had a Hb mean value of 10.2 +/- 0.1 g/dl (X +/- SE), whereas the other patients had mild anemia with Hb mean value of 13.2 +/- 0.17 (X +/- SE).",12820454_10,-1,-1,-1,3610,-1,0.106024735,0.89397526
3612,p,29,30,153,154,The development of severe anemia at 6 months post-CAB was predictable by the reduction of Hb baseline value of more than 2.5 g/dl after 3 months of CAB (p = 0.01).,12820454_11,-1,-1,-1,3612,-1,0.33069807,0.6693019
3622,body weight,14,16,57,68,"Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.",12842176_1,-1,-1,-1,3622,-1,0.24000056,0.75999945
3624,3-methylcholanthrene,9,10,64,84,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,-1,-1,-1,3624,-1,0.9990085,0.0009915077
3625,MC,11,12,86,88,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,-1,-1,-1,3625,-1,0.9988877,0.0011122543
3629,PB,37,38,239,241,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,-1,-1,-1,3629,-1,0.99862814,0.0013718879
3634,cobalt chloride,11,13,71,86,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,-1,-1,3634,-1,0.9990883,0.00091166416
3638,se,27,28,186,188,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,-1,-1,3638,-1,0.995924,0.004076032
3639,PB,33,34,218,220,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,-1,-1,3639,-1,0.9988944,0.001105644
3641,neurobehavioral,43,44,278,293,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,-1,-1,3641,-1,0.0019898734,0.9980101
3642,neurobehavioral toxicity,43,45,278,302,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,-1,-1,3642,-1,0.0015808331,0.99841917
3643,venous thromboembolism,5,7,34,56,Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol.,12851669_0,-1,-1,-1,3643,-1,0.001275526,0.9987244
3644,cyproterone acetate,11,13,78,97,Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol.,12851669_0,-1,-1,-1,3644,-1,0.9992538,0.0007462135
3645,ethinylestradiol,14,15,102,118,Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol.,12851669_0,-1,-1,-1,3645,-1,0.9992524,0.00074754556
3646,venous thromboembolism,8,10,49,71,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3646,-1,0.0013419177,0.99865806
3647,VTE,11,12,73,76,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3647,-1,0.0013861603,0.99861383
3648,cyproterone acetate,16,18,93,112,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3648,-1,0.9992669,0.0007330872
3649,ethinylestradiol,19,20,118,134,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3649,-1,0.9992623,0.0007377417
3650,combined oral contraceptives,28,31,164,192,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3650,-1,0.99794513,0.0020548687
3651,COCs,32,33,194,198,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3651,-1,0.9976119,0.0023881614
3652,VTE,36,37,168,171,"METHODS: From the Danish National Register of Patients (NRP), 1996 to 1998, the records of 1.1 million Danish women, ages 15 to 44 years, were searched for evidence of VTE.",12851669_2,-1,-1,-1,3652,-1,0.0017923111,0.9982077
3653,COC,0,1,0,3,COC use was ascertained through mailed questionnaires.,12851669_3,-1,-1,-1,3653,-1,0.99752,0.0024799637
3654,COCs,3,4,20,24,Sales statistics of COCs and CPA/EE were provided through Danish Drug Statistics.,12851669_4,-1,-1,-1,3654,-1,0.99811184,0.0018881479
3655,VTE,17,18,78,81,"RESULTS: During the time frame of the study, 330 women were found to have had VTE while on COCs.",12851669_5,-1,-1,-1,3655,-1,0.0016415446,0.9983584
3656,COCs,20,21,91,95,"RESULTS: During the time frame of the study, 330 women were found to have had VTE while on COCs.",12851669_5,-1,-1,-1,3656,-1,0.9937929,0.006207066
3657,COCs,8,9,53,57,"Of these women, 67 were on levonorgestrel-containing COCs.",12851669_6,-1,-1,-1,3657,-1,0.9954913,0.004508703
3658,VTE,5,6,35,38,"The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.",12851669_8,-1,-1,-1,3658,-1,0.0016787619,0.99832124
3659,COCs,24,25,106,110,"The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.",12851669_8,-1,-1,-1,3659,-1,0.99368966,0.0063102785
3660,COCs,43,44,197,201,"The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.",12851669_8,-1,-1,-1,3660,-1,0.9891054,0.010894577
3661,VTE,9,10,53,56,CONCLUSION: Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking CPA/EE.,12851669_9,-1,-1,-1,3661,-1,0.0016692295,0.9983308
3662,COCs,14,15,79,83,CONCLUSION: Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking CPA/EE.,12851669_9,-1,-1,-1,3662,-1,0.9939453,0.006054712
3665,NSAIDs,11,12,81,87,BACKGROUND: Analysis of the literature for nonsteroidal anti-inflammatory drugs (NSAIDs) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis.,12852481_1,-1,-1,-1,3665,-1,0.99847764,0.0015223911
3666,developmental anomalies,19,21,122,145,BACKGROUND: Analysis of the literature for nonsteroidal anti-inflammatory drugs (NSAIDs) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis.,12852481_1,-1,-1,-1,3666,-1,0.0021371108,0.9978629
3667,NSAIDs,25,26,167,173,BACKGROUND: Analysis of the literature for nonsteroidal anti-inflammatory drugs (NSAIDs) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis.,12852481_1,-1,-1,-1,3667,-1,0.9985933,0.0014067012
3670,ASA,5,6,31,34,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,-1,-1,-1,3670,-1,0.9987979,0.0012020997
3671,developmental anomalies,18,20,96,119,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,-1,-1,-1,3671,-1,0.0019259929,0.99807394
3672,Teratology,0,1,0,10,"Teratology 4:15-24, 1971).",12852481_3,-1,-1,-1,3672,-1,0.012369051,0.9876309
3673,ASA,4,5,23,26,There are no published ASA studies using the multiple dosing paradigm of GDs 6 to 17.,12852481_4,-1,-1,-1,3673,-1,0.9974107,0.002589309
3674,SD,12,13,80,82,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3674,-1,0.060854305,0.9391457
3675,ASA,18,19,108,111,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3675,-1,0.99891555,0.0010844728
3676,malformation,33,34,163,175,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3676,-1,0.0015333667,0.9984666
3677,SD,43,44,247,249,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3677,-1,0.037404206,0.96259576
3678,gastrointestinal toxicity,53,55,297,322,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3678,-1,0.001761634,0.9982383
3679,malformations,61,62,364,377,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3679,-1,0.0015153968,0.9984847
3680,ASA,63,64,383,386,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3680,-1,0.99888915,0.001110835
3681,ASA,2,3,9,12,"METHODS: ASA was administered as a single dose on GD 9 (0, 250, 500, or 625 mg/kg), 10 (0, 500, 625, or 750 mg/kg), or 11 (0, 500, 750, or 1000 mg/kg) and from GD 6 to GD 17 (0, 50, 125, or 250 mg/kg a day) in the multiple dose study to SD rats.",12852481_6,-1,-1,-1,3681,-1,0.9988625,0.001137565
3682,SD,76,77,237,239,"METHODS: ASA was administered as a single dose on GD 9 (0, 250, 500, or 625 mg/kg), 10 (0, 500, 625, or 750 mg/kg), or 11 (0, 500, 750, or 1000 mg/kg) and from GD 6 to GD 17 (0, 50, 125, or 250 mg/kg a day) in the multiple dose study to SD rats.",12852481_6,-1,-1,-1,3682,-1,0.022465648,0.9775343
3683,NSAIDs,7,8,50,56,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3683,-1,0.99877113,0.001228837
3684,ventricular septal defects,9,12,64,90,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3684,-1,0.002793872,0.99720615
3685,VSDs,13,14,92,96,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3685,-1,0.0023208915,0.9976792
3686,midline defects,16,18,102,117,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3686,-1,0.002157624,0.9978423
3687,MDs,19,20,119,122,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3687,-1,0.0017710507,0.99822897
3688,diaphragmatic hernia,24,26,136,156,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3688,-1,0.0031786966,0.9968213
3689,DH,27,28,158,160,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3689,-1,0.0022732355,0.99772674
3690,MDs,30,31,163,166,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3690,-1,0.0016432889,0.99835664
3691,VSDs,33,34,172,176,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3691,-1,0.001850928,0.99814904
3692,malformations,53,54,254,267,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3692,-1,0.0017169261,0.99828315
3693,ASA,57,58,281,284,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3693,-1,0.9987219,0.0012781139
3694,malformations,62,63,321,334,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3694,-1,0.0016285226,0.99837154
3695,DH,5,6,24,26,"In single dose studies, DH, MD, and VSD were induced on GDs 9 and 10.",12852481_9,-1,-1,-1,3695,-1,0.0029748345,0.9970252
3696,MD,7,8,28,30,"In single dose studies, DH, MD, and VSD were induced on GDs 9 and 10.",12852481_9,-1,-1,-1,3696,-1,0.0030827587,0.99691725
3697,VSD,10,11,36,39,"In single dose studies, DH, MD, and VSD were induced on GDs 9 and 10.",12852481_9,-1,-1,-1,3697,-1,0.0029096096,0.99709034
3698,VSD,0,1,0,3,VSD also was noted following treatment on GD 11.,12852481_10,-1,-1,-1,3698,-1,0.0019348485,0.9980652
3699,contrast,1,2,3,11,"In contrast, DH and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.",12852481_11,-1,-1,-1,3699,-1,0.04370501,0.95629495
3700,DH,3,4,13,15,"In contrast, DH and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.",12852481_11,-1,-1,-1,3700,-1,0.0019205476,0.9980794
3701,MD,5,6,20,22,"In contrast, DH and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.",12852481_11,-1,-1,-1,3701,-1,0.001897841,0.9981021
3702,VSD,21,22,101,104,"In contrast, DH and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.",12852481_11,-1,-1,-1,3702,-1,0.0022182725,0.9977817
3703,developmental anomalies,6,8,39,62,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,-1,3703,-1,0.0017903023,0.9982097
3704,SD,11,12,82,84,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,-1,3704,-1,0.066117644,0.9338824
3705,VSD,19,20,123,126,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,-1,3705,-1,0.0019259426,0.99807405
3706,SD,22,23,134,136,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,-1,3706,-1,0.05802187,0.9419781
3707,hydrocephalus,25,26,146,159,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,-1,3707,-1,0.0015094446,0.9984906
3708,malformations,2,3,15,28,Variations and malformations were similar when ASA was administered as a single dose or during the period of organogenesis (GDs 6 to 17).,12852481_13,-1,-1,-1,3708,-1,0.0015015026,0.99849856
3709,ASA,6,7,47,50,Variations and malformations were similar when ASA was administered as a single dose or during the period of organogenesis (GDs 6 to 17).,12852481_13,-1,-1,-1,3709,-1,0.9989011,0.0010988545
3710,malformations,17,18,85,98,"It was also evident that, by titrating the dose to achieve a maximum tolerated dose, malformations that normally occur at low incidence, as reported from previous single dose studies, could also be induced with ASA given at multiple doses.",12852481_14,-1,-1,-1,3710,-1,0.0016201532,0.9983798
3711,ASA,38,39,211,214,"It was also evident that, by titrating the dose to achieve a maximum tolerated dose, malformations that normally occur at low incidence, as reported from previous single dose studies, could also be induced with ASA given at multiple doses.",12852481_14,-1,-1,-1,3711,-1,0.998767,0.0012330044
3713,flumazenil,6,7,46,56,Reversal of central benzodiazepine effects by flumazenil after intravenous conscious sedation with diazepam and opioids: report of a double-blind multicenter study.,1286498_0,-1,-1,-1,3713,-1,0.99924797,0.0007520485
3715,Flumazenil,1,2,4,14,"The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II.The efficacy and safety of a new benzodiazepine antagonist, flumazenil, were assessed in a double-blind multicenter study.",1286498_1,-1,-1,-1,3715,-1,0.9992316,0.0007684823
3718,flumazenil,21,22,150,160,"The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II.The efficacy and safety of a new benzodiazepine antagonist, flumazenil, were assessed in a double-blind multicenter study.",1286498_1,-1,-1,-1,3718,-1,0.9992912,0.00070875656
3719,Flumazenil,0,1,0,10,"Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.",1286498_2,-1,-1,-1,3719,-1,0.9993079,0.0006921208
3720,mg,6,7,28,30,"Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.",1286498_2,-1,-1,-1,3720,-1,0.9666228,0.033377137
3723,meperidine,41,42,201,211,"Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.",1286498_2,-1,-1,-1,3723,-1,0.9993119,0.00068807544
3725,flumazenil,10,11,70,80,The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo.,1286498_3,-1,-1,-1,3725,-1,0.9991922,0.00080787856
3726,Flumazenil,0,1,0,10,"Flumazenil was well tolerated, with no serious adverse effects reported.",1286498_7,-1,-1,-1,3726,-1,0.99917716,0.0008228555
3727,nausea and vomiting,6,9,37,56,The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.,1286498_9,-1,-1,-1,3727,-1,0.0017306999,0.9982693
3728,flumazenil,11,12,64,74,The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.,1286498_9,-1,-1,-1,3728,-1,0.9991937,0.00080629834
3731,Flumazenil,0,1,0,10,Flumazenil was found to promptly reverse sedation induced by diazepam in the presence of opioids.,1286498_10,-1,-1,-1,3731,-1,0.9992855,0.0007145106
3740,n,4,5,19,20,"RESULTS: Subjects (n = 139) were 72 women and 67 men, aged 40.8 +/- 12.1 years, hospitalized for 24.9 +/- 23.3 days, and given clozapine, gradually increased to an average daily dose of 282 +/- 203 mg (3.45 +/- 2.45 mg/kg) for 18.9 +/- 16.4 days.",12905102_3,-1,-1,-1,3740,-1,0.1877129,0.81228715
3742,mg,46,47,198,200,"RESULTS: Subjects (n = 139) were 72 women and 67 men, aged 40.8 +/- 12.1 years, hospitalized for 24.9 +/- 23.3 days, and given clozapine, gradually increased to an average daily dose of 282 +/- 203 mg (3.45 +/- 2.45 mg/kg) for 18.9 +/- 16.4 days.",12905102_3,-1,-1,-1,3742,-1,0.9863218,0.013678112
3747,MPEP,3,4,26,30,"Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.",12907309_0,-1,-1,-1,3747,-1,0.9991357,0.0008643376
3755,h,25,26,143,144,"Methamphetamine (10 mg/kg sc), administered five times, reduced the levels of dopamine and its metabolites in striatal tissue when measured 72 h after the last injection.",12907309_2,-1,-1,-1,3755,-1,0.2232358,0.7767643
3757,MPEP,8,9,70,74,"A selective antagonist of mGluR5, 2-methyl-6-(phenylethynyl)pyridine (MPEP; 5 mg/kg ip), when administered five times immediately before each methamphetamine injection reversed the above-mentioned methamphetamine effects.",12907309_3,-1,-1,-1,3757,-1,0.99893326,0.0010667508
3760,MPEP,2,3,9,13,"A single MPEP (5 mg/kg ip) injection reduced the basal extracellular dopamine level in the striatum, as well as dopamine release stimulated either by methamphetamine (10 mg/kg sc) or by intrastriatally administered veratridine (100 microM).",12907309_4,-1,-1,-1,3760,-1,0.9991805,0.0008194822
3764,veratridine,37,38,215,226,"A single MPEP (5 mg/kg ip) injection reduced the basal extracellular dopamine level in the striatum, as well as dopamine release stimulated either by methamphetamine (10 mg/kg sc) or by intrastriatally administered veratridine (100 microM).",12907309_4,-1,-1,-1,3764,-1,0.9993824,0.00061754783
3767,MPEP,0,1,0,4,"MPEP administered into the striatum at high concentrations (500 microM) increased extracellular dopamine levels, while lower concentrations (50-100 microM) were devoid of any effect.",12907309_6,-1,-1,-1,3767,-1,0.9991628,0.0008372711
3769,MPEP,12,13,65,69,The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against methamphetamine-induced toxicity.,12907309_7,-1,-1,-1,3769,-1,0.9991528,0.00084727025
3771,MPEP,3,4,28,32,"Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine-induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in hyperthermia.",12907309_8,-1,-1,-1,3771,-1,0.99916804,0.00083202915
3775,Alzheimer's disease,8,11,65,84,An 82-year-old man with treatment-resistant depression and early Alzheimer's disease was started on methylphenidate.,12907924_1,-1,-1,-1,3775,-1,0.0017560498,0.9982439
3778,fluvoxamine,14,15,120,131,Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine.,12907924_2,-1,-1,-1,3778,-1,0.99933296,0.0006669673
3791,renal disease,12,14,97,110,"Unfortunately, acute interstitial nephritis was irreversible and the patient developed end-stage renal disease.",12911170_5,-1,-1,-1,3791,-1,0.0013754265,0.99862456
3795,psychiatric disorders,14,16,108,129,Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of neurological and psychiatric disorders.,12921865_1,-1,-1,-1,3795,-1,0.0016066006,0.99839336
3797,drug dependence,17,19,98,113,They offer protection against seizures in a range of models and seem to inhibit certain stages of drug dependence in preclinical assessments.,12921865_2,-1,-1,-1,3797,-1,0.20099196,0.799008
3802,Allopregnanolone,0,1,0,16,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,-1,-1,-1,3802,-1,0.99930704,0.0006929484
3803,pregnanolone,5,6,57,69,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,-1,-1,-1,3803,-1,0.9992587,0.00074125646
3804,ganaxolone,10,11,112,122,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,-1,-1,-1,3804,-1,0.9992194,0.00078054564
3805,allopregnanolone,16,17,150,166,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,-1,-1,-1,3805,-1,0.9992679,0.0007321206
3810,allopregnanolone,16,17,101,117,"All of these positive GABA(A) modulators suppressed the expression of kindled seizures, whereas only allopregnanolone and ganaxolone inhibited the development of kindling.",12921865_6,-1,-1,-1,3810,-1,0.999328,0.00067199604
3811,ganaxolone,18,19,122,132,"All of these positive GABA(A) modulators suppressed the expression of kindled seizures, whereas only allopregnanolone and ganaxolone inhibited the development of kindling.",12921865_6,-1,-1,-1,3811,-1,0.99926966,0.0007303805
3812,Allopregnanolone,0,1,0,16,"Allopregnanolone and pregnanolone, but not ganaxolone, also reduced cumulative lethality associated with kindling.",12921865_7,-1,-1,-1,3812,-1,0.99928916,0.000710874
3813,pregnanolone,2,3,21,33,"Allopregnanolone and pregnanolone, but not ganaxolone, also reduced cumulative lethality associated with kindling.",12921865_7,-1,-1,-1,3813,-1,0.9992446,0.0007554485
3814,ganaxolone,6,7,43,53,"Allopregnanolone and pregnanolone, but not ganaxolone, also reduced cumulative lethality associated with kindling.",12921865_7,-1,-1,-1,3814,-1,0.9992519,0.00074812566
3821,renal insufficiency,15,17,90,109,"18 patients, referred to a radiocontrast study, considered at risk because of preexisting renal insufficiency, were enrolled in a prospective, randomized, controlled trial, performed at the secondary care center of a 1,100-bed private university hospital.",1300436_2,-1,-1,-1,3821,-1,0.0014820034,0.99851805
3823,mg,14,15,78,80,"In addition to fluids, the treatment group received furosemide (mean dose 110 mg) intravenously 30 min prior to the injection of contrast material.",1300436_3,-1,-1,-1,3823,-1,0.98064053,0.019359456
3824,contrast material,24,26,129,146,"In addition to fluids, the treatment group received furosemide (mean dose 110 mg) intravenously 30 min prior to the injection of contrast material.",1300436_3,-1,-1,-1,3824,-1,0.9982389,0.0017611143
3825,contrast material,11,13,87,104,"Radiological studies were mostly angiographies performed with both ionic and non-ionic contrast material, at an average dose of 245 ml.",1300436_5,-1,-1,-1,3825,-1,0.9933309,0.0066690478
3826,Renal function significantly deteriorated,0,4,0,41,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,-1,-1,-1,3826,-1,0.006134112,0.9938659
3828,p,11,12,83,84,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,-1,-1,-1,3828,-1,0.3790415,0.6209585
3830,h,37,38,180,181,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,-1,-1,-1,3830,-1,0.29874942,0.70125055
3831,Renal failure,0,2,0,13,Renal failure was associated with weight loss in the furosemide-treated group.,1300436_7,-1,-1,-1,3831,-1,0.0014930229,0.99850696
3832,weight loss,5,7,34,45,Renal failure was associated with weight loss in the furosemide-treated group.,1300436_7,-1,-1,-1,3832,-1,0.013883272,0.9861167
3838,blood coagulation factors,14,17,111,136,Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.,133615_2,-1,-1,-1,3838,-1,0.17965373,0.82034624
3842,hypercoagulability,11,12,64,82,"All four had an abnormal blood coagulation profile, suggesting ""hypercoagulability"" before initiation of therapy.",133615_6,-1,-1,-1,3842,-1,0.0017325744,0.9982674
3843,myocardial infarction,6,8,34,55,"One of these patients developed a myocardial infarction before receiving any medication, shortly after the base-line values were obtained.",133615_8,-1,-1,-1,3843,-1,0.0015497953,0.99845016
3844,retinopathy,3,4,22,33,"One patient developed retinopathy 19 months after she began therapy, and another developed thrombophlebitis after 27 months of therapy.",133615_9,-1,-1,-1,3844,-1,0.0011960941,0.99880385
3845,thrombophlebitis,14,15,91,107,"One patient developed retinopathy 19 months after she began therapy, and another developed thrombophlebitis after 27 months of therapy.",133615_9,-1,-1,-1,3845,-1,0.0012126722,0.99878734
3846,thrombophlebitis,4,5,29,45,The fourth patient developed thrombophlebitis 14 days after initiation of contraceptive therapy.,133615_10,-1,-1,-1,3846,-1,0.001180245,0.99881977
3847,contraceptive,10,11,74,87,The fourth patient developed thrombophlebitis 14 days after initiation of contraceptive therapy.,133615_10,-1,-1,-1,3847,-1,0.9984407,0.0015592864
3848,thromboembolic episodes,9,11,72,95,Previous studies suggested the possiblility of increased propensity for thromboembolic episodes in patients possessing the A antigen.,133615_12,-1,-1,-1,3848,-1,0.0013438368,0.99865615
3855,mg,28,29,134,136,2. Conscious SHR (male 300-350 g) were subjected to 90 degrees head-up tilts for 60 s following acute administration of prazosin (0.1 mg kg-1 i.p.) or rauwolscine (3 mg kg-1 i.v.).,1355091_2,-1,-1,-1,3855,-1,0.9876951,0.012304859
3856,rauwolscine,34,35,151,162,2. Conscious SHR (male 300-350 g) were subjected to 90 degrees head-up tilts for 60 s following acute administration of prazosin (0.1 mg kg-1 i.p.) or rauwolscine (3 mg kg-1 i.v.).,1355091_2,-1,-1,-1,3856,-1,0.99921703,0.00078296865
3857,mg,37,38,166,168,2. Conscious SHR (male 300-350 g) were subjected to 90 degrees head-up tilts for 60 s following acute administration of prazosin (0.1 mg kg-1 i.p.) or rauwolscine (3 mg kg-1 i.v.).,1355091_2,-1,-1,-1,3857,-1,0.9887743,0.011225687
3859,MAP,16,17,94,97,Orthostatic hypotension was determined by the average decrease (%) in mean arterial pressure (MAP femoral) over the 60-s tilt period.,1355091_3,-1,-1,-1,3859,-1,0.12779856,0.8722015
3860,MAP,2,3,10,13,The basal MAP of conscious SHR was reduced to a similar extent by prazosin (-23%(-)-26% MAP) and rauwolscine (-16%(-)-33% MAP).,1355091_4,-1,-1,-1,3860,-1,0.6516694,0.3483306
3862,MAP,17,18,88,91,The basal MAP of conscious SHR was reduced to a similar extent by prazosin (-23%(-)-26% MAP) and rauwolscine (-16%(-)-33% MAP).,1355091_4,-1,-1,-1,3862,-1,0.7143685,0.28563148
3863,rauwolscine,20,21,97,108,The basal MAP of conscious SHR was reduced to a similar extent by prazosin (-23%(-)-26% MAP) and rauwolscine (-16%(-)-33% MAP).,1355091_4,-1,-1,-1,3863,-1,0.9991763,0.00082369964
3864,MAP,24,25,122,125,The basal MAP of conscious SHR was reduced to a similar extent by prazosin (-23%(-)-26% MAP) and rauwolscine (-16%(-)-33% MAP).,1355091_4,-1,-1,-1,3864,-1,0.7698346,0.23016542
3867,MAP,17,18,97,100,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,-1,3867,-1,0.4161366,0.58386344
3868,n,19,20,102,103,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,-1,3868,-1,0.07660871,0.9233913
3869,rauwolscine,31,32,142,153,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,-1,3869,-1,0.9991905,0.00080944505
3870,MAP,38,39,169,172,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,-1,3870,-1,0.27835214,0.72164786
3871,n,40,41,174,175,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,-1,3871,-1,0.08907095,0.910929
3873,mg,13,14,60,62,3. Conscious SHR were treated for 4 days with prazosin at 2 mg kg-1 day-1 i.p. for chronic alpha 1-adrenoceptor blockade.,1355091_6,-1,-1,-1,3873,-1,0.9930996,0.006900459
3874,MAP,0,1,0,3,MAP in conscious SHR after chronic prazosin treatment was 14% lower than in the untreated SHR (n = 8).,1355091_7,-1,-1,-1,3874,-1,0.9695869,0.030413127
3876,n,18,19,95,96,MAP in conscious SHR after chronic prazosin treatment was 14% lower than in the untreated SHR (n = 8).,1355091_7,-1,-1,-1,3876,-1,0.14963679,0.85036325
3879,mg,23,24,138,140,Head-up tilts in these rats did not produce orthostatic hypotension when performed either prior to or after acute dosing of prazosin (0.1 mg kg-1 i.p.).,1355091_8,-1,-1,-1,3879,-1,0.98731947,0.012680534
3880,rauwolscine,4,5,30,41,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,-1,3880,-1,0.9992442,0.000755863
3881,mg,7,8,45,47,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,-1,3881,-1,0.98778826,0.012211733
3883,MAP,20,21,111,114,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,-1,3883,-1,0.87718797,0.122812025
3884,n,27,28,126,127,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,-1,3884,-1,0.090351366,0.90964866
3885,MAP,39,40,180,183,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,-1,3885,-1,0.86071646,0.13928351
3887,cirazoline,11,12,64,74,"4. The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.",1355091_10,-1,-1,-1,3887,-1,0.9993156,0.0006844247
3888,Abbott-53693,25,26,129,141,"4. The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.",1355091_10,-1,-1,-1,3888,-1,0.9989157,0.0010843121
3892,cirazoline,7,8,44,54,Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).,1355091_11,-1,-1,-1,3892,-1,0.99932635,0.0006737107
3894,n,16,17,103,104,Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).,1355091_11,-1,-1,-1,3894,-1,0.052442975,0.94755703
3895,n,27,28,144,145,Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).,1355091_11,-1,-1,-1,3895,-1,0.061990608,0.93800944
3896,Abbott-53693,9,10,42,54,"On the other hand, the pressor effects of Abbott-53693 were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment.",1355091_12,-1,-1,-1,3896,-1,0.9989911,0.0010088701
3901,increase in locomotor activity,6,10,49,79,Effect of humoral modulators of morphine-induced increase in locomotor activity of mice.,137340_0,-1,-1,-1,3901,-1,0.003434369,0.99656564
3902,increase in locomotor activity,8,12,57,87,The effect of humoral modulators on the morphine-induced increase in locomotor activity of mice was studied.,137340_1,-1,-1,-1,3902,-1,0.004098549,0.9959014
3905,physostigmine,10,11,84,97,The morphine-induced hyperactivity was potentiated by scopolamine and attenuated by physostigmine.,137340_3,-1,-1,-1,3905,-1,0.9992791,0.00072091393
3906,contrast,1,2,3,11,"In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.",137340_4,-1,-1,-1,3906,-1,0.57323736,0.42676264
3907,methscopolamine,4,5,18,33,"In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.",137340_4,-1,-1,-1,3907,-1,0.99920005,0.0007999926
3908,neostigmine,6,7,38,49,"In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.",137340_4,-1,-1,-1,3908,-1,0.99929523,0.00070474844
3923,renal failure,35,37,208,221,"Rats with lithium-induced nephropathy were subjected to high protein (HP) feeding, uninephrectomy (NX) or a combination of these, in an attempt to induce glomerular hyperfiltration and further progression of renal failure.",1378968_1,-1,-1,-1,3923,-1,0.0014390114,0.99856097
3928,Li,15,16,102,104,"Consequently, lithium pretreatment caused a fall in filtration fraction and an increase in fractional Li excretion.",1378968_5,-1,-1,-1,3928,-1,0.99820566,0.0017943154
3931,systolic hypertension,5,7,36,57,Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis.,1378968_6,-1,-1,-1,3931,-1,0.0013910037,0.998609
3933,renal failure,6,8,40,53,HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats.,1378968_7,-1,-1,-1,3933,-1,0.0015698362,0.9984302
3936,rise in blood pressure,4,8,23,45,NX+HP caused a further rise in blood pressure in Li-pretreated rats.,1378968_9,-1,-1,-1,3936,-1,0.007010859,0.99298906
3939,arterial systolic hypertension,21,24,129,159,"The results indicate that Li-induced nephropathy, even when the GFR is only modestly reduced, is associated with proteinuria and arterial systolic hypertension.",1378968_10,-1,-1,-1,3939,-1,0.0015591995,0.9984408
3948,Crohn's disease,2,5,13,28,Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.,1420741_0,-1,-1,-1,3948,-1,0.002274364,0.99772567
3949,fusidic acid,6,8,34,46,Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.,1420741_0,-1,-1,-1,3949,-1,0.99894136,0.001058684
3950,cyclosporin,16,17,107,118,Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.,1420741_0,-1,-1,-1,3950,-1,0.99915206,0.0008479896
3951,Fusidic acid,0,2,0,12,Fusidic acid is an antibiotic with T-cell specific immunosuppressive effects similar to those of cyclosporin.,1420741_1,-1,-1,-1,3951,-1,0.9991035,0.000896531
3952,cyclosporin,14,15,97,108,Fusidic acid is an antibiotic with T-cell specific immunosuppressive effects similar to those of cyclosporin.,1420741_1,-1,-1,-1,3952,-1,0.9991804,0.00081955246
3953,Crohn's disease,11,14,62,77,"Because of the need for the development of new treatments for Crohn's disease, a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active, therapy-resistant patients.",1420741_2,-1,-1,-1,3953,-1,0.002344747,0.9976553
3954,fusidic acid,27,29,161,173,"Because of the need for the development of new treatments for Crohn's disease, a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active, therapy-resistant patients.",1420741_2,-1,-1,-1,3954,-1,0.9991073,0.0008926185
3955,Crohn's disease,1,4,6,21,Eight Crohn's disease patients were included.,1420741_3,-1,-1,-1,3955,-1,0.003623217,0.9963768
3956,Fusidic acid,0,2,0,12,Fusidic acid was administered orally in a dose of 500 mg t.d.s. and the treatment was planned to last 8 weeks.,1420741_4,-1,-1,-1,3956,-1,0.9989491,0.0010509543
3957,mg,10,11,54,56,Fusidic acid was administered orally in a dose of 500 mg t.d.s. and the treatment was planned to last 8 weeks.,1420741_4,-1,-1,-1,3957,-1,0.98216015,0.017839897
3958,fusidic acid,10,12,41,53,Five of 8 patients (63%) improved during fusidic acid treatment: 3 at two weeks and 2 after four weeks.,1420741_6,-1,-1,-1,3958,-1,0.9989102,0.0010898215
3960,alkaline phosphatases,5,7,30,51,"Biochemically, an increase in alkaline phosphatases was noted in 5 of 8 cases (63%), and the greatest increases were seen in those who had elevated levels prior to treatment.",1420741_8,-1,-1,-1,3960,-1,0.96666324,0.033336755
3961,fusidic acid,8,10,45,57,The results of this pilot study suggest that fusidic acid may be of benefit in selected chronic active Crohn's disease patients in whom conventional treatment is ineffective.,1420741_10,-1,-1,-1,3961,-1,0.9988563,0.0011436521
3962,Crohn's disease,18,21,103,118,The results of this pilot study suggest that fusidic acid may be of benefit in selected chronic active Crohn's disease patients in whom conventional treatment is ineffective.,1420741_10,-1,-1,-1,3962,-1,0.0032051194,0.9967949
3963,fusidic acid,12,14,67,79,"Because there seems to exist a scientific rationale for the use of fusidic acid at the cytokine level in inflammatory bowel disease, we suggest that the role of this treatment should be further investigated.",1420741_11,-1,-1,-1,3963,-1,0.9990608,0.0009392358
3964,inflammatory bowel disease,19,22,105,131,"Because there seems to exist a scientific rationale for the use of fusidic acid at the cytokine level in inflammatory bowel disease, we suggest that the role of this treatment should be further investigated.",1420741_11,-1,-1,-1,3964,-1,0.0016033915,0.9983966
3965,Amnestic syndrome,0,2,0,17,Amnestic syndrome associated with propranolol toxicity: a case report.,1423339_0,-1,-1,-1,3965,-1,0.0013358752,0.99866414
3966,propranolol toxicity,4,6,34,54,Amnestic syndrome associated with propranolol toxicity: a case report.,1423339_0,-1,-1,-1,3966,-1,0.6659764,0.33402357
3968,propranolol toxicity,12,14,78,98,An elderly woman developed an Alzheimer-like subacute dementia as a result of propranolol toxicity.,1423339_1,-1,-1,-1,3968,-1,0.6887728,0.31122723
3969,impairment of memory,7,10,50,70,Analysis of the manifestations showed that severe impairment of memory accounted for virtually all of the abnormalities.,1423339_2,-1,-1,-1,3969,-1,0.004413089,0.9955869
3970,drug toxicity,7,9,45,58,There is evidence that cerebral reactions to drug toxicity can exhibit patterns that suggest highly selective involvement of functional subdivisions of the brain.,1423339_3,-1,-1,-1,3970,-1,0.16958907,0.8304109
3975,betaxolol,24,25,147,156,We performed a preliminary study in order to determine any difference between a non selective beta-blocker (timolol) and a selective beta-blocker (betaxolol) regarding CNS side effects.,1428568_2,-1,-1,-1,3975,-1,0.9992367,0.0007632912
3976,glaucomatous,1,2,6,18,"Eight glaucomatous patients chronically treated with timolol 0.5%/12h, suffering from depression diagnosed through DMS-III-R criteria, were included in the study.",1428568_3,-1,-1,-1,3976,-1,0.0020529756,0.99794704
3982,p,28,29,180,181,"In a double blind cross-over study with control group, the patients under timolol treatment presented higher depression values measured through the Beck and the Zung-Conde scales (p < 0.001 vs control).",1428568_5,-1,-1,-1,3982,-1,0.36624822,0.6337518
3983,betaxolol,4,5,27,36,These results suggest that betaxolol could be less of a depression-inducer than timolol in predisposed patients.,1428568_6,-1,-1,-1,3983,-1,0.9991586,0.00084140437
3987,LY274614,11,12,100,108,"Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.",1436384_0,-1,-1,-1,3987,-1,0.99898595,0.0010140351
3989,"LY274614, 3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3- carboxylic acid",0,6,0,88,"LY274614, 3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3- carboxylic acid, has been described as a potent antagonist of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor.",1436384_1,-1,-1,-1,3989,-1,0.9981352,0.0018647094
3990,NMDA,18,19,161,165,"LY274614, 3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3- carboxylic acid, has been described as a potent antagonist of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor.",1436384_1,-1,-1,-1,3990,-1,0.9983228,0.0016772202
3994,iprindole,18,19,96,105,"A single 18.4 mg/kg (i.p.) dose of (+/-)-amphetamine hemisulfate, given to rats pretreated with iprindole, resulted in persistent depletion of dopamine in the striatum 1 week later.",1436384_3,-1,-1,-1,3994,-1,0.9992968,0.00070321414
3997,dizocilpine,11,12,72,83,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,-1,-1,-1,3997,-1,0.99927443,0.000725613
3998,MK-801,13,14,85,91,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,-1,-1,-1,3998,-1,0.9990331,0.0009669524
3999,NMDA,19,20,125,129,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,-1,-1,-1,3999,-1,0.9989635,0.0010364653
4000,LY274614,24,25,147,155,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,-1,-1,-1,4000,-1,0.9989304,0.0010695878
4001,NMDA,30,31,185,189,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,-1,-1,-1,4001,-1,0.9989606,0.0010393952
4002,LY274614,4,5,25,33,"The protective effect of LY274614 was dose-dependent, being maximum at 10-40 mgkg (i.p.).",1436384_5,-1,-1,-1,4002,-1,0.9987368,0.0012632218
4003,LY274614,5,6,19,27,"A 10 mg/kg dose of LY274614 was effective in antagonizing the depletion of dopamine in the striatum, when given as long as 8 hr prior to amphetamine but not when given 24 hr prior to amphetamine.",1436384_6,-1,-1,-1,4003,-1,0.9989982,0.0010017835
4008,LY274614,10,11,64,72,Depletion of dopamine in the striatum was also antagonized when LY274614 was given after the injection of amphetamine; LY274614 protected when given up to 4 hr after but not when given 8 or 24 hr after amphetamine.,1436384_7,-1,-1,-1,4008,-1,0.99898726,0.0010127617
4010,LY274614,19,20,119,127,Depletion of dopamine in the striatum was also antagonized when LY274614 was given after the injection of amphetamine; LY274614 protected when given up to 4 hr after but not when given 8 or 24 hr after amphetamine.,1436384_7,-1,-1,-1,4010,-1,0.99907327,0.0009266863
4014,LY274614,24,25,163,171,"The prolonged depletion of dopamine in the striatum in mice, given multiple injections of methamphetamine, was also antagonized dose-dependently and completely by LY274614.",1436384_8,-1,-1,-1,4014,-1,0.9988557,0.0011443442
4018,NMDA,19,20,144,148,The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.,1436384_9,-1,-1,-1,4018,-1,0.99883014,0.0011698578
4019,LY274614,23,24,168,176,The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.,1436384_9,-1,-1,-1,4019,-1,0.9989728,0.0010272039
4020,NMDA,26,27,183,187,The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.,1436384_9,-1,-1,-1,4020,-1,0.99868685,0.0013131216
4023,penicillins,15,16,110,121,Immune hemolytic anemia due to a drug-adsorption mechanism has been described primarily in patients receiving penicillins and first-generation cephalosporins.,1445986_1,-1,-1,-1,4023,-1,0.9988626,0.0011374123
4026,cefotetan,10,11,71,80,We describe a patient who developed anemia while receiving intravenous cefotetan.,1445986_2,-1,-1,-1,4026,-1,0.99901843,0.000981568
4027,cefotetan,13,14,70,79,"The eluate also reacted weakly with red blood cells in the absence of cefotetan, suggesting the concomitant formation of warm-reactive autoantibodies.",1445986_4,-1,-1,-1,4027,-1,0.9990452,0.00095480174
4030,hemolytic,9,10,57,66,This case emphasizes the need for increased awareness of hemolytic reactions to all cephalosporins.,1445986_6,-1,-1,-1,4030,-1,0.0013348376,0.9986652
4032,neurologic sequelae,1,3,21,40,Ketoconazole-induced neurologic sequelae.,14513889_0,-1,-1,-1,4032,-1,0.0011943972,0.99880564
4033,weakness of extremities,4,7,29,52,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,-1,-1,4033,-1,0.0018161313,0.9981838
4034,legs paralysis,8,10,54,68,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,-1,-1,4034,-1,0.0016791023,0.9983209
4035,dysarthria,11,12,70,80,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,-1,-1,4035,-1,0.0012479561,0.998752
4037,h,15,16,94,95,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,-1,-1,4037,-1,0.18695085,0.8130492
4038,mg ketoconazole,20,22,119,134,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,-1,-1,4038,-1,0.9985599,0.0014401253
4039,h.,6,7,36,38,"All complaints faded away within 24 h. Few days later, the patient used another 200 mg ketoconazole tablet, and within an hour experienced a similar clinical picture, which resolved again spontaneously within hours.",14513889_2,-1,-1,-1,4039,-1,0.15277807,0.847222
4040,mg ketoconazole,16,18,84,99,"All complaints faded away within 24 h. Few days later, the patient used another 200 mg ketoconazole tablet, and within an hour experienced a similar clinical picture, which resolved again spontaneously within hours.",14513889_2,-1,-1,-1,4040,-1,0.99842334,0.0015766699
4041,adverse drug reactions,9,12,54,76,"This case illustrates the need for close vigilance in adverse drug reactions, particularly in the elderly.",14513889_4,-1,-1,-1,4041,-1,0.002434259,0.99756575
4045,LIDs,3,4,30,34,Levodopa-induced dyskinesias (LIDs) present a major problem for the long-term management of Parkinson's disease (PD) patients.,14568327_1,-1,-1,-1,4045,-1,0.0013789705,0.998621
4046,Parkinson's disease,14,17,92,111,Levodopa-induced dyskinesias (LIDs) present a major problem for the long-term management of Parkinson's disease (PD) patients.,14568327_1,-1,-1,-1,4046,-1,0.002487741,0.9975122
4047,PD,18,19,113,115,Levodopa-induced dyskinesias (LIDs) present a major problem for the long-term management of Parkinson's disease (PD) patients.,14568327_1,-1,-1,-1,4047,-1,0.0023362949,0.99766374
4048,LIDs,24,25,155,159,"Due to the interdependence of risk factors in clinical populations, it is difficult to independently examine factors that may influence the development of LIDs.",14568327_2,-1,-1,-1,4048,-1,0.0017483566,0.9982516
4051,LIDs,41,42,255,259,"Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs.",14568327_3,-1,-1,-1,4051,-1,0.0013460411,0.9986539
4052,MPTP,6,7,32,36,"Monkeys with acute (short-term) MPTP exposure, rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration.",14568327_4,-1,-1,-1,4052,-1,0.999212,0.00078798394
4056,contrast,1,2,3,11,"In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).",14568327_5,-1,-1,-1,4056,-1,0.1082851,0.8917149
4057,MPTP,6,7,36,40,"In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).",14568327_5,-1,-1,-1,4057,-1,0.99917537,0.00082459726
4059,LIDs,27,28,179,183,"In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).",14568327_5,-1,-1,-1,4059,-1,0.001446686,0.99855334
4063,LIDs,10,11,69,73,These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to levodopa and demonstrate the value of these models for further studying the pathophysiology of LIDs.,14568327_7,-1,-1,-1,4063,-1,0.0014884424,0.9985115
4065,LIDs,38,39,254,258,These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to levodopa and demonstrate the value of these models for further studying the pathophysiology of LIDs.,14568327_7,-1,-1,-1,4065,-1,0.0015054969,0.9984945
4066,sugar dependency,3,5,17,33,A diet promoting sugar dependency causes behavioral cross-sensitization to a low dose of amphetamine.,14596845_0,-1,-1,-1,4066,-1,0.43534046,0.56465954
4068,sugar,13,14,85,90,Previous research in this laboratory has shown that a diet of intermittent excessive sugar consumption produces a state with neurochemical and behavioral similarities to drug dependency.,14596845_1,-1,-1,-1,4068,-1,0.9987174,0.0012826207
4069,drug dependency,24,26,170,185,Previous research in this laboratory has shown that a diet of intermittent excessive sugar consumption produces a state with neurochemical and behavioral similarities to drug dependency.,14596845_1,-1,-1,-1,4069,-1,0.29779997,0.70220006
4071,sucrose,30,31,155,162,"After a 30-min baseline measure of locomotor activity (day 0), animals were maintained on a cyclic diet of 12-h deprivation followed by 12-h access to 10% sucrose solution and chow pellets (12 h access starting 4 h after onset of the dark period) for 21 days.",14596845_3,-1,-1,-1,4071,-1,0.99881685,0.0011832325
4072,h,37,38,193,194,"After a 30-min baseline measure of locomotor activity (day 0), animals were maintained on a cyclic diet of 12-h deprivation followed by 12-h access to 10% sucrose solution and chow pellets (12 h access starting 4 h after onset of the dark period) for 21 days.",14596845_3,-1,-1,-1,4072,-1,0.800475,0.19952503
4073,h,41,42,213,214,"After a 30-min baseline measure of locomotor activity (day 0), animals were maintained on a cyclic diet of 12-h deprivation followed by 12-h access to 10% sucrose solution and chow pellets (12 h access starting 4 h after onset of the dark period) for 21 days.",14596845_3,-1,-1,-1,4073,-1,0.1879315,0.81206846
4075,sucrose,6,7,40,47,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,-1,4075,-1,0.9988361,0.0011638551
4076,hyperactive,10,11,62,73,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,-1,4076,-1,0.004054752,0.9959453
4078,sucrose,25,26,151,158,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,-1,4078,-1,0.9990388,0.00096123485
4082,sucrose,50,51,298,305,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,-1,4082,-1,0.9990144,0.000985581
4087,hemorrhagic cystitis,10,12,73,93,Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.,14633084_0,-1,-1,-1,4087,-1,0.0010465693,0.99895346
4088,Hemorrhagic cystitis,2,4,5,25,AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).,14633084_1,-1,-1,-1,4088,-1,0.0012640848,0.99873596
4089,HC,5,6,27,29,AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).,14633084_1,-1,-1,-1,4089,-1,0.0016743403,0.99832565
4091,IFS,16,17,90,93,AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).,14633084_1,-1,-1,-1,4091,-1,0.99621624,0.003783811
4094,HC,21,22,130,132,"In the study presented here, we investigated the use of dexamethasone in combination with mesna for the prevention of IFS-induced HC.",14633084_2,-1,-1,-1,4094,-1,0.0021994233,0.9978005
4096,h,33,34,122,123,METHODS: Male Wistar rats (150-200 g; 6 rats per group) were treated with saline or mesna 5 min (i.p.) before and 2 and 6 h after (v.o.) administration of IFS.,14633084_3,-1,-1,-1,4096,-1,0.7738138,0.2261862
4097,IFS,41,42,155,158,METHODS: Male Wistar rats (150-200 g; 6 rats per group) were treated with saline or mesna 5 min (i.p.) before and 2 and 6 h after (v.o.) administration of IFS.,14633084_3,-1,-1,-1,4097,-1,0.99805033,0.0019497083
4103,h,4,5,26,27,Cystitis was evaluated 24 h after its induction by the changes in bladder wet weight and by macroscopic and microscopic analysis.,14633084_5,-1,-1,-1,4103,-1,0.16859205,0.83140796
4106,IFS,26,27,146,149,"RESULTS: The replacement of the last dose or the last two doses of mesna with dexamethasone reduced the increase in bladder wet weight induced by IFS by 84.79% and 89.13%, respectively.",14633084_6,-1,-1,-1,4106,-1,0.9969771,0.003022889
4107,IFS,13,14,88,91,"In addition, it almost abolished the macroscopic and microscopic alterations induced by IFS.",14633084_7,-1,-1,-1,4107,-1,0.98736227,0.01263776
4113,HC,12,13,90,92,CONCLUSION: Dexamethasone in combination with mesna was efficient in blocking IFS-induced HC.,14633084_9,-1,-1,-1,4113,-1,0.0022130567,0.9977869
4117,HC,23,24,125,127,"However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC.",14633084_10,-1,-1,-1,4117,-1,0.20071322,0.79928684
4118,erythema nodosum,3,5,33,49,All- trans-retinoic acid-induced erythema nodosum in patients with acute promyelocytic leukemia.,14648024_0,-1,-1,-1,4118,-1,0.001241791,0.9987582
4119,acute promyelocytic leukemia,8,11,67,95,All- trans-retinoic acid-induced erythema nodosum in patients with acute promyelocytic leukemia.,14648024_0,-1,-1,-1,4119,-1,0.0017952233,0.9982047
4120,Erythema nodosum,0,2,0,16,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,-1,-1,-1,4120,-1,0.0014353839,0.99856466
4121,ATRA,8,9,59,63,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,-1,-1,-1,4121,-1,0.3438792,0.6561208
4122,acute promyelocytic leukemia,11,14,69,97,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,-1,-1,-1,4122,-1,0.0016302663,0.99836975
4123,APL,15,16,99,102,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,-1,-1,-1,4123,-1,0.0014375118,0.9985625
4124,APL,6,7,39,42,We describe four patients with classic APL who developed erythema nodosum during ATRA therapy.,14648024_2,-1,-1,-1,4124,-1,0.0015809837,0.99841905
4125,erythema nodosum,9,11,57,73,We describe four patients with classic APL who developed erythema nodosum during ATRA therapy.,14648024_2,-1,-1,-1,4125,-1,0.0017037701,0.9982962
4126,ATRA,12,13,81,85,We describe four patients with classic APL who developed erythema nodosum during ATRA therapy.,14648024_2,-1,-1,-1,4126,-1,0.99136317,0.008636792
4128,painful erythematous nodules,4,7,30,58,"Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.",14648024_3,-1,-1,-1,4128,-1,0.0017503324,0.9982496
4129,ATRA,23,24,133,137,"Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.",14648024_3,-1,-1,-1,4129,-1,0.9988387,0.0011612555
4130,erythema nodosum,10,12,60,76,The skin biopsy taken from each patient was consistent with erythema nodosum.,14648024_4,-1,-1,-1,4130,-1,0.0018744513,0.9981255
4133,skin lesions,5,7,31,43,Fever subsided rapidly and the skin lesions regressed completely.,14648024_6,-1,-1,-1,4133,-1,0.0021736668,0.9978263
4134,ATRA,8,9,63,67,All patients achieved complete remission without withdrawal of ATRA.,14648024_7,-1,-1,-1,4134,-1,0.9955401,0.004459878
4135,ATRA,0,1,0,4,ATRA seemed to be the most possible etiology of erythema nodosum in our patients.,14648024_8,-1,-1,-1,4135,-1,0.0015031047,0.9984969
4136,erythema nodosum,9,11,48,64,ATRA seemed to be the most possible etiology of erythema nodosum in our patients.,14648024_8,-1,-1,-1,4136,-1,0.0016103176,0.9983897
4138,erythema nodosum,9,11,60,76,Short-term use of steroid is very effective in ATRA-induced erythema nodosum.,14648024_9,-1,-1,-1,4138,-1,0.0014087369,0.99859124
4140,amphotericin B,5,7,45,59,Reversible dilated cardiomyopathy related to amphotericin B therapy.,14657095_0,-1,-1,-1,4140,-1,0.9985513,0.0014486809
4142,congestive heart failure,10,13,72,96,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,-1,-1,-1,4142,-1,0.0011989704,0.998801
4143,amphotericin B,19,21,128,142,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,-1,-1,-1,4143,-1,0.9988257,0.0011742959
4144,AmB,22,23,144,147,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,-1,-1,-1,4144,-1,0.9985384,0.0014616583
4145,coccidioidomycosis,26,27,166,184,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,-1,-1,-1,4145,-1,0.13356228,0.8664377
4146,heart failure,4,6,40,53,His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.,14657095_2,-1,-1,-1,4146,-1,0.0014975601,0.9985025
4147,posaconazole,8,9,69,81,His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.,14657095_2,-1,-1,-1,4147,-1,0.99902797,0.0009720975
4148,AmB.,12,13,102,106,His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.,14657095_2,-1,-1,-1,4148,-1,0.89441496,0.10558502
4150,AmB.,25,26,184,188,His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.,14657095_2,-1,-1,-1,4150,-1,0.89621246,0.10378747
4153,CGRP,12,13,87,91,NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.,14659530_0,-1,-1,-1,4153,-1,0.99860877,0.0013912526
4156,CGRP,17,18,103,107,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,-1,-1,-1,4156,-1,0.9987565,0.001243477
4159,5-HT,26,27,168,172,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,-1,-1,-1,4159,-1,0.99852836,0.0014715854
4163,migraineurs,2,3,15,26,Fifteen female migraineurs (without aura) and eight controls participated in the study.,14659530_2,-1,-1,-1,4163,-1,0.003318918,0.99668103
4164,without aura,4,6,28,40,Fifteen female migraineurs (without aura) and eight controls participated in the study.,14659530_2,-1,-1,-1,4164,-1,0.0021076547,0.9978923
4166,mg,4,5,30,32,Sublingual nitroglycerin (0.5 mg) was administered.,14659530_3,-1,-1,-1,4166,-1,0.9822504,0.01774958
4170,CGRP,1,2,7,11,Plasma CGRP concentration increased significantly (P<0.01) during the migraine attack and returned to baseline after the cessation of the migraine.,14659530_6,-1,-1,-1,4170,-1,0.99842334,0.0015767309
4171,P<0.01,6,7,51,57,Plasma CGRP concentration increased significantly (P<0.01) during the migraine attack and returned to baseline after the cessation of the migraine.,14659530_6,-1,-1,-1,4171,-1,0.4319468,0.5680532
4174,migraine headache,13,15,81,98,"In addition, both change and peak, showed significant positive correlations with migraine headache intensity (P<0.001).",14659530_7,-1,-1,-1,4174,-1,0.0016283279,0.99837166
4175,P<0.001,17,18,110,117,"In addition, both change and peak, showed significant positive correlations with migraine headache intensity (P<0.001).",14659530_7,-1,-1,-1,4175,-1,0.32859036,0.6714096
4176,CGRP,3,4,16,20,"However, plasma CGRP concentrations failed to change during immediate headache and in the subjects with no migraine attack.",14659530_8,-1,-1,-1,4176,-1,0.99856,0.0014399413
4179,CGRP,1,2,6,10,Basal CGRP concentration was significantly higher and platelet 5-HT content tended to be lower in subjects who experienced a migraine attack.,14659530_9,-1,-1,-1,4179,-1,0.99868494,0.0013150842
4180,5-HT,8,9,63,67,Basal CGRP concentration was significantly higher and platelet 5-HT content tended to be lower in subjects who experienced a migraine attack.,14659530_9,-1,-1,-1,4180,-1,0.99768615,0.0023138556
4183,P<0.01,6,7,52,58,Platelet serotonin content decreased significantly (P<0.01) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with migraine attack.,14659530_10,-1,-1,-1,4183,-1,0.35748643,0.6425136
4187,CGRP,7,8,36,40,"In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.",14659530_11,-1,-1,-1,4187,-1,0.99895954,0.0010404246
4188,migraine headache,17,19,100,117,"In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.",14659530_11,-1,-1,-1,4188,-1,0.0014557551,0.9985442
4189,CGRP,24,25,157,161,"In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.",14659530_11,-1,-1,-1,4189,-1,0.9989642,0.0010358266
4191,contrast,1,2,3,11,"In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant CGRP release in this model.",14659530_12,-1,-1,-1,4191,-1,0.56500596,0.43499404
4195,CGRP,21,22,129,133,"In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant CGRP release in this model.",14659530_12,-1,-1,-1,4195,-1,0.9988709,0.0011291192
4197,hemorrhagic cystitis,8,10,78,98,Hyperbaric oxygen therapy for control of intractable cyclophosphamide-induced hemorrhagic cystitis.,1468485_0,-1,-1,-1,4197,-1,0.0010131274,0.9989869
4198,hemorrhagic cystitis,6,8,32,52,We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener's granulomatosis.,1468485_1,-1,-1,-1,4198,-1,0.0010542445,0.9989458
4200,Wegener's granulomatosis,13,16,89,113,We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener's granulomatosis.,1468485_1,-1,-1,-1,4200,-1,0.002415481,0.99758446
4201,prostaglandin F2 alpha,12,15,99,121,"Conservative treatment, including bladder irrigation with physiological saline and instillation of prostaglandin F2 alpha, failed to totally control hemorrhage.",1468485_2,-1,-1,-1,4201,-1,0.9986187,0.0013812495
4206,hemorrhagic cystitis,17,19,106,126,"In future, this form of therapy can offer a safe alternative in the treatment of cyclophosphamide-induced hemorrhagic cystitis.",1468485_6,-1,-1,-1,4206,-1,0.0010300189,0.99897003
4207,psychosis,1,2,6,15,Acute psychosis due to treatment with phenytoin in a nonepileptic patient.,14698717_0,-1,-1,-1,4207,-1,0.0012226385,0.99877733
4209,psychosis,3,4,19,28,The development of psychosis related to antiepileptic drug treatment is usually attributed to the interaction between the epileptic brain substratum and the antiepileptic drugs.,14698717_1,-1,-1,-1,4209,-1,0.0012027068,0.9987973
4211,psychosis,8,9,49,58,The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described.,14698717_2,-1,-1,-1,4211,-1,0.0011315849,0.99886847
4213,trigeminal neuralgia,13,15,93,113,The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described.,14698717_2,-1,-1,-1,4213,-1,0.0011812892,0.9988187
4218,convulsants,3,4,15,26,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,-1,-1,-1,4218,-1,0.35718006,0.64282
4219,loreclezole,9,10,57,68,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,-1,-1,-1,4219,-1,0.99920887,0.0007911063
4220,valproate,14,15,95,104,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,-1,-1,-1,4220,-1,0.9993338,0.0006662012
4221,clonazepam,16,17,108,118,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,-1,-1,-1,4221,-1,0.99926203,0.0007379766
4222,Loreclezole,0,1,0,11,"Loreclezole (5 mg/kg) exerted a significant protective action in amygdala-kindled rats, reducing both seizure and afterdischarge durations.",14704468_1,-1,-1,-1,4222,-1,0.9991303,0.00086965156
4224,loreclezole,3,4,20,31,"The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.",14704468_2,-1,-1,-1,4224,-1,0.9992705,0.0007295472
4225,valproate,9,10,49,58,"The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.",14704468_2,-1,-1,-1,4225,-1,0.99937916,0.000620823
4226,clonazepam,11,12,60,70,"The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.",14704468_2,-1,-1,-1,4226,-1,0.9993013,0.0006986484
4229,BAY k-8644,9,11,74,84,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,-1,-1,-1,4229,-1,0.9991025,0.00089755567
4231,loreclezole,24,25,161,172,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,-1,-1,-1,4231,-1,0.9992455,0.0007545337
4232,valproate,30,31,204,213,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,-1,-1,-1,4232,-1,0.9993413,0.0006586193
4235,BAY k-8644,9,11,50,60,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,-1,-1,-1,4235,-1,0.9988953,0.0011046828
4236,loreclezole,16,17,100,111,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,-1,-1,-1,4236,-1,0.99916816,0.0008318927
4237,clonazepam,19,20,126,136,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,-1,-1,-1,4237,-1,0.9992385,0.0007615417
4238,loreclezole,10,11,67,78,The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L-type of calcium channels.,14704468_6,-1,-1,-1,4238,-1,0.99922657,0.000773472
4240,doxorubicin nephrosis,10,12,70,91,Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis.,14736955_0,-1,-1,-1,4240,-1,0.09937649,0.9006235
4243,tubular lesions,13,15,113,128,BACKGROUND: Doxorubicin induces a self-perpetuating nephropathy characterized by early glomerular and late-onset tubular lesions in rats.,14736955_1,-1,-1,-1,4243,-1,0.0017281643,0.9982718
4244,mitochondrial injury,6,8,38,58,We investigated the potential role of mitochondrial injury in the onset of these lesions.,14736955_2,-1,-1,-1,4244,-1,0.008798641,0.9912013
4246,mg,10,11,59,61,METHODS: Rats were treated with intravenous doxorubicin (1 mg kg(-1) week(-1)) for 7 weeks and were sacrificed either 1 week ('short-term') or 30 weeks ('long-term') following the last dose.,14736955_3,-1,-1,-1,4246,-1,0.9840995,0.015900511
4247,h,11,12,58,59,Additional rats received a single dose either 6 days or 2 h prior to euthanasia.,14736955_4,-1,-1,-1,4247,-1,0.36073297,0.639267
4248,Glomerular and tubular injury,0,4,0,29,Glomerular and tubular injury was monitored and correlated to the activity or expression of respiratory chain components.,14736955_6,-1,-1,-1,4248,-1,0.0027815043,0.9972185
4250,glomerular and tubular lesions,9,13,47,77,"RESULTS: The 'long-term' group had significant glomerular and tubular lesions, depressed activities of mtDNA-encoded NADH dehydrogenase and cytochrome-c oxidase (COX) and increased citrate synthase activity.",14736955_8,-1,-1,-1,4250,-1,0.0017310878,0.99826884
4252,NADH,18,19,117,121,"RESULTS: The 'long-term' group had significant glomerular and tubular lesions, depressed activities of mtDNA-encoded NADH dehydrogenase and cytochrome-c oxidase (COX) and increased citrate synthase activity.",14736955_8,-1,-1,-1,4252,-1,0.99785125,0.002148753
4253,citrate,28,29,181,188,"RESULTS: The 'long-term' group had significant glomerular and tubular lesions, depressed activities of mtDNA-encoded NADH dehydrogenase and cytochrome-c oxidase (COX) and increased citrate synthase activity.",14736955_8,-1,-1,-1,4253,-1,0.9978867,0.0021132585
4254,tubular lesions,9,11,39,54,"In 'short-term' rats, there were fewer tubular lesions, but similar numbers of glomerular lesions activity.",14736955_10,-1,-1,-1,4254,-1,0.0021127167,0.9978873
4255,glomerular lesions,16,18,79,97,"In 'short-term' rats, there were fewer tubular lesions, but similar numbers of glomerular lesions activity.",14736955_10,-1,-1,-1,4255,-1,0.0021926337,0.9978073
4256,tubular injury,6,8,34,48,"Among all animals, glomerular and tubular injury were inversely correlated with mtDNA levels, mtDNA-encoded respiratory chain activities and with the expression of the mtDNA-encoded respiratory chain subunit COX-I. Injury was positively correlated with superoxide production and the activities of nucleus-encoded mitochondrial or cytoplasmic enzymes.",14736955_11,-1,-1,-1,4256,-1,0.0023699517,0.99763
4259,renal lesions,28,30,221,234,CONCLUSIONS: These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA-encoded respiratory chain function and induction of superoxide in doxorubicin-induced renal lesions.,14736955_13,-1,-1,-1,4259,-1,0.0016427092,0.99835724
4264,sexually dysfunctional,1,3,9,31,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,-1,-1,-1,4264,-1,0.0024477143,0.99755234
4269,mg,30,31,207,209,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,-1,-1,-1,4269,-1,0.9925095,0.0074904864
4270,mg ephedrine,16,18,119,131,"Although there were significant improvements relative to baseline in sexual desire and orgasm intensity/pleasure on 50 mg ephedrine 1-hr prior to sexual activity, significant improvements in these measures, as well as in sexual arousal and orgasmic ability also were noted with placebo.",14742097_3,-1,-1,-1,4270,-1,0.9985574,0.0014426111
4273,anastrozole,7,8,48,59,"Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.",14745746_3,-1,-1,-1,4273,-1,0.99918836,0.00081168965
4275,n=94,17,18,97,101,"Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.",14745746_3,-1,-1,-1,4275,-1,0.08311097,0.9168891
4277,n=35,28,29,147,151,"Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.",14745746_3,-1,-1,-1,4277,-1,0.060358305,0.9396417
4278,p=0.032,16,17,88,95,"Compared with the control group, the patients were impaired on a processing speed task (p=0.032) and on a measure of immediate verbal memory (p=0.026) after controlling for the use of hormone replacement therapy in both groups.",14745746_4,-1,-1,-1,4278,-1,0.32338205,0.676618
4279,p=0.026,27,28,142,149,"Compared with the control group, the patients were impaired on a processing speed task (p=0.032) and on a measure of immediate verbal memory (p=0.026) after controlling for the use of hormone replacement therapy in both groups.",14745746_4,-1,-1,-1,4279,-1,0.37088344,0.6291166
4281,oestrogen,9,10,56,65,"Verbal memory may be especially sensitive to changes in oestrogen levels, a finding commonly reported in studies of hormone replacement therapy in healthy women.",14745746_7,-1,-1,-1,4281,-1,0.998845,0.0011550413
4283,leg cramps,13,15,85,95,"Although the United States Food and Drug Administration banned its use for nocturnal leg cramps due to lack of safety and efficacy, quinine is widely available in beverages including tonic water and bitter lemon.",14765563_1,-1,-1,-1,4283,-1,0.0018857833,0.9981142
4286,neurological complications,10,12,80,106,"Numerous anecdotal reports suggest that products containing quinine may produce neurological complications, including confusion, altered mental status, seizures, and coma, particularly in older women.",14765563_2,-1,-1,-1,4286,-1,0.0011052875,0.99889475
4294,heart failure,19,21,148,161,These findings demonstrate that overexpression of p300 protects cardiac myocytes from doxorubicin-induced apoptosis and reduces the extent of acute heart failure in adult mice in vivo.,14975762_8,-1,-1,-1,4294,-1,0.0013034901,0.9986965
4295,propafenone overdose,5,7,57,77,Transient platypnea-orthodeoxia-like syndrome induced by propafenone overdose in a young woman with Ebstein's anomaly.,14976857_0,-1,-1,-1,4295,-1,0.6361164,0.36388364
4296,Ebstein's anomaly,12,15,100,117,Transient platypnea-orthodeoxia-like syndrome induced by propafenone overdose in a young woman with Ebstein's anomaly.,14976857_0,-1,-1,-1,4296,-1,0.0031323025,0.9968677
4297,Ebstein's anomaly,13,16,70,87,"In this report we describe the case of a 37-year-old white woman with Ebstein's anomaly, who developed a rare syndrome called platypnea-orthodeoxia, characterized by massive right-to-left interatrial shunting with transient profound hypoxia and cyanosis.",14976857_1,-1,-1,-1,4297,-1,0.004957496,0.99504244
4299,cyanosis,36,37,245,253,"In this report we describe the case of a 37-year-old white woman with Ebstein's anomaly, who developed a rare syndrome called platypnea-orthodeoxia, characterized by massive right-to-left interatrial shunting with transient profound hypoxia and cyanosis.",14976857_1,-1,-1,-1,4299,-1,0.0013600341,0.99864
4300,propafenone overdose,26,28,146,166,"This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure, and was probably precipitated by a propafenone overdose.",14976857_2,-1,-1,-1,4300,-1,0.7469996,0.25300035
4301,biventricular dysfunction,3,5,17,42,"This drug caused biventricular dysfunction, due to its negative inotropic effect, and hypotension, due to its peripheral vasodilatory effect.",14976857_3,-1,-1,-1,4301,-1,0.0018109331,0.99818903
4303,contrast,12,13,74,82,In our case this interatrial shunt was very accurately detected at bubble contrast echocardiography.,14976857_5,-1,-1,-1,4303,-1,0.9517145,0.048285518
4304,cholestatic jaundice,1,3,20,40,Methimazole-induced cholestatic jaundice.,14982270_0,-1,-1,-1,4304,-1,0.001349566,0.9986505
4305,Methimazole,0,1,0,11,Methimazole is a widely used and generally well-tolerated antithyroid agent.,14982270_1,-1,-1,-1,4305,-1,0.9991891,0.00081097643
4307,itching,7,8,44,51,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,-1,-1,-1,4307,-1,0.001242822,0.9987571
4308,methimazole,12,13,76,87,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,-1,-1,-1,4308,-1,0.9993345,0.000665427
4309,mg,15,16,92,94,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,-1,-1,-1,4309,-1,0.9945312,0.0054688235
4311,mg,22,23,120,122,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,-1,-1,-1,4311,-1,0.9921462,0.007853755
4314,emergency department,4,6,17,37,"When seen at the emergency department 2 weeks later, she still had severe icterus, pruritus, and hyperbilirubinemia, formed mainly of the conjugated fraction.",14982270_4,-1,-1,-1,4314,-1,0.017394938,0.9826051
4315,icterus,14,15,74,81,"When seen at the emergency department 2 weeks later, she still had severe icterus, pruritus, and hyperbilirubinemia, formed mainly of the conjugated fraction.",14982270_4,-1,-1,-1,4315,-1,0.0013383101,0.99866164
4317,hyperbilirubinemia,19,20,97,115,"When seen at the emergency department 2 weeks later, she still had severe icterus, pruritus, and hyperbilirubinemia, formed mainly of the conjugated fraction.",14982270_4,-1,-1,-1,4317,-1,0.0036414515,0.9963586
4321,methimazole,19,20,112,123,"Over the following 9 days, the symptoms improved and plasma bilirubin levels were normal after 12 weeks without methimazole.",14982270_6,-1,-1,-1,4321,-1,0.99926025,0.00073970365
4322,cholestatic jaundice,18,20,95,115,"In rare cases within the first few weeks of therapy, this drug can cause severe and reversible cholestatic jaundice.",14982270_7,-1,-1,-1,4322,-1,0.0013348109,0.9986652
4323,methimazole,19,20,110,121,"Physicians and patients should be aware of this adverse effect so that, upon occurrence, they can discontinue methimazole therapy and avoid unnecessary invasive procedures.",14982270_8,-1,-1,-1,4323,-1,0.9992866,0.0007134798
4324,vascular dysfunctions,20,22,154,175,Noxious chemical stimulation of rat facial mucosa increases intracranial blood flow through a trigemino-parasympathetic reflex--an experimental model for vascular dysfunctions in cluster headache.,15009014_0,-1,-1,-1,4324,-1,0.0015943676,0.99840564
4325,cluster headache,23,25,179,195,Noxious chemical stimulation of rat facial mucosa increases intracranial blood flow through a trigemino-parasympathetic reflex--an experimental model for vascular dysfunctions in cluster headache.,15009014_0,-1,-1,-1,4325,-1,0.0016421558,0.99835783
4326,Cluster headache,0,2,0,16,Cluster headache is characterized by typical autonomic dysfunctions including facial and intracranial vascular disturbances.,15009014_1,-1,-1,-1,4326,-1,0.0014815814,0.9985184
4327,dysfunctions,7,8,55,67,Cluster headache is characterized by typical autonomic dysfunctions including facial and intracranial vascular disturbances.,15009014_1,-1,-1,-1,4327,-1,0.001502272,0.9984977
4328,vascular disturbances,12,14,102,123,Cluster headache is characterized by typical autonomic dysfunctions including facial and intracranial vascular disturbances.,15009014_1,-1,-1,-1,4328,-1,0.0013887667,0.9986112
4330,mm,5,6,18,20,Capsaicin (0.01-1 mm) applied to oral or nasal mucosa induced increases in dural and cortical blood flow and provoked lacrimation.,15009014_5,-1,-1,-1,4330,-1,0.97949857,0.02050141
4331,hexamethonium chloride,8,10,63,85,These responses were blocked by systemic pre-administration of hexamethonium chloride (20 mg/kg).,15009014_6,-1,-1,-1,4331,-1,0.99906987,0.00093013176
4332,increases in,2,4,11,23,"The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.",15009014_7,-1,-1,-1,4332,-1,0.009271224,0.99072886
4334,mm,17,18,106,108,"The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.",15009014_7,-1,-1,-1,4334,-1,0.9866067,0.013393208
4335,mm,30,31,152,154,"The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.",15009014_7,-1,-1,-1,4335,-1,0.9812397,0.018760368
4337,cluster headache,9,11,58,74,Similar mechanisms may be involved in the pathogenesis of cluster headache.,15009014_10,-1,-1,-1,4337,-1,0.0015445977,0.9984554
4339,neuropathological damages,5,7,54,79,Organophosphate-induced convulsions and prevention of neuropathological damages.,15036754_0,-1,-1,-1,4339,-1,0.0013867817,0.99861324
4340,organophosphorus,1,2,5,21,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4340,-1,0.9975311,0.0024689427
4341,OP,3,4,23,25,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4341,-1,0.99796945,0.0020304758
4342,diisopropylfluorophosphate,7,8,40,66,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4342,-1,0.9988458,0.001154158
4343,DFP,9,10,68,71,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4343,-1,0.9990037,0.0009963234
4344,sarin,12,13,74,79,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4344,-1,0.99891865,0.0010813309
4345,soman,14,15,84,89,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4345,-1,0.99911433,0.0008856365
4347,OPs,4,5,22,25,"The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels.",15036754_2,-1,-1,-1,4347,-1,0.9978417,0.0021583133
4349,ACh,27,28,148,151,"The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels.",15036754_2,-1,-1,-1,4349,-1,0.9981535,0.0018464247
4350,DFP,14,15,93,96,The protective action of subcutaneously (SC) administered antidotes or their combinations in DFP (2.0 mg/kg BW) intoxication was studied in 9-10-weeks-old Han-Wistar male rats.,15036754_3,-1,-1,-1,4350,-1,0.9990878,0.00091220177
4351,pralidoxime-2-chloride,5,6,35,57,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4351,-1,0.99897075,0.0010292674
4352,2PAM,7,8,59,63,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4352,-1,0.9988404,0.0011596894
4354,N(6)-cyclopentyl adenosine,26,28,154,180,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4354,-1,0.998577,0.0014229416
4355,CPA,29,30,182,185,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4355,-1,0.9990476,0.0009524013
4356,dizocilpine maleate,39,41,228,247,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4356,-1,0.99918395,0.0008160816
4357,hydrogen maleate,44,46,257,273,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4357,-1,0.9986443,0.0013557206
4358,atropine sulfate,58,60,335,351,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4358,-1,0.99925,0.0007500063
4359,DFP,75,76,423,426,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4359,-1,0.9990984,0.00090161513
4360,atropine sulfate,4,6,26,42,"The control rats received atropine sulfate, but also saline and olive oil instead of other antidotes and DFP, respectively.",15036754_5,-1,-1,-1,4360,-1,0.99921453,0.0007854339
4361,olive oil,11,13,64,73,"The control rats received atropine sulfate, but also saline and olive oil instead of other antidotes and DFP, respectively.",15036754_5,-1,-1,-1,4361,-1,0.9988417,0.0011583682
4362,DFP,18,19,105,108,"The control rats received atropine sulfate, but also saline and olive oil instead of other antidotes and DFP, respectively.",15036754_5,-1,-1,-1,4362,-1,0.99855036,0.001449658
4363,h,6,7,35,36,All rats were terminated either 24 h or 3 weeks after the DFP injection.,15036754_6,-1,-1,-1,4363,-1,0.3374806,0.66251934
4364,DFP,12,13,58,61,All rats were terminated either 24 h or 3 weeks after the DFP injection.,15036754_6,-1,-1,-1,4364,-1,0.99910897,0.0008910185
4366,CPA,1,2,5,8,"When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning.",15036754_8,-1,-1,-1,4366,-1,0.99921656,0.0007834295
4368,2PAM,5,6,22,26,"When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning.",15036754_8,-1,-1,-1,4368,-1,0.9991192,0.0008807552
4370,DFP toxicity,8,10,63,75,Atropine-MK801 did not offer any additional protection against DFP toxicity.,15036754_9,-1,-1,-1,4370,-1,0.22232679,0.77767324
4371,CPA,3,4,15,18,"In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.",15036754_10,-1,-1,-1,4371,-1,0.9991654,0.000834613
4373,2PAM,7,8,33,37,"In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.",15036754_10,-1,-1,-1,4373,-1,0.9991177,0.0008823327
4377,DFP,26,27,155,158,"In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.",15036754_10,-1,-1,-1,4377,-1,0.99901104,0.0009889331
4378,Atrial fibrillation,0,2,0,19,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4378,-1,0.0015531686,0.9984469
4379,gastric lymphoma,10,12,79,95,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4379,-1,0.0033135184,0.9966865
4380,myotonic dystrophy,16,18,114,132,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4380,-1,0.0016756911,0.99832433
4381,Steinert's disease).The,19,22,134,157,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4381,-1,0.032921717,0.96707827
4382,gastric lymphoma,30,32,222,238,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4382,-1,0.004067558,0.9959324
4383,myotonic dystrophy,33,35,243,261,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4383,-1,0.0016599518,0.99834
4384,muscular dystrophy,42,44,293,311,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4384,-1,0.0016972432,0.9983027
4385,atrial fibrillation,47,49,324,343,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4385,-1,0.0015931892,0.9984068
4386,Atrial fibrillation,0,2,0,19,Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy.,15042318_1,-1,-1,-1,4386,-1,0.0013392791,0.9986607
4392,dilevalol,7,8,46,55,OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.,1504402_1,-1,-1,-1,4392,-1,0.9991365,0.0008635774
4393,dilevalol,15,16,97,106,OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.,1504402_1,-1,-1,-1,4393,-1,0.9990833,0.0009167316
4396,dilevalol,19,20,118,127,METHODS: Peripheral blood mononuclear cells collected from the patient were cultured in the presence of a solution of dilevalol and also with sera collected from a volunteer before and after dilevalol intake.,1504402_3,-1,-1,-1,4396,-1,0.99919754,0.0008024444
4397,dilevalol,31,32,191,200,METHODS: Peripheral blood mononuclear cells collected from the patient were cultured in the presence of a solution of dilevalol and also with sera collected from a volunteer before and after dilevalol intake.,1504402_3,-1,-1,-1,4397,-1,0.9991404,0.0008596219
4398,dilevalol,20,21,119,128,RESULTS: No lymphocyte proliferation was observed either in the patient or in the healthy volunteer in the presence of dilevalol solutions.,1504402_5,-1,-1,-1,4398,-1,0.9991309,0.0008691579
4399,dilevalol,8,9,62,71,A significant proliferative response to serum collected after dilevalol intake was observed in the case of the patient compared with the proliferative response to the serum collected before the drug intake.,1504402_6,-1,-1,-1,4399,-1,0.9991648,0.000835212
4400,dilevalol,16,17,120,129,"CONCLUSIONS: The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo-prepared dilevalol antigens, suggesting the involvement of an immunologic mechanism in dilevalol-induced liver injury.",1504402_8,-1,-1,-1,4400,-1,0.9990257,0.00097433623
4402,nephrotic syndrome,12,14,102,120,Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats.,15075188_0,-1,-1,-1,4402,-1,0.0011938575,0.9988061
4403,Nephrotic syndrome,0,2,0,18,Nephrotic syndrome is often accompanied by sodium retention and generalized edema.,15075188_1,-1,-1,-1,4403,-1,0.0012577375,0.9987423
4407,Na,4,5,32,34,We hypothesized that epithelial Na channel (ENaC) subunit dysregulation may be responsible for the increased sodium retention.,15075188_3,-1,-1,-1,4407,-1,0.998428,0.0015720535
4409,puromycin aminonucleoside,8,10,47,72,"An experimental group of rats was treated with puromycin aminonucleoside (PAN; 180 mg/kg iv), whereas the control group received only vehicle.",15075188_4,-1,-1,-1,4409,-1,0.99921167,0.00078827527
4410,PAN,11,12,74,77,"An experimental group of rats was treated with puromycin aminonucleoside (PAN; 180 mg/kg iv), whereas the control group received only vehicle.",15075188_4,-1,-1,-1,4410,-1,0.99860555,0.0013944813
4411,PAN,4,5,14,17,"After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.",15075188_5,-1,-1,-1,4411,-1,0.9892574,0.0107425675
4413,hypoalbuminemia,10,11,61,76,"After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.",15075188_5,-1,-1,-1,4413,-1,0.0014627374,0.9985373
4416,contrast,1,2,3,11,"In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.",15075188_10,-1,-1,-1,4416,-1,0.15267485,0.84732515
4418,nephrotic syndrome,39,41,241,259,"In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.",15075188_12,-1,-1,-1,4418,-1,0.0013499402,0.99865013
4420,behavioral disorder,2,4,23,42,A pyridoxine-dependent behavioral disorder unmasked by isoniazid.,150790_0,-1,-1,-1,4420,-1,0.001367312,0.9986326
4422,behavioral deterioration,4,6,22,46,"A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.",150790_1,-1,-1,-1,4422,-1,0.0015392556,0.99846077
4423,hyperkinesis,8,9,53,65,"A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.",150790_1,-1,-1,-1,4423,-1,0.0011965072,0.9988035
4425,sleeping difficulties,13,15,85,106,"A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.",150790_1,-1,-1,-1,4425,-1,0.0017182268,0.99828184
4427,pyridoxine hydrochloride,6,8,45,69,The administration of pharmacologic doses of pyridoxine hydrochloride led to a disappearance of symptoms.,150790_2,-1,-1,-1,4427,-1,0.9991473,0.00085269264
4430,niacinamide,7,8,29,40,"A placebo had no effect, but niacinamide was as effective as pyridoxine.",150790_4,-1,-1,-1,4430,-1,0.9991466,0.00085335824
4433,hyperkinesis,10,11,68,80,Periodic withdrawal of pyridoxine was associated with return of the hyperkinesis.,150790_5,-1,-1,-1,4433,-1,0.0012628074,0.99873716
4434,pyridoxal,3,4,13,22,The level of pyridoxal in the blood was normal during the periods of relapse.,150790_6,-1,-1,-1,4434,-1,0.99923253,0.00076752173
4435,kynurenine,7,8,43,53,Metabolic studies suggested a block in the kynurenine pathway of tryptophan metabolism.,150790_7,-1,-1,-1,4435,-1,0.9990048,0.0009952404
4436,tryptophan,10,11,65,75,Metabolic studies suggested a block in the kynurenine pathway of tryptophan metabolism.,150790_7,-1,-1,-1,4436,-1,0.9987325,0.0012675462
4438,Parkinson's disease,15,18,106,125,Pallidal stimulation: an alternative to pallidotomy?A resurgence of interest in the surgical treatment of Parkinson's disease (PD) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985.,15096016_0,-1,-1,-1,4438,-1,0.0026575625,0.9973424
4439,PD,19,20,127,129,Pallidal stimulation: an alternative to pallidotomy?A resurgence of interest in the surgical treatment of Parkinson's disease (PD) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985.,15096016_0,-1,-1,-1,4439,-1,0.002480563,0.99751943
4440,PD,8,9,62,64,"Laitinen's procedure improved most symptoms in drug-resistant PD, which engendered wide interest in the neurosurgical community.",15096016_1,-1,-1,-1,4440,-1,0.0018962856,0.99810374
4441,PD,12,13,70,72,"According to the literature pallidotomy improves the ""on"" symptoms of PD, such as dyskinesias, as well as the ""off"" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.",15096016_4,-1,-1,-1,4441,-1,0.0016504648,0.99834955
4444,bradykinesia,31,32,144,156,"According to the literature pallidotomy improves the ""on"" symptoms of PD, such as dyskinesias, as well as the ""off"" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.",15096016_4,-1,-1,-1,4444,-1,0.0012572166,0.99874276
4445,bradykinesia,3,4,30,42,"Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.",15096016_5,-1,-1,-1,4445,-1,0.0011315111,0.99886847
4448,dyskinetic,9,10,59,69,"Stimulation often produces an improvement in the hyper- or dyskinetic upper limbs, but increases the ""freezing"" phenomenon in the lower limbs at the same time.",15096016_6,-1,-1,-1,4448,-1,0.0020763683,0.9979236
4451,status epilepticus,8,10,55,73,"Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.",15120741_1,-1,-1,-1,4451,-1,0.0014366495,0.99856335
4452,SE,11,12,75,77,"Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.",15120741_1,-1,-1,-1,4452,-1,0.0014717684,0.99852824
4455,SE,40,41,276,278,"In Mg(2+)-free bathing medium containing bicuculline, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience SE.",15120741_3,-1,-1,-1,4455,-1,0.0029815144,0.99701846
4456,SE,1,2,3,5,"In SE survivors, similar stimulation resulted in a population spike followed, at a variable latency, by negative DC shifts and repetitive afterdischarges of 3-60 s duration, which were blocked by ionotropic glutamate receptor antagonists.",15120741_4,-1,-1,-1,4456,-1,0.008226398,0.99177366
4459,SE,28,29,170,172,Focal glutamate photostimulation of the granule cell layer at sites distant from the recording pipette resulted in population responses of 1-30 s duration in slices from SE survivors but not other groups.,15120741_5,-1,-1,-1,4459,-1,0.758146,0.24185398
4462,Urinary bladder cancer,0,3,0,22,Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.,15130900_0,-1,-1,-1,4462,-1,0.0019898415,0.9980102
4463,Wegener's granulomatosis,4,7,26,50,Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.,15130900_0,-1,-1,-1,4463,-1,0.0033010633,0.9966989
4467,Wegener's granulomatosis,21,24,121,145,"OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with Wegener's granulomatosis.",15130900_1,-1,-1,-1,4467,-1,0.0033257515,0.9966742
4468,Wegener's granulomatosis,17,20,103,127,"METHODS: In the population based, nationwide Swedish Inpatient Register a cohort of 1065 patients with Wegener's granulomatosis, 1969-95, was identified.",15130900_2,-1,-1,-1,4468,-1,0.0040355236,0.9959644
4474,Wegener's granulomatosis,10,13,58,82,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,-1,-1,-1,4474,-1,0.005838529,0.9941614
4476,Wegener's granulomatosis,30,33,171,195,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,-1,-1,-1,4476,-1,0.006539959,0.99346006
4478,n,11,12,70,71,"RESULTS: The median cumulative doses of cyclophosphamide among cases (n = 11) and controls (n = 25) were 113 g and 25 g, respectively.",15130900_6,-1,-1,-1,4478,-1,0.08844506,0.91155493
4479,n,18,19,92,93,"RESULTS: The median cumulative doses of cyclophosphamide among cases (n = 11) and controls (n = 25) were 113 g and 25 g, respectively.",15130900_6,-1,-1,-1,4479,-1,0.08337464,0.9166254
4483,Wegener's granulomatosis,17,20,91,115,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,-1,-1,-1,4483,-1,0.0044372077,0.9955628
4485,Wegener's granulomatosis,42,45,229,253,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,-1,-1,-1,4485,-1,0.0051714634,0.9948285
4488,Wegener's granulomatosis,35,38,226,250,"CONCLUSION: The results indicate a dose-response relationship between cyclophosphamide and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.",15130900_10,-1,-1,-1,4488,-1,0.0030473017,0.99695265
4495,rilmenidine,8,9,56,67,"Changes evoked by a single intraperitoneal injection of rilmenidine (600 microg/kg) or alpha-methyldopa (100 mg/kg), selective I1- and alpha2-receptor agonists, respectively, in blood pressure, hemodynamic variability, and locomotor activity were assessed in radiotelemetered sham-operated and ovariectomized (Ovx) Sprague-Dawley female rats with or without 12-wk estrogen replacement.",15145918_3,-1,-1,-1,4495,-1,0.99924797,0.00075198937
4497,rilmenidine,4,5,23,34,"In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.",15145918_5,-1,-1,-1,4497,-1,0.99913687,0.00086319854
4499,h,15,16,107,108,"In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.",15145918_5,-1,-1,-1,4499,-1,0.050916873,0.94908315
4501,contrast,10,11,76,84,"Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.",15145918_7,-1,-1,-1,4501,-1,0.106627665,0.8933723
4502,rilmenidine hypotension,15,17,101,124,"Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.",15145918_7,-1,-1,-1,4502,-1,0.68199563,0.31800443
4504,reduced locomotor activity,16,19,106,132,The enhanced alpha-methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity.,15145918_8,-1,-1,-1,4504,-1,0.0059104436,0.9940896
4508,left ventricular systolic and diastolic dysfunction,2,8,18,69,Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose.,15188772_0,-1,-1,-1,4508,-1,0.0029469458,0.997053
4509,epinephrine overdose,12,14,99,119,Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose.,15188772_0,-1,-1,-1,4509,-1,0.1706336,0.8293664
4512,contrast,1,2,3,11,"In contrast, reports of myocardial dysfunction due to acute iatrogenic overdose are rare.",15188772_2,-1,-1,-1,4512,-1,0.07777334,0.92222667
4513,myocardial dysfunction,5,7,24,46,"In contrast, reports of myocardial dysfunction due to acute iatrogenic overdose are rare.",15188772_2,-1,-1,-1,4513,-1,0.0015370856,0.9984629
4515,mg,11,12,73,75,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,-1,-1,-1,4515,-1,0.99405503,0.005944903
4517,myocardial stunning,15,17,101,120,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,-1,-1,-1,4517,-1,0.00171244,0.9982875
4518,left ventricular systolic and diastolic dysfunction,30,36,206,257,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,-1,-1,-1,4518,-1,0.005100082,0.9948999
4519,myocardial necrosis,44,46,309,328,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,-1,-1,-1,4519,-1,0.001978194,0.99802184
4520,tincture of Crataegus,3,6,27,48,Cardioprotective effect of tincture of Crataegus on isoproterenol-induced myocardial infarction in rats.,15233872_0,-1,-1,-1,4520,-1,0.031824518,0.9681755
4521,myocardial infarction,8,10,74,95,Cardioprotective effect of tincture of Crataegus on isoproterenol-induced myocardial infarction in rats.,15233872_0,-1,-1,-1,4521,-1,0.0014008186,0.99859923
4522,Tincture of Crataegus,0,3,0,21,"Tincture of Crataegus (TCR), an alcoholic extract of the berries of hawthorn (Crataegus oxycantha), is used in herbal and homeopathic medicine.",15233872_1,-1,-1,-1,4522,-1,0.2519018,0.74809825
4523,TCR,4,5,23,26,"Tincture of Crataegus (TCR), an alcoholic extract of the berries of hawthorn (Crataegus oxycantha), is used in herbal and homeopathic medicine.",15233872_1,-1,-1,-1,4523,-1,0.4777257,0.52227426
4524,berries of hawthorn,12,15,57,76,"Tincture of Crataegus (TCR), an alcoholic extract of the berries of hawthorn (Crataegus oxycantha), is used in herbal and homeopathic medicine.",15233872_1,-1,-1,-1,4524,-1,0.98970556,0.010294422
4525,TCR,11,12,67,70,The present study was done to investigate the protective effect of TCR on experimentally induced myocardial infarction in rats.,15233872_2,-1,-1,-1,4525,-1,0.99594146,0.004058468
4526,myocardial infarction,15,17,97,118,The present study was done to investigate the protective effect of TCR on experimentally induced myocardial infarction in rats.,15233872_2,-1,-1,-1,4526,-1,0.0016646697,0.9983353
4527,TCR,2,3,16,19,"Pretreatment of TCR, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).",15233872_3,-1,-1,-1,4527,-1,0.99709475,0.0029052524
4528,bodyweight,11,12,47,57,"Pretreatment of TCR, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).",15233872_3,-1,-1,-1,4528,-1,0.41738528,0.5826147
4529,mg,37,38,206,208,"Pretreatment of TCR, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).",15233872_3,-1,-1,-1,4529,-1,0.9912418,0.008758145
4530,h,50,51,254,255,"Pretreatment of TCR, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).",15233872_3,-1,-1,-1,4530,-1,0.34586462,0.6541354
4531,TCR,0,1,0,3,TCR prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of ADP-stimulated oxygen uptake and respiratory coupling ratio.,15233872_4,-1,-1,-1,4531,-1,0.99846125,0.0015388145
4534,TCR,6,7,40,43,The results show that pretreatment with TCR may be useful in preventing the damage induced by isoproterenol in rat heart.,15233872_6,-1,-1,-1,4534,-1,0.9965256,0.003474458
4536,valdecoxib,6,7,51,61,Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.,15266215_0,-1,-1,-1,4536,-1,0.9989784,0.0010217086
4539,thrombotic events,9,11,57,74,There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs).,15266215_1,-1,-1,-1,4539,-1,0.001461888,0.99853814
4540,NSAIDs,24,25,192,198,There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs).,15266215_1,-1,-1,-1,4540,-1,0.99766564,0.0023344164
4541,valdecoxib,6,7,43,53,"We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.",15266215_2,-1,-1,-1,4541,-1,0.99915445,0.00084560155
4542,osteoarthritis,17,18,122,136,"We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.",15266215_2,-1,-1,-1,4542,-1,0.0015582266,0.99844176
4546,valdecoxib,23,24,160,170,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4546,-1,0.9992386,0.00076136715
4547,mg,28,29,178,180,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4547,-1,0.99397534,0.0060246554
4548,NSAID,33,34,202,207,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4548,-1,0.9989624,0.0010375927
4550,mg,37,38,223,225,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4550,-1,0.9932532,0.006746878
4552,mg,42,43,245,247,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4552,-1,0.98887295,0.011127102
4553,naproxen,46,47,256,264,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4553,-1,0.9992281,0.0007718443
4554,mg,48,49,269,271,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4554,-1,0.9863452,0.013654871
4555,osteoarthritis,57,58,313,327,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4555,-1,0.0019838032,0.99801624
4557,n,11,12,63,64,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,-1,-1,-1,4557,-1,0.08151887,0.9184812
4558,mg,25,26,109,111,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,-1,-1,-1,4558,-1,0.9956625,0.004337544
4560,n,30,31,128,129,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,-1,-1,-1,4560,-1,0.0774431,0.92255694
4562,n,39,40,163,164,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,-1,-1,-1,4562,-1,0.067261204,0.93273884
4563,thrombotic events,5,7,42,59,"Crude and exposure-adjusted incidences of thrombotic events were similar for valdecoxib, NSAIDs, and placebo.",15266215_5,-1,-1,-1,4563,-1,0.0013619782,0.998638
4564,valdecoxib,10,11,77,87,"Crude and exposure-adjusted incidences of thrombotic events were similar for valdecoxib, NSAIDs, and placebo.",15266215_5,-1,-1,-1,4564,-1,0.9990564,0.0009435634
4565,NSAIDs,12,13,89,95,"Crude and exposure-adjusted incidences of thrombotic events were similar for valdecoxib, NSAIDs, and placebo.",15266215_5,-1,-1,-1,4565,-1,0.9988366,0.0011634202
4566,thrombotic events,4,6,20,37,The risk of serious thrombotic events was also similar for each valdecoxib dose.,15266215_6,-1,-1,-1,4566,-1,0.0014313979,0.99856853
4567,valdecoxib,11,12,64,74,The risk of serious thrombotic events was also similar for each valdecoxib dose.,15266215_6,-1,-1,-1,4567,-1,0.999059,0.0009410211
4571,valdecoxib,23,24,115,125,"Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).",15266215_7,-1,-1,-1,4571,-1,0.9990578,0.00094219175
4572,NSAIDs,31,32,142,148,"Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).",15266215_7,-1,-1,-1,4572,-1,0.99882895,0.0011710979
4574,valdecoxib,17,18,91,101,The rates of events in users of aspirin were similar for all 3 treatment groups and across valdecoxib doses.,15266215_8,-1,-1,-1,4574,-1,0.9991629,0.0008370995
4575,mg,10,11,66,68,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4575,-1,0.9934655,0.006534502
4576,mg,19,20,107,109,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4576,-1,0.9921928,0.007807197
4577,valdecoxib,22,23,117,127,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4577,-1,0.9992242,0.0007758601
4578,thrombotic events,32,34,184,201,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4578,-1,0.0013044724,0.99869555
4579,NSAIDs,37,38,227,233,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4579,-1,0.99905664,0.0009434184
4580,osteoarthritis,41,42,248,262,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4580,-1,0.001767628,0.9982324
4582,Hypersensitivity myocarditis,0,2,0,28,Hypersensitivity myocarditis complicating hypertrophic cardiomyopathy heart.,15266362_0,-1,-1,-1,4582,-1,0.0015300012,0.99847
4583,hypertrophic cardiomyopathy,3,5,42,69,Hypersensitivity myocarditis complicating hypertrophic cardiomyopathy heart.,15266362_0,-1,-1,-1,4583,-1,0.0016208044,0.99837923
4584,eosinophilic myocarditis,7,9,39,63,The present report describes a case of eosinophilic myocarditis complicating hypertrophic cardiomyopathy.,15266362_1,-1,-1,-1,4584,-1,0.0011765234,0.99882346
4585,hypertrophic cardiomyopathy,10,12,77,104,The present report describes a case of eosinophilic myocarditis complicating hypertrophic cardiomyopathy.,15266362_1,-1,-1,-1,4585,-1,0.0012652098,0.9987348
4586,hypertrophic cardiomyopathy,8,10,46,73,"The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.",15266362_2,-1,-1,-1,4586,-1,0.0013591794,0.99864084
4587,biventricular failure,14,16,93,114,"The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.",15266362_2,-1,-1,-1,4587,-1,0.0016776418,0.9983223
4589,left ventricular dysfunction,7,10,50,78,"On transthoracic echocardiogram, she had moderate left ventricular dysfunction with regional variability and moderate mitral regurgitation.",15266362_3,-1,-1,-1,4589,-1,0.002681682,0.9973183
4591,hypertrophic cardiomyopathy,9,11,52,79,The recipient's heart showed the features of apical hypertrophic cardiomyopathy and myocarditis with abundant eosinophils.,15266362_4,-1,-1,-1,4591,-1,0.0013454739,0.9986545
4594,eosinophilic myocarditis,4,6,24,48,Myocarditis is rare and eosinophilic myocarditis is rarer.,15266362_5,-1,-1,-1,4594,-1,0.0015962063,0.99840385
4596,eosinophilic,7,8,40,52,It is likely that the hypersensitivity (eosinophilic) myocarditis was related to dobutamine infusion therapy.,15266362_6,-1,-1,-1,4596,-1,0.0015959739,0.9984041
4599,Eosinophilic myocarditis,0,2,0,24,Eosinophilic myocarditis has been reported with an incidence of 2.4% to 7.2% in explanted hearts and may be related to multidrug therapy.,15266362_7,-1,-1,-1,4599,-1,0.0010920417,0.9989079
4603,Idiopathic subjective tinnitus,0,3,0,30,Idiopathic subjective tinnitus (IST) is one of the most obscure otological pathologies.,1527456_1,-1,-1,-1,4603,-1,0.0015257341,0.9984743
4604,IST,4,5,32,35,Idiopathic subjective tinnitus (IST) is one of the most obscure otological pathologies.,1527456_1,-1,-1,-1,4604,-1,0.0016572326,0.99834275
4605,IST,7,8,44,47,"This paper presents the results of treating IST by intratympanic instillation of lignocaine (lidocaine) 2 per cent through a grommet, for five weekly courses.",1527456_2,-1,-1,-1,4605,-1,0.0028181002,0.9971819
4611,vertigo,9,10,52,59,"Patients should be warned about the side effects of vertigo and vomiting, which subsides gradually with every new instillation, and that the tinnitus may not disappear but will be alleviated, enabling them to cope more easily with the disease and lead a more normal life.",1527456_6,-1,-1,-1,4611,-1,0.0017104187,0.9982895
4614,lead,43,44,247,251,"Patients should be warned about the side effects of vertigo and vomiting, which subsides gradually with every new instillation, and that the tinnitus may not disappear but will be alleviated, enabling them to cope more easily with the disease and lead a more normal life.",1527456_6,-1,-1,-1,4614,-1,0.103836685,0.8961633
4617,hypolocomotion,14,15,111,125,The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice.,15275829_0,-1,-1,-1,4617,-1,0.0016810186,0.998319
4624,hypolocomotion,12,13,76,90,We examined the role of the beta4 subunits in nicotine-induced seizures and hypolocomotion in beta4 homozygous null (beta4 -/-) and alpha3 heterozygous (+/-) mice.,15275829_4,-1,-1,-1,4624,-1,0.0016480536,0.99835193
4629,hypolocomotion,18,19,118,132,"Together, these results suggest that the beta4 and the alpha3 subunits are mediators of nicotine-induced seizures and hypolocomotion.",15275829_9,-1,-1,-1,4629,-1,0.0018635242,0.9981364
4632,intracranial bleeding,7,9,42,63,"The proportion of patients with major and intracranial bleeding increased from 20.2% and 1.9%, respectively, in the first time period, to 33.3% and 7.8%, respectively, in the second.",15276120_2,-1,-1,-1,4632,-1,0.0016057106,0.9983943
4638,SD,7,8,35,37,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,-1,-1,-1,4638,-1,0.19862376,0.8013763
4639,mg,14,15,56,58,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,-1,-1,-1,4639,-1,0.96157986,0.03842018
4641,mg,34,35,155,157,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,-1,-1,-1,4641,-1,0.96931636,0.030683657
4643,mg,9,10,37,39,"However, the threshold (61.6 +/- 8.7 mg. l(-1)) during 1.6% sevoflurane was not significant from that during 0.8% sevoflurane, indicating a celling effect.",15278670_3,-1,-1,-1,4643,-1,0.88207793,0.117922045
4655,Apamin,0,1,0,6,"Apamin, a selective blocker of calcium-dependent potassium channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects.",15278670_7,-1,-1,-1,4655,-1,0.9992835,0.0007165437
4658,Apamin,0,1,0,6,Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant.,15278670_8,-1,-1,-1,4658,-1,0.9992384,0.00076161535
4659,ng,3,4,11,13,Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant.,15278670_8,-1,-1,-1,4659,-1,0.96520644,0.03479357
4661,mg,23,24,97,99,Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant.,15278670_8,-1,-1,-1,4661,-1,0.9696,0.030399939
4664,lidocaine toxicity,10,12,66,84,It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.,15278670_9,-1,-1,-1,4664,-1,0.27691656,0.72308344
4665,circulatory depression,18,20,114,136,It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.,15278670_9,-1,-1,-1,4665,-1,0.0011592208,0.99884075
4674,thiotepa,12,13,80,88,"STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.",15325671_3,-1,-1,-1,4674,-1,0.99921334,0.00078664103
4679,congestive heart failure,30,33,238,262,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,-1,-1,4679,-1,0.0012270849,0.9987729
4680,CHF,34,35,264,267,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,-1,-1,4680,-1,0.0013040284,0.998696
4683,diabetes mellitus,60,62,419,436,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,-1,-1,4683,-1,0.0021274176,0.9978726
4684,anthracyclines,66,67,451,465,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,-1,-1,4684,-1,0.9984968,0.0015032206
4685,CHF,15,16,71,74,RESULTS: Six of 61 women (10%) developed clinically reversible grade 3 CHF following infusional cyclophosphamide with a median percent decline in ejection fraction of 31%.,15325671_5,-1,-1,-1,4685,-1,0.001307528,0.99869245
4688,CHF,7,8,48,51,"Older age was significantly correlated with the CHF development; with median ages for the entire group and for patients developing CHF of 45 and 59, respectively.",15325671_7,-1,-1,-1,4688,-1,0.0013569284,0.9986431
4689,CHF,21,22,131,134,"Older age was significantly correlated with the CHF development; with median ages for the entire group and for patients developing CHF of 45 and 59, respectively.",15325671_7,-1,-1,-1,4689,-1,0.0013952558,0.9986047
4691,CHF,9,10,74,77,Routine EKG monitoring during infusional cyclophosphamide did not predict CHF development.,15325671_10,-1,-1,-1,4691,-1,0.0013629631,0.998637
4698,obstructive lung disease,10,13,64,88,To determine sensitivity we assessed tremor in 44 patients with obstructive lung disease after administration of cumulative doses of salbutamol.,15338796_5,-1,-1,-1,4698,-1,0.001462727,0.9985373
4707,P,14,15,75,76,Within healthy adults no age-dependency could be found (b = 0.262 mm/year; P = 0.72).,15338796_13,-1,-1,-1,4707,-1,0.17150523,0.8284947
4709,P,15,16,81,82,There was no agreement between the questionnaire and tremor severity (r = 0.093; P = 0.53).,15338796_14,-1,-1,-1,4709,-1,0.1414581,0.8585419
4710,Postural tremor,0,2,0,15,Postural tremor showed no significant difference between the first and third session (P = 0.07).,15338796_15,-1,-1,-1,4710,-1,0.001993479,0.9980065
4711,P,13,14,86,87,Postural tremor showed no significant difference between the first and third session (P = 0.07).,15338796_15,-1,-1,-1,4711,-1,0.15988538,0.8401146
4716,sexual side effects,3,6,23,42,Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers.,1535072_0,-1,-1,-1,4716,-1,0.0015169047,0.9984831
4719,male impotence,20,22,135,149,BACKGROUND: Preclinical and clinical studies suggest that yohimbine facilitates sexual behavior and may be helpful in the treatment of male impotence.,1535072_1,-1,-1,-1,4719,-1,0.0022839091,0.99771607
4721,sexual side effects,13,16,70,89,A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine.,1535072_2,-1,-1,-1,4721,-1,0.0019469341,0.9980531
4724,sexual side effects,9,12,54,73,This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_3,-1,-1,-1,4724,-1,0.001782752,0.99821717
4726,obsessive compulsive disorder,6,9,33,62,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,-1,-1,4726,-1,0.0014110317,0.998589
4727,trichotillomania,10,11,64,80,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,-1,-1,4727,-1,0.001749792,0.9982502
4728,anxiety,12,13,82,89,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,-1,-1,4728,-1,0.0014325761,0.99856734
4729,affective disorders,15,17,94,113,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,-1,-1,4729,-1,0.0012712446,0.9987287
4730,sexual side effects,19,22,127,146,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,-1,-1,4730,-1,0.0016168253,0.99838316
4737,excessive sweating,5,7,35,53,"Side effects of yohimbine included excessive sweating, increased anxiety, and a wound-up feeling in some patients.",1535072_9,-1,-1,-1,4737,-1,0.0017090931,0.99829096
4738,anxiety,9,10,65,72,"Side effects of yohimbine included excessive sweating, increased anxiety, and a wound-up feeling in some patients.",1535072_9,-1,-1,-1,4738,-1,0.0015531591,0.9984469
4740,sexual side effects,17,20,100,119,CONCLUSION: The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_10,-1,-1,-1,4740,-1,0.0017105743,0.9982894
4743,Hemorrhagic cystitis,0,2,0,20,Hemorrhagic cystitis complicating bone marrow transplantation.,1545575_0,-1,-1,-1,4743,-1,0.0012891165,0.9987109
4744,Hemorrhagic cystitis,0,2,0,20,Hemorrhagic cystitis is a potentially serious complication of high-dose cyclophosphamide therapy administered before bone marrow transplantation.,1545575_1,-1,-1,-1,4744,-1,0.0011712885,0.9988287
4748,hemorrhagic cystitis,30,32,202,222,"In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis.",1545575_3,-1,-1,-1,4748,-1,0.001151687,0.9988483
4749,hemorrhagic cystitis,11,13,68,88,"Of 97 patients who received standard prophylaxis, 4 had symptomatic hemorrhagic cystitis.",1545575_4,-1,-1,-1,4749,-1,0.0011392795,0.9988607
4750,contrast,1,2,3,11,"In contrast, two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks.",1545575_5,-1,-1,-1,4750,-1,0.025816293,0.9741837
4752,hemorrhagic cystitis,19,21,137,157,"In contrast, two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks.",1545575_5,-1,-1,-1,4752,-1,0.0011483085,0.99885166
4753,hemorrhagic cystitis,21,23,121,141,"Because of this suboptimal result, we resumed the use of bladder irrigation and forced hydration to minimize the risk of hemorrhagic cystitis.",1545575_6,-1,-1,-1,4753,-1,0.0012124365,0.9987876
4754,raloxifene,6,7,43,53,Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.,15458908_0,-1,-1,-1,4754,-1,0.9992192,0.00078085175
4755,raloxifene,11,12,76,86,Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.,15458908_0,-1,-1,-1,4755,-1,0.9992046,0.00079548283
4756,raloxifene,7,8,36,46,OBJECTIVE: To examine the effect of raloxifene on major adverse events that occur with postmenopausal estrogen therapy or tamoxifen.,15458908_1,-1,-1,-1,4756,-1,0.9992299,0.00077011413
4759,Raloxifene,6,7,34,44,"METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with osteoporosis.",15458908_2,-1,-1,-1,4759,-1,0.9992016,0.0007984778
4761,raloxifene,5,6,32,42,Women were randomly assigned to raloxifene 60 mg/d or 120 mg/d or placebo.,15458908_3,-1,-1,-1,4761,-1,0.999223,0.00077702315
4762,venous thromboembolism,2,4,18,40,"Outcomes included venous thromboembolism, cataracts, gallbladder disease, and endometrial hyperplasia or cancer.",15458908_4,-1,-1,-1,4762,-1,0.0014752586,0.9985247
4765,endometrial hyperplasia,11,13,78,101,"Outcomes included venous thromboembolism, cataracts, gallbladder disease, and endometrial hyperplasia or cancer.",15458908_4,-1,-1,-1,4765,-1,0.0018838949,0.99811614
4767,raloxifene,10,11,47,57,"RESULTS: During a mean follow-up of 3.3 years, raloxifene was associated with an increased risk for venous thromboembolism (relative risk [RR] 2.1; 95% confidence interval [CI] 1.2-3.8).",15458908_5,-1,-1,-1,4767,-1,0.9992322,0.0007678088
4768,venous thromboembolism,18,20,100,122,"RESULTS: During a mean follow-up of 3.3 years, raloxifene was associated with an increased risk for venous thromboembolism (relative risk [RR] 2.1; 95% confidence interval [CI] 1.2-3.8).",15458908_5,-1,-1,-1,4768,-1,0.0014228325,0.9985771
4769,raloxifene,3,4,12,22,"Risk in the raloxifene group was higher than in the placebo group for the first 2 years, but decreased to about the same rate as in the placebo group thereafter.",15458908_7,-1,-1,-1,4769,-1,0.99923253,0.0007674504
4770,Raloxifene,0,1,0,10,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,-1,-1,-1,4770,-1,0.9992255,0.00077452115
4773,endometrial hyperplasia,33,35,119,142,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,-1,-1,-1,4773,-1,0.0020458077,0.99795413
4775,Raloxifene,2,3,12,22,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,-1,-1,-1,4775,-1,0.9992366,0.00076339307
4776,venous thromboembolism,10,12,65,87,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,-1,-1,-1,4776,-1,0.0012509683,0.998749
4779,endometrial hyperplasia,25,27,157,180,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,-1,-1,-1,4779,-1,0.0018180348,0.99818194
4783,lead,45,46,264,268,"While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate carbidopa-levodopa to the point of ""normality,"" which can lead to toxicity.",1549199_1,-1,-1,-1,4783,-1,0.011036296,0.9889637
4785,dopamine agonist,24,26,160,176,"Following the initial period of therapy, emerging difficulties require a reassessment of therapeutic approaches, such as dosage adjustment or introduction of a dopamine agonist.",1549199_3,-1,-1,-1,4785,-1,0.99900097,0.0009990404
4786,gastrointestinal disorders,7,9,40,66,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,-1,-1,-1,4786,-1,0.0014178636,0.9985821
4788,psychosis,14,15,110,119,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,-1,-1,-1,4788,-1,0.0012308822,0.9987691
4789,sleep disturbances,16,18,121,139,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,-1,-1,-1,4789,-1,0.0014423543,0.9985576
4790,parasomnias,19,20,143,154,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,-1,-1,-1,4790,-1,0.0014768146,0.9985232
4791,Parkinson's disease,5,8,39,58,"Nonpharmacologic concerns can help the Parkinson's disease patient achieve and maintain optimal functioning, including daily exercise, physical therapy, and involvement with support groups.",1549199_5,-1,-1,-1,4791,-1,0.0026954855,0.99730456
4792,hearing loss,18,20,103,115,OBJECTIVE: The objective of this study was to identify the incidence and to monitor the progression of hearing loss in children and young adults with beta-thalassemia major.,15515654_1,-1,-1,-1,4792,-1,0.0022920987,0.99770784
4794,DFO,5,6,41,44,"Subjects were receiving desferrioxamine (DFO) chelation treatment with a mean daily dose of 50-60 mg/kg, 5-6 days a week during the first six years of the study, which was then reduced to 40-50 mg/kg for the following eight years.",15515654_4,-1,-1,-1,4794,-1,0.9989242,0.0010757764
4796,SNHL,21,22,107,111,"RESULTS: Overall, 21 out of 104 patients (20.2%) presented with high frequency sensorineural hearing loss (SNHL), either unilateral or bilateral.",15515654_6,-1,-1,-1,4796,-1,0.0021246234,0.99787533
4797,ototoxic,1,2,3,11,"No ototoxic factor, other than DFO, was present in any of the patients.",15515654_7,-1,-1,-1,4797,-1,0.0021637978,0.9978362
4798,DFO,6,7,31,34,"No ototoxic factor, other than DFO, was present in any of the patients.",15515654_7,-1,-1,-1,4798,-1,0.5450078,0.4549922
4799,SNHL,2,3,14,18,"Patients with SNHL presented with relatively lower serum ferritin levels than those with normal hearing, however, no statistically significant difference was observed.",15515654_8,-1,-1,-1,4799,-1,0.0027510982,0.9972488
4800,SNHL,2,3,14,18,Subjects with SNHL were submitted to DFO reduction or temporary withdrawal.,15515654_9,-1,-1,-1,4800,-1,0.002170647,0.9978294
4801,DFO,6,7,37,40,Subjects with SNHL were submitted to DFO reduction or temporary withdrawal.,15515654_9,-1,-1,-1,4801,-1,0.9938226,0.0061774263
4802,DFO,7,8,43,46,CONCLUSION: The findings are indicative of DFO's contributing role in the development of hearing impairment.,15515654_11,-1,-1,-1,4802,-1,0.006154459,0.9938455
4803,hearing impairment,15,17,89,107,CONCLUSION: The findings are indicative of DFO's contributing role in the development of hearing impairment.,15515654_11,-1,-1,-1,4803,-1,0.0019709708,0.99802905
4804,thalassemic,7,8,51,62,Regular audiologic evaluation is imperative in all thalassemic patients so that early changes may be recognized and treatment may be judiciously adjusted in order to prevent or reverse hearing impairment.,15515654_12,-1,-1,-1,4804,-1,0.0038014234,0.9961986
4805,hearing impairment,28,30,185,203,Regular audiologic evaluation is imperative in all thalassemic patients so that early changes may be recognized and treatment may be judiciously adjusted in order to prevent or reverse hearing impairment.,15515654_12,-1,-1,-1,4805,-1,0.0018060326,0.9981939
4807,autoimmune diseases,14,16,124,143,"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.",15517007_0,-1,-1,-1,4807,-1,0.001448189,0.9985518
4808,systemic sclerosis,21,23,171,189,"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.",15517007_0,-1,-1,-1,4808,-1,0.0017882712,0.99821174
4809,multiple sclerosis,24,26,194,212,"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.",15517007_0,-1,-1,-1,4809,-1,0.0018681652,0.9981318
4810,autoimmune diseases,17,19,128,147,Autologous haematopoietic stem cell transplantation is now a feasible and effective treatment for selected patients with severe autoimmune diseases.,15517007_1,-1,-1,-1,4810,-1,0.0013251473,0.99867487
4815,anthracyclines,8,9,54,68,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,-1,-1,-1,4815,-1,0.99849236,0.001507597
4817,heart damage,20,22,138,150,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,-1,-1,-1,4817,-1,0.0015996266,0.9984004
4818,systemic sclerosis,26,28,165,183,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,-1,-1,-1,4818,-1,0.0019919807,0.9980081
4819,autoimmune disease,25,27,144,162,"The object of the meeting was to analyse existing data, both published or available, in the European Group for Blood and Marrow Transplantation autoimmune disease database, and to propose a safe approach to such patients.",15517007_9,-1,-1,-1,4819,-1,0.002068971,0.997931
4820,vitamin C,2,4,18,27,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,-1,-1,-1,4820,-1,0.99861896,0.0013809943
4821,cardiovascular disease,5,7,37,59,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,-1,-1,-1,4821,-1,0.0017517019,0.99824834
4822,diabetes?BACKGROUND,11,12,79,98,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,-1,-1,-1,4822,-1,0.00926136,0.99073863
4823,Vitamin C,13,15,100,109,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,-1,-1,-1,4823,-1,0.9986634,0.0013365573
4824,vitamin C,11,13,63,72,These observations led us to hypothesize that a high intake of vitamin C in diabetic persons might promote atherosclerosis.,15531665_1,-1,-1,-1,4824,-1,0.99830914,0.0016909112
4827,vitamin C,10,12,61,70,OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease.,15531665_2,-1,-1,-1,4827,-1,0.99857247,0.0014274911
4828,cardiovascular disease,16,18,97,119,OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease.,15531665_2,-1,-1,-1,4828,-1,0.0016018288,0.9983981
4829,vitamin C,7,9,40,49,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4829,-1,0.9985989,0.0014011106
4830,cardiovascular disease,14,16,82,104,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4830,-1,0.0017442005,0.9982558
4831,n,17,18,106,107,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4831,-1,0.014982109,0.98501784
4832,coronary artery disease,22,25,116,139,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4832,-1,0.0020457725,0.99795425
4833,n,26,27,141,142,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4833,-1,0.014325304,0.9856747
4835,n,34,35,163,164,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4835,-1,0.011255382,0.9887446
4837,coronary artery disease,15,18,98,121,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4837,-1,0.0016699592,0.99833006
4838,cardiovascular disease,29,31,190,212,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4838,-1,0.001990653,0.9980094
4841,folate,47,48,298,304,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4841,-1,0.9985996,0.0014004717
4842,vitamin E,49,51,306,315,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4842,-1,0.99821943,0.0017805796
4843,cardiovascular disease,61,63,373,395,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4843,-1,0.0018437947,0.99815625
4844,P,76,77,444,445,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4844,-1,0.3892555,0.6107445
4845,vitamin C,86,88,490,499,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4845,-1,0.99799347,0.0020065363
4846,coronary artery disease,4,7,27,50,"Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).",15531665_5,-1,-1,-1,4846,-1,0.0021199319,0.9978801
4847,P,19,20,89,90,"Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).",15531665_5,-1,-1,-1,4847,-1,0.3810465,0.61895347
4849,P,40,41,161,162,"Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).",15531665_5,-1,-1,-1,4849,-1,0.3748393,0.62516075
4850,vitamin C,4,6,30,39,"When dietary and supplemental vitamin C were analyzed separately, only supplemental vitamin C showed a positive association with mortality endpoints.",15531665_6,-1,-1,-1,4850,-1,0.9984334,0.0015665928
4851,vitamin C,12,14,84,93,"When dietary and supplemental vitamin C were analyzed separately, only supplemental vitamin C showed a positive association with mortality endpoints.",15531665_6,-1,-1,-1,4851,-1,0.9984629,0.0015371017
4852,Vitamin C,0,2,0,9,Vitamin C intake was unrelated to mortality from cardiovascular disease in the nondiabetic subjects at baseline.,15531665_7,-1,-1,-1,4852,-1,0.9987005,0.0012995042
4853,cardiovascular disease,8,10,49,71,Vitamin C intake was unrelated to mortality from cardiovascular disease in the nondiabetic subjects at baseline.,15531665_7,-1,-1,-1,4853,-1,0.0013355763,0.9986644
4854,vitamin C,4,6,19,28,CONCLUSION: A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes.,15531665_8,-1,-1,-1,4854,-1,0.9984749,0.0015250592
4855,cardiovascular disease,16,18,93,115,CONCLUSION: A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes.,15531665_8,-1,-1,-1,4855,-1,0.0015796189,0.99842036
4857,optic neuropathy,11,13,89,105,Optical coherence tomography can measure axonal loss in patients with ethambutol-induced optic neuropathy.,15565293_0,-1,-1,-1,4857,-1,0.0012652556,0.9987348
4858,map,3,4,12,15,"PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).",15565293_1,-1,-1,-1,4858,-1,0.05265065,0.94734937
4859,axonal degeneration,13,15,54,73,"PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).",15565293_1,-1,-1,-1,4859,-1,0.0014790749,0.9985209
4860,optic neuropathy,17,19,96,112,"PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).",15565293_1,-1,-1,-1,4860,-1,0.0014255972,0.9985744
4861,OCT,24,25,149,152,"PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).",15565293_1,-1,-1,-1,4861,-1,0.42946398,0.570536
4862,Ethambutol,0,1,0,10,Ethambutol is an antimycobacterial agent often used to treat tuberculosis.,15565293_2,-1,-1,-1,4862,-1,0.9987669,0.0012331419
4864,ethambutol,4,5,26,36,"A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.",15565293_3,-1,-1,-1,4864,-1,0.9989309,0.0010691569
4865,optic neuropathy,7,9,43,59,"A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.",15565293_3,-1,-1,-1,4865,-1,0.001358907,0.9986411
4866,contrast,14,15,88,96,"A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.",15565293_3,-1,-1,-1,4866,-1,0.99256283,0.0074372
4867,toxic optic neuropathy,7,10,28,50,"However, early on, when the toxic optic neuropathy is mild and partly reversible, the funduscopic findings are often subtle and easy to miss.",15565293_4,-1,-1,-1,4867,-1,0.0014291683,0.9985708
4868,ethambutol,8,9,42,52,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,-1,-1,4868,-1,0.9990507,0.00094931753
4869,optic neuropathy,10,12,67,83,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,-1,-1,4869,-1,0.001282455,0.99871755
4870,visual deficits,19,21,124,139,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,-1,-1,4870,-1,0.0019860477,0.998014
4871,contrast,34,35,237,245,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,-1,-1,4871,-1,0.99444985,0.0055501168
4872,OCT,3,4,13,16,"In addition, OCT (OCT 3000, Humphrey-Zeiss, Dublin, CA) was performed on both eyes of each subject using the retinal nerve fiber layer (RNFL) analysis protocol.",15565293_6,-1,-1,-1,4872,-1,0.501356,0.498644
4873,OCT,5,6,18,21,"In addition, OCT (OCT 3000, Humphrey-Zeiss, Dublin, CA) was performed on both eyes of each subject using the retinal nerve fiber layer (RNFL) analysis protocol.",15565293_6,-1,-1,-1,4873,-1,0.6457324,0.35426754
4874,OCT,0,1,0,3,OCT interpolates data from 100 points around the optic nerve to effectively map out the RNFL.,15565293_7,-1,-1,-1,4874,-1,0.5169599,0.48304006
4875,OCT,20,21,123,126,"RESULTS: The results were compared to the calculated average RNFL of normal eyes accumulated from four prior studies using OCT, n=661.",15565293_8,-1,-1,-1,4875,-1,0.87219244,0.12780759
4876,n=661,22,23,128,133,"RESULTS: The results were compared to the calculated average RNFL of normal eyes accumulated from four prior studies using OCT, n=661.",15565293_8,-1,-1,-1,4876,-1,0.19588175,0.8041182
4877,optic neuropathy,7,9,44,60,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,-1,-1,-1,4877,-1,0.0012815295,0.9987185
4878,visual deficits,48,50,247,262,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,-1,-1,-1,4878,-1,0.0024128077,0.9975872
4879,visual deficits,60,62,298,313,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,-1,-1,-1,4879,-1,0.0021393897,0.9978606
4880,visual deficits,13,15,60,75,"In both sets (four) of eyes of the subjects with persistent visual deficits (patients B and C), there was an average loss of 79% of nerve fiber thickness in the temporal quadrant.",15565293_11,-1,-1,-1,4880,-1,0.0019826668,0.9980173
4881,OCT,3,4,17,20,CONCLUSIONS: The OCT results in these patients with EMB-induced optic neuropathy show considerable loss especially of the temporal fibers.,15565293_12,-1,-1,-1,4881,-1,0.55185395,0.44814608
4882,optic neuropathy,10,12,64,80,CONCLUSIONS: The OCT results in these patients with EMB-induced optic neuropathy show considerable loss especially of the temporal fibers.,15565293_12,-1,-1,-1,4882,-1,0.0013307096,0.99866927
4883,optic neuropathies,27,29,189,207,This is consistent with prior histopathological studies that show predominant loss of parvo-cellular axons (or small-caliber axons) within the papillo-macular bundle in toxic or hereditary optic neuropathies.,15565293_13,-1,-1,-1,4883,-1,0.0015544508,0.9984456
4884,OCT,0,1,0,3,OCT can be a valuable tool in the quantitative analysis of optic neuropathies.,15565293_14,-1,-1,-1,4884,-1,0.21115744,0.7888425
4885,optic neuropathies,11,13,59,77,OCT can be a valuable tool in the quantitative analysis of optic neuropathies.,15565293_14,-1,-1,-1,4885,-1,0.0015365231,0.9984635
4886,optic neuropathy,8,10,52,68,"Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.",15565293_15,-1,-1,-1,4886,-1,0.0012149983,0.99878496
4887,ethambutol,17,18,105,115,"Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.",15565293_15,-1,-1,-1,4887,-1,0.99909973,0.00090032234
4888,renal impairment,22,24,140,156,"Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.",15565293_15,-1,-1,-1,4888,-1,0.0015703645,0.9984296
4894,n,19,20,96,97,"After 1 week of recovery, proteinuria was induced by adriamycin [1.5 mg/kg intravenously (i.v.) n = 18; controls, saline i.v.",15572383_5,-1,-1,-1,4894,-1,0.1387533,0.86124665
4895,n,0,1,0,1,n = 9].,15572383_6,-1,-1,-1,4895,-1,0.123395376,0.8766046
4900,renal interstitial damage,11,14,74,99,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,-1,-1,-1,4900,-1,0.0014006704,0.99859935
4901,focal glomerulosclerosis,16,18,109,133,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,-1,-1,-1,4901,-1,0.0013401014,0.99865985
4904,focal glomerulosclerosis,7,9,42,66,"Baseline renal ACE did not correlate with focal glomerulosclerosis (r = 0.22, NS).",15572383_11,-1,-1,-1,4904,-1,0.0015077378,0.99849224
4905,NS,14,15,78,80,"Baseline renal ACE did not correlate with focal glomerulosclerosis (r = 0.22, NS).",15572383_11,-1,-1,-1,4905,-1,0.028452272,0.97154766
4909,renal disease,2,4,11,24,Hypoxia in renal disease with proteinuria and/or glomerular hypertension.,15579441_0,-1,-1,-1,4909,-1,0.0016702325,0.9983298
4911,glomerular hypertension,7,9,49,72,Hypoxia in renal disease with proteinuria and/or glomerular hypertension.,15579441_0,-1,-1,-1,4911,-1,0.0014696863,0.99853027
4913,diseased kidney,14,16,88,103,We then applied this animal model to the detection of tubulointerstitial hypoxia in the diseased kidney.,15579441_3,-1,-1,-1,4913,-1,0.0030416066,0.9969584
4915,nephrotic syndrome,16,18,108,126,"With this model, we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.",15579441_4,-1,-1,-1,4915,-1,0.0011831761,0.99881685
4917,puromycin aminonucleoside,18,20,128,153,"Expression of the hypoxia-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the puromycin aminonucleoside model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.",15579441_5,-1,-1,-1,4917,-1,0.9989774,0.0010226371
4919,tubulointerstitial injury,10,12,69,94,The degree of hypoxia showed a positive correlation with microscopic tubulointerstitial injury in both models.,15579441_6,-1,-1,-1,4919,-1,0.0017233782,0.9982766
4920,dUTP,16,17,116,120,"Finally, we identified the localization of proliferating cell nuclear antigen-positive, ED-1-positive, and terminal dUTP nick-end labeled-positive cells in the hypoxic cortical area in the remnant kidney model.",15579441_7,-1,-1,-1,4920,-1,0.99747247,0.002527524
4921,hypoxic,22,23,160,167,"Finally, we identified the localization of proliferating cell nuclear antigen-positive, ED-1-positive, and terminal dUTP nick-end labeled-positive cells in the hypoxic cortical area in the remnant kidney model.",15579441_7,-1,-1,-1,4921,-1,0.003940459,0.99605954
4923,progressive glomerular diseases,12,15,91,122,We propose here a possible pathological tie between chronic tubulointerstitial hypoxia and progressive glomerular diseases.,15579441_8,-1,-1,-1,4923,-1,0.0015015168,0.99849844
4926,interferon,13,14,96,106,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,-1,-1,-1,4926,-1,0.9989936,0.0010064438
4928,chronic hepatitis C.BACKGROUND,17,20,125,155,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,-1,-1,-1,4928,-1,0.005143216,0.99485683
4930,interferon,35,36,239,249,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,-1,-1,-1,4930,-1,0.9990095,0.0009904522
4937,mg,14,15,72,74,"After that, these 37 patients were reduced one tablet of ribavirin (200 mg) per day.",15580403_4,-1,-1,-1,4937,-1,0.989556,0.010443953
4941,P,26,27,96,97,"A 34.4% (12/27) of SVR + biological response in group A was higher than 10% (1/10) in group B ( P = 0.051), with slight significance.",15580403_8,-1,-1,-1,4941,-1,0.28692377,0.7130763
4943,P,38,39,194,195,"With respect to hemoglobin level at the time of ribavirin reduction, a rate of continuation of therapy in patients with > or =10 g/dl hemoglobin was higher than that in patients with <10 g/dl ( P = 0.036).",15580403_9,-1,-1,-1,4943,-1,0.30576712,0.6942329
4948,corticosteroid,17,18,97,111,"The second episode was more severe than the first; and although both were treated with intensive corticosteroid therapy, renal function remained impaired.",15602202_2,-1,-1,-1,4948,-1,0.9987858,0.0012142024
4949,renal function,20,22,121,135,"The second episode was more severe than the first; and although both were treated with intensive corticosteroid therapy, renal function remained impaired.",15602202_2,-1,-1,-1,4949,-1,0.008821919,0.9911781
4950,impaired,23,24,145,153,"The second episode was more severe than the first; and although both were treated with intensive corticosteroid therapy, renal function remained impaired.",15602202_2,-1,-1,-1,4950,-1,0.0029351388,0.9970649
4953,renal insufficiency,1,3,23,42,Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.,15632880_0,-1,-1,-1,4953,-1,0.001303171,0.99869686
4955,heart failure,8,10,77,90,Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.,15632880_0,-1,-1,-1,4955,-1,0.00136102,0.9986389
4957,heart failure,13,15,91,104,BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).,15632880_1,-1,-1,-1,4957,-1,0.0016978565,0.9983021
4959,renal insufficiency,27,29,159,178,BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).,15632880_1,-1,-1,-1,4959,-1,0.0015368222,0.99846315
4960,heart failure,3,5,23,36,"Because treatments for heart failure have changed since the benefits of spironolactone were reported, the prevalence of these complications may differ in current clinical practice.",15632880_2,-1,-1,-1,4960,-1,0.001372585,0.9986274
4963,renal insufficiency,13,15,94,113,We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone.,15632880_3,-1,-1,-1,4963,-1,0.0013882245,0.9986118
4964,heart failure,16,18,117,130,We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone.,15632880_3,-1,-1,-1,4964,-1,0.0016769997,0.998323
4966,heart failure,9,11,46,59,METHODS: We performed a case control study of heart failure patients treated with spironolactone in our clinical practice.,15632880_4,-1,-1,-1,4966,-1,0.0018333104,0.9981667
4969,renal insufficiency,14,16,68,87,"Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.",15632880_5,-1,-1,-1,4969,-1,0.0016522824,0.99834776
4970,Cr,17,18,89,91,"Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.",15632880_5,-1,-1,-1,4970,-1,0.0034299525,0.99657
4973,n,18,19,108,109,RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34).,15632880_7,-1,-1,-1,4973,-1,0.007955467,0.99204457
4974,renal failure,23,25,119,132,RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34).,15632880_7,-1,-1,-1,4974,-1,0.0015543376,0.9984457
4975,n,26,27,134,135,RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34).,15632880_7,-1,-1,-1,4975,-1,0.008849425,0.9911506
4980,n,38,39,240,241,"Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134).",15632880_8,-1,-1,-1,4980,-1,0.16530448,0.8346955
4981,renal insufficiency,3,5,23,42,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,-1,-1,-1,4981,-1,0.0016167901,0.99838316
4982,body weight,8,10,62,73,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,-1,-1,-1,4982,-1,0.065437354,0.9345626
4984,thiazide,31,32,193,201,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,-1,-1,-1,4984,-1,0.99911827,0.00088178134
4986,renal insufficiency,5,7,53,72,CONCLUSIONS: Spironolactone-induced hyperkalemia and renal insufficiency are more common in our clinical experience than reported previously.,15632880_10,-1,-1,-1,4986,-1,0.0012466802,0.9987533
4991,HAL,17,18,97,100,"The aim of the study was to examine the influence of hyperprolactinemia, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.",15638391_1,-1,-1,-1,4991,-1,0.99898785,0.0010120806
4992,PRL,5,6,35,38,Serum concentrations of prolactin (PRL) and testosterone (T) were measured.,15638391_3,-1,-1,-1,4992,-1,0.9971819,0.0028180813
4994,PRL,12,13,62,65,"In rats of the experimental group, the mean concentration of: PRL was more than twice higher, whereas T concentration was almost twice lower than that in the control group.",15638391_6,-1,-1,-1,4994,-1,0.99849296,0.0015070863
4996,hyperplasia,9,10,70,81,"Light microscopy visualized the following: hypertrophy and epithelium hyperplasia of the glandular ducts, associated with increased PCNA expression.",15638391_7,-1,-1,-1,4996,-1,0.0026868545,0.9973131
4997,contrast,7,8,55,63,Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis: correlation with thallium-201 single-photon emission tomography.,1564236_0,-1,-1,-1,4997,-1,0.95123297,0.048766986
4998,coronary stenosis,13,15,100,117,Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis: correlation with thallium-201 single-photon emission tomography.,1564236_0,-1,-1,-1,4998,-1,0.0018554882,0.9981445
4999,contrast,7,8,45,53,It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation.,1564236_1,-1,-1,-1,4999,-1,0.97258997,0.027409976
5000,coronary occlusion,21,23,161,179,It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation.,1564236_1,-1,-1,-1,5000,-1,0.0019815352,0.9980185
5001,coronary stenoses,26,28,196,213,It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation.,1564236_1,-1,-1,-1,5001,-1,0.0020547386,0.99794525
5002,hyperemic,32,33,233,242,It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation.,1564236_1,-1,-1,-1,5002,-1,0.0025336407,0.9974663
5003,contrast,10,11,58,66,The aim of this study was to determine whether myocardial contrast echocardiography performed with a stable solution of sonicated albumin could detect regions of myocardial underperfusion resulting from various degrees of coronary stenosis.,1564236_2,-1,-1,-1,5003,-1,0.6498725,0.35012752
5004,coronary stenosis,31,33,222,239,The aim of this study was to determine whether myocardial contrast echocardiography performed with a stable solution of sonicated albumin could detect regions of myocardial underperfusion resulting from various degrees of coronary stenosis.,1564236_2,-1,-1,-1,5004,-1,0.001953059,0.9980469
5005,coronary occlusion,6,8,26,44,"During a transient (20-s) coronary occlusion, a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced.",1564236_4,-1,-1,-1,5005,-1,0.002697991,0.99730194
5006,contrast,15,16,83,91,"During a transient (20-s) coronary occlusion, a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced.",1564236_4,-1,-1,-1,5006,-1,0.9963232,0.0036768422
5007,p,16,17,88,89,The perfusion defect correlated significantly with the anatomic area at risk (r = 0.74; p less than 0.002).,1564236_5,-1,-1,-1,5007,-1,0.40106985,0.5989301
5009,coronary stenosis,12,14,72,89,"During dipyridamole-induced hyperemia, 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography.",1564236_6,-1,-1,-1,5009,-1,0.0018065452,0.99819344
5010,contrast,21,22,129,137,"During dipyridamole-induced hyperemia, 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography.",1564236_6,-1,-1,-1,5010,-1,0.9981634,0.0018366432
5011,stenosis,9,10,47,55,The four dogs without a perfusion defect had a stenosis that resulted in a mild (0% to 50%) reduction in dipyridamole-induced hyperemia.,1564236_7,-1,-1,-1,5011,-1,0.0014389463,0.9985611
5013,stenosis,7,8,40,48,The size of the perfusion defect during stenosis correlated significantly with the anatomic area at risk (r = 0.61; p = 0.02).,1564236_8,-1,-1,-1,5013,-1,0.001840441,0.9981596
5014,p,21,22,116,117,The size of the perfusion defect during stenosis correlated significantly with the anatomic area at risk (r = 0.61; p = 0.02).,1564236_8,-1,-1,-1,5014,-1,0.4498626,0.5501374
5016,p,33,34,200,201,Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).,1564236_9,-1,-1,-1,5016,-1,0.44140503,0.55859494
5017,contrast,44,45,251,259,Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).,1564236_9,-1,-1,-1,5017,-1,0.9972466,0.0027533534
5018,p,51,52,288,289,Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).,1564236_9,-1,-1,-1,5018,-1,0.43628058,0.56371945
5019,contrast,3,4,17,25,"Thus, myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of coronary stenosis.",1564236_10,-1,-1,-1,5019,-1,0.98425746,0.015742533
5020,coronary stenosis,23,25,157,174,"Thus, myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of coronary stenosis.",1564236_10,-1,-1,-1,5020,-1,0.0020648718,0.9979352
5024,orofacial dyskinesia,13,15,108,128,Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.,15649445_0,-1,-1,-1,5024,-1,0.0015932021,0.9984068
5025,orofacial dyskinesia,3,5,35,55,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,-1,-1,-1,5025,-1,0.0012044918,0.9987955
5026,tardive dyskinesia,10,12,86,104,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,-1,-1,-1,5026,-1,0.0011887754,0.99881124
5027,TD,13,14,106,108,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,-1,-1,-1,5027,-1,0.0016056838,0.9983943
5028,orofacial dyskinesia,8,10,42,62,"In the present study, the authors induced orofacial dyskinesia by acute reserpine and subchronic haloperidol administration to rats.",15649445_2,-1,-1,-1,5028,-1,0.001460424,0.99853957
5038,orofacial diskinesia,16,18,103,123,"Importantly, a decrease in glutamate uptake correlates negatively with an increase in the incidence of orofacial diskinesia.",15649445_7,-1,-1,-1,5038,-1,0.0018906865,0.99810934
5041,spinal cord ischemia,23,26,174,194,The activation of spinal N-methyl-D-aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of spinal cord ischemia.,15673851_0,-1,-1,-1,5041,-1,0.0019556466,0.9980444
5042,NMDA,16,17,122,126,We investigated the relationship between the degeneration of spinal motor neurons and activation of N-methyl-d-aspartate (NMDA) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats.,15673851_1,-1,-1,-1,5042,-1,0.99887747,0.0011224701
5044,aortic occlusion,27,29,200,216,We investigated the relationship between the degeneration of spinal motor neurons and activation of N-methyl-d-aspartate (NMDA) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats.,15673851_1,-1,-1,-1,5044,-1,0.0044415807,0.9955584
5045,Spinal cord ischemia,0,3,0,20,Spinal cord ischemia was induced by aortic occlusion for 6 min with a balloon catheter.,15673851_2,-1,-1,-1,5045,-1,0.002354404,0.99764556
5046,aortic occlusion,6,8,36,52,Spinal cord ischemia was induced by aortic occlusion for 6 min with a balloon catheter.,15673851_2,-1,-1,-1,5046,-1,0.0055435915,0.9944564
5047,n,13,14,53,54,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,5047,-1,0.28467733,0.71532273
5049,n,25,26,92,93,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,5049,-1,0.31695232,0.6830477
5050,h,35,36,135,136,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,5050,-1,0.19831143,0.8016886
5052,n,48,49,185,186,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,5052,-1,0.26886025,0.7311398
5053,n,60,61,223,224,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,5053,-1,0.30677986,0.69322014
5054,h,67,68,250,251,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,5054,-1,0.23920894,0.760791
5055,h,22,23,98,99,"Microdialysis samples were collected preischemia, before IT injection, and at 2, 4, 8, 24, and 48 h of reperfusion (after IT injection).",15673851_4,-1,-1,-1,5055,-1,0.18370354,0.81629646
5056,MK-801,8,9,41,47,"Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after morphine-induced spastic paraparesis.",15673851_5,-1,-1,-1,5056,-1,0.99878746,0.0012125677
5057,spastic paraparesis,23,25,130,149,"Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after morphine-induced spastic paraparesis.",15673851_5,-1,-1,-1,5057,-1,0.0011270161,0.99887294
5060,P,25,26,137,138,"After IT morphine, the cerebrospinal fluid (CSF) glutamate concentration was increased in group M relative to both baseline and group C (P < 0.05).",15673851_6,-1,-1,-1,5060,-1,0.4806454,0.5193546
5061,MK-801,1,2,3,9,IT MK-801 significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group.,15673851_8,-1,-1,-1,5061,-1,0.9985222,0.00147775
5062,spastic paraparesis,11,13,100,119,IT MK-801 significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group.,15673851_8,-1,-1,-1,5062,-1,0.0011005627,0.99889946
5064,spastic paraparesis,7,9,45,64,"These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.",15673851_9,-1,-1,-1,5064,-1,0.001095783,0.9989042
5066,NMDA,21,22,132,136,"These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.",15673851_9,-1,-1,-1,5066,-1,0.9988165,0.001183503
5068,spinal cord ischemia,11,14,60,80,We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via NMDA receptor activation.,15673851_10,-1,-1,-1,5068,-1,0.0018114677,0.99818856
5069,NMDA,15,16,85,89,We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via NMDA receptor activation.,15673851_10,-1,-1,-1,5069,-1,0.9987708,0.0012291904
5070,low back pain,1,4,6,19,Acute low back pain during intravenous administration of amiodarone: a report of two cases.,15686794_0,-1,-1,-1,5070,-1,0.0014378477,0.99856216
5073,atrial fibrillation,10,12,89,108,Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.,15686794_1,-1,-1,-1,5073,-1,0.001810954,0.99818903
5074,AF,13,14,110,112,Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.,15686794_1,-1,-1,-1,5074,-1,0.0015663458,0.99843365
5075,atrial fibrillation,8,10,61,80,"We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.",15686794_2,-1,-1,-1,5075,-1,0.001892217,0.9981078
5076,low back pain,16,19,119,132,"We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.",15686794_2,-1,-1,-1,5076,-1,0.0015920239,0.998408
5078,biliary pseudolithiasis,1,3,23,46,Ceftriaxone-associated biliary pseudolithiasis in paediatric surgical patients.,15737522_0,-1,-1,-1,5078,-1,0.0013722569,0.9986278
5081,gallbladder dysfunction,9,11,71,94,"Clinical and experimental studies also suggest that situations causing gallbladder dysfunction, such as fasting, may have a role for the development of pseudolithiasis.",15737522_2,-1,-1,-1,5081,-1,0.0019864182,0.9980136
5089,psychosis,5,6,38,47,"Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia.",15764424_0,-1,-1,-1,5089,-1,0.0015040368,0.99849594
5091,hyperkinesia,14,15,102,114,"Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia.",15764424_0,-1,-1,-1,5091,-1,0.0012311953,0.99876875
5094,psychiatric emergency,20,22,135,156,"To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.",15764424_1,-1,-1,-1,5094,-1,0.0042802184,0.99571985
5095,psychosis,30,31,217,226,"To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.",15764424_1,-1,-1,-1,5095,-1,0.0014222431,0.9985777
5099,psychopathology,8,9,62,77,Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.,15764424_2,-1,-1,-1,5099,-1,0.0015381421,0.99846184
5100,hyperkinesia,13,14,100,112,Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.,15764424_2,-1,-1,-1,5100,-1,0.0013140162,0.998686
5101,HVA,0,1,0,3,HVA levels were related to global hyperkinesia but not to psychopathology ratings.,15764424_3,-1,-1,-1,5101,-1,0.99474865,0.005251289
5102,hyperkinesia,6,7,34,46,HVA levels were related to global hyperkinesia but not to psychopathology ratings.,15764424_3,-1,-1,-1,5102,-1,0.0012992666,0.99870074
5103,psychopathology,10,11,58,73,HVA levels were related to global hyperkinesia but not to psychopathology ratings.,15764424_3,-1,-1,-1,5103,-1,0.0016035633,0.99839646
5105,Coronary aneurysm,0,2,0,17,Coronary aneurysm after implantation of a paclitaxel-eluting stent.,15804801_0,-1,-1,-1,5105,-1,0.002214462,0.99778557
5106,coronary aneurysm,2,4,13,30,"Formation of coronary aneurysm is a rare complication of stenting with bare metal stents, but based on experimental studies drug-eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition, aneurysm formation and with the potential of stent thrombosis or vessel rupture.",15804801_1,-1,-1,-1,5106,-1,0.0022933052,0.99770665
5109,vessel rupture,45,47,287,301,"Formation of coronary aneurysm is a rare complication of stenting with bare metal stents, but based on experimental studies drug-eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition, aneurysm formation and with the potential of stent thrombosis or vessel rupture.",15804801_1,-1,-1,-1,5109,-1,0.0021445386,0.9978555
5110,coronary aneurysm,8,10,45,62,We present a 43-year-old man who developed a coronary aneurysm in the right coronary artery 6 months after receiving a paclitaxel-eluting stent.,15804801_2,-1,-1,-1,5110,-1,0.0020225076,0.99797755
5113,mm,24,25,162,164,Angiography and intracoronary ultrasound demonstrated lack of contact between stent and vessel wall in a 15-mm long segment with maximal aneurysm diameter of 6.0 mm.,15804801_4,-1,-1,-1,5113,-1,0.024769764,0.9752303
5114,Pheochromocytoma,0,1,0,16,Pheochromocytoma unmasked by amisulpride and tiapride.,15811908_0,-1,-1,-1,5114,-1,0.0019210862,0.99807894
5115,amisulpride,3,4,29,40,Pheochromocytoma unmasked by amisulpride and tiapride.,15811908_0,-1,-1,-1,5115,-1,0.99929225,0.0007077206
5116,tiapride,5,6,45,53,Pheochromocytoma unmasked by amisulpride and tiapride.,15811908_0,-1,-1,-1,5116,-1,0.99931467,0.00068529084
5117,pheochromocytoma,7,8,40,56,OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride.,15811908_1,-1,-1,-1,5117,-1,0.001785845,0.9982141
5118,amisulpride,13,14,83,94,OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride.,15811908_1,-1,-1,-1,5118,-1,0.99927205,0.00072799076
5119,tiapride,15,16,99,107,OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride.,15811908_1,-1,-1,-1,5119,-1,0.9993055,0.00069453847
5123,amisulpride,22,23,134,145,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,-1,-1,-1,5123,-1,0.99931395,0.0006860364
5124,mg,24,25,150,152,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,-1,-1,-1,5124,-1,0.99291855,0.0070814257
5125,tiapride,26,27,157,165,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,-1,-1,-1,5125,-1,0.9993113,0.0006887203
5126,mg,28,29,170,172,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,-1,-1,-1,5126,-1,0.99167496,0.008325072
5127,nicardipine,12,13,85,96,"Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and verapamil treatment.",15811908_3,-1,-1,-1,5127,-1,0.99935967,0.00064034044
5129,pheochromocytoma,15,16,113,129,"Abdominal ultrasound showed an adrenal mass, and postoperative histologic examination confirmed the diagnosis of pheochromocytoma.",15811908_4,-1,-1,-1,5129,-1,0.0025417008,0.9974583
5130,pheochromocytoma,5,6,37,53,"DISCUSSION: Drug-induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs, but the underlying mechanism is unknown.",15811908_5,-1,-1,-1,5130,-1,0.001483743,0.99851626
5131,benzamide,14,15,103,112,"DISCUSSION: Drug-induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs, but the underlying mechanism is unknown.",15811908_5,-1,-1,-1,5131,-1,0.99921966,0.0007802991
5133,amisulpride,19,20,120,131,"In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.",15811908_6,-1,-1,-1,5133,-1,0.9992706,0.00072941923
5134,tiapride,21,22,136,144,"In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.",15811908_6,-1,-1,-1,5134,-1,0.99926704,0.0007329848
5136,pheochromocytoma,25,26,142,158,"CONCLUSIONS: As of March 24, 2005, this is the first reported case of amisulpride- and tiapride-induced hypertensive crisis in a patient with pheochromocytoma.",15811908_7,-1,-1,-1,5136,-1,0.0016143058,0.99838567
5137,tiapride,14,15,98,106,Physicians and other healthcare professionals should be aware of this potential adverse effect of tiapride and amisulpride.,15811908_8,-1,-1,-1,5137,-1,0.9992736,0.00072639267
5138,amisulpride,16,17,111,122,Physicians and other healthcare professionals should be aware of this potential adverse effect of tiapride and amisulpride.,15811908_8,-1,-1,-1,5138,-1,0.99928147,0.00071855687
5139,neurological dysfunction,1,3,6,30,"Minor neurological dysfunction, cognitive development, and somatic development at the age of 3 to 7 years after dexamethasone treatment in very-low birth-weight infants.",15814210_0,-1,-1,-1,5139,-1,0.0012741017,0.99872583
5141,neurological dysfunction,9,11,48,72,"The objective of this study was to assess minor neurological dysfunction, cognitive development, and somatic development after dexamethasone therapy in very-low-birthweight infants.",15814210_1,-1,-1,-1,5141,-1,0.0012635551,0.99873644
5146,asphyxia,3,4,24,32,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,-1,-1,5146,-1,0.0012290126,0.998771
5147,malformations,5,6,34,47,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,-1,-1,5147,-1,0.0013389233,0.99866104
5148,haemorrhage,17,18,123,134,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,-1,-1,5148,-1,0.0012887912,0.9987112
5149,periventricular leukomalacia,23,25,154,182,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,-1,-1,5149,-1,0.0012796827,0.9987203
5150,psychomotor retardation,28,30,195,218,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,-1,-1,5150,-1,0.0013218549,0.99867815
5151,neurological dysfunctions,9,11,57,82,Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw-a-Man Test.,15814210_6,-1,-1,-1,5151,-1,0.0016264407,0.9983735
5152,p<0.01,15,16,91,97,Fine motor skills and gross motor function were significantly better in the control group (p<0.01).,15814210_8,-1,-1,-1,5152,-1,0.43237853,0.5676214
5153,p<0.001,12,13,65,72,"In the Draw-a-Man Test, the control group showed better results (p<0.001).",15814210_9,-1,-1,-1,5153,-1,0.36008188,0.63991815
5155,neurological dysfunctions,11,13,70,95,"After dexamethasone treatment, children showed a higher rate of minor neurological dysfunctions.",15814210_11,-1,-1,-1,5155,-1,0.001368555,0.9986314
5157,Valproic acid,0,2,0,13,"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.",15858223_0,-1,-1,-1,5157,-1,0.99917823,0.0008217565
5158,liver toxicity,11,13,63,77,"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.",15858223_0,-1,-1,-1,5158,-1,0.0018438428,0.99815613
5159,valproic acid,15,17,83,96,"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.",15858223_0,-1,-1,-1,5159,-1,0.99916387,0.00083613175
5160,valproic acid,4,6,17,30,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,-1,-1,-1,5160,-1,0.99914277,0.00085722696
5161,VPA,7,8,32,35,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,-1,-1,-1,5161,-1,0.9991068,0.00089315197
5162,15-F(2t)-isoprostane,33,34,173,193,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,-1,-1,-1,5162,-1,0.9986241,0.0013759481
5163,15-F(2t)-IsoP,35,36,195,208,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,-1,-1,-1,5163,-1,0.9983151,0.0016848712
5165,VPA,23,24,167,170,"To determine whether there was a temporal relationship between VPA-associated oxidative stress and hepatotoxicity, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.",15858223_2,-1,-1,-1,5165,-1,0.9992613,0.0007386541
5166,15-F(2t)-IsoP,11,12,72,85,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,-1,5166,-1,0.99844724,0.0015528012
5167,lipid hydroperoxides,13,15,87,107,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,-1,5167,-1,0.9975769,0.0024231272
5168,LPO,16,17,109,112,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,-1,5168,-1,0.9958553,0.0041447305
5169,thiobarbituric acid reactive substances,20,24,119,158,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,-1,5169,-1,0.9922787,0.007721273
5170,TBARs,25,26,160,165,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,-1,5170,-1,0.9971374,0.0028625997
5171,15-F(2t)-IsoP,3,4,17,30,Plasma and liver 15-F(2t)-IsoP were elevated and reached a plateau after day 2 of VPA treatment compared to control.,15858223_4,-1,-1,-1,5171,-1,0.9982133,0.0017867336
5172,VPA,14,15,82,85,Plasma and liver 15-F(2t)-IsoP were elevated and reached a plateau after day 2 of VPA treatment compared to control.,15858223_4,-1,-1,-1,5172,-1,0.9991798,0.00082023186
5173,LPO,1,2,6,9,"Liver LPO levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05).",15858223_5,-1,-1,-1,5173,-1,0.9794327,0.02056725
5174,p,16,17,86,87,"Liver LPO levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05).",15858223_5,-1,-1,-1,5174,-1,0.4074194,0.59258056
5175,TBARs,3,4,17,22,"Liver and plasma TBARs were not increased until 14 days (2-fold vs. control, p < 0.05).",15858223_6,-1,-1,-1,5175,-1,0.99674404,0.003255892
5176,p,15,16,77,78,"Liver and plasma TBARs were not increased until 14 days (2-fold vs. control, p < 0.05).",15858223_6,-1,-1,-1,5176,-1,0.43105417,0.5689458
5177,Liver toxicity,0,2,0,14,Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology.,15858223_7,-1,-1,-1,5177,-1,0.0017048832,0.9982951
5181,steatosis,30,31,187,196,"Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.",15858223_8,-1,-1,-1,5181,-1,0.0013267576,0.9986733
5182,VPA,7,8,50,53,"The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study.",15858223_9,-1,-1,-1,5182,-1,0.99905497,0.00094508147
5183,VPA,6,7,38,41,"Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.",15858223_10,-1,-1,-1,5183,-1,0.99922204,0.0007779733
5184,15-F(2t)-IsoP,18,19,106,119,"Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.",15858223_10,-1,-1,-1,5184,-1,0.9985367,0.001463324
5186,steatosis,27,28,159,168,"Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.",15858223_10,-1,-1,-1,5186,-1,0.0013632993,0.99863666
5193,n=25,45,46,252,256,"MATERIALS AND METHODS: We investigated the causes of thrombotic microangiopathy during a 1-year period, from June 2003 to June 2004, at the King Fahad National Guard Hospital in Riyadh, Saudi Arabia, by reviewing the slides of all transplant biopsies (n=25) performed during this interval.",15859940_4,-1,-1,-1,5193,-1,0.13578193,0.86421806
5199,antiphospholipid syndrome,11,13,72,97,The fifth case had features of thrombotic microangiopathy related to an antiphospholipid syndrome in a patient with systemic lupus erythematosus.,15859940_9,-1,-1,-1,5199,-1,0.011823836,0.9881762
5200,systemic lupus erythematosus,17,20,116,144,The fifth case had features of thrombotic microangiopathy related to an antiphospholipid syndrome in a patient with systemic lupus erythematosus.,15859940_9,-1,-1,-1,5200,-1,0.0013769416,0.998623
5210,DFU,15,16,125,128,Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study.,15863244_0,-1,-1,-1,5210,-1,0.9990841,0.0009158249
5215,DFU,20,21,117,120,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,-1,-1,-1,5215,-1,0.99899477,0.0010052809
5216,"5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon",22,25,122,196,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,-1,-1,-1,5216,-1,0.99774605,0.0022538968
5217,COX-2 inhibitors,26,28,198,214,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,-1,-1,-1,5217,-1,0.99126375,0.008736283
5219,DFU,18,19,86,89,"Doses were set at 0.3, 3.0 and 30.0mg/kg for piroxicam and 0.2, 2.0 and 20.0mg/kg for DFU.",15863244_5,-1,-1,-1,5219,-1,0.9988864,0.0011136509
5220,MD,13,14,74,76,"The pooled statistical analysis for ventricular septal (VSD) and midline (MD) defects was performed for rat fetuses exposed to piroxicam, selective and non-selective COX-2 inhibitor based on present and historic data.",15863244_8,-1,-1,-1,5220,-1,0.0035086498,0.9964914
5223,intrauterine growth retardation,5,8,28,59,"RESULTS: Maternal toxicity, intrauterine growth retardation, and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam.",15863244_9,-1,-1,-1,5223,-1,0.0016949277,0.9983051
5224,increase of external and skeletal variations,10,16,65,109,"RESULTS: Maternal toxicity, intrauterine growth retardation, and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam.",15863244_9,-1,-1,-1,5224,-1,0.0020626541,0.9979373
5226,DFU,10,11,51,54,Decrease of fetal length was the only signs of the DFU developmental toxicity observed in pups exposed to the highest compound dose.,15863244_10,-1,-1,-1,5226,-1,0.9973488,0.00265116
5228,teratogenicity,2,3,8,22,Lack of teratogenicity was found in piroxicam and DFU-exposed groups.,15863244_11,-1,-1,-1,5228,-1,0.0015532743,0.99844676
5230,COX inhibitors,4,6,35,49,Prenatal exposure to non-selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX-2 inhibitors.,15863244_12,-1,-1,-1,5230,-1,0.99742186,0.0025780923
5231,VSD,10,11,72,75,Prenatal exposure to non-selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX-2 inhibitors.,15863244_12,-1,-1,-1,5231,-1,0.0016396302,0.99836034
5232,MD,12,13,80,82,Prenatal exposure to non-selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX-2 inhibitors.,15863244_12,-1,-1,-1,5232,-1,0.0016072418,0.99839276
5233,COX-2 inhibitors,22,24,140,156,Prenatal exposure to non-selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX-2 inhibitors.,15863244_12,-1,-1,-1,5233,-1,0.99765354,0.0023464921
5234,COX-2 inhibitors,6,8,45,61,CONCLUSION: Both selective and non-selective COX-2 inhibitors were toxic for rats fetuses when administered in the highest dose.,15863244_13,-1,-1,-1,5234,-1,0.992304,0.0076959566
5235,DFU,1,2,7,10,"Unlike DFU, piroxicam was also highly toxic to the dams.",15863244_14,-1,-1,-1,5235,-1,0.9988103,0.0011897684
5237,COX-2 inhibitors,4,6,31,47,Prenatal exposure to selective COX-2 inhibitors does not increase the risk of ventricular septal and midline defects in rat when compared to non-selective drugs and historic control.,15863244_15,-1,-1,-1,5237,-1,0.99727803,0.002722
5238,midline defects,15,17,101,116,Prenatal exposure to selective COX-2 inhibitors does not increase the risk of ventricular septal and midline defects in rat when compared to non-selective drugs and historic control.,15863244_15,-1,-1,-1,5238,-1,0.002381904,0.997618
5239,hepatitis B,3,5,24,35,Assessment of perinatal hepatitis B and rubella prevention in New Hampshire delivery hospitals.,15867025_0,-1,-1,-1,5239,-1,0.003157305,0.99684274
5240,rubella,6,7,40,47,Assessment of perinatal hepatitis B and rubella prevention in New Hampshire delivery hospitals.,15867025_0,-1,-1,-1,5240,-1,0.0047844476,0.99521554
5241,hepatitis B,9,11,68,79,OBJECTIVE: To evaluate current performance on recommended perinatal hepatitis B and rubella prevention practices in New Hampshire.,15867025_1,-1,-1,-1,5241,-1,0.004587046,0.995413
5242,rubella,12,13,84,91,OBJECTIVE: To evaluate current performance on recommended perinatal hepatitis B and rubella prevention practices in New Hampshire.,15867025_1,-1,-1,-1,5242,-1,0.008525991,0.99147403
5243,hepatitis B,10,12,61,72,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5243,-1,0.012342168,0.9876579
5244,rubella,13,14,77,84,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5244,-1,0.017770326,0.9822297
5245,hepatitis B vaccine,18,21,108,127,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5245,-1,0.96253854,0.037461452
5246,hepatitis B,29,31,173,184,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5246,-1,0.3487619,0.6512381
5247,hepatitis B,39,41,229,240,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5247,-1,0.18320398,0.81679606
5248,rubella,45,46,275,282,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5248,-1,0.033102345,0.96689767
5249,rubella vaccine,53,55,338,353,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5249,-1,0.9173164,0.08268356
5250,rubella,56,57,357,364,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5250,-1,0.06788673,0.93211323
5251,hepatitis B,6,8,38,49,RESULTS: Prenatal screening rates for hepatitis B (98.8%) and rubella (99.4%) were high.,15867025_4,-1,-1,-1,5251,-1,0.0027622802,0.9972377
5252,rubella,13,14,62,69,RESULTS: Prenatal screening rates for hepatitis B (98.8%) and rubella (99.4%) were high.,15867025_4,-1,-1,-1,5252,-1,0.0031813253,0.99681866
5253,Hepatitis B vaccine,0,3,0,19,Hepatitis B vaccine birth dose was administered to 76.2% of all infants.,15867025_5,-1,-1,-1,5253,-1,0.94077706,0.059222948
5254,hepatitis B,6,8,29,40,All infants who were born to hepatitis B surface antigen-positive mothers also received hepatitis B immune globulin.,15867025_6,-1,-1,-1,5254,-1,0.027328607,0.9726714
5255,hepatitis B,13,15,88,99,All infants who were born to hepatitis B surface antigen-positive mothers also received hepatitis B immune globulin.,15867025_6,-1,-1,-1,5255,-1,0.03622482,0.9637752
5256,birth weight,11,13,78,90,Multivariate logistic regression showed that the month of delivery and infant birth weight were independent predictors of hepatitis B vaccination.,15867025_7,-1,-1,-1,5256,-1,0.048764136,0.9512359
5257,hepatitis B,17,19,122,133,Multivariate logistic regression showed that the month of delivery and infant birth weight were independent predictors of hepatitis B vaccination.,15867025_7,-1,-1,-1,5257,-1,0.504087,0.49591306
5258,rubella,13,14,66,73,Women who were born between 1971 and 1975 had the highest rate of rubella nonimmunity (9.5%).,15867025_9,-1,-1,-1,5258,-1,0.012557125,0.9874429
5259,rubella vaccine,2,4,23,38,In-hospital postpartum rubella vaccine administration was documented for 75.6% of nonimmune women.,15867025_10,-1,-1,-1,5259,-1,0.96717304,0.032826994
5260,hepatitis B,18,20,126,137,CONCLUSION: This study documents good compliance in New Hampshire's birthing hospitals with national guidelines for perinatal hepatitis B and rubella prevention and highlights potential areas for improvement.,15867025_11,-1,-1,-1,5260,-1,0.0054631466,0.9945368
5261,rubella,21,22,142,149,CONCLUSION: This study documents good compliance in New Hampshire's birthing hospitals with national guidelines for perinatal hepatitis B and rubella prevention and highlights potential areas for improvement.,15867025_11,-1,-1,-1,5261,-1,0.012286253,0.9877137
5262,masseter muscle rigidity,1,4,24,48,Succinylcholine-induced masseter muscle rigidity during bronchoscopic removal of a tracheal foreign body.,15893386_0,-1,-1,-1,5262,-1,0.003691355,0.9963086
5263,Masseter muscle rigidity,0,3,0,24,Masseter muscle rigidity during general anesthesia is considered an early warning sign of a possible episode of malignant hyperthermia.,15893386_1,-1,-1,-1,5263,-1,0.0067321407,0.9932679
5264,malignant hyperthermia,17,19,112,134,Masseter muscle rigidity during general anesthesia is considered an early warning sign of a possible episode of malignant hyperthermia.,15893386_1,-1,-1,-1,5264,-1,0.0012800259,0.99872005
5265,masseter muscle rigidity,19,22,116,140,The decision whether to continue or discontinue the procedure depends on the urgency of the surgery and severity of masseter muscle rigidity.,15893386_2,-1,-1,-1,5265,-1,0.007932919,0.9920671
5266,masseter muscle rigidity,8,11,35,59,"Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.",15893386_3,-1,-1,-1,5266,-1,0.004010449,0.9959895
5267,jaw of steel,12,15,61,73,"Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.",15893386_3,-1,-1,-1,5267,-1,0.0031481904,0.99685186
5269,Sch,19,20,98,101,"Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.",15893386_3,-1,-1,-1,5269,-1,0.9985876,0.001412421
5271,malignant hyperthermia,16,18,117,139,Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat malignant hyperthermia.,15893386_4,-1,-1,-1,5271,-1,0.0013738862,0.9986261
5272,Dexrazoxane,0,1,0,11,Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.,15897593_0,-1,-1,-1,5272,-1,0.99920505,0.00079496484
5277,anthracyclines daunorubicin,3,5,13,40,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",15897593_1,-1,-1,-1,5277,-1,0.99872917,0.001270815
5279,epipodophyllotoxin etoposide,9,11,65,93,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",15897593_1,-1,-1,-1,5279,-1,0.9989755,0.001024548
5282,Dexrazoxane,0,1,0,11,Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.,15897593_2,-1,-1,-1,5282,-1,0.999153,0.00084699655
5283,ICRF-187,2,3,13,21,Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.,15897593_2,-1,-1,-1,5283,-1,0.99790597,0.0020940858
5285,hematologic toxicity,10,12,58,78,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,-1,-1,-1,5285,-1,0.00156705,0.99843293
5286,dexrazoxane,15,16,109,120,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,-1,-1,-1,5286,-1,0.9991768,0.0008231307
5290,dexrazoxane,44,45,304,315,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,-1,-1,-1,5290,-1,0.99917006,0.0008299553
5294,dexrazoxane,20,21,107,118,"Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.",15897593_4,-1,-1,-1,5294,-1,0.999183,0.0008169942
5295,dexrazoxane,5,6,27,38,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,-1,5295,-1,0.99912494,0.0008751029
5297,weight loss,9,11,68,79,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,-1,5297,-1,0.0019178679,0.99808216
5300,dexrazoxane,29,30,198,209,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,-1,5300,-1,0.9991628,0.0008371936
5302,weight loss,34,36,244,255,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,-1,5302,-1,0.002159104,0.9978409
5303,cytotoxicity,41,42,274,286,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,-1,5303,-1,0.0016350292,0.998365
5305,dexrazoxane,9,10,63,74,"CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.",15897593_6,-1,-1,-1,5305,-1,0.99918836,0.0008115778
5309,dexrazoxane,16,17,99,110,Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane.,15897593_7,-1,-1,-1,5309,-1,0.99916935,0.000830665
5310,brain metastases,5,7,33,49,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,-1,-1,-1,5310,-1,0.0014845344,0.9985154
5311,dexrazoxane,8,9,60,71,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,-1,-1,-1,5311,-1,0.99920243,0.0007975347
5313,hematologic toxicity,24,26,166,186,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,-1,-1,-1,5313,-1,0.0014026026,0.99859744
5314,atrial fibrillation,1,3,5,24,Lone atrial fibrillation associated with creatine monohydrate supplementation.,15899738_0,-1,-1,-1,5314,-1,0.0015684367,0.9984315
5316,Atrial fibrillation,0,2,0,19,Atrial fibrillation in young patients without structural heart disease is rare.,15899738_1,-1,-1,-1,5316,-1,0.0014115705,0.9985884
5317,structural heart disease,6,9,46,70,Atrial fibrillation in young patients without structural heart disease is rare.,15899738_1,-1,-1,-1,5317,-1,0.0016712554,0.99832875
5319,Thyroid disorders,0,2,0,17,"Thyroid disorders, illicit drug or stimulant use, and acute alcohol intoxication are among these causes.",15899738_3,-1,-1,-1,5319,-1,0.0015378617,0.9984622
5321,emergency department,13,15,66,86,We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response.,15899738_4,-1,-1,-1,5321,-1,0.01080836,0.9891916
5322,atrial fibrillation,16,18,90,109,We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response.,15899738_4,-1,-1,-1,5322,-1,0.001585636,0.9984144
5328,unfractionated heparin,10,12,62,84,"The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous diltiazem for rate control and intravenous amiodarone for rate and rhythm control.",15899738_8,-1,-1,-1,5328,-1,0.99779946,0.0022005297
5365,inability to repeat words,8,12,48,73,The mean highest BIS score corresponding to the inability to repeat words was 81.5 (95% CI = 78.1 to 84.8).,15930398_13,-1,-1,-1,5365,-1,0.1372347,0.86276525
5366,retrograde amnesia,25,27,161,179,"Furthermore, patients had no recall of words repeated prior to procedural sedation in BIS ranges associated with recall after procedural sedation, suggestive of retrograde amnesia.",15930398_19,-1,-1,-1,5366,-1,0.0021026726,0.99789727
5367,Ro4368554,5,6,40,49,The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.,15957009_0,-1,-1,-1,5367,-1,0.99871874,0.0012812561
5368,memory deficiency,15,17,120,137,The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.,15957009_0,-1,-1,-1,5368,-1,0.0020262462,0.99797374
5370,5-HT(6,6,7,33,39,Antagonists at serotonin type 6 (5-HT(6)) receptors show activity in models of learning and memory.,15957009_1,-1,-1,-1,5370,-1,0.9977203,0.0022796383
5372,ACh,19,20,118,121,"Although the underlying mechanism(s) are not well understood, these effects may involve an increase in acetylcholine (ACh) levels.",15957009_2,-1,-1,-1,5372,-1,0.9985455,0.0014545282
5373,5-HT(6,11,12,80,86,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5373,-1,0.9985897,0.0014102483
5374,Ro4368554,14,15,99,108,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5374,-1,0.9988181,0.0011819077
5375,3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole,16,17,110,164,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5375,-1,0.998021,0.001978947
5377,tryptophan,35,36,271,281,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5377,-1,0.99874413,0.0012558725
5378,TRP,37,38,283,286,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5378,-1,0.99826294,0.0017370492
5379,metrifonate,56,57,399,410,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5379,-1,0.9992607,0.0007392788
5380,metrifonate,17,18,116,127,"Initial testing in a time-dependent forgetting task employing a 24-h delay between training and testing showed that metrifonate improved object recognition (at 10 and 30 mg/kg, p.o.), whereas Ro4368554 was inactive.",15957009_4,-1,-1,-1,5380,-1,0.99922585,0.0007741736
5381,Ro4368554,33,34,192,201,"Initial testing in a time-dependent forgetting task employing a 24-h delay between training and testing showed that metrifonate improved object recognition (at 10 and 30 mg/kg, p.o.), whereas Ro4368554 was inactive.",15957009_4,-1,-1,-1,5381,-1,0.9988838,0.0011162227
5382,Ro4368554,2,3,6,15,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,-1,-1,-1,5382,-1,0.99883324,0.001166714
5383,metrifonate,16,17,63,74,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,-1,-1,-1,5383,-1,0.99922204,0.0007779823
5384,memory deficits,27,29,115,130,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,-1,-1,-1,5384,-1,0.0027031216,0.99729687
5386,TRP,33,34,158,161,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,-1,-1,-1,5386,-1,0.99886835,0.0011316722
5387,Ro4368554,4,5,24,33,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,-1,-1,-1,5387,-1,0.99860555,0.0013945174
5388,retention deficit,10,12,65,82,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,-1,-1,-1,5388,-1,0.002671128,0.9973289
5389,memory deficit,20,22,129,143,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,-1,-1,-1,5389,-1,0.0023653947,0.99763465
5390,Ro4368554,37,38,233,242,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,-1,-1,-1,5390,-1,0.998728,0.0012719652
5391,5-HT(6,43,44,264,270,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,-1,-1,-1,5391,-1,0.9980617,0.0019382806
5392,Amiodarone pulmonary toxicity,0,3,0,29,Amiodarone pulmonary toxicity.,1595783_0,-1,-1,-1,5392,-1,0.56775796,0.43224207
5394,pneumonitis,18,19,122,133,"Amiodarone is an effective antiarrhythmic agent whose utility is limited by many side-effects, the most problematic being pneumonitis.",1595783_1,-1,-1,-1,5394,-1,0.0012453307,0.9987546
5395,pulmonary toxicity,1,3,4,22,The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.,1595783_2,-1,-1,-1,5395,-1,0.0011996729,0.9988003
5397,hypersensitivity pneumonitis,22,24,155,183,The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.,1595783_2,-1,-1,-1,5397,-1,0.0010951656,0.9989048
5398,pulmonary toxicity,7,9,61,79,The clinical and radiographic features of amiodarone-induced pulmonary toxicity are characteristic but nonspecific.,1595783_3,-1,-1,-1,5398,-1,0.0011648041,0.99883527
5399,heart failure,11,13,62,75,"The diagnosis depends on exclusion of other entities, such as heart failure, infection, and malignancy.",1595783_4,-1,-1,-1,5399,-1,0.0015717855,0.9984282
5404,kainate,7,8,43,50,Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain.,15974569_0,-1,-1,-1,5404,-1,0.9984384,0.0015615901
5406,Amino acids,0,2,0,11,"Amino acids 5 and 7, two potent and selective competitive GluR5 KA receptor antagonists, exhibited high GluR5 receptor affinity over other glutamate receptors.",15974569_1,-1,-1,-1,5406,-1,0.9972625,0.0027375096
5409,thermal hyperalgesia,22,24,135,155,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,-1,-1,-1,5409,-1,0.0016270455,0.9983729
5410,mechanical hyperalgesia,27,29,179,202,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,-1,-1,-1,5410,-1,0.0015728389,0.99842715
5416,pharyngitis,17,18,116,127,CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning azithromycin for the treatment of pharyngitis.,15985056_2,-1,-1,-1,5416,-1,0.001966845,0.9980331
5419,baclofen,6,7,49,57,Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups.,15985056_4,-1,-1,-1,5419,-1,0.99919385,0.0008061935
5430,macrolide,10,11,64,73,Few cases of drug-induced hiccups have been reported related to macrolide antimicrobials.,15985056_8,-1,-1,-1,5430,-1,0.99864334,0.0013566369
5431,macrolides,36,37,213,223,"Using the Naranjo adverse effect reaction probability scale this event could be classified as possible (score 5 points), mostly because of the close temporal sequence, previous reports on this reaction with other macrolides and the absence of any alternative explanation for hiccups.",15985056_9,-1,-1,-1,5431,-1,0.9980882,0.0019117693
5436,macrolide,2,3,9,18,"However, macrolide antimicrobials have been reported to be associated with hiccups and vagal mechanism could explain the development of this side-effect.",15985056_12,-1,-1,-1,5436,-1,0.99805945,0.0019404736
5438,GNC92H2,6,7,50,57,Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose.,16005948_0,-1,-1,-1,5438,-1,0.99414283,0.0058571636
5439,cocaine overdose,11,13,82,98,Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose.,16005948_0,-1,-1,-1,5439,-1,0.17486936,0.82513064
5441,cocaine overdose,12,14,79,95,The illicit use of cocaine continues in epidemic proportions and treatment for cocaine overdose remains elusive.,16005948_1,-1,-1,-1,5441,-1,0.22829664,0.7717033
5442,GNC92H2,7,8,54,61,The therapeutic potential of the anticocaine antibody GNC92H2 was examined using a model of cocaine overdose.,16005948_3,-1,-1,-1,5442,-1,0.9967874,0.0032126326
5443,cocaine overdose,14,16,92,108,The therapeutic potential of the anticocaine antibody GNC92H2 was examined using a model of cocaine overdose.,16005948_3,-1,-1,-1,5443,-1,0.20443577,0.79556423
5445,GNC92H2,23,24,141,148,Swiss albino mice prepared with intrajugular catheters were tested in photocell cages after administration of 93 mg/kg (LD50) of cocaine and GNC92H2 infusions ranging from 30 to 190 mg/kg.,16005948_4,-1,-1,-1,5445,-1,0.9982305,0.0017695583
5446,GNC92H2,0,1,0,7,"GNC92H2 was delivered 30 min before, concomitantly or 3 min after cocaine treatment.",16005948_5,-1,-1,-1,5446,-1,0.9978154,0.0021846627
5448,cocaine toxicity,3,5,24,40,"Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%.",16005948_6,-1,-1,-1,5448,-1,0.2652224,0.73477757
5449,GNC92H2,12,13,78,85,"Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%.",16005948_6,-1,-1,-1,5449,-1,0.9985933,0.0014066778
5452,GNC92H2,2,3,13,20,"Importantly, GNC92H2 prevented death even post-cocaine injection.",16005948_7,-1,-1,-1,5452,-1,0.99604106,0.003958956
5454,post-cocaine,6,7,42,54,"Importantly, GNC92H2 prevented death even post-cocaine injection.",16005948_7,-1,-1,-1,5454,-1,0.9640098,0.035990197
5455,GNC92H2,7,8,47,54,The results support the important potential of GNC92H2 as a therapeutic tool against cocaine overdose.,16005948_8,-1,-1,-1,5455,-1,0.99543935,0.0045606615
5456,cocaine overdose,13,15,85,101,The results support the important potential of GNC92H2 as a therapeutic tool against cocaine overdose.,16005948_8,-1,-1,-1,5456,-1,0.16742013,0.8325799
5457,Calcium carbonate toxicity,0,3,0,26,Calcium carbonate toxicity: the updated milk-alkali syndrome; report of 3 cases and review of the literature.,16006300_0,-1,-1,-1,5457,-1,0.5015193,0.4984807
5462,acute renal insufficiency,6,9,28,53,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,-1,-1,-1,5462,-1,0.0011910258,0.998809
5463,metabolic alkalosis,11,13,64,83,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,-1,-1,-1,5463,-1,0.0013229656,0.99867696
5464,low parathyroid hormone,15,18,89,112,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,-1,-1,-1,5464,-1,0.80744195,0.19255811
5465,PTH,19,20,114,117,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,-1,-1,-1,5465,-1,0.99825877,0.0017412524
5466,"1,25-dihydroxyvitamin D",26,28,145,168,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,-1,-1,-1,5466,-1,0.99846125,0.0015387608
5469,pamidronate,10,11,69,80,"The 2 patients with the higher serum calcium concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe hypocalcemia.",16006300_6,-1,-1,-1,5469,-1,0.9991774,0.00082259247
5470,mg,16,17,106,108,"The 2 patients with the higher serum calcium concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe hypocalcemia.",16006300_6,-1,-1,-1,5470,-1,0.97717786,0.022822112
5473,calcium carbonate,27,29,123,140,"Of the 3 patients, 2 were ingesting acceptable doses of elemental calcium (1 g and 2 g daily, respectively) in the form of calcium carbonate.",16006300_7,-1,-1,-1,5473,-1,0.9987979,0.0012020413
5475,calcium carbonate,22,24,144,161,CONCLUSION: Milk-alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons.,16006300_9,-1,-1,-1,5475,-1,0.998901,0.0010989326
5478,vitamin D,12,14,77,86,"Treatment with hydration, furosemide, and discontinuation of the calcium and vitamin D source is adequate.",16006300_10,-1,-1,-1,5478,-1,0.9989324,0.0010675386
5479,Pamidronate,0,1,0,11,"Pamidronate treatment is associated with considerable risk for hypocalcemia, even in cases of initially severe hypercalcemia.",16006300_11,-1,-1,-1,5479,-1,0.99910647,0.0008935457
5487,myocardial infarction,19,21,116,137,"Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.",1601297_2,-1,-1,-1,5487,-1,0.001644174,0.9983558
5489,bundle branch block,25,28,153,172,"Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.",1601297_2,-1,-1,-1,5489,-1,0.0040132427,0.99598676
5490,leukocytoclastic vasculitis,1,3,17,44,Warfarin-induced leukocytoclastic vasculitis.,16047871_0,-1,-1,-1,5490,-1,0.0011433968,0.99885666
5491,Skin reactions,0,2,0,14,Skin reactions associated with oral coumarin-derived anticoagulants are an uncommon occurrence.,16047871_1,-1,-1,-1,5491,-1,0.001775024,0.99822503
5492,Leukocytoclastic vasculitis,0,2,0,27,"Leukocytoclastic vasculitis (LV) is primarily a cutaneous small vessel vasculitis, though systemic involvement may be encountered.",16047871_2,-1,-1,-1,5492,-1,0.0011280527,0.998872
5493,LV,3,4,29,31,"Leukocytoclastic vasculitis (LV) is primarily a cutaneous small vessel vasculitis, though systemic involvement may be encountered.",16047871_2,-1,-1,-1,5493,-1,0.0015576243,0.99844235
5494,small vessel vasculitis,9,12,58,81,"Leukocytoclastic vasculitis (LV) is primarily a cutaneous small vessel vasculitis, though systemic involvement may be encountered.",16047871_2,-1,-1,-1,5494,-1,0.0013955628,0.9986045
5495,LV,6,7,37,39,We report 4 patients with late-onset LV probably due to warfarin.,16047871_3,-1,-1,-1,5495,-1,0.0019120788,0.99808794
5497,skin eruptions,5,7,30,44,All 4 patients presented with skin eruptions that developed after receiving warfarin for several years.,16047871_4,-1,-1,-1,5497,-1,0.0018156223,0.9981844
5499,skin lesion,3,5,15,26,"The results of skin lesion biopsies were available in 3 patients, confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued.",16047871_5,-1,-1,-1,5499,-1,0.003101346,0.99689865
5500,LV Cutaneous lesions,13,16,77,97,"The results of skin lesion biopsies were available in 3 patients, confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued.",16047871_5,-1,-1,-1,5500,-1,0.004328599,0.9956714
5503,LV,0,1,0,2,LV may be a late-onset adverse reaction associated with warfarin therapy.,16047871_7,-1,-1,-1,5503,-1,0.0020229165,0.9979771
5514,Parkinson disease,9,11,74,91,rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease.,16116131_0,-1,-1,-1,5514,-1,0.0016179804,0.998382
5516,Parkinson disease,23,25,135,152,"Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.",16116131_2,-1,-1,-1,5516,-1,0.0018518497,0.9981482
5517,dyskinetic,41,42,252,262,"Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.",16116131_2,-1,-1,-1,5517,-1,0.0019085401,0.9980914
5521,brain tumors,2,4,16,28,Human malignant brain tumors have a poor prognosis in spite of surgery and radiation therapy.,16132524_1,-1,-1,-1,5521,-1,0.0026939525,0.997306
5522,lipid,6,7,45,50,"Cubic phases consist of curved biocontinuous lipid bilayers, separating two congruent networks of water channels.",16132524_2,-1,-1,-1,5522,-1,0.9384453,0.061554693
5526,glioblastoma multiforme,10,12,46,69,A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages.,16132524_5,-1,-1,-1,5526,-1,0.0019018287,0.9980982
5529,mg paclitaxel,8,10,42,55,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,-1,-1,-1,5529,-1,0.99685585,0.003144109
5530,brain edema,16,18,93,104,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,-1,-1,-1,5530,-1,0.0012240321,0.9987759
5531,mg paclitaxel,29,31,163,176,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,-1,-1,-1,5531,-1,0.99676174,0.0032382384
5532,brain edema,5,7,21,32,"In the latter group, brain edema was markedly reduced and dealt medically.",16132524_7,-1,-1,-1,5532,-1,0.0015445697,0.9984554
5534,Lamotrigine,0,1,0,11,Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies.,16157917_0,-1,-1,-1,5534,-1,0.9992157,0.0007842175
5536,idiopathic generalized epilepsies,9,12,65,98,Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies.,16157917_0,-1,-1,-1,5536,-1,0.0015310418,0.99846894
5537,idiopathic generalized epilepsies,3,6,19,52,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,-1,5537,-1,0.0014603491,0.9985397
5538,IGE,7,8,54,57,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,-1,5538,-1,0.0017571938,0.99824286
5539,lamotrigine,11,12,72,83,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,-1,5539,-1,0.9992287,0.00077132747
5540,LTG,13,14,85,88,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,-1,5540,-1,0.37402338,0.6259766
5542,MJ,25,26,157,159,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,-1,5542,-1,0.0016538972,0.9983461
5543,LTG,4,5,19,22,"In three patients, LTG exacerbated MJ in a dose-dependent manner with early aggravation during titration.",16157917_2,-1,-1,-1,5543,-1,0.9927885,0.007211536
5544,MJ,6,7,35,37,"In three patients, LTG exacerbated MJ in a dose-dependent manner with early aggravation during titration.",16157917_2,-1,-1,-1,5544,-1,0.0018571155,0.99814284
5545,MJ,0,1,0,2,MJ disappeared when LTG dose was decreased by 25 to 50%.,16157917_3,-1,-1,-1,5545,-1,0.019008033,0.980992
5546,LTG,3,4,20,23,MJ disappeared when LTG dose was decreased by 25 to 50%.,16157917_3,-1,-1,-1,5546,-1,0.99838686,0.0016131134
5547,LTG,4,5,17,20,"In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.",16157917_4,-1,-1,-1,5547,-1,0.9969674,0.0030326669
5548,MJ,6,7,33,35,"In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.",16157917_4,-1,-1,-1,5548,-1,0.0015541504,0.9984459
5549,myoclonic status,16,18,78,94,"In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.",16157917_4,-1,-1,-1,5549,-1,0.0014333875,0.9985667
5550,LTG,22,23,118,121,"In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.",16157917_4,-1,-1,-1,5550,-1,0.99765426,0.0023458225
5553,thyrotropin,16,17,116,127,Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion.,16160878_2,-1,-1,-1,5553,-1,0.9990396,0.0009604248
5554,penile erection,20,22,126,141,"Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced penile erection and climbing behavior, and stress-induced plasma corticosterone level.",16160878_8,-1,-1,-1,5554,-1,0.0020198287,0.9979802
5556,psychiatric disorders,12,14,64,85,These data suggest that U-II may be involved in some aspects of psychiatric disorders.,16160878_10,-1,-1,-1,5556,-1,0.0014713254,0.9985286
5562,memory dissociation,4,6,18,37,It was shown that memory dissociation occurred in both groups.,1616457_5,-1,-1,-1,5562,-1,0.0043290593,0.9956709
5565,raloxifene,4,5,26,36,"The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.",16167916_0,-1,-1,-1,5565,-1,0.99917406,0.0008258924
5566,raloxifene,52,53,331,341,"The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.",16167916_0,-1,-1,-1,5566,-1,0.9992199,0.00078007305
5567,osteopenia,6,7,47,57,"METHODS: Thirty-nine postmenopausal women with osteopenia or osteoporosis were included in this prospective, controlled clinical study.",16167916_1,-1,-1,-1,5567,-1,0.0011353868,0.99886465
5569,raloxifene hydrochloride,4,6,29,53,Twenty-five women were given raloxifene hydrochloride (60 mg/day) plus calcium (500 mg/day).,16167916_2,-1,-1,-1,5569,-1,0.9990866,0.00091333874
5571,n,3,4,22,23,Age-matched controls (n = 14) were given only calcium.,16167916_3,-1,-1,-1,5571,-1,0.1626693,0.83733064
5573,raloxifene,5,6,25,35,"RESULTS: Three months of raloxifene treatment was associated with a significant decrease in the plasma TAFI antigen concentrations (16% change, P < 0.01), and a significant increase in tPA antigen concentrations (25% change, P < 0.05).",16167916_7,-1,-1,-1,5573,-1,0.9992367,0.0007632581
5574,P,24,25,144,145,"RESULTS: Three months of raloxifene treatment was associated with a significant decrease in the plasma TAFI antigen concentrations (16% change, P < 0.01), and a significant increase in tPA antigen concentrations (25% change, P < 0.05).",16167916_7,-1,-1,-1,5574,-1,0.47754362,0.52245635
5575,P,42,43,225,226,"RESULTS: Three months of raloxifene treatment was associated with a significant decrease in the plasma TAFI antigen concentrations (16% change, P < 0.01), and a significant increase in tPA antigen concentrations (25% change, P < 0.05).",16167916_7,-1,-1,-1,5575,-1,0.47326496,0.526735
5576,amenorrhea,14,15,101,111,A significant correlation was found between baseline TAFI antigen concentrations and the duration of amenorrhea (P < 0.05; r = 0.33).,16167916_8,-1,-1,-1,5576,-1,0.0014518215,0.9985482
5577,P,16,17,113,114,A significant correlation was found between baseline TAFI antigen concentrations and the duration of amenorrhea (P < 0.05; r = 0.33).,16167916_8,-1,-1,-1,5577,-1,0.4230897,0.5769103
5578,venous thromboembolism,9,11,50,72,"CONCLUSION: We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels, but not TAFI levels.",16167916_9,-1,-1,-1,5578,-1,0.0013539877,0.9986461
5579,raloxifene,13,14,80,90,"CONCLUSION: We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels, but not TAFI levels.",16167916_9,-1,-1,-1,5579,-1,0.9992824,0.00071759545
5580,subarachnoid hemorrhage,7,9,68,91,Absence of acute cerebral vasoconstriction after cocaine-associated subarachnoid hemorrhage.,16174948_0,-1,-1,-1,5580,-1,0.0014101262,0.9985898
5582,neurovascular complications,8,10,51,78,"INTRODUCTION: Cocaine use has been associated with neurovascular complications, including arterial vasoconstriction and vasculitis.",16174948_1,-1,-1,-1,5582,-1,0.0011791695,0.99882084
5585,subarachnoid hemorrhage,13,15,99,122,Information on these effects could be obtained from angiograms of patients with cocaine-associated subarachnoid hemorrhage (SAH) who underwent angiography shortly after cocaine use.,16174948_3,-1,-1,-1,5585,-1,0.0016640755,0.9983359
5586,SAH,16,17,124,127,Information on these effects could be obtained from angiograms of patients with cocaine-associated subarachnoid hemorrhage (SAH) who underwent angiography shortly after cocaine use.,16174948_3,-1,-1,-1,5586,-1,0.0012960186,0.99870396
5588,SAH,6,7,35,38,METHODS: We screened patients with SAH retrospectively and identified those with positive urine toxicology for cocaine or its metabolites.,16174948_4,-1,-1,-1,5588,-1,0.0015618942,0.99843806
5590,SAH,17,18,135,138,Quantitative arterial diameter measurements from angiograms of these patients were compared to measurements from control patients with SAH who were matched for factors known to influence arterial diameter.,16174948_5,-1,-1,-1,5590,-1,0.0019060287,0.998094
5592,p,35,36,226,227,"There were no significant differences between groups in the mean diameters of the intradural internal carotid, sphenoidal segment of the middle cerebral, precommunicating segment of the anterior cerebral, or basilar arteries (p greater than 0.05 for all comparisons, unpaired t-tests).",16174948_8,-1,-1,-1,5592,-1,0.23249121,0.7675088
5593,p,48,49,316,317,"There also were no significant differences between groups when expressing diameters as the sum of the precommunicating segment of the anterior cerebral + sphenoidal segment of the middle cerebral + supraclinoid internal carotid artery + basilar artery divided by the diameter of the petrous internal carotid artery (p greater than 0.05, unpaired t-tests).",16174948_9,-1,-1,-1,5593,-1,0.22983564,0.7701644
5595,aneurysmal SAH,29,31,209,223,CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use.,16174948_11,-1,-1,-1,5595,-1,0.0013795432,0.9986205
5604,Aggressive behaviors,0,2,0,20,"Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.",16192988_1,-1,-1,-1,5604,-1,0.0019108652,0.99808913
5605,psychiatric disorders,11,13,73,94,"Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.",16192988_1,-1,-1,-1,5605,-1,0.0015866078,0.9984133
5607,METH,20,21,131,135,"Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.",16192988_1,-1,-1,-1,5607,-1,0.9981881,0.0018119058
5608,METH,13,14,63,67,"Herein, we report that multiple (but not single) injections of METH significantly increased aggressiveness in male CD-1 mice.",16192988_2,-1,-1,-1,5608,-1,0.9985733,0.0014266688
5612,MAP,14,15,112,115,Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase-related pathways after multiple and single METH injections.,16192988_4,-1,-1,-1,5612,-1,0.99459743,0.0054025347
5613,METH,21,22,166,170,Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase-related pathways after multiple and single METH injections.,16192988_4,-1,-1,-1,5613,-1,0.99856734,0.0014326028
5614,p<0.05,5,6,38,44,"There were statistically significant (p<0.05) decreases in MEK1, Erk2p, GSK3alpha, 14-3-3e, and MEK7 in the striata of mice after multiple injections of METH.",16192988_5,-1,-1,-1,5614,-1,0.5010973,0.49890262
5615,METH,32,33,153,157,"There were statistically significant (p<0.05) decreases in MEK1, Erk2p, GSK3alpha, 14-3-3e, and MEK7 in the striata of mice after multiple injections of METH.",16192988_5,-1,-1,-1,5615,-1,0.9989693,0.0010307482
5616,METH,10,11,66,70,"MEK1 was significantly decreased also after a single injection of METH, but to a much lesser degree than after multiple injections of METH.",16192988_6,-1,-1,-1,5616,-1,0.9987587,0.0012412746
5617,METH,23,24,134,138,"MEK1 was significantly decreased also after a single injection of METH, but to a much lesser degree than after multiple injections of METH.",16192988_6,-1,-1,-1,5617,-1,0.99877423,0.001225808
5618,METH,22,23,129,133,"In the frontal cortex, there was a statistically significant decrease in GSK3alpha after multiple (but not single) injections of METH.",16192988_7,-1,-1,-1,5618,-1,0.9988945,0.0011054765
5619,MAP,6,7,43,46,These findings suggest that alterations in MAP kinase-related pathways in the prefronto-striatal circuitries might be involved in the manifestation of aggressive behaviors in mice.,16192988_8,-1,-1,-1,5619,-1,0.9960155,0.003984432
5620,aggressive behaviors,20,22,151,171,These findings suggest that alterations in MAP kinase-related pathways in the prefronto-striatal circuitries might be involved in the manifestation of aggressive behaviors in mice.,16192988_8,-1,-1,-1,5620,-1,0.0021952207,0.9978048
5621,Amisulpride,0,1,0,11,Amisulpride related tic-like symptoms in an adolescent schizophrenic.,16225977_0,-1,-1,-1,5621,-1,0.99927753,0.00072242663
5623,Tic disorders,0,2,0,13,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,-1,-1,-1,5623,-1,0.001319347,0.99868065
5624,antipsychotics,8,9,53,67,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,-1,-1,-1,5624,-1,0.99813676,0.0018632743
5627,ziprasidone,15,16,104,115,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,-1,-1,-1,5627,-1,0.9992842,0.0007158721
5628,quetiapine,22,23,134,144,"However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.",16225977_2,-1,-1,-1,5628,-1,0.9993303,0.00066973554
5631,amisulpride,16,17,120,131,We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day).,16225977_3,-1,-1,-1,5631,-1,0.99935585,0.0006441738
5632,mg,20,21,148,150,We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day).,16225977_3,-1,-1,-1,5632,-1,0.99241227,0.0075877192
5633,amisulpride,11,12,71,82,The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.,16225977_4,-1,-1,-1,5633,-1,0.99932504,0.0006750196
5634,mg,15,16,95,97,The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.,16225977_4,-1,-1,-1,5634,-1,0.98999447,0.010005542
5635,psychosis,3,4,13,22,"However, her psychosis recurred after the dose reduction.",16225977_5,-1,-1,-1,5635,-1,0.0013335814,0.9986664
5636,mg,8,9,40,42,We then placed her on an additional 100 mg per day of quetiapine.,16225977_6,-1,-1,-1,5636,-1,0.9889965,0.011003473
5637,quetiapine,12,13,54,64,We then placed her on an additional 100 mg per day of quetiapine.,16225977_6,-1,-1,-1,5637,-1,0.999321,0.0006790182
5638,antipsychotics,22,23,162,176,"Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.",16225977_9,-1,-1,-1,5638,-1,0.99876463,0.0012354103
5639,quetiapine,25,26,185,195,"Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.",16225977_9,-1,-1,-1,5639,-1,0.99937385,0.00062621414
5641,amisulpride,30,31,211,222,"Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.",16225977_9,-1,-1,-1,5641,-1,0.9993548,0.0006451688
5642,dysphonia,1,2,10,19,Recurrent dysphonia and acitretin.,16274958_0,-1,-1,-1,5642,-1,0.001302261,0.99869776
5643,acitretin,3,4,24,33,Recurrent dysphonia and acitretin.,16274958_0,-1,-1,-1,5643,-1,0.9973527,0.0026472404
5644,dysphonia,9,10,45,54,We report the case of a woman complaining of dysphonia while she was treated by acitretin.,16274958_1,-1,-1,-1,5644,-1,0.0012494191,0.99875057
5645,acitretin,15,16,80,89,We report the case of a woman complaining of dysphonia while she was treated by acitretin.,16274958_1,-1,-1,-1,5645,-1,0.9989209,0.0010791298
5646,acitretin,10,11,73,82,Her symptoms totally regressed after drug withdrawal and reappeared when acitretin was reintroduced.,16274958_2,-1,-1,-1,5646,-1,0.9989398,0.0010601757
5647,dysphonia,11,12,62,71,"To our knowledge, this is the first case of acitretin-induced dysphonia.",16274958_3,-1,-1,-1,5647,-1,0.001187944,0.9988121
5649,heart block,3,5,29,40,Chloroquine related complete heart block with blindness: case report.,1628552_0,-1,-1,-1,5649,-1,0.0015868263,0.9984132
5650,blindness,6,7,46,55,Chloroquine related complete heart block with blindness: case report.,1628552_0,-1,-1,-1,5650,-1,0.0012576479,0.9987424
5652,deterioration of vision,14,17,101,124,"A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.",1628552_1,-1,-1,-1,5652,-1,0.004706605,0.9952933
5653,fatiguability,19,20,131,144,"A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.",1628552_1,-1,-1,-1,5653,-1,0.001734156,0.9982659
5654,dyspnoea,21,22,146,154,"A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.",1628552_1,-1,-1,-1,5654,-1,0.0014342373,0.99856573
5656,syncopal attacks,26,28,181,197,"A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.",1628552_1,-1,-1,-1,5656,-1,0.0017023302,0.99829763
5657,chloroquine retinopathy,5,7,49,72,"Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.",1628552_2,-1,-1,-1,5657,-1,0.66892517,0.33107483
5658,heart failure,13,15,114,127,"Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.",1628552_2,-1,-1,-1,5658,-1,0.0017800411,0.9982199
5659,heart block,18,20,143,154,"Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.",1628552_2,-1,-1,-1,5659,-1,0.0024387147,0.99756134
5660,right bundle branch block,21,25,160,185,"Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.",1628552_2,-1,-1,-1,5660,-1,0.0050423387,0.9949576
5661,heart block,1,3,4,15,The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation.,1628552_3,-1,-1,-1,5661,-1,0.0018494009,0.9981505
5662,heart failure,10,12,59,72,The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation.,1628552_3,-1,-1,-1,5662,-1,0.001758406,0.99824154
5664,gentamicin ototoxicity,8,10,61,83,Nitro-L-arginine methyl ester: a potential protector against gentamicin ototoxicity.,16298782_0,-1,-1,-1,5664,-1,0.09859229,0.90140766
5665,nitric oxide,1,3,4,16,"The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.",16298782_1,-1,-1,-1,5665,-1,0.99810505,0.0018949016
5666,hearing loss,20,22,122,134,"The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.",16298782_1,-1,-1,-1,5666,-1,0.0017617312,0.9982382
5670,ototoxic,11,12,60,68,"Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.",16298782_3,-1,-1,-1,5670,-1,0.0016438297,0.99835616
5673,hearing loss,9,11,53,65,"Its effect was determined in terms of attenuation of hearing loss, measured by shifts in the auditory brainstem response threshold.",16298782_6,-1,-1,-1,5673,-1,0.0024413466,0.9975586
5674,hearing loss,3,5,34,46,"L-NAME reduced gentamicin-induced hearing loss in the high-frequency range, but gave no protection in the middle or low frequencies.",16298782_7,-1,-1,-1,5674,-1,0.0019257098,0.9980743
5683,heart disease,15,17,84,97,"METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or diabetes mellitus.",16330293_4,-1,-1,-1,5683,-1,0.0016082627,0.9983917
5685,diabetes mellitus,25,27,149,166,"METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or diabetes mellitus.",16330293_4,-1,-1,-1,5685,-1,0.0015586228,0.9984414
5698,tissue injury,27,29,184,197,Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury (secondary hyperalgesia).,16330766_1,-1,-1,-1,5698,-1,0.0029369898,0.997063
5701,neurogenic hyperalgesia,6,8,60,83,Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain.,16330766_2,-1,-1,-1,5701,-1,0.0011805135,0.9988194
5708,mg,6,7,33,35,"The dose of gabapentin was 1,800 mg per os, in a single administration.",16330766_6,-1,-1,-1,5708,-1,0.98672915,0.013270872
5716,Mitochondrial abnormalities,0,2,0,27,"Mitochondrial abnormalities have been associated with several aspects of epileptogenesis, such as energy generation, control of cell death, neurotransmitter synthesis, and free radical (FR) production.",16337777_1,-1,-1,-1,5716,-1,0.0071104323,0.9928895
5718,status epilepticus,12,14,73,91,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,-1,-1,-1,5718,-1,0.00232604,0.9976739
5719,c,30,31,195,196,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,-1,-1,-1,5719,-1,0.9962997,0.0037003113
5722,mitochondrial abnormalities,3,5,22,49,"Although evidences of mitochondrial abnormalities were found in previously published studies, our results do not suggest that the FRs, generated during the acute phase, determined important abnormalities in mtDNA, in expression of CCO-I, and in CCO activity.",16337777_7,-1,-1,-1,5722,-1,0.012468516,0.9875315
5723,suprofen,2,3,11,19,Effects of suprofen on the isolated perfused rat kidney.,1636026_0,-1,-1,-1,5723,-1,0.99891937,0.0010806709
5724,suprofen,1,2,9,17,"Although suprofen has been associated with the development of acute renal failure in greater than 100 subjects, the mechanism of damage remains unclear.",1636026_1,-1,-1,-1,5724,-1,0.9989152,0.0010848121
5725,acute renal failure,9,12,62,81,"Although suprofen has been associated with the development of acute renal failure in greater than 100 subjects, the mechanism of damage remains unclear.",1636026_1,-1,-1,-1,5725,-1,0.0011157885,0.99888426
5727,mg,10,11,54,56,The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.,1636026_2,-1,-1,-1,5727,-1,0.9921699,0.007830086
5728,suprofen,12,13,60,68,The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.,1636026_2,-1,-1,-1,5728,-1,0.9990295,0.0009704835
5729,uric acid,34,36,198,207,The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.,1636026_2,-1,-1,-1,5729,-1,0.9989807,0.001019311
5732,suprofen,21,22,132,140,"There were no significant differences in renal sodium excretion, oxygen consumption, or urinary flow rates in kidneys perfused with suprofen compared with the drug-free control groups.",1636026_3,-1,-1,-1,5732,-1,0.9990927,0.0009072829
5733,contrast,1,2,3,11,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,-1,-1,-1,5733,-1,0.16605514,0.83394486
5734,suprofen,16,17,101,109,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,-1,-1,-1,5734,-1,0.9990902,0.0009098033
5735,uric acid,22,24,138,147,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,-1,-1,-1,5735,-1,0.9987639,0.0012360859
5736,suprofen,30,31,176,184,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,-1,-1,-1,5736,-1,0.9991171,0.0008828599
5737,uric acid,35,37,203,212,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,-1,-1,-1,5737,-1,0.99881446,0.0011855474
5738,uric acid,9,11,57,66,"A significant decrease in the baseline excretion rate of uric acid was found in rats given suprofen, compared with drug-free controls.",1636026_5,-1,-1,-1,5738,-1,0.9984701,0.001529862
5739,suprofen,16,17,91,99,"A significant decrease in the baseline excretion rate of uric acid was found in rats given suprofen, compared with drug-free controls.",1636026_5,-1,-1,-1,5739,-1,0.9990926,0.00090743904
5740,uric acid,6,8,37,46,"However, the fractional excretion of uric acid was unchanged between the groups over the experimental period.",1636026_6,-1,-1,-1,5740,-1,0.99763596,0.002364038
5741,suprofen,3,4,12,20,"In summary, suprofen causes acute declines in renal function, most likely by directly altering the intrarenal distribution of uric acid.",1636026_7,-1,-1,-1,5741,-1,0.9989126,0.001087491
5742,declines in renal function,6,10,34,60,"In summary, suprofen causes acute declines in renal function, most likely by directly altering the intrarenal distribution of uric acid.",1636026_7,-1,-1,-1,5742,-1,0.0039418777,0.9960581
5743,uric acid,20,22,126,135,"In summary, suprofen causes acute declines in renal function, most likely by directly altering the intrarenal distribution of uric acid.",1636026_7,-1,-1,-1,5743,-1,0.99884135,0.0011587115
5744,ritanserin,2,3,18,28,Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine-induced amnesia in adult male rats.,16364460_0,-1,-1,-1,5744,-1,0.9993112,0.0006888164
5746,ritanserin,3,4,14,24,The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.,16364460_1,-1,-1,-1,5746,-1,0.9993173,0.0006826938
5749,DMSO,11,12,59,63,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5749,-1,0.99838734,0.0016126835
5750,saline+DMSO,13,14,65,76,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5750,-1,0.9978148,0.0021852627
5752,ritanserin,29,30,150,160,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5752,-1,0.9993461,0.0006538869
5754,ritanserin,55,56,278,288,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5754,-1,0.9992993,0.00070071785
5755,injection)+ritanserin,56,57,289,310,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5755,-1,0.99810046,0.0018995454
5756,DMSO,61,62,332,336,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5756,-1,0.9981584,0.0018416398
5758,ritanserin,4,5,25,35,"However, scopolamine and ritanserin co-administration resulted in a significant decrease in escape latencies and traveled distances as compared to the scopolamine-treated rats.",16364460_8,-1,-1,-1,5758,-1,0.99934405,0.00065595604
5759,ritanserin,6,7,41,51,Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine-induced amnesia.,16364460_9,-1,-1,-1,5759,-1,0.9993019,0.0006981206
5763,nephrosclerosis,9,10,62,77,Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.,1639466_0,-1,-1,-1,5763,-1,0.0011516475,0.9988483
5764,renovascular hypertension,13,15,91,116,Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.,1639466_0,-1,-1,-1,5764,-1,0.0015338989,0.99846613
5770,renovascular hypertension,43,45,274,299,"The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.",1639466_1,-1,-1,-1,5770,-1,0.0016523706,0.99834764
5772,mm Hg,16,18,75,80,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,-1,-1,5772,-1,0.01797257,0.9820274
5774,n,30,31,155,156,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,-1,-1,5774,-1,0.12374553,0.87625444
5775,n,36,37,182,183,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,-1,-1,5775,-1,0.13844848,0.86155146
5776,n,43,44,215,216,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,-1,-1,5776,-1,0.19090202,0.80909795
5777,mm Hg,11,13,62,67,"Sham-operated rats served as normotensive controls (128 +/- 3 mm Hg, n = 8).",1639466_3,-1,-1,-1,5777,-1,0.018010888,0.98198915
5778,n,14,15,69,70,"Sham-operated rats served as normotensive controls (128 +/- 3 mm Hg, n = 8).",1639466_3,-1,-1,-1,5778,-1,0.14279495,0.8572051
5779,sclerosis,10,11,67,76,Renal tissue was obtained for determination of glomerular size and sclerosis.,1639466_5,-1,-1,-1,5779,-1,0.0020938246,0.9979062
5784,contrast,1,2,3,11,"In contrast, in the nitrendipine-treated group albuminuria increased from 12.8 +/- 2 progressively to 163 +/- 55 compared with 19.2 +/- 9 mg/24 hr in the hypertensive controls.",1639466_9,-1,-1,-1,5784,-1,0.16519953,0.8348005
5791,torsades de pointes,2,5,21,40,Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.,16403073_0,-1,-1,-1,5791,-1,0.0018022603,0.99819773
5793,coronary artery disease,5,8,23,46,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,-1,-1,5793,-1,0.0019486212,0.9980514
5794,prolonged QT interval,12,15,72,93,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,-1,-1,5794,-1,0.0072417124,0.9927583
5795,torsades de pointes,16,19,98,117,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,-1,-1,5795,-1,0.0020287896,0.99797124
5796,TdP,20,21,119,122,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,-1,-1,5796,-1,0.0028973785,0.99710256
5798,fungal infection,28,30,167,183,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,-1,-1,5798,-1,0.0018237499,0.9981762
5802,long QT syndrome,37,40,227,243,"We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP. This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome.",16403073_5,-1,-1,-1,5802,-1,0.0021898379,0.9978102
5804,Turner Syndrome,6,8,41,56,PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.,16418614_0,-1,-1,-1,5804,-1,0.0017207935,0.9982792
5805,Graves' disease,9,12,61,76,PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.,16418614_0,-1,-1,-1,5805,-1,0.0020899752,0.99790996
5806,purpura,1,2,9,16,"Palpable purpura is a concerning clinical finding in pediatric patients and can have many causes, including infectious and autoimmune processes.",16418614_1,-1,-1,-1,5806,-1,0.0014388859,0.9985611
5808,Turner syndrome,5,7,22,37,We report a girl with Turner syndrome and Graves' disease who presented with palpable purpuric lesions.,16418614_3,-1,-1,-1,5808,-1,0.002007712,0.9979923
5809,Graves' disease,8,11,42,57,We report a girl with Turner syndrome and Graves' disease who presented with palpable purpuric lesions.,16418614_3,-1,-1,-1,5809,-1,0.0024891493,0.9975108
5810,purpuric lesions,15,17,86,102,We report a girl with Turner syndrome and Graves' disease who presented with palpable purpuric lesions.,16418614_3,-1,-1,-1,5810,-1,0.001550641,0.9984493
5813,PTU,36,37,245,248,"The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.",16418614_4,-1,-1,-1,5813,-1,0.99002343,0.009976569
5816,Cerebral vasculitis,0,2,0,19,Cerebral vasculitis following oral methylphenidate intake in an adult: a case report.,16428221_0,-1,-1,-1,5816,-1,0.0012449642,0.998755
5820,Cerebral vasculitis,0,2,0,19,"Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.",16428221_2,-1,-1,-1,5820,-1,0.0011818301,0.9988181
5821,amphetamine abuse,4,6,36,53,"Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.",16428221_2,-1,-1,-1,5821,-1,0.8722328,0.1277672
5822,ischaemic stroke,14,16,92,108,"Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.",16428221_2,-1,-1,-1,5822,-1,0.0013710924,0.998629
5826,ischaemic strokes,20,22,128,145,We report the case of a 63-year-old female who was treated with methylphenidate due to hyperactivity and suffered from multiple ischaemic strokes.,16428221_3,-1,-1,-1,5826,-1,0.001333059,0.998667
5827,cerebral vasculitis,3,5,25,44,We consider drug-induced cerebral vasculitis as the most likely cause of recurrent ischaemic strokes in the absence of any pathological findings during the diagnostic work-up.,16428221_4,-1,-1,-1,5827,-1,0.0010885342,0.9989115
5828,ischaemic strokes,12,14,83,100,We consider drug-induced cerebral vasculitis as the most likely cause of recurrent ischaemic strokes in the absence of any pathological findings during the diagnostic work-up.,16428221_4,-1,-1,-1,5828,-1,0.0012162363,0.99878377
5831,neurological symptoms,12,14,91,112,We conclude that methylphenidate mediated vasculitis should be considered in patients with neurological symptoms and a history of methylphenidate therapy.,16428221_5,-1,-1,-1,5831,-1,0.0011808455,0.9988192
5834,Daidzein,0,1,0,8,Daidzein activates choline acetyltransferase from MC-IXC cells and improves drug-induced amnesia.,16428827_0,-1,-1,-1,5834,-1,0.9991984,0.0008015843
5839,ACh,22,23,154,157,"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).",16428827_1,-1,-1,-1,5839,-1,0.99839324,0.0016066816
5840,Alzheimer's disease,33,36,203,222,"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).",16428827_1,-1,-1,-1,5840,-1,0.0027714043,0.99722856
5841,AD,37,38,224,226,"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).",16428827_1,-1,-1,-1,5841,-1,0.0021340877,0.997866
5842,daidzein,15,16,105,113,"Via the sequential isolation of Pueraria thunbergiana, the active component was ultimately identified as daidzein (4',7-dihydroxy-isoflavone).",16428827_3,-1,-1,-1,5842,-1,0.99899536,0.0010046604
5843,daidzein,7,8,39,47,"In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine-induced impairments of learning and memory, we conducted a series of in vivo tests.",16428827_4,-1,-1,-1,5843,-1,0.9991548,0.00084519305
5844,daidzein,2,3,18,26,"Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.",16428827_5,-1,-1,-1,5844,-1,0.99921346,0.00078652106
5845,body weight,6,8,38,49,"Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.",16428827_5,-1,-1,-1,5845,-1,0.80986834,0.19013171
5848,contrast,3,4,10,18,"By way of contrast, mice treated with daidzein prior to the scopolamine injections were noticeably protected from this performance impairment (an approximately 12%-21% decrease in alternation behavior).",16428827_7,-1,-1,-1,5848,-1,0.9910993,0.008900647
5849,daidzein,8,9,38,46,"By way of contrast, mice treated with daidzein prior to the scopolamine injections were noticeably protected from this performance impairment (an approximately 12%-21% decrease in alternation behavior).",16428827_7,-1,-1,-1,5849,-1,0.99914455,0.0008554531
5851,daidzein,4,5,28,36,"These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced amnesia.",16428827_8,-1,-1,-1,5851,-1,0.9991954,0.00080463436
5854,overactive bladder,11,13,64,82,Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment.,16471092_0,-1,-1,-1,5854,-1,0.0016138278,0.99838614
5855,tolterodine,14,15,89,100,Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment.,16471092_0,-1,-1,-1,5855,-1,0.9992132,0.0007867422
5856,overactive bladder,16,18,89,107,OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after tolterodine treatment.,16471092_1,-1,-1,-1,5856,-1,0.0015214188,0.9984786
5857,OAB,19,20,109,112,OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after tolterodine treatment.,16471092_1,-1,-1,-1,5857,-1,0.0016530827,0.9983469
5858,tolterodine,22,23,120,131,OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after tolterodine treatment.,16471092_1,-1,-1,-1,5858,-1,0.9991922,0.0008078277
5859,OAB,16,17,73,76,"MATERIAL AND METHOD: Thirty women (aged 30-77 years) diagnosed as having OAB at the Gynecology Clinic, King Chulalongkorn Memorial Hospital from January to April 2004 were included in the present study.",16471092_2,-1,-1,-1,5859,-1,0.0022045106,0.99779546
5860,Tolterodine,0,1,0,11,"Tolterodine 2 mg, twice daily was given.",16471092_3,-1,-1,-1,5860,-1,0.99919516,0.00080489635
5861,mg,2,3,14,16,"Tolterodine 2 mg, twice daily was given.",16471092_3,-1,-1,-1,5861,-1,0.99489,0.005109951
5862,nocturia,3,4,14,22,The number of nocturia episodes decreased from 5.4 +/- 4.2 to 1.1 +/- 1.0 times per night.,16471092_8,-1,-1,-1,5862,-1,0.0015143862,0.9984856
5863,dry month,6,8,32,41,The most common side effect was dry month in 5 cases (16.7%) with 2 cases reporting a moderate degree and 1 case with severe degree.,16471092_9,-1,-1,-1,5863,-1,0.0021271766,0.9978728
5865,Tolterodine,2,3,12,23,CONCLUSION: Tolterodine was well tolerated and its effects improved the quality of life in Thai women with OAB.,16471092_12,-1,-1,-1,5865,-1,0.999171,0.00082901435
5866,OAB,18,19,107,110,CONCLUSION: Tolterodine was well tolerated and its effects improved the quality of life in Thai women with OAB.,16471092_12,-1,-1,-1,5866,-1,0.0026872326,0.9973127
5867,Remifentanil,0,1,0,12,Remifentanil pretreatment reduces myoclonus after etomidate.,16563323_0,-1,-1,-1,5867,-1,0.9992939,0.00070599536
5869,etomidate,5,6,50,59,Remifentanil pretreatment reduces myoclonus after etomidate.,16563323_0,-1,-1,-1,5869,-1,0.99924684,0.0007531454
5870,remifentanil,16,17,85,97,STUDY OBJECTIVE: The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg/kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate.,16563323_1,-1,-1,-1,5870,-1,0.9993248,0.0006752467
5872,etomidate,33,34,197,206,STUDY OBJECTIVE: The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg/kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate.,16563323_1,-1,-1,-1,5872,-1,0.9992945,0.0007054776
5873,remifentanil,12,13,85,97,PATIENTS: Sixty patients were pretreated in a randomized double-blinded fashion with remifentanil 1 microg/kg or placebo.,16563323_4,-1,-1,-1,5873,-1,0.9992772,0.00072280056
5874,remifentanil,3,4,18,30,"Two minutes after remifentanil or placebo injection, etomidate 0.3 mg/kg was given.",16563323_5,-1,-1,-1,5874,-1,0.99931705,0.00068290986
5875,etomidate,8,9,53,62,"Two minutes after remifentanil or placebo injection, etomidate 0.3 mg/kg was given.",16563323_5,-1,-1,-1,5875,-1,0.9992612,0.00073874916
5881,remifentanil,12,13,72,84,MAIN RESULTS: The incidence of myoclonus was significantly lower in the remifentanil group (6.7%) than in the placebo group (70%) (P < 0.001).,16563323_8,-1,-1,-1,5881,-1,0.9992568,0.0007432148
5882,P,28,29,131,132,MAIN RESULTS: The incidence of myoclonus was significantly lower in the remifentanil group (6.7%) than in the placebo group (70%) (P < 0.001).,16563323_8,-1,-1,-1,5882,-1,0.37719023,0.6228097
5887,etomidate,16,17,110,119,"In the placebo group, male patients were associated with significantly increased incidence of myoclonus after etomidate administration.",16563323_10,-1,-1,-1,5887,-1,0.99925894,0.0007410845
5888,remifentanil,4,5,30,42,"CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.",16563323_11,-1,-1,-1,5888,-1,0.99933016,0.0006698293
5890,etomidate,10,11,79,88,"CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.",16563323_11,-1,-1,-1,5890,-1,0.9993067,0.0006932981
5895,etomidate,9,10,65,74,Men experience increased incidence of myoclonus than women after etomidate administration.,16563323_12,-1,-1,-1,5895,-1,0.99924266,0.0007573691
5896,MDMA,0,1,0,4,MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.,16574712_0,-1,-1,-1,5896,-1,0.9988446,0.0011554022
5897,central executive impairments,5,8,42,71,MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.,16574712_0,-1,-1,-1,5897,-1,0.0056572896,0.9943427
5898,impaired social and emotional judgement processes,10,16,85,134,MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.,16574712_0,-1,-1,-1,5898,-1,0.0076410268,0.992359
5899,working memory deficits,3,6,16,39,"In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).",16574712_1,-1,-1,-1,5899,-1,0.00715769,0.9928423
5900,MDMA,12,13,71,75,"In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).",16574712_1,-1,-1,-1,5900,-1,0.9992644,0.0007355907
5903,MDMA,9,10,48,52,"The current study aimed to assess the impact of MDMA use on three separate central executive processes (set shifting, inhibition and memory updating) and also on ""prefrontal"" mediated social and emotional judgement processes.",16574712_2,-1,-1,-1,5903,-1,0.9990409,0.00095908967
5905,MDMA,6,7,43,47,"Compared with MDMA-free polydrug controls, MDMA polydrug users showed impairments in set shifting and memory updating, and also in social and emotional judgement processes.",16574712_4,-1,-1,-1,5905,-1,0.99890137,0.0010985594
5909,MDMA,11,12,81,85,Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users.,16574713_0,-1,-1,-1,5909,-1,0.9991227,0.0008773504
5911,MDMA,3,4,44,48,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,-1,-1,-1,5911,-1,0.99921846,0.00078150496
5914,5-HT,15,16,103,107,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,-1,-1,-1,5914,-1,0.9987005,0.0012995129
5915,5-HT neurotoxic lesions,33,36,214,237,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,-1,-1,-1,5915,-1,0.3975796,0.6024204
5916,5-HT,40,41,260,264,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,-1,-1,-1,5916,-1,0.9987,0.0012999634
5917,5-HT,1,2,8,12,Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.,16574713_2,-1,-1,-1,5917,-1,0.99844956,0.0015503663
5918,5-HT,12,13,75,79,Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.,16574713_2,-1,-1,-1,5918,-1,0.9984285,0.001571497
5919,5-HT,30,31,185,189,Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.,16574713_2,-1,-1,-1,5919,-1,0.99835205,0.0016479227
5920,MDMA,43,44,263,267,Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.,16574713_2,-1,-1,-1,5920,-1,0.9991074,0.0008925071
5921,MDMA,14,15,74,78,"The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function, as well as the effects of long-term abstention from MDMA, in subjects genotyped for 5-HTTLPR.",16574713_3,-1,-1,-1,5921,-1,0.9991466,0.0008533867
5922,MDMA,29,30,158,162,"The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function, as well as the effects of long-term abstention from MDMA, in subjects genotyped for 5-HTTLPR.",16574713_3,-1,-1,-1,5922,-1,0.9991825,0.00081742246
5923,MDMA,2,3,17,21,"Fifteen moderate MDMA users (<55 lifetime tablets), 22 heavy MDMA+ users (>55 lifetime tablets), 16 ex-MDMA+ users (last tablet > 1 year ago) and 13 controls were compared on a battery of neuropsychological tests.",16574713_5,-1,-1,-1,5923,-1,0.9985576,0.0014424216
5924,p,12,13,71,72,A significant group effect was observed only on memory function tasks (p = 0.04) but not on reaction times (p = 0.61) or attention/executive functioning (p = 0.59).,16574713_7,-1,-1,-1,5924,-1,0.24403034,0.75596964
5925,p,22,23,108,109,A significant group effect was observed only on memory function tasks (p = 0.04) but not on reaction times (p = 0.61) or attention/executive functioning (p = 0.59).,16574713_7,-1,-1,-1,5925,-1,0.06773026,0.93226975
5926,p,30,31,154,155,A significant group effect was observed only on memory function tasks (p = 0.04) but not on reaction times (p = 0.61) or attention/executive functioning (p = 0.59).,16574713_7,-1,-1,-1,5926,-1,0.07294876,0.9270513
5927,contrast,1,2,3,11,"In contrast, no evidence of memory impairment was observed in moderate MDMA users.",16574713_9,-1,-1,-1,5927,-1,0.12802811,0.8719719
5929,MDMA,12,13,71,75,"In contrast, no evidence of memory impairment was observed in moderate MDMA users.",16574713_9,-1,-1,-1,5929,-1,0.9988417,0.001158339
5930,MDMA,4,5,17,21,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,-1,5930,-1,0.9992028,0.0007972548
5931,impaired memory functioning,18,21,93,120,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,-1,5931,-1,0.0023860969,0.9976139
5932,MDMA,25,26,135,139,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,-1,5932,-1,0.99916446,0.0008355432
5933,lead,28,29,148,152,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,-1,5933,-1,0.012299274,0.9877007
5934,memory impairments,32,34,169,187,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,-1,5934,-1,0.0020408167,0.99795914
5935,MDMA,10,11,54,58,No effect of 5-HTTLPR or gender on memory function or MDMA use was observed.,16574713_12,-1,-1,-1,5935,-1,0.99906296,0.00093708077
5936,mangiferin,2,3,8,18,Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol-induced myocardial infarction in rats.,16584858_0,-1,-1,-1,5936,-1,0.9990683,0.00093170704
5937,myocardial infarction,11,13,94,115,Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol-induced myocardial infarction in rats.,16584858_0,-1,-1,-1,5937,-1,0.0014103437,0.9985896
5938,mangiferin,9,10,52,62,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,-1,-1,-1,5938,-1,0.9986833,0.0013166668
5939,polyphenol,12,13,66,76,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,-1,-1,-1,5939,-1,0.9955166,0.0044834446
5941,myocardial infarction,25,27,154,175,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,-1,-1,-1,5941,-1,0.0016056753,0.9983943
5942,MI,28,29,177,179,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,-1,-1,-1,5942,-1,0.0017283042,0.9982717
5943,ISPH,3,4,26,30,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,-1,-1,-1,5943,-1,0.9987552,0.0012448042
5944,body weight,7,9,42,53,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,-1,-1,-1,5944,-1,0.8454269,0.15457313
5946,lactate,36,37,196,203,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,-1,-1,-1,5946,-1,0.9983088,0.0016912459
5948,uric acid,50,52,281,290,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,-1,-1,-1,5948,-1,0.99867755,0.0013224569
5950,mangiferin,4,5,23,33,The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.,16584858_3,-1,-1,-1,5950,-1,0.99915504,0.0008449918
5951,triphenyl tetrazolium chloride,8,11,50,80,The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.,16584858_3,-1,-1,-1,5951,-1,0.9989542,0.0010457429
5952,TTC,12,13,82,85,The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.,16584858_3,-1,-1,-1,5952,-1,0.99795854,0.002041491
5953,ischemic myocardium,23,25,141,160,The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.,16584858_3,-1,-1,-1,5953,-1,0.003055996,0.996944
5954,superoxide dismutase,7,9,45,65,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5954,-1,0.99821633,0.0017836398
5955,glutathione peroxidase,12,14,77,99,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5955,-1,0.9954953,0.0045046774
5956,glutathione transferase,15,17,101,124,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5956,-1,0.9953668,0.0046331496
5957,glutathione reductase,18,20,129,150,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5957,-1,0.9971174,0.0028826515
5958,Vitamin C,28,30,212,221,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5958,-1,0.9986406,0.0013594513
5959,Vitamin E,31,33,223,232,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5959,-1,0.9985728,0.0014272139
5961,MI,39,40,272,274,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5961,-1,0.0052054054,0.99479455
5962,mangiferin,3,4,23,33,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,-1,-1,5962,-1,0.9991309,0.00086910365
5963,body weight,7,9,45,56,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,-1,-1,5963,-1,0.8671728,0.13282718
5964,dimethyl sulphoxide,14,16,78,97,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,-1,-1,5964,-1,0.99904805,0.0009519496
5965,MI,23,24,138,140,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,-1,-1,5965,-1,0.0067077987,0.9932922
5966,mangiferin,14,15,114,124,Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.,16584858_6,-1,-1,-1,5966,-1,0.9991353,0.0008647536
5967,MI,20,21,168,170,Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.,16584858_6,-1,-1,-1,5967,-1,0.0026836174,0.9973164
5968,mangiferin,8,9,44,54,"From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.",16584858_7,-1,-1,-1,5968,-1,0.99896955,0.0010304251
5969,MI,15,16,103,105,"From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.",16584858_7,-1,-1,-1,5969,-1,0.0015011252,0.9984989
5970,cardiac damage,29,31,191,205,"From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.",16584858_7,-1,-1,-1,5970,-1,0.0017473149,0.9982527
5971,cyclooxygenase inhibitors,3,5,25,50,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,-1,-1,5971,-1,0.9983014,0.0016985686
5972,myocardial infarction,23,25,189,210,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,-1,-1,5972,-1,0.0016767906,0.99832314
5975,heart failure,30,32,237,250,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,-1,-1,5975,-1,0.0016755228,0.99832445
5976,cyclooxygenase inhibitors,35,37,273,298,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,-1,-1,5976,-1,0.9984604,0.0015395699
5977,Cyclooxygenase inhibitors,0,2,0,25,"Cyclooxygenase inhibitors cause complex changes in renal, vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention.",16586083_2,-1,-1,-1,5977,-1,0.9981833,0.001816721
5978,cyclooxygenase inhibitors,7,9,53,78,"A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin-independent effects.",16586083_4,-1,-1,-1,5978,-1,0.9921198,0.007880248
5979,cardiovascular toxicity,33,35,217,240,"Diagnostic markers such as N-terminal pro brain natriuretic peptide (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious cardiovascular toxicity.",16586083_5,-1,-1,-1,5979,-1,0.0013051132,0.99869496
5980,Pilocarpine seizures,0,2,0,20,Pilocarpine seizures cause age-dependent impairment in auditory location discrimination.,16596970_0,-1,-1,-1,5980,-1,0.7095317,0.29046825
5981,impairment in auditory location discrimination,4,9,41,87,Pilocarpine seizures cause age-dependent impairment in auditory location discrimination.,16596970_0,-1,-1,-1,5981,-1,0.008465056,0.99153495
5982,status epilepticus,3,5,18,36,Children who have status epilepticus have continuous or rapidly repeating seizures that may be life-threatening and may cause life-long changes in brain and behavior.,16596970_1,-1,-1,-1,5982,-1,0.0015388182,0.99846125
5984,status epilepticus,4,6,20,38,The extent to which status epilepticus causes deficits in auditory discrimination is unknown.,16596970_2,-1,-1,-1,5984,-1,0.002072923,0.99792707
5985,deficits in auditory discrimination,7,11,46,81,The extent to which status epilepticus causes deficits in auditory discrimination is unknown.,16596970_2,-1,-1,-1,5985,-1,0.01140008,0.9885999
5986,status epilepticus,17,19,115,133,A naturalistic auditory location discrimination method was used to evaluate this question using an animal model of status epilepticus.,16596970_3,-1,-1,-1,5986,-1,0.0018456884,0.99815434
5989,status epilepticus,5,7,34,52,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,-1,-1,-1,5989,-1,0.0014607522,0.9985392
5990,status epilepticus,8,10,54,72,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,-1,-1,-1,5990,-1,0.0017366927,0.9982633
5993,status epilepticus,1,3,3,21,"In status epilepticus (P20) rats, acquisition of the sound-source location discrimination was moderately impaired.",16596970_8,-1,-1,-1,5993,-1,0.0030580566,0.99694186
5994,Status epilepticus,0,2,0,18,Status epilepticus (P45) rats failed to acquire either sound-source location or sound-silence discriminations.,16596970_9,-1,-1,-1,5994,-1,0.003197785,0.9968022
5995,Status epilepticus,0,2,0,18,"Status epilepticus in rat causes an age-dependent, long-term impairment in auditory discrimination.",16596970_10,-1,-1,-1,5995,-1,0.0019208795,0.99807906
5996,impairment in auditory discrimination,9,13,61,98,"Status epilepticus in rat causes an age-dependent, long-term impairment in auditory discrimination.",16596970_10,-1,-1,-1,5996,-1,0.009791668,0.99020827
5997,impaired auditory location discrimination,7,11,41,82,This impairment may explain one cause of impaired auditory location discrimination in humans.,16596970_11,-1,-1,-1,5997,-1,0.015540488,0.9844595
5998,Nerve growth factor,0,3,0,19,Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder.,16600756_0,-1,-1,-1,5998,-1,0.9966563,0.0033436408
6000,overactive bladder,12,14,76,94,Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder.,16600756_0,-1,-1,-1,6000,-1,0.0018292903,0.99817073
6001,NGF,2,3,9,12,PURPOSE: NGF and PGs in the bladder can be affected by pathological changes in the bladder and these changes can be detected in urine.,16600756_1,-1,-1,-1,6001,-1,0.9987312,0.0012688327
6002,PGs,4,5,17,20,PURPOSE: NGF and PGs in the bladder can be affected by pathological changes in the bladder and these changes can be detected in urine.,16600756_1,-1,-1,-1,6002,-1,0.9983581,0.0016419479
6003,NGF,5,6,35,38,We investigated changes in urinary NGF and PGs in women with OAB.,16600756_2,-1,-1,-1,6003,-1,0.9975376,0.002462405
6004,PGs,7,8,43,46,We investigated changes in urinary NGF and PGs in women with OAB.,16600756_2,-1,-1,-1,6004,-1,0.99573684,0.004263173
6005,OAB,11,12,61,64,We investigated changes in urinary NGF and PGs in women with OAB.,16600756_2,-1,-1,-1,6005,-1,0.0033768888,0.99662316
6006,OAB,11,12,63,66,MATERIALS AND METHODS: The study groups included 65 women with OAB and 20 without bladder symptoms who served as controls.,16600756_3,-1,-1,-1,6006,-1,0.001652616,0.9983474
6007,bladder symptoms,15,17,82,98,MATERIALS AND METHODS: The study groups included 65 women with OAB and 20 without bladder symptoms who served as controls.,16600756_3,-1,-1,-1,6007,-1,0.0015110457,0.9984889
6008,NGF,0,1,0,3,"NGF, PGE2, PGF2alpha and PGI2 were measured using enzyme-linked immunosorbent assay and compared between the groups.",16600756_6,-1,-1,-1,6008,-1,0.9987204,0.001279611
6009,PGE2,2,3,5,9,"NGF, PGE2, PGF2alpha and PGI2 were measured using enzyme-linked immunosorbent assay and compared between the groups.",16600756_6,-1,-1,-1,6009,-1,0.99869174,0.001308223
6010,PGF2alpha,4,5,11,20,"NGF, PGE2, PGF2alpha and PGI2 were measured using enzyme-linked immunosorbent assay and compared between the groups.",16600756_6,-1,-1,-1,6010,-1,0.9985526,0.001447337
6011,PGI2,6,7,25,29,"NGF, PGE2, PGF2alpha and PGI2 were measured using enzyme-linked immunosorbent assay and compared between the groups.",16600756_6,-1,-1,-1,6011,-1,0.99863917,0.0013608075
6012,NGF,6,7,42,45,"In addition, correlations between urinary NGF and PG, and urodynamic parameters in patients with OAB were examined.",16600756_7,-1,-1,-1,6012,-1,0.9974558,0.0025442727
6013,PG,8,9,50,52,"In addition, correlations between urinary NGF and PG, and urodynamic parameters in patients with OAB were examined.",16600756_7,-1,-1,-1,6013,-1,0.9965312,0.0034688371
6014,OAB,16,17,97,100,"In addition, correlations between urinary NGF and PG, and urodynamic parameters in patients with OAB were examined.",16600756_7,-1,-1,-1,6014,-1,0.0020597826,0.99794024
6015,NGF,3,4,17,20,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,-1,-1,-1,6015,-1,0.9985954,0.0014045615
6016,PGE2,5,6,22,26,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,-1,-1,-1,6016,-1,0.99842477,0.0015753008
6017,PGF2alpha,7,8,31,40,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,-1,-1,-1,6017,-1,0.9983473,0.001652775
6018,OAB,14,15,87,90,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,-1,-1,-1,6018,-1,0.0027636508,0.9972364
6019,p,19,20,115,116,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,-1,-1,-1,6019,-1,0.5911648,0.40883514
6020,PGI2,3,4,17,21,"However, urinary PGI2 was not different between controls and patients with OAB.",16600756_9,-1,-1,-1,6020,-1,0.99746454,0.0025354503
6021,OAB,12,13,75,78,"However, urinary PGI2 was not different between controls and patients with OAB.",16600756_9,-1,-1,-1,6021,-1,0.0022825033,0.9977175
6022,OAB,3,4,17,20,In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).,16600756_10,-1,-1,-1,6022,-1,0.0042803176,0.99571973
6023,PGE2,5,6,29,33,In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).,16600756_10,-1,-1,-1,6023,-1,0.99866796,0.001332102
6024,p,20,21,126,127,In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).,16600756_10,-1,-1,-1,6024,-1,0.45986688,0.54013306
6025,NGF,1,2,8,11,"Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.",16600756_11,-1,-1,-1,6025,-1,0.99851793,0.0014820611
6026,PGF2alpha,3,4,13,22,"Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.",16600756_11,-1,-1,-1,6026,-1,0.9983936,0.0016064049
6027,PGI2,5,6,27,31,"Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.",16600756_11,-1,-1,-1,6027,-1,0.99842876,0.0015712274
6028,OAB,15,16,94,97,"Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.",16600756_11,-1,-1,-1,6028,-1,0.0021385225,0.99786144
6029,NGF,2,3,13,16,CONCLUSIONS: NGF and PGs have important roles in the development of OAB symptoms in female patients.,16600756_12,-1,-1,-1,6029,-1,0.998125,0.001875035
6030,PGs,4,5,21,24,CONCLUSIONS: NGF and PGs have important roles in the development of OAB symptoms in female patients.,16600756_12,-1,-1,-1,6030,-1,0.9972759,0.0027240845
6031,OAB,12,13,68,71,CONCLUSIONS: NGF and PGs have important roles in the development of OAB symptoms in female patients.,16600756_12,-1,-1,-1,6031,-1,0.0017432442,0.99825674
6032,OAB,12,13,67,70,Urinary levels of these factors may be used as markers to evaluate OAB symptoms.,16600756_13,-1,-1,-1,6032,-1,0.0020039072,0.9979961
6034,infected with hepatitis C virus,7,12,48,79,Definition and management of anemia in patients infected with hepatitis C virus.,16629641_0,-1,-1,-1,6034,-1,0.009404256,0.9905957
6035,Chronic infection with hepatitis C virus,0,6,0,40,"Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease.",16629641_1,-1,-1,-1,6035,-1,0.010493962,0.98950607
6036,HCV,7,8,42,45,"Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease.",16629641_1,-1,-1,-1,6036,-1,0.0077838167,0.9922161
6040,HCV infection,5,7,31,44,The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.,16629641_2,-1,-1,-1,6040,-1,0.0034731273,0.9965269
6041,pegylated interferon,11,13,73,93,The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.,16629641_2,-1,-1,-1,6041,-1,0.99913776,0.00086217717
6046,HCV infection,20,22,138,151,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.",16629641_4,-1,-1,-1,6046,-1,0.0107379025,0.98926204
6047,renal,28,29,188,193,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.",16629641_4,-1,-1,-1,6047,-1,0.0018804113,0.99811953
6048,cardiovascular disorders,30,32,197,221,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.",16629641_4,-1,-1,-1,6048,-1,0.0013842658,0.99861574
6052,Viramidine,0,1,0,10,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",16629641_8,-1,-1,-1,6052,-1,0.99899024,0.0010097335
6056,chronic hepatitis C.,28,31,181,201,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",16629641_8,-1,-1,-1,6056,-1,0.011616169,0.98838377
6060,fetal growth impairment,10,13,74,97,This study examined the utility of biometry for detecting alcohol-related fetal growth impairment.,16634859_3,-1,-1,-1,6060,-1,0.0018943868,0.99810565
6066,reduced cerebellar growth,11,14,87,112,Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.,16634859_11,-1,-1,-1,6066,-1,0.009848876,0.99015117
6067,decreased,17,18,124,133,Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.,16634859_11,-1,-1,-1,6067,-1,0.008730421,0.9912696
6068,to body growth,19,22,142,156,Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.,16634859_11,-1,-1,-1,6068,-1,0.027749106,0.9722509
6069,Amphetamine abuse,0,2,0,17,Amphetamine abuse was predictive of larger cranial to body growth ratios.,16634859_12,-1,-1,-1,6069,-1,0.94467074,0.055329293
6071,amsacrine,5,6,22,31,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,-1,-1,-1,6071,-1,0.99918205,0.0008179406
6072,CI-921,7,8,41,47,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,-1,-1,-1,6072,-1,0.99887043,0.0011295765
6073,NSC 343499,9,11,49,59,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,-1,-1,-1,6073,-1,0.99795294,0.0020470598
6074,lung cancer,15,17,79,90,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,-1,-1,-1,6074,-1,0.0023837485,0.9976163
6075,CI-921,0,1,0,6,"CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity.",1664218_1,-1,-1,-1,6075,-1,0.99740463,0.0025953453
6076,NSC 343499,2,4,8,18,"CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity.",1664218_1,-1,-1,-1,6076,-1,0.9836285,0.016371569
6077,"9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide",5,9,20,110,"CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity.",1664218_1,-1,-1,-1,6077,-1,0.9967728,0.0032271254
6078,lung cancer,14,16,84,95,"It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial.",1664218_2,-1,-1,-1,6078,-1,0.0016767507,0.99832326
6079,NSCLC,17,18,97,102,"It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial.",1664218_2,-1,-1,-1,6079,-1,0.0014968294,0.9985032
6080,squamous carcinoma,3,5,24,42,"The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1).",1664218_4,-1,-1,-1,6080,-1,0.0032652745,0.9967347
6081,adenocarcinoma,9,10,49,63,"The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1).",1664218_4,-1,-1,-1,6081,-1,0.0029468827,0.99705315
6083,large cell undifferentiated carcinoma,26,30,126,163,"The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1).",1664218_4,-1,-1,-1,6083,-1,0.0053369286,0.994663
6086,grand mal seizures,21,24,105,123,"Neutropenia grade greater than or equal to 3 was seen in 15 patients, infections with recovery in 3, and grand mal seizures in 1 patient.",1664218_5,-1,-1,-1,6086,-1,0.0016117155,0.9983883
6087,nausea and vomiting,7,10,30,49,Grade less than or equal to 2 nausea and vomiting occurred in 66% courses and phlebitis in the infusion arm in 37%.,1664218_6,-1,-1,-1,6087,-1,0.001629685,0.99837035
6088,phlebitis,16,17,78,87,Grade less than or equal to 2 nausea and vomiting occurred in 66% courses and phlebitis in the infusion arm in 37%.,1664218_6,-1,-1,-1,6088,-1,0.0013953516,0.9986047
6089,squamous cell carcinoma,3,6,15,38,1 patient with squamous cell carcinoma achieved a partial response lasting 5 months.,1664218_7,-1,-1,-1,6089,-1,0.0023605812,0.9976394
6090,tumour,6,7,34,40,Further testing in this and other tumour types using multiple daily schedules is warranted.,1664218_8,-1,-1,-1,6090,-1,0.0038188272,0.99618125
6091,desipramine HCl,2,4,20,35,Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.,16680561_0,-1,-1,-1,6091,-1,0.9989661,0.0010339406
6092,cinacalcet HCl,7,9,59,73,Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.,16680561_0,-1,-1,-1,6092,-1,0.9989839,0.0010160407
6097,mg,31,32,191,193,"METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).",16680561_3,-1,-1,-1,6097,-1,0.98940593,0.010594028
6099,mg,49,50,281,283,"METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).",16680561_3,-1,-1,-1,6099,-1,0.98158824,0.018411713
6100,h,9,10,49,50,Blood samples were obtained predose and up to 72 h postdose.,16680561_4,-1,-1,-1,6100,-1,0.19029725,0.80970275
6116,optic neuropathy,1,3,22,38,Ethambutol-associated optic neuropathy.,16710500_0,-1,-1,-1,6116,-1,0.0013191447,0.9986809
6117,Ethambutol,2,3,14,24,"INTRODUCTION: Ethambutol is used in the treatment of tuberculosis, which is still prevalent in Southeast Asia, and can be associated with permanent visual loss.",16710500_1,-1,-1,-1,6117,-1,0.9988778,0.001122129
6120,hemianopia,8,9,50,60,We report 3 cases which presented with bitemporal hemianopia.,16710500_2,-1,-1,-1,6120,-1,0.0015234279,0.99847656
6121,toxic optic neuropathy,7,10,60,82,CLINICAL PICTURE: Three patients with ethambutol-associated toxic optic neuropathy are described.,16710500_3,-1,-1,-1,6121,-1,0.001241407,0.99875855
6122,loss of,4,6,19,26,"All 3 patients had loss of central visual acuity, colour vision (Ishihara) and visual field.",16710500_4,-1,-1,-1,6122,-1,0.0039739436,0.99602604
6123,visual,7,8,35,41,"All 3 patients had loss of central visual acuity, colour vision (Ishihara) and visual field.",16710500_4,-1,-1,-1,6123,-1,0.0065532904,0.99344665
6124,", colour vision",9,12,48,63,"All 3 patients had loss of central visual acuity, colour vision (Ishihara) and visual field.",16710500_4,-1,-1,-1,6124,-1,0.012426487,0.98757344
6125,Ishihara,13,14,65,73,"All 3 patients had loss of central visual acuity, colour vision (Ishihara) and visual field.",16710500_4,-1,-1,-1,6125,-1,0.0034481583,0.9965519
6126,and visual field.,15,19,75,92,"All 3 patients had loss of central visual acuity, colour vision (Ishihara) and visual field.",16710500_4,-1,-1,-1,6126,-1,0.012081101,0.9879189
6127,visual field loss,1,4,4,21,"The visual field loss had a bitemporal flavour, suggesting involvement of the optic chiasm.",16710500_5,-1,-1,-1,6127,-1,0.0038728516,0.9961272
6128,ethambutol,4,5,28,38,"TREATMENT: Despite stopping ethambutol on diagnosis, visual function continued to deteriorate for a few months.",16710500_6,-1,-1,-1,6128,-1,0.9989999,0.0010001694
6129,visual,8,9,53,59,"TREATMENT: Despite stopping ethambutol on diagnosis, visual function continued to deteriorate for a few months.",16710500_6,-1,-1,-1,6129,-1,0.009435461,0.9905646
6130,loss of visual function,8,12,43,66,OUTCOME: All 3 patients had some permanent loss of visual function.,16710500_9,-1,-1,-1,6130,-1,0.0038077126,0.99619234
6131,Ethambutol,2,3,13,23,CONCLUSIONS: Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow-up.,16710500_10,-1,-1,-1,6131,-1,0.9990043,0.0009957394
6133,ethambutol,7,8,39,49,"The author postulates that in cases of ethambutol associated chiasmopathy, ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm.",16710500_11,-1,-1,-1,6133,-1,0.99906045,0.00093961536
6134,chiasmopathy,9,10,61,73,"The author postulates that in cases of ethambutol associated chiasmopathy, ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm.",16710500_11,-1,-1,-1,6134,-1,0.001193794,0.99880624
6135,ethambutol,11,12,75,85,"The author postulates that in cases of ethambutol associated chiasmopathy, ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm.",16710500_11,-1,-1,-1,6135,-1,0.9990852,0.00091482245
6136,neuroleptic malignant syndrome,1,4,9,39,Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.,16720068_0,-1,-1,-1,6136,-1,0.0053727087,0.9946273
6139,depressive symptoms,4,6,23,42,"A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.",16720068_1,-1,-1,-1,6139,-1,0.0013181852,0.99868184
6141,insomnia,14,15,89,97,"A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.",16720068_1,-1,-1,-1,6141,-1,0.0011914321,0.9988086
6142,loss of appetite,16,19,99,115,"A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.",16720068_1,-1,-1,-1,6142,-1,0.0023477941,0.99765223
6144,mg paroxetine,10,12,54,67,Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.,16720068_2,-1,-1,-1,6144,-1,0.9982224,0.0017776198
6145,mg alprazolam,14,16,76,89,Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.,16720068_2,-1,-1,-1,6145,-1,0.9982504,0.0017495379
6148,psychomotor retardation,14,16,85,108,"On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",16720068_3,-1,-1,-1,6148,-1,0.0014940945,0.99850595
6149,disorientation,17,18,110,124,"On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",16720068_3,-1,-1,-1,6149,-1,0.0013770583,0.9986229
6150,muscle rigidity,21,23,137,152,"On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",16720068_3,-1,-1,-1,6150,-1,0.001596251,0.9984037
6153,C,8,9,38,39,"The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.",16720068_4,-1,-1,-1,6153,-1,0.010288744,0.9897113
6154,mg mm Hg,19,22,96,104,"The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.",16720068_4,-1,-1,-1,6154,-1,0.3933339,0.60666615
6159,BUN,28,29,155,158,"Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.",16720068_5,-1,-1,-1,6159,-1,0.99810576,0.0018942152
6163,neuroleptic malignant syndrome,6,9,40,70,"This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.",16720068_8,-1,-1,-1,6163,-1,0.13635458,0.86364543
6164,NMS,10,11,72,75,"This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.",16720068_8,-1,-1,-1,6164,-1,0.001441463,0.9985586
6167,adverse drug reaction,1,4,4,25,"The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.",16720068_9,-1,-1,-1,6167,-1,0.0024581007,0.9975419
6168,adverse symptoms,25,27,151,167,"The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.",16720068_9,-1,-1,-1,6168,-1,0.0014048504,0.9985952
6169,NMS,4,5,25,28,"Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion.",16720068_11,-1,-1,-1,6169,-1,0.001419447,0.9985806
6173,malnutrition,20,21,129,141,"Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion.",16720068_11,-1,-1,-1,6173,-1,0.0014148914,0.9985851
6184,tricaine,6,7,47,55,"Co-administration of lidocaine, bupivacaine or tricaine with desipramine reversed this effect.",16725121_3,-1,-1,-1,6184,-1,0.9993105,0.000689461
6197,lidocaine convulsions,21,23,167,188,These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of lidocaine convulsions.,16725121_7,-1,-1,-1,6197,-1,0.105583034,0.894417
6199,lidocaine seizures,3,5,37,55,Desipramine-induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of cocaine.,16725121_10,-1,-1,-1,6199,-1,0.29129127,0.7087087
6204,plant extracts,16,18,100,114,METHODS: The son of an 84-year-old male discovered a newspaper report stating clinical success with plant extracts in Alzheimer's disease.,16740173_3,-1,-1,-1,6204,-1,0.99441,0.0055899993
6205,Alzheimer's disease,19,22,118,137,METHODS: The son of an 84-year-old male discovered a newspaper report stating clinical success with plant extracts in Alzheimer's disease.,16740173_3,-1,-1,-1,6205,-1,0.0030059717,0.996994
6206,carbamylcholin,16,17,80,94,"The mode of action was said to be comparable to that of the synthetic compound 'carbamylcholin'; that is, carbachol.",16740173_4,-1,-1,-1,6206,-1,0.99920255,0.0007975196
6209,mg,21,22,104,106,"He bought 25 g of carbachol as pure substance in a pharmacy, and the father was administered 400 to 500 mg.",16740173_5,-1,-1,-1,6209,-1,0.99422693,0.005773027
6212,sweating,12,13,74,82,"RESULTS: Minutes after oral administration, the patient developed nausea, sweating and hypotension, and finally collapsed.",16740173_7,-1,-1,-1,6212,-1,0.0015811087,0.9984189
6220,hyperhidrosis,3,4,19,32,"Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation.",16740173_11,-1,-1,-1,6220,-1,0.0013909084,0.9986091
6221,hypersalivation,5,6,34,49,"Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation.",16740173_11,-1,-1,-1,6221,-1,0.0017112121,0.9982888
6222,bronchorrhoea,7,8,51,64,"Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation.",16740173_11,-1,-1,-1,6222,-1,0.001396858,0.99860317
6223,miosis,11,12,77,83,"Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation.",16740173_11,-1,-1,-1,6223,-1,0.0013048657,0.9986952
6225,mg,8,9,33,35,"High doses of atropine (up to 50 mg per 24 hours), adrenaline and dopamine were necessary.",16740173_12,-1,-1,-1,6225,-1,0.9828551,0.017144933
6228,dyspnoea,3,4,19,27,"However, increased dyspnoea and bronchospasm necessitated reintubation.",16740173_14,-1,-1,-1,6228,-1,0.0012720684,0.998728
6229,bronchospasm,5,6,32,44,"However, increased dyspnoea and bronchospasm necessitated reintubation.",16740173_14,-1,-1,-1,6229,-1,0.0012190707,0.9987809
6230,Respiratory insufficiency,0,2,0,25,Respiratory insufficiency was further worsened by Proteus mirabilis infection and severe bronchoconstriction.,16740173_15,-1,-1,-1,6230,-1,0.0013673564,0.9986326
6231,Proteus mirabilis infection,6,9,50,77,Respiratory insufficiency was further worsened by Proteus mirabilis infection and severe bronchoconstriction.,16740173_15,-1,-1,-1,6231,-1,0.032379463,0.9676205
6232,bronchoconstriction,11,12,89,108,Respiratory insufficiency was further worsened by Proteus mirabilis infection and severe bronchoconstriction.,16740173_15,-1,-1,-1,6232,-1,0.001323903,0.9986761
6233,heart failure,12,14,49,62,"On the next day he died, probably as a result of heart failure.",16740173_17,-1,-1,-1,6233,-1,0.0022321737,0.9977678
6237,cholinergics,11,12,77,89,"Especially in old patients, intensivists should consider intoxications (with cholinergics) as a cause of acute cardiovascular failure.",16740173_23,-1,-1,-1,6237,-1,0.99472505,0.0052749095
6238,acute cardiovascular failure,17,20,105,133,"Especially in old patients, intensivists should consider intoxications (with cholinergics) as a cause of acute cardiovascular failure.",16740173_23,-1,-1,-1,6238,-1,0.0012455467,0.9987545
6239,cognitive dysfunctions,12,14,81,103,Pharmacological evidence for the potential of Daucus carota in the management of cognitive dysfunctions.,16755009_0,-1,-1,-1,6239,-1,0.0013429181,0.9986571
6241,DCE,8,9,46,49,"The ethanolic extract of Daucus carota seeds (DCE) was administered orally in three doses (100, 200, 400 mg/kg) for seven successive days to different groups of young and aged mice.",16755009_2,-1,-1,-1,6241,-1,0.9977011,0.002298951
6243,DCE,0,1,0,3,"DCE (200, 400 mg/kg, p.o.) showed significant improvement in memory scores of young and aged mice.",16755009_5,-1,-1,-1,6243,-1,0.9989152,0.0010848349
6244,DCE,7,8,43,46,The extent of memory improvement evoked by DCE was 23% at the dose of 200 mg/kg and 35% at the dose of 400 mg/kg in young mice using elevated plus maze.,16755009_6,-1,-1,-1,6244,-1,0.99856275,0.0014372495
6245,DCE,2,3,13,16,"Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.).",16755009_8,-1,-1,-1,6245,-1,0.99880695,0.0011930721
6250,DCE,10,11,68,71,The extent of inhibition of brain cholinesterase activity evoked by DCE at the dose of 400 mg/kg was 22% in young and 19% in aged mice.,16755009_10,-1,-1,-1,6250,-1,0.99901223,0.0009877114
6252,DCE,30,31,141,144,"There was a remarkable reduction in total cholesterol level as well, to the extent of 23% in young and 21% in aged animals with this dose of DCE.",16755009_11,-1,-1,-1,6252,-1,0.99884975,0.001150288
6253,DCE,2,3,11,14,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",16755009_12,-1,-1,-1,6253,-1,0.9986106,0.0013894163
6254,cognitive dysfunctions,14,16,69,91,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",16755009_12,-1,-1,-1,6254,-1,0.0017027565,0.9982973
6256,Valproic acid,0,2,0,13,Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.,16787750_0,-1,-1,-1,6256,-1,0.9991912,0.000808802
6257,Valproic acid,0,2,0,13,Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually well-tolerated.,16787750_1,-1,-1,-1,6257,-1,0.999038,0.0009620604
6258,VPA,3,4,15,18,Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually well-tolerated.,16787750_1,-1,-1,-1,6258,-1,0.9989643,0.0010356639
6259,haemorrhagic pancreatitis,10,12,65,90,"Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.",16787750_2,-1,-1,-1,6259,-1,0.0012014037,0.9987986
6264,impaired consciousness,7,9,52,74,"The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia.",16787750_3,-1,-1,-1,6264,-1,0.002303082,0.99769694
6267,VPA,9,10,47,50,"There is still no proof of causative effect of VPA in patients with encephalopathy, but only of an association with an assumed causal relation.",16787750_4,-1,-1,-1,6267,-1,0.9758557,0.02414423
6270,Atorvastatin,0,1,0,12,Atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.,16820346_0,-1,-1,-1,6270,-1,0.9991505,0.0008494228
6272,atorvastatin,6,7,37,49,"To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.",16820346_1,-1,-1,-1,6272,-1,0.9990852,0.0009148648
6273,atorva,8,9,51,57,"To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.",16820346_1,-1,-1,-1,6273,-1,0.9988895,0.0011105431
6276,atorva,22,23,150,156,"To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.",16820346_1,-1,-1,-1,6276,-1,0.9990068,0.0009931589
6280,P,36,37,152,153,"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma superoxide (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml dex, P < 0.001).",16820346_2,-1,-1,-1,6280,-1,0.48209074,0.5179093
6281,atorva,8,9,37,43,"In this prevention study, SBP in the atorva + dex group was increased from 115 +/- 0.4 to 124 +/- 1.5 mmHg, but this was significantly lower than in the dex-only group (P' < 0.05).",16820346_3,-1,-1,-1,6281,-1,0.8417956,0.1582044
6283,P,37,38,169,170,"In this prevention study, SBP in the atorva + dex group was increased from 115 +/- 0.4 to 124 +/- 1.5 mmHg, but this was significantly lower than in the dex-only group (P' < 0.05).",16820346_3,-1,-1,-1,6283,-1,0.4084892,0.5915108
6284,Atorva,0,1,0,6,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,-1,-1,6284,-1,0.9911109,0.0088890735
6286,mmHg,9,10,54,58,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,-1,-1,6286,-1,0.0071721505,0.99282783
6287,mmHg P,16,18,76,82,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,-1,-1,6287,-1,0.13560876,0.86439127
6290,atorva,37,38,160,166,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,-1,-1,6290,-1,0.98871243,0.011287531
6292,P,41,42,174,175,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,-1,-1,6292,-1,0.39253506,0.6074649
6293,P,29,30,154,155,"Plasma nitrate/nitrite (NOx) was decreased in dex-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).",16820346_5,-1,-1,-1,6293,-1,0.4585488,0.5414512
6294,Atorva,0,1,0,6,Atorva affected neither plasma NOx nor thymus weight.,16820346_6,-1,-1,-1,6294,-1,0.2874415,0.7125585
6295,atorvastatin,2,3,6,18,"Thus, atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.",16820346_7,-1,-1,-1,6295,-1,0.9991291,0.00087091705
6298,cytosine arabinoside,5,7,42,62,Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.,16826348_0,-1,-1,-1,6298,-1,0.9991923,0.00080768525
6299,acute myeloid leukemia,12,15,91,113,Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.,16826348_0,-1,-1,-1,6299,-1,0.0013326348,0.99866736
6300,central nervous system toxicity,1,5,4,35,"The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.",16826348_1,-1,-1,-1,6300,-1,0.0018825049,0.99811757
6301,cytosine arabinoside,7,9,49,69,"The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.",16826348_1,-1,-1,-1,6301,-1,0.9992937,0.00070632383
6303,cytosine arabinoside,17,19,110,130,"The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.",16826348_1,-1,-1,-1,6303,-1,0.9992556,0.00074436865
6304,acute myeloid leukemia,7,10,46,68,A 49-year-old Japanese man was diagnosed with acute myeloid leukemia.,16826348_2,-1,-1,-1,6304,-1,0.0012909663,0.9987091
6305,cytosine arabinoside,9,11,60,80,"After he achieved complete remission, he received high-dose cytosine arabinoside treatment (2 g/m2 twice a day for 5 days; total, 20 g/m2) as consolidation therapy.",16826348_3,-1,-1,-1,6305,-1,0.9992679,0.00073213945
6306,cytosine arabinoside,5,7,30,50,"The first course of high-dose cytosine arabinoside resulted in no unusual symptoms, but on day 21 of the second course of treatment, the patient complained of numbness in his right foot.",16826348_4,-1,-1,-1,6306,-1,0.9992551,0.0007448942
6307,numbness,28,29,159,167,"The first course of high-dose cytosine arabinoside resulted in no unusual symptoms, but on day 21 of the second course of treatment, the patient complained of numbness in his right foot.",16826348_4,-1,-1,-1,6307,-1,0.0014786342,0.9985214
6312,cytosine arabinoside,11,13,78,98,"Although the mechanisms of peripheral neuropathy are still unclear, high-dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system, and auto/alloimmunity may play an important role in these mechanisms.",16826348_7,-1,-1,-1,6312,-1,0.9992409,0.000759172
6316,dopaminergic neurotoxicity,2,4,29,55,Methamphetamine (MA)-induced dopaminergic neurotoxicity is believed to be associated with the increased formation of free radicals.,16844102_1,-1,-1,-1,6316,-1,0.107187286,0.89281267
6317,reactive oxygen species,14,17,78,101,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,-1,-1,-1,6317,-1,0.3522876,0.6477124
6319,DFO,21,22,121,124,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,-1,-1,-1,6319,-1,0.99890494,0.0010950387
6322,MA,5,6,28,30,"Male rats were treated with MA (10 mg/kg, every 2 h for four injections).",16844102_3,-1,-1,-1,6322,-1,0.9986644,0.0013356616
6323,h,12,13,50,51,"Male rats were treated with MA (10 mg/kg, every 2 h for four injections).",16844102_3,-1,-1,-1,6323,-1,0.9080613,0.09193867
6324,DFO,21,22,114,117,The rat received either alpha-TC (20 mg/kg) intraperitoneally for 3 days and 30 min prior to MA administration or DFO (50 mg/kg) subcutaneously 30 min before MA administration.,16844102_4,-1,-1,-1,6324,-1,0.99912685,0.0008732063
6326,DA,5,6,32,34,"The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.",16844102_5,-1,-1,-1,6326,-1,0.9988103,0.001189769
6328,DFO,25,26,158,161,"The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.",16844102_5,-1,-1,-1,6328,-1,0.99906725,0.0009328325
6329,DFO,2,3,13,16,alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.,16844102_6,-1,-1,-1,6329,-1,0.998784,0.0012159563
6331,reduced glutathione,9,11,51,70,The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA-treated rats.,16844102_7,-1,-1,-1,6331,-1,0.99795675,0.0020432265
6332,DFO,8,9,60,63,These changes were significantly attenuated by alpha-TC and DFO.,16844102_8,-1,-1,-1,6332,-1,0.9982014,0.0017986543
6333,DFO,5,6,32,35,This suggests that alpha-TC and DFO ameliorate the MA-induced neuronal damage by decreasing the level of oxidative stress.,16844102_9,-1,-1,-1,6333,-1,0.99880207,0.0011979002
6337,cerebral haemorrhages,12,14,84,105,"PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden. METHODS: All patients with a diagnosed cerebral haemorrhage at three hospitals during the period 2000-2002 were identified.",16858720_1,-1,-1,-1,6337,-1,0.001411023,0.998589
6344,p,27,28,102,103,"Of the 59 cases, 26 (44%) had a fatal outcome, compared to 136 (25%) among the non-warfarin patients (p < 0.01).",16858720_6,-1,-1,-1,6344,-1,0.3255507,0.6744493
6345,haemorrhage,8,9,58,69,A warfarin-drug interaction could have contributed to the haemorrhage in 24 (41%) of the warfarin patients and in 7 of these (12%) the bleeding complication was considered being possible to avoid.,16858720_7,-1,-1,-1,6345,-1,0.0015360432,0.998464
6348,cerebral haemorrhages,3,5,30,51,CONCLUSIONS: Warfarin-induced cerebral haemorrhages are a major clinical problem with a high fatality rate.,16858720_8,-1,-1,-1,6348,-1,0.0013553067,0.99864465
6349,cerebral haemorrhages,5,7,45,66,A significant proportion of warfarin-related cerebral haemorrhages might have been prevented if greater caution had been taken when prescribing drugs known to interact with warfarin.,16858720_10,-1,-1,-1,6349,-1,0.0014726304,0.9985273
6351,thioperamide,3,4,30,42,"Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.",16867021_0,-1,-1,-1,6351,-1,0.9992461,0.00075385446
6359,RAMH,2,3,27,31,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,-1,-1,-1,6359,-1,0.9988349,0.0011651048
6360,thioperamide,11,12,55,67,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,-1,-1,-1,6360,-1,0.9992742,0.00072586886
6361,THP,13,14,69,72,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,-1,-1,-1,6361,-1,0.99896204,0.0010379595
6362,se,23,24,95,97,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,-1,-1,-1,6362,-1,0.98820484,0.01179516
6364,THP,2,3,18,21,"Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).",16867021_5,-1,-1,-1,6364,-1,0.99916804,0.0008319641
6365,h,14,15,54,55,"Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).",16867021_5,-1,-1,-1,6365,-1,0.88767475,0.11232528
6368,P,28,29,139,140,"Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).",16867021_5,-1,-1,-1,6368,-1,0.40045473,0.59954524
6369,RAMH,4,5,27,31,"However, pretreatment with RAMH significantly reversed such an effect of THP (15 mg/kg i.p.).",16867021_6,-1,-1,-1,6369,-1,0.9988218,0.0011781488
6370,THP,11,12,73,76,"However, pretreatment with RAMH significantly reversed such an effect of THP (15 mg/kg i.p.).",16867021_6,-1,-1,-1,6370,-1,0.9989974,0.0010025855
6371,RAMH,0,1,0,4,"RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters.",16867021_7,-1,-1,-1,6371,-1,0.9985489,0.0014510212
6372,se,2,3,9,11,"RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters.",16867021_7,-1,-1,-1,6372,-1,0.9961845,0.0038154689
6373,THP,16,17,100,103,"RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters.",16867021_7,-1,-1,-1,6373,-1,0.99901307,0.000986918
6374,se,24,25,124,126,"RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters.",16867021_7,-1,-1,-1,6374,-1,0.99605954,0.0039404696
6376,THP,4,5,38,41,"On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05).",16867021_8,-1,-1,-1,6376,-1,0.9991085,0.00089154334
6377,P,23,24,129,130,"On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05).",16867021_8,-1,-1,-1,6377,-1,0.5042069,0.49579307
6378,RAMH,2,3,18,22,Pretreatment with RAMH (5 microg i.c.v.) could partially reverse such effects of THP (3.75 mg/kg i.p.).,16867021_9,-1,-1,-1,6378,-1,0.99891675,0.0010832233
6379,THP,15,16,81,84,Pretreatment with RAMH (5 microg i.c.v.) could partially reverse such effects of THP (3.75 mg/kg i.p.).,16867021_9,-1,-1,-1,6379,-1,0.9990275,0.0009724758
6381,THP,11,12,77,80,Climbing behavior induced by apomorphine was reduced in animals treated with THP.,16867021_10,-1,-1,-1,6381,-1,0.99897695,0.0010230395
6382,RAMH,11,12,53,57,"Such an effect was, however, reversed in presence of RAMH.",16867021_11,-1,-1,-1,6382,-1,0.9982874,0.0017126129
6383,THP,0,1,0,3,"THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.",16867021_12,-1,-1,-1,6383,-1,0.99905723,0.00094282714
6386,THP,3,4,16,19,Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors.,16867021_13,-1,-1,-1,6386,-1,0.9989122,0.0010877443
6387,RAMH,7,8,37,41,Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors.,16867021_13,-1,-1,-1,6387,-1,0.9988581,0.0011419043
6397,fluphenazine,4,5,23,35,"2. Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.",1687392_2,-1,-1,-1,6397,-1,0.9992531,0.0007469389
6398,SCH 23390,8,10,52,61,"2. Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.",1687392_2,-1,-1,-1,6398,-1,0.99910945,0.0008905755
6401,fluphenazine,3,4,14,26,The effect of fluphenazine and sulpiride was dose-dependent.,1687392_3,-1,-1,-1,6401,-1,0.99927205,0.00072795845
6403,SCH 23390,2,4,15,24,Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation.,1687392_4,-1,-1,-1,6403,-1,0.9991767,0.0008233018
6406,SKF 38393,4,6,15,24,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,-1,-1,-1,6406,-1,0.99876803,0.0012319126
6407,quinpirole,9,10,40,50,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,-1,-1,-1,6407,-1,0.99932873,0.00067132036
6409,fluphenazine,15,16,86,98,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,-1,-1,-1,6409,-1,0.99931705,0.0006829242
6410,SCH 23390,17,19,100,109,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,-1,-1,-1,6410,-1,0.99912614,0.00087382295
6412,SKF 38393,2,4,15,24,Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists.,1687392_7,-1,-1,-1,6412,-1,0.99887794,0.0011220601
6413,quinpirole,5,6,30,40,Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists.,1687392_7,-1,-1,-1,6413,-1,0.9993395,0.0006604976
6417,Cauda equina syndrome,0,3,0,21,Cauda equina syndrome after epidural steroid injection: a case report.,16904497_0,-1,-1,-1,6417,-1,0.0019503088,0.99804974
6419,radiculopathy,7,8,57,70,"OBJECTIVE: Conventional treatment methods of lumbusacral radiculopathy are physical therapy, epidural steroid injections, oral medications, and spinal manipulative therapy.",16904497_1,-1,-1,-1,6419,-1,0.0016087865,0.9983912
6421,Cauda equina syndrome,0,3,0,21,Cauda equina syndrome is a rare complication of epidural anesthesia.,16904497_2,-1,-1,-1,6421,-1,0.001763651,0.9982363
6422,cauda equina syndrome,7,10,34,55,The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine.,16904497_3,-1,-1,-1,6422,-1,0.0016294033,0.9983706
6423,triamcinolone,16,17,97,110,The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine.,16904497_3,-1,-1,-1,6423,-1,0.99921834,0.0007816815
6425,low,7,8,44,47,CLINICAL FEATURES: A 50-year-old woman with low back and right leg pain was scheduled for epidural steroid injection.,16904497_4,-1,-1,-1,6425,-1,0.0027464125,0.9972536
6426,leg pain,11,13,63,71,CLINICAL FEATURES: A 50-year-old woman with low back and right leg pain was scheduled for epidural steroid injection.,16904497_4,-1,-1,-1,6426,-1,0.002766563,0.99723345
6428,contrast medium,3,5,14,29,Spread of the contrast medium within the epidural space was determined by radiographic imaging.,16904497_6,-1,-1,-1,6428,-1,0.9894298,0.01057028
6431,perineal numbness,7,9,37,54,"Three hours later, she complained of perineal numbness and lower extremity weakness.",16904497_9,-1,-1,-1,6431,-1,0.0016313104,0.9983687
6432,lower extremity weakness,10,13,59,83,"Three hours later, she complained of perineal numbness and lower extremity weakness.",16904497_9,-1,-1,-1,6432,-1,0.0023097654,0.9976902
6433,loss of sensation,4,7,35,52,The neurologic evaluation revealed loss of sensation in the saddle area and medial aspect of her right leg.,16904497_10,-1,-1,-1,6433,-1,0.002415242,0.9975847
6435,neurologic deterioration,6,8,49,73,Clinical examination and continued vigilance for neurologic deterioration after epidural steroid injections is important.,16904497_18,-1,-1,-1,6435,-1,0.0013430902,0.99865687
6439,androgen,8,9,46,54,OBJECTIVES: To study the long-term effects of androgen treatment on atherosclerosis in postmenopausal women.,16938416_1,-1,-1,-1,6439,-1,0.9986908,0.0013091991
6446,n=11,14,15,79,83,"In almost half of these women severe atherosclerosis of the aorta was present (n=11), while in women without hormone use severe atherosclerosis of the aorta was present in less than 20% (OR 3.1; 95% CI, 1.1-8.5, adjusted for age, years since menopause, smoking, and body mass index).",16938416_6,-1,-1,-1,6446,-1,0.038037833,0.9619621
6454,androgen,19,20,147,155,CONCLUSION: Our results suggest that high-dose testosterone therapy may adversely affect atherosclerosis in postmenopausal women and indicate that androgen replacement in these women may not be harmless.,16938416_9,-1,-1,-1,6454,-1,0.99891424,0.0010858016
6455,hepatitis B,8,10,63,74,Sustained clinical improvement of a patient with decompensated hepatitis B virus-related cirrhosis after treatment with lamivudine monotherapy.,16960342_0,-1,-1,-1,6455,-1,0.0048906105,0.9951094
6458,Hepatitis B virus (HBV) infection,0,7,0,33,"Hepatitis B virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.",16960342_1,-1,-1,-1,6458,-1,0.011365245,0.9886347
6459,liver cirrhosis,10,12,48,63,"Hepatitis B virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.",16960342_1,-1,-1,-1,6459,-1,0.0016369997,0.99836296
6463,hepatitis B,3,5,15,26,"Moreover, both hepatitis B surface antigen and e antigen were observed to have disappeared in this patient.",16960342_9,-1,-1,-1,6463,-1,0.00919396,0.99080604
6466,cibenzoline,6,7,45,56,Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias.,1700207_0,-1,-1,-1,6466,-1,0.9990978,0.0009021428
6468,ventricular arrhythmia,11,13,93,115,Antiarrhythmic effects of (+)-cibenzoline and (-)-cibenzoline were examined using two canine ventricular arrhythmia models.,1700207_1,-1,-1,-1,6468,-1,0.0016618717,0.9983381
6469,Digitalis arrhythmia,0,2,0,20,"Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in pentobarbital-anesthetized dogs.",1700207_2,-1,-1,-1,6469,-1,0.021669239,0.97833073
6470,Na channel,7,9,45,55,"Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in pentobarbital-anesthetized dogs.",1700207_2,-1,-1,-1,6470,-1,0.9969277,0.0030722923
6472,Adrenaline arrhythmia,0,2,0,21,"Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.",1700207_3,-1,-1,-1,6472,-1,0.54803675,0.45196325
6473,Ca,7,8,46,48,"Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.",1700207_3,-1,-1,-1,6473,-1,0.99877197,0.0012280414
6474,blockers,9,10,57,65,"Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.",1700207_3,-1,-1,-1,6474,-1,0.9980166,0.0019834351
6478,SD,29,30,184,186,"The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and adrenaline-induced arrhythmias were 1.4 +/- 0.4 and 2.0 +/- 0.6 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_6,-1,-1,-1,6478,-1,0.26086223,0.7391378
6479,n,31,32,188,189,"The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and adrenaline-induced arrhythmias were 1.4 +/- 0.4 and 2.0 +/- 0.6 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_6,-1,-1,-1,6479,-1,0.22923814,0.77076185
6483,SD,29,30,185,187,"The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and adrenaline-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_8,-1,-1,-1,6483,-1,0.27127075,0.72872925
6484,n,31,32,189,190,"The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and adrenaline-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_8,-1,-1,-1,6484,-1,0.23045993,0.76954
6485,Na,21,22,141,143,"The stronger antiarrhythmic effect of (-)-cibenzoline indicates that (-)-isomer may have an effect nearly 5-20 times stronger in suppressing Na channels, but effects of both drugs on Ca channels may be almost equipotent.",1700207_9,-1,-1,-1,6485,-1,0.9985291,0.001470887
6486,Ca,30,31,183,185,"The stronger antiarrhythmic effect of (-)-cibenzoline indicates that (-)-isomer may have an effect nearly 5-20 times stronger in suppressing Na channels, but effects of both drugs on Ca channels may be almost equipotent.",1700207_9,-1,-1,-1,6486,-1,0.998159,0.00184105
6488,gliomas,7,8,42,49,Passage of mannitol into the brain around gliomas: a potential cause of rebound phenomenon.,17019386_0,-1,-1,-1,6488,-1,0.0018860687,0.998114
6490,brain edema,8,10,42,53,AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.,17019386_2,-1,-1,-1,6490,-1,0.0012766661,0.9987233
6491,ICP,13,14,73,76,AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.,17019386_2,-1,-1,-1,6491,-1,0.0021786375,0.99782133
6492,brain tumor,15,17,80,91,AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.,17019386_2,-1,-1,-1,6492,-1,0.0021093416,0.99789065
6495,brain tumor,22,24,130,141,As a contribution to this issue we decided to research the possible passage of mannitol into the brain after administration to 21 brain tumor patients.,17019386_5,-1,-1,-1,6495,-1,0.0030983284,0.99690175
6497,malignant glioma,21,23,90,106,"METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.",17019386_6,-1,-1,-1,6497,-1,0.0018882513,0.9981117
6498,brain metastases,25,27,114,130,"METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.",17019386_6,-1,-1,-1,6498,-1,0.0018311887,0.9981688
6499,meningioma,29,30,140,150,"METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.",17019386_6,-1,-1,-1,6499,-1,0.0017152285,0.99828476
6500,edematous,8,9,46,55,"During resection, a sample of the surrounding edematous white matter was taken at the same time as a 10 ml venous blood sample.",17019386_7,-1,-1,-1,6500,-1,0.0029349015,0.9970651
6502,glioma,25,26,144,150,"Mannitol concentrations were measured in plasma and white matter by a modified version of the enzyme assay of Blonquist et al. RESULTS: In most glioma patients, mannitol concentrations in white matter were 2 to 6 times higher than in plasma (mean 3.5 times).",17019386_8,-1,-1,-1,6502,-1,0.002167916,0.9978321
6504,meningioma,1,2,3,13,In meningioma and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.,17019386_9,-1,-1,-1,6504,-1,0.0019936762,0.9980063
6505,metastases,3,4,18,28,In meningioma and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.,17019386_9,-1,-1,-1,6505,-1,0.0020521083,0.9979479
6508,gliomas,23,24,122,129,"CONCLUSIONS: The results of our study show that even after a single bolus, mannitol may leak through the altered BBB near gliomas, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral edema and promoting rebound of ICP.",17019386_10,-1,-1,-1,6508,-1,0.0022702129,0.99772984
6511,atrial fibrillation,5,7,45,64,Optimising stroke prevention in non-valvular atrial fibrillation.,17020434_0,-1,-1,-1,6511,-1,0.0017093704,0.9982906
6512,Atrial fibrillation,0,2,0,19,Atrial fibrillation is associated with substantial morbidity and mortality.,17020434_1,-1,-1,-1,6512,-1,0.0015347851,0.9984653
6519,Ximelagatran,0,1,0,12,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,-1,-1,-1,6519,-1,0.9992291,0.0007708828
6520,direct thrombin inhibitor,4,7,22,47,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,-1,-1,-1,6520,-1,0.99405056,0.0059494106
6521,vitamin K,15,17,81,90,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,-1,-1,-1,6521,-1,0.9990152,0.0009848188
6522,embolic events,23,25,129,143,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,-1,-1,-1,6522,-1,0.0013910248,0.998609
6523,abnormal liver function tests,33,37,188,217,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,-1,-1,-1,6523,-1,0.004268743,0.9957313
6524,Atrial Fibrillation Clopidogrel,3,6,14,45,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,-1,-1,-1,6524,-1,0.38362244,0.6163776
6525,Irbesartan,8,9,57,67,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,-1,-1,-1,6525,-1,0.9992004,0.0007996168
6526,Vascular Events,12,14,86,101,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,-1,-1,-1,6526,-1,0.0013727519,0.9986273
6530,af embolic events,33,36,217,234,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,-1,-1,-1,6530,-1,0.0016006763,0.9983993
6531,Idraparinux,0,1,0,11,"Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation.",17020434_6,-1,-1,-1,6531,-1,0.99853206,0.001467917
6532,Factor Xa,3,5,15,24,"Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation.",17020434_6,-1,-1,-1,6532,-1,0.94812435,0.05187559
6533,atrial fibrillation,13,15,72,91,"Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation.",17020434_6,-1,-1,-1,6533,-1,0.0015974804,0.99840254
6534,enzyme inhibitors,1,3,23,40,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,-1,-1,-1,6534,-1,0.997477,0.0025230115
6535,angiotensin II,4,6,45,59,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,-1,-1,-1,6535,-1,0.99827015,0.0017298086
6536,atrial fibrillation,11,13,100,119,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,-1,-1,-1,6536,-1,0.0017641353,0.9982358
6537,cardiac remodelling,14,16,128,147,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,-1,-1,-1,6537,-1,0.0016851013,0.99831486
6540,EPS,6,7,52,55,Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.,17042884_0,-1,-1,-1,6540,-1,0.0012997369,0.99870026
6541,quetiapine,9,10,62,72,Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.,17042884_0,-1,-1,-1,6541,-1,0.9992848,0.00071525224
6542,bipolar mania,16,18,112,125,Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.,17042884_0,-1,-1,-1,6542,-1,0.0013438854,0.99865615
6544,EPS,7,8,49,52,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,-1,-1,-1,6544,-1,0.0013499928,0.99865
6545,akathisia,11,12,65,74,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,-1,-1,-1,6545,-1,0.0012763937,0.99872357
6546,quetiapine,14,15,81,91,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,-1,-1,-1,6546,-1,0.99925655,0.0007434811
6547,bipolar mania,18,20,109,122,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,-1,-1,-1,6547,-1,0.0015876913,0.99841225
6548,quetiapine,3,4,22,32,"Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with lithium or haloperidol monotherapy as respective active controls.",17042884_3,-1,-1,-1,6548,-1,0.9993364,0.0006635468
6549,n,12,13,65,66,"Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with lithium or haloperidol monotherapy as respective active controls.",17042884_3,-1,-1,-1,6549,-1,0.22221875,0.77778125
6550,n,19,20,90,91,"Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with lithium or haloperidol monotherapy as respective active controls.",17042884_3,-1,-1,-1,6550,-1,0.22673164,0.77326834
6553,quetiapine,3,4,22,32,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,-1,6553,-1,0.9993197,0.0006803231
6555,divalproex,19,20,102,112,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,-1,6555,-1,0.9992261,0.0007738807
6556,n,26,27,129,130,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,-1,6556,-1,0.16339031,0.83660966
6557,n,42,43,194,195,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,-1,6557,-1,0.13312845,0.8668716
6559,Akathisia,14,15,87,96,"Extrapyramidal symptoms were evaluated using the Simpson-Angus Scale (SAS), the Barnes Akathisia Rating Scale (BARS), adverse event reports and anticholinergic drug usage.",17042884_5,-1,-1,-1,6559,-1,0.0015467466,0.99845326
6560,akathisia,10,11,64,73,"RESULTS: The incidence of EPS-related adverse events, including akathisia, was no different with quetiapine monotherapy (12.9%) than with placebo (13.1%).",17042884_6,-1,-1,-1,6560,-1,0.0012177235,0.99878234
6561,quetiapine,16,17,97,107,"RESULTS: The incidence of EPS-related adverse events, including akathisia, was no different with quetiapine monotherapy (12.9%) than with placebo (13.1%).",17042884_6,-1,-1,-1,6561,-1,0.9993137,0.0006863016
6562,QTP,6,7,43,46,"Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).",17042884_7,-1,-1,-1,6562,-1,0.003023402,0.9969766
6563,EPS,4,5,26,29,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,-1,-1,-1,6563,-1,0.0014062223,0.99859375
6565,n,15,16,86,87,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,-1,-1,-1,6565,-1,0.24486089,0.7551391
6567,n,30,31,155,156,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,-1,-1,-1,6567,-1,0.22542162,0.7745784
6568,EPS,40,41,213,216,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,-1,-1,-1,6568,-1,0.001396062,0.998604
6569,akathisia,3,4,17,26,"The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).",17042884_9,-1,-1,-1,6569,-1,0.0013250438,0.9986749
6570,quetiapine,9,10,52,62,"The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).",17042884_9,-1,-1,-1,6570,-1,0.99930656,0.00069348817
6572,p,9,10,62,63,"Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.",17042884_10,-1,-1,-1,6572,-1,0.4179404,0.5820596
6574,quetiapine,20,21,95,105,"Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.",17042884_10,-1,-1,-1,6574,-1,0.99934894,0.00065101753
6580,p,7,8,54,55,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,-1,-1,-1,6580,-1,0.35295108,0.6470489
6581,akathisia,12,13,68,77,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,-1,-1,-1,6581,-1,0.0011725968,0.9988274
6583,extrapyramidal syndrome,31,33,131,154,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,-1,-1,-1,6583,-1,0.0012586651,0.9987413
6584,quetiapine,41,42,180,190,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,-1,-1,-1,6584,-1,0.99933356,0.00066641293
6585,quetiapine,6,7,49,59,No significant differences were observed between quetiapine and placebo on SAS and BARS scores.,17042884_12,-1,-1,-1,6585,-1,0.9992568,0.0007431372
6586,quetiapine,7,8,45,55,Anticholinergic use was low and similar with quetiapine or placebo.,17042884_13,-1,-1,-1,6586,-1,0.99928623,0.0007138243
6587,bipolar mania,3,5,16,29,"CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.",17042884_14,-1,-1,-1,6587,-1,0.0014912381,0.99850875
6588,EPS,9,10,48,51,"CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.",17042884_14,-1,-1,-1,6588,-1,0.0011601523,0.9988399
6589,akathisia,12,13,63,72,"CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.",17042884_14,-1,-1,-1,6589,-1,0.0012877109,0.9987123
6590,quetiapine,15,16,79,89,"CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.",17042884_14,-1,-1,-1,6590,-1,0.9992747,0.0007253544
6591,atorvastatin,3,4,24,36,Anti-oxidant effects of atorvastatin in dexamethasone-induced hypertension in the rat.1.,17042910_0,-1,-1,-1,6591,-1,0.99923086,0.00076918124
6595,dysfunction,7,8,73,84,Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.,17042910_1,-1,-1,-1,6595,-1,0.001319364,0.99868065
6596,nitric oxide,10,12,101,113,Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.,17042910_1,-1,-1,-1,6596,-1,0.9978015,0.0021984712
6598,O2-,20,21,156,159,Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.,17042910_1,-1,-1,-1,6598,-1,0.99521613,0.0047839186
6599,Atorvastatin,0,1,0,12,Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.,17042910_2,-1,-1,-1,6599,-1,0.9991015,0.00089853036
6600,Ato,2,3,14,17,Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.,17042910_2,-1,-1,-1,6600,-1,0.9982889,0.0017110319
6601,O2-,22,23,157,160,Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.,17042910_2,-1,-1,-1,6601,-1,0.995555,0.004444964
6603,Ato,16,17,70,73,"In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in O2- in Sprague-Dawley (SD) rats, thereby reducing blood pressure.",17042910_3,-1,-1,-1,6603,-1,0.9974815,0.0025184758
6604,O2-,30,31,154,157,"In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in O2- in Sprague-Dawley (SD) rats, thereby reducing blood pressure.",17042910_3,-1,-1,-1,6604,-1,0.99057883,0.009421117
6605,SD,34,35,177,179,"In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in O2- in Sprague-Dawley (SD) rats, thereby reducing blood pressure.",17042910_3,-1,-1,-1,6605,-1,0.19597338,0.8040266
6606,SD,3,4,8,10,2. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.,17042910_4,-1,-1,-1,6606,-1,0.021876656,0.97812337
6607,n,6,7,17,18,2. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.,17042910_4,-1,-1,-1,6607,-1,0.13720606,0.8627939
6608,Ato,13,14,43,46,2. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.,17042910_4,-1,-1,-1,6608,-1,0.9983571,0.0016429112
6609,water,21,22,77,82,2. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.,17042910_4,-1,-1,-1,6609,-1,0.9895594,0.010440582
6612,P,30,31,119,120,"In rats treated with Dex alone, SBP was increased from 109 +/- 2 to 133 +/- 2 mmHg on Days 4 and Day 14, respectively (P < 0.001).",17042910_10,-1,-1,-1,6612,-1,0.39745525,0.6025447
6613,Ato,2,3,7,10,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,-1,-1,-1,6613,-1,0.9851474,0.014852565
6615,P,29,30,106,107,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,-1,-1,-1,6615,-1,0.46837503,0.531625
6617,P,48,49,192,193,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,-1,-1,-1,6617,-1,0.49615255,0.5038474
6619,Ato,12,13,84,87,"Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).",17042910_12,-1,-1,-1,6619,-1,0.9964624,0.0035376274
6621,P,21,22,122,123,"Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).",17042910_12,-1,-1,-1,6621,-1,0.51375765,0.48624235
6622,P,25,26,135,136,"Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).",17042910_12,-1,-1,-1,6622,-1,0.58833,0.41166997
6625,Ato,9,10,52,55,Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001).,17042910_13,-1,-1,-1,6625,-1,0.9933808,0.006619273
6627,P,20,21,110,111,Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001).,17042910_13,-1,-1,-1,6627,-1,0.389777,0.61022305
6628,Ato,2,3,15,18,"Treatment with Ato improved endothelial function, reduced superoxide production and reduced SBP in Dex-treated SD rats.",17042910_15,-1,-1,-1,6628,-1,0.997678,0.0023220698
6630,SD,15,16,111,113,"Treatment with Ato improved endothelial function, reduced superoxide production and reduced SBP in Dex-treated SD rats.",17042910_15,-1,-1,-1,6630,-1,0.04840109,0.9515989
6632,hypothermic,6,7,38,49,Is phenytoin administration safe in a hypothermic child?A male neonate with a Chiari malformation and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele.,17049862_0,-1,-1,-1,6632,-1,0.0024752545,0.9975248
6633,Chiari malformation,12,14,78,97,Is phenytoin administration safe in a hypothermic child?A male neonate with a Chiari malformation and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele.,17049862_0,-1,-1,-1,6633,-1,0.0017725199,0.99822754
6634,hypothermic,9,10,67,78,"During anaesthesia and surgery, he inadvertently became moderately hypothermic.",17049862_1,-1,-1,-1,6634,-1,0.0032533153,0.99674666
6645,lead,9,10,63,67,Administration of phenytoin in the presence of hypothermia may lead to an adverse cardiac event in children.,17049862_5,-1,-1,-1,6645,-1,0.003872465,0.99612755
6646,cardiac,13,14,82,89,Administration of phenytoin in the presence of hypothermia may lead to an adverse cardiac event in children.,17049862_5,-1,-1,-1,6646,-1,0.0015899491,0.99841
6648,chorea,1,2,18,24,Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.,17074608_0,-1,-1,-1,6648,-1,0.0011088579,0.9988912
6650,nonketotic hyperglycinemia,6,8,56,82,Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.,17074608_0,-1,-1,-1,6650,-1,0.0018284075,0.99817157
6651,hyperglycinemia,1,2,11,26,Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.,17074608_1,-1,-1,-1,6651,-1,0.012064101,0.9879359
6652,disorder of amino acid metabolism,4,9,32,65,Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.,17074608_1,-1,-1,-1,6652,-1,0.0292759,0.97072405
6655,neonatal apnea,7,9,37,51,"In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.",17074608_2,-1,-1,-1,6655,-1,0.0012709158,0.99872905
6657,hypotonia,14,15,79,88,"In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.",17074608_2,-1,-1,-1,6657,-1,0.0011754228,0.99882454
6658,psychomotor retardation,19,21,114,137,"In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.",17074608_2,-1,-1,-1,6658,-1,0.0013054537,0.9986946
6659,nonketotic hyperglycinemia,6,8,37,63,An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.,17074608_3,-1,-1,-1,6659,-1,0.0024386134,0.99756134
6660,language delay,7,9,42,56,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,-1,-1,6660,-1,0.0020956045,0.9979044
6661,mental retardation,10,12,61,79,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,-1,-1,6661,-1,0.0013781814,0.9986218
6662,hyperglycinemia,19,20,114,129,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,-1,-1,6662,-1,0.0035192638,0.99648076
6664,chorea,27,28,187,193,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,-1,-1,6664,-1,0.0011141924,0.9988858
6665,valproate,32,33,222,231,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,-1,-1,6665,-1,0.99929905,0.0007009139
6666,citrate toxicity,1,3,7,23,Severe citrate toxicity complicating volunteer apheresis platelet donation.,17111419_0,-1,-1,-1,6666,-1,0.010226859,0.9897731
6667,citrate toxicity,6,8,27,43,We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection.,17111419_1,-1,-1,-1,6667,-1,0.09452576,0.9054742
6669,hyperlipidemia,8,9,54,68,"Past medical history was remarkable for hypertension, hyperlipidemia, and depression.",17111419_3,-1,-1,-1,6669,-1,0.001561924,0.99843806
6671,bumetanide,3,4,30,40,"Reported medications included bumetanide, pravastatin, and paroxetine.",17111419_4,-1,-1,-1,6671,-1,0.99918705,0.0008129645
6675,calcium gluconate,4,6,37,54,"Empirical treatment with intravenous calcium gluconate was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes.",17111419_7,-1,-1,-1,6675,-1,0.99907756,0.00092236826
6676,muscle contractions,10,12,74,93,"Empirical treatment with intravenous calcium gluconate was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes.",17111419_7,-1,-1,-1,6676,-1,0.00251749,0.9974825
6680,bumetanide,9,10,58,68,"Upon additional retrospective analysis, it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia.",17111419_9,-1,-1,-1,6680,-1,0.99917954,0.0008204448
6681,loop diuretic,12,14,74,87,"Upon additional retrospective analysis, it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia.",17111419_9,-1,-1,-1,6681,-1,0.96666145,0.03333849
6684,citrate toxicity,22,24,161,177,We conclude that careful screening for medications and underlying conditions predisposing to hypocalcemia is recommended to help prevent severe reactions due to citrate toxicity.,17111419_10,-1,-1,-1,6684,-1,0.19949137,0.8005087
6687,cerebral ischemia,6,8,49,66,Delayed institution of hypertension during focal cerebral ischemia: effect on brain edema.,1711760_0,-1,-1,-1,6687,-1,0.0012069473,0.998793
6688,brain edema,11,13,78,89,Delayed institution of hypertension during focal cerebral ischemia: effect on brain edema.,1711760_0,-1,-1,-1,6688,-1,0.0012961352,0.99870384
6690,middle cerebral artery occlusion,11,15,74,106,The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.,1711760_1,-1,-1,-1,6690,-1,0.005851677,0.9941484
6691,MCAO,16,17,108,112,The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.,1711760_1,-1,-1,-1,6691,-1,0.0031977484,0.9968022
6692,brain edema,19,21,117,128,The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.,1711760_1,-1,-1,-1,6692,-1,0.0014485719,0.9985514
6695,n,5,6,22,23,"In the control group (n = 7), the mean arterial pressure (MAP) was not manipulated.",1711760_3,-1,-1,-1,6695,-1,0.14791006,0.85208994
6696,MAP,15,16,58,61,"In the control group (n = 7), the mean arterial pressure (MAP) was not manipulated.",1711760_3,-1,-1,-1,6696,-1,0.08665622,0.9133438
6698,n,5,6,27,28,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,-1,-1,6698,-1,0.06166118,0.9383388
6699,MAP,11,12,39,42,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,-1,-1,6699,-1,0.3274451,0.6725549
6700,mm Hg,18,20,65,70,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,-1,-1,6700,-1,0.25173593,0.74826413
6701,h,22,23,83,84,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,-1,-1,6701,-1,0.11834646,0.88165355
6702,MCAO,24,25,91,95,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,-1,-1,6702,-1,0.0796737,0.92032635
6703,MCAO,3,4,17,21,"Four hours after MCAO, the rats were killed and the brains harvested.",1711760_5,-1,-1,-1,6703,-1,0.009576896,0.9904231
6705,MCAO,14,15,97,101,The brains were sectioned along coronal planes spanning the distribution of ischemia produced by MCAO.,1711760_6,-1,-1,-1,6705,-1,0.020459713,0.97954035
6706,ischemic,23,24,112,120,Specific gravity (SG) was determined in the subcortex and in two sites in the cortex (core and periphery of the ischemic territory).,1711760_7,-1,-1,-1,6706,-1,0.0034980308,0.9965019
6707,neuronal injury,3,5,14,29,"The extent of neuronal injury was determined by 2,3,5-triphenyltetrazolium staining.",1711760_8,-1,-1,-1,6707,-1,0.0017609281,0.99823904
6708,"2,3,5-triphenyltetrazolium",8,9,48,74,"The extent of neuronal injury was determined by 2,3,5-triphenyltetrazolium staining.",1711760_8,-1,-1,-1,6708,-1,0.99788624,0.0021138038
6709,ischemic,2,3,7,15,"In the ischemic core, there was no difference in SG in the subcortex and cortex in the two groups.",1711760_9,-1,-1,-1,6709,-1,0.0022854244,0.99771464
6710,ischemic,5,6,24,32,"In the periphery of the ischemic territory, SG in the cortex was greater (less edema accumulation) in the hypertensive group (1.041 +/- 0.001 vs 1.039 +/- 0.001, P less than 0.05).",1711760_10,-1,-1,-1,6710,-1,0.0023285132,0.9976714
6713,P,34,35,162,163,"In the periphery of the ischemic territory, SG in the cortex was greater (less edema accumulation) in the hypertensive group (1.041 +/- 0.001 vs 1.039 +/- 0.001, P less than 0.05).",1711760_10,-1,-1,-1,6713,-1,0.43986568,0.5601343
6715,P,36,37,154,155,"The area of histochemical injury (as a percent of the cross-sectional area of the hemisphere) was less in the hypertensive group (33 +/- 3% vs 21 +/- 2%, P less than 0.05).",1711760_11,-1,-1,-1,6715,-1,0.42424676,0.5757532
6717,h,8,9,71,72,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,-1,-1,6717,-1,0.106091276,0.8939087
6718,MCAO,10,11,79,83,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,-1,-1,6718,-1,0.018643757,0.98135626
6720,ischemic,17,18,116,124,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,-1,-1,6720,-1,0.0019102432,0.99808973
6722,ischemic,29,30,178,186,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,-1,-1,6722,-1,0.0024433313,0.9975567
6723,neuronal dysfunction,40,42,244,264,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,-1,-1,6723,-1,0.0014245387,0.99857545
6728,chronic allograft nephropathy,15,18,106,135,Sirolimus represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft nephropathy.,17147461_2,-1,-1,-1,6728,-1,0.0015850972,0.9984149
6730,autoimmunity,8,9,47,59,"Its role in the therapy of glomerulonephritis, autoimmunity, cystic renal diseases and renal cancer is under investigation.",17147461_3,-1,-1,-1,6730,-1,0.0012036327,0.99879634
6731,cystic renal diseases,10,13,61,82,"Its role in the therapy of glomerulonephritis, autoimmunity, cystic renal diseases and renal cancer is under investigation.",17147461_3,-1,-1,-1,6731,-1,0.0013870279,0.998613
6732,renal cancer,14,16,87,99,"Its role in the therapy of glomerulonephritis, autoimmunity, cystic renal diseases and renal cancer is under investigation.",17147461_3,-1,-1,-1,6732,-1,0.001745825,0.9982541
6734,calcineurin inhibitors,12,14,82,104,"Because sirolimus does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors, it has been designated a 'non-nephrotoxic drug'.",17147461_4,-1,-1,-1,6734,-1,0.9989164,0.0010836141
6737,acute renal dysfunction,17,20,111,134,"However, clinical reports suggest that, under some circumstances, sirolimus is associated with proteinuria and acute renal dysfunction.",17147461_5,-1,-1,-1,6737,-1,0.0011962622,0.99880373
6738,chronic renal damage,10,13,60,80,A common risk factor appears to be presence of pre-existing chronic renal damage.,17147461_6,-1,-1,-1,6738,-1,0.0015183887,0.9984816
6740,calcineurin,19,20,143,154,The mechanisms of sirolimus-associated proteinuria are multifactorial and may be due to an increase in glomerular capillary pressure following calcineurin inhibitor withdrawal.,17147461_7,-1,-1,-1,6740,-1,0.9991554,0.00084456184
6742,acute renal dysfunction,1,4,4,27,The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes.,17147461_9,-1,-1,-1,6742,-1,0.0014129519,0.99858713
6744,delayed graft function,11,14,66,88,The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes.,17147461_9,-1,-1,-1,6744,-1,0.0023591376,0.99764085
6748,angiotensin II,49,51,317,331,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,-1,-1,-1,6748,-1,0.9985625,0.0014375398
6754,SRL,2,3,11,14,"Sirolimus (SRL) is a new, potent immunosuppressive agent.",17175308_1,-1,-1,-1,6754,-1,0.9980738,0.0019261166
6758,SRL,18,19,128,131,"We retrospectively examined the records of 25 renal transplant patients, who developed or displayed increased proteinuria after SRL conversion.",17175308_3,-1,-1,-1,6758,-1,0.99719536,0.002804616
6759,SRL,13,14,55,58,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6759,-1,0.9983442,0.0016558054
6760,chronic allograft nephropathy,20,23,89,118,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6760,-1,0.0015714924,0.9984285
6761,CAN,24,25,120,123,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6761,-1,0.0021334256,0.9978666
6762,n,27,28,126,127,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6762,-1,0.009679092,0.99032086
6763,neoplasia,31,32,134,143,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6763,-1,0.0015600817,0.99843997
6764,n,33,34,145,146,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6764,-1,0.008848927,0.99115103
6765,Kaposi's sarcoma,37,40,153,169,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6765,-1,0.0025523894,0.9974476
6766,skin cancers,42,44,176,188,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6766,-1,0.0023314676,0.99766856
6767,intestinal tumors,46,48,194,211,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6767,-1,0.0022078005,0.99779224
6768,renal cell carsinom,50,53,217,236,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6768,-1,0.002715778,0.9972842
6770,n,59,60,263,264,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6770,-1,0.0065051047,0.9934949
6771,SRL,0,1,0,3,SRL was started at a mean of 78 +/- 42 (15 to 163) months after transplantation.,17175308_5,-1,-1,-1,6771,-1,0.9863216,0.01367835
6772,SRL,3,4,18,21,Mean follow-up on SRL therapy was 20 +/- 12 (6 to 43) months.,17175308_6,-1,-1,-1,6772,-1,0.9948494,0.005150639
6774,P,23,24,108,109,Proteinuria increased from 0.445 (0 to 1.5) g/d before conversion to 3.2 g/dL (0.2 to 12) after conversion (P = 0.001).,17175308_7,-1,-1,-1,6774,-1,0.3173795,0.6826205
6780,membranoproliferative glomerulopathy,11,13,75,111,Biopsies performed in five patients revealed new pathological changes: One membranoproliferative glomerulopathy and interstitial nephritis.,17175308_12,-1,-1,-1,6780,-1,0.0013721857,0.9986278
6783,SRL,3,4,17,20,0.8 mg/dL before SRL therapy and 2.53 +/- 1.9 mg/dL at last follow-up (P = .14).,17175308_15,-1,-1,-1,6783,-1,0.998429,0.0015709822
6784,P,15,16,71,72,0.8 mg/dL before SRL therapy and 2.53 +/- 1.9 mg/dL at last follow-up (P = .14).,17175308_15,-1,-1,-1,6784,-1,0.2199545,0.7800455
6785,Kaposi's sarcoma,5,8,32,48,Five patients displayed CAN and Kaposi's sarcoma.,17175308_17,-1,-1,-1,6785,-1,0.0023329519,0.9976671
6786,P,29,30,131,132,Mean urinary protein of patients who returned to dialysis was 1.26 (0.5 to 3.5) g/d before and 4.7 (3 to 12) g/d after conversion (P = .01).,17175308_18,-1,-1,-1,6786,-1,0.3118215,0.68817854
6788,P,15,16,89,90,"Mean serum creatinine level before conversion was 2.21 mg/dL and thereafter, 4.93 mg/dL (P = .02).",17175308_19,-1,-1,-1,6788,-1,0.34244,0.65755993
6790,SRL,8,9,46,49,Heavy proteinuria was common after the use of SRL as rescue therapy for renal transplantation.,17175308_20,-1,-1,-1,6790,-1,0.99862254,0.0013774439
6792,SRL,8,9,54,57,The possibility of de novo glomerular pathology under SRL treatment requires further investigation by renal biopsy.,17175308_22,-1,-1,-1,6792,-1,0.99770844,0.002291591
6796,AAS,17,18,101,104,"The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats.",17194457_1,-1,-1,-1,6796,-1,0.9988018,0.0011981609
6799,5-HT,26,27,157,161,"The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats.",17194457_1,-1,-1,-1,6799,-1,0.9982278,0.0017722836
6801,parachlorophenylalanine,9,10,58,81,"Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine (PCPA 100 mg/kg, every other day); controls received saline.",17194457_2,-1,-1,-1,6801,-1,0.9991366,0.0008633766
6802,PCPA,11,12,83,87,"Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine (PCPA 100 mg/kg, every other day); controls received saline.",17194457_2,-1,-1,-1,6802,-1,0.99914324,0.0008567247
6807,5-HT,3,4,16,20,"Brain levels of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were determined using HPLC.",17194457_6,-1,-1,-1,6807,-1,0.9982173,0.0017827258
6808,5-hydroxyindoleacetic acid,8,10,41,67,"Brain levels of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were determined using HPLC.",17194457_6,-1,-1,-1,6808,-1,0.9983835,0.0016164429
6809,5-HIAA,11,12,69,75,"Brain levels of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were determined using HPLC.",17194457_6,-1,-1,-1,6809,-1,0.99837154,0.001628483
6810,PCPA,0,1,0,4,PCPA significantly and substantially depleted 5-HT and 5-HIAA in all brain regions examined.,17194457_7,-1,-1,-1,6810,-1,0.9990416,0.0009584033
6811,5-HT,5,6,46,50,PCPA significantly and substantially depleted 5-HT and 5-HIAA in all brain regions examined.,17194457_7,-1,-1,-1,6811,-1,0.99828595,0.0017139993
6812,5-HIAA,7,8,55,61,PCPA significantly and substantially depleted 5-HT and 5-HIAA in all brain regions examined.,17194457_7,-1,-1,-1,6812,-1,0.9985033,0.0014966561
6813,T,1,2,8,9,"Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",17194457_8,-1,-1,-1,6813,-1,0.9986726,0.0013273692
6814,5-HT,5,6,44,48,"Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",17194457_8,-1,-1,-1,6814,-1,0.99814916,0.0018508814
6815,5-HIAA,7,8,53,59,"Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",17194457_8,-1,-1,-1,6815,-1,0.99845076,0.0015492805
6816,PCPA,20,21,117,121,"Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",17194457_8,-1,-1,-1,6816,-1,0.999129,0.00087097427
6817,PCPA,3,4,20,24,"Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior, partner preference, or aggression.",17194457_9,-1,-1,-1,6817,-1,0.99914694,0.00085306
6822,5-HT,16,17,83,87,"Based on these data, it can be speculated that pubertal AAS users with low central 5-HT may be especially prone to exhibit aggressive behavior.",17194457_12,-1,-1,-1,6822,-1,0.99851984,0.0014801365
6824,ifosfamide renal toxicity,3,6,23,48,Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.,1720453_0,-1,-1,-1,6824,-1,0.5620607,0.43793923
6825,malignant mesenchymal tumors,10,13,73,101,Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.,1720453_0,-1,-1,-1,6825,-1,0.0022045476,0.99779546
6826,malignant mesenchymal tumors,7,10,39,67,The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment.,1720453_1,-1,-1,-1,6826,-1,0.0034462216,0.9965538
6828,Malignant Mesenchymal Tumor,28,31,199,226,The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment.,1720453_1,-1,-1,-1,6828,-1,0.006161468,0.9938385
6832,dactinomycin,21,22,106,118,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,-1,-1,-1,6832,-1,0.99926215,0.000737812
6833,IVA,23,24,120,123,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,-1,-1,-1,6833,-1,0.9965766,0.003423407
6836,glucosuria,11,12,78,88,"Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.",1720453_6,-1,-1,-1,6836,-1,0.07260233,0.92739767
6838,aminoaciduria,15,16,103,116,"Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.",1720453_6,-1,-1,-1,6838,-1,0.38088727,0.61911273
6841,renal abnormalities,19,21,81,100,"Fifty-eight patients (78%) had normal renal tests, whereas 16 patients (22%) had renal abnormalities.",1720453_7,-1,-1,-1,6841,-1,0.0030404849,0.99695957
6843,Fanconi's syndrome,30,33,168,186,Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.,1720453_8,-1,-1,-1,6843,-1,0.0022216071,0.99777836
6844,TDFS,34,35,188,192,Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.,1720453_8,-1,-1,-1,6844,-1,0.0015977406,0.9984023
6849,TDFS,8,9,28,32,This low percentage (5%) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children.,1720453_11,-1,-1,-1,6849,-1,0.0030902913,0.9969097
6851,mesenchymal tumors,23,25,114,132,This low percentage (5%) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children.,1720453_11,-1,-1,-1,6851,-1,0.0021498636,0.9978502
6855,contrast,1,2,3,11,"In contrast, the contribution of sigma2 receptors is unclear because experimental tools to selectively target this subtype are unavailable.",17241657_2,-1,-1,-1,6855,-1,0.2846831,0.71531683
6856,1-(2-phenethyl)-4-(2-pyridyl)-piperazine,10,11,55,95,"To begin addressing this need, we characterized UMB24 (1-(2-phenethyl)-4-(2-pyridyl)-piperazine) and (+/-)-SM 21 (3alpha-tropanyl-2-(4-chorophenoxy)butyrate) in receptor binding and behavioral studies.",17241657_3,-1,-1,-1,6856,-1,0.9980692,0.0019307607
6857,1-(2-phenethyl)-4-(2-pyridyl)-piperazine,10,11,55,95,"To begin addressing this need, we characterized UMB24 (1-(2-phenethyl)-4-(2-pyridyl)-piperazine) and (+/-)-SM 21 (3alpha-tropanyl-2-(4-chorophenoxy)butyrate) in receptor binding and behavioral studies.",17241657_3,-1,-1,-1,6857,-1,0.9980692,0.0019307607
6858,3alpha-tropanyl-2-(4-chorophenoxy)butyrate,16,17,114,156,"To begin addressing this need, we characterized UMB24 (1-(2-phenethyl)-4-(2-pyridyl)-piperazine) and (+/-)-SM 21 (3alpha-tropanyl-2-(4-chorophenoxy)butyrate) in receptor binding and behavioral studies.",17241657_3,-1,-1,-1,6858,-1,0.9981489,0.0018510477
6859,3alpha-tropanyl-2-(4-chorophenoxy)butyrate,16,17,114,156,"To begin addressing this need, we characterized UMB24 (1-(2-phenethyl)-4-(2-pyridyl)-piperazine) and (+/-)-SM 21 (3alpha-tropanyl-2-(4-chorophenoxy)butyrate) in receptor binding and behavioral studies.",17241657_3,-1,-1,-1,6859,-1,0.9981489,0.0018510477
6860,UMB24,10,11,63,68,"In behavioral studies, pretreatment of Swiss Webster mice with UMB24 or (+/-)-SM 21 significantly attenuated cocaine-induced convulsions and locomotor activity, but not lethality.",17241657_5,-1,-1,-1,6860,-1,0.9991301,0.0008699973
6862,UMB24,18,19,115,120,"When administered alone, (+/-)-SM 21 produced no significant effects compared to control injections of saline, but UMB24 had locomotor depressant actions.",17241657_6,-1,-1,-1,6862,-1,0.99912363,0.00087638875
6868,hyperCKaemia,7,8,45,57,Statins can cause a necrotizing myopathy and hyperCKaemia which is reversible on cessation of the drug.,17241784_1,-1,-1,-1,6868,-1,0.0014830692,0.998517
6893,contrast,8,9,49,57,"Generally, atropine reduced contractions, but in contrast to controls, it also reduced responses to low electrical field stimulation intensity (1-5 Hz) in inflamed preparations.",17244258_4,-1,-1,-1,6893,-1,0.14476179,0.8552382
6894,adenosine-5'-triphosphate,10,11,70,95,"In both types, purinoceptor desensitization with alpha,beta-methylene adenosine-5'-triphosphate (alpha,beta-meATP) caused further reductions at low frequencies (<10 Hz).",17244258_5,-1,-1,-1,6894,-1,0.9989581,0.0010418996
6896,4-DAMP,8,9,84,90,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,-1,-1,-1,6896,-1,0.99886924,0.0011307832
6897,methoctramine,16,17,122,135,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,-1,-1,-1,6897,-1,0.9992281,0.0007719194
6898,pirenzepine,23,24,159,170,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,-1,-1,-1,6898,-1,0.99930143,0.0006985279
6899,4-DAMP,0,1,0,6,4-DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine.,17244258_7,-1,-1,-1,6899,-1,0.9990466,0.0009533246
6900,methoctramine,10,11,71,84,4-DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine.,17244258_7,-1,-1,-1,6900,-1,0.999233,0.0007670136
6901,pirenzepine,12,13,89,100,4-DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine.,17244258_7,-1,-1,-1,6901,-1,0.9992913,0.0007086276
6902,pirenzepine,22,23,162,173,"In inflamed preparations, the muscarinic receptor antagonism on the phasic component of the electrical field stimulation-evoked contraction was decreased and the pirenzepine and 4-DAMP antagonism on the tonic component was much less efficient than in controls.",17244258_8,-1,-1,-1,6902,-1,0.9992317,0.00076828676
6903,4-DAMP,24,25,178,184,"In inflamed preparations, the muscarinic receptor antagonism on the phasic component of the electrical field stimulation-evoked contraction was decreased and the pirenzepine and 4-DAMP antagonism on the tonic component was much less efficient than in controls.",17244258_8,-1,-1,-1,6903,-1,0.9990865,0.00091353856
6904,contrast,1,2,3,11,"In contrast to controls, methoctramine increased -- instead of decreased -- the tonic responses at high frequencies.",17244258_9,-1,-1,-1,6904,-1,0.3933317,0.60666835
6905,methoctramine,5,6,25,38,"In contrast to controls, methoctramine increased -- instead of decreased -- the tonic responses at high frequencies.",17244258_9,-1,-1,-1,6905,-1,0.99914145,0.0008585562
6907,ATP,5,6,36,39,"While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response, isoprenaline-induced relaxations were smaller in inflamed strips.",17244258_10,-1,-1,-1,6907,-1,0.9991621,0.0008379591
6911,cardiovascular disease,14,16,101,123,"BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, coronary heart disease, and chronic heart failure.",17261653_1,-1,-1,-1,6911,-1,0.0012593529,0.9987406
6913,coronary heart disease,20,23,147,169,"BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, coronary heart disease, and chronic heart failure.",17261653_1,-1,-1,-1,6913,-1,0.0015156933,0.9984843
6914,chronic heart failure,25,28,175,196,"BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, coronary heart disease, and chronic heart failure.",17261653_1,-1,-1,-1,6914,-1,0.0015991452,0.99840087
6921,bradycardic,2,3,10,21,A similar bradycardic effect of clonidine was observed in isolated spontaneously beating right atria from alpha2ABC-knockout and wild-type mice.,17261653_6,-1,-1,-1,6921,-1,0.0018027305,0.99819726
6925,bradycardic,12,13,84,95,"CONCLUSIONS: Direct inhibition of cardiac HCN pacemaker channels contributes to the bradycardic effects of clonidine gene-targeted mice in vivo, and thus, clonidine-like drugs represent novel structures for future HCN channel inhibitors.",17261653_9,-1,-1,-1,6925,-1,0.0015825516,0.9984175
6928,cerebral palsy,6,8,31,45,Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.,17263743_0,-1,-1,-1,6928,-1,0.0012258383,0.9987741
6932,cerebral palsy,9,11,45,59,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,-1,-1,-1,6932,-1,0.0012014483,0.9987985
6933,seizure disorder,12,14,64,80,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,-1,-1,-1,6933,-1,0.0010659382,0.9989341
6935,restlessness,18,19,106,118,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,-1,-1,-1,6935,-1,0.0013373259,0.9986627
6936,baclofen,26,27,153,161,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,-1,-1,-1,6936,-1,0.9992781,0.00072186644
6938,anxiety,27,28,166,173,"Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.",17263743_3,-1,-1,-1,6938,-1,0.0017901065,0.99820995
6944,mg,26,27,166,168,"This is a case report on a 45-year old African-American female with newly diagnosed hypertension, who was started on a combination pill of amlodipine/benazapril 10/5 mg.",17285209_1,-1,-1,-1,6944,-1,0.99553937,0.004460649
6945,abdominal pain,15,17,65,79,"The very next day, she presented at the emergency room (ER) with abdominal pain, nausea and vomiting.",17285209_2,-1,-1,-1,6945,-1,0.0016064378,0.9983936
6951,ARB,13,14,89,92,"The recognition of angiotensin-converting enzyme (ACE) and angiotensin receptor blocker (ARB) intestinal angioedema constitutes a challenge to primary care physicians, internists, emergency room personal and surgeons.",17285209_10,-1,-1,-1,6951,-1,0.99810934,0.0018905964
6953,Granulomatous hepatitis,0,2,0,23,Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid.,1728522_0,-1,-1,-1,6953,-1,0.0013140049,0.998686
6955,clavulanic acid,8,10,62,77,Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid.,1728522_0,-1,-1,-1,6955,-1,0.9988457,0.0011543174
6957,granulomas,14,15,108,118,We report the case of a patient with amoxicillin-clavulanic acid-induced hepatitis with histologic multiple granulomas.,1728522_1,-1,-1,-1,6957,-1,0.0014103437,0.9985896
6959,cholestatic syndrome,21,23,119,139,"This type of lesion broadens the spectrum of liver injury due to this drug combination, mainly represented by a benign cholestatic syndrome.",1728522_2,-1,-1,-1,6959,-1,0.0013501381,0.9986499
6960,granulomas,3,4,19,29,The association of granulomas and eosinophilia favor an immunoallergic mechanism.,1728522_3,-1,-1,-1,6960,-1,0.0013911984,0.9986089
6965,clavulanic acid,26,28,159,174,"As penicillin derivatives and amoxicillin alone are known to induce such types of lesions, the amoxicillin component, with or without a potentiating effect of clavulanic acid, might have a major role.",1728522_4,-1,-1,-1,6965,-1,0.9989427,0.0010573504
6968,atrioventricular block,6,8,37,59,"A patient with sinus bradycardia and atrioventricular block, induced by carbamazepine, prompted an extensive literature review of all previously reported cases.",1728915_2,-1,-1,-1,6968,-1,0.0021417353,0.9978582
6971,sinus tachycardias,4,6,28,46,One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose.,1728915_4,-1,-1,-1,6971,-1,0.0019471323,0.99805284
6972,carbamazepine overdose,12,14,75,97,One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose.,1728915_4,-1,-1,-1,6972,-1,0.677766,0.32223397
6973,bradyarrhythmias,13,14,106,122,"The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.",1728915_5,-1,-1,-1,6973,-1,0.0011818643,0.9988181
6974,atrioventricular conduction delay,15,18,126,159,"The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.",1728915_5,-1,-1,-1,6974,-1,0.0023893882,0.99761057
6982,cardiac damage,9,11,65,79,"To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.",1732369_2,-1,-1,-1,6982,-1,0.0015311548,0.9984688
6991,mm,17,18,116,118,End-systolic left ventricular posterior wall dimension at baseline for the doxorubicin-treated group was 11 +/- 1.9 mm versus 13.1 +/- 1.5 mm for control subjects (p less than 0.01).,1732369_8,-1,-1,-1,6991,-1,0.02486095,0.975139
6992,mm,23,24,139,141,End-systolic left ventricular posterior wall dimension at baseline for the doxorubicin-treated group was 11 +/- 1.9 mm versus 13.1 +/- 1.5 mm for control subjects (p less than 0.01).,1732369_8,-1,-1,-1,6992,-1,0.025135746,0.9748642
6993,p,28,29,164,165,End-systolic left ventricular posterior wall dimension at baseline for the doxorubicin-treated group was 11 +/- 1.9 mm versus 13.1 +/- 1.5 mm for control subjects (p less than 0.01).,1732369_8,-1,-1,-1,6993,-1,0.30998373,0.69001627
6995,mm,22,23,157,159,End-systolic left ventricular posterior wall dimension at the 5-micrograms/kg per min dobutamine infusion for the doxorubicin-treated group was 14.1 +/- 2.4 mm versus 19.3 +/- 2.6 mm for control subjects (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS),1732369_9,-1,-1,-1,6995,-1,0.018697998,0.98130196
6996,mm,28,29,180,182,End-systolic left ventricular posterior wall dimension at the 5-micrograms/kg per min dobutamine infusion for the doxorubicin-treated group was 14.1 +/- 2.4 mm versus 19.3 +/- 2.6 mm for control subjects (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS),1732369_9,-1,-1,-1,6996,-1,0.0184753,0.9815247
6997,p,33,34,205,206,End-systolic left ventricular posterior wall dimension at the 5-micrograms/kg per min dobutamine infusion for the doxorubicin-treated group was 14.1 +/- 2.4 mm versus 19.3 +/- 2.6 mm for control subjects (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS),1732369_9,-1,-1,-1,6997,-1,0.29396418,0.70603585
6999,iodine-125-metaiodobenzylguanidine,11,12,99,133,Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine.,1732442_0,-1,-1,-1,6999,-1,0.9991435,0.0008565566
7000,metaiodobenzylguanidine,1,2,13,36,"Radiolabeled metaiodobenzylguanidine (MIBG), an analog of norepinephrine (NE), serves as an index of adrenergic neuron integrity and function.",1732442_1,-1,-1,-1,7000,-1,0.9990982,0.00090178347
7001,MIBG,3,4,38,42,"Radiolabeled metaiodobenzylguanidine (MIBG), an analog of norepinephrine (NE), serves as an index of adrenergic neuron integrity and function.",1732442_1,-1,-1,-1,7001,-1,0.9989994,0.0010005768
7003,NE,11,12,74,76,"Radiolabeled metaiodobenzylguanidine (MIBG), an analog of norepinephrine (NE), serves as an index of adrenergic neuron integrity and function.",1732442_1,-1,-1,-1,7003,-1,0.9987286,0.001271424
7005,adriamycin cardiomyopathy,25,27,180,205,"Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy.",1732442_2,-1,-1,-1,7005,-1,0.70753,0.29247
7006,degeneration of myocardial cells,4,8,23,55,"The degree of vacuolar degeneration of myocardial cells was analyzed in relation to the duration of adriamycin treatment (2 mg/kg, once a week).",1732442_3,-1,-1,-1,7006,-1,0.0040708915,0.99592906
7008,p,39,40,202,203,"However, the 4-wk group had a slightly lower accumulation in the right ventricular wall (82% of the control) and significantly lower accumulation in the left ventricular wall (about 66% of the control: p less than 0.05).",1732442_6,-1,-1,-1,7008,-1,0.4006324,0.5993676
7009,MIBG,5,6,19,23,"In the 5-wk group, MIBG accumulation in the right and left ventricular wall was 35% and 27% of that in controls, respectively (p less than 0.001).",1732442_7,-1,-1,-1,7009,-1,0.99848,0.0015199417
7010,p,27,28,127,128,"In the 5-wk group, MIBG accumulation in the right and left ventricular wall was 35% and 27% of that in controls, respectively (p less than 0.001).",1732442_7,-1,-1,-1,7010,-1,0.39249447,0.60750556
7011,MIBG,5,6,19,23,"In the 8-wk group, MIBG accumulation in the right and left ventricular wall was 18% and 14% of that in controls, respectively (p less than 0.001).",1732442_8,-1,-1,-1,7011,-1,0.9984034,0.0015966693
7012,p,27,28,127,128,"In the 8-wk group, MIBG accumulation in the right and left ventricular wall was 18% and 14% of that in controls, respectively (p less than 0.001).",1732442_8,-1,-1,-1,7012,-1,0.37880555,0.6211945
7013,MIBG,2,3,6,10,"Thus, MIBG accumulation in the myocardium decreased in an adriamycin dose-dependent manner.",1732442_9,-1,-1,-1,7013,-1,0.9981316,0.0018684934
7015,myocardial impairment,13,15,88,109,The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.,1732442_10,-1,-1,-1,7015,-1,0.0016299993,0.99837
7022,hearing loss,22,24,145,157,"The influence of smoking during pregnancy on the developing cochlea has not been estimated, although smoking has been positively associated with hearing loss in adults.",17343925_1,-1,-1,-1,7022,-1,0.0032737665,0.99672616
7024,hearing impairment,12,14,69,87,METHODS: This study was undertaken as part of neonatal screening for hearing impairment and involved both ears of 200 newborns.,17343925_3,-1,-1,-1,7024,-1,0.0023628394,0.99763715
7026,n=200,8,9,58,63,"Newborns whose mothers reported smoking during pregnancy (n=200 ears) were compared to a control group of newborns (n=200 ears), whose mothers were non-smokers.",17343925_4,-1,-1,-1,7026,-1,0.094805904,0.90519416
7027,n=200,20,21,116,121,"Newborns whose mothers reported smoking during pregnancy (n=200 ears) were compared to a control group of newborns (n=200 ears), whose mothers were non-smokers.",17343925_4,-1,-1,-1,7027,-1,0.10014467,0.8998553
7028,n=88,14,15,69,73,"Exposure to tobacco was characterized as low (<5 cigarettes per day, n=88 ears), moderate (5< or =cigarettes per day<10, n=76) or high (> or =10 cigarettes per day, n=36).",17343925_5,-1,-1,-1,7028,-1,0.14175612,0.8582439
7029,n=76,28,29,121,125,"Exposure to tobacco was characterized as low (<5 cigarettes per day, n=88 ears), moderate (5< or =cigarettes per day<10, n=76) or high (> or =10 cigarettes per day, n=36).",17343925_5,-1,-1,-1,7029,-1,0.1469097,0.85309035
7030,n=36,41,42,165,169,"Exposure to tobacco was characterized as low (<5 cigarettes per day, n=88 ears), moderate (5< or =cigarettes per day<10, n=76) or high (> or =10 cigarettes per day, n=36).",17343925_5,-1,-1,-1,7030,-1,0.13717099,0.86282897
7034,QT prolongation,2,4,12,27,Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.,17344330_0,-1,-1,-1,7034,-1,0.0033486707,0.99665135
7036,heroin dependence,10,12,70,87,Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.,17344330_0,-1,-1,-1,7036,-1,0.6009843,0.3990157
7038,heroin,6,7,39,45,BACKGROUND: Methadone is prescribed to heroin addicts to decrease illicit opioid use.,17344330_1,-1,-1,-1,7038,-1,0.9987967,0.0012032245
7039,Prolongation of the QT interval,0,5,0,31,Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.,17344330_2,-1,-1,-1,7039,-1,0.0057678595,0.9942321
7040,torsade de pointes,11,14,60,78,Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.,17344330_2,-1,-1,-1,7040,-1,0.0020099797,0.99799
7041,TdP,15,16,80,83,Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.,17344330_2,-1,-1,-1,7041,-1,0.0022840078,0.99771595
7043,heroin,1,2,3,9,"As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.",17344330_3,-1,-1,-1,7043,-1,0.99898213,0.0010178108
7045,TdP,28,29,177,180,"As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.",17344330_3,-1,-1,-1,7045,-1,0.0023609372,0.99763906
7047,heroin,19,20,113,119,"METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis.",17344330_4,-1,-1,-1,7047,-1,0.99897027,0.0010297529
7049,buprenorphine,25,26,154,167,"METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis.",17344330_4,-1,-1,-1,7049,-1,0.999276,0.0007239922
7050,Drug,5,6,23,27,"Of the patients at the Drug Addiction Service in the municipal of Copenhagen, 450 (approximately 52%) were included.",17344330_5,-1,-1,-1,7050,-1,0.99492246,0.005077613
7055,p,14,15,79,80,RESULTS: Methadone dose was associated with longer QT interval of 0.140 ms/mg (p = 0.002).,17344330_9,-1,-1,-1,7055,-1,0.34574267,0.6542573
7056,buprenorphine,3,4,23,36,No association between buprenorphine and QTc was found.,17344330_10,-1,-1,-1,7056,-1,0.9992594,0.00074061716
7058,prolonged QTc interval,15,18,69,91,"Among the subjects treated with methadone, 28% men and 32% women had prolonged QTc interval.",17344330_11,-1,-1,-1,7058,-1,0.009898447,0.9901016
7059,buprenorphine,6,7,34,47,None of the subjects treated with buprenorphine had QTc interval >0.440 s((1/2)).,17344330_12,-1,-1,-1,7059,-1,0.99927586,0.00072417746
7060,mg,2,3,5,7,A 50 mg higher methadone dose was associated with a 1.2 (95% CI 1.1 to 1.4) times higher odds for syncope.,17344330_13,-1,-1,-1,7060,-1,0.98734206,0.012658019
7064,QT prolongation,6,8,42,57,CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.,17344330_14,-1,-1,-1,7064,-1,0.0028511214,0.99714893
7066,heroin,17,18,109,115,CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.,17344330_14,-1,-1,-1,7066,-1,0.9989042,0.0010957693
7067,leg compartment syndrome,2,5,30,54,Simvastatin-induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism.,17344566_0,-1,-1,-1,7067,-1,0.0014705011,0.99852943
7068,myonecrosis,6,7,59,70,Simvastatin-induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism.,17344566_0,-1,-1,-1,7068,-1,0.0011919553,0.998808
7073,compartment syndrome,12,14,93,113,A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.,17344566_1,-1,-1,-1,7073,-1,0.001239147,0.9987608
7074,myonecrosis,15,16,118,129,A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.,17344566_1,-1,-1,-1,7074,-1,0.0011959485,0.9988041
7076,arteriopathic,24,25,131,144,It is likely that this complication will be seen more often with the increased worldwide use of this drug and its approval for all arteriopathic patients.,17344566_3,-1,-1,-1,7076,-1,0.0015313777,0.9984686
7077,Neuroleptic malignant syndrome,0,3,0,30,Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.,17366349_0,-1,-1,-1,7077,-1,0.1762198,0.8237802
7078,ziprasidone,5,6,42,53,Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.,17366349_0,-1,-1,-1,7078,-1,0.99927133,0.0007286529
7079,Neuroleptic malignant syndrome,0,3,0,30,Neuroleptic malignant syndrome (NMS) is the rarest and most serious of the neuroleptic-induced movement disorders.,17366349_1,-1,-1,-1,7079,-1,0.24749331,0.7525067
7080,NMS,4,5,32,35,Neuroleptic malignant syndrome (NMS) is the rarest and most serious of the neuroleptic-induced movement disorders.,17366349_1,-1,-1,-1,7080,-1,0.0014117399,0.99858826
7081,movement disorders,15,17,95,113,Neuroleptic malignant syndrome (NMS) is the rarest and most serious of the neuroleptic-induced movement disorders.,17366349_1,-1,-1,-1,7081,-1,0.0011826094,0.9988174
7082,neuroleptic malignant syndrome,5,8,22,52,We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.,17366349_2,-1,-1,-1,7082,-1,0.059273593,0.9407264
7083,NMS,9,10,54,57,We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.,17366349_2,-1,-1,-1,7083,-1,0.0014205883,0.9985794
7084,ziprasidone,16,17,86,97,We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.,17366349_2,-1,-1,-1,7084,-1,0.9992487,0.00075134257
7085,neuroleptics,2,3,22,34,"Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.",17366349_3,-1,-1,-1,7085,-1,0.99893016,0.0010697859
7086,NMS,8,9,71,74,"Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.",17366349_3,-1,-1,-1,7086,-1,0.0015095236,0.99849045
7087,antipsychotic drugs,11,13,85,104,"Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.",17366349_3,-1,-1,-1,7087,-1,0.9984358,0.0015641967
7088,ziprasidone,14,15,110,121,"Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.",17366349_3,-1,-1,-1,7088,-1,0.99925715,0.0007428579
7090,signs and symptoms,13,16,80,98,The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.,17366349_4,-1,-1,-1,7090,-1,0.0016209779,0.998379
7091,NMS,17,18,102,105,The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.,17366349_4,-1,-1,-1,7091,-1,0.001440139,0.9985599
7092,ziprasidone,30,31,179,190,The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.,17366349_4,-1,-1,-1,7092,-1,0.99927944,0.00072060316
7093,NMS,11,12,52,55,This case is the earliest (second day of treatment) NMS due to ziprasidone reported in the literature.,17366349_5,-1,-1,-1,7093,-1,0.0017092981,0.9982907
7094,ziprasidone,14,15,63,74,This case is the earliest (second day of treatment) NMS due to ziprasidone reported in the literature.,17366349_5,-1,-1,-1,7094,-1,0.9992293,0.0007706353
7095,Neuroinflammation,0,1,0,17,Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.,17400887_0,-1,-1,-1,7095,-1,0.0013669097,0.9986331
7096,behavioral abnormalities,2,4,22,46,Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.,17400887_0,-1,-1,-1,7096,-1,0.0015674119,0.9984326
7098,autism,13,14,110,116,Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.,17400887_0,-1,-1,-1,7098,-1,0.0021619094,0.9978381
7099,Autism,0,1,0,6,Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors.,17400887_1,-1,-1,-1,7099,-1,0.0016489335,0.9983511
7100,neurodevelopmental disorder,3,5,12,39,Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors.,17400887_1,-1,-1,-1,7100,-1,0.0016976326,0.99830234
7101,deficits in communication and social skills,12,18,78,121,Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors.,17400887_1,-1,-1,-1,7101,-1,0.0052962047,0.9947038
7102,repetitive behaviors,19,21,126,146,Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors.,17400887_1,-1,-1,-1,7102,-1,0.0022299509,0.9977701
7103,autism,19,20,120,126,"In addition to genetic influences, recent studies suggest that prenatal drug or chemical exposures are risk factors for autism.",17400887_2,-1,-1,-1,7103,-1,0.0018788654,0.9981211
7105,preterm labor,8,10,57,70,"Terbutaline, a beta2-adrenoceptor agonist used to arrest preterm labor, has been associated with increased concordance for autism in dizygotic twins.",17400887_3,-1,-1,-1,7105,-1,0.0018540253,0.99814594
7106,autism,18,19,123,129,"Terbutaline, a beta2-adrenoceptor agonist used to arrest preterm labor, has been associated with increased concordance for autism in dizygotic twins.",17400887_3,-1,-1,-1,7106,-1,0.0016162791,0.99838376
7109,h,27,28,114,115,Newborn rats were given terbutaline (10 mg/kg) daily on postnatal days (PN) 2 to 5 or PN 11 to 14 and examined 24 h after the last dose and at PN 30.,17400887_5,-1,-1,-1,7109,-1,0.22002096,0.7799791
7113,startle,37,38,210,217,"In behavioral tests, animals treated with terbutaline on PN 2 to 5 showed consistent patterns of hyper-reactivity to novelty and aversive stimuli when assessed in a novel open field, as well as in the acoustic startle response test.",17400887_8,-1,-1,-1,7113,-1,0.014936496,0.98506355
7114,behavioral abnormalities,21,23,181,205,"Our findings indicate that beta2-adrenoceptor overstimulation during an early critical period results in microglial activation associated with innate neuroinflammatory pathways and behavioral abnormalities, similar to those described in autism.",17400887_9,-1,-1,-1,7114,-1,0.0018299312,0.99817
7115,autism,29,30,237,243,"Our findings indicate that beta2-adrenoceptor overstimulation during an early critical period results in microglial activation associated with innate neuroinflammatory pathways and behavioral abnormalities, similar to those described in autism.",17400887_9,-1,-1,-1,7115,-1,0.0023645104,0.9976355
7116,autism spectrum disorders,13,16,103,128,This study provides a useful animal model for understanding the neuropathological processes underlying autism spectrum disorders.,17400887_10,-1,-1,-1,7116,-1,0.0017816907,0.99821824
7120,tariquidar,14,15,108,118,Experiments with systemic administration of the Pgp substrate phenobarbital and the selective Pgp inhibitor tariquidar in TR(-) rats substantiated that Pgp is functional and compensates for the lack of MRP2 in the BBB.,17437408_11,-1,-1,-1,7120,-1,0.9992499,0.0007501317
7121,injury to the brain,10,14,67,86,"Because such a compensatory mechanism most likely occurs to reduce injury to the brain from cytotoxic compounds, the present data substantiate the concept that MRP2 performs a protective role in the BBB.",17437408_13,-1,-1,-1,7121,-1,0.0058929506,0.994107
7123,xanthine oxidase,2,4,8,24,Role of xanthine oxidase in dexamethasone-induced hypertension in rats.1.,17439425_0,-1,-1,-1,7123,-1,0.9983917,0.0016083111
7126,xanthine oxidase,7,9,26,42,"2. We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).",17439425_2,-1,-1,-1,7126,-1,0.9978124,0.0021876008
7127,reactive oxygen species,20,23,90,113,"2. We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).",17439425_2,-1,-1,-1,7127,-1,0.79164773,0.20835228
7131,allopurinol,21,22,114,125,"3. Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.",17439425_3,-1,-1,-1,7131,-1,0.9992481,0.00075192057
7132,allopurinol,26,27,143,154,"3. Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.",17439425_3,-1,-1,-1,7132,-1,0.9992418,0.000758239
7134,urate,13,14,73,78,"Thymus weight was used as a marker of glucocorticoid activity, and serum urate to assess XO inhibition.",17439425_5,-1,-1,-1,7134,-1,0.9986694,0.0013306031
7136,P,15,16,45,46,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,-1,7136,-1,0.372584,0.627416
7137,decreased thymus,20,22,60,76,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,-1,7137,-1,0.045946915,0.95405304
7138,P,23,24,78,79,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,-1,7138,-1,0.3650677,0.63493234
7139,bodyweights,28,29,93,104,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,-1,7139,-1,0.025658837,0.9743412
7140,P,30,31,106,107,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,-1,7140,-1,0.33045822,0.6695417
7141,Allopurinol,0,1,0,11,Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.,17439425_8,-1,-1,-1,7141,-1,0.99920315,0.00079682673
7142,urate,3,4,28,33,Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.,17439425_8,-1,-1,-1,7142,-1,0.99324167,0.0067583206
7143,P,16,17,72,73,Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.,17439425_8,-1,-1,-1,7143,-1,0.5019556,0.49804434
7144,P,37,38,151,152,Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.,17439425_8,-1,-1,-1,7144,-1,0.5288786,0.47112143
7145,Allopurinol,2,3,3,14,6. Allopurinol did not prevent dex-HT.,17439425_9,-1,-1,-1,7145,-1,0.99915826,0.00084173144
7146,allopurinol,8,9,47,58,"This, together with our previous findings that allopurinol failed to prevent adrenocorticotrophic hormone induced hypertension, suggests that XO activity is not a major determinant of GC-HT in the rat.",17439425_10,-1,-1,-1,7146,-1,0.9992415,0.0007584958
7154,n,10,11,38,39,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,-1,-1,-1,7154,-1,0.17593691,0.8240631
7157,n,37,38,175,176,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,-1,-1,-1,7157,-1,0.17545557,0.8245444
7158,"nausea, vomiting",9,12,60,76,"Postoperatively, all patients were assessed for symptoms of nausea, vomiting, and headache.",17466854_5,-1,-1,-1,7158,-1,0.0018517051,0.9981483
7160,postoperative emetic symptoms,8,11,44,73,"RESULTS: Sixty percent in Group A developed postoperative emetic symptoms, headache, or both; 1 patient in Group B developed symptoms.",17466854_7,-1,-1,-1,7160,-1,0.0014678206,0.9985322
7167,iron dextran,1,3,11,23,Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra.,17490790_0,-1,-1,-1,7167,-1,0.9983006,0.0016993694
7168,degeneration of dopaminergic neurons,4,8,32,68,Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra.,17490790_0,-1,-1,-1,7168,-1,0.0030952194,0.9969048
7170,Parkinson's disease,11,14,70,89,Iron accumulation is considered to be involved in the pathogenesis of Parkinson's disease.,17490790_1,-1,-1,-1,7170,-1,0.0025673392,0.99743265
7171,iron overload,6,8,51,64,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7171,-1,0.36728573,0.6327143
7172,loss,11,12,89,93,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7172,-1,0.0023617002,0.99763834
7173,SN,17,18,119,121,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7173,-1,0.03251627,0.9674837
7176,of dopaminergic,52,54,343,358,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7176,-1,0.02075616,0.9792438
7178,SN,61,62,401,403,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7178,-1,0.029875899,0.9701241
7179,iron dextran,63,65,407,419,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7179,-1,0.9980216,0.0019783773
7180,iron dextran,5,7,36,48,The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH-immunoreactive neurons in the SN.,17490790_3,-1,-1,-1,7180,-1,0.9986431,0.0013569148
7182,SN,23,24,160,162,The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH-immunoreactive neurons in the SN.,17490790_3,-1,-1,-1,7182,-1,0.03406623,0.96593374
7184,iron dextran,5,7,38,50,"These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.",17490790_6,-1,-1,-1,7184,-1,0.9982803,0.0017196938
7186,SN,14,15,86,88,"These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.",17490790_6,-1,-1,-1,7186,-1,0.020074574,0.97992545
7188,degeneration of,21,23,122,137,"These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.",17490790_6,-1,-1,-1,7188,-1,0.0034743568,0.9965256
7189,neurons,24,25,151,158,"These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.",17490790_6,-1,-1,-1,7189,-1,0.005071671,0.99492836
7190,iron overload,2,4,12,25,The chronic iron overload may be more destructive to dopaminergic neurons than the acute iron overload.,17490790_7,-1,-1,-1,7190,-1,0.4115621,0.588438
7191,iron overload,14,16,89,102,The chronic iron overload may be more destructive to dopaminergic neurons than the acute iron overload.,17490790_7,-1,-1,-1,7191,-1,0.3933878,0.60661215
7203,myocardial ischemia,13,15,98,117,Assessment of a new non-invasive index of cardiac performance for detection of dobutamine-induced myocardial ischemia.,17491223_0,-1,-1,-1,7203,-1,0.0014450654,0.9985549
7204,myocardial ischemia,11,13,91,110,BACKGROUND: Electrocardiography has a very low sensitivity in detecting dobutamine-induced myocardial ischemia.,17491223_1,-1,-1,-1,7204,-1,0.001599258,0.99840075
7205,myocardial ischemia,36,38,217,236,"OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.",17491223_2,-1,-1,-1,7205,-1,0.0015524523,0.99844754
7210,myocardial ischemia,34,36,208,227,"CONCLUSIONS: If ECG alone is used for specificity, the combination with dP/dtejc improved the sensitivity of the test and could be a cost-savings alternative to cardiac imaging or perfusion studies to detect myocardial ischemia, especially in patients unable to exercise.",17491223_9,-1,-1,-1,7210,-1,0.0020264727,0.9979735
7211,myocardial infarction,1,3,16,37,Cocaine-induced myocardial infarction: clinical observations and pathogenetic considerations.,1749407_0,-1,-1,-1,7211,-1,0.0014199716,0.99858
7216,atherosclerotic obstruction,6,8,40,67,"In other individuals with no underlying atherosclerotic obstruction, coronary occlusion may be due to spasm, thrombus, or both.",1749407_3,-1,-1,-1,7216,-1,0.001438788,0.9985612
7217,coronary occlusion,9,11,69,87,"In other individuals with no underlying atherosclerotic obstruction, coronary occlusion may be due to spasm, thrombus, or both.",1749407_3,-1,-1,-1,7217,-1,0.0017976963,0.9982023
7219,thrombus,17,18,109,117,"In other individuals with no underlying atherosclerotic obstruction, coronary occlusion may be due to spasm, thrombus, or both.",1749407_3,-1,-1,-1,7219,-1,0.001372272,0.9986278
7225,delusional parasitosis,5,7,26,48,An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.,17511042_0,-1,-1,-1,7225,-1,0.0013682618,0.99863166
7226,chronic hepatitis C,9,12,54,73,An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.,17511042_0,-1,-1,-1,7226,-1,0.0025621746,0.99743783
7227,pegylated interferon alpha-2b,14,17,89,118,An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.,17511042_0,-1,-1,-1,7227,-1,0.999064,0.00093600503
7229,chronic hepatitis C,3,6,20,39,"During treatment of chronic hepatitis C patients with interferon and ribavirin, a lot of side effects are described.",17511042_1,-1,-1,-1,7229,-1,0.002756023,0.997244
7230,interferon,8,9,54,64,"During treatment of chronic hepatitis C patients with interferon and ribavirin, a lot of side effects are described.",17511042_1,-1,-1,-1,7230,-1,0.99891675,0.0010832828
7233,psychosis,6,7,33,42,A minority of patients evolve to psychosis.,17511042_3,-1,-1,-1,7233,-1,0.0016681349,0.99833184
7234,psychogenic parasitosis,10,12,42,65,"To the best of our knowledge, no cases of psychogenic parasitosis occurring during interferon therapy have been described in the literature.",17511042_4,-1,-1,-1,7234,-1,0.0012099002,0.9987901
7235,interferon,14,15,83,93,"To the best of our knowledge, no cases of psychogenic parasitosis occurring during interferon therapy have been described in the literature.",17511042_4,-1,-1,-1,7235,-1,0.9988147,0.0011853673
7236,delusional parasitosis,8,10,47,69,We present a 49-year-old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha-2b weekly and ribavirin.,17511042_5,-1,-1,-1,7236,-1,0.0013037763,0.99869627
7237,pegylated interferon alpha-2b,13,16,92,121,We present a 49-year-old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha-2b weekly and ribavirin.,17511042_5,-1,-1,-1,7237,-1,0.9990501,0.0009498997
7239,pegylated interferon alpha-2b,6,9,46,75,All the complaints disappeared after stopping pegylated interferon alpha-2b and reappeared after restarting it.,17511042_8,-1,-1,-1,7239,-1,0.9989524,0.0010475428
7242,LID,3,4,27,30,L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.,17532790_1,-1,-1,-1,7242,-1,0.0012807474,0.99871933
7243,Parkinson's disease,13,16,79,98,L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.,17532790_1,-1,-1,-1,7243,-1,0.0025508697,0.9974491
7244,PD,17,18,100,102,L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.,17532790_1,-1,-1,-1,7244,-1,0.002083754,0.9979163
7245,LID,14,15,73,76,"To this day, transcriptome analysis has been performed in a rat model of LID [Neurobiol. Dis., 17 (2004), 219] but information regarding the proteome is still lacking.",17532790_2,-1,-1,-1,7245,-1,0.0022135118,0.9977865
7246,PD,25,26,170,172,"In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).",17532790_3,-1,-1,-1,7246,-1,0.0032179386,0.99678206
7248,LID,16,17,90,93,Rats treated with L-DOPA were allocated to two groups based on the presence or absence of LID.,17532790_4,-1,-1,-1,7248,-1,0.003786576,0.9962134
7249,LID,6,7,26,29,"Out of these 67 proteins, LID significantly changed the expression level of five proteins: alphabeta-crystalin, gamma-enolase, guanidoacetate methyltransferase, vinculin, and proteasome alpha-2 subunit.",17532790_6,-1,-1,-1,7249,-1,0.9935202,0.006479825
7250,guanidoacetate,20,21,127,141,"Out of these 67 proteins, LID significantly changed the expression level of five proteins: alphabeta-crystalin, gamma-enolase, guanidoacetate methyltransferase, vinculin, and proteasome alpha-2 subunit.",17532790_6,-1,-1,-1,7250,-1,0.9991736,0.00082643563
7251,LID,14,15,86,89,"In conclusion, this study provides new insights into the protein changes occurring in LID.",17532790_8,-1,-1,-1,7251,-1,0.0034911064,0.9965089
7253,chronic kidney disease,21,24,144,166,Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease.,17562951_0,-1,-1,-1,7253,-1,0.0017679645,0.99823207
7254,contrast medium iopamidol,13,16,88,113,BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients.,17562951_1,-1,-1,-1,7254,-1,0.9987,0.001299904
7255,contrast medium iodixanol,21,24,146,171,BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients.,17562951_1,-1,-1,-1,7255,-1,0.9986249,0.0013750835
7258,chronic kidney disease,22,25,137,159,"METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.",17562951_2,-1,-1,-1,7258,-1,0.0016604846,0.99833953
7260,contrast,4,5,17,25,"In 414 patients, contrast volume, presence of diabetes mellitus, use of N-acetylcysteine, mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups.",17562951_6,-1,-1,-1,7260,-1,0.9951668,0.0048332503
7261,diabetes mellitus,9,11,46,63,"In 414 patients, contrast volume, presence of diabetes mellitus, use of N-acetylcysteine, mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups.",17562951_6,-1,-1,-1,7261,-1,0.0017019347,0.9982981
7264,P=0.39,31,32,131,137,"SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).",17562951_7,-1,-1,-1,7264,-1,0.21061535,0.7893846
7265,P=0.44,53,54,217,223,"SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).",17562951_7,-1,-1,-1,7265,-1,0.18945016,0.81054986
7269,P=0.11,35,36,148,154,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,-1,-1,-1,7269,-1,0.23388429,0.7661157
7270,P=0.37,55,56,226,232,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,-1,-1,-1,7270,-1,0.22944127,0.7705587
7272,P=0.03,22,23,130,136,"Mean post-SCr increases were significantly less with iopamidol (all patients: 0.07 versus 0.12 mg/dL, 6.2 versus 10.6 micromol/L, P=0.03; patients with diabetes: 0.07 versus 0.16 mg/dL, 6.2 versus 14.1 micromol/L, P=0.01).",17562951_9,-1,-1,-1,7272,-1,0.2416036,0.7583964
7274,P=0.01,38,39,214,220,"Mean post-SCr increases were significantly less with iopamidol (all patients: 0.07 versus 0.12 mg/dL, 6.2 versus 10.6 micromol/L, P=0.03; patients with diabetes: 0.07 versus 0.16 mg/dL, 6.2 versus 14.1 micromol/L, P=0.01).",17562951_9,-1,-1,-1,7274,-1,0.25763792,0.74236214
7278,diabetes mellitus,33,35,222,239,"CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.",17562951_10,-1,-1,-1,7278,-1,0.0014923739,0.99850756
7279,Hepatonecrosis,0,1,0,14,Hepatonecrosis and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients.,17574447_0,-1,-1,-1,7279,-1,0.0012033617,0.9987966
7280,cholangitis,2,3,19,30,Hepatonecrosis and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients.,17574447_0,-1,-1,-1,7280,-1,0.0011511056,0.9988489
7283,PB,2,3,15,17,"Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.",17574447_1,-1,-1,-1,7283,-1,0.9983151,0.0016849249
7284,chronic liver disease,31,34,193,214,"Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.",17574447_1,-1,-1,-1,7284,-1,0.0014468321,0.9985532
7286,PB,15,16,82,84,"Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.",17574447_2,-1,-1,-1,7286,-1,0.0063863173,0.99361366
7288,bronchopneumonia,31,32,161,177,"Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.",17574447_2,-1,-1,-1,7288,-1,0.00129956,0.9987004
7290,PB,4,5,29,31,"Our findings illustrate that PB may be associated with chronic liver damage, which may lead to more serious and deleterious consequences.",17574447_5,-1,-1,-1,7290,-1,0.99570197,0.004297961
7291,chronic liver damage,9,12,55,75,"Our findings illustrate that PB may be associated with chronic liver damage, which may lead to more serious and deleterious consequences.",17574447_5,-1,-1,-1,7291,-1,0.0017589612,0.99824107
7292,lead,15,16,87,91,"Our findings illustrate that PB may be associated with chronic liver damage, which may lead to more serious and deleterious consequences.",17574447_5,-1,-1,-1,7292,-1,0.02333787,0.97666216
7293,chronic hepatic enzyme dysfunction,17,21,118,152,"For this reason, each clinician should recognize this entity in the differential diagnosis of PB-related asymptomatic chronic hepatic enzyme dysfunction.",17574447_6,-1,-1,-1,7293,-1,0.0020790002,0.99792105
7296,maltol,24,25,164,170,"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid.",17600377_1,-1,-1,-1,7296,-1,0.9988588,0.0011411431
7297,cognitive decline,12,14,81,98,"In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.",17600377_2,-1,-1,-1,7297,-1,0.0021507281,0.9978492
7301,H2O2,19,20,108,112,"Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2.",17600377_5,-1,-1,-1,7301,-1,0.99777883,0.0022211329
7303,reactive oxygen species,12,15,92,115,"We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.",17600377_6,-1,-1,-1,7303,-1,0.8053796,0.1946204
7304,cytochrome c,16,18,117,129,"We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.",17600377_6,-1,-1,-1,7304,-1,0.9966484,0.003351637
7305,Alzheimer's disease,22,25,142,161,"Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.",17600377_7,-1,-1,-1,7305,-1,0.0020221544,0.9979779
7306,neuronal death,31,33,199,213,"Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.",17600377_7,-1,-1,-1,7306,-1,0.0015602777,0.9984397
7307,decline of cognitive function,35,39,230,259,"Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.",17600377_7,-1,-1,-1,7307,-1,0.0046975985,0.99530244
7310,dopaminergic terminal damage,11,14,85,113,Immunological activation has been proposed to play a role in methamphetamine-induced dopaminergic terminal damage.,17608141_1,-1,-1,-1,7310,-1,0.15876694,0.8412331
7312,dopamine neurotoxicity,23,25,170,192,"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.",17608141_2,-1,-1,-1,7312,-1,0.2179083,0.78209174
7317,"3,4-dihydroxyphenylacetic acid",9,11,99,129,"Such systemic lipopolysaccharide treatment mitigated methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions in a dose-dependent manner.",17608141_4,-1,-1,-1,7317,-1,0.9985,0.0015000441
7321,"3,4-dihydroxyphenylacetic acid",30,32,190,220,"As the most potent dose (1 mg/kg) of lipopolysaccharide was administered two weeks, one day before or after the methamphetamine dosing regimen, methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions remained unaltered.",17608141_5,-1,-1,-1,7321,-1,0.9984642,0.0015358306
7325,"3,4-dihydroxyphenylacetic acid",15,17,125,155,"Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.",17608141_6,-1,-1,-1,7325,-1,0.99861383,0.0013861529
7329,dopamine neurotoxicity,17,19,160,182,We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine neurotoxicity.,17608141_7,-1,-1,-1,7329,-1,0.2257075,0.7742925
7343,psychosis,11,12,79,88,"Considering that clozapine remains the gold standard in treatment of resistant psychosis, there is an urgent need to raise awareness among medical and paramedical staff involved in the care of these patients.",17612891_9,-1,-1,-1,7343,-1,0.0012417666,0.9987582
7346,acute renal failure,3,6,26,45,"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.",17615423_0,-1,-1,-1,7346,-1,0.0011453747,0.99885464
7349,atazanavir,16,17,107,117,"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.",17615423_0,-1,-1,-1,7349,-1,0.9992299,0.0007701428
7352,atazanavir,16,17,89,99,"OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.",17615423_1,-1,-1,-1,7352,-1,0.9992157,0.000784284
7354,acute renal failure,21,24,132,151,"OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.",17615423_1,-1,-1,-1,7354,-1,0.0011616417,0.99883837
7355,human immunodeficiency virus,8,11,52,80,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,-1,-1,-1,7355,-1,0.037717283,0.9622827
7356,atrial fibrillation,12,14,82,101,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,-1,-1,-1,7356,-1,0.0014636465,0.99853635
7357,coronary artery disease,15,18,103,126,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,-1,-1,-1,7357,-1,0.001754986,0.998245
7358,hyperlipidemia,20,21,132,146,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,-1,-1,-1,7358,-1,0.0013740335,0.998626
7361,mg simvastatin,5,7,26,40,"The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).",17615423_3,-1,-1,-1,7361,-1,0.9985176,0.001482445
7363,mg,22,23,109,111,"The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).",17615423_3,-1,-1,-1,7363,-1,0.99248886,0.0075111785
7364,mg,30,31,139,141,"The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).",17615423_3,-1,-1,-1,7364,-1,0.9926339,0.007366083
7365,mg atazanavir,41,43,185,198,"The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).",17615423_3,-1,-1,-1,7365,-1,0.99816656,0.0018334185
7366,creatine kinase,5,7,42,57,"Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.",17615423_4,-1,-1,-1,7366,-1,0.9981931,0.0018069313
7373,human immunodeficiency virus,8,11,43,71,"Simvastatin, amiodarone, and the patient's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis.",17615423_5,-1,-1,-1,7373,-1,0.050491724,0.94950825
7374,creatine kinase,6,8,30,45,Nine days later the patient's creatine kinase had dropped to 1695 U/L and creatinine was 3.3 mg/dL. The patient was discharged and continued outpatient dialysis for 1 month until his renal function recovered.,17615423_6,-1,-1,-1,7374,-1,0.9977379,0.002262074
7380,atazanavir,2,3,15,25,Amiodarone and atazanavir are recognized CYP3A4 inhibitors.,17615423_9,-1,-1,-1,7380,-1,0.9991535,0.0008464527
7384,fluvastatin,14,15,88,99,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,-1,-1,-1,7384,-1,0.9991629,0.000837086
7385,rosuvastatin,17,18,105,117,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,-1,-1,-1,7385,-1,0.9992186,0.0007814476
7386,atorvastatin,26,27,162,174,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,-1,-1,-1,7386,-1,0.99923,0.0007699347
7393,fluoroquinolone,3,4,16,31,"Levofloxacin, a fluoroquinolone, is one of the most commonly prescribed antibiotics in clinical practice and is effective against Gram-positive, Gram-negative, and atypical bacteria.",17639754_2,-1,-1,-1,7393,-1,0.9991314,0.000868628
7405,cerebrovascular accident,6,8,54,78,"BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.",17682013_1,-1,-1,-1,7405,-1,0.0011731521,0.9988268
7407,leukaemia,26,27,203,212,"BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.",17682013_1,-1,-1,-1,7407,-1,0.0015229305,0.99847704
7408,cerebrovascular accidents,2,4,14,39,Patients with cerebrovascular accidents were excluded.,17682013_5,-1,-1,-1,7408,-1,0.0015629402,0.9984371
7412,carmofur,24,25,160,168,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,-1,-1,-1,7412,-1,0.99916625,0.0008338248
7414,white,17,18,118,123,"Diffusion weighted imaging (DWI) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum, corresponding to areas of decreased proton diffusion on apparent diffusion coefficient (ADC) maps (available in 21/27 patients).",17682013_7,-1,-1,-1,7414,-1,0.017791245,0.9822088
7415,white matter abnormalities,13,16,94,120,"However, fluid attenuated inversion recovery (FLAIR) sequences frequently revealed persistent white matter abnormalities.",17682013_10,-1,-1,-1,7415,-1,0.0032280611,0.9967719
7417,oedema,9,10,56,62,DWI findings in this cohort are indicative of cytotoxic oedema within cerebral white matter and lend support to an at least partially reversible metabolic derangement as the basis for this syndrome.,17682013_12,-1,-1,-1,7417,-1,0.0013638372,0.9986362
7424,pulmonary hypertension syndrome,12,15,104,135,Epidemiological data suggest that fluoxetine exposure prenatally increases the prevalence of persistent pulmonary hypertension syndrome of the newborn.,17702969_2,-1,-1,-1,7424,-1,0.0012208219,0.9987791
7431,P,32,33,194,195,"As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).",17702969_7,-1,-1,-1,7431,-1,0.34309816,0.6569019
7432,P,46,47,263,264,"As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).",17702969_7,-1,-1,-1,7432,-1,0.4330135,0.5669865
7434,P,26,27,161,162,"Postnatal mortality was increased among experimental animals, and arterial oxygen saturation was 96 +/- 1% in 1-day-old control animals and significantly lower (P < 0.01) in fluoxetine-exposed pups (79 +/- 2%).",17702969_8,-1,-1,-1,7434,-1,0.53662586,0.46337414
7436,P,18,19,101,102,"In vitro, fluoxetine induced pulmonary arterial muscle contraction in fetal, but not adult, animals (P < 0.01) and reduced serotonin-induced contraction at both ages (P < 0.01).",17702969_9,-1,-1,-1,7436,-1,0.44720474,0.5527953
7437,P,30,31,167,168,"In vitro, fluoxetine induced pulmonary arterial muscle contraction in fetal, but not adult, animals (P < 0.01) and reduced serotonin-induced contraction at both ages (P < 0.01).",17702969_9,-1,-1,-1,7437,-1,0.51717573,0.48282424
7439,P,29,30,179,180,"After in utero exposure to a low fluoxetine concentration the pulmonary arterial smooth muscle cell proliferation rate was significantly increased in fetal, but not adult, cells (P < 0.01).",17702969_10,-1,-1,-1,7439,-1,0.49697694,0.503023
7440,contrast,3,4,16,24,"CONCLUSIONS: In contrast to the adult, fluoxetine exposure in utero induces pulmonary hypertension in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation.",17702969_11,-1,-1,-1,7440,-1,0.03394785,0.9660522
7446,alcohol dependence,17,19,93,111,AIM: To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management.,17786501_1,-1,-1,-1,7446,-1,0.49558833,0.50441164
7447,loss of vision,8,11,51,65,RESULTS: A 57-year-old male presented with gradual loss of vision in both eyes with intermittent headaches for 2 months.,17786501_3,-1,-1,-1,7447,-1,0.003897943,0.9961021
7448,headaches,16,17,97,106,RESULTS: A 57-year-old male presented with gradual loss of vision in both eyes with intermittent headaches for 2 months.,17786501_3,-1,-1,-1,7448,-1,0.0014446616,0.99855536
7449,paraesthesia,4,5,22,34,He also complained of paraesthesia with numbness in both feet.,17786501_4,-1,-1,-1,7449,-1,0.001472496,0.9985275
7450,numbness,6,7,40,48,He also complained of paraesthesia with numbness in both feet.,17786501_4,-1,-1,-1,7450,-1,0.0014575529,0.9985424
7451,scotomata,6,7,56,65,Visual field testing confirmed bilateral central-caecal scotomata.,17786501_7,-1,-1,-1,7451,-1,0.0014717915,0.99852824
7453,alcohol dependence,6,8,34,52,He had been taking disulfiram for alcohol dependence for the preceding 3 years.,17786501_8,-1,-1,-1,7453,-1,0.39993244,0.60006756
7455,lead,2,3,27,31,Disulfiram discontinuation lead to an immediate symptomatic improvement.,17786501_9,-1,-1,-1,7455,-1,0.03088853,0.9691115
7457,hepatitis B virus,8,11,66,83,Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.,17854040_0,-1,-1,-1,7457,-1,0.007097268,0.9929027
7458,HBV,12,13,85,88,Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.,17854040_0,-1,-1,-1,7458,-1,0.00627423,0.99372584
7459,infected,14,15,90,98,Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.,17854040_0,-1,-1,-1,7459,-1,0.006304045,0.9936959
7460,hepatitis B,8,10,66,77,This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.,17854040_1,-1,-1,-1,7460,-1,0.0055419956,0.99445796
7461,human immunodeficiency virus,25,28,158,186,This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.,17854040_1,-1,-1,-1,7461,-1,0.027549783,0.9724502
7462,HBV infected,4,6,30,42,Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.,17854040_2,-1,-1,-1,7462,-1,0.00867353,0.9913265
7463,HBsAg,0,1,0,5,"HBsAg, anti-HBs, anti-HBc, and anti-HIV 1/2 were determined as part of routine diagnosis using Axsym assays (Abbott Laboratories, North Chicago, IL).",17854040_4,-1,-1,-1,7463,-1,0.19446045,0.8055395
7464,chronic hepatitis B,10,13,72,91,HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients.,17854040_7,-1,-1,-1,7464,-1,0.0038525334,0.9961475
7465,Rabbit syndrome,0,2,0,15,"Rabbit syndrome, antidepressant use, and cerebral perfusion SPECT scan findings.",1786266_0,-1,-1,-1,7465,-1,0.0019969675,0.99800307
7467,rabbit syndrome,1,3,4,19,The rabbit syndrome is an extrapyramidal side effect associated with chronic neuroleptic therapy.,1786266_1,-1,-1,-1,7467,-1,0.0017471038,0.9982529
7468,neuroleptic,11,12,77,88,The rabbit syndrome is an extrapyramidal side effect associated with chronic neuroleptic therapy.,1786266_1,-1,-1,-1,7468,-1,0.99830246,0.0016974978
7469,imipramine,8,9,47,57,"Its occurrence in a patient being treated with imipramine is described, representing the first reported case of this syndrome in conjunction with antidepressants.",1786266_2,-1,-1,-1,7469,-1,0.99929786,0.00070207304
7471,movement disorder,12,14,93,110,"Repeated cerebral perfusion SPECT scans revealed decreased basal ganglia perfusion while the movement disorder was present, and a return to normal perfusion when the rabbit syndrome resolved.",1786266_3,-1,-1,-1,7471,-1,0.0015712993,0.99842864
7472,rabbit syndrome,25,27,166,181,"Repeated cerebral perfusion SPECT scans revealed decreased basal ganglia perfusion while the movement disorder was present, and a return to normal perfusion when the rabbit syndrome resolved.",1786266_3,-1,-1,-1,7472,-1,0.0019664632,0.9980336
7474,cholesteryl ester,2,4,18,35,Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir.,17879945_0,-1,-1,-1,7474,-1,0.998574,0.0014260006
7476,protease inhibitors,14,16,83,102,Individuals with HIV can now live long lives with drug therapy that often includes protease inhibitors such as ritonavir.,17879945_1,-1,-1,-1,7476,-1,0.9987519,0.0012480958
7478,premature atherosclerosis,12,14,72,97,"Many patients, however, develop negative long-term side effects such as premature atherosclerosis.",17879945_2,-1,-1,-1,7478,-1,0.0014873148,0.9985127
7480,atherosclerotic lesion,8,10,67,89,We have previously demonstrated that ritonavir treatment increases atherosclerotic lesion formation in male mice to a greater extent than in female mice.,17879945_3,-1,-1,-1,7480,-1,0.0019839127,0.9980161
7481,cholesteryl ester,11,13,89,106,"Furthermore, peripheral blood monocytes isolated from ritonavir-treated females had less cholesteryl ester accumulation.",17879945_4,-1,-1,-1,7481,-1,0.99852127,0.00147872
7484,E2,27,28,151,153,"Briefly, cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage-like phenotype in the presence or absence of 1 nM 17beta-estradiol (E2), 100 nM progesterone or vehicle (0.01% ethanol).",17879945_7,-1,-1,-1,7484,-1,0.9987398,0.0012602269
7488,E2,0,1,0,2,E2 decreased the accumulation of cholesteryl esters in macrophages following ritonavir treatment.,17879945_9,-1,-1,-1,7488,-1,0.99893254,0.0010673921
7489,cholesteryl esters,5,7,33,51,E2 decreased the accumulation of cholesteryl esters in macrophages following ritonavir treatment.,17879945_9,-1,-1,-1,7489,-1,0.99837625,0.0016237275
7493,E2,2,3,15,17,"Treatment with E2, however, failed to prevent these increases at the mRNA level.",17879945_12,-1,-1,-1,7493,-1,0.99861693,0.0013830198
7494,E2,0,1,0,2,"E2 did, however, significantly suppress CD36 protein levels as measured by fluorescent immunocytochemistry.",17879945_13,-1,-1,-1,7494,-1,0.99845874,0.0015413113
7495,E2,4,5,24,26,This data suggests that E2 modifies the expression of CD36 at the level of protein expression in monocyte-derived macrophages resulting in reduced cholesteryl ester accumulation following ritonavir treatment.,17879945_14,-1,-1,-1,7495,-1,0.9990151,0.0009848846
7496,cholesteryl ester,22,24,147,164,This data suggests that E2 modifies the expression of CD36 at the level of protein expression in monocyte-derived macrophages resulting in reduced cholesteryl ester accumulation following ritonavir treatment.,17879945_14,-1,-1,-1,7496,-1,0.99914527,0.0008546554
7498,Acute hepatitis attack,0,3,0,22,Acute hepatitis attack after exposure to telithromycin.,17919553_0,-1,-1,-1,7498,-1,0.0016284242,0.99837166
7502,adverse drug reactions,16,19,98,120,"With widespread use of antimicrobial agents, however, hepatic injury occurs frequently, and among adverse drug reactions, idiosyncratic reactions are the most serious.",17919553_2,-1,-1,-1,7502,-1,0.0023165487,0.9976834
7503,Emergency Department,24,26,127,147,"CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, nausea, and vomiting.",17919553_3,-1,-1,-1,7503,-1,0.020114224,0.97988576
7505,malaise,39,40,201,208,"CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, nausea, and vomiting.",17919553_3,-1,-1,-1,7505,-1,0.0014893785,0.99851066
7509,upper respiratory tract infection,11,15,61,94,He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior.,17919553_4,-1,-1,-1,7509,-1,0.0016635703,0.9983365
7512,alkaline phosphatase,34,36,155,175,"Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL).",17919553_5,-1,-1,-1,7512,-1,0.9959745,0.004025509
7516,acute hepatitis,9,11,48,63,"The patient had suffered a previous episode of ""acute hepatitis of unknown origin,"" that occurred after telithromycin usage.",17919553_7,-1,-1,-1,7516,-1,0.0011963962,0.9988036
7519,hepatic dysfunction,10,12,69,88,It has been associated with infrequent and usually reversible severe hepatic dysfunction.,17919553_10,-1,-1,-1,7519,-1,0.0014512512,0.9985487
7520,adverse drug reaction,9,12,37,58,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",17919553_11,-1,-1,-1,7520,-1,0.003478971,0.996521
7522,acute hepatitis,21,23,118,133,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",17919553_11,-1,-1,-1,7522,-1,0.0012527126,0.9987472
7523,toxic hepatitis,32,34,200,215,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",17919553_11,-1,-1,-1,7523,-1,0.0012312328,0.99876875
7526,acute hepatitis,8,10,37,52,CONCLUSION: Here we report a case of acute hepatitis probably associated with the administration of telithromycin.,17919553_13,-1,-1,-1,7526,-1,0.001224302,0.99877566
7528,uveitis,5,6,38,45,Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants.,17923537_0,-1,-1,-1,7528,-1,0.0013252433,0.99867475
7529,fluocinolone acetonide,8,10,59,81,Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants.,17923537_0,-1,-1,-1,7529,-1,0.99924195,0.00075802975
7530,elevated intraocular pressure,9,12,53,82,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,-1,-1,-1,7530,-1,0.0049720732,0.99502796
7531,IOP,13,14,84,87,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,-1,-1,-1,7531,-1,0.0031488999,0.99685115
7532,uveitis,18,19,106,113,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,-1,-1,-1,7532,-1,0.0013053245,0.9986947
7533,fluocinolone acetonide,22,24,131,153,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,-1,-1,-1,7533,-1,0.9992207,0.0007792332
7534,FA,25,26,155,157,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,-1,-1,-1,7534,-1,0.9975453,0.0024547335
7535,FA,28,29,166,168,"DESIGN: Pooled data from 3 multicenter, double-masked, randomized, controlled, phase 2b/3 clinical trials evaluating the safety and efficacy of the 0.59-mg or 2.1-mg FA intravitreal implant or standard therapy were analyzed.",17923537_2,-1,-1,-1,7535,-1,0.99720263,0.0027974267
7536,mm Hg,18,20,88,93,"RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively.",17923537_3,-1,-1,-1,7536,-1,0.03922935,0.96077067
7537,mm Hg,41,43,172,177,"RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively.",17923537_3,-1,-1,-1,7537,-1,0.034270108,0.9657299
7538,mm Hg,47,49,190,195,"RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively.",17923537_3,-1,-1,-1,7538,-1,0.03885698,0.96114296
7539,mm Hg,54,56,212,217,"RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively.",17923537_3,-1,-1,-1,7539,-1,0.03682013,0.9631799
7540,mm Hg,14,16,93,98,Intraocular pressure-lowering surgeries were considered a success (postoperative IOP of 6-21 mm Hg with or without additional IOP-lowering medication) in 85.1% of eyes at 1 year.,17923537_5,-1,-1,-1,7540,-1,0.018101478,0.9818985
7541,hypotony,3,4,12,20,The rate of hypotony (IOP </= 5 mm Hg) following IOP-lowering surgery (42.5%) was not different from that of implanted eyes not subjected to surgery (35.4%) (P = .09).,17923537_6,-1,-1,-1,7541,-1,0.0013040309,0.998696
7542,mm Hg,9,11,32,37,The rate of hypotony (IOP </= 5 mm Hg) following IOP-lowering surgery (42.5%) was not different from that of implanted eyes not subjected to surgery (35.4%) (P = .09).,17923537_6,-1,-1,-1,7542,-1,0.02481409,0.97518593
7543,P,36,37,158,159,The rate of hypotony (IOP </= 5 mm Hg) following IOP-lowering surgery (42.5%) was not different from that of implanted eyes not subjected to surgery (35.4%) (P = .09).,17923537_6,-1,-1,-1,7543,-1,0.26889104,0.73110896
7544,FA,10,11,64,66,CONCLUSION: Elevated IOP is a significant complication with the FA intravitreal implant but may be controlled with medication and surgery.,17923537_7,-1,-1,-1,7544,-1,0.7731814,0.22681862
7573,DCM,5,6,36,39,"BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.",17943461_1,-1,-1,-1,7573,-1,0.0013922295,0.9986078
7575,heart failure,18,20,122,135,"BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.",17943461_1,-1,-1,-1,7575,-1,0.0013085136,0.9986915
7576,acquired immunodeficiency syndrome,14,17,98,132,"Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.",17943461_2,-1,-1,-1,7576,-1,0.00173197,0.998268
7577,AIDS,18,19,134,138,"Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.",17943461_2,-1,-1,-1,7577,-1,0.0014549812,0.99854505
7578,skeletal myopathies,30,32,188,207,"Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.",17943461_2,-1,-1,-1,7578,-1,0.0013139186,0.99868613
7580,"3'-azido-2',3'-deoxythymidine",14,15,85,114,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7580,-1,0.99834406,0.0016559607
7581,AZT,16,17,116,119,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7581,-1,0.99899346,0.0010065746
7582,DCM,32,33,222,225,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7582,-1,0.002002145,0.9979978
7583,NTg,50,51,320,323,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7583,-1,0.008570238,0.99142975
7584,AZT,61,62,395,398,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7584,-1,0.9991326,0.00086745684
7585,NTg,0,1,0,3,NTg and untreated FasL Tg mice showed little or no change in cardiac structure or function.,17943461_5,-1,-1,-1,7585,-1,0.9985877,0.0014123006
7586,Tg,4,5,23,25,NTg and untreated FasL Tg mice showed little or no change in cardiac structure or function.,17943461_5,-1,-1,-1,7586,-1,0.1256647,0.8743353
7587,contrast,1,2,3,11,"In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.",17943461_6,-1,-1,-1,7587,-1,0.09469534,0.9053046
7588,cardiac dilation,8,10,48,64,"In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.",17943461_6,-1,-1,-1,7588,-1,0.0017674462,0.99823254
7590,troponin I,9,11,61,71,"These were associated with changes in dystrophin and cardiac troponin I localization, as well as loss of sarcolemmal integrity.",17943461_8,-1,-1,-1,7590,-1,0.9969983,0.0030017162
7592,cardiac dilation,33,35,221,237,"CONCLUSIONS: The expression of Fas ligand in the myocardium, as identified in HIV-positive patients, might increase the susceptibility to HAART-induced cardiomyopathy due to activation of apoptotic pathways, resulting in cardiac dilation and dysfunction.",17943461_9,-1,-1,-1,7592,-1,0.0017972917,0.9982027
7593,dysfunction,36,37,242,253,"CONCLUSIONS: The expression of Fas ligand in the myocardium, as identified in HIV-positive patients, might increase the susceptibility to HAART-induced cardiomyopathy due to activation of apoptotic pathways, resulting in cardiac dilation and dysfunction.",17943461_9,-1,-1,-1,7593,-1,0.0013629255,0.998637
7594,etoricoxib,3,4,33,43,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,-1,7594,-1,0.99904853,0.0009514563
7596,etoricoxib,12,13,93,103,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,-1,7596,-1,0.999046,0.0009539989
7597,diclofenac sodium,14,16,107,124,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,-1,7597,-1,0.99898094,0.0010190926
7598,etoricoxib,41,42,307,317,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,-1,7598,-1,0.99908113,0.00091883645
7601,RA,50,51,372,374,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,-1,7601,-1,0.0021455952,0.9978544
7602,RA,17,18,84,86,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7602,-1,0.0021618365,0.9978382
7603,etoricoxib,22,23,114,124,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7603,-1,0.9991892,0.00081078475
7604,mg,24,25,128,130,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7604,-1,0.9954242,0.004575801
7605,n,27,28,138,139,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7605,-1,0.50558496,0.49441507
7607,mg,34,35,165,167,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7607,-1,0.9938453,0.0061546396
7608,n,38,39,181,182,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7608,-1,0.5102736,0.48972645
7610,thrombotic cardiovascular event,8,11,56,87,"General safety was also assessed, including adjudicated thrombotic cardiovascular event data.",17965424_4,-1,-1,-1,7610,-1,0.001714968,0.998285
7611,SD,4,5,15,17,"RESULTS: Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the etoricoxib and diclofenac groups, respectively.",17965424_6,-1,-1,-1,7611,-1,0.15704666,0.8429533
7612,etoricoxib,28,29,108,118,"RESULTS: Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the etoricoxib and diclofenac groups, respectively.",17965424_6,-1,-1,-1,7612,-1,0.9990783,0.00092173356
7614,GI AEs,6,8,43,49,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_7,-1,-1,-1,7614,-1,0.0018471957,0.9981528
7615,etoricoxib,12,13,79,89,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_7,-1,-1,-1,7615,-1,0.99901414,0.000985849
7617,p,38,39,201,202,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_7,-1,-1,-1,7617,-1,0.3712995,0.62870055
7618,etoricoxib,13,14,113,123,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_8,-1,-1,-1,7618,-1,0.9990978,0.00090215565
7620,p<0.001,33,34,207,214,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_8,-1,-1,-1,7620,-1,0.30657724,0.69342273
7622,p<0.01,37,38,236,242,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_8,-1,-1,-1,7622,-1,0.318645,0.681355
7623,oedema,39,40,247,253,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_8,-1,-1,-1,7623,-1,0.001363276,0.99863666
7624,Etoricoxib,0,1,0,10,"Etoricoxib and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively).",17965424_9,-1,-1,-1,7624,-1,0.9990816,0.00091842207
7626,Etoricoxib,2,3,13,23,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,-1,-1,-1,7626,-1,0.9990835,0.0009165124
7627,mg,4,5,27,29,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,-1,-1,-1,7627,-1,0.987129,0.0128711015
7628,AEs,16,17,108,111,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,-1,-1,-1,7628,-1,0.0018194418,0.9981806
7630,mg,21,22,141,143,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,-1,-1,-1,7630,-1,0.9907064,0.009293587
7631,etoricoxib,18,19,127,137,"Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with etoricoxib.",17965424_11,-1,-1,-1,7631,-1,0.9988844,0.0011156263
7633,norfloxacin,5,6,42,53,Anxiogenic potential of ciprofloxacin and norfloxacin in rats.,17975693_0,-1,-1,-1,7633,-1,0.9992168,0.0007831637
7634,fluoroquinolones,7,8,49,65,"INTRODUCTION: The possible anxiogenic effects of fluoroquinolones, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.",17975693_1,-1,-1,-1,7634,-1,0.9991928,0.00080724206
7636,norfloxacin,12,13,92,103,"INTRODUCTION: The possible anxiogenic effects of fluoroquinolones, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.",17975693_1,-1,-1,-1,7636,-1,0.9992549,0.0007451061
7637,anxious behaviour,11,13,86,103,RESULTS: The results indicate that ciprofloxacin- and norfloxacin-treated rats showed anxious behaviour in comparison to control rats in all the parameters studied.,17975693_3,-1,-1,-1,7637,-1,0.0022972974,0.99770266
7639,norfloxacin,15,16,125,136,CONCLUSION: The present experimental findings substantiate the clinically observed anxiogenic potential of ciprofloxacin and norfloxacin.,17975693_5,-1,-1,-1,7639,-1,0.999275,0.00072495354
7648,liver failure,16,18,92,105,CASE REPORT: We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3-5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol/day.,18004067_2,-1,-1,-1,7648,-1,0.0016119329,0.99838805
7654,liver failure,14,16,80,93,"CONCLUSION: In patients with risk factors, e.g. regular consumption of alcohol, liver failure is possible when therapeutic doses are ingested.",18004067_5,-1,-1,-1,7654,-1,0.0015762264,0.9984238
7659,remifentanil,9,10,71,83,Reduction of pain during induction with target-controlled propofol and remifentanil.,18006530_0,-1,-1,-1,7659,-1,0.9993057,0.0006942403
7664,remifentanil,11,12,75,87,We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.,18006530_2,-1,-1,-1,7664,-1,0.99934167,0.0006583024
7666,remifentanil,20,21,131,143,"A prospective, randomized, double-blind, placebo-controlled trial was performed to determine the effect-site concentration (Ce) of remifentanil to prevent the pain without producing complications.",18006530_3,-1,-1,-1,7666,-1,0.99931216,0.00068786327
7668,remifentanil,21,22,122,134,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,-1,-1,-1,7668,-1,0.9993168,0.00068314024
7669,Ce,25,26,147,149,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,-1,-1,-1,7669,-1,0.9170489,0.08295116
7670,ng,28,29,155,157,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,-1,-1,-1,7670,-1,0.9736351,0.026364954
7671,ng,36,37,173,175,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,-1,-1,-1,7671,-1,0.96610373,0.033896293
7672,ng,45,46,194,196,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,-1,-1,-1,7672,-1,0.9702275,0.029772485
7674,remifentanil,6,7,60,72,"Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.",18006530_6,-1,-1,-1,7674,-1,0.9992855,0.0007144589
7679,P<0.001,32,33,159,166,"RESULTS: The incidence of pain was significantly lower in Groups R4 and R6 than in the control and R2 groups (12/32 and 6/31 vs 26/31 and 25/32, respectively, P<0.001).",18006530_7,-1,-1,-1,7679,-1,0.34725425,0.6527457
7681,P<0.001,17,18,76,83,Pain was less severe in Groups R4 and R6 than in the control and R2 groups (P<0.001).,18006530_8,-1,-1,-1,7681,-1,0.35352814,0.6464718
7684,remifentanil,11,12,70,82,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,-1,-1,-1,7684,-1,0.9992938,0.0007061865
7687,remifentanil,29,30,208,220,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,-1,-1,-1,7687,-1,0.9993205,0.0006795184
7688,Ce,33,34,233,235,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,-1,-1,-1,7688,-1,0.9012125,0.09878744
7689,ng,36,37,241,243,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,-1,-1,-1,7689,-1,0.96935713,0.030642867
7692,SD,10,11,47,49,164 patients (mean age +/- standard deviation [SD] 81.6 +/- 6.8 years) were admitted.,18020536_3,-1,-1,-1,7692,-1,0.1718077,0.8281923
7693,n,6,7,23,24,"Of these, nearly half (n = 78)",18020536_4,-1,-1,-1,7693,-1,0.26172358,0.7382764
7694,n,10,11,55,56,"had used BZDs/RDs before admission, and the remainder (n = 86) were non-users.",18020536_5,-1,-1,-1,7694,-1,0.16370274,0.8362972
7695,n,12,13,60,61,Patients scoring > or =20 MMSE sum points were interviewed (n = 79) and questioned regarding symptoms and functional abilities during the week prior to admission.,18020536_7,-1,-1,-1,7695,-1,0.14030467,0.8596953
7696,oxazepam,5,6,37,45,"The residual serum concentrations of oxazepam, temazepam and zopiclone were analysed.",18020536_10,-1,-1,-1,7696,-1,0.9990553,0.00094472535
7697,temazepam,7,8,47,56,"The residual serum concentrations of oxazepam, temazepam and zopiclone were analysed.",18020536_10,-1,-1,-1,7697,-1,0.9990422,0.00095781445
7698,zopiclone,9,10,61,70,"The residual serum concentrations of oxazepam, temazepam and zopiclone were analysed.",18020536_10,-1,-1,-1,7698,-1,0.9991665,0.0008335305
7699,SD,6,7,22,24,RESULTS: The mean +/- SD duration of BZD/RD use was 7 +/- 7 years (range 1-31).,18020536_11,-1,-1,-1,7699,-1,0.094630875,0.9053691
7700,n,13,14,64,65,Two or three BZDs/RDs were concomitantly taken by 26% of users (n = 20).,18020536_12,-1,-1,-1,7700,-1,0.11776159,0.88223845
7703,inability to sleep,10,13,56,74,"However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.",18020536_15,-1,-1,-1,7703,-1,0.0072509125,0.99274915
7704,tiredness,18,19,102,111,"However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.",18020536_15,-1,-1,-1,7704,-1,0.0018809089,0.99811906
7705,depressive symptoms,31,33,181,200,"However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.",18020536_15,-1,-1,-1,7705,-1,0.0017210165,0.998279
7706,temazepam,6,7,41,50,A higher residual serum concentration of temazepam correlated with a lower MMSE sum score after adjustment for confounding variables.,18020536_17,-1,-1,-1,7706,-1,0.9989942,0.0010057895
7707,vocal fold palsy,1,4,6,22,Acute vocal fold palsy after acute disulfiram intoxication.,18023325_0,-1,-1,-1,7707,-1,0.0024764321,0.9975236
7710,disulfiram overdose,6,8,40,59,Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy.,18023325_1,-1,-1,-1,7710,-1,0.5019678,0.4980322
7711,vocal fold palsy,20,23,113,129,Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy.,18023325_1,-1,-1,-1,7711,-1,0.0037912845,0.99620867
7712,quadriparesis,10,11,65,78,"A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and paresthesia of the distal limbs.",18023325_2,-1,-1,-1,7712,-1,0.0014073744,0.99859256
7714,sensory loss,15,17,98,110,"A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and paresthesia of the distal limbs.",18023325_2,-1,-1,-1,7714,-1,0.0013504442,0.99864954
7715,paresthesia,19,20,116,127,"A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and paresthesia of the distal limbs.",18023325_2,-1,-1,-1,7715,-1,0.0012077614,0.99879223
7719,giddiness,21,22,104,113,"For the first few days after ingestion, she was in a confused state and had mild to moderate ataxia and giddiness.",18023325_6,-1,-1,-1,7719,-1,0.0013807137,0.9986193
7721,and sensory dysfunction,7,10,54,77,She noticed hoarseness and distally accentuated motor and sensory dysfunction after she had recovered from this state.,18023325_7,-1,-1,-1,7721,-1,0.0023751988,0.9976248
7722,axonal polyneuropathy,9,11,65,86,A nerve conduction study was consistent with severe sensorimotor axonal polyneuropathy.,18023325_8,-1,-1,-1,7722,-1,0.001348851,0.9986512
7724,palsy,6,7,25,30,This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high-dose disulfiram intoxication.,18023325_12,-1,-1,-1,7724,-1,0.0011928799,0.9988071
7729,valproate,6,7,49,58,Encephalopathy induced by levetiracetam added to valproate.,18081909_0,-1,-1,-1,7729,-1,0.9993604,0.0006396732
7733,generalized seizures,10,12,68,88,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7733,-1,0.0013472427,0.9986527
7734,LEV,15,16,106,109,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7734,-1,0.9991009,0.00089907285
7735,mg,18,19,116,118,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7735,-1,0.98876536,0.011234673
7736,valproate,22,23,129,138,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7736,-1,0.99933606,0.00066393707
7737,VPA,24,25,140,143,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7737,-1,0.99923086,0.00076919515
7738,mg,28,29,151,153,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7738,-1,0.98756146,0.012438478
7740,"impaired word fluency, psychomotor speed and working memory",3,12,34,93,"Neuropsychological testing showed impaired word fluency, psychomotor speed and working memory.",18081909_4,-1,-1,-1,7740,-1,0.0065120733,0.99348795
7741,LEV,5,6,38,41,"OUTCOME: Following discontinuation of LEV, EEG and neuropsychological findings improved and seizure frequency decreased.",18081909_6,-1,-1,-1,7741,-1,0.9975708,0.0024291235
7744,anxiety,11,12,105,112,Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety.,18083142_0,-1,-1,-1,7744,-1,0.001494868,0.9985051
7748,anxiety,29,30,184,191,"While the mechanisms underlying cocaine's rewarding effects have been studied extensively, less attention has been paid to the unpleasant behavioral states induced by cocaine, such as anxiety.",18083142_2,-1,-1,-1,7748,-1,0.0014619505,0.998538
7751,NE,24,25,134,136,"METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.",18083142_3,-1,-1,-1,7751,-1,0.9986828,0.0013171372
7752,anxiety,44,45,245,252,"METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.",18083142_3,-1,-1,-1,7752,-1,0.0016416899,0.9983583
7755,anxiety,1,2,16,23,"Cocaine-induced anxiety was also attenuated in Dbh +/- mice following administration of disulfiram, a dopamine beta-hydroxylase (DBH) inhibitor.",18083142_6,-1,-1,-1,7755,-1,0.0013582568,0.9986418
7758,adrenergic antagonists,4,6,30,52,"In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.",18083142_7,-1,-1,-1,7758,-1,0.9983346,0.0016653966
7762,anxiety,15,16,127,134,CONCLUSIONS: These results indicate that noradrenergic signaling via beta-adrenergic receptors is required for cocaine-induced anxiety in mice.,18083142_8,-1,-1,-1,7762,-1,0.0014853813,0.9985146
7763,Dexmedetomidine,0,1,0,15,Dexmedetomidine and cardiac protection for non-cardiac surgery: a meta-analysis of randomised controlled trials.,18086064_0,-1,-1,-1,7763,-1,0.999175,0.00082500954
7764,dexmedetomidine,9,10,51,66,We conducted a systematic review of the effects of dexmedetomidine on cardiac outcomes following non-cardiac surgery.,18086064_1,-1,-1,-1,7764,-1,0.9992342,0.00076577667
7765,dexmedetomidine,8,9,62,77,"We included prospective, randomised peri-operative studies of dexmedetomidine that reported mortality, cardiac morbidity or adverse drug events.",18086064_2,-1,-1,-1,7765,-1,0.9992399,0.0007601312
7766,Dexmedetomidine,0,1,0,15,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,-1,-1,-1,7766,-1,0.99916327,0.000836761
7767,p,24,25,127,128,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,-1,-1,-1,7767,-1,0.22686733,0.7731327
7768,myocardial infarction,30,32,148,169,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,-1,-1,-1,7768,-1,0.0017485747,0.9982514
7769,p,43,44,198,199,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,-1,-1,-1,7769,-1,0.23855183,0.76144814
7770,myocardial ischaemia,49,51,213,233,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,-1,-1,-1,7770,-1,0.0016417821,0.9983582
7771,p,62,63,262,263,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,-1,-1,-1,7771,-1,0.2450394,0.7549606
7773,p,16,17,60,61,"Peri-operative hypotension (26%, OR 3.80, 95% CI 1.91-7.54, p = 0.0001) and bradycardia (17%, OR 5.45, 95% CI 2.98-9.95, p < 0.00001) were significantly increased.",18086064_7,-1,-1,-1,7773,-1,0.3507248,0.64927524
7775,p,36,37,121,122,"Peri-operative hypotension (26%, OR 3.80, 95% CI 1.91-7.54, p = 0.0001) and bradycardia (17%, OR 5.45, 95% CI 2.98-9.95, p < 0.00001) were significantly increased.",18086064_7,-1,-1,-1,7775,-1,0.4063837,0.5936163
7777,p,10,11,64,65,An anticholinergic did not reduce the incidence of bradycardia (p = 0.43).,18086064_8,-1,-1,-1,7777,-1,0.11239524,0.8876048
7778,dexmedetomidine,5,6,41,56,A randomised placebo-controlled trial of dexmedetomidine is warranted.,18086064_9,-1,-1,-1,7778,-1,0.9991866,0.00081345346
7779,Myocardial infarction,0,2,0,21,Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction: a case report.,18161408_0,-1,-1,-1,7779,-1,0.0015306387,0.9984693
7780,clomiphene citrate,6,8,51,69,Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction: a case report.,18161408_0,-1,-1,-1,7780,-1,0.99910957,0.0008904164
7781,Clomiphene citrate,2,4,12,30,BACKGROUND: Clomiphene citrate (CC) is commonly prescribed for ovulation induction.,18161408_1,-1,-1,-1,7781,-1,0.9990884,0.00091158994
7782,CC,5,6,32,34,BACKGROUND: Clomiphene citrate (CC) is commonly prescribed for ovulation induction.,18161408_1,-1,-1,-1,7782,-1,0.9956934,0.004306702
7783,Thromboembolism,0,1,0,15,Thromboembolism is a rare but life-threatening complication that has been reported after ovulation induction with CC.,18161408_3,-1,-1,-1,7783,-1,0.0014165815,0.99858344
7784,CC,15,16,114,116,Thromboembolism is a rare but life-threatening complication that has been reported after ovulation induction with CC.,18161408_3,-1,-1,-1,7784,-1,0.9632471,0.03675294
7785,coronary thrombosis,1,3,12,31,"Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.",18161408_4,-1,-1,-1,7785,-1,0.0014674013,0.99853253
7786,thromboembolism,4,5,35,50,"Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.",18161408_4,-1,-1,-1,7786,-1,0.0011474305,0.9988526
7787,myocardial infarction,20,22,133,154,"Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.",18161408_4,-1,-1,-1,7787,-1,0.0013241053,0.9986759
7788,MI,23,24,156,158,"Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.",18161408_4,-1,-1,-1,7788,-1,0.0014628111,0.9985372
7789,CC,12,13,72,74,CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with chest pain.,18161408_5,-1,-1,-1,7789,-1,0.99656796,0.0034320331
7790,chest pain,19,21,118,128,CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with chest pain.,18161408_5,-1,-1,-1,7790,-1,0.0018102421,0.99818975
7791,wall myocardial infarction,7,10,51,77,An electrocardiogram showed a lateral and anterior wall myocardial infarction.,18161408_6,-1,-1,-1,7791,-1,0.0023181604,0.99768186
7792,troponin I,7,9,38,48,Cardiac enzymes showed a peak rise in troponin I to 9.10 ng/mL. An initial exercise stress test was normal.,18161408_7,-1,-1,-1,7792,-1,0.9884064,0.011593618
7793,radiation injury,13,15,58,74,"At the time of admission, the patient was at high risk of radiation injury to the fetus, so a coronary angiogram was postponed until the second trimester.",18161408_8,-1,-1,-1,7793,-1,0.011825948,0.9881741
7794,CC,15,16,98,100,CONCLUSION: This appears to be the first reported case documenting a possible association between CC and myocardial infarction.,18161408_10,-1,-1,-1,7794,-1,0.0035106628,0.99648935
7795,myocardial infarction,17,19,105,126,CONCLUSION: This appears to be the first reported case documenting a possible association between CC and myocardial infarction.,18161408_10,-1,-1,-1,7795,-1,0.0017344061,0.99826556
7797,CC,9,10,57,59,Thrombosis might be a rare but hazardous complication of CC.,18161408_11,-1,-1,-1,7797,-1,0.0046289447,0.99537104
7798,messenger ribonucleic acid,3,6,32,58,"Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.",18162529_0,-1,-1,-1,7798,-1,0.99467754,0.0053224545
7799,hyperprolactinemic,12,13,92,110,"Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.",18162529_0,-1,-1,-1,7799,-1,0.004347114,0.9956529
7800,luteinizing hormone,16,18,135,154,"Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.",18162529_0,-1,-1,-1,7800,-1,0.99854857,0.001451408
7818,left ventricular apical ballooning syndrome,3,8,20,63,Reverse or inverted left ventricular apical ballooning syndrome (reverse Takotsubo cardiomyopathy) in a young woman in the setting of amphetamine use.,18177388_0,-1,-1,-1,7818,-1,0.003691008,0.996309
7819,Takotsubo cardiomyopathy,10,12,73,97,Reverse or inverted left ventricular apical ballooning syndrome (reverse Takotsubo cardiomyopathy) in a young woman in the setting of amphetamine use.,18177388_0,-1,-1,-1,7819,-1,0.0023148595,0.9976851
7821,left ventricular apical ballooning syndrome,1,6,10,53,"Transient left ventricular apical ballooning syndrome was first described in Japan as ""Takotsubo cardiomyopathy."" This syndrome has been identified in many other countries.",18177388_1,-1,-1,-1,7821,-1,0.003852321,0.99614763
7822,Takotsubo cardiomyopathy,13,15,87,111,"Transient left ventricular apical ballooning syndrome was first described in Japan as ""Takotsubo cardiomyopathy."" This syndrome has been identified in many other countries.",18177388_1,-1,-1,-1,7822,-1,0.0028541363,0.99714583
7823,akinesia,17,18,92,100,"One of the rarest is the reverse type of this syndrome, with hyperdynamic apex and complete akinesia of the base (as opposed to the classic apical ballooning).",18177388_3,-1,-1,-1,7823,-1,0.0017695221,0.9982305
7824,apical ballooning,27,29,140,157,"One of the rarest is the reverse type of this syndrome, with hyperdynamic apex and complete akinesia of the base (as opposed to the classic apical ballooning).",18177388_3,-1,-1,-1,7824,-1,0.00367327,0.99632674
7825,apical ballooning syndrome,21,24,109,135,"In this article, we report an interesting case of a young woman who presented with this rare type of reverse apical ballooning syndrome occurring after amphetamine use.",18177388_4,-1,-1,-1,7825,-1,0.003078579,0.9969214
7830,ADHD,21,22,157,161,OBJECTIVE: To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD).,18182964_2,-1,-1,-1,7830,-1,0.0017187741,0.99828124
7831,ADHD,13,14,72,76,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,-1,7831,-1,0.0019557972,0.99804413
7833,n,20,21,114,115,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,-1,7833,-1,0.20377599,0.79622394
7835,n,27,28,140,141,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,-1,7835,-1,0.24117342,0.7588266
7838,n,36,37,180,181,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,-1,7838,-1,0.25289127,0.7471087
7839,n,44,45,201,202,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,-1,7839,-1,0.26617467,0.7338253
7845,p,27,28,152,153,"RESULTS: There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine (17.5% versus 3.4%; p =.02), but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes.",18182964_6,-1,-1,-1,7845,-1,0.2563778,0.74362224
7849,p,19,20,97,98,Moderate or severe adverse events were more common in subjects on clonidine (79.4% versus 49.2%; p =.0006) but not associated with higher rates of early study withdrawal.,18182964_8,-1,-1,-1,7849,-1,0.27346328,0.72653675
7850,Drowsiness,0,1,0,10,"Drowsiness was common on clonidine, but generally resolved by 6 to 8 weeks.",18182964_9,-1,-1,-1,7850,-1,0.0013374023,0.9986626
7854,ADHD,17,18,105,109,"CONCLUSIONS: Clonidine, used alone or with methylphenidate, appears safe and well tolerated in childhood ADHD.",18182964_10,-1,-1,-1,7854,-1,0.0017868239,0.9982132
7857,drowsiness,16,17,121,131,Physicians prescribing clonidine should monitor for bradycardia and advise patients about the high likelihood of initial drowsiness.,18182964_11,-1,-1,-1,7857,-1,0.001233214,0.9987668
7858,Renal Fanconi syndrome,0,3,0,22,Renal Fanconi syndrome and myopathy after liver transplantation: drug-related mitochondrial cytopathy?Advances in the field of transplantation provide a better quality of life and allow more favorable conditions for growth and development in children.,18186898_0,-1,-1,-1,7858,-1,0.0017902494,0.9982097
7860,Wilson's disease,12,15,81,97,We describe a 15-yr-old girl who had orthotopic liver transplantation because of Wilson's disease.,18186898_2,-1,-1,-1,7860,-1,0.0018162231,0.9981838
7862,MMF,2,3,12,15,"Tacrolimus, MMF, and steroids were given as immunosuppressant.",18186898_3,-1,-1,-1,7862,-1,0.99796164,0.0020383135
7865,hepatitis B infection,7,10,40,61,Lamivudine was added because of de nova hepatitis B infection during her follow-up.,18186898_4,-1,-1,-1,7865,-1,0.0017061246,0.99829394
7866,renal Fanconi syndrome,6,9,45,67,"Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria.",18186898_5,-1,-1,-1,7866,-1,0.0016428612,0.9983571
7868,hypophosphatemia,14,15,100,116,"Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria.",18186898_5,-1,-1,-1,7868,-1,0.0018019164,0.9981981
7870,aminoaciduria,19,20,134,147,"Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria.",18186898_5,-1,-1,-1,7870,-1,0.33856457,0.6614354
7875,muscle weakness,1,3,9,24,Proximal muscle weakness has developed during her follow-up.,18186898_7,-1,-1,-1,7875,-1,0.002237486,0.99776256
7876,Fanconi syndrome,0,2,0,16,"Fanconi syndrome, as well as myopathy, is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA.",18186898_8,-1,-1,-1,7876,-1,0.0018024851,0.9981975
7878,mitochondrial disorders,14,16,75,98,"Fanconi syndrome, as well as myopathy, is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA.",18186898_8,-1,-1,-1,7878,-1,0.002150811,0.9978492
7879,tubular dysfunction,6,8,30,49,We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.,18186898_9,-1,-1,-1,7879,-1,0.0022151782,0.9977848
7884,telmisartan,28,29,172,183,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,-1,-1,-1,7884,-1,0.99932754,0.0006725416
7885,amlodipine,30,31,188,198,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,-1,-1,-1,7885,-1,0.999331,0.0006690063
7886,amlodipine,32,33,206,216,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,-1,-1,-1,7886,-1,0.99933404,0.00066595746
7888,telmisartan,23,24,120,131,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,-1,-1,-1,7888,-1,0.99933165,0.00066830224
7889,mg,25,26,135,137,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,-1,-1,-1,7889,-1,0.9958192,0.004180807
7890,amlodipine,27,28,140,150,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,-1,-1,-1,7890,-1,0.9993426,0.00065732404
7891,mg,29,30,153,155,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,-1,-1,-1,7891,-1,0.9957445,0.0042555085
7892,amlodipine,35,36,176,186,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,-1,-1,-1,7892,-1,0.9989374,0.0010625903
7895,FDC,5,6,32,35,Patients were treated with oral FDC of T+A or A QD before breakfast for 12 weeks; blood pressure (BP) and heart rate were measured in the sitting position.,18201582_3,-1,-1,-1,7895,-1,0.9978732,0.0021268693
7896,mm Hg,36,38,197,202,"Primary efficacy end points were reduction in clinical systolic BP (SBP)/ diastolic BP (DBP) from baseline to study end and number of responders (ie, patients who achieved target SBP/ DBP <130/<80 mm Hg) at end of study.",18201582_4,-1,-1,-1,7896,-1,0.068674944,0.9313251
7897,P,50,51,198,199,"At study end, statistically significant percentage reductions from baseline within groups and between groups were observed in SBP (T+A [-27.4%]; A [-16.6%]) and DBP (T+A [-20.1%]; A [-13.3%]) (all, P < 0.05).",18201582_7,-1,-1,-1,7897,-1,0.3379639,0.6620361
7898,P,23,24,87,88,Response rates were 87.3% (89/102) in the T+A group and 69.3% (70/101) in the A group (P < 0.05).,18201582_8,-1,-1,-1,7898,-1,0.3492533,0.6507467
7899,Peripheral edema,0,2,0,16,"Peripheral edema was reported in 8.5% patients (9/106) in the T+A group compared with 13.5% (14/104) in the A group, and cough was reported in 3.8% patients (4/106) in the T+A group and 1.0% (1/104) patients in the A group; these differences did not reach statistical significance.",18201582_10,-1,-1,-1,7899,-1,0.0015876499,0.9984124
7900,cough,28,29,121,126,"Peripheral edema was reported in 8.5% patients (9/106) in the T+A group compared with 13.5% (14/104) in the A group, and cough was reported in 3.8% patients (4/106) in the T+A group and 1.0% (1/104) patients in the A group; these differences did not reach statistical significance.",18201582_10,-1,-1,-1,7900,-1,0.0014996742,0.99850035
7905,BP reductions,26,28,145,158,"CONCLUSIONS: Among these Indian patients with stage II hypertension, the FDC of T+A was found to be significantly more effective, with regard to BP reductions, than A, and both treatments were well tolerated.",18201582_12,-1,-1,-1,7905,-1,0.011077463,0.9889226
7909,HIT,15,16,112,115,OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration.,18208574_1,-1,-1,-1,7909,-1,0.0016767913,0.99832314
7915,HIT,5,6,21,24,RESULTS: Forty of 94 HIT patients had thrombosis at diagnosis; 54/94 had isolated-HIT without thrombosis.,18208574_3,-1,-1,-1,7915,-1,0.0017138517,0.99828607
7920,HIT,10,11,63,66,At diagnosis there was no significant difference in OD between HIT patients with thrombosis and those with isolated-HIT.,18208574_5,-1,-1,-1,7920,-1,0.0019828859,0.9980171
7923,n,12,13,70,71,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,-1,-1,7923,-1,0.058199253,0.9418008
7925,n,33,34,170,171,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,-1,-1,7925,-1,0.053941764,0.9460583
7927,P,58,59,276,277,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,-1,-1,7927,-1,0.41291344,0.58708656
7928,P,62,63,290,291,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,-1,-1,7928,-1,0.5240286,0.47597137
7934,lymphomas,11,12,93,102,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7934,-1,0.0017487028,0.99825126
7936,Leukemia,21,22,139,147,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7936,-1,0.003522767,0.9964772
7937,B.Thalidomide,23,24,154,167,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7937,-1,0.96688384,0.03311611
7938,multiple myeloma,32,34,227,243,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7938,-1,0.0019307075,0.99806935
7939,mantle cell lymphoma,35,38,245,265,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7939,-1,0.0022352154,0.9977648
7940,lymphoplasmacytic lymphoma,39,41,270,296,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7940,-1,0.0025252842,0.99747473
7941,tumour,10,11,53,59,"Its activity is believed to be due modulation of the tumour milieu, including downregulation of angiogenesis and inflammatory cytokines.",18217897_1,-1,-1,-1,7941,-1,0.0057322406,0.9942677
7942,lymphomas,12,13,80,89,"Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.",18217897_2,-1,-1,-1,7942,-1,0.0016656915,0.99833435
7944,mg,16,17,115,117,"Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.",18217897_2,-1,-1,-1,7944,-1,0.9973527,0.0026472996
7945,mg,22,23,147,149,"Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.",18217897_2,-1,-1,-1,7945,-1,0.99580574,0.004194228
7946,mg,38,39,209,211,"Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.",18217897_2,-1,-1,-1,7946,-1,0.9931878,0.006812211
7950,dyspnea,16,17,104,111,"Grade 3-4 adverse effects included myelosuppression, fatigue, somnolence/depressed mood, neuropathy and dyspnea.",18217897_6,-1,-1,-1,7950,-1,0.0012518645,0.99874806
7953,lymphomas,15,16,101,110,"Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.",18217897_8,-1,-1,-1,7953,-1,0.0022162106,0.99778384
7954,contrast,17,18,115,123,"Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.",18217897_8,-1,-1,-1,7954,-1,0.102533266,0.8974667
7955,lenalidomide,31,32,215,227,"Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.",18217897_8,-1,-1,-1,7955,-1,0.99927,0.00072994555
7956,NMDA,3,4,19,23,Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.,18221780_0,-1,-1,-1,7956,-1,0.99905246,0.0009475491
7961,acute pain,1,3,3,13,"In acute pain models, N-methyl-D-aspartate (NMDA) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females.",18221780_1,-1,-1,-1,7961,-1,0.002857917,0.997142
7962,NMDA,7,8,44,48,"In acute pain models, N-methyl-D-aspartate (NMDA) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females.",18221780_1,-1,-1,-1,7962,-1,0.9989231,0.0010768427
7968,acute pain,8,10,44,54,"For comparison, tests were conducted in two acute pain models, the hotplate and warm water tail-withdrawal procedures.",18221780_4,-1,-1,-1,7968,-1,0.0027768458,0.99722314
7969,NMDA,5,6,30,34,"In males, the non-competitive NMDA antagonist dextromethorphan enhanced the antihyperalgesic effect of low to moderate doses of morphine in a dose-and time-dependent manner.",18221780_5,-1,-1,-1,7969,-1,0.99908185,0.0009181105
7970,dextromethorphan,7,8,46,62,"In males, the non-competitive NMDA antagonist dextromethorphan enhanced the antihyperalgesic effect of low to moderate doses of morphine in a dose-and time-dependent manner.",18221780_5,-1,-1,-1,7970,-1,0.9990971,0.0009029133
7973,dextromethorphan,5,6,43,59,"Enhancement of morphine antinociception by dextromethorphan was seen in both males and females in the acute pain models, with the magnitude of this effect being greater in males.",18221780_7,-1,-1,-1,7973,-1,0.9990779,0.0009220352
7975,NMDA,7,8,68,72,These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models.,18221780_8,-1,-1,-1,7975,-1,0.9990231,0.0009769744
7979,mental slowing,1,3,10,24,Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly.,18239197_0,-1,-1,-1,7979,-1,0.0021415958,0.99785835
7983,mg,4,5,30,32,All participants received 1.0 mg or 2.0 mg trihexyphenidyl or placebo administered in counterbalanced sequences over a period of three consecutive weeks.,18239197_4,-1,-1,-1,7983,-1,0.99011797,0.009882086
7984,mg trihexyphenidyl,7,9,40,58,All participants received 1.0 mg or 2.0 mg trihexyphenidyl or placebo administered in counterbalanced sequences over a period of three consecutive weeks.,18239197_4,-1,-1,-1,7984,-1,0.9978745,0.002125486
7986,mental slowness,14,16,91,106,RESULTS: A 2.0-mg oral dose of trihexyphenidyl resulted in increased subjective ratings of mental slowness in carriers of the APOE epsilon4 allele only.,18239197_6,-1,-1,-1,7986,-1,0.0019251031,0.9980749
7987,mg trihexyphenidyl,9,11,60,78,Drug effects as determined by difference scores between 2.0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.,18239197_7,-1,-1,-1,7987,-1,0.99822205,0.0017779717
7988,mental slowness,16,18,105,120,Drug effects as determined by difference scores between 2.0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.,18239197_7,-1,-1,-1,7988,-1,0.0025434473,0.9974566
7989,mental slowing,13,15,92,106,CONCLUSION: The epsilon4 allele in healthy elderly was associated with increased subjective mental slowing after trihexyphenidyl anticholinergic challenge.,18239197_9,-1,-1,-1,7989,-1,0.0018408701,0.9981591
7992,lead,3,4,34,38,Calcineurin-inhibitor therapy can lead to renal dysfunction in heart transplantation patients.,18261172_1,-1,-1,-1,7992,-1,0.005489569,0.9945104
7994,sirolmus,7,8,38,46,"The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.",18261172_2,-1,-1,-1,7994,-1,0.9987727,0.0012272951
7995,Srl,9,10,48,51,"The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.",18261172_2,-1,-1,-1,7995,-1,0.99672925,0.0032706887
7998,Srl,20,21,117,120,"The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.",18261172_2,-1,-1,-1,7998,-1,0.87777954,0.12222047
8000,Srl,10,11,73,76,"In cardiac transplantation, the incidence of proteinuria associated with Srl is unknown.",18261172_3,-1,-1,-1,8000,-1,0.0018234662,0.9981766
8002,mycophenolate mofetil,4,6,28,49,Concomitant IS consisted of mycophenolate mofetil +/- steroids.,18261172_5,-1,-1,-1,8002,-1,0.99901223,0.0009877919
8005,p,29,30,136,137,Proteinuria increased significantly from a median of 0.13 g/day (range 0-5.7) preswitch to 0.23 g/day (0-9.88) at 24 months postswitch (p = 0.0024).,18261172_6,-1,-1,-1,8005,-1,0.28093085,0.7190691
8007,p,24,25,114,115,"Before the switch, 11.5% of patients had high-grade proteinuria (>1.0 g/day); this increased to 22.9% postswitch (p = 0.006).",18261172_7,-1,-1,-1,8007,-1,0.2781813,0.7218187
8008,ARB,6,7,49,52,ACE inhibitor and angiotensin-releasing blocker (ARB) therapy reduced proteinuria development.,18261172_8,-1,-1,-1,8008,-1,0.9985197,0.0014803235
8011,increased renal function,4,7,33,57,"Patients without proteinuria had increased renal function (median 42.5 vs. 64.1, p = 0.25), whereas patients who developed high-grade proteinuria showed decreased renal function at the end of follow-up (median 39.6 vs. 29.2, p = 0.125).",18261172_9,-1,-1,-1,8011,-1,0.0035977936,0.99640226
8012,p,13,14,81,82,"Patients without proteinuria had increased renal function (median 42.5 vs. 64.1, p = 0.25), whereas patients who developed high-grade proteinuria showed decreased renal function at the end of follow-up (median 39.6 vs. 29.2, p = 0.125).",18261172_9,-1,-1,-1,8012,-1,0.2651914,0.7348086
8014,decreased renal function,25,28,153,177,"Patients without proteinuria had increased renal function (median 42.5 vs. 64.1, p = 0.25), whereas patients who developed high-grade proteinuria showed decreased renal function at the end of follow-up (median 39.6 vs. 29.2, p = 0.125).",18261172_9,-1,-1,-1,8014,-1,0.004426144,0.9955739
8015,p,39,40,225,226,"Patients without proteinuria had increased renal function (median 42.5 vs. 64.1, p = 0.25), whereas patients who developed high-grade proteinuria showed decreased renal function at the end of follow-up (median 39.6 vs. 29.2, p = 0.125).",18261172_9,-1,-1,-1,8015,-1,0.26238745,0.73761255
8017,Srl,12,13,77,80,"Thus, proteinuria may develop in cardiac transplant patients after switch to Srl, which may have an adverse effect on renal function in these patients.",18261172_10,-1,-1,-1,8017,-1,0.9977309,0.0022691363
8018,Srl,0,1,0,3,Srl should be used with ACEi/ARB therapy and patients monitored for proteinuria and increased renal dysfunction.,18261172_11,-1,-1,-1,8018,-1,0.99880195,0.0011980439
8021,Ginsenoside Rg1,0,2,0,15,Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats.,18308784_0,-1,-1,-1,8021,-1,0.99772424,0.00227572
8022,impairment of learning,4,7,29,51,Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats.,18308784_0,-1,-1,-1,8022,-1,0.0047887387,0.9952113
8024,Rg1,0,1,0,3,"Rg1, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial learning impairment.",18308784_1,-1,-1,-1,8024,-1,0.99500054,0.004999383
8025,ginsenoside,4,5,10,21,"Rg1, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial learning impairment.",18308784_1,-1,-1,-1,8025,-1,0.9958091,0.0041909073
8026,learning impairment,13,15,77,96,"Rg1, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial learning impairment.",18308784_1,-1,-1,-1,8026,-1,0.005762393,0.99423754
8027,Rg1,5,6,40,43,Previous studies have demonstrated that Rg1 might be a useful agent for the prevention and treatment of the adverse effects of morphine.,18308784_2,-1,-1,-1,8027,-1,0.99759907,0.0024009335
8029,Rg1,11,12,55,58,The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect.,18308784_3,-1,-1,-1,8029,-1,0.9962196,0.0037804851
8030,learning impairment,13,15,62,81,The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect.,18308784_3,-1,-1,-1,8030,-1,0.0041381205,0.9958619
8033,Rg1,23,24,114,117,"Male rats were subcutaneously injected with morphine (10 mg/kg) twice a day at 12 hour intervals for 10 days, and Rg1 (30 mg/kg) was intraperitoneally injected 2 hours after the second injection of morphine once a day for 10 days.",18308784_4,-1,-1,-1,8033,-1,0.99873096,0.0012690852
8035,Rg1,14,15,98,101,"By implantation of electrodes and electrophysiological recording in vivo, the results showed that Rg1 restored the long-term potentiation (LTP) impaired by morphine in both freely moving and anaesthetised rats.",18308784_7,-1,-1,-1,8035,-1,0.9977992,0.0022007548
8037,Rg1,7,8,56,59,"The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.",18308784_8,-1,-1,-1,8037,-1,0.99854654,0.0014534122
8039,NMDA,42,43,269,273,"The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.",18308784_8,-1,-1,-1,8039,-1,0.9988218,0.0011782125
8040,MK801,46,47,295,300,"The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.",18308784_8,-1,-1,-1,8040,-1,0.9988707,0.0011293628
8041,Rg1,3,4,17,20,We conclude that Rg1 may significantly improve the spatial learning capacity impaired by chonic morphine administration and restore the morphine-inhibited LTP.,18308784_9,-1,-1,-1,8041,-1,0.9950518,0.004948228
8043,NMDA,3,4,15,19,This effect is NMDA receptor dependent.,18308784_10,-1,-1,-1,8043,-1,0.99653983,0.0034601565
8047,Parkinson's disease,41,44,187,206,"SAR studies led to compound 14 with excellent potency (K(i) = 0.4 nM), selectivity (A(1)/A(2A) > 100), and efficacy (MED 10 mg/kg p.o.) in the rat haloperidol-induced catalepsy model for Parkinson's disease.",18329269_2,-1,-1,-1,8047,-1,0.0020004297,0.9979996
8055,increase,8,9,42,50,"Nicotine (1.0 mg/kg) caused a significant increase in locomotor activity in rats that were habituated to the test environment, but had only a weak and delayed stimulant action in rats that were unfamiliar with the test environment.",1833784_5,-1,-1,-1,8055,-1,0.0065821004,0.993418
8057,mecamylamine,12,13,81,93,"The stimulant action of nicotine was blocked by the central nicotinic antagonist mecamylamine but not by the peripheral nicotinic blocker hexamethonium, indicating that the response is probably mediated by central nicotinic receptors.",1833784_6,-1,-1,-1,8057,-1,0.999343,0.0006570319
8060,SCH 23390,9,11,74,83,"Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.",1833784_7,-1,-1,-1,8060,-1,0.9991841,0.00081589445
8061,raclopride,16,17,113,123,"Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.",1833784_7,-1,-1,-1,8061,-1,0.99928844,0.0007115788
8062,fluphenazine,21,22,149,161,"Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.",1833784_7,-1,-1,-1,8062,-1,0.9993032,0.00069680455
8063,PHNO,5,6,33,37,"Pretreatment with the D2 agonist PHNO enhanced nicotine-induced hyperactivity, whereas the D1 agonist SKF 38393 had no effect.",1833784_8,-1,-1,-1,8063,-1,0.9986571,0.0013428413
8065,SKF 38393,14,16,102,111,"Pretreatment with the D2 agonist PHNO enhanced nicotine-induced hyperactivity, whereas the D1 agonist SKF 38393 had no effect.",1833784_8,-1,-1,-1,8065,-1,0.99878114,0.0012188794
8070,Central retinal vein occlusion,0,4,0,30,Central retinal vein occlusion associated with clomiphene-induced ovulation.,18343374_0,-1,-1,-1,8070,-1,0.0018677046,0.9981323
8071,central retinal vein occlusion,7,11,31,61,OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (CC).,18343374_1,-1,-1,-1,8071,-1,0.001702519,0.9982975
8072,clomiphene citrate,13,15,78,96,OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (CC).,18343374_1,-1,-1,-1,8072,-1,0.99918944,0.0008106168
8073,CC,16,17,98,100,OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (CC).,18343374_1,-1,-1,-1,8073,-1,0.99018574,0.009814293
8074,infertility,8,9,50,61,PATIENT(S): A 36-year-old woman referred from the infertility clinic for blurred vision.,18343374_4,-1,-1,-1,8074,-1,0.004659569,0.99534047
8075,blurred vision,11,13,73,87,PATIENT(S): A 36-year-old woman referred from the infertility clinic for blurred vision.,18343374_4,-1,-1,-1,8075,-1,0.0032866702,0.9967133
8076,CC,5,6,46,48,INTERVENTION(S): Ophthalmic examination after CC therapy.,18343374_5,-1,-1,-1,8076,-1,0.99164385,0.008356109
8077,Central retinal vein occlusion,4,8,25,55,MAIN OUTCOME MEASURE(S): Central retinal vein occlusion after ovulation induction with CC.,18343374_6,-1,-1,-1,8077,-1,0.002490579,0.99750936
8078,CC,12,13,87,89,MAIN OUTCOME MEASURE(S): Central retinal vein occlusion after ovulation induction with CC.,18343374_6,-1,-1,-1,8078,-1,0.9899524,0.010047567
8079,central retinal vein occlusion,7,11,49,79,RESULT(S): A 36-year-old Chinese woman developed central retinal vein occlusion after eight courses of CC.,18343374_7,-1,-1,-1,8079,-1,0.0018716565,0.99812835
8080,CC,15,16,103,105,RESULT(S): A 36-year-old Chinese woman developed central retinal vein occlusion after eight courses of CC.,18343374_7,-1,-1,-1,8080,-1,0.98081344,0.019186543
8082,CC,10,11,66,68,"A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.",18343374_8,-1,-1,-1,8082,-1,0.40886098,0.591139
8083,visual disturbance,21,23,137,155,"A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.",18343374_8,-1,-1,-1,8083,-1,0.0013598119,0.99864024
8084,CC,24,25,162,164,"A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.",18343374_8,-1,-1,-1,8084,-1,0.9969554,0.0030446304
8085,central retinal vein occlusion,9,13,50,80,CONCLUSION(S): This is the first reported case of central retinal vein occlusion after treatment with CC.,18343374_9,-1,-1,-1,8085,-1,0.0019647737,0.99803525
8086,CC,16,17,102,104,CONCLUSION(S): This is the first reported case of central retinal vein occlusion after treatment with CC.,18343374_9,-1,-1,-1,8086,-1,0.9537548,0.046245255
8087,infertility,6,7,39,50,"Extra caution is warranted in treating infertility patients with CC, and patients should be well informed of this side effect before commencement of therapy.",18343374_10,-1,-1,-1,8087,-1,0.0016216101,0.9983784
8088,CC,9,10,65,67,"Extra caution is warranted in treating infertility patients with CC, and patients should be well informed of this side effect before commencement of therapy.",18343374_10,-1,-1,-1,8088,-1,0.0018046895,0.99819535
8089,ipratropium bromide,4,6,33,52,Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease.,1835291_0,-1,-1,-1,8089,-1,0.9990134,0.0009865522
8091,chronic obstructive pulmonary disease,9,13,73,110,Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease.,1835291_0,-1,-1,-1,8091,-1,0.0016104126,0.9983896
8092,ipratropium bromide,8,10,47,66,"The bronchodilator effects of a single dose of ipratropium bromide aerosol (36 micrograms) and short-acting theophylline tablets (dose titrated to produce serum levels of 10-20 micrograms/mL) were compared in a double-blind, placebo-controlled crossover study in 21 patients with stable, chronic obstructive pulmonary disease.",1835291_1,-1,-1,-1,8092,-1,0.9991967,0.00080330175
8094,chronic obstructive pulmonary disease,47,51,288,325,"The bronchodilator effects of a single dose of ipratropium bromide aerosol (36 micrograms) and short-acting theophylline tablets (dose titrated to produce serum levels of 10-20 micrograms/mL) were compared in a double-blind, placebo-controlled crossover study in 21 patients with stable, chronic obstructive pulmonary disease.",1835291_1,-1,-1,-1,8094,-1,0.0016676052,0.99833244
8095,ipratropium,42,43,204,215,"Mean peak forced expiratory volume in 1 second (FEV1) increases over baseline and the proportion of patients attaining at least a 15% increase in the FEV1 (responders) were 31% and 90%, respectively, for ipratropium and 17% and 50%, respectively, for theophylline.",1835291_2,-1,-1,-1,8095,-1,0.9992055,0.0007944748
8097,ipratropium,13,14,77,88,The average FEV1 increases during the 6-hour observation period were 18% for ipratropium and 8% for theophylline.,1835291_3,-1,-1,-1,8097,-1,0.99924755,0.0007524811
8099,ipratropium,9,10,47,58,The mean duration of action was 3.8 hours with ipratropium and 2.4 hours with theophylline.,1835291_4,-1,-1,-1,8099,-1,0.9992441,0.0007559191
8102,ipratropium,4,5,24,35,These results show that ipratropium is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction.,1835291_6,-1,-1,-1,8102,-1,0.999204,0.0007960151
8104,airflow obstruction,17,19,116,135,These results show that ipratropium is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction.,1835291_6,-1,-1,-1,8104,-1,0.0016636511,0.9983364
8105,amikacin nephrotoxicity,3,5,17,40,An evaluation of amikacin nephrotoxicity in the hematology/oncology population.,18356633_0,-1,-1,-1,8105,-1,0.30341434,0.69658566
8108,febrile neutropenia,13,15,100,119,Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.,18356633_1,-1,-1,-1,8108,-1,0.0011953794,0.99880457
8117,P,22,23,129,130,"The occurrence of nephrotoxicity was similar between the conventional and extended-interval groups, at 10% and 5%, respectively (P = 1.00).",18356633_6,-1,-1,-1,8117,-1,0.23148455,0.7685155
8118,P,19,20,114,115,"Six patients in the conventional group had a positive culture, compared with none in the extended-interval group (P = 0.002).",18356633_7,-1,-1,-1,8118,-1,0.22443148,0.7755685
8120,dexmedetomidine,2,3,10,25,High dose dexmedetomidine as the sole sedative for pediatric MRI.OBJECTIVE: This large-scale retrospective review evaluates the sedation profile of dexmedetomidine.,18363626_0,-1,-1,-1,8120,-1,0.99924684,0.00075319316
8121,dexmedetomidine,20,21,148,163,High dose dexmedetomidine as the sole sedative for pediatric MRI.OBJECTIVE: This large-scale retrospective review evaluates the sedation profile of dexmedetomidine.,18363626_0,-1,-1,-1,8121,-1,0.9992822,0.0007178827
8122,dexmedetomidine,19,20,110,125,"AIM: To determine the hemodynamic responses, efficacy and adverse events associated with the use of high dose dexmedetomidine as the sole sedative for magnetic resonance imaging (MRI) studies.",18363626_1,-1,-1,-1,8122,-1,0.9991708,0.0008292767
8123,Dexmedetomidine,2,3,12,27,BACKGROUND: Dexmedetomidine has been used at our institution since 2005 to provide sedation for pediatric radiological imaging studies.,18363626_2,-1,-1,-1,8123,-1,0.99915683,0.0008431226
8124,dexmedetomidine,9,10,53,68,"Over time, an effective protocol utilizing high dose dexmedetomidine as the sole sedative agent has evolved.",18363626_3,-1,-1,-1,8124,-1,0.99920744,0.0007925935
8125,dexmedetomidine,10,11,66,81,Data were analyzed from all 747 consecutive patients who received dexmedetomidine for MRI sedation from April 2005 to April 2007.,18363626_5,-1,-1,-1,8125,-1,0.99922895,0.000771082
8126,dexmedetomidine,11,12,52,67,"RESULTS: Since 2005, the 10-min loading dose of our dexmedetomidine protocol increased from 2 to 3 microg.kg(-1), and the infusion rate increased from 1 to 1.5 to 2 microg.kg(-1).h(-1).",18363626_6,-1,-1,-1,8126,-1,0.99924636,0.0007536728
8127,dexmedetomidine,21,22,134,149,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,-1,-1,-1,8127,-1,0.99923337,0.0007665882
8128,P,30,31,177,178,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,-1,-1,-1,8128,-1,0.40521082,0.5947892
8130,dexmedetomidine,48,49,279,294,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,-1,-1,-1,8130,-1,0.99923813,0.0007618477
8131,P,60,61,349,350,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,-1,-1,-1,8131,-1,0.49425438,0.50574565
8132,dexmedetomidine,1,2,9,24,"Although dexmedetomidine sedation was associated with a 16% incidence of bradycardia, all concomitant mean arterial blood pressures were within 20% of age-adjusted normal range and oxygen saturations were 95% or higher.",18363626_8,-1,-1,-1,8132,-1,0.99919873,0.00080123567
8135,Dexmedetomidine,2,3,12,27,CONCLUSION: Dexmedetomidine in high doses provides adequate sedation for pediatric MRI studies.,18363626_9,-1,-1,-1,8135,-1,0.999201,0.00079902913
8136,dexmedetomidine,5,6,23,38,"While use of high dose dexmedetomidine is associated with decreases in heart rate and blood pressure outside the established 'awake' norms, this deviation is generally within 20% of norms, and is not associated with adverse sequelae.",18363626_10,-1,-1,-1,8136,-1,0.9992067,0.0007932645
8137,Dexmedetomidine,0,1,0,15,Dexmedetomidine is useful as the sole sedative for pediatric MRI.,18363626_11,-1,-1,-1,8137,-1,0.99910295,0.0008970692
8140,inflammatory arthritis,5,7,48,70,Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.,18405372_0,-1,-1,-1,8140,-1,0.0012652086,0.9987348
8141,adverse drug reactions,6,9,46,68,BACKGROUND: Spontaneous reporting systems for adverse drug reactions (ADRs) are handicapped by under-reporting and limited detail on individual cases.,18405372_1,-1,-1,-1,8141,-1,0.001912693,0.9980872
8142,ADRs,10,11,70,74,BACKGROUND: Spontaneous reporting systems for adverse drug reactions (ADRs) are handicapped by under-reporting and limited detail on individual cases.,18405372_1,-1,-1,-1,8142,-1,0.002391788,0.9976082
8143,adverse drug reactions,10,13,65,87,We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti-rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients.,18405372_2,-1,-1,-1,8143,-1,0.0026008317,0.9973992
8144,liver failure,26,28,183,196,We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti-rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients.,18405372_2,-1,-1,-1,8144,-1,0.0014259809,0.998574
8145,ADR,3,4,17,20,METHODS: Serious ADR reports have been solicited from local clinicians by regular postcards over the past seven years.,18405372_3,-1,-1,-1,8145,-1,0.002873816,0.99712616
8148,ADR,15,16,85,88,"Patients', who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR, were identified.",18405372_4,-1,-1,-1,8148,-1,0.0015262914,0.9984737
8151,hepatic failure,7,9,41,56,"Eight patients were hospitalised, two in hepatic failure - one died after a liver transplant.",18405372_8,-1,-1,-1,8151,-1,0.0019545609,0.99804544
8152,skin rash,4,6,21,30,"Seven patients had a skin rash, three eosinophilia and one interstitial nephritis.",18405372_10,-1,-1,-1,8152,-1,0.0013932242,0.99860674
8162,METH,2,3,17,21,Methamphetamine (METH) damages dopamine (DA) nerve endings by a process that has been linked to microglial activation but the signaling pathways that mediate this response have not yet been delineated.,18410508_1,-1,-1,-1,8162,-1,0.9984384,0.0015616103
8164,DA,7,8,41,43,Methamphetamine (METH) damages dopamine (DA) nerve endings by a process that has been linked to microglial activation but the signaling pathways that mediate this response have not yet been delineated.,18410508_1,-1,-1,-1,8164,-1,0.9984463,0.0015537256
8165,neurodegeneration,22,23,130,147,"9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced neurodegeneration of DA neurons.",18410508_3,-1,-1,-1,8165,-1,0.0012967465,0.99870324
8166,DA,24,25,151,153,"9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced neurodegeneration of DA neurons.",18410508_3,-1,-1,-1,8166,-1,0.9966788,0.0033211834
8167,CNS damage,2,4,12,22,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,-1,-1,8167,-1,0.0012922665,0.9987078
8168,METH,6,7,33,37,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,-1,-1,8168,-1,0.9989722,0.0010278779
8169,MPTP,8,9,42,46,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,-1,-1,8169,-1,0.9990029,0.0009971168
8170,DA,14,15,75,77,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,-1,-1,8170,-1,0.99874854,0.0012514795
8173,METH,25,26,141,145,Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein (eGFP) were treated with METH and examined for striatal neurotoxicity.,18410508_5,-1,-1,-1,8173,-1,0.9986583,0.0013416281
8175,METH,0,1,0,4,"METH depleted DA, caused microglial activation, and increased body temperature in CX3CR1 knockout mice to the same extent and over the same time course seen in wild-type controls.",18410508_6,-1,-1,-1,8175,-1,0.99895227,0.0010477169
8176,DA,2,3,14,16,"METH depleted DA, caused microglial activation, and increased body temperature in CX3CR1 knockout mice to the same extent and over the same time course seen in wild-type controls.",18410508_6,-1,-1,-1,8176,-1,0.9989355,0.0010644748
8177,METH,3,4,15,19,The effects of METH in CX3CR1 knockout mice were not gender-dependent and did not extend beyond the striatum.,18410508_7,-1,-1,-1,8177,-1,0.9987796,0.0012203936
8178,METH,9,10,83,87,Striatal microglia expressing eGFP constitutively show morphological changes after METH that are characteristic of activation.,18410508_8,-1,-1,-1,8178,-1,0.9981343,0.001865695
8179,METH,22,23,152,156,This response was restricted to the striatum and contrasted sharply with unresponsive eGFP-microglia in surrounding brain areas that are not damaged by METH.,18410508_9,-1,-1,-1,8179,-1,0.99868137,0.0013186372
8180,METH neurotoxicity,11,13,71,89,We conclude from these studies that CX3CR1 signaling does not modulate METH neurotoxicity or microglial activation.,18410508_10,-1,-1,-1,8180,-1,0.24745017,0.7525498
8181,METH,9,10,68,72,"Furthermore, it appears that striatal-resident microglia respond to METH with an activation cascade and then return to a surveying state without undergoing apoptosis or migration.",18410508_11,-1,-1,-1,8181,-1,0.9985121,0.0014878495
8182,nystagmus,1,2,17,26,Nicotine-induced nystagmus correlates with midpontine activation.,18417364_0,-1,-1,-1,8182,-1,0.0012756431,0.9987243
8183,nystagmus,4,5,39,48,The pathomechanism of nicotine-induced nystagmus (NIN) is unknown.,18417364_1,-1,-1,-1,8183,-1,0.0011959416,0.9988041
8184,NIN,6,7,50,53,The pathomechanism of nicotine-induced nystagmus (NIN) is unknown.,18417364_1,-1,-1,-1,8184,-1,0.0026013707,0.9973986
8185,NIN,14,15,77,80,The aim of this study was to delineate brain structures that are involved in NIN generation.,18417364_2,-1,-1,-1,8185,-1,0.087905586,0.9120944
8187,NIN,0,1,0,3,NIN correlated with blood oxygen level-dependent (BOLD) activity levels in a midpontine site in the posterior basis pontis.,18417364_4,-1,-1,-1,8187,-1,0.99139905,0.008600938
8189,N-(2-propylpentanoyl)urea,3,4,17,42,Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in pilocarpine-induced seizure in rats.,18439803_0,-1,-1,-1,8189,-1,0.9982834,0.0017166447
8190,N-(2-propylpentanoyl)urea,3,4,17,42,Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in pilocarpine-induced seizure in rats.,18439803_0,-1,-1,-1,8190,-1,0.9982834,0.0017166447
8197,GABA,29,30,182,186,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,-1,-1,-1,8197,-1,0.99881136,0.0011885981
8198,N-(2-propylpentanoyl)urea,32,33,191,216,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,-1,-1,-1,8198,-1,0.9984308,0.0015692001
8199,VPU,34,35,218,221,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,-1,-1,-1,8199,-1,0.9990293,0.00097074575
8200,valproic acid,43,45,261,274,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,-1,-1,-1,8200,-1,0.9990927,0.00090733875
8201,VPA,46,47,276,279,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,-1,-1,-1,8201,-1,0.9990729,0.0009270108
8202,VPU,0,1,0,3,"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.",18439803_2,-1,-1,-1,8202,-1,0.9991891,0.00081090105
8203,VPA,5,6,25,28,"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.",18439803_2,-1,-1,-1,8203,-1,0.9992717,0.0007283065
8205,VPA,30,31,179,182,"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.",18439803_2,-1,-1,-1,8205,-1,0.99923754,0.000762513
8210,GABA,31,32,230,234,In vivo microdialysis demonstrated that an intraperitoneal administration of pilocarpine induced a pronounced increment of hippocampal glutamate and aspartate whereas no significant change was observed on the level of glycine and GABA.,18439803_3,-1,-1,-1,8210,-1,0.99900997,0.0009900271
8211,VPU,3,4,25,28,Pretreatment with either VPU (50 and 100 mg/kg) or VPA (300 and 600 mg/kg) completely abolished pilocarpine-evoked increases in extracellular glutamate and aspartate.,18439803_4,-1,-1,-1,8211,-1,0.99925715,0.0007428086
8212,VPA,11,12,51,54,Pretreatment with either VPU (50 and 100 mg/kg) or VPA (300 and 600 mg/kg) completely abolished pilocarpine-evoked increases in extracellular glutamate and aspartate.,18439803_4,-1,-1,-1,8212,-1,0.9992963,0.00070362905
8215,GABA,14,15,85,89,"In addition, a statistically significant reduction was also observed on the level of GABA and glycine but less than a drastic reduction of glutamate and aspartate level.",18439803_5,-1,-1,-1,8215,-1,0.99875355,0.0012464498
8219,VPU,5,6,26,29,Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,18439803_6,-1,-1,-1,8219,-1,0.99916494,0.00083508785
8220,VPA,7,8,34,37,Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,18439803_6,-1,-1,-1,8220,-1,0.9992269,0.0007730187
8225,VPA,3,4,16,19,"Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.",18439803_7,-1,-1,-1,8225,-1,0.9992092,0.000790847
8226,VPU,8,9,38,41,"Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.",18439803_7,-1,-1,-1,8226,-1,0.99909353,0.0009064863
8230,atrioventricular block,1,3,9,31,Complete atrioventricular block secondary to lithium therapy.,18441470_0,-1,-1,-1,8230,-1,0.0030868412,0.9969132
8232,Sinus node dysfunction,0,3,0,22,Sinus node dysfunction has been reported most frequently among the adverse cardiovascular effects of lithium.,18441470_1,-1,-1,-1,8232,-1,0.0038748204,0.99612516
8234,atrioventricular (AV) block,6,11,30,57,"In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.",18441470_2,-1,-1,-1,8234,-1,0.0029861617,0.9970138
8235,syncopal attacks,12,14,63,79,"In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.",18441470_2,-1,-1,-1,8235,-1,0.0013706152,0.99862945
8238,syncopal attacks,12,14,79,95,Serum lithium levels remained under or within the therapeutic range during the syncopal attacks.,18441470_3,-1,-1,-1,8238,-1,0.0016529101,0.99834704
8241,gastric hemorrhagic ulcers,5,8,34,60,Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats.,18442015_0,-1,-1,-1,8241,-1,0.0016402386,0.99835974
8243,gastric hemorrhage,5,7,40,58,Studies concerning with pathogenesis of gastric hemorrhage and mucosal ulceration produced in atherosclerotic rats are lacking.,18442015_1,-1,-1,-1,8243,-1,0.0018066268,0.9981933
8246,lipid peroxide,20,22,106,120,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,-1,-1,8246,-1,0.9987614,0.001238605
8247,LPO,23,24,122,125,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,-1,-1,8247,-1,0.9977743,0.0022256293
8248,gastric hemorrhage,32,34,191,209,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,-1,-1,8248,-1,0.0020828925,0.9979171
8251,vitamin D2,44,46,280,290,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,-1,-1,8251,-1,0.99891675,0.0010832563
8255,corn oil,15,17,90,98,Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.,18442015_4,-1,-1,-1,8255,-1,0.99836165,0.0016383695
8256,vitamin D2,18,20,110,120,Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.,18442015_4,-1,-1,-1,8256,-1,0.9988483,0.00115161
8259,corn oil,3,5,22,30,Control rats received corn oil only.,18442015_5,-1,-1,-1,8259,-1,0.9972228,0.002777242
8260,h,10,11,57,58,"After gastric surgery, rat stomachs were irrigated for 3 h with either simulated gastric juice or normal saline.",18442015_6,-1,-1,-1,8260,-1,0.28669417,0.71330583
8261,LPO,5,6,37,40,"Gastric acid back-diffusion, mucosal LPO generation, histamine concentration, microvascular permeability, luminal hemoglobin content and ulcer areas were determined.",18442015_7,-1,-1,-1,8261,-1,0.017015047,0.98298496
8268,gastric ulcers,1,3,7,21,"Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.",18442015_9,-1,-1,-1,8268,-1,0.0016597101,0.99834025
8270,LPO,17,18,128,131,"Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.",18442015_9,-1,-1,-1,8270,-1,0.9965371,0.0034628639
8272,gastric hemorrhage,8,10,49,67,"Moreover, a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats.",18442015_10,-1,-1,-1,8272,-1,0.0021135963,0.99788636
8275,hemorrhagic ulcer,1,3,5,22,This hemorrhagic ulcer and various ulcerogenic parameters were dose-dependently ameliorated by daily intragastric verapamil.,18442015_11,-1,-1,-1,8275,-1,0.001271198,0.9987288
8278,hemorrhagic ulcer,4,6,38,55,"Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.",18442015_12,-1,-1,-1,8278,-1,0.0014133455,0.99858665
8279,LPO,13,14,104,107,"Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.",18442015_12,-1,-1,-1,8279,-1,0.73342717,0.2665728
8283,hepatitis B,5,7,33,44,Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.,18464113_0,-1,-1,-1,8283,-1,0.008388446,0.99161154
8285,Hepatitis B,0,2,0,11,Hepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.,18464113_1,-1,-1,-1,8285,-1,0.009947716,0.9900523
8286,chronic liver disease,13,16,54,75,Hepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.,18464113_1,-1,-1,-1,8286,-1,0.0017800445,0.9982199
8288,hepatic complication,11,13,62,82,Cancer patients who are chronic carriers of HBV have a higher hepatic complication rate while receiving cytotoxic chemotherapy (CT) and this has mainly been attributed to HBV reactivation.,18464113_2,-1,-1,-1,8288,-1,0.0015075217,0.9984925
8290,hematological malignancies,10,12,50,76,"In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.",18464113_3,-1,-1,-1,8290,-1,0.0016148378,0.9983852
8291,HBV infection,14,16,90,103,"In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.",18464113_3,-1,-1,-1,8291,-1,0.010462193,0.98953784
8295,lamivudin,2,3,17,26,The prophylactic lamivudin group consisted of 37 patients who received prophylactic lamivudine treatment.,18464113_6,-1,-1,-1,8295,-1,0.99927646,0.000723607
8298,n=,5,6,22,24,"Of our control group (n= 50), 21 patients (42%) were established hepatitis.",18464113_10,-1,-1,-1,8298,-1,0.11830958,0.8816904
8303,p,21,22,109,110,In the prophylactic lamivudine group severe hepatitis were observed only in 1 patient (2.7%) of 37 patients (p < 0.006).,18464113_12,-1,-1,-1,8303,-1,0.28155264,0.7184474
8306,p,28,29,176,177,Comparison of the mean ALT values revealed significantly higher mean alanine aminotransferase (ALT) values in the control group than the prophylactic lamivudine group; 154:64 (p < 0.32).,18464113_13,-1,-1,-1,8306,-1,0.5018031,0.49819696
8309,nucleoside,9,10,61,71,Further studies are needed to determine the most appropriate nucleoside or nucleotide analogue for antiviral prophylaxis during CT and the optimal duration of administration after completion of CT.,18464113_15,-1,-1,-1,8309,-1,0.9988876,0.0011124585
8310,nucleotide,11,12,75,85,Further studies are needed to determine the most appropriate nucleoside or nucleotide analogue for antiviral prophylaxis during CT and the optimal duration of administration after completion of CT.,18464113_15,-1,-1,-1,8310,-1,0.99859923,0.0014007444
8317,h,42,43,223,224,A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and VIP(-/-) mice with or without CYP-induced cystitis (150 mg/kg; i.p.; 48 h).,18483878_4,-1,-1,-1,8317,-1,0.2016975,0.7983025
8318,CYP,9,10,53,56,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8318,-1,0.99751174,0.0024882085
8319,h,13,14,71,72,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8319,-1,0.29931837,0.7006816
8320,CYP,20,21,99,102,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8320,-1,0.9972429,0.0027571057
8321,h,24,25,117,118,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8321,-1,0.3339626,0.66603744
8322,CYP,37,38,169,172,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8322,-1,0.9975303,0.0024697785
8323,h,41,42,187,188,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8323,-1,0.3263535,0.6736465
8324,CYP,47,48,211,214,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8324,-1,0.9973519,0.0026481433
8325,h,51,52,229,230,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8325,-1,0.27562886,0.72437114
8326,p,19,20,95,96,The genes presented represent (1) greater than 1.5-fold change in either direction and (2) the p value is less than 0.05 for the comparison being made.,18483878_6,-1,-1,-1,8326,-1,0.45347342,0.54652655
8327,CYP,0,1,0,3,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,-1,-1,-1,8327,-1,0.99895227,0.0010476535
8328,p,4,5,29,30,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,-1,-1,-1,8328,-1,0.53998274,0.4600173
8329,CYP,34,35,173,176,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,-1,-1,-1,8329,-1,0.9988813,0.001118736
8330,p,39,40,206,207,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,-1,-1,-1,8330,-1,0.5362247,0.46377528
8331,bladder inflammation,9,11,44,64,"The data suggest that in VIP(-/-) mice with bladder inflammation, inflammatory mediators are increased above that observed in WT with CYP.",18483878_9,-1,-1,-1,8331,-1,0.0016249393,0.99837506
8332,bladder dysfunction,8,10,50,69,This shift in balance may contribute to increased bladder dysfunction in VIP(-/-) mice with bladder inflammation and altered neurochemical expression in micturition pathways.,18483878_10,-1,-1,-1,8332,-1,0.0014684582,0.9985316
8333,bladder inflammation,15,17,92,112,This shift in balance may contribute to increased bladder dysfunction in VIP(-/-) mice with bladder inflammation and altered neurochemical expression in micturition pathways.,18483878_10,-1,-1,-1,8333,-1,0.0015148155,0.99848527
8334,Debrisoquine,0,1,0,12,Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.,1848636_0,-1,-1,-1,8334,-1,0.99936956,0.00063042034
8340,hypokalemia,11,12,80,91,The drug effect studied was the antagonism by metoprolol of terbutaline-induced hypokalemia.,1848636_4,-1,-1,-1,8340,-1,0.0014410678,0.99855894
8343,mg,4,5,21,23,Six EMs received 0.5 mg of terbutaline s.c. on two different occasions: 1) 1 hr after administration of a placebo and 2) 1 hr after 150 mg of metoprolol p.o.,1848636_6,-1,-1,-1,8343,-1,0.9941624,0.0058376635
8345,mg,30,31,136,138,Six EMs received 0.5 mg of terbutaline s.c. on two different occasions: 1) 1 hr after administration of a placebo and 2) 1 hr after 150 mg of metoprolol p.o.,1848636_6,-1,-1,-1,8345,-1,0.9921583,0.00784175
8348,mg,18,19,97,99,"Five PMs were studied according to the same protocol, except for a higher terbutaline dose (0.75 mg) on day 2.",1848636_7,-1,-1,-1,8348,-1,0.98758334,0.012416626
8357,P,31,32,142,143,"There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs (72 +/- 7 ng.ml-1) than EMs (42 +/- 8 ng.ml-1, P less than .001).(ABSTRACT TRUNCATED AT 250 WORDS)",1848636_11,-1,-1,-1,8357,-1,0.3648972,0.6351028
8358,brachial neuritis,3,5,34,51,Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature.,18503483_0,-1,-1,-1,8358,-1,0.0012381615,0.9987619
8360,TAC,0,1,0,3,TAC has been shown to be a potent immunosuppressive agent for solid organ transplantation in pediatrics.,18503483_1,-1,-1,-1,8360,-1,0.99666315,0.003336807
8363,headaches,6,7,39,48,"It is characterized by encephalopathy, headaches, seizures, or neurological deficits.",18503483_3,-1,-1,-1,8363,-1,0.0013338082,0.99866617
8365,neurological deficits,11,13,63,84,"It is characterized by encephalopathy, headaches, seizures, or neurological deficits.",18503483_3,-1,-1,-1,8365,-1,0.0013016571,0.99869835
8366,myelitis,17,18,113,121,MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis.,18503483_5,-1,-1,-1,8366,-1,0.0011853414,0.9988147
8367,brachial plexitis,20,22,132,149,MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis.,18503483_5,-1,-1,-1,8367,-1,0.0020094882,0.9979905
8368,TAC,6,7,44,47,"Symptoms persisted for three months despite TAC dose reduction, administration of IVIG and four doses of methylprednisolone pulse therapy.",18503483_6,-1,-1,-1,8368,-1,0.9986314,0.001368525
8370,TAC,8,9,61,64,Improvement and eventually full recovery only occurred after TAC was completely discontinued and successfully replaced by everolimus.,18503483_7,-1,-1,-1,8370,-1,0.99722517,0.0027748605
8379,blood loss,10,12,83,93,Oxytocin-induced hypotension at cesarean delivery may be incorrectly attributed to blood loss.,18513945_4,-1,-1,-1,8379,-1,0.0020756095,0.9979243
8384,puromycin aminonucleoside nephrosis,5,8,38,73,Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats.,18541230_0,-1,-1,-1,8384,-1,0.54446965,0.45553032
8385,coagulation factors,11,13,67,86,"We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.",18541230_1,-1,-1,-1,8385,-1,0.07747218,0.9225278
8387,nephrotic syndrome,28,30,186,204,"We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.",18541230_1,-1,-1,-1,8387,-1,0.0012679271,0.99873203
8388,puromycin aminonucleoside,23,25,119,144,Antithrombin (50 or 500 IU/kg/i.v.) was administered to rats once a day for 10 days immediately after the injection of puromycin aminonucleoside (50 mg/kg/i.v.).,18541230_2,-1,-1,-1,8388,-1,0.9991534,0.0008466053
8389,hematological abnormalities,7,9,77,104,Treatment with antithrombin attenuated the puromycin aminonucleoside-induced hematological abnormalities.,18541230_3,-1,-1,-1,8389,-1,0.0012532998,0.99874663
8391,hyperlipidemia,5,6,56,70,Puromycin aminonucleoside-induced renal dysfunction and hyperlipidemia were also suppressed.,18541230_4,-1,-1,-1,8391,-1,0.0012018908,0.99879813
8393,nephrotic syndrome,15,17,118,136,These findings suggest that thrombin plays an important role in the pathogenesis of puromycin aminonucleoside-induced nephrotic syndrome.,18541230_8,-1,-1,-1,8393,-1,0.0011512624,0.9988487
8394,nephrotic syndrome,10,12,73,91,Treatment with antithrombin may be clinically effective in patients with nephrotic syndrome.,18541230_9,-1,-1,-1,8394,-1,0.0012729865,0.998727
8396,nausea and vomiting,3,6,26,45,"Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.",18544179_0,-1,-1,-1,8396,-1,0.0016600649,0.9983399
8400,postoperative nausea and vomiting,15,19,107,140,"BACKGROUND AND OBJECTIVE: Despite advantages of induction and maintenance of anaesthesia with sevoflurane, postoperative nausea and vomiting occurs frequently.",18544179_1,-1,-1,-1,8400,-1,0.0016387462,0.9983613
8402,analgesia,17,18,97,106,"Fentanyl is a commonly used supplement that may contribute to this, although it may also improve analgesia.",18544179_2,-1,-1,-1,8402,-1,0.0029586372,0.9970414
8403,postoperative nausea and vomiting,11,15,72,105,METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.,18544179_3,-1,-1,-1,8403,-1,0.0017139039,0.99828607
8405,h,21,22,131,132,METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.,18544179_3,-1,-1,-1,8405,-1,0.10425139,0.8957486
8411,postoperative nausea and vomiting,12,16,70,103,"RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).",18544179_5,-1,-1,-1,8411,-1,0.0015810304,0.9984189
8415,P,49,50,278,279,"RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).",18544179_5,-1,-1,-1,8415,-1,0.39151454,0.6084854
8416,P,14,15,61,62,Antiemetic requirements were reduced from 24% and 31% to 7% (P = 0.0012).,18544179_6,-1,-1,-1,8416,-1,0.28683093,0.7131691
8418,postoperative nausea and vomiting,11,15,72,105,Dexamethasone had no significant effect on the incidence or severity of postoperative nausea and vomiting.,18544179_7,-1,-1,-1,8418,-1,0.001708508,0.99829143
8420,postoperative nausea and vomiting,16,20,112,145,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,-1,-1,-1,8420,-1,0.0019413799,0.9980586
8422,P,38,39,209,210,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,-1,-1,-1,8422,-1,0.30328274,0.69671726
8423,P,42,43,223,224,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,-1,-1,-1,8423,-1,0.43069395,0.569306
8425,h,55,56,278,279,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,-1,-1,-1,8425,-1,0.0633329,0.9366671
8426,P,65,66,311,312,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,-1,-1,-1,8426,-1,0.2983411,0.7016589
8430,respiratory depression,13,15,102,124,"Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.",18544179_10,-1,-1,-1,8430,-1,0.0014674657,0.99853253
8434,postoperative nausea and vomiting,5,9,36,69,"CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.",18544179_11,-1,-1,-1,8434,-1,0.0017477392,0.9982522
8435,postoperative pain,13,15,96,114,"CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.",18544179_11,-1,-1,-1,8435,-1,0.0017359375,0.99826413
8438,Parkinson's disease,6,9,40,59,Valvular heart disease in patients with Parkinson's disease treated with pergolide.,18560792_0,-1,-1,-1,8438,-1,0.0020310346,0.997969
8440,Valvular heart abnormalities,0,3,0,28,Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide.,18560792_2,-1,-1,-1,8440,-1,0.0014604415,0.99853957
8441,Parkinson's disease,9,12,65,84,Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide.,18560792_2,-1,-1,-1,8441,-1,0.002766263,0.9972338
8442,PD,13,14,86,88,Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide.,18560792_2,-1,-1,-1,8442,-1,0.002285897,0.99771416
8444,valvular heart abnormality,9,12,54,80,OBJECTIVES: To estimate the frequency and severity of valvular heart abnormality and its possible reversibility after drug withdrawal in a case-control study.,18560792_4,-1,-1,-1,8444,-1,0.0013544494,0.9986456
8445,PD,3,4,13,15,METHODS: All PD patients in the Amiens area treated with pergolide were invited to attend a cardiologic assessment including transthoracic echocardiography.,18560792_5,-1,-1,-1,8445,-1,0.0029549228,0.9970451
8447,PD,1,2,7,9,Thirty PD patients participated in the study.,18560792_6,-1,-1,-1,8447,-1,0.005465448,0.9945346
8449,n=10,16,17,97,101,A second echocardiography was performed (median interval: 13 months) after pergolide withdrawal (n=10 patients).,18560792_7,-1,-1,-1,8449,-1,0.13936861,0.8606314
8450,aortic regurgitation,6,8,31,51,"RESULTS: Compared to controls, aortic regurgitation (OR: 3.1; 95% IC: 1.1-8.8) and mitral regurgitation (OR: 10.7; 95% IC: 2.1-53) were more frequent in PD patients (tricuspid: NS).",18560792_9,-1,-1,-1,8450,-1,0.0024137788,0.99758625
8452,PD,41,42,153,155,"RESULTS: Compared to controls, aortic regurgitation (OR: 3.1; 95% IC: 1.1-8.8) and mitral regurgitation (OR: 10.7; 95% IC: 2.1-53) were more frequent in PD patients (tricuspid: NS).",18560792_9,-1,-1,-1,8452,-1,0.0047813673,0.9952186
8453,tricuspid,44,45,166,175,"RESULTS: Compared to controls, aortic regurgitation (OR: 3.1; 95% IC: 1.1-8.8) and mitral regurgitation (OR: 10.7; 95% IC: 2.1-53) were more frequent in PD patients (tricuspid: NS).",18560792_9,-1,-1,-1,8453,-1,0.0043144133,0.9956856
8454,NS,46,47,177,179,"RESULTS: Compared to controls, aortic regurgitation (OR: 3.1; 95% IC: 1.1-8.8) and mitral regurgitation (OR: 10.7; 95% IC: 2.1-53) were more frequent in PD patients (tricuspid: NS).",18560792_9,-1,-1,-1,8454,-1,0.0034090495,0.996591
8455,n=2.4+/-0.7,6,7,31,42,"The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group.",18560792_10,-1,-1,-1,8455,-1,0.06074672,0.9392533
8456,n=2.8+/-1.09,15,16,81,93,"The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group.",18560792_10,-1,-1,-1,8456,-1,0.081135385,0.9188646
8457,p=0.008,20,21,108,115,"The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group.",18560792_10,-1,-1,-1,8457,-1,0.41899955,0.58100045
8458,p=0.006,22,23,120,127,"The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group.",18560792_10,-1,-1,-1,8458,-1,0.43348134,0.5665187
8461,valvular regurgitation,4,6,25,47,"A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure.",18560792_12,-1,-1,-1,8461,-1,0.0014224498,0.9985776
8463,heart failure,26,28,142,155,"A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure.",18560792_12,-1,-1,-1,8463,-1,0.0015255039,0.99847454
8466,p=0.01,18,19,113,119,"Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.",18560792_13,-1,-1,-1,8466,-1,0.2536769,0.74632317
8467,heart failure,30,32,192,205,"Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.",18560792_13,-1,-1,-1,8467,-1,0.0014650152,0.99853504
8468,valve regurgitation,8,10,54,73,This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.,18560792_14,-1,-1,-1,8468,-1,0.0015938537,0.9984061
8469,PD,11,12,77,79,This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.,18560792_14,-1,-1,-1,8469,-1,0.0031088565,0.9968912
8471,dopamine agonists,31,33,209,226,This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.,18560792_14,-1,-1,-1,8471,-1,0.9991522,0.0008478566
8473,Unfractionated heparin sodium,2,5,12,41,BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.,18589141_1,-1,-1,-1,8473,-1,0.9980744,0.0019255632
8474,UFH,6,7,43,46,BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.,18589141_1,-1,-1,-1,8474,-1,0.9978999,0.0021000656
8476,LMWH,13,14,81,85,BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.,18589141_1,-1,-1,-1,8476,-1,0.9983277,0.0016723569
8479,HIT,3,4,34,37,"Heparin-induced thrombocytopenia (HIT) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.",18589141_2,-1,-1,-1,8479,-1,0.0012611877,0.9987388
8481,HIT,3,4,19,22,"The frequencies of HIT after liver transplantation and platelet factor 4/heparin-reactive antibody (HIT antibody) positivity in liver transplantation patients, however, are unknown.",18589141_3,-1,-1,-1,8481,-1,0.0017458751,0.9982541
8482,HIT,13,14,100,103,"The frequencies of HIT after liver transplantation and platelet factor 4/heparin-reactive antibody (HIT antibody) positivity in liver transplantation patients, however, are unknown.",18589141_3,-1,-1,-1,8482,-1,0.004720475,0.99527955
8483,LMWH,2,3,11,15,"We started LMWH (25 IU/kg/h) on postoperative day (POD) 1, switching to UFH (5000 U/d) on POD 2 or 3.",18589141_5,-1,-1,-1,8483,-1,0.9989048,0.0010952179
8484,UFH,17,18,72,75,"We started LMWH (25 IU/kg/h) on postoperative day (POD) 1, switching to UFH (5000 U/d) on POD 2 or 3.",18589141_5,-1,-1,-1,8484,-1,0.99873525,0.0012647327
8485,UFH,3,4,12,15,The dose of UFH was changed according to the activated clotting time level.,18589141_6,-1,-1,-1,8485,-1,0.99820554,0.0017944273
8486,HIT,0,1,0,3,HIT antibody levels were measured the day before surgery and on POD 7 and 14.,18589141_7,-1,-1,-1,8486,-1,0.329393,0.670607
8488,HIT,17,18,100,103,"Two patients developed hepatic artery thrombosis on POD 11 and 19, respectively, although they were HIT antibody-negative and their platelet counts were stable.",18589141_10,-1,-1,-1,8488,-1,0.28352526,0.7164747
8490,HIT,3,4,18,21,"The percentage of HIT antibody-positive patients was 0.5% preoperatively, 5.6% on POD 7, and 5.6% on POD 14.",18589141_13,-1,-1,-1,8490,-1,0.02318546,0.97681457
8491,HIT,6,7,52,55,None of the subjects/patients developed UFH-related HIT.,18589141_14,-1,-1,-1,8491,-1,0.0015259207,0.99847406
8492,HIT,9,10,46,49,"CONCLUSIONS: In our series, the occurrence of HIT after liver transplantation was uncommon.",18589141_15,-1,-1,-1,8492,-1,0.0016932922,0.99830675
8494,heart failure,13,15,92,105,Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure.,18619688_0,-1,-1,-1,8494,-1,0.0013896194,0.9986104
8495,heart failure,5,7,38,51,BACKGROUND: The mechanisms underlying heart failure induced by adriamycin are very complicated and still unclear.,18619688_1,-1,-1,-1,8495,-1,0.0015162945,0.9984837
8497,heart failure,16,18,94,107,"The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin, so that we can develop a novel treatment strategy for heart failure.",18619688_2,-1,-1,-1,8497,-1,0.0015844258,0.9984156
8499,heart failure,32,34,185,198,"The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin, so that we can develop a novel treatment strategy for heart failure.",18619688_2,-1,-1,-1,8499,-1,0.0016932898,0.99830675
8501,3MA,4,5,26,29,"METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.",18619688_3,-1,-1,-1,8501,-1,0.9988016,0.0011983823
8502,heart failure,16,18,80,93,"METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.",18619688_3,-1,-1,-1,8502,-1,0.0019594391,0.9980406
8504,3MA,20,21,140,143,"Neonatal cardiomyocytes were isolated from Sprague-Dawley rat hearts and randomly divided into controls, an adriamycin-treated group, and a 3MA plus adriamycin-treated group.",18619688_4,-1,-1,-1,8504,-1,0.99853635,0.0014636738
8505,3MA,2,3,9,12,RESULTS: 3MA significantly improved cardiac function and reduced mitochondrial injury.,18619688_8,-1,-1,-1,8505,-1,0.9965127,0.0034872764
8506,mitochondrial injury,9,11,65,85,RESULTS: 3MA significantly improved cardiac function and reduced mitochondrial injury.,18619688_8,-1,-1,-1,8506,-1,0.004008214,0.99599177
8508,3MA,11,12,74,77,"Furthermore, adriamycin induced the formation of autophagic vacuoles, and 3MA strongly downregulated the expression of beclin 1 in adriamycin-induced failing heart and inhibited the formation of autophagic vacuoles.",18619688_9,-1,-1,-1,8508,-1,0.99865973,0.0013402809
8510,heart failure,13,15,90,103,CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin.,18619688_10,-1,-1,-1,8510,-1,0.001349782,0.99865025
8512,Mitochondrial injury,0,2,0,20,Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.,18619688_11,-1,-1,-1,8512,-1,0.003985513,0.9960145
8513,heart failure,9,11,59,72,Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.,18619688_11,-1,-1,-1,8513,-1,0.0014957216,0.9985043
8517,anthracycline doxorubicin,4,6,20,45,"Clinical use of the anthracycline doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.",18627295_1,-1,-1,-1,8517,-1,0.99880075,0.0011992268
8518,DOX,7,8,47,50,"Clinical use of the anthracycline doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.",18627295_1,-1,-1,-1,8518,-1,0.99859744,0.0014025705
8520,DOX cardiomyopathy,17,19,88,106,"To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.",18627295_2,-1,-1,-1,8520,-1,0.18646659,0.81353337
8521,cardiac inflammation,31,33,165,185,"To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.",18627295_2,-1,-1,-1,8521,-1,0.0020779632,0.997922
8523,DOX,0,1,0,3,DOX control mice showed cardiac dysfunction measured by pressure-volume loops in vivo.,18627295_3,-1,-1,-1,8523,-1,0.9978009,0.0021990759
8525,cardiac apoptosis,23,25,128,145,"This was associated with a reduced activation state of AKT, as well as an increased bax/bcl2 ratio in Western blots, indicating cardiac apoptosis.",18627295_4,-1,-1,-1,8525,-1,0.0030958198,0.9969042
8526,DOX,1,2,3,6,"In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.",18627295_6,-1,-1,-1,8526,-1,0.99876344,0.0012365734
8528,DOX,12,13,67,70,"In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.",18627295_6,-1,-1,-1,8528,-1,0.9986879,0.0013120902
8529,DOX cardiomyopathy,8,10,50,68,These findings suggest that B1R is detrimental in DOX cardiomyopathy in that it mediates the inflammatory response and apoptosis.,18627295_7,-1,-1,-1,8529,-1,0.1949441,0.80505586
8530,DOX cardiomyopathy,16,18,114,132,These insights might have useful implications for future studies utilizing B1R antagonists for treatment of human DOX cardiomyopathy.,18627295_8,-1,-1,-1,8530,-1,0.07426184,0.92573816
8532,protein,2,3,16,23,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,-1,-1,-1,8532,-1,0.9969036,0.0030964115
8533,calcineurin inhibitors,10,12,74,96,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,-1,-1,-1,8533,-1,0.99908626,0.0009136821
8535,chronic allograft nephropathy,30,33,207,236,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,-1,-1,-1,8535,-1,0.0017388982,0.99826115
8539,calcineurin inhibitors,11,13,66,88,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,-1,-1,-1,8539,-1,0.99914753,0.00085242616
8543,focal segmental glomerulosclerosis,3,6,20,54,"Podocyte injury and focal segmental glomerulosclerosis have been related to mToR inhibition in some patients, but the pathways underlying these lesions remain hypothetic.",18631865_4,-1,-1,-1,8543,-1,0.0014261676,0.9985738
8545,epileptiform activity,6,8,57,78,Detailed spectral profile analysis of penicillin-induced epileptiform activity in anesthetized rats.,18657397_0,-1,-1,-1,8545,-1,0.0013263406,0.9986737
8548,epileptiform activity,14,16,92,113,In the present study we aimed to portray a detailed spectral analysis of penicillin-induced epileptiform activity in comparison with basal brain activity in anesthetized Wistar rats.,18657397_2,-1,-1,-1,8548,-1,0.0015569556,0.99844307
8549,urethane,8,9,45,53,Male Wistar rats were anesthetized with i.p. urethane and connected to an electrocorticogram setup.,18657397_3,-1,-1,-1,8549,-1,0.9986401,0.001359828
8552,epileptiform activity,8,10,57,78,"Basal activity, latent period and the penicillin-induced epileptiform activity periods were then analyzed using both conventional methods and spectral analysis.",18657397_5,-1,-1,-1,8552,-1,0.0023860105,0.997614
8553,epileptiform activity,20,22,111,132,"Our results show that the most affected frequency bands were delta, theta, beta-2 and gamma-2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes (basal activity, latent period and epileptiform activity).",18657397_7,-1,-1,-1,8553,-1,0.0022974613,0.99770254
8554,epileptiform activity,43,45,269,290,"Our results show that the most affected frequency bands were delta, theta, beta-2 and gamma-2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes (basal activity, latent period and epileptiform activity).",18657397_7,-1,-1,-1,8554,-1,0.002393354,0.99760664
8555,epilepsies,39,40,246,256,Our results may help to analyze novel data obtained using similar experimental models and the simple analysis method described here can be used in similar studies to investigate the basic neuronal mechanism of this or other types of experimental epilepsies.,18657397_8,-1,-1,-1,8555,-1,0.0016167869,0.99838316
8559,psychoses,7,8,46,55,"Reactions consisted mainly of seizures, acute psychoses, anxiety neurosis, and major disturbances of sleep-wake rhythm.",1867351_2,-1,-1,-1,8559,-1,0.0012642667,0.9987357
8560,anxiety neurosis,9,11,57,73,"Reactions consisted mainly of seizures, acute psychoses, anxiety neurosis, and major disturbances of sleep-wake rhythm.",1867351_2,-1,-1,-1,8560,-1,0.0011236394,0.9988764
8562,neuropsychiatric reactions,27,29,157,183,"The incidence calculation revealed that one of 215 therapeutic users had reactions, compared with one of 13,000 in the prophylaxis group, making the risk of neuropsychiatric reactions after mefloquine treatment 60 times higher than after prophylaxis.",1867351_5,-1,-1,-1,8562,-1,0.0014507138,0.9985493
8564,malaria,5,6,35,42,"Therefore, certain limitations for malaria prophylaxis and treatment with mefloquine are recommended.",1867351_6,-1,-1,-1,8564,-1,0.0023049035,0.997695
8566,fat,1,2,5,8,High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.,18674790_0,-1,-1,-1,8566,-1,0.9634805,0.036519546
8567,obese,3,4,18,23,High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.,18674790_0,-1,-1,-1,8567,-1,0.0069741993,0.9930258
8573,triglycerides,10,11,79,92,"This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.",18674790_3,-1,-1,-1,8573,-1,0.99597,0.0040299734
8574,ATP,17,18,137,140,"This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.",18674790_3,-1,-1,-1,8574,-1,0.99755365,0.0024463383
8575,high fat,15,17,90,98,"In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.",18674790_4,-1,-1,-1,8575,-1,0.9733785,0.026621457
8576,obesity,24,25,125,132,"In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.",18674790_4,-1,-1,-1,8576,-1,0.0014091595,0.99859077
8578,mg,6,7,17,19,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,-1,-1,8578,-1,0.9857119,0.014288167
8579,HFD,17,18,70,73,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,-1,-1,8579,-1,0.97838163,0.021618368
8582,obese,37,38,186,191,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,-1,-1,8582,-1,0.00694464,0.9930554
8583,OB,39,40,193,195,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,-1,-1,8583,-1,0.007840854,0.9921591
8584,renal,48,49,236,241,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,-1,-1,8584,-1,0.0023897681,0.9976102
8585,hepatic toxicity,50,52,245,261,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,-1,-1,8585,-1,0.0016102637,0.9983897
8588,doxorubicinol,11,12,89,102,Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.,18674790_6,-1,-1,-1,8588,-1,0.9989717,0.0010283225
8589,OB,24,25,154,156,Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.,18674790_6,-1,-1,-1,8589,-1,0.080606304,0.9193937
8590,OB,4,5,34,36,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,-1,8590,-1,0.85985696,0.14014299
8591,ND,58,59,349,351,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,-1,8591,-1,0.85607225,0.14392781
8592,OB,64,65,392,394,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,-1,8592,-1,0.78797394,0.21202613
8593,ATP,85,86,480,483,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,-1,8593,-1,0.9983089,0.0016911511
8595,obese,4,5,27,32,"In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",18674790_9,-1,-1,-1,8595,-1,0.003850424,0.99614954
8597,ATP,17,18,152,155,"In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",18674790_9,-1,-1,-1,8597,-1,0.99713445,0.0028654905
8600,PD,7,8,44,46,We report that prenatally protein deprived (PD) female rats showed an increased stereotypic response to apomorphine and an increased locomotor response to amphetamine in adulthood.,18703024_3,-1,-1,-1,8600,-1,0.015407877,0.98459214
8604,PD,11,12,93,95,No changes in haloperidol-induced catalepsy or MK-801-induced locomotion were seen following PD.,18703024_5,-1,-1,-1,8604,-1,0.09950528,0.9004947
8605,PD,3,4,13,15,"In addition, PD female rats showed increased (3)H-MK-801 binding in the striatum and hippocampus, but not in the cortex.",18703024_6,-1,-1,-1,8605,-1,0.054811813,0.9451882
8606,PD,0,1,0,2,PD female rats also showed increased (3)H-haloperidol binding and decreased dopamine transporter binding in striatum.,18703024_7,-1,-1,-1,8606,-1,0.010304706,0.9896953
8608,PD,12,13,83,85,No statistically significant changes in behavior or receptor binding were found in PD males with the exception of increased (3)H-MK-801 binding in cortex.,18703024_8,-1,-1,-1,8608,-1,0.008836386,0.9911636
8609,nutritional deficiency,13,15,76,98,This animal model may be useful to explore the mechanisms by which prenatal nutritional deficiency enhances risk for schizophrenia in humans and may also have implications for developmental processes leading to differential sensitivity to drugs of abuse.,18703024_9,-1,-1,-1,8609,-1,0.80915797,0.190842
8612,Papaverine hydrochloride,2,4,12,36,BACKGROUND: Papaverine hydrochloride is a direct-acting vasodilator used to manage vasospasm during various neurosurgical operations.,18726058_1,-1,-1,-1,8612,-1,0.9991358,0.00086428615
8614,cranial nerve dysfunction,1,4,10,35,Transient cranial nerve dysfunction has been described in a few cases with topical papaverine.,18726058_2,-1,-1,-1,8614,-1,0.0015716936,0.99842834
8627,cranial nerve deficits,4,7,35,57,Recommendations to avoid potential cranial nerve deficits from papaverine are provided.,18726058_16,-1,-1,-1,8627,-1,0.0017873206,0.9982127
8629,hepatic failure,1,3,30,45,Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation.,18752389_0,-1,-1,-1,8629,-1,0.0012279745,0.99877197
8630,coenzyme A,12,14,109,119,Abstract Serum aminotransferase elevations are a commonly known adverse effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy.,18752389_1,-1,-1,-1,8630,-1,0.99877805,0.001221898
8633,ezetimibe,10,11,64,73,"However, hepatotoxic events have not been widely published with ezetimibe or the combination agent simvastatin-ezetimibe.",18752389_2,-1,-1,-1,8633,-1,0.99918336,0.00081668055
8639,Simvastatinezetimibe,0,1,0,20,"Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.",18752389_6,-1,-1,-1,8639,-1,0.99913955,0.00086043397
8640,escitalopram,2,3,25,37,"Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.",18752389_6,-1,-1,-1,8640,-1,0.99924266,0.0007574096
8643,drug toxicity,17,19,130,143,"A repeat work-up revealed further elevations in aminotransferase levels, and liver biopsy revealed evidence of moderate-to-severe drug toxicity.",18752389_7,-1,-1,-1,8643,-1,0.15062456,0.84937537
8644,Ezetimibe,0,1,0,9,"Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.",18752389_10,-1,-1,-1,8644,-1,0.99920326,0.0007967197
8645,uridine diphosphate,5,7,49,68,"Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.",18752389_10,-1,-1,-1,8645,-1,0.99912924,0.00087078346
8649,liver failure,12,14,81,94,"To our knowledge, this is the first case report of simvastatin-ezetimibe-induced liver failure that resulted in liver transplantation.",18752389_11,-1,-1,-1,8649,-1,0.001492165,0.9985078
8652,ezetimibe,15,16,124,133,We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.,18752389_12,-1,-1,-1,8652,-1,0.99912256,0.0008774448
8655,acute renal failure,3,6,24,43,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,-1,-1,-1,8655,-1,0.0012530254,0.998747
8656,bisphosphonate,8,9,55,69,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,-1,-1,-1,8656,-1,0.99925846,0.00074148434
8657,alendronate,10,11,71,82,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,-1,-1,-1,8657,-1,0.9991867,0.00081335194
8658,focal segmental glomerulosclerosis,17,20,117,151,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,-1,-1,-1,8658,-1,0.0014573351,0.99854267
8659,nephrotic syndrome,5,7,32,50,A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.,18754075_1,-1,-1,-1,8659,-1,0.0012094394,0.99879056
8660,focal segmental glomerulosclerosis,9,12,58,92,A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.,18754075_1,-1,-1,-1,8660,-1,0.0013110497,0.998689
8662,bisphosphonate,18,19,93,107,"The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.",18754075_2,-1,-1,-1,8662,-1,0.9992531,0.00074682635
8663,alendronate sodium,20,22,109,127,"The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.",18754075_2,-1,-1,-1,8663,-1,0.9989988,0.001001191
8664,acute renal failure,38,41,217,236,"The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.",18754075_2,-1,-1,-1,8664,-1,0.0014700154,0.9985299
8665,alendronate,4,5,29,40,"After discontinuing the oral alendronate, the patient underwent six cycles of hemodialysis and four cycles of LDL apheresis.",18754075_3,-1,-1,-1,8665,-1,0.9991159,0.0008840628
8667,bisphosphonates,11,12,66,81,"This report demonstrates that not only intravenous, but also oral bisphosphonates can aggravate proteinuria and acute renal failure.",18754075_5,-1,-1,-1,8667,-1,0.99900657,0.0009934495
8669,acute renal failure,16,19,112,131,"This report demonstrates that not only intravenous, but also oral bisphosphonates can aggravate proteinuria and acute renal failure.",18754075_5,-1,-1,-1,8669,-1,0.0011504698,0.9988495
8670,nephrotic syndrome,7,9,68,86,Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome.,18768591_0,-1,-1,-1,8670,-1,0.0012293169,0.99877065
8673,volume retention,8,10,84,100,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.,18768591_1,-1,-1,-1,8673,-1,0.020992141,0.97900784
8675,renal fibrosis,20,22,146,160,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess.,18768591_2,-1,-1,-1,8675,-1,0.0018601605,0.99813986
8677,volume retention,13,15,69,85,The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome.,18768591_3,-1,-1,-1,8677,-1,0.030553311,0.9694467
8679,nephrotic syndrome,18,20,106,124,The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome.,18768591_3,-1,-1,-1,8679,-1,0.0013316135,0.99866843
8683,mg,9,10,58,60,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,-1,-1,-1,8683,-1,0.87833226,0.12166771
8684,nephrotic syndrome,27,29,146,164,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,-1,-1,-1,8684,-1,0.0011531635,0.99884677
8686,lipidemia,32,33,179,188,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,-1,-1,-1,8686,-1,0.0013593031,0.9986407
8687,hypoalbuminemia,35,36,194,209,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,-1,-1,-1,8687,-1,0.0012195262,0.9987804
8691,body weight gain,39,42,197,213,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).,18768591_7,-1,-1,-1,8691,-1,0.022178378,0.9778216
8692,nephrotic syndrome,4,6,21,39,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).",18768591_8,-1,-1,-1,8692,-1,0.0012254716,0.99877447
8694,uremia,24,25,150,156,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).",18768591_8,-1,-1,-1,8694,-1,0.0011554005,0.9988446
8695,volume,9,10,62,68,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",18768591_9,-1,-1,-1,8695,-1,0.84912527,0.15087473
8697,nephrotic syndrome,21,23,146,164,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",18768591_9,-1,-1,-1,8697,-1,0.0012656582,0.9987343
8699,haemolytic anaemia,3,5,28,46,Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome.,18791946_0,-1,-1,-1,8699,-1,0.0012874705,0.99871254
8702,abdominal pain,7,9,42,56,A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.,18791946_2,-1,-1,-1,8702,-1,0.0012514861,0.99874854
8705,urinary tract infection,21,24,136,159,A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.,18791946_2,-1,-1,-1,8705,-1,0.0018017276,0.99819833
8707,haemolysis,10,11,83,93,Clinical evaluations suggested an initial diagnosis of severe thrombocytopenia and haemolysis.,18791946_3,-1,-1,-1,8707,-1,0.0012228563,0.9987771
8708,petechiae,4,5,36,45,The patient progressively developed petechiae and purpura on thorax and lower limbs.,18791946_4,-1,-1,-1,8708,-1,0.0016059949,0.99839395
8709,purpura,6,7,50,57,The patient progressively developed petechiae and purpura on thorax and lower limbs.,18791946_4,-1,-1,-1,8709,-1,0.001663195,0.9983368
8710,petechial haemorrhages,8,10,54,76,An accurate autopsy revealed most organs with diffuse petechial haemorrhages.,18791946_6,-1,-1,-1,8710,-1,0.0020924897,0.9979075
8711,bone marrow depression,3,6,12,34,No signs of bone marrow depression were found.,18791946_7,-1,-1,-1,8711,-1,0.0035458747,0.9964541
8713,microangiopathies,5,6,23,40,No thrombi or signs of microangiopathies were observed in arterial vessels.,18791946_8,-1,-1,-1,8713,-1,0.0013136369,0.9986864
8716,haemolytic anaemia,11,13,96,114,"This case report shows that ciprofloxacin may precipitate life-threatening thrombocytopenia and haemolytic anaemia, even in the early phases of treatment and without apparent previous exposures.",18791946_10,-1,-1,-1,8716,-1,0.0012281097,0.99877185
8721,coronary hypotension,18,20,122,142,"The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.",18808529_1,-1,-1,-1,8721,-1,0.0016885157,0.9983115
8722,myocardial hyperactivity,21,23,147,171,"The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.",18808529_1,-1,-1,-1,8722,-1,0.0016288683,0.9983712
8727,ischaemic injury,5,7,26,42,"These changes, related to ischaemic injury, explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by isoproterenol.",18808529_9,-1,-1,-1,8727,-1,0.0021260593,0.9978739
8729,mitochondrial damage,3,5,27,47,Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.,18809400_0,-1,-1,-1,8729,-1,0.0023239474,0.9976761
8733,mitochondrial damage,14,16,110,130,"The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.",18809400_1,-1,-1,-1,8733,-1,0.008779573,0.9912204
8737,axonal damage,11,13,84,97,This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.,18809400_3,-1,-1,-1,8737,-1,0.00222135,0.9977786
8738,apoptosis,14,15,102,111,This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.,18809400_3,-1,-1,-1,8738,-1,0.001936691,0.99806327
8741,mitochondrial impairment,10,12,71,95,Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.,18809400_4,-1,-1,-1,8741,-1,0.005057769,0.99494225
8743,mitochondrial toxicity,16,18,127,149,"Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.",18809400_5,-1,-1,-1,8743,-1,0.003739058,0.99626094
8744,mitochondrial toxicity,2,4,14,36,In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.,18809400_6,-1,-1,-1,8744,-1,0.0019435078,0.9980565
8748,peripheral nerve toxicity,12,15,82,107,These findings suggest that alpha-lipoic acid might reduce the risk of developing peripheral nerve toxicity in patients undergoing chemotherapy and encourage further confirmatory clinical trials.,18809400_8,-1,-1,-1,8748,-1,0.0014729425,0.99852705
8751,5-(l-hexyloxy)-6-methoxy-4-methylquinoline,10,11,110,152,Toxicity in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511).INTRODUCTION: Many substances that form methemoglobin (MHb) effectively counter cyanide (CN) toxicity.,18821488_0,-1,-1,-1,8751,-1,0.99816954,0.001830461
8752,cyanide,23,24,244,251,Toxicity in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511).INTRODUCTION: Many substances that form methemoglobin (MHb) effectively counter cyanide (CN) toxicity.,18821488_0,-1,-1,-1,8752,-1,0.99846953,0.0015304829
8754,CN poisoning,9,11,61,73,"Although MHb formers are generally applied as treatments for CN poisoning, it has been proposed that a stable, long-acting MHb former could serve as a CN pretreatment.",18821488_1,-1,-1,-1,8754,-1,0.18598822,0.8140118
8755,CN,27,28,151,153,"Although MHb formers are generally applied as treatments for CN poisoning, it has been proposed that a stable, long-acting MHb former could serve as a CN pretreatment.",18821488_1,-1,-1,-1,8755,-1,0.9966323,0.0033677584
8757,WR242511,6,7,24,32,"METHODS: In this study, WR242511 was administered intravenously (IV) in 2 female and 4 male rhesus monkeys in doses of 3.5 and/or 7.0 mg/kg; a single male also received WR242511 orally (PO) at 7.0 mg/kg.",18821488_3,-1,-1,-1,8757,-1,0.9985978,0.0014021905
8758,WR242511,34,35,169,177,"METHODS: In this study, WR242511 was administered intravenously (IV) in 2 female and 4 male rhesus monkeys in doses of 3.5 and/or 7.0 mg/kg; a single male also received WR242511 orally (PO) at 7.0 mg/kg.",18821488_3,-1,-1,-1,8758,-1,0.99881065,0.0011893638
8759,WR242511,6,7,31,39,"RESULTS: The selected doses of WR242511, which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean < 2.0%) in the rhesus monkey.",18821488_5,-1,-1,-1,8759,-1,0.99857116,0.0014288252
8760,methemoglobinemia,11,12,68,85,"RESULTS: The selected doses of WR242511, which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean < 2.0%) in the rhesus monkey.",18821488_5,-1,-1,-1,8760,-1,0.00884743,0.9911526
8761,hemoglobinuria,3,4,23,37,"Furthermore, transient hemoglobinuria was noted approximately 60 minutes postinjection of WR242511 (3.5 or 7.0 mg/kg), and 2 lethalities occurred (one IV and one PO) following the 7.0 mg/kg dose.",18821488_6,-1,-1,-1,8761,-1,0.01738454,0.9826155
8762,WR242511,11,12,90,98,"Furthermore, transient hemoglobinuria was noted approximately 60 minutes postinjection of WR242511 (3.5 or 7.0 mg/kg), and 2 lethalities occurred (one IV and one PO) following the 7.0 mg/kg dose.",18821488_6,-1,-1,-1,8762,-1,0.9985753,0.0014246826
8763,Myoglobinuria,0,1,0,13,Myoglobinuria was also observed following the 7.0 mg/kg dose.,18821488_7,-1,-1,-1,8763,-1,0.0017879691,0.9982121
8766,WR242511,4,5,21,29,It is concluded that WR242511 should not be pursued as a pretreatment for CN poisoning unless the anti-CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity.,18821488_10,-1,-1,-1,8766,-1,0.99842983,0.001570197
8767,CN poisoning,13,15,74,86,It is concluded that WR242511 should not be pursued as a pretreatment for CN poisoning unless the anti-CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity.,18821488_10,-1,-1,-1,8767,-1,0.007914851,0.99208516
8769,liver tumors,6,8,41,53,Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives.,188339_0,-1,-1,-1,8769,-1,0.0017937005,0.99820626
8771,liver tumors,8,10,47,59,"Within the last several years, previously rare liver tumors have been seen in young women using oral contraceptive steroids.",188339_1,-1,-1,-1,8771,-1,0.0020090654,0.99799097
8772,oral contraceptive steroids,17,20,96,123,"Within the last several years, previously rare liver tumors have been seen in young women using oral contraceptive steroids.",188339_1,-1,-1,-1,8772,-1,0.9988225,0.0011774814
8773,Liver Tumors,3,5,17,29,"The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.",188339_2,-1,-1,-1,8773,-1,0.0021648111,0.9978352
8775,focal nodular hyperplasia,11,14,65,90,"Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, hamartoma, and hepatoma.",188339_4,-1,-1,-1,8775,-1,0.0019780053,0.99802196
8776,adenoma,15,16,92,99,"Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, hamartoma, and hepatoma.",188339_4,-1,-1,-1,8776,-1,0.0017081205,0.9982919
8777,hamartoma,17,18,101,110,"Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, hamartoma, and hepatoma.",188339_4,-1,-1,-1,8777,-1,0.0021585291,0.9978415
8778,hepatoma,20,21,116,124,"Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, hamartoma, and hepatoma.",188339_4,-1,-1,-1,8778,-1,0.001589499,0.99841046
8779,oral contraceptive steroids,9,12,83,110,Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive steroids.,188339_5,-1,-1,-1,8779,-1,0.9986873,0.0013126715
8781,liver rupture,3,5,17,30,Eight deaths and liver rupture in 18 patients attest to the seriousness of this new potentially lethal adverse phenomenon.,188339_6,-1,-1,-1,8781,-1,0.0016165015,0.9983835
8783,Parkinson's disease,8,11,81,100,Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.,18951540_0,-1,-1,-1,8783,-1,0.0020933545,0.9979067
8785,Parkinson's disease,39,42,214,233,"In a placebo-controlled, single-blinded, crossover study, we assessed the effect of ""real"" repetitive transcranial magnetic stimulation (rTMS) versus ""sham"" rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD).",18951540_1,-1,-1,-1,8785,-1,0.002737296,0.9972627
8786,PD,43,44,235,237,"In a placebo-controlled, single-blinded, crossover study, we assessed the effect of ""real"" repetitive transcranial magnetic stimulation (rTMS) versus ""sham"" rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD).",18951540_1,-1,-1,-1,8786,-1,0.002264267,0.99773574
8787,PD,3,4,18,20,"Ten patients with PD and prominent dyskinesias had rTMS (1,800 pulses; 1 Hz rate) delivered over the motor cortex for 4 consecutive days twice, once real stimuli and once sham stimulation were used; evaluations were done at the baseline and 1 day after the end of each of the treatment series.",18951540_2,-1,-1,-1,8787,-1,0.0018044611,0.9981956
8793,PD,14,15,77,79,"Following rTMS, no side effects and no adverse effects on motor function and PD symptoms were noted.",18951540_7,-1,-1,-1,8793,-1,0.001774251,0.99822575
8795,PD,20,21,153,155,The results suggest the existence of residual beneficial clinical aftereffects of consecutive daily applications of low-frequency rTMS on dyskinesias in PD.,18951540_8,-1,-1,-1,8795,-1,0.0021360237,0.99786395
8814,priapism,8,9,63,71,Intracavernous epinephrine: a minimally invasive treatment for priapism in the emergency department.,18996674_0,-1,-1,-1,8814,-1,0.001597336,0.99840266
8815,emergency department,11,13,79,99,Intracavernous epinephrine: a minimally invasive treatment for priapism in the emergency department.,18996674_0,-1,-1,-1,8815,-1,0.0033830886,0.9966169
8816,Priapism,0,1,0,8,Priapism is the prolonged erection of the penis in the absence of sexual arousal.,18996674_1,-1,-1,-1,8816,-1,0.0015927146,0.9984073
8818,Emergency Department,13,15,71,91,"A 45-year-old man, an admitted frequent cocaine user, presented to the Emergency Department (ED) on two separate occasions with a history of priapism after cocaine use.",18996674_2,-1,-1,-1,8818,-1,0.012178973,0.98782104
8819,priapism,26,27,141,149,"A 45-year-old man, an admitted frequent cocaine user, presented to the Emergency Department (ED) on two separate occasions with a history of priapism after cocaine use.",18996674_2,-1,-1,-1,8819,-1,0.0017690202,0.998231
8828,ventricular ectopy,26,28,178,196,Intravenous caffeine is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy.,18997632_2,-1,-1,-1,8828,-1,0.0012954101,0.99870455
8829,cardiac disease,9,11,50,65,We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.,18997632_3,-1,-1,-1,8829,-1,0.001381993,0.998618
8831,bigeminy,16,17,104,112,We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.,18997632_3,-1,-1,-1,8831,-1,0.0025254604,0.9974745
8837,rheumatologic disorders,9,11,74,97,Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders.,19037603_0,-1,-1,-1,8837,-1,0.0015708684,0.9984291
8839,hepatitis B,20,22,138,149,The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (HBs Ag) positive patients with rheumatologic disease.,19037603_1,-1,-1,-1,8839,-1,0.037686117,0.96231383
8840,HBs Ag,26,28,173,179,The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (HBs Ag) positive patients with rheumatologic disease.,19037603_1,-1,-1,-1,8840,-1,0.06433917,0.9356608
8841,rheumatologic disease,32,34,204,225,The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (HBs Ag) positive patients with rheumatologic disease.,19037603_1,-1,-1,-1,8841,-1,0.0015318269,0.9984681
8842,Ag,9,10,39,41,"From June 2004 to October 2006, 11 HBs Ag positive patients with rheumatologic diseases, who were on both immunosuppressive and prophylactic lamivudine therapies, were retrospectively assessed.",19037603_2,-1,-1,-1,8842,-1,0.024358401,0.97564155
8843,rheumatologic diseases,13,15,65,87,"From June 2004 to October 2006, 11 HBs Ag positive patients with rheumatologic diseases, who were on both immunosuppressive and prophylactic lamivudine therapies, were retrospectively assessed.",19037603_2,-1,-1,-1,8843,-1,0.0018440974,0.9981559
8845,hepatitis B,4,6,22,33,"Liver function tests, hepatitis B virus (HBV) serologic markers, and HBV DNA levels of the patients during follow-up were obtained from hospital file records.",19037603_3,-1,-1,-1,8845,-1,0.05802206,0.9419779
8847,abnormal liver function tests,15,19,100,129,Shortly after treatment their tests normalized and during follow-up period none of the patients had abnormal liver function tests.,19037603_7,-1,-1,-1,8847,-1,0.007075119,0.9929249
8851,vitamin E,5,7,24,33,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.,19058010_0,-1,-1,-1,8851,-1,0.9989606,0.0010394295
8853,myocardial infarction,11,13,71,92,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.,19058010_0,-1,-1,-1,8853,-1,0.001366969,0.99863297
8855,vitamin E,14,16,81,90,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,-1,-1,-1,8855,-1,0.99889624,0.001103713
8856,weight,18,19,100,106,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,-1,-1,-1,8856,-1,0.022217551,0.9777825
8857,body weight,20,22,108,119,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,-1,-1,-1,8857,-1,0.01621751,0.9837825
8859,myocardial infarction,39,41,245,266,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,-1,-1,-1,8859,-1,0.001775984,0.99822396
8860,ISO,7,8,37,40,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8860,-1,0.9989537,0.001046318
8861,h,23,24,91,92,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8861,-1,0.7078204,0.29217958
8862,P<0.05,28,29,115,121,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8862,-1,0.43917394,0.560826
8863,heart weight,32,34,136,148,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8863,-1,0.04173189,0.9582681
8864,P<0.05,51,52,246,252,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8864,-1,0.42108122,0.5789188
8865,body weight,55,57,266,277,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8865,-1,0.041100178,0.9588998
8867,vitamin E,12,14,54,63,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8867,-1,0.9987161,0.0012838726
8868,ISO,29,30,139,142,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8868,-1,0.99859184,0.0014081426
8869,P<0.05,41,42,191,197,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8869,-1,0.52437454,0.47562546
8870,heart weight,45,47,211,223,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8870,-1,0.046509895,0.95349014
8871,body weight,63,65,313,324,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8871,-1,0.050548762,0.94945127
8872,ISO,77,78,400,403,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8872,-1,0.9985146,0.0014854126
8874,vitamin E,84,86,435,444,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8874,-1,0.99855286,0.0014471256
8876,vitamin E,11,13,75,84,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,19058010_4,-1,-1,-1,8876,-1,0.99867,0.0013300463
8877,ISO,14,15,92,95,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,19058010_4,-1,-1,-1,8877,-1,0.995893,0.0041069696
8878,myocardial infarction,16,18,104,125,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,19058010_4,-1,-1,-1,8878,-1,0.0014742644,0.9985258
8879,gastrointestinal haemorrhage,3,5,27,55,Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.,19058474_0,-1,-1,-1,8879,-1,0.0015483911,0.9984516
8881,haemorrhage,7,8,35,46,We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin.,19058474_1,-1,-1,-1,8881,-1,0.0014846277,0.9985154
8883,flavonoids,8,9,54,64,"We propose that naturally occurring compounds such as flavonoids, which are present in fruit juices, may increase the potency of warfarin by competing for the enzymes that normally inactivate warfarin.",19058474_2,-1,-1,-1,8883,-1,0.99845576,0.0015442182
8886,adverse drug reactions,16,19,115,137,"While traditionally regarded as foodstuffs, consumption of fruit juices should be considered when patients develop adverse drug reactions.",19058474_3,-1,-1,-1,8886,-1,0.002277826,0.9977222
8890,bupropion HCl,13,15,85,98,"METHODS: We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of bupropion-induced convulsions in the Swiss albino mice.",19105845_3,-1,-1,-1,8890,-1,0.99918467,0.0008152996
8893,bupropion HCl,22,24,104,117,"A total of 69 mice, approximately 7 weeks of age, and weighing 21.0 to 29.1 g were randomly assigned to bupropion HCl 120 mg/kg treatment by intraperitoneal (IP) administration in 7 groups (9 to 10 animals per group).",19105845_4,-1,-1,-1,8893,-1,0.9991172,0.00088278466
8894,Bupropion HCl,0,2,0,13,"Bupropion HCl was infused through a surgically implanted IP dosing catheter with infusions in each group of 0 min, 15 min, 30 min, 60 min, 90 min, 120 min, and 240 min.",19105845_5,-1,-1,-1,8894,-1,0.99908483,0.00091520825
8897,bupropion HCl,9,11,54,67,RESULTS: The results showed that IP administration of bupropion HCl 120 mg/kg by bolus injection induced convulsions in 6 out of 10 mice (60% of convulsing mice) in group 1.,19105845_7,-1,-1,-1,8897,-1,0.99915576,0.0008442554
8899,p,10,11,74,75,Logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the IP infusion time of bupropion HCl 120 mg/kg was associated with a 91% reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection.,19105845_8,-1,-1,-1,8899,-1,0.32610726,0.67389274
8900,bupropion HCl,26,28,145,158,Logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the IP infusion time of bupropion HCl 120 mg/kg was associated with a 91% reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection.,19105845_8,-1,-1,-1,8900,-1,0.99915254,0.0008474301
8908,sinusoidal obstruction syndrome,14,17,108,139,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,-1,-1,-1,8908,-1,0.0012998608,0.99870014
8909,microangiopathy,18,19,144,159,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,-1,-1,-1,8909,-1,0.0011706878,0.9988293
8910,calcineurin inhibitor,1,3,2,23,A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).,19135948_1,-1,-1,-1,8910,-1,0.9983729,0.0016270517
8912,GVHD,14,15,110,114,A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).,19135948_1,-1,-1,-1,8912,-1,0.001336089,0.9986639
8917,myelodysplastic syndrome,21,23,106,130,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8917,-1,0.0011793402,0.9988206
8918,MDS,24,25,132,135,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8918,-1,0.0013207524,0.9986792
8919,n,26,27,137,138,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8919,-1,0.0038000834,0.9961999
8920,acute myeloid leukemia,31,34,148,170,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8920,-1,0.0013752092,0.9986248
8921,AML,35,36,172,175,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8921,-1,0.0015266271,0.99847335
8922,n,37,38,177,178,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8922,-1,0.0039755083,0.9960245
8923,n,50,51,249,250,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8923,-1,0.0064996835,0.9935003
8924,n,57,58,270,271,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8924,-1,0.007794833,0.9922052
8926,GVHD,10,11,48,52,"Nine patients (37%) developed acute grade II-IV GVHD, and 11 of 17 evaluable patients (64%) developed chronic extensive GVHD.",19135948_5,-1,-1,-1,8926,-1,0.0011793684,0.9988206
8927,GVHD,25,26,120,124,"Nine patients (37%) developed acute grade II-IV GVHD, and 11 of 17 evaluable patients (64%) developed chronic extensive GVHD.",19135948_5,-1,-1,-1,8927,-1,0.0011924652,0.99880755
8928,microangiopathy,1,2,27,42,"Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of acute renal failure.",19135948_6,-1,-1,-1,8928,-1,0.0010646484,0.9989354
8929,TMA,3,4,44,47,"Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of acute renal failure.",19135948_6,-1,-1,-1,8929,-1,0.0013326851,0.99866736
8930,acute renal failure,18,21,95,114,"Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of acute renal failure.",19135948_6,-1,-1,-1,8930,-1,0.0010742949,0.9989256
8931,sinusoidal obstruction syndrome,15,18,86,117,"The study was terminated prematurely because an additional 6 patients (25%) developed sinusoidal obstruction syndrome (SOS), which was fatal in 2 cases.",19135948_7,-1,-1,-1,8931,-1,0.0014448356,0.9985551
8932,SOS,19,20,119,122,"The study was terminated prematurely because an additional 6 patients (25%) developed sinusoidal obstruction syndrome (SOS), which was fatal in 2 cases.",19135948_7,-1,-1,-1,8932,-1,0.00139073,0.9986092
8933,GVHD,14,15,90,94,"Although this new combination appears to be effective as a prophylactic regimen for acute GVHD, the incidence of TMA and SOS is considerably higher than seen with other regimens.",19135948_9,-1,-1,-1,8933,-1,0.0011456595,0.9988543
8934,TMA,19,20,113,116,"Although this new combination appears to be effective as a prophylactic regimen for acute GVHD, the incidence of TMA and SOS is considerably higher than seen with other regimens.",19135948_9,-1,-1,-1,8934,-1,0.0016402792,0.99835974
8935,SOS,21,22,121,124,"Although this new combination appears to be effective as a prophylactic regimen for acute GVHD, the incidence of TMA and SOS is considerably higher than seen with other regimens.",19135948_9,-1,-1,-1,8935,-1,0.0013420128,0.99865794
8936,difluoromethylornithine,13,14,86,109,Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.,19139001_0,-1,-1,-1,8936,-1,0.999129,0.000871044
8938,colorectal adenomas,20,22,150,169,Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.,19139001_0,-1,-1,-1,8938,-1,0.0017642808,0.9982357
8939,adenomatous polyps,9,11,54,72,A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.,19139001_1,-1,-1,-1,8939,-1,0.0019352885,0.9980647
8940,difluoromethylornithine,17,18,108,131,A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.,19139001_1,-1,-1,-1,8940,-1,0.999164,0.00083602016
8941,DFMO,19,20,133,137,A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.,19139001_1,-1,-1,-1,8941,-1,0.99915326,0.000846778
8943,hearing loss,1,3,10,22,"Temporary hearing loss is a known toxicity of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.",19139001_2,-1,-1,-1,8943,-1,0.0018493527,0.99815065
8945,DFMO,10,11,61,65,"Temporary hearing loss is a known toxicity of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.",19139001_2,-1,-1,-1,8945,-1,0.9956867,0.0043132417
8946,DFMO,17,18,96,100,"Based on 290 subjects, there was an average difference of 0.50 dB between subjects treated with DFMO plus sulindac compared with those treated with placebo (95% confidence interval, -0.64 to 1.63 dB; P = 0.39), adjusted for baseline values, age, and frequencies.",19139001_4,-1,-1,-1,8946,-1,0.99901843,0.0009815736
8948,P,37,38,200,201,"Based on 290 subjects, there was an average difference of 0.50 dB between subjects treated with DFMO plus sulindac compared with those treated with placebo (95% confidence interval, -0.64 to 1.63 dB; P = 0.39), adjusted for baseline values, age, and frequencies.",19139001_4,-1,-1,-1,8948,-1,0.25939375,0.7406062
8949,P,23,24,101,102,"In the normal speech range of 500 to 3,000 Hz, an estimated difference of 0.99 dB (-0.17 to 2.14 dB; P = 0.09) was detected.",19139001_5,-1,-1,-1,8949,-1,0.28838235,0.71161765
8950,DFMO,11,12,35,39,There were 14 of 151 (9.3%) in the DFMO plus sulindac group and 4 of 139 (2.9%) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested (P = 0.02).,19139001_7,-1,-1,-1,8950,-1,0.99890804,0.001091985
8952,hearing reduction,33,35,132,149,There were 14 of 151 (9.3%) in the DFMO plus sulindac group and 4 of 139 (2.9%) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested (P = 0.02).,19139001_7,-1,-1,-1,8952,-1,0.005036797,0.99496317
8953,P,49,50,233,234,There were 14 of 151 (9.3%) in the DFMO plus sulindac group and 4 of 139 (2.9%) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested (P = 0.02).,19139001_7,-1,-1,-1,8953,-1,0.19272257,0.80727744
8954,P,29,30,158,159,Follow-up air conduction done at least 6 months after end of treatment showed an adjusted mean difference in hearing thresholds of 1.08 dB (-0.81 to 2.96 dB; P = 0.26) between treatment arms.,19139001_8,-1,-1,-1,8954,-1,0.30491856,0.6950814
8955,DFMO,12,13,73,77,There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group.,19139001_9,-1,-1,-1,8955,-1,0.9989793,0.0010206968
8957,hearing loss,20,22,137,149,There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group.,19139001_9,-1,-1,-1,8957,-1,0.0021246697,0.99787533
8959,P,26,27,123,124,"The estimated attributable risk of ototoxicity from exposure to the drug is 8.4% (95% confidence interval, -2.0% to 18.8%; P = 0.12).",19139001_10,-1,-1,-1,8959,-1,0.2545214,0.7454786
8960,DFMO,14,15,72,76,There is a <2 dB difference in mean threshold for patients treated with DFMO plus sulindac compared with those treated with placebo.,19139001_11,-1,-1,-1,8960,-1,0.9989661,0.0010338923
8964,RPN,4,5,26,29,Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.,1919871_1,-1,-1,-1,8964,-1,0.0017177698,0.9982823
8967,RPN,27,28,183,186,This study shows that prolonged analgesic treatment in Fischer 344 rats causes progressive and irreversible damage to the interstitial matrix and type 1 interstitial cells leading to RPN.,1919871_6,-1,-1,-1,8967,-1,0.0019678008,0.99803215
8970,ulcerative colitis,4,6,25,43,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,-1,-1,-1,8970,-1,0.0012512018,0.9987488
8971,red eyes,7,9,54,62,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,-1,-1,-1,8971,-1,0.0019484857,0.9980515
8972,pleural effusion,10,12,64,80,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,-1,-1,-1,8972,-1,0.0013678853,0.99863213
8974,urinary abnormalities,15,17,99,120,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,-1,-1,-1,8974,-1,0.0016400978,0.99835986
8976,necrotizing glomerulonephritis,8,10,55,85,Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.,19203554_2,-1,-1,-1,8976,-1,0.0012843289,0.99871564
8977,pleural effusions,8,10,39,56,"PR3-ANCA titer was 250 and 1,070 EU in pleural effusions on right and left side, respectively.",19203554_4,-1,-1,-1,8977,-1,0.0023682632,0.99763167
8980,red eyes,11,13,82,90,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,-1,-1,-1,8980,-1,0.0024507071,0.99754924
8981,chest pain,14,16,92,102,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,-1,-1,-1,8981,-1,0.0016642277,0.9983358
8982,pleural effusions,25,27,150,167,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,-1,-1,-1,8982,-1,0.0025075257,0.99749243
8984,pleural effusion,50,52,296,312,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,-1,-1,-1,8984,-1,0.00201249,0.9979875
8986,pleural effusion,7,9,37,53,"One month after steroid therapy, the pleural effusion disappeared, and PR3-ANCA titer normalized 3 months later.",19203554_6,-1,-1,-1,8986,-1,0.0017627497,0.99823725
8991,contrast,1,2,3,11,"In contrast to the systemic renin-angiotensin system, which is suppressed in response to HS in male DS, intrarenal angiotensinogen expression is increased, and intrarenal levels of ANG II are not suppressed.",19211690_3,-1,-1,-1,8991,-1,0.31107152,0.6889285
8993,increases in BP,26,29,174,189,"In this study, the hypothesis was tested that there is a sexual dimorphism in HS-induced upregulation of intrarenal angiotensinogen mediated by testosterone that also causes increases in BP and renal injury.",19211690_4,-1,-1,-1,8993,-1,0.0074239722,0.992576
9001,idiopathic Parkinson's disease,9,13,77,107,Comparison of unilateral pallidotomy and subthalamotomy findings in advanced idiopathic Parkinson's disease.,19234905_0,-1,-1,-1,9001,-1,0.0025916274,0.99740833
9002,idiopathic Parkinson's disease,20,24,145,175,"A prospective, randomized, double-blind pilot study to compare the results of stereotactic unilateral pallidotomy and subthalamotomy in advanced idiopathic Parkinson's disease (PD) refractory to medical treatment was designed.",19234905_1,-1,-1,-1,9002,-1,0.0035731073,0.9964269
9003,PD,25,26,177,179,"A prospective, randomized, double-blind pilot study to compare the results of stereotactic unilateral pallidotomy and subthalamotomy in advanced idiopathic Parkinson's disease (PD) refractory to medical treatment was designed.",19234905_1,-1,-1,-1,9003,-1,0.0028888145,0.9971112
9006,Parkinson's Disease,8,11,52,71,"Clinical evaluation included the use of the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn_Yahr score and Schwab England activities of daily living (ADL) score in 'on'- and 'off'-drug conditions before surgery and 6 months after surgery.",19234905_5,-1,-1,-1,9006,-1,0.0048020785,0.99519795
9007,ADL,27,28,158,161,"Clinical evaluation included the use of the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn_Yahr score and Schwab England activities of daily living (ADL) score in 'on'- and 'off'-drug conditions before surgery and 6 months after surgery.",19234905_5,-1,-1,-1,9007,-1,0.007276023,0.992724
9010,ADL,10,11,50,53,"Changes in UPDRS, Hoehn _ Yahr and Schwab England ADL scores were similar in both groups.",19234905_8,-1,-1,-1,9010,-1,0.012277201,0.98772275
9011,hemianopsia,12,13,71,82,Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.,19234905_10,-1,-1,-1,9011,-1,0.001355254,0.99864477
9012,Valproate,33,34,226,235,Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.,19234905_10,-1,-1,-1,9012,-1,0.9992699,0.0007300544
9013,PD,22,23,137,139,The findings of this study suggest that lesions of the unilateral STN and GPi are equally effective treatment for patients with advanced PD refractory to medical treatment.,19234905_11,-1,-1,-1,9013,-1,0.0021645103,0.99783546
9022,pains,4,5,29,34,Subjects also recalled their pains one week later.,19269743_5,-1,-1,-1,9022,-1,0.0025388808,0.9974611
9024,p<0.001,8,9,61,68,Capsaicin injection reliably induced a dose-dependent flare (p<0.001) without any difference within or across sessions.,19269743_6,-1,-1,-1,9024,-1,0.30025175,0.6997483
9028,p<0.001,15,16,101,108,"Subjects were able to reliably discriminate pain magnitude and duration across capsaicin doses (both p<0.001), regardless of whether first-time ratings were requested immediately, after one hour or after one day.",19269743_8,-1,-1,-1,9028,-1,0.29733938,0.70266056
9030,p<0.01,11,12,61,67,"Pain recall after one week was similarly precise (magnitude: p<0.01, duration: p<0.05).",19269743_9,-1,-1,-1,9030,-1,0.32494867,0.67505133
9031,p<0.05,15,16,79,85,"Pain recall after one week was similarly precise (magnitude: p<0.01, duration: p<0.05).",19269743_9,-1,-1,-1,9031,-1,0.333496,0.66650397
9034,myeloma,21,22,166,173,DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.,19274460_0,-1,-1,-1,9034,-1,0.0015837312,0.9984163
9036,bortezomib,15,16,104,114,A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).,19274460_1,-1,-1,-1,9036,-1,0.9990915,0.00090854603
9038,multiple myeloma,31,33,231,247,A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).,19274460_1,-1,-1,-1,9038,-1,0.0020455138,0.9979545
9039,MM,34,35,249,251,A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).,19274460_1,-1,-1,-1,9039,-1,0.0018246303,0.9981754
9040,bortezomib,9,10,57,67,"Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1.",19274460_2,-1,-1,-1,9040,-1,0.9991635,0.00083652785
9042,mg,26,27,126,128,"Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1.",19274460_2,-1,-1,-1,9042,-1,0.99681705,0.0031830287
9043,bortezomib,31,32,143,153,"Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1.",19274460_2,-1,-1,-1,9043,-1,0.9990409,0.00095902925
9046,CR,8,9,46,48,"The overall response rate [complete response (CR) plus partial response (PR)] across all dose levels was 77%, with a 10% CR rate.",19274460_5,-1,-1,-1,9046,-1,0.004327103,0.9956729
9047,CR,29,30,121,123,"The overall response rate [complete response (CR) plus partial response (PR)] across all dose levels was 77%, with a 10% CR rate.",19274460_5,-1,-1,-1,9047,-1,0.0035326905,0.99646735
9050,bortezomib,4,5,25,35,The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.,19274460_8,-1,-1,-1,9050,-1,0.99908507,0.0009149397
9053,MM,25,26,176,178,The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.,19274460_8,-1,-1,-1,9053,-1,0.0017183437,0.9982817
9056,captopril overdose,6,8,40,58,Naloxone reversal of hypotension due to captopril overdose.,1928887_0,-1,-1,-1,9056,-1,0.5316705,0.46832946
9058,inhibitors,9,10,77,87,The hemodynamic effects of captopril and other angiotensin-converting enzyme inhibitors may be mediated by the endogenous opioid system.,1928887_1,-1,-1,-1,9058,-1,0.9984713,0.001528687
9062,captopril overdose,7,9,35,53,"We report a case of an intentional captopril overdose, manifested by marked hypotension, that resolved promptly with the administration of naloxone.",1928887_3,-1,-1,-1,9062,-1,0.56960315,0.43039683
9070,chondroitin sulfate,13,15,93,112,Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products.,19289093_0,-1,-1,-1,9070,-1,0.9989017,0.0010982371
9073,critically ill,9,11,62,76,Heparin is a commonly implemented anticoagulant used to treat critically ill patients.,19289093_1,-1,-1,-1,9073,-1,0.0033347856,0.9966652
9075,chondroitin sulfate,18,20,109,128,"Recently, a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate (OSCS) derivative that could elicit a hypotensive response in pigs following a single high-dose infusion.",19289093_2,-1,-1,-1,9075,-1,0.9988722,0.0011277964
9083,Pneumocystis pneumonia,10,12,81,103,Severe and long lasting cholestasis after high-dose co-trimoxazole treatment for Pneumocystis pneumonia in HIV-infected patients--a report of two cases.,19299179_0,-1,-1,-1,9083,-1,0.0016998177,0.99830025
9084,Pneumocystis pneumonia,0,2,0,22,"Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.",19299179_1,-1,-1,-1,9084,-1,0.0015335858,0.9984665
9085,PCP,3,4,24,27,"Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.",19299179_1,-1,-1,-1,9085,-1,0.0013059487,0.9986941
9086,opportunistic infection,8,10,39,62,"Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.",19299179_1,-1,-1,-1,9086,-1,0.0015116899,0.9984883
9088,liver abscess,23,25,162,175,"Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.",19299179_3,-1,-1,-1,9088,-1,0.0019149239,0.99808514
9089,PCP,34,35,243,246,"Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.",19299179_3,-1,-1,-1,9089,-1,0.0016890381,0.9983109
9090,cm,9,10,44,46,"Whereas patient 1 showed lesions of up to 1 cm readily detectable on magnetic resonance imaging under prolonged co-trimoxazole treatment, therapy of patient 2 was switched early.",19299179_4,-1,-1,-1,9090,-1,0.012902861,0.98709714
9091,apical ballooning syndrome,2,5,23,49,5 flourouracil-induced apical ballooning syndrome: a case report.,19300240_0,-1,-1,-1,9091,-1,0.0016106442,0.99838936
9092,apical ballooning syndrome,1,4,4,30,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,-1,-1,9092,-1,0.0029622286,0.99703777
9093,ABS,5,6,32,35,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,-1,-1,9093,-1,0.0020623854,0.9979377
9094,acute cardiac syndrome,12,15,77,99,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,-1,-1,9094,-1,0.0012254473,0.9987746
9095,hyperkinesis,26,27,194,206,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,-1,-1,9095,-1,0.0013903705,0.99860954
9096,epicardial coronary disease,38,41,271,298,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,-1,-1,9096,-1,0.0019671146,0.99803287
9098,ABS,7,8,33,36,"However, there are no reports of ABS secondary to chemotherapeutic agents.",19300240_3,-1,-1,-1,9098,-1,0.0019067997,0.9980932
9100,ischemic chest pain,6,9,43,62,"A 79-year-old woman presented with typical ischemic chest pain, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.",19300240_5,-1,-1,-1,9100,-1,0.00129112,0.99870884
9101,fluorouracil,5,6,39,51,She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.,19300240_6,-1,-1,-1,9101,-1,0.99838257,0.0016174059
9102,colorectal cancer,8,10,67,84,She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.,19300240_6,-1,-1,-1,9102,-1,0.0020246704,0.9979753
9104,coronary lesions,5,7,45,61,Coronary angiography revealed no obstructive coronary lesions.,19300240_8,-1,-1,-1,9104,-1,0.002628962,0.9973711
9105,akinesis,12,13,82,90,Echocardiogram revealed a normal ejection fraction and a resolution of the apical akinesis.,19300240_11,-1,-1,-1,9105,-1,0.0015247865,0.99847525
9106,cardiac complications,3,5,27,48,"Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation.",19300240_12,-1,-1,-1,9106,-1,0.0012402998,0.99875975
9108,coronary vasospasm,11,13,100,118,"Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation.",19300240_12,-1,-1,-1,9108,-1,0.0011956864,0.99880433
9109,thrombus,18,19,154,162,"Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation.",19300240_12,-1,-1,-1,9109,-1,0.0016345693,0.99836546
9112,ABS,28,29,194,197,"In our patient, both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS.",19300240_13,-1,-1,-1,9112,-1,0.0034942992,0.99650574
9114,nitric oxide,4,6,37,49,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,-1,-1,-1,9114,-1,0.9985946,0.0014054099
9118,diabetic neuropathy,17,19,145,164,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,-1,-1,-1,9118,-1,0.0014324152,0.9985676
9120,HOE 140,68,70,385,392,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,-1,-1,-1,9120,-1,0.9983444,0.0016556075
9121,des Arg10,76,78,412,421,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,-1,-1,-1,9121,-1,0.9989274,0.0010725908
9122,HOE 140,78,80,422,429,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,-1,-1,-1,9122,-1,0.9985605,0.0014395165
9127,diabetic hyperalgesia,24,26,155,176,RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia.,19300402_3,-1,-1,-1,9127,-1,0.0015530296,0.998447
9128,HOE 140,14,16,105,112,"Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140.",19300402_4,-1,-1,-1,9128,-1,0.9985331,0.0014668893
9129,des Arg10 HOE 140,17,21,117,134,"Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140.",19300402_4,-1,-1,-1,9129,-1,0.9989191,0.0010808515
9133,HOE 140,12,14,80,87,"Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.",19300402_6,-1,-1,-1,9133,-1,0.9986504,0.0013496792
9134,toxic neuropathy,18,20,111,127,"Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.",19300402_6,-1,-1,-1,9134,-1,0.0012914544,0.9987085
9136,toxic neuropathy,23,25,143,159,CONCLUSIONS: Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both diabetic and toxic neuropathy.,19300402_7,-1,-1,-1,9136,-1,0.0015797867,0.99842024
9139,hyperalgesia bradykinin,17,19,148,171,"In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.",19300402_8,-1,-1,-1,9139,-1,0.46874964,0.53125036
9143,adverse drug reaction,5,8,28,49,"Confusion, a rather serious adverse drug reaction with valproic acid: a review of the French Pharmacovigilance database.",19308880_0,-1,-1,-1,9143,-1,0.0016741952,0.99832577
9144,valproic acid,9,11,55,68,"Confusion, a rather serious adverse drug reaction with valproic acid: a review of the French Pharmacovigilance database.",19308880_0,-1,-1,-1,9144,-1,0.99896383,0.0010361574
9146,adverse drug reaction,5,8,30,51,INTRODUCTION: Confusion is an adverse drug reaction frequently observed with valproic acid.,19308880_1,-1,-1,-1,9146,-1,0.002477589,0.9975224
9147,valproic acid,11,13,77,90,INTRODUCTION: Confusion is an adverse drug reaction frequently observed with valproic acid.,19308880_1,-1,-1,-1,9147,-1,0.9991223,0.0008776672
9148,adverse drug reaction,13,16,78,99,We performed this study in order to describe the main characteristics of this adverse drug reaction.,19308880_3,-1,-1,-1,9148,-1,0.0021131954,0.99788684
9150,valproic acid,18,20,114,127,"METHODS: Using the French Pharmacovigilance database, we selected the cases of confusion reported since 1985 with valproic acid.",19308880_4,-1,-1,-1,9150,-1,0.9991373,0.0008627101
9152,valproic acid,9,11,51,64,RESULTS: 272 cases of confusion were reported with valproic acid: 153 women and 119 men.,19308880_5,-1,-1,-1,9152,-1,0.9991061,0.00089382706
9154,valproic acid,9,11,63,76,Confusion mostly occurred during the two first weeks following valproic acid exposure (39.7%).,19308880_6,-1,-1,-1,9154,-1,0.999199,0.0008010555
9155,ADR,4,5,23,26,The occurrence of this ADR was more frequent in patients aged between 61 and 80 years.,19308880_8,-1,-1,-1,9155,-1,0.0021845761,0.9978154
9157,valproic acid,8,10,48,61,"CONCLUSION: This work shows that confusion with valproic acid is a serious, rather frequent but reversible adverse drug reaction.",19308880_9,-1,-1,-1,9157,-1,0.9991335,0.00086646626
9158,adverse drug reaction,18,21,107,128,"CONCLUSION: This work shows that confusion with valproic acid is a serious, rather frequent but reversible adverse drug reaction.",19308880_9,-1,-1,-1,9158,-1,0.002812673,0.9971873
9160,intracerebral hemorrhage,13,15,100,124,Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.,19319147_0,-1,-1,-1,9160,-1,0.0011609736,0.9988391
9161,intracerebral hemorrhage,1,3,20,44,Warfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke.,19319147_1,-1,-1,-1,9161,-1,0.0012513377,0.99874866
9163,prothrombin complex concentrate,15,18,89,120,"Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume.",19319147_3,-1,-1,-1,9163,-1,0.99632335,0.0036766394
9164,PCC,19,20,122,125,"Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume.",19319147_3,-1,-1,-1,9164,-1,0.9941658,0.00583418
9167,h,12,13,59,60,"Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9.",19319147_4,-1,-1,-1,9167,-1,0.47873226,0.5212677
9168,PCC,10,11,61,64,"First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice.",19319147_5,-1,-1,-1,9168,-1,0.9687035,0.031296495
9170,PCC,10,11,65,68,"Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group).",19319147_7,-1,-1,-1,9170,-1,0.998696,0.0013040534
9171,n=12,20,21,96,100,"Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group).",19319147_7,-1,-1,-1,9171,-1,0.22032766,0.7796724
9175,P=0.015,22,23,139,146,"The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015).",19319147_9,-1,-1,-1,9175,-1,0.4288985,0.5711015
9176,hematomas,12,13,53,62,"In the saline group, 45% of the mice developed large hematomas (i.e., >15 microL).",19319147_10,-1,-1,-1,9176,-1,0.0016503707,0.99834967
9177,contrast,1,2,3,11,"In contrast, such extensive lesions were never found in the PCC group.",19319147_11,-1,-1,-1,9177,-1,0.071202286,0.92879766
9178,PCC,11,12,60,63,"In contrast, such extensive lesions were never found in the PCC group.",19319147_11,-1,-1,-1,9178,-1,0.023261355,0.9767387
9179,PCC,5,6,40,43,We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume.,19319147_12,-1,-1,-1,9179,-1,0.99691534,0.0030846703
9181,inferior colliculus lesion,1,4,11,37,Reversible inferior colliculus lesion in metronidazole-induced encephalopathy: magnetic resonance findings on diffusion-weighted and fluid attenuated inversion recovery imaging.,19346865_0,-1,-1,-1,9181,-1,0.006670075,0.99332994
9183,inferior colliculus lesions,7,10,41,68,"OBJECTIVE: This is to present reversible inferior colliculus lesions in metronidazole-induced encephalopathy, to focus on the diffusion-weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) imaging.",19346865_1,-1,-1,-1,9183,-1,0.0072545037,0.99274546
9188,map,26,27,146,149,"Initial brain magnetic resonance imaging (MRI) were obtained after the hospitalization, including DWI (8/8), apparent diffusion coefficient (ADC) map (4/8), FLAIR (7/8), and T2-weighted image (8/8).",19346865_4,-1,-1,-1,9188,-1,0.0893437,0.91065633
9190,map,13,14,80,83,"High-signal intensity lesions on DWI tended to show low signal intensity on ADC map (3/4), but in one patient, high signal intensity was shown at bilateral dentate nuclei on not only DWI but also ADC map.",19346865_8,-1,-1,-1,9190,-1,0.20016521,0.7998348
9191,map,39,40,200,203,"High-signal intensity lesions on DWI tended to show low signal intensity on ADC map (3/4), but in one patient, high signal intensity was shown at bilateral dentate nuclei on not only DWI but also ADC map.",19346865_8,-1,-1,-1,9191,-1,0.22205023,0.77794975
9192,corpus callosal lesion,31,34,156,178,"All the lesions in dentate, inferior colliculus, pons, and medullas had been resolved completely on follow-up MRIs in 5 patients, but in 1 patient of them, corpus callosal lesion persisted.",19346865_9,-1,-1,-1,9192,-1,0.010851155,0.9891488
9193,inferior colliculus lesions,3,6,24,51,"CONCLUSIONS: Reversible inferior colliculus lesions could be considered as the characteristic for metronidazole-induced encephalopathy, next to the dentate nucleus involvement.",19346865_10,-1,-1,-1,9193,-1,0.012640848,0.9873591
9225,PA,16,17,111,113,The anti-dementia effects of s-limonene and s-perillyl alcohol were observed using the passive avoidance test (PA) and the open field habituation test (OFH).,19356307_1,-1,-1,-1,9225,-1,0.06613688,0.93386304
9226,memory impaired,9,11,60,75,"These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.",19356307_2,-1,-1,-1,9226,-1,0.0039089615,0.99609107
9229,deficit of associative memory,20,24,133,162,"These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.",19356307_2,-1,-1,-1,9229,-1,0.004705314,0.99529463
9230,PA,25,26,166,168,"These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.",19356307_2,-1,-1,-1,9230,-1,0.9278742,0.07212583
9234,HT,5,6,29,31,"BACKGROUND: Hormone therapy (HT) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women.",19370593_1,-1,-1,-1,9234,-1,0.99629515,0.003704823
9235,menopausal symptoms,12,14,64,83,"BACKGROUND: Hormone therapy (HT) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women.",19370593_1,-1,-1,-1,9235,-1,0.0024212375,0.9975788
9236,cardiovascular disease,25,27,144,166,"BACKGROUND: Hormone therapy (HT) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women.",19370593_1,-1,-1,-1,9236,-1,0.0013086469,0.9986914
9239,HT,8,9,46,48,"OBJECTIVES: To assess the effect of long-term HT on mortality, cardiovascular outcomes, cancer, gallbladder disease, cognition, fractures and quality of life.",19370593_3,-1,-1,-1,9239,-1,0.9518182,0.048181802
9243,Menstrual Disorders,17,19,103,122,"SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.",19370593_4,-1,-1,-1,9243,-1,0.0023211695,0.9976788
9244,Subfertility,20,21,127,139,"SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.",19370593_4,-1,-1,-1,9244,-1,0.002399487,0.9976005
9245,HT,7,8,54,56,"SELECTION CRITERIA: Randomised double-blind trials of HT versus placebo, taken for at least one year by perimenopausal or postmenopausal women.",19370593_6,-1,-1,-1,9245,-1,0.9965622,0.0034378176
9246,HT,0,1,0,2,"HT included oestrogens, with or without progestogens, via oral, transdermal, subcutaneous or transnasal routes.",19370593_7,-1,-1,-1,9246,-1,0.0069549074,0.99304503
9247,oestrogens,2,3,12,22,"HT included oestrogens, with or without progestogens, via oral, transdermal, subcutaneous or transnasal routes.",19370593_7,-1,-1,-1,9247,-1,0.9985191,0.001480833
9248,progestogens,7,8,40,52,"HT included oestrogens, with or without progestogens, via oral, transdermal, subcutaneous or transnasal routes.",19370593_7,-1,-1,-1,9248,-1,0.99830985,0.0016901772
9249,HT,7,8,49,51,"In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), stroke (after three years), breast cancer and gallbladder disease.",19370593_10,-1,-1,-1,9249,-1,0.9969614,0.003038621
9253,HT,2,3,25,27,"Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.",19370593_11,-1,-1,-1,9253,-1,0.99675506,0.0032449302
9257,HT,6,7,47,49,"The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.",19370593_12,-1,-1,-1,9257,-1,0.994745,0.0052550565
9259,HT,17,18,108,110,"The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.",19370593_12,-1,-1,-1,9259,-1,0.9873921,0.012607848
9260,colon cancer,19,21,112,124,"The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.",19370593_12,-1,-1,-1,9260,-1,0.0019400748,0.9980599
9261,HT,22,23,128,130,"Among women aged over 65 who were relatively healthy (i.e. generally fit, without overt disease) and taking continuous combined HT, there was a statistically significant increase in the incidence of dementia.",19370593_13,-1,-1,-1,9261,-1,0.99725455,0.0027454814
9263,cardiovascular disease,3,5,17,39,"Among women with cardiovascular disease, long-term use of combined continuous HT significantly increased the risk of venous thrombo-embolism.",19370593_14,-1,-1,-1,9263,-1,0.0013297733,0.9986702
9264,HT,11,12,78,80,"Among women with cardiovascular disease, long-term use of combined continuous HT significantly increased the risk of venous thrombo-embolism.",19370593_14,-1,-1,-1,9264,-1,0.99374074,0.0062592193
9265,HT,17,18,107,109,"One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking oestrogen-only HT, versus similar-sized placebo groups.",19370593_15,-1,-1,-1,9265,-1,0.9980921,0.0019079081
9266,HT,22,23,141,143,"One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking oestrogen-only HT, versus similar-sized placebo groups.",19370593_15,-1,-1,-1,9266,-1,0.9978067,0.002193306
9267,HT,15,16,115,117,"The only significantly increased risk reported was for venous thrombo-embolism in women taking combined continuous HT: their absolute risk remained low, at less than 1/500.",19370593_16,-1,-1,-1,9267,-1,0.99333584,0.0066641886
9268,HT,4,5,22,24,AUTHORS' CONCLUSIONS: HT is not indicated for the routine management of chronic disease.,19370593_18,-1,-1,-1,9268,-1,0.96864736,0.031352688
9269,chronic disease,13,15,72,87,AUTHORS' CONCLUSIONS: HT is not indicated for the routine management of chronic disease.,19370593_18,-1,-1,-1,9269,-1,0.0023110239,0.997689
9270,HT,8,9,39,41,"We need more evidence on the safety of HT for menopausal symptom control, though short-term use appears to be relatively safe for healthy younger women.",19370593_19,-1,-1,-1,9270,-1,0.993317,0.0066829356
9278,painful,19,20,125,132,Here we show that perceived pain intensity in secondary hyperalgesia is decreased when attention is distracted away from the painful pinprick stimulus with a visual task.,19387625_3,-1,-1,-1,9278,-1,0.0026738578,0.99732614
9282,mechanical pain,21,23,173,188,"Our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin-induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms.",19387625_5,-1,-1,-1,9282,-1,0.002544824,0.9974552
9283,salvianolic acid A,3,6,27,45,Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_0,-1,-1,-1,9283,-1,0.99805427,0.0019457892
9284,myocardial infarction,8,10,71,92,Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_0,-1,-1,-1,9284,-1,0.0013908792,0.9986091
9285,salvianolic acid A,11,14,77,95,The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_1,-1,-1,-1,9285,-1,0.9982218,0.0017781833
9286,myocardial infarction,16,18,121,142,The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_1,-1,-1,-1,9286,-1,0.0015634767,0.9984365
9287,lactate,9,10,73,80,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,-1,-1,-1,9287,-1,0.9986279,0.0013720845
9289,creatine kinase,15,17,120,135,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,-1,-1,-1,9289,-1,0.9983065,0.0016935001
9291,superoxide dismutase,26,28,203,223,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,-1,-1,-1,9291,-1,0.99844056,0.0015594475
9292,glutathione peroxidase,31,33,238,260,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,-1,-1,-1,9292,-1,0.9965384,0.0034616368
9293,mitochondrial respiratory dysfunction,3,6,13,50,"In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats.",19445921_7,-1,-1,-1,9293,-1,0.0071415245,0.9928585
9294,salvianolic acid A,2,5,18,36,Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.,19445921_8,-1,-1,-1,9294,-1,0.99857724,0.0014227458
9297,salvianolic acid A,4,7,23,41,The protective role of salvianolic acid A against isoproterenol-induced myocardial damage was further confirmed by histopathological examination.,19445921_9,-1,-1,-1,9297,-1,0.99839634,0.0016036992
9299,salvianolic acid A,7,10,38,56,The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol-induced myocardial infarction.,19445921_10,-1,-1,-1,9299,-1,0.99778336,0.0022167051
9300,myocardial infarction,20,22,155,176,The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol-induced myocardial infarction.,19445921_10,-1,-1,-1,9300,-1,0.001512113,0.99848783
9302,peripheral neurotoxicity,7,9,62,86,Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.,19473225_0,-1,-1,-1,9302,-1,0.0016557894,0.9983442
9304,Toxic peripheral neuropathy,0,3,0,27,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,-1,-1,-1,9304,-1,0.0012388652,0.9987612
9306,PAC,14,15,101,104,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,-1,-1,-1,9306,-1,0.99840885,0.0015911381
9308,amino acid glutamine,23,26,150,170,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,-1,-1,-1,9308,-1,0.9972548,0.0027451876
9309,PAC neurotoxicity,30,32,198,215,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,-1,-1,-1,9309,-1,0.16644068,0.83355933
9314,mg,37,38,226,228,"Forty-three ovarian cancer patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P).",19473225_3,-1,-1,-1,9314,-1,0.9917665,0.008233458
9317,P,44,45,291,292,"There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G. However, this difference reached statistical significance only with regard to reported pain sensation (P = 0.011).",19473225_5,-1,-1,-1,9317,-1,0.22666173,0.77333826
9318,P,21,22,118,119,Also the frequency of abnormal electro-diagnostic findings showed similarity between the two groups (G: 7/23 = 30.4%; P: 6/20 = 30%).,19473225_6,-1,-1,-1,9318,-1,0.11437731,0.8856226
9320,peripheral neurotoxicity,18,20,119,143,This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of PAC.,19473225_7,-1,-1,-1,9320,-1,0.0017437505,0.99825627
9321,PAC,21,22,147,150,This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of PAC.,19473225_7,-1,-1,-1,9321,-1,0.9942812,0.0057187984
9322,ocular myasthenia,2,4,15,32,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9322,-1,0.0011085222,0.99889153
9323,pegylated interferon,5,7,40,60,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9323,-1,0.99908483,0.00091511314
9325,chronic hepatitis C.A,11,14,89,110,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9325,-1,0.0081695635,0.9918304
9326,diplopia,18,19,147,155,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9326,-1,0.0011055566,0.9988945
9327,pegylated interferon,25,27,191,211,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9327,-1,0.9990784,0.000921626
9328,IFN) alpha-2b,28,31,213,226,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9328,-1,0.99863917,0.0013608814
9330,chronic hepatitis C,34,37,245,264,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9330,-1,0.0029275306,0.99707246
9331,CHC,38,39,266,269,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9331,-1,0.0015923126,0.99840766
9332,ptosis on the,3,6,35,48,Ophthalmologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurological signs.,19581773_1,-1,-1,-1,9332,-1,0.00477894,0.9952211
9333,lid,8,9,61,64,Ophthalmologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurological signs.,19581773_1,-1,-1,-1,9333,-1,0.0066762096,0.99332374
9334,restricted right eye movement,10,14,69,98,Ophthalmologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurological signs.,19581773_1,-1,-1,-1,9334,-1,0.0032872986,0.9967127
9336,acetylcholinesterase inhibitors,8,10,58,89,"The acetylcholine receptor antibody titer and response to acetylcholinesterase inhibitors were negative, and the results of thyroid function tests were normal.",19581773_3,-1,-1,-1,9336,-1,0.9989121,0.0010879448
9337,pegylated IFN alpha-2b,12,15,90,112,The patient's ophthalmological symptoms improved rapidly 3 weeks after discontinuation of pegylated IFN alpha-2b and ribavirin.,19581773_4,-1,-1,-1,9337,-1,0.9990097,0.0009901852
9339,ocular myasthenia,1,3,4,21,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,-1,-1,-1,9339,-1,0.0011009921,0.998899
9340,pegylated IFN alpha-2b,8,11,61,83,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,-1,-1,-1,9340,-1,0.99906605,0.00093394314
9342,CHC,14,15,102,105,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,-1,-1,-1,9342,-1,0.0012262961,0.99877363
9343,IFN,35,36,213,216,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,-1,-1,-1,9343,-1,0.9990012,0.0009988182
9344,memory deficits,2,4,13,28,Learning and memory deficits in ecstasy users and their neural correlates during a face-learning task.,19631624_0,-1,-1,-1,9344,-1,0.0031842797,0.99681574
9353,hypoactivity,10,11,82,94,Deficits in learning and memory: parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users.,19631624_5,-1,-1,-1,9353,-1,0.0017758961,0.9982241
9358,hypoactivity,1,2,17,29,Ecstasy-specific hypoactivity was evident in the right dorsal anterior cingulated cortex (ACC) and left posterior cingulated cortex.,19631624_9,-1,-1,-1,9358,-1,0.0021246963,0.99787533
9364,Acute renal failure,0,3,0,19,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.,19642243_0,-1,-1,-1,9364,-1,0.0011395596,0.9988605
9365,AIDS,6,7,37,41,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.,19642243_0,-1,-1,-1,9365,-1,0.0014658378,0.9985342
9366,tenofovir,8,9,45,54,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.,19642243_0,-1,-1,-1,9366,-1,0.99906105,0.0009389208
9368,osteomyelitis,15,16,103,116,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.,19642243_0,-1,-1,-1,9368,-1,0.001116798,0.9988832
9369,Renal failure,0,2,0,13,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.,19642243_1,-1,-1,-1,9369,-1,0.0014436644,0.9985563
9371,tenofovir disoproxil fumarate,16,19,104,133,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.,19642243_1,-1,-1,-1,9371,-1,0.99923754,0.0007625166
9372,Tenofovir,0,1,0,9,Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.,19642243_2,-1,-1,-1,9372,-1,0.99907947,0.00092054036
9373,Fanconi syndrome,8,10,52,68,Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.,19642243_2,-1,-1,-1,9373,-1,0.0016618287,0.9983381
9374,renal insufficiency,11,13,73,92,Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.,19642243_2,-1,-1,-1,9374,-1,0.0015080724,0.9984919
9375,Vancomycin nephrotoxicity,0,2,0,25,Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent.,19642243_3,-1,-1,-1,9375,-1,0.05977423,0.9402258
9377,tenofovir,5,6,32,41,Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.,19642243_4,-1,-1,-1,9377,-1,0.9991009,0.00089907413
9378,renal failure,11,13,64,77,Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.,19642243_4,-1,-1,-1,9378,-1,0.0015102279,0.99848974
9380,hydrogen cyanamide,3,5,31,49,Disulfiram-like syndrome after hydrogen cyanamide professional skin exposure: two case reports in France.,19657887_0,-1,-1,-1,9380,-1,0.9990858,0.0009141824
9381,Hydrogen cyanamide,0,2,0,18,Hydrogen cyanamide is a plant growth regulator used in agriculture to induce bud break in fruit trees.,19657887_1,-1,-1,-1,9381,-1,0.9987049,0.0012951283
9382,aldehyde,14,15,91,99,Contact with the skin can result in percutaneous absorption of the substance that inhibits aldehyde dehydrogenase and can induce acetaldehyde syndrome in case of alcohol use.,19657887_2,-1,-1,-1,9382,-1,0.99849975,0.0015002134
9383,acetaldehyde,19,20,129,141,Contact with the skin can result in percutaneous absorption of the substance that inhibits aldehyde dehydrogenase and can induce acetaldehyde syndrome in case of alcohol use.,19657887_2,-1,-1,-1,9383,-1,0.9989016,0.0010983502
9385,hydrogen cyanamide,18,20,117,135,The purpose of this report is to describe two cases of a disulfiram-like syndrome following occupational exposure to hydrogen cyanamide.,19657887_3,-1,-1,-1,9385,-1,0.99914527,0.00085476047
9386,Dormex,9,10,51,57,"The first case involved a 59-year-old man who used Dormex, which contains hydrogen cyanamide, without protection after consuming a large amount of alcohol during a meal.",19657887_4,-1,-1,-1,9386,-1,0.9981881,0.0018118988
9387,hydrogen cyanamide,13,15,74,92,"The first case involved a 59-year-old man who used Dormex, which contains hydrogen cyanamide, without protection after consuming a large amount of alcohol during a meal.",19657887_4,-1,-1,-1,9387,-1,0.99890757,0.0010923793
9390,malaise,13,14,65,72,"In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.",19657887_5,-1,-1,-1,9390,-1,0.001358953,0.9986411
9391,flushing,15,16,78,86,"In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.",19657887_5,-1,-1,-1,9391,-1,0.0015714504,0.9984285
9393,dyspnea,23,24,117,124,"In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.",19657887_5,-1,-1,-1,9393,-1,0.0013005369,0.9986994
9394,Dormex,12,13,82,88,The second case occurred in a 55-year-old farmer following cutaneous contact with Dormex.,19657887_7,-1,-1,-1,9394,-1,0.968375,0.031624977
9395,flushing,10,11,70,78,"Five hours after exposure, he developed disulfiram-like syndrome with flushing, tachycardia, and arterial hypotension after consuming three glasses of wine.",19657887_8,-1,-1,-1,9395,-1,0.00138449,0.9986155
9397,arterial hypotension,15,17,97,117,"Five hours after exposure, he developed disulfiram-like syndrome with flushing, tachycardia, and arterial hypotension after consuming three glasses of wine.",19657887_8,-1,-1,-1,9397,-1,0.0013003064,0.99869967
9399,Dormex,17,18,112,118,These cases confirm the necessity of avoiding alcohol consumption as recommended in the instructions for use of Dormex and of preventing cutaneous contact during use.,19657887_10,-1,-1,-1,9399,-1,0.9982522,0.0017478026
9400,dysosmia,1,2,10,18,Recurrent dysosmia induced by pyrazinamide.,19674115_0,-1,-1,-1,9400,-1,0.0011876916,0.9988123
9401,pyrazinamide,4,5,30,42,Recurrent dysosmia induced by pyrazinamide.,19674115_0,-1,-1,-1,9401,-1,0.9990244,0.0009755716
9402,Pyrazinamide,0,1,0,12,"Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.",19674115_1,-1,-1,-1,9402,-1,0.99907684,0.00092317886
9403,hepatic toxicity,7,9,46,62,"Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.",19674115_1,-1,-1,-1,9403,-1,0.0013619692,0.998638
9404,hyperuricemia,10,11,64,77,"Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.",19674115_1,-1,-1,-1,9404,-1,0.0013575377,0.9986425
9405,digestive disorders,12,14,81,100,"Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.",19674115_1,-1,-1,-1,9405,-1,0.0013498027,0.99865025
9406,pyrazinamide,14,15,78,90,"In rare cases, alterations in taste and smell function have been reported for pyrazinamide when combined with other drugs.",19674115_2,-1,-1,-1,9406,-1,0.9992223,0.0007777384
9407,olfactory disorder,6,8,31,49,"We report a case of reversible olfactory disorder related to pyrazinamide in a woman, with a positive rechallenge.",19674115_3,-1,-1,-1,9407,-1,0.0012727306,0.99872726
9408,pyrazinamide,10,11,61,73,"We report a case of reversible olfactory disorder related to pyrazinamide in a woman, with a positive rechallenge.",19674115_3,-1,-1,-1,9408,-1,0.9991308,0.0008692345
9409,Dysosmia,0,1,0,8,Dysosmia disappeared completely after pyrazinamide withdrawal and recurred after its rechallenge.,19674115_5,-1,-1,-1,9409,-1,0.0013261309,0.9986739
9410,pyrazinamide,4,5,38,50,Dysosmia disappeared completely after pyrazinamide withdrawal and recurred after its rechallenge.,19674115_5,-1,-1,-1,9410,-1,0.9990909,0.00090906286
9411,tardive dystonia,1,3,18,34,Sulpiride-induced tardive dystonia.,1967484_0,-1,-1,-1,9411,-1,0.0011589681,0.9988411
9414,tardive dyskinesia,12,14,88,106,"Although initially thought to be free of extrapyramidal side effects, sulpiride-induced tardive dyskinesia and parkinsonism have been reported occasionally.",1967484_2,-1,-1,-1,9414,-1,0.0010570765,0.9989429
9418,tardive dystonia,9,11,60,76,We could not find any previous reports of sulpiride-induced tardive dystonia.,1967484_4,-1,-1,-1,9418,-1,0.0011091934,0.9988908
9421,prostaglandin,9,10,49,62,"However, the involvement of a specific, terminal prostaglandin (PG) isomerase has not been evaluated.",19692487_2,-1,-1,-1,9421,-1,0.9977331,0.002266839
9422,PG,11,12,64,66,"However, the involvement of a specific, terminal prostaglandin (PG) isomerase has not been evaluated.",19692487_2,-1,-1,-1,9422,-1,0.996507,0.0034929812
9424,prostaglandin E,14,16,100,115,The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).,19692487_3,-1,-1,-1,9424,-1,0.9980775,0.0019224462
9425,LiCl,4,5,25,29,A 2-wk administration of LiCl (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.,19692487_4,-1,-1,-1,9425,-1,0.99894637,0.001053626
9427,PGE(2),12,14,87,93,This was associated with elevated renal mPGES-1 protein expression and increased urine PGE(2) excretion.,19692487_5,-1,-1,-1,9427,-1,0.99635637,0.0036436145
9428,contrast,1,2,3,11,"In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.",19692487_6,-1,-1,-1,9428,-1,0.17598438,0.82401556
9430,PGE(2),26,28,169,175,"In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.",19692487_6,-1,-1,-1,9430,-1,0.99745744,0.0025425765
9431,cAMP,29,30,180,184,"In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.",19692487_6,-1,-1,-1,9431,-1,0.9988165,0.0011835729
9433,contrast,1,2,3,11,"In contrast, the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the -/- mice.",19692487_11,-1,-1,-1,9433,-1,0.31574264,0.6842574
9434,PGE(2),4,6,33,39,We conclude that mPGES-1-derived PGE(2) mediates lithium-induced polyuria likely via inhibition of AQP2 and NKCC2 expression.,19692487_12,-1,-1,-1,9434,-1,0.99768364,0.002316307
9437,fenoldopam,9,10,65,75,Preservation of renal blood flow during hypotension induced with fenoldopam in dogs.,1969772_0,-1,-1,-1,9437,-1,0.9991672,0.0008328171
9439,Fenoldopam mesylate,0,2,0,19,Fenoldopam mesylate is a specific DA1 receptor agonist that lowers blood pressure by vasodilatation.,1969772_3,-1,-1,-1,9439,-1,0.99922407,0.00077595573
9440,fenoldopam,3,4,20,30,The hypothesis that fenoldopam could be used to induce hypotension and preserve blood flow to the kidney was tested.,1969772_4,-1,-1,-1,9440,-1,0.99922585,0.00077411084
9442,fenoldopam,34,35,229,239,"Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively, in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia.",1969772_5,-1,-1,-1,9442,-1,0.99927443,0.00072554586
9445,fenoldopam,16,17,85,95,Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).,1969772_6,-1,-1,-1,9445,-1,0.99925226,0.0007477486
9447,NS,41,42,221,223,Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).,1969772_6,-1,-1,-1,9447,-1,0.05817345,0.9418266
9451,P,29,30,170,171,Renal blood flow (RBF) increased during fenoldopam-induced hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside-induced hypotension (P less than 0.01).,1969772_7,-1,-1,-1,9451,-1,0.31843498,0.681565
9454,Fenoldopam,0,1,0,10,Fenoldopam is a selective dopamine-1 (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension.,1969772_9,-1,-1,-1,9454,-1,0.99922407,0.0007759787
9465,Etodolac,0,1,0,8,"Etodolac (E), is a non-narcotic analgesic and antiinflammatory drug.",19719056_1,-1,-1,-1,9465,-1,0.9989096,0.0010904435
9466,E,2,3,10,11,"Etodolac (E), is a non-narcotic analgesic and antiinflammatory drug.",19719056_1,-1,-1,-1,9466,-1,0.9972765,0.002723516
9468,etodolac,8,9,56,64,"An activated moiety, i.e. N-acylimidazole derivative of etodolac (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).",19719056_3,-1,-1,-1,9468,-1,0.99874926,0.0012506953
9469,EAI,10,11,66,69,"An activated moiety, i.e. N-acylimidazole derivative of etodolac (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).",19719056_3,-1,-1,-1,9469,-1,0.9959443,0.004055665
9471,Etodolac,0,1,0,8,Etodolac contents were evaluated by UV-spectrophotometric analysis.,19719056_5,-1,-1,-1,9471,-1,0.9982022,0.0017977982
9472,etodolac,8,9,26,34,"At pH 9, a higher rate of etodolac release from ED was observed as compared to aqueous buffer of pH 7.4 and 80% human plasma (pH 7.4), following first-order kinetics.",19719056_8,-1,-1,-1,9472,-1,0.9990139,0.0009861079
9473,acetic acid,8,10,71,82,"Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.",19719056_10,-1,-1,-1,9473,-1,0.99845076,0.0015492138
9474,writhing,11,12,91,99,"Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.",19719056_10,-1,-1,-1,9474,-1,0.0017127206,0.99828726
9475,paw edema,19,21,141,150,"Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.",19719056_10,-1,-1,-1,9475,-1,0.0021025524,0.9978974
9476,E,5,6,26,27,"In comparison to control, E and ED1-ED4 showed highly significant analgesic and antiinflammatory activities (p <0.001).",19719056_11,-1,-1,-1,9476,-1,0.9936801,0.006319914
9477,p,16,17,109,110,"In comparison to control, E and ED1-ED4 showed highly significant analgesic and antiinflammatory activities (p <0.001).",19719056_11,-1,-1,-1,9477,-1,0.39505276,0.60494727
9478,etodolac,25,26,193,201,Biological evaluation suggested that conjugates (ED1-ED4) retained comparable analgesic and antiinflammatory activities with remarkably reduced ulcerogenicity as compared to their parent drug--etodolac.,19719056_12,-1,-1,-1,9478,-1,0.9990363,0.00096372503
9485,fibrillation,20,21,142,154,"The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.",19721134_3,-1,-1,-1,9485,-1,0.0013610512,0.9986389
9487,arrhythmic,32,33,217,227,"The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.",19721134_3,-1,-1,-1,9487,-1,0.0014001097,0.99859995
9488,aconitine,5,6,32,41,[Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.,19721134_4,-1,-1,-1,9488,-1,0.9993241,0.0006759314
9492,4-DAMP,9,10,68,74,"Moreover, M(3)-muscarinic acetylcholine receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine.",19721134_5,-1,-1,-1,9492,-1,0.99894077,0.0010592731
9495,arrhythmic,9,10,71,81,These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.,19721134_6,-1,-1,-1,9495,-1,0.0016724014,0.99832755
9496,aconitine,17,18,119,128,These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.,19721134_6,-1,-1,-1,9496,-1,0.99933004,0.0006699813
9503,P,11,12,74,75,"Plasma oxycodone concentration peaked between 60 and 90 minutes postdose (P < .01) and pupil size, an indication of physiological effects of the medication, peaked at approximately 90 to 120 minutes postdose (P < .01).",19729346_3,-1,-1,-1,9503,-1,0.41906196,0.58093804
9504,P,37,38,209,210,"Plasma oxycodone concentration peaked between 60 and 90 minutes postdose (P < .01) and pupil size, an indication of physiological effects of the medication, peaked at approximately 90 to 120 minutes postdose (P < .01).",19729346_3,-1,-1,-1,9504,-1,0.45632705,0.5436729
9505,chronic pain,13,15,77,89,"This study suggests that for healthy older adults who are not suffering from chronic pain, neurocognitive and pharmacodynamic changes in response to a 10-mg dose of immediate-release oxycodone are similar to those observed for middle-aged adults.",19729346_6,-1,-1,-1,9505,-1,0.0016972875,0.9983027
9508,opioids,8,9,56,63,"Therefore, clinicians should not avoid prescribing oral opioids to older adults based on the belief that older adults are at higher risk for side effects than younger adults.",19729346_8,-1,-1,-1,9508,-1,0.99828535,0.0017146261
9510,SSR103800,4,5,36,45,The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.,19759529_0,-1,-1,-1,9510,-1,0.9987382,0.001261842
9514,NMDA,11,12,81,85,"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.",19759529_2,-1,-1,-1,9514,-1,0.99844956,0.0015504631
9515,NMDA,33,34,218,222,"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.",19759529_2,-1,-1,-1,9515,-1,0.9983224,0.0016775155
9516,antipsychotic,17,18,101,114,"As a result, there is a growing interest in the development of pharmacological agents with potential antipsychotic properties that enhance the activity of the glutamatergic system via a modulation of the NMDA receptor.",19759529_3,-1,-1,-1,9516,-1,0.99809116,0.0019087746
9517,NMDA,32,33,204,208,"As a result, there is a growing interest in the development of pharmacological agents with potential antipsychotic properties that enhance the activity of the glutamatergic system via a modulation of the NMDA receptor.",19759529_3,-1,-1,-1,9517,-1,0.9984504,0.0015496382
9519,SSR103800,11,12,64,73,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",19759529_4,-1,-1,-1,9519,-1,0.9990728,0.000927169
9520,NMDA,16,17,100,104,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",19759529_4,-1,-1,-1,9520,-1,0.9987445,0.00125546
9522,NMDA,28,29,171,175,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",19759529_4,-1,-1,-1,9522,-1,0.99867344,0.0013266363
9523,SSR103800,10,11,81,90,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,-1,-1,-1,9523,-1,0.99910104,0.00089903304
9526,MK-801,30,31,197,203,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,-1,-1,-1,9526,-1,0.9990681,0.0009319969
9527,NMDA,38,39,229,233,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,-1,-1,-1,9527,-1,0.99892277,0.0010772367
9528,SSR103800,3,4,20,29,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,-1,-1,-1,9528,-1,0.9990584,0.0009415833
9530,NMDA,18,19,102,106,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,-1,-1,-1,9530,-1,0.9989171,0.0010828731
9531,MK-801,22,23,128,134,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,-1,-1,-1,9531,-1,0.999008,0.0009920445
9533,NMDA,29,30,187,191,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,-1,-1,-1,9533,-1,0.9989378,0.0010621864
9534,contrast,1,2,3,11,"In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).",19759529_7,-1,-1,-1,9534,-1,0.4550517,0.54494834
9535,SSR103800,3,4,13,22,"In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).",19759529_7,-1,-1,-1,9535,-1,0.9990386,0.0009614226
9542,aripiprazole,14,15,82,94,"Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.",19759529_8,-1,-1,-1,9542,-1,0.99929214,0.00070780964
9543,antipsychotics,16,17,96,110,"Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.",19759529_8,-1,-1,-1,9543,-1,0.99859554,0.0014045108
9545,SSR103800,6,7,30,39,"However, unlike these latter, SSR103800 did not produce catalepsy (retention on the bar test) up to 30 mg/kg p.o.",19759529_9,-1,-1,-1,9545,-1,0.9986695,0.0013304625
9547,SSR103800,9,10,55,64,"Together these findings show that the GlyT1 inhibitor, SSR103800, produces antipsychotic-like effects, which differ from those observed with compounds primarily targeting the dopaminergic system, and has a reduced side-effect potential as compared with these latter drugs.",19759529_10,-1,-1,-1,9547,-1,0.99883765,0.0011623877
9548,orofacial dyskinesia,18,20,104,124,Effect of methanolic extract of Hibiscus rosa sinensis (100-300 mg/kg) was studied on reserpine-induced orofacial dyskinesia and neurochemical alterations.,19761039_1,-1,-1,-1,9548,-1,0.0015174731,0.9984825
9552,superoxide dismutase,17,19,135,155,"Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process.",19761039_5,-1,-1,-1,9552,-1,0.9985499,0.0014500624
9553,glutathione reductase,28,30,182,203,"Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process.",19761039_5,-1,-1,-1,9553,-1,0.998142,0.0018580139
9554,GSH,31,32,205,208,"Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process.",19761039_5,-1,-1,-1,9554,-1,0.9983967,0.0016032968
9555,GSH,18,19,121,124,"Coadministration of extract significantly reduced the lipid peroxidation and reversed the decrease in brain SOD, CAT and GSH levels.",19761039_6,-1,-1,-1,9555,-1,0.9984504,0.0015495716
9556,orofacial dyskinesia,17,19,119,139,The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine-induced orofacial dyskinesia and oxidative stress.,19761039_7,-1,-1,-1,9556,-1,0.001571921,0.9984281
9557,Pyrrolidine dithiocarbamate,0,2,0,27,Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model.,19767176_0,-1,-1,-1,9557,-1,0.99921787,0.00078217185
9558,pilocarpine status epilepticus,8,11,64,94,Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model.,19767176_0,-1,-1,-1,9558,-1,0.47752267,0.5224773
9559,Pyrrolidine dithiocarbamate,0,2,0,27,Pyrrolidine dithiocarbamate (PDTC) has a dual mechanism of action as an antioxidant and an inhibitor of the transcription factor kappa-beta.,19767176_1,-1,-1,-1,9559,-1,0.9991543,0.00084561756
9560,PDTC,3,4,29,33,Pyrrolidine dithiocarbamate (PDTC) has a dual mechanism of action as an antioxidant and an inhibitor of the transcription factor kappa-beta.,19767176_1,-1,-1,-1,9560,-1,0.99873227,0.001267677
9561,reactive oxygen species,4,7,20,43,"Both, production of reactive oxygen species as well as activation of NF-kappaB have been implicated in severe neuronal damage in different sub-regions of the hippocampus as well as in the surrounding cortices.",19767176_2,-1,-1,-1,9561,-1,0.7873726,0.21262737
9563,PDTC,3,4,14,18,The effect of PDTC on status epilepticus-associated cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated pilocarpine model.,19767176_3,-1,-1,-1,9563,-1,0.99859947,0.0014005236
9565,PDTC,4,5,25,29,Treatment with 150 mg/kg PDTC before and following status epilepticus significantly increased the mortality rate to 100%.,19767176_4,-1,-1,-1,9565,-1,0.99781394,0.002186061
9566,status epilepticus,8,10,51,69,Treatment with 150 mg/kg PDTC before and following status epilepticus significantly increased the mortality rate to 100%.,19767176_4,-1,-1,-1,9566,-1,0.0018635651,0.9981364
9567,PDTC,4,5,27,31,Administration of 50 mg/kg PDTC (low-dose) did not exert major effects on the development of a status epilepticus or the mortality rate.,19767176_5,-1,-1,-1,9567,-1,0.99788684,0.0021131218
9568,status epilepticus,18,20,95,113,Administration of 50 mg/kg PDTC (low-dose) did not exert major effects on the development of a status epilepticus or the mortality rate.,19767176_5,-1,-1,-1,9568,-1,0.0015594682,0.99844056
9569,status epilepticus,4,6,25,43,"In vehicle-treated rats, status epilepticus caused pronounced neuronal damage in the piriform cortex comprising both pyramidal cells and interneurons.",19767176_6,-1,-1,-1,9569,-1,0.0018281587,0.9981718
9571,PDTC,1,2,9,13,Low-dose PDTC treatment almost completely protected from lesions in the piriform cortex.,19767176_7,-1,-1,-1,9571,-1,0.99583375,0.004166165
9572,status epilepticus,19,21,137,155,A significant decrease in neuronal density of the hippocampal hilar formation was identified in vehicle- and PDTC-treated rats following status epilepticus.,19767176_8,-1,-1,-1,9572,-1,0.0025448326,0.9974552
9573,PDTC,8,9,55,59,"In conclusion, the NF-kappaB inhibitor and antioxidant PDTC protected the piriform cortex, whereas it did not affect hilar neuronal loss.",19767176_9,-1,-1,-1,9573,-1,0.9982508,0.001749214
9574,neuronal loss,20,22,123,136,"In conclusion, the NF-kappaB inhibitor and antioxidant PDTC protected the piriform cortex, whereas it did not affect hilar neuronal loss.",19767176_9,-1,-1,-1,9574,-1,0.0025300232,0.99747
9575,reactive oxygen species,8,11,49,72,These data might indicate that the generation of reactive oxygen species and activation of NF-kappaB plays a more central role in seizure-associated neuronal damage in the temporal cortex as compared to the hippocampal hilus.,19767176_10,-1,-1,-1,9575,-1,0.81714976,0.18285027
9577,PDTC,14,15,100,104,"However, future investigations are necessary to exactly analyze the biochemical mechanisms by which PDTC exerted its beneficial effects in the piriform cortex.",19767176_11,-1,-1,-1,9577,-1,0.998698,0.0013019247
9578,masseter spasm,4,6,26,40,Anaesthetists' nightmare: masseter spasm after induction in an undiagnosed case of myotonia congenita.,19803309_0,-1,-1,-1,9578,-1,0.0036281247,0.99637187
9579,myotonia congenita,13,15,83,101,Anaesthetists' nightmare: masseter spasm after induction in an undiagnosed case of myotonia congenita.,19803309_0,-1,-1,-1,9579,-1,0.0017564411,0.9982436
9580,myotonia congenita,6,8,33,51,"We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia.",19803309_1,-1,-1,-1,9580,-1,0.0013925424,0.99860746
9581,masseter spasm,19,21,133,147,"We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia.",19803309_1,-1,-1,-1,9581,-1,0.0024537083,0.99754626
9584,human immunodeficiency virus infection,17,21,92,130,We report twin neonates who were born prematurely at 32 weeks of gestation to a mother with human immunodeficiency virus infection.,19820426_1,-1,-1,-1,9584,-1,0.06697031,0.9330297
9585,heart block,6,8,36,47,"One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.",19820426_2,-1,-1,-1,9585,-1,0.0012463927,0.99875355
9588,right heart failure,8,11,71,90,"Twenty-three hours after heart transplantation, life-threatening acute right heart failure was diagnosed in a patient requiring continuous venovenous hemodiafiltration (CVVHDF).",19843802_1,-1,-1,-1,9588,-1,0.0017048392,0.9982951
9604,birth defects,8,10,58,71,Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study.,19884587_0,-1,-1,-1,9604,-1,0.0022236872,0.9977763
9605,Birth Defects,12,14,82,95,Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study.,19884587_0,-1,-1,-1,9605,-1,0.0032034102,0.99679655
9606,birth defects,11,13,86,99,OBJECTIVE: To estimate the association between antibacterial medications and selected birth defects.,19884587_1,-1,-1,-1,9606,-1,0.0023378592,0.9976622
9607,birth defects,27,29,157,170,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,-1,-1,-1,9607,-1,0.0029306659,0.9970694
9608,birth defect,31,33,186,198,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,-1,-1,-1,9608,-1,0.0034338862,0.9965661
9609,n,39,40,235,236,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,-1,-1,-1,9609,-1,0.15325156,0.8467484
9610,n,55,56,319,320,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,-1,-1,-1,9610,-1,0.17621453,0.8237854
9611,birth defects,17,19,105,118,MAIN OUTCOME MEASURE: Odds ratios (ORs) measuring the association between antibacterial use and selected birth defects adjusted for potential confounders.,19884587_4,-1,-1,-1,9611,-1,0.0025003406,0.99749964
9612,Sulfonamides,0,1,0,12,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9612,-1,0.99915683,0.0008431121
9614,hypoplastic left heart syndrome,27,31,112,143,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9614,-1,0.001785467,0.9982146
9615,coarctation of the aorta,45,49,174,198,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9615,-1,0.0028970328,0.9971029
9616,choanal atresia,63,65,229,244,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9616,-1,0.0021123658,0.9978877
9617,transverse limb deficiency,79,82,276,302,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9617,-1,0.0025934526,0.99740654
9618,diaphragmatic hernia,97,99,337,357,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9618,-1,0.0019555471,0.9980445
9619,Nitrofurantoins,0,1,0,15,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9619,-1,0.9989705,0.0010294842
9620,anophthalmia,4,5,37,49,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9620,-1,0.0016140338,0.998386
9621,microphthalmos,6,7,53,67,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9621,-1,0.0019297613,0.9980703
9622,hypoplastic left heart syndrome,21,25,99,130,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9622,-1,0.002053949,0.9979461
9623,atrial septal defects,39,42,161,182,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9623,-1,0.002829225,0.99717075
9624,cleft lip,57,59,217,226,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9624,-1,0.0021988573,0.9978011
9625,cleft palate,60,62,232,244,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9625,-1,0.0023015223,0.9976985
9626,erythromycins,7,8,61,74,"Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect).",19884587_8,-1,-1,-1,9626,-1,0.9982774,0.0017225795
9627,penicillins,13,14,88,99,"Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect).",19884587_8,-1,-1,-1,9627,-1,0.9984792,0.0015208321
9629,quinolones,26,27,143,153,"Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect).",19884587_8,-1,-1,-1,9629,-1,0.9986744,0.0013256245
9630,penicillins,4,5,27,38,"CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.",19884587_9,-1,-1,-1,9630,-1,0.9986355,0.0013644717
9631,erythromycins,6,7,40,53,"CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.",19884587_9,-1,-1,-1,9631,-1,0.9985164,0.0014835733
9633,birth defects,23,25,147,160,"CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.",19884587_9,-1,-1,-1,9633,-1,0.0020490128,0.997951
9634,Sulfonamides,0,1,0,12,"Sulfonamides and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny.",19884587_10,-1,-1,-1,9634,-1,0.99911267,0.00088738045
9635,nitrofurantoins,2,3,17,32,"Sulfonamides and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny.",19884587_10,-1,-1,-1,9635,-1,0.99901164,0.000988343
9636,birth defects,7,9,62,75,"Sulfonamides and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny.",19884587_10,-1,-1,-1,9636,-1,0.0019042722,0.9980957
9637,hepatitis B,15,17,106,117,Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.,19889778_0,-1,-1,-1,9637,-1,0.018883035,0.98111695
9638,e,18,19,124,125,Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.,19889778_0,-1,-1,-1,9638,-1,0.12587959,0.87412035
9639,hepatitis B,5,7,30,41,"Immune escape variants of the hepatitis B virus (HBV) represent an emerging clinical challenge, because they can be associated with vaccine escape, HBV reactivation, and failure of diagnostic tests.",19889778_1,-1,-1,-1,9639,-1,0.013354766,0.9866453
9641,LAM,40,41,274,277,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.",19889778_3,-1,-1,-1,9641,-1,0.9986821,0.0013178914
9642,HBeAg,43,44,286,291,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.",19889778_3,-1,-1,-1,9642,-1,0.016266584,0.9837335
9643,LAM,9,10,60,63,Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.,19889778_4,-1,-1,-1,9643,-1,0.9982893,0.0017106736
9644,HBsAg,5,6,37,42,"The sG145R mutation strongly reduced HBsAg levels and was able to fully restore the impaired replication of LAM-resistant HBV mutants to the levels of wild-type HBV, and PC or BCP mutations further enhanced viral replication.",19889778_5,-1,-1,-1,9644,-1,0.99450064,0.0054993657
9645,HBsAg,7,8,47,52,"Although the sP120T substitution also impaired HBsAg secretion, it did not enhance the replication of LAM-resistant clones.",19889778_6,-1,-1,-1,9645,-1,0.99111193,0.008887998
9646,HBeAg,6,7,39,44,"However, the concomitant occurrence of HBeAg negativity (PC/BCP), sP120T, and LAM resistance resulted in the restoration of replication to levels of wild-type HBV.",19889778_7,-1,-1,-1,9646,-1,0.90007985,0.09992018
9647,LAM,16,17,78,81,"However, the concomitant occurrence of HBeAg negativity (PC/BCP), sP120T, and LAM resistance resulted in the restoration of replication to levels of wild-type HBV.",19889778_7,-1,-1,-1,9647,-1,0.99873656,0.0012634482
9648,LAM,8,9,46,49,"In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.",19889778_8,-1,-1,-1,9648,-1,0.8021964,0.19780362
9649,nucleotide,13,14,76,86,"In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.",19889778_8,-1,-1,-1,9649,-1,0.99883,0.001169942
9650,adefovir,15,16,97,105,"In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.",19889778_8,-1,-1,-1,9650,-1,0.9992052,0.000794797
9651,tenofovir,17,18,110,119,"In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.",19889778_8,-1,-1,-1,9651,-1,0.9992274,0.0007725836
9652,acute renal failure,6,9,36,55,Dynamic response of blood vessel in acute renal failure.,19893084_0,-1,-1,-1,9652,-1,0.0015192566,0.99848074
9653,acute renal failure,7,10,40,59,"In this study we postulated that during acute renal failure induced by gentamicin the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels.",19893084_1,-1,-1,-1,9653,-1,0.001520371,0.99847966
9655,vitamin C,4,6,26,35,The beneficial effects of vitamin C administration to gentamicin-treated animals are also confirmed through: lower level of blood urea and creatinine and higher level of potassium.,19893084_4,-1,-1,-1,9655,-1,0.99891734,0.0010827009
9659,Vitamin C,0,2,0,9,Vitamin C administration induced slowdown of pressure change back to the control values.,19893084_6,-1,-1,-1,9659,-1,0.998871,0.0011289966
9660,vitamin C,37,39,262,271,"The pressure dynamic properties, quantitatively defined by comparative pressure dynamic and total pressure dynamic, confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin-treated animals and beneficial effects of vitamin C administration.",19893084_7,-1,-1,-1,9660,-1,0.99900347,0.0009965873
9661,myocardial hypertrophy,1,3,11,33,Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient: case report.,19917396_0,-1,-1,-1,9661,-1,0.0016859823,0.998314
9665,myocardial hypertrophy,4,6,29,51,Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation.,19917396_3,-1,-1,-1,9665,-1,0.002087276,0.9979127
9669,myocardial hypertrophy,18,20,120,142,"Initially, allograft rejection was feared; however, myocardial biopsy samples revealed only interstitial edema and mild myocardial hypertrophy; neither cellular nor humoral rejection was detected.",19917396_5,-1,-1,-1,9669,-1,0.0020686346,0.99793136
9672,Myocardial hypertrophy,0,2,0,22,"Myocardial hypertrophy completely resolved upon reducing the target concentration of tacrolimus and did not recur, as confirmed at echocardiography and myocardial biopsy.",19917396_7,-1,-1,-1,9672,-1,0.0022083572,0.99779165
9675,myocardial hypertrophy,8,10,53,75,"Thus, we conclude that tacrolimus induces reversible myocardial hypertrophy.",19917396_8,-1,-1,-1,9675,-1,0.0019704143,0.99802953
9681,cognitive dysfunction,18,20,115,136,BACKGROUND: Hypotension and a resultant decrease in cerebral blood flow have been implicated in the development of cognitive dysfunction.,19923525_1,-1,-1,-1,9681,-1,0.0012494118,0.99875057
9683,NIMO,7,8,42,46,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.,19923525_2,-1,-1,-1,9683,-1,0.99876,0.0012400446
9686,PA,6,7,32,34,METHODS: The passive avoidance (PA) paradigm was used to assess memory retention.,19923525_3,-1,-1,-1,9686,-1,0.2865054,0.71349466
9687,PA,1,2,4,6,"For PA training, latencies (seconds) were recorded for entry from a suspended platform into a Plexiglas tube where a shock was automatically delivered.",19923525_4,-1,-1,-1,9687,-1,0.9826282,0.01737174
9689,h,4,5,27,28,Latencies were recorded 48 h later for a testing trial.,19923525_5,-1,-1,-1,9689,-1,0.09672806,0.903272
9690,NTG,29,30,103,106,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9690,-1,0.9982089,0.0017911838
9691,NTG,36,37,138,141,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9691,-1,0.9982395,0.0017605327
9692,h,38,39,144,145,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9692,-1,0.34518263,0.65481734
9693,NTG,44,45,165,168,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9693,-1,0.9981211,0.0018789255
9694,NIMO,46,47,173,177,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9694,-1,0.99831486,0.001685156
9695,NIMO,55,56,198,202,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9695,-1,0.9984982,0.0015017499
9698,NTG,26,27,143,146,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,-1,-1,-1,9698,-1,0.9980411,0.0019588934
9699,NIMO,28,29,149,153,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,-1,-1,-1,9699,-1,0.9982186,0.0017814195
9700,NTG,32,33,166,169,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,-1,-1,-1,9700,-1,0.9978841,0.0021158908
9701,H,16,17,109,110,A Kruskal-Wallis 1-way analysis of variance indicated a significant difference among the 4 treatment groups (H = 15.34; P < 0.001).,19923525_10,-1,-1,-1,9701,-1,0.19734295,0.802657
9702,P,20,21,120,121,A Kruskal-Wallis 1-way analysis of variance indicated a significant difference among the 4 treatment groups (H = 15.34; P < 0.001).,19923525_10,-1,-1,-1,9702,-1,0.35833746,0.64166254
9703,NTG,16,17,82,85,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9703,-1,0.99883515,0.001164868
9704,n,18,19,87,88,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9704,-1,0.32300922,0.67699075
9705,NTG,23,24,98,101,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9705,-1,0.9987476,0.0012523559
9706,NIMO,25,26,104,108,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9706,-1,0.99828655,0.0017134438
9707,n,27,28,110,111,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9707,-1,0.3265937,0.6734063
9708,mm Hg,43,45,183,188,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9708,-1,0.061341625,0.9386584
9709,mm Hg,51,53,209,214,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9709,-1,0.07727794,0.92272204
9710,mm Hg,60,62,241,246,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9710,-1,0.067921974,0.932078
9711,mm Hg,68,70,267,272,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9711,-1,0.089154124,0.9108459
9712,NIMO,8,9,50,54,Mean arterial blood pressure in mice treated with NIMO alone decreased from 88.1 +/- 3.8 mm Hg to 80.0 +/- 2.9 mm Hg.,19923525_12,-1,-1,-1,9712,-1,0.9985518,0.0014482202
9713,mm Hg,16,18,89,94,Mean arterial blood pressure in mice treated with NIMO alone decreased from 88.1 +/- 3.8 mm Hg to 80.0 +/- 2.9 mm Hg.,19923525_12,-1,-1,-1,9713,-1,0.023217473,0.9767825
9714,mm Hg,23,25,111,116,Mean arterial blood pressure in mice treated with NIMO alone decreased from 88.1 +/- 3.8 mm Hg to 80.0 +/- 2.9 mm Hg.,19923525_12,-1,-1,-1,9714,-1,0.025406353,0.97459364
9715,P,7,8,57,58,The intergroup difference was statistically significant (P < 0.05).,19923525_13,-1,-1,-1,9715,-1,0.3438703,0.6561297
9716,mm Hg,8,10,36,41,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9716,-1,0.5009938,0.4990062
9717,mm Hg,16,18,62,67,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9717,-1,0.4632896,0.5367104
9718,NTG,21,22,79,82,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9718,-1,0.99702233,0.002977683
9719,mm Hg,29,31,111,116,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9719,-1,0.4138173,0.5861827
9720,mm Hg,37,39,137,142,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9720,-1,0.41807765,0.5819223
9721,NTG,42,43,154,157,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9721,-1,0.9969574,0.0030425524
9722,NIMO,44,45,160,164,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9722,-1,0.9981071,0.0018928543
9723,PA,4,5,17,19,"CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect.",19923525_16,-1,-1,-1,9723,-1,0.99521834,0.0047816215
9724,NTG,11,12,57,60,"CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect.",19923525_16,-1,-1,-1,9724,-1,0.9985185,0.0014815214
9726,NIMO,0,1,0,4,NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.,19923525_17,-1,-1,-1,9726,-1,0.9983973,0.0016027229
9727,NTG,11,12,78,81,NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.,19923525_17,-1,-1,-1,9727,-1,0.9985238,0.0014762974
9729,NIMO,4,5,23,27,"The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension, because there were no differences in the PbtO(2) indices among groups.",19923525_18,-1,-1,-1,9729,-1,0.998524,0.0014759542
9735,peptic ulcer disease,12,15,64,84,"It has been shown to be extremely effective in the treatment of peptic ulcer disease, reflux esophagitis, and the Zollinger-Ellison syndrome.",1992636_2,-1,-1,-1,9735,-1,0.0014630118,0.99853694
9736,reflux esophagitis,16,18,86,104,"It has been shown to be extremely effective in the treatment of peptic ulcer disease, reflux esophagitis, and the Zollinger-Ellison syndrome.",1992636_2,-1,-1,-1,9736,-1,0.0012263908,0.99877363
9741,lethargy,5,6,32,40,"The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with omeprazole.",1992636_5,-1,-1,-1,9741,-1,0.0014416443,0.99855834
9742,shortness of breath,8,11,46,65,"The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with omeprazole.",1992636_5,-1,-1,-1,9742,-1,0.0024299303,0.9975701
9749,Parkinson's disease,12,15,87,106,Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease.,19940105_0,-1,-1,-1,9749,-1,0.0020499357,0.99795014
9751,Parkinson's disease,23,26,174,193,Metabotropic glutamate (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).,19940105_1,-1,-1,-1,9751,-1,0.003038962,0.99696106
9752,PD,27,28,195,197,Metabotropic glutamate (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).,19940105_1,-1,-1,-1,9752,-1,0.0026063393,0.9973936
9753,PD,28,29,163,165,"Among the eight mGlu receptor subtypes, mGlu7 receptor is prominently expressed in the basal ganglia, but its role in restoring motor function in animal models of PD is not known.",19940105_2,-1,-1,-1,9753,-1,0.002032927,0.99796706
9754,"N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride",3,7,15,66,"The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD.",19940105_3,-1,-1,-1,9754,-1,0.9979715,0.0020285514
9755,AMN082,8,9,68,74,"The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD.",19940105_3,-1,-1,-1,9755,-1,0.99864703,0.0013530229
9756,PD,28,29,185,187,"The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD.",19940105_3,-1,-1,-1,9756,-1,0.0023642653,0.9976357
9757,AMN082,20,21,88,94,"Here, we show that oral (5 mg/kg) or intrastriatal administration (0.1 and 0.5 nmol) of AMN082 reverses haloperidol-induced catalepsy in rats.",19940105_4,-1,-1,-1,9757,-1,0.9990576,0.000942365
9759,AMN082,0,1,0,6,AMN082 (2.5 and 5 mg/kg) reduces apomorphine-induced rotations in unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats.,19940105_5,-1,-1,-1,9759,-1,0.9991359,0.00086410745
9762,PD,13,14,76,78,"In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.",19940105_6,-1,-1,-1,9762,-1,0.0022924894,0.9977075
9763,AMN082,18,19,97,103,"In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.",19940105_6,-1,-1,-1,9763,-1,0.9990978,0.00090221665
9764,AMN082,3,4,13,19,"In addition, AMN082 reduces the duration of haloperidol-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.",19940105_7,-1,-1,-1,9764,-1,0.99906725,0.0009327226
9766,AMN082,3,4,16,22,Higher doses of AMN082 (10 and 20 mg/kg p.o.) have no effect on the same models of PD.,19940105_8,-1,-1,-1,9766,-1,0.99894005,0.0010599504
9767,PD,20,21,83,85,Higher doses of AMN082 (10 and 20 mg/kg p.o.) have no effect on the same models of PD.,19940105_8,-1,-1,-1,9767,-1,0.00223716,0.9977628
9768,motor dysfunction,10,12,74,91,Overall these findings suggest that mGlu7 receptor activation can reverse motor dysfunction associated with reduced dopamine activity.,19940105_9,-1,-1,-1,9768,-1,0.0015642839,0.9984357
9771,coronary artery spasm,6,9,53,74,Sorafenib-induced acute myocardial infarction due to coronary artery spasm.,19944333_0,-1,-1,-1,9771,-1,0.0013566396,0.99864334
9772,renal cell carcinoma,5,8,32,52,A 65-year-old man with advanced renal cell carcinoma was admitted due to continuing chest pain at rest.,19944333_1,-1,-1,-1,9772,-1,0.0031988674,0.99680114
9773,chest pain,13,15,84,94,A 65-year-old man with advanced renal cell carcinoma was admitted due to continuing chest pain at rest.,19944333_1,-1,-1,-1,9773,-1,0.0015085507,0.9984914
9775,myocardial infarction,5,7,39,60,He was diagnosed with non-ST-elevation myocardial infarction by laboratory data and electrocardiogram.,19944333_3,-1,-1,-1,9775,-1,0.0014284865,0.9985715
9776,subendocardial infarction,7,9,54,79,Enhanced heart magnetic resonance imaging also showed subendocardial infarction.,19944333_4,-1,-1,-1,9776,-1,0.002613551,0.9973864
9777,stenosis,5,6,22,30,"However, there was no stenosis in coronary arteries on angiography.",19944333_5,-1,-1,-1,9777,-1,0.002180128,0.9978199
9778,Coronary artery spasm,0,3,0,21,Coronary artery spasm was induced by a provocative test.,19944333_6,-1,-1,-1,9778,-1,0.0024080593,0.997592
9780,nitrates,9,10,68,76,"Cessation of sorafenib and administration of Ca-channel blocker and nitrates ameliorated his symptoms, but relapse occurred after resumption of sorafenib.",19944333_7,-1,-1,-1,9780,-1,0.9988927,0.0011073062
9782,nicorandil,3,4,17,27,Addition of oral nicorandil reduced his symptoms and maintained stable angina status.,19944333_8,-1,-1,-1,9782,-1,0.99915445,0.0008456104
9783,angina,10,11,71,77,Addition of oral nicorandil reduced his symptoms and maintained stable angina status.,19944333_8,-1,-1,-1,9783,-1,0.0016474426,0.9983525
9784,coronary artery spasm,7,10,46,67,We report the first case of sorafenib-induced coronary artery spasm.,19944333_9,-1,-1,-1,9784,-1,0.0016670385,0.99833304
9786,coronary artery spasm,16,19,85,106,"On the other hand, the Rho/ROCK pathway has an important role in the pathogenesis of coronary artery spasm.",19944333_11,-1,-1,-1,9786,-1,0.0018741239,0.99812585
9788,Tacrine,0,1,0,7,"Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.",19944736_2,-1,-1,-1,9788,-1,0.9991835,0.00081652415
9789,LiCl,4,5,25,29,"Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.",19944736_2,-1,-1,-1,9789,-1,0.9990939,0.0009061063
9791,hippocampal damage,13,15,99,117,"Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.",19944736_2,-1,-1,-1,9791,-1,0.00255257,0.9974475
9792,tacrine,16,17,100,107,"The toxic effects of tacrine-loaded poly-L-lactid acid nanoparticles (5mg/kg), a saline solution of tacrine (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i.p.",19944736_3,-1,-1,-1,9792,-1,0.9992219,0.00077812164
9794,tacrine,27,28,175,182,"In addition, tacrine-loaded nanoparticles administration induced damage of neuronal cells in CA1 field of the hippocampus in all treated animals, while the saline solution of tacrine only in 60% of animals.",19944736_6,-1,-1,-1,9794,-1,0.9991929,0.0008070894
9804,mg,10,11,61,63,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,-1,-1,-1,9804,-1,0.9883632,0.011636761
9806,mg,18,19,90,92,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,-1,-1,-1,9806,-1,0.98427767,0.015722353
9808,mg,29,30,142,144,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,-1,-1,-1,9808,-1,0.98691005,0.013090009
9810,mg,39,40,188,190,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,-1,-1,-1,9810,-1,0.9806575,0.01934255
9811,MAP,48,49,230,233,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,-1,-1,-1,9811,-1,0.070233345,0.9297667
9812,MAP,6,7,17,20,"Heart rate (HR), MAP, stroke volume (SV), cardiac output (CO), and frontal lobe oxygenation (S(c)O(2)) were registered.",19957053_4,-1,-1,-1,9812,-1,0.011166589,0.9888334
9814,CO,17,18,58,60,"Heart rate (HR), MAP, stroke volume (SV), cardiac output (CO), and frontal lobe oxygenation (S(c)O(2)) were registered.",19957053_4,-1,-1,-1,9814,-1,0.027487217,0.9725127
9815,MAP,11,12,63,66,"RESULTS: Induction of anesthesia was followed by a decrease in MAP, HR, SV, and CO concomitant with an elevation in S(c)O(2).",19957053_5,-1,-1,-1,9815,-1,0.48627493,0.51372504
9816,CO,18,19,80,82,"RESULTS: Induction of anesthesia was followed by a decrease in MAP, HR, SV, and CO concomitant with an elevation in S(c)O(2).",19957053_5,-1,-1,-1,9816,-1,0.88563025,0.11436983
9818,MAP,5,6,39,42,"After administration of phenylephrine, MAP increased (51 +/- 12 to 81 +/- 13 mmHg; P < 0.001; mean +/- SD).",19957053_6,-1,-1,-1,9818,-1,0.35286677,0.64713323
9819,P,19,20,83,84,"After administration of phenylephrine, MAP increased (51 +/- 12 to 81 +/- 13 mmHg; P < 0.001; mean +/- SD).",19957053_6,-1,-1,-1,9819,-1,0.47689712,0.52310294
9820,SD,26,27,103,105,"After administration of phenylephrine, MAP increased (51 +/- 12 to 81 +/- 13 mmHg; P < 0.001; mean +/- SD).",19957053_6,-1,-1,-1,9820,-1,0.27238864,0.72761136
9821,P,24,25,68,69,"However, a 14% (from 70 +/- 8% to 60 +/- 7%) reduction in S(c)O(2) (P < 0.05) followed with no change in CO (3.7 +/- 1.1 to 3.4 +/- 0.9 l min(-1)).",19957053_7,-1,-1,-1,9821,-1,0.442212,0.5577881
9822,CO,33,34,105,107,"However, a 14% (from 70 +/- 8% to 60 +/- 7%) reduction in S(c)O(2) (P < 0.05) followed with no change in CO (3.7 +/- 1.1 to 3.4 +/- 0.9 l min(-1)).",19957053_7,-1,-1,-1,9822,-1,0.9917325,0.008267551
9824,MAP,10,11,61,64,"The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 l min(-1)), and preserved S(c)O(2).",19957053_8,-1,-1,-1,9824,-1,0.7869523,0.21304765
9825,mmHg,21,22,87,91,"The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 l min(-1)), and preserved S(c)O(2).",19957053_8,-1,-1,-1,9825,-1,0.048264068,0.9517359
9826,P,23,24,93,94,"The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 l min(-1)), and preserved S(c)O(2).",19957053_8,-1,-1,-1,9826,-1,0.4574976,0.5425024
9827,CO,29,30,114,116,"The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 l min(-1)), and preserved S(c)O(2).",19957053_8,-1,-1,-1,9827,-1,0.9904619,0.0095380545
9831,CO,31,32,214,216,CONCLUSIONS: The utilization of phenylephrine to correct hypotension induced by anesthesia has a negative impact on S(c)O(2) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO.,19957053_9,-1,-1,-1,9831,-1,0.9937733,0.0062267105
9832,tranexamic Acid,1,3,10,25,High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.,19996135_0,-1,-1,-1,9832,-1,0.9991333,0.0008667211
9834,convulsive seizures,17,19,100,119,"BACKGROUND: In 2 separate centers, we observed a notable increase in the incidence of postoperative convulsive seizures from 1.3% to 3.8% in patients having undergone major cardiac surgical procedures.",19996135_1,-1,-1,-1,9834,-1,0.0012016629,0.9987984
9835,tranexamic acid,11,13,74,89,These events were temporally coincident with the initial use of high-dose tranexamic acid (TXA) therapy after withdrawal of aprotinin from general clinical usage.,19996135_2,-1,-1,-1,9835,-1,0.9992975,0.00070243847
9836,TXA,14,15,91,94,These events were temporally coincident with the initial use of high-dose tranexamic acid (TXA) therapy after withdrawal of aprotinin from general clinical usage.,19996135_2,-1,-1,-1,9836,-1,0.99916565,0.00083441776
9837,TXA,19,20,115,118,The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between TXA usage and seizures after cardiac surgery.,19996135_3,-1,-1,-1,9837,-1,0.9990017,0.0009983458
9840,cerebral ischemic injury,13,16,68,92,"RESULTS: Twenty-one of the 24 patients did not have evidence of new cerebral ischemic injury, but seizures were likely due to ischemic brain injury in 3 patients.",19996135_6,-1,-1,-1,9840,-1,0.0012096674,0.9987903
9842,ischemic brain injury,23,26,126,147,"RESULTS: Twenty-one of the 24 patients did not have evidence of new cerebral ischemic injury, but seizures were likely due to ischemic brain injury in 3 patients.",19996135_6,-1,-1,-1,9842,-1,0.0011411216,0.9988589
9844,permanent neurological abnormalities,7,10,40,76,All patients with seizures did not have permanent neurological abnormalities.,19996135_7,-1,-1,-1,9844,-1,0.0014713331,0.9985286
9846,TXA,9,10,53,56,"All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg/kg, had a mean age of 69.9 years, and 21 of 24 had undergone open chamber rather than coronary bypass procedures.",19996135_8,-1,-1,-1,9846,-1,0.9989913,0.0010087246
9847,ischemic,4,5,21,29,"No evidence of brain ischemic, metabolic, or hyperthermia-induced causes for their seizures was apparent.",19996135_10,-1,-1,-1,9847,-1,0.0014906015,0.99850935
9849,TXA,9,10,54,57,CONCLUSION: Our results suggest that use of high-dose TXA in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical seizures in susceptible patients.,19996135_11,-1,-1,-1,9849,-1,0.99896073,0.0010392716
9854,Direct thrombin inhibitors,2,5,12,38,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,-1,-1,9854,-1,0.99395907,0.0060409824
9856,HIT,23,24,160,163,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,-1,-1,9856,-1,0.0012897768,0.9987103
9857,HIT,26,27,168,171,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,-1,-1,9857,-1,0.0012512923,0.99874866
9859,HITT,30,31,189,193,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,-1,-1,9859,-1,0.0017849145,0.9982151
9860,critically ill,7,9,39,53,"In the following report, a 65-year-old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation.",20003049_2,-1,-1,-1,9860,-1,0.004576208,0.99542385
9861,HITT,15,16,90,94,"In the following report, a 65-year-old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation.",20003049_2,-1,-1,-1,9861,-1,0.0020709443,0.9979291
9863,Factor VIIa,35,37,195,206,"The patient required massive transfusion support (55 units of red blood cells, 42 units of fresh-frozen plasma, 40 units of cryoprecipitate, 40 units of platelets, and three doses of recombinant Factor VIIa) for severe intraoperative and postoperative bleeding.",20003049_3,-1,-1,-1,9863,-1,0.99739444,0.0026055945
9864,postoperative bleeding,42,44,238,260,"The patient required massive transfusion support (55 units of red blood cells, 42 units of fresh-frozen plasma, 40 units of cryoprecipitate, 40 units of platelets, and three doses of recombinant Factor VIIa) for severe intraoperative and postoperative bleeding.",20003049_3,-1,-1,-1,9864,-1,0.0022391025,0.9977609
9868,hepatic impairment,54,56,265,283,"RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with hepatic impairment]).",20003049_5,-1,-1,-1,9868,-1,0.0021298635,0.9978701
9875,psychotropic drugs,8,10,75,93,Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs.,2004_0,-1,-1,-1,9875,-1,0.99842936,0.001570612
9876,psychotropic drugs,12,14,90,108,"Eight patients had cardiac manifestations that were life-threatening in five while taking psychotropic drugs, either phenothiazines or tricyclic antidepressants.",2004_1,-1,-1,-1,9876,-1,0.99896896,0.0010310997
9877,phenothiazines,16,17,117,131,"Eight patients had cardiac manifestations that were life-threatening in five while taking psychotropic drugs, either phenothiazines or tricyclic antidepressants.",2004_1,-1,-1,-1,9877,-1,0.9991202,0.0008797805
9879,Mellaril,8,9,53,61,"Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.",2004_2,-1,-1,-1,9879,-1,0.99869895,0.0013010753
9880,thioridazine,10,11,63,75,"Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.",2004_2,-1,-1,-1,9880,-1,0.99925226,0.00074767513
9882,Supraventricular tachycardia,0,2,0,28,Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).,2004_3,-1,-1,-1,9882,-1,0.0016424935,0.9983575
9883,Thorazine,7,8,64,73,Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).,2004_3,-1,-1,-1,9883,-1,0.9989913,0.0010087173
9885,Aventyl,0,1,0,7,Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.,2004_4,-1,-1,-1,9885,-1,0.9992495,0.00075046916
9886,nortriptyline,2,3,9,22,Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.,2004_4,-1,-1,-1,9886,-1,0.9993161,0.0006839484
9887,Elavil,5,6,28,34,Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.,2004_4,-1,-1,-1,9887,-1,0.99927,0.00072995323
9889,left bundle branch block,11,15,65,89,Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.,2004_4,-1,-1,-1,9889,-1,0.00499032,0.99500966
9892,electric shock,13,15,103,117,The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.,2004_6,-1,-1,-1,9892,-1,0.0013304348,0.9986696
9894,tachyarrhythmias,1,2,4,20,The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped.,2004_7,-1,-1,-1,9894,-1,0.0012456499,0.9987544
9895,heart disease,18,20,92,105,Five of the eight patients were 50 years of age or younger; only one clearly had antecedent heart disease.,2004_8,-1,-1,-1,9895,-1,0.0018673164,0.99813277
9897,heart disease,10,12,69,82,Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs.,2004_9,-1,-1,-1,9897,-1,0.0015254136,0.99847454
9898,psychotropic drugs,19,21,132,150,Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs.,2004_9,-1,-1,-1,9898,-1,0.9988084,0.0011916347
9899,cardiac complications,11,13,66,87,A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs.,2004_10,-1,-1,-1,9899,-1,0.0014939238,0.99850607
9900,phenothiazines,16,17,110,124,A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs.,2004_10,-1,-1,-1,9900,-1,0.99921644,0.0007834959
9903,immunodeficient,10,11,89,104,Sensitivity of erythroid progenitor colonies to erythropoietin in azidothymidine treated immunodeficient mice.,2004015_0,-1,-1,-1,9903,-1,0.0044203107,0.99557966
9904,anaemia,1,2,4,11,The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.,2004015_1,-1,-1,-1,9904,-1,0.001332027,0.99866796
9905,3'-azido-3'dideoxythymidine,4,5,23,50,The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.,2004015_1,-1,-1,-1,9905,-1,0.9982566,0.0017434036
9906,AZT,6,7,52,55,The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.,2004015_1,-1,-1,-1,9906,-1,0.99867886,0.0013210758
9907,AIDS,7,8,31,35,"We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).",2004015_2,-1,-1,-1,9907,-1,0.0015497996,0.99845016
9909,leukaemia,17,18,89,98,"We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).",2004015_2,-1,-1,-1,9909,-1,0.002057576,0.9979424
9910,anaemia,27,28,141,148,"We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).",2004015_2,-1,-1,-1,9910,-1,0.0013004843,0.99869955
9911,AZT,11,12,58,61,Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.,2004015_3,-1,-1,-1,9911,-1,0.99880946,0.001190538
9912,drinking water,14,16,71,85,Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.,2004015_3,-1,-1,-1,9912,-1,0.972583,0.027417047
9913,AZT,0,1,0,3,"AZT produced anaemia in both groups, in a dose-dependent fashion.",2004015_4,-1,-1,-1,9913,-1,0.9986451,0.0013549132
9914,anaemia,2,3,13,20,"AZT produced anaemia in both groups, in a dose-dependent fashion.",2004015_4,-1,-1,-1,9914,-1,0.0014269699,0.99857306
9915,anaemia,2,3,12,19,"Despite the anaemia, the number of splenic and bone marrow BFU-e in AZT treated mice increased up to five-fold over levels observed in infected untreated animals after 15 d of treatment.",2004015_5,-1,-1,-1,9915,-1,0.0015325915,0.9984674
9916,AZT,13,14,68,71,"Despite the anaemia, the number of splenic and bone marrow BFU-e in AZT treated mice increased up to five-fold over levels observed in infected untreated animals after 15 d of treatment.",2004015_5,-1,-1,-1,9916,-1,0.9987728,0.0012271373
9917,AZT,18,19,113,116,"Colony formation by splenic and bone marrow BFUe was stimulated at lower concentrations of EPO in mice receiving AZT for 15 d than for infected, untreated mice.",2004015_6,-1,-1,-1,9917,-1,0.99905235,0.0009476891
9918,AZT,8,9,42,45,The mean plasma levels of EPO observed in AZT treated mice,2004015_8,-1,-1,-1,9918,-1,0.9981856,0.0018144094
9919,anaemia,6,7,35,42,were appropriate for the degree of anaemia observed when compared with phenylhydrazine (PHZ) treated mice.,2004015_9,-1,-1,-1,9919,-1,0.0012737088,0.9987263
9920,phenylhydrazine,11,12,71,86,were appropriate for the degree of anaemia observed when compared with phenylhydrazine (PHZ) treated mice.,2004015_9,-1,-1,-1,9920,-1,0.99918777,0.0008122545
9921,PHZ,13,14,88,91,were appropriate for the degree of anaemia observed when compared with phenylhydrazine (PHZ) treated mice.,2004015_9,-1,-1,-1,9921,-1,0.9987908,0.0012091703
9922,AZT,15,16,97,100,The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia.,2004015_10,-1,-1,-1,9922,-1,0.9986571,0.0013428874
9923,PHZ,17,18,105,108,The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia.,2004015_10,-1,-1,-1,9923,-1,0.9983876,0.0016124856
9924,anaemia,24,25,146,153,The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia.,2004015_10,-1,-1,-1,9924,-1,0.0013076863,0.99869233
9925,reticulocytosis,2,3,9,24,"However, reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice.",2004015_11,-1,-1,-1,9925,-1,0.001538203,0.99846184
9926,anaemia,9,10,61,68,"However, reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice.",2004015_11,-1,-1,-1,9926,-1,0.0012700767,0.9987299
9927,AZT,12,13,81,84,"However, reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice.",2004015_11,-1,-1,-1,9927,-1,0.9983777,0.0016223446
9928,peripheral anaemia,1,3,12,30,AZT-induced peripheral anaemia in the face of increased numbers of BFU-e and increased levels of plasma EPO suggest a lesion in terminal differentiation.,2004015_12,-1,-1,-1,9928,-1,0.0014564494,0.9985436
9929,postoperative delirium,9,11,63,85,Sedation depth during spinal anesthesia and the development of postoperative delirium in elderly patients undergoing hip fracture repair.,20042557_0,-1,-1,-1,9929,-1,0.0015943184,0.99840575
9930,hip fracture,15,17,117,129,Sedation depth during spinal anesthesia and the development of postoperative delirium in elderly patients undergoing hip fracture repair.,20042557_0,-1,-1,-1,9930,-1,0.0047593177,0.9952407
9931,hip fracture,13,15,100,112,OBJECTIVE: To determine whether limiting intraoperative sedation depth during spinal anesthesia for hip fracture repair in elderly patients can decrease the prevalence of postoperative delirium.,20042557_1,-1,-1,-1,9931,-1,0.003877144,0.9961229
9932,postoperative delirium,24,26,171,193,OBJECTIVE: To determine whether limiting intraoperative sedation depth during spinal anesthesia for hip fracture repair in elderly patients can decrease the prevalence of postoperative delirium.,20042557_1,-1,-1,-1,9932,-1,0.0016971487,0.9983028
9935,hip fracture,33,35,207,219,"PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation.",20042557_2,-1,-1,-1,9935,-1,0.0074342964,0.99256575
9937,Postoperative delirium,0,2,0,22,Postoperative delirium was assessed as defined by Diagnostic and Statistical Manual of Mental Disorders (Third Edition Revised) criteria using the Confusion Assessment Method beginning at any time from the second day after surgery.,20042557_4,-1,-1,-1,9937,-1,0.0021228127,0.99787724
9938,Mental Disorders,12,14,87,103,Postoperative delirium was assessed as defined by Diagnostic and Statistical Manual of Mental Disorders (Third Edition Revised) criteria using the Confusion Assessment Method beginning at any time from the second day after surgery.,20042557_4,-1,-1,-1,9938,-1,0.00974817,0.9902518
9940,postoperative delirium,3,5,18,40,"The prevalence of postoperative delirium was significantly lower in the light sedation group (11/57 [19%] vs 23/57 [40%] in the deep sedation group; P=.02), indicating that 1 incident of delirium will be prevented for every 4.7 patients treated with light sedation.",20042557_6,-1,-1,-1,9940,-1,0.0017706031,0.99822944
9941,P=.02,31,32,149,154,"The prevalence of postoperative delirium was significantly lower in the light sedation group (11/57 [19%] vs 23/57 [40%] in the deep sedation group; P=.02), indicating that 1 incident of delirium will be prevented for every 4.7 patients treated with light sedation.",20042557_6,-1,-1,-1,9941,-1,0.23984976,0.76015025
9943,SD,4,5,13,15,The mean +/- SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group (0.5+/-1.5 days vs 1.4+/-4.0 days; P=.01).,20042557_7,-1,-1,-1,9943,-1,0.117316164,0.8826839
9945,P=.01,32,33,171,176,The mean +/- SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group (0.5+/-1.5 days vs 1.4+/-4.0 days; P=.01).,20042557_7,-1,-1,-1,9945,-1,0.296842,0.70315796
9947,postoperative delirium,12,14,75,97,CONCLUSION: The use of light propofol sedation decreased the prevalence of postoperative delirium by 50% compared with deep sedation.,20042557_8,-1,-1,-1,9947,-1,0.0016554426,0.99834454
9948,postoperative delirium,18,20,118,140,"Limiting depth of sedation during spinal anesthesia is a simple, safe, and cost-effective intervention for preventing postoperative delirium in elderly patients that could be widely and readily adopted.",20042557_9,-1,-1,-1,9948,-1,0.0015630415,0.998437
9954,SD,20,21,123,125,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,-1,-1,9954,-1,0.001464317,0.99853563
9956,SSRI,30,31,180,184,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,-1,-1,9956,-1,0.99852955,0.001470434
9957,SD,34,35,190,192,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,-1,-1,9957,-1,0.0014323028,0.9985677
9958,SSRIs,40,41,220,225,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,-1,-1,9958,-1,0.99827445,0.0017255238
9959,SSRI,18,19,106,110,PATIENTS AND METHODS: The randomized sample consisted of 234 euthymic men who were receiving some type of SSRI.,20067456_2,-1,-1,-1,9959,-1,0.9985928,0.001407242
9961,mg,10,11,52,54,"The men were randomly assigned to bupropion SR (150 mg twice daily, 117) or placebo (twice daily, 117) for 12 weeks.",20067456_3,-1,-1,-1,9961,-1,0.9940149,0.0059850593
9962,Erectile Dysfunction,37,39,212,232,"Efficacy was evaluated using the Clinical Global Impression-Sexual Function (CGI-SF; the primary outcome measure), the International Index of Erectile Function (IIEF), Arizona Sexual Experience Scale (ASEX), and Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) (secondary outcome measures).",20067456_4,-1,-1,-1,9962,-1,0.00415349,0.99584657
9963,sd,11,12,48,50,"RESULTS: After 12 weeks of treatment, the mean (sd) scores for CGI-SF were significantly lower, i.e. better, in patients on bupropion SR, at 2.4 (1.2), than in the placebo group, at 3.9 (1.1) (P= 0.01).",20067456_6,-1,-1,-1,9963,-1,0.16163519,0.83836484
9965,P=,47,48,193,195,"RESULTS: After 12 weeks of treatment, the mean (sd) scores for CGI-SF were significantly lower, i.e. better, in patients on bupropion SR, at 2.4 (1.2), than in the placebo group, at 3.9 (1.1) (P= 0.01).",20067456_6,-1,-1,-1,9965,-1,0.32838833,0.67161167
9967,P=,20,21,94,96,"Men who received bupropion had a significant increase in the total IIEF score (54.4% vs 1.2%; P= 0.003), and in the five different domains of the IIEF.",20067456_7,-1,-1,-1,9967,-1,0.29212135,0.70787865
9969,P=,29,30,133,135,"Total ASEX scores were significantly lower, i.e. better, among men who received bupropion than placebo, at 15.5 (4.3) vs 21.5 (4.7) (P= 0.002).",20067456_8,-1,-1,-1,9969,-1,0.2827103,0.7172897
9971,P=,21,22,91,93,The EDITS scores were 67.4 (10.2) for the bupropion and 36.3 (11.7) for the placebo group (P= 0.001).,20067456_9,-1,-1,-1,9971,-1,0.34069562,0.6593044
9972,P=,9,10,49,51,The ASEX score and CGI-SF score were correlated (P= 0.003).,20067456_10,-1,-1,-1,9972,-1,0.2215142,0.7784858
9973,SD,15,16,97,99,"In linear regression analyses the CGI-SF score was not affected significantly by the duration of SD, type of SSRI used and age.",20067456_11,-1,-1,-1,9973,-1,0.0026347372,0.9973653
9974,SSRI,19,20,109,113,"In linear regression analyses the CGI-SF score was not affected significantly by the duration of SD, type of SSRI used and age.",20067456_11,-1,-1,-1,9974,-1,0.99835336,0.0016467184
9976,SD,9,10,58,60,CONCLUSIONS: Bupropion is an effective treatment for male SD induced by SSRIs.,20067456_12,-1,-1,-1,9976,-1,0.0018783959,0.99812156
9977,SSRIs,12,13,72,77,CONCLUSIONS: Bupropion is an effective treatment for male SD induced by SSRIs.,20067456_12,-1,-1,-1,9977,-1,0.99874,0.0012600123
9983,status epilepticus,19,21,126,144,BMCs obtained from green fluorescent protein (GFP) transgenic mice or rats were transplanted intravenously after induction of status epilepticus (SE).,20080419_2,-1,-1,-1,9983,-1,0.0016715681,0.9983284
9984,SE,22,23,146,148,BMCs obtained from green fluorescent protein (GFP) transgenic mice or rats were transplanted intravenously after induction of status epilepticus (SE).,20080419_2,-1,-1,-1,9984,-1,0.0018368933,0.99816316
9985,Spontaneous recurrent seizures,0,3,0,30,Spontaneous recurrent seizures (SRS) were monitored using Racine's seizure severity scale.,20080419_3,-1,-1,-1,9985,-1,0.0017517937,0.9982482
9986,SRS,4,5,32,35,Spontaneous recurrent seizures (SRS) were monitored using Racine's seizure severity scale.,20080419_3,-1,-1,-1,9986,-1,0.0020229726,0.9979771
9989,SRS,11,12,72,75,"All of the rats in the saline-treated epileptic control group developed SRS, whereas none of the BMC-treated epileptic animals had seizures in the short term (15 days after transplantation), regardless of the BMC source.",20080419_4,-1,-1,-1,9989,-1,0.0018816674,0.9981184
10001,daytime sleepiness,19,21,112,130,OBJECTIVE: The purpose of the present study was to determine the effect of morning-dosed modafinil on sleep and daytime sleepiness in chronic cocaine users.,20080983_1,-1,-1,-1,10001,-1,0.0020513816,0.9979486
10004,mg,13,14,95,97,"METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.",20080983_2,-1,-1,-1,10004,-1,0.99448556,0.0055144173
10005,N=10,15,16,99,103,"METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.",20080983_2,-1,-1,-1,10005,-1,0.4054492,0.5945508
10006,N=10,21,22,118,122,"METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.",20080983_2,-1,-1,-1,10006,-1,0.50214,0.49786004
10012,daytime sleepiness,25,27,159,177,"Modafinil was associated with increased daytime sleep latency, as measured by the Multiple Sleep Latency Test, and a nearly significant decrease in subjective daytime sleepiness.",20080983_10,-1,-1,-1,10012,-1,0.0017455611,0.9982545
10014,daytime sleepiness,14,16,108,126,"CONCLUSIONS: Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.",20080983_11,-1,-1,-1,10014,-1,0.0019254899,0.99807453
10016,cocaine dependence,9,11,50,68,These effects may be relevant in the treatment of cocaine dependence.,20080983_12,-1,-1,-1,10016,-1,0.38927764,0.61072236
10017,Midazolan,13,14,69,78,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,-1,-1,-1,10017,-1,0.9992268,0.0007732085
10018,MZ,15,16,80,82,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,-1,-1,-1,10018,-1,0.9986909,0.0013090532
10019,Flumazenil,18,19,88,98,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,-1,-1,-1,10019,-1,0.9992398,0.0007602341
10020,FL,20,21,100,102,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,-1,-1,-1,10020,-1,0.996779,0.003221002
10021,MZ,11,12,68,70,METHOD: prospective study with 137 patients that underwent TEE with MZ associated to moderate sedation.,20084309_3,-1,-1,-1,10021,-1,0.9946175,0.0053824997
10022,MZ,14,15,90,92,"We analyzed the following events: complications related with the topical anesthesia, with MZ use and with the procedure.",20084309_4,-1,-1,-1,10022,-1,0.9986708,0.0013291895
10024,myocardiopathy,21,22,108,122,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,-1,-1,10024,-1,0.0016358779,0.99836415
10025,MP,23,24,124,126,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,-1,-1,10025,-1,0.0018967737,0.99810314
10027,MR,34,35,173,175,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,-1,-1,10027,-1,0.0017518221,0.9982482
10028,MZ,38,39,185,187,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,-1,-1,10028,-1,0.9987772,0.0012227386
10029,MZ,4,5,18,20,"The mean doses of MZ and FL were 4.3+/-1.9 mg and 0.28+/-0.2 mg, respectively.",20084309_7,-1,-1,-1,10029,-1,0.9932956,0.0067043873
10030,FL,6,7,25,27,"The mean doses of MZ and FL were 4.3+/-1.9 mg and 0.28+/-0.2 mg, respectively.",20084309_7,-1,-1,-1,10030,-1,0.8264402,0.1735598
10031,mg,9,10,43,45,"The mean doses of MZ and FL were 4.3+/-1.9 mg and 0.28+/-0.2 mg, respectively.",20084309_7,-1,-1,-1,10031,-1,0.9703527,0.02964729
10032,mg,12,13,61,63,"The mean doses of MZ and FL were 4.3+/-1.9 mg and 0.28+/-0.2 mg, respectively.",20084309_7,-1,-1,-1,10032,-1,0.9713309,0.028669037
10035,upper airway obstruction,27,30,115,139,Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.,20084309_9,-1,-1,-1,10035,-1,0.002116076,0.99788386
10037,MZ,44,45,200,202,Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.,20084309_9,-1,-1,-1,10037,-1,0.9986512,0.001348849
10039,MR,6,7,45,47,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,-1,-1,-1,10039,-1,0.0014250124,0.998575
10040,MP,8,9,49,51,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,-1,-1,-1,10040,-1,0.0015100369,0.99849
10041,MZ,17,18,79,81,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,-1,-1,-1,10041,-1,0.99874735,0.0012526548
10042,mg,21,22,85,87,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,-1,-1,-1,10042,-1,0.9871476,0.01285232
10043,p<0.001,28,29,118,125,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,-1,-1,-1,10043,-1,0.32028833,0.6797117
10044,MP,10,11,34,36,"The EF was 40%, in the group with MP and 44% in the group with severe MR and it can be a factor associated with clinical events in the last group.",20084309_12,-1,-1,-1,10044,-1,0.001841559,0.9981584
10045,MR,19,20,70,72,"The EF was 40%, in the group with MP and 44% in the group with severe MR and it can be a factor associated with clinical events in the last group.",20084309_12,-1,-1,-1,10045,-1,0.0015335813,0.9984665
10046,methylergonovine,6,7,49,65,Effect of direct intracoronary administration of methylergonovine in patients with and without variant angina.,2008831_0,-1,-1,-1,10046,-1,0.9991473,0.00085274666
10048,methylergonovine,6,7,47,63,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,-1,-1,-1,10048,-1,0.999164,0.00083607365
10050,chest pain,20,22,142,152,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,-1,-1,-1,10050,-1,0.0013358078,0.99866414
10051,angina pectoris,26,28,175,190,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,-1,-1,-1,10051,-1,0.0010814052,0.99891865
10052,Methylergonovine,0,1,0,16,Methylergonovine was administered continuously at a rate of 10 micrograms/min up to 50 micrograms.,2008831_2,-1,-1,-1,10052,-1,0.9991648,0.000835169
10055,SD,25,26,114,116,"In all patients with variant angina, coronary spasm was provoked at a mean dose of 28 +/- 13 micrograms (mean +/- SD).",2008831_3,-1,-1,-1,10055,-1,0.270852,0.729148
10056,ischemic,5,6,29,37,In the control group neither ischemic ST change nor localized spasm occurred.,2008831_4,-1,-1,-1,10056,-1,0.0019070002,0.99809295
10059,methylergonovine,19,20,117,133,"These results suggest that spasm provocation tests, which use an intracoronary injection of a relatively low dose of methylergonovine, have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries.",2008831_7,-1,-1,-1,10059,-1,0.99921334,0.0007866954
10064,cardiac dysrhythmias,23,25,155,175,"BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, hallucinations, and violent behavior.",20098969_2,-1,-1,-1,10064,-1,0.0013969843,0.99860305
10067,violent behavior,31,33,211,227,"BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, hallucinations, and violent behavior.",20098969_2,-1,-1,-1,10067,-1,0.0014528434,0.99854714
10069,xerostomia,11,12,76,86,"Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries (""meth mouth""), and excessive tooth wear.",20098969_3,-1,-1,-1,10069,-1,0.001308946,0.998691
10070,caries,14,15,96,102,"Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries (""meth mouth""), and excessive tooth wear.",20098969_3,-1,-1,-1,10070,-1,0.0015367733,0.9984633
10072,tooth wear,24,26,133,143,"Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries (""meth mouth""), and excessive tooth wear.",20098969_3,-1,-1,-1,10072,-1,0.002498411,0.99750155
10075,bad breath,12,14,76,86,"CASE DESCRIPTION: A 30-year-old Caucasian woman presented with dental pain, bad breath, and self-reported poor esthetics.",20098969_5,-1,-1,-1,10075,-1,0.0019363868,0.9980636
10076,carious lesions,16,18,119,134,"A comprehensive examination including her medical history, panoramic radiograph, and intraoral examination revealed 19 carious lesions, which is not very common for a healthy adult.",20098969_6,-1,-1,-1,10076,-1,0.0028142582,0.99718577
10078,carious episodes,15,17,89,105,She reported her use of methamphetamine for five years and had not experienced any major carious episodes before she started using the drug.,20098969_7,-1,-1,-1,10078,-1,0.0019663677,0.9980336
10079,lead,15,16,98,102,"SUMMARY: The patient's medical and dental histories along with radiographic and clinical findings lead to a diagnosis of ""meth mouth."" Although three different dental treatment modalities (either conventional or implant-supported) have been offered to the patient since August 2007, the patient has yet to initiate any treatment.",20098969_8,-1,-1,-1,10079,-1,0.030088702,0.96991134
10082,methamphetamines,26,27,176,192,CLINICAL SIGNIFICANCE: This clinical case showing oral manifestations of meth mouth was presented to help dental practitioners recognize and manage patients who may be abusing methamphetamines.,20098969_9,-1,-1,-1,10082,-1,0.9987072,0.0012928316
10085,renal failure,11,13,62,75,"OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS).",20103708_1,-1,-1,-1,10085,-1,0.0014796074,0.99852043
10086,reactive oxygen species,21,24,119,142,"OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS).",20103708_1,-1,-1,-1,10086,-1,0.9162173,0.08378271
10093,DNA damage,16,18,100,110,This is evident by Nrf2(-/-) mice having higher ROS production and suffering from greater oxidative DNA damage and renal injury compared with Nrf2(+/+) mice.,20103708_7,-1,-1,-1,10093,-1,0.007816921,0.992183
10099,Metformin,0,1,0,9,Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway.,20164825_0,-1,-1,-1,10099,-1,0.9988662,0.0011338362
10101,metformin,3,4,22,31,The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent vascular dysfunction even in nondiabetic patients.,20164825_1,-1,-1,-1,10101,-1,0.99883217,0.0011678064
10102,vascular dysfunction,16,18,116,136,The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent vascular dysfunction even in nondiabetic patients.,20164825_1,-1,-1,-1,10102,-1,0.0016143004,0.99838567
10103,gentamicin toxicity,14,16,68,87,Here we tested whether it has a beneficial effect in a rat model of gentamicin toxicity.,20164825_2,-1,-1,-1,10103,-1,0.26435494,0.7356451
10104,reactive oxygen species,8,11,57,80,"Mitochondrial analysis, respiration intensity, levels of reactive oxygen species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration.",20164825_3,-1,-1,-1,10104,-1,0.92778796,0.07221204
10105,c,17,18,122,123,"Mitochondrial analysis, respiration intensity, levels of reactive oxygen species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration.",20164825_3,-1,-1,-1,10105,-1,0.99476755,0.0052324343
10107,Metformin,0,1,0,9,Metformin treatment fully blocked gentamicin-mediated acute renal failure.,20164825_4,-1,-1,-1,10107,-1,0.9989349,0.0010650438
10108,acute renal failure,5,8,54,73,Metformin treatment fully blocked gentamicin-mediated acute renal failure.,20164825_4,-1,-1,-1,10108,-1,0.0011332592,0.9988668
10109,Metformin,0,1,0,9,Metformin also protected the kidney from histological damage 6 days after gentamicin administration.,20164825_6,-1,-1,-1,10109,-1,0.9988707,0.001129358
10111,kidney dysfunction,5,7,25,43,These in vivo markers of kidney dysfunction and their correction by metformin were complemented by in vitro studies of mitochondrial function.,20164825_7,-1,-1,-1,10111,-1,0.001824381,0.9981756
10112,metformin,11,12,68,77,These in vivo markers of kidney dysfunction and their correction by metformin were complemented by in vitro studies of mitochondrial function.,20164825_7,-1,-1,-1,10112,-1,0.9988954,0.0011045575
10114,cytochrome c,9,11,68,80,"We found that gentamicin treatment depleted respiratory components (cytochrome c, NADH), probably due to the opening of mitochondrial transition pores.",20164825_8,-1,-1,-1,10114,-1,0.99636465,0.0036354184
10115,NADH,12,13,82,86,"We found that gentamicin treatment depleted respiratory components (cytochrome c, NADH), probably due to the opening of mitochondrial transition pores.",20164825_8,-1,-1,-1,10115,-1,0.9976532,0.00234678
10116,reactive oxygen species,9,12,45,68,"These injuries, partly mediated by a rise in reactive oxygen species from the electron transfer chain, were significantly decreased by metformin.",20164825_9,-1,-1,-1,10116,-1,0.70692253,0.29307747
10117,metformin,22,23,135,144,"These injuries, partly mediated by a rise in reactive oxygen species from the electron transfer chain, were significantly decreased by metformin.",20164825_9,-1,-1,-1,10117,-1,0.99891007,0.0010899886
10118,metformin,9,10,53,62,"Thus, our study suggests that pleiotropic effects of metformin can lessen gentamicin nephrotoxicity and improve mitochondrial homeostasis.",20164825_10,-1,-1,-1,10118,-1,0.99898106,0.0010188954
10119,gentamicin nephrotoxicity,12,14,74,99,"Thus, our study suggests that pleiotropic effects of metformin can lessen gentamicin nephrotoxicity and improve mitochondrial homeostasis.",20164825_10,-1,-1,-1,10119,-1,0.075180344,0.92481965
10121,contrast media,7,9,50,64,Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography: a prospective study.,20195852_0,-1,-1,-1,10121,-1,0.97791004,0.02208994
10122,contrast,5,6,39,47,"Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.",20195852_1,-1,-1,-1,10122,-1,0.9920042,0.007995782
10124,CIN,9,10,75,78,"Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.",20195852_1,-1,-1,-1,10124,-1,0.0016152529,0.9983847
10125,CIN,7,8,51,54,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,10125,-1,0.0014730345,0.99852693
10126,contrast media,11,13,72,86,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,10126,-1,0.9857062,0.014293861
10127,CM,14,15,88,90,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,10127,-1,0.23535118,0.7646488
10128,iopromide,17,18,93,102,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,10128,-1,0.9992392,0.0007607725
10129,iohexol,19,20,107,114,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,10129,-1,0.999276,0.0007240588
10130,CM,43,44,239,241,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,10130,-1,0.0083337845,0.99166626
10131,cyanosis,48,49,262,270,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,10131,-1,0.0013699672,0.99863005
10132,iopromide,9,10,59,68,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).",20195852_3,-1,-1,-1,10132,-1,0.99925333,0.00074670336
10133,n,14,15,79,80,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).",20195852_3,-1,-1,-1,10133,-1,0.27058545,0.7294146
10134,iohexol,19,20,90,97,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).",20195852_3,-1,-1,-1,10134,-1,0.999271,0.00072900916
10135,n,24,25,108,109,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).",20195852_3,-1,-1,-1,10135,-1,0.2598188,0.74018127
10137,Na,3,4,14,16,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,-1,10137,-1,0.9980768,0.001923159
10139,K,8,9,30,31,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,-1,10139,-1,0.99783,0.0021700026
10141,Cr,14,15,50,52,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,-1,10141,-1,0.9884256,0.011574406
10142,h,19,20,71,72,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,-1,10142,-1,0.266128,0.733872
10143,CM,38,39,170,172,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,-1,10143,-1,0.9981578,0.0018421673
10144,Na,3,4,18,20,Urine samples for Na and Cr also were checked at the same intervals.,20195852_5,-1,-1,-1,10144,-1,0.996718,0.0032819812
10145,Cr,5,6,25,27,Urine samples for Na and Cr also were checked at the same intervals.,20195852_5,-1,-1,-1,10145,-1,0.9949744,0.005025674
10146,renal failure,2,4,8,21,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,-1,10146,-1,0.001743602,0.9982564
10147,Injury to the kidney,5,9,23,43,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,-1,10147,-1,0.0028387047,0.99716127
10148,Failure of kidney function,10,14,45,71,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,-1,10148,-1,0.0037170227,0.996283
10149,Loss of kidney function,15,19,73,96,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,-1,10149,-1,0.0038565323,0.99614346
10151,CIN,32,33,162,165,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,-1,10151,-1,0.001419174,0.9985808
10152,CIN,5,6,26,29,"Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.",20195852_7,-1,-1,-1,10152,-1,0.00170308,0.9982969
10155,CIN,7,8,35,38,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).",20195852_8,-1,-1,-1,10155,-1,0.0013940763,0.9986059
10156,CM,17,18,90,92,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).",20195852_8,-1,-1,-1,10156,-1,0.99734676,0.0026531944
10157,CIN,40,41,217,220,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).",20195852_8,-1,-1,-1,10157,-1,0.0013778777,0.9986222
10158,CM,47,48,257,259,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).",20195852_8,-1,-1,-1,10158,-1,0.99727184,0.0027281241
10159,p,49,50,261,262,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).",20195852_8,-1,-1,-1,10159,-1,0.25894678,0.7410533
10160,CIN,5,6,27,30,"Among the 15 patients with CIN, 6 had cyanotic congenital heart diseases, but the incidence did not differ significantly from that for the noncyanotic patients (p = 0.243).",20195852_9,-1,-1,-1,10160,-1,0.0014726593,0.9985273
10161,congenital heart diseases,10,13,47,72,"Among the 15 patients with CIN, 6 had cyanotic congenital heart diseases, but the incidence did not differ significantly from that for the noncyanotic patients (p = 0.243).",20195852_9,-1,-1,-1,10161,-1,0.0017110581,0.9982889
10162,p,28,29,161,162,"Among the 15 patients with CIN, 6 had cyanotic congenital heart diseases, but the incidence did not differ significantly from that for the noncyanotic patients (p = 0.243).",20195852_9,-1,-1,-1,10162,-1,0.2051376,0.7948624
10163,CIN,4,5,28,31,"Although clinically silent, CIN is not rare in pediatrics.",20195852_10,-1,-1,-1,10163,-1,0.0014904311,0.9985096
10164,CM,13,14,73,75,"The incidence depends on dosage but not on the type of consumed nonionic CM, nor on the presence of cyanosis, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.",20195852_11,-1,-1,-1,10164,-1,0.32857987,0.6714201
10165,cyanosis,20,21,100,108,"The incidence depends on dosage but not on the type of consumed nonionic CM, nor on the presence of cyanosis, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.",20195852_11,-1,-1,-1,10165,-1,0.0012516058,0.9987484
10166,CIN,24,25,123,126,"The incidence depends on dosage but not on the type of consumed nonionic CM, nor on the presence of cyanosis, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.",20195852_11,-1,-1,-1,10166,-1,0.0014808464,0.9985191
10167,Antituberculosis,0,1,0,16,"Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome.",20196116_0,-1,-1,-1,10167,-1,0.99187076,0.008129295
10169,Antituberculosis,0,1,0,16,Antituberculosis therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia.,20196116_1,-1,-1,-1,10169,-1,0.8711143,0.1288857
10171,ALF,13,14,102,105,Antituberculosis therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia.,20196116_1,-1,-1,-1,10171,-1,0.0012471622,0.99875283
10172,ALF,9,10,52,55,"From January 1986 to January 2009, 1223 consecutive ALF patients were evaluated: ATT alone was the cause in 70 (5.7%) patients.",20196116_4,-1,-1,-1,10172,-1,0.0021787486,0.9978212
10173,hepatitis virus infection,10,13,43,68,Another 15 (1.2%) had ATT and simultaneous hepatitis virus infection.,20196116_5,-1,-1,-1,10173,-1,0.0018269185,0.9981731
10175,icterus encephalopathy,7,9,45,67,Most had hyperacute presentation; the median icterus encephalopathy interval was 4.5 (0-30) days.,20196116_8,-1,-1,-1,10175,-1,0.0019053003,0.99809474
10176,ALF,6,7,34,37,The median duration of ATT before ALF was 30 (7-350) days.,20196116_9,-1,-1,-1,10176,-1,0.0018498589,0.9981502
10178,cerebral edema,6,8,45,59,"At presentation, advanced encephalopathy and cerebral edema were present in 51 (76%) and 29 (41.4%) patients, respectively.",20196116_10,-1,-1,-1,10178,-1,0.0011609604,0.9988391
10179,Gastrointestinal bleed,0,2,0,22,"Gastrointestinal bleed, seizures, infection, and acute renal failure were documented in seven (10%), five (7.1%), 26 (37.1%), and seven (10%) patients, respectively.",20196116_11,-1,-1,-1,10179,-1,0.0013577614,0.99864227
10182,acute renal failure,8,11,49,68,"Gastrointestinal bleed, seizures, infection, and acute renal failure were documented in seven (10%), five (7.1%), 26 (37.1%), and seven (10%) patients, respectively.",20196116_11,-1,-1,-1,10182,-1,0.0012597393,0.99874026
10183,hepatitis E,2,4,14,25,"Compared with hepatitis E virus (HEV) and non-A non-E-induced ALF, ATT-ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes.",20196116_12,-1,-1,-1,10183,-1,0.0103582,0.98964185
10184,ALF,11,12,62,65,"Compared with hepatitis E virus (HEV) and non-A non-E-induced ALF, ATT-ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes.",20196116_12,-1,-1,-1,10184,-1,0.001413017,0.998587
10185,n,13,14,64,65,"The mortality rate among patients with ATT-ALF was high (67.1%, n = 47), and only 23 (32.9%) patients recovered with medical treatment.",20196116_13,-1,-1,-1,10185,-1,0.0605742,0.93942577
10188,ALF,7,8,40,43,CONCLUSION: ATT-ALF constituted 5.7% of ALF at our center and had a high mortality rate.,20196116_15,-1,-1,-1,10188,-1,0.0014920102,0.9985079
10191,PAH,21,22,121,124,"Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured by inulin and para-aminohippurate (PAH) clearance, respectively.",2021202_2,-1,-1,-1,10191,-1,0.99774927,0.0022507687
10193,nitrous oxide,6,8,41,54,"Anesthesia was maintained with fentanyl, nitrous oxide, oxygen, and isoflurane.",2021202_3,-1,-1,-1,10193,-1,0.9985441,0.0014559501
10203,congestive heart failure,20,23,122,146,Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure.,2024540_0,-1,-1,-1,10203,-1,0.0012746748,0.99872535
10205,ACE,8,9,57,60,"Since the introduction of angiotensin converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with congestive heart failure, cases of severe hypotension, especially on the first day of treatment, have occasionally been reported.",2024540_1,-1,-1,-1,10205,-1,0.9984199,0.0015801529
10206,congestive heart failure,18,21,120,144,"Since the introduction of angiotensin converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with congestive heart failure, cases of severe hypotension, especially on the first day of treatment, have occasionally been reported.",2024540_1,-1,-1,-1,10206,-1,0.0011097009,0.99889034
10210,mg enalapril,4,6,25,37,Trial medication was 2.5 mg enalapril or 0.5 prazosin.,2024540_3,-1,-1,-1,10210,-1,0.99843246,0.0015674895
10217,Brainstem dysgenesis,0,2,0,20,Brainstem dysgenesis in an infant prenatally exposed to cocaine.,20304337_0,-1,-1,-1,10217,-1,0.0014405086,0.99855953
10220,fetal anomalies,15,17,89,104,Vasoconstriction appears to be the common mechanism of action leading to a wide range of fetal anomalies.,20304337_2,-1,-1,-1,10220,-1,0.0015192638,0.99848074
10221,brainstem dysgenesis,11,13,79,99,"We report on an infant with multiple cranial-nerve involvement attributable to brainstem dysgenesis, born to a cocaine-addicted mother.",20304337_3,-1,-1,-1,10221,-1,0.0012758529,0.99872416
10223,selective serotonin reuptake inhibitors,9,13,62,101,A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys.,20331935_0,-1,-1,-1,10223,-1,0.99905914,0.0009408498
10227,n,12,13,59,60,RESULTS: Hyperprolactinemia was present in 49% of 83 boys (n = 41) treated with risperidone for a mean of 2.9 years.,20331935_6,-1,-1,-1,10227,-1,0.056139432,0.9438606
10231,P,29,30,181,182,"After adjusting for the stage of sexual development and height and BMI z scores, serum prolactin was negatively associated with trabecular volumetric BMD at the ultradistal radius (P < .03).",20331935_9,-1,-1,-1,10231,-1,0.42927128,0.5707287
10232,serotonin reuptake inhibitors,11,14,76,105,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,-1,-1,-1,10232,-1,0.998594,0.001405978
10233,SSRIs,15,16,107,112,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,-1,-1,-1,10233,-1,0.9985393,0.0014606682
10234,P,28,29,172,173,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,-1,-1,-1,10234,-1,0.26822188,0.7317781
10235,P,41,42,218,219,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,-1,-1,-1,10235,-1,0.36416507,0.6358349
10238,SSRIs,10,11,61,66,"Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.",20331935_12,-1,-1,-1,10238,-1,0.99890494,0.001095078
10241,SSRI,12,13,88,92,CONCLUSIONS: This is the first study to link risperidone-induced hyperprolactinemia and SSRI treatment to lower BMD in children and adolescents.,20331935_13,-1,-1,-1,10241,-1,0.9991264,0.0008736007
10242,fracture,20,21,135,143,Future research should evaluate the longitudinal course of this adverse event to determine its temporal stability and whether a higher fracture rate ensues.,20331935_14,-1,-1,-1,10242,-1,0.0019924887,0.9980075
10243,startle,1,2,17,24,"Fear-potentiated startle, but not light-enhanced startle, is enhanced by anxiogenic drugs.",20394767_0,-1,-1,-1,10243,-1,0.0040894696,0.9959105
10244,startle,6,7,49,56,"Fear-potentiated startle, but not light-enhanced startle, is enhanced by anxiogenic drugs.",20394767_0,-1,-1,-1,10244,-1,0.004051457,0.9959486
10245,startle,6,7,45,52,"RATIONALE AND OBJECTIVES: The light-enhanced startle paradigm (LES) is suggested to model anxiety, because of the non-specific cue and the long-term effect.",20394767_1,-1,-1,-1,10245,-1,0.11576722,0.8842327
10246,anxiety,15,16,90,97,"RATIONALE AND OBJECTIVES: The light-enhanced startle paradigm (LES) is suggested to model anxiety, because of the non-specific cue and the long-term effect.",20394767_1,-1,-1,-1,10246,-1,0.0018274611,0.9981725
10247,contrast,1,2,3,11,"In contrast, the fear-potentiated startle (FPS) is suggested to model conditioned fear.",20394767_2,-1,-1,-1,10247,-1,0.18182644,0.8181735
10248,startle,5,6,34,41,"In contrast, the fear-potentiated startle (FPS) is suggested to model conditioned fear.",20394767_2,-1,-1,-1,10248,-1,0.0031165178,0.99688345
10250,mCPP,26,27,168,172,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,-1,-1,-1,10250,-1,0.9989906,0.0010094432
10251,pentylenetetrazole,39,40,228,246,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,-1,-1,-1,10251,-1,0.9992888,0.0007111918
10252,PTZ,41,42,248,251,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,-1,-1,-1,10252,-1,0.99889684,0.0011030792
10253,mCPP,10,11,49,53,"RESULTS: None of the drugs enhanced LES, whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values.",20394767_6,-1,-1,-1,10253,-1,0.99906725,0.0009327248
10256,startle,5,6,42,49,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,-1,10256,-1,0.024087181,0.9759128
10257,mCPP,12,13,78,82,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,-1,10257,-1,0.9991093,0.0008906654
10258,startle,15,16,103,110,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,-1,10258,-1,0.015660629,0.98433936
10259,PTZ,23,24,139,142,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,-1,10259,-1,0.99883586,0.0011641029
10260,startle,26,27,163,170,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,-1,10260,-1,0.017464587,0.98253536
10261,contrast,3,4,16,24,"CONCLUSIONS: In contrast to findings in the FPS paradigm, none of the drugs were able to exacerbate the LES response.",20394767_8,-1,-1,-1,10261,-1,0.093064286,0.90693575
10264,dermatitis eruptions,8,10,57,77,We describe herein 3 patients who developed rosacea-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.,20466178_1,-1,-1,-1,10264,-1,0.0013225942,0.99867743
10266,facial dermatitis,20,22,128,145,We describe herein 3 patients who developed rosacea-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.,20466178_1,-1,-1,-1,10266,-1,0.001436094,0.99856395
10267,telangiectasia,4,5,29,43,Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis.,20466178_2,-1,-1,-1,10267,-1,0.001415926,0.99858415
10269,pimecrolimus,9,10,65,77,"Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis, although many cases have not been reported.",20466178_3,-1,-1,-1,10269,-1,0.9991504,0.00084960664
10271,Central nervous system complications,0,4,0,36,Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution.,20470218_0,-1,-1,-1,10271,-1,0.001258299,0.9987417
10273,Central nervous system (CNS) complications,0,7,0,42,Central nervous system (CNS) complications during treatment of childhood acute lymphoblastic leukemia (ALL) remain a challenging clinical problem.,20470218_1,-1,-1,-1,10273,-1,0.0015122195,0.9984877
10275,ALL,15,16,103,106,Central nervous system (CNS) complications during treatment of childhood acute lymphoblastic leukemia (ALL) remain a challenging clinical problem.,20470218_1,-1,-1,-1,10275,-1,0.0021876178,0.9978124
10276,neurological complications,6,8,37,63,"This study analyzed the incidence of neurological complications during ALL treatment in a single pediatric institution, focusing on clinical, radiological, and electrophysiological findings.",20470218_3,-1,-1,-1,10276,-1,0.0012602776,0.9987398
10277,leukemic infiltration,4,6,32,53,"Exclusion criteria included CNS leukemic infiltration at diagnosis, therapy-related peripheral neuropathy, late-onset encephalopathy, or long-term neurocognitive defects.",20470218_4,-1,-1,-1,10277,-1,0.0011769722,0.998823
10280,neurocognitive defects,18,20,147,169,"Exclusion criteria included CNS leukemic infiltration at diagnosis, therapy-related peripheral neuropathy, late-onset encephalopathy, or long-term neurocognitive defects.",20470218_4,-1,-1,-1,10280,-1,0.0011434839,0.99885654
10281,leukoencephalopathy syndrome,5,7,48,76,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10281,-1,0.0011568195,0.9988432
10282,n,8,9,78,79,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10282,-1,0.0056987107,0.9943013
10284,n,15,16,95,96,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10284,-1,0.005544861,0.99445516
10286,n,24,25,127,128,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10286,-1,0.006158181,0.99384177
10287,methotrexate toxicity,30,32,145,166,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10287,-1,0.20400748,0.79599255
10288,n,33,34,168,169,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10288,-1,0.005879669,0.9941203
10289,syndrome of inappropriate antidiuretic hormone secretion,38,44,176,232,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10289,-1,0.0100916205,0.98990834
10290,n,45,46,234,235,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10290,-1,0.005145574,0.99485445
10291,n,55,56,273,274,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10291,-1,0.007318769,0.9926812
10292,CNS complications,3,5,15,32,"In conclusion, CNS complications are frequent events during ALL therapy, and require rapid detection and prompt treatment to limit permanent damage.",20470218_7,-1,-1,-1,10292,-1,0.0014274395,0.9985726
10294,topiramate,22,23,134,144,"Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.",20477932_0,-1,-1,-1,10294,-1,0.99933136,0.00066872814
10295,cocaine toxicity,6,8,45,61,Different mechanisms have been suggested for cocaine toxicity including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced-behaviour is poorly understood.,20477932_1,-1,-1,-1,10295,-1,0.34333515,0.6566648
10297,drug toxicity,23,25,129,142,Nuclear factor kappa B (NFkappaB) is a sensor of oxidative stress and participates in memory formation that could be involved in drug toxicity and addiction mechanisms.,20477932_2,-1,-1,-1,10297,-1,0.23920572,0.76079434
10298,nitric oxide synthase,8,11,56,77,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,-1,-1,-1,10298,-1,0.99330926,0.006690756
10299,topiramate,26,27,148,158,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,-1,-1,-1,10299,-1,0.999373,0.00062700786
10300,cocaine addiction,33,35,194,211,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,-1,-1,-1,10300,-1,0.5728148,0.42718518
10303,GSH,16,17,90,93,"NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.",20477932_4,-1,-1,-1,10303,-1,0.9990037,0.0009962525
10304,glutathione peroxidase,19,21,112,134,"NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.",20477932_4,-1,-1,-1,10304,-1,0.99399096,0.006008999
10306,contrast,1,2,3,11,"In contrast, learning of new tasks was enhanced and correlated with the increase of nNOS activity and the decrease of glutathione peroxidase.",20477932_6,-1,-1,-1,10306,-1,0.28979403,0.710206
10307,glutathione peroxidase,21,23,118,140,"In contrast, learning of new tasks was enhanced and correlated with the increase of nNOS activity and the decrease of glutathione peroxidase.",20477932_6,-1,-1,-1,10307,-1,0.9972555,0.0027445091
10309,Topiramate,0,1,0,10,"Topiramate prevented all the alterations observed, showing novel neuroprotective properties.",20477932_8,-1,-1,-1,10309,-1,0.99929786,0.0007020784
10310,Coenzyme Q10,0,2,0,12,Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice.,20510337_0,-1,-1,-1,10310,-1,0.9989422,0.0010577847
10311,cisplatin nephrotoxicity,5,7,41,65,Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice.,20510337_0,-1,-1,-1,10311,-1,0.057878137,0.94212186
10312,coenzyme Q10,4,6,31,43,The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i.p.,20510337_1,-1,-1,-1,10312,-1,0.9991079,0.0008921046
10313,acute renal injury,11,14,74,92,The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i.p.,20510337_1,-1,-1,-1,10313,-1,0.0013037869,0.99869627
10315,Coenzyme Q10,0,2,0,12,"Coenzyme Q10 treatment (10 mg/kg/day, i.p.) was applied for 6 consecutive days, starting 1 day before cisplatin administration.",20510337_3,-1,-1,-1,10315,-1,0.9991104,0.0008895882
10317,Coenzyme Q10,0,2,0,12,Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin.,20510337_4,-1,-1,-1,10317,-1,0.9990767,0.0009232395
10321,Coenzyme Q10,0,2,0,12,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10321,-1,0.99905914,0.0009408865
10322,reduced glutathione,11,13,87,106,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10322,-1,0.97523767,0.02476241
10323,superoxide dismutase,15,17,117,137,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10323,-1,0.9981693,0.0018306596
10325,nitric oxide,32,34,237,249,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10325,-1,0.99872595,0.001274066
10326,platinum,35,36,254,262,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10326,-1,0.9989899,0.0010101676
10327,selenium,44,45,315,323,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10327,-1,0.9989982,0.0010018245
10328,zinc,46,47,328,332,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10328,-1,0.9988752,0.001124796
10330,renal tissue damage,3,6,24,43,"Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.",20510337_6,-1,-1,-1,10330,-1,0.0017697361,0.9982303
10332,coenzyme Q10,12,14,85,97,"Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.",20510337_6,-1,-1,-1,10332,-1,0.9991468,0.0008531998
10333,coenzyme Q10,4,6,43,55,"Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.",20510337_7,-1,-1,-1,10333,-1,0.99903834,0.0009616837
10334,nitric oxide synthase,13,16,130,151,"Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.",20510337_7,-1,-1,-1,10334,-1,0.99673116,0.0032688675
10335,coenzyme Q10,4,6,22,34,It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin nephrotoxicity commonly encountered in clinical practice.,20510337_8,-1,-1,-1,10335,-1,0.9989157,0.0010842863
10336,cisplatin nephrotoxicity,15,17,102,126,It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin nephrotoxicity commonly encountered in clinical practice.,20510337_8,-1,-1,-1,10336,-1,0.056672994,0.943327
10338,bile duct injury,3,6,28,44,Reversible cholestasis with bile duct injury following azathioprine therapy.,2051906_0,-1,-1,-1,10338,-1,0.002857258,0.99714273
10340,primary polymyositis,5,7,28,48,"A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.",2051906_2,-1,-1,-1,10340,-1,0.001436382,0.9985636
10347,bile duct injury,19,22,140,156,It is believed that this is the first reported case of reversible azathioprine-induced cholestasis associated with histological evidence of bile duct injury.,2051906_5,-1,-1,-1,10347,-1,0.0054021785,0.9945978
10353,bipolar I disorder,24,27,152,170,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.,20520283_1,-1,-1,-1,10353,-1,0.0017770039,0.998223
10354,psychotic features,30,32,187,205,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.,20520283_1,-1,-1,-1,10354,-1,0.0014280351,0.998572
10357,mg,21,22,137,139,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,-1,-1,-1,10357,-1,0.9925074,0.00749266
10359,mg,31,32,175,177,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,-1,-1,-1,10359,-1,0.99101615,0.008983811
10361,mg,40,41,212,214,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,-1,-1,-1,10361,-1,0.9898801,0.010119941
10363,mg,29,30,185,187,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,-1,-1,-1,10363,-1,0.9950348,0.0049651703
10365,P,45,46,250,251,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,-1,-1,-1,10365,-1,0.35436523,0.6456348
10367,mg,73,74,381,383,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,-1,-1,-1,10367,-1,0.9947076,0.0052924408
10369,P,93,94,469,470,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,-1,-1,-1,10369,-1,0.3628212,0.6371788
10370,Syndrome,5,6,29,37,"On the Positive and Negative Syndrome Scale positive subscale, all treatments were superior to placebo with LOCF and MMRM; asenapine at 5 mg BID was superior to placebo on the negative subscale with MMRM and on the general psychopathology subscale with LOCF and MMRM.",20520283_4,-1,-1,-1,10370,-1,0.0023356937,0.99766433
10372,mg,24,25,138,140,"On the Positive and Negative Syndrome Scale positive subscale, all treatments were superior to placebo with LOCF and MMRM; asenapine at 5 mg BID was superior to placebo on the negative subscale with MMRM and on the general psychopathology subscale with LOCF and MMRM.",20520283_4,-1,-1,-1,10372,-1,0.9947667,0.0052333176
10373,general psychopathology,39,41,215,238,"On the Positive and Negative Syndrome Scale positive subscale, all treatments were superior to placebo with LOCF and MMRM; asenapine at 5 mg BID was superior to placebo on the negative subscale with MMRM and on the general psychopathology subscale with LOCF and MMRM.",20520283_4,-1,-1,-1,10373,-1,0.0029526425,0.99704736
10375,mg,27,28,106,108,"Treatment-related adverse events (AEs) occurred in 44% and 52%, 57%, and 41% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_5,-1,-1,-1,10375,-1,0.99466383,0.00533614
10379,mg,26,27,107,109,"Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_6,-1,-1,-1,10379,-1,0.99466115,0.0053388663
10381,weight change,14,16,74,87,"Across all groups, no more than 5% of patients had clinically significant weight change.",20520283_7,-1,-1,-1,10381,-1,0.03386294,0.9661371
10388,leukaemia,14,15,120,129,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.",20528871_0,-1,-1,-1,10388,-1,0.0014957829,0.9985043
10389,lymphoma,16,17,134,142,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.",20528871_0,-1,-1,-1,10389,-1,0.001441072,0.99855894
10391,AraG,8,9,36,40,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,-1,10391,-1,0.99860674,0.0013933352
10393,VP,16,17,65,67,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,-1,10393,-1,0.99801564,0.0019843811
10395,CPM,21,22,91,94,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,-1,10395,-1,0.9960848,0.0039151357
10396,leukaemia,40,41,219,228,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,-1,10396,-1,0.0013245454,0.9986754
10397,lymphoma,42,43,232,240,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,-1,10397,-1,0.0013444327,0.99865556
10398,AraG,8,9,49,53,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.,20528871_2,-1,-1,-1,10398,-1,0.8681485,0.13185157
10399,sensory and motor neuropathy,14,18,77,105,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.,20528871_2,-1,-1,-1,10399,-1,0.0016049838,0.998395
10400,musculoskeletal pain,19,21,110,130,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.,20528871_2,-1,-1,-1,10400,-1,0.0014156598,0.9985844
10401,Haematological toxicity,0,2,0,23,"Haematological toxicity was greater for the combination than AraG alone, although median time to neutrophil and platelet recovery was consistent with other salvage therapies.",20528871_3,-1,-1,-1,10401,-1,0.0014762664,0.9985238
10402,AraG,8,9,61,65,"Haematological toxicity was greater for the combination than AraG alone, although median time to neutrophil and platelet recovery was consistent with other salvage therapies.",20528871_3,-1,-1,-1,10402,-1,0.9988212,0.0011787652
10403,AraG,7,8,45,49,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",20528871_5,-1,-1,-1,10403,-1,0.9988814,0.0011185873
10406,neurological toxicity,19,21,128,149,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",20528871_5,-1,-1,-1,10406,-1,0.0013310562,0.9986689
10410,DA,7,8,37,39,"It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.",20533999_1,-1,-1,-1,10410,-1,0.9986236,0.0013763615
10413,DA,23,24,155,157,"It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.",20533999_1,-1,-1,-1,10413,-1,0.99874026,0.0012597789
10415,DA,32,33,223,225,"It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.",20533999_1,-1,-1,-1,10415,-1,0.99860954,0.0013904634
10417,DA,13,14,78,80,"However, temperature effects of drugs that have been used to manipulate brain DA neurotransmission confound interpretation of the data.",20533999_2,-1,-1,-1,10417,-1,0.99822134,0.001778648
10418,DA neurotoxicity,19,21,155,171,Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.,20533999_3,-1,-1,-1,10418,-1,0.27597332,0.7240267
10419,DA,13,14,75,77,"Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.",20533999_4,-1,-1,-1,10419,-1,0.983453,0.016546983
10420,METH neurotoxicity,15,17,86,104,"Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.",20533999_4,-1,-1,-1,10420,-1,0.248892,0.75110793
10421,METH,25,26,140,144,"Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.",20533999_4,-1,-1,-1,10421,-1,0.9986162,0.0013837175
10422,DA deficits,13,15,86,97,"In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH-induced dopaminergic deficits that are of comparable magnitude on both sides of the brain.",20533999_5,-1,-1,-1,10422,-1,0.28439665,0.71560335
10423,dopaminergic deficits,17,19,119,140,"In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH-induced dopaminergic deficits that are of comparable magnitude on both sides of the brain.",20533999_5,-1,-1,-1,10423,-1,0.22334331,0.7766567
10424,DA,7,8,48,50,"Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation.",20533999_6,-1,-1,-1,10424,-1,0.9988619,0.0011381551
10425,dopaminergic neurotoxicity,16,18,104,130,"Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation.",20533999_6,-1,-1,-1,10425,-1,0.21441327,0.7855867
10426,DA,24,25,174,176,"Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation.",20533999_6,-1,-1,-1,10426,-1,0.9987846,0.0012154615
10437,kidney injury,21,23,127,140,"Acute normal tissue toxicities (i.e., leukopenia and thrombocytopenia) and late normal tissue toxicities (i.e., myocardial and kidney injury) were evaluated by functional/physiological assays and by morphological techniques.",2054792_3,-1,-1,-1,10437,-1,0.001979483,0.9980205
10439,renal lesions,27,29,159,172,"Thermal enhancement ratios estimated for ""acute"" hematological changes were 1.3, whereas those estimated for ""late"" damage (based on morphological cardiac and renal lesions) varied between 2.4 and 4.3.",2054792_6,-1,-1,-1,10439,-1,0.0025035667,0.9974964
10442,atrial tachyarrhythmia,1,3,19,41,Swallowing-induced atrial tachyarrhythmia triggered by salbutamol: case report and review of the literature.,20552622_0,-1,-1,-1,10442,-1,0.0012944888,0.9987055
10444,atrial tachyarrhythmia,5,7,34,56,"On electrocardiogram, episodes of atrial tachyarrhythmia were recorded immediately after swallowing; 24-hour Holter monitoring recorded several events.",20552622_2,-1,-1,-1,10444,-1,0.0013432186,0.99865675
10446,atenolol,6,7,43,51,"The arrhythmia resolved after therapy with atenolol, but recurred a year later.",20552622_3,-1,-1,-1,10446,-1,0.99882835,0.0011716903
10448,atenolol,11,12,59,67,"After stopping the beta-agonist, and after a week with the atenolol, the arrhythmia disappeared.",20552622_5,-1,-1,-1,10448,-1,0.99914134,0.00085866335
10450,atrial tachyarrhythmia,3,5,31,53,DISCUSSION: Swallowing-induced atrial tachyarrhythmia (SIAT) is a rare phenomenon.,20552622_6,-1,-1,-1,10450,-1,0.0013394508,0.99866056
10451,SIAT,6,7,55,59,DISCUSSION: Swallowing-induced atrial tachyarrhythmia (SIAT) is a rare phenomenon.,20552622_6,-1,-1,-1,10451,-1,0.0028445607,0.9971554
10452,SIAT,5,6,23,27,Fewer than 50 cases of SIAT have been described in the literature.,20552622_7,-1,-1,-1,10452,-1,0.0039431793,0.9960568
10453,SIAT,19,20,122,126,"This article summarizes all the cases published, creating a comprehensive review of the current knowledge and approach to SIAT.",20552622_8,-1,-1,-1,10453,-1,0.027759498,0.9722405
10455,SIAT,14,15,102,106,"It discusses demographics, clinical characteristics and types of arrhythmia, postulated mechanisms of SIAT, and different treatment possibilities such as medications, surgery, and radiofrequency catheter ablation (RFCA).",20552622_9,-1,-1,-1,10455,-1,0.0052409093,0.994759
10457,SIAT,11,12,67,71,CONCLUSION: Salbutamol is presented here as a possible trigger for SIAT.,20552622_10,-1,-1,-1,10457,-1,0.0043941904,0.99560577
10460,atenolol,47,48,272,280,"Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like salbutamol (known to induce tachycardia) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as atenolol (that blocks the adrenergic activity) may relieve it.",20552622_11,-1,-1,-1,10460,-1,0.99918705,0.0008129482
10461,diabetes mellitus.1,18,20,128,147,The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by streptozotocin-induced diabetes mellitus.1.,2055425_0,-1,-1,-1,10461,-1,0.021763034,0.978237
10463,body weight,11,13,58,69,"2. Diabetes of 2 months duration resulted in decreases in body weight and increases in fluid consumption, urine volume, frequency of micturition, and average volume per micturition; effects which were prevented by insulin treatment.",2055425_2,-1,-1,-1,10463,-1,0.051029522,0.9489705
10465,ATP,22,23,139,142,"3. Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_3,-1,-1,-1,10465,-1,0.99914336,0.00085662433
10466,bethanechol,25,26,148,159,"3. Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_3,-1,-1,-1,10466,-1,0.99922776,0.0007722114
10468,body weight,10,12,60,71,"Diabetes of 4 months duration also resulted in decreases in body weight, and increases in fluid consumption, urine volume, frequency of micturition, and average volume per micturition, effects which were reversed by insulin treatment for the final 2 months of the study.",2055425_5,-1,-1,-1,10468,-1,0.07001645,0.92998356
10470,ATP,19,20,130,133,"Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_7,-1,-1,-1,10470,-1,0.99914014,0.0008597792
10471,bethanechol,22,23,139,150,"Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_7,-1,-1,-1,10471,-1,0.9992599,0.0007401212
10473,NMDA,4,5,44,48,Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.,20558148_0,-1,-1,-1,10473,-1,0.9990318,0.0009682582
10480,glutamate NMDA,9,11,91,105,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10480,-1,0.99892575,0.0010742157
10481,MK-801,14,15,128,134,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10481,-1,0.9991033,0.0008966975
10482,AP7,23,24,166,169,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10482,-1,0.9992107,0.00078920607
10483,NMDA,35,36,208,212,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10483,-1,0.99871624,0.0012837761
10484,NMDA,40,41,252,256,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10484,-1,0.99876404,0.0012360071
10485,MK-801,7,8,58,64,"The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.",20558148_6,-1,-1,-1,10485,-1,0.99896574,0.0010343081
10486,AP7,9,10,69,72,"The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.",20558148_6,-1,-1,-1,10486,-1,0.99908876,0.00091125997
10489,NMDA,5,6,47,51,"Accordingly, intracollicular microinjection of NMDA increased the latency to step down the bar.",20558148_7,-1,-1,-1,10489,-1,0.99862576,0.0013743058
10491,puromycin aminonucleoside nephrosis,16,19,109,144,"Permeability, ultrastructural changes, and distribution of novel proteins in the glomerular barrier in early puromycin aminonucleoside nephrosis.",20588063_0,-1,-1,-1,10491,-1,0.60536754,0.39463243
10493,puromycin aminonucleoside nephrosis,1,4,6,41,"Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.",20588063_2,-1,-1,-1,10493,-1,0.64927167,0.35072833
10494,PAN,5,6,43,46,"Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.",20588063_2,-1,-1,-1,10494,-1,0.0024600308,0.99754
10497,PAN,2,3,13,16,"CONCLUSIONS: PAN glomeruli already showed significant pathology by day 4, despite relatively mild proteinuria.",20588063_12,-1,-1,-1,10497,-1,0.005495831,0.9945042
10499,PAN,13,14,78,81,"The novel proteins dendrin and plekhh2 were both reduced, suggesting roles in PAN, whereas a-actinin was unchanged.",20588063_14,-1,-1,-1,10499,-1,0.0090421885,0.99095774
10500,OCD,9,10,68,71,"BACKGROUND: Current animal models of obsessive-compulsive disorder (OCD) typically involve acute, drug-induced symptom provocation or a genetic association with stereotypies or anxiety.",20619828_1,-1,-1,-1,10500,-1,0.0015436317,0.99845636
10501,anxiety,25,26,177,184,"BACKGROUND: Current animal models of obsessive-compulsive disorder (OCD) typically involve acute, drug-induced symptom provocation or a genetic association with stereotypies or anxiety.",20619828_1,-1,-1,-1,10501,-1,0.0013013621,0.9986986
10502,antidepressant clomipramine,9,11,55,82,METHODS: Neonatal rats were treated with the tricyclic antidepressant clomipramine or vehicle between days 9 and 16 twice daily and behaviorally tested in adulthood.,20619828_3,-1,-1,-1,10502,-1,0.9989723,0.0010277404
10504,anxiety,16,17,126,133,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,-1,-1,-1,10504,-1,0.0014428172,0.99855715
10505,behavioral inflexibility,26,28,175,199,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,-1,-1,-1,10505,-1,0.0020546643,0.99794537
10506,perseveration,29,30,201,214,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,-1,-1,-1,10506,-1,0.0023991868,0.99760085
10507,working memory impairment,41,44,284,309,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,-1,-1,-1,10507,-1,0.005104078,0.9948959
10508,hoarding,51,52,338,346,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,-1,-1,-1,10508,-1,0.0028816052,0.99711835
10509,corticostriatal dysfunction,54,56,352,379,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,-1,-1,-1,10509,-1,0.01736134,0.9826386
10513,OCD,17,18,119,122,"Moreover, these behaviors are accompanied by biochemical changes in brain regions previously identified as relevant to OCD.",20619828_7,-1,-1,-1,10513,-1,0.0021796166,0.9978204
10514,OCD,4,5,20,23,"This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease-like systems permanently, which could have implications for current and future therapeutic strategies for this and other psychiatric disorders.",20619828_8,-1,-1,-1,10514,-1,0.0017610657,0.9982389
10515,psychiatric disorders,33,35,223,244,"This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease-like systems permanently, which could have implications for current and future therapeutic strategies for this and other psychiatric disorders.",20619828_8,-1,-1,-1,10515,-1,0.0018342119,0.9981658
10516,thoracic aortic aneurysm,15,18,103,127,"Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model.",20621845_0,-1,-1,-1,10516,-1,0.0020699282,0.99793005
10517,thoracic aortic aneurysm,12,15,61,85,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10517,-1,0.0024201367,0.9975799
10518,TAA,16,17,87,90,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10518,-1,0.0018805553,0.9981194
10519,calcium chloride,19,21,95,111,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10519,-1,0.99868375,0.0013162897
10520,arterial injury,23,25,130,145,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10520,-1,0.0013799926,0.99862003
10521,TAA,53,54,303,306,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10521,-1,0.0019859031,0.9980141
10522,CaCl(2),13,15,72,79,METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).,20621845_2,-1,-1,-1,10522,-1,0.99761426,0.0023857383
10523,NaCl,19,20,98,102,METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).,20621845_2,-1,-1,-1,10523,-1,0.99843246,0.001567565
10524,n=12,12,13,80,84,"After 12weeks, animals were euthanized, and CaCl(2)-treated, CaCl(2)-untreated (n=12) and NaCl-treated aortic segments (n=12) were collected for histological and molecular assessments.",20621845_3,-1,-1,-1,10524,-1,0.101211175,0.8987888
10525,n=12,19,20,120,124,"After 12weeks, animals were euthanized, and CaCl(2)-treated, CaCl(2)-untreated (n=12) and NaCl-treated aortic segments (n=12) were collected for histological and molecular assessments.",20621845_3,-1,-1,-1,10525,-1,0.103647485,0.89635247
10526,n=6,17,18,136,139,"RESULTS: Despite similar external diameters among CaCl(2)-treated, non-CaCl(2)-treated and NaCl-treated segments, aneurymal alteration (n=6, 50%), media degeneration with regional disruption, fragmentation of elastic fiber, and increased collagen deposition (n=12, 100%) were demonstrated in CaCl(2)-treated segments.",20621845_5,-1,-1,-1,10526,-1,0.034786526,0.96521354
10527,n=12,39,40,259,263,"RESULTS: Despite similar external diameters among CaCl(2)-treated, non-CaCl(2)-treated and NaCl-treated segments, aneurymal alteration (n=6, 50%), media degeneration with regional disruption, fragmentation of elastic fiber, and increased collagen deposition (n=12, 100%) were demonstrated in CaCl(2)-treated segments.",20621845_5,-1,-1,-1,10527,-1,0.035281923,0.9647181
10528,p<0.01,16,17,94,100,"MMP-2, MMP-9, ADAM-10 and ADAM-17 mRNA levels were increased in CaCl(2)-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.",20621845_6,-1,-1,-1,10528,-1,0.393442,0.606558
10529,p<0.01,15,16,109,115,"Immunohistochemistry displayed significantly increased expressions of MMP-2, MMP-9, ADAM-10 and ADAM-17 (all p<0.01) in intima and media for CaCl(2)-treated segments.",20621845_7,-1,-1,-1,10529,-1,0.4348031,0.5651969
10530,TAA,6,7,37,40,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,-1,-1,-1,10530,-1,0.0037644638,0.99623555
10531,CaCl(2),10,12,63,70,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,-1,-1,-1,10531,-1,0.9976598,0.0023401983
10532,vascular remodeling,35,37,202,221,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,-1,-1,-1,10532,-1,0.0015718814,0.9984281
10537,organophosphorus,13,14,105,121,Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.,20633755_1,-1,-1,-1,10537,-1,0.9978859,0.0021141043
10538,OP) poisons,15,18,123,134,Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.,20633755_1,-1,-1,-1,10538,-1,0.8182338,0.18176618
10541,OP compound,13,15,85,96,Prolonged apnea in our case ensued because the information about suicidal attempt by OP compound was concealed from the treating team.,20633755_3,-1,-1,-1,10541,-1,0.9979499,0.0020501052
10542,congestive heart failure,1,4,7,31,Severe congestive heart failure patient on amiodarone presenting with myxedemic coma: a case report.,20635749_0,-1,-1,-1,10542,-1,0.0011984645,0.99880147
10547,congestive heart failure,17,20,111,135,This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).,20635749_1,-1,-1,-1,10547,-1,0.0011261088,0.9988739
10548,CHF,21,22,137,140,This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).,20635749_1,-1,-1,-1,10548,-1,0.001296181,0.99870384
10553,T4,8,9,53,55,The condition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine (T3).,20635749_4,-1,-1,-1,10553,-1,0.99763536,0.002364581
10554,T3,14,15,92,94,The condition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine (T3).,20635749_4,-1,-1,-1,10554,-1,0.99752253,0.0024774878
10555,CHF,2,3,14,17,"Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.",20635749_5,-1,-1,-1,10555,-1,0.0013422002,0.9986578
10559,CHF,15,16,104,107,This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients.,20635749_6,-1,-1,-1,10559,-1,0.0020490366,0.997951
10561,CHF,22,23,148,151,"The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension, weakness or other unexplained symptoms.",20635749_7,-1,-1,-1,10561,-1,0.001641378,0.99835855
10565,cognitive dysfunction,2,4,21,42,Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.,20667451_0,-1,-1,-1,10565,-1,0.001806092,0.9981939
10570,cognitive impairment,12,14,82,102,"The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.",20667451_1,-1,-1,-1,10570,-1,0.0014198945,0.9985801
10571,cognitive impairment,16,18,98,118,The increase in free radical generation has been implicated as one of the important mechanisms of cognitive impairment by antiepileptic drugs.,20667451_2,-1,-1,-1,10571,-1,0.0014685309,0.99853146
10574,cognitive impairment,20,22,151,171,"Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.",20667451_4,-1,-1,-1,10574,-1,0.0016771356,0.9983229
10581,reduced glutathione,16,18,100,119,"At the end of study period, serum phenobarbitone and carbamazepine, whole brain malondialdehyde and reduced glutathione levels were estimated.",20667451_8,-1,-1,-1,10581,-1,0.9984396,0.0015604271
10584,impairment,11,12,87,97,The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress.,20667451_9,-1,-1,-1,10584,-1,0.002766221,0.9972338
10586,cognitive impairment,5,7,50,70,Concomitant curcumin administration prevented the cognitive impairment and decreased the increased oxidative stress induced by these antiepileptic drugs.,20667451_10,-1,-1,-1,10586,-1,0.0015604612,0.9984395
10591,deterioration of cognitive functions,11,15,73,109,These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.,20667451_12,-1,-1,-1,10591,-1,0.0027896955,0.9972103
10597,cognitive impairment,22,24,154,174,The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.,20667451_13,-1,-1,-1,10597,-1,0.001388686,0.99861133
10598,crocin,9,10,53,59,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.",20683499_0,-1,-1,-1,10598,-1,0.9989467,0.0010533019
10599,Alzheimer's disease,15,18,102,121,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.",20683499_0,-1,-1,-1,10599,-1,0.0020458214,0.99795413
10600,carotenoids,6,7,45,56,"BACKGROUND: The involvement of water-soluble carotenoids, crocins, as the main and active components of Crocus sativus L. extract in learning and memory processes has been proposed.",20683499_1,-1,-1,-1,10600,-1,0.9984819,0.0015180497
10601,crocins,8,9,58,65,"BACKGROUND: The involvement of water-soluble carotenoids, crocins, as the main and active components of Crocus sativus L. extract in learning and memory processes has been proposed.",20683499_1,-1,-1,-1,10601,-1,0.9986467,0.0013533952
10602,crocins,8,9,36,43,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,-1,-1,-1,10602,-1,0.9990889,0.0009110646
10603,Alzheimer's disease,11,14,56,75,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,-1,-1,-1,10603,-1,0.0018035056,0.99819654
10604,streptozocin,20,21,117,129,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,-1,-1,-1,10604,-1,0.9992331,0.0007668655
10605,STZ,22,23,131,134,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,-1,-1,-1,10605,-1,0.9990226,0.0009774516
10606,n,7,8,33,34,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,-1,-1,-1,10606,-1,0.19891673,0.8010833
10607,crocins,27,28,94,101,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,-1,-1,-1,10607,-1,0.9991554,0.00084465736
10608,STZ,37,38,124,127,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,-1,-1,-1,10608,-1,0.9987596,0.0012403611
10609,STZ,43,44,138,141,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,-1,-1,-1,10609,-1,0.9986123,0.0013877195
10610,crocins,45,46,144,151,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,-1,-1,-1,10610,-1,0.99907553,0.0009243988
10611,Alzheimer's disease,1,4,3,22,"In Alzheimer's disease groups, rats were injected with STZ-icv bilaterally (3 mg/kg) in first day and 3 days later, a similar STZ-icv application was repeated.",20683499_4,-1,-1,-1,10611,-1,0.0030461068,0.99695385
10612,STZ,1,2,3,6,"In STZ + crocin animal groups, crocin was applied in doses of 15 and 30 mg/kg, i.p., one day pre-surgery and continued for three weeks.",20683499_5,-1,-1,-1,10612,-1,0.998847,0.0011529977
10613,crocin,3,4,9,15,"In STZ + crocin animal groups, crocin was applied in doses of 15 and 30 mg/kg, i.p., one day pre-surgery and continued for three weeks.",20683499_5,-1,-1,-1,10613,-1,0.9990281,0.0009718723
10614,crocin,7,8,31,37,"In STZ + crocin animal groups, crocin was applied in doses of 15 and 30 mg/kg, i.p., one day pre-surgery and continued for three weeks.",20683499_5,-1,-1,-1,10614,-1,0.99914575,0.00085425685
10615,crocin,2,3,16,22,Prescription of crocin in each dose was repeated once for two days.,20683499_6,-1,-1,-1,10615,-1,0.99883515,0.0011648618
10616,crocin,7,8,31,37,RESULTS: It was found out that crocin (30 mg/kg)-treated STZ-injected rats show higher correct choices and lower errors in Y-maze than vehicle-treated STZ-injected rats.,20683499_8,-1,-1,-1,10616,-1,0.9992718,0.0007282531
10617,crocin,3,4,13,19,"In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test.",20683499_9,-1,-1,-1,10617,-1,0.9991991,0.0008009044
10619,crocin,10,11,70,76,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",20683499_10,-1,-1,-1,10619,-1,0.999185,0.0008150142
10621,neurodegenerative diseases,32,34,191,217,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",20683499_10,-1,-1,-1,10621,-1,0.0013018008,0.9986981
10622,Alzheimer's disease,36,39,226,245,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",20683499_10,-1,-1,-1,10622,-1,0.0018296421,0.9981704
10624,hemolytic anemia?BACKGROUND/AIMS,10,12,67,99,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,-1,-1,-1,10624,-1,0.007613716,0.99238634
10626,sunitinib,29,30,207,216,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,-1,-1,-1,10626,-1,0.9991264,0.0008736436
10630,chronically infected with hepatitis C virus,4,10,27,70,METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin.,20698227_2,-1,-1,-1,10630,-1,0.0052606026,0.99473935
10631,pegylated interferon alpha 2a,13,17,87,116,METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin.,20698227_2,-1,-1,-1,10631,-1,0.9990589,0.0009411304
10633,contrast,1,2,3,11,"In contrast with the literature, serum levels of angiogenesis factors did not change significantly by pegylated interferon and ribavirin therapy.",20698227_6,-1,-1,-1,10633,-1,0.11239884,0.8876011
10634,pegylated interferon,16,18,102,122,"In contrast with the literature, serum levels of angiogenesis factors did not change significantly by pegylated interferon and ribavirin therapy.",20698227_6,-1,-1,-1,10634,-1,0.9992175,0.0007824297
10638,hepatitis C,24,26,158,169,CONCLUSION: This is the first study in the literature investigating a link between angiogenesis soluble markers and ribavirin induced anemia in patients with hepatitis C and we could not find any relation.,20698227_8,-1,-1,-1,10638,-1,0.002584659,0.9974153
10652,P,28,29,140,141,"The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine (2.7 +/- 1.9 vs. 3.8 +/- 2.2, P = 0.03).",2070391_4,-1,-1,-1,10652,-1,0.34357706,0.656423
10656,psychosis,8,9,69,78,Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population.,20705401_0,-1,-1,-1,10656,-1,0.0012169395,0.99878305
10657,psychotic disorders,14,16,103,122,BACKGROUND: Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for psychotic disorders such as schizophrenia.,20705401_1,-1,-1,-1,10657,-1,0.0017441317,0.9982559
10660,antipsychotics,14,15,90,104,"The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.",20705401_2,-1,-1,-1,10660,-1,0.99866986,0.0013301261
10664,phencyclidine,11,12,75,88,"In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.",20705401_3,-1,-1,-1,10664,-1,0.99933976,0.00066027284
10666,psychotic disorders,28,30,187,206,"These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.",20705401_4,-1,-1,-1,10666,-1,0.0015120555,0.99848795
10668,psychosis,5,6,47,56,The symptoms of methamphetamine (METH)-induced psychosis are similar to those of paranoid type schizophrenia.,20705401_5,-1,-1,-1,10668,-1,0.0013156001,0.99868435
10669,paranoid type schizophrenia,11,14,81,108,The symptoms of methamphetamine (METH)-induced psychosis are similar to those of paranoid type schizophrenia.,20705401_5,-1,-1,-1,10669,-1,0.0019609334,0.99803907
10670,5-HT6,11,12,62,67,"Therefore, we conducted an analysis of the association of the 5-HT6 gene (HTR6) with METH-induced psychosis.",20705401_6,-1,-1,-1,10670,-1,0.9978955,0.0021045285
10671,psychosis,18,19,98,107,"Therefore, we conducted an analysis of the association of the 5-HT6 gene (HTR6) with METH-induced psychosis.",20705401_6,-1,-1,-1,10671,-1,0.0013336925,0.9986663
10672,psychosis,30,31,178,187,"METHOD: Using five tagging SNPs (rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.",20705401_7,-1,-1,-1,10672,-1,0.0016074084,0.9983925
10673,methamphetamine dependence,15,17,73,99,The age and sex of the control subjects did not differ from those of the methamphetamine dependence patients.,20705401_8,-1,-1,-1,10673,-1,0.76694834,0.23305166
10674,psychosis,7,8,52,61,RESULTS: rs6693503 was associated with METH-induced psychosis patients in the allele/genotype-wise analysis.,20705401_9,-1,-1,-1,10674,-1,0.0013167547,0.9986833
10675,psychosis,31,32,185,194,"In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and rs4912138) in HTR6 and METH-induced psychosis patients, respectively.",20705401_11,-1,-1,-1,10675,-1,0.001437911,0.99856216
10676,psychosis,13,14,83,92,CONCLUSION: HTR6 may play an important role in the pathophysiology of METH-induced psychosis in the Japanese population.,20705401_12,-1,-1,-1,10676,-1,0.0011419218,0.9988581
10682,h,12,13,31,32,"Before and 0.5, 1, 2, 3, and 6 h after injection the subjects were given attention and mnemonic tests.",2071257_4,-1,-1,-1,10682,-1,0.49271145,0.5072885
10683,impairment of attention and memory,13,18,72,106,The findings of this study indicate that the drug is able to antagonize impairment of attention and memory induced by scopolamine.,2071257_5,-1,-1,-1,10683,-1,0.005853104,0.99414694
10686,Fluoropyrimidines,5,6,25,42,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.",20722491_1,-1,-1,-1,10686,-1,0.9986584,0.0013415688
10688,5-FU,11,12,74,78,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.",20722491_1,-1,-1,-1,10688,-1,0.99836284,0.001637168
10690,head and neck cancers,30,34,176,197,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.",20722491_1,-1,-1,-1,10690,-1,0.0037066543,0.99629337
10693,renal,27,28,154,159,"WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age, renal and kidney disease.",20722491_3,-1,-1,-1,10693,-1,0.0025642663,0.99743575
10694,kidney disease,29,31,164,178,"WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age, renal and kidney disease.",20722491_3,-1,-1,-1,10694,-1,0.0021629576,0.997837
10697,5-FU,10,11,54,58,TAKE HOME MESSAGE: Capecitabine is an oral prodrug of 5-FU and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile.,20722491_5,-1,-1,-1,10697,-1,0.99854374,0.0014563232
10698,head and neck cancers,25,29,157,178,"It has shown promising results alone or in combination with other chemotherapeutic agents in colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers.",20722491_6,-1,-1,-1,10698,-1,0.0036406177,0.9963594
10705,renal dysfunctions,19,21,118,136,"Capecitabine has a well-established safety profile and can be given safely to patients with advanced age, hepatic and renal dysfunctions.",20722491_8,-1,-1,-1,10705,-1,0.0020051685,0.9979949
10706,psychosis,5,6,40,49,Neural correlates of S-ketamine induced psychosis during overt continuous verbal fluency.,20727411_0,-1,-1,-1,10706,-1,0.001296652,0.99870336
10707,NMDA,4,5,40,44,The glutamatergic N-methyl-D-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia.,20727411_1,-1,-1,-1,10707,-1,0.9985259,0.0014740608
10709,NMDA,11,12,80,84,"Administered to healthy volunteers, a subanesthetic dose of the non-competitive NMDA receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in schizophrenia.",20727411_2,-1,-1,-1,10709,-1,0.998691,0.0013090046
10711,psychopathological,17,18,123,141,"Administered to healthy volunteers, a subanesthetic dose of the non-competitive NMDA receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in schizophrenia.",20727411_2,-1,-1,-1,10711,-1,0.0017430203,0.998257
10712,psychopathological,17,18,123,141,"Administered to healthy volunteers, a subanesthetic dose of the non-competitive NMDA receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in schizophrenia.",20727411_2,-1,-1,-1,10712,-1,0.0017430203,0.998257
10716,glutamatergic dysfunction,18,20,114,139,"In patients with schizophrenia, ketamine exacerbates the core symptoms of illness, supporting the hypothesis of a glutamatergic dysfunction.",20727411_3,-1,-1,-1,10716,-1,0.3218779,0.6781221
10717,psychopathological,1,2,17,35,Ketamine-induced psychopathological symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS).,20727411_6,-1,-1,-1,10717,-1,0.0018011198,0.9981989
10719,psychosis,2,3,18,27,Ketamine elicited psychosis like psychopathology.,20727411_7,-1,-1,-1,10719,-1,0.0014323341,0.9985676
10720,psychopathology,4,5,33,48,Ketamine elicited psychosis like psychopathology.,20727411_7,-1,-1,-1,10720,-1,0.0014964953,0.99850357
10725,NMDA,10,11,61,65,Our results provide further support for the hypothesis of an NMDA receptor dysfunction in the pathophysiology of schizophrenia.,20727411_11,-1,-1,-1,10725,-1,0.99794954,0.002050445
10730,acute liver injury,10,13,77,95,"METHODS: We followed up all transplant-free survivors of paracetamol-induced acute liver injury, hospitalized in a Danish national referral centre during 1984-2004.",20735774_3,-1,-1,-1,10730,-1,0.0012348362,0.99876523
10738,substance abuse,17,19,113,128,"More likely, the elevated mortality rate ratio resulted from incomplete adjustment for the greater prevalence of substance abuse among survivors of acute liver failure.",20735774_8,-1,-1,-1,10738,-1,0.69145614,0.30854386
10741,liver failure,10,12,56,69,"Clinical follow-up may be justified by the cause of the liver failure, but not by the liver failure itself.",20735774_10,-1,-1,-1,10741,-1,0.0017095193,0.9982905
10742,liver failure,17,19,86,99,"Clinical follow-up may be justified by the cause of the liver failure, but not by the liver failure itself.",20735774_10,-1,-1,-1,10742,-1,0.0017288785,0.9982711
10744,Parkinson's disease,5,8,46,65,Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.,20880751_0,-1,-1,-1,10744,-1,0.0022938116,0.9977062
10746,Parkinson's disease,10,13,57,76,Levodopa is the most effective drug for the treatment of Parkinson's disease.,20880751_1,-1,-1,-1,10746,-1,0.0023030492,0.99769694
10750,Parkinson's disease,9,12,48,67,"In recent years, evidence from animal models of Parkinson's disease has provided important information to understand the effect of specific receptor and post-receptor molecular mechanisms underlying the development of dyskinetic movements.",20880751_4,-1,-1,-1,10750,-1,0.0018606023,0.9981394
10751,dyskinetic movements,31,33,218,238,"In recent years, evidence from animal models of Parkinson's disease has provided important information to understand the effect of specific receptor and post-receptor molecular mechanisms underlying the development of dyskinetic movements.",20880751_4,-1,-1,-1,10751,-1,0.0014341037,0.998566
10756,parkinsonian catalepsy,6,8,55,77,Effects of pallidal neurotensin on haloperidol-induced parkinsonian catalepsy: behavioral and electrophysiological studies.,20882060_0,-1,-1,-1,10756,-1,0.001423824,0.99857616
10759,parkinsonian symptoms,13,15,98,119,The present study aimed to investigate the effects of pallidal neurotensin on haloperidol-induced parkinsonian symptoms.,20882060_3,-1,-1,-1,10759,-1,0.0014758544,0.9985241
10761,parkinsonian catalepsy,12,14,98,120,RESULTS: Bilateral infusions of neurotensin into the globus pallidus reversed haloperidol-induced parkinsonian catalepsy in rats.,20882060_5,-1,-1,-1,10761,-1,0.0015902627,0.99840975
10765,SR48692,5,6,43,50,The neurotensin type-1 receptor antagonist SR48692 blocked both the behavioral and the electrophysiological effects induced by neurotensin.,20882060_7,-1,-1,-1,10765,-1,0.99903786,0.0009622002
10768,organic mental disorders,1,4,17,41,Carmofur-induced organic mental disorders.,2096243_0,-1,-1,-1,10768,-1,0.0015125178,0.9984875
10769,Organic mental disorder,0,3,0,23,Organic mental disorder was observed in a 29-year-old female in the prognostic period after the onset of carmofur-induced leukoencephalopathy.,2096243_1,-1,-1,-1,10769,-1,0.0011645579,0.9988355
10771,organic personality syndrome,17,20,106,134,"Symptoms such as euphoria, emotional lability and puerile attitude noted in the patient were diagnosed as organic personality syndrome according to the criteria defined in the DSM-III-R. It is referred to as a frontal lobe syndrome.",2096243_2,-1,-1,-1,10771,-1,0.0021209065,0.99787915
10772,frontal lobe syndrome,34,37,210,231,"Symptoms such as euphoria, emotional lability and puerile attitude noted in the patient were diagnosed as organic personality syndrome according to the criteria defined in the DSM-III-R. It is referred to as a frontal lobe syndrome.",2096243_2,-1,-1,-1,10772,-1,0.004390677,0.99560934
10774,organic personality syndrome,8,11,76,104,"Consequently, carmofur-induced leukoencephalopathy may uncommonly result in organic personality syndrome in the residual state.",2096243_4,-1,-1,-1,10774,-1,0.0014201895,0.99857986
10775,structural damage to the frontal lobe,6,12,28,65,It may be attributed to the structural damage to the frontal lobe.,2096243_5,-1,-1,-1,10775,-1,0.0102205,0.98977953
10777,Parkinson's disease,14,17,92,111,In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.,20973483_0,-1,-1,-1,10777,-1,0.0020226643,0.9979773
10779,Parkinson's disease,17,20,108,127,The in vivo characterization of a dual adenosine A(2A)/A(1) receptor antagonist in several animal models of Parkinson's disease is described.,20973483_1,-1,-1,-1,10779,-1,0.0020939251,0.9979061
10780,Parkinson's disease,44,47,198,217,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,-1,10780,-1,0.0019840433,0.998016
10782,akinesia,60,61,316,324,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,-1,10782,-1,0.0018324746,0.9981675
10784,6-OHDA,65,66,349,355,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,-1,10784,-1,0.9988933,0.0011067304
10785,rotation,71,72,386,394,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,-1,10785,-1,0.0016694383,0.99833053
10800,n=10,3,4,12,16,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,-1,-1,-1,10800,-1,0.12308673,0.87691325
10801,n=10,14,15,62,66,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,-1,-1,-1,10801,-1,0.1085984,0.8914016
10802,penicillin G,37,39,143,155,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,-1,-1,-1,10802,-1,0.9987858,0.0012142546
10804,lead,8,9,52,56,"In the control group, hippocampal stimulation alone lead only to diffuse slowing of cerebral bioelectrical activity at 5V stimulation.",21294084_8,-1,-1,-1,10804,-1,0.060182944,0.9398171
10808,CCNU,0,1,0,4,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,-1,-1,-1,10808,-1,0.99869114,0.0013088512
10809,lomustine,2,3,6,15,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,-1,-1,-1,10809,-1,0.9991998,0.0008002549
10811,gastrointestinal toxicities,26,28,142,169,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,-1,-1,-1,10811,-1,0.0015844695,0.99841547
10812,1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea,32,33,203,247,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,-1,-1,-1,10812,-1,0.99836713,0.0016328527
10813,CCNU,34,35,249,253,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,-1,-1,-1,10813,-1,0.99893194,0.0010681013
10814,CCNU,12,13,63,67,DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.,21418164_1,-1,-1,-1,10814,-1,0.99042904,0.009570919
10815,CCNU,8,9,38,42,"RESULTS: Of the 206 dogs treated with CCNU, 185 met the inclusion criteria for at least one class of toxicity.",21418164_2,-1,-1,-1,10815,-1,0.99808323,0.0019167617
10817,CCNU,0,1,0,4,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10817,-1,0.9973477,0.0026522698
10818,lymphoma,9,10,48,56,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10818,-1,0.001723549,0.9982765
10819,mast cell tumour,11,14,58,74,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10819,-1,0.0027736588,0.9972263
10820,brain tumour,15,17,76,88,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10820,-1,0.0021210536,0.9978789
10821,histiocytic tumours,18,20,90,109,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10821,-1,0.003326956,0.996673
10822,epitheliotropic lymphoma,21,23,114,138,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10822,-1,0.005751192,0.99424875
10824,anaemia,13,14,79,86,"Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.",21418164_4,-1,-1,-1,10824,-1,0.0013868681,0.9986131
10826,Gastrointestinal toxicosis,0,2,0,26,"Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%).",21418164_5,-1,-1,-1,10826,-1,0.0013015665,0.99869835
10830,hepatic failure,3,5,17,32,The incidence of hepatic failure was 1.2%.,21418164_7,-1,-1,-1,10830,-1,0.0016016811,0.99839836
10836,angina pectoris,35,37,201,216,"Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris.",220563_1,-1,-1,-1,10836,-1,0.0010979496,0.9989021
10837,demyelinating disorder,22,24,142,164,"In 24 patients with this complication, the marked slowing of motor nerve conduction velocity and the electromyographic changes imply mainly a demyelinating disorder.",220563_2,-1,-1,-1,10837,-1,0.0011836914,0.9988164
10839,Central vein thrombosis,0,3,0,23,Central vein thrombosis and topical dipivalyl epinephrine.,2220369_0,-1,-1,-1,10839,-1,0.0023259572,0.99767405
10840,dipivalyl epinephrine,5,7,36,57,Central vein thrombosis and topical dipivalyl epinephrine.,2220369_0,-1,-1,-1,10840,-1,0.9988325,0.0011674868
10841,central vein thrombosis,10,13,56,79,A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye.,2220369_1,-1,-1,-1,10841,-1,0.001807265,0.9981927
10842,dipivalyl epinephrine,25,27,151,172,A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye.,2220369_1,-1,-1,-1,10842,-1,0.99901676,0.0009832513
10846,Pirarubicin,12,13,76,87,A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refractory tumors.,2224762_2,-1,-1,-1,10846,-1,0.9992292,0.0007707859
10848,hepatic dysfunction,25,27,119,138,"Twenty-six had minimal prior therapy (good risk), 23 had extensive prior therapy (poor risk), and six had renal and/or hepatic dysfunction.",2224762_3,-1,-1,-1,10848,-1,0.0021722878,0.9978277
10849,granulocytopenia,7,8,59,75,The dose-limiting toxic effect was transient noncumulative granulocytopenia.,2224762_6,-1,-1,-1,10849,-1,0.0011956235,0.99880433
10853,alopecia,12,13,76,84,"Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis.",2224762_8,-1,-1,-1,10853,-1,0.0013891832,0.99861073
10854,phlebitis,14,15,86,95,"Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis.",2224762_8,-1,-1,-1,10854,-1,0.0013257393,0.9986743
10857,hepatic dysfunction,6,8,43,62,Myelosuppression was more in patients with hepatic dysfunction.,2224762_9,-1,-1,-1,10857,-1,0.0014867272,0.9985133
10858,Pirarubicin,6,7,49,60,"Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours.",2224762_10,-1,-1,-1,10858,-1,0.9990508,0.0009492389
10859,SE,14,15,85,87,"Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours.",2224762_10,-1,-1,-1,10859,-1,0.16096522,0.8390348
10860,Adriamycinol,0,1,0,12,"Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites.",2224762_12,-1,-1,-1,10860,-1,0.9991303,0.00086970214
10862,adriamycinone,4,5,27,40,"Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites.",2224762_12,-1,-1,-1,10862,-1,0.99906665,0.0009333694
10863,tetrahydropyranyladriamycinol,7,8,46,75,"Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites.",2224762_12,-1,-1,-1,10863,-1,0.9990677,0.00093226903
10865,Pirarubicin,3,4,21,32,Urinary excretion of Pirarubicin in the first 24 hours was less than or equal to 10%.,2224762_13,-1,-1,-1,10865,-1,0.9991247,0.00087532465
10866,mesothelioma,4,5,22,34,"Activity was noted in mesothelioma, leiomyosarcoma, and basal cell carcinoma.",2224762_14,-1,-1,-1,10866,-1,0.002459956,0.9975401
10867,leiomyosarcoma,6,7,36,50,"Activity was noted in mesothelioma, leiomyosarcoma, and basal cell carcinoma.",2224762_14,-1,-1,-1,10867,-1,0.0024059962,0.99759394
10868,basal cell carcinoma,9,12,56,76,"Activity was noted in mesothelioma, leiomyosarcoma, and basal cell carcinoma.",2224762_14,-1,-1,-1,10868,-1,0.0034823585,0.99651766
10869,auditory toxicity,2,4,11,28,Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine.,2234245_0,-1,-1,-1,10869,-1,0.0014501839,0.99854976
10872,audiovisual toxicity,29,31,169,189,During an 18-month period of study 41 hemodialyzed patients receiving desferrioxamine (10-40 mg/kg BW/3 times weekly) for the first time were monitored for detection of audiovisual toxicity.,2234245_1,-1,-1,-1,10872,-1,0.0019836295,0.99801636
10873,visual or auditory toxicity,6,10,42,69,6 patients presented clinical symptoms of visual or auditory toxicity.,2234245_2,-1,-1,-1,10873,-1,0.0020340888,0.99796593
10874,Visual toxicity,0,2,0,15,"Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits.",2234245_4,-1,-1,-1,10874,-1,0.0017226385,0.9982774
10875,dyschromatopsy,12,13,77,91,"Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits.",2234245_4,-1,-1,-1,10875,-1,0.0013162418,0.99868375
10876,loss of visual acuity,18,22,121,142,"Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits.",2234245_4,-1,-1,-1,10876,-1,0.0037685134,0.9962315
10877,pigmentary retinal deposits,23,26,147,174,"Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits.",2234245_4,-1,-1,-1,10877,-1,0.0018086021,0.9981914
10878,Auditory toxicity,0,2,0,17,Auditory toxicity was characterized by a mid- to high-frequency neurosensorial hearing loss and the lesion was of the cochlear type.,2234245_5,-1,-1,-1,10878,-1,0.0017467396,0.9982533
10879,neurosensorial hearing loss,9,12,64,91,Auditory toxicity was characterized by a mid- to high-frequency neurosensorial hearing loss and the lesion was of the cochlear type.,2234245_5,-1,-1,-1,10879,-1,0.0014313251,0.99856865
10881,hearing loss,24,26,145,157,"Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3, and a complete reversal of hearing loss in 3 patients and partial recovery in 3.",2234245_6,-1,-1,-1,10881,-1,0.0024454216,0.9975546
10884,aluminium,19,20,132,141,This toxicity appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or aluminium serum levels.,2234245_7,-1,-1,-1,10884,-1,0.9986198,0.0013802515
10885,audiovisual toxicity,4,6,23,43,The data indicate that audiovisual toxicity is not an infrequent complication in hemodialyzed patients receiving desferrioxamine.,2234245_8,-1,-1,-1,10885,-1,0.0015855439,0.9984144
10887,Benzylacyclouridine,0,1,0,19,Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.,2257294_0,-1,-1,-1,10887,-1,0.9991178,0.00088217296
10888,marrow suppression,3,5,52,70,Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.,2257294_0,-1,-1,-1,10888,-1,0.002369699,0.99763024
10889,immunodeficiency,9,10,104,120,Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.,2257294_0,-1,-1,-1,10889,-1,0.01116102,0.988839
10890,uridine,4,5,42,49,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,-1,-1,-1,10890,-1,0.9992052,0.00079482433
10891,Urd,6,7,51,54,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,-1,-1,-1,10891,-1,0.99888045,0.001119495
10893,immunodeficiency,30,31,221,237,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,-1,-1,-1,10893,-1,0.008431008,0.991569
10895,Urd,8,9,59,62,"Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.",2257294_2,-1,-1,-1,10895,-1,0.9010141,0.098985925
10896,benzylacyclouridine,14,15,94,113,"Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.",2257294_2,-1,-1,-1,10896,-1,0.9991922,0.00080783037
10897,BAU,16,17,115,118,"Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.",2257294_2,-1,-1,-1,10897,-1,0.9986173,0.0013826828
10900,Urd,3,4,20,23,"This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without Urd-related toxicity.",2257294_3,-1,-1,-1,10900,-1,0.9987231,0.001276857
10901,Urd,15,16,87,90,"This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without Urd-related toxicity.",2257294_3,-1,-1,-1,10901,-1,0.9987446,0.0012553728
10903,anemic,3,4,17,23,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10903,-1,0.0014629916,0.99853706
10904,leukopenic,5,6,28,38,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10904,-1,0.0012616424,0.99873835
10905,AZT,10,11,64,67,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10905,-1,0.9991091,0.0008908814
10906,drinking water,15,17,83,97,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10906,-1,0.9904488,0.009551259
10907,AZT,26,27,143,146,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10907,-1,0.9991124,0.0008875241
10908,BAU,29,30,158,161,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10908,-1,0.9987206,0.0012793257
10911,P,43,44,236,237,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10911,-1,0.22893439,0.77106565
10912,P,57,58,299,300,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10912,-1,0.27113232,0.72886765
10913,megaloblastosis,71,72,367,382,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10913,-1,0.0015491651,0.99845076
10914,AZT,3,4,25,28,"When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.",2257294_5,-1,-1,-1,10914,-1,0.9991062,0.00089375133
10915,BAU,11,12,68,71,"When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.",2257294_5,-1,-1,-1,10915,-1,0.9983285,0.0016715148
10916,marrow toxicity,14,16,92,107,"When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.",2257294_5,-1,-1,-1,10916,-1,0.0015153853,0.9984847
10917,BAU,10,11,45,48,"In vitro, at a concentration of 100 mumol/L, BAU possesses minimal anti-HIV activity and has no effect on the ability of AZT to reverse the HIV-induced cytopathic effect in MT4 cells.",2257294_6,-1,-1,-1,10917,-1,0.9987233,0.0012766419
10918,AZT,23,24,121,124,"In vitro, at a concentration of 100 mumol/L, BAU possesses minimal anti-HIV activity and has no effect on the ability of AZT to reverse the HIV-induced cytopathic effect in MT4 cells.",2257294_6,-1,-1,-1,10918,-1,0.9990025,0.0009974963
10921,hallucinosis,43,44,259,271,"Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a carbidopa/levodopa preparation; and both had the onset of hallucinosis and recurrent seizures, which were refractory to anticonvulsants.",2265898_1,-1,-1,-1,10921,-1,0.0014148544,0.9985852
10923,vitamin B6,19,21,119,129,The first patient died without a diagnosis; the second patient had a dramatic recovery following the administration of vitamin B6.,2265898_2,-1,-1,-1,10923,-1,0.9988176,0.0011822939
10925,Duchenne dystrophy,7,9,46,64,"Randomized, double-blind trial of mazindol in Duchenne dystrophy.",2266990_0,-1,-1,-1,10925,-1,0.002675094,0.9973248
10926,growth hormone,4,6,23,37,There is evidence that growth hormone may be related to the progression of weakness in Duchenne dystrophy.,2266990_1,-1,-1,-1,10926,-1,0.9985953,0.001404728
10928,Duchenne dystrophy,15,17,87,105,There is evidence that growth hormone may be related to the progression of weakness in Duchenne dystrophy.,2266990_1,-1,-1,-1,10928,-1,0.0024060728,0.99759394
10930,growth hormone,11,13,65,79,"We conducted a 12-month controlled trial of mazindol, a putative growth hormone secretion inhibitor, in 83 boys with Duchenne dystrophy.",2266990_2,-1,-1,-1,10930,-1,0.997957,0.002043003
10931,Duchenne dystrophy,20,22,117,135,"We conducted a 12-month controlled trial of mazindol, a putative growth hormone secretion inhibitor, in 83 boys with Duchenne dystrophy.",2266990_2,-1,-1,-1,10931,-1,0.0036093725,0.99639064
10932,contractures,3,4,17,29,"Muscle strength, contractures, functional ability and pulmonary function were tested at baseline, and 6 and 12 months after treatment with mazindol (3 mg/d) or placebo.",2266990_3,-1,-1,-1,10932,-1,0.0019416044,0.9980584
10933,pulmonary function,8,10,54,72,"Muscle strength, contractures, functional ability and pulmonary function were tested at baseline, and 6 and 12 months after treatment with mazindol (3 mg/d) or placebo.",2266990_3,-1,-1,-1,10933,-1,0.0070080846,0.9929919
10936,P,28,29,138,139,The study was designed to have a power of greater than 0.90 to detect a slowing to 25% of the expected rate of progression of weakness at P less than 0.05.,2266990_4,-1,-1,-1,10936,-1,0.5111212,0.48887876
10939,decreased appetite,6,8,47,65,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,-1,-1,-1,10939,-1,0.0018975683,0.9981025
10941,gastrointestinal symptoms,28,30,119,144,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,-1,-1,-1,10941,-1,0.0014810065,0.998519
10944,GH,5,6,26,28,"The effect of mazindol on GH secretion was estimated indirectly by comparing the postabsorptive IGF-I levels obtained following 3, 6, 9, and 12 months in the mazindol treated to those in the placebo groups.",2266990_7,-1,-1,-1,10944,-1,0.9968624,0.0031376507
10948,Duchenne dystrophy,9,11,55,73,Mazindol doses not slow the progression of weakness in Duchenne dystrophy.,2266990_9,-1,-1,-1,10948,-1,0.002203848,0.9977962
10966,nalozone,29,30,184,192,"In unanesthetized, spontaneously hypertensive rats the decrease in blood pressure and heart rate produced by intravenous clonidine, 5 to 20 micrograms/kg, was inhibited or reversed by nalozone, 0.2 to 2 mg/kg.",227508_1,-1,-1,-1,10966,-1,0.999276,0.0007240636
10978,halogenated hydroxyquinolines,2,4,17,46,Neurotoxicity of halogenated hydroxyquinolines: clinical analysis of cases reported outside Japan.,230316_0,-1,-1,-1,10978,-1,0.9979133,0.0020866967
10980,halogenated hydroxyquinolines,12,14,74,103,An analysis is presented of 220 cases of possible neurotoxic reactions to halogenated hydroxyquinolines reported from outside Japan.,230316_1,-1,-1,-1,10980,-1,0.99844044,0.0015595818
10981,clioquinol,19,20,122,132,In 80 cases insufficient information was available for adequate comment and in 29 a relationship to the administration of clioquinol could be excluded.,230316_2,-1,-1,-1,10981,-1,0.99921584,0.00078416074
10982,clioquinol,7,8,36,46,"Of the remainder, a relationship to clioquinol was considered probable in 42 and possible in 69 cases.",230316_3,-1,-1,-1,10982,-1,0.9991748,0.00082514266
10983,neurological disturbance,7,9,33,57,In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period.,230316_4,-1,-1,-1,10983,-1,0.0011714916,0.9988285
10985,clioquinol,25,26,157,167,In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period.,230316_4,-1,-1,-1,10985,-1,0.9992317,0.00076833914
10986,optic atrophy,13,15,74,87,"The most common manifestation, observed in 15 further cases, was isolated optic atrophy.",230316_5,-1,-1,-1,10986,-1,0.0017822745,0.99821776
10987,clioquinol,13,14,70,80,"This was most frequently found in children, many of whom had received clioquinol as treatment for acrodermatitis enteropathica.",230316_6,-1,-1,-1,10987,-1,0.99915993,0.0008400239
10988,acrodermatitis enteropathica,17,19,98,126,"This was most frequently found in children, many of whom had received clioquinol as treatment for acrodermatitis enteropathica.",230316_6,-1,-1,-1,10988,-1,0.0015986657,0.99840134
10989,myelopathy,8,9,41,51,"In the remaining cases, a combination of myelopathy, visual disturbance, and peripheral neuropathy was the most common manifestation.",230316_7,-1,-1,-1,10989,-1,0.0011395682,0.9988605
10990,visual disturbance,10,12,53,71,"In the remaining cases, a combination of myelopathy, visual disturbance, and peripheral neuropathy was the most common manifestation.",230316_7,-1,-1,-1,10990,-1,0.0013269951,0.9986731
10992,myelopathy,1,2,9,19,"Isolated myelopathy or peripheral neuropathy, or these manifestations occurring together, were infrequent.",230316_8,-1,-1,-1,10992,-1,0.0011888038,0.99881124
10994,toxic encephalopathy,7,9,40,60,"The onset of all manifestations (except toxic encephalopathy) was usually subacute, with subsequent partial recovery.",230316_9,-1,-1,-1,10994,-1,0.0013389846,0.99866104
11006,Myocardial infarction,0,2,0,21,Myocardial infarction following sublingual administration of isosorbide dinitrate.,2312209_0,-1,-1,-1,11006,-1,0.001678554,0.9983215
11007,isosorbide dinitrate,6,8,61,81,Myocardial infarction following sublingual administration of isosorbide dinitrate.,2312209_0,-1,-1,-1,11007,-1,0.99920875,0.00079130306
11008,septal necrosis,4,6,26,41,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,-1,-1,-1,11008,-1,0.0018866863,0.9981133
11009,myocardial infarction,9,11,63,84,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,-1,-1,-1,11009,-1,0.0014898663,0.99851006
11010,isosorbide dinitrate,19,21,138,158,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,-1,-1,-1,11010,-1,0.99929583,0.00070414087
11011,mg,22,23,161,163,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,-1,-1,-1,11011,-1,0.9950192,0.004980736
11013,myocardial ischemia,17,19,113,132,"After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency.",2312209_2,-1,-1,-1,11013,-1,0.0013215994,0.9986784
11014,coronary arterial stenosis,23,26,169,195,"After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency.",2312209_2,-1,-1,-1,11014,-1,0.0020263176,0.99797374
11015,acute coronary insufficiency,30,33,222,250,"After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency.",2312209_2,-1,-1,-1,11015,-1,0.0012909919,0.99870896
11019,impaired renal function,14,17,96,119,Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.,2320800_0,-1,-1,-1,11019,-1,0.0037181037,0.9962819
11022,renal failure,17,19,120,133,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,-1,-1,-1,11022,-1,0.0014558155,0.9985442
11025,Postrenal failure,0,2,0,17,Postrenal failure was excluded by echography.,2320800_2,-1,-1,-1,11025,-1,0.0020312956,0.99796873
11026,renal failure,7,9,47,60,"A prerenal component could have contributed to renal failure because of a transient hypotension, due to an increasing ascitis, occurring just before anuria.",2320800_3,-1,-1,-1,11026,-1,0.0015204165,0.99847955
11028,ascitis,19,20,118,125,"A prerenal component could have contributed to renal failure because of a transient hypotension, due to an increasing ascitis, occurring just before anuria.",2320800_3,-1,-1,-1,11028,-1,0.0014135306,0.99858654
11032,tubulopathies,8,9,57,70,Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies.,2320800_5,-1,-1,-1,11032,-1,0.0012480869,0.9987519
11039,prostaglandin D2,7,9,61,77,"Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice.",2322844_0,-1,-1,-1,11039,-1,0.9988803,0.0011196657
11040,E2,10,11,79,81,"Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice.",2322844_0,-1,-1,-1,11040,-1,0.99854386,0.0014562219
11041,F2,13,14,86,88,"Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice.",2322844_0,-1,-1,-1,11041,-1,0.99812084,0.0018790835
11044,acetic acid writhing,20,23,134,154,The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests.,2322844_1,-1,-1,-1,11044,-1,0.34878826,0.6512118
11045,Prostaglandin D2,0,2,0,16,Prostaglandin D2 (0.5-3 ng/mouse) had a hyperalgesic action on the response to a hot plate during a 3-60 min period after injection.,2322844_2,-1,-1,-1,11045,-1,0.99901056,0.0009893582
11046,hyperalgesic,10,11,40,52,Prostaglandin D2 (0.5-3 ng/mouse) had a hyperalgesic action on the response to a hot plate during a 3-60 min period after injection.,2322844_2,-1,-1,-1,11046,-1,0.0024061783,0.9975938
11047,Prostaglandin E2,0,2,0,16,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,-1,-1,-1,11047,-1,0.9988372,0.001162843
11048,hyperalgesic,4,5,26,38,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,-1,-1,-1,11048,-1,0.0022906186,0.9977094
11049,pg,10,11,60,62,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,-1,-1,-1,11049,-1,0.9950728,0.004927222
11050,prostaglandin D2,29,31,133,149,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,-1,-1,-1,11050,-1,0.9988907,0.0011093483
11051,acetic acid writhing,5,8,33,53,Similar results were obtained by acetic acid writhing tests.,2322844_4,-1,-1,-1,11051,-1,0.22254083,0.77745914
11052,hyperalgesic,1,2,4,16,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,-1,-1,-1,11052,-1,0.0021407888,0.9978592
11053,prostaglandin D2,4,6,27,43,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,-1,-1,-1,11053,-1,0.99906653,0.00093349075
11054,substance P,13,15,87,98,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,-1,-1,-1,11054,-1,0.9990466,0.0009534055
11055,ng,23,24,140,142,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,-1,-1,-1,11055,-1,0.98966265,0.010337353
11056,AH6809,28,29,155,161,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,-1,-1,-1,11056,-1,0.99909914,0.000900844
11057,prostaglandin,2,3,12,25,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,-1,-1,-1,11057,-1,0.9991604,0.0008395975
11059,AH6809,8,9,65,71,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,-1,-1,-1,11059,-1,0.99910575,0.00089421635
11060,ng,16,17,102,104,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,-1,-1,-1,11060,-1,0.9829116,0.017088443
11061,substance P,22,24,121,132,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,-1,-1,-1,11061,-1,0.9990269,0.0009731149
11062,Prostaglandin F2 alpha,0,3,0,22,Prostaglandin F2 alpha had little effect on pain responses.,2322844_7,-1,-1,-1,11062,-1,0.99834704,0.001652978
11064,prostaglandin D2,5,7,36,52,"These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.",2322844_8,-1,-1,-1,11064,-1,0.9987942,0.0012057555
11065,prostaglandin E2,8,10,57,73,"These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.",2322844_8,-1,-1,-1,11065,-1,0.99869746,0.0013025772
11067,localized scleroderma,5,7,36,57,D-penicillamine in the treatment of localized scleroderma.,2334179_0,-1,-1,-1,11067,-1,0.0014340368,0.998566
11068,Localized scleroderma,0,2,0,21,Localized scleroderma has no recognized internal organ involvement but may be disfiguring and disabling when the cutaneous lesions are extensive or affect children.,2334179_1,-1,-1,-1,11068,-1,0.0014006891,0.99859935
11069,localized scleroderma,8,10,45,66,There is no accepted or proven treatment for localized scleroderma.,2334179_2,-1,-1,-1,11069,-1,0.0015974926,0.99840254
11070,localized scleroderma,9,11,51,72,"Case reports of 11 patients with severe, extensive localized scleroderma who were treated with D-penicillamine are summarized in this article.",2334179_3,-1,-1,-1,11070,-1,0.0013002162,0.9986998
11071,cutaneous,13,14,76,85,"Improvement began within 3 to 6 months and consisted of cessation of active cutaneous lesions in all 7 patients, skin softening in 5, and more normal growth of the affected limb in 2 of 3 children.",2334179_5,-1,-1,-1,11071,-1,0.0021899731,0.99781007
11072,contractures,3,4,20,32,Joint stiffness and contractures also improved.,2334179_6,-1,-1,-1,11072,-1,0.0017136878,0.9982863
11073,nephrotic syndrome,2,4,23,41,D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.,2334179_8,-1,-1,-1,11073,-1,0.0011443839,0.9988556
11075,renal insufficiency,18,20,125,144,D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.,2334179_8,-1,-1,-1,11075,-1,0.0013247839,0.99867517
11076,localized scleroderma,12,14,76,97,These data suggest that D-penicillamine may be effective in severe cases of localized scleroderma.,2334179_9,-1,-1,-1,11076,-1,0.0013305519,0.9986695
11078,analgesia,5,6,35,44,infusions of morphine and regional analgesia by extradural block.,2334618_1,-1,-1,-1,11078,-1,0.002414144,0.9975859
11079,postoperative respiratory apnoea,3,6,17,49,The incidence of postoperative respiratory apnoea was compared between five patients receiving a continuous i.v.,2334618_2,-1,-1,-1,11079,-1,0.0014971509,0.99850285
11081,mg,6,7,32,34,infusion of morphine (mean 73.6 mg) and five patients receiving a continuous extradural infusion of 0.25% bupivacaine (mean 192 mg) in the 24-h period following upper abdominal surgery.,2334618_3,-1,-1,-1,11081,-1,0.95192,0.048080098
11083,mg,23,24,128,130,infusion of morphine (mean 73.6 mg) and five patients receiving a continuous extradural infusion of 0.25% bupivacaine (mean 192 mg) in the 24-h period following upper abdominal surgery.,2334618_3,-1,-1,-1,11083,-1,0.96175677,0.03824327
11084,carbon dioxide,7,9,47,61,"Monitoring consisted of airflow detection by a carbon dioxide analyser, chest wall movement detected by pneumatic capsules, and continuous electrocardiograph recorded with a Holter ambulatory monitor.",2334618_4,-1,-1,-1,11084,-1,0.99714786,0.0028521505
11085,P,3,4,18,19,Both obstructive (P less than 0.05) and central apnoea (P less than 0.05) occurred more frequently in patients who had a morphine infusion.,2334618_5,-1,-1,-1,11085,-1,0.20020208,0.7997979
11087,P,12,13,56,57,Both obstructive (P less than 0.05) and central apnoea (P less than 0.05) occurred more frequently in patients who had a morphine infusion.,2334618_5,-1,-1,-1,11087,-1,0.1630293,0.83697075
11089,tachyarrhythmias,7,8,37,53,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,-1,-1,-1,11089,-1,0.0012872263,0.9987128
11090,P,9,10,55,56,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,-1,-1,-1,11090,-1,0.23307523,0.7669248
11091,ventricular ectopic beats,15,18,77,102,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,-1,-1,-1,11091,-1,0.0014918483,0.99850816
11092,P,19,20,104,105,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,-1,-1,-1,11092,-1,0.26197073,0.7380293
11094,Cerebral sinus thrombosis,0,3,0,25,Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia.,2339463_0,-1,-1,-1,11094,-1,0.001528646,0.9984713
11095,menorrhagia,11,12,81,92,Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia.,2339463_0,-1,-1,-1,11095,-1,0.0018439516,0.998156
11097,menorrhagia,21,22,165,176,We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.,2339463_1,-1,-1,-1,11097,-1,0.0018209319,0.9981791
11098,menorrhagia,9,10,56,67,This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce blood loss.,2339463_2,-1,-1,-1,11098,-1,0.0018404288,0.9981596
11099,blood loss,15,17,99,109,This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce blood loss.,2339463_2,-1,-1,-1,11099,-1,0.0031876175,0.9968124
11100,thromboembolic disease,4,6,27,49,"Although increased risk of thromboembolic disease has been reported during treatment with epsilon-aminocaproic acid, cerebral sinus thrombosis has not been previously described.",2339463_3,-1,-1,-1,11100,-1,0.0012398285,0.9987602
11101,cerebral sinus thrombosis,15,18,117,142,"Although increased risk of thromboembolic disease has been reported during treatment with epsilon-aminocaproic acid, cerebral sinus thrombosis has not been previously described.",2339463_3,-1,-1,-1,11101,-1,0.0013404588,0.9986595
11103,imipenem,3,4,22,30,Seizure activity with imipenem therapy: incidence and risk factors.,2343592_0,-1,-1,-1,11103,-1,0.9990734,0.00092653616
11104,cerebral vascular accident,8,11,46,72,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,-1,-1,-1,11104,-1,0.0012208193,0.99877924
11105,CVA,12,13,74,77,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,-1,-1,-1,11105,-1,0.0013127445,0.9986872
11106,head trauma,15,17,82,93,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,-1,-1,-1,11106,-1,0.0013154786,0.99868447
11107,renal disease,21,23,113,126,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,-1,-1,-1,11107,-1,0.001357839,0.99864215
11114,ventricular fibrillation,8,10,57,81,Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure.,234669_0,-1,-1,-1,11114,-1,0.0015678364,0.9984321
11115,respiratory failure,11,13,89,108,Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure.,234669_0,-1,-1,-1,11115,-1,0.0015644468,0.99843556
11117,respiratory failure,9,11,70,89,Cardiac arrhythmias have frequently been reported in association with respiratory failure.,234669_1,-1,-1,-1,11117,-1,0.0014629673,0.99853706
11118,cardiac disturbances,9,11,68,88,The possible additive role of pharmacologic agents in precipitating cardiac disturbances in patients with respiratory failure has only recently been emphasized.,234669_2,-1,-1,-1,11118,-1,0.0012337955,0.9987662
11119,respiratory failure,14,16,106,125,The possible additive role of pharmacologic agents in precipitating cardiac disturbances in patients with respiratory failure has only recently been emphasized.,234669_2,-1,-1,-1,11119,-1,0.001215418,0.9987846
11121,ventricular fibrillation,6,8,36,60,The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs.,234669_3,-1,-1,-1,11121,-1,0.0019902077,0.99800986
11122,respiratory failure,15,17,117,136,The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs.,234669_3,-1,-1,-1,11122,-1,0.001799769,0.9982002
11123,ventricular fibrillation,1,3,4,28,The ventricular fibrillation threshold was measured by passing a gated train of 12 constant current pulses through the ventricular myocardium during the vulnerable period of the cardiac cycle.,234669_4,-1,-1,-1,11123,-1,0.0025576698,0.99744236
11125,ventricular fibrillation,7,9,42,66,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,-1,-1,-1,11125,-1,0.0017046406,0.99829537
11127,PO2,28,29,165,168,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,-1,-1,-1,11127,-1,0.9968136,0.0031864601
11128,carbon dioxide,31,33,174,188,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,-1,-1,-1,11128,-1,0.9979602,0.0020397766
11129,CO2,34,35,190,193,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,-1,-1,-1,11129,-1,0.99476695,0.0052330876
11130,respiratory failure,1,3,5,24,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,-1,11130,-1,0.0015036273,0.9984964
11131,hypoventilation,6,7,41,56,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,-1,11131,-1,0.0016559724,0.99834406
11132,mm Hg,17,19,90,95,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,-1,11132,-1,0.8349946,0.16500542
11133,mm Hg,24,26,110,115,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,-1,11133,-1,0.88150203,0.11849791
11135,ventricular fibrillation,38,40,184,208,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,-1,11135,-1,0.0017261187,0.99827385
11137,respiratory failure,17,19,125,144,"These experiments suggest that although many factors may contribute to the increased incidence of ventricular arrhythmias in respiratory failure, pharmacologic agents, particularly aminophylline, may play a significant role.",234669_7,-1,-1,-1,11137,-1,0.0013221697,0.9986778
11140,Trental,2,3,16,23,Pentoxifylline (Trental) does not inhibit dipyridamole-induced coronary hyperemia: implications for dipyridamole-thallium-201 myocardial imaging.,2348231_0,-1,-1,-1,11140,-1,0.99913186,0.0008681394
11142,peripheral vascular disease,12,15,95,122,Dipyridamole-thallium-201 imaging is often performed in patients unable to exercise because of peripheral vascular disease.,2348231_1,-1,-1,-1,11142,-1,0.0014897161,0.9985103
11144,Trental,8,9,50,57,"Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent claudication.",2348231_2,-1,-1,-1,11144,-1,0.99916923,0.0008308506
11145,methylxanthine,12,13,62,76,"Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent claudication.",2348231_2,-1,-1,-1,11145,-1,0.99926466,0.00073534757
11146,intermittent claudication,17,19,106,131,"Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent claudication.",2348231_2,-1,-1,-1,11146,-1,0.0015082692,0.99849176
11148,coronary hyperemia,4,6,53,71,Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.,2348231_3,-1,-1,-1,11148,-1,0.0013771987,0.9986228
11149,methylxanthines,8,9,83,98,Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.,2348231_3,-1,-1,-1,11149,-1,0.99928516,0.00071481813
11151,hyperemic,5,6,26,35,"Therefore, we studied the hyperemic response to dipyridamole in seven open-chest anesthetized dogs after pretreatment with either pentoxifylline (0, 7.5, or 15 mg/kg i.v.) or theophylline (3 mg/kg i.v.).",2348231_4,-1,-1,-1,11151,-1,0.0017504516,0.9982495
11157,p,2,3,16,17,pentoxifylline (p less than 0.002).,2348231_7,-1,-1,-1,11157,-1,0.61660755,0.38339248
11161,p,21,22,166,167,"Neither dose of pentoxifylline significantly decreased the dipyridamole-induced hyperemia, while peak coronary blood flow was significantly lower after theophylline (p less than 0.01).",2348231_8,-1,-1,-1,11161,-1,0.50342053,0.4965795
11162,pentoxyifylline,3,4,17,32,We conclude that pentoxyifylline does not inhibit dipyridamole-induced coronary hyperemia even at high doses.,2348231_9,-1,-1,-1,11162,-1,0.9992181,0.00078193186
11163,coronary hyperemia,8,10,71,89,We conclude that pentoxyifylline does not inhibit dipyridamole-induced coronary hyperemia even at high doses.,2348231_9,-1,-1,-1,11163,-1,0.0014996058,0.99850047
11165,Parkinson's disease,6,9,35,54,Cause of death among patients with Parkinson's disease: a rare mortality due to cerebral haemorrhage.,2355241_0,-1,-1,-1,11165,-1,0.0021421514,0.99785787
11169,Parkinson's disease,17,20,113,132,"Causes of death, with special reference to cerebral haemorrhage, among 240 patients with pathologically verified Parkinson's disease were investigated using the Annuals of the Pathological Autopsy Cases in Japan from 1981 to 1985.",2355241_1,-1,-1,-1,11169,-1,0.0029336766,0.9970663
11171,pneumonia,6,7,33,42,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,11171,-1,0.0014309891,0.998569
11172,bronchitis,8,9,47,57,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,11172,-1,0.0015530364,0.998447
11173,malignant neoplasms,14,16,67,86,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,11173,-1,0.0019826025,0.99801743
11174,heart diseases,21,23,96,110,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,11174,-1,0.0019462226,0.9980538
11175,cerebral infarction,28,30,119,138,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,11175,-1,0.0016265474,0.9983734
11176,septicaemia,35,36,150,161,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,11176,-1,0.0015392401,0.99846077
11183,Parkinson's disease,14,17,79,98,The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.,2355241_4,-1,-1,-1,11183,-1,0.0023791592,0.9976209
11189,cardiorespiratory arrest,3,5,44,68,Possible intramuscular midazolam-associated cardiorespiratory arrest and death.,2375138_0,-1,-1,-1,11189,-1,0.0012281945,0.9987717
11191,Midazolam hydrochloride,0,2,0,23,Midazolam hydrochloride is commonly used for dental or endoscopic procedures.,2375138_1,-1,-1,-1,11191,-1,0.9991855,0.00081447995
11192,cardiovascular depression,16,18,123,148,"Although generally consisted safe when given intramuscularly, intravenous administration is known to cause respiratory and cardiovascular depression.",2375138_2,-1,-1,-1,11192,-1,0.0014385469,0.99856144
11193,cardiorespiratory arrest,8,10,50,74,This report describes the first published case of cardiorespiratory arrest and death associated with intramuscular administration of midazolam.,2375138_3,-1,-1,-1,11193,-1,0.0012460153,0.998754
11197,Myasthenia gravis,0,2,0,17,Myasthenia gravis presenting as weakness after magnesium administration.,2385256_0,-1,-1,-1,11197,-1,0.0016236895,0.99837625
11200,neuromuscular disease,9,11,46,67,We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia.,2385256_1,-1,-1,-1,11200,-1,0.0012054743,0.99879456
11201,quadriplegic,14,15,89,101,We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia.,2385256_1,-1,-1,-1,11201,-1,0.0020729576,0.99792707
11203,preeclampsia,20,21,148,160,We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia.,2385256_1,-1,-1,-1,11203,-1,0.0012783889,0.99872154
11206,neuromuscular blockade,23,25,160,182,"While she was weak, 2-Hz repetitive stimulation revealed a decrement without significant facilitation at rapid rates or after exercise, suggesting postsynaptic neuromuscular blockade.",2385256_4,-1,-1,-1,11206,-1,0.040829156,0.9591708
11210,myasthenia gravis,12,14,92,109,"Although paralysis after magnesium administration has been described in patients with known myasthenia gravis, it has not previously been reported to be the initial or only manifestation of the disease.",2385256_7,-1,-1,-1,11210,-1,0.0013529467,0.99864703
11212,disorder of neuromuscular transmission,18,22,123,161,Patients who are unusually sensitive to the neuromuscular effects of magnesium should be suspected of having an underlying disorder of neuromuscular transmission.,2385256_8,-1,-1,-1,11212,-1,0.0035704158,0.9964296
11216,hepatocellular carcinomas,5,7,36,61,"No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline-supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital.",2396046_3,-1,-1,-1,11216,-1,0.0020244266,0.9979755
11219,hepatocellular carcinomas,7,9,46,71,"The incidence of preneoplastic nodules and of hepatocellular carcinomas was 10% and 37%, respectively, in rats fed the plain choline-devoid diet, and 17% and 30%, in rats fed the phenobarbital-containing choline-devoid diet.",2396046_4,-1,-1,-1,11219,-1,0.0018920089,0.998108
11221,neoplastic lesions,1,3,9,27,"Sporadic neoplastic lesions were observed in organs other than the liver of some of the animals, irrespective of the diet fed.",2396046_6,-1,-1,-1,11221,-1,0.0020564604,0.9979436
11233,mm Hg,32,34,192,197,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,-1,-1,-1,11233,-1,0.013168064,0.9868319
11234,h,41,42,221,222,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,-1,-1,-1,11234,-1,0.19851173,0.8014883
11236,"5,7-dihydroxytryptamine",51,52,290,313,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,-1,-1,-1,11236,-1,0.9985998,0.0014002157
11237,"5,7-DHT",53,54,315,322,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,-1,-1,-1,11237,-1,0.99854314,0.0014568722
11238,"5,7-DHT",5,6,34,41,"However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.",2422478_4,-1,-1,-1,11238,-1,0.99868435,0.001315624
11241,"5,7-DHT",2,3,9,16,"Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.",2422478_5,-1,-1,-1,11241,-1,0.9987472,0.001252709
11244,fall,30,31,170,174,"Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.",2422478_5,-1,-1,-1,11244,-1,0.005605123,0.9943949
11245,blood pressure,32,34,178,192,"Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.",2422478_5,-1,-1,-1,11245,-1,0.18161722,0.8183828
11246,serotonin methyldopa,39,41,222,242,"Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.",2422478_5,-1,-1,-1,11246,-1,0.9990415,0.0009584507
11252,Liver enlargement,0,2,0,17,Liver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone.,2425813_1,-1,-1,-1,11252,-1,0.002219622,0.9977804
11253,muscle wastage,3,5,22,36,Liver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone.,2425813_1,-1,-1,-1,11253,-1,0.0022106164,0.9977894
11256,cibenzoline,4,5,40,51,Antiarrhythmic plasma concentrations of cibenzoline on canine ventricular arrhythmias.,2435991_0,-1,-1,-1,11256,-1,0.9990965,0.0009034933
11259,cibenzoline,16,17,129,140,"Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.",2435991_1,-1,-1,-1,11259,-1,0.9992675,0.00073248596
11261,Cibenzoline,0,1,0,11,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,-1,-1,-1,11261,-1,0.9991591,0.00084094546
11264,digitalis,24,25,167,176,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,-1,-1,-1,11264,-1,0.99804974,0.0019502912
11266,n,86,87,368,369,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,-1,-1,-1,11266,-1,0.19847813,0.80152184
11270,tocainide,10,11,67,76,"This pharmacological profile is similar to those of mexiletine and tocainide, and all three drugs have central nervous system (CNS) stimulant action.",2435991_4,-1,-1,-1,11270,-1,0.9993487,0.00065135205
11271,cibenzoline,1,2,8,19,"Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected.",2435991_5,-1,-1,-1,11271,-1,0.99909115,0.0009088221
11278,pentylenetrazol,21,22,139,154,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,-1,-1,-1,11278,-1,0.9992513,0.0007486705
11279,PTZ,23,24,156,159,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,-1,-1,-1,11279,-1,0.9988432,0.0011568195
11280,h,26,27,163,164,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,-1,-1,-1,11280,-1,0.31031916,0.6896808
11282,h,39,40,254,255,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,-1,-1,-1,11282,-1,0.22773863,0.7722614
11283,h,19,20,101,102,"In this study, the severity of response to other seizure-inducing agents was tested in mice 1 and 24 h after intraperitoneal administration of 80 mg/kg gamma-HCH.",2440413_2,-1,-1,-1,11283,-1,0.26932088,0.73067915
11284,h,23,24,143,144,"One hour after the administration of gamma-HCH, the activity of seizure-inducing agents was increased, regardless of their mechanism, while 24 h after gamma-HCH a differential response was observed.",2440413_3,-1,-1,-1,11284,-1,0.53185356,0.46814644
11286,PTZ,4,5,24,27,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11286,-1,0.9989159,0.001084087
11288,PTX,8,9,44,47,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11288,-1,0.9987686,0.0012312926
11290,3-mercaptopropionic acid,20,22,111,135,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11290,-1,0.99886,0.0011399911
11291,MPA,23,24,137,140,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11291,-1,0.9989575,0.0010424653
11293,BCC,28,29,156,159,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11293,-1,0.9984499,0.0015500668
11294,DMCM,34,35,218,222,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11294,-1,0.99871194,0.001288045
11295,strychnine,38,39,228,238,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11295,-1,0.9991698,0.0008301609
11296,STR,40,41,240,243,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11296,-1,0.99847955,0.0015204984
11297,pentylenetetrazol,5,6,21,38,"In vitro, gamma-HCH, pentylenetetrazol and picrotoxin were shown to inhibit 3H-TBOB binding in mouse whole brain, with IC50 values of 4.6, 404 and 9.4 microM, respectively.",2440413_5,-1,-1,-1,11297,-1,0.9992717,0.0007283676
11299,MPA,0,1,0,3,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,-1,-1,-1,11299,-1,0.998985,0.0010149901
11300,DMCM,4,5,10,14,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,-1,-1,-1,11300,-1,0.9988601,0.0011398742
11301,STR,7,8,20,23,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,-1,-1,-1,11301,-1,0.99860305,0.0013970083
11303,PTZ,14,15,99,102,"The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.",2440413_7,-1,-1,-1,11303,-1,0.9989747,0.0010252865
11304,PTX,16,17,107,110,"The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.",2440413_7,-1,-1,-1,11304,-1,0.9989404,0.0010596017
11305,h,18,19,114,115,"The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.",2440413_7,-1,-1,-1,11305,-1,0.26523307,0.73476696
11307,h,16,17,92,93,The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.,2440413_8,-1,-1,-1,11307,-1,0.16994691,0.8300531
11308,chloride,24,25,144,152,The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.,2440413_8,-1,-1,-1,11308,-1,0.99881727,0.0011826949
11310,Argentine hemorrhagic fever,9,12,61,88,Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever.,2445283_0,-1,-1,-1,11310,-1,0.17750812,0.8224919
11312,Argentine hemorrhagic fever,12,15,75,102,Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever (AHF) of more than 8 days of evolution.,2445283_1,-1,-1,-1,11312,-1,0.083189026,0.916811
11313,AHF,16,17,104,107,Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever (AHF) of more than 8 days of evolution.,2445283_1,-1,-1,-1,11313,-1,0.001436101,0.99856395
11315,viremia,8,9,60,67,Administration of ribavirin resulted in a neutralization of viremia and a drop of endogenous interferon titers.,2445283_2,-1,-1,-1,11315,-1,0.0012656896,0.9987343
11316,interferon,14,15,93,103,Administration of ribavirin resulted in a neutralization of viremia and a drop of endogenous interferon titers.,2445283_2,-1,-1,-1,11316,-1,0.99849534,0.0015047045
11320,AHF,16,17,92,95,"From these results, we conclude that ribavirin has an antiviral effect in advanced cases of AHF, and that anemia, the only secondary reaction observed, can be easily managed.",2445283_5,-1,-1,-1,11320,-1,0.0011932926,0.9988067
11323,AHF,11,12,71,74,The possible beneficial effect of ribavirin during the initial days of AHF is discussed.,2445283_6,-1,-1,-1,11323,-1,0.0014549568,0.99854505
11324,fluorouracil,5,6,44,56,Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study.,2466960_0,-1,-1,-1,11324,-1,0.99897337,0.0010266085
11326,fluorouracil,11,12,79,91,"Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.",2466960_1,-1,-1,-1,11326,-1,0.9990939,0.0009061798
11327,5-FU,13,14,93,97,"Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.",2466960_1,-1,-1,-1,11327,-1,0.9987214,0.0012785827
11328,5-FU,11,12,90,94,We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes.,2466960_2,-1,-1,-1,11328,-1,0.9987601,0.0012399018
11330,ischemic,25,26,170,178,We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes.,2466960_2,-1,-1,-1,11330,-1,0.0015205294,0.9984794
11331,5-FU,10,11,50,54,"Patients were monitored for 23 +/- 4 hours before 5-FU infusion, and 98 +/- 9 hours during 5-FU infusion.",2466960_3,-1,-1,-1,11331,-1,0.99877924,0.0012207697
11332,5-FU,20,21,91,95,"Patients were monitored for 23 +/- 4 hours before 5-FU infusion, and 98 +/- 9 hours during 5-FU infusion.",2466960_3,-1,-1,-1,11332,-1,0.99875057,0.0012493893
11333,Anginal episodes,0,2,0,16,Anginal episodes were rare: only one patient had angina (during 5-FU infusion).,2466960_4,-1,-1,-1,11333,-1,0.0013382375,0.99866176
11334,angina,9,10,49,55,Anginal episodes were rare: only one patient had angina (during 5-FU infusion).,2466960_4,-1,-1,-1,11334,-1,0.0012878464,0.9987122
11335,5-FU,12,13,64,68,Anginal episodes were rare: only one patient had angina (during 5-FU infusion).,2466960_4,-1,-1,-1,11335,-1,0.99860257,0.0013974562
11336,mm,12,13,61,63,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,-1,-1,-1,11336,-1,0.01051992,0.98948
11337,5-FU,31,32,138,142,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,-1,-1,-1,11337,-1,0.99888116,0.0011188922
11338,5-FU,40,41,170,174,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,-1,-1,-1,11338,-1,0.9988431,0.0011568386
11339,P,43,44,185,186,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,-1,-1,-1,11339,-1,0.21913174,0.7808683
11340,ischemic,3,4,17,25,The incidence of ischemic episodes per patient per hour was 0.05 +/-,2466960_6,-1,-1,-1,11340,-1,0.0016623336,0.9983376
11341,5-FU,3,4,14,18,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11341,-1,0.9988009,0.0011991606
11342,5-FU,11,12,51,55,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11342,-1,0.9988071,0.0011929453
11343,P,14,15,66,67,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11343,-1,0.35497436,0.6450257
11344,5-FU,36,37,165,169,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11344,-1,0.99873656,0.0012634974
11345,5-FU,48,49,220,224,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11345,-1,0.99874914,0.0012507985
11346,P,50,51,226,227,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11346,-1,0.35670623,0.6432938
11347,coronary artery disease,9,12,55,78,ECG changes were more common among patients with known coronary artery disease.,2466960_8,-1,-1,-1,11347,-1,0.002229688,0.9977703
11348,sudden death,5,7,24,36,"There were two cases of sudden death, both of which occurred at the end of the chemotherapy course.",2466960_9,-1,-1,-1,11348,-1,0.001611148,0.9983889
11349,5-FU,3,4,17,21,"We conclude that 5-FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with coronary artery disease.",2466960_10,-1,-1,-1,11349,-1,0.9988016,0.0011983749
11351,coronary artery disease,24,27,161,184,"We conclude that 5-FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with coronary artery disease.",2466960_10,-1,-1,-1,11351,-1,0.002202743,0.99779725
11352,scabies,4,5,20,27,Is the treatment of scabies hazardous?Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.,2476560_0,-1,-1,-1,11352,-1,0.0017501819,0.9982498
11353,scabies,7,8,52,59,Is the treatment of scabies hazardous?Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.,2476560_0,-1,-1,-1,11353,-1,0.001863512,0.9981365
11355,gamma benzene hexachloride,19,22,130,156,Is the treatment of scabies hazardous?Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.,2476560_0,-1,-1,-1,11355,-1,0.9986411,0.0013588687
11358,toxic to the central nervous system,7,13,45,80,Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with aplastic anaemia.,2476560_2,-1,-1,-1,11358,-1,0.0029674892,0.9970325
11359,aplastic anaemia,18,20,108,124,Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with aplastic anaemia.,2476560_2,-1,-1,-1,11359,-1,0.0011990789,0.9988009
11363,biogenic amines,9,11,66,81,Mouse strain-dependent effect of amantadine on motility and brain biogenic amines.,2484011_0,-1,-1,-1,11363,-1,0.9986173,0.0013826762
11364,amantadine hydrochloride,3,5,14,38,"The effect of amantadine hydrochloride, injected i.p. in 6 increments of 100 mg/kg each over 30 hr, on mouse motility and whole brain content of selected biogenic amines and major metabolites was studied in 4 strains of mice.",2484011_1,-1,-1,-1,11364,-1,0.9992512,0.00074884325
11365,biogenic amines,29,31,154,169,"The effect of amantadine hydrochloride, injected i.p. in 6 increments of 100 mg/kg each over 30 hr, on mouse motility and whole brain content of selected biogenic amines and major metabolites was studied in 4 strains of mice.",2484011_1,-1,-1,-1,11365,-1,0.997837,0.0021630628
11367,amantadine depressed,4,6,20,40,The initial dose of amantadine depressed locomotor activity in all mouse strains studied with the BALB/C mice being the most sensitive.,2484011_4,-1,-1,-1,11367,-1,0.90018904,0.09981099
11371,suppression of motility,26,29,173,196,"Readministration of amantadine, after a drug-free overnight period, increased motility from respective saline control in all strains with exception of the BALB/C mice where suppression of motility occurred.",2484011_7,-1,-1,-1,11371,-1,0.0032349483,0.996765
11374,"3,4-dihydroxyphenylacetic acid",15,17,97,127,"Treatment with amantadine did not alter whole brain dopamine levels but decreased the amounts of 3,4-dihydroxyphenylacetic acid in the BALB/C mice compared to saline control.",2484011_8,-1,-1,-1,11374,-1,0.9987544,0.0012456226
11375,normetanephrine,3,4,18,33,"Conversely, brain normetanephrine concentration was increased from saline control by amantadine in the BALB/C mice.",2484011_9,-1,-1,-1,11375,-1,0.9989158,0.0010841654
11379,biogenic amines,5,7,33,48,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,-1,-1,-1,11379,-1,0.99892044,0.0010796337
11381,monoamine,22,23,152,161,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,-1,-1,-1,11381,-1,0.9991002,0.00089976226
11383,behavioral depression,37,39,254,275,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,-1,-1,-1,11383,-1,0.0018968098,0.99810314
11385,Chloroacetaldehyde,0,1,0,18,Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide.,2505783_0,-1,-1,-1,11385,-1,0.99919444,0.0008055914
11388,chloroacetaldehyde,7,8,40,58,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,-1,-1,-1,11388,-1,0.9991197,0.0008802786
11389,CAA,9,10,60,63,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,-1,-1,-1,11389,-1,0.9982047,0.0017952704
11390,oxazaphosphorine,16,17,95,111,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,-1,-1,-1,11390,-1,0.99918205,0.0008179828
11391,CAA,32,33,197,200,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,-1,-1,-1,11391,-1,0.9978573,0.0021427548
11392,hemorrhagic cystitis,37,39,223,243,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,-1,-1,-1,11392,-1,0.001178847,0.9988211
11393,CAA,4,5,26,29,The data demonstrate that CAA after i.v. administration does not contribute to bladder damage.,2505783_3,-1,-1,-1,11393,-1,0.9982318,0.0017681901
11394,bladder damage,13,15,79,93,The data demonstrate that CAA after i.v. administration does not contribute to bladder damage.,2505783_3,-1,-1,-1,11394,-1,0.0017963818,0.99820364
11395,CAA,7,8,42,45,"When instilled directly into the bladder, CAA exerts urotoxic effects, it is, however, susceptible to detoxification with mesna.",2505783_4,-1,-1,-1,11395,-1,0.9981749,0.0018250793
11401,migraine attacks,2,4,12,28,Early onset migraine attacks were induced by nitroglycerin in seven out of 10 patients versus no patient in the placebo group.,2515254_1,-1,-1,-1,11401,-1,0.0013875299,0.9986124
11412,leukemoid reaction,6,8,52,70,"Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.",2522601_0,-1,-1,-1,11412,-1,0.0011968235,0.99880314
11414,erythroderma,11,12,86,98,"Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.",2522601_0,-1,-1,-1,11414,-1,0.00111403,0.9988859
11415,renal failure,14,16,104,117,"Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.",2522601_0,-1,-1,-1,11415,-1,0.0012778584,0.99872214
11418,erythroderma,12,13,89,101,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,-1,-1,-1,11418,-1,0.001125853,0.9988741
11419,leukemoid reaction,16,18,112,130,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,-1,-1,-1,11419,-1,0.0011782432,0.9988218
11422,renal failure,24,26,164,177,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,-1,-1,-1,11422,-1,0.00131072,0.99868923
11425,HIV disease,30,32,161,172,"Our study group consisted of 74 HIV-positive homosexual men belonging to groups II B, III and IV C2 from the Centers for Disease Control (CDC) classification of HIV disease.",2528969_1,-1,-1,-1,11425,-1,0.0069493838,0.9930506
11430,megaloblastosis,8,9,56,71,Bone marrow changes occurred rapidly as demonstrated by megaloblastosis in 95% of 65 specimens at week 18.(ABSTRACT TRUNCATED AT 250 WORDS),2528969_11,-1,-1,-1,11430,-1,0.0015863194,0.9984137
11432,hepatitis B virus,9,12,68,85,"National project on the prevention of mother-to-infant infection by hepatitis B virus in Japan.In Japan, a nationwide prevention program against mother-to-infant infection by hepatitis B virus (HBV) started in 1985.",2533791_0,-1,-1,-1,11432,-1,0.03217539,0.9678246
11434,hepatitis B,26,28,175,186,"National project on the prevention of mother-to-infant infection by hepatitis B virus in Japan.In Japan, a nationwide prevention program against mother-to-infant infection by hepatitis B virus (HBV) started in 1985.",2533791_0,-1,-1,-1,11434,-1,0.0361132,0.96388674
11435,hepatitis B surface,18,21,116,135,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,-1,-1,-1,11435,-1,0.5149416,0.4850585
11436,HBsAg,23,24,145,150,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,-1,-1,-1,11436,-1,0.98071426,0.01928576
11437,hepatitis B e,26,29,156,169,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,-1,-1,-1,11437,-1,0.5424376,0.45756242
11438,HBeAg,31,32,179,184,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,-1,-1,-1,11438,-1,0.9502389,0.049761128
11439,hepatitis B,8,10,49,60,These infants are treated with two injections of hepatitis B immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine.,2533791_2,-1,-1,-1,11439,-1,0.0794305,0.92056954
11440,hepatitis B vaccine,23,26,132,151,These infants are treated with two injections of hepatitis B immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine.,2533791_2,-1,-1,-1,11440,-1,0.7330779,0.2669221
11441,HBsAg,11,12,55,60,"93.4% pregnant women had the chance to be examined for HBsAg, and the positive rate was 1.4 to 1.5%.",2533791_4,-1,-1,-1,11441,-1,0.9882451,0.011754934
11442,HBeAg,1,2,4,9,The HBeAg positive rate in HBsAg positive was 23 to 26%.,2533791_5,-1,-1,-1,11442,-1,0.6713542,0.32864586
11443,HBsAg,5,6,27,32,The HBeAg positive rate in HBsAg positive was 23 to 26%.,2533791_5,-1,-1,-1,11443,-1,0.9059152,0.09408485
11444,HBsAg,1,2,4,9,The HBsAg positive rate in neonates and in infants before two months were 3% and 2% respectively.,2533791_6,-1,-1,-1,11444,-1,0.99385166,0.0061483136
11445,akathisia,1,2,19,28,Fluoxetine-induced akathisia: clinical and theoretical implications.,2549018_0,-1,-1,-1,11445,-1,0.0013047415,0.9986953
11447,obsessive compulsive disorder,8,11,56,85,Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.,2549018_1,-1,-1,-1,11447,-1,0.0014268293,0.9985732
11449,akathisia,15,16,116,125,Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.,2549018_1,-1,-1,-1,11449,-1,0.0012466197,0.9987534
11450,restlessness,5,6,43,55,"The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.",2549018_2,-1,-1,-1,11450,-1,0.001382804,0.9986172
11451,anxiety,20,21,129,136,"The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.",2549018_2,-1,-1,-1,11451,-1,0.001254849,0.9987451
11452,akathisia,27,28,194,203,"The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.",2549018_2,-1,-1,-1,11452,-1,0.0011754935,0.99882454
11453,akathisia,6,7,55,64,"Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.",2549018_3,-1,-1,-1,11453,-1,0.0012898196,0.99871016
11454,akathisia,16,17,126,135,"Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.",2549018_3,-1,-1,-1,11454,-1,0.0013061123,0.9986939
11455,Akathisia,0,1,0,9,"Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.",2549018_4,-1,-1,-1,11455,-1,0.0013242447,0.99867576
11458,akathisia,5,6,44,53,"The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced ""jitteriness"" may be identical.",2549018_5,-1,-1,-1,11458,-1,0.0015596888,0.9984403
11459,akathisia,22,23,193,202,"The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced ""jitteriness"" may be identical.",2549018_5,-1,-1,-1,11459,-1,0.0016475149,0.9983525
11460,jitteriness,27,28,241,252,"The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced ""jitteriness"" may be identical.",2549018_5,-1,-1,-1,11460,-1,0.0011467787,0.9988532
11461,analgesia,7,8,52,61,Involvement of the mu-opiate receptor in peripheral analgesia.,2557556_0,-1,-1,-1,11461,-1,0.0022555294,0.99774444
11463,"trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl",15,16,98,145,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,-1,-1,-1,11463,-1,0.9964759,0.0035241367
11464,cyclohexyl]benzeneactemide,17,18,147,173,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,-1,-1,-1,11464,-1,0.9986999,0.0013000476
11465,prostaglandin,18,19,116,129,"Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.",2557556_2,-1,-1,-1,11465,-1,0.9991116,0.0008883981
11469,pertussis toxin,17,19,126,141,The analgesic effect of the mu-agonist morphine was dose-dependently antagonized by naloxone and prevented by co-injection of pertussis toxin.,2557556_3,-1,-1,-1,11469,-1,0.999164,0.00083603215
11472,8-bromo cyclic adenosine monophosphate,11,15,61,99,"Morphine did not, however, alter the hyperalgesia induced by 8-bromo cyclic adenosine monophosphate.",2557556_4,-1,-1,-1,11472,-1,0.99881315,0.0011868192
11473,cyclic adenosine monophosphate,36,39,221,251,We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu-opioid receptor and that this action is mediated by inhibition of the cyclic adenosine monophosphate second messenger system.,2557556_5,-1,-1,-1,11473,-1,0.9986706,0.0013294239
11476,adriamycin nephrosis,18,20,114,134,The effect of the converting enzyme inhibitor (CEI) enalapril was assessed in Munich-Wistar rats with established adriamycin nephrosis.,2559236_1,-1,-1,-1,11476,-1,0.51221496,0.48778507
11481,mm Hg,20,22,104,109,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,-1,11481,-1,0.02966141,0.9703386
11482,P,28,29,126,127,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,-1,11482,-1,0.32854348,0.6714565
11483,mm Hg,47,49,201,206,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,-1,11483,-1,0.028658602,0.9713414
11484,P,50,51,208,209,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,-1,11484,-1,0.29778174,0.70221823
11488,adriamycin nephrosis,24,26,122,142,Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis.,2559236_6,-1,-1,-1,11488,-1,0.5250597,0.47494033
11492,P,33,34,150,151,"Enalapril treatment blunted but did not prevent reduction in GFR in group 4 (0.86 +/- 0.15 ml/min at 4 months, 0.69 +/- 0.13 ml/min at 6 months, both P less than 0.05 vs. group 3).",2559236_9,-1,-1,-1,11492,-1,0.31306735,0.6869327
11494,muscular rigidity,9,11,87,104,Involvement of locus coeruleus and noradrenergic neurotransmission in fentanyl-induced muscular rigidity in the rat.,2564649_0,-1,-1,-1,11494,-1,0.0013975765,0.99860245
11495,muscular rigidity,1,3,8,25,"Whereas muscular rigidity is a well-known side effect that is associated with high-dose fentanyl anesthesia, a paucity of information exists with regard to its underlying mechanism(s).",2564649_1,-1,-1,-1,11495,-1,0.001462527,0.9985374
11498,CO2,10,11,68,71,"Under proper control of respiration, body temperature and end-tidal CO2, intravenous administration of fentanyl (50 or 100 micrograms/kg) consistently promoted an increase in electromyographic activity recorded from the gastrocnemius and abdominal rectus muscles.",2564649_3,-1,-1,-1,11498,-1,0.9939156,0.0060843322
11500,muscular rigidity,3,5,16,33,"Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, prazosin.",2564649_4,-1,-1,-1,11500,-1,0.0016359044,0.99836415
11503,muscular rigidity,7,9,39,56,It is speculated that the induction of muscular rigidity by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons.,2564649_6,-1,-1,-1,11503,-1,0.0015087791,0.99849117
11505,Dexmedetomidine,0,1,0,15,"Dexmedetomidine, acting through central alpha-2 adrenoceptors, prevents opiate-induced muscle rigidity in the rat.",2569282_0,-1,-1,-1,11505,-1,0.9992269,0.00077308214
11506,muscle rigidity,10,12,87,102,"Dexmedetomidine, acting through central alpha-2 adrenoceptors, prevents opiate-induced muscle rigidity in the rat.",2569282_0,-1,-1,-1,11506,-1,0.0015370504,0.9984629
11507,dexmedetomidine,5,6,48,63,The highly-selective alpha-2 adrenergic agonist dexmedetomidine (D-MED) is capable of inducing muscle flaccidity and anesthesia in rats and dogs.,2569282_1,-1,-1,-1,11507,-1,0.9991824,0.0008175308
11508,muscle flaccidity,13,15,95,112,The highly-selective alpha-2 adrenergic agonist dexmedetomidine (D-MED) is capable of inducing muscle flaccidity and anesthesia in rats and dogs.,2569282_1,-1,-1,-1,11508,-1,0.0017033257,0.9982967
11509,muscle rigidity,2,4,20,35,Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists.,2569282_2,-1,-1,-1,11509,-1,0.0016532377,0.9983468
11511,muscle rigidity,14,16,82,97,"In the present study, the authors determined if treatment with D-MED prevents the muscle rigidity caused by high-dose alfentanil anesthesia in the rat.",2569282_4,-1,-1,-1,11511,-1,0.0019041671,0.9980958
11513,n,2,3,9,10,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,-1,-1,-1,11513,-1,0.17466733,0.8253327
11514,medetomidine,25,26,123,135,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,-1,-1,-1,11514,-1,0.9992555,0.0007445471
11515,idazoxan,58,59,283,291,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,-1,-1,-1,11515,-1,0.99920243,0.0007975894
11516,DG-5128,76,77,377,384,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,-1,-1,-1,11516,-1,0.9990464,0.00095360266
11518,ALF,8,9,44,47,"Each rat was then injected with alfentanil (ALF, 0.5 mg/kg sc).",2569282_7,-1,-1,-1,11518,-1,0.99781656,0.0021834632
11519,ALF,0,1,0,3,ALF injection resulted in a marked increase in hindlimb EMG activity in the L-MED treatment group which was indistinguishable from that seen in animals treated with saline.,2569282_8,-1,-1,-1,11519,-1,0.997934,0.0020660167
11520,contrast,1,2,3,11,"In contrast, D-MED prevented alfentanil-induced muscle rigidity in a dose-dependent fashion.",2569282_9,-1,-1,-1,11520,-1,0.5484747,0.45152527
11521,muscle rigidity,6,8,48,63,"In contrast, D-MED prevented alfentanil-induced muscle rigidity in a dose-dependent fashion.",2569282_9,-1,-1,-1,11521,-1,0.0015540126,0.99844605
11523,startle,12,13,65,72,"The high-dose D-MED animals were flaccid, akinetic, and lacked a startle response during the entire experimental period.(ABSTRACT TRUNCATED AT 250 WORDS)",2569282_11,-1,-1,-1,11523,-1,0.0062029883,0.99379706
11524,acute hepatitis,1,3,20,35,Clotiazepam-induced acute hepatitis.,2572625_0,-1,-1,-1,11524,-1,0.0012324573,0.9987676
11525,acute hepatitis,9,11,46,61,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,-1,-1,-1,11525,-1,0.0011940894,0.9988059
11526,hepatocellular necrosis,13,15,77,100,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,-1,-1,-1,11526,-1,0.0012839364,0.9987161
11527,clotiazepam,24,25,148,159,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,-1,-1,-1,11527,-1,0.99924785,0.0007521208
11528,thienodiazepine,27,28,163,178,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,-1,-1,-1,11528,-1,0.99917233,0.0008277234
11529,Clotiazepam,0,1,0,11,Clotiazepam withdrawal was followed by prompt recovery.,2572625_2,-1,-1,-1,11529,-1,0.99871945,0.0012806132
11531,clotiazepam,9,10,69,80,"The administration of several benzodiazepines, chemically related to clotiazepam, did not interfere with recovery and did not induce any relapse of hepatitis.",2572625_3,-1,-1,-1,11531,-1,0.999213,0.0007869521
11533,clotiazepam,4,5,28,39,This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.,2572625_4,-1,-1,-1,11533,-1,0.9992472,0.00075281
11534,acute hepatitis,7,9,51,66,This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.,2572625_4,-1,-1,-1,11534,-1,0.0011899729,0.99881005
11536,clotiazepam,18,19,126,137,This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.,2572625_4,-1,-1,-1,11536,-1,0.99923444,0.0007655527
11538,fluvoxamine,7,8,48,59,Some central effects of repeated treatment with fluvoxamine.,2576810_0,-1,-1,-1,11538,-1,0.9992561,0.0007438957
11539,fluvoxamine,8,9,54,65,"We investigated the effect of repeated treatment with fluvoxamine, a selective serotonin uptake inhibitor, on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the ""behavioral despair"" test.",2576810_1,-1,-1,-1,11539,-1,0.99930656,0.0006934491
11541,methoxamine,22,23,153,164,"We investigated the effect of repeated treatment with fluvoxamine, a selective serotonin uptake inhibitor, on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the ""behavioral despair"" test.",2576810_1,-1,-1,-1,11541,-1,0.9993569,0.0006430951
11542,fluvoxamine,4,5,26,37,A repeated treatment with fluvoxamine (twice daily for 14 days) potentiated in mice and in rats (weaker) the amphetamine-induced hyperactivity.,2576810_2,-1,-1,-1,11542,-1,0.99931204,0.00068792916
11545,nomifensine,4,5,29,40,The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine.,2576810_3,-1,-1,-1,11545,-1,0.99931633,0.0006837112
11546,fluvoxamine,10,11,72,83,The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine.,2576810_3,-1,-1,-1,11546,-1,0.99928707,0.000713005
11547,methoxamine,8,9,80,91,The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine.,2576810_4,-1,-1,-1,11547,-1,0.9993405,0.0006594757
11548,fluvoxamine,16,17,136,147,The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine.,2576810_4,-1,-1,-1,11548,-1,0.9992938,0.00070620066
11549,fluvoxamine,3,4,18,29,"Given three times fluvoxamine had no effect on the immobilization time in the ""behavioral despair"" test in rats.",2576810_5,-1,-1,-1,11549,-1,0.99922824,0.00077174284
11550,fluvoxamine,4,5,26,37,"The results indicate that fluvoxamine given repeatedly acts differently than citalopram, another selective serotonin uptake inhibitor, and differs also from other antidepressant drugs.",2576810_6,-1,-1,-1,11550,-1,0.999297,0.0007029263
11555,carcinogens,5,6,48,59,5-azacytidine potentiates initiation induced by carcinogens in rat liver.,2578334_0,-1,-1,-1,11555,-1,0.99182093,0.00817911
11556,carcinogenic,19,20,112,124,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,-1,11556,-1,0.008102237,0.9918977
11558,5-AzC,24,25,149,154,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,-1,11558,-1,0.99891543,0.001084619
11559,carcinogens,51,52,277,288,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,-1,11559,-1,0.7515709,0.24842912
11560,benzo[a]-pyrene,53,54,290,305,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,-1,11560,-1,0.99886775,0.001132242
11562,"1,2-DMH",67,68,380,387,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,-1,11562,-1,0.9975049,0.0024951359
11564,CCl4,34,35,238,242,The initiated hepatocytes in the liver were assayed as the gamma-glutamyltransferase (gamma-GT) positive foci formed following a 2-week selection regimen consisting of dietary 0.02% 2-acetylaminofluorene coupled with a necrogenic dose of CCl4.,2578334_2,-1,-1,-1,11564,-1,0.9986065,0.001393511
11565,5-AzC,12,13,81,86,"The results obtained indicate that with all three carcinogens, administration of 5-AzC during repair synthesis increased the incidence of initiated hepatocytes, for example 10-20 foci/cm2 in 5-AzC and carcinogen-treated rats compared with 3-5 foci/cm2 in rats treated with carcinogen only.",2578334_3,-1,-1,-1,11565,-1,0.99907625,0.0009237446
11566,5-AzC,30,31,191,196,"The results obtained indicate that with all three carcinogens, administration of 5-AzC during repair synthesis increased the incidence of initiated hepatocytes, for example 10-20 foci/cm2 in 5-AzC and carcinogen-treated rats compared with 3-5 foci/cm2 in rats treated with carcinogen only.",2578334_3,-1,-1,-1,11566,-1,0.99897707,0.0010229464
11567,"1,2-DMH",9,10,81,88,"Administration of [3H]-5-azadeoxycytidine during the repair synthesis induced by 1,2-DMH further showed that 0.019 mol % of cytosine residues in DNA were substituted by the analogue, indicating that incorporation of 5-AzC occurs during repair synthesis.",2578334_4,-1,-1,-1,11567,-1,0.99837625,0.0016237724
11568,cytosine,17,18,124,132,"Administration of [3H]-5-azadeoxycytidine during the repair synthesis induced by 1,2-DMH further showed that 0.019 mol % of cytosine residues in DNA were substituted by the analogue, indicating that incorporation of 5-AzC occurs during repair synthesis.",2578334_4,-1,-1,-1,11568,-1,0.99903,0.00096996763
11569,5-AzC,31,32,216,221,"Administration of [3H]-5-azadeoxycytidine during the repair synthesis induced by 1,2-DMH further showed that 0.019 mol % of cytosine residues in DNA were substituted by the analogue, indicating that incorporation of 5-AzC occurs during repair synthesis.",2578334_4,-1,-1,-1,11569,-1,0.9989083,0.0010916729
11570,5-AzC,7,8,34,39,"In the absence of the carcinogen, 5-AzC given after a two thirds partial hepatectomy, when its incorporation should be maximum, failed to induce any gamma-GT positive foci.",2578334_5,-1,-1,-1,11570,-1,0.99892515,0.0010748642
11571,se,8,9,52,54,The results suggest that hypomethylation of DNA per se may not be sufficient for initiation.,2578334_6,-1,-1,-1,11571,-1,0.38395262,0.6160474
11572,BN 52021,9,11,71,79,"Protective effect of a specific platelet-activating factor antagonist, BN 52021, on bupivacaine-induced cardiovascular impairments in rats.",2594614_0,-1,-1,-1,11572,-1,0.99897814,0.0010219187
11573,cardiovascular impairments,14,16,104,130,"Protective effect of a specific platelet-activating factor antagonist, BN 52021, on bupivacaine-induced cardiovascular impairments in rats.",2594614_0,-1,-1,-1,11573,-1,0.0012681959,0.9987318
11576,BN 52021,11,13,82,90,"Intravenous injection of the specific platelet-activating factor (PAF) antagonist BN 52021 (10 mg/kg), 30 min before bupivacaine administration (2 mg/kg i.v.) suppressed both the decrease of MBP and HR.",2594614_2,-1,-1,-1,11576,-1,0.9991677,0.0008323102
11578,contrast,1,2,3,11,"In contrast, doses of 1 mg/kg BN 52021 given 30 min before or 10 mg/kg administered 5 min before i.v.",2594614_3,-1,-1,-1,11578,-1,0.57622164,0.42377833
11579,BN 52021,7,9,30,38,"In contrast, doses of 1 mg/kg BN 52021 given 30 min before or 10 mg/kg administered 5 min before i.v.",2594614_3,-1,-1,-1,11579,-1,0.9989391,0.0010609344
11581,BN 52021,1,3,5,13,"When BN 52021 (20 mg/kg i.v.) was injected immediately after bupivacaine (2 mg/kg), a partial reversion of the decrease of MBP and HR was observed, whereas the dose of 10 mg/kg was ineffective.",2594614_5,-1,-1,-1,11581,-1,0.99913186,0.0008681414
11583,BN 52021,15,17,107,115,A partial recovery of bupivacaine-induced ECG alterations was observed after pretreatment of the rats with BN 52021.,2594614_6,-1,-1,-1,11583,-1,0.99910814,0.0008918283
11584,BN 52021,4,6,28,36,"Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.",2594614_7,-1,-1,-1,11584,-1,0.99901307,0.0009868803
11585,BN 52021,34,36,173,181,"Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.",2594614_7,-1,-1,-1,11585,-1,0.9990282,0.0009717942
11586,cardiovascular toxicity,45,47,241,264,"Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.",2594614_7,-1,-1,-1,11586,-1,0.0014083277,0.9985916
11587,cardiovascular alterations,17,19,102,128,"Thus, consistent with its direct effect on heart, PAF appears to be implicated in bupivacaine-induced cardiovascular alterations.",2594614_8,-1,-1,-1,11587,-1,0.0013678116,0.99863213
11588,flank pain,5,7,30,40,The epidemiology of the acute flank pain syndrome from suprofen.,2598570_0,-1,-1,-1,11588,-1,0.0015753892,0.99842465
11589,suprofen,9,10,55,63,The epidemiology of the acute flank pain syndrome from suprofen.,2598570_0,-1,-1,-1,11589,-1,0.99815243,0.0018475323
11590,Suprofen,0,1,0,8,"Suprofen, a new nonsteroidal anti-inflammatory drug, was marketed in early 1986 as an analgesic agent.",2598570_1,-1,-1,-1,11590,-1,0.998838,0.0011620369
11591,flank pain,7,9,50,60,"Until physicians began reporting an unusual acute flank pain syndrome to the spontaneous reporting system, 700,000 persons used the drug in the United States. Through August 1986, a total of 163 cases of this syndrome were reported.",2598570_2,-1,-1,-1,11591,-1,0.0015296777,0.99847025
11592,hay fever,26,28,107,116,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,-1,11592,-1,0.0018876313,0.9981123
11593,asthma,29,30,121,127,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,-1,11593,-1,0.0016870534,0.99831295
11594,p,75,76,316,317,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,-1,11594,-1,0.30999202,0.690008
11597,renal disease,19,21,119,132,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,-1,-1,-1,11597,-1,0.0014501563,0.9985499
11598,kidney stones,25,27,147,160,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,-1,-1,-1,11598,-1,0.0015529513,0.9984471
11599,gout,31,32,175,179,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,-1,-1,-1,11599,-1,0.0012844256,0.99871564
11600,uric acid,17,19,120,129,These findings are consistent with the postulated mechanism for this unusual syndrome: acute diffuse crystallization of uric acid in renal tubules.,2598570_7,-1,-1,-1,11600,-1,0.9980685,0.0019315106
11601,Antihypertensive drugs,0,2,0,22,Antihypertensive drugs and depression: a reappraisal.,26094_0,-1,-1,-1,11601,-1,0.99721247,0.0027875581
11609,depressions,9,10,50,61,This was accounted for by a significant number of depressions occurring in methyl dopa treated patients with psychiatric histories.,26094_4,-1,-1,-1,11609,-1,0.0015265617,0.99847347
11612,Chronic active hepatitis,0,3,0,24,Chronic active hepatitis associated with diclofenac sodium therapy.,2611118_0,-1,-1,-1,11612,-1,0.0017019728,0.998298
11613,diclofenac sodium,5,7,41,58,Chronic active hepatitis associated with diclofenac sodium therapy.,2611118_0,-1,-1,-1,11613,-1,0.99907255,0.00092739024
11614,Diclofenac sodium,0,2,0,17,"Diclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.",2611118_1,-1,-1,-1,11614,-1,0.9991696,0.0008304204
11615,Voltarol,3,4,19,27,"Diclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.",2611118_1,-1,-1,-1,11615,-1,0.9991191,0.0008809248
11617,abnormalities of liver function,5,9,48,79,"Although generally well-tolerated, asymptomatic abnormalities of liver function have been recorded and, less commonly, severe hepatitis induced by diclofenac.",2611118_2,-1,-1,-1,11617,-1,0.0027151224,0.9972849
11620,chronic active hepatitis,4,7,32,56,"The patient described developed chronic active hepatitis after six months therapy with diclofenac sodium which progressed despite the withdrawal of the drug, a finding not previously reported.",2611118_3,-1,-1,-1,11620,-1,0.0014154736,0.9985845
11621,diclofenac sodium,12,14,87,104,"The patient described developed chronic active hepatitis after six months therapy with diclofenac sodium which progressed despite the withdrawal of the drug, a finding not previously reported.",2611118_3,-1,-1,-1,11621,-1,0.9992747,0.0007253817
11622,Arterial hypertension,0,2,0,21,Arterial hypertension as a complication of prolonged ketoconazole treatment.,2632720_0,-1,-1,-1,11622,-1,0.0014454301,0.9985545
11624,Cushing's syndrome,5,8,24,42,Two of 14 patients with Cushing's syndrome treated on a long-term basis with ketoconazole developed sustained hypertension.,2632720_1,-1,-1,-1,11624,-1,0.0015269121,0.9984731
11630,deoxycorticosterone,7,8,31,50,"In patient 1, plasma levels of deoxycorticosterone and 11-deoxycortisol were elevated.",2632720_3,-1,-1,-1,11630,-1,0.99880815,0.0011919169
11632,deoxycorticosterone,11,12,49,68,"In patient 2, in addition to an increase in both deoxycorticosterone and 11-deoxycortisol levels, plasma aldosterone values were raised, with a concomitant suppression of renin levels.",2632720_4,-1,-1,-1,11632,-1,0.9988882,0.001111783
11639,renal insufficiency,14,16,86,105,Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.,2670794_0,-1,-1,-1,11639,-1,0.0015854578,0.9984145
11640,intravascular coagulation,18,20,113,138,Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.,2670794_0,-1,-1,-1,11640,-1,0.0013189336,0.998681
11641,intravascular coagulation,2,4,13,38,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,-1,-1,11641,-1,0.0014730091,0.99852693
11642,tranexamic acid,13,15,99,114,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,-1,-1,11642,-1,0.999204,0.00079598965
11643,AMCA,16,17,116,120,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,-1,-1,11643,-1,0.99894685,0.0010531644
11644,renal insufficiency,26,28,161,180,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,-1,-1,11644,-1,0.0016139816,0.998386
11645,trauma,32,33,213,219,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,-1,-1,11645,-1,0.0017558493,0.99824417
11649,renal insufficiency,22,24,114,133,"Injection of Captopril (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both pulmonary and renal insufficiency in this rat model.",2670794_2,-1,-1,-1,11649,-1,0.0016070672,0.9983929
11653,weight,13,14,69,75,Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril.,2670794_5,-1,-1,-1,11653,-1,0.026072567,0.9739274
11655,AMCA,18,19,108,112,The amount of fibrin in the kidneys was also considerably lower than in animals which received thrombin and AMCA alone.,2670794_6,-1,-1,-1,11655,-1,0.99876773,0.0012322454
11657,Angiotension,27,28,151,163,It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin (secondary to an increase in bradykinin).,2670794_7,-1,-1,-1,11657,-1,0.9697603,0.03023975
11658,prostacyclin,33,34,186,198,It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin (secondary to an increase in bradykinin).,2670794_7,-1,-1,-1,11658,-1,0.9989035,0.001096482
11661,kidney damage,48,50,276,289,"Captopril may, by the same mechanism, reduce the increase in glomerular filtration that is known to occur after an injection of thrombin, thereby diminishing the aggregation of fibrin monomers in the glomeruli, with the result that less fibrin will be deposited and thus less kidney damage will be produced.",2670794_8,-1,-1,-1,11661,-1,0.0025633092,0.9974367
11666,SD,9,10,38,40,Among these 47 patients the mean (+/- SD) age was 32.5 +/- 12.1 years; 76% (34/45) were men.,2673163_2,-1,-1,-1,11666,-1,0.20476234,0.79523766
11669,Intracranial aneurysms,0,2,0,22,Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy; cerebral vasculitis was present in two patients.,2673163_4,-1,-1,-1,11669,-1,0.0015038191,0.9984962
11670,arteriovenous malformations,3,5,26,53,Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy; cerebral vasculitis was present in two patients.,2673163_4,-1,-1,-1,11670,-1,0.0017062237,0.9982938
11671,cerebral vasculitis,18,20,128,147,Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy; cerebral vasculitis was present in two patients.,2673163_4,-1,-1,-1,11671,-1,0.0012104996,0.9987895
11672,Cerebral infarction,0,2,0,19,"Cerebral infarction occurred in 10 patients (22%), intracerebral hemorrhage in 22 (49%), and subarachnoid hemorrhage in 13 (29%).",2673163_5,-1,-1,-1,11672,-1,0.0014035165,0.9985965
11673,intracerebral hemorrhage,11,13,51,75,"Cerebral infarction occurred in 10 patients (22%), intracerebral hemorrhage in 22 (49%), and subarachnoid hemorrhage in 13 (29%).",2673163_5,-1,-1,-1,11673,-1,0.0013886344,0.99861133
11674,subarachnoid hemorrhage,21,23,93,116,"Cerebral infarction occurred in 10 patients (22%), intracerebral hemorrhage in 22 (49%), and subarachnoid hemorrhage in 13 (29%).",2673163_5,-1,-1,-1,11674,-1,0.0016268729,0.99837315
11682,intracranial aneurysms,53,55,282,304,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,-1,-1,11682,-1,0.0014762705,0.9985238
11683,arteriovenous malformations,56,58,309,336,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,-1,-1,11683,-1,0.0019645607,0.9980355
11685,intracranial hemorrhage,70,72,393,416,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,-1,-1,11685,-1,0.0013526273,0.9986474
11686,cerebral infarction,75,77,433,452,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,-1,-1,11686,-1,0.0013480468,0.9986519
11692,reductions in mean arterial blood pressure,12,18,88,130,Each patient was subjected to an identical anesthetic protocol and similar drug-induced reductions in mean arterial blood pressure (BP) (50 to 55 mmHg).,2696505_2,-1,-1,-1,11692,-1,0.01847204,0.9815279
11693,BP,19,20,132,134,Each patient was subjected to an identical anesthetic protocol and similar drug-induced reductions in mean arterial blood pressure (BP) (50 to 55 mmHg).,2696505_2,-1,-1,-1,11693,-1,0.013478678,0.98652136
11695,p,8,9,58,59,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,-1,-1,-1,11695,-1,0.264812,0.73518795
11696,cardiac,18,19,103,110,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,-1,-1,-1,11696,-1,0.027149212,0.97285074
11700,PO2,1,2,9,12,Arterial PO2 decreased in both groups.,2696505_5,-1,-1,-1,11700,-1,0.7928117,0.2071883
11704,gentamicin nephrotoxicity,5,7,46,71,Phlorizin-induced glycosuria does not prevent gentamicin nephrotoxicity in rats.,2709684_0,-1,-1,-1,11704,-1,0.069836885,0.9301631
11705,diabetes mellitus,4,6,41,58,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,-1,-1,-1,11705,-1,0.0012311694,0.99876875
11706,DM,7,8,60,62,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,-1,-1,-1,11706,-1,0.0014336886,0.9985663
11708,acute renal failure,38,41,222,241,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,-1,-1,-1,11708,-1,0.0010962052,0.99890375
11709,ARF,42,43,243,246,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,-1,-1,-1,11709,-1,0.0012900659,0.9987099
11710,gentamicin nephrotoxicity,3,5,20,45,The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).,2709684_2,-1,-1,-1,11710,-1,0.07610802,0.92389196
11712,phlorizin,22,23,165,174,The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).,2709684_2,-1,-1,-1,11712,-1,0.99917454,0.0008253888
11713,P,24,25,176,177,The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).,2709684_2,-1,-1,-1,11713,-1,0.9982547,0.001745315
11714,DM,0,1,0,2,DM rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied.,2709684_3,-1,-1,-1,11714,-1,0.008057108,0.9919429
11716,P,13,14,63,64,DM rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied.,2709684_3,-1,-1,-1,11716,-1,0.9972541,0.002745958
11717,P,3,4,9,10,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,-1,-1,-1,11717,-1,0.9978891,0.0021108708
11718,P,7,8,27,28,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,-1,-1,-1,11718,-1,0.9983393,0.0016606385
11719,P,19,20,65,66,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,-1,-1,-1,11719,-1,0.9975763,0.0024236825
11722,DM,35,36,130,132,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,-1,-1,-1,11722,-1,0.0029235014,0.9970765
11726,P,4,5,12,13,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,-1,-1,-1,11726,-1,0.9974383,0.0025616747
11728,SE,18,19,75,77,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,-1,-1,-1,11728,-1,0.036218308,0.96378165
11731,P,4,5,13,14,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,-1,-1,-1,11731,-1,0.997841,0.0021589776
11732,P,19,20,85,86,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,-1,-1,-1,11732,-1,0.63962436,0.3603757
11734,P,18,19,86,87,"These values were not different from those of Group III: maximal decrease in CCr 73% (P less than 0.001); lysozymuria, 2147 +/- 701 micrograms/day; tubular necrosis score, 3.8 +/- 0.1.(ABSTRACT TRUNCATED AT 250 WORDS)",2709684_9,-1,-1,-1,11734,-1,0.34527084,0.6547291
11741,analgesia,9,10,70,79,Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat.,2716967_1,-1,-1,-1,11741,-1,0.0017519888,0.998248
11747,cataleptic,22,23,169,179,"Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.",2716967_2,-1,-1,-1,11747,-1,0.0052931006,0.9947069
11759,cataleptic,4,5,31,41,Naloxone inhibited the induced cataleptic effects.,2716967_6,-1,-1,-1,11759,-1,0.002910163,0.99708986
11771,mm Hg,15,17,104,109,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,-1,-1,-1,11771,-1,0.03263295,0.9673671
11772,p,23,24,124,125,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,-1,-1,-1,11772,-1,0.36512747,0.63487256
11773,increased cardiac output,32,35,162,186,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,-1,-1,-1,11773,-1,0.026341103,0.9736589
11774,p,46,47,219,220,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,-1,-1,-1,11774,-1,0.380324,0.61967593
11775,mm,9,10,60,62,"Total peripheral vascular resistance fell from 15.1 to 12.2 mm Hg/l/min (SED +/- 1.03, p less than 0.05).",2722224_4,-1,-1,-1,11775,-1,0.054992743,0.9450072
11776,p,17,18,87,88,"Total peripheral vascular resistance fell from 15.1 to 12.2 mm Hg/l/min (SED +/- 1.03, p less than 0.05).",2722224_4,-1,-1,-1,11776,-1,0.48707274,0.5129273
11777,mm,26,27,166,168,"Resting forearm vascular resistance remained unchanged, but the reflex response to the cold pressor test was accentuated, the rise in resistance increasing from 10.5 mm Hg/ml/100 ml/min (R units) before treatment to 32.6 R units after treatment (SED +/- 6.4, p less than 0.025).",2722224_5,-1,-1,-1,11777,-1,0.94370353,0.056296505
11778,p,47,48,259,260,"Resting forearm vascular resistance remained unchanged, but the reflex response to the cold pressor test was accentuated, the rise in resistance increasing from 10.5 mm Hg/ml/100 ml/min (R units) before treatment to 32.6 R units after treatment (SED +/- 6.4, p less than 0.025).",2722224_5,-1,-1,-1,11778,-1,0.4663479,0.53365207
11782,p,53,54,288,289,"The rise in forearm vascular resistance accompanying intra-arterial norepinephrine (25, 50, and 100 ng/min) was also significantly greater after hydrocortisone, increasing from an average of 14.9 +/- 2.4 R units before treatment to 35.1 +/- 5.5 R units after hydrocortisone (SED +/- 6.0, p less than 0.05).",2722224_6,-1,-1,-1,11782,-1,0.4394487,0.5605512
11786,rise in resting blood pressure,1,6,4,34,The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output (presumably due to increased blood volume).(ABSTRACT TRUNCATED AT 250 WORDS),2722224_9,-1,-1,-1,11786,-1,0.020495672,0.9795043
11788,increased cardiac output,12,15,77,101,The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output (presumably due to increased blood volume).(ABSTRACT TRUNCATED AT 250 WORDS),2722224_9,-1,-1,-1,11788,-1,0.014626909,0.9853731
11789,increased blood volume).(ABSTRACT,19,22,121,154,The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output (presumably due to increased blood volume).(ABSTRACT TRUNCATED AT 250 WORDS),2722224_9,-1,-1,-1,11789,-1,0.23142904,0.76857096
11790,Neuromuscular blockade,0,2,0,22,Neuromuscular blockade with magnesium sulfate and nifedipine.,2750819_0,-1,-1,-1,11790,-1,0.0024655645,0.9975344
11791,magnesium sulfate,3,5,28,45,Neuromuscular blockade with magnesium sulfate and nifedipine.,2750819_0,-1,-1,-1,11791,-1,0.9989008,0.001099241
11794,neuromuscular blockade,8,10,59,81,A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.,2750819_1,-1,-1,-1,11794,-1,0.0016125916,0.99838746
11795,mg,12,13,92,94,A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.,2750819_1,-1,-1,-1,11795,-1,0.9887073,0.011292732
11796,magnesium sulfate,14,16,98,115,A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.,2750819_1,-1,-1,-1,11796,-1,0.99914,0.00085989136
11805,CBZ,5,6,30,33,The effects of carbamazepine (CBZ) treatment on local anesthetic-kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.,2790457_1,-1,-1,-1,11805,-1,0.99920124,0.00079880876
11807,CBZ,28,29,186,189,The effects of carbamazepine (CBZ) treatment on local anesthetic-kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.,2790457_1,-1,-1,-1,11807,-1,0.9992324,0.000767552
11808,CBZ,2,3,13,16,"Chronic oral CBZ inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic seizures.",2790457_2,-1,-1,-1,11808,-1,0.9991259,0.00087412365
11811,CBZ,1,2,8,11,Chronic CBZ also decreased the incidence of seizure-related mortality in the cocaine-injected rats.,2790457_3,-1,-1,-1,11811,-1,0.99897987,0.0010201369
11812,CBZ,1,2,6,9,Acute CBZ over a range of doses (15-50 mg/kg) had no effect on completed lidocaine-kindled or acute cocaine-induced seizures.,2790457_4,-1,-1,-1,11812,-1,0.99897814,0.0010219169
11814,CBZ,2,3,13,16,injection of CBZ (15 mg/kg) also was without effect on the development of lidocaine- or cocaine-kindled seizures.,2790457_6,-1,-1,-1,11814,-1,0.9991936,0.00080634863
11816,CBZ,4,5,28,31,The differential effects of CBZ depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic-kindled seizures.,2790457_7,-1,-1,-1,11816,-1,0.999121,0.0008789749
11819,CBZ,11,12,74,77,"The effectiveness of chronic but not repeated, intermittent injections of CBZ suggests that different biochemical consequences result from the different treatment regimens.",2790457_8,-1,-1,-1,11819,-1,0.9990821,0.0009178621
11820,CBZ,5,6,32,35,"The possible utility of chronic CBZ in preventing the development of toxic side effects in human cocaine users is suggested by these data, but remains to be directly evaluated.",2790457_9,-1,-1,-1,11820,-1,0.9989938,0.0010061517
11823,amphotericin B nephrotoxicity,4,7,33,62,Sodium status influences chronic amphotericin B nephrotoxicity in rats.,2802551_0,-1,-1,-1,11823,-1,0.3193068,0.6806932
11825,amphotericin B,4,6,29,43,"The nephrotoxic potential of amphotericin B (5 mg/kg per day intraperitoneally for 3 weeks) has been investigated in salt-depleted, normal-salt, and salt-loaded rats.",2802551_1,-1,-1,-1,11825,-1,0.99896014,0.0010399104
11826,amphotericin B,4,6,23,37,"In salt-depleted rats, amphotericin B decreased creatinine clearance linearly with time, with an 85% reduction by week 3.",2802551_2,-1,-1,-1,11826,-1,0.998831,0.001169024
11828,contrast,1,2,3,11,"In contrast, in normal-salt rats creatinine clearance was decreased but to a lesser extent at week 2 and 3, and in salt-loaded rats creatinine clearance did not change for 2 weeks and was decreased by 43% at week 3.",2802551_3,-1,-1,-1,11828,-1,0.21924216,0.7807579
11831,amphotericin B,2,4,18,32,Concentrations of amphotericin B in plasma were not significantly different among the three groups at any time during the study.,2802551_5,-1,-1,-1,11831,-1,0.99895513,0.0010447929
11832,amphotericin B,9,11,32,46,"However, at the end of 3 weeks, amphotericin B levels in the kidneys and liver were significantly higher in salt-depleted and normal-salt rats than those in salt-loaded rats, with plasma/kidney ratios of 21, 14, and 8 in salt-depleted, normal-salt, and salt-loaded rats, respectively.",2802551_6,-1,-1,-1,11832,-1,0.99893016,0.001069862
11834,amphotericin B,9,11,60,74,"In conclusion, reductions in creatinine clearance and renal amphotericin B accumulation after chronic amphotericin B administration were enhanced by salt depletion and attenuated by sodium loading in rats.",2802551_7,-1,-1,-1,11834,-1,0.99902093,0.0009790895
11835,amphotericin B,14,16,102,116,"In conclusion, reductions in creatinine clearance and renal amphotericin B accumulation after chronic amphotericin B administration were enhanced by salt depletion and attenuated by sodium loading in rats.",2802551_7,-1,-1,-1,11835,-1,0.99899346,0.0010064988
11838,venous thrombosis,5,7,39,56,"Magnetic resonance imaging of cerebral venous thrombosis secondary to ""low-dose"" birth control pills.",2819587_0,-1,-1,-1,11838,-1,0.0014506535,0.9985493
11839,deep venous thrombosis,7,10,51,73,The clinical and radiographic features of cerebral deep venous thrombosis in a 21-year-old white woman are presented.,2819587_1,-1,-1,-1,11839,-1,0.0015355203,0.99846447
11840,oral contraceptive pills,9,12,42,66,"The only known risk factor was ""low-dose"" oral contraceptive pills.",2819587_3,-1,-1,-1,11840,-1,0.99717593,0.0028241086
11841,hypokalemia,1,2,29,40,Beta-2-adrenoceptor-mediated hypokalemia and its abolishment by oxprenolol.,2826064_0,-1,-1,-1,11841,-1,0.0013182416,0.9986817
11842,oxprenolol,6,7,64,74,Beta-2-adrenoceptor-mediated hypokalemia and its abolishment by oxprenolol.,2826064_0,-1,-1,-1,11842,-1,0.99908924,0.0009107283
11843,hypokalemia,8,9,77,88,"The time course and concentration-effect relationship of terbutaline-induced hypokalemia was studied, using computer-aided pharmacokinetic-dynamic modeling.",2826064_1,-1,-1,-1,11843,-1,0.001227425,0.99877256
11844,oxprenolol,6,7,45,55,"Subsequently we investigated the efficacy of oxprenolol in antagonizing such hypokalemia, together with the pharmacokinetic interaction between both drugs.",2826064_2,-1,-1,-1,11844,-1,0.99915385,0.0008461399
11845,hypokalemia,10,11,77,88,"Subsequently we investigated the efficacy of oxprenolol in antagonizing such hypokalemia, together with the pharmacokinetic interaction between both drugs.",2826064_2,-1,-1,-1,11845,-1,0.0014735962,0.99852633
11846,mg,7,8,38,40,Six healthy subjects were given a 0.5 mg subcutaneous dose of terbutaline on two occasions: 1 hour after oral administration of a placebo and 1 hour after 80 mg oxprenolol orally.,2826064_3,-1,-1,-1,11846,-1,0.9910691,0.008930921
11848,mg oxprenolol,29,31,158,171,Six healthy subjects were given a 0.5 mg subcutaneous dose of terbutaline on two occasions: 1 hour after oral administration of a placebo and 1 hour after 80 mg oxprenolol orally.,2826064_3,-1,-1,-1,11848,-1,0.9983437,0.0016562672
11853,Oxprenolol,0,1,0,10,"Oxprenolol caused decreases of 65% and 56% of terbutaline volume of distribution and clearance, respectively, and an increase of 130% of its AUC.",2826064_6,-1,-1,-1,11853,-1,0.99916697,0.00083310093
11856,oxprenolol,7,8,52,62,"In spite of higher terbutaline concentrations after oxprenolol pretreatment, the hypokalemia was almost completely antagonized by the beta 2-blocking action.",2826064_7,-1,-1,-1,11856,-1,0.9991937,0.0008062734
11857,hypokalemia,11,12,81,92,"In spite of higher terbutaline concentrations after oxprenolol pretreatment, the hypokalemia was almost completely antagonized by the beta 2-blocking action.",2826064_7,-1,-1,-1,11857,-1,0.0014491265,0.99855083
11858,movement disorder,1,3,4,21,"The movement disorder investigated in these studies has some features in common with human idiopathic dystonia, and information obtained in these studies may be of potential clinical benefit.",2840807_1,-1,-1,-1,11858,-1,0.0013517052,0.99864835
11859,idiopathic dystonia,14,16,91,110,"The movement disorder investigated in these studies has some features in common with human idiopathic dystonia, and information obtained in these studies may be of potential clinical benefit.",2840807_1,-1,-1,-1,11859,-1,0.001424939,0.9985751
11860,ACTH,20,21,90,94,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,-1,-1,-1,11860,-1,0.9987307,0.0012692773
11861,NE,36,37,170,172,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,-1,-1,-1,11861,-1,0.9985844,0.0014156523
11863,movement disorder,75,77,410,427,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,-1,-1,-1,11863,-1,0.0018560932,0.9981439
11866,ACC-9089,2,3,11,19,"Flestolol (ACC-9089) is a nonselective, competitive, ultra-short-acting beta-adrenergic blocking agent, without any intrinsic sympathomimetic activity.",2870085_1,-1,-1,-1,11866,-1,0.9987544,0.0012456594
11874,contrast,1,2,3,11,"In contrast with other beta blockers, flestolol-induced effects reverse rapidly (within 30 minutes) following discontinuation because of its short half-life.",2870085_8,-1,-1,-1,11874,-1,0.47232994,0.52767
11876,supraventricular tachyarrhythmia,8,10,58,90,Flestolol effectively reduced heart rate in patients with supraventricular tachyarrhythmia.,2870085_9,-1,-1,-1,11876,-1,0.0013146669,0.9986853
11877,unstable angina,3,5,17,32,"In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling chest pain.",2870085_10,-1,-1,-1,11877,-1,0.001309209,0.9986908
11879,chest pain,17,19,103,113,"In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling chest pain.",2870085_10,-1,-1,-1,11879,-1,0.0014014057,0.99859864
11884,h,14,15,92,93,"The present study examines the effect of 6-day epinephrine treatment (100 micrograms/kg per h, s.c.) on stimulus-induced (1 Hz) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle- and epinephrine-treated rats.",2886572_1,-1,-1,-1,11884,-1,0.98406976,0.015930204
11897,Phentolamine,0,1,0,12,Phentolamine increased stimulus-induced overflow in both groups although the increment in overflow was greater in the epinephrine-treated group.,2886572_8,-1,-1,-1,11897,-1,0.9993212,0.0006788465
11899,phentolamine,5,6,32,44,"Furthermore, data obtained with phentolamine alone do not suggest alpha-adrenoceptor desensitization as the cause of the enhanced neurotransmitter overflow after epinephrine treatment.",2886572_11,-1,-1,-1,11899,-1,0.99938595,0.0006140317
11901,prolactinomas,10,11,91,104,"Immunohistochemical, electron microscopic and morphometric studies of estrogen-induced rat prolactinomas after bromocriptine treatment.",2887062_0,-1,-1,-1,11901,-1,0.155521,0.84447896
11906,h,26,27,194,195,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,-1,-1,11906,-1,0.57939327,0.42060673
11907,h,29,30,202,203,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,-1,-1,11907,-1,0.45990947,0.54009056
11909,body weight,38,40,249,260,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,-1,-1,11909,-1,0.8672804,0.13271955
11910,h,1,2,4,5,"One h after treatment, serum prolactin levels decreased markedly.",2887062_2,-1,-1,-1,11910,-1,0.39464414,0.6053559
11913,h,2,3,5,6,"At 6 h after injection, serum prolactin levels were still considerably lower than in controls.",2887062_6,-1,-1,-1,11913,-1,0.35401013,0.6459899
11916,h,13,14,87,88,"However, only secretory granules showed the positive reaction products for prolactin 6 h after bromocriptine treatment of the adenoma cells.",2887062_9,-1,-1,-1,11916,-1,0.27104744,0.7289525
11918,adenoma,19,20,126,133,"However, only secretory granules showed the positive reaction products for prolactin 6 h after bromocriptine treatment of the adenoma cells.",2887062_9,-1,-1,-1,11918,-1,0.004720269,0.9952798
11920,GABA,0,1,0,4,GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental.,2893236_0,-1,-1,-1,11920,-1,0.99908817,0.0009118511
11922,respiratory paralysis,7,9,49,70,GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental.,2893236_0,-1,-1,-1,11922,-1,0.0014508091,0.99854916
11923,thiopental,11,12,83,93,GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental.,2893236_0,-1,-1,-1,11923,-1,0.99931836,0.0006816269
11924,respiratory paralysis,7,9,37,58,"No agent is yet available to reverse respiratory paralysis produced by CNS depressants, such as general anesthetics.",2893236_1,-1,-1,-1,11924,-1,0.0015498684,0.99845016
11925,CNS depressants,11,13,71,86,"No agent is yet available to reverse respiratory paralysis produced by CNS depressants, such as general anesthetics.",2893236_1,-1,-1,-1,11925,-1,0.7417914,0.25820857
11927,respiratory paralysis,5,7,32,53,In this study naloxone reversed respiratory paralysis induced by thiopental in rats.,2893236_2,-1,-1,-1,11927,-1,0.0016694311,0.99833053
11928,thiopental,9,10,65,75,In this study naloxone reversed respiratory paralysis induced by thiopental in rats.,2893236_2,-1,-1,-1,11928,-1,0.9993253,0.0006747819
11929,thiopental,5,6,15,25,"25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.",2893236_3,-1,-1,-1,11929,-1,0.9992993,0.0007007008
11930,GABA,14,15,91,95,"25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.",2893236_3,-1,-1,-1,11930,-1,0.9990246,0.0009753411
11934,thiosemicarbazide,4,5,26,43,Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.,2893236_4,-1,-1,-1,11934,-1,0.9992204,0.000779583
11935,thiopental,20,21,139,149,Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.,2893236_4,-1,-1,-1,11935,-1,0.9992737,0.00072623417
11936,thiopental,5,6,15,25,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,-1,-1,-1,11936,-1,0.9992816,0.0007183802
11937,respiratory arrest,7,9,35,53,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,-1,-1,-1,11937,-1,0.0019976518,0.99800235
11938,GABA,13,14,79,83,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,-1,-1,-1,11938,-1,0.99901676,0.0009832405
11940,amino acids,29,31,170,181,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,-1,-1,-1,11940,-1,0.9982951,0.0017049214
11942,respiratory paralysis,9,11,36,57,"Naloxone (2.5 mg/kg, i.v.) reversed respiratory paralysis, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.",2893236_6,-1,-1,-1,11942,-1,0.0020495942,0.9979504
11944,GABA,14,15,73,77,"Naloxone (2.5 mg/kg, i.v.) reversed respiratory paralysis, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.",2893236_6,-1,-1,-1,11944,-1,0.9990357,0.0009642976
11946,respiratory paralysis,5,7,37,58,These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.,2893236_7,-1,-1,-1,11946,-1,0.0016909754,0.998309
11947,thiopental,9,10,71,81,These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.,2893236_7,-1,-1,-1,11947,-1,0.9993524,0.0006476164
11948,GABA,12,13,95,99,These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.,2893236_7,-1,-1,-1,11948,-1,0.9991968,0.00080316473
11953,mg,8,9,45,47,Intravenous administration of diazepam (1-30 mg kg-1) produced a dose-dependent decrease in both the mean arterial pressure and the heart rate.,2894433_2,-1,-1,-1,11953,-1,0.9879045,0.012095554
11961,chloride,25,26,171,179,"However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).",2894433_5,-1,-1,-1,11961,-1,0.99906546,0.00093458814
11964,lupus erythematosus,1,3,22,41,Sulfasalazine-induced lupus erythematosus.,2894766_0,-1,-1,-1,11964,-1,0.0012732564,0.9987268
11965,Pneumonitis,0,1,0,11,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,-1,-1,-1,11965,-1,0.0010838256,0.99891615
11966,pleural effusions,3,5,23,40,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,-1,-1,-1,11966,-1,0.0013997157,0.9986003
11967,cardiac tamponade,9,11,72,89,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,-1,-1,-1,11967,-1,0.001450825,0.99854916
11969,ulcerative colitis,29,31,213,231,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,-1,-1,-1,11969,-1,0.001438154,0.9985619
11972,lupus,8,9,59,64,"It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.",2894766_3,-1,-1,-1,11972,-1,0.0010921526,0.9989078
11973,serositis,13,14,88,97,"It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.",2894766_3,-1,-1,-1,11973,-1,0.0012130904,0.998787
11974,pulmonary,15,16,102,111,"It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.",2894766_3,-1,-1,-1,11974,-1,0.0022094268,0.9977906
11975,involvement,17,18,124,135,"It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.",2894766_3,-1,-1,-1,11975,-1,0.0013413471,0.99865866
11976,joint symptoms,22,24,154,168,"It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.",2894766_3,-1,-1,-1,11976,-1,0.0015442924,0.99845564
11978,inflammatory bowel disease,8,11,56,82,Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.,2894766_4,-1,-1,-1,11978,-1,0.0012182768,0.99878174
11979,lupus syndrome,19,21,137,151,Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.,2894766_4,-1,-1,-1,11979,-1,0.0011009104,0.9988991
11981,hypokalaemia,4,5,27,39,Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.,28952_0,-1,-1,-1,11981,-1,0.0015089235,0.99849105
11982,chlorthalidone,6,7,47,61,Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.,28952_0,-1,-1,-1,11982,-1,0.9992467,0.00075334386
11983,essential hypertension,11,13,94,116,Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.,28952_0,-1,-1,-1,11983,-1,0.0018390819,0.9981609
11986,hypokalaemia,9,10,61,73,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,-1,-1,-1,11986,-1,0.0016295026,0.99837047
11987,diuretic,16,17,111,119,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,-1,-1,-1,11987,-1,0.99886525,0.0011347985
11988,essential hypertension,27,29,183,205,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,-1,-1,-1,11988,-1,0.0018748762,0.99812514
11989,hypokalaemia,32,33,220,232,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,-1,-1,-1,11989,-1,0.0016234029,0.9983766
11990,diuretic,36,37,250,258,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,-1,-1,-1,11990,-1,0.99888784,0.00111214
11991,Chlorthalidone,0,1,0,14,Chlorthalidone (50 mg daily) was given for 14 days.,28952_2,-1,-1,-1,11991,-1,0.99919397,0.0008060476
11992,mg,3,4,19,21,Chlorthalidone (50 mg daily) was given for 14 days.,28952_2,-1,-1,-1,11992,-1,0.9887965,0.011203495
11994,K,11,12,58,59,All patients had a normal initial total body potassium (40K).,28952_4,-1,-1,-1,11994,-1,0.9685069,0.031493112
11995,bromide,6,7,34,41,"The electrolyte balances, weight, bromide space, plasma renin activity, and aldosterone secretion rate were measured.",28952_5,-1,-1,-1,11995,-1,0.9986174,0.0013825694
12007,buspirone,5,6,27,36,"The novel anxiolytic drug, buspirone, reverses catalepsy induced by haloperidol.",2907585_1,-1,-1,-1,12007,-1,0.999345,0.0006550262
12010,buspirone,6,7,41,50,A series of aryl-piperazine analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.,2907585_2,-1,-1,-1,12010,-1,0.9993635,0.00063652784
12011,5-hydroxytryptaminergic agonists,9,11,61,93,A series of aryl-piperazine analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.,2907585_2,-1,-1,-1,12011,-1,0.99855953,0.0014404297
12015,5-HT,5,6,30,34,Drugs with affinity for other 5-HT receptors or weak affinity were ineffective.,2907585_4,-1,-1,-1,12015,-1,0.9973459,0.0026541033
12016,5-HT,5,6,36,40,"However, inhibition of postsynaptic 5-HT receptors neither inhibited nor potentiated reversal of catalepsy and leaves open the question as to the site or mechanism for this effect.",2907585_5,-1,-1,-1,12016,-1,0.998226,0.0017740129
12018,Glycopyrronium,0,1,0,14,Glycopyrronium requirements for antagonism of the muscarinic side effects of edrophonium.,2917114_0,-1,-1,-1,12018,-1,0.99891436,0.0010856232
12019,edrophonium,10,11,77,88,Glycopyrronium requirements for antagonism of the muscarinic side effects of edrophonium.,2917114_0,-1,-1,-1,12019,-1,0.9970816,0.0029183892
12020,glycopyrronium,13,14,70,84,"We have compared, in 60 adult patients, the cardiovascular effects of glycopyrronium 5 micrograms kg-1 and 10 micrograms kg-1 given either simultaneously or 1 min before edrophonium 1 mg kg-1.",2917114_1,-1,-1,-1,12020,-1,0.99913687,0.0008631364
12021,edrophonium,28,29,170,181,"We have compared, in 60 adult patients, the cardiovascular effects of glycopyrronium 5 micrograms kg-1 and 10 micrograms kg-1 given either simultaneously or 1 min before edrophonium 1 mg kg-1.",2917114_1,-1,-1,-1,12021,-1,0.9989153,0.001084686
12022,mg,30,31,184,186,"We have compared, in 60 adult patients, the cardiovascular effects of glycopyrronium 5 micrograms kg-1 and 10 micrograms kg-1 given either simultaneously or 1 min before edrophonium 1 mg kg-1.",2917114_1,-1,-1,-1,12022,-1,0.995002,0.004997995
12023,P,9,10,63,64,Significant differences between the four groups were detected (P less than 0.001).,2917114_2,-1,-1,-1,12023,-1,0.2800445,0.71995544
12024,glycopyrronium,2,3,7,21,"Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.",2917114_4,-1,-1,-1,12024,-1,0.99913615,0.0008639301
12025,edrophonium,17,18,110,121,"Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.",2917114_4,-1,-1,-1,12025,-1,0.9981882,0.0018118013
12026,bradycardias,26,27,177,189,"Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.",2917114_4,-1,-1,-1,12026,-1,0.0012861375,0.99871385
12027,glycopyrronium,4,5,17,31,This low dose of glycopyrronium provided good control of oropharyngeal secretions.,2917114_5,-1,-1,-1,12027,-1,0.9989126,0.0010874304
12030,folate,17,18,96,102,"Chronic carbamazepine treatment in the rat: efficacy, toxicity, and effect on plasma and tissue folate concentrations.",2924746_0,-1,-1,-1,12030,-1,0.9989791,0.0010209843
12031,Folate,0,1,0,6,Folate depletion has often been a problem in chronic antiepileptic drug (AED) therapy.,2924746_1,-1,-1,-1,12031,-1,0.9980944,0.001905625
12033,CBZ,2,3,15,18,"Carbamazepine (CBZ), a commonly used AED, has been implicated in some clinical studies.",2924746_2,-1,-1,-1,12033,-1,0.9991353,0.0008647639
12034,CBZ,11,12,60,63,A rat model was developed to examine the effects of chronic CBZ treatment on folate concentrations in the rat.,2924746_3,-1,-1,-1,12034,-1,0.9991185,0.000881494
12035,folate,14,15,77,83,A rat model was developed to examine the effects of chronic CBZ treatment on folate concentrations in the rat.,2924746_3,-1,-1,-1,12035,-1,0.99901295,0.0009870242
12036,propylene glycol,12,14,58,74,"In the course of developing this model, a common vehicle, propylene glycol, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited weight gain.",2924746_4,-1,-1,-1,12036,-1,0.9991185,0.0008815134
12038,weight gain,32,34,183,194,"In the course of developing this model, a common vehicle, propylene glycol, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited weight gain.",2924746_4,-1,-1,-1,12038,-1,0.012245831,0.98775417
12040,hexafluorodiethyl ether,3,5,20,43,Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).,2924746_5,-1,-1,-1,12040,-1,0.99835145,0.0016485788
12041,HFDE,6,7,45,49,Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).,2924746_5,-1,-1,-1,12041,-1,0.9978331,0.0021669082
12042,CBZ,20,21,115,118,Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).,2924746_5,-1,-1,-1,12042,-1,0.9990658,0.0009341504
12044,CBZ,3,4,23,26,Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.,2924746_6,-1,-1,-1,12044,-1,0.99903417,0.00096582307
12045,h,10,11,60,61,Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.,2924746_6,-1,-1,-1,12045,-1,0.86722875,0.13277128
12047,weight gain,30,32,182,193,Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.,2924746_6,-1,-1,-1,12047,-1,0.0140889585,0.985911
12048,CBZ,1,2,4,7,"The CBZ levels measured in plasma and brain of these animals, however, were below those normally considered protective.",2924746_7,-1,-1,-1,12048,-1,0.99889934,0.0011005825
12049,CBZ,3,4,20,23,"This treatment with CBZ had no apparent adverse effect on folate concentrations in the rat, and, indeed, the folate concentration increased in liver after 6 weeks of treatment and in plasma at 8 weeks of treatment.",2924746_8,-1,-1,-1,12049,-1,0.99909663,0.0009034193
12050,folate,10,11,58,64,"This treatment with CBZ had no apparent adverse effect on folate concentrations in the rat, and, indeed, the folate concentration increased in liver after 6 weeks of treatment and in plasma at 8 weeks of treatment.",2924746_8,-1,-1,-1,12050,-1,0.9990097,0.0009902644
12051,folate,21,22,109,115,"This treatment with CBZ had no apparent adverse effect on folate concentrations in the rat, and, indeed, the folate concentration increased in liver after 6 weeks of treatment and in plasma at 8 weeks of treatment.",2924746_8,-1,-1,-1,12051,-1,0.99893624,0.0010637064
12052,myocardial ischemia,1,3,21,40,Dipyridamole-induced myocardial ischemia.,2950248_0,-1,-1,-1,12052,-1,0.0016613763,0.9983386
12053,Angina,0,1,0,6,Angina and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures.,2950248_1,-1,-1,-1,12053,-1,0.0012600381,0.99874
12054,ischemic,2,3,11,19,Angina and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures.,2950248_1,-1,-1,-1,12054,-1,0.0014696284,0.9985304
12057,myocardial ischemia,21,23,141,160,"To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease.",2950248_2,-1,-1,-1,12057,-1,0.0015004834,0.9984995
12058,coronary artery disease,33,36,219,242,"To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease.",2950248_2,-1,-1,-1,12058,-1,0.0016915996,0.9983084
12060,atrial natriuretic factor,5,8,42,67,Inhibition of sympathoadrenal activity by atrial natriuretic factor in dogs.,2951327_0,-1,-1,-1,12060,-1,0.9968341,0.003165869
12064,p,37,38,155,156,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,-1,12064,-1,0.336718,0.663282
12065,p,48,49,184,185,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,-1,12065,-1,0.3188586,0.68114144
12066,p,61,62,217,218,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,-1,12066,-1,0.2811338,0.7188662
12069,contrast,92,93,381,389,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,-1,12069,-1,0.0460762,0.95392376
12071,hydralazine,98,99,427,438,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,-1,12071,-1,0.9993148,0.00068525167
12074,atrial natriuretic factor,19,22,106,131,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,-1,-1,-1,12074,-1,0.99838316,0.0016167947
12075,p,34,35,170,171,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,-1,-1,-1,12075,-1,0.46445814,0.5355419
12076,p,53,54,252,253,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,-1,-1,-1,12076,-1,0.85942566,0.1405743
12077,atrial natriuretic factor,6,9,47,72,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,-1,-1,-1,12077,-1,0.9953868,0.00461323
12078,n,16,17,95,96,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,-1,-1,-1,12078,-1,0.11626435,0.88373566
12079,n,31,32,151,152,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,-1,-1,-1,12079,-1,0.13272378,0.86727625
12080,n,42,43,182,183,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,-1,-1,-1,12080,-1,0.11475439,0.8852456
12081,iopentol,3,4,23,31,"Selective injection of iopentol, iohexol and metrizoate into the left coronary artery of the dog.",2980315_0,-1,-1,-1,12081,-1,0.9991658,0.00083421933
12082,iohexol,5,6,33,40,"Selective injection of iopentol, iohexol and metrizoate into the left coronary artery of the dog.",2980315_0,-1,-1,-1,12082,-1,0.9992424,0.0007575719
12083,metrizoate,7,8,45,55,"Selective injection of iopentol, iohexol and metrizoate into the left coronary artery of the dog.",2980315_0,-1,-1,-1,12083,-1,0.9992281,0.0007718936
12084,ventricular fibrillation,2,4,13,37,Induction of ventricular fibrillation and decrease of aortic pressure.,2980315_1,-1,-1,-1,12084,-1,0.0014322039,0.9985678
12085,iopentol,14,15,88,96,"In twenty beagle dogs selective injections were made into the left coronary artery with iopentol, iohexol and metrizoate in doses of 4 ml, 8 ml and 16 ml.",2980315_2,-1,-1,-1,12085,-1,0.999209,0.0007910286
12086,iohexol,16,17,98,105,"In twenty beagle dogs selective injections were made into the left coronary artery with iopentol, iohexol and metrizoate in doses of 4 ml, 8 ml and 16 ml.",2980315_2,-1,-1,-1,12086,-1,0.9992539,0.0007460909
12087,metrizoate,18,19,110,120,"In twenty beagle dogs selective injections were made into the left coronary artery with iopentol, iohexol and metrizoate in doses of 4 ml, 8 ml and 16 ml.",2980315_2,-1,-1,-1,12087,-1,0.9992305,0.00076949206
12088,iopentol,1,2,11,19,"Thirty-six iopentol injections, 35 iohexol injections and 37 metrizoate injections were made.",2980315_3,-1,-1,-1,12088,-1,0.99909306,0.000906952
12089,iohexol,5,6,35,42,"Thirty-six iopentol injections, 35 iohexol injections and 37 metrizoate injections were made.",2980315_3,-1,-1,-1,12089,-1,0.99919254,0.00080746214
12090,metrizoate,9,10,61,71,"Thirty-six iopentol injections, 35 iohexol injections and 37 metrizoate injections were made.",2980315_3,-1,-1,-1,12090,-1,0.9991855,0.000814513
12091,ventricular fibrillation,2,4,15,39,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,-1,-1,-1,12091,-1,0.0016175692,0.99838245
12092,p,8,9,66,67,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,-1,-1,-1,12092,-1,0.4513332,0.54866683
12093,iopentol,14,15,90,98,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,-1,-1,-1,12093,-1,0.9991968,0.0008032421
12094,iohexol,20,21,108,115,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,-1,-1,-1,12094,-1,0.9992805,0.0007194881
12095,metrizoate,27,28,132,142,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,-1,-1,-1,12095,-1,0.99923754,0.00076245226
12096,Iopentol,0,1,0,8,Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses.,2980315_5,-1,-1,-1,12096,-1,0.99912435,0.00087563245
12097,iohexol,2,3,13,20,Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses.,2980315_5,-1,-1,-1,12097,-1,0.99923766,0.0007623938
12098,metrizoate,13,14,93,103,Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses.,2980315_5,-1,-1,-1,12098,-1,0.9991966,0.00080338435
12100,nephrogenic diabetes insipidus,16,19,100,130,It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during lithium treatment.,3001299_1,-1,-1,-1,12100,-1,0.0017560199,0.99824405
12107,euthyroid,6,7,32,41,Impaired Umax was found in both euthyroid and hypothyroid patients while some hypothyroid patients concentrated their urine well.,3001299_4,-1,-1,-1,12107,-1,0.005843962,0.994156
12111,isoniazid neuropathy,6,8,47,67,Remodelling of nerve structure in experimental isoniazid neuropathy in the rat.,3015327_0,-1,-1,-1,12111,-1,0.5973288,0.40267128
12115,ACTH,3,4,41,45,Nitroprusside-induced hypotension evokes ACTH secretion which is primarily mediated by enhanced secretion of immunoreactive corticotropin-releasing factor (irCRF) into the hypophysial-portal circulation.,3015567_1,-1,-1,-1,12115,-1,0.99820054,0.0017994436
12116,arginine vasopressin,5,7,40,60,Portal plasma concentrations of neither arginine vasopressin nor oxytocin are significantly altered in this paradigm.,3015567_2,-1,-1,-1,12116,-1,0.9991015,0.0008985586
12119,arginine vasopressin,34,36,231,251,"Application of a delayed feedback signal, in the form of a 2-h systemic corticosterone infusion in urethane-anesthetized rats with pharmacological blockade of glucocorticoid synthesis, is without effect on the resting secretion of arginine vasopressin and oxytocin at any corticosterone feedback dose tested.",3015567_3,-1,-1,-1,12119,-1,0.99925107,0.00074889814
12127,delta 9-tetrahydrocannabinol,6,8,50,78,Noradrenergic involvement in catalepsy induced by delta 9-tetrahydrocannabinol.,3031535_0,-1,-1,-1,12127,-1,0.99893385,0.001066131
12128,delta 9-tetrahydrocannabinol,15,17,95,123,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,-1,-1,-1,12128,-1,0.9991677,0.00083238835
12129,THC,18,19,125,128,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,-1,-1,-1,12129,-1,0.999092,0.0009079765
12131,6-OHDA,28,29,182,188,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,-1,-1,-1,12131,-1,0.9989774,0.001022623
12133,6-OHDA,34,35,214,220,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,-1,-1,-1,12133,-1,0.9990765,0.00092346565
12134,THC,4,5,29,32,"The cataleptogenic effect of THC was significantly reduced in rats treated with 6-OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6-OHDA, as compared with control rats.",3031535_2,-1,-1,-1,12134,-1,0.999159,0.0008410244
12135,6-OHDA,12,13,80,86,"The cataleptogenic effect of THC was significantly reduced in rats treated with 6-OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6-OHDA, as compared with control rats.",3031535_2,-1,-1,-1,12135,-1,0.9990853,0.00091465993
12137,6-OHDA,30,31,180,186,"The cataleptogenic effect of THC was significantly reduced in rats treated with 6-OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6-OHDA, as compared with control rats.",3031535_2,-1,-1,-1,12137,-1,0.9990958,0.0009042154
12140,6-OHDA,18,19,121,127,"On the contrary, the cataleptogenic effect of haloperidol was significantly reduced in rats treated with desipramine and 6-OHDA but not in rats treated with 6-OHDA or in rats with lesions of the locus coeruleus.",3031535_3,-1,-1,-1,12140,-1,0.9991061,0.0008938169
12141,6-OHDA,25,26,157,163,"On the contrary, the cataleptogenic effect of haloperidol was significantly reduced in rats treated with desipramine and 6-OHDA but not in rats treated with 6-OHDA or in rats with lesions of the locus coeruleus.",3031535_3,-1,-1,-1,12141,-1,0.9991578,0.0008422458
12143,THC,17,18,118,121,"These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC, whereas dopaminergic neurons are important in catalepsy induced by haloperidol.",3031535_4,-1,-1,-1,12143,-1,0.9991621,0.0008379671
12146,azelastine,12,13,87,97,"Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.",3057041_0,-1,-1,-1,12146,-1,0.99912435,0.0008756784
12147,chlorpheniramine,14,15,99,115,"Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.",3057041_0,-1,-1,-1,12147,-1,0.9992218,0.00077821437
12148,spring allergic rhinitis,22,25,149,173,"Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.",3057041_0,-1,-1,-1,12148,-1,0.0013859022,0.9986141
12149,Azelastine,0,1,0,10,"Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.",3057041_1,-1,-1,-1,12149,-1,0.9990852,0.00091479585
12150,chlorpheniramine maleate,10,12,63,87,"Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.",3057041_1,-1,-1,-1,12150,-1,0.99920195,0.00079809356
12151,spring allergic rhinitis,22,25,144,168,"Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.",3057041_1,-1,-1,-1,12151,-1,0.0015319466,0.998468
12152,spring allergic rhinitis,19,22,87,111,"Subjects ranged in age from 18 to 60 years of age and had at least a 2-year history of spring allergic rhinitis, confirmed by positive skin test to spring aeroallergens.",3057041_3,-1,-1,-1,12152,-1,0.0014934401,0.9985065
12153,azelastine,8,9,45,55,"Medications were given four times daily; the azelastine groups received 0.5, 1.0, or 2.0 mg in the morning and evening with placebo in the early and late afternoon; the chlorpheniramine group received 4.0 mg four times daily.",3057041_4,-1,-1,-1,12153,-1,0.9990471,0.00095284515
12154,mg,17,18,89,91,"Medications were given four times daily; the azelastine groups received 0.5, 1.0, or 2.0 mg in the morning and evening with placebo in the early and late afternoon; the chlorpheniramine group received 4.0 mg four times daily.",3057041_4,-1,-1,-1,12154,-1,0.99614346,0.0038564547
12155,chlorpheniramine,33,34,169,185,"Medications were given four times daily; the azelastine groups received 0.5, 1.0, or 2.0 mg in the morning and evening with placebo in the early and late afternoon; the chlorpheniramine group received 4.0 mg four times daily.",3057041_4,-1,-1,-1,12155,-1,0.9992155,0.0007845172
12156,mg,37,38,205,207,"Medications were given four times daily; the azelastine groups received 0.5, 1.0, or 2.0 mg in the morning and evening with placebo in the early and late afternoon; the chlorpheniramine group received 4.0 mg four times daily.",3057041_4,-1,-1,-1,12156,-1,0.9953838,0.0046162372
12157,body weights,3,5,13,25,"Vital signs, body weights, serum chemistry values, complete blood cell counts, urine studies, and electrocardiograms were obtained for each subject and compared among groups.",3057041_8,-1,-1,-1,12157,-1,0.021172386,0.97882754
12158,azelastine,10,11,68,78,Symptoms relief in the group receiving the highest concentration of azelastine (2.0 mg twice daily) was statistically greater than in the placebo group during all weeks of the study.,3057041_9,-1,-1,-1,12158,-1,0.9990376,0.00096241146
12159,mg,13,14,84,86,Symptoms relief in the group receiving the highest concentration of azelastine (2.0 mg twice daily) was statistically greater than in the placebo group during all weeks of the study.,3057041_9,-1,-1,-1,12159,-1,0.99007404,0.009925997
12160,azelastine,3,4,15,25,Lower doses of azelastine were statistically more effective than placebo only during portions of the first 3 weeks of the study.,3057041_10,-1,-1,-1,12160,-1,0.99899095,0.0010090037
12161,contrast,1,2,3,11,"In contrast, although the chlorpheniramine group did have fewer symptoms than the placebo group during the study, the difference never reached statistical significance during any week of the study.",3057041_11,-1,-1,-1,12161,-1,0.18439473,0.8156053
12162,chlorpheniramine,5,6,26,42,"In contrast, although the chlorpheniramine group did have fewer symptoms than the placebo group during the study, the difference never reached statistical significance during any week of the study.",3057041_11,-1,-1,-1,12162,-1,0.99923635,0.0007636437
12163,Drowsiness,0,1,0,10,Drowsiness and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.,3057041_13,-1,-1,-1,12163,-1,0.0014580889,0.99854195
12164,altered taste perception,2,5,15,39,Drowsiness and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.,3057041_13,-1,-1,-1,12164,-1,0.0021592479,0.99784076
12165,azelastine,14,15,104,114,Drowsiness and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.,3057041_13,-1,-1,-1,12165,-1,0.9990073,0.000992745
12166,Azelastine,0,1,0,10,"Azelastine appears to be a safe, efficacious medication for seasonal allergic rhinitis.",3057041_14,-1,-1,-1,12166,-1,0.9986461,0.0013539741
12167,seasonal allergic rhinitis,10,13,60,86,"Azelastine appears to be a safe, efficacious medication for seasonal allergic rhinitis.",3057041_14,-1,-1,-1,12167,-1,0.0015603802,0.9984396
12168,renal insufficiency,3,5,35,54,Reversibility of captopril-induced renal insufficiency after prolonged use in an unusual case of renovascular hypertension.,3070035_0,-1,-1,-1,12168,-1,0.0011405163,0.9988595
12169,renovascular hypertension,13,15,97,122,Reversibility of captopril-induced renal insufficiency after prolonged use in an unusual case of renovascular hypertension.,3070035_0,-1,-1,-1,12169,-1,0.0012561048,0.99874395
12171,solitary kidney,14,16,75,90,"We report a case of severe hypertension with an occluded renal artery to a solitary kidney, who developed sudden deterioration of renal function following treatment with captopril.",3070035_1,-1,-1,-1,12171,-1,0.0025719053,0.9974281
12172,sudden deterioration of renal function,19,24,106,144,"We report a case of severe hypertension with an occluded renal artery to a solitary kidney, who developed sudden deterioration of renal function following treatment with captopril.",3070035_1,-1,-1,-1,12172,-1,0.002664092,0.99733585
12174,renal function,1,3,4,18,His renal function remained impaired but stable during 2 years' treatment with captopril but returned to pre-treatment levels soon after cessation of the drug.,3070035_2,-1,-1,-1,12174,-1,0.00984365,0.9901564
12176,renal failure,5,7,50,63,This indicates reversibility in captopril-induced renal failure even after its prolonged use and suggests that no organic damage occurs to glomerular arterioles following chronic ACE inhibition.,3070035_3,-1,-1,-1,12176,-1,0.0013499671,0.99865
12177,HMG CoA,0,2,0,7,HMG CoA reductase inhibitors.,3076126_0,-1,-1,-1,12177,-1,0.99829465,0.0017053204
12184,creatine kinase,3,5,20,35,Minor elevations of creatine kinase levels are reported in about 5% of patients.,3076126_11,-1,-1,-1,12184,-1,0.9979067,0.0020933123
12186,myoglobinuria,7,8,40,53,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,-1,12186,-1,0.0013669123,0.9986331
12187,renal failure,15,17,85,98,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,-1,12187,-1,0.0013276474,0.99867237
12189,cyclosporin,31,32,192,203,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,-1,12189,-1,0.9992368,0.0007631319
12190,gemfibrozil,33,34,205,216,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,-1,12190,-1,0.99925977,0.0007402121
12191,niacin,35,36,220,226,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,-1,12191,-1,0.9992778,0.00072227797
12195,hypercholesterolaemia,18,19,112,133,"As wider use confirms their safety profile, they will gain increasing importance in the therapeutic approach to hypercholesterolaemia and its consequences.",3076126_14,-1,-1,-1,12195,-1,0.0025096603,0.9974903
12199,RA,6,7,48,50,Twenty-five patients with rheumatoid arthritis (RA) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens.,3084782_2,-1,-1,-1,12199,-1,0.0014078598,0.9985921
12202,nephritis,7,8,44,53,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,-1,-1,-1,12202,-1,0.0012788299,0.9987212
12204,Tiopronin,12,13,76,85,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,-1,-1,-1,12204,-1,0.99929416,0.00070577074
12206,gold thiosulphate,30,32,180,197,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,-1,-1,-1,12206,-1,0.99918133,0.0008186834
12207,RA,13,14,81,83,Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.,3084782_4,-1,-1,-1,12207,-1,0.001652989,0.99834704
12208,Tiopronin,17,18,99,108,Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.,3084782_4,-1,-1,-1,12208,-1,0.9991854,0.00081457896
12209,nephritis,19,20,117,126,Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.,3084782_4,-1,-1,-1,12209,-1,0.0012034391,0.9987966
12210,contralateral rotation,1,3,10,32,Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine.,3088349_0,-1,-1,-1,12210,-1,0.006820116,0.9931799
12211,substantia nigra lesion,5,8,54,77,Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine.,3088349_0,-1,-1,-1,12211,-1,0.069539025,0.93046093
12213,6-OHDA,2,3,21,27,"Following unilateral 6-OHDA induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.",3088349_1,-1,-1,-1,12213,-1,0.9987902,0.0012098283
12214,SN lesion,4,6,36,45,"Following unilateral 6-OHDA induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.",3088349_1,-1,-1,-1,12214,-1,0.005309898,0.9946902
12215,contralateral rotation,11,13,69,91,"Following unilateral 6-OHDA induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.",3088349_1,-1,-1,-1,12215,-1,0.0047299517,0.9952701
12216,ipsilateral circling,20,22,137,157,"Following unilateral 6-OHDA induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.",3088349_1,-1,-1,-1,12216,-1,0.0047317254,0.9952683
12217,contralateral rotation,9,11,47,69,"In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion, on amphetamine-induced rotational behavior.",3088349_2,-1,-1,-1,12217,-1,0.0040396773,0.9959603
12218,rotational behavior,27,29,169,188,"In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion, on amphetamine-induced rotational behavior.",3088349_2,-1,-1,-1,12218,-1,0.0022764173,0.9977235
12219,contralateral rotation,1,3,5,27,"Such contralateral rotation may result from either degeneration-induced breakdown of the DA pool, or lesion-induced increase of DA turnover in the spared neurons.",3088349_4,-1,-1,-1,12219,-1,0.025291929,0.97470814
12220,DA,11,12,89,91,"Such contralateral rotation may result from either degeneration-induced breakdown of the DA pool, or lesion-induced increase of DA turnover in the spared neurons.",3088349_4,-1,-1,-1,12220,-1,0.9982387,0.0017612752
12221,DA,18,19,128,130,"Such contralateral rotation may result from either degeneration-induced breakdown of the DA pool, or lesion-induced increase of DA turnover in the spared neurons.",3088349_4,-1,-1,-1,12221,-1,0.9981008,0.0018991865
12223,contralateral rotation,29,31,191,213,"A substantial degree of contralateral preference was still evident when amphetamine was administered for the first time 24 days after lesioning, indicating involvement of spared cells in the contralateral rotation.",3088349_5,-1,-1,-1,12223,-1,0.017634235,0.9823658
12225,rotation,26,27,161,169,"However, regardless of the duration of recovery (and irrespective of either lesion volume, amphetamine dose, or post-lesion motor exercise), amphetamine-induced rotation tended to become gradually more ipsilateral as the observation session progressed, and all rats circled ipsilaterally to the lesion in response to further amphetamine injections.",3088349_6,-1,-1,-1,12225,-1,0.005501074,0.9944989
12228,DA,12,13,86,88,These findings suggest that amphetamine has an irreversible effect on the post-lesion DA pool contributing to contralateral rotation.,3088349_7,-1,-1,-1,12228,-1,0.9989838,0.0010161743
12229,contralateral rotation,16,18,110,132,These findings suggest that amphetamine has an irreversible effect on the post-lesion DA pool contributing to contralateral rotation.,3088349_7,-1,-1,-1,12229,-1,0.006752101,0.99324787
12237,hepatocellular injury,8,10,52,73,The results of serum liver function tests suggested hepatocellular injury in 10 (63%); the rest showed a mixed pattern.,3101906_8,-1,-1,-1,12237,-1,0.0014629241,0.99853706
12238,contrast,1,2,3,11,"In contrast, the results of histological examination of the liver often showed evidence of cholestasis.",3101906_9,-1,-1,-1,12238,-1,0.13929874,0.86070126
12240,Allergic,0,1,0,8,Allergic manifestations such as rash and eosinophilia were rare.,3101906_11,-1,-1,-1,12240,-1,0.0016626455,0.99833727
12253,sulfonylureas,12,13,87,100,"Drug-induced hepatotoxicity, although common, has been reported only infrequently with sulfonylureas.",3107448_1,-1,-1,-1,12253,-1,0.99886715,0.0011328965
12254,glyburide,1,2,4,13,"For glyburide, a second-generation sulfonylurea, only two brief reports of hepatotoxicity exist.",3107448_2,-1,-1,-1,12254,-1,0.9993291,0.00067090784
12255,sulfonylurea,5,6,35,47,"For glyburide, a second-generation sulfonylurea, only two brief reports of hepatotoxicity exist.",3107448_2,-1,-1,-1,12255,-1,0.99920815,0.00079182914
12257,type II diabetes mellitus,3,7,18,43,Two patients with type II diabetes mellitus developed an acute hepatitis-like syndrome soon after initiation of glyburide therapy.,3107448_3,-1,-1,-1,12257,-1,0.0018820213,0.99811804
12258,glyburide,16,17,112,121,Two patients with type II diabetes mellitus developed an acute hepatitis-like syndrome soon after initiation of glyburide therapy.,3107448_3,-1,-1,-1,12258,-1,0.9993118,0.0006881442
12259,viral infection,6,8,35,50,"There was no serologic evidence of viral infection, and a liver biopsy sample showed a histologic pattern consistent with drug-induced hepatitis.",3107448_4,-1,-1,-1,12259,-1,0.0017947543,0.9982052
12261,glyburide,6,7,47,56,Both patients recovered quickly after stopping glyburide therapy and have remained well for a follow-up period of 1 year.,3107448_5,-1,-1,-1,12261,-1,0.99929905,0.00070093654
12262,Glyburide,0,1,0,9,Glyburide can produce an acute hepatitis-like illness in some persons.,3107448_6,-1,-1,-1,12262,-1,0.99926025,0.00073978375
12263,Mitomycin C,0,2,0,11,Mitomycin C associated hemolytic uremic syndrome.,3108839_0,-1,-1,-1,12263,-1,0.99883264,0.0011673649
12265,Mitomycin C,0,2,0,11,Mitomycin C associated Hemolytic Uremic Syndrome (HUS) is a potentially fatal but uncommon condition that is not yet widely recognised.,3108839_1,-1,-1,-1,12265,-1,0.99893075,0.0010692063
12267,HUS,7,8,50,53,Mitomycin C associated Hemolytic Uremic Syndrome (HUS) is a potentially fatal but uncommon condition that is not yet widely recognised.,3108839_1,-1,-1,-1,12267,-1,0.001347468,0.9986525
12268,microangiopathic hemolytic anemia,3,6,15,48,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,-1,-1,-1,12268,-1,0.0012855773,0.99871445
12270,progressive renal failure,9,12,71,96,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,-1,-1,-1,12270,-1,0.0011592155,0.99884087
12271,mitomycin C,14,16,113,124,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,-1,-1,-1,12271,-1,0.99910295,0.0008970585
12272,renal failure,1,3,4,17,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,-1,-1,-1,12272,-1,0.0015438581,0.9984561
12273,mitomycin C,13,15,65,76,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,-1,-1,-1,12273,-1,0.999175,0.00082492805
12274,renal failure,24,26,131,144,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,-1,-1,-1,12274,-1,0.0015317833,0.9984682
12275,pulmonary edema,27,29,148,163,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,-1,-1,-1,12275,-1,0.0012933908,0.9987066
12276,Renal lesions,0,2,0,13,"Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.",3108839_4,-1,-1,-1,12276,-1,0.0017775799,0.9982224
12277,HUS,9,10,54,57,"Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.",3108839_4,-1,-1,-1,12277,-1,0.0016088127,0.9983912
12278,fibrin thrombi,13,15,81,95,"Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.",3108839_4,-1,-1,-1,12278,-1,0.0027755075,0.99722457
12279,ischemic,24,25,158,166,"Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.",3108839_4,-1,-1,-1,12279,-1,0.0018807666,0.9981192
12280,gastric adenocarcinoma,14,16,82,104,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,-1,-1,-1,12280,-1,0.0028089548,0.997191
12281,renal failure,18,20,119,132,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,-1,-1,-1,12281,-1,0.0014886318,0.9985114
12283,mitomycin C,26,28,178,189,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,-1,-1,-1,12283,-1,0.9990539,0.0009460804
12284,pulmonary edema,31,33,202,217,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,-1,-1,-1,12284,-1,0.0012240142,0.998776
12285,Ketanserin,0,1,0,10,Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.,3115150_0,-1,-1,-1,12285,-1,0.9993036,0.0006963541
12286,muscle rigidity,4,6,52,67,Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.,3115150_0,-1,-1,-1,12286,-1,0.0016966616,0.9983033
12287,ketanserin,3,4,27,37,"Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.",3115150_1,-1,-1,-1,12287,-1,0.99934846,0.0006514777
12289,muscle rigidity,16,18,128,143,"Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.",3115150_1,-1,-1,-1,12289,-1,0.001770995,0.99822897
12292,ketanserin,1,2,16,26,Intraperitoneal ketanserin administration at doses of 0.63 and 2.5 mg/kg prevented the alfentanil-induced increase in electromyographic activity compared with animals pretreated with saline.,3115150_3,-1,-1,-1,12292,-1,0.99934787,0.0006521141
12293,Chlordiazepoxide,0,1,0,16,Chlordiazepoxide at doses up to 10 mg/kg failed to significantly influence the rigidity produced by alfentanil.,3115150_4,-1,-1,-1,12293,-1,0.99924636,0.00075365696
12297,ketanserin,9,10,55,65,"Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.",3115150_5,-1,-1,-1,12297,-1,0.9993549,0.0006451529
12300,ketanserin,3,4,19,29,Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone.,3115150_6,-1,-1,-1,12300,-1,0.9993476,0.00065240817
12302,ketanserin,25,26,166,176,Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone.,3115150_6,-1,-1,-1,12302,-1,0.99935657,0.00064345996
12303,muscle rigidity,11,13,63,78,"These results, in combination with previous work, suggest that muscle rigidity, a clinically relevant side-effect of parenteral narcotic administration, may be partly mediated via serotonergic pathways.",3115150_7,-1,-1,-1,12303,-1,0.0017678906,0.9982322
12304,serotonin antagonists,3,5,25,46,"Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression.",3115150_8,-1,-1,-1,12304,-1,0.9989391,0.001060935
12306,respiratory depression,32,34,227,249,"Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression.",3115150_8,-1,-1,-1,12306,-1,0.0016863935,0.99831367
12307,Ro15-1788,6,9,51,60,Antagonism of diazepam-induced sedative effects by Ro15-1788 in patients after surgery under lumbar epidural block.,3120485_0,-1,-1,-1,12307,-1,0.9989342,0.0010657806
12308,Ro15-1788,11,14,52,61,"The aim of this study was to assess the efficacy of Ro15-1788 and a placebo in reversing diazepam-induced effects after surgery under epidural block, and to evaluate the local tolerance and general safety of Ro15-1788.",3120485_2,-1,-1,-1,12308,-1,0.99907875,0.0009212704
12309,Ro15-1788,37,40,208,217,"The aim of this study was to assess the efficacy of Ro15-1788 and a placebo in reversing diazepam-induced effects after surgery under epidural block, and to evaluate the local tolerance and general safety of Ro15-1788.",3120485_2,-1,-1,-1,12309,-1,0.99916816,0.0008318261
12311,Ro15-1788,5,8,42,51,Antagonism of diazepam-induced effects by Ro15-1788 was investigated postoperatively in a double-blind placebo-controlled trial.,3120485_4,-1,-1,-1,12311,-1,0.9989832,0.0010167535
12314,Ro15-1788,1,4,4,13,The Ro15-1788 group showed a significant improvement in the performance test up to 120 min after administration of the drug.,3120485_7,-1,-1,-1,12314,-1,0.99893063,0.0010693648
12315,Chorea,0,1,0,6,Chorea associated with oral contraception.,3123611_0,-1,-1,-1,12315,-1,0.0015487286,0.99845123
12316,oral contraception,3,5,23,41,Chorea associated with oral contraception.,3123611_0,-1,-1,-1,12316,-1,0.99423087,0.0057692057
12317,chorea,3,4,25,31,Three patients developed chorea while receiving oral contraceptives.,3123611_1,-1,-1,-1,12317,-1,0.0017032487,0.9982968
12319,chorea,5,6,30,36,Two were young patients whose chorea developed long after treatment had been started and disappeared soon after it had been discontinued.,3123611_2,-1,-1,-1,12319,-1,0.0015279804,0.99847203
12320,chorea,6,7,48,54,The third patient had acute amphetamine-induced chorea after prolonged oral contraception.,3123611_3,-1,-1,-1,12320,-1,0.0013402432,0.99865973
12321,oral contraception,9,11,71,89,The third patient had acute amphetamine-induced chorea after prolonged oral contraception.,3123611_3,-1,-1,-1,12321,-1,0.9979097,0.0020903025
12322,sex hormones,4,6,35,47,Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever.,3123611_4,-1,-1,-1,12322,-1,0.9969229,0.0030770309
12323,chorea,11,12,71,77,Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever.,3123611_4,-1,-1,-1,12323,-1,0.0012753122,0.99872464
12324,chorea,19,20,115,121,Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever.,3123611_4,-1,-1,-1,12324,-1,0.0013156064,0.99868435
12325,rheumatic fever,21,23,125,140,Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever.,3123611_4,-1,-1,-1,12325,-1,0.0013030302,0.998697
12329,normocarbia,7,8,52,63,"The animals were mechanically ventilated to achieve normocarbia (PCO2 = 42 +/- 1 mmHg, mean +/- SE).",3125768_3,-1,-1,-1,12329,-1,0.0057040784,0.9942959
12330,PCO2,9,10,65,69,"The animals were mechanically ventilated to achieve normocarbia (PCO2 = 42 +/- 1 mmHg, mean +/- SE).",3125768_3,-1,-1,-1,12330,-1,0.53853434,0.46146566
12331,SE,20,21,96,98,"The animals were mechanically ventilated to achieve normocarbia (PCO2 = 42 +/- 1 mmHg, mean +/- SE).",3125768_3,-1,-1,-1,12331,-1,0.16646521,0.83353484
12335,somatic rigidity,6,8,32,48,"In the five rats that developed somatic rigidity, ICP and CVP increased significantly above baseline (delta ICP 7.5 +/- 1.0 mmHg, delta CVP 5.9 +/- 1.3 mmHg).",3125768_5,-1,-1,-1,12335,-1,0.0014832563,0.99851674
12337,metocurine,10,11,70,80,These variables returned to baseline when rigidity was abolished with metocurine.,3125768_6,-1,-1,-1,12337,-1,0.99903643,0.0009636144
12341,retinyl acetate,3,5,26,41,Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.,3131282_0,-1,-1,-1,12341,-1,0.9991373,0.0008627056
12342,forestomach carcinogenesis,6,8,45,71,Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.,3131282_0,-1,-1,-1,12342,-1,0.00791518,0.9920848
12343,butylated hydroxyanisole,14,16,103,127,Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.,3131282_0,-1,-1,-1,12343,-1,0.9991198,0.0008802099
12344,retinyl acetate,5,7,34,49,The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.,3131282_1,-1,-1,-1,12344,-1,0.9991177,0.00088237476
12345,RA,8,9,51,53,The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.,3131282_1,-1,-1,-1,12345,-1,0.9988764,0.0011235377
12346,butylated hydroxyanisole,11,13,58,82,The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.,3131282_1,-1,-1,-1,12346,-1,0.999132,0.00086801325
12347,forestomach tumorigenesis,15,17,101,126,The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.,3131282_1,-1,-1,-1,12347,-1,0.018824074,0.98117596
12348,BHA,19,20,76,79,"Male F344 rats, 5 weeks of age, were maintained on diet containing 1% or 2% BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations (w/v) for 52 weeks.",3131282_2,-1,-1,-1,12348,-1,0.9986877,0.00131229
12349,RA,29,30,145,147,"Male F344 rats, 5 weeks of age, were maintained on diet containing 1% or 2% BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations (w/v) for 52 weeks.",3131282_2,-1,-1,-1,12349,-1,0.99878234,0.0012177003
12350,BHA,5,6,19,22,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,-1,-1,12350,-1,0.9984968,0.0015031777
12351,RA,25,26,148,150,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,-1,-1,12351,-1,0.99883074,0.0011692864
12352,P,28,29,166,167,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,-1,-1,12352,-1,0.55248076,0.44751924
12353,forestomach tumors,37,39,211,229,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,-1,-1,12353,-1,0.0039991634,0.9960008
12354,squamous cell papilloma,40,43,231,254,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,-1,-1,12354,-1,0.0020152577,0.99798477
12358,BHA,5,6,17,20,"In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.",3131282_4,-1,-1,-1,12358,-1,0.9982943,0.0017057625
12359,RA,7,8,22,24,"In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.",3131282_4,-1,-1,-1,12359,-1,0.9987526,0.0012474344
12360,epithelial hyperplasia,32,34,157,179,"In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.",3131282_4,-1,-1,-1,12360,-1,0.0018875559,0.99811244
12362,papillomas,3,4,12,22,"Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.",3131282_5,-1,-1,-1,12362,-1,0.0019125192,0.99808747
12363,RA,17,18,64,66,"Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.",3131282_5,-1,-1,-1,12363,-1,0.99865997,0.0013400721
12364,RA,29,30,99,101,"Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.",3131282_5,-1,-1,-1,12364,-1,0.9986418,0.0013582542
12365,RA,0,1,0,2,RA alone did not induce hyperplastic changes in the forestomach.,3131282_6,-1,-1,-1,12365,-1,0.99726874,0.002731198
12366,RA,4,5,29,31,These findings indicate that RA acted as a co-carcinogen in the BHA forestomach carcinogenesis of the rat.,3131282_7,-1,-1,-1,12366,-1,0.99828523,0.0017147722
12367,BHA forestomach carcinogenesis,11,14,64,94,These findings indicate that RA acted as a co-carcinogen in the BHA forestomach carcinogenesis of the rat.,3131282_7,-1,-1,-1,12367,-1,0.040024962,0.959975
12369,mitomycin C.Since,11,13,72,89,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,-1,-1,-1,12369,-1,0.9714892,0.028510824
12370,mitomycin C,14,16,95,106,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,-1,-1,-1,12370,-1,0.99913377,0.00086627895
12371,MMC,17,18,108,111,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,-1,-1,-1,12371,-1,0.99867415,0.0013258795
12374,cardiac failure,5,7,30,45,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_6,-1,-1,-1,12374,-1,0.0015316579,0.99846834
12375,mg,9,10,55,57,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_6,-1,-1,-1,12375,-1,0.98856676,0.011433177
12376,MMC,11,12,62,65,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_6,-1,-1,-1,12376,-1,0.9952891,0.004710959
12377,mg,15,16,79,81,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_6,-1,-1,-1,12377,-1,0.9840178,0.015982233
12379,cardiac failure,1,3,4,19,The cardiac failure was predicted by a drop in EF determined during a cold pressor test.,3137399_7,-1,-1,-1,12379,-1,0.0016443555,0.99835557
12382,mg,29,30,174,176,"Based on the combined data from the present study and the literature, we suggest that MMC-related cardiotoxicity is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with doxorubicin.",3137399_10,-1,-1,-1,12382,-1,0.9932376,0.006762381
12385,myocardial infarction,7,9,44,65,Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram.,3173179_0,-1,-1,-1,12385,-1,0.0012752528,0.99872476
12389,myocardial infarction,6,8,26,47,We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension.,3173179_3,-1,-1,-1,12389,-1,0.0013129927,0.99868697
12398,cerebral lesions,1,3,11,27,Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.,3183120_0,-1,-1,-1,12398,-1,0.0016059813,0.99839395
12399,tiazofurin,5,6,44,54,Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.,3183120_0,-1,-1,-1,12399,-1,0.9988967,0.0011032636
12400,MR,8,9,62,64,Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.,3183120_0,-1,-1,-1,12400,-1,0.0034797583,0.9965203
12401,Tiazofurin,0,1,0,10,Tiazofurin is an experimental chemotherapeutic agent currently undergoing clinical evaluation.,3183120_1,-1,-1,-1,12401,-1,0.9989278,0.0010721551
12402,MR,8,9,47,49,We report our results with magnetic resonance (MR) in demonstrating reversible cerebral abnormalities concurrent with the use of this drug.,3183120_2,-1,-1,-1,12402,-1,0.007828515,0.9921714
12403,cerebral abnormalities,13,15,79,101,We report our results with magnetic resonance (MR) in demonstrating reversible cerebral abnormalities concurrent with the use of this drug.,3183120_2,-1,-1,-1,12403,-1,0.0014446332,0.99855536
12404,MR,3,4,21,23,The abnormalities on MR were correlated with findings on CT as well as with cerebral angiography.,3183120_3,-1,-1,-1,12404,-1,0.034123644,0.96587634
12405,MR,3,4,15,17,The utility of MR in the evaluation of patients receiving this new agent is illustrated.,3183120_4,-1,-1,-1,12405,-1,0.0035725436,0.9964275
12407,head and neck carcinoma,5,9,36,59,Survival for patients with advanced head and neck carcinoma and esophageal carcinoma is poor with radiotherapy and/or surgery.,3187073_1,-1,-1,-1,12407,-1,0.0023689237,0.9976311
12408,esophageal carcinoma,10,12,64,84,Survival for patients with advanced head and neck carcinoma and esophageal carcinoma is poor with radiotherapy and/or surgery.,3187073_1,-1,-1,-1,12408,-1,0.0021996223,0.9978004
12409,5-FU,13,14,55,59,"In the present study, cis-platin (80-120 mg/m2BSA) and 5-FU (1000 mg/m2BSA daily as a continuous infusion during 5 days) were given to 76 patients before radiotherapy and surgery.",3187073_3,-1,-1,-1,12409,-1,0.9987804,0.0012196278
12410,cardiovascular disease,7,9,42,64,"In the pre-treatment evaluation, signs of cardiovascular disease were found in 33 patients (43%).",3187073_6,-1,-1,-1,12410,-1,0.00138638,0.9986136
12412,cardiovascular disease,12,14,73,95,The incidence of cardiotoxicity was not higher in patients with signs of cardiovascular disease than in those without in the pre-treatment evaluation.,3187073_9,-1,-1,-1,12412,-1,0.0011898505,0.9988102
12414,chest pain,7,9,45,55,"The most common signs of cardiotoxicity were chest pain, ST-T wave changes and atrial fibrillation.",3187073_10,-1,-1,-1,12414,-1,0.0013758824,0.9986241
12415,atrial fibrillation,14,16,79,98,"The most common signs of cardiotoxicity were chest pain, ST-T wave changes and atrial fibrillation.",3187073_10,-1,-1,-1,12415,-1,0.0017306017,0.9982693
12416,ventricular fibrillation,4,6,21,45,This was followed by ventricular fibrillation in one patient and sudden death in another.,3187073_11,-1,-1,-1,12416,-1,0.0013940126,0.998606
12417,sudden death,10,12,65,77,This was followed by ventricular fibrillation in one patient and sudden death in another.,3187073_11,-1,-1,-1,12417,-1,0.0017396178,0.99826044
12418,5-FU,6,7,33,37,It is concluded that patients on 5-FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed.,3187073_12,-1,-1,-1,12418,-1,0.998456,0.0015439668
12419,chest pain,21,23,131,141,It is concluded that patients on 5-FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed.,3187073_12,-1,-1,-1,12419,-1,0.0013135943,0.9986864
12420,tachyarrhythmia,24,25,145,160,It is concluded that patients on 5-FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed.,3187073_12,-1,-1,-1,12420,-1,0.0011928607,0.9988072
12422,gestational trophoblastic disease,4,7,27,60,Death from chemotherapy in gestational trophoblastic disease.,3192036_0,-1,-1,-1,12422,-1,0.0018660218,0.99813396
12423,choriocarcinoma,16,17,113,128,Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high-risk stage of choriocarcinoma.,3192036_1,-1,-1,-1,12423,-1,0.004412398,0.9955876
12431,pulmonary obstruction,16,18,103,124,"Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus.",3192036_5,-1,-1,-1,12431,-1,0.0012765907,0.9987233
12432,tumor necrosis,9,11,55,69,"Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli.",3192036_6,-1,-1,-1,12432,-1,0.0018496107,0.9981504
12436,massive embolism,17,19,95,111,"In view of the close time association between the start of chemotherapy and the acute onset of massive embolism other explanations, such as spontaneous necrosis, must be considered less likely.",3192036_7,-1,-1,-1,12436,-1,0.0016147947,0.9983852
12446,DA,41,42,255,257,"In rats which were pretreated with nicotine for 5 days, there was a significant increase in the nicotine-stimulated locomotor response which was associated with an increase in the number of L-[3H]nicotine binding sites and also with an elevated dopamine (DA) level in the striatum.",3220106_4,-1,-1,-1,12446,-1,0.9988655,0.0011345494
12448,DA,27,28,180,182,"However, this response was correlated with an elevated number of striatal [3H]spiperone binding sites, whereas the number of striatal L-[3H]nicotine binding sites and the striatal DA level were normal.",3220106_7,-1,-1,-1,12448,-1,0.999022,0.0009780263
12451,DA,26,27,187,189,"These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.",3220106_8,-1,-1,-1,12451,-1,0.9991672,0.00083280803
12452,DA,32,33,226,228,"These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.",3220106_8,-1,-1,-1,12452,-1,0.99908876,0.0009112314
12456,cm H2O,5,7,33,39,"Before nitroprusside infusion, 5 cm H2O CPAP significantly, P less than .05, decreased arterial blood pressure, but did not significantly alter heart rate, cardiac output, systemic vascular resistance, or QS/QT.",322550_2,-1,-1,-1,12456,-1,0.99706036,0.0029396513
12457,P,10,11,60,61,"Before nitroprusside infusion, 5 cm H2O CPAP significantly, P less than .05, decreased arterial blood pressure, but did not significantly alter heart rate, cardiac output, systemic vascular resistance, or QS/QT.",322550_2,-1,-1,-1,12457,-1,0.51038647,0.48961356
12458,cm H2O,1,3,4,10,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,-1,-1,-1,12458,-1,0.99703157,0.0029683982
12460,decrease in,10,12,65,76,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,-1,-1,-1,12460,-1,0.011460367,0.98853964
12461,blood pressure,13,15,86,100,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,-1,-1,-1,12461,-1,0.035646703,0.96435326
12462,decreased cardiac output,21,24,144,168,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,-1,-1,-1,12462,-1,0.018835042,0.98116493
12464,cm H2O,1,3,5,11,Five cm H2O CPAP during nitroprusside did not further alter any of the above-mentioned variables.,322550_5,-1,-1,-1,12464,-1,0.9957353,0.0042647114
12466,cm H2O,3,5,12,18,"However, 10 cm H2O CPAP decreased arterial blood pressure, cardiac output, and QS/QT.",322550_6,-1,-1,-1,12466,-1,0.99508107,0.004918941
12469,cm H2O,21,23,124,130,"During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm H2O), while decreasing QS/QT, produce marked decreases in arterial blood pressure and cardiac output.",322550_8,-1,-1,-1,12469,-1,0.99683553,0.003164538
12470,decreases in arterial blood pressure and cardiac output,31,39,172,227,"During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm H2O), while decreasing QS/QT, produce marked decreases in arterial blood pressure and cardiac output.",322550_8,-1,-1,-1,12470,-1,0.010955421,0.98904455
12471,hypokalemia,3,4,39,50,Amelioration of bendrofluazide-induced hypokalemia by timolol.,326460_0,-1,-1,-1,12471,-1,0.0012795562,0.9987205
12474,hypokalemia,12,13,66,77,"The beta adrenergic blocking drug, timolol, tended to correct the hypokalemia of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.",326460_1,-1,-1,-1,12474,-1,0.0013779255,0.99862206
12475,bendrofluazide,15,16,92,106,"The beta adrenergic blocking drug, timolol, tended to correct the hypokalemia of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.",326460_1,-1,-1,-1,12475,-1,0.9992434,0.00075658533
12479,bendrofluazide,13,14,92,106,Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine sodium/potassium ratio.,326460_2,-1,-1,-1,12479,-1,0.99918395,0.0008160723
12482,methysergide,20,21,122,134,"A rare case of morbid vasospasm, together with striking angiographic findings, is described secondary to the ingestion of methysergide by a 48-year-old woman.",3300918_1,-1,-1,-1,12482,-1,0.9992956,0.00070433615
12483,ergot,6,7,31,36,"A discussion of the history of ergot includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache.",3300918_3,-1,-1,-1,12483,-1,0.9975809,0.0024191353
12484,gangrene,15,16,87,95,"A discussion of the history of ergot includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache.",3300918_3,-1,-1,-1,12484,-1,0.0013577783,0.99864227
12485,migraine headache,33,35,183,200,"A discussion of the history of ergot includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache.",3300918_3,-1,-1,-1,12485,-1,0.0014228846,0.9985771
12486,calcium channel blockers,4,7,22,46,"Despite the advent of calcium channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of St. Anthony's fire persists.",3300918_4,-1,-1,-1,12486,-1,0.9985531,0.0014469161
12487,ergot,11,12,80,85,"Despite the advent of calcium channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of St. Anthony's fire persists.",3300918_4,-1,-1,-1,12487,-1,0.99888426,0.001115691
12503,mm Hg,7,9,43,48,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,-1,-1,-1,12503,-1,0.052718222,0.9472817
12505,HEM,16,17,86,89,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,-1,-1,-1,12505,-1,0.002101366,0.9978986
12506,n,18,19,91,92,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,-1,-1,-1,12506,-1,0.036348242,0.9636518
12508,SNP,30,31,149,152,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,-1,-1,-1,12508,-1,0.9989011,0.0010988776
12509,n,32,33,154,155,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,-1,-1,-1,12509,-1,0.052051328,0.94794863
12511,SNP,19,20,140,143,During HEM-induced hypotension the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the SNP group.,3341566_3,-1,-1,-1,12511,-1,0.9981578,0.0018422271
12513,mm Hg,9,11,44,49,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,-1,12513,-1,0.013177331,0.9868226
12514,HEM,13,14,57,60,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,-1,12514,-1,0.39524603,0.604754
12515,mm Hg,22,24,94,99,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,-1,12515,-1,0.014532773,0.9854672
12516,SNP,26,27,107,110,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,-1,12516,-1,0.9973907,0.002609286
12517,P,29,30,118,119,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,-1,12517,-1,0.3654773,0.6345227
12518,mm Hg,27,29,117,122,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,-1,-1,-1,12518,-1,0.03725882,0.96274114
12519,HEM,31,32,130,133,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,-1,-1,-1,12519,-1,0.9852792,0.014720797
12520,SNP,33,34,138,141,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,-1,-1,-1,12520,-1,0.9964468,0.0035532163
12522,P,41,42,184,185,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,-1,-1,-1,12522,-1,0.33770478,0.6622952
12524,hypovolemia,7,8,45,56,They are thus more important during absolute hypovolemia than during deliberate hypotension.,3341566_9,-1,-1,-1,12524,-1,0.0015322376,0.99846774
12526,Ventricular tachyarrhythmias,0,2,0,28,Ventricular tachyarrhythmias during cesarean section after ritodrine therapy: interaction with anesthetics.,3358181_0,-1,-1,-1,12526,-1,0.0014026212,0.9985973
12527,ritodrine,6,7,59,68,Ventricular tachyarrhythmias during cesarean section after ritodrine therapy: interaction with anesthetics.,3358181_0,-1,-1,-1,12527,-1,0.9993056,0.0006943405
12528,ritodrine,6,7,46,55,This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.,3358181_1,-1,-1,-1,12528,-1,0.9993461,0.00065390836
12529,preterm labor,8,10,60,73,This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.,3358181_1,-1,-1,-1,12529,-1,0.0019030274,0.998097
12530,ritodrine,19,20,140,149,This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.,3358181_1,-1,-1,-1,12530,-1,0.9993525,0.0006474673
12531,cardiovascular complications,6,8,40,68,Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ritodrine.,3358181_2,-1,-1,-1,12531,-1,0.0013815338,0.9986185
12532,ritodrine,15,16,108,117,Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ritodrine.,3358181_2,-1,-1,-1,12532,-1,0.9993241,0.0006759327
12538,carbamazepine neurotoxicity,1,3,18,45,Verapamil-induced carbamazepine neurotoxicity.,3371379_0,-1,-1,-1,12538,-1,0.6838649,0.31613517
12539,carbamazepine neurotoxicity,5,7,27,54,Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker.,3371379_2,-1,-1,-1,12539,-1,0.7066782,0.2933218
12546,Ethopropazine,0,1,0,13,Ethopropazine and benztropine in neuroleptic-induced parkinsonism.,33969_0,-1,-1,-1,12546,-1,0.99923325,0.0007667113
12547,benztropine,2,3,18,29,Ethopropazine and benztropine in neuroleptic-induced parkinsonism.,33969_0,-1,-1,-1,12547,-1,0.9993305,0.0006695451
12549,ethopropazine,5,6,30,43,In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.,33969_1,-1,-1,-1,12549,-1,0.99928916,0.00071077974
12550,benztropine,9,10,60,71,In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.,33969_1,-1,-1,-1,12550,-1,0.9993587,0.0006412975
12554,Ethopropazine,0,1,0,13,"Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.",33969_2,-1,-1,-1,12554,-1,0.99925214,0.00074779347
12555,benztropine,2,3,18,29,"Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.",33969_2,-1,-1,-1,12555,-1,0.9993364,0.0006636038
12556,parkinsonian symptoms,11,13,80,101,"Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.",33969_2,-1,-1,-1,12556,-1,0.0015899115,0.9984101
12557,procyclidine,18,19,129,141,"Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.",33969_2,-1,-1,-1,12557,-1,0.99937856,0.00062140054
12558,benztropine,2,3,9,20,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,-1,-1,12558,-1,0.99935716,0.0006428485
12559,tardive dyskinesia,10,12,68,86,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,-1,-1,12559,-1,0.0011503098,0.99884963
12560,procyclindine,17,18,122,135,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,-1,-1,12560,-1,0.9993005,0.00069949514
12561,anxiety,23,24,170,177,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,-1,-1,12561,-1,0.0014177826,0.99858224
12563,ethopropazine,27,28,198,211,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,-1,-1,12563,-1,0.9993228,0.00067727495
12564,benztropine,3,4,19,30,"This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic-induced parkinsonian symptoms, because of its more toxic central and peripheral atropinic effect.",33969_4,-1,-1,-1,12564,-1,0.9993654,0.000634607
12565,parkinsonian symptoms,16,18,113,134,"This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic-induced parkinsonian symptoms, because of its more toxic central and peripheral atropinic effect.",33969_4,-1,-1,-1,12565,-1,0.0013293504,0.9986707
12568,renal,6,7,49,54,"Paracetamol-associated coma, metabolic acidosis, renal and hepatic failure.",3403780_0,-1,-1,-1,12568,-1,0.0021248218,0.9978752
12569,hepatic failure,8,10,59,74,"Paracetamol-associated coma, metabolic acidosis, renal and hepatic failure.",3403780_0,-1,-1,-1,12569,-1,0.0014896111,0.9985104
12571,acute renal failure,6,9,30,49,"A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.",3403780_1,-1,-1,-1,12571,-1,0.0014084177,0.9985916
12572,hepatic failure,10,12,54,69,"A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.",3403780_1,-1,-1,-1,12572,-1,0.0014032299,0.9985967
12579,osteoarthritis,16,17,116,130,"The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, osteoarthritis and spondyloarthropathy, 130 of whom were pair-matched to controls.",3409645_1,-1,-1,-1,12579,-1,0.0013494065,0.9986506
12580,spondyloarthropathy,18,19,135,154,"The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, osteoarthritis and spondyloarthropathy, 130 of whom were pair-matched to controls.",3409645_1,-1,-1,-1,12580,-1,0.0013536593,0.9986463
12582,Sexual dysfunctions,0,2,0,19,"Sexual dysfunctions were found to be common among patients and controls, the majority in both groups reporting one or more dysfunctions.",3409645_3,-1,-1,-1,12582,-1,0.0022077425,0.99779224
12583,dysfunctions,21,22,123,135,"Sexual dysfunctions were found to be common among patients and controls, the majority in both groups reporting one or more dysfunctions.",3409645_3,-1,-1,-1,12583,-1,0.0019216669,0.99807835
12584,Impotence,0,1,0,9,Impotence was more common among male patients than controls and was found to be associated with co-morbidity and the taking of methotrexate.,3409645_4,-1,-1,-1,12584,-1,0.0015459176,0.9984541
12586,Depressed mood,0,2,0,14,"Depressed mood was more common among patients and was associated with certain sexual difficulties, but not with impotence.",3409645_5,-1,-1,-1,12586,-1,0.0019262717,0.9980737
12587,sexual difficulties,12,14,78,97,"Depressed mood was more common among patients and was associated with certain sexual difficulties, but not with impotence.",3409645_5,-1,-1,-1,12587,-1,0.002020391,0.9979796
12588,impotence,18,19,112,121,"Depressed mood was more common among patients and was associated with certain sexual difficulties, but not with impotence.",3409645_5,-1,-1,-1,12588,-1,0.0021612376,0.9978388
12591,Quinidine,0,1,0,9,Quinidine phenylethylbarbiturate-induced fulminant hepatitis in a pregnant woman.,3411101_0,-1,-1,-1,12591,-1,0.9992755,0.00072447356
12592,fulminant hepatitis,2,4,41,60,Quinidine phenylethylbarbiturate-induced fulminant hepatitis in a pregnant woman.,3411101_0,-1,-1,-1,12592,-1,0.0014460372,0.99855393
12593,fulminant hepatitis,11,13,64,83,We report the case of a 19-year-old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1-month administration of quinidine phenylethylbarbiturate.,3411101_2,-1,-1,-1,12593,-1,0.0014290062,0.9985709
12594,quinidine phenylethylbarbiturate,25,27,162,194,We report the case of a 19-year-old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1-month administration of quinidine phenylethylbarbiturate.,3411101_2,-1,-1,-1,12594,-1,0.9992029,0.00079711725
12595,Quinidine,0,1,0,9,Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient.,3411101_5,-1,-1,-1,12595,-1,0.9993438,0.00065619336
12596,phenylethylbarbiturate,3,4,20,42,Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient.,3411101_5,-1,-1,-1,12596,-1,0.9991303,0.0008697171
12597,fulminant hepatitis,8,10,66,85,Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient.,3411101_5,-1,-1,-1,12597,-1,0.0014049961,0.99859494
12599,urothelial cancer,3,5,23,40,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,-1,-1,-1,12599,-1,0.0021170739,0.9978829
12600,renal papillary necrosis?The,6,9,44,72,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,-1,-1,-1,12600,-1,0.017014338,0.9829857
12608,ureteric cancer,31,33,181,196,"The risk of renal papillary necrosis was increased nearly 20-fold by consumption of phenacetin, which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer.",3412544_1,-1,-1,-1,12608,-1,0.0031432887,0.9968567
12609,contrast,1,2,3,11,"By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.",3412544_2,-1,-1,-1,12609,-1,0.62840074,0.3715993
12611,papillary necrosis,16,18,101,119,"By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.",3412544_2,-1,-1,-1,12611,-1,0.002270609,0.99772936
12614,the ureter,34,36,209,219,"By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.",3412544_2,-1,-1,-1,12614,-1,0.0053675887,0.99463236
12615,myocardial ischemia,2,4,14,33,Mechanisms of myocardial ischemia induced by epinephrine: comparison with exercise-induced ischemia.,3413271_0,-1,-1,-1,12615,-1,0.0018015725,0.99819845
12619,myocardial ischemia,6,8,37,56,The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease.,3413271_1,-1,-1,-1,12619,-1,0.0015186847,0.99848133
12620,coronary artery disease,13,16,87,110,The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease.,3413271_1,-1,-1,-1,12620,-1,0.0017574547,0.9982425
12625,myocardial ischemia,5,7,39,58,Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.,3413271_3,-1,-1,-1,12625,-1,0.0016758441,0.9983241
12627,angina,14,15,101,107,Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.,3413271_3,-1,-1,-1,12627,-1,0.001218155,0.99878186
12628,myocardial ischemia,5,7,27,46,"However, the mechanisms of myocardial ischemia induced by epinephrine were significantly different from those of exercise.",3413271_4,-1,-1,-1,12628,-1,0.0018251184,0.9981749
12630,myocardial ischemia,1,3,17,36,"Exercise-induced myocardial ischemia was marked predominantly by increased heart rate and rate-pressure product with a minor contribution of end-diastolic volume, while epinephrine-induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate-pressure product.",3413271_5,-1,-1,-1,12630,-1,0.0017713818,0.9982286
12635,E,11,12,84,85,Dapsone-associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait.,3425586_0,-1,-1,-1,12635,-1,0.0048808274,0.9951192
12636,E,5,6,34,35,A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.,3425586_1,-1,-1,-1,12636,-1,0.003036498,0.99696344
12637,leprosy,11,12,51,58,A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.,3425586_1,-1,-1,-1,12637,-1,0.0013682331,0.9986318
12641,reduced glutathione,15,17,83,102,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,-1,-1,-1,12641,-1,0.9977297,0.0022702601
12642,GSH,18,19,104,107,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,-1,-1,-1,12642,-1,0.99786794,0.0021320751
12643,GSH,23,24,124,127,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,-1,-1,-1,12643,-1,0.99802506,0.0019749468
12644,pentose phosphate,1,3,4,21,The pentose phosphate shunt activity of the dapsone-exposed AE RBCs was increased compared to normal RBCs.,3425586_3,-1,-1,-1,12644,-1,0.99867564,0.0013243682
12646,GSH,18,19,109,112,"Although the AE RBCs from an individual not taking dapsone had increased incubated Heinz body formation, the GSH content and GSH stability were normal.",3425586_4,-1,-1,-1,12646,-1,0.99804974,0.0019502707
12647,GSH,21,22,125,128,"Although the AE RBCs from an individual not taking dapsone had increased incubated Heinz body formation, the GSH content and GSH stability were normal.",3425586_4,-1,-1,-1,12647,-1,0.9980825,0.0019175502
12648,pentose phosphate,1,3,4,21,The pentose phosphate shunt activity of the non-dapsone-exposed AE RBCs was decreased compared to normal RBCs.,3425586_5,-1,-1,-1,12648,-1,0.99859494,0.0014050566
12652,thymidylate,7,8,49,60,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12652,-1,0.9986216,0.0013784125
12653,"N10-propargyl-5,8-dideazafolic acid",10,12,80,115,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12653,-1,0.9981146,0.0018854864
12654,"N10-propargyl-5,8-dideazafolic acid",17,19,135,170,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12654,-1,0.99816304,0.0018369684
12655,thymidylate,25,26,204,215,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12655,-1,0.9987081,0.0012919023
12656,TS,28,29,226,228,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12656,-1,0.9165161,0.08348385
12657,cytotoxicity,31,32,236,248,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12657,-1,0.0028513356,0.9971487
12658,CB 3717,10,12,74,81,Recent preclinical studies have focused on the intracellular formation of CB 3717 polyglutamates.,3431591_1,-1,-1,-1,12658,-1,0.99844724,0.0015528175
12659,CB,7,8,36,38,"As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.",3431591_3,-1,-1,-1,12659,-1,0.99823475,0.0017652753
12660,CB,27,28,130,132,"As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.",3431591_3,-1,-1,-1,12660,-1,0.99833566,0.0016644069
12661,CB,44,45,220,222,"As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.",3431591_3,-1,-1,-1,12661,-1,0.99838364,0.0016163551
12662,cytotoxicity,46,47,228,240,"As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.",3431591_3,-1,-1,-1,12662,-1,0.0035576408,0.9964424
12663,CB 3717,5,7,31,38,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,-1,-1,-1,12663,-1,0.99841344,0.0015865762
12666,hepatoma,19,20,97,105,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,-1,-1,-1,12666,-1,0.0014613924,0.9985386
12667,mesothelioma,22,23,111,123,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,-1,-1,-1,12667,-1,0.0018765597,0.99812347
12670,malaise,4,5,36,43,"Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.",3431591_5,-1,-1,-1,12670,-1,0.0013048223,0.9986952
12672,CB 3717,23,25,124,131,This latter effect is thought to be due to drug precipitation within the renal tubule as a result of the poor solubility of CB 3717 under acidic conditions.,3431591_6,-1,-1,-1,12672,-1,0.9988341,0.0011659274
12673,CB 3717,12,14,60,67,"In an attempt to overcome this problem, a clinical trial of CB 3717 administered with alkaline diuresis is under way.",3431591_7,-1,-1,-1,12673,-1,0.99862325,0.0013768139
12677,malaise,2,3,19,26,Hepatotoxicity and malaise are again the most frequent side effects.,3431591_9,-1,-1,-1,12677,-1,0.0014962914,0.9985037
12678,CB 3717,10,12,80,87,Pharmacokinetic investigations have shown that alkaline diuresis does not alter CB 3717 plasma levels or urinary excretion and that satisfactory urinary alkalinization can be readily achieved.,3431591_11,-1,-1,-1,12678,-1,0.9987884,0.0012116007
12679,Type B hepatitis,0,3,0,16,Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin.,343678_0,-1,-1,-1,12679,-1,0.0021378929,0.99786216
12680,hepatitis B,9,11,62,73,Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin.,343678_0,-1,-1,-1,12680,-1,0.0033264596,0.99667346
12681,Hepatitis B,0,2,0,11,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,-1,-1,-1,12681,-1,0.0076815207,0.9923185
12682,type B hepatitis,29,32,167,183,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,-1,-1,-1,12682,-1,0.0025806588,0.99741936
12683,hepatitis B,36,38,215,226,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,-1,-1,-1,12683,-1,0.036068108,0.9639319
12685,P,16,17,76,77,"Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001).",343678_3,-1,-1,-1,12685,-1,0.21570948,0.7842905
12686,P,37,38,167,168,"Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001).",343678_3,-1,-1,-1,12686,-1,0.31547493,0.6845251
12687,e,12,13,65,66,Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE).,343678_5,-1,-1,-1,12687,-1,0.9682855,0.03171448
12688,HBeAg,17,18,89,94,Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE).,343678_5,-1,-1,-1,12688,-1,0.07766096,0.922339
12689,HBeAg,3,4,14,19,Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors.,343678_6,-1,-1,-1,12689,-1,0.995883,0.004117061
12690,Hepatitis B,0,2,0,11,Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups.,343678_7,-1,-1,-1,12690,-1,0.0034553222,0.99654466
12691,type B hepatitis,11,14,81,97,Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups.,343678_7,-1,-1,-1,12691,-1,0.0021914116,0.99780864
12692,type B hepatitis,6,9,34,50,The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included.,343678_8,-1,-1,-1,12692,-1,0.0018433373,0.9981566
12694,propafenone,17,18,110,121,"Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine.",3437726_0,-1,-1,-1,12694,-1,0.9993704,0.00062962685
12697,coronary artery disease,5,8,37,60,A 47-year-old patient suffering from coronary artery disease was admitted to the CCU in shock with III.,3437726_1,-1,-1,-1,12697,-1,0.002601048,0.997399
12699,AV block,0,2,0,8,"AV block, severe hypotension, and impairment of ventricular function.",3437726_2,-1,-1,-1,12699,-1,0.0015267172,0.9984732
12701,impairment of ventricular function,7,11,34,68,"AV block, severe hypotension, and impairment of ventricular function.",3437726_2,-1,-1,-1,12701,-1,0.0027177574,0.99728227
12703,mg,14,15,77,79,One week prior to admission a therapy with standard doses of metoprolol (100 mg t.i.d. and then 100 mg b.i.d.) had been initiated.,3437726_3,-1,-1,-1,12703,-1,0.99069107,0.00930898
12704,mg,20,21,100,102,One week prior to admission a therapy with standard doses of metoprolol (100 mg t.i.d. and then 100 mg b.i.d.) had been initiated.,3437726_3,-1,-1,-1,12704,-1,0.99001515,0.009984857
12706,mg,7,8,40,42,Two days before admission diltiazem (60 mg b.i.d.) was prescribed in addition.,3437726_4,-1,-1,-1,12706,-1,0.9875709,0.012429059
12711,propafenone,16,17,86,97,"Three months later the patient was exposed to a single dose of metoprolol, diltiazem, propafenone (since he had received this drug in the past), and sparteine (as a probe for the debrisoquine/sparteine type polymorphism of oxidative drug metabolism).",3437726_7,-1,-1,-1,12711,-1,0.999376,0.0006240735
12713,adverse drug reactions,26,29,187,209,"Therefore, patients belonging to the poor-metabolizer phenotype of sparteine/debrisoquine polymorphism in drug metabolism, which constitutes 6.4% of the German population, may experience adverse drug reactions when treated with standard doses of one of these drugs alone.",3437726_9,-1,-1,-1,12713,-1,0.003378086,0.99662197
12716,prostate adenocarcinomas,15,17,75,99,"More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.",3461217_1,-1,-1,-1,12716,-1,0.0020441941,0.9979558
12717,PAs,18,19,101,104,"More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.",3461217_1,-1,-1,-1,12717,-1,0.0027838913,0.9972161
12718,testosterone propionate,34,36,175,198,"More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.",3461217_1,-1,-1,-1,12718,-1,0.9990989,0.000901148
12719,TP,38,39,201,203,"More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.",3461217_1,-1,-1,-1,12719,-1,0.99783945,0.0021604665
12720,PA,12,13,67,69,"Within the same timeframe, no L-W rat developed a similar palpable PA when treated only with TP.",3461217_3,-1,-1,-1,12720,-1,0.0026744914,0.99732554
12721,TP,17,18,93,95,"Within the same timeframe, no L-W rat developed a similar palpable PA when treated only with TP.",3461217_3,-1,-1,-1,12721,-1,0.9985008,0.0014991795
12722,TP,4,5,13,15,"In L-W rats, TP acted as a tumor enhancement agent, with primary emphasis on the development of prostate cancer.",3461217_4,-1,-1,-1,12722,-1,0.99840975,0.0015902718
12725,bromperidol,8,9,43,54,"A total of sixty patients were trated with bromperidol first in open conditions (20 patients), then on a double blind basis (40 patients) with haloperidol as the reference substance.",347884_1,-1,-1,-1,12725,-1,0.99928194,0.000718064
12727,mg,17,18,82,84,The open study lasted for four weeks; the drug was administrated in the form of 1 mg tablets.,347884_2,-1,-1,-1,12727,-1,0.9923631,0.0076369317
12728,mg,8,9,32,34,The daily dose (initial dose: 1 mg; mean dose at the end of the trial: 4.47 mg) was always administered in one single dose.,347884_3,-1,-1,-1,12728,-1,0.9631246,0.036875453
12729,mg,20,21,76,78,The daily dose (initial dose: 1 mg; mean dose at the end of the trial: 4.47 mg) was always administered in one single dose.,347884_3,-1,-1,-1,12729,-1,0.94143957,0.058560405
12730,extrapyramidal concomitant symptoms,6,9,41,76,Nine patients exhibited mild to moderate extrapyramidal concomitant symptoms; no other side effects were observed.,347884_6,-1,-1,-1,12730,-1,0.0013925597,0.99860746
12732,psychotic syndromes,20,22,114,133,"In the double blind study with haloperidol, both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group.",347884_8,-1,-1,-1,12732,-1,0.0015555064,0.9984445
12734,bromperidol,17,18,90,101,"Certain clues, including the onset of action, seem to be indicative of the superiority of bromperidol.",347884_9,-1,-1,-1,12734,-1,0.9992767,0.0007232808
12736,acute hepatitis,4,6,51,66,Prolonged cholestasis after troleandomycin-induced acute hepatitis.,3496378_0,-1,-1,-1,12736,-1,0.0011967507,0.99880326
12740,troleandomycin,5,6,42,56,Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia.,3496378_2,-1,-1,-1,12740,-1,0.99835795,0.0016420011
12741,hypereosinophilia,13,14,92,109,Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia.,3496378_2,-1,-1,-1,12741,-1,0.0015175635,0.9984824
12745,alkaline phosphatase,19,21,127,147,Jaundice disappeared within 3 months but was followed by prolonged anicteric cholestasis marked by pruritus and high levels of alkaline phosphatase and gammaglutamyltransferase activities.,3496378_3,-1,-1,-1,12745,-1,0.9978307,0.0021692717
12749,acute hepatitis,9,11,91,106,This observation demonstrates that prolonged cholestasis can follow troleandomycin-induced acute hepatitis.,3496378_5,-1,-1,-1,12749,-1,0.0011463882,0.99885356
12750,auditory neurotoxicity,3,5,18,40,Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.,3503576_0,-1,-1,-1,12750,-1,0.001550794,0.9984492
12756,abnormal audiograms,7,9,46,65,"Twenty-two patients in the affected group had abnormal audiograms with deficits mostly in the high frequency range of 4,000 to 8,000 Hz and in the hearing threshold levels of 30 to 100 decibels.",3503576_2,-1,-1,-1,12756,-1,0.0031552643,0.99684477
12757,"deficits mostly in the high frequency range of 4,000",10,19,71,123,"Twenty-two patients in the affected group had abnormal audiograms with deficits mostly in the high frequency range of 4,000 to 8,000 Hz and in the hearing threshold levels of 30 to 100 decibels.",3503576_2,-1,-1,-1,12757,-1,0.074679926,0.92532015
12758,"4,000 to",18,20,118,126,"Twenty-two patients in the affected group had abnormal audiograms with deficits mostly in the high frequency range of 4,000 to 8,000 Hz and in the hearing threshold levels of 30 to 100 decibels.",3503576_2,-1,-1,-1,12758,-1,0.65152174,0.34847823
12759,"8,000 Hz",20,22,127,135,"Twenty-two patients in the affected group had abnormal audiograms with deficits mostly in the high frequency range of 4,000 to 8,000 Hz and in the hearing threshold levels of 30 to 100 decibels.",3503576_2,-1,-1,-1,12759,-1,0.7500913,0.2499087
12761,hearing aids,10,12,73,85,Audiograms from 15 patients remained abnormal and four patients required hearing aids because of permanent disability.,3503576_4,-1,-1,-1,12761,-1,0.0048182677,0.99518174
12762,permanent disability,14,16,97,117,Audiograms from 15 patients remained abnormal and four patients required hearing aids because of permanent disability.,3503576_4,-1,-1,-1,12762,-1,0.0017440958,0.9982559
12764,auditory abnormality,41,43,230,250,"Since 18 of the 22 patients were initially receiving deferoxamine doses in excess of the commonly recommended 50 mg/kg per dose, therapy was restarted with lower doses, usually 50 mg/kg per dose or less depending on the degree of auditory abnormality, and with the exception of two cases no further toxicity was demonstrated.",3503576_5,-1,-1,-1,12764,-1,0.0015966548,0.9984034
12772,hearing loss,5,7,26,38,"In those with symptoms of hearing loss, the drug should be stopped for four weeks, and when the audiogram is stable or improved, therapy should be restarted at 10 to 25 mg/kg per dose.",3503576_11,-1,-1,-1,12772,-1,0.001994071,0.9980059
12773,auditory dysfunction,27,29,171,191,Serial audiograms should be performed every six months in those without problems and more frequently in young patients with normal serum ferritin values and in those with auditory dysfunction.,3503576_12,-1,-1,-1,12773,-1,0.0015976022,0.9984024
12775,netilmicin,5,6,34,44,Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients.,3535719_0,-1,-1,-1,12775,-1,0.9990268,0.0009732197
12777,netilmicin sulfate,8,10,53,71,We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.,3535719_1,-1,-1,-1,12777,-1,0.9990777,0.0009222944
12778,tobramycin sulfate,11,13,75,93,We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.,3535719_1,-1,-1,-1,12778,-1,0.9990452,0.0009547845
12779,piperacillin sodium,16,18,114,133,We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.,3535719_1,-1,-1,-1,12779,-1,0.9991991,0.00080095365
12782,netilmicin,10,11,73,83,Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%).,3535719_3,-1,-1,-1,12782,-1,0.99906844,0.00093160314
12785,netilmicin,10,11,42,52,Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.,3535719_4,-1,-1,-1,12785,-1,0.99914515,0.00085487944
12786,piperacillin,12,13,57,69,Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.,3535719_4,-1,-1,-1,12786,-1,0.9992267,0.0007733625
12788,netilmicin,10,11,62,72,"Of those evaluated with posttherapy audiograms, three of four netilmicin and piperacillin-treated patients had auditory thresholds return to baseline compared with one of nine tobramycin and piperacillin-treated patients.",3535719_5,-1,-1,-1,12788,-1,0.9991425,0.0008574177
12790,netilmicin,34,35,194,204,The number of greater than or equal to 15-dB increases in auditory threshold as a proportion of total greater than or equal to 15-dB changes (increases and decreases) was significantly lower in netilmicin and piperacillin- vs tobramycin and piperacillin-treated patients (18 of 78 vs 67 of 115).,3535719_6,-1,-1,-1,12790,-1,0.99918896,0.00081107067
12793,netilmicin,13,14,102,112,We conclude that aminoglycoside-associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin.,3535719_7,-1,-1,-1,12793,-1,0.9991622,0.0008378577
12795,cardiac asystole,1,3,18,34,Lidocaine-induced cardiac asystole.,354896_0,-1,-1,-1,12795,-1,0.0015371605,0.9984629
12798,bradyarrhythmias,16,17,105,121,"The patient had no apparent associated conditions which might have predisposed him to the development of bradyarrhythmias; and, thus, this probably represented a true idiosyncrasy to lidocaine.",354896_2,-1,-1,-1,12798,-1,0.0013125752,0.99868745
12800,Flurbiprofen,0,1,0,12,Flurbiprofen in the treatment of juvenile rheumatoid arthritis.,3560095_0,-1,-1,-1,12800,-1,0.9990671,0.0009328506
12801,juvenile rheumatoid arthritis,5,8,33,62,Flurbiprofen in the treatment of juvenile rheumatoid arthritis.,3560095_0,-1,-1,-1,12801,-1,0.0018964306,0.9981035
12802,juvenile rheumatoid arthritis,3,6,26,55,"Thirty-four patients with juvenile rheumatoid arthritis, who were treated with flurbiprofen at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment.",3560095_1,-1,-1,-1,12802,-1,0.0017151958,0.99828476
12803,flurbiprofen,11,12,79,91,"Thirty-four patients with juvenile rheumatoid arthritis, who were treated with flurbiprofen at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment.",3560095_1,-1,-1,-1,12803,-1,0.99914956,0.000850402
12805,tender joints,7,9,40,53,"Improvements were seen in the number of tender joints, the severity of swelling and tenderness, the time of walk 50 feet, the duration of morning stiffness and the circumference of the left knee.",3560095_2,-1,-1,-1,12805,-1,0.0018838259,0.99811614
12806,swelling,13,14,71,79,"Improvements were seen in the number of tender joints, the severity of swelling and tenderness, the time of walk 50 feet, the duration of morning stiffness and the circumference of the left knee.",3560095_2,-1,-1,-1,12806,-1,0.0016519899,0.998348
12807,tenderness,15,16,84,94,"Improvements were seen in the number of tender joints, the severity of swelling and tenderness, the time of walk 50 feet, the duration of morning stiffness and the circumference of the left knee.",3560095_2,-1,-1,-1,12807,-1,0.0015790551,0.99842095
12808,morning stiffness,27,29,138,155,"Improvements were seen in the number of tender joints, the severity of swelling and tenderness, the time of walk 50 feet, the duration of morning stiffness and the circumference of the left knee.",3560095_2,-1,-1,-1,12808,-1,0.0018842727,0.9981158
12809,fecal occult blood,7,10,45,63,"The most frequently observed side effect was fecal occult blood (25% of patients); however, there was no other evidence of gastrointestinal (GI) bleeding in these patients.",3560095_3,-1,-1,-1,12809,-1,0.002780975,0.99721897
12810,gastrointestinal (GI) bleeding,25,30,123,153,"The most frequently observed side effect was fecal occult blood (25% of patients); however, there was no other evidence of gastrointestinal (GI) bleeding in these patients.",3560095_3,-1,-1,-1,12810,-1,0.0017115939,0.99828833
12812,abdominal pain,12,14,80,94,One patient was prematurely discontinued from the study for severe headache and abdominal pain.,3560095_4,-1,-1,-1,12812,-1,0.0013606688,0.9986393
12816,NSAID,13,14,101,106,Hyperkalemia has recently been recognized as a complication of nonsteroidal antiinflammatory agents (NSAID) such as indomethacin.,3560096_1,-1,-1,-1,12816,-1,0.99805117,0.0019487862
12819,prostacyclin,20,21,122,134,"Several recent studies have stressed the renal sparing features of sulindac, owing to its lack of interference with renal prostacyclin synthesis.",3560096_2,-1,-1,-1,12819,-1,0.9990094,0.0009906343
12828,NSAID,19,20,123,128,These observations indicate that initial hopes that sulindac may not be associated with the adverse renal effects of other NSAID are probably not justified.,3560096_6,-1,-1,-1,12828,-1,0.9987674,0.0012326721
12831,sodium pentothal,9,11,59,75,"Following major intracranial surgery in a 35-year-old man, sodium pentothal was intravenously infused to minimize cerebral ischaemia.",3564823_2,-1,-1,-1,12831,-1,0.99905866,0.0009413151
12832,cerebral ischaemia,16,18,114,132,"Following major intracranial surgery in a 35-year-old man, sodium pentothal was intravenously infused to minimize cerebral ischaemia.",3564823_2,-1,-1,-1,12832,-1,0.0013810833,0.99861896
12834,gangrene,4,5,34,42,Intense vasospasm with threatened gangrene arose in the arm used for the infusion.,3564823_3,-1,-1,-1,12834,-1,0.0012769798,0.998723
12847,cephalosporin hematotoxicity,15,17,85,113,The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man.,3629586_0,-1,-1,-1,12847,-1,0.3902228,0.6097772
12848,Cephalosporin,0,1,0,13,"Cephalosporin antibiotics cause a variety of hematologic disturbances in man, the pathogeneses and hematopathology of which remain poorly characterized.",3629586_1,-1,-1,-1,12848,-1,0.9990495,0.00095055474
12849,hematologic disturbances,6,8,45,69,"Cephalosporin antibiotics cause a variety of hematologic disturbances in man, the pathogeneses and hematopathology of which remain poorly characterized.",3629586_1,-1,-1,-1,12849,-1,0.0013193627,0.99868065
12850,blood dyscrasias,12,14,63,79,There is a need for a well-defined animal model in which these blood dyscrasias can be studied.,3629586_2,-1,-1,-1,12850,-1,0.0021223288,0.9978777
12858,cytopenias,9,10,58,68,A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.,3629586_4,-1,-1,-1,12858,-1,0.0011075743,0.9988925
12861,cytopenias,2,3,10,20,All three cytopenias were completely reversible following cessation of treatment; the time required for recovery of the erythron (approximately 1 month) was considerably longer than that of the granulocytes and platelets (hours to a few days).,3629586_5,-1,-1,-1,12861,-1,0.001268141,0.9987319
12862,cephalosporin,4,5,29,42,"Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).",3629586_6,-1,-1,-1,12862,-1,0.99919134,0.0008086826
12863,hematologic syndrome,7,9,48,68,"Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).",3629586_6,-1,-1,-1,12863,-1,0.0013197265,0.9986803
12865,hemolytic,22,23,117,126,"This observation, along with the rapid rate of decline in red cell mass parameters of affected dogs, suggests that a hemolytic component complicated the red cell production problem and that multiple toxicologic mechanisms contributed to the cytopenia.",3629586_7,-1,-1,-1,12865,-1,0.001241413,0.99875855
12866,cytopenia,38,39,241,250,"This observation, along with the rapid rate of decline in red cell mass parameters of affected dogs, suggests that a hemolytic component complicated the red cell production problem and that multiple toxicologic mechanisms contributed to the cytopenia.",3629586_7,-1,-1,-1,12866,-1,0.0011299407,0.9988701
12869,hematotoxicity,16,17,96,110,We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.,3629586_8,-1,-1,-1,12869,-1,0.0011380764,0.9988619
12870,blood dyscrasias,21,23,148,164,We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.,3629586_8,-1,-1,-1,12870,-1,0.0016879244,0.9983121
12871,injury,8,9,54,60,Urinary enzymes and protein patterns as indicators of injury to different regions of the kidney.,3653576_0,-1,-1,-1,12871,-1,0.0031435427,0.99685645
12873,hexachloro-1:3-butadiene,24,25,147,171,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12873,-1,0.998609,0.0013910361
12874,HCBD,26,27,173,177,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12874,-1,0.9984528,0.0015472401
12875,puromycin aminonucleoside,29,31,180,205,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12875,-1,0.9989784,0.0010216467
12876,PAN,32,33,207,210,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12876,-1,0.9977869,0.0022130713
12877,2-bromoethylamine,36,37,217,234,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12877,-1,0.99853563,0.0014643596
12878,BEA,38,39,236,239,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12878,-1,0.9977349,0.0022650547
12880,alkaline phosphatase,8,10,58,78,"Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples.",3653576_2,-1,-1,-1,12880,-1,0.9912868,0.008713143
12881,protein,18,19,142,149,"Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples.",3653576_2,-1,-1,-1,12881,-1,0.9973744,0.0026255834
12882,Tubular damage,0,2,0,14,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,-1,-1,-1,12882,-1,0.002374443,0.9976255
12883,HCBD,4,5,27,31,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,-1,-1,-1,12883,-1,0.9910028,0.0089971945
12884,BEA,6,7,35,38,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,-1,-1,-1,12884,-1,0.9893511,0.010648954
12885,glomerular damage,14,16,100,117,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,-1,-1,-1,12885,-1,0.002141702,0.99785835
12886,PAN,18,19,130,133,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,-1,-1,-1,12886,-1,0.80400693,0.19599305
12887,protein,9,10,57,64,"The latter was characterized by a pronounced increase in protein excretion, especially proteins with molecular weight greater than 40,000 Da.",3653576_4,-1,-1,-1,12887,-1,0.99588865,0.0041113915
12888,Da,20,21,138,140,"The latter was characterized by a pronounced increase in protein excretion, especially proteins with molecular weight greater than 40,000 Da.",3653576_4,-1,-1,-1,12888,-1,0.7214138,0.27858624
12889,contrast,1,2,3,11,"In contrast, protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights.",3653576_5,-1,-1,-1,12889,-1,0.17089833,0.8291017
12890,protein,3,4,13,20,"In contrast, protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights.",3653576_5,-1,-1,-1,12890,-1,0.9965663,0.0034336972
12891,tubular damage,6,8,34,48,"In contrast, protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights.",3653576_5,-1,-1,-1,12891,-1,0.0024500708,0.99754995
12892,Proximal tubular damage,0,3,0,23,Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.,3653576_6,-1,-1,-1,12892,-1,0.002653447,0.9973465
12893,HCBD,5,6,34,38,Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.,3653576_6,-1,-1,-1,12893,-1,0.0024544485,0.99754554
12894,papillary damage,7,9,43,59,Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.,3653576_6,-1,-1,-1,12894,-1,0.0020716467,0.9979284
12895,BEA,11,12,70,73,Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.,3653576_6,-1,-1,-1,12895,-1,0.0035830813,0.9964169
12896,Alkaline phosphatase,0,2,0,20,Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in papillary damage.,3653576_7,-1,-1,-1,12896,-1,0.9981622,0.0018378247
12898,proximal tubular damage,10,13,75,98,Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in papillary damage.,3653576_7,-1,-1,-1,12898,-1,0.0040482236,0.9959518
12899,papillary damage,20,22,165,181,Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in papillary damage.,3653576_7,-1,-1,-1,12899,-1,0.0032742755,0.9967257
12901,Reye,4,5,15,19,A catch in the Reye.,3670965_0,-1,-1,-1,12901,-1,0.02423147,0.97576857
12902,Reye syndrome,3,5,20,33,"Twenty-six cases of Reye syndrome from The Children's Hospital, Camperdown, Australia, occurring between 1973 and 1982 were reviewed.",3670965_1,-1,-1,-1,12902,-1,0.001517674,0.9984823
12903,Reye syndrome,20,22,110,123,"Of these, 20 cases met the US Public Health Service Centers for Disease Control criteria for the diagnosis of Reye syndrome.",3670965_2,-1,-1,-1,12903,-1,0.0018824638,0.99811757
12905,salicylate,2,3,11,21,"Aspirin or salicylate ingestion had occurred in only one of the 20 cases (5%), and paracetamol (acetaminophen) had been administered in only six of the cases (30%).",3670965_3,-1,-1,-1,12905,-1,0.9992392,0.0007607993
12908,Reye syndrome,6,8,44,57,Pathologic confirmation of the diagnosis of Reye syndrome was accomplished in 90% of the cases.,3670965_4,-1,-1,-1,12908,-1,0.0015893573,0.9984106
12909,Reye syndrome,3,5,17,30,"The incidence of Reye syndrome in New South Wales, Australia, is estimated from this study to be approximately nine cases per 1 million children compared with recent US data of ten to 20 cases per 1 million children and three to seven cases per 1 million children in Great Britain.",3670965_5,-1,-1,-1,12909,-1,0.00175071,0.9982493
12910,Reye syndrome,4,6,24,37,The mortality for these Reye syndrome cases in Australia was 45% as compared with a 32% case-fatality rate in the United States.,3670965_6,-1,-1,-1,12910,-1,0.0015984101,0.9984016
12914,Reye syndrome,0,2,0,13,"Reye syndrome may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion, since there were no cases found at The Children's Hospital in 1983, 1984, or 1985.",3670965_8,-1,-1,-1,12914,-1,0.001604294,0.99839574
12915,salicylates,14,15,90,101,"Reye syndrome may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion, since there were no cases found at The Children's Hospital in 1983, 1984, or 1985.",3670965_8,-1,-1,-1,12915,-1,0.9990196,0.0009804225
12918,cerebral aneurysms,14,16,110,128,Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.,3676049_0,-1,-1,-1,12918,-1,0.0015535983,0.9984464
12921,cerebral aneurysm,24,26,168,185,Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.,3676049_1,-1,-1,-1,12921,-1,0.0021264947,0.99787354
12922,subarachnoid haemorrhage,11,13,54,78,Flow and metabolism were measured 5-13 days after the subarachnoid haemorrhage by a modification of the classical Kety-Schmidt technique using xenon-133 i.v.,3676049_2,-1,-1,-1,12922,-1,0.0022997297,0.9977003
12924,nitrous oxide,15,17,88,101,"Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM).",3676049_3,-1,-1,-1,12924,-1,0.99871397,0.0012860979
12927,MAP,5,6,37,40,"Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/- 0.2%.",3676049_4,-1,-1,-1,12927,-1,0.01744037,0.9825597
12928,mm Hg,10,12,50,55,"Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/- 0.2%.",3676049_4,-1,-1,-1,12928,-1,0.015556832,0.9844432
12933,psychosis,1,2,11,20,Postpartum psychosis induced by bromocriptine.,3686155_0,-1,-1,-1,12933,-1,0.0013455002,0.9986545
12936,psychosis,12,13,86,95,"Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.",3686155_1,-1,-1,-1,12936,-1,0.0012772889,0.99872273
12938,inhibition of lactation,18,21,131,154,"Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.",3686155_1,-1,-1,-1,12938,-1,0.06355274,0.9364472
12940,psychosis,9,10,59,68,Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.,3686155_2,-1,-1,-1,12940,-1,0.001176274,0.9988237
12941,Parkinson's disease,16,19,104,123,Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.,3686155_2,-1,-1,-1,12941,-1,0.0020118877,0.9979881
12943,psychosis,7,8,53,62,These cases demonstrate that bromocriptine may cause psychosis even when given in low doses.,3686155_3,-1,-1,-1,12943,-1,0.0012888636,0.9987111
12944,secondary mania,4,6,36,51,Triazolam-induced brief episodes of secondary mania in a depressed patient.,3693336_0,-1,-1,-1,12944,-1,0.001239558,0.99876046
12946,triazolam,3,4,15,24,Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman.,3693336_1,-1,-1,-1,12946,-1,0.99919933,0.00080073625
12947,mania,9,10,62,67,Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman.,3693336_1,-1,-1,-1,12947,-1,0.0014077118,0.9985923
12949,organic mental disorder,2,5,12,35,Features of organic mental disorder (delirium) were not present.,3693336_2,-1,-1,-1,12949,-1,0.0014464677,0.9985536
12952,triazolam,10,11,63,72,Manic excitement was coincident with the duration of action of triazolam.,3693336_3,-1,-1,-1,12952,-1,0.9992449,0.00075513363
12953,triazolo,5,6,33,41,The possible contribution of the triazolo group to changes in affective status is discussed.,3693336_4,-1,-1,-1,12953,-1,0.99876946,0.00123052
12954,Hyperglycemic,0,1,0,13,Hyperglycemic acidotic coma and death in Kearns-Sayre syndrome.,3703509_0,-1,-1,-1,12954,-1,0.0019961672,0.9980038
12958,lethargy,10,11,65,73,"Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.",3703509_2,-1,-1,-1,12958,-1,0.0012757072,0.9987243
12961,polyphagia,17,18,110,120,"Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.",3703509_2,-1,-1,-1,12961,-1,0.0015524798,0.99844754
12965,hyperglycemia,13,14,77,90,"Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.",3703509_3,-1,-1,-1,12965,-1,0.0013410557,0.9986589
12967,lactic acidosis,1,3,11,26,Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.,3703509_4,-1,-1,-1,12967,-1,0.0017064397,0.9982936
12968,ketosis,8,9,50,57,Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.,3703509_4,-1,-1,-1,12968,-1,0.0016259676,0.998374
12969,lactate,13,14,80,87,Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.,3703509_4,-1,-1,-1,12969,-1,0.9977616,0.0022383654
12970,Respiratory failure,0,2,0,19,Respiratory failure rapidly ensued and both patients expired in spite of efforts at resuscitation.,3703509_5,-1,-1,-1,12970,-1,0.0014907178,0.9985092
12971,cyclosporine nephrotoxicity,1,3,13,40,Experimental cyclosporine nephrotoxicity: risk of concomitant chemotherapy.,3708922_0,-1,-1,-1,12971,-1,0.16063145,0.8393685
12973,CSA,5,6,26,29,The role of cyclosporine (CSA) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats.,3708922_1,-1,-1,-1,12973,-1,0.99895465,0.0010453754
12975,CSA,4,5,31,34,Administration of 20 mg/kg/day CSA for 4 weeks caused renal functional and structural changes similar to those reported in man.,3708922_2,-1,-1,-1,12975,-1,0.99904674,0.00095318834
12976,CSA,4,5,31,34,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,-1,-1,-1,12976,-1,0.99906343,0.00093654514
12979,amphothericin B,23,25,143,158,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,-1,-1,-1,12979,-1,0.9987238,0.001276136
12981,CSA,40,41,255,258,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,-1,-1,-1,12981,-1,0.9989279,0.001072077
12984,CSA nephrotoxicity,8,10,46,64,"Gentamicin at toxic doses, however, increased CSA nephrotoxicity.",3708922_4,-1,-1,-1,12984,-1,0.04506096,0.95493907
12986,CSA,6,7,36,39,"Thus, the nephrotoxicity induced by CSA has a different pathogenetic mechanism.",3708922_5,-1,-1,-1,12986,-1,0.99859005,0.0014099309
12988,neuropathic damage,8,10,75,93,The correlation between neurotoxic esterase inhibition and mipafox-induced neuropathic damage in rats.,3714122_0,-1,-1,-1,12988,-1,0.00119572,0.99880433
12989,neuropathic damage,3,5,24,42,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,-1,-1,-1,12989,-1,0.001358989,0.99864095
12992,Mipafox,24,25,155,162,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,-1,-1,-1,12992,-1,0.99920005,0.0007999918
12993,"N, N'-diisopropylphosphorodiamidofluoridate",26,29,164,207,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,-1,-1,-1,12993,-1,0.9980398,0.001960297
12994,neurotoxic organophosphate,32,34,212,238,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,-1,-1,-1,12994,-1,0.69259936,0.30740067
12995,Mipafox,19,20,116,123,"Brain and spinal cord NTE activities were measured in Long-Evans male rats 1 hr post-exposure to various dosages of Mipafox (ip, 1-15 mg/kg).",3714122_2,-1,-1,-1,12995,-1,0.9991775,0.00082240545
12996,cervical cord damage,7,10,54,74,These data were correlated with histologically scored cervical cord damage in a separate group of similarly dosed rats sampled 14-21 days post-exposure.,3714122_3,-1,-1,-1,12996,-1,0.002615996,0.997384
12997,contrast,1,2,3,11,"In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.",3714122_5,-1,-1,-1,12997,-1,0.4124872,0.58751273
12998,Mipafox,5,6,24,31,"In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.",3714122_5,-1,-1,-1,12998,-1,0.9991466,0.0008534462
12999,cord damage,43,45,199,210,"In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.",3714122_5,-1,-1,-1,12999,-1,0.0019141365,0.99808586
13000,Mipafox,18,19,112,119,These data indicate that a critical percentage of NTE inhibition in brain and spinal cord sampled shortly after Mipafox exposure can predict neuropathic damage in rats several weeks later.,3714122_6,-1,-1,-1,13000,-1,0.9991316,0.00086842565
13001,neuropathic damage,22,24,141,159,These data indicate that a critical percentage of NTE inhibition in brain and spinal cord sampled shortly after Mipafox exposure can predict neuropathic damage in rats several weeks later.,3714122_6,-1,-1,-1,13001,-1,0.001346763,0.9986532
13005,angioneurotic edema,5,7,35,54,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,-1,-1,-1,13005,-1,0.0011002277,0.9988997
13007,carcinoma of the,18,21,140,156,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,-1,-1,-1,13007,-1,0.002851836,0.9971482
13009,impaired renal function,28,31,203,226,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,-1,-1,-1,13009,-1,0.003559325,0.9964407
13010,diphenhydramine,1,2,5,20,Oral diphenhydramine and prednisone were ineffective in preventing the recurrence of the allergic reaction.,3719553_3,-1,-1,-1,13010,-1,0.99893886,0.0010611153
13013,disease progression,13,15,100,119,Discontinuance of effective chemotherapy in this patient during partial remission resulted in fatal disease progression.,3719553_4,-1,-1,-1,13013,-1,0.0017320854,0.9982679
13016,hypertensive coronary disease,6,9,40,69,"Diuretics, potassium and arrhythmias in hypertensive coronary disease.",3732088_0,-1,-1,-1,13016,-1,0.0015863654,0.99841356
13019,coronary artery disease,7,10,31,54,"If this were so, patients with coronary artery disease might be especially susceptible.",3732088_2,-1,-1,-1,13019,-1,0.0023252235,0.99767476
13020,essential hypertension,11,13,76,98,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,-1,-1,-1,13020,-1,0.0017377464,0.9982622
13021,coronary artery disease,15,18,109,132,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,-1,-1,-1,13021,-1,0.0016158475,0.9983841
13022,diuretic,26,27,188,196,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,-1,-1,-1,13022,-1,0.99840003,0.0015999579
13024,diuretic,37,38,252,260,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,-1,-1,-1,13024,-1,0.9981522,0.0018477567
13025,chlorthalidone,39,40,262,276,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,-1,-1,-1,13025,-1,0.9992874,0.0007126498
13027,chlorthalidone,11,12,74,88,Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy.,3732088_4,-1,-1,-1,13027,-1,0.9993374,0.00066264125
13032,chlorthalidone,6,7,37,51,"Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.",3732088_6,-1,-1,-1,13032,-1,0.9993055,0.0006945547
13033,ventricular ectopic beats,15,18,104,129,"Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.",3732088_6,-1,-1,-1,13033,-1,0.0023328287,0.9976672
13034,diuretic,7,8,57,65,"The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease, even minor falls in plasma potassium concentrations are probably best avoided in such patients.",3732088_7,-1,-1,-1,13034,-1,0.9988714,0.001128618
13035,ischaemic heart disease,17,20,139,162,"The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease, even minor falls in plasma potassium concentrations are probably best avoided in such patients.",3732088_7,-1,-1,-1,13035,-1,0.0016645476,0.9983354
13037,Myasthenia gravis,0,2,0,17,Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_0,-1,-1,-1,13037,-1,0.0014537805,0.99854624
13041,myasthenia gravis,11,13,71,88,We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_1,-1,-1,-1,13041,-1,0.0011771674,0.99882287
13046,Wernicke's encephalopathy,4,7,48,73,Transketolase abnormality in tolazamide-induced Wernicke's encephalopathy.,3762968_0,-1,-1,-1,13046,-1,0.0019139216,0.9980861
13048,Wernicke's encephalopathy,16,19,108,133,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,-1,-1,13048,-1,0.0025041038,0.99749583
13049,tolazamide,22,23,152,162,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,-1,-1,13049,-1,0.9992311,0.0007689189
13050,thiamine pyrophosphate,39,41,250,272,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,-1,-1,13050,-1,0.99897826,0.0010217186
13051,TPP,42,43,274,277,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,-1,-1,13051,-1,0.998505,0.0014950522
13053,Wernicke's encephalopathy,19,22,109,134,"In addition to this patient, we also studied this enzyme from three diabetic kindreds without any history of Wernicke's encephalopathy and from four normal controls.",3762968_2,-1,-1,-1,13053,-1,0.0027059694,0.997294
13055,Wernicke's encephalopathy,16,19,94,119,We found that the above-mentioned patient and one of the diabetic kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.,3762968_3,-1,-1,-1,13055,-1,0.002959698,0.99704033
13056,TPP,28,29,175,178,We found that the above-mentioned patient and one of the diabetic kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.,3762968_3,-1,-1,-1,13056,-1,0.9986778,0.0013221488
13057,Wernicke's encephalopathy,14,17,122,147,These data suggest a similarity between postalcoholic Wernicke-Korsakoff syndrome and the patient with tolazamide-induced Wernicke's encephalopathy from the standpoint of transketolase abnormality.,3762968_4,-1,-1,-1,13057,-1,0.0022943465,0.99770564
13059,trihexyphenidyl hydrochloride,3,5,19,48,Bradycardia due to trihexyphenidyl hydrochloride.,3769769_0,-1,-1,-1,13059,-1,0.99877876,0.001221257
13061,trihexyphenidyl hydrochloride,11,13,74,103,"A chronic schizophrenic patient was treated with an anticholinergic drug, trihexyphenidyl hydrochloride.",3769769_1,-1,-1,-1,13061,-1,0.99898106,0.001018911
13068,respiratory failure,7,9,48,67,A case of thoraco-abdominal rigidity leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl.,3780697_1,-1,-1,-1,13068,-1,0.0013370131,0.99866295
13072,diethylnitrosamine,7,8,68,86,Anti-carcinogenic action of phenobarbital given simultaneously with diethylnitrosamine in the rat.,3780814_0,-1,-1,-1,13072,-1,0.99916816,0.0008319169
13074,PB,15,16,85,87,The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).,3780814_1,-1,-1,-1,13074,-1,0.9983423,0.0016577408
13075,mg,18,19,92,94,The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).,3780814_1,-1,-1,-1,13075,-1,0.9822044,0.017795654
13077,diethylnitrosamine,33,34,183,201,The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).,3780814_1,-1,-1,-1,13077,-1,0.99923277,0.0007672204
13078,DEN,35,36,203,206,The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).,3780814_1,-1,-1,-1,13078,-1,0.9980956,0.0019044282
13079,DEN,9,10,36,39,"Wistar rats (180 g) were treated by DEN alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis.",3780814_2,-1,-1,-1,13079,-1,0.9976792,0.002320865
13080,DEN,13,14,52,55,"Wistar rats (180 g) were treated by DEN alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis.",3780814_2,-1,-1,-1,13080,-1,0.99763334,0.0023666914
13081,PB,15,16,58,60,"Wistar rats (180 g) were treated by DEN alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis.",3780814_2,-1,-1,-1,13081,-1,0.9975569,0.0024430219
13082,hepatocarcinogenesis,28,29,115,135,"Wistar rats (180 g) were treated by DEN alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis.",3780814_2,-1,-1,-1,13082,-1,0.0014497325,0.99855024
13083,PAS,14,15,67,70,"After the end of the treatment, the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks.",3780814_3,-1,-1,-1,13083,-1,0.9323924,0.06760753
13084,preneoplastic foci,16,18,80,98,"After the end of the treatment, the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks.",3780814_3,-1,-1,-1,13084,-1,0.002579731,0.9974203
13085,PB,22,23,130,132,"After the end of the treatment, the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks.",3780814_3,-1,-1,-1,13085,-1,0.99825126,0.0017487162
13086,DEN,27,28,163,166,"After the end of the treatment, the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks.",3780814_3,-1,-1,-1,13086,-1,0.99795735,0.0020426197
13087,micronuclei,7,8,45,56,The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats.,3780814_4,-1,-1,-1,13087,-1,0.0029858411,0.99701416
13088,DEN,14,15,104,107,The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats.,3780814_4,-1,-1,-1,13088,-1,0.9976428,0.0023572138
13089,DEN,22,23,158,161,The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats.,3780814_4,-1,-1,-1,13089,-1,0.99763215,0.0023678176
13090,PB,24,25,164,166,The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats.,3780814_4,-1,-1,-1,13090,-1,0.9982315,0.0017685081
13091,PB,11,12,54,56,"When the treatment last only 2 weeks, the presence of PB did not change significantly the last parameters.",3780814_5,-1,-1,-1,13091,-1,0.9878148,0.01218528
13092,DEN,1,2,3,6,"In DEN + PB treated rats, the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone.",3780814_6,-1,-1,-1,13092,-1,0.9972983,0.0027016911
13093,PB,3,4,9,11,"In DEN + PB treated rats, the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone.",3780814_6,-1,-1,-1,13093,-1,0.99779934,0.0022006207
13095,DEN,23,24,128,131,"In DEN + PB treated rats, the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone.",3780814_6,-1,-1,-1,13095,-1,0.9976023,0.0023977046
13096,PB,4,5,21,23,"It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.",3780814_7,-1,-1,-1,13096,-1,0.99830234,0.0016976601
13098,DEN,13,14,83,86,"It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.",3780814_7,-1,-1,-1,13098,-1,0.9979311,0.002068916
13099,DEN,24,25,159,162,"It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.",3780814_7,-1,-1,-1,13099,-1,0.9982167,0.0017833132
13100,precancerous lesions,17,19,88,108,This 'anti-carcinogen' effect acts on the initiation as well as on the promotion of the precancerous lesions.,3780814_8,-1,-1,-1,13100,-1,0.0022248735,0.99777514
13101,PB,14,15,95,97,Biochemical investigations are in progress to obtain more information about this 'paradoxical' PB effect.,3780814_9,-1,-1,-1,13101,-1,0.97174996,0.028250085
13102,muscular rigidity,10,12,57,74,On the mechanisms of the development of tolerance to the muscular rigidity produced by morphine in rats.,3780846_0,-1,-1,-1,13102,-1,0.0017270673,0.9982729
13104,muscular rigidity,6,8,36,53,The development of tolerance to the muscular rigidity produced by morphine was studied in rats.,3780846_1,-1,-1,-1,13104,-1,0.0017454148,0.9982546
13109,h,13,14,63,64,Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic (A group).,3780846_3,-1,-1,-1,13109,-1,0.39297304,0.607027
13115,hyperkinetic,26,27,144,156,"The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped (S) licking and/or gnawing in presence of akinetic or hyperkinetic (K) behaviour (AS/KS group), suggesting signs of dopaminergic activation.",3780846_4,-1,-1,-1,13115,-1,0.002325697,0.9976743
13116,K,28,29,158,159,"The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped (S) licking and/or gnawing in presence of akinetic or hyperkinetic (K) behaviour (AS/KS group), suggesting signs of dopaminergic activation.",3780846_4,-1,-1,-1,13116,-1,0.03078914,0.96921086
13126,molindone,6,7,43,52,A case of massive rhabdomyolysis following molindone administration.,3782049_0,-1,-1,-1,13126,-1,0.99926203,0.00073800684
13129,signs and symptoms,2,5,13,31,"The clinical signs and symptoms, typical laboratory features, and complications of rhabdomyolysis are presented.",3782049_2,-1,-1,-1,13129,-1,0.0020315142,0.9979685
13133,acute renal failure,14,17,100,119,The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration.,3782049_3,-1,-1,-1,13133,-1,0.0012255895,0.99877435
13134,molindone,18,19,130,139,The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration.,3782049_3,-1,-1,-1,13134,-1,0.9993074,0.00069262856
13135,molindone,3,4,25,34,Physicians who prescribe molindone should be aware of this reaction.,3782049_4,-1,-1,-1,13135,-1,0.9991567,0.00084327935
13136,Compression neuropathy,0,2,0,22,Compression neuropathy of the radial nerve due to pentazocine-induced fibrous myopathy.,3800626_0,-1,-1,-1,13136,-1,0.0012850987,0.9987149
13137,fibrous myopathy,9,11,70,86,Compression neuropathy of the radial nerve due to pentazocine-induced fibrous myopathy.,3800626_0,-1,-1,-1,13137,-1,0.0012082234,0.99879175
13138,Fibrous myopathy,0,2,0,16,"Fibrous myopathy is a common, well-known side effect of repeated pentazocine injection.",3800626_1,-1,-1,-1,13138,-1,0.0012114287,0.99878854
13140,compression neuropathy,2,4,9,31,"However, compression neuropathy due to fibrotic muscle affected by pentazocine-induced myopathy has not previously been reported.",3800626_2,-1,-1,-1,13140,-1,0.0012303863,0.9987696
13142,fibrous myopathy,7,9,59,75,"In a 37-year-old woman with documented pentazocine-induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop, electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps, in addition to the fibrous myopathy.",3800626_3,-1,-1,-1,13142,-1,0.0012760492,0.9987239
13143,fibrous myopathy,49,51,314,330,"In a 37-year-old woman with documented pentazocine-induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop, electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps, in addition to the fibrous myopathy.",3800626_3,-1,-1,-1,13143,-1,0.0012971541,0.9987029
13144,acute renal failure,2,5,21,40,Recurrent reversible acute renal failure from amphotericin.,3827439_0,-1,-1,-1,13144,-1,0.0013215842,0.9986784
13145,amphotericin,6,7,46,58,Recurrent reversible acute renal failure from amphotericin.,3827439_0,-1,-1,-1,13145,-1,0.99889046,0.0011095495
13147,sporotrichosis,7,8,54,68,A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.,3827439_1,-1,-1,-1,13147,-1,0.001515059,0.9984849
13148,acute renal failure,9,12,79,98,A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.,3827439_1,-1,-1,-1,13148,-1,0.0011594971,0.9988405
13149,amphotericin B,17,19,143,157,A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.,3827439_1,-1,-1,-1,13149,-1,0.99888974,0.0011102934
13150,renal failure,4,6,22,35,The abruptness of the renal failure and its reversibility within days suggests that there was a functional component to the renal dysfunction.,3827439_2,-1,-1,-1,13150,-1,0.0014872496,0.9985127
13152,amphotericin,3,4,16,28,"We propose that amphotericin, in the setting of reduced effective arterial volume, may activate tubuloglomerular feedback, thereby contributing to acute renal failure.",3827439_3,-1,-1,-1,13152,-1,0.9990062,0.0009938215
13153,acute renal failure,22,25,147,166,"We propose that amphotericin, in the setting of reduced effective arterial volume, may activate tubuloglomerular feedback, thereby contributing to acute renal failure.",3827439_3,-1,-1,-1,13153,-1,0.0012739527,0.99872607
13154,Cerebral infarction,0,2,0,19,Cerebral infarction with a single oral dose of phenylpropanolamine.,3828020_0,-1,-1,-1,13154,-1,0.0015337332,0.99846625
13155,phenylpropanolamine,8,9,47,66,Cerebral infarction with a single oral dose of phenylpropanolamine.,3828020_0,-1,-1,-1,13155,-1,0.99915636,0.00084368524
13156,Phenylpropanolamine,0,1,0,19,"Phenylpropanolamine (PPA), a synthetic sympathomimetic that is structurally similar to amphetamine, is available over the counter in anorectics, nasal congestants, and cold preparations.",3828020_1,-1,-1,-1,13156,-1,0.9992531,0.0007468598
13157,PPA,2,3,21,24,"Phenylpropanolamine (PPA), a synthetic sympathomimetic that is structurally similar to amphetamine, is available over the counter in anorectics, nasal congestants, and cold preparations.",3828020_1,-1,-1,-1,13157,-1,0.99882036,0.0011796481
13160,intracerebral hemorrhage,11,13,64,88,"Its prolonged use or overuse has been associated with seizures, intracerebral hemorrhage, neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction.",3828020_2,-1,-1,-1,13160,-1,0.0011568492,0.9988431
13161,neuropsychiatric symptoms,14,16,90,115,"Its prolonged use or overuse has been associated with seizures, intracerebral hemorrhage, neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction.",3828020_2,-1,-1,-1,13161,-1,0.001219806,0.9987802
13162,cerebral infarction,19,21,136,155,"Its prolonged use or overuse has been associated with seizures, intracerebral hemorrhage, neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction.",3828020_2,-1,-1,-1,13162,-1,0.0011912124,0.99880874
13163,cerebral infarction,11,13,51,70,We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of PPA.,3828020_3,-1,-1,-1,13163,-1,0.0013077566,0.9986922
13164,PPA,20,21,106,109,We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of PPA.,3828020_3,-1,-1,-1,13164,-1,0.99812907,0.0018708949
13165,optic neuropathy,1,3,10,26,Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment.,384871_0,-1,-1,-1,13165,-1,0.0015020574,0.99849796
13166,ethambutol,6,7,43,53,Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment.,384871_0,-1,-1,-1,13166,-1,0.99894875,0.0010512256
13168,ethambutol,17,18,116,126,The case of a 40-year-old patient who underwent an unsuccessful cadaver kidney transplantation and was treated with ethambutol and isoniazid is reported.,384871_1,-1,-1,-1,13168,-1,0.99894243,0.0010576342
13170,retrobulbar neuropathy,2,4,12,34,A bilateral retrobulbar neuropathy with an unusual central bitemporal hemianopic scotoma was found.,384871_2,-1,-1,-1,13170,-1,0.002712972,0.99728703
13171,scotoma,10,11,81,88,A bilateral retrobulbar neuropathy with an unusual central bitemporal hemianopic scotoma was found.,384871_2,-1,-1,-1,13171,-1,0.0012817956,0.99871826
13172,Ethambutol,0,1,0,10,Ethambutol was stopped and only small improvement of the visual acuity followed.,384871_3,-1,-1,-1,13172,-1,0.9989004,0.0010995416
13174,optic nerve toxicity,3,6,15,35,The hazards of optic nerve toxicity due to ethambutol are known.,384871_5,-1,-1,-1,13174,-1,0.0017070612,0.998293
13175,ethambutol,8,9,43,53,The hazards of optic nerve toxicity due to ethambutol are known.,384871_5,-1,-1,-1,13175,-1,0.99897504,0.0010250151
13176,ethambutol,9,10,48,58,We emphasize the potential danger in the use of ethambutol and isoniazid.,384871_6,-1,-1,-1,13176,-1,0.9989415,0.0010585712
13178,meningeal leukemia,3,5,23,41,Remission induction of meningeal leukemia with high-dose intravenous methotrexate.,3856631_0,-1,-1,-1,13178,-1,0.0015930291,0.99840695
13181,meningeal disease,8,10,64,81,Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.,3856631_1,-1,-1,-1,13181,-1,0.0013442643,0.9986557
13185,Leucovorin,0,1,0,10,"Leucovorin rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg/m2 followed by 12 mg/m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10(-7) mol/L. The mean steady-state plasma and CSF methotrexate concentrations achieved were 1.1 X 10(-3) mol/L and 3.6 X 10(-5) mol/L, respectively.",3856631_3,-1,-1,-1,13185,-1,0.999156,0.00084398227
13193,transient hemiparesis,6,8,35,56,One patient had focal seizures and transient hemiparesis but recovered completely.,3856631_6,-1,-1,-1,13193,-1,0.0013110116,0.998689
13196,cyclosporin A,2,4,15,28,Interaction of cyclosporin A with antineoplastic agents.,3865016_0,-1,-1,-1,13196,-1,0.9989748,0.0010252256
13198,cyclosporin A,6,8,38,51,A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T-lymphocytic leukemia in relapse.,3865016_1,-1,-1,-1,13198,-1,0.99905044,0.0009495047
13199,leukemia,16,17,103,111,A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T-lymphocytic leukemia in relapse.,3865016_1,-1,-1,-1,13199,-1,0.0012884438,0.9987116
13201,cyclosporin A,6,8,48,61,The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow.,3865016_2,-1,-1,-1,13201,-1,0.9991014,0.0008986442
13202,leukemic infiltration,14,16,109,130,The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow.,3865016_2,-1,-1,-1,13202,-1,0.0015447492,0.9984553
13204,hyperbilirubinemia,10,11,65,83,"Severe side effects in terms of mental confusion and progressive hyperbilirubinemia, however, point to an enhancement not only of antineoplastic effects but also of toxicity in normal tissues.",3865016_3,-1,-1,-1,13204,-1,0.0016966268,0.9983033
13206,cyclosporin A,12,14,83,96,This report demonstrates for the first time that the pharmacodynamic properties of cyclosporin A may not be confined strictly to suppression of normal T-cell functions.,3865016_4,-1,-1,-1,13206,-1,0.9991523,0.00084766187
13212,thrombophlebitis,2,3,19,35,"Reactions included thrombophlebitis (20 of 54 patients), rash (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).",3934126_4,-1,-1,-1,13212,-1,0.0011693132,0.99883074
13217,Thrombophlebitis,0,1,0,16,Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.,3934126_5,-1,-1,-1,13217,-1,0.0011930185,0.99880695
13230,P,16,17,108,109,"When the parameters were examined individually, duration of therapy and total AUC correlated significantly (P less than .05) with nephrotoxicity.",3950060_5,-1,-1,-1,13230,-1,0.36839366,0.63160634
13232,contrast,1,2,3,11,"In contrast, a stepwise discriminant function analysis identified only duration of therapy (P less than .001) as an important factor.",3950060_6,-1,-1,-1,13232,-1,0.23476794,0.765232
13233,P,14,15,92,93,"In contrast, a stepwise discriminant function analysis identified only duration of therapy (P less than .001) as an important factor.",3950060_6,-1,-1,-1,13233,-1,0.42992184,0.5700782
13235,P,25,26,120,121,"When examined individually, mean IF, MIC, total dose, mean daily dose, and ln (mean Cmax/MIC) correlated significantly (P less than .05) with cure.",3950060_8,-1,-1,-1,13235,-1,0.4139103,0.5860897
13236,contrast,1,2,3,11,"In contrast, a simultaneous multivariable analysis identified IF, MIC, and total dose according to one model and ln (mean Cmax/MIC) according to a second statistical model of parameters selected to have the greatest prospective value.",3950060_9,-1,-1,-1,13236,-1,0.2475047,0.7524953
13239,angina,6,7,32,38,Report of a case of spontaneous angina.,3952818_1,-1,-1,-1,13239,-1,0.0015345658,0.9984654
13240,colon carcinoma,8,10,35,50,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,-1,-1,-1,13240,-1,0.0020174137,0.9979825
13241,liver metastasis,11,13,55,71,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,-1,-1,-1,13241,-1,0.0018315737,0.99816835
13242,chest pain,15,17,86,96,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,-1,-1,-1,13242,-1,0.0014781132,0.99852186
13244,5-FU,20,21,119,123,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,-1,-1,-1,13244,-1,0.99875665,0.0012433295
13245,Prinzmetal's angina,9,12,72,91,"Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.",3952818_3,-1,-1,-1,13245,-1,0.37918565,0.6208143
13246,chest pain,14,16,97,107,"Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.",3952818_3,-1,-1,-1,13246,-1,0.0015841322,0.9984158
13250,5-FU,14,15,81,85,"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.",3952818_4,-1,-1,-1,13250,-1,0.99880123,0.0011987987
13252,5-FU cardiotoxicity,30,32,171,190,"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.",3952818_4,-1,-1,-1,13252,-1,0.22634144,0.7736586
13254,delayed neuropathy,10,12,98,116,Dose-related beneficial and adverse effects of dietary corticosterone on organophosphorus-induced delayed neuropathy in chickens.,3961813_0,-1,-1,-1,13254,-1,0.0013338259,0.99866617
13255,Tri-ortho-tolyl phosphate,0,2,0,25,"Tri-ortho-tolyl phosphate (TOTP), 360 mg/kg, po, and 0,0'-diisopropyl phosphorofluoridate (DFP), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone.",3961813_1,-1,-1,-1,13255,-1,0.9987488,0.0012512304
13256,TOTP,3,4,27,31,"Tri-ortho-tolyl phosphate (TOTP), 360 mg/kg, po, and 0,0'-diisopropyl phosphorofluoridate (DFP), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone.",3961813_1,-1,-1,-1,13256,-1,0.9987833,0.0012166996
13257,"0,0'-diisopropyl phosphorofluoridate",12,14,53,89,"Tri-ortho-tolyl phosphate (TOTP), 360 mg/kg, po, and 0,0'-diisopropyl phosphorofluoridate (DFP), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone.",3961813_1,-1,-1,-1,13257,-1,0.9982235,0.0017765295
13258,DFP,15,16,91,94,"Tri-ortho-tolyl phosphate (TOTP), 360 mg/kg, po, and 0,0'-diisopropyl phosphorofluoridate (DFP), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone.",3961813_1,-1,-1,-1,13258,-1,0.99884295,0.0011570086
13263,TOTP,35,36,213,217,"Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.",3961813_3,-1,-1,-1,13263,-1,0.9987463,0.0012537559
13264,DFP,37,38,221,224,"Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.",3961813_3,-1,-1,-1,13264,-1,0.9988925,0.0011075194
13266,TOTP,6,7,43,47,Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.,3961813_4,-1,-1,-1,13266,-1,0.99868613,0.0013138722
13267,DFP,8,9,51,54,Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.,3961813_4,-1,-1,-1,13267,-1,0.998961,0.0010389972
13268,organophosphorous compounds,21,23,115,142,Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.,3961813_4,-1,-1,-1,13268,-1,0.9987338,0.001266211
13270,TOTP,6,7,46,50,Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase.,3961813_5,-1,-1,-1,13270,-1,0.9988482,0.0011518269
13271,DFP,8,9,54,57,Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase.,3961813_5,-1,-1,-1,13271,-1,0.9990339,0.0009660955
13272,Degenerating myelinated fibers,0,3,0,30,Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP.,3961813_6,-1,-1,-1,13272,-1,0.0034231693,0.99657685
13273,TOTP,16,17,109,113,Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP.,3961813_6,-1,-1,-1,13273,-1,0.99859387,0.0014060697
13274,DFP,18,19,117,120,Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP.,3961813_6,-1,-1,-1,13274,-1,0.99883586,0.0011641786
13278,cardiac tachyarrhythmias,11,13,77,101,Amiodarone has proved very effective in the treatment of otherwise resistant cardiac tachyarrhythmias.,3962737_1,-1,-1,-1,13278,-1,0.0012360188,0.99876404
13280,cholestatic hepatitis,3,5,15,36,A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given.,3962737_3,-1,-1,-1,13280,-1,0.0013605703,0.9986394
13286,steatosis,16,17,100,109,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,-1,-1,13286,-1,0.0011947596,0.9988053
13287,alcoholic hepatitis,20,22,134,153,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,-1,-1,13287,-1,0.0016310037,0.99836904
13288,cholestatic hepatitis,23,25,155,176,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,-1,-1,13288,-1,0.0019935747,0.9980064
13289,cirrhosis of the liver,27,31,194,216,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,-1,-1,13289,-1,0.0023808596,0.9976191
13291,cholestatic injury,8,10,51,69,Therapy should be discontinued on the suspicion of cholestatic injury or hepatomegaly.,3962737_6,-1,-1,-1,13291,-1,0.0013690883,0.99863094
13294,fat,6,7,48,51,Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats.,3969369_0,-1,-1,-1,13294,-1,0.9970067,0.0029933583
13295,prostate carcinogenesis,8,10,55,78,Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats.,3969369_0,-1,-1,-1,13295,-1,0.0020464787,0.99795353
13296,prostate adenocarcinomas,19,21,87,111,"Germfree (GF) Lobund strain Wistar (LW) rats, fed vegetable diet L-485, have developed prostate adenocarcinomas spontaneously (10% incidence) at average age 34 months.",3969369_1,-1,-1,-1,13296,-1,0.002509806,0.99749017
13301,corn oil,18,20,120,128,"Preliminary results indicate that testosterone-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months.",3969369_3,-1,-1,-1,13301,-1,0.9982608,0.0017392061
13302,fat,24,25,139,142,"Preliminary results indicate that testosterone-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months.",3969369_3,-1,-1,-1,13302,-1,0.98774606,0.012253949
13304,SD,4,5,24,26,Aged GF Sprague-Dawley (SD) rats have not developed prostate cancer spontaneously.,3969369_4,-1,-1,-1,13304,-1,0.23201537,0.7679846
13306,SD,1,2,13,15,Conventional SD rats fed diet L-485 and treated with testosterone developed only prostatitis.,3969369_5,-1,-1,-1,13306,-1,0.023899589,0.97610044
13308,prostatitis,12,13,81,92,Conventional SD rats fed diet L-485 and treated with testosterone developed only prostatitis.,3969369_5,-1,-1,-1,13308,-1,0.0012699412,0.99873
13310,neoplasms,2,3,13,22,Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens.,3970039_0,-1,-1,-1,13310,-1,0.0017781334,0.9982218
13314,chlorambucil,7,8,49,61,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,-1,-1,-1,13314,-1,0.9992054,0.000794632
13315,alkylating agents,9,11,63,80,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,-1,-1,-1,13315,-1,0.99167633,0.008323678
13317,purine,15,16,97,103,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,-1,-1,-1,13317,-1,0.99912196,0.0008780035
13319,folic acid,22,24,133,143,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,-1,-1,-1,13319,-1,0.9991302,0.0008698443
13320,synovitis,10,11,67,76,"There is evidence that all four immunosuppressive drugs can reduce synovitis, but disease activity almost always recurs after therapy is stopped.",3970039_3,-1,-1,-1,13320,-1,0.0013803818,0.9986197
13321,alkylating agents,3,5,22,39,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,-1,-1,-1,13321,-1,0.9989209,0.0010791514
13322,acute nonlymphocytic leukemia,12,15,81,110,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,-1,-1,-1,13322,-1,0.0012744338,0.9987256
13323,alkylating agents,18,20,121,138,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,-1,-1,-1,13323,-1,0.9989936,0.001006377
13325,lymphoma,30,31,209,217,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,-1,-1,-1,13325,-1,0.0012649742,0.998735
13334,alkylating agents,30,32,194,211,"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.",3970039_9,-1,-1,-1,13334,-1,0.99843544,0.001564611
13336,disease,47,48,310,317,"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.",3970039_9,-1,-1,-1,13336,-1,0.0012337996,0.9987662
13337,hypaque 76.Sequential,8,10,47,68,"Time course alterations of QTC interval due to hypaque 76.Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one, three, five and ten minutes after injection of hypaque 76.",3973521_0,-1,-1,-1,13337,-1,0.9523606,0.04763949
13338,hypaque 76,34,36,208,218,"Time course alterations of QTC interval due to hypaque 76.Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one, three, five and ten minutes after injection of hypaque 76.",3973521_0,-1,-1,-1,13338,-1,0.9980831,0.0019169169
13339,QTC prolongation,1,3,12,28,Significant QTC prolongation occurred in 30 seconds to one minute in association with marked hypotension and elevation of cardiac output.,3973521_2,-1,-1,-1,13339,-1,0.003992303,0.9960077
13341,elevation of,16,18,109,121,Significant QTC prolongation occurred in 30 seconds to one minute in association with marked hypotension and elevation of cardiac output.,3973521_2,-1,-1,-1,13341,-1,0.0043840474,0.99561596
13342,output,19,20,130,136,Significant QTC prolongation occurred in 30 seconds to one minute in association with marked hypotension and elevation of cardiac output.,3973521_2,-1,-1,-1,13342,-1,0.022035303,0.97796476
13344,femoral nerve palsy,5,8,54,73,Warfarin-induced iliopsoas hemorrhage with subsequent femoral nerve palsy.,3985451_0,-1,-1,-1,13344,-1,0.0020030313,0.997997
13346,muscle tear,16,18,91,102,We present the case of a 28-year-old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip.,3985451_1,-1,-1,-1,13346,-1,0.002216452,0.9977836
13348,flexure contracture,24,26,139,158,We present the case of a 28-year-old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip.,3985451_1,-1,-1,-1,13348,-1,0.0019318525,0.99806815
13350,femoral nerve entrapment,7,10,56,80,"Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment, resulting in a femoral nerve palsy and partial loss of quadriceps functions.",3985451_2,-1,-1,-1,13350,-1,0.0025901615,0.9974099
13351,femoral nerve palsy,14,17,97,116,"Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment, resulting in a femoral nerve palsy and partial loss of quadriceps functions.",3985451_2,-1,-1,-1,13351,-1,0.003097168,0.99690276
13352,partial loss of quadriceps functions,18,23,121,157,"Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment, resulting in a femoral nerve palsy and partial loss of quadriceps functions.",3985451_2,-1,-1,-1,13352,-1,0.0058855894,0.99411446
13353,femoral nerve palsy,1,4,22,41,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,-1,-1,-1,13353,-1,0.0022686827,0.9977314
13356,motor and sensory impairment,28,32,195,223,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,-1,-1,-1,13356,-1,0.0020913172,0.9979087
13357,flexure contracture,34,36,229,248,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,-1,-1,-1,13357,-1,0.0017444147,0.99825555
13358,Pneumonitis,0,1,0,11,Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy.,3997294_0,-1,-1,-1,13358,-1,0.0011273436,0.9988726
13359,pericardial effusion,4,6,29,49,Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy.,3997294_0,-1,-1,-1,13359,-1,0.0019731403,0.9980268
13362,sinuatrial disease,3,5,15,33,"A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.",3997294_1,-1,-1,-1,13362,-1,0.003420106,0.99657995
13364,mg,16,17,105,107,"A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.",3997294_1,-1,-1,-1,13364,-1,0.9918726,0.008127418
13365,mg,21,22,130,132,"A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.",3997294_1,-1,-1,-1,13365,-1,0.99120635,0.00879364
13366,supraventricular tachyarrhythmias,31,33,170,203,"A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.",3997294_1,-1,-1,-1,13366,-1,0.0014661336,0.99853384
13367,pneumonitis,2,3,13,24,"He developed pneumonitis, pleural and pericardial effusions, and a predominantly proximal motor neuropathy.",3997294_2,-1,-1,-1,13367,-1,0.0012015885,0.9987984
13368,pericardial effusions,6,8,38,59,"He developed pneumonitis, pleural and pericardial effusions, and a predominantly proximal motor neuropathy.",3997294_2,-1,-1,-1,13368,-1,0.0020386046,0.9979614
13369,proximal motor neuropathy,12,15,81,106,"He developed pneumonitis, pleural and pericardial effusions, and a predominantly proximal motor neuropathy.",3997294_2,-1,-1,-1,13369,-1,0.001954664,0.9980453
13372,amiodarone pneumonitis,14,16,87,109,"Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis, immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery.",3997294_4,-1,-1,-1,13372,-1,0.39818892,0.6018111
13375,sinoatrial block,1,3,19,35,Amiodarone-induced sinoatrial block.,4008111_0,-1,-1,-1,13375,-1,0.0344195,0.9655805
13376,sinoatrial block,2,4,12,28,"We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.",4008111_1,-1,-1,-1,13376,-1,0.016254686,0.98374534
13378,primary cardiomyopathy,14,16,95,117,"We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.",4008111_1,-1,-1,-1,13378,-1,0.0016138339,0.99838614
13379,supraventricular tachycardia,20,22,154,182,"We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.",4008111_1,-1,-1,-1,13379,-1,0.0014222683,0.9985777
13381,sinoatrial block,12,14,75,91,Reduction in the dosage of amiodarone resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic sinus bradycardia.,4008111_2,-1,-1,-1,13381,-1,0.0070482763,0.9929517
13388,bupivacaine hydrochloride,12,14,70,95,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,-1,-1,-1,13388,-1,0.9991302,0.0008697962
13389,mepivacaine hydrochloride,17,19,102,127,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,-1,-1,-1,13389,-1,0.9991277,0.0008722844
13390,lidocaine hydrochloride,23,25,138,161,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,-1,-1,-1,13390,-1,0.9988605,0.0011395736
13392,Muscle degeneration,0,2,0,19,Muscle degeneration is followed by regeneration of the damaged muscle fibers.,4038130_5,-1,-1,-1,13392,-1,0.002919401,0.9970806
13393,muscle damage,3,5,15,28,"In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.",4038130_6,-1,-1,-1,13393,-1,0.002412086,0.9975879
13394,mepivacaine,19,20,108,119,"In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.",4038130_6,-1,-1,-1,13394,-1,0.9993351,0.0006648559
13397,diplopia,12,13,67,75,"With these findings in rats, it is hypothesized that the temporary diplopia sometimes seen in patients after ophthalmic surgery might be due to anesthetic-induced damage to the extraocular muscles.",4038130_7,-1,-1,-1,13397,-1,0.001315471,0.99868447
13398,Gentamicin nephropathy,0,2,0,22,Gentamicin nephropathy in a neonate.,4069770_0,-1,-1,-1,13398,-1,0.21744414,0.7825559
13399,acute renal failure,12,15,66,85,The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.,4069770_1,-1,-1,-1,13399,-1,0.0012246515,0.9987753
13404,PAS,5,6,31,34,"Numerous periodic acid Schiff (PAS) positive, diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules.",4069770_3,-1,-1,-1,13404,-1,0.99683255,0.003167409
13406,renal insufficiency,1,3,21,40,Indomethacin-induced renal insufficiency: recurrence on rechallenge.,4071154_0,-1,-1,-1,13406,-1,0.0013561836,0.9986438
13407,renal failure,8,10,42,55,"We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.",4071154_1,-1,-1,-1,13407,-1,0.0012781299,0.9987219
13411,cor pulmonale,21,23,116,129,"We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.",4071154_1,-1,-1,-1,13411,-1,0.0017599093,0.9982401
13414,oliguria,22,23,152,160,"Prompt restoration of renal function followed drug withdrawal, while re-exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria.",4071154_2,-1,-1,-1,13414,-1,0.0012427393,0.99875724
13416,acute renal failure,12,15,101,120,"Since nonsteroidal anti-inflammatory agents interfere with this compensatory mechanism and may cause acute renal failure, they should be used with caution in such patients.",4071154_4,-1,-1,-1,13416,-1,0.0012597673,0.99874026
13418,tumours,7,8,46,53,Induction by paracetamol of bladder and liver tumours in the rat.,4090988_0,-1,-1,-1,13418,-1,0.0020572434,0.99794275
13420,Papillomas,0,1,0,10,"Papillomas of the transitional epithelium of the bladder developed in all paracetamol-treated groups, and three rats bore bladder carcinomas.",4090988_5,-1,-1,-1,13420,-1,0.0018344362,0.99816555
13421,bladder carcinomas,18,20,122,140,"Papillomas of the transitional epithelium of the bladder developed in all paracetamol-treated groups, and three rats bore bladder carcinomas.",4090988_5,-1,-1,-1,13421,-1,0.002141711,0.9978582
13422,bladder tumours,5,7,31,46,"However, significant yields of bladder tumours were only obtained from low dosage females and high dosage males.",4090988_6,-1,-1,-1,13422,-1,0.0020090635,0.99799097
13423,hyperplasia,10,11,62,73,"Additionally, 20 to 25% of paracetamol-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of bladder calculi.",4090988_7,-1,-1,-1,13423,-1,0.001543886,0.9984561
13424,bladder calculi,24,26,147,162,"Additionally, 20 to 25% of paracetamol-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of bladder calculi.",4090988_7,-1,-1,-1,13424,-1,0.0020563253,0.9979437
13425,tumours,4,5,15,22,A low yield of tumours at various other sites also arose following paracetamol feeding.,4090988_8,-1,-1,-1,13425,-1,0.0023227357,0.99767727
13427,hepatocarcinogens,28,29,191,208,An electron microscope study of the livers of paracetamol-treated rats revealed ultrastructural changes in the hepatocytes that resemble those that result from exposure to a variety of known hepatocarcinogens.,4090988_9,-1,-1,-1,13427,-1,0.036468904,0.96353114
13433,tender hepatomegaly,2,4,14,33,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,-1,-1,13433,-1,0.0015258924,0.99847406
13434,malaise,10,11,67,74,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,-1,-1,13434,-1,0.0013429986,0.998657
13435,anorexia,12,13,76,84,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,-1,-1,13435,-1,0.0012563248,0.9987437
13436,nausea and vomiting,14,17,86,105,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,-1,-1,13436,-1,0.0016180174,0.998382
13437,upper abdominal pain,21,24,127,147,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,-1,-1,13437,-1,0.0014272451,0.9985727
13438,hepatocellular necrosis,5,7,43,66,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,-1,-1,-1,13438,-1,0.0016571175,0.9983429
13440,fatty change,22,24,167,179,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,-1,-1,-1,13440,-1,0.001947288,0.9980527
13441,hepatocellular necrosis,26,28,190,213,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,-1,-1,-1,13441,-1,0.0017481636,0.99825186
13442,massive hepatic necrosis,29,32,217,241,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,-1,-1,-1,13442,-1,0.0020964495,0.9979036
13443,acute hepatitis,6,8,40,55,Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated cholestasis.,424937_5,-1,-1,-1,13443,-1,0.0013679196,0.998632
13444,chronic active hepatitis,9,12,59,83,Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated cholestasis.,424937_5,-1,-1,-1,13444,-1,0.0015483785,0.9984516
13446,hepatic failure,7,9,38,53,"One patient died, having presented in hepatic failure, and another, who had been taking methyldopa for 7 years, showed slower clinical and biochemical resolution over a period of several months.",424937_7,-1,-1,-1,13446,-1,0.0017344324,0.99826556
13448,fulminant hepatitis,7,9,46,65,The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of methyldopa-induced hepatitis.,424937_8,-1,-1,-1,13448,-1,0.001332989,0.998667
13451,hepatic dysfunction,16,18,88,107,"In this latter patient, and in 2 others, the causal relationship between methyldopa and hepatic dysfunction was proved with the recurrence of hepatitis within 2 weeks of re-exposure to the drug.",424937_9,-1,-1,-1,13451,-1,0.0013829673,0.99861705
13453,Transient hemiparesis,0,2,0,21,Transient hemiparesis: a rare manifestation of diphenylhydantoin toxicity.,430165_0,-1,-1,-1,13453,-1,0.0012264983,0.9987735
13454,diphenylhydantoin toxicity,7,9,47,73,Transient hemiparesis: a rare manifestation of diphenylhydantoin toxicity.,430165_0,-1,-1,-1,13454,-1,0.6609475,0.33905253
13455,diphenylhydantoin,6,7,33,50,"Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.",430165_2,-1,-1,-1,13455,-1,0.9990521,0.00094790803
13456,DPH,8,9,52,55,"Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.",430165_2,-1,-1,-1,13456,-1,0.99821967,0.0017802631
13458,cerebellar dysfunction,21,23,131,153,"Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.",430165_2,-1,-1,-1,13458,-1,0.0014065611,0.9985934
13459,hemiparesis,7,8,52,63,Two patients are presented who suffered progressive hemiparesis due to DPH overdose.,430165_4,-1,-1,-1,13459,-1,0.0010569155,0.99894315
13460,DPH overdose,10,12,71,83,Two patients are presented who suffered progressive hemiparesis due to DPH overdose.,430165_4,-1,-1,-1,13460,-1,0.003001345,0.99699867
13461,DPH,5,6,30,33,Both had brain surgery before DPH treatment.,430165_5,-1,-1,-1,13461,-1,0.9983537,0.001646316
13462,cerebral damage,7,9,38,53,It is assumed that patients with some cerebral damage are liable to manifest DPH toxicity as focal neurological signs.,430165_6,-1,-1,-1,13462,-1,0.0014445068,0.9985555
13463,DPH toxicity,13,15,77,89,It is assumed that patients with some cerebral damage are liable to manifest DPH toxicity as focal neurological signs.,430165_6,-1,-1,-1,13463,-1,0.0029719002,0.9970282
13465,fasciculations,5,6,41,55,Suxamethonium infusion rate and observed fasciculations.,435349_0,-1,-1,-1,13465,-1,0.0020772773,0.9979227
13466,Suxamethonium chloride,0,2,0,22,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,-1,-1,-1,13466,-1,0.9990558,0.0009442128
13467,Sch,3,4,24,27,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,-1,-1,-1,13467,-1,0.9979785,0.0020215474
13468,mg,18,19,88,90,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,-1,-1,-1,13468,-1,0.9922443,0.00775565
13469,mg,22,23,101,103,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,-1,-1,-1,13469,-1,0.9911465,0.008853496
13470,tetanic,12,13,76,83,The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded.,435349_3,-1,-1,-1,13470,-1,0.005406346,0.9945937
13471,Sch,20,21,123,126,The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded.,435349_3,-1,-1,-1,13471,-1,0.9989011,0.0010988739
13472,mg,22,23,131,133,The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded.,435349_3,-1,-1,-1,13472,-1,0.99748623,0.0025137533
13473,Fasciculations,0,1,0,14,Fasciculations in six areas of the body were scored from 0 to 3 and summated as a total fasciculation score.,435349_6,-1,-1,-1,13473,-1,0.0031375326,0.99686253
13476,twitch,6,7,34,40,"The times to first fasciculation, twitch suppression and tetanus suppression were inversely related to the infusion rates.",435349_7,-1,-1,-1,13476,-1,0.0021389592,0.9978611
13477,tetanus,9,10,57,64,"The times to first fasciculation, twitch suppression and tetanus suppression were inversely related to the infusion rates.",435349_7,-1,-1,-1,13477,-1,0.0020682614,0.9979317
13478,Fasciculations,0,1,0,14,Fasciculations in the six areas and the total fasciculation score were related directly to the rate of infusion.,435349_8,-1,-1,-1,13478,-1,0.002937452,0.9970625
13481,Tiapride,0,1,0,8,Tiapride in levodopa-induced involuntary movements.,458486_0,-1,-1,-1,13481,-1,0.9992255,0.0007744983
13482,involuntary movements,3,5,29,50,Tiapride in levodopa-induced involuntary movements.,458486_0,-1,-1,-1,13482,-1,0.0017114589,0.9982886
13483,Tiapride,0,1,0,8,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,-1,-1,-1,13483,-1,0.9993007,0.0006992932
13484,benzamide,4,5,24,33,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,-1,-1,-1,13484,-1,0.99921,0.00078991376
13486,involuntary movements,15,17,115,136,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,-1,-1,-1,13486,-1,0.0017158623,0.99828416
13487,idiopathic Parkinson's disease,21,25,157,187,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,-1,-1,-1,13487,-1,0.0027704795,0.9972295
13488,disability,6,7,37,47,"However, an unacceptable increase in disability from Parkinsonism with aggravation of end-of-dose akinesia led to its cessation in 14 patients.",458486_2,-1,-1,-1,13488,-1,0.001166308,0.9988337
13490,akinesia,13,14,98,106,"However, an unacceptable increase in disability from Parkinsonism with aggravation of end-of-dose akinesia led to its cessation in 14 patients.",458486_2,-1,-1,-1,13490,-1,0.0013578137,0.99864215
13491,Tiapride,0,1,0,8,"Tiapride had no effect on levodopa-induced early morning of ""off-period"" segmental dystonia.",458486_3,-1,-1,-1,13491,-1,0.9992423,0.00075765856
13503,Quinidine hepatitis,0,2,0,19,Quinidine hepatitis.,48362_0,-1,-1,-1,13503,-1,0.5844261,0.41557392
13504,quinidine,3,4,28,37,"Long-term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT, lactic acid dehydrogenase, and alkaline phosphatase.",48362_1,-1,-1,-1,13504,-1,0.99922884,0.00077114516
13505,lactic acid,15,17,112,123,"Long-term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT, lactic acid dehydrogenase, and alkaline phosphatase.",48362_1,-1,-1,-1,13505,-1,0.9952447,0.0047552995
13506,alkaline phosphatase,20,22,143,163,"Long-term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT, lactic acid dehydrogenase, and alkaline phosphatase.",48362_1,-1,-1,-1,13506,-1,0.9964502,0.0035497958
13507,active hepatitis,3,5,20,36,Liver biopsy showed active hepatitis.,48362_2,-1,-1,-1,13507,-1,0.0021630113,0.997837
13508,quinidine,2,3,18,27,Discontinuance of quinidine therapy led to normalization of liver function tests.,48362_3,-1,-1,-1,13508,-1,0.9992417,0.00075835065
13509,quinidine,4,5,20,29,"A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT, alkaline phosphatase, and lactic acid dehydrogenase values.",48362_4,-1,-1,-1,13509,-1,0.99917465,0.00082537666
13510,alkaline phosphatase,14,16,85,105,"A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT, alkaline phosphatase, and lactic acid dehydrogenase values.",48362_4,-1,-1,-1,13510,-1,0.9891039,0.010896081
13511,lactic acid,18,20,111,122,"A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT, alkaline phosphatase, and lactic acid dehydrogenase values.",48362_4,-1,-1,-1,13511,-1,0.99491876,0.0050812424
13512,quinidine hepatotoxicity,6,8,35,59,We concluded that this patient had quinidine hepatotoxicity and believe that this is the first case reported with liver biopsy documentation.,48362_5,-1,-1,-1,13512,-1,0.28416553,0.7158345
13513,hepatic toxicity,12,14,73,89,"This report also suggests that, even after long-term administration, the hepatic toxicity is reversible.",48362_6,-1,-1,-1,13513,-1,0.0015513013,0.9984487
13514,Angiosarcoma,0,1,0,12,Angiosarcoma of the liver associated with diethylstilbestrol.,567256_0,-1,-1,-1,13514,-1,0.0015312392,0.9984687
13516,Angiosarcoma,0,1,0,12,Angiosarcoma of the liver occurred in a 76-year-old man who had been treated for a well-differentiated adenocarcinoma of the liver with diethylstilbestrol for 13 years.,567256_1,-1,-1,-1,13516,-1,0.0012877537,0.9987123
13517,adenocarcinoma,16,17,103,117,Angiosarcoma of the liver occurred in a 76-year-old man who had been treated for a well-differentiated adenocarcinoma of the liver with diethylstilbestrol for 13 years.,567256_1,-1,-1,-1,13517,-1,0.0015063888,0.99849355
13519,Angiosarcoma,0,1,0,12,Angiosarcoma was also present within pulmonary and renal arteries.,567256_2,-1,-1,-1,13519,-1,0.0015509159,0.9984491
13520,intraarterial lesions,4,6,25,46,The possibility that the intraarterial lesions might represent independent primary tumors is considered.,567256_3,-1,-1,-1,13520,-1,0.0067856624,0.99321437
13522,thromboembolism,1,2,9,24,Arterial thromboembolism in patients receiving systemic heparin therapy: a complication associated with heparin-induced thrombocytopenia.,591536_0,-1,-1,-1,13522,-1,0.0011532207,0.99884677
13525,thromboembolism,1,2,9,24,Arterial thromboembolism is a recognized complication of systemic heparin therapy.,591536_1,-1,-1,-1,13525,-1,0.0012865803,0.9987134
13527,arterial occlusion,5,7,32,50,"Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.",591536_2,-1,-1,-1,13527,-1,0.001491719,0.9985083
13529,distal ischemia,11,13,83,98,"Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.",591536_2,-1,-1,-1,13529,-1,0.001535554,0.99846447
13532,ischemic,16,17,117,125,"The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin, and might serve to warn the clinician of these complications.",591536_3,-1,-1,-1,13532,-1,0.0013039538,0.998696
13534,thromboembolism,4,5,27,42,The common factor relating thromboembolism and thrombocytopenia is heparin-induced platelet aggregation.,591536_5,-1,-1,-1,13534,-1,0.0011140507,0.9988859
13538,sodium warfarin,11,13,87,102,"Appropriate treatment consists of discontinuation of heparin, and anticoagulation with sodium warfarin if necessary.",591536_6,-1,-1,-1,13538,-1,0.9987452,0.001254785
13539,Galanthamine hydrobromide,0,2,0,25,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,-1,-1,-1,13539,-1,0.9990896,0.0009104655
13541,(Hyoscine).Galanthamine,18,19,123,146,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,-1,-1,-1,13541,-1,0.9981225,0.0018775105
13542,(Hyoscine).Galanthamine hydrobromide,18,20,123,159,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,-1,-1,-1,13542,-1,0.9980184,0.0019816235
13544,hyoscine,42,43,304,312,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,-1,-1,-1,13544,-1,0.9991866,0.00081346044
13545,overdosage,44,45,314,324,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,-1,-1,-1,13545,-1,0.006761916,0.9932381
13546,physostigmine,5,6,25,38,It is longer acting than physostigmine and is used in anaesthesia to reverse the non-depolarizing neuromuscular block.,603022_1,-1,-1,-1,13546,-1,0.9991831,0.00081684155
13548,flunitrazepam,2,3,18,31,administration of flunitrazepam in volunteers.,6103707_1,-1,-1,-1,13548,-1,0.9990257,0.00097434747
13549,Flunitrazepam,0,1,0,13,"Flunitrazepam 0.5, 1.0 or 2.0 mg was given by the oral or i.m.",6103707_2,-1,-1,-1,13549,-1,0.9990269,0.00097316824
13550,mg,6,7,30,32,"Flunitrazepam 0.5, 1.0 or 2.0 mg was given by the oral or i.m.",6103707_2,-1,-1,-1,13550,-1,0.9882217,0.01177831
13551,mg,13,14,71,73,"The most striking effect was sedation which increased with the dose, 2 mg producing deep sleep although the subjects could still be aroused.",6103707_5,-1,-1,-1,13551,-1,0.9928746,0.0071253707
13554,flunitrazepam,2,3,13,26,injection of flunitrazepam significantly more often than with isotonic saline.,6103707_9,-1,-1,-1,13554,-1,0.99912983,0.0008701597
13555,h,10,11,61,62,The drug was still present in measurable quantities after 24 h even with the smallest dose.,6103707_11,-1,-1,-1,13555,-1,0.2520983,0.74790174
13556,GYKI-41 099,2,4,16,27,"Pharmacology of GYKI-41 099 (chlorpropanol, Tobanum) a new potent beta-adrenergic antagonist.",6111982_0,-1,-1,-1,13556,-1,0.9978992,0.0021008633
13557,chlorpropanol,5,6,29,42,"Pharmacology of GYKI-41 099 (chlorpropanol, Tobanum) a new potent beta-adrenergic antagonist.",6111982_0,-1,-1,-1,13557,-1,0.99911827,0.0008817191
13558,Tobanum,7,8,44,51,"Pharmacology of GYKI-41 099 (chlorpropanol, Tobanum) a new potent beta-adrenergic antagonist.",6111982_0,-1,-1,-1,13558,-1,0.9987172,0.0012828876
13559,GYKI-41 099,2,4,13,24,"The compound GYKI-41 099, as a beta-adrenergic antagonist, is 3-8 times more potent than propranolol in vitro and in vivo.",6111982_1,-1,-1,-1,13559,-1,0.9979247,0.0020753273
13562,pindolol,8,9,67,75,Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.,6111982_2,-1,-1,-1,13562,-1,0.9992446,0.0007555108
13563,ouabain arrhythmia,11,13,91,109,Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.,6111982_2,-1,-1,-1,13563,-1,0.63743067,0.3625693
13564,GYKI-41 900,0,2,0,11,GYKI-41 900 has a negligible cardiodepressant activity; it is not cardioselective.,6111982_3,-1,-1,-1,13564,-1,0.9939336,0.0060663274
13565,14C-41 099,12,14,78,88,There was a prolonged elimination of the radioactivity after the injection of 14C-41 099 to rats and dogs.,6111982_5,-1,-1,-1,13565,-1,0.99781585,0.0021841626
13566,bendrofluazide,3,4,21,35,Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension.,6115999_0,-1,-1,-1,13566,-1,0.9991359,0.00086408766
13571,bendrofluazide,21,22,139,153,"Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.",6115999_2,-1,-1,-1,13571,-1,0.9992472,0.00075279054
13573,bendrofluazide,6,7,40,54,"The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.",6115999_5,-1,-1,-1,13573,-1,0.9991872,0.00081276963
13574,impotence,9,10,69,78,"The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.",6115999_5,-1,-1,-1,13574,-1,0.0014954096,0.99850464
13575,impotence,12,13,84,93,"The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.",6115999_5,-1,-1,-1,13575,-1,0.0015992153,0.99840075
13577,impaired glucose tolerance,9,12,71,97,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,-1,13577,-1,0.0049476693,0.9950524
13578,gout,17,18,119,123,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,-1,13578,-1,0.0012153237,0.9987847
13579,bendrofluazide,23,24,148,162,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,-1,13579,-1,0.9992304,0.0007696189
13580,Raynaud's phenomenon,27,30,178,198,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,-1,13580,-1,0.0020331445,0.9979668
13581,dyspnoea,31,32,203,211,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,-1,13581,-1,0.0012349914,0.998765
13583,corneal disease,1,3,3,18,No corneal disease is known to have occurred in the propranolol group.,6115999_7,-1,-1,-1,13583,-1,0.0016749447,0.99832505
13587,uric acid,9,11,46,55,"Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide.",6115999_8,-1,-1,-1,13587,-1,0.99877566,0.0012243472
13588,bendrofluazide,19,20,93,107,"Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide.",6115999_8,-1,-1,-1,13588,-1,0.9991742,0.00082574715
13591,uric acid,8,10,46,55,"In the propranolol group, serum potassium and uric acid levels rose in both sexes, but the urea level rose significantly in women only.",6115999_9,-1,-1,-1,13591,-1,0.99894184,0.0010581304
13594,baclofen,5,6,40,48,"Serotonergic drugs, benzodiazepines and baclofen block muscimol-induced myoclonic jerks in a strain of mice.",6118280_0,-1,-1,-1,13594,-1,0.9992531,0.0007468498
13596,muscimol,5,6,20,28,"In male Swiss mice, muscimol produced myoclonic jerks.",6118280_1,-1,-1,-1,13596,-1,0.9990308,0.00096914097
13600,muscimol,29,30,188,196,Increasing the brain serotonin levels by the administration of 5-hydroxytryptophan (80-160 mg/kg) in combination with a peripheral decarboxylase inhibitor resulted in an inhibition of the muscimol effect.,6118280_3,-1,-1,-1,13600,-1,0.999345,0.00065499183
13602,MK-212,12,13,55,61,"In doses of 3-10 mg/kg, the serotonin receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.",6118280_5,-1,-1,-1,13602,-1,0.9991702,0.0008298992
13603,muscimol,21,22,114,122,"In doses of 3-10 mg/kg, the serotonin receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.",6118280_5,-1,-1,-1,13603,-1,0.99930394,0.00069608574
13605,clonazepam,4,5,24,34,"Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.",6118280_6,-1,-1,-1,13605,-1,0.99925345,0.0007465197
13608,muscimol,15,16,71,79,"While (-)-baclofen (1-3 mg/kg) proved to be an effective antagonist of muscimol, its (+)-isomer (5-20 mg/kg) lacked this property.",6118280_7,-1,-1,-1,13608,-1,0.9993237,0.00067633454
13609,5-HTP,4,5,26,31,"Considering the fact that 5-HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.",6118280_8,-1,-1,-1,13609,-1,0.9988342,0.0011657692
13613,MK-212,8,9,50,56,Our present study indicated the possible value of MK-212 and (-)-baclofen in the management of clinical myoclonus.,6118280_9,-1,-1,-1,13613,-1,0.99895406,0.0010459092
13615,ischaemic heart disease,3,6,20,43,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,-1,-1,-1,13615,-1,0.0013455854,0.99865437
13616,cardiac failure,8,10,63,78,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,-1,-1,-1,13616,-1,0.001273881,0.99872607
13621,teratogenicity,1,2,9,23,Possible teratogenicity of sulphasalazine.,6133211_0,-1,-1,-1,13621,-1,0.0021555994,0.99784434
13623,inflammatory bowel disease,8,11,40,66,"Three infants, born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy, were found to have major congenital anomalies.",6133211_1,-1,-1,-1,13623,-1,0.0014129303,0.99858713
13625,congenital anomalies,24,26,157,177,"Three infants, born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy, were found to have major congenital anomalies.",6133211_1,-1,-1,-1,13625,-1,0.0017848671,0.9982152
13626,ulcerative colitis,8,10,43,61,"In the singleton pregnancy, the mother had ulcerative colitis, and the infant, a male, had coarctation of the aorta and a ventricular septal defect.",6133211_2,-1,-1,-1,13626,-1,0.0012731198,0.9987269
13627,coarctation of the aorta,19,23,91,115,"In the singleton pregnancy, the mother had ulcerative colitis, and the infant, a male, had coarctation of the aorta and a ventricular septal defect.",6133211_2,-1,-1,-1,13627,-1,0.0038462398,0.9961538
13628,ventricular septal defect,25,28,122,147,"In the singleton pregnancy, the mother had ulcerative colitis, and the infant, a male, had coarctation of the aorta and a ventricular septal defect.",6133211_2,-1,-1,-1,13628,-1,0.0040195337,0.9959805
13629,Crohn's disease,8,11,38,53,"In the twin pregnancy, the mother had Crohn's disease.",6133211_3,-1,-1,-1,13629,-1,0.0024696495,0.9975304
13630,Potter's facies,11,14,46,61,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,-1,-1,-1,13630,-1,0.006259806,0.9937402
13631,hypoplastic lungs,15,17,63,80,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,-1,-1,-1,13631,-1,0.0026418515,0.99735814
13632,absent kidneys and ureters,18,22,82,108,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,-1,-1,-1,13632,-1,0.004991924,0.9950081
13633,talipes equinovarus,24,26,114,133,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,-1,-1,-1,13633,-1,0.0042607645,0.9957392
13635,teratogenic,13,14,76,87,"Despite reports to the contrary, it is suggested that sulphasalazine may be teratogenic.",6133211_6,-1,-1,-1,13635,-1,0.0030169985,0.996983
13640,systemic mastocytosis,9,11,66,87,"Nineteen patients had Zollinger-Ellison syndrome, one patient had systemic mastocytosis, and two patients had idiopathic hypersecretion.",6150641_2,-1,-1,-1,13640,-1,0.0014131753,0.9985869
13647,impotence,9,10,55,64,Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine.,6150641_6,-1,-1,-1,13647,-1,0.001613933,0.998386
13653,hematologic toxicity,36,38,165,185,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,-1,-1,-1,13653,-1,0.0017089839,0.99829096
13654,gastrin,42,43,210,217,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,-1,-1,-1,13654,-1,0.9988533,0.0011467148
13670,epileptic foci,16,18,77,91,"On the other hand, enflurane may prove to be a safe fast acting activator of epileptic foci during corticography or depth electrode intraoperative recordings.",6153967_7,-1,-1,-1,13670,-1,0.0017425374,0.99825746
13672,renal failure,3,5,31,44,Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy.,6203452_0,-1,-1,-1,13672,-1,0.0013470845,0.99865294
13675,renal insufficiency,10,12,84,103,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,-1,-1,13675,-1,0.0013342858,0.9986657
13676,microangiopathic hemolytic anemia,13,16,105,138,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,-1,-1,13676,-1,0.0013036751,0.9986964
13679,bleomycin,26,27,202,211,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,-1,-1,13679,-1,0.9990828,0.00091722654
13680,vinca alkaloid,30,32,219,233,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,-1,-1,13680,-1,0.9985409,0.0014591187
13681,thrombotic thrombocytopenic purpura,3,6,16,51,"One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders.",6203452_2,-1,-1,-1,13681,-1,0.0012499255,0.9987501
13682,intravascular coagulation,9,11,62,87,"Histologic examination of the renal tissue showed evidence of intravascular coagulation, primarily affecting the small arteries, arterioles, and glomeruli.",6203452_3,-1,-1,-1,13682,-1,0.0014462948,0.9985537
13685,renal failure,24,26,145,158,"Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.",6203452_5,-1,-1,-1,13685,-1,0.0013056011,0.9986945
13686,cisplatin nephrotoxicity,30,32,178,202,"Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.",6203452_5,-1,-1,-1,13686,-1,0.06558462,0.93441546
13693,ISO,19,20,137,140,The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).,6203632_1,-1,-1,-1,13693,-1,0.99901307,0.0009869566
13694,body weight,24,26,153,164,The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).,6203632_1,-1,-1,-1,13694,-1,0.8553685,0.14463153
13695,hydroxyproline,20,21,93,107,"A time course was established for the change in tissue mass, RNA and DNA content, as well as hydroxyproline content.",6203632_2,-1,-1,-1,13695,-1,0.9991364,0.0008636012
13696,h,9,10,50,51,Ventricular RNA content was elevated 26% after 24 h of a single injection and reached a maximal level following 8 days of therapy.,6203632_4,-1,-1,-1,13696,-1,0.44728085,0.5527191
13697,hydroxyproline,4,5,21,35,The total content of hydroxyproline remained stable during the first 2 days of treatment but increased 46% after 4 days of therapy.,6203632_6,-1,-1,-1,13697,-1,0.99902356,0.00097648386
13698,hypertrophic growth,16,18,75,94,Ventricular DNA content was unchanged during the early stage (1-4 days) of hypertrophic growth but increased to a new steady-state level 19% above the controls after 8 days of treatment.,6203632_7,-1,-1,-1,13698,-1,0.0022714974,0.9977285
13700,P,12,13,73,74,"However, dP/dt in the ISO-treated hearts was slightly but significantly (P less than 0.05) elevated.",6203632_9,-1,-1,-1,13700,-1,0.53080297,0.4691971
13701,ISO,8,9,50,53,These data indicate that the adaptive response to ISO shows an early hypertrophic phase (1-4 days) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA.,6203632_10,-1,-1,-1,13701,-1,0.9982439,0.0017560666
13702,hypertrophic,12,13,69,81,These data indicate that the adaptive response to ISO shows an early hypertrophic phase (1-4 days) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA.,6203632_10,-1,-1,-1,13702,-1,0.0023354895,0.9976646
13704,hyperplasia,21,22,119,130,"However, prolonged stimulation (8-12 days) appears to represent a complex integration of both cellular hypertrophy and hyperplasia within the heart.",6203632_11,-1,-1,-1,13704,-1,0.0018238723,0.9981761
13708,myocardial infarction,26,28,178,199,The antiarrhythmic effects of the sustained release form of mexiletine (Mexitil-Perlongets) were evaluated in a double-blind placebo trial in 630 patients with recent documented myocardial infarction.,6209318_2,-1,-1,-1,13708,-1,0.001285543,0.99871445
13714,gastrointestinal problems,8,10,60,85,"Previously recognized side effects, particularly tremor and gastrointestinal problems, were more frequent in the mexiletine group than in the placebo group.",6209318_8,-1,-1,-1,13714,-1,0.0014140058,0.99858606
13718,Skin rashes,0,2,0,11,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,-1,-1,-1,13718,-1,0.0013415322,0.9986584
13720,systemic lupus erythematosus,5,8,26,54,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,-1,-1,-1,13720,-1,0.0012687927,0.9987312
13721,polymyositis,9,10,56,68,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,-1,-1,-1,13721,-1,0.0013625142,0.9986375
13722,myasthenia gravis,11,13,73,90,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,-1,-1,-1,13722,-1,0.0013390025,0.99866104
13725,skin lesion,1,3,4,15,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,-1,-1,-1,13725,-1,0.0018509836,0.99814904
13726,elastosis perforans serpiginosa,4,7,26,57,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,-1,-1,-1,13726,-1,0.0020156768,0.9979843
13727,Wilson's disease,20,23,122,138,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,-1,-1,-1,13727,-1,0.0025235047,0.9974765
13731,myocardial infarction,9,11,63,84,Changes in heart size during long-term timolol treatment after myocardial infarction.,6229975_0,-1,-1,-1,13731,-1,0.0016291862,0.9983708
13733,myocardial infarction,10,12,62,83,"The effect of long-term timolol treatment on heart size after myocardial infarction was evaluated by X-ray in a double-blind study including 241 patients (placebo 126, timolol 115).",6229975_1,-1,-1,-1,13733,-1,0.0015787767,0.9984212
13735,contrast,15,16,100,108,The timolol-treated patients showed a small but significant increase in heart size from baseline in contrast to a decrease in the placebo group.,6229975_3,-1,-1,-1,13735,-1,0.054775085,0.9452249
13737,cardiomegaly,3,4,17,29,"In patients with cardiomegaly, the increase in heart size was similar in both groups.",6229975_6,-1,-1,-1,13737,-1,0.0012103193,0.9987897
13739,hypercalcaemia,4,5,18,32,One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.,625456_1,-1,-1,-1,13739,-1,0.0016503282,0.99834967
13742,carbon-ate-sodium bicarbonate,22,24,147,176,One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.,625456_1,-1,-1,-1,13742,-1,0.9986104,0.0013896029
13743,Vitamin D3 toxicity,0,3,0,19,Vitamin D3 toxicity in dairy cows.,6286738_0,-1,-1,-1,13743,-1,0.6578731,0.34212694
13744,vitamin D3,4,6,26,36,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,-1,-1,-1,13744,-1,0.9988477,0.0011522158
13745,vitamin D3,14,16,60,70,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,-1,-1,-1,13745,-1,0.9987941,0.0012059198
13747,hyperphosphatemia,23,24,118,135,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,-1,-1,-1,13747,-1,0.0018333208,0.9981667
13748,vitamin D3,29,31,160,170,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,-1,-1,-1,13748,-1,0.99886274,0.0011372679
13750,vitamin D3,11,13,73,83,Calcium concentrations 1 day postpartum were higher in cows treated with vitamin D3 about 32 days prepartum (8.8 mg/100 ml) than in control cows (5.5 mg/100 ml).,6286738_2,-1,-1,-1,13750,-1,0.99884915,0.001150813
13751,vitamin D3,6,8,30,40,"None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period.",6286738_3,-1,-1,-1,13751,-1,0.9988445,0.0011554505
13754,vitamin D3 toxicity,2,5,9,28,"Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died.",6286738_4,-1,-1,-1,13754,-1,0.61106277,0.38893723
13755,vitamin D3 toxicity,22,25,139,158,"Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died.",6286738_4,-1,-1,-1,13755,-1,0.59792817,0.40207186
13758,vitamin D3,6,8,35,45,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,-1,-1,13758,-1,0.9990409,0.00095907773
13759,vitamin D3,21,23,116,126,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,-1,-1,13759,-1,0.9989786,0.0010214131
13762,vitamin D3,37,39,203,213,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,-1,-1,13762,-1,0.99900645,0.0009935937
13764,Diseases of peripheral nerves,0,4,0,29,Diseases of peripheral nerves as seen in the Nigerian African.,6287825_0,-1,-1,-1,13764,-1,0.0033157775,0.99668425
13765,peripheral nerve disease,6,9,45,69,"The anatomical and aetiological diagnoses of peripheral nerve disease excluding its primary benign and malignant disorders, as seen in 358 Nigerians are presented.",6287825_1,-1,-1,-1,13765,-1,0.0023048841,0.99769515
13767,motor neuropathy,20,22,109,125,"Guillain-Barr   syndrome was the commonest identifiable cause (15.6%), accounting for half of the cases with motor neuropathy.",6287825_4,-1,-1,-1,13767,-1,0.0013971578,0.9986028
13769,nutritional deficiency,4,6,29,51,Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.,6287825_5,-1,-1,-1,13769,-1,0.011432736,0.98856723
13770,thiamine,7,8,55,63,Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.,6287825_5,-1,-1,-1,13770,-1,0.9991505,0.0008494455
13771,riboflavin,9,10,68,78,Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.,6287825_5,-1,-1,-1,13771,-1,0.99923337,0.0007666309
13773,Diabetes mellitus,0,2,0,17,Diabetes mellitus was the major cause of autonomic neuropathy.,6287825_6,-1,-1,-1,13773,-1,0.0016288202,0.9983712
13778,cranial neuropathy,11,13,44,62,Migraine (20%) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent (26%).,6287825_8,-1,-1,-1,13778,-1,0.0011711535,0.9988288
13781,connective tissue disorders,2,5,19,46,Heredofamilial and connective tissue disorders were rare.,6287825_10,-1,-1,-1,13781,-1,0.0018960842,0.99810386
13782,neuropathies,13,14,81,93,Some of the factors related to the clinical presentation and pathogenesis of the neuropathies are briefly discussed.,6287825_11,-1,-1,-1,13782,-1,0.0014260265,0.998574
13783,Doxorubicin cardiomyopathy,0,2,0,26,Doxorubicin cardiomyopathy in children with left-sided Wilms tumor.,6292680_0,-1,-1,-1,13783,-1,0.21774091,0.7822591
13784,Wilms tumor,6,8,55,66,Doxorubicin cardiomyopathy in children with left-sided Wilms tumor.,6292680_0,-1,-1,-1,13784,-1,0.0028293487,0.9971706
13785,Wilms tumor,3,5,18,29,Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.,6292680_1,-1,-1,-1,13785,-1,0.002923971,0.99707603
13786,anthracycline cardiomyopathy,11,13,68,96,Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.,6292680_1,-1,-1,-1,13786,-1,0.4974115,0.5025885
13790,Wilms tumor,14,16,79,90,The cardiomyopathy is attributed 1) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2) to the interaction of doxorubicin and irradiation on cardiac muscle.,6292680_2,-1,-1,-1,13790,-1,0.0043856837,0.9956143
13793,Wilms tumor,12,14,81,92,It is recommended that doxorubicin dosage be sharply restricted in children with Wilms tumor of the left kidney who receive postoperative irradiation.,6292680_3,-1,-1,-1,13793,-1,0.003194997,0.9968051
13800,DA,15,16,100,102,Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity.,6293644_4,-1,-1,-1,13800,-1,0.99897087,0.0010291762
13801,DOPAC,17,18,107,112,Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity.,6293644_4,-1,-1,-1,13801,-1,0.9991035,0.0008964959
13803,caffeine toxicity,2,4,13,30,Reduction in caffeine toxicity by acetaminophen.,6308277_0,-1,-1,-1,13803,-1,0.31228855,0.6877115
13805,sodium acetylsalicylate,12,14,89,112,"A patient who allegedly consumed 100 tablets of an over-the-counter analgesic containing sodium acetylsalicylate, caffeine, and acetaminophen displayed no significant CNS stimulation despite the presence of 175 micrograms of caffeine per mL of serum.",6308277_1,-1,-1,-1,13805,-1,0.9991856,0.0008143166
13809,salicylates,1,2,8,19,"Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS toxicity of caffeine.",6308277_2,-1,-1,-1,13809,-1,0.99921227,0.0007877482
13826,pentylenetetrezol,30,31,161,178,"In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).",6308277_5,-1,-1,-1,13826,-1,0.9992793,0.000720678
13829,ATP,16,17,103,106,Acetaminophen (up to 150 micrograms/mL) did not retard the incorporation of radioactive adenosine into ATP in slices of rat cerebral cortex.,6308277_6,-1,-1,-1,13829,-1,0.9989109,0.0010890553
13832,Naloxazone,0,1,0,10,"Naloxazone pretreatment modifies cardiorespiratory, temperature, and behavioral effects of morphine.",6308526_0,-1,-1,-1,13832,-1,0.9992949,0.0007051253
13835,naloxazone,18,19,121,131,"Behavioral and cardiorespiratory responses to a lethal dose of morphine were evaluated in rats pretreated with saline or naloxazone, an antagonist of high-affinity mu 1 opioid receptors.",6308526_1,-1,-1,-1,13835,-1,0.99929297,0.0007070377
13836,naloxazone,2,3,18,28,"Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.",6308526_2,-1,-1,-1,13836,-1,0.99927086,0.000729103
13837,morphine analgesia,5,7,51,69,"Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.",6308526_2,-1,-1,-1,13837,-1,0.48925605,0.5107439
13840,naloxazone,2,3,10,20,"Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.",6308526_3,-1,-1,-1,13840,-1,0.99927443,0.00072562473
13842,respiratory depression,9,11,83,105,"Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.",6308526_3,-1,-1,-1,13842,-1,0.0012164447,0.9987835
13847,NH4Ac,5,6,36,41,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,-1,-1,-1,13847,-1,0.99885,0.0011499603
13848,incoordination,28,29,172,186,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,-1,-1,-1,13848,-1,0.0013821522,0.9986179
13850,NH4Ac,33,34,204,209,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,-1,-1,-1,13850,-1,0.9989807,0.0010192513
13855,mM NH4Ac,21,23,140,148,Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.,6323692_3,-1,-1,-1,13855,-1,0.99798584,0.0020141178
13856,mM NH4Ac,35,37,222,230,Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.,6323692_3,-1,-1,-1,13856,-1,0.9980757,0.0019243173
13860,acetaldehyde,16,17,117,129,"Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.",6323692_4,-1,-1,-1,13860,-1,0.9992211,0.00077885384
13861,NH4Ac,21,22,149,154,"Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.",6323692_4,-1,-1,-1,13861,-1,0.9990767,0.000923266
13862,ammonia,4,5,29,36,These results suggested that ammonia blocks calcium channels.,6323692_5,-1,-1,-1,13862,-1,0.9985043,0.0014956851
13864,NH4Ac,5,6,28,33,Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept.,6323692_6,-1,-1,-1,13864,-1,0.9986375,0.0013625246
13868,NH4Ac,9,10,35,40,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,-1,-1,-1,13868,-1,0.99918574,0.0008142154
13870,muscular incoordination,16,18,104,127,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,-1,-1,-1,13870,-1,0.0015796851,0.99842036
13872,NH4Ac,28,29,206,211,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,-1,-1,-1,13872,-1,0.99921274,0.00078720035
13873,metrazol,34,35,246,254,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,-1,-1,-1,13873,-1,0.99932706,0.00067294197
13876,central nervous system depressants,16,20,108,142,The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics.,6323692_8,-1,-1,-1,13876,-1,0.7654224,0.23457758
13880,dystonic,17,18,108,116,"Levodopa-induced dyskinesia of the limbs in thirteen cases of Parkinsonism, which was choreic, ballistic or dystonic in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.",6381653_1,-1,-1,-1,13880,-1,0.0016810377,0.998319
13882,thalamic lesions,5,7,43,59,Control of levodopa-induced dyskinesias by thalamic lesions in the course of routine treatment of Parkinsonism is discussed.,6381653_2,-1,-1,-1,13882,-1,0.0034964639,0.9965036
13884,dothiepin hydrochloride,9,11,51,74,A double-blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder.,6386793_0,-1,-1,-1,13884,-1,0.99909234,0.00090772705
13885,major depressive disorder,15,18,95,120,A double-blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder.,6386793_0,-1,-1,-1,13885,-1,0.0016720368,0.9983279
13886,dothiepin,8,9,51,60,"In a 6-week double-blind parallel treatment study, dothiepin and amitriptyline were compared to placebo in the treatment of 33 depressed outpatients.",6386793_1,-1,-1,-1,13886,-1,0.9991609,0.000839178
13889,Dothiepin,0,1,0,9,"Dothiepin and amitriptyline were equally effective in alleviating the symptoms of depressive illness, and both were significantly superior to placebo.",6386793_2,-1,-1,-1,13889,-1,0.99919575,0.0008042829
13891,depressive illness,11,13,82,100,"Dothiepin and amitriptyline were equally effective in alleviating the symptoms of depressive illness, and both were significantly superior to placebo.",6386793_2,-1,-1,-1,13891,-1,0.0013906937,0.9986093
13892,blurred vision,12,14,72,86,"The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.",6386793_3,-1,-1,-1,13892,-1,0.0021162988,0.99788374
13894,drowsiness,19,20,103,113,"The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.",6386793_3,-1,-1,-1,13894,-1,0.001354737,0.99864525
13895,dothiepin,24,25,143,152,"The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.",6386793_3,-1,-1,-1,13895,-1,0.9991283,0.0008717049
13897,Dothiepin,0,1,0,9,Dothiepin also produced fewer CNS and cardiovascular effects.,6386793_4,-1,-1,-1,13897,-1,0.99909055,0.00090943545
13898,Dothiepin,0,1,0,9,Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients.,6386793_6,-1,-1,-1,13898,-1,0.99924135,0.0007587005
13904,panic disorder,9,11,64,78,Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia.,6387529_0,-1,-1,-1,13904,-1,0.0014396185,0.99856037
13907,mg,12,13,57,59,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,-1,-1,-1,13907,-1,0.99400216,0.0059978506
13909,mg,31,32,139,141,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,-1,-1,-1,13909,-1,0.99317896,0.0068210172
13910,panic disorders,49,51,233,248,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,-1,-1,-1,13910,-1,0.0015435406,0.9984565
13912,impaired immediate free recall,2,6,11,41,Both drugs impaired immediate free recall but the decrease was greater for diazepam than propranolol.,6387529_2,-1,-1,-1,13912,-1,0.011194117,0.9888059
13915,Delayed free recall,0,3,0,19,Delayed free recall was also impaired but the two drugs did not differ.,6387529_3,-1,-1,-1,13915,-1,0.025940314,0.9740597
13916,impaired,5,6,29,37,Delayed free recall was also impaired but the two drugs did not differ.,6387529_3,-1,-1,-1,13916,-1,0.0038715329,0.99612844
13921,h,11,12,48,49,"After 2 weeks of treatment, patients tested 5-8 h after the last dose of medication did not show any decrement of performance.",6387529_5,-1,-1,-1,13921,-1,0.48124126,0.5187588
13922,behavioral impairment,8,10,53,74,Accumulation of drugs was not reflected in prolonged behavioral impairment.,6387529_7,-1,-1,-1,13922,-1,0.0021122925,0.9978877
13923,urothelial toxicity,3,5,32,51,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,-1,-1,-1,13923,-1,0.0011404598,0.9988595
13924,sodium 2-mercaptoethane sulphonate,9,12,78,112,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,-1,-1,-1,13924,-1,0.9990351,0.00096489553
13926,lung cancer,19,21,149,160,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,-1,-1,-1,13926,-1,0.001477992,0.998522
13927,thiol,8,9,52,57,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,-1,-1,-1,13927,-1,0.9978631,0.0021368482
13928,sodium 2-mercaptoethane sulphonate,10,13,67,101,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,-1,-1,-1,13928,-1,0.9988826,0.0011174344
13930,urothelial toxicity,17,19,118,137,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,-1,-1,-1,13930,-1,0.0019077056,0.99809223
13932,lung cancer,35,37,218,229,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,-1,-1,-1,13932,-1,0.001709106,0.99829084
13934,haematuria,17,18,99,109,Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic haematuria and no episodes of gross haematuria.,6402369_3,-1,-1,-1,13934,-1,0.0014206897,0.99857926
13935,haematuria,23,24,135,145,Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic haematuria and no episodes of gross haematuria.,6402369_3,-1,-1,-1,13935,-1,0.0014150579,0.998585
13937,haematuria,24,25,121,131,"In this group there were 1 complete and 5 partial remissions (total 24%), but nearly all patients developed either gross haematuria and/or symptoms of bladder irritation (cystitis and pollakisuria).",6402369_6,-1,-1,-1,13937,-1,0.0013385586,0.9986614
13938,bladder irritation,28,30,151,169,"In this group there were 1 complete and 5 partial remissions (total 24%), but nearly all patients developed either gross haematuria and/or symptoms of bladder irritation (cystitis and pollakisuria).",6402369_6,-1,-1,-1,13938,-1,0.001625655,0.99837434
13940,pollakisuria,33,34,184,196,"In this group there were 1 complete and 5 partial remissions (total 24%), but nearly all patients developed either gross haematuria and/or symptoms of bladder irritation (cystitis and pollakisuria).",6402369_6,-1,-1,-1,13940,-1,0.0025058624,0.9974941
13945,absence seizures,5,7,23,39,"Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children.",6415512_0,-1,-1,-1,13945,-1,0.0014333951,0.9985667
13954,ceroid lipofuscinosis,12,14,65,86,The child in whom the seizures persisted was later found to have ceroid lipofuscinosis.,6415512_3,-1,-1,-1,13954,-1,0.04563637,0.9543636
13955,prostaglandin,2,3,10,23,Effect of prostaglandin synthetase inhibitors on experimentally induced convulsions in rats.,6433367_0,-1,-1,-1,13955,-1,0.9980539,0.0019460781
13958,PGs,7,8,51,54,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,-1,-1,13958,-1,0.99810386,0.0018961149
13960,PG,17,18,97,99,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,-1,-1,13960,-1,0.99724966,0.0027503385
13962,flurothyl,24,25,148,157,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,-1,-1,13962,-1,0.9993,0.00070003606
13964,pentetrazol,28,29,171,182,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,-1,-1,13964,-1,0.9993057,0.0006943128
13965,PTZ,30,31,184,187,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,-1,-1,13965,-1,0.99896896,0.0010310236
13969,mefenamic acid,4,6,21,35,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,-1,-1,-1,13969,-1,0.99909985,0.00090015674
13970,meclofenamic acid,10,12,50,67,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,-1,-1,-1,13970,-1,0.9992173,0.0007826668
13971,flurothyl,17,18,106,115,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,-1,-1,-1,13971,-1,0.99930596,0.0006940097
13972,PTZ,19,20,123,126,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,-1,-1,-1,13972,-1,0.9986072,0.0013927759
13975,PGs,4,5,27,30,"These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.",6433367_3,-1,-1,-1,13975,-1,0.9981938,0.0018061744
13978,ammonia,4,5,23,30,Acute changes of blood ammonia may predict short-term adverse effects of valproic acid.,6436733_0,-1,-1,-1,13978,-1,0.97757554,0.022424428
13979,valproic acid,11,13,73,86,Acute changes of blood ammonia may predict short-term adverse effects of valproic acid.,6436733_0,-1,-1,-1,13979,-1,0.999199,0.00080104754
13980,Valproic acid,0,2,0,13,Valproic acid (VPA) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs.,6436733_1,-1,-1,-1,13980,-1,0.999064,0.0009360144
13981,VPA,3,4,15,18,Valproic acid (VPA) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs.,6436733_1,-1,-1,-1,13981,-1,0.9990446,0.00095539424
13983,VPA,5,6,31,34,"A standardized loading dose of VPA was administered, and venous blood was sampled at 0, 1, 2, 3, and 4 hours.",6436733_2,-1,-1,-1,13983,-1,0.99910957,0.00089043804
13984,Ammonia,0,1,0,7,"Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.",6436733_3,-1,-1,-1,13984,-1,0.9986137,0.0013862203
13985,NH3,2,3,9,12,"Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.",6436733_3,-1,-1,-1,13985,-1,0.9974642,0.0025358265
13986,drowsiness,16,17,83,93,"Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.",6436733_3,-1,-1,-1,13986,-1,0.0015429315,0.9984571
13987,VPA,33,34,167,170,"Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.",6436733_3,-1,-1,-1,13987,-1,0.9989213,0.0010787515
13988,NH3,6,7,42,45,"By measuring VPA-induced changes of blood NH3 content, it may be possible to identify patients at higher risk of obtundation when VPA is given chronically.",6436733_4,-1,-1,-1,13988,-1,0.9969478,0.0030521513
13989,VPA,22,23,130,133,"By measuring VPA-induced changes of blood NH3 content, it may be possible to identify patients at higher risk of obtundation when VPA is given chronically.",6436733_4,-1,-1,-1,13989,-1,0.9991623,0.0008376988
13996,renal abnormality,6,8,40,57,The possibility of reproducing the same renal abnormality with captopril was examined in SHR.,6454943_2,-1,-1,-1,13996,-1,0.002001559,0.9979984
14002,puromycin aminonucleoside,15,17,107,132,"Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR.",6454943_4,-1,-1,-1,14002,-1,0.99930906,0.0006909029
14007,body weight,24,26,160,171,"Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption.",6454943_5,-1,-1,-1,14007,-1,0.08184901,0.918151
14008,ketone bodies,2,4,9,22,"However, ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR.",6454943_6,-1,-1,-1,14008,-1,0.99811256,0.0018874301
14027,heart block,1,3,9,20,Complete heart block following a single dose of trazodone.,6496797_0,-1,-1,-1,14027,-1,0.0024322523,0.9975677
14028,trazodone,8,9,48,57,Complete heart block following a single dose of trazodone.,6496797_0,-1,-1,-1,14028,-1,0.99915063,0.0008493565
14029,trazodone,9,10,56,65,"Forty minutes after receiving a single starting dose of trazodone, a patient developed complete heart block.",6496797_1,-1,-1,-1,14029,-1,0.999198,0.0008019709
14030,heart block,15,17,96,107,"Forty minutes after receiving a single starting dose of trazodone, a patient developed complete heart block.",6496797_1,-1,-1,-1,14030,-1,0.0019377255,0.9980623
14031,trazodone,12,13,67,76,"The case illustrates that, despite the results of earlier studies, trazodone's effect on cardiac conduction may be severe in individuals at risk for conduction delay.",6496797_2,-1,-1,-1,14031,-1,0.9991536,0.0008463342
14032,delay,27,28,160,165,"The case illustrates that, despite the results of earlier studies, trazodone's effect on cardiac conduction may be severe in individuals at risk for conduction delay.",6496797_2,-1,-1,-1,14032,-1,0.0017444545,0.99825555
14034,dacarbazine,4,5,35,46,Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.,6503301_0,-1,-1,-1,14034,-1,0.9990422,0.0009578167
14035,DTIC,7,8,56,60,Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.,6503301_0,-1,-1,-1,14035,-1,0.0033731223,0.99662685
14036,melanoma,10,11,66,74,Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.,6503301_0,-1,-1,-1,14036,-1,0.0020788326,0.99792117
14037,dacarbazine,12,13,71,82,A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.,6503301_1,-1,-1,-1,14037,-1,0.9990996,0.0009004064
14038,DTIC,14,15,84,88,A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.,6503301_1,-1,-1,-1,14038,-1,0.9981262,0.0018737501
14039,melanoma,18,19,102,110,A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.,6503301_1,-1,-1,-1,14039,-1,0.0019068713,0.99809307
14041,venous congestion,11,13,57,74,At autopsy the liver was enlarged and firm with signs of venous congestion.,6503301_3,-1,-1,-1,14041,-1,0.0023515811,0.9976484
14043,Eosinophilic,0,1,0,12,Eosinophilic infiltrations were found around the vessels.,6503301_5,-1,-1,-1,14043,-1,0.0039769947,0.99602294
14045,neurologic impairment,5,7,30,51,A 2-year-old child with known neurologic impairment developed a dyskinesia soon after starting phenobarbital therapy for seizures.,6504332_1,-1,-1,-1,14045,-1,0.0010700659,0.9989299
14049,movement disorders,3,5,16,34,Known causes of movement disorders were eliminated after evaluation.,6504332_2,-1,-1,-1,14049,-1,0.0016295586,0.99837047
14053,movement disorders,13,15,81,99,Phenobarbital should be added to the list of anticonvulsant drugs that can cause movement disorders.,6504332_4,-1,-1,-1,14053,-1,0.0015267885,0.9984732
14055,Ebstein's anomaly,4,7,30,47,Maternal lithium and neonatal Ebstein's anomaly: evaluation with cross-sectional echocardiography.,6518066_0,-1,-1,-1,14055,-1,0.0027364306,0.99726355
14057,Ebstein's anomaly,4,7,15,32,"In one infant, Ebstein's anomaly of the tricuspid valve was identified.",6518066_2,-1,-1,-1,14057,-1,0.004247881,0.9957521
14058,Ebstein's anomaly,14,17,103,120,In the other infant cross-sectional echocardiography provided reassurance that the infant did not have Ebstein's anomaly.,6518066_3,-1,-1,-1,14058,-1,0.0046548005,0.9953452
14060,cardiac malformations,24,26,190,211,"Cross-sectional echocardiographic screening of newborns exposed to lithium during gestation can provide highly accurate, noninvasive assessment of the presence or absence of lithium-induced cardiac malformations.",6518066_4,-1,-1,-1,14060,-1,0.0015837061,0.9984163
14061,myocardial infarction,8,10,50,71,Effects of training on the extent of experimental myocardial infarction in aging rats.,6534871_0,-1,-1,-1,14061,-1,0.00152271,0.9984773
14062,myocardial infarction,9,11,65,86,"The effects of exercise on the severity of isoproterenol-induced myocardial infarction were studied in female albino rats of 20,40,60 and 80 weeks of age.",6534871_1,-1,-1,-1,14062,-1,0.0013896696,0.99861026
14063,infarcts,3,4,18,26,The occurrence of infarcts were confirmed by histological methods.,6534871_3,-1,-1,-1,14063,-1,0.0018961942,0.99810374
14064,myocardial infarction,3,5,21,42,Studies dealing with myocardial infarction are more informative when dealt with age.,6534871_7,-1,-1,-1,14064,-1,0.0020286834,0.99797136
14066,adriamycin toxicity,6,8,37,56,Effect of polyethylene glycol 400 on adriamycin toxicity in mice.,6538499_0,-1,-1,-1,14066,-1,0.70912725,0.29087275
14068,PEG,13,14,70,73,"The effect of a widely used organic solvent, polyethylene glycol 400 (PEG 400), on the toxic action of an acute or chronic treatment with adriamycin (ADR) was evaluated in mice.",6538499_1,-1,-1,-1,14068,-1,0.99860126,0.001398805
14070,ADR,30,31,150,153,"The effect of a widely used organic solvent, polyethylene glycol 400 (PEG 400), on the toxic action of an acute or chronic treatment with adriamycin (ADR) was evaluated in mice.",6538499_1,-1,-1,-1,14070,-1,0.9576761,0.042323876
14071,PEG 400,0,2,0,7,PEG 400 impressively decreased both acute high-dose and chronic low-dose-ADR-associated lethality.,6538499_2,-1,-1,-1,14071,-1,0.9988311,0.0011688945
14072,cardiac morphological alterations,9,12,79,112,Light microscopic analysis showed a significant protection against ADR-induced cardiac morphological alterations.,6538499_3,-1,-1,-1,14072,-1,0.0020356365,0.9979644
14073,ADR,6,7,36,39,Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor.,6538499_4,-1,-1,-1,14073,-1,0.9963547,0.0036452627
14074,L1210 leukemia,10,12,62,76,Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor.,6538499_4,-1,-1,-1,14074,-1,0.06518039,0.9348196
14075,Ehrlich ascites tumor,14,17,84,105,Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor.,6538499_4,-1,-1,-1,14075,-1,0.0045915656,0.99540836
14076,amine,2,3,11,16,Effects of amine pretreatment on ketamine catatonia in pinealectomized or hypophysectomized animals.,6540303_0,-1,-1,-1,14076,-1,0.99902093,0.0009790363
14077,ketamine catatonia,5,7,33,51,Effects of amine pretreatment on ketamine catatonia in pinealectomized or hypophysectomized animals.,6540303_0,-1,-1,-1,14077,-1,0.09213813,0.9078618
14079,catatonia,16,17,114,123,"The present studies were designed to clarify the role of catecholamines and pineal idolamines on ketamine-induced catatonia in the intact, pinealectomized or hypophysectomized chick and rat.",6540303_1,-1,-1,-1,14079,-1,0.0016412118,0.9983588
14081,catatonia,12,13,83,92,"In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.",6540303_2,-1,-1,-1,14081,-1,0.0016495106,0.9983505
14082,DOC,14,15,94,97,"In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.",6540303_2,-1,-1,-1,14082,-1,0.99851555,0.001484485
14088,melatonin,22,23,121,130,"Serotonin and N-acetyl serotonin which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick.",6540303_4,-1,-1,-1,14088,-1,0.99889696,0.001102995
14091,melatonin,22,23,132,141,"Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent; furthermore, melatonin did not augment the ketamine DOC whereas dopamine continued to do so.",6540303_5,-1,-1,-1,14091,-1,0.9990256,0.0009744184
14094,amines,13,14,78,84,This study did not demonstrate a species difference regarding the role of the amines on the pineal in spite of the immature blood-brain barrier in the young chick and the intact barrier in the rat.,6540303_6,-1,-1,-1,14094,-1,0.9984646,0.0015354817
14096,melatonin,20,21,111,120,"In addition, these data indicate a direct role of the pituitary in the augmentation of ketamine DOC induced by melatonin.",6540303_7,-1,-1,-1,14096,-1,0.99905235,0.0009476484
14098,ketamine catatonia,15,17,93,111,"Furthermore, dopamine appeared to act on systems more closely involved with the induction of ketamine catatonia rather than directly on the pituitary.",6540303_8,-1,-1,-1,14098,-1,0.09007135,0.9099287
14115,Ventricular fibrillation,0,2,0,24,Ventricular fibrillation from diatrizoate with and without chelating agents.,663266_0,-1,-1,-1,14115,-1,0.001512263,0.9984877
14116,diatrizoate,3,4,30,41,Ventricular fibrillation from diatrizoate with and without chelating agents.,663266_0,-1,-1,-1,14116,-1,0.99903524,0.00096481235
14117,chelating agents,7,9,59,75,Ventricular fibrillation from diatrizoate with and without chelating agents.,663266_0,-1,-1,-1,14117,-1,0.9979905,0.0020094612
14119,Renografin,3,4,16,26,The toxicity of Renografin 76% was compared with that of Hypaque 76% by selective injection of each into the right coronary artery of dogs.,663266_1,-1,-1,-1,14119,-1,0.9986473,0.0013527987
14120,Hypaque,11,12,57,64,The toxicity of Renografin 76% was compared with that of Hypaque 76% by selective injection of each into the right coronary artery of dogs.,663266_1,-1,-1,-1,14120,-1,0.99660826,0.0033917686
14121,Renografin,0,1,0,10,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,-1,-1,-1,14121,-1,0.99647313,0.003526837
14122,chelating agents sodium citrate,3,7,24,55,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,-1,-1,-1,14122,-1,0.99615,0.0038499776
14123,disodium edetate,8,10,60,76,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,-1,-1,-1,14123,-1,0.9990189,0.0009810976
14124,Hypaque,12,13,84,91,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,-1,-1,-1,14124,-1,0.9954242,0.0045758076
14125,calcium disodium edetate,14,17,101,125,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,-1,-1,-1,14125,-1,0.9989221,0.0010778644
14127,Ventricular fibrillation,0,2,0,24,"Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography.",663266_3,-1,-1,-1,14127,-1,0.0013849416,0.998615
14128,Renografin,7,8,64,74,"Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography.",663266_3,-1,-1,-1,14128,-1,0.9972046,0.002795379
14129,chelating agents,11,13,92,108,"Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography.",663266_3,-1,-1,-1,14129,-1,0.99751735,0.0024826901
14131,quaternary ammonium,4,6,29,48,"Sublingual absorption of the quaternary ammonium antiarrhythmic agent, UM-272.UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.",6634932_0,-1,-1,-1,14131,-1,0.9987876,0.0012124134
14132,ventricular tachycardias,28,30,206,230,"Sublingual absorption of the quaternary ammonium antiarrhythmic agent, UM-272.UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.",6634932_0,-1,-1,-1,14132,-1,0.0014524064,0.9985476
14133,UM-272,1,2,11,17,Sublingual UM-272 converted ventricular tachycardia to sinus rhythm in all 5 dogs.,6634932_2,-1,-1,-1,14133,-1,0.99854624,0.0014537789
14138,ventricular fibrillation,12,14,95,119,Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.,6637851_0,-1,-1,-1,14138,-1,0.0012775449,0.9987224
14141,VT,14,15,100,102,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,-1,-1,-1,14141,-1,0.0012470424,0.99875295
14142,n,17,18,105,106,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,-1,-1,-1,14142,-1,0.0117578795,0.9882421
14144,n,26,27,135,136,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,-1,-1,-1,14144,-1,0.007011217,0.99298877
14146,VT,14,15,104,106,Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).,6637851_3,-1,-1,-1,14146,-1,0.0013336266,0.9986664
14147,ventricular fibrillation,16,18,110,134,Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).,6637851_3,-1,-1,-1,14147,-1,0.0013768518,0.99862313
14148,VF,19,20,136,138,Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).,6637851_3,-1,-1,-1,14148,-1,0.0015473327,0.99845266
14149,VT,10,11,57,59,Six percent of the patients had a nonfatal recurrence of VT and were successfully managed by continuing amiodarone at a higher dose or by the addition of a conventional antiarrhythmic drug.,6637851_4,-1,-1,-1,14149,-1,0.0013171324,0.9986829
14151,adverse drug reactions,3,6,12,34,One or more adverse drug reactions occurred in 51% of patients.,6637851_5,-1,-1,-1,14151,-1,0.0021622623,0.9978377
14157,anorexia,17,18,86,94,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,-1,-1,14157,-1,0.0012971874,0.99870276
14158,visual halos,23,25,101,113,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,-1,-1,14158,-1,0.0016979139,0.9983021
14159,blurring,26,27,117,125,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,-1,-1,14159,-1,0.0014630563,0.99853694
14160,thyroid function abnormalities,32,35,132,162,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,-1,-1,14160,-1,0.0074597113,0.9925403
14161,pulmonary interstitial infiltrates,40,43,172,206,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,-1,-1,14161,-1,0.0014500832,0.9985499
14163,VT,11,12,81,83,"Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.",6637851_8,-1,-1,-1,14163,-1,0.0012625279,0.9987375
14164,VF,13,14,87,89,"Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.",6637851_8,-1,-1,-1,14164,-1,0.0012889071,0.9987111
14166,VT,23,24,122,124,"However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with VT or VF can be successfully managed with amiodarone.",6637851_9,-1,-1,-1,14166,-1,0.0013292707,0.9986707
14167,VF,25,26,128,130,"However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with VT or VF can be successfully managed with amiodarone.",6637851_9,-1,-1,-1,14167,-1,0.0013547285,0.99864525
14170,bladder carcinoma,5,7,41,58,Early adjuvant adriamycin in superficial bladder carcinoma.,6640832_0,-1,-1,-1,14170,-1,0.0019777578,0.9980222
14171,transitional cell carcinoma,10,13,67,94,A multicenter study was performed in 110 patients with superficial transitional cell carcinoma of the bladder.,6640832_1,-1,-1,-1,14171,-1,0.0037766728,0.99622333
14173,h,11,12,67,68,Adriamycin (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors.,6640832_2,-1,-1,-1,14173,-1,0.1105864,0.88941354
14174,bladder tumors,20,22,114,128,Adriamycin (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors.,6640832_2,-1,-1,-1,14174,-1,0.002648103,0.9973519
14178,angiopathy,1,2,24,34,D-penicillamine-induced angiopathy in rats.,6666578_0,-1,-1,-1,14178,-1,0.0010352486,0.9989648
14179,hyaluronate,43,44,264,275,"The aorta/serum-ratio and the radioactive build-up 24 and 48 hours after injection of 131I-HSA was reduced in animals treated with D-pen for 42 days, indicating an impeded transmural transport of tracer which may be caused by a steric exclusion effect of abundant hyaluronate.",6666578_8,-1,-1,-1,14179,-1,0.9991685,0.00083155796
14180,EACA,5,6,35,39,Why may epsilon-aminocaproic acid (EACA) induce myopathy in man? Report of a case and literature review.,6674249_0,-1,-1,-1,14180,-1,0.004718795,0.99528116
14183,EACA,12,13,73,77,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,-1,-1,-1,14183,-1,0.99440837,0.0055916905
14184,subarachnoid haemorrhage,21,23,119,143,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,-1,-1,-1,14184,-1,0.0014255965,0.9985744
14185,SAH,24,25,145,148,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,-1,-1,-1,14185,-1,0.0012575076,0.9987425
14188,N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide,5,6,38,83,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,-1,14188,-1,0.9984523,0.0015476997
14189,N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide,5,6,38,83,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,-1,14189,-1,0.9984523,0.0015476997
14190,N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide,5,6,38,83,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,-1,14190,-1,0.9984523,0.0015476997
14191,N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide,5,6,38,83,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,-1,14191,-1,0.9984523,0.0015476997
14192,N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide,5,6,38,83,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,-1,14192,-1,0.9984523,0.0015476997
14193,FANFT,7,8,85,90,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,-1,14193,-1,0.9986027,0.0013973356
14194,bladder carcinomas,18,20,149,167,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,-1,14194,-1,0.0018053717,0.99819463
14195,forestomach tumors,25,27,199,217,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,-1,14195,-1,0.006153374,0.9938466
14196,FANFT,12,13,79,84,An autoradiographic study was performed on male F-344 rats fed diet containing FANFT at a level of 0.2% and/or aspirin at a level of 0.5% to evaluate the effect of aspirin on the increased cell proliferation induced by FANFT in the forestomach and bladder.,6692345_2,-1,-1,-1,14196,-1,0.9985019,0.0014981277
14199,FANFT,40,41,219,224,An autoradiographic study was performed on male F-344 rats fed diet containing FANFT at a level of 0.2% and/or aspirin at a level of 0.5% to evaluate the effect of aspirin on the increased cell proliferation induced by FANFT in the forestomach and bladder.,6692345_2,-1,-1,-1,14199,-1,0.99852115,0.0014788883
14202,FANFT carcinogenesis,16,18,124,144,"The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.",6692345_5,-1,-1,-1,14202,-1,0.183553,0.81644696
14204,FANFT,30,31,206,211,"The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.",6692345_5,-1,-1,-1,14204,-1,0.9587474,0.041252613
14206,Cerebral hemorrhage,0,2,0,19,Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine.,6695415_0,-1,-1,-1,14206,-1,0.001368327,0.99863166
14207,phenylpropanolamine,4,5,36,55,Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine.,6695415_0,-1,-1,-1,14207,-1,0.9992022,0.00079777493
14209,Phenylpropanolamine,0,1,0,19,Phenylpropanolamine (PPA) is a drug that has been associated with serious side effects including stroke.,6695415_1,-1,-1,-1,14209,-1,0.9991708,0.0008292644
14210,PPA,2,3,21,24,Phenylpropanolamine (PPA) is a drug that has been associated with serious side effects including stroke.,6695415_1,-1,-1,-1,14210,-1,0.9978682,0.002131808
14213,lead,7,8,42,46,"In order to determine if PPA/caffeine can lead to stroke in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.",6695415_3,-1,-1,-1,14213,-1,0.0060682828,0.9939318
14216,cerebral hemorrhage,2,4,17,36,Subarachnoid and cerebral hemorrhage was noted in 18% of the hypertensive rats.,6695415_4,-1,-1,-1,14216,-1,0.0015223215,0.99847764
14218,lead,8,9,49,53,A single PPA/caffeine administration (same dose) lead to acute hypertension in both the normotensive and hypertensive animals.,6695415_5,-1,-1,-1,14218,-1,0.019906938,0.9800931
14221,lead,6,7,44,48,These results suggest that PPA/caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage.,6695415_6,-1,-1,-1,14221,-1,0.0041084406,0.9958916
14222,cerebral hemorrhage,8,10,52,71,These results suggest that PPA/caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage.,6695415_6,-1,-1,-1,14222,-1,0.0011725131,0.9988275
14224,elevation in blood pressure,2,6,9,36,An acute elevation in blood pressure may be a contributing factor.,6695415_7,-1,-1,-1,14224,-1,0.008195651,0.99180436
14226,naproxen,5,6,32,40,Renal papillary necrosis due to naproxen.,6699841_0,-1,-1,-1,14226,-1,0.99916315,0.00083691487
14229,fenoprofen calcium,15,17,92,110,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,-1,-1,14229,-1,0.9991767,0.00082332763
14230,salicylates,20,21,122,133,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,-1,-1,14230,-1,0.9991886,0.00081138336
14231,gold salts,22,24,138,148,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,-1,-1,14231,-1,0.99898547,0.0010144785
14233,RPN,30,31,186,189,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,-1,-1,14233,-1,0.001648635,0.99835134
14234,naproxen,37,38,221,229,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,-1,-1,14234,-1,0.9993193,0.00068072655
14235,RPN,5,6,32,35,No other factor predisposing to RPN could be discovered.,6699841_2,-1,-1,-1,14235,-1,0.0024922453,0.9975077
14237,naproxen,4,5,29,37,Sulindac was substituted for naproxen and no further adverse renal effects occurred over the next 12 months.,6699841_3,-1,-1,-1,14237,-1,0.99926096,0.00073897303
14238,RPN,5,6,35,38,We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents.,6699841_4,-1,-1,-1,14238,-1,0.0014601002,0.9985399
14241,tardive dyskinesia,3,5,10,28,A case of tardive dyskinesia caused by metoclopramide.,6727060_0,-1,-1,-1,14241,-1,0.0010991415,0.9989009
14243,Abnormal involuntary movements,0,3,0,30,"Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.",6727060_1,-1,-1,-1,14243,-1,0.0020468573,0.99795306
14245,gastrointestinal disorder,23,25,142,167,"Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.",6727060_1,-1,-1,-1,14245,-1,0.001379823,0.99862015
14246,mg,30,31,187,189,"Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.",6727060_1,-1,-1,-1,14246,-1,0.99520737,0.0047926125
14248,abnormal movements,8,10,61,79,"When the metoclopramide administration was discontinued, the abnormal movements gradually improved to a considerable extent.",6727060_3,-1,-1,-1,14248,-1,0.00163206,0.99836797
14249,tardive dyskinesia,7,9,48,66,Attention to the possible induction of specific tardive dyskinesia is called for in the use of this drug.,6727060_4,-1,-1,-1,14249,-1,0.0010965592,0.9989034
14252,protein,7,8,57,64,Nephrotoxic effects of aminoglycoside treatment on renal protein reabsorption and accumulation.,6728084_0,-1,-1,-1,14252,-1,0.9933729,0.006627041
14255,netilmicin,9,10,53,63,"To quantify the effects of gentamicin, kanamycin and netilmicin on renal protein reabsorption and accumulation, these drugs were administered to rats intraperitoneally (30 mg/kg/day) for 7, 14 or 21 days.",6728084_1,-1,-1,-1,14255,-1,0.99913114,0.0008688689
14256,protein,12,13,73,80,"To quantify the effects of gentamicin, kanamycin and netilmicin on renal protein reabsorption and accumulation, these drugs were administered to rats intraperitoneally (30 mg/kg/day) for 7, 14 or 21 days.",6728084_1,-1,-1,-1,14256,-1,0.9940348,0.0059652575
14261,netilmicin,2,3,14,24,Kanamycin and netilmicin appeared to have no effect at the dose used.,6728084_5,-1,-1,-1,14261,-1,0.9989796,0.0010203478
14267,netilmicin,4,5,37,47,administration of egg-white lysozyme netilmicin had no effect.,6728084_8,-1,-1,-1,14267,-1,0.9987085,0.001291532
14271,nephrotoxicants,6,7,33,48,"Thus, aminoglycosides may act as nephrotoxicants at glomerular and/or tubular level inducing impairment of renal reabsorption and accumulation of proteins.",6728084_10,-1,-1,-1,14271,-1,0.025908243,0.9740917
14272,obstructive sleep apnea syndrome,3,7,17,49,Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration.,6732043_0,-1,-1,-1,14272,-1,0.0012644966,0.9987355
14273,androgen,12,13,74,82,Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration.,6732043_0,-1,-1,-1,14273,-1,0.99886525,0.0011347958
14274,syndrome of obstructive sleep apnea,25,30,167,202,We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens.,6732043_1,-1,-1,-1,14274,-1,0.0015659715,0.998434
14275,androgens,34,35,238,247,We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens.,6732043_1,-1,-1,-1,14275,-1,0.99894816,0.0010518889
14276,androgens,2,3,9,18,"When the androgens were withdrawn, the patient's physical changes, symptoms, sleep study, and supraglottic resistance all returned to normal.",6732043_2,-1,-1,-1,14276,-1,0.9986349,0.0013650728
14277,androgen,3,4,19,27,A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.,6732043_3,-1,-1,-1,14277,-1,0.99875176,0.001248173
14278,obstructive sleep apnea,7,10,49,72,A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.,6732043_3,-1,-1,-1,14278,-1,0.0012179915,0.998782
14279,androgens,7,8,40,49,Previous reports have favored a role of androgens in the pathogenesis of sleep apnea.,6732043_4,-1,-1,-1,14279,-1,0.99867344,0.0013266173
14280,sleep apnea,12,14,73,84,Previous reports have favored a role of androgens in the pathogenesis of sleep apnea.,6732043_4,-1,-1,-1,14280,-1,0.0015323164,0.9984676
14281,androgens,6,7,53,62,Structural and functional measurements indicate that androgens exert a permissive or necessary action on the structural configuration of the oropharynx that predisposes to obstruction during sleep.,6732043_6,-1,-1,-1,14281,-1,0.9987513,0.0012486951
14282,obstructive sleep apnea syndrome,3,7,19,51,Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy.,6732043_7,-1,-1,-1,14282,-1,0.0013794893,0.9986205
14283,androgen,15,16,97,105,Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy.,6732043_7,-1,-1,-1,14283,-1,0.99891484,0.0010851693
14284,BCNU,1,2,15,19,Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.,6747681_0,-1,-1,-1,14284,-1,0.9970655,0.002934561
14285,malignant gliomas,6,8,50,67,Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.,6747681_0,-1,-1,-1,14285,-1,0.0020164386,0.9979836
14286,BCNU,7,8,43,47,"Because of the rapid systemic clearance of BCNU (1,3-bis-(2-chloroethyl)-1-nitrosourea), intra-arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas.",6747681_1,-1,-1,-1,14286,-1,0.9981115,0.0018885623
14288,malignant gliomas,26,28,211,228,"Because of the rapid systemic clearance of BCNU (1,3-bis-(2-chloroethyl)-1-nitrosourea), intra-arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas.",6747681_1,-1,-1,-1,14288,-1,0.0017717826,0.99822825
14289,BCNU,5,6,38,42,"Thirty-six patients were treated with BCNU every 6 to 8 weeks, either by transfemoral catheterization of the internal carotid or vertebral artery or through a fully implantable intracarotid drug delivery system, beginning with a dose of 200 mg/sq m body surface area.",6747681_2,-1,-1,-1,14289,-1,0.99363285,0.006367223
14290,astrocytomas,7,8,37,49,Twelve patients with Grade III or IV astrocytomas were treated after partial resection of the tumor without prior radiation therapy.,6747681_3,-1,-1,-1,14290,-1,0.0017479921,0.998252
14294,astrocytomas,8,9,50,62,"Twenty-four patients with recurrent Grade I to IV astrocytomas, whose resection and irradiation therapy had failed, received two to eight courses of intra-arterial BCNU therapy.",6747681_7,-1,-1,-1,14294,-1,0.0020552021,0.9979448
14295,BCNU,25,26,164,168,"Twenty-four patients with recurrent Grade I to IV astrocytomas, whose resection and irradiation therapy had failed, received two to eight courses of intra-arterial BCNU therapy.",6747681_7,-1,-1,-1,14295,-1,0.9968867,0.003113349
14296,BCNU,14,15,90,94,"The catheterization procedure is safe, with no immediate complication in 111 infusions of BCNU.",6747681_9,-1,-1,-1,14296,-1,0.25025496,0.7497451
14297,loss of vision,9,12,60,74,A delayed complication in nine patients has been unilateral loss of vision secondary to a retinal vasculitis.,6747681_10,-1,-1,-1,14297,-1,0.0025601475,0.99743986
14298,retinal vasculitis,15,17,90,108,A delayed complication in nine patients has been unilateral loss of vision secondary to a retinal vasculitis.,6747681_10,-1,-1,-1,14298,-1,0.0012963192,0.9987037
14304,congestive heart failure,6,9,30,54,8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man.,6769133_1,-1,-1,-1,14304,-1,0.0012352667,0.99876475
14306,myocardial lesions,3,5,20,38,"Histologically, the myocardial lesions resembled those found in human anthracycline-induced cardiomyopathy.",6769133_2,-1,-1,-1,14306,-1,0.002119716,0.99788034
14308,acute myeloblastic leukemia,6,9,30,57,1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.,6769133_3,-1,-1,-1,14308,-1,0.0011477744,0.99885225
14311,leukemia,18,19,98,106,"Our results suggest that adriamycin is a more potent cardiotoxin in monkeys than in man, and that leukemia may be a consequence of prolonged treatment with this drug.",6769133_4,-1,-1,-1,14311,-1,0.001419197,0.9985808
14312,postural hypotension,2,4,15,35,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,-1,-1,-1,14312,-1,0.0015301199,0.9984699
14314,diabetic autonomic neuropathy?The,7,10,56,89,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,-1,-1,-1,14314,-1,0.013676864,0.9863231
14325,vasodilator drugs,11,13,76,93,"It is therefore suggested that caution should be exercised when prescribing vasodilator drugs in diabetic patients, particularly those with autonomic neuropathy.",6773726_2,-1,-1,-1,14325,-1,0.99472445,0.0052754777
14328,Tricuspid valve regurgitation,0,3,0,29,Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant.,6794356_0,-1,-1,-1,14328,-1,0.0026634387,0.99733657
14329,lithium carbonate toxicity,4,7,34,60,Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant.,6794356_0,-1,-1,-1,14329,-1,0.5173121,0.4826879
14330,tricuspid regurgitation,4,6,23,46,"A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.",6794356_1,-1,-1,-1,14330,-1,0.0016898778,0.9983101
14331,atrial flutter,7,9,48,62,"A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.",6794356_1,-1,-1,-1,14331,-1,0.0013177871,0.9986822
14332,congestive heart failure,10,13,64,88,"A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.",6794356_1,-1,-1,-1,14332,-1,0.0012251314,0.9987748
14334,tricuspid regurgitation,8,10,48,71,"This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.",6794356_2,-1,-1,-1,14334,-1,0.0018205956,0.99817944
14335,atrial flutter,11,13,76,90,"This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.",6794356_2,-1,-1,-1,14335,-1,0.0014682414,0.9985317
14336,cardiac disease,20,22,128,143,"This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.",6794356_2,-1,-1,-1,14336,-1,0.0013366198,0.9986634
14338,Lithium carbonate,0,2,0,17,Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy.,6794356_4,-1,-1,-1,14338,-1,0.99899143,0.0010085376
14339,congenital heart disease,11,14,65,89,Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy.,6794356_4,-1,-1,-1,14339,-1,0.0016944928,0.99830544
14340,neurologic depression,3,5,15,36,"It also causes neurologic depression, cyanosis, and cardiac arrhythmia when consumed prior to delivery.",6794356_5,-1,-1,-1,14340,-1,0.0011970424,0.9988029
14341,cyanosis,6,7,38,46,"It also causes neurologic depression, cyanosis, and cardiac arrhythmia when consumed prior to delivery.",6794356_5,-1,-1,-1,14341,-1,0.0012398339,0.9987602
14342,cardiac arrhythmia,9,11,52,70,"It also causes neurologic depression, cyanosis, and cardiac arrhythmia when consumed prior to delivery.",6794356_5,-1,-1,-1,14342,-1,0.0013261449,0.9986739
14343,aniracetam,5,6,30,40,Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.,6817363_0,-1,-1,-1,14343,-1,0.9990429,0.00095701666
14344,Ro 13-5057,7,11,42,52,Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.,6817363_0,-1,-1,-1,14344,-1,0.99858356,0.0014164129
14345,aniracetam,3,4,14,24,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14345,-1,0.9991953,0.00080467423
14346,Ro 13-5057,5,9,26,36,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14346,-1,0.99872106,0.0012789627
14347,1-anisoyl-2-pyrrolidinone,10,11,38,63,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14347,-1,0.9988048,0.0011951358
14348,impaired cognitive functions,19,22,112,140,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14348,-1,0.0037065202,0.9962935
14349,hypercapnia,55,56,324,335,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14349,-1,0.0050133714,0.99498665
14353,chloramphenicol,130,131,781,796,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14353,-1,0.9991659,0.0008341773
14355,h,149,150,903,904,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14355,-1,0.48270014,0.5172999
14357,hypercapnia,197,198,1178,1189,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14357,-1,0.028931027,0.9710689
14358,h,205,206,1239,1240,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14358,-1,0.16672167,0.83327836
14359,impaired cognitive functions,5,8,40,68,These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.,6817363_2,-1,-1,-1,14359,-1,0.0028334376,0.9971666
14360,aniracetam,12,13,87,97,These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.,6817363_2,-1,-1,-1,14360,-1,0.99905187,0.00094807014
14361,aniracetam,6,7,42,52,The mechanisms underlying the activity of aniracetam and its 'therapeutic window' are unknown.,6817363_4,-1,-1,-1,14361,-1,0.9989355,0.0010644961
14362,Piracetam,0,1,0,9,"Piracetam, another pyrrolidinone derivative was used for comparison.",6817363_5,-1,-1,-1,14362,-1,0.9992735,0.0007264875
14363,pyrrolidinone,3,4,19,32,"Piracetam, another pyrrolidinone derivative was used for comparison.",6817363_5,-1,-1,-1,14363,-1,0.9990815,0.0009185568
14364,aniracetam,16,17,79,89,It was active only in six of nine tests and had about one-tenth the potency of aniracetam.,6817363_6,-1,-1,-1,14364,-1,0.99906427,0.0009357968
14365,aniracetam,4,5,26,36,The results indicate that aniracetam improves cognitive functions which are impaired by different procedure and in different phases of the learning and memory process.,6817363_7,-1,-1,-1,14365,-1,0.9990885,0.00091152964
14367,Sodium chloride,0,2,0,15,"Sodium chloride solution (0.9%) or noradrenaline in doses of 4, 12 and 36 micrograms h-1 kg-1 was infused for five consecutive days, either intrarenally (by a new technique) or intravenously into rats with one kidney removed.",6861444_1,-1,-1,-1,14367,-1,0.99913603,0.0008639823
14378,adenohypophyseal tumors,3,5,37,60,Characterization of estrogen-induced adenohypophyseal tumors in the Fischer 344 rat.,6888657_0,-1,-1,-1,14378,-1,0.005606388,0.9943936
14379,Pituitary tumors,0,2,0,16,"Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.",6888657_1,-1,-1,-1,14379,-1,0.0025821172,0.9974179
14381,DES,14,15,96,99,"Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.",6888657_1,-1,-1,-1,14381,-1,0.998939,0.001060992
14382,mg,19,20,106,108,"Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.",6888657_1,-1,-1,-1,14382,-1,0.9878806,0.012119376
14383,DES,9,10,30,33,"Over a range of 1-150 days of DES treatment, pairs of control and DES-treated rats were sacrificed, and their pituitaries dissociated enzymatically into single-cell preparations.",6888657_2,-1,-1,-1,14383,-1,0.99887854,0.0011214538
14384,prolactin,15,16,109,118,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,-1,-1,-1,14384,-1,0.9988349,0.001165131
14385,PRL,17,18,120,123,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,-1,-1,-1,14385,-1,0.9985902,0.0014097918
14386,PRL,28,29,195,198,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,-1,-1,-1,14386,-1,0.9986247,0.0013753781
14387,acriflavine,51,52,340,351,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,-1,-1,-1,14387,-1,0.99908876,0.0009112022
14388,PRL,1,2,14,17,"Intracellular PRL content ranged from 1.9 to 9.4 times control levels, and PRL release in vitro was significantly and consistently higher than controls, after at least 8 days of DES exposure.",6888657_5,-1,-1,-1,14388,-1,0.9982022,0.0017977725
14389,PRL,13,14,75,78,"Intracellular PRL content ranged from 1.9 to 9.4 times control levels, and PRL release in vitro was significantly and consistently higher than controls, after at least 8 days of DES exposure.",6888657_5,-1,-1,-1,14389,-1,0.99820757,0.0017923912
14390,DES,31,32,178,181,"Intracellular PRL content ranged from 1.9 to 9.4 times control levels, and PRL release in vitro was significantly and consistently higher than controls, after at least 8 days of DES exposure.",6888657_5,-1,-1,-1,14390,-1,0.9989157,0.0010843452
14391,DES,4,5,17,20,"Beyond 8 days of DES exposure, the immunochemically PRL-positive proportion of cells increased to over 50% of the total population.",6888657_6,-1,-1,-1,14391,-1,0.9988674,0.0011325948
14392,PRL,5,6,34,37,Increased density and/or size and PRL content were indicated for the majority of the PRL cell population in both types of separation protocols.,6888657_7,-1,-1,-1,14392,-1,0.99705553,0.0029444413
14393,PRL,14,15,85,88,Increased density and/or size and PRL content were indicated for the majority of the PRL cell population in both types of separation protocols.,6888657_7,-1,-1,-1,14393,-1,0.99607736,0.0039226618
14394,DES,4,5,21,24,All these effects of DES were more pronounced among previously ovariectomized animals.,6888657_8,-1,-1,-1,14394,-1,0.9987546,0.0012453538
14396,PRL,20,21,120,123,"The data extend the findings of other investigators, further establishing the DES-induced tumor as a model for study of PRL cellular control mechanisms.",6888657_9,-1,-1,-1,14396,-1,0.99842846,0.0015715236
14397,calcium chloride,2,4,10,26,Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats.,6892185_0,-1,-1,-1,14397,-1,0.99909437,0.00090562296
14399,eserine,12,13,82,89,Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats.,6892185_0,-1,-1,-1,14399,-1,0.99929595,0.0007039956
14400,calcium chloride,3,5,14,30,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,-1,-1,-1,14400,-1,0.99913627,0.00086374936
14401,mydriasis,41,42,233,242,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,-1,-1,-1,14401,-1,0.0016614335,0.9983386
14405,eserine,51,52,306,313,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,-1,-1,-1,14405,-1,0.999305,0.00069496024
14406,Calcium chloride depressed,0,3,0,26,Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine.,6892185_2,-1,-1,-1,14406,-1,0.8811775,0.1188225
14408,eserine,15,16,109,116,Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine.,6892185_2,-1,-1,-1,14408,-1,0.9992939,0.0007060024
14409,mydriasis,5,6,19,28,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,-1,-1,-1,14409,-1,0.0013785943,0.99862146
14413,eserine,15,16,90,97,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,-1,-1,-1,14413,-1,0.999281,0.0007189932
14414,calcium chloride,21,23,132,148,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,-1,-1,-1,14414,-1,0.9991584,0.00084162725
14415,calcium chloride,4,6,20,36,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,-1,-1,-1,14415,-1,0.9991026,0.0008974412
14416,mydriasis,20,21,123,132,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,-1,-1,-1,14416,-1,0.0013921713,0.9986078
14420,eserine,30,31,194,201,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,-1,-1,-1,14420,-1,0.9992939,0.00070600683
14421,Calcium chloride,0,2,0,16,Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.,6892185_5,-1,-1,-1,14421,-1,0.99909174,0.0009082131
14423,eserine,11,12,83,90,Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.,6892185_5,-1,-1,-1,14423,-1,0.9993044,0.0006955824
14425,Thiazide,0,1,0,8,"Thiazide diuretics, hypokalemia and cardiac arrhythmias.",6942642_0,-1,-1,-1,14425,-1,0.99889684,0.001103158
14426,hypokalemia,3,4,20,31,"Thiazide diuretics, hypokalemia and cardiac arrhythmias.",6942642_0,-1,-1,-1,14426,-1,0.001349298,0.9986507
14428,Thiazide,0,1,0,8,Thiazide diuretics are widely accepted as the cornerstone of antihypertensive treatment programs.,6942642_1,-1,-1,-1,14428,-1,0.99892443,0.0010755156
14429,Hypokalemia,0,1,0,11,Hypokalemia is a commonly encountered metabolic consequence of chronic thiazide therapy.,6942642_2,-1,-1,-1,14429,-1,0.0014197429,0.9985802
14430,thiazide,9,10,71,79,Hypokalemia is a commonly encountered metabolic consequence of chronic thiazide therapy.,6942642_2,-1,-1,-1,14430,-1,0.9991393,0.00086069317
14431,diastolic hypertension,15,17,69,91,"We treated 38 patients (22 low renin, 16 normal renin) with moderate diastolic hypertension with hydrochlorothiazide (HCTC) administered on a twice daily schedule.",6942642_3,-1,-1,-1,14431,-1,0.001380383,0.9986197
14432,hydrochlorothiazide,18,19,97,116,"We treated 38 patients (22 low renin, 16 normal renin) with moderate diastolic hypertension with hydrochlorothiazide (HCTC) administered on a twice daily schedule.",6942642_3,-1,-1,-1,14432,-1,0.9992071,0.0007929997
14433,HCTC,20,21,118,122,"We treated 38 patients (22 low renin, 16 normal renin) with moderate diastolic hypertension with hydrochlorothiazide (HCTC) administered on a twice daily schedule.",6942642_3,-1,-1,-1,14433,-1,0.99859196,0.0014079845
14434,mg,4,5,20,22,"Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized.",6942642_4,-1,-1,-1,14434,-1,0.98885405,0.011145937
14435,mg,15,16,78,80,"Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized.",6942642_4,-1,-1,-1,14435,-1,0.9918994,0.008100689
14436,mg,18,19,86,88,"Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized.",6942642_4,-1,-1,-1,14436,-1,0.99276215,0.007237788
14437,mg,21,22,97,99,"Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized.",6942642_4,-1,-1,-1,14437,-1,0.9931727,0.006827271
14438,K,2,3,10,11,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,-1,-1,-1,14438,-1,0.99767584,0.0023241285
14439,an,13,14,60,62,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,-1,-1,-1,14439,-1,0.99382645,0.006173525
14440,mg HCTZ,22,24,87,94,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,-1,-1,-1,14440,-1,0.9977811,0.002218921
14441,K,5,6,37,38,"Corresponding figures for whole body K were 4107 +/- 208, 3722 +/- 319, 3628 +/- 257, 3551 +/- 336, and 3269 +/- 380 mEq, respectively.",6942642_6,-1,-1,-1,14441,-1,0.9946437,0.005356339
14442,HCTZ,8,9,42,46,In 13 patients we observed the effects of HCTZ therapy (100 mg daily) on the occurrence of PVC's during rest as well as during static and dynamic exercise.,6942642_7,-1,-1,-1,14442,-1,0.9991387,0.0008613167
14443,mg,12,13,60,62,In 13 patients we observed the effects of HCTZ therapy (100 mg daily) on the occurrence of PVC's during rest as well as during static and dynamic exercise.,6942642_7,-1,-1,-1,14443,-1,0.9938583,0.00614177
14444,PVC,19,20,91,94,In 13 patients we observed the effects of HCTZ therapy (100 mg daily) on the occurrence of PVC's during rest as well as during static and dynamic exercise.,6942642_7,-1,-1,-1,14444,-1,0.0018142539,0.9981857
14445,PVC,8,9,37,40,"During rest we observed 0.6 +/- 0.08 PVC beats/min +/- SEM and during static and dynamic exercise 0.6 +/- 0.06 and 0.8 +/- 0.15, respectively.",6942642_8,-1,-1,-1,14445,-1,0.0052469866,0.994753
14446,HCTZ,3,4,29,33,"Corresponding figures during HCTZ therapy 100 mg daily were 1.4 +/- 0.1, 3.6 +/- 0.7 and 5.7 4/- 0.8, respectively.",6942642_9,-1,-1,-1,14446,-1,0.9988967,0.0011033047
14447,mg,6,7,46,48,"Corresponding figures during HCTZ therapy 100 mg daily were 1.4 +/- 0.1, 3.6 +/- 0.7 and 5.7 4/- 0.8, respectively.",6942642_9,-1,-1,-1,14447,-1,0.9932655,0.0067344746
14448,PVC,3,4,18,21,"The occurrence of PVC's correlated significantly with the fall in serum K+ observed r = 0.72, p less than 0.001.",6942642_10,-1,-1,-1,14448,-1,0.0017653948,0.9982346
14449,p,18,19,94,95,"The occurrence of PVC's correlated significantly with the fall in serum K+ observed r = 0.72, p less than 0.001.",6942642_10,-1,-1,-1,14449,-1,0.4945202,0.5054799
14450,thiazide,5,6,28,36,In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body potassium.,6942642_11,-1,-1,-1,14450,-1,0.9990258,0.00097417843
14451,hypokalemia,8,9,53,64,In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body potassium.,6942642_11,-1,-1,-1,14451,-1,0.0016999533,0.9983
14453,hypokalemia,3,4,18,29,"The more profound hypokalemia, the greater the propensity for the occurrence of PVC's.",6942642_12,-1,-1,-1,14453,-1,0.0015103142,0.9984896
14454,PVC,13,14,80,83,"The more profound hypokalemia, the greater the propensity for the occurrence of PVC's.",6942642_12,-1,-1,-1,14454,-1,0.0015814007,0.99841857
14455,acute hepatic necrosis,4,7,34,56,Circulating lysosomal enzymes and acute hepatic necrosis.,7007443_0,-1,-1,-1,14455,-1,0.0015310994,0.99846894
14456,acid phosphatase,14,16,96,112,"The activities of the lysosomal enzymes acid and neutral protease, N-acetylglucosaminidase, and acid phosphatase were measured in the serum of patients with fulminant hepatic failure.",7007443_1,-1,-1,-1,14456,-1,0.9913634,0.00863663
14459,paracetamol overdose,26,28,160,180,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,-1,-1,-1,14459,-1,0.71799815,0.28200182
14461,viral hepatitis,42,44,274,289,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,-1,-1,-1,14461,-1,0.0014454948,0.9985545
14462,D,18,19,113,114,"A correlation was found between serum acid protease activity and prothrombin time, and the increase in cathepsin D activity was sustained over several days compared with aspartate aminotransferase, which showed a sharp early peak and then a fall.",7007443_3,-1,-1,-1,14462,-1,0.99227387,0.0077261194
14478,kidney disease,34,36,164,178,There was only one case of dementia possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1.25 microgram/ml.,7053303_6,-1,-1,-1,14478,-1,0.0016756703,0.99832433
14482,6-thioguanine,5,6,41,54,Hepatic veno-occlusive disease caused by 6-thioguanine.,7053705_0,-1,-1,-1,14482,-1,0.998792,0.0012080295
14483,acute lymphocytic leukemia,13,16,94,120,Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6-thioguanine.,7053705_1,-1,-1,-1,14483,-1,0.0013433901,0.99865663
14484,6-thioguanine,23,24,165,178,Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6-thioguanine.,7053705_1,-1,-1,-1,14484,-1,0.99893135,0.0010686945
14486,6-thioguanine,31,32,205,218,"This case presented a unique opportunity to observe the histologic features of clinically reversible hepatic veno-occlusive disease over time, and may be the first case of veno-occlusive related solely to 6-thioguanine.",7053705_4,-1,-1,-1,14486,-1,0.99891603,0.0010839362
14487,optic neuropathy,1,3,23,39,Chlorpropamide-induced optic neuropathy.,7059267_0,-1,-1,-1,14487,-1,0.0013274313,0.9986726
14489,chlorpropamide,8,9,59,73,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,-1,-1,-1,14489,-1,0.9992393,0.00076064345
14490,Diabenese,10,11,75,84,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,-1,-1,-1,14490,-1,0.99632096,0.0036790823
14491,toxic optic neuropathy,14,17,92,114,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,-1,-1,-1,14491,-1,0.0013133453,0.9986866
14492,chlorpropamide,22,23,153,167,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,-1,-1,-1,14492,-1,0.9992322,0.0007678446
14494,diabetics,4,5,22,31,"Visual loss occurs in diabetics for a variety of reasons, and accurate diagnosis is necessary to institute appropriate therapy.",7059267_2,-1,-1,-1,14494,-1,0.00290436,0.9970956
14495,optic neuropathy,5,7,34,50,The possibility of a drug-induced optic neuropathy should be considered in the differential diagnosis of visual loss in diabetics.,7059267_3,-1,-1,-1,14495,-1,0.0012433372,0.99875665
14497,diabetics,18,19,120,129,The possibility of a drug-induced optic neuropathy should be considered in the differential diagnosis of visual loss in diabetics.,7059267_3,-1,-1,-1,14497,-1,0.0022850097,0.997715
14498,nephrotic syndrome,10,12,69,87,Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside.,7066357_0,-1,-1,-1,14498,-1,0.0012263797,0.99877363
14499,puromycin aminonucleoside,17,19,110,135,Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside.,7066357_0,-1,-1,-1,14499,-1,0.99919826,0.0008017026
14500,nephrotic syndrome,14,16,95,113,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,-1,-1,14500,-1,0.0013545855,0.9986455
14501,puromycin aminonucleoside,18,20,125,150,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,-1,-1,14501,-1,0.999193,0.00080695434
14502,nephrotic syndrome,23,25,163,181,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,-1,-1,14502,-1,0.0013373062,0.9986627
14503,se,26,27,186,188,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,-1,-1,14503,-1,0.028821135,0.9711789
14504,aminonucleoside,37,38,219,234,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,-1,-1,14504,-1,0.9991374,0.0008625913
14505,puromycin aminonucleoside,20,22,128,153,The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of puromycin aminonucleoside (20 mg/kg for 7 days) and the subsequent development of nephrotic syndrome.,7066357_2,-1,-1,-1,14505,-1,0.99926716,0.00073282624
14506,nephrotic syndrome,34,36,210,228,The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of puromycin aminonucleoside (20 mg/kg for 7 days) and the subsequent development of nephrotic syndrome.,7066357_2,-1,-1,-1,14506,-1,0.0012289563,0.998771
14509,fatty acids,7,9,43,54,"In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.",7066357_4,-1,-1,-1,14509,-1,0.99762005,0.0023799278
14510,triacylglycerol,10,11,56,71,"In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.",7066357_4,-1,-1,-1,14510,-1,0.99832684,0.001673177
14511,cholesteryl esters,19,21,119,137,"In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.",7066357_4,-1,-1,-1,14511,-1,0.9980445,0.001955438
14514,puromycin aminonucleoside,4,6,33,58,These observations indicate that puromycin aminonucleoside alters plasma lipoproteins by lowering VLDL and increasing HDL.,7066357_11,-1,-1,-1,14514,-1,0.9990658,0.00093415764
14517,chloramphenicol,8,9,69,84,Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol.,7072798_0,-1,-1,-1,14517,-1,0.99892324,0.0010766827
14520,chloramphenicol,20,21,137,152,A 73-year-old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol.,7072798_1,-1,-1,-1,14520,-1,0.99909437,0.0009056239
14521,pancytopenia,4,5,19,31,The first signs of pancytopenia began within one month of the surgery.,7072798_2,-1,-1,-1,14521,-1,0.0012386834,0.9987613
14523,chloramphenicol,13,14,84,99,The pattern of the aplastic anemia was associated with an idiosyncratic response to chloramphenicol.,7072798_3,-1,-1,-1,14523,-1,0.9991742,0.0008258365
14525,chloramphenicol,13,14,81,96,"This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported.",7072798_4,-1,-1,-1,14525,-1,0.9991104,0.0008895815
14526,bone marrow hypoplasia,23,26,153,175,"This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported.",7072798_4,-1,-1,-1,14526,-1,0.0022056692,0.9977944
14527,ocular toxicity,5,7,29,44,"Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, Portland, OR 97201.",7072798_5,-1,-1,-1,14527,-1,0.0012396153,0.99876034
14528,chloramphenicol,11,12,79,94,"Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, Portland, OR 97201.",7072798_5,-1,-1,-1,14528,-1,0.999185,0.00081492285
14530,block,8,9,49,54,A case is presented of a reversible intra-Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities.,7083920_1,-1,-1,-1,14530,-1,0.001244688,0.99875534
14532,atrial tachycardia,14,16,96,114,A case is presented of a reversible intra-Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities.,7083920_1,-1,-1,-1,14532,-1,0.0013775358,0.9986224
14533,intraventricular conduction abnormalities,21,24,142,183,A case is presented of a reversible intra-Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities.,7083920_1,-1,-1,-1,14533,-1,0.0019402871,0.9980597
14534,atrial tachycardia,5,7,32,50,"His bundle recordings showed an atrial tachycardia with intermittent exit block and greatly prolonged BH and HV intervals (40 and 100 msec, respectively).",7083920_2,-1,-1,-1,14534,-1,0.0018861766,0.9981139
14536,atrial flutter,10,12,77,91,"Thirty days after amiodarone discontinuation, His bundle electrograms showed atrial flutter without intra-Hisian or infra-Hisian delay.",7083920_3,-1,-1,-1,14536,-1,0.002010297,0.99798965
14538,conduction defects,17,19,120,138,Amiodarone should be used with caution during long-term oral therapy in patients with or without clear intraventricular conduction defects.,7083920_4,-1,-1,-1,14538,-1,0.0015745598,0.9984255
14539,clear cell adenocarcinoma,2,5,15,40,Development of clear cell adenocarcinoma in DES-exposed offspring under observation.,7088431_0,-1,-1,-1,14539,-1,0.0024284255,0.9975715
14540,clear cell adenocarcinoma,3,6,13,38,Two cases of clear cell adenocarcinoma of the vagina detected at follow-up in young women exposed in utero to diethylstilbestrol are reported.,7088431_1,-1,-1,-1,14540,-1,0.0021630486,0.997837
14548,mg nitrazepam,10,12,57,70,"In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.",7102237_1,-1,-1,-1,14548,-1,0.9982337,0.0017663311
14562,Akathisia,0,1,0,9,"Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective.",7161250_5,-1,-1,-1,14562,-1,0.0013752746,0.9986247
14563,benzodiazepine lorazepam,5,7,32,56,"Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective.",7161250_5,-1,-1,-1,14563,-1,0.9988667,0.001133319
14564,EPS,16,17,102,105,The present study points to patient characteristics that may be of significance in the development of EPS due to haloperidol.,7161250_6,-1,-1,-1,14564,-1,0.0014902084,0.9985098
14571,chloroprocaine,28,29,142,156,"The CD50 and LD50, respectively, were 57.7 and 58.7 mg/kg for bupivacaine, 111.0 and 133.1 mg/kg for lidocaine, and 243.4 and 266.5 mg/kg for chloroprocaine.",7189975_2,-1,-1,-1,14571,-1,0.99932826,0.0006717735
14574,chloroprocaine,20,21,117,131,"When given intraperitoneally, bupivacaine thus was only about twice as toxic as lidocaine and four times as toxic as chloroprocaine.",7189975_3,-1,-1,-1,14574,-1,0.9993237,0.00067624036
14577,cardiopulmonary arrest,8,10,60,82,"Convulsions always preceded death, except after precipitous cardiopulmonary arrest from extreme doses.",7189975_4,-1,-1,-1,14577,-1,0.0014847585,0.9985152
14580,chloroprocaine,29,30,133,147,"A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.",7189975_5,-1,-1,-1,14580,-1,0.9993018,0.00069820974
14583,REM sleep deprivation,0,3,0,21,REM sleep deprivation changes behavioral response to catecholaminergic and serotonergic receptor activation in rats.,7197363_0,-1,-1,-1,14583,-1,0.081028864,0.9189711
14584,REM sleep deprivation,3,6,15,36,The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.,7197363_1,-1,-1,-1,14584,-1,0.22707497,0.772925
14585,REMD,7,8,38,42,The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.,7197363_1,-1,-1,-1,14585,-1,0.016877186,0.98312277
14587,head twitches,14,16,104,117,The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.,7197363_1,-1,-1,-1,14587,-1,0.0022030303,0.997797
14588,REMD,3,4,18,22,"Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.",7197363_2,-1,-1,-1,14588,-1,0.6397523,0.36024767
14590,REMD,15,16,114,118,"Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.",7197363_2,-1,-1,-1,14590,-1,0.6925497,0.3074503
14591,REMD,25,26,160,164,"Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.",7197363_2,-1,-1,-1,14591,-1,0.70724934,0.2927507
14592,head twitches,28,30,184,197,"Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.",7197363_2,-1,-1,-1,14592,-1,0.0022580524,0.99774194
14596,N,22,23,109,110,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,-1,-1,-1,14596,-1,0.35152036,0.64847964
14597,N,29,30,139,140,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,-1,-1,-1,14597,-1,0.2943569,0.70564306
14598,N,43,44,179,180,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,-1,-1,-1,14598,-1,0.23425792,0.76574206
14599,N,52,53,206,207,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,-1,-1,-1,14599,-1,0.26040736,0.7395927
14603,subpial necrosis,14,16,83,99,"Of the 15 spinal cords of the animals that received 2-chloroprocaine-CE, 13 showed subpial necrosis; the nerve roots and subarachnoid vessels were normal.",7199841_6,-1,-1,-1,14603,-1,0.0033611022,0.9966389
14608,mg,15,16,111,113,"In four patients, polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia.",7234705_2,-1,-1,-1,14608,-1,0.9934455,0.0065545235
14612,premature ventricular contractions,14,17,95,129,"In the remaining three patients, procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter.",7234705_3,-1,-1,-1,14612,-1,0.0013104103,0.9986896
14613,atrial flutter,18,20,133,147,"In the remaining three patients, procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter.",7234705_3,-1,-1,-1,14613,-1,0.0016303167,0.99836975
14619,ventricular fibrillation,9,11,62,86,"In two patients, the arrhythmia degenerated into irreversible ventricular fibrillation and both patients died.",7234705_6,-1,-1,-1,14619,-1,0.0012976576,0.9987023
14624,enlargement of the liver,1,5,23,47,Phenobarbitone-induced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced cirrhosis.,7248170_0,-1,-1,-1,14624,-1,0.002599773,0.9974003
14625,carbon,12,13,80,86,Phenobarbitone-induced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced cirrhosis.,7248170_0,-1,-1,-1,14625,-1,0.99904615,0.00095378346
14627,cirrhosis of the liver,4,8,20,42,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14627,-1,0.0027359375,0.997264
14629,splenomegaly,33,34,179,191,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14629,-1,0.0015321444,0.99846786
14630,testicular atrophy,41,43,214,232,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14630,-1,0.0019652543,0.9980348
14631,carbon tetrachloride,52,54,285,305,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14631,-1,0.9992299,0.000770102
14632,carbon tetrachloride,77,79,436,456,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14632,-1,0.9992823,0.0007176798
14633,enlargement of the liver,85,89,499,523,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14633,-1,0.0023911363,0.9976089
14635,body weight,36,38,186,197,"The optimal rat size to begin phenobarbitone was determined as 100 g, and this size as a group had a mean maximum relative liver weight increase 47% greater than normal rats of the same body weight.",7248170_3,-1,-1,-1,14635,-1,0.11543391,0.88456607
14636,carbon tetrachloride,8,10,41,61,The optimal time for the initial dose of carbon tetrachloride was after 14 days on phenobarbitone.,7248170_4,-1,-1,-1,14636,-1,0.9992791,0.0007208943
14642,allopurinol,14,15,74,85,A case of fatal aplastic anemia is described in which no drugs other than allopurinol and indomethacin were given.,7263204_2,-1,-1,-1,14642,-1,0.999169,0.00083106564
14647,Triamterene nephrolithiasis,0,2,0,27,Triamterene nephrolithiasis complicating dyazide therapy.,7265370_0,-1,-1,-1,14647,-1,0.34558633,0.65441364
14648,dyazide,3,4,41,48,Triamterene nephrolithiasis complicating dyazide therapy.,7265370_0,-1,-1,-1,14648,-1,0.99916685,0.0008331934
14649,triamterene nephrolithiasis,3,5,10,37,A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for hypertension.,7265370_1,-1,-1,-1,14649,-1,0.39824185,0.6017581
14651,triamterene,10,11,58,69,The stone passed spontaneously and was found to contain a triamterene metabolite admixed with uric acid salts.,7265370_2,-1,-1,-1,14651,-1,0.9992385,0.0007614818
14652,uric acid salts,14,17,94,109,The stone passed spontaneously and was found to contain a triamterene metabolite admixed with uric acid salts.,7265370_2,-1,-1,-1,14652,-1,0.99860793,0.001392077
14653,triamterene nephrolithiasis,2,4,18,45,Factors affecting triamterene nephrolithiasis are discussed and 2 previously reported cases are reviewed.,7265370_3,-1,-1,-1,14653,-1,0.4051437,0.59485626
14654,hemorrhagic cystitis,1,3,17,37,Busulfan-induced hemorrhagic cystitis.,7269015_0,-1,-1,-1,14654,-1,0.0011448998,0.9988551
14655,hemorrhage cystitis,5,7,29,48,A case of a busulfan-induced hemorrhage cystitis is reported.,7269015_1,-1,-1,-1,14655,-1,0.0012814386,0.9987186
14656,busulfan cystitis,7,9,53,70,The similarity between the histologic appearances of busulfan cystitis and both radiation and cyclophosphamide-induced cystitis is discussed and the world literature reviewed.,7269015_3,-1,-1,-1,14656,-1,0.44441923,0.5555808
14660,doxorubicin cardiomyopathy,5,7,52,78,Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.,7282516_0,-1,-1,-1,14660,-1,0.22583349,0.77416646
14662,CM,3,4,20,22,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,-1,-1,-1,14662,-1,0.0017032243,0.9982968
14664,DXR,12,13,69,72,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,-1,-1,-1,14664,-1,0.999014,0.0009859162
14666,myocardial disease,30,32,199,217,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,-1,-1,-1,14666,-1,0.0013973276,0.9986027
14667,DXR,26,27,195,198,We measured the degree of morphologic damage by ultrastructural examination of endomyocardial biopsy and the degree of performance abnormally by right heart catheterization in patients receiving DXR.,7282516_2,-1,-1,-1,14667,-1,0.9985378,0.0014621863
14668,DXR,11,12,77,80,Morphologic damage was variable but was proportional to the total cumulative DXR dose between 100 and 600 mg/m2.,7282516_3,-1,-1,-1,14668,-1,0.9988418,0.0011581801
14670,DXR,13,14,79,82,"In DXR-CM myocardial damage is proportional to the degree of cytotoxic insult (DXR dose) while myocardial function is preserved until a critical dose or degree of damage is reached, after which myocardial performance deteriorates rapidly.",7282516_6,-1,-1,-1,14670,-1,0.9972529,0.0027471127
14672,desipramine toxicity,4,6,35,55,Variant ventricular tachycardia in desipramine toxicity.,7292072_0,-1,-1,-1,14672,-1,0.6416072,0.35839278
14674,desipramine toxicity,10,12,63,83,We report a case of variant ventricular tachycardia induced by desipramine toxicity.,7292072_1,-1,-1,-1,14674,-1,0.6513769,0.34862307
14678,Massive cerebral edema,0,3,0,22,Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose: possible role of cranial decompression.,7337133_0,-1,-1,-1,14678,-1,0.0013854285,0.99861455
14680,acetaminophen overdose,9,11,68,90,Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose: possible role of cranial decompression.,7337133_0,-1,-1,-1,14680,-1,0.5057552,0.4942448
14681,Cerebral edema,0,2,0,14,Cerebral edema may complicate the course of fulminant hepatic failure.,7337133_1,-1,-1,-1,14681,-1,0.001267656,0.9987324
14684,signs and symptoms,12,15,86,104,"We present a patient with fatal acetaminophen-induced fulminant hepatic failure, with signs and symptoms of cerebral edema, unresponsive to conventional medical therapy.",7337133_3,-1,-1,-1,14684,-1,0.0018019017,0.9981981
14685,cerebral edema,16,18,108,122,"We present a patient with fatal acetaminophen-induced fulminant hepatic failure, with signs and symptoms of cerebral edema, unresponsive to conventional medical therapy.",7337133_3,-1,-1,-1,14685,-1,0.0011352457,0.99886477
14693,SNP,15,16,77,80,"Control rats received halothane anesthesia (1 MAC) for one hour, followed by SNP infusion, 40 microgram/kg/min, for 30 min, followed by a 30-min recovery period.",7352670_2,-1,-1,-1,14693,-1,0.9991398,0.0008601389
14695,angiotensin II,23,25,127,141,"A second group of rats was treated identically and, in addition, received an infusion of saralasin (a competitive inhibitor of angiotensin II) throughout the experimental period.",7352670_3,-1,-1,-1,14695,-1,0.9989962,0.0010037514
14696,SNP,4,5,15,18,"In each group, SNP infusion resulted in an initial decrease in blood pressure from 86 torr and 83 torr, respectively, to 48 torr.",7352670_4,-1,-1,-1,14696,-1,0.99880064,0.0011994051
14697,in blood pressure,11,14,60,77,"In each group, SNP infusion resulted in an initial decrease in blood pressure from 86 torr and 83 torr, respectively, to 48 torr.",7352670_4,-1,-1,-1,14697,-1,0.0313513,0.9686487
14698,SNP,2,3,11,14,"During the SNP infusion the control animals demonstrated a progressive increase in blood pressure to 61 torr, whereas the saralasin-treated animals showed no change.",7352670_5,-1,-1,-1,14698,-1,0.9990336,0.0009664214
14699,increase in blood pressure,10,14,71,97,"During the SNP infusion the control animals demonstrated a progressive increase in blood pressure to 61 torr, whereas the saralasin-treated animals showed no change.",7352670_5,-1,-1,-1,14699,-1,0.01949741,0.98050267
14700,SNP,3,4,29,32,"Following discontinuation of SNP, blood pressure in the control animals rebounded to 94 torr, as compared with 78 torr in the saralasin-treated rats.",7352670_6,-1,-1,-1,14700,-1,0.99912745,0.00087257
14702,SNP,16,17,106,109,"This study indicates that with stable halothane anesthesia, the partial recovery of blood pressure during SNP infusion and the post-SNP rebound of blood pressure can be completely blocked by saralasin.",7352670_7,-1,-1,-1,14702,-1,0.99914634,0.0008536059
14706,SNP,19,20,135,138,This demonstrates the participation of the renin--angiotensin system in antagonizing the combined hypotensive effects of halothane and SNP.,7352670_8,-1,-1,-1,14706,-1,0.99907696,0.0009230184
14708,digoxin,11,12,87,94,Subjective assessment of sexual dysfunction of patients on long-term administration of digoxin.,7416947_0,-1,-1,-1,14708,-1,0.9991559,0.0008440743
14709,digoxin,9,10,58,65,Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone (LH).,7416947_1,-1,-1,-1,14709,-1,0.9991441,0.000855932
14712,luteinizing hormone,27,29,174,193,Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone (LH).,7416947_1,-1,-1,-1,14712,-1,0.99822086,0.0017790941
14713,digoxin,13,14,91,98,"This study was undertaken to investigate the links between the long-term administration of digoxin therapy and sexual behavior, and the effect of digoxin on plasma levels of estradiol, testosterone, and LH.",7416947_2,-1,-1,-1,14713,-1,0.9992488,0.00075118255
14714,digoxin,23,24,146,153,"This study was undertaken to investigate the links between the long-term administration of digoxin therapy and sexual behavior, and the effect of digoxin on plasma levels of estradiol, testosterone, and LH.",7416947_2,-1,-1,-1,14714,-1,0.99921596,0.0007840057
14717,digoxin,10,11,53,60,The patients of the study and control group (without digoxin) were of similar cardiac functional capacity and age (25-40 years) and were randomly selected from the rheumatic heart disease patients.,7416947_3,-1,-1,-1,14717,-1,0.9989869,0.0010130294
14718,rheumatic heart disease,32,35,164,187,The patients of the study and control group (without digoxin) were of similar cardiac functional capacity and age (25-40 years) and were randomly selected from the rheumatic heart disease patients.,7416947_3,-1,-1,-1,14718,-1,0.0022164097,0.9977836
14719,digoxin,6,7,44,51,"The findings support the reports concerning digoxin effect on plasma estradiol, testosterone, and LH.",7416947_6,-1,-1,-1,14719,-1,0.99912304,0.00087695883
14726,Gentamicin sulfate,0,2,0,18,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,7420681_3,-1,-1,-1,14726,-1,0.99897337,0.0010265968
14727,tobramycin sulfate,3,5,23,41,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,7420681_3,-1,-1,-1,14727,-1,0.99894434,0.0010557269
14730,renal,10,11,57,62,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,-1,-1,-1,14730,-1,0.007562862,0.9924372
14731,gentamicin sulfate,20,22,109,127,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,-1,-1,-1,14731,-1,0.9989944,0.0010055873
14732,tobramycin sulfate,23,25,131,149,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,-1,-1,-1,14732,-1,0.99899703,0.0010029676
14733,renal failure,40,42,255,268,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,-1,-1,-1,14733,-1,0.0015754784,0.99842453
14734,reduction in renal function,49,53,302,329,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,-1,-1,-1,14734,-1,0.0048285625,0.9951715
14735,renal failure,9,11,42,55,"In these 62 patients, no other causes for renal failure could be identified.",7420681_5,-1,-1,-1,14735,-1,0.0014965964,0.99850345
14736,renal failure,24,26,112,125,Five of 33 (15%) of the tobramycin-treated patients and 16 of 29 (55.2%) of the gentamicin-treated patients had renal failure.,7420681_6,-1,-1,-1,14736,-1,0.001570846,0.9984291
14738,renal failure,6,8,37,50,"Thus, gentamicin was associated with renal failure more than three times as often as was tobramycin.",7420681_7,-1,-1,-1,14738,-1,0.0014873631,0.9985127
14740,Endometrial carcinoma,0,2,0,21,Endometrial carcinoma after Hodgkin disease in childhood.,7421734_0,-1,-1,-1,14740,-1,0.0022088743,0.9977912
14741,Hodgkin disease,3,5,28,43,Endometrial carcinoma after Hodgkin disease in childhood.,7421734_0,-1,-1,-1,14741,-1,0.0029122669,0.9970878
14742,endometrial carcinoma,5,7,41,62,A 34-year-old patient developed metastic endometrial carcinoma after Hodgkin disease in childhood.,7421734_1,-1,-1,-1,14742,-1,0.0015498551,0.99845016
14743,Hodgkin disease,8,10,69,84,A 34-year-old patient developed metastic endometrial carcinoma after Hodgkin disease in childhood.,7421734_1,-1,-1,-1,14743,-1,0.002389885,0.9976101
14744,ovarian failure,2,4,8,23,"She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.",7421734_2,-1,-1,-1,14744,-1,0.0016147916,0.9983852
14745,Hodgkin disease,10,12,73,88,"She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.",7421734_2,-1,-1,-1,14745,-1,0.0022765982,0.9977234
14746,estrogens,16,17,113,122,"She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.",7421734_2,-1,-1,-1,14746,-1,0.9988815,0.0011184434
14748,estrogens,4,5,27,36,Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.,7421734_3,-1,-1,-1,14748,-1,0.998606,0.001393998
14749,ovarian failure,6,8,41,56,Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.,7421734_3,-1,-1,-1,14749,-1,0.001566243,0.99843377
14751,endometrial carcinoma,17,19,110,131,Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.,7421734_3,-1,-1,-1,14751,-1,0.0017437672,0.99825627
14752,adriamycin cardiotoxicity,3,5,25,50,Metabolic involvement in adriamycin cardiotoxicity.,7423039_0,-1,-1,-1,14752,-1,0.33459103,0.66540897
14756,phosphorylcreatine,19,20,120,138,"A possible involvement of energy metabolism was suggested previously, and in this study the adenylate energy charge and phosphorylcreatine mole fraction were determined in the adriamycin-treated cells.",7423039_3,-1,-1,-1,14756,-1,0.9990029,0.0009971652
14757,phophorylcreatine,13,14,79,96,"The adenylate energy charge was found to be significantly decreased, while the phophorylcreatine mole fraction was unchanged.",7423039_4,-1,-1,-1,14757,-1,0.99818856,0.0018113779
14759,mM adenosine,4,6,18,30,The addition of 1 mM adenosine to the myocardial cell cultures markedly increases the ATP concentration through a pathway reportedly leading to a compartmentalized ATP pool.,7423039_6,-1,-1,-1,14759,-1,0.998276,0.0017240511
14760,ATP,14,15,86,89,The addition of 1 mM adenosine to the myocardial cell cultures markedly increases the ATP concentration through a pathway reportedly leading to a compartmentalized ATP pool.,7423039_6,-1,-1,-1,14760,-1,0.99870443,0.0012956127
14761,ATP,24,25,164,167,The addition of 1 mM adenosine to the myocardial cell cultures markedly increases the ATP concentration through a pathway reportedly leading to a compartmentalized ATP pool.,7423039_6,-1,-1,-1,14761,-1,0.9986523,0.0013477099
14773,Abnormal movements,0,2,0,18,"Abnormal movements and deafness occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to streptomycin than the site (vestibular or central) responsible for the dyskinesias.",7444978_3,-1,-1,-1,14773,-1,0.0015066859,0.9984933
14774,deafness,3,4,23,31,"Abnormal movements and deafness occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to streptomycin than the site (vestibular or central) responsible for the dyskinesias.",7444978_3,-1,-1,-1,14774,-1,0.0012822754,0.9987178
14777,doxorubicin cardiotoxicity,3,5,11,37,"Late, late doxorubicin cardiotoxicity.",7449470_0,-1,-1,-1,14777,-1,0.046751495,0.9532485
14788,LiCl,35,36,209,213,"The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.",7453952_1,-1,-1,-1,14788,-1,0.9991667,0.00083327637
14790,h,16,17,77,78,Amiloride reduced the drinking and urine volume of rats in an acute (6 or 12 h) and a subacute (3 days) experiment.,7453952_2,-1,-1,-1,14790,-1,0.20173915,0.79826087
14791,h,1,2,2,3,"6 h after the administration of amiloride, a reduction was observed in the lithium content of the renal medulla but not in the other organs studied.",7453952_3,-1,-1,-1,14791,-1,0.48421192,0.5157881
14794,h,2,3,6,7,"At 12 h, all the tissues showed a slight increase in lithium levels.",7453952_4,-1,-1,-1,14794,-1,0.5489734,0.45102662
14805,Cardiovascular complications,0,2,0,28,Cardiovascular complications associated with terbutaline treatment for preterm labor.,7468724_0,-1,-1,-1,14805,-1,0.0013443533,0.9986557
14807,preterm labor,7,9,71,84,Cardiovascular complications associated with terbutaline treatment for preterm labor.,7468724_0,-1,-1,-1,14807,-1,0.0017311043,0.99826884
14808,cardiovascular complications,1,3,7,35,Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor.,7468724_1,-1,-1,-1,14808,-1,0.0012088618,0.99879116
14810,preterm labor,13,15,99,112,Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor.,7468724_1,-1,-1,-1,14810,-1,0.001706433,0.9982936
14811,corticosteroid,1,2,11,25,Associated corticosteroid therapy and twin gestations appear to be predisposing factors.,7468724_2,-1,-1,-1,14811,-1,0.9987086,0.0012914435
14812,Toxic hepatitis,0,2,0,15,Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.,7504976_0,-1,-1,-1,14812,-1,0.001319039,0.9986809
14813,antithyroid drugs,4,6,27,44,Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.,7504976_0,-1,-1,-1,14813,-1,0.9784923,0.021507604
14815,benzylthiouracil,16,17,117,133,Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.,7504976_0,-1,-1,-1,14815,-1,0.9992737,0.0007262324
14816,adverse,12,13,72,79,OBJECTIVE: This study was conducted to assess the occurrence of hepatic adverse effects encountered with antithyroid drugs.,7504976_1,-1,-1,-1,14816,-1,0.0015481462,0.9984518
14817,antithyroid drugs,16,18,105,122,OBJECTIVE: This study was conducted to assess the occurrence of hepatic adverse effects encountered with antithyroid drugs.,7504976_1,-1,-1,-1,14817,-1,0.9970162,0.0029837848
14819,toxic hepatitis,11,13,51,66,RESULTS: Four patients (1.7%) were identified with toxic hepatitis which could reasonably be attributed to the use of antithyroid agent.,7504976_3,-1,-1,-1,14819,-1,0.0012273805,0.99877256
14820,antithyroid agent,22,24,118,135,RESULTS: Four patients (1.7%) were identified with toxic hepatitis which could reasonably be attributed to the use of antithyroid agent.,7504976_3,-1,-1,-1,14820,-1,0.9978313,0.002168677
14821,cholestatic hepatitis,4,6,19,40,Two patients had a cholestatic hepatitis induced by carbimazole (N  omercazole).,7504976_4,-1,-1,-1,14821,-1,0.0014243441,0.9985757
14823,cholestatic,6,7,24,35,Two others had a mixed (cholestatic and cytolytic) hepatitis following carbimazole.,7504976_5,-1,-1,-1,14823,-1,0.0019005566,0.9980995
14827,Benzylthiouracil,14,15,94,110,One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil (Basd  ne) had replaced carbimazole.,7504976_6,-1,-1,-1,14827,-1,0.9992092,0.0007908327
14831,Toxic hepatitis,2,4,12,27,"CONCLUSION: Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants, as for haematological disturbances, a pre-therapeutic determination and a careful follow-up of relevant biological markers.",7504976_9,-1,-1,-1,14831,-1,0.0014119106,0.998588
14832,antithyroid drugs,10,12,61,78,"CONCLUSION: Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants, as for haematological disturbances, a pre-therapeutic determination and a careful follow-up of relevant biological markers.",7504976_9,-1,-1,-1,14832,-1,0.9969476,0.0030524095
14833,haematological disturbances,17,19,102,129,"CONCLUSION: Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants, as for haematological disturbances, a pre-therapeutic determination and a careful follow-up of relevant biological markers.",7504976_9,-1,-1,-1,14833,-1,0.0013870933,0.9986129
14835,antithyroid agents,11,13,63,81,"Moreover, hepatotoxicity may not be restricted to one class of antithyroid agents.",7504976_10,-1,-1,-1,14835,-1,0.9493335,0.05066652
14836,Na,8,9,59,61,"The effects of varying the extracellular concentrations of Na and Ca ([Na]o and [Ca]o) on both, the spontaneous beating and the negative chronotropic action of verapamil, were studied in the isolated rat atria.",7516729_1,-1,-1,-1,14836,-1,0.99882084,0.0011791595
14837,Ca,10,11,66,68,"The effects of varying the extracellular concentrations of Na and Ca ([Na]o and [Ca]o) on both, the spontaneous beating and the negative chronotropic action of verapamil, were studied in the isolated rat atria.",7516729_1,-1,-1,-1,14837,-1,0.9986719,0.0013281463
14839,mM Na,5,7,39,44,in control Krebs-Ringer containing 137 mM Na and 1.35 mM Ca (N).,7516729_3,-1,-1,-1,14839,-1,0.99391264,0.006087335
14840,mM Ca,9,11,54,59,in control Krebs-Ringer containing 137 mM Na and 1.35 mM Ca (N).,7516729_3,-1,-1,-1,14840,-1,0.9939083,0.006091655
14841,N,12,13,61,62,in control Krebs-Ringer containing 137 mM Na and 1.35 mM Ca (N).,7516729_3,-1,-1,-1,14841,-1,0.9738273,0.02617272
14842,mM,13,14,50,52,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,-1,14842,-1,0.8560521,0.14394784
14843,mM,29,30,109,111,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,-1,14843,-1,0.8287638,0.17123622
14844,mM,34,35,131,133,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,-1,14844,-1,0.9259731,0.07402689
14845,mM,49,50,182,184,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,-1,14845,-1,0.8179166,0.18208341
14846,mM,55,56,214,216,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,-1,14846,-1,0.89526206,0.10473793
14847,mM,7,8,33,35,"At normal [Na]o, decrease (0.675 mM) or increase (3.6 mM) of [Ca]o did not modify BF; a reduction of ten times (0.135 mM of normal [Ca]o was effective to reduce BF by 40 +/- 13%.",7516729_5,-1,-1,-1,14847,-1,0.94051284,0.059487175
14848,mM,13,14,54,56,"At normal [Na]o, decrease (0.675 mM) or increase (3.6 mM) of [Ca]o did not modify BF; a reduction of ten times (0.135 mM of normal [Ca]o was effective to reduce BF by 40 +/- 13%.",7516729_5,-1,-1,-1,14848,-1,0.89660716,0.103392914
14849,mM,29,30,118,120,"At normal [Na]o, decrease (0.675 mM) or increase (3.6 mM) of [Ca]o did not modify BF; a reduction of ten times (0.135 mM of normal [Ca]o was effective to reduce BF by 40 +/- 13%.",7516729_5,-1,-1,-1,14849,-1,0.8716078,0.1283922
14852,Na,6,7,40,42,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,-1,-1,-1,14852,-1,0.9988263,0.0011736641
14853,Ca,8,9,47,49,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,-1,-1,-1,14853,-1,0.9986286,0.0013713783
14856,cyclosporin A,2,4,18,31,Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.,7542793_0,-1,-1,-1,14856,-1,0.9990915,0.00090853905
14857,FK506,5,6,36,41,Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.,7542793_0,-1,-1,-1,14857,-1,0.9992118,0.00078818144
14858,Cyclosporin A,0,2,0,13,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,-1,14858,-1,0.9991848,0.00081517216
14859,CsA,3,4,15,18,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,-1,14859,-1,0.99902976,0.0009702714
14860,Fujimycine,9,10,34,44,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,-1,14860,-1,0.9991159,0.0008841412
14861,FK506,11,12,46,51,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,-1,14861,-1,0.99915314,0.0008468299
14862,macrolide,21,22,83,92,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,-1,14862,-1,0.99859613,0.0014038514
14864,CsA,4,5,28,31,The molecular mechanisms of CsA and FK506 toxicity were investigated.,7542793_2,-1,-1,-1,14864,-1,0.9990846,0.0009153743
14865,FK506 toxicity,6,8,36,50,The molecular mechanisms of CsA and FK506 toxicity were investigated.,7542793_2,-1,-1,-1,14865,-1,0.6620469,0.33795312
14866,Cyclophilin A,0,2,0,13,"Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.",7542793_3,-1,-1,-1,14866,-1,0.9981592,0.0018407458
14867,CsA,11,12,81,84,"Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.",7542793_3,-1,-1,-1,14867,-1,0.99908817,0.0009118649
14868,FK506,13,14,89,94,"Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.",7542793_3,-1,-1,-1,14868,-1,0.99918324,0.0008167093
14869,CsA,20,21,140,143,"In the kidney, high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506, but not by rapamycin.",7542793_4,-1,-1,-1,14869,-1,0.99908364,0.0009163294
14870,FK506,22,23,148,153,"In the kidney, high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506, but not by rapamycin.",7542793_4,-1,-1,-1,14870,-1,0.9992556,0.00074443757
14872,CsA,11,12,89,92,"Finally, specific immunophilin-drug-calcineurin complexes formed only in the presence of CsA and FK506, but not rapamycin.",7542793_5,-1,-1,-1,14872,-1,0.9991073,0.0008927079
14873,FK506,13,14,97,102,"Finally, specific immunophilin-drug-calcineurin complexes formed only in the presence of CsA and FK506, but not rapamycin.",7542793_5,-1,-1,-1,14873,-1,0.9992138,0.0007861936
14876,CsA,8,9,54,57,These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.,7542793_6,-1,-1,-1,14876,-1,0.9991092,0.00089072733
14877,FK506,10,11,62,67,These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.,7542793_6,-1,-1,-1,14877,-1,0.9991999,0.00080009014
14878,Acute renal failure,0,3,0,19,Acute renal failure in high dose carboplatin chemotherapy.,7565311_0,-1,-1,-1,14878,-1,0.0012969892,0.998703
14881,acute renal failure,6,9,39,58,Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients.,7565311_1,-1,-1,-1,14881,-1,0.001174477,0.9988255
14883,embryonal rhabdomyosarcoma,15,17,104,130,We report a 4 1/2-year-old girl who was treated with high-dose carboplatin for metastatic parameningeal embryonal rhabdomyosarcoma.,7565311_2,-1,-1,-1,14883,-1,0.0016736503,0.99832636
14884,Acute renal failure,0,3,0,19,Acute renal failure developed followed by a slow partial recovery of renal function.,7565311_3,-1,-1,-1,14884,-1,0.0012986677,0.99870133
14887,Triniol,7,8,52,59,Two patients treated with parenteral paramethasone (Triniol) and dexamethasone (Sedionbel) are described.,7582165_1,-1,-1,-1,14887,-1,0.9982449,0.0017550964
14890,conjunctivitis,19,20,97,111,"A few minutes after administration of the drugs, they presented urticaria (patients 1 and 2) and conjunctivitis (patient 1).",7582165_2,-1,-1,-1,14890,-1,0.0014485201,0.9985514
14893,Triniol,5,6,41,48,"A single-blind parenteral challenge with Triniol was positive in both patients after the administration of 1 ml of the drug, and negative with its excipients.",7582165_6,-1,-1,-1,14893,-1,0.9989673,0.0010327249
14898,hypersensitivity reactions,6,8,59,85,"Corticosteroids different from paramethasone also produced hypersensitivity reactions in these patients; however, a few of them were tolerated.",7582165_9,-1,-1,-1,14898,-1,0.0013922825,0.9986077
14900,prostacyclin,7,8,55,67,Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol.,7596955_0,-1,-1,-1,14900,-1,0.9991073,0.00089271297
14901,beraprost,9,10,77,86,Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol.,7596955_0,-1,-1,-1,14901,-1,0.99922204,0.0007779904
14902,cilostazol,13,14,119,129,Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol.,7596955_0,-1,-1,-1,14902,-1,0.999225,0.0007750276
14903,prostacyclin,10,11,59,71,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14903,-1,0.99916923,0.00083077967
14904,beraprost,12,13,81,90,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14904,-1,0.9992318,0.0007682019
14905,BPT,14,15,92,95,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14905,-1,0.99887973,0.0011202322
14906,cilostazol,21,22,138,148,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14906,-1,0.999244,0.000756029
14907,CLZ,23,24,150,153,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14907,-1,0.9989172,0.0010828453
14908,cAMP,38,39,250,254,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14908,-1,0.9986261,0.0013739014
14909,"cyclic adenosine 3',5'-monophosphate",40,43,256,292,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14909,-1,0.9981729,0.0018271148
14910,BPT,13,14,83,86,"Twelve healthy volunteers were assigned to take BPT/CLZ in the following schedule; BPT: 40 micrograms at day 1 and 120 micrograms t.i.d. from day 7 to 14, CLZ: 200 mg t.i.d. from day 3 to 14.",7596955_3,-1,-1,-1,14910,-1,0.9989441,0.001055924
14911,CLZ,31,32,155,158,"Twelve healthy volunteers were assigned to take BPT/CLZ in the following schedule; BPT: 40 micrograms at day 1 and 120 micrograms t.i.d. from day 7 to 14, CLZ: 200 mg t.i.d. from day 3 to 14.",7596955_3,-1,-1,-1,14911,-1,0.9987514,0.0012485499
14912,mg,34,35,164,166,"Twelve healthy volunteers were assigned to take BPT/CLZ in the following schedule; BPT: 40 micrograms at day 1 and 120 micrograms t.i.d. from day 7 to 14, CLZ: 200 mg t.i.d. from day 3 to 14.",7596955_3,-1,-1,-1,14912,-1,0.99477226,0.0052278056
14914,cAMP,19,20,137,141,"At various time intervals, physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed.",7596955_4,-1,-1,-1,14914,-1,0.9985165,0.0014835453
14916,facial flush,12,14,79,91,"Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.",7596955_6,-1,-1,-1,14916,-1,0.0016991785,0.99830085
14918,CLZ,25,26,148,151,"Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.",7596955_6,-1,-1,-1,14918,-1,0.9987753,0.0012246397
14919,cAMP,1,2,14,18,Intraplatelet cAMP content was gradually but significantly increased to 9.84 +/- 4.59 pmol per 10(9) platelets at day 14 in comparison with the initial value (6.87 +/- 2.25 pmol).,7596955_8,-1,-1,-1,14919,-1,0.998417,0.001582975
14923,coenzyme,18,19,123,131,"A case of acute inflammatory myopathy associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.",7604176_2,-1,-1,-1,14923,-1,0.99857986,0.0014201691
14924,coenzyme A,18,20,123,133,"A case of acute inflammatory myopathy associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.",7604176_2,-1,-1,-1,14924,-1,0.99872214,0.0012778279
14925,diabetes mellitus,10,12,69,86,"The patient, a 69-year-old man was affected by non-insulin-dependent diabetes mellitus and hypertension.",7604176_3,-1,-1,-1,14925,-1,0.0013977268,0.99860233
14932,chronic autoimmune thyroiditis,8,11,53,83,"A previously unknown hypothyroidism, probably due to chronic autoimmune thyroiditis, was evidenced.",7604176_6,-1,-1,-1,14932,-1,0.0015305672,0.9984694
14937,ammonia coma,2,4,12,24,Reversal of ammonia coma in rats by L-dopa: a peripheral effect.,761833_0,-1,-1,-1,14937,-1,0.25001296,0.74998707
14938,Ammonia coma,0,2,0,12,Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol NH4CL.,761833_1,-1,-1,-1,14938,-1,0.18105853,0.8189414
14939,NH4CL,17,18,101,106,Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol NH4CL.,761833_1,-1,-1,-1,14939,-1,0.998212,0.0017880541
14941,ammonium salt,16,18,96,109,This coma was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the ammonium salt injection.,761833_2,-1,-1,-1,14941,-1,0.9990847,0.0009153059
14942,ammonia,13,14,71,78,"The effect of L-dopa was correlated with a decrease in blood and brain ammonia, an increase in brain dopamine, and an increase in renal excretion of ammonia and urea.",761833_3,-1,-1,-1,14942,-1,0.9984701,0.001529811
14944,ammonia,28,29,149,156,"The effect of L-dopa was correlated with a decrease in blood and brain ammonia, an increase in brain dopamine, and an increase in renal excretion of ammonia and urea.",761833_3,-1,-1,-1,14944,-1,0.99846494,0.0015351154
14948,ammonia coma,18,20,116,128,Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.,761833_4,-1,-1,-1,14948,-1,0.27818936,0.7218107
14949,ammonia,26,27,160,167,Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.,761833_4,-1,-1,-1,14949,-1,0.9983157,0.0016842962
14950,ammonia,12,13,84,91,Bilateral nephrectomy eliminated the beneficial effect of L-dopa on blood and brain ammonia and the ammonia coma was not prevented.,761833_5,-1,-1,-1,14950,-1,0.9969723,0.003027681
14951,ammonia coma,15,17,100,112,Bilateral nephrectomy eliminated the beneficial effect of L-dopa on blood and brain ammonia and the ammonia coma was not prevented.,761833_5,-1,-1,-1,14951,-1,0.2224349,0.7775651
14952,ammonia,8,9,39,46,"Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.",761833_6,-1,-1,-1,14952,-1,0.99723697,0.0027630408
14953,ammonia coma,13,15,69,81,"Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.",761833_6,-1,-1,-1,14953,-1,0.2584654,0.7415346
14955,encephalopathic,13,14,91,106,These results provide a reasonable explanation for the beneficial effects observed in some encephalopathic patients receiving L-dopa.,761833_7,-1,-1,-1,14955,-1,0.0014247017,0.9985753
14956,myocardial infarction,1,3,18,39,Etoposide-related myocardial infarction.,7619765_0,-1,-1,-1,14956,-1,0.0014588257,0.99854124
14957,myocardial infarction,4,6,20,41,"The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.",7619765_1,-1,-1,-1,14957,-1,0.0014819808,0.99851805
14959,coronary heart disease,21,24,129,151,"The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.",7619765_1,-1,-1,-1,14959,-1,0.0016002877,0.9983997
14960,vitamin B12,5,7,21,32,Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine.,7628595_0,-1,-1,-1,14960,-1,0.99889404,0.0011060402
14962,hematologic toxicity,13,15,80,100,Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine.,7628595_0,-1,-1,-1,14962,-1,0.0013784729,0.9986216
14964,vitamin B12,12,14,70,81,"A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression.",7628595_1,-1,-1,-1,14964,-1,0.99895966,0.0010403438
14968,human immunodeficiency,1,3,13,35,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,14968,-1,0.019794697,0.98020536
14969,ZDV,18,19,132,135,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,14969,-1,0.9989808,0.0010192061
14970,mg,21,22,141,143,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,14970,-1,0.99276286,0.0072371406
14971,n,29,30,167,168,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,14971,-1,0.18838973,0.8116103
14973,mg,41,42,215,217,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,14973,-1,0.9924238,0.0075762086
14974,vitamin B12,46,48,243,254,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,14974,-1,0.9987502,0.0012497295
14975,n,57,58,292,293,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,14975,-1,0.17465958,0.8253404
14977,vitamin B12,4,6,18,29,"During the study, vitamin B12 and folate levels were significantly higher in group II patients; however, no differences in hemoglobin, hematocrit, mean corpuscular volume, and white-cell, neutrophil and platelet counts were observed between groups at 3, 6, 9 and 12 months.",7628595_5,-1,-1,-1,14977,-1,0.99846786,0.0015321143
14978,folate,7,8,34,40,"During the study, vitamin B12 and folate levels were significantly higher in group II patients; however, no differences in hemoglobin, hematocrit, mean corpuscular volume, and white-cell, neutrophil and platelet counts were observed between groups at 3, 6, 9 and 12 months.",7628595_5,-1,-1,-1,14978,-1,0.9986576,0.0013424245
14979,hematologic toxicity,1,3,7,27,Severe hematologic toxicity (neutrophil count < 1000/mm3 and/or hemoglobin < 8 g/dl) occurred in 4 patients assigned to group I and 7 assigned to group II.,7628595_6,-1,-1,-1,14979,-1,0.0013678788,0.99863213
14980,vitamin B12,5,7,33,44,There was no correlation between vitamin B12 or folate levels and development of myelosuppression.,7628595_7,-1,-1,-1,14980,-1,0.9984201,0.0015799003
14981,folate,8,9,48,54,There was no correlation between vitamin B12 or folate levels and development of myelosuppression.,7628595_7,-1,-1,-1,14981,-1,0.9987674,0.0012326168
14983,Vitamin B12,0,2,0,11,"Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.",7628595_8,-1,-1,-1,14983,-1,0.9989272,0.0010727451
14985,ZDV,7,8,48,51,"Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.",7628595_8,-1,-1,-1,14985,-1,0.998944,0.0010560831
14986,myelotoxicity,18,19,119,132,"Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.",7628595_8,-1,-1,-1,14986,-1,0.0011321726,0.99886787
14991,Halothane hepatitis,0,2,0,19,Halothane hepatitis appears to involve an aberrant immune response.,7647582_2,-1,-1,-1,14991,-1,0.72569543,0.27430457
14992,trifluoroacetyl,9,10,67,82,An antibody response to a protein-bound biotransformation product (trifluoroacetyl adduct) has been detected on halothane hepatitis patients.,7647582_3,-1,-1,-1,14992,-1,0.99864024,0.0013597129
14993,halothane hepatitis,16,18,112,131,An antibody response to a protein-bound biotransformation product (trifluoroacetyl adduct) has been detected on halothane hepatitis patients.,7647582_3,-1,-1,-1,14993,-1,0.7806788,0.2193212
15006,Cholinergic toxicity,0,2,0,20,Cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops.,7650771_0,-1,-1,-1,15006,-1,0.0017570298,0.998243
15007,echothiophate iodide,7,9,59,79,Cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops.,7650771_0,-1,-1,-1,15007,-1,0.996788,0.0032120002
15008,syndrome,6,7,41,49,"A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.",7650771_1,-1,-1,-1,15008,-1,0.0012034414,0.9987966
15009,echothiophate iodide,11,13,66,86,"A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.",7650771_1,-1,-1,-1,15009,-1,0.9964644,0.0035356511
15010,muscle weakness,19,21,129,144,"A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.",7650771_1,-1,-1,-1,15010,-1,0.0014095219,0.9985904
15011,myasthenia gravis,28,30,186,203,"A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.",7650771_1,-1,-1,-1,15011,-1,0.0017967768,0.99820316
15014,flumazenil,2,3,14,24,Seizure after flumazenil administration in a pediatric patient.,7651879_0,-1,-1,-1,15014,-1,0.99915755,0.00084241916
15015,Flumazenil,0,1,0,10,Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.,7651879_1,-1,-1,-1,15015,-1,0.9992768,0.00072323333
15017,respiratory depression,11,13,80,102,Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.,7651879_1,-1,-1,-1,15017,-1,0.0013040868,0.9986959
15023,flumazenil,7,8,56,66,Little information exists concerning adverse effects of flumazenil in children.,7651879_4,-1,-1,-1,15023,-1,0.99919254,0.0008074428
15025,flumazenil,17,18,118,128,We report the occurrence of a generalized tonic-clonic seizure in a pediatric patient following the administration of flumazenil.,7651879_5,-1,-1,-1,15025,-1,0.99923325,0.0007667939
15026,neuroblastoma,9,10,55,68,Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation.,7707116_0,-1,-1,-1,15026,-1,0.0015708228,0.9984291
15027,neuroblastoma,4,5,22,35,PURPOSE: Treatment of neuroblastoma cell lines with 13-cis-retinoic acid (cis-RA) can cause sustained inhibition of proliferation.,7707116_1,-1,-1,-1,15027,-1,0.0035228746,0.9964772
15028,neuroblastoma,7,8,52,65,"Since cis-RA has demonstrated clinical responses in neuroblastoma patients, it may be effective in preventing relapse after cytotoxic therapy.",7707116_2,-1,-1,-1,15028,-1,0.0018844662,0.99811554
15030,neuroblastoma,29,30,182,195,"This phase I trial was designed to determine the maximal-tolerated dosage (MTD), toxicities, and pharmacokinetics of cis-RA administered on an intermittent schedule in children with neuroblastoma following bone marrow transplantation (BMT).",7707116_3,-1,-1,-1,15030,-1,0.0016556429,0.9983443
15034,n,13,14,88,89,"Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and anemia/thrombocytopenia/emesis/rash (n = 1).",7707116_8,-1,-1,-1,15034,-1,0.002703118,0.99729687
15036,n,20,21,102,103,"Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and anemia/thrombocytopenia/emesis/rash (n = 1).",7707116_8,-1,-1,-1,15036,-1,0.003544901,0.9964551
15037,n,28,29,151,152,"Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and anemia/thrombocytopenia/emesis/rash (n = 1).",7707116_8,-1,-1,-1,15037,-1,0.0041841115,0.99581593
15039,marrow metastases,6,8,42,59,Three complete responses were observed in marrow metastases.,7707116_10,-1,-1,-1,15039,-1,0.003525557,0.99647444
15040,neuroblastoma,7,8,43,56,Serum levels known to be effective against neuroblastoma in vitro were achieved at this dose.,7707116_13,-1,-1,-1,15040,-1,0.0016690564,0.998331
15044,oxypurines,6,7,43,53,"Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.",7710775_0,-1,-1,-1,15044,-1,0.9990727,0.0009273081
15045,nucleosides,9,10,59,70,"Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.",7710775_0,-1,-1,-1,15045,-1,0.99903023,0.00096976024
15046,cerebral ischemia,12,14,89,106,"Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.",7710775_0,-1,-1,-1,15046,-1,0.0015786019,0.99842143
15047,cerebral ischemia,1,3,11,28,Incomplete cerebral ischemia (30 min) was induced in the rat by bilaterally clamping the common carotid arteries.,7710775_1,-1,-1,-1,15047,-1,0.001625483,0.99837446
15051,oxypurines,19,20,148,158,"Plasma extracts were analyzed by a highly sensitive high-performance liquid chromatographic method for the direct determination of malondialdehyde, oxypurines, and nucleosides.",7710775_3,-1,-1,-1,15051,-1,0.99886036,0.0011396962
15052,nucleosides,22,23,164,175,"Plasma extracts were analyzed by a highly sensitive high-performance liquid chromatographic method for the direct determination of malondialdehyde, oxypurines, and nucleosides.",7710775_3,-1,-1,-1,15052,-1,0.9983746,0.0016254445
15054,oxypurines,8,9,53,63,"During ischemia, a time-dependent increase of plasma oxypurines and nucleosides was observed.",7710775_4,-1,-1,-1,15054,-1,0.9988864,0.0011136614
15055,nucleosides,10,11,68,79,"During ischemia, a time-dependent increase of plasma oxypurines and nucleosides was observed.",7710775_4,-1,-1,-1,15055,-1,0.9987446,0.0012553716
15057,SD,17,18,100,102,"Plasma malondialdehyde, which was present in minimal amount at zero time (0.058 mumol/liter plasma; SD 0.015), increased after 5 min of ischemia, resulting in a fivefold increase after 30 min of carotid occlusion (0.298 mumol/liter plasma; SD 0.078).",7710775_5,-1,-1,-1,15057,-1,0.3414213,0.6585787
15059,SD,44,45,240,242,"Plasma malondialdehyde, which was present in minimal amount at zero time (0.058 mumol/liter plasma; SD 0.015), increased after 5 min of ischemia, resulting in a fivefold increase after 30 min of carotid occlusion (0.298 mumol/liter plasma; SD 0.078).",7710775_5,-1,-1,-1,15059,-1,0.2603512,0.73964876
15061,acetylsalicylate,29,30,184,200,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,-1,-1,-1,15061,-1,0.9991008,0.0008992095
15068,oxypurines,10,11,69,79,"The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)",7710775_7,-1,-1,-1,15068,-1,0.9989654,0.0010345895
15069,nucleosides,13,14,85,96,"The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)",7710775_7,-1,-1,-1,15069,-1,0.9988325,0.0011675308
15070,ischemic,30,31,195,203,"The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)",7710775_7,-1,-1,-1,15070,-1,0.0018500208,0.99815
15071,Acute renal toxicity,0,3,0,20,Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles.,7724492_0,-1,-1,-1,15071,-1,0.0014120728,0.9985879
15073,cyanoacrylate,6,7,56,69,Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles.,7724492_0,-1,-1,-1,15073,-1,0.99881625,0.0011837273
15077,DX,10,11,49,51,"In normal rats, 2/6 rats given free doxorubicin (DX) (5 mg/kg) died within one week, whereas all control animals and all rats having received free NP or DXNP survived.",7724492_2,-1,-1,-1,15077,-1,0.99877626,0.0012237512
15080,p,16,17,85,86,"Two hr post-injection, DXNP was 2.7 times more concentrated in kidneys than free DX (p < 0.025).",7724492_5,-1,-1,-1,15080,-1,0.4679459,0.53205407
15082,contrast,17,18,94,102,"In rats with immune experimental glomerulonephritis, 5/6 rats given DX died within 7 days, in contrast to animals treated by DXNP, NP, or untreated, which all survived.",7724492_6,-1,-1,-1,15082,-1,0.053473424,0.9465266
15084,p,15,16,68,69,"Proteinuria appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and DX.",7724492_7,-1,-1,-1,15084,-1,0.29624507,0.7037549
15088,Prostaglandin,0,1,0,13,"Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure.",7752389_0,-1,-1,-1,15088,-1,0.99900764,0.0009923449
15089,bladder hyperactivity,2,4,25,46,"Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure.",7752389_0,-1,-1,-1,15089,-1,0.00159014,0.99840987
15090,tachykinins?In,12,13,89,103,"Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure.",7752389_0,-1,-1,-1,15090,-1,0.8600557,0.13994439
15091,prostaglandin,23,24,190,203,"Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure.",7752389_0,-1,-1,-1,15091,-1,0.99904495,0.0009549956
15092,PG) E2,25,28,205,211,"Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure.",7752389_0,-1,-1,-1,15092,-1,0.99870586,0.00129418
15093,"RP 67,580",11,13,72,81,"The effect was attenuated by both the NK1 receptor selective antagonist RP 67,580 and the NK2 receptor selective antagonist SR 48,968, given intra-arterially, suggesting that it was mediated by stimulation of both NK1 and NK2 receptors.",7752389_1,-1,-1,-1,15093,-1,0.99843055,0.001569475
15094,"SR 48,968",19,21,124,133,"The effect was attenuated by both the NK1 receptor selective antagonist RP 67,580 and the NK2 receptor selective antagonist SR 48,968, given intra-arterially, suggesting that it was mediated by stimulation of both NK1 and NK2 receptors.",7752389_1,-1,-1,-1,15094,-1,0.9984658,0.0015342379
15095,PGE2,2,3,23,27,"Intra-arterially given PGE2 produced a distinct increase in bladder pressure before initiating a micturition reflex, indicating that the PG had a direct contractant effect on the detrusor smooth muscle.",7752389_2,-1,-1,-1,15095,-1,0.99890554,0.0010944699
15096,PG,19,20,137,139,"Intra-arterially given PGE2 produced a distinct increase in bladder pressure before initiating a micturition reflex, indicating that the PG had a direct contractant effect on the detrusor smooth muscle.",7752389_2,-1,-1,-1,15096,-1,0.9986821,0.0013179379
15097,PGE2,4,5,29,33,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,-1,15097,-1,0.99892825,0.0010717476
15098,"RP 67,580",11,13,73,82,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,-1,15098,-1,0.9987532,0.0012468263
15099,"SR 48,968",14,16,86,95,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,-1,15099,-1,0.9986223,0.0013777129
15100,PGE2,28,29,180,184,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,-1,15100,-1,0.9989705,0.0010294812
15101,PG,40,41,251,253,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,-1,15101,-1,0.99878186,0.0012181156
15102,PGE2,7,8,53,57,"The present results thus suggest that intra-arterial PGE2, given near the bladder, may initiate micturition in the normal rat chiefly by directly contracting the smooth muscle of the detrusor.",7752389_4,-1,-1,-1,15102,-1,0.99892765,0.0010723508
15103,PGE2,6,7,36,40,"However, when given intravesically, PGE2 may stimulate micturition by releasing tachykinins from nerves in and/or immediately below the urothelium.",7752389_5,-1,-1,-1,15103,-1,0.99899846,0.0010014961
15104,tachykinins,12,13,80,91,"However, when given intravesically, PGE2 may stimulate micturition by releasing tachykinins from nerves in and/or immediately below the urothelium.",7752389_5,-1,-1,-1,15104,-1,0.99854064,0.0014593968
15105,tachykinins,1,2,6,17,"These tachykinins, in turn, initiate a micturition reflex by stimulating NK1 and NK2 receptors.",7752389_6,-1,-1,-1,15105,-1,0.9979394,0.0020605489
15106,Prostanoids,0,1,0,11,"Prostanoids may, via release of tachykinins, contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract.",7752389_7,-1,-1,-1,15106,-1,0.9986002,0.0013998157
15107,tachykinins,6,7,32,43,"Prostanoids may, via release of tachykinins, contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract.",7752389_7,-1,-1,-1,15107,-1,0.99802244,0.0019775953
15108,bladder hyperactivity,13,15,73,94,"Prostanoids may, via release of tachykinins, contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract.",7752389_7,-1,-1,-1,15108,-1,0.0014363726,0.9985637
15109,cardiogenic shock,1,3,11,28,Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.,7785794_0,-1,-1,-1,15109,-1,0.0011503827,0.99884963
15110,heart block,5,7,42,53,Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.,7785794_0,-1,-1,-1,15110,-1,0.0015278261,0.99847215
15113,heart block,6,8,55,66,A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.,7785794_2,-1,-1,-1,15113,-1,0.0013771842,0.9986228
15118,heart block,8,10,58,69,"The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.",7785794_3,-1,-1,-1,15118,-1,0.0016328195,0.99836725
15122,calcium chloride,8,10,46,62,"However, shortly after the use of intravenous calcium chloride, the refractory hypotension and complete heart block resolved.",7785794_4,-1,-1,-1,15122,-1,0.9989297,0.0010703248
15124,heart block,16,18,104,115,"However, shortly after the use of intravenous calcium chloride, the refractory hypotension and complete heart block resolved.",7785794_4,-1,-1,-1,15124,-1,0.0014738629,0.9985261
15125,misoprostol,3,4,21,32,Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients.,7791169_0,-1,-1,-1,15125,-1,0.99925345,0.00074658304
15128,misoprostol,9,10,58,69,OBJECTIVE: To evaluate the possible protective effects of misoprostol on renal function in hospitalized elderly patients treated with indomethacin.,7791169_1,-1,-1,-1,15128,-1,0.9992736,0.00072637055
15130,NSAID,20,21,130,135,"METHODS: Forty-five hospitalized elderly patients (> 65 years old) who required therapy with nonsteroidal antiinflammatory drugs (NSAID) were randomly assigned to receive either indomethacin, 150 mg/day (Group A), or indomethacin 150 mg/day plus misoprostol at 0.6 mg/day (Group B).",7791169_2,-1,-1,-1,15130,-1,0.9987219,0.0012780732
15133,misoprostol,42,43,246,257,"METHODS: Forty-five hospitalized elderly patients (> 65 years old) who required therapy with nonsteroidal antiinflammatory drugs (NSAID) were randomly assigned to receive either indomethacin, 150 mg/day (Group A), or indomethacin 150 mg/day plus misoprostol at 0.6 mg/day (Group B).",7791169_2,-1,-1,-1,15133,-1,0.99929893,0.0007011066
15136,BUN,13,14,79,82,"Laboratory variables of renal function [serum creatinine, blood urea nitrogen (BUN) and electrolytes] were evaluated before initiation of therapy and every 2 days, until termination of the study (a period of at least 6 days).",7791169_3,-1,-1,-1,15136,-1,0.99777156,0.0022284044
15138,BUN,17,18,82,85,"RESULTS: Forty-two patients completed the study, 22 in Group A and 20 in Group B. BUN and creatinine increased by > 50% of baseline levels in 54 and 45% of Group A patients, respectively, compared to only 20 and 10% of Group B patients (p < 0.05).",7791169_5,-1,-1,-1,15138,-1,0.9977048,0.0022951693
15140,p,52,53,237,238,"RESULTS: Forty-two patients completed the study, 22 in Group A and 20 in Group B. BUN and creatinine increased by > 50% of baseline levels in 54 and 45% of Group A patients, respectively, compared to only 20 and 10% of Group B patients (p < 0.05).",7791169_5,-1,-1,-1,15140,-1,0.4117579,0.5882421
15142,K,2,3,11,12,"Potassium (K) increment of 0.6 mEq/l or more was observed in 50% of Group A, but in only 15% of Group B patients (p < 0.05).",7791169_6,-1,-1,-1,15142,-1,0.9978993,0.0021007166
15143,p,29,30,114,115,"Potassium (K) increment of 0.6 mEq/l or more was observed in 50% of Group A, but in only 15% of Group B patients (p < 0.05).",7791169_6,-1,-1,-1,15143,-1,0.38392222,0.61607784
15144,BUN,4,5,23,26,"The mean increments in BUN, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups.",7791169_7,-1,-1,-1,15144,-1,0.9979183,0.0020816785
15146,K,9,10,44,45,"The mean increments in BUN, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups.",7791169_7,-1,-1,-1,15146,-1,0.9978472,0.002152793
15149,misoprostol,2,3,12,23,Addition of misoprostol can minimize this renal impairment without affecting pain control.,7791169_9,-1,-1,-1,15149,-1,0.99928445,0.00071556447
15150,renal impairment,6,8,42,58,Addition of misoprostol can minimize this renal impairment without affecting pain control.,7791169_9,-1,-1,-1,15150,-1,0.0015445079,0.9984555
15154,panic disorder,5,7,37,51,Controlled study in agoraphobia with panic disorder.,7802851_1,-1,-1,-1,15154,-1,0.0016318968,0.9983681
15157,panic disorder,7,9,42,56,"The efficacy of alprazolam and placebo in panic disorder with agoraphobia, and the side-effect and adverse effect profiles of both drug groups were measured.",7802851_3,-1,-1,-1,15157,-1,0.0014893975,0.99851054
15159,panic disorder,13,15,72,86,METHOD: In London and Toronto 154 patients who met DSM-III criteria for panic disorder with agoraphobia were randomised to alprazolam or placebo.,7802851_4,-1,-1,-1,15159,-1,0.0018679323,0.99813205
15163,mg,7,8,36,38,RESULTS: Mean alprazolam dose was 5 mg daily.,7802851_7,-1,-1,-1,15163,-1,0.98896605,0.011033903
15166,enuresis,21,22,112,120,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,-1,-1,15166,-1,0.0013730276,0.99862695
15167,disinhibition,23,24,122,135,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,-1,-1,15167,-1,0.0015120152,0.99848795
15170,impaired memory,36,38,212,227,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,-1,-1,15170,-1,0.0019609157,0.99803907
15171,weight loss,39,41,229,240,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,-1,-1,15171,-1,0.0020435096,0.9979565
15174,Cognitive deterioration,0,2,0,23,Cognitive deterioration from long-term abuse of dextromethorphan: a case report.,7803371_0,-1,-1,-1,15174,-1,0.0017031789,0.9982968
15175,dextromethorphan,6,7,48,64,Cognitive deterioration from long-term abuse of dextromethorphan: a case report.,7803371_0,-1,-1,-1,15175,-1,0.99840075,0.0015992138
15176,Dextromethorphan,0,1,0,16,"Dextromethorphan (DM), the dextrorotatory isomer of 3-hydroxy-N-methylmorphinan, is the main ingredient in a number of widely available, over-the-counter antitussives.",7803371_1,-1,-1,-1,15176,-1,0.99912304,0.0008769869
15177,DM,2,3,18,20,"Dextromethorphan (DM), the dextrorotatory isomer of 3-hydroxy-N-methylmorphinan, is the main ingredient in a number of widely available, over-the-counter antitussives.",7803371_1,-1,-1,-1,15177,-1,0.99861133,0.0013886105
15179,restlessness,17,18,82,94,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15179,-1,0.0012556418,0.99874437
15180,insomnia,19,20,96,104,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15180,-1,0.0011911131,0.99880886
15182,slurred speech,23,25,114,128,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15182,-1,0.0021877426,0.9978123
15183,nystagmus,26,27,133,142,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15183,-1,0.001328536,0.99867153
15184,inattention,34,35,184,195,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15184,-1,0.0016710914,0.99832886
15185,disorientation,36,37,197,211,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15185,-1,0.0013537548,0.9986462
15187,DM overdoses,8,10,50,62,There have also been two reported fatalities from DM overdoses (Fleming 1986).,7803371_5,-1,-1,-1,15187,-1,0.002571789,0.99742824
15188,cognitive deterioration,6,8,32,55,This report describes a case of cognitive deterioration resulting from prolonged use of DM.,7803371_7,-1,-1,-1,15188,-1,0.0014711735,0.99852884
15189,DM,13,14,88,90,This report describes a case of cognitive deterioration resulting from prolonged use of DM.,7803371_7,-1,-1,-1,15189,-1,0.94668937,0.05331064
15192,coronary artery disease,13,16,83,106,Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease.,783197_0,-1,-1,-1,15192,-1,0.002006819,0.99799323
15193,heart failure,11,13,67,80,"A hemodynamic, volumetric, and metabolic study in patients without heart failure.",783197_1,-1,-1,-1,15193,-1,0.0018665335,0.9981335
15194,digitalis glycosides,3,5,15,35,"The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man.",783197_2,-1,-1,-1,15194,-1,0.99900407,0.0009959238
15196,coronary artery disease,20,23,133,156,"The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man.",783197_2,-1,-1,-1,15196,-1,0.0017289971,0.998271
15198,body weight,9,11,48,59,"We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.",783197_3,-1,-1,-1,15198,-1,0.90874434,0.09125569
15199,coronary artery disease,26,29,149,172,"We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.",783197_3,-1,-1,-1,15199,-1,0.0017092559,0.9982907
15200,congestive heart failure,31,34,190,214,"We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.",783197_3,-1,-1,-1,15200,-1,0.0011839754,0.998816
15203,mean+/-SE,8,9,62,71,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,-1,-1,15203,-1,0.31080762,0.68919235
15204,mm Hg,12,14,86,91,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,-1,-1,15204,-1,0.11709464,0.8829053
15205,P,15,16,93,94,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,-1,-1,15205,-1,0.37077525,0.6292248
15206,P,32,33,191,192,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,-1,-1,15206,-1,0.38711557,0.6128844
15207,h,38,39,211,212,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,-1,-1,15207,-1,0.25940004,0.74059993
15209,P,15,16,120,121,The maximum velocity of contractile element shortening increased from 1.68+/-0.11 ml/s to 2.18+/-0.21 muscle-lengths/s (P less than 0.05) and is consistent with an increase in contractility.,783197_7,-1,-1,-1,15209,-1,0.41558418,0.58441585
15213,chronic coronary artery disease,6,10,34,65,We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.,783197_10,-1,-1,-1,15213,-1,0.0018723364,0.99812764
15214,congestive heart failure,15,18,90,114,We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.,783197_10,-1,-1,-1,15214,-1,0.0015190535,0.998481
15218,deterioration,6,7,48,61,"Nevertheless, compensatory mechanisms prevent a deterioration of resting myocardial metabolism.",783197_12,-1,-1,-1,15218,-1,0.0031179937,0.9968821
15221,pulmonary tuberculosis,9,11,91,113,Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis.,7834920_0,-1,-1,-1,15221,-1,0.0018103566,0.9981896
15226,pulmonary tuberculosis,11,13,72,94,This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.,7834920_2,-1,-1,-1,15226,-1,0.0017152921,0.99828464
15227,renal failure,22,24,148,161,This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.,7834920_2,-1,-1,-1,15227,-1,0.001460173,0.9985398
15233,ocular hypertension,1,3,22,41,Dexamethasone-induced ocular hypertension in perfusion-cultured human eyes.,7843916_0,-1,-1,-1,15233,-1,0.001341425,0.99865854
15234,lead,5,6,43,47,PURPOSE: Glucocorticoid administration can lead to the development of ocular hypertension and corticosteroid glaucoma in a subset of the population through a decrease in the aqueous humor outflow facility.,7843916_1,-1,-1,-1,15234,-1,0.011737712,0.98826224
15235,ocular hypertension,10,12,70,89,PURPOSE: Glucocorticoid administration can lead to the development of ocular hypertension and corticosteroid glaucoma in a subset of the population through a decrease in the aqueous humor outflow facility.,7843916_1,-1,-1,-1,15235,-1,0.001380717,0.9986193
15236,corticosteroid glaucoma,13,15,94,117,PURPOSE: Glucocorticoid administration can lead to the development of ocular hypertension and corticosteroid glaucoma in a subset of the population through a decrease in the aqueous humor outflow facility.,7843916_1,-1,-1,-1,15236,-1,0.29145384,0.7085461
15239,mm Hg,30,32,170,175,RESULTS: A significant increase in intraocular pressure developed in 13 of the 44 pairs of eyes perfused with dexamethasone with an average pressure rise of 17.5 +/- 3.8 mm Hg after 12 days of dexamethasone exposure.,7843916_7,-1,-1,-1,15239,-1,0.08267673,0.9173233
15242,contrast,1,2,3,11,"In contrast, the dexamethasone-treated hypertensive eyes had thickened trabecular beams, decreased intertrabecular spaces, thickened juxtacanalicular tissue, activated trabecular meshwork cells, and increased amounts of amorphogranular extracellular material, especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm.",7843916_10,-1,-1,-1,15242,-1,0.06333935,0.93666065
15243,hypertensive eyes,5,7,39,56,"In contrast, the dexamethasone-treated hypertensive eyes had thickened trabecular beams, decreased intertrabecular spaces, thickened juxtacanalicular tissue, activated trabecular meshwork cells, and increased amounts of amorphogranular extracellular material, especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm.",7843916_10,-1,-1,-1,15243,-1,0.0041964096,0.99580365
15245,ocular hypertension,15,17,104,123,"CONCLUSION: Dexamethasone treatment of isolated, perfusion-cultured human eyes led to the generation of ocular hypertension in approximately 30% of the dexamethasone-treated eyes.",7843916_12,-1,-1,-1,15245,-1,0.0012571568,0.9987429
15247,corticosteroid glaucoma,15,17,107,130,Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.,7843916_13,-1,-1,-1,15247,-1,0.39036617,0.60963386
15248,open angle glaucoma,18,21,135,154,Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.,7843916_13,-1,-1,-1,15248,-1,0.002851139,0.99714893
15249,steroid glaucoma,16,18,95,111,This system may provide an acute model in which to study the pathogenic mechanisms involved in steroid glaucoma and primary open angle glaucoma.,7843916_14,-1,-1,-1,15249,-1,0.32986426,0.67013574
15250,primary open angle glaucoma,19,23,116,143,This system may provide an acute model in which to study the pathogenic mechanisms involved in steroid glaucoma and primary open angle glaucoma.,7843916_14,-1,-1,-1,15250,-1,0.0028027282,0.9971973
15254,cisplatinum,9,10,74,85,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,-1,-1,-1,15254,-1,0.9990395,0.0009605346
15258,gastric adenocarcinoma,26,28,181,203,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,-1,-1,-1,15258,-1,0.0020878152,0.9979121
15260,disorientation,9,10,60,74,"He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.",7858459_2,-1,-1,-1,15260,-1,0.001421474,0.99857855
15270,5-fluorouracil neurotoxicity,3,5,20,48,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,-1,15270,-1,0.6760336,0.32396638
15271,fluoroacetate,14,15,89,102,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,-1,15271,-1,0.9992261,0.0007738778
15272,fluorocitrate,16,17,107,120,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,-1,15272,-1,0.99923694,0.00076305994
15273,thiamine,18,19,122,130,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,-1,15273,-1,0.99924386,0.0007561597
15274,dihydrouracil,22,23,146,159,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,-1,15274,-1,0.9992685,0.0007314768
15277,oxcarbazepine,5,6,37,50,Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics.,7862923_0,-1,-1,-1,15277,-1,0.9992617,0.00073830364
15278,neuroleptics,11,12,75,87,Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics.,7862923_0,-1,-1,-1,15278,-1,0.9992337,0.00076627673
15280,10-keto,5,6,34,41,"Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.",7862923_2,-1,-1,-1,15280,-1,0.9966043,0.0033956813
15281,oxcarbazepine,7,8,51,64,"Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.",7862923_2,-1,-1,-1,15281,-1,0.99927515,0.00072485686
15283,organic psychotic,13,15,111,128,"Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.",7862923_2,-1,-1,-1,15283,-1,0.0024211705,0.9975788
15287,neuroleptics,21,22,92,104,This change resulted within 2-4 weeks in the 50-200% increase in the plasma levels of these neuroleptics and the appearance of extrapyramidal symptoms.,7862923_3,-1,-1,-1,15287,-1,0.99885297,0.001147012
15289,contrast,11,12,57,65,The results of this case report support the idea that in contrast with carbamazepine oxcarbazepine does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs.,7862923_5,-1,-1,-1,15289,-1,0.9758872,0.024112884
15290,carbamazepine oxcarbazepine,13,15,71,98,The results of this case report support the idea that in contrast with carbamazepine oxcarbazepine does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs.,7862923_5,-1,-1,-1,15290,-1,0.9992919,0.00070807844
15291,antipsychotic drugs,27,29,184,203,The results of this case report support the idea that in contrast with carbamazepine oxcarbazepine does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs.,7862923_5,-1,-1,-1,15291,-1,0.9989759,0.0010241576
15292,Auditory disturbance,0,2,0,20,Auditory disturbance associated with interscalene brachial plexus block.,7880714_0,-1,-1,-1,15292,-1,0.0014796188,0.99852043
15296,h,23,24,104,105,"Three audiometric threshold measurements (0.25-18 kHz) were made: the first before IBPB, the second 2-6 h after surgery and the third on the first day after operation.",7880714_3,-1,-1,-1,15296,-1,0.3050739,0.69492614
15297,hearing impairment,3,5,17,35,"In four patients hearing impairment on the side of the block was demonstrated after operation, in three measurements on the day of surgery and in one on the following day.",7880714_4,-1,-1,-1,15297,-1,0.0031036234,0.9968964
15299,auditory dysfunction,4,6,25,45,"IBPB may cause transient auditory dysfunction in the ipsilateral ear, possibly via an effect on sympathetic innervation.",7880714_8,-1,-1,-1,15299,-1,0.001584578,0.99841535
15301,Reactive oxygen species,0,3,0,23,"Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the proteinuria.",7881871_1,-1,-1,-1,15301,-1,0.16177188,0.8382281
15302,puromycin aminonucleoside,11,13,74,99,"Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the proteinuria.",7881871_1,-1,-1,-1,15302,-1,0.99918455,0.0008154573
15306,puromycin aminonucleoside,9,11,48,73,"Rats were treated with a single IV injection of puromycin aminonucleoside, (PAN, 7.5 mg/kg) and 24 hour urine samples were obtained prior to sacrifice on days 3,5,7,10,17,27,41 (N = 5-10 per group).",7881871_3,-1,-1,-1,15306,-1,0.999129,0.00087105314
15307,PAN,13,14,76,79,"Rats were treated with a single IV injection of puromycin aminonucleoside, (PAN, 7.5 mg/kg) and 24 hour urine samples were obtained prior to sacrifice on days 3,5,7,10,17,27,41 (N = 5-10 per group).",7881871_3,-1,-1,-1,15307,-1,0.9973865,0.0026134765
15308,N,32,33,178,179,"Rats were treated with a single IV injection of puromycin aminonucleoside, (PAN, 7.5 mg/kg) and 24 hour urine samples were obtained prior to sacrifice on days 3,5,7,10,17,27,41 (N = 5-10 per group).",7881871_3,-1,-1,-1,15308,-1,0.26241538,0.7375846
15309,TRIS,9,10,48,52,"The kidneys were removed, flushed with ice cold TRIS buffer.",7881871_4,-1,-1,-1,15309,-1,0.9882708,0.01172917
15310,thiobarbituric acid reactive substances,17,21,109,148,Tissue lipid peroxidation was measured in whole homogenates as well as in lipid extracts from homogenates as thiobarbituric acid reactive substances.,7881871_6,-1,-1,-1,15310,-1,0.96145356,0.038546465
15312,proteinuric injury,11,13,68,86,This study supports the role of lipid peroxidation in mediating the proteinuric injury in PAN nephropathy.,7881871_9,-1,-1,-1,15312,-1,0.010568982,0.989431
15313,PAN nephropathy,14,16,90,105,This study supports the role of lipid peroxidation in mediating the proteinuric injury in PAN nephropathy.,7881871_9,-1,-1,-1,15313,-1,0.0017414645,0.99825853
15314,gall bladder stones,2,5,15,34,Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.,7890216_0,-1,-1,-1,15314,-1,0.0028183935,0.99718165
15316,ursodeoxycholic acid,12,14,80,100,Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.,7890216_0,-1,-1,-1,15316,-1,0.9991617,0.0008383177
15318,acromegaly,6,7,39,49,"Octreotide, an effective treatment for acromegaly, induces gall bladder stones in 13-60% of patients.",7890216_1,-1,-1,-1,15318,-1,0.0017155911,0.9982844
15319,gall bladder stones,9,12,59,78,"Octreotide, an effective treatment for acromegaly, induces gall bladder stones in 13-60% of patients.",7890216_1,-1,-1,-1,15319,-1,0.0024789318,0.9975211
15321,acromegalic,30,31,192,203,"Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones.",7890216_2,-1,-1,-1,15321,-1,0.003575213,0.99642473
15322,gall stones,33,35,218,229,"Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones.",7890216_2,-1,-1,-1,15322,-1,0.0062834914,0.99371654
15323,gall stones,3,5,21,32,"Chemical analysis of gall stones retrieved at cholecystectomy from two patients, showed that they contained 71% and 87% cholesterol by weight.",7890216_3,-1,-1,-1,15323,-1,0.009393034,0.9906069
15329,ursodeoxycholic acid,7,9,39,59,"Of the 12 patients considered for oral ursodeoxycholic acid (UDCA) treatment, two had a blocked cystic duct and were not started on UDCA while one was lost to follow up.",7890216_7,-1,-1,-1,15329,-1,0.9991375,0.0008623998
15330,UDCA,10,11,61,65,"Of the 12 patients considered for oral ursodeoxycholic acid (UDCA) treatment, two had a blocked cystic duct and were not started on UDCA while one was lost to follow up.",7890216_7,-1,-1,-1,15330,-1,0.9988318,0.0011681854
15331,UDCA,25,26,132,136,"Of the 12 patients considered for oral ursodeoxycholic acid (UDCA) treatment, two had a blocked cystic duct and were not started on UDCA while one was lost to follow up.",7890216_7,-1,-1,-1,15331,-1,0.99875116,0.0012488408
15332,n,16,17,88,89,"After one year of treatment, five of the remaining nine patients showed either partial (n = 3) or complete (n = 2) gall stone dissolution, suggesting that their stones were cholesterol rich.",7890216_8,-1,-1,-1,15332,-1,0.012150649,0.9878493
15333,n,23,24,108,109,"After one year of treatment, five of the remaining nine patients showed either partial (n = 3) or complete (n = 2) gall stone dissolution, suggesting that their stones were cholesterol rich.",7890216_8,-1,-1,-1,15333,-1,0.012132578,0.9878675
15334,gall stone,27,29,115,125,"After one year of treatment, five of the remaining nine patients showed either partial (n = 3) or complete (n = 2) gall stone dissolution, suggesting that their stones were cholesterol rich.",7890216_8,-1,-1,-1,15334,-1,0.014231065,0.985769
15336,gall stone,14,16,68,78,"This corresponds, by actuarial (life table) analysis, to a combined gall stone dissolution rate of 58.3 (15.9%).",7890216_9,-1,-1,-1,15336,-1,0.009043122,0.99095696
15338,gall stones,5,7,34,45,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,-1,-1,-1,15338,-1,0.0028627452,0.9971373
15340,gall stone disease,22,25,135,153,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,-1,-1,-1,15340,-1,0.0025054,0.9974946
15341,gall stones,38,40,226,237,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,-1,-1,-1,15341,-1,0.0035806734,0.9964193
15343,SC-48334,8,9,65,73,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,-1,-1,-1,15343,-1,0.9989083,0.0010917188
15345,HIV-1 infection,15,17,107,122,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,-1,-1,-1,15345,-1,0.012429831,0.9875702
15346,SC-48334,43,44,294,302,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,-1,-1,-1,15346,-1,0.9990029,0.0009971053
15350,SC-48334,19,20,106,114,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,-1,15350,-1,0.99915457,0.00084541936
15351,mg,22,23,121,123,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,-1,15351,-1,0.9894299,0.010570135
15352,h,25,26,132,133,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,-1,15352,-1,0.9199751,0.08002488
15354,mg,31,32,155,157,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,-1,15354,-1,0.9871727,0.012827312
15355,h,34,35,166,167,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,-1,15355,-1,0.91085416,0.08914584
15359,p,25,26,120,121,"Twenty-three patients (38%) and 15 (26%), in the combination and zidovudine groups, respectively, discontinued therapy (p = 0.15).",7905523_3,-1,-1,-1,15359,-1,0.22935502,0.770645
15360,SC-48334,2,3,9,17,The mean SC-48334 steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV).,7905523_4,-1,-1,-1,15360,-1,0.9983152,0.0016848112
15361,human immunodeficiency virus,21,24,126,154,The mean SC-48334 steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV).,7905523_4,-1,-1,-1,15361,-1,0.016688796,0.9833112
15363,p,24,25,136,137,"The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and zidovudine groups, respectively (p > 0.36).",7905523_5,-1,-1,-1,15363,-1,0.24413109,0.7558689
15367,p,32,33,143,144,"The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively.",7905523_7,-1,-1,-1,15367,-1,0.23155627,0.7684437
15368,p,52,53,194,195,"The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively.",7905523_7,-1,-1,-1,15368,-1,0.24827774,0.7517222
15370,flatulence,2,3,10,20,"Diarrhea, flatulence, abdominal pain, and weight loss were common for combination recipients.(ABSTRACT TRUNCATED AT 250 WORDS)",7905523_8,-1,-1,-1,15370,-1,0.0014073451,0.9985927
15371,abdominal pain,4,6,22,36,"Diarrhea, flatulence, abdominal pain, and weight loss were common for combination recipients.(ABSTRACT TRUNCATED AT 250 WORDS)",7905523_8,-1,-1,-1,15371,-1,0.0014472061,0.99855274
15372,weight loss,8,10,42,53,"Diarrhea, flatulence, abdominal pain, and weight loss were common for combination recipients.(ABSTRACT TRUNCATED AT 250 WORDS)",7905523_8,-1,-1,-1,15372,-1,0.0035717036,0.9964283
15374,nondepolarizing neuromuscular blocking agents,4,8,27,72,Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids.,7910951_0,-1,-1,-1,15374,-1,0.4293422,0.5706578
15376,nondepolarizing neuromuscular blocking agents,4,8,21,66,"The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.",7910951_1,-1,-1,-1,15376,-1,0.96945167,0.030548338
15377,muscle weakness,20,22,130,145,"The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.",7910951_1,-1,-1,-1,15377,-1,0.0015695432,0.99843043
15378,respiratory insufficiency,13,15,50,75,We report 3 patients (age 37-52 years) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of ND-NMBAs.,7910951_2,-1,-1,-1,15378,-1,0.0012132787,0.99878675
15381,impaired,8,9,51,59,"Renal function was normal but hepatic function was impaired in all patients, and all had acidosis.",7910951_4,-1,-1,-1,15381,-1,0.0034197809,0.9965802
15383,fibrillations,15,16,112,125,"Electrophysiologic studies revealed low amplitude compound motor action potentials, normal sensory studies, and fibrillations.",7910951_5,-1,-1,-1,15383,-1,0.001953425,0.9980465
15384,vecuronium,2,3,10,20,"The serum vecuronium level measured in 1 patient 14 days after the drug had been discontinued was 172 ng/mL. A muscle biopsy in this patient showed loss of thick, myosin filaments.",7910951_7,-1,-1,-1,15384,-1,0.99932957,0.000670492
15386,pathology at,8,10,41,53,The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).,7910951_8,-1,-1,-1,15386,-1,0.0048265513,0.9951735
15387,the neuromuscular junction,11,14,59,85,The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).,7910951_8,-1,-1,-1,15387,-1,0.012098545,0.98790145
15389,Hepatic dysfunction,0,2,0,19,Hepatic dysfunction and acidosis are contributing risk factors.,7910951_9,-1,-1,-1,15389,-1,0.0017290842,0.99827087
15391,Erythema multiforme,0,2,0,19,Erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_0,-1,-1,-1,15391,-1,0.0018758693,0.99812406
15392,hypersensitivity myocarditis,3,5,24,52,Erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_0,-1,-1,-1,15392,-1,0.0013675283,0.9986325
15394,erythema multiforme,7,9,31,50,OBJECTIVE: To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_1,-1,-1,-1,15394,-1,0.0015881126,0.9984119
15395,hypersensitivity myocarditis,10,12,55,83,OBJECTIVE: To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_1,-1,-1,-1,15395,-1,0.0012002793,0.9987997
15399,septicemia,15,16,96,106,CASE SUMMARY: A 13-year-old boy was treated with ampicillin and gentamicin because of suspected septicemia.,7919560_2,-1,-1,-1,15399,-1,0.0011392148,0.99886084
15400,erythema multiforme,4,6,35,54,Medications were discontinued when erythema multiforme and congestive heart failure caused by myocarditis occurred.,7919560_3,-1,-1,-1,15400,-1,0.001590249,0.99840975
15401,congestive heart failure,7,10,59,83,Medications were discontinued when erythema multiforme and congestive heart failure caused by myocarditis occurred.,7919560_3,-1,-1,-1,15401,-1,0.0011572173,0.9988427
15406,erythema multiforme,6,8,42,61,"DISCUSSION: After most infections causing erythema multiforme and myocarditis were ruled out, a drug-induced allergic reaction was suspected.",7919560_6,-1,-1,-1,15406,-1,0.001494389,0.9985056
15411,Hypersensitivity myocarditis,2,4,13,41,CONCLUSIONS: Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to penicillins.,7919560_8,-1,-1,-1,15411,-1,0.0013300634,0.99867
15412,allergy,11,12,83,90,CONCLUSIONS: Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to penicillins.,7919560_8,-1,-1,-1,15412,-1,0.0014605729,0.99853945
15413,penicillins,13,14,94,105,CONCLUSIONS: Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to penicillins.,7919560_8,-1,-1,-1,15413,-1,0.99856323,0.0014367362
15414,sleep disturbance,1,3,21,38,Clomipramine-induced sleep disturbance does not impair its prolactin-releasing action.,7930386_0,-1,-1,-1,15414,-1,0.001499338,0.9985007
15415,sleep disturbance,10,12,56,73,"The present study was undertaken to examine the role of sleep disturbance, induced by clomipramine administration, on the secretory rate of prolactin (PRL) in addition to the direct drug effect.",7930386_1,-1,-1,-1,15415,-1,0.0019733328,0.99802667
15417,PRL,25,26,151,154,"The present study was undertaken to examine the role of sleep disturbance, induced by clomipramine administration, on the secretory rate of prolactin (PRL) in addition to the direct drug effect.",7930386_1,-1,-1,-1,15417,-1,0.99835443,0.0016455457
15418,n,19,20,117,118,"Two groups of supine subjects were studied under placebo-controlled conditions, one during the night, when sleeping (n = 7) and the other at daytime, when awake (n = 6).",7930386_2,-1,-1,-1,15418,-1,0.15123133,0.84876865
15419,n,32,33,162,163,"Two groups of supine subjects were studied under placebo-controlled conditions, one during the night, when sleeping (n = 7) and the other at daytime, when awake (n = 6).",7930386_2,-1,-1,-1,15419,-1,0.13770561,0.8622943
15420,mg,6,7,34,36,Each subject received a single 50 mg dose of clomipramine given orally 2 hours before blood collection.,7930386_3,-1,-1,-1,15420,-1,0.99342513,0.0065748803
15422,PRL,1,2,7,10,Plasma PRL concentrations were analysed at 10 min intervals and underlying secretory rates calculated by a deconvolution procedure.,7930386_4,-1,-1,-1,15422,-1,0.9982755,0.0017244408
15423,PRL,11,12,69,72,"For both experiments the drug intake led to significant increases in PRL secretion, acting preferentially on tonic secretion as pulse amplitude and frequency did not differ significantly from corresponding control values.",7930386_5,-1,-1,-1,15423,-1,0.99670094,0.003298996
15425,PRL,5,6,28,31,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,-1,-1,-1,15425,-1,0.99720156,0.0027984616
15426,sleep disturbance,46,48,214,231,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,-1,-1,-1,15426,-1,0.002020321,0.9979797
15427,se,56,57,275,277,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,-1,-1,-1,15427,-1,0.78760535,0.21239467
15429,indocyanine green,4,6,27,44,Survey of complications of indocyanine green angiography in Japan.,7977601_0,-1,-1,-1,15429,-1,0.99762195,0.0023779809
15430,indocyanine green,7,9,36,53,PURPOSE: We evaluated the safety of indocyanine green for use in fundus angiography.,7977601_1,-1,-1,-1,15430,-1,0.99856585,0.0014342185
15431,indocyanine green,9,11,61,78,"METHODS: We sent a questionnaire concerning complications of indocyanine green to 32 institutions in Japan, which were selected on the basis of the client list from the Topcon Company, which manufactures the indocyanine green fundus camera.",7977601_2,-1,-1,-1,15431,-1,0.99885535,0.0011446422
15432,indocyanine green,35,37,208,225,"METHODS: We sent a questionnaire concerning complications of indocyanine green to 32 institutions in Japan, which were selected on the basis of the client list from the Topcon Company, which manufactures the indocyanine green fundus camera.",7977601_2,-1,-1,-1,15432,-1,0.9987362,0.001263808
15433,indocyanine green,13,15,83,100,"RESULTS: Ophthalmologists at 15 institutions responded, reporting a total of 3,774 indocyanine green angiograms performed on 2,820 patients between June 1984 and September 1992.",7977601_3,-1,-1,-1,15433,-1,0.9979803,0.0020197674
15434,indocyanine green,6,8,47,64,"Before angiography, intradermal or intravenous indocyanine green testing, or both was performed at 13 of 15 institutions.",7977601_4,-1,-1,-1,15434,-1,0.99788505,0.0021149071
15435,indocyanine green,3,5,14,31,"The dosage of indocyanine green used for angiography varied from 25 to 75 mg, depending upon the institution.",7977601_6,-1,-1,-1,15435,-1,0.9986292,0.0013708004
15436,mg,13,14,74,76,"The dosage of indocyanine green used for angiography varied from 25 to 75 mg, depending upon the institution.",7977601_6,-1,-1,-1,15436,-1,0.9627586,0.037241448
15438,exanthema,22,23,99,108,"There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as nausea, exanthema, urtication, itchiness, and urgency to defecate, and did not require treatment.",7977601_7,-1,-1,-1,15438,-1,0.0013962807,0.99860376
15439,urtication,24,25,110,120,"There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as nausea, exanthema, urtication, itchiness, and urgency to defecate, and did not require treatment.",7977601_7,-1,-1,-1,15439,-1,0.001350616,0.9986494
15440,itchiness,26,27,122,131,"There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as nausea, exanthema, urtication, itchiness, and urgency to defecate, and did not require treatment.",7977601_7,-1,-1,-1,15440,-1,0.001595594,0.99840444
15445,indocyanine green,10,12,63,80,CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography.,7977601_10,-1,-1,-1,15445,-1,0.99882394,0.0011760651
15446,fluorescein sodium,21,23,141,159,CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography.,7977601_10,-1,-1,-1,15446,-1,0.9987589,0.0012411288
15447,indocyanine green,25,27,175,192,CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography.,7977601_10,-1,-1,-1,15447,-1,0.99889165,0.0011083516
15451,pulmonary edema,12,14,62,77,"A 72-year-old woman was admitted to the hospital with ""flash"" pulmonary edema, preceded by chest pain, requiring intubation.",7988234_1,-1,-1,-1,15451,-1,0.0012162211,0.99878377
15452,chest pain,17,19,91,101,"A 72-year-old woman was admitted to the hospital with ""flash"" pulmonary edema, preceded by chest pain, requiring intubation.",7988234_1,-1,-1,-1,15452,-1,0.0012330872,0.9987669
15453,coronary artery disease,4,7,29,52,"Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus.",7988234_2,-1,-1,-1,15453,-1,0.0016391566,0.9983608
15454,myocardial infarctions,9,11,67,89,"Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus.",7988234_2,-1,-1,-1,15454,-1,0.0015086327,0.9984914
15456,diabetes mellitus,15,17,109,126,"Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus.",7988234_2,-1,-1,-1,15456,-1,0.0013741999,0.9986259
15458,lisinopril,6,7,37,47,A history of angioedema secondary to lisinopril therapy was elicited.,7988234_3,-1,-1,-1,15458,-1,0.99918467,0.00081536255
15459,angiotensin-converting enzyme inhibitors,5,8,36,76,Current medications did not include angiotensin-converting enzyme inhibitors or beta-blockers.,7988234_4,-1,-1,-1,15459,-1,0.9980362,0.0019638576
15464,diphenhydramine hydrochloride,9,11,68,97,The angioedema resolved after therapy with intravenous steroids and diphenhydramine hydrochloride.,7988234_7,-1,-1,-1,15464,-1,0.9987935,0.0012064787
15465,arterial thrombosis,8,10,54,73,Failure of ancrod in the treatment of heparin-induced arterial thrombosis.,8012887_0,-1,-1,-1,15465,-1,0.0012380176,0.998762
15471,thrombosis syndrome,34,36,230,249,"Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.",8012887_2,-1,-1,-1,15471,-1,0.0011220799,0.99887794
15473,Water,0,1,0,5,Water intoxication associated with oxytocin administration during saline-induced abortion.,803783_0,-1,-1,-1,15473,-1,0.9980216,0.0019784162
15475,abortion,8,9,81,89,Water intoxication associated with oxytocin administration during saline-induced abortion.,803783_0,-1,-1,-1,15475,-1,0.0013887613,0.9986112
15476,water,3,4,14,19,Four cases of water intoxication in connection with oxytocin administration during saline-induced abortions are described.,803783_1,-1,-1,-1,15476,-1,0.99825925,0.0017407965
15478,abortions,12,13,98,107,Four cases of water intoxication in connection with oxytocin administration during saline-induced abortions are described.,803783_1,-1,-1,-1,15478,-1,0.0014557157,0.99854434
15479,water,3,4,17,22,The mechanism of water intoxication is discussed in regard to these cases.,803783_2,-1,-1,-1,15479,-1,0.99150085,0.008499095
15481,abortions,4,5,52,61,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,-1,-1,-1,15481,-1,0.0014857932,0.99851424
15482,water,28,29,184,189,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,-1,-1,-1,15482,-1,0.9961662,0.0038337633
15483,asthenia,45,46,287,295,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,-1,-1,-1,15483,-1,0.0013873152,0.99861264
15484,muscular irritability,47,49,297,318,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,-1,-1,-1,15484,-1,0.0017129454,0.998287
15485,headaches,51,52,323,332,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,-1,-1,-1,15485,-1,0.0014323511,0.9985676
15487,lactate,8,9,45,52,"The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.",803783_4,-1,-1,-1,15487,-1,0.998151,0.0018489248
15488,lactate,15,16,81,88,"The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.",803783_4,-1,-1,-1,15488,-1,0.9981881,0.0018119697
15489,dextrose,21,22,106,114,"The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.",803783_4,-1,-1,-1,15489,-1,0.998818,0.0011819352
15500,tuberculous,8,9,35,46,as well as of those of seven other tuberculous patients.,804391_4,-1,-1,-1,15500,-1,0.00404511,0.9959549
15502,KF17837,0,1,0,7,KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.,8045270_0,-1,-1,-1,15502,-1,0.9983177,0.0016822929
15504,KF17837,0,1,0,7,KF17837 is a novel selective adenosine A2A receptor antagonist.,8045270_1,-1,-1,-1,15504,-1,0.9984365,0.00156347
15506,KF17837,3,4,23,30,"Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.",8045270_2,-1,-1,-1,15506,-1,0.99888307,0.0011169321
15507,cataleptic,15,16,88,98,"Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.",8045270_2,-1,-1,-1,15507,-1,0.027896753,0.9721032
15509,CGS 21680,28,30,197,206,"Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.",8045270_2,-1,-1,-1,15509,-1,0.9989957,0.0010042422
15510,KF17837,0,1,0,7,KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.).,8045270_3,-1,-1,-1,15510,-1,0.9989379,0.0010620467
15514,KF17837,2,3,10,17,"Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.).",8045270_5,-1,-1,-1,15514,-1,0.99878854,0.0012114963
15515,"L-3,4-dihydroxyphenylalanine",18,19,102,130,"Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.).",8045270_5,-1,-1,-1,15515,-1,0.99882704,0.0011729588
15516,"L-3,4-dihydroxyphenylalanine",18,19,102,130,"Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.).",8045270_5,-1,-1,-1,15516,-1,0.99882704,0.0011729588
15517,"L-3,4-dihydroxyphenylalanine",18,19,102,130,"Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.).",8045270_5,-1,-1,-1,15517,-1,0.99882704,0.0011729588
15518,benserazide,28,29,160,171,"Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.).",8045270_5,-1,-1,-1,15518,-1,0.99922657,0.0007734133
15519,KF17837,4,5,29,36,These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists.,8045270_6,-1,-1,-1,15519,-1,0.99872786,0.0012720854
15522,KF17837,2,3,13,20,"Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism.",8045270_7,-1,-1,-1,15522,-1,0.99828476,0.0017152138
15526,teratogenic,17,18,82,93,"Coniine, an alkaloid from Conium maculatum (poison hemlock), has been shown to be teratogenic in livestock.",8073369_1,-1,-1,-1,15526,-1,0.002660818,0.9973392
15527,arthrogryposis,5,6,33,47,"The major teratogenic outcome is arthrogryposis, presumably due to nicotinic receptor blockade.",8073369_2,-1,-1,-1,15527,-1,0.001298591,0.99870133
15529,arthrogryposis,7,8,39,53,"However, coniine has failed to produce arthrogryposis in rats or mice and is only weakly teratogenic in rabbits.",8073369_3,-1,-1,-1,15529,-1,0.0014054246,0.9985946
15530,teratogenic,16,17,89,100,"However, coniine has failed to produce arthrogryposis in rats or mice and is only weakly teratogenic in rabbits.",8073369_3,-1,-1,-1,15530,-1,0.0022979863,0.99770206
15535,deformations,3,4,22,34,Both compounds caused deformations and lethality in a dose-dependent manner.,8073369_6,-1,-1,-1,15535,-1,0.0018573295,0.9981427
15536,nicotine sulfate,3,5,22,38,All concentrations of nicotine sulfate caused some lethality but a no effect level for coniine lethality was 0.75%.,8073369_7,-1,-1,-1,15536,-1,0.99890983,0.0010901266
15538,deformations,1,2,4,16,The deformations caused by both coniine and nicotine sulfate were excessive flexion or extension of one or more toes.,8073369_8,-1,-1,-1,15538,-1,0.0018848215,0.9981152
15541,excessive flexion or extension of one or more toes,10,19,66,116,The deformations caused by both coniine and nicotine sulfate were excessive flexion or extension of one or more toes.,8073369_8,-1,-1,-1,15541,-1,0.0055234623,0.9944765
15542,cranial hemorrhage,25,27,146,164,"No histopathological alterations or differences in bone formation were seen in the limbs or toes of any chicks from any group; however, extensive cranial hemorrhage occurred in all nicotine sulfate-treated chicks.",8073369_9,-1,-1,-1,15542,-1,0.0016567475,0.9983432
15544,P,6,7,39,40,There was a statistically significant (P < or = 0.01) decrease in movement in coniine and nicotine sulfate treated chicks as determined by ultrasound.,8073369_10,-1,-1,-1,15544,-1,0.4148536,0.5851464
15548,arthrogryposis,16,17,105,119,"In summary, the chick embryo provides a reliable and simple experimental animal model of coniine-induced arthrogryposis.",8073369_12,-1,-1,-1,15548,-1,0.0012618101,0.9987382
15552,allergic,27,28,159,167,"A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.",8092427_2,-1,-1,-1,15552,-1,0.0040664054,0.9959336
15553,allergic,34,35,219,227,"A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.",8092427_2,-1,-1,-1,15553,-1,0.002306875,0.9976931
15555,AX,39,40,254,256,"A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.",8092427_2,-1,-1,-1,15555,-1,0.98263794,0.017362049
15557,benzylpenicilloate,10,11,74,92,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,-1,-1,-1,15557,-1,0.9989133,0.001086678
15558,benzylpenicillin,12,13,94,110,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,-1,-1,-1,15558,-1,0.99906415,0.00093591004
15559,PG,14,15,112,114,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,-1,-1,-1,15559,-1,0.9979145,0.0020855514
15561,AMP,19,20,129,132,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,-1,-1,-1,15561,-1,0.9980077,0.001992323
15562,AX,23,24,139,141,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,-1,-1,-1,15562,-1,0.97003484,0.029965209
15563,BPO,7,8,33,36,"When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX.",8092427_5,-1,-1,-1,15563,-1,0.0032272837,0.9967727
15564,PG,22,23,134,136,"When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX.",8092427_5,-1,-1,-1,15564,-1,0.99636334,0.0036366847
15565,AX,26,27,155,157,"When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX.",8092427_5,-1,-1,-1,15565,-1,0.99412054,0.0058793817
15566,allergic,8,9,42,50,A total of 177 patients were diagnosed as allergic to beta-lactam antibiotics.,8092427_6,-1,-1,-1,15566,-1,0.0026286268,0.9973713
15567,AX allergy,11,13,46,56,We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of PG.,8092427_7,-1,-1,-1,15567,-1,0.0029122753,0.9970878
15568,PG,17,18,80,82,We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of PG.,8092427_7,-1,-1,-1,15568,-1,0.043589555,0.9564104
15572,BPO,8,9,44,47,"All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to MDM, and 44 of 46 (96%) to PG.",8092427_9,-1,-1,-1,15572,-1,0.009768818,0.9902312
15573,MDM,21,22,86,89,"All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to MDM, and 44 of 46 (96%) to PG.",8092427_9,-1,-1,-1,15573,-1,0.9927504,0.007249636
15574,PG,32,33,113,115,"All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to MDM, and 44 of 46 (96%) to PG.",8092427_9,-1,-1,-1,15574,-1,0.9748073,0.025192704
15575,AX,3,4,16,18,Skin tests with AX were positive in 34 (63%) patients.,8092427_10,-1,-1,-1,15575,-1,0.120596856,0.8794031
15576,AX,4,5,22,24,RAST was positive for AX in 22 patients (41%) and to BPO in just 5 (9%).,8092427_11,-1,-1,-1,15576,-1,0.007022534,0.99297744
15577,BPO,14,15,53,56,RAST was positive for AX in 22 patients (41%) and to BPO in just 5 (9%).,8092427_11,-1,-1,-1,15577,-1,0.0031815202,0.9968184
15578,AX,8,9,40,42,None of the sera with negative RAST for AX were positive to BPO.,8092427_12,-1,-1,-1,15578,-1,0.018779159,0.98122084
15579,BPO,12,13,60,63,None of the sera with negative RAST for AX were positive to BPO.,8092427_12,-1,-1,-1,15579,-1,0.017148614,0.9828514
15580,AX,3,4,21,23,"Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.",8092427_13,-1,-1,-1,15580,-1,0.9230275,0.07697251
15582,AX,22,23,121,123,"Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.",8092427_13,-1,-1,-1,15582,-1,0.8602169,0.13978305
15583,AX,38,39,175,177,"Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.",8092427_13,-1,-1,-1,15583,-1,0.87643427,0.123565726
15584,PG,0,1,0,2,PG was well tolerated by all 54 patients.,8092427_14,-1,-1,-1,15584,-1,0.9893111,0.010688977
15585,PG,11,12,73,75,We describe the largest group of AX-allergic patients who have tolerated PG reported so far.,8092427_15,-1,-1,-1,15585,-1,0.9254235,0.074576445
15594,myocardial infarctions,5,7,35,57,"Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0.001), for 60 minutes.",809711_3,-1,-1,-1,15594,-1,0.0016493347,0.99835074
15596,mm Hg,27,29,165,170,"Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0.001), for 60 minutes.",809711_3,-1,-1,-1,15596,-1,0.13163348,0.8683665
15597,P,30,31,172,173,"Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0.001), for 60 minutes.",809711_3,-1,-1,-1,15597,-1,0.48733672,0.51266325
15598,mm Hg,15,17,70,75,Left ventricular filling pressure decreased from 19 +/- 2 to 11 +/- 2 mm Hg (P less than 0.001).,809711_4,-1,-1,-1,15598,-1,0.035541017,0.964459
15599,P,18,19,77,78,Left ventricular filling pressure decreased from 19 +/- 2 to 11 +/- 2 mm Hg (P less than 0.001).,809711_4,-1,-1,-1,15599,-1,0.376037,0.62396294
15600,P,14,15,77,78,"SigmaST, the sum of ST-segment elevations in 16 precordial leads, decreased (P less than 0.02) with intravenous nitroglycerin.",809711_5,-1,-1,-1,15600,-1,0.40502483,0.5949752
15603,mm Hg,17,19,108,113,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,-1,15603,-1,0.09255621,0.90744376
15604,P,20,21,115,116,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,-1,15604,-1,0.585697,0.41430303
15605,mm Hg,39,41,206,211,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,-1,15605,-1,0.08049177,0.9195082
15606,P,42,43,213,214,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,-1,15606,-1,0.5370927,0.46290734
15607,P,53,54,273,274,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,-1,15607,-1,0.59962356,0.40037638
15613,MPTP,11,12,65,69,A group of four monkeys was rendered parkinsonian with the toxin MPTP.,8106150_1,-1,-1,-1,15613,-1,0.99868196,0.001318042
15616,dyskinetic movements,22,24,135,155,A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.,8106150_4,-1,-1,-1,15616,-1,0.001622309,0.9983777
15618,physostigmine,6,7,36,49,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,-1,-1,15618,-1,0.999268,0.0007320229
15619,methysergide,8,9,51,63,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,-1,-1,15619,-1,0.999238,0.00076196523
15620,5-MDOT,10,11,65,71,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,-1,-1,15620,-1,0.99870014,0.0012998608
15622,MK-801,15,16,90,96,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,-1,-1,15622,-1,0.9990386,0.00096147205
15623,dyskinetic movements,20,22,119,139,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,-1,-1,15623,-1,0.0014340244,0.998566
15626,meperidine,4,5,23,33,"However, yohimbine and meperidine reduced predominantly the dyskinetic movements.",8106150_6,-1,-1,-1,15626,-1,0.9993175,0.00068245636
15627,dyskinetic movements,8,10,60,80,"However, yohimbine and meperidine reduced predominantly the dyskinetic movements.",8106150_6,-1,-1,-1,15627,-1,0.0015130593,0.9984869
15628,Baclofen,0,1,0,8,Baclofen was also useful in one monkey against a more dystonic form of dyskinesia.,8106150_7,-1,-1,-1,15628,-1,0.99912685,0.00087310886
15629,dystonic,10,11,54,62,Baclofen was also useful in one monkey against a more dystonic form of dyskinesia.,8106150_7,-1,-1,-1,15629,-1,0.0014773569,0.9985227
15632,dystonic movements,3,5,23,41,Atropine converted the dystonic movements into chorea.,8106150_8,-1,-1,-1,15632,-1,0.0015061923,0.9984938
15633,chorea,6,7,47,53,Atropine converted the dystonic movements into chorea.,8106150_8,-1,-1,-1,15633,-1,0.0013802174,0.9986198
15648,hallucinatory,22,23,148,161,"The clinician should be alerted for possible ifosfamide-induced hallucinations, which may occur without other signs of neurotoxicity. ""Eyes-closed"" hallucinatory experiences appear to be an unusual feature of this presentation.",8111719_9,-1,-1,-1,15648,-1,0.0014860979,0.9985139
15650,neuroleptics,6,7,42,54,"If agitation becomes marked, high-potency neuroleptics (i.e., haloperidol) may be effective.",8111719_12,-1,-1,-1,15650,-1,0.9988794,0.0011205812
15653,neuromuscular disorders,7,9,69,92,Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders.,8170551_0,-1,-1,-1,15653,-1,0.0012576622,0.9987424
15654,Carbonic anhydrase,0,2,0,18,Carbonic anhydrase inhibitors can cause nephrolithiasis.,8170551_1,-1,-1,-1,15654,-1,0.99638224,0.003617754
15656,periodic paralysis,11,13,86,104,We studied 20 patients receiving long-term carbonic anhydrase inhibitor treatment for periodic paralysis and myotonia.,8170551_2,-1,-1,-1,15656,-1,0.0011946567,0.9988054
15657,myotonia,14,15,109,117,We studied 20 patients receiving long-term carbonic anhydrase inhibitor treatment for periodic paralysis and myotonia.,8170551_2,-1,-1,-1,15657,-1,0.0011685069,0.99883145
15658,acetazolamide,3,4,18,31,Three patients on acetazolamide (15%) developed renal calculi.,8170551_3,-1,-1,-1,15658,-1,0.9991222,0.00087775086
15659,renal calculi,9,11,48,61,Three patients on acetazolamide (15%) developed renal calculi.,8170551_3,-1,-1,-1,15659,-1,0.001756661,0.99824333
15660,calculus,6,7,56,64,"Extracorporeal lithotripsy successfully removed a renal calculus in one patient and surgery removed a staghorn calculus in another, permitting continued treatment.",8170551_4,-1,-1,-1,15660,-1,0.0022934538,0.99770653
15661,calculus,15,16,111,119,"Extracorporeal lithotripsy successfully removed a renal calculus in one patient and surgery removed a staghorn calculus in another, permitting continued treatment.",8170551_4,-1,-1,-1,15661,-1,0.0027052732,0.9972947
15663,acetazolamide,5,6,37,50,Nephrolithiasis is a complication of acetazolamide but does not preclude its use.,8170551_6,-1,-1,-1,15663,-1,0.9991923,0.00080767134
15664,calcium channel blockers,2,5,11,35,Effects of calcium channel blockers on bupivacaine-induced toxicity.,8231633_0,-1,-1,-1,15664,-1,0.9989335,0.0010665252
15666,calcium channel blockers,11,14,62,86,The purpose of this study was to investigate the influence of calcium channel blockers on bupivacaine-induced acute toxicity.,8231633_1,-1,-1,-1,15666,-1,0.9990557,0.00094431994
15668,calcium channel blockers,6,9,29,53,"For each of the three tested calcium channel blockers (diltiazem, verapamil and bepridil) 6 groups of mice were treated by two different doses, i.e. 2 and 10 mg/kg/i.p., or an equal volume of saline for the control group (n = 20); 15 minutes later, all the animals were injected with a single 50 mg/kg/i.p.",8231633_2,-1,-1,-1,15668,-1,0.9983993,0.0016006763
15672,n,45,46,222,223,"For each of the three tested calcium channel blockers (diltiazem, verapamil and bepridil) 6 groups of mice were treated by two different doses, i.e. 2 and 10 mg/kg/i.p., or an equal volume of saline for the control group (n = 20); 15 minutes later, all the animals were injected with a single 50 mg/kg/i.p.",8231633_2,-1,-1,-1,15672,-1,0.22511636,0.7748836
15674,calcium channel blockers,11,14,90,114,The local anesthetic-induced mortality was significantly increased by the three different calcium channel blockers.,8231633_5,-1,-1,-1,15674,-1,0.998321,0.001678979
15676,calcium channel blockers,10,13,74,98,The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.,8231633_6,-1,-1,-1,15676,-1,0.99894077,0.0010592317
15679,facial telangiectasia,2,4,36,57,Photodistributed nifedipine-induced facial telangiectasia.,8251368_0,-1,-1,-1,15679,-1,0.0015250585,0.9984749
15681,Adalat,6,7,39,45,"Five months after starting nifedipine (Adalat), two patients developed photodistributed facial telangiectasia, which became more noticeable with time.",8251368_1,-1,-1,-1,15681,-1,0.9989221,0.0010778598
15682,telangiectasia,14,15,95,109,"Five months after starting nifedipine (Adalat), two patients developed photodistributed facial telangiectasia, which became more noticeable with time.",8251368_1,-1,-1,-1,15682,-1,0.0014513859,0.99854857
15683,flushing,6,7,50,58,Neither patient complained of photosensitivity or flushing.,8251368_2,-1,-1,-1,15683,-1,0.0014987092,0.9985013
15684,amlodipine,6,7,39,49,"One commenced the closely related drug amlodipine 3 years later, with recurrence of telangiectasia.",8251368_4,-1,-1,-1,15684,-1,0.9993857,0.00061425765
15685,telangiectasia,14,15,84,98,"One commenced the closely related drug amlodipine 3 years later, with recurrence of telangiectasia.",8251368_4,-1,-1,-1,15685,-1,0.0013871052,0.9986129
15686,telangiectasia,4,5,29,43,The photodistribution of the telangiectasia suggests a significant drug/light interaction.,8251368_5,-1,-1,-1,15686,-1,0.0012018937,0.99879813
15691,RPGN,11,12,96,100,A 67-year-old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.,8267029_1,-1,-1,-1,15691,-1,0.0013205513,0.99867946
15695,antiplatelet,12,13,81,93,"The patient was treated with steroid pulse, plasmapheresis, cyclophosphamide and antiplatelet agents.",8267029_4,-1,-1,-1,15695,-1,0.9969627,0.003037226
15696,RPGN,4,5,17,21,This new case of RPGN in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients.,8267029_6,-1,-1,-1,15696,-1,0.0014621747,0.9985378
15698,polymyositis,3,4,10,22,A case of polymyositis in a patient with primary biliary cirrhosis treated with D-penicillamine.,8268147_0,-1,-1,-1,15698,-1,0.0013132591,0.99868673
15699,primary biliary cirrhosis,8,11,41,66,A case of polymyositis in a patient with primary biliary cirrhosis treated with D-penicillamine.,8268147_0,-1,-1,-1,15699,-1,0.0018492399,0.99815077
15700,rheumatologic diseases,7,9,48,70,"Although D-penicillamine has been used for many rheumatologic diseases, toxicity limits its usefulness in many patients.",8268147_1,-1,-1,-1,15700,-1,0.0016525319,0.9983475
15702,primary biliary cirrhosis,5,8,25,50,"We report a patient with primary biliary cirrhosis, who developed polymyositis while receiving D-penicillamine therapy.",8268147_3,-1,-1,-1,15702,-1,0.0016847532,0.9983152
15703,polymyositis,11,12,66,78,"We report a patient with primary biliary cirrhosis, who developed polymyositis while receiving D-penicillamine therapy.",8268147_3,-1,-1,-1,15703,-1,0.0012821523,0.9987179
15704,autoimmune,12,13,95,105,Patients receiving D-penicillamine therapy should be followed carefully for the development of autoimmune complications like polymyositis/dermatomyositis.,8268147_5,-1,-1,-1,15704,-1,0.0012426232,0.99875736
15713,hyperesthesia,6,7,51,64,Five patients developed universal hyperalgesia and hyperesthesia which in 2 cases were accompanied by myoclonus.,8278214_3,-1,-1,-1,15713,-1,0.001196667,0.9988034
15715,neuralgia,5,6,29,38,In 3 patients a pre-existing neuralgia increased to excruciating intensity and in 2 of these cases myoclonus occurred simultaneously.,8278214_4,-1,-1,-1,15715,-1,0.0011025791,0.99889743
15719,prostaglandin E1,4,6,27,43,Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension.,8302922_0,-1,-1,-1,15719,-1,0.9988199,0.0011801089
15720,trimethaphan,7,8,47,59,Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension.,8302922_0,-1,-1,-1,15720,-1,0.99896634,0.0010337043
15722,prostaglandin E1,5,7,26,42,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,-1,-1,-1,15722,-1,0.99888986,0.0011101655
15723,PGE1,8,9,44,48,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,-1,-1,-1,15723,-1,0.99863297,0.0013669911
15724,trimethaphan,11,12,53,65,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,-1,-1,-1,15724,-1,0.9990891,0.0009108459
15725,TMP,13,14,67,70,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,-1,-1,-1,15725,-1,0.99877375,0.0012262523
15728,PGE1,7,8,47,51,"An initial dose of 0.1 microgram.kg-1.min-1 of PGE1 (15 patients), or 10 micrograms.kg-1.min-1 of TMP (15 patients) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure (MAP) at about 60 mmHg.",8302922_2,-1,-1,-1,15728,-1,0.9990113,0.0009886381
15729,TMP,17,18,98,101,"An initial dose of 0.1 microgram.kg-1.min-1 of PGE1 (15 patients), or 10 micrograms.kg-1.min-1 of TMP (15 patients) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure (MAP) at about 60 mmHg.",8302922_2,-1,-1,-1,15729,-1,0.99909115,0.0009088313
15730,MAP,42,43,243,246,"An initial dose of 0.1 microgram.kg-1.min-1 of PGE1 (15 patients), or 10 micrograms.kg-1.min-1 of TMP (15 patients) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure (MAP) at about 60 mmHg.",8302922_2,-1,-1,-1,15730,-1,0.06924102,0.930759
15732,PGE1,2,3,15,19,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,-1,15732,-1,0.9990074,0.0009926079
15733,TMP,4,5,23,26,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,-1,15733,-1,0.9985207,0.0014793073
15734,MAP,6,7,28,31,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,-1,15734,-1,0.82964903,0.17035101
15735,P,21,22,122,123,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,-1,15735,-1,0.5249431,0.47505686
15737,PGE1,33,34,170,174,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,-1,15737,-1,0.99893385,0.001066189
15738,PGE1,5,6,27,31,"EBFF did not change during PGE1 infusion whereas in the TMP group, EBF decreased significantly at 30 and 60 min after the start of TMP (preinfusion: 45.9 +/- 13.9 ml/100g/min.",8302922_6,-1,-1,-1,15738,-1,0.9990802,0.00091983454
15739,TMP,10,11,56,59,"EBFF did not change during PGE1 infusion whereas in the TMP group, EBF decreased significantly at 30 and 60 min after the start of TMP (preinfusion: 45.9 +/- 13.9 ml/100g/min.",8302922_6,-1,-1,-1,15739,-1,0.9989807,0.0010192815
15740,TMP,25,26,131,134,"EBFF did not change during PGE1 infusion whereas in the TMP group, EBF decreased significantly at 30 and 60 min after the start of TMP (preinfusion: 45.9 +/- 13.9 ml/100g/min.",8302922_6,-1,-1,-1,15740,-1,0.99904495,0.0009550456
15741,P,10,11,35,36,30 min: 32.3 +/- 9.9 ml/100 g/min (P < 0.05).,8302922_7,-1,-1,-1,15741,-1,0.4150999,0.5849001
15742,P,10,11,33,34,60 min: 30 +/- 7.5 ml/100 g/min (P < 0.05)).,8302922_8,-1,-1,-1,15742,-1,0.3921746,0.6078254
15743,PGE1,4,5,27,31,These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.,8302922_9,-1,-1,-1,15743,-1,0.9988024,0.0011975911
15744,TMP,9,10,53,56,These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.,8302922_9,-1,-1,-1,15744,-1,0.9987161,0.0012838984
15746,TMP,17,18,111,114,These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.,8302922_9,-1,-1,-1,15746,-1,0.99844533,0.0015547142
15748,Kaposi's sarcoma,4,7,35,51,Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study.,8305357_0,-1,-1,-1,15748,-1,0.0024225577,0.9975775
15750,DaunoXome,18,19,112,121,We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.,8305357_1,-1,-1,-1,15750,-1,0.99921274,0.0007871838
15751,AIDS,24,25,143,147,We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.,8305357_1,-1,-1,-1,15751,-1,0.0022119114,0.9977881
15752,Kaposi's sarcoma,26,29,156,172,We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.,8305357_1,-1,-1,-1,15752,-1,0.0018439533,0.998156
15753,Kaposi's sarcoma,5,8,36,52,Eleven homosexual men with advanced Kaposi's sarcoma were entered in the trial.,8305357_2,-1,-1,-1,15753,-1,0.0021824476,0.9978175
15754,oedema,7,8,39,45,"Changes in size, colour and associated oedema of selected 'target' lesions were measured.",8305357_3,-1,-1,-1,15754,-1,0.0020146777,0.99798536
15756,Kaposi's sarcoma,2,5,17,33,"Stabilization of Kaposi's sarcoma occurred in the remaining six, maintained until the end of the trial period in four.",8305357_7,-1,-1,-1,15756,-1,0.002194475,0.99780554
15758,haematological toxicity,5,7,33,56,"The main problem encountered was haematological toxicity, with three subjects experiencing severe neutropenia (neutrophil count < 0.5 x 10(9)/l).",8305357_9,-1,-1,-1,15758,-1,0.0014270466,0.99857295
15762,Kaposi's sarcoma,19,22,115,131,"In this small patient sample, liposomal daunorubicin was an effective and well tolerated agent in the treatment of Kaposi's sarcoma.",8305357_11,-1,-1,-1,15762,-1,0.0022982745,0.9977017
15763,Dup 753,0,2,0,7,Dup 753 prevents the development of puromycin aminonucleoside-induced nephrosis.,8319760_0,-1,-1,-1,15763,-1,0.9988219,0.001178013
15765,nephrotic syndromes,3,5,18,37,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15765,-1,0.0011484169,0.99885154
15767,hypoalbuminemia,9,10,59,74,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15767,-1,0.0012494237,0.99875057
15769,increase in blood nitrogen urea,13,18,101,132,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15769,-1,0.58677834,0.4132216
15770,puromycin aminonucleoside,25,27,166,191,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15770,-1,0.9992538,0.00074611214
15771,Dup 753,34,36,241,248,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15771,-1,0.99914956,0.0008504652
15774,hearing loss,9,11,72,84,Neuroplasticity of the adult primate auditory cortex following cochlear hearing loss.,8372922_0,-1,-1,-1,15774,-1,0.0023555479,0.9976445
15775,hearing loss,17,19,110,122,The purpose of this study was to determine if changes occur in this tonotopic organization following cochlear hearing loss.,8372922_3,-1,-1,-1,15775,-1,0.003283323,0.9967167
15778,hearing loss,16,18,100,112,The region of cortex that represents the low frequencies was not obviously affected by the cochlear hearing loss.,8372922_10,-1,-1,-1,15778,-1,0.0027728414,0.99722713
15780,Lymphoma,5,6,34,42,Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.,8384253_1,-1,-1,-1,15780,-1,0.0019861497,0.99801385
15782,mg,17,18,110,112,Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.,8384253_1,-1,-1,-1,15782,-1,0.99380976,0.006190232
15784,neuropathic symptoms,7,9,47,67,The patients were interviewed with emphasis on neuropathic symptoms.,8384253_2,-1,-1,-1,15784,-1,0.0015417588,0.99845827
15786,neuropathic symptoms,3,5,31,51,Twenty-seven patients reported neuropathic symptoms.,8384253_4,-1,-1,-1,15786,-1,0.0014271146,0.9985728
15787,signs and symptoms,4,7,26,44,In these patients sensory signs and symptoms predominated.,8384253_6,-1,-1,-1,15787,-1,0.0027298192,0.99727017
15788,Neuropathic,0,1,0,11,Neuropathic complaints were not very troublesome on the long term.,8384253_11,-1,-1,-1,15788,-1,0.001636412,0.99836355
15790,signs and symptoms,11,14,72,90,It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good.,8384253_12,-1,-1,-1,15790,-1,0.0023758127,0.9976242
15791,vincristine neuropathy,15,17,94,116,It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good.,8384253_12,-1,-1,-1,15791,-1,0.68934286,0.31065717
15792,Sodium bicarbonate,0,2,0,18,Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.,8386779_0,-1,-1,-1,15792,-1,0.99889886,0.0011011474
15794,erectile dysfunction,10,12,83,103,Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.,8386779_0,-1,-1,-1,15794,-1,0.0014272451,0.9985727
15797,sodium bicarbonate,42,44,275,293,"In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication, we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications.",8386779_1,-1,-1,-1,15797,-1,0.9989642,0.0010357576
15798,impotence,12,13,68,77,A total of 38 consecutive patients who presented to our clinic with impotence received 0.2 ml.,8386779_2,-1,-1,-1,15798,-1,0.0016804121,0.99831957
15799,mg,8,9,31,33,of a combination of 3 drugs: 6 mg.,8386779_3,-1,-1,-1,15799,-1,0.978626,0.021374043
15801,phentolamine,0,1,0,12,phentolamine and 10 micrograms.,8386779_5,-1,-1,-1,15801,-1,0.99923766,0.00076230726
15802,prostaglandin E1,0,2,0,16,prostaglandin E1 with (pH 7.05) or without (pH 4.17) the addition of sodium bicarbonate (0.03 mEq.).,8386779_6,-1,-1,-1,15802,-1,0.9987417,0.0012583548
15803,sodium bicarbonate,16,18,69,87,prostaglandin E1 with (pH 7.05) or without (pH 4.17) the addition of sodium bicarbonate (0.03 mEq.).,8386779_6,-1,-1,-1,15803,-1,0.9990814,0.0009186706
15804,sodium bicarbonate,5,7,27,45,"Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.",8386779_7,-1,-1,-1,15804,-1,0.9989924,0.0010075656
15806,sodium bicarbonate,38,40,173,191,"Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.",8386779_7,-1,-1,-1,15806,-1,0.99905473,0.0009452939
15811,ddI,7,8,36,39,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,-1,-1,-1,15811,-1,0.99775404,0.0022459507
15813,(AZT)One,16,17,103,111,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,-1,-1,-1,15813,-1,0.9241983,0.07580171
15815,AZT,25,26,169,172,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,-1,-1,-1,15815,-1,0.9989158,0.0010842057
15817,ddI,30,31,195,198,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,-1,-1,-1,15817,-1,0.99742657,0.0025734224
15818,opportunistic infections,4,6,33,57,Seventy patients developed major opportunistic infections whilst on therapy; this was the first AIDS diagnosis in 17.,8387218_2,-1,-1,-1,15818,-1,0.0014260658,0.9985739
15819,AIDS,14,15,96,100,Seventy patients developed major opportunistic infections whilst on therapy; this was the first AIDS diagnosis in 17.,8387218_2,-1,-1,-1,15819,-1,0.0017203375,0.9982797
15820,AIDS,12,13,68,72,"Only minor changes in CD4+ lymphocyte subset count were observed in AIDS patients, although a more significant rise occurred in those with earlier stages of disease.",8387218_3,-1,-1,-1,15820,-1,0.002860655,0.99713933
15822,diarrhoea,5,6,32,41,"The most common side-effect was diarrhoea, which resulted in cessation of therapy in 19 individuals.",8387218_8,-1,-1,-1,15822,-1,0.0014697468,0.99853027
15824,pancreatitis,7,8,50,62,Peripheral neuropathy occurred in 12 patients and pancreatitis in six.,8387218_9,-1,-1,-1,15824,-1,0.0013972856,0.9986027
15825,abdominal pain,8,10,59,73,Thirteen patients developed a raised serum amylase without abdominal pain.,8387218_10,-1,-1,-1,15825,-1,0.0017014416,0.9982986
15829,adenomas,1,2,8,16,Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives: case reports.,839274_0,-1,-1,-1,15829,-1,0.0016836462,0.9983164
15830,nodular hyperplasia,4,6,27,46,Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives: case reports.,839274_0,-1,-1,-1,15830,-1,0.0017635822,0.9982364
15832,adenoma,4,5,21,28,"Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.",839274_1,-1,-1,-1,15832,-1,0.0015168642,0.9984831
15833,focal nodular hyperplasia,8,11,40,65,"Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.",839274_1,-1,-1,-1,15833,-1,0.0016559408,0.99834406
15835,adenoma,7,8,65,72,Histologic differences and clinical similarities between hepatic adenoma and focal nodular hyperplasia of the liver are discussed.,839274_4,-1,-1,-1,15835,-1,0.0018747743,0.99812526
15836,focal nodular hyperplasia,9,12,77,102,Histologic differences and clinical similarities between hepatic adenoma and focal nodular hyperplasia of the liver are discussed.,839274_4,-1,-1,-1,15836,-1,0.0021281417,0.9978719
15837,neurofilament,5,6,47,60,Immunohistochemical studies with antibodies to neurofilament proteins on axonal damage in experimental focal lesions in rat.,8410052_0,-1,-1,-1,15837,-1,0.9959998,0.0040001962
15838,proteins,6,7,61,69,Immunohistochemical studies with antibodies to neurofilament proteins on axonal damage in experimental focal lesions in rat.,8410052_0,-1,-1,-1,15838,-1,0.988827,0.011173005
15839,axonal damage,8,10,73,86,Immunohistochemical studies with antibodies to neurofilament proteins on axonal damage in experimental focal lesions in rat.,8410052_0,-1,-1,-1,15839,-1,0.0019542538,0.9980457
15840,axonal injury,26,28,160,173,"Immunohistochemistry with monoclonal antibodies against neurofilament (NF) proteins of middle and high molecular weight class, NF-M and NF-H, was used to study axonal injury in the borderzone of focal lesions in rats.",8410052_1,-1,-1,-1,15840,-1,0.0019648934,0.99803513
15841,lactate,10,11,55,62,Focal injury in the cortex was produced by infusion of lactate at acid pH or by stab caused by needle insertion.,8410052_2,-1,-1,-1,15841,-1,0.99879897,0.0012010004
15842,Infarcts,0,1,0,8,Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine-induced status epilepticus.,8410052_3,-1,-1,-1,15842,-1,0.001902189,0.99809784
15843,status epilepticus,11,13,90,108,Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine-induced status epilepticus.,8410052_3,-1,-1,-1,15843,-1,0.0016146334,0.9983854
15844,axonal damage,11,13,67,80,These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental traumatic or ischemic lesions.,8410052_6,-1,-1,-1,15844,-1,0.00194083,0.9980591
15845,traumatic,16,17,105,114,These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental traumatic or ischemic lesions.,8410052_6,-1,-1,-1,15845,-1,0.0024947599,0.99750525
15846,ischemic lesions,18,20,118,134,These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental traumatic or ischemic lesions.,8410052_6,-1,-1,-1,15846,-1,0.0017087401,0.9982913
15849,glutamic acid,9,11,56,69,In situ hybridization methods were used to determine if glutamic acid decarboxylase (GAD) mRNA-containing neurons within the hilus of the dentate gyrus are vulnerable to seizure-induced damage in a model of chronic seizures.,8410199_1,-1,-1,-1,15849,-1,0.9978027,0.0021973534
15854,neuronal degeneration,9,11,71,92,"Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.",8410199_4,-1,-1,-1,15854,-1,0.0018504877,0.9981495
15855,glial fibrillary acidic protein,17,21,136,167,"Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.",8410199_4,-1,-1,-1,15855,-1,0.99219394,0.007806089
15856,neuronal loss,36,38,257,270,"Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.",8410199_4,-1,-1,-1,15856,-1,0.001981599,0.9980184
15857,GABA,12,13,89,93,Such differential vulnerability appears to be another indication of the heterogeneity of GABA neurons.,8410199_9,-1,-1,-1,15857,-1,0.99730265,0.0026973756
15858,confusion.15,9,10,83,95,Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion.15 cases of cimetidine-associated mental confusion have been reported.,84204_0,-1,-1,-1,15858,-1,0.004920059,0.9950799
15861,liver dysfunction,7,9,36,53,"These 6 patients had both renal and liver dysfunction (P less than 0.05), as well as cimetidine trough-concentrations of more than 1.25 microgram/ml (P less than 0.05).",84204_2,-1,-1,-1,15861,-1,0.0016374206,0.9983626
15862,P,10,11,55,56,"These 6 patients had both renal and liver dysfunction (P less than 0.05), as well as cimetidine trough-concentrations of more than 1.25 microgram/ml (P less than 0.05).",84204_2,-1,-1,-1,15862,-1,0.12630397,0.873696
15864,P,27,28,150,151,"These 6 patients had both renal and liver dysfunction (P less than 0.05), as well as cimetidine trough-concentrations of more than 1.25 microgram/ml (P less than 0.05).",84204_2,-1,-1,-1,15864,-1,0.29691195,0.70308805
15869,hepatic dysfunction,17,19,116,135,Patients likely to have both raised trough-concentrations and mental confusion are those with both severe renal and hepatic dysfunction.,84204_5,-1,-1,-1,15869,-1,0.0017189834,0.998281
15872,gallstone,16,17,107,116,Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.,8421099_0,-1,-1,-1,15872,-1,0.0026213261,0.9973787
15873,acromegalic,20,21,138,149,Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.,8421099_0,-1,-1,-1,15873,-1,0.0020501034,0.9979499
15874,acromegaly,17,18,120,130,This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active acromegaly treated with sc injection of the somatostatin analog octreotide in dosages of 300-1500 micrograms/day for a mean of 24.2 +/- 13.9 months.,8421099_1,-1,-1,-1,15874,-1,0.0018060344,0.9981939
15877,gallstones,12,13,71,81,"During treatment with octreotide, 17 patients developed sludge, 10 had gallstones, and 1 developed acute cholecystitis requiring surgery.",8421099_2,-1,-1,-1,15877,-1,0.0019520386,0.99804795
15878,cholecystitis,18,19,105,118,"During treatment with octreotide, 17 patients developed sludge, 10 had gallstones, and 1 developed acute cholecystitis requiring surgery.",8421099_2,-1,-1,-1,15878,-1,0.001379666,0.9986204
15881,gallstones,8,9,54,64,"After withdrawal of octreotide in 10 patients without gallstones, 8 patients assessed had return of normal gallbladder contractility within 1 month.",8421099_5,-1,-1,-1,15881,-1,0.0020443266,0.9979557
15882,gallstones,9,10,48,58,"In 8 of the remaining 10 patients who developed gallstones during treatment, gallbladder contractility normalized in 5 patients (3 of whom has disappearance of their stones within 3 weeks), and remained depressed in 3 (2 of whom had stones present at 6 months).",8421099_6,-1,-1,-1,15882,-1,0.0023601097,0.9976399
15884,gallstones,20,21,127,137,"Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.",8421099_7,-1,-1,-1,15884,-1,0.002841218,0.99715877
15885,cholecystitis,23,24,143,156,"Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.",8421099_7,-1,-1,-1,15885,-1,0.0015093826,0.9984906
15887,acromegalic,29,30,194,205,"Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.",8421099_7,-1,-1,-1,15887,-1,0.0023799597,0.99762005
15889,acromegalic,17,18,116,127,It is therefore very important to follow the changes of gallbladder function during long-term octreotide therapy of acromegalic patients.,8421099_8,-1,-1,-1,15889,-1,0.0020292723,0.99797076
15890,Parkinson disability,2,4,12,32,Increase of Parkinson disability after fluoxetine medication.,8423889_0,-1,-1,-1,15890,-1,0.001717598,0.99828243
15893,Parkinson's disease,7,10,42,61,Depression is a major clinical feature of Parkinson's disease.,8423889_1,-1,-1,-1,15893,-1,0.002530862,0.9974692
15895,idiopathic Parkinson's disease,12,16,73,103,We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine.,8423889_2,-1,-1,-1,15895,-1,0.002050725,0.9979493
15896,antidepressant fluoxetine,20,22,126,151,We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine.,8423889_2,-1,-1,-1,15896,-1,0.9988644,0.0011356567
15898,Parkinson's disease,11,14,89,108,The possibility of a clinically relevant dopamine-antagonistic capacity of fluoxetine in Parkinson's disease patients must be considered.,8423889_3,-1,-1,-1,15898,-1,0.002958575,0.9970414
15911,anxiety,37,38,214,221,"The following psychological tests were performed: four subtests of the Wechsler Adult Intelligence Scale (similarities, digit span, vocabulary and digit symbol), Trail-Making tests A and B, Zung tests (self-rating anxiety scale and self-rating depression scale) and two-part memory test battery with immediate and delayed recall.",8424298_5,-1,-1,-1,15911,-1,0.005022427,0.99497753
15916,Sinus arrest,0,2,0,12,Sinus arrest associated with continuous-infusion cimetidine.,8437969_0,-1,-1,-1,15916,-1,0.0019396592,0.9980603
15919,bradyarrhythmias,15,16,122,138,The administration of intermittent intravenous infusions of cimetidine is infrequently associated with the development of bradyarrhythmias.,8437969_1,-1,-1,-1,15919,-1,0.0012192508,0.9987808
15920,leukemia,4,5,23,31,"A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.",8437969_2,-1,-1,-1,15920,-1,0.001181597,0.99881834
15921,cardiac disease,9,11,50,65,"A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.",8437969_2,-1,-1,-1,15921,-1,0.0014107844,0.9985892
15922,sinus arrest,18,20,114,126,"A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.",8437969_2,-1,-1,-1,15922,-1,0.0015881942,0.9984118
15927,sinus arrest,7,9,35,47,This is the first reported case of sinus arrest associated with continuous-infusion cimetidine.,8437969_4,-1,-1,-1,15927,-1,0.001617774,0.9983822
15930,erosive rheumatoid arthritis,12,15,78,106,We describe the induction of sustained remissions and possible cure of severe erosive rheumatoid arthritis (RA) by bone marrow transplantation (BMT) in 2 patients.,8441146_1,-1,-1,-1,15930,-1,0.0012813403,0.99871874
15931,RA,16,17,108,110,We describe the induction of sustained remissions and possible cure of severe erosive rheumatoid arthritis (RA) by bone marrow transplantation (BMT) in 2 patients.,8441146_1,-1,-1,-1,15931,-1,0.0014081737,0.99859184
15933,gold,12,13,65,69,BMT was used to treat severe aplastic anemia which was caused by gold in one case and D-penicillamine in the other.,8441146_2,-1,-1,-1,15933,-1,0.99867576,0.001324184
15934,RA,26,27,140,142,"In the 8 and 6 years since the transplants (representing 8 and 4 years since cessation of all immunosuppressive therapy, respectively), the RA in each case has been completely quiescent.",8441146_3,-1,-1,-1,15934,-1,0.0018981557,0.9981019
15935,RA,6,7,40,42,"Although short term remission of severe RA following BMT has been reported, these are the first cases for which prolonged followup has been available.",8441146_4,-1,-1,-1,15935,-1,0.0013773994,0.99862266
15936,synovitis,20,21,129,138,This experience raises the question of the role of BMT itself as a therapeutic option for patients with uncontrolled destructive synovitis.,8441146_5,-1,-1,-1,15936,-1,0.0012933408,0.9987067
15939,fluvoxamine,6,7,36,47,It seems that combined treatment of fluvoxamine with phenothiazines may possess proconvulsive activity.,8473723_2,-1,-1,-1,15939,-1,0.9992725,0.0007275088
15940,phenothiazines,8,9,53,67,It seems that combined treatment of fluvoxamine with phenothiazines may possess proconvulsive activity.,8473723_2,-1,-1,-1,15940,-1,0.9992341,0.0007658803
15941,pentamidine,3,4,13,24,Case report: pentamidine and polymorphic ventricular tachycardia revisited.,8475949_0,-1,-1,-1,15941,-1,0.999154,0.00084597094
15943,Pentamidine isethionate,0,2,0,23,"Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.",8475949_1,-1,-1,-1,15943,-1,0.9990007,0.0009993018
15944,ventricular tachyarrhythmias,6,8,49,77,"Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.",8475949_1,-1,-1,-1,15944,-1,0.0012649207,0.99873513
15945,torsade de pointes,10,13,89,107,"Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.",8475949_1,-1,-1,-1,15945,-1,0.0016507666,0.9983492
15946,torsade de pointes,1,4,20,38,Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.,8475949_3,-1,-1,-1,15946,-1,0.0015210203,0.99847895
15948,hypomagnesemia,12,13,84,98,Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.,8475949_3,-1,-1,-1,15948,-1,0.0017802963,0.99821967
15949,torsade.,16,18,126,134,Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.,8475949_3,-1,-1,-1,15949,-1,0.0060103405,0.9939897
15950,Torsade de pointes,0,3,0,18,Torsade de pointes occurred after an average of 10 days of treatment with pentamidine.,8475949_4,-1,-1,-1,15950,-1,0.0018484015,0.9981516
15951,pentamidine,13,14,74,85,Torsade de pointes occurred after an average of 10 days of treatment with pentamidine.,8475949_4,-1,-1,-1,15951,-1,0.9992169,0.00078309997
15952,pentamidine,10,11,50,61,"In these patients, no other acute side effects of pentamidine were observed.",8475949_5,-1,-1,-1,15952,-1,0.9991528,0.00084719795
15953,Torsade de pointes,0,3,0,18,"Torsade de pointes can be treated when recognized early, possibly without discontinuation of pentamidine.",8475949_6,-1,-1,-1,15953,-1,0.0017945716,0.9982054
15954,pentamidine,14,15,93,104,"Torsade de pointes can be treated when recognized early, possibly without discontinuation of pentamidine.",8475949_6,-1,-1,-1,15954,-1,0.99923563,0.0007643703
15955,QTc interval prolongation,1,4,5,30,"When QTc interval prolongation is observed, early magnesium supplementation is advocated.",8475949_7,-1,-1,-1,15955,-1,0.006326763,0.9936732
15963,mg,40,41,234,236,"DESIGN: The Expanded Clinical Evaluation of Lovastatin (EXCEL) Study, a multicenter, double-blind, diet- and placebo-controlled trial, in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily, or 20 or 40 mg twice daily for 48 weeks.",8480959_2,-1,-1,-1,15963,-1,0.9947695,0.005230429
15964,mg,48,49,261,263,"DESIGN: The Expanded Clinical Evaluation of Lovastatin (EXCEL) Study, a multicenter, double-blind, diet- and placebo-controlled trial, in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily, or 20 or 40 mg twice daily for 48 weeks.",8480959_2,-1,-1,-1,15964,-1,0.9953389,0.004661066
15965,n,4,5,17,18,PATIENTS: Women (n = 3390) from the total cohort of 8245 volunteers.,8480959_4,-1,-1,-1,15965,-1,0.14462756,0.8553725
15967,triglycerides,20,21,111,124,"MEASUREMENTS: Plasma total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol, and triglycerides; and laboratory and clinical evidence of adverse events monitored periodically throughout the study.",8480959_5,-1,-1,-1,15967,-1,0.99599564,0.004004363
15969,P,23,24,108,109,"RESULTS: Among women, lovastatin (20 to 80 mg/d) produced sustained (12- to 48-week), dose-related changes (P < 0.001): decreases in LDL cholesterol (24% to 40%) and triglycerides (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%).",8480959_6,-1,-1,-1,15969,-1,0.30441454,0.6955855
15971,triglycerides,39,40,166,179,"RESULTS: Among women, lovastatin (20 to 80 mg/d) produced sustained (12- to 48-week), dose-related changes (P < 0.001): decreases in LDL cholesterol (24% to 40%) and triglycerides (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%).",8480959_6,-1,-1,-1,15971,-1,0.97547174,0.024528332
15976,creatine kinase,7,9,42,57,"Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).",8480959_9,-1,-1,-1,15976,-1,0.99815375,0.0018462182
15978,mg,34,35,200,202,"Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).",8480959_9,-1,-1,-1,15978,-1,0.9877293,0.012270732
15986,hypokalemia,3,4,21,32,"Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.",8492347_1,-1,-1,-1,15986,-1,0.0015616238,0.9984384
15988,hypomagnesemia,7,8,51,65,"Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.",8492347_1,-1,-1,-1,15988,-1,0.0017295608,0.9982704
15989,hypokalemia,2,3,13,24,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,-1,-1,-1,15989,-1,0.0018081254,0.9981919
15990,muscle weakness,5,7,35,50,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,-1,-1,-1,15990,-1,0.0014693057,0.9985306
15991,hypomagnesemia,9,10,59,73,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,-1,-1,-1,15991,-1,0.0018509509,0.99814904
15992,muscle spasms,13,15,93,106,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,-1,-1,-1,15992,-1,0.0014515158,0.99854845
15996,diuretic,1,2,14,22,"Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.",8492347_3,-1,-1,-1,15996,-1,0.9948442,0.0051558116
15997,obese,16,17,101,106,"Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.",8492347_3,-1,-1,-1,15997,-1,0.0033526057,0.9966474
15998,edematous,18,19,110,119,"Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.",8492347_3,-1,-1,-1,15998,-1,0.002029645,0.9979703
15999,hypokalemia,1,2,12,23,"Symptomatic hypokalemia has been reported in such patients (3-7) and in one case hypocalcemia was observed (8), but the effects of magnesium depletion were not noted in these patients.",8492347_4,-1,-1,-1,15999,-1,0.001487829,0.9985122
16007,acute renal failure,6,9,40,59,Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.,8494478_2,-1,-1,-1,16007,-1,0.0011789752,0.99882096
16010,Allergic interstitial nephritis,0,3,0,31,Allergic interstitial nephritis is believed to be the underlying pathological-process.,8494478_4,-1,-1,-1,16010,-1,0.001284863,0.99871516
16011,acute renal failure,19,22,155,174,An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of ciprofloxacin-induced acute renal failure.,8494478_6,-1,-1,-1,16011,-1,0.0011880508,0.99881196
16012,Venous complications,0,2,0,20,Venous complications of midazolam versus diazepam.,8514073_0,-1,-1,-1,16012,-1,0.0018635005,0.9981365
16015,venous complications,6,8,43,63,"Although some studies have suggested fewer venous complications are associated with midazolam than with diazepam for endoscopic procedures, this variable has not been well documented.",8514073_1,-1,-1,-1,16015,-1,0.0018607448,0.99813926
16018,venous complications,6,8,44,64,We prospectively evaluated the incidence of venous complications after intravenous injection of diazepam or midazolam in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy.,8514073_2,-1,-1,-1,16018,-1,0.0016393472,0.9983607
16021,venous complications,2,4,9,29,"Overall, venous complications were more frequent with diazepam (22 of 62 patients) than with midazolam (4 of 60 patients) (p < 0.001).",8514073_3,-1,-1,-1,16021,-1,0.0016591048,0.99834085
16024,p,25,26,123,124,"Overall, venous complications were more frequent with diazepam (22 of 62 patients) than with midazolam (4 of 60 patients) (p < 0.001).",8514073_3,-1,-1,-1,16024,-1,0.24942653,0.75057346
16027,p,36,37,148,149,"A palpable venous cord was present in 23% (14 of 62) of patients in the diazepam group, compared with 2% (1 of 60 patients) in the midazolam group (p < 0.002).",8514073_4,-1,-1,-1,16027,-1,0.25329816,0.74670184
16031,p,35,36,148,149,Pain at the injection site occurred in 35% (22 of 62) of patients in the diazepam group compared with 7% (4 of 60 patients) in the midazolam group (p < 0.001).,8514073_5,-1,-1,-1,16031,-1,0.25519225,0.7448077
16032,Swelling,0,1,0,8,Swelling and warmth at the injection site were not significantly different between the two groups.,8514073_6,-1,-1,-1,16032,-1,0.0018961076,0.99810386
16036,venous complications,32,34,180,200,"Smoking, nonsteroidal anti-inflammatory drug use, intravenous catheter site, dwell time of the needle, alcohol use, and pain during the injection had no effect on the incidence of venous complications.",8514073_7,-1,-1,-1,16036,-1,0.001643969,0.99835604
16041,uremia,14,15,83,89,Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se.,8546130_1,-1,-1,-1,16041,-1,0.0013680441,0.9986319
16042,se,16,17,94,96,Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se.,8546130_1,-1,-1,-1,16042,-1,0.004743755,0.99525625
16044,macrolide,13,14,92,101,"Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.",8546130_2,-1,-1,-1,16044,-1,0.99870217,0.0012978158
16045,clarithromycin,16,17,114,128,"Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.",8546130_2,-1,-1,-1,16045,-1,0.9991571,0.00084295514
16046,renal disease,10,12,52,65,We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD).,8546130_3,-1,-1,-1,16046,-1,0.0014758657,0.9985241
16047,ESRD,13,14,67,71,We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD).,8546130_3,-1,-1,-1,16047,-1,0.0013619874,0.998638
16048,clarithromycin,8,9,45,59,"The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.",8546130_4,-1,-1,-1,16048,-1,0.9992411,0.0007588848
16050,aluminum,23,24,145,153,"The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.",8546130_4,-1,-1,-1,16050,-1,0.99820673,0.0017932291
16053,ESRD,33,34,204,208,"It is important to understand the pharmacokinetics of medications in face of chronic renal failure, the possibility of drug interactions, and how these factors should help guide medication therapy in the ESRD patient.",8546130_5,-1,-1,-1,16053,-1,0.0015002548,0.99849975
16054,hepatoma,7,8,50,58,Changes in peroxisomes in preneoplastic liver and hepatoma of mice induced by alpha-benzene hexachloride.,85485_0,-1,-1,-1,16054,-1,0.00150066,0.9984994
16055,hepatomas,2,3,15,24,Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically.,85485_1,-1,-1,-1,16055,-1,0.0016408415,0.99835914
16056,liver lesions,6,8,56,69,Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically.,85485_1,-1,-1,-1,16056,-1,0.0019186329,0.9980813
16057,hepatomas,4,5,21,30,"Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.",85485_2,-1,-1,-1,16057,-1,0.0022476579,0.99775237
16060,hepatomas,17,18,96,105,"These cells proliferated further, replacing the most part of the nodules, and with this process hepatomas appeared to have been formed.",85485_6,-1,-1,-1,16060,-1,0.0038670502,0.99613297
16062,squamous cell esophageal carcinoma,7,11,44,78,Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma.,8558192_0,-1,-1,-1,16062,-1,0.0023220442,0.997678
16066,VNB,27,28,180,183,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,-1,-1,-1,16066,-1,0.9987664,0.0012335618
16067,squamous cell esophageal carcinoma,36,40,230,264,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,-1,-1,-1,16067,-1,0.0026502698,0.99734974
16069,VNB,0,1,0,3,VNB was administered weekly as a 25-mg/m2 short intravenous (i.v.) infusion.,8558192_3,-1,-1,-1,16069,-1,0.99736744,0.0026326305
16070,CR,16,17,73,75,"One of 16 patients (6%) with prior chemotherapy had a complete response (CR) of 31 weeks' duration (95% CI, 0% to 30%).",8558192_6,-1,-1,-1,16070,-1,0.003439831,0.99656016
16071,DI,4,5,27,29,The median dose-intensity (DI) was 20 mg/m2/wk.,8558192_8,-1,-1,-1,16071,-1,0.0108093275,0.9891907
16072,VNB,0,1,0,3,VNB was well tolerated and zero instances of WHO grade 4 nonhematologic toxicity occurred.,8558192_9,-1,-1,-1,16072,-1,0.99200624,0.007993756
16074,granulocytopenia,9,10,37,53,At least one episode of grade 3 or 4 granulocytopenia was seen in 59% of patients.,8558192_10,-1,-1,-1,16074,-1,0.0011748105,0.99882513
16077,peripheral neurotoxicity,7,9,34,58,"Other side effects were rare, and peripheral neurotoxicity has been minor (26% grade 1).",8558192_12,-1,-1,-1,16077,-1,0.0014493736,0.9985506
16078,VNB,6,7,37,40,CONCLUSION: These data indicate that VNB is an active agent in metastatic esophageal squamous cell carcinoma.,8558192_13,-1,-1,-1,16078,-1,0.99835265,0.0016473862
16079,esophageal squamous cell carcinoma,13,17,74,108,CONCLUSION: These data indicate that VNB is an active agent in metastatic esophageal squamous cell carcinoma.,8558192_13,-1,-1,-1,16079,-1,0.0024562636,0.99754375
16081,VNB,12,13,78,81,"Given its excellent tolerance profile and low toxicity, further evaluation of VNB in combination therapy is warranted.",8558192_14,-1,-1,-1,16081,-1,0.9960299,0.003970112
16085,sodium chloride,30,32,202,217,"OBJECTIVE: To test the hypothesis that, in lifetime captopril-treated spontaneously hypertensive rats (SHR), the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation.",8586822_1,-1,-1,-1,16085,-1,0.999159,0.00084103004
16087,sodium chloride,25,27,131,146,METHODS: Male SHR (aged 6 weeks) that had been treated from conception onward with either captopril or vehicle remained on a basal sodium chloride diet or were fed a high sodium chloride diet.,8586822_2,-1,-1,-1,16087,-1,0.99906975,0.00093032775
16088,sodium chloride,33,35,171,186,METHODS: Male SHR (aged 6 weeks) that had been treated from conception onward with either captopril or vehicle remained on a basal sodium chloride diet or were fed a high sodium chloride diet.,8586822_2,-1,-1,-1,16088,-1,0.99870753,0.0012925221
16092,MAP,13,14,92,95,Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced increase in MAP in both groups.,8586822_5,-1,-1,-1,16092,-1,0.651532,0.348468
16094,MAP,22,23,160,163,Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced increase in MAP in both groups.,8586822_5,-1,-1,-1,16094,-1,0.58619463,0.41380534
16096,MAP,17,18,124,127,Infusion of the central nervous system alpha2-adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.,8586822_6,-1,-1,-1,16096,-1,0.93134815,0.06865181
16097,sodium chloride,34,36,199,214,Infusion of the central nervous system alpha2-adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.,8586822_6,-1,-1,-1,16097,-1,0.9990721,0.00092785957
16098,sodium chloride,22,24,141,156,"CONCLUSIONS: In both lifetime captopril-treated and control SHR, the sympathetic nervous system contributes to the pressor effects of a high sodium chloride diet.",8586822_7,-1,-1,-1,16098,-1,0.9991037,0.00089624827
16099,aponidine hydrochloride,5,7,35,58,Evaluation of adverse reactions of aponidine hydrochloride ophthalmic solution.,8590259_0,-1,-1,-1,16099,-1,0.99922657,0.0007734222
16100,apraclonidine,7,8,52,65,We prospectively evaluated the adverse reactions of apraclonidine in 20 normal volunteers by instilling a single drop of 1% apraclonidine in their right eyes.,8590259_1,-1,-1,-1,16100,-1,0.99921143,0.00078858266
16101,apraclonidine,20,21,124,137,We prospectively evaluated the adverse reactions of apraclonidine in 20 normal volunteers by instilling a single drop of 1% apraclonidine in their right eyes.,8590259_1,-1,-1,-1,16101,-1,0.9992293,0.00077074073
16102,ocular hypotensive,1,3,4,22,The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% apraclonidine.,8590259_3,-1,-1,-1,16102,-1,0.0016494549,0.9983506
16103,apraclonidine,29,30,224,237,The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% apraclonidine.,8590259_3,-1,-1,-1,16103,-1,0.99923456,0.0007654243
16104,Decreases in systolic blood pressure,0,5,0,36,"Decreases in systolic blood pressure were statistically, but not clinically, significant.",8590259_4,-1,-1,-1,16104,-1,0.014984433,0.9850155
16105,Conjunctival blanching,0,2,0,22,Conjunctival blanching and mydriasis were commonly found.,8590259_6,-1,-1,-1,16105,-1,0.002172949,0.997827
16106,mydriasis,3,4,27,36,Conjunctival blanching and mydriasis were commonly found.,8590259_6,-1,-1,-1,16106,-1,0.0015950121,0.99840504
16107,mm,16,17,83,85,"While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance, one subject suffered from mechanical entropion and marked corneal abrasion 3 hours after instillation of the medication.",8590259_8,-1,-1,-1,16107,-1,0.015377308,0.98462266
16108,entropion,31,32,174,183,"While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance, one subject suffered from mechanical entropion and marked corneal abrasion 3 hours after instillation of the medication.",8590259_8,-1,-1,-1,16108,-1,0.0015514076,0.9984486
16109,corneal abrasion,34,36,195,211,"While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance, one subject suffered from mechanical entropion and marked corneal abrasion 3 hours after instillation of the medication.",8590259_8,-1,-1,-1,16109,-1,0.0018178143,0.9981822
16117,mg,21,22,81,83,"Patients in Group C received 2 ml normal saline, Group L, 2 ml, lidocaine 2% (40 mg) and Group T, 2 ml thiopentone 2.5% (50 mg).",8595686_3,-1,-1,-1,16117,-1,0.98007995,0.019920068
16119,mg,34,35,124,126,"Patients in Group C received 2 ml normal saline, Group L, 2 ml, lidocaine 2% (40 mg) and Group T, 2 ml thiopentone 2.5% (50 mg).",8595686_3,-1,-1,-1,16119,-1,0.9736213,0.02637868
16121,Loss of consciousness,0,3,0,21,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,-1,-1,16121,-1,0.0029769626,0.99702305
16122,SD,16,17,78,80,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,-1,-1,16122,-1,0.17460635,0.8253937
16123,C,42,43,170,171,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,-1,-1,16123,-1,0.9359607,0.064039215
16124,P,50,51,187,188,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,-1,-1,16124,-1,0.3198147,0.68018526
16125,P,14,15,64,65,The incidence of venous discomfort was lower in Group L (76.6%; P < 0.05) than in Group C (100%) but not different from Group T (90%).,8595686_6,-1,-1,-1,16125,-1,0.43716267,0.5628373
16127,P,24,25,121,122,The VAS scores for recall of pain in the recovery room were correlated with the VAS scores during induction (r = 0.7045; P < 0.0001).,8595686_7,-1,-1,-1,16127,-1,0.44299895,0.5570011
16128,C,7,8,44,45,Recovery room discharge times were similar: C (75.9 +/- 19.4 min); L 73.6 +/- 21.6 min); T (77.1 +/- 18.9 min).,8595686_8,-1,-1,-1,16128,-1,0.9221085,0.077891566
16135,droperidol,3,4,27,37,Angioedema associated with droperidol administration.,8599504_0,-1,-1,-1,16135,-1,0.9982651,0.0017349711
16137,angioneurotic edema,5,7,26,45,"Angioedema, also known as angioneurotic edema or Quincke's disease, is a well-demarcated, localized edema involving the subcutaneous tissues that may cause upper-airway obstruction.",8599504_1,-1,-1,-1,16137,-1,0.0012652496,0.9987348
16138,Quincke's disease,8,11,49,66,"Angioedema, also known as angioneurotic edema or Quincke's disease, is a well-demarcated, localized edema involving the subcutaneous tissues that may cause upper-airway obstruction.",8599504_1,-1,-1,-1,16138,-1,0.024577927,0.975422
16140,drug allergies,13,15,73,87,We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.,8599504_2,-1,-1,-1,16140,-1,0.08082263,0.9191774
16142,tongue swelling,20,22,124,139,We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.,8599504_2,-1,-1,-1,16142,-1,0.0017341205,0.9982659
16143,droperidol,37,38,228,238,We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.,8599504_2,-1,-1,-1,16143,-1,0.99898475,0.0010152105
16145,malignant bone tumor,6,9,42,62,Late cardiotoxicity after treatment for a malignant bone tumor.,8600333_0,-1,-1,-1,16145,-1,0.0020230012,0.99797696
16146,bone tumors,9,11,66,77,"Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.",8600333_1,-1,-1,-1,16146,-1,0.0019751687,0.9980248
16147,Rosen's T5,16,19,108,118,"Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.",8600333_1,-1,-1,-1,16147,-1,0.955512,0.044487968
16148,T10,20,21,122,125,"Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.",8600333_1,-1,-1,-1,16148,-1,0.9717937,0.028206322
16153,left ventricular dilation,30,33,167,192,"Eighteen of 31 (58%) patients showed cardiac toxicity, defined as having one or more of the following abnormalities: late potentials, complex ventricular arrhythmias, left ventricular dilation, decreased shortening fraction, or decreased ejection fraction.",8600333_5,-1,-1,-1,16153,-1,0.0026565061,0.9973435
16154,cardiac abnormalities,3,5,17,38,The incidence of cardiac abnormalities increased with length of follow-up (P< or = .05).,8600333_6,-1,-1,-1,16154,-1,0.0018892457,0.9981108
16155,P,11,12,75,76,The incidence of cardiac abnormalities increased with length of follow-up (P< or = .05).,8600333_6,-1,-1,-1,16155,-1,0.3648652,0.6351348
16160,systemic hypertension,10,12,69,90,Acute blood pressure elevations with caffeine in men with borderline systemic hypertension.,8607407_0,-1,-1,-1,16160,-1,0.0017048985,0.9982951
16165,n,4,5,29,30,Borderline hypertensive men (n = 24) were selected with screening systolic blood pressure (BP) of 140 to 160 mm Hg and/or diastolic BP 90 to 99 mm Hg.,8607407_3,-1,-1,-1,16165,-1,0.050172403,0.9498277
16166,mm Hg,22,24,109,114,Borderline hypertensive men (n = 24) were selected with screening systolic blood pressure (BP) of 140 to 160 mm Hg and/or diastolic BP 90 to 99 mm Hg.,8607407_3,-1,-1,-1,16166,-1,0.04078314,0.9592169
16167,mm Hg,30,32,144,149,Borderline hypertensive men (n = 24) were selected with screening systolic blood pressure (BP) of 140 to 160 mm Hg and/or diastolic BP 90 to 99 mm Hg.,8607407_3,-1,-1,-1,16167,-1,0.03724261,0.96275735
16168,n,3,4,19,20,Low-risk controls (n = 24) reported no parental history of hypertension and had screening BP < 130/85 mm Hg.,8607407_4,-1,-1,-1,16168,-1,0.09891845,0.90108156
16170,mm Hg,19,21,102,107,Low-risk controls (n = 24) reported no parental history of hypertension and had screening BP < 130/85 mm Hg.,8607407_4,-1,-1,-1,16170,-1,0.033836704,0.9661632
16172,mm Hg,23,25,120,125,"Caffeine-induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls (+8.4 vs +3.8 mm Hg, p < 0.0001), and were attributable to larger changes in impedance-derived measures of systemic vascular resistance (+135 vs +45 dynes.s.cm-5, p < 0.004).",8607407_6,-1,-1,-1,16172,-1,0.02145125,0.9785487
16173,p,26,27,127,128,"Caffeine-induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls (+8.4 vs +3.8 mm Hg, p < 0.0001), and were attributable to larger changes in impedance-derived measures of systemic vascular resistance (+135 vs +45 dynes.s.cm-5, p < 0.004).",8607407_6,-1,-1,-1,16173,-1,0.36652952,0.6334705
16174,p,52,53,269,270,"Caffeine-induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls (+8.4 vs +3.8 mm Hg, p < 0.0001), and were attributable to larger changes in impedance-derived measures of systemic vascular resistance (+135 vs +45 dynes.s.cm-5, p < 0.004).",8607407_6,-1,-1,-1,16174,-1,0.33467227,0.6653277
16179,hypertensives,34,35,219,232,"Thus, in borderline hypertensive men, exaggerated responses to caffeine were: selective for diastolic BP, consistent with greater vasoconstriction, replicated in 2 protocols, and representative of nearly all borderline hypertensives.",8607407_10,-1,-1,-1,16179,-1,0.0026550791,0.9973449
16181,disease progression,22,24,145,164,"We suspect that the potential for caffeine to stabilize high resistance states in susceptible persons suggests that its use may facilitate their disease progression, as well as hinder accurate diagnosis and treatment.",8607407_11,-1,-1,-1,16181,-1,0.002223992,0.997776
16183,cognitive impairment,9,11,63,83,Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol.,8617710_0,-1,-1,-1,16183,-1,0.0013216786,0.99867827
16189,mg,12,13,65,67,METHOD: All subjects received placebo on Day 1 and haloperidol 2 mg on Days 2 and 25.,8617710_2,-1,-1,-1,16189,-1,0.99530363,0.004696332
16192,Impairment of cognitive function,2,6,9,41,RESULTS: Impairment of cognitive function was observed 6 to 8 hours after administration of haloperidol on Day 2 but was not evident 23 hours after dosing.,8617710_5,-1,-1,-1,16192,-1,0.0029499186,0.99705005
16200,cognitive impairment,8,10,52,72,CONCLUSION: Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant sertraline administration.,8617710_11,-1,-1,-1,16200,-1,0.0013699417,0.99863005
16203,atracurium,6,7,44,54,Persistent paralysis after prolonged use of atracurium in the absence of corticosteroids.,8638206_0,-1,-1,-1,16203,-1,0.99901915,0.0009808027
16205,Neuromuscular blocking agents,0,3,0,29,Neuromuscular blocking agents (NMBAs) are often used for patients requiring prolonged mechanical ventilation.,8638206_1,-1,-1,-1,16205,-1,0.97449255,0.025507463
16207,vecuronium bromide,18,20,130,148,"Reports of persistent paralysis after the discontinuance of these drugs have most often involved aminosteroid-based NMBAs such as vecuronium bromide, especially when used in conjunction with corticosteroids.",8638206_2,-1,-1,-1,16207,-1,0.99924636,0.0007536189
16209,Atracurium besylate,0,2,0,19,"Atracurium besylate, a short-acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function, has also been associated with persistent paralysis, but only when used with corticosteroids.",8638206_3,-1,-1,-1,16209,-1,0.9992507,0.0007492572
16210,benzylisoquinolinium,5,6,36,56,"Atracurium besylate, a short-acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function, has also been associated with persistent paralysis, but only when used with corticosteroids.",8638206_3,-1,-1,-1,16210,-1,0.999044,0.0009560106
16215,internal carotid artery thrombosis,6,10,41,75,Coexistence of cerebral venous sinus and internal carotid artery thrombosis associated with exogenous sex hormones.,8638876_0,-1,-1,-1,16215,-1,0.0027298112,0.99727017
16216,sex,13,14,102,105,Coexistence of cerebral venous sinus and internal carotid artery thrombosis associated with exogenous sex hormones.,8638876_0,-1,-1,-1,16216,-1,0.9981242,0.0018757757
16218,nausea and vomiting,8,11,61,80,"A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.",8638876_2,-1,-1,-1,16218,-1,0.0015315148,0.99846846
16219,hemiparesis,13,14,87,98,"A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.",8638876_2,-1,-1,-1,16219,-1,0.0011984857,0.99880147
16223,Diabetes mellitus,0,2,0,17,Diabetes mellitus (DM) was found during admission.,8638876_3,-1,-1,-1,16223,-1,0.002019727,0.9979803
16224,DM,3,4,19,21,Diabetes mellitus (DM) was found during admission.,8638876_3,-1,-1,-1,16224,-1,0.002032188,0.9979678
16225,hemorrhagic infarct,4,6,29,48,Computed tomography showed a hemorrhagic infarct in the right frontal lobe and increased density in the superior sagittal sinus (SSS).,8638876_4,-1,-1,-1,16225,-1,0.0015364067,0.99846363
16226,venous sinus thrombosis,15,18,91,114,"Right carotid angiograms failed to show the SSS and inferior sagittal sinus, suggestive of venous sinus thrombosis.",8638876_6,-1,-1,-1,16226,-1,0.0017679443,0.99823207
16227,occlusion,9,10,56,65,Coexistence of the cerebral artery and the venous sinus occlusion has been described infrequently.,8638876_7,-1,-1,-1,16227,-1,0.0019452632,0.99805474
16230,DM,17,18,98,100,"In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.",8638876_8,-1,-1,-1,16230,-1,0.0022888756,0.99771106
16232,lung cancer,6,8,51,62,Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.,8643966_0,-1,-1,-1,16232,-1,0.0018206042,0.99817944
16235,Taxol,2,3,12,17,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.",8643966_1,-1,-1,-1,16235,-1,0.9990637,0.0009363409
16239,lung cancer,18,20,120,131,Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.,8643966_2,-1,-1,-1,16239,-1,0.0018355489,0.9981645
16240,NSCLC,21,22,133,138,Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.,8643966_2,-1,-1,-1,16240,-1,0.0017886057,0.9982114
16245,NSCLC,24,25,139,144,We investigated the efficacy and toxicity of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.,8643966_4,-1,-1,-1,16245,-1,0.0019676588,0.9980324
16246,NSCLC,9,10,35,40,Most patients (72.4%) had stage IV NSCLC.,8643966_6,-1,-1,-1,16246,-1,0.0021533894,0.9978466
16248,disease progression,28,30,106,125,"Of 50 patients evaluable for response, 12 (24%) had partial remission, 26 (52%) had no change, and 12 had disease progression (24%).",8643966_8,-1,-1,-1,16248,-1,0.002177333,0.99782264
16249,Hematologic toxicities,0,2,0,22,"Hematologic toxicities were mild: only one patient (2%) developed grade 3 or 4 neutropenia, while 29% had grade 1 or 2.",8643966_9,-1,-1,-1,16249,-1,0.0015415342,0.9984585
16253,Nausea and vomiting,0,3,0,19,"Nausea and vomiting were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4.",8643966_12,-1,-1,-1,16253,-1,0.0016949743,0.99830496
16257,NSCLC,12,13,82,87,"Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated, and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed.",8643966_14,-1,-1,-1,16257,-1,0.002078626,0.9979214
16261,head and neck cancers,12,16,74,95,A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.,8643971_0,-1,-1,-1,16261,-1,0.002593857,0.9974062
16262,head and neck carcinomas,5,9,38,62,Improved outcomes among patients with head and neck carcinomas require investigations of new drugs for induction therapy.,8643971_1,-1,-1,-1,16262,-1,0.0022581022,0.99774194
16264,Taxol,13,14,95,100,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,-1,-1,-1,16264,-1,0.99913067,0.00086940813
16265,head and neck cancer,32,36,193,213,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,-1,-1,-1,16265,-1,0.0020881114,0.9979119
16270,head and neck carcinoma,32,36,243,266,We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.,8643971_3,-1,-1,-1,16270,-1,0.002308289,0.99769175
16278,Alopecia,0,1,0,8,"Alopecia, paresthesias, and arthralgias/myalgias have occurred frequently, but with one exception (a grade 3 myalgia) they have been grade 1 or 2.",8643971_16,-1,-1,-1,16278,-1,0.0014554196,0.9985446
16279,paresthesias,2,3,10,22,"Alopecia, paresthesias, and arthralgias/myalgias have occurred frequently, but with one exception (a grade 3 myalgia) they have been grade 1 or 2.",8643971_16,-1,-1,-1,16279,-1,0.0015612721,0.9984388
16281,hematologic toxicity,2,4,17,37,No dose-limiting hematologic toxicity has been seen.,8643971_17,-1,-1,-1,16281,-1,0.0016245982,0.9983754
16282,head and neck cancer,9,13,84,104,Paclitaxel/cisplatin is an effective first-line regimen for locoregionally advanced head and neck cancer and continued study is warranted.,8643971_18,-1,-1,-1,16282,-1,0.002017892,0.997982
16288,Taxol,14,15,74,79,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,-1,-1,-1,16288,-1,0.9991873,0.0008127177
16298,granulocytopenia,11,12,80,96,"The dose-limiting toxicity of the combination was myelosuppression (leukopenia, granulocytopenia, and thrombocytopenia).",8643973_5,-1,-1,-1,16298,-1,0.0013559238,0.99864405
16301,disease progression,3,5,15,34,No patient had disease progression.,8643973_8,-1,-1,-1,16301,-1,0.002091359,0.9979087
16308,Parkinson's disease,7,10,61,80,Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.,8649546_0,-1,-1,-1,16308,-1,0.0019291837,0.9980709
16309,Parkinson's disease,4,7,30,49,Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.,8649546_1,-1,-1,-1,16309,-1,0.001964168,0.99803585
16310,PD,8,9,51,53,Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.,8649546_1,-1,-1,-1,16310,-1,0.0016463607,0.9983537
16314,parkinsonian motor disability,14,17,84,113,There was a significant 40% improvement in the dyskinesia score without increase of parkinsonian motor disability.,8649546_2,-1,-1,-1,16314,-1,0.0013879231,0.99861205
16318,PD,18,19,135,137,This study suggests that administration of low doses of beta-blockers may improve levodopa-induced ballistic and choreic dyskinesia in PD.,8649546_4,-1,-1,-1,16318,-1,0.0019892778,0.9980107
16324,triamcinolone,24,25,116,129,"Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).",8665051_3,-1,-1,-1,16324,-1,0.999213,0.00078703166
16325,reduction of food,45,48,225,242,"Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).",8665051_3,-1,-1,-1,16325,-1,0.26197898,0.738021
16326,loss in body weight,6,10,35,54,This was associated with a similar loss in body weight.,8665051_4,-1,-1,-1,16326,-1,0.018164793,0.98183525
16328,twitches,1,2,8,16,"Maximal twitches of the diaphragm were lower in the C group (653 +/- 174 g/cm(2)) than in the M group (837 +/- 171 g/cm(2); p < 0.05) and the T group (765 +/- 145 g/cm(2), NS).",8665051_7,-1,-1,-1,16328,-1,0.0028764654,0.99712354
16329,C,9,10,52,53,"Maximal twitches of the diaphragm were lower in the C group (653 +/- 174 g/cm(2)) than in the M group (837 +/- 171 g/cm(2); p < 0.05) and the T group (765 +/- 145 g/cm(2), NS).",8665051_7,-1,-1,-1,16329,-1,0.9857013,0.014298699
16330,p,32,33,124,125,"Maximal twitches of the diaphragm were lower in the C group (653 +/- 174 g/cm(2)) than in the M group (837 +/- 171 g/cm(2); p < 0.05) and the T group (765 +/- 145 g/cm(2), NS).",8665051_7,-1,-1,-1,16330,-1,0.36738846,0.6326116
16331,NS,48,49,172,174,"Maximal twitches of the diaphragm were lower in the C group (653 +/- 174 g/cm(2)) than in the M group (837 +/- 171 g/cm(2); p < 0.05) and the T group (765 +/- 145 g/cm(2), NS).",8665051_7,-1,-1,-1,16331,-1,0.055586442,0.94441354
16333,tetanic,20,21,111,118,"Half-relaxation time was prolonged in both steroid groups, and time to peak tension was longer with M, whereas tetanic tensions were similar.",8665051_8,-1,-1,-1,16333,-1,0.017858522,0.9821415
16335,p,22,23,130,131,Steroid treatment also induced a leftward shift of the force-frequency curve at 25 and 50 Hz when compared with saline treatment (p < 0.05).,8665051_9,-1,-1,-1,16335,-1,0.45705095,0.542949
16340,muscle atrophy,24,26,81,95,"Finally, a pair-fed (PF) study, performed in 18 rats (C, T, and PF), showed that muscle atrophy was considerably less pronounced in PF animals than in T-treated animals.",8665051_11,-1,-1,-1,16340,-1,0.0032974568,0.9967025
16345,muscle necrosis,50,52,294,309,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,-1,-1,-1,16345,-1,0.0019379671,0.9980621
16347,nutritional deprivation,64,66,356,379,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,-1,-1,-1,16347,-1,0.8730171,0.1269829
16353,renal disease,26,28,173,186,"Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.",8669433_1,-1,-1,-1,16353,-1,0.0015341335,0.9984659
16354,ESRD,29,30,188,192,"Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.",8669433_1,-1,-1,-1,16354,-1,0.0014615754,0.9985384
16358,ESRD,36,37,202,206,"However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD, with a relative risk in the range of 2 to 4.",8669433_3,-1,-1,-1,16358,-1,0.0013429685,0.998657
16361,ESRD,14,15,93,97,"These studies suggest that both phenacetin and acetaminophen may contribute to the burden of ESRD, with the risk of the latter being somewhat less than that of the former.",8669433_4,-1,-1,-1,16361,-1,0.0013216453,0.9986784
16367,ESRD,12,13,79,83,"The possibility that habitual use of acetaminophen alone increases the risk of ESRD has not been clearly demonstrated, but cannot be dismissed.",8669433_8,-1,-1,-1,16367,-1,0.0014318071,0.9985682
16369,hemorrhagic cystitis,8,10,78,98,Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.,8677458_0,-1,-1,-1,16369,-1,0.001068496,0.99893147
16370,Hemorrhagic cystitis,0,2,0,20,Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.,8677458_1,-1,-1,-1,16370,-1,0.0011992616,0.99880075
16378,emesis,34,35,223,229,"In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced emesis and is unable to absorb the drug.",8677458_4,-1,-1,-1,16378,-1,0.0011894511,0.9988105
16384,cardiovascular toxicities,6,8,43,68,The potential for acetaminophen to produce cardiovascular toxicities is very low.,8682684_2,-1,-1,-1,16384,-1,0.001439371,0.9985606
16388,critically ill,4,6,27,41,This article describes two critically ill patients in whom transient episodes of hypotension reproducibly developed after administration of acetaminophen.,8682684_4,-1,-1,-1,16388,-1,0.0039317175,0.99606824
16395,Leg and back pain,0,4,0,17,Leg and back pain after spinal anaesthesia involving hyperbaric 5% lignocaine.,8686832_0,-1,-1,-1,16395,-1,0.0024214261,0.99757856
16400,p,6,7,36,37,The patients affected were younger (p < 0.05) and the site of the dural puncture was higher (p < 0.01) than those individuals without pain.,8686832_3,-1,-1,-1,16400,-1,0.4344975,0.56550246
16401,p,20,21,93,94,The patients affected were younger (p < 0.05) and the site of the dural puncture was higher (p < 0.01) than those individuals without pain.,8686832_3,-1,-1,-1,16401,-1,0.468058,0.53194207
16406,Leg and/or back pain,0,4,0,20,Leg and/or back pain is associated with the intrathecal use of hyperbaric 5% lignocaine.,8686832_5,-1,-1,-1,16406,-1,0.0031029196,0.9968971
16411,cuprolinic blue,33,35,223,238,"Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.",8690168_1,-1,-1,-1,16411,-1,0.99897754,0.0010224866
16412,heparan sulphate,1,3,4,20,"The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by glycosaminoglycan-degrading enzymes, showing that pretreatment of the sections with heparitinase abolished all staining, whereas chondroitinase ABC had no effect.",8690168_3,-1,-1,-1,16412,-1,0.998811,0.0011889696
16413,cuprolinic blue,6,8,40,55,"The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by glycosaminoglycan-degrading enzymes, showing that pretreatment of the sections with heparitinase abolished all staining, whereas chondroitinase ABC had no effect.",8690168_3,-1,-1,-1,16413,-1,0.99899715,0.0010028717
16415,p<0.001,33,34,202,209,"A minority of anionic sites were scattered throughout the lamina densa and lamina rara interna, and were significantly smaller than those in the lamina rara externa of the glomerular basement membrane (p<0.001 and p<0.01 for diabetic and control rats, respectively).",8690168_5,-1,-1,-1,16415,-1,0.40781194,0.59218806
16419,h,13,14,82,83,"Diabetic rats progressively developed albuminuria reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002).",8690168_6,-1,-1,-1,16419,-1,0.31035,0.68965
16420,contrast,18,19,102,110,"Diabetic rats progressively developed albuminuria reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002).",8690168_6,-1,-1,-1,16420,-1,0.069157965,0.93084204
16421,h,31,32,155,156,"Diabetic rats progressively developed albuminuria reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002).",8690168_6,-1,-1,-1,16421,-1,0.3913745,0.6086255
16422,p<0.002,33,34,158,165,"Diabetic rats progressively developed albuminuria reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002).",8690168_6,-1,-1,-1,16422,-1,0.3779808,0.6220192
16423,heparan sulphate,8,10,32,48,"At the same time, the number of heparan sulphate anionic sites and the total anionic site surface (number of anionic sites x mean anionic site surface) in the lamina rara externa of the glomerular basement membrane was reduced by 19% (p<0.021) and by 26% (p<0.02), respectively.",8690168_7,-1,-1,-1,16423,-1,0.99875546,0.0012445564
16424,p<0.021,45,46,235,242,"At the same time, the number of heparan sulphate anionic sites and the total anionic site surface (number of anionic sites x mean anionic site surface) in the lamina rara externa of the glomerular basement membrane was reduced by 19% (p<0.021) and by 26% (p<0.02), respectively.",8690168_7,-1,-1,-1,16424,-1,0.43985143,0.5601486
16425,p<0.02,52,53,256,262,"At the same time, the number of heparan sulphate anionic sites and the total anionic site surface (number of anionic sites x mean anionic site surface) in the lamina rara externa of the glomerular basement membrane was reduced by 19% (p<0.021) and by 26% (p<0.02), respectively.",8690168_7,-1,-1,-1,16425,-1,0.43148524,0.56851476
16426,heparan sulphate,15,17,104,120,"We conclude that in streptozotocin-diabetic rats with an increased urinary albumin excretion, a reduced heparan sulphate charge barrier/density is found at the lamina rara externa of the glomerular basement membrane.",8690168_9,-1,-1,-1,16426,-1,0.9989772,0.0010228207
16429,MK-486,18,19,112,118,L-Dopa (5 mg/kg i.v.) decreased blood pressure and heart rate after extracerebral decarboxylase inhibition with MK-486 (25 mg/kg i.v.) in anesthetize MAO-inhibited dogs.,869641_1,-1,-1,-1,16429,-1,0.9990791,0.00092093606
16433,FLA-63,0,1,0,6,"FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the hypotension, bradycardia or reflex-enhancing effect of L-dopa.",869641_3,-1,-1,-1,16433,-1,0.99892175,0.0010782953
16436,Pimozide,0,1,0,8,Pimozide did not affect the actions of L-dopa on blood pressure and heart rate but completely blocked the enhancement of reflexes.,869641_4,-1,-1,-1,16436,-1,0.99934787,0.0006520762
16440,5-HTP,0,1,0,5,5-HTP (5 mg/kg i.v.) decreased blood pressure and heart rate and decreased the reflex bradycardia to norepinephrine.,869641_7,-1,-1,-1,16440,-1,0.9989587,0.001041256
16446,Microangiopathic hemolytic anemia,0,3,0,33,Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy.,8701950_0,-1,-1,-1,16446,-1,0.0013394617,0.99866056
16447,FK506,4,5,47,52,Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy.,8701950_0,-1,-1,-1,16447,-1,0.99902904,0.00097093993
16449,microangiopathic hemolytic anemia,5,8,26,59,We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.,8701950_1,-1,-1,-1,16449,-1,0.0011331928,0.9988668
16450,MAHA,9,10,61,65,We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.,8701950_1,-1,-1,-1,16450,-1,0.0012231243,0.99877685
16451,FK506,17,18,101,106,We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.,8701950_1,-1,-1,-1,16451,-1,0.99913126,0.00086876954
16453,FK506,6,7,34,39,"In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.",8701950_2,-1,-1,-1,16453,-1,0.99928445,0.0007155242
16457,MAHA,28,29,173,177,"In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.",8701950_2,-1,-1,-1,16457,-1,0.0014443375,0.9985556
16458,FK506,6,7,34,39,"In one patient, reintroduction of FK506 led to rapid recurrence of MAHA.",8701950_3,-1,-1,-1,16458,-1,0.99894816,0.001051914
16459,MAHA,12,13,67,71,"In one patient, reintroduction of FK506 led to rapid recurrence of MAHA.",8701950_3,-1,-1,-1,16459,-1,0.0013971973,0.9986028
16460,MAHA,1,2,17,21,FK506-associated MAHA is probably rare but physicians must be aware of this severe complication.,8701950_4,-1,-1,-1,16460,-1,0.0012723767,0.9987276
16461,FK506,9,10,51,56,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,-1,-1,-1,16461,-1,0.99920493,0.0007950845
16462,cyclosporin A,16,18,91,104,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,-1,-1,-1,16462,-1,0.9991425,0.000857423
16463,CyA,19,20,106,109,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,-1,-1,-1,16463,-1,0.99809915,0.001900884
16464,MAHA,29,30,163,167,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,-1,-1,-1,16464,-1,0.0013996923,0.9986003
16465,succinylcholine apnoea,6,8,35,57,The use of serum cholinesterase in succinylcholine apnoea.,871943_0,-1,-1,-1,16465,-1,0.34212264,0.6578774
16469,succinylcholine apnoea,6,8,35,57,The use of serum cholinesterase in succinylcholine apnoea provided considerable relief to both patient and anaesthetist.,871943_6,-1,-1,-1,16469,-1,0.3313173,0.6686827
16470,deoxycholic acid,6,8,58,74,Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol-induced cholestasis in rats.,873132_0,-1,-1,-1,16470,-1,0.9990069,0.0009930411
16472,Deoxycholic acid,0,2,0,16,"Deoxycholic acid conjugation, transport capacity, and metabolism were compared in control and ethinyl estradiol-treated rats.",873132_1,-1,-1,-1,16472,-1,0.9990062,0.0009937665
16473,deoxycholic acid,11,13,62,78,"Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid, and both were decreased by ethinyl estradiol treatment.",873132_2,-1,-1,-1,16473,-1,0.999121,0.00087903946
16474,taurodeoxycholic acid,14,16,84,105,"Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid, and both were decreased by ethinyl estradiol treatment.",873132_2,-1,-1,-1,16474,-1,0.99911696,0.0008829878
16475,ethinyl estradiol,22,24,134,151,"Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid, and both were decreased by ethinyl estradiol treatment.",873132_2,-1,-1,-1,16475,-1,0.9991304,0.00086956297
16476,bile acid,8,10,58,67,"During [24-14C]sodium deoxycholate infusion, [14C]biliary bile acid secretion increased, but bile flow did not change significantly in either control or ethinyl estradiol-treated rats.",873132_3,-1,-1,-1,16476,-1,0.996727,0.0032730012
16477,taurocholic acid,8,10,69,85,"Ethinyl estradiol-treated animals excreted significantly less 14C as taurocholic acid than did control animals, consistent with an impairment of 7alpha-hydroxylation of taurodeoxycholic acid.",873132_4,-1,-1,-1,16477,-1,0.99894553,0.0010545218
16478,taurodeoxycholic acid,22,24,169,190,"Ethinyl estradiol-treated animals excreted significantly less 14C as taurocholic acid than did control animals, consistent with an impairment of 7alpha-hydroxylation of taurodeoxycholic acid.",873132_4,-1,-1,-1,16478,-1,0.99896586,0.0010341179
16479,Ethinyl estradiol,0,2,0,17,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,-1,-1,-1,16479,-1,0.9990345,0.00096544955
16480,deoxycholic acid,8,10,58,74,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,-1,-1,-1,16480,-1,0.99902546,0.0009745897
16481,taurodeoxycholic acid,20,22,122,143,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,-1,-1,-1,16481,-1,0.9990959,0.0009041168
16482,P,32,33,182,183,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,-1,-1,-1,16482,-1,0.44765666,0.55234337
16483,deoxycholic acid,15,17,89,105,These results are consistent with the hypothesis that the rat has a poorer tolerance for deoxycholic acid than do certain other species.,873132_6,-1,-1,-1,16483,-1,0.99893755,0.0010625094
16484,deoxycholic acid,5,7,30,46,"Furthermore, the rat converts deoxycholic acid, a poor choleretic, to taurocholic acid, a good choleretic.",873132_7,-1,-1,-1,16484,-1,0.9988211,0.0011788921
16485,taurocholic acid,13,15,70,86,"Furthermore, the rat converts deoxycholic acid, a poor choleretic, to taurocholic acid, a good choleretic.",873132_7,-1,-1,-1,16485,-1,0.9989466,0.0010534409
16486,ethinyl estradiol,6,8,38,55,"When this conversion is impaired with ethinyl estradiol treatment, sulfation may be an important alternate pathway for excretion of this potentially harmful bile acid.",873132_8,-1,-1,-1,16486,-1,0.99899346,0.0010065986
16487,bile acid,23,25,157,166,"When this conversion is impaired with ethinyl estradiol treatment, sulfation may be an important alternate pathway for excretion of this potentially harmful bile acid.",873132_8,-1,-1,-1,16487,-1,0.99464613,0.005353816
16490,nitrogranulogen,8,9,51,66,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16490,-1,0.99818724,0.0018126984
16491,NG,10,11,68,70,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16491,-1,0.99727017,0.0027297852
16493,MTX,15,16,87,90,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16493,-1,0.99864286,0.0013571694
16495,5-FU,20,21,109,113,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16495,-1,0.9985512,0.0014488009
16497,CY,25,26,137,139,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16497,-1,0.9982822,0.0017178014
16498,MTX,33,34,179,182,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16498,-1,0.99869245,0.0013075381
16499,5-FU,35,36,185,189,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16499,-1,0.99859315,0.0014068426
16500,CY,37,38,192,194,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16500,-1,0.99822384,0.0017761693
16503,MTX,1,2,6,9,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,-1,-1,-1,16503,-1,0.99882215,0.0011778786
16504,p,7,8,49,50,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,-1,-1,-1,16504,-1,0.25935274,0.74064726
16506,p,20,21,119,120,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,-1,-1,-1,16506,-1,0.30659473,0.6934053
16508,NG,4,5,28,30,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,-1,-1,-1,16508,-1,0.9988657,0.001134336
16509,5-FU,6,7,32,36,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,-1,-1,-1,16509,-1,0.9988557,0.0011442372
16510,CY,8,9,41,43,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,-1,-1,-1,16510,-1,0.99879223,0.0012078277
16513,CMF,5,6,39,42,"Following polytherapy according to the CMF regimen, a statistically significant decrease (p = 0.0343) in creatinine clearance was found, but creatinine concentration did not increase significantly compared to controls.",8739323_6,-1,-1,-1,16513,-1,0.9973508,0.0026491953
16514,p,13,14,90,91,"Following polytherapy according to the CMF regimen, a statistically significant decrease (p = 0.0343) in creatinine clearance was found, but creatinine concentration did not increase significantly compared to controls.",8739323_6,-1,-1,-1,16514,-1,0.2695689,0.73043114
16517,CY,0,1,0,2,"CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.",8739323_7,-1,-1,-1,16517,-1,0.9954266,0.0045734164
16518,hemorrhagic cystitis,2,4,10,30,"CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.",8739323_7,-1,-1,-1,16518,-1,0.0011198305,0.9988802
16519,5-FU,20,21,105,109,"CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.",8739323_7,-1,-1,-1,16519,-1,0.9984906,0.001509456
16520,MTX,22,23,114,117,"CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.",8739323_7,-1,-1,-1,16520,-1,0.99867344,0.0013266046
16521,MTX,10,11,69,72,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16521,-1,0.9989611,0.0010389151
16522,CY,12,13,74,76,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16522,-1,0.9986162,0.0013838211
16523,NG,14,15,81,83,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16523,-1,0.9983518,0.0016482256
16524,5-FU,23,24,125,129,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16524,-1,0.9988783,0.0011216375
16525,MTX,28,29,158,161,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16525,-1,0.99889827,0.0011017013
16526,5-FU,30,31,164,168,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16526,-1,0.99880075,0.0011992091
16527,CY,32,33,171,173,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16527,-1,0.99851316,0.0014868297
16529,MTX,6,7,44,47,Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.,8739323_9,-1,-1,-1,16529,-1,0.99854136,0.0014586686
16530,5-FU,8,9,50,54,Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.,8739323_9,-1,-1,-1,16530,-1,0.99853003,0.001469906
16531,CY,10,11,57,59,Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.,8739323_9,-1,-1,-1,16531,-1,0.99773407,0.0022659365
16533,kainic acid,5,7,31,42,Partial lesions were made with kainic acid in the interpeduncular nucleus of the ventral midbrain of the rat.,8741744_1,-1,-1,-1,16533,-1,0.9992305,0.00076950376
16534,p,8,9,61,62,"Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.",8741744_2,-1,-1,-1,16534,-1,0.7547691,0.24523091
16535,locomotor hypoactivity,21,23,110,132,"Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.",8741744_2,-1,-1,-1,16535,-1,0.0018224033,0.99817765
16537,mg,28,29,157,159,"Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.",8741744_2,-1,-1,-1,16537,-1,0.98303384,0.016966205
16540,p,15,16,120,121,"Lesions reduced the extent of immunohistological staining for choline acetyltransferase in the interpeduncular nucleus (p <0.025), but not for tyrosine hydroxylase in the surrounding catecholaminergic A10 region.",8741744_3,-1,-1,-1,16540,-1,0.66077435,0.33922565
16543,acetaminophen hepatotoxicity,7,9,44,72,Influence of diet free of NAD-precursors on acetaminophen hepatotoxicity in mice.,8742498_0,-1,-1,-1,16543,-1,0.40730846,0.59269154
16544,nicotinic acid amide,8,11,58,78,"Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.",8742498_1,-1,-1,-1,16544,-1,0.99906296,0.0009371022
16547,NAD,13,14,75,78,"The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.",8742498_2,-1,-1,-1,16547,-1,0.9990075,0.0009924612
16548,AAP hepatitis,27,29,139,152,"The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.",8742498_2,-1,-1,-1,16548,-1,0.47335333,0.5266467
16550,Liver injuries,0,2,0,14,Liver injuries were quantified as serum activities of glutamate-oxaloacetate transaminase (GOT) and glutamate-pyruvate transaminase (GPT).,8742498_3,-1,-1,-1,16550,-1,0.0020145588,0.9979855
16551,AAP,1,2,6,9,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,-1,-1,-1,16551,-1,0.9989692,0.0010308607
16553,nicotinic acid amide,28,31,179,199,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,-1,-1,-1,16553,-1,0.9990128,0.0009871663
16554,NAA,32,33,201,204,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,-1,-1,-1,16554,-1,0.9989028,0.0010971338
16555,NAD,48,49,278,281,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,-1,-1,-1,16555,-1,0.99884856,0.0011514379
16556,AAP,17,18,105,108,"In these animals, only minor increases of serum transaminase activities were measured in the presence of AAP, and unlike the exacerbation caused by ethanol in mice on a standard diet, the liver damage was inhibited by 50% by ethanol.",8742498_5,-1,-1,-1,16556,-1,0.998911,0.0010890389
16561,NAA,11,12,56,59,"A further 64% reduction of hepatitis was observed, when NAA was given to ethanol/AAP-mice.",8742498_6,-1,-1,-1,16561,-1,0.9991049,0.0008950138
16564,NAA,23,24,151,154,Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.,8742498_7,-1,-1,-1,16564,-1,0.9991278,0.0008722417
16565,NAD,33,34,205,208,Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.,8742498_7,-1,-1,-1,16565,-1,0.99891853,0.0010814803
16566,NAA,6,7,31,34,We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic.,8742498_8,-1,-1,-1,16566,-1,0.9990157,0.0009842954
16569,cognitive and functional deficits,1,5,19,52,Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series.,8752018_0,-1,-1,-1,16569,-1,0.0021149213,0.99788505
16570,divalproex sodium,10,12,76,93,Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series.,8752018_0,-1,-1,-1,16570,-1,0.9991351,0.00086494186
16572,bipolar disorder,14,16,94,110,BACKGROUND: Lithium remains a first-line treatment for the acute and maintenance treatment of bipolar disorder.,8752018_1,-1,-1,-1,16572,-1,0.001718738,0.99828124
16578,loss of creativity,33,36,189,207,"Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.",8752018_2,-1,-1,-1,16578,-1,0.004594297,0.9954057
16579,functional impairments,38,40,213,235,"Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.",8752018_2,-1,-1,-1,16579,-1,0.0027071105,0.9972928
16582,divalproex sodium,12,14,84,101,This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.,8752018_3,-1,-1,-1,16582,-1,0.99911064,0.000889373
16583,cognitive and functional impairments,17,21,120,156,This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.,8752018_3,-1,-1,-1,16583,-1,0.0021720685,0.99782795
16585,divalproex sodium,17,19,94,111,"RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients.",8752018_5,-1,-1,-1,16585,-1,0.9990902,0.00090977043
16586,"cognitive, motivational,",25,29,150,174,"RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients.",8752018_5,-1,-1,-1,16586,-1,0.03440184,0.96559817
16587,creative deficits,30,32,178,195,"RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients.",8752018_5,-1,-1,-1,16587,-1,0.003347285,0.9966528
16590,divalproex sodium,7,9,40,57,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,-1,-1,-1,16590,-1,0.9990422,0.0009578103
16594,loss of creativity,22,25,149,167,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,-1,-1,-1,16594,-1,0.003023921,0.99697614
16595,functional impairments,27,29,173,195,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,-1,-1,-1,16595,-1,0.0023125086,0.99768746
16597,tramadol,7,8,56,64,Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants.,8766220_0,-1,-1,-1,16597,-1,0.999318,0.0006819655
16599,Tramadol,0,1,0,8,Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.,8766220_1,-1,-1,-1,16599,-1,0.9992618,0.00073817
16600,cancer pain,17,19,110,121,Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.,8766220_1,-1,-1,-1,16600,-1,0.0022296358,0.9977704
16603,dosulepine hydrochloride,9,11,59,83,This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.,8766220_2,-1,-1,-1,16603,-1,0.9990651,0.0009348757
16604,tetraparetic,13,14,89,101,This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.,8766220_2,-1,-1,-1,16604,-1,0.0022436804,0.9977563
16605,chronic pain,16,18,115,127,This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.,8766220_2,-1,-1,-1,16605,-1,0.0016423669,0.9983576
16607,tramadol,21,22,152,160,Fifty-six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho-active drugs and tramadol.,8766220_3,-1,-1,-1,16607,-1,0.9993193,0.00068065256
16611,calcium chloride,2,4,10,26,Effect of calcium chloride and 4-aminopyridine therapy on desipramine toxicity in rats.,8800187_0,-1,-1,-1,16611,-1,0.99909365,0.00090630224
16612,4-aminopyridine,5,6,31,46,Effect of calcium chloride and 4-aminopyridine therapy on desipramine toxicity in rats.,8800187_0,-1,-1,-1,16612,-1,0.9991291,0.00087084895
16613,desipramine toxicity,8,10,58,78,Effect of calcium chloride and 4-aminopyridine therapy on desipramine toxicity in rats.,8800187_0,-1,-1,-1,16613,-1,0.7081406,0.29185936
16615,antidepressant overdose,11,13,73,96,BACKGROUND: Hypotension is a major contributor to mortality in tricyclic antidepressant overdose.,8800187_1,-1,-1,-1,16615,-1,0.14860429,0.8513957
16622,CaCl2,0,1,0,5,CaCl2 and 4-aminopyridine.,8800187_5,-1,-1,-1,16622,-1,0.99833316,0.0016668139
16623,4-aminopyridine,2,3,10,25,CaCl2 and 4-aminopyridine.,8800187_5,-1,-1,-1,16623,-1,0.99879813,0.0012018535
16624,antidepressant desipramine,5,7,41,67,"Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension, QRS prolongation, and bradycardia.",8800187_6,-1,-1,-1,16624,-1,0.9988599,0.0011400686
16627,CaCl2,6,7,36,41,"Fifteen min later, animals received CaCl2, NaHCO3, or saline.",8800187_7,-1,-1,-1,16627,-1,0.99863833,0.0013616865
16628,NaHCO3,8,9,43,49,"Fifteen min later, animals received CaCl2, NaHCO3, or saline.",8800187_7,-1,-1,-1,16628,-1,0.9982437,0.0017563442
16629,antidepressant desipramine,8,10,48,74,"In a second experiment, rats received tricyclic antidepressant desipramine IP followed in 15 min by 4-aminopyridine or saline.",8800187_8,-1,-1,-1,16629,-1,0.9990656,0.0009344416
16630,4-aminopyridine,16,17,100,115,"In a second experiment, rats received tricyclic antidepressant desipramine IP followed in 15 min by 4-aminopyridine or saline.",8800187_8,-1,-1,-1,16630,-1,0.9991543,0.0008456966
16631,NaHCO3,2,3,9,15,RESULTS: NaHCO3 briefly (5 min) reversed hypotension and QRS prolongation.,8800187_9,-1,-1,-1,16631,-1,0.99863476,0.0013652744
16633,CaCl2,0,1,0,5,CaCl2 and 4-aminopyridine failed to improve blood pressure.,8800187_10,-1,-1,-1,16633,-1,0.99864036,0.0013596546
16634,4-aminopyridine,2,3,10,25,CaCl2 and 4-aminopyridine failed to improve blood pressure.,8800187_10,-1,-1,-1,16634,-1,0.99894935,0.001050648
16636,p,6,7,42,43,The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.,8800187_11,-1,-1,-1,16636,-1,0.16208626,0.8379137
16638,p,13,14,67,68,The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.,8800187_11,-1,-1,-1,16638,-1,0.11976445,0.88023555
16639,CaCl2,19,20,84,89,The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.,8800187_11,-1,-1,-1,16639,-1,0.99890244,0.0010975051
16640,CaCl2,5,6,34,39,CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.,8800187_12,-1,-1,-1,16640,-1,0.99898976,0.0010102016
16641,4-aminopyridine,7,8,43,58,CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.,8800187_12,-1,-1,-1,16641,-1,0.999089,0.0009110356
16643,CaCl2,0,1,0,5,CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity.,8800187_13,-1,-1,-1,16643,-1,0.9990287,0.0009713527
16644,central nervous system toxicity,8,12,58,89,CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity.,8800187_13,-1,-1,-1,16644,-1,0.0014492845,0.9985507
16662,cerebral hypoxia,9,11,58,74,Alpha and beta coma in drug intoxication uncomplicated by cerebral hypoxia.,88336_0,-1,-1,-1,16662,-1,0.0014313441,0.99856865
16663,comatose,5,6,32,40,"Four patients who were rendered comatose or stuporous by drug intoxication, but who were not hypoxic, are described.",88336_1,-1,-1,-1,16663,-1,0.0017432151,0.99825674
16664,stuporous,7,8,44,53,"Four patients who were rendered comatose or stuporous by drug intoxication, but who were not hypoxic, are described.",88336_1,-1,-1,-1,16664,-1,0.0018866091,0.9981134
16665,hypoxic,16,17,93,100,"Four patients who were rendered comatose or stuporous by drug intoxication, but who were not hypoxic, are described.",88336_1,-1,-1,-1,16665,-1,0.0018628165,0.9981371
16666,chlormethiazole,6,7,38,53,"Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.",88336_2,-1,-1,-1,16666,-1,0.99929297,0.0007070465
16667,alcohol withdrawal symptoms,8,11,58,85,"Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.",88336_2,-1,-1,-1,16667,-1,0.14238738,0.85761267
16669,nitrazepam,19,20,123,133,"Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.",88336_2,-1,-1,-1,16669,-1,0.9992601,0.00073990325
16670,nitrazepam overdose,3,5,17,36,"The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.",88336_3,-1,-1,-1,16670,-1,0.41868883,0.5813112
16671,chlormethiazole,10,11,59,74,"The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.",88336_3,-1,-1,-1,16671,-1,0.9992287,0.00077127595
16673,chlormethiazole,7,8,45,60,The fourth patient who was unconscious after chlormethiazole administration exhibite generalized non-reactive activity in the slow beta range.,88336_4,-1,-1,-1,16673,-1,0.99919957,0.00080043095
16674,neurological sequelae,5,7,38,59,All four recovered completely without neurological sequelae following the withdrawal of the offending agents.,88336_5,-1,-1,-1,16674,-1,0.001472667,0.9985273
16677,hypoxaemia,21,22,139,149,"It is concluded that when this electroencephalographic and behavioural picture is seen in drug intoxication, in the absence of significant hypoxaemia, a favourable outcome may be anticipated.",88336_8,-1,-1,-1,16677,-1,0.0013522962,0.99864775
16678,Valsartan,0,1,0,9,"Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.",8841157_0,-1,-1,-1,16678,-1,0.99939466,0.0006052926
16680,essential hypertension,11,13,64,86,"Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.",8841157_0,-1,-1,-1,16680,-1,0.0017505067,0.9982495
16681,amlodipine,23,24,143,153,"Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.",8841157_0,-1,-1,-1,16681,-1,0.9993856,0.0006143484
16682,valsartan,14,15,88,97,"OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine.",8841157_1,-1,-1,-1,16682,-1,0.99938214,0.00061785604
16683,amlodipine,21,22,125,135,"OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine.",8841157_1,-1,-1,-1,16683,-1,0.9993656,0.0006343391
16685,mg valsartan,24,26,165,177,METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.,8841157_2,-1,-1,-1,16685,-1,0.998711,0.0012889968
16686,mg amlodipine,28,30,183,196,METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.,8841157_2,-1,-1,-1,16686,-1,0.9987043,0.0012956365
16687,mg amlodipine,15,17,84,97,"After 8 weeks of therapy, in patients whose blood pressure remained uncontrolled, 5 mg amlodipine was added to the initial therapy.",8841157_3,-1,-1,-1,16687,-1,0.99861944,0.0013805868
16688,valsartan,3,4,14,23,"RESULTS: Both valsartan and amlodipine were effective at lowering blood pressure at 4, 8, and 12 weeks.",8841157_7,-1,-1,-1,16688,-1,0.9993843,0.0006157036
16689,amlodipine,5,6,28,38,"RESULTS: Both valsartan and amlodipine were effective at lowering blood pressure at 4, 8, and 12 weeks.",8841157_7,-1,-1,-1,16689,-1,0.9993813,0.00061864353
16690,mm Hg,8,10,48,53,"For the primary variable the difference was 0.5 mm Hg in favor of valsartan (p = 0.68; 95% confidence interval, -2.7 to 1.7).",8841157_9,-1,-1,-1,16690,-1,0.061211176,0.9387889
16691,valsartan,13,14,66,75,"For the primary variable the difference was 0.5 mm Hg in favor of valsartan (p = 0.68; 95% confidence interval, -2.7 to 1.7).",8841157_9,-1,-1,-1,16691,-1,0.99918,0.0008199477
16692,p,15,16,77,78,"For the primary variable the difference was 0.5 mm Hg in favor of valsartan (p = 0.68; 95% confidence interval, -2.7 to 1.7).",8841157_9,-1,-1,-1,16692,-1,0.18157282,0.8184272
16693,valsartan,9,10,42,51,Responder rates at 8 weeks were 66.7% for valsartan and 60.2% for amlodipine (p = 0.39).,8841157_10,-1,-1,-1,16693,-1,0.9994106,0.0005894096
16694,amlodipine,14,15,66,76,Responder rates at 8 weeks were 66.7% for valsartan and 60.2% for amlodipine (p = 0.39).,8841157_10,-1,-1,-1,16694,-1,0.99937624,0.0006237856
16695,p,16,17,78,79,Responder rates at 8 weeks were 66.7% for valsartan and 60.2% for amlodipine (p = 0.39).,8841157_10,-1,-1,-1,16695,-1,0.28648084,0.71351916
16697,amlodipine,11,12,73,83,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16697,-1,0.99937195,0.00062805874
16698,mg,20,21,120,122,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16698,-1,0.9949704,0.0050296932
16699,mg valsartan,28,30,144,156,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16699,-1,0.998779,0.0012210204
16700,mg amlodipine,35,37,169,182,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16700,-1,0.9986218,0.0013781288
16701,valsartan,41,42,191,200,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16701,-1,0.99938285,0.0006170789
16702,mg amlodipine,44,46,208,221,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16702,-1,0.998531,0.0014690064
16703,mg amlodipine,51,53,236,249,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16703,-1,0.99849963,0.001500432
16704,valsartan,6,7,32,41,CONCLUSIONS: The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension.,8841157_13,-1,-1,-1,16704,-1,0.99940944,0.00059057056
16705,amlodipine,13,14,70,80,CONCLUSIONS: The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension.,8841157_13,-1,-1,-1,16705,-1,0.99940443,0.0005955382
16707,valsartan,4,5,22,31,"The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class, dihydropyridine calcium antagonists.",8841157_14,-1,-1,-1,16707,-1,0.99934703,0.00065299886
16708,dihydropyridine calcium,25,27,150,173,"The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class, dihydropyridine calcium antagonists.",8841157_14,-1,-1,-1,16708,-1,0.9992169,0.0007830443
16709,pupillary oscillation,3,5,13,34,A measure of pupillary oscillation as a marker of cocaine-induced paranoia.,8854309_0,-1,-1,-1,16709,-1,0.0037279413,0.9962721
16710,paranoia,10,11,66,74,A measure of pupillary oscillation as a marker of cocaine-induced paranoia.,8854309_0,-1,-1,-1,16710,-1,0.0017712656,0.9982287
16711,paranoia,1,2,16,24,Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.,8854309_1,-1,-1,-1,16711,-1,0.0013622903,0.99863774
16712,CIP,3,4,26,29,Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.,8854309_1,-1,-1,-1,16712,-1,0.0015512465,0.9984487
16713,paranoia,12,13,85,93,Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.,8854309_1,-1,-1,-1,16713,-1,0.0013190503,0.9986809
16714,pupillary oscillation,2,4,12,33,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16714,-1,0.013864137,0.98613584
16715,crack cocaine,13,15,94,107,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16715,-1,0.9982539,0.0017461053
16716,CIP,18,19,131,134,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16716,-1,0.0030062348,0.9969938
16717,n,20,21,136,137,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16717,-1,0.08746792,0.9125321
16718,crack,28,29,166,171,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16718,-1,0.99787223,0.002127787
16719,CIP,33,34,196,199,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16719,-1,0.0030559783,0.996944
16720,n,35,36,201,202,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16720,-1,0.07745062,0.9225494
16722,phenytoin overdosages,10,12,75,96,Magnetic resonance volumetry of the cerebellum in epileptic patients after phenytoin overdosages.,8864707_0,-1,-1,-1,16722,-1,0.8421203,0.15787971
16724,cerebellar atrophy,14,16,88,106,The aim of this study was to evaluate the relationship between phenytoin medication and cerebellar atrophy in patients who had experienced clinical intoxication.,8864707_1,-1,-1,-1,16724,-1,0.0013692367,0.9986307
16728,phenytoin overdosage,3,5,17,37,We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.,8864707_10,-1,-1,-1,16728,-1,0.6639859,0.3360141
16729,cerebellar atrophy,10,12,69,87,We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.,8864707_10,-1,-1,-1,16729,-1,0.001366777,0.9986332
16731,cerebellar atrophy,24,26,155,173,We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.,8864707_10,-1,-1,-1,16731,-1,0.001344546,0.99865544
16732,cerebellar disorders,13,15,103,123,Quantitative morphometric studies of the cerebellum provide valuable insights into the pathogenesis of cerebellar disorders.,8864707_11,-1,-1,-1,16732,-1,0.0016742743,0.99832577
16733,Serotonin syndrome,0,2,0,18,Serotonin syndrome from venlafaxine-tranylcypromine interaction.,8888541_0,-1,-1,-1,16733,-1,0.006155212,0.99384487
16736,muscle rigidity,17,19,117,132,"Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.",8888541_1,-1,-1,-1,16736,-1,0.0015735616,0.99842644
16740,monoamine oxidase,12,14,67,84,The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.,8888541_2,-1,-1,-1,16740,-1,0.9987478,0.0012521406
16746,serotonin syndrome,9,11,62,80,We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.,8888541_4,-1,-1,-1,16746,-1,0.118961826,0.8810382
16747,tranylcypromine,18,19,115,130,We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.,8888541_4,-1,-1,-1,16747,-1,0.99916923,0.0008307655
16750,h,2,3,9,10,"Within 2 h he became confused with jerking movements of his extremities, tremors and rigidity.",8888541_6,-1,-1,-1,16750,-1,0.1651985,0.8348015
16753,agitated,13,14,63,71,"He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.",8888541_7,-1,-1,-1,16753,-1,0.0017218792,0.99827814
16756,salivation,24,25,128,138,"He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.",8888541_7,-1,-1,-1,16756,-1,0.0014206276,0.9985794
16757,diaphoresis,26,27,143,154,"He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.",8888541_7,-1,-1,-1,16757,-1,0.0014151037,0.99858487
16758,mm,4,5,18,20,His pupils were 7 mm and sluggishly reactive to light.,8888541_8,-1,-1,-1,16758,-1,0.016282653,0.9837173
16759,mm Hg,7,9,40,45,"Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.",8888541_9,-1,-1,-1,16759,-1,0.06788914,0.93211085
16760,mg,24,25,124,126,"Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.",8888541_9,-1,-1,-1,16760,-1,0.98764706,0.01235299
16762,muscle rigidity,33,35,171,186,"Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.",8888541_9,-1,-1,-1,16762,-1,0.0029334242,0.99706656
16763,hypoventilation,9,10,54,69,"He was intubated for airway protection and because of hypoventilation, and was paralyzed to control muscle rigidity.",8888541_10,-1,-1,-1,16763,-1,0.0013795733,0.9986204
16764,paralyzed,13,14,79,88,"He was intubated for airway protection and because of hypoventilation, and was paralyzed to control muscle rigidity.",8888541_10,-1,-1,-1,16764,-1,0.008944242,0.9910557
16765,muscle rigidity,16,18,100,115,"He was intubated for airway protection and because of hypoventilation, and was paralyzed to control muscle rigidity.",8888541_10,-1,-1,-1,16765,-1,0.0020321347,0.9979679
16768,neuromuscular paralysis,11,13,74,97,This patient survived without sequelae due to the aggressive sedation and neuromuscular paralysis.,8888541_14,-1,-1,-1,16768,-1,0.0012897988,0.99871016
16771,HUS,10,11,53,56,A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking oral contraceptives.,891050_1,-1,-1,-1,16771,-1,0.0012842029,0.99871576
16776,HUS,6,7,42,45,"This case emphasizes the possibility that HUS in adults is not invariably irreversible and that, despite prolonged oliguria, recovery of renal function can be obtained.",891050_3,-1,-1,-1,16776,-1,0.0013542764,0.9986457
16777,oliguria,18,19,115,123,"This case emphasizes the possibility that HUS in adults is not invariably irreversible and that, despite prolonged oliguria, recovery of renal function can be obtained.",891050_3,-1,-1,-1,16777,-1,0.0013339607,0.99866605
16778,HUS,7,8,41,44,"Therefore, in adult patients affected by HUS, dialysis should not be discontinued prematurely; moreover, bilateral nephrectomy, for treatment of severe hypertension and microangiopathic hemolytic anemia, should be performed with caution.",891050_4,-1,-1,-1,16778,-1,0.001184544,0.99881554
16780,microangiopathic hemolytic anemia,27,30,169,202,"Therefore, in adult patients affected by HUS, dialysis should not be discontinued prematurely; moreover, bilateral nephrectomy, for treatment of severe hypertension and microangiopathic hemolytic anemia, should be performed with caution.",891050_4,-1,-1,-1,16780,-1,0.0012545522,0.99874544
16784,urothelial cancer,15,17,102,119,"PURPOSE: We gained knowledge of the etiology, treatment and prevention of cyclophosphamide associated urothelial cancer.",8911359_1,-1,-1,-1,16784,-1,0.0018874382,0.99811256
16788,transitional cell carcinoma,9,12,38,65,RESULTS: All tumors were grade 3 or 4 transitional cell carcinoma.,8911359_3,-1,-1,-1,16788,-1,0.0037464972,0.9962535
16791,bladder tumor,4,6,41,54,CONCLUSIONS: Cyclophosphamide associated bladder tumor is an aggressive disease.,8911359_7,-1,-1,-1,16791,-1,0.0018693391,0.9981306
16792,bladder tumors,12,14,81,95,"However, long-term survival is possible when radical cystectomy is performed for bladder tumors with any sign of invasion and for recurrent high grade disease, even when noninvasive.",8911359_8,-1,-1,-1,16792,-1,0.003089654,0.9969104
16794,valproate,11,12,96,105,Morphological features of encephalopathy after chronic administration of the antiepileptic drug valproate to rats.,8919272_0,-1,-1,-1,16794,-1,0.9992298,0.0007702558
16795,sodium valproate,7,9,61,77,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,-1,-1,-1,16795,-1,0.999243,0.00075704046
16796,neurological disorders,40,42,193,215,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,-1,-1,-1,16796,-1,0.0012114391,0.99878854
16797,cerebellum damage,43,45,227,244,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,-1,-1,-1,16797,-1,0.0022674308,0.9977325
16798,valproate encephalopathy,47,49,247,271,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,-1,-1,-1,16798,-1,0.62153995,0.37846008
16802,valproate encephalopathy,15,17,93,117,"The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of valproate encephalopathy is discussed.",8919272_15,-1,-1,-1,16802,-1,0.65523946,0.34476057
16803,intracranial bleeding,1,3,6,27,Fatal intracranial bleeding associated with prehospital use of epinephrine.,8953972_0,-1,-1,-1,16803,-1,0.0015422315,0.9984578
16806,pulmonary edema,23,25,126,141,We present a case of paramedic misjudgment in the execution of a protocol for the treatment of allergic reaction in a case of pulmonary edema with wheezing.,8953972_1,-1,-1,-1,16806,-1,0.0011711982,0.9988288
16807,wheezing,26,27,147,155,We present a case of paramedic misjudgment in the execution of a protocol for the treatment of allergic reaction in a case of pulmonary edema with wheezing.,8953972_1,-1,-1,-1,16807,-1,0.00129495,0.998705
16808,respiratory distress,4,6,20,40,"The sudden onset of respiratory distress, rash, and a history of a new medicine led the two paramedics on the scene to administer subcutaneous epinephrine.",8953972_2,-1,-1,-1,16808,-1,0.0014108086,0.9985892
16812,subarachnoid hemorrhage,7,9,45,68,"Subsequently, acute cardiac arrest and fatal subarachnoid hemorrhage occurred.",8953972_3,-1,-1,-1,16812,-1,0.0017707202,0.9982293
16824,Hoe-140,24,25,192,199,Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute hypertension in rats treated with vehicle and Hoe-140 (0.1 microM).,8955532_3,-1,-1,-1,16824,-1,0.9991923,0.00080768677
16829,antipurine,7,8,32,42,A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.,8958188_0,-1,-1,-1,16829,-1,0.9985738,0.0014262273
16830,lometrexol,9,10,54,64,A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.,8958188_0,-1,-1,-1,16830,-1,0.9992812,0.0007187363
16831,DDATHF,11,12,66,72,A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.,8958188_0,-1,-1,-1,16831,-1,0.99910694,0.00089306606
16832,folic acid,16,18,90,100,A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.,8958188_0,-1,-1,-1,16832,-1,0.99921703,0.00078294694
16833,Lometrexol,0,1,0,10,"Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.",8958188_1,-1,-1,-1,16833,-1,0.99925286,0.0007471507
16835,purine,19,20,129,135,"Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.",8958188_1,-1,-1,-1,16835,-1,0.99838316,0.0016168078
16836,lometrexol,9,10,65,75,"Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.",8958188_2,-1,-1,-1,16836,-1,0.9992918,0.0007081912
16837,tumours,13,14,97,104,"Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.",8958188_2,-1,-1,-1,16837,-1,0.0024224354,0.9975776
16839,lometrexol,7,8,45,55,"However, the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative toxicities.",8958188_3,-1,-1,-1,16839,-1,0.9992293,0.0007706956
16842,lometrexol,8,9,61,71,"Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration, i.e. for 7 days prior to and 7 days following a single bolus dose.",8958188_4,-1,-1,-1,16842,-1,0.99932504,0.0006750215
16843,folic acid,15,17,101,111,"Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration, i.e. for 7 days prior to and 7 days following a single bolus dose.",8958188_4,-1,-1,-1,16843,-1,0.9993285,0.0006715815
16844,lometrexol,9,10,54,64,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,-1,-1,-1,16844,-1,0.99932075,0.00067923765
16845,folic acid,12,14,76,86,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,-1,-1,-1,16845,-1,0.99925286,0.0007470655
16847,lometrexol,22,23,144,154,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,-1,-1,-1,16847,-1,0.9993383,0.00066159305
16848,folic acid,28,30,182,192,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,-1,-1,-1,16848,-1,0.9992619,0.0007380455
16853,folate,13,14,83,89,There was no clear relationship between clinical toxicity and the extent of plasma folate elevation.,8958188_7,-1,-1,-1,16853,-1,0.9984518,0.0015481403
16854,lometrexol,4,5,37,47,Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.,8958188_8,-1,-1,-1,16854,-1,0.99928075,0.0007192138
16855,folic acid,11,13,92,102,Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.,8958188_8,-1,-1,-1,16855,-1,0.9992933,0.0007066079
16857,lometrexol,24,25,194,204,Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.,8958188_8,-1,-1,-1,16857,-1,0.9992841,0.0007159799
16861,cocaine toxicity,15,17,108,124,Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity.,8988571_0,-1,-1,-1,16861,-1,0.28815773,0.71184224
16864,EDDs,11,12,73,77,"We describe an outbreak of deaths from cocaine-induced excited delirium (EDDs) in Dade County, Florida between 1979 and 1990.",8988571_1,-1,-1,-1,16864,-1,0.0016424302,0.9983576
16866,EDDs,19,20,90,94,"From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium.",8988571_2,-1,-1,-1,16866,-1,0.0020434987,0.9979565
16867,cocaine overdose,27,29,140,156,"From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium.",8988571_2,-1,-1,-1,16867,-1,0.17568725,0.82431275
16869,EDDs,4,5,24,28,"Compared with controls, EDDs were more frequently black, male, and younger.",8988571_3,-1,-1,-1,16869,-1,0.002155536,0.99784446
16872,EDDs,0,1,0,4,EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls.,8988571_5,-1,-1,-1,16872,-1,0.007395274,0.99260473
16880,sudden death,37,39,250,262,"The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.",8988571_6,-1,-1,-1,16880,-1,0.001674821,0.99832517
16882,preterm infants,7,9,46,61,Risk factors of sensorineural hearing loss in preterm infants.,8996652_0,-1,-1,-1,16882,-1,0.005796879,0.99420315
16883,preterm infants,2,4,10,25,"Among 547 preterm infants of < or = 34 weeks gestation born between 1987 and 1991, 8 children (1.46%) developed severe progressive and bilateral sensorineural hearing loss.",8996652_1,-1,-1,-1,16883,-1,0.006995546,0.9930045
16885,hearing loss,6,8,39,51,Perinatal risk factors of infants with hearing loss were compared with those of two control groups matched for gestation and birth weight and for perinatal complications.,8996652_2,-1,-1,-1,16885,-1,0.0018848007,0.9981152
16886,birth weight,20,22,125,137,Perinatal risk factors of infants with hearing loss were compared with those of two control groups matched for gestation and birth weight and for perinatal complications.,8996652_2,-1,-1,-1,16886,-1,0.024145221,0.9758548
16887,perinatal complications,24,26,146,169,Perinatal risk factors of infants with hearing loss were compared with those of two control groups matched for gestation and birth weight and for perinatal complications.,8996652_2,-1,-1,-1,16887,-1,0.0017667852,0.9982332
16888,hearing loss,6,8,48,60,Our observations demonstrated an association of hearing loss with a higher incidence of perinatal complications.,8996652_3,-1,-1,-1,16888,-1,0.0018973913,0.9981026
16890,ototoxic,13,14,92,100,"Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and furosemide.",8996652_4,-1,-1,-1,16890,-1,0.0017484614,0.9982515
16893,hearing loss,17,19,120,132,"Finally, we strongly recommend to prospectively and regularly perform audiologic assessment in sick preterm children as hearing loss is of delayed onset and in most cases bilateral and severe.",8996652_5,-1,-1,-1,16893,-1,0.0026543695,0.9973456
16894,Pemoline,0,1,0,8,Pemoline induced acute choreoathetosis: case report and review of the literature.,9022662_0,-1,-1,-1,16894,-1,0.9986939,0.0013061253
16895,choreoathetosis,3,4,23,38,Pemoline induced acute choreoathetosis: case report and review of the literature.,9022662_0,-1,-1,-1,16895,-1,0.0017074471,0.9982925
16896,Pemoline,2,3,12,20,BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.,9022662_1,-1,-1,-1,16896,-1,0.9992125,0.00078750576
16897,oxazolidine,5,6,27,38,BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.,9022662_1,-1,-1,-1,16897,-1,0.99925,0.00074993866
16898,amphetamines,12,13,86,98,BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.,9022662_1,-1,-1,-1,16898,-1,0.99911994,0.0008801185
16899,attention deficit disorder,19,22,128,154,BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.,9022662_1,-1,-1,-1,16899,-1,0.0021032789,0.9978967
16900,Pemoline,0,1,0,8,Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.,9022662_2,-1,-1,-1,16900,-1,0.9990301,0.00096989516
16901,movement disorders,14,16,80,98,Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.,9022662_2,-1,-1,-1,16901,-1,0.001227918,0.9987721
16902,pemoline,9,10,64,72,The following case describes two children acutely poisoned with pemoline who experienced profound choreoathetosis.,9022662_3,-1,-1,-1,16902,-1,0.9986559,0.0013441172
16903,choreoathetosis,13,14,98,113,The following case describes two children acutely poisoned with pemoline who experienced profound choreoathetosis.,9022662_3,-1,-1,-1,16903,-1,0.0020042725,0.99799573
16904,emergency department,14,16,76,96,"CASE REPORT: Two, 3-year-old male, identical twin siblings presented to the emergency department after found playing with a an empty bottle of pemoline originally containing 59 tablets.",9022662_4,-1,-1,-1,16904,-1,0.008889427,0.99111056
16905,pemoline,25,26,143,151,"CASE REPORT: Two, 3-year-old male, identical twin siblings presented to the emergency department after found playing with a an empty bottle of pemoline originally containing 59 tablets.",9022662_4,-1,-1,-1,16905,-1,0.9990564,0.00094361027
16906,attention deficit disorder,8,11,51,77,The children had a medical history significant for attention deficit disorder previously treated with methylphenidate without success.,9022662_5,-1,-1,-1,16906,-1,0.002570708,0.9974293
16908,pemoline,6,7,28,36,This was their first day of pemoline therapy.,9022662_6,-1,-1,-1,16908,-1,0.99886155,0.0011384815
16909,choreoathetoid movements,1,3,4,28,The choreoathetoid movements began 45 min to 1 h after ingestion.,9022662_7,-1,-1,-1,16909,-1,0.004939483,0.9950605
16910,h,8,9,47,48,The choreoathetoid movements began 45 min to 1 h after ingestion.,9022662_7,-1,-1,-1,16910,-1,0.14670455,0.8532954
16911,movement disorders,7,9,38,56,The children gave no history of prior movement disorders and there was no family history of movement disorders.,9022662_8,-1,-1,-1,16911,-1,0.0013967807,0.9986033
16912,movement disorders,16,18,92,110,The children gave no history of prior movement disorders and there was no family history of movement disorders.,9022662_8,-1,-1,-1,16912,-1,0.0014050324,0.99859494
16914,choreoathetoid movements,17,19,130,154,The children received gastrointestinal decontamination and high doses of intravenous benzodiazepines in an attempt to control the choreoathetoid movements.,9022662_9,-1,-1,-1,16914,-1,0.007249065,0.9927509
16915,choreoathetosis,8,9,50,65,"Despite treatment, the children continued to have choreoathetosis for approximately 24 hours.",9022662_10,-1,-1,-1,16915,-1,0.0025104699,0.9974896
16916,Pemoline,2,3,12,20,CONCLUSION: Pemoline associated movement disorder has been rarely reported in the acute toxicology literature.,9022662_12,-1,-1,-1,16916,-1,0.99906653,0.00093347166
16917,movement disorder,4,6,32,49,CONCLUSION: Pemoline associated movement disorder has been rarely reported in the acute toxicology literature.,9022662_12,-1,-1,-1,16917,-1,0.0012122078,0.9987878
16918,choreoathetoid movements,3,5,19,43,The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose.,9022662_13,-1,-1,-1,16918,-1,0.0023404052,0.99765956
16919,pemoline overdose,12,14,94,111,The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose.,9022662_13,-1,-1,-1,16919,-1,0.45149112,0.54850894
16921,venlafaxine overdose,4,6,25,45,Seizure resulting from a venlafaxine overdose.,9034419_0,-1,-1,-1,16921,-1,0.62596303,0.37403703
16922,venlafaxine overdose,7,9,31,51,OBJECTIVE: To report a case of venlafaxine overdose.,9034419_1,-1,-1,-1,16922,-1,0.63277096,0.36722898
16926,suicide,17,18,103,110,CASE SUMMARY: A 40-year-old woman with major depression took an overdose of venlafaxine in an apparent suicide attempt.,9034419_2,-1,-1,-1,16926,-1,0.005971634,0.99402833
16930,venlafaxine overdose,13,15,65,85,"DISCUSSION: To our knowledge, this is the first reported case of venlafaxine overdose that resulted in a generalized seizure.",9034419_5,-1,-1,-1,16930,-1,0.64608485,0.35391515
16933,venlafaxine overdose,3,5,17,37,CONCLUSIONS: The venlafaxine overdose in our patient resulted in a single episode of generalized seizure but elicited no further sequelae.,9034419_7,-1,-1,-1,16933,-1,0.6505311,0.34946883
16935,elevated intraocular pressure,12,15,65,94,"During the follow-up, 3 patients (12%) developed steroid-induced elevated intraocular pressure (IOP) that resolved after corticosteroid therapy was discontinued.",9041081_6,-1,-1,-1,16935,-1,0.004524676,0.99547535
16936,IOP,16,17,96,99,"During the follow-up, 3 patients (12%) developed steroid-induced elevated intraocular pressure (IOP) that resolved after corticosteroid therapy was discontinued.",9041081_6,-1,-1,-1,16936,-1,0.004378294,0.99562174
16937,corticosteroid,21,22,121,135,"During the follow-up, 3 patients (12%) developed steroid-induced elevated intraocular pressure (IOP) that resolved after corticosteroid therapy was discontinued.",9041081_6,-1,-1,-1,16937,-1,0.99886286,0.0011371305
16938,rise,4,5,34,38,The transient steroid-induced IOP rise did not seem to cause functional impairment.,9041081_9,-1,-1,-1,16938,-1,0.003942574,0.9960574
16939,functional impairment,10,12,61,82,The transient steroid-induced IOP rise did not seem to cause functional impairment.,9041081_9,-1,-1,-1,16939,-1,0.0029352645,0.99706477
16941,hydrogen peroxide,3,5,26,43,Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure.,9061311_0,-1,-1,-1,16941,-1,0.99740005,0.0026000165
16944,hydrogen peroxide,4,6,26,43,Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).,9061311_1,-1,-1,-1,16944,-1,0.99826753,0.0017324819
16945,bacterial infections,15,17,98,118,Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).,9061311_1,-1,-1,-1,16945,-1,0.0015732516,0.9984268
16947,ALF,24,25,157,160,Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).,9061311_1,-1,-1,-1,16947,-1,0.0013473084,0.9986527
16949,ALF,11,12,65,68,"In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.",9061311_2,-1,-1,-1,16949,-1,0.0015693437,0.99843067
16950,paracetamol overdose,14,16,76,96,"In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.",9061311_2,-1,-1,-1,16950,-1,0.6059265,0.3940735
16951,ALF,3,4,20,23,Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum.,9061311_3,-1,-1,-1,16951,-1,0.003923767,0.99607617
16952,ALF,15,16,107,110,Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum.,9061311_3,-1,-1,-1,16952,-1,0.015088883,0.9849111
16954,hydrogen peroxide,2,4,15,32,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,-1,-1,-1,16954,-1,0.99814403,0.0018559836
16955,ALF,6,7,47,50,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,-1,-1,-1,16955,-1,0.86550075,0.13449931
16956,ALF,13,14,102,105,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,-1,-1,-1,16956,-1,0.9918576,0.008142409
16957,P,24,25,174,175,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,-1,-1,-1,16957,-1,0.4842977,0.51570225
16958,P,12,13,72,73,This defect persisted when zymosan opsonized by control serum was used (P < 0.05).,9061311_5,-1,-1,-1,16958,-1,0.43177596,0.568224
16960,hydrogen peroxide,2,4,15,32,Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.,9061311_6,-1,-1,-1,16960,-1,0.99836653,0.0016335325
16961,fMLP,11,12,114,118,Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.,9061311_6,-1,-1,-1,16961,-1,0.99856985,0.0014301029
16962,ALF,17,18,138,141,Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.,9061311_6,-1,-1,-1,16962,-1,0.0037252004,0.9962748
16963,ALF,8,9,57,60,Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005).,9061311_7,-1,-1,-1,16963,-1,0.0029953953,0.99700457
16964,P,15,16,102,103,Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005).,9061311_7,-1,-1,-1,16964,-1,0.4138213,0.5861787
16965,ALF,7,8,49,52,"These results demonstrate a neutrophil defect in ALF due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.",9061311_8,-1,-1,-1,16965,-1,0.0015270095,0.998473
16966,paracetamol overdose,10,12,60,80,"These results demonstrate a neutrophil defect in ALF due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.",9061311_8,-1,-1,-1,16966,-1,0.64690894,0.35309106
16967,Cholesteryl hemisuccinate,0,2,0,25,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,-1,-1,-1,16967,-1,0.9989641,0.0010359546
16970,carbon tetrachloride,14,16,106,126,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,-1,-1,-1,16970,-1,0.9991818,0.0008181686
16971,chloroform,17,18,128,138,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,-1,-1,-1,16971,-1,0.99895096,0.0010489894
16972,galactosamine,19,20,143,156,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,-1,-1,-1,16972,-1,0.99888724,0.0011128008
16973,cholesteryl hemisuccinate,11,13,64,89,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,-1,-1,16973,-1,0.99893516,0.0010648764
16974,tris salt,14,16,91,100,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,-1,-1,16974,-1,0.9986461,0.0013538799
16975,CS,17,18,102,104,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,-1,-1,16975,-1,0.9986883,0.0013117491
16977,carbon tetrachloride,32,34,189,209,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,-1,-1,16977,-1,0.999099,0.0009010273
16978,CCl4,35,36,211,215,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,-1,-1,16978,-1,0.99865687,0.0013430817
16979,CS,8,9,49,51,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,16979,-1,0.9987645,0.0012354786
16980,CS,21,22,125,127,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,16980,-1,0.9989091,0.0010908652
16981,ether,25,26,153,158,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,16981,-1,0.99314004,0.0068599135
16982,CS,28,29,167,169,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,16982,-1,0.9988286,0.0011714268
16983,tris salt,33,35,205,214,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,16983,-1,0.99821943,0.0017805735
16984,CSE,36,37,216,219,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,16984,-1,0.998095,0.0019049755
16985,carbon,43,44,258,264,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,16985,-1,0.9988373,0.0011627682
16987,CS,13,14,64,66,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,-1,-1,16987,-1,0.9990075,0.0009925308
16989,CCl4,30,31,155,159,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,-1,-1,16989,-1,0.9989574,0.0010426274
16990,CHCl3,32,33,161,166,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,-1,-1,16990,-1,0.9989642,0.0010357916
16992,galactosamine,36,37,186,199,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,-1,-1,16992,-1,0.99892277,0.0010771875
16995,h,10,11,82,83,Maximal CS-mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult.,9067481_5,-1,-1,-1,16995,-1,0.1272418,0.8727582
16996,CS,4,5,24,26,These data suggest that CS intervenes in a critical cellular event that is an important common pathway to toxic cell death.,9067481_6,-1,-1,-1,16996,-1,0.998151,0.0018489186
16998,CS,3,4,17,19,The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate (in light of the protection observed against galactosamine hepatotoxicity).,9067481_7,-1,-1,-1,16998,-1,0.9983601,0.0016398606
16999,galactosamine hepatotoxicity,30,32,185,213,The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate (in light of the protection observed against galactosamine hepatotoxicity).,9067481_7,-1,-1,-1,16999,-1,0.25514254,0.7448575
17000,CS,15,16,78,80,"However, based on the data presented, we can not exclude the possibility that CS administration inhibits chemical bioactivation.",9067481_8,-1,-1,-1,17000,-1,0.99847263,0.0015273059
17001,CS,16,17,101,103,"Our findings do suggest that CS-mediated protection is dependent on the action of the intact anionic CS molecule (non-hydrolyzable CSE was as protective as CS), whose mechanism has yet to be defined.",9067481_9,-1,-1,-1,17001,-1,0.9984793,0.0015206671
17002,CSE,20,21,131,134,"Our findings do suggest that CS-mediated protection is dependent on the action of the intact anionic CS molecule (non-hydrolyzable CSE was as protective as CS), whose mechanism has yet to be defined.",9067481_9,-1,-1,-1,17002,-1,0.9982791,0.0017209059
17003,CS,25,26,156,158,"Our findings do suggest that CS-mediated protection is dependent on the action of the intact anionic CS molecule (non-hydrolyzable CSE was as protective as CS), whose mechanism has yet to be defined.",9067481_9,-1,-1,-1,17003,-1,0.9986064,0.0013936025
17004,prostaglandin,4,5,30,43,Combined effects of prolonged prostaglandin E1-induced hypotension and haemodilution on human hepatic function.,9088814_0,-1,-1,-1,17004,-1,0.9989723,0.001027734
17007,prostaglandin E1,4,6,30,46,Combined effects of prolonged prostaglandin E1 (PGE1)-induced hypotension and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery.,9088814_1,-1,-1,-1,17007,-1,0.9987436,0.0012564613
17010,n,16,17,79,80,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,-1,-1,-1,17010,-1,0.12002125,0.8799788
17012,n,32,33,153,154,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,-1,-1,-1,17012,-1,0.08440237,0.9155977
17014,n,45,46,206,207,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,-1,-1,-1,17014,-1,0.0741186,0.92588145
17020,PGE1,10,11,58,62,Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min.,9088814_4,-1,-1,-1,17020,-1,0.9988834,0.0011165832
17021,ketone body,3,5,31,42,"Measurements included arterial ketone body ratio (AKBR, aceto-acetate/3-hydroxybutyrate) and clinical hepatic function parameters.",9088814_5,-1,-1,-1,17021,-1,0.9977059,0.0022941674
17026,impairment of hepatic function,20,24,137,167,The results suggest that a prolonged combination of more than 120 min of PGE1-induced hypotension and moderate haemodilution would cause impairment of hepatic function.,9088814_7,-1,-1,-1,17026,-1,0.0048420536,0.9951579
17027,adenomyosis,4,5,18,29,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,-1,-1,-1,17027,-1,0.0014787215,0.99852127
17029,fluoxetine hydrochloride,12,14,76,100,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,-1,-1,-1,17029,-1,0.9991173,0.0008827288
17031,adenomyosis,22,23,147,158,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,-1,-1,-1,17031,-1,0.0015953897,0.9984047
17034,adenomyosis,26,27,170,181,OBJECTIVE: The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis.,9098464_1,-1,-1,-1,17034,-1,0.0016138278,0.99838614
17039,adenomyosis,6,7,42,53,"Histological studies revealed 11 cases of adenomyosis, all within the noncastrated group receiving fluoxetine.",9098464_8,-1,-1,-1,17039,-1,0.0015089732,0.99849105
17042,adenomyosis,5,6,39,50,This invasion eventually progresses to adenomyosis.,9098464_10,-1,-1,-1,17042,-1,0.0017724582,0.99822754
17043,Cardiovascular alterations,0,2,0,26,Cardiovascular alterations in rat fetuses exposed to calcium channel blockers.,9100294_0,-1,-1,-1,17043,-1,0.0016372958,0.9983627
17044,calcium channel blockers,7,10,53,77,Cardiovascular alterations in rat fetuses exposed to calcium channel blockers.,9100294_0,-1,-1,-1,17044,-1,0.99814737,0.0018526361
17046,Ro 40-5967,11,15,84,94,"Preclinical toxicologic investigation suggested that a new calcium channel blocker, Ro 40-5967, induced cardiovascular alterations in rat fetuses exposed to this agent during organogenesis.",9100294_1,-1,-1,-1,17046,-1,0.99852115,0.0014788065
17047,cardiovascular alterations,17,19,104,130,"Preclinical toxicologic investigation suggested that a new calcium channel blocker, Ro 40-5967, induced cardiovascular alterations in rat fetuses exposed to this agent during organogenesis.",9100294_1,-1,-1,-1,17047,-1,0.0014141296,0.99858594
17048,calcium channel blockers,10,13,66,90,The present study was designed to investigate the hypothesis that calcium channel blockers in general induce cardiovascular malformations indicating a pharmacologic class effect.,9100294_2,-1,-1,-1,17048,-1,0.9983353,0.001664757
17049,cardiovascular malformations,16,18,109,137,The present study was designed to investigate the hypothesis that calcium channel blockers in general induce cardiovascular malformations indicating a pharmacologic class effect.,9100294_2,-1,-1,-1,17049,-1,0.0013672535,0.9986327
17050,calcium channel blockers,3,6,17,41,"We studied three calcium channel blockers of different structure, nifedipine, diltiazem, and verapamil, along with the new agent.",9100294_3,-1,-1,-1,17050,-1,0.998389,0.0016110591
17054,calcium channel blockers,7,10,45,69,Pregnant rats were administered one of these calcium channel blockers during the period of cardiac morphogenesis and the offspring examined on day 20 of gestation for cardiovascular malformations.,9100294_4,-1,-1,-1,17054,-1,0.99845123,0.0015487598
17055,cardiovascular malformations,26,28,167,195,Pregnant rats were administered one of these calcium channel blockers during the period of cardiac morphogenesis and the offspring examined on day 20 of gestation for cardiovascular malformations.,9100294_4,-1,-1,-1,17055,-1,0.0015285384,0.99847144
17056,cardiovascular malformations,4,6,19,47,"A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.",9100294_5,-1,-1,-1,17056,-1,0.0013979239,0.9986021
17057,calcium channel blockers,15,18,96,120,"A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.",9100294_5,-1,-1,-1,17057,-1,0.99876934,0.001230683
17060,Ro 40-5967,16,20,111,121,"All four agents were associated with aortic arch branching variants, although significantly increased only for Ro 40-5967 and verapamil.",9100294_6,-1,-1,-1,17060,-1,0.9988398,0.0011601698
17062,ventricular septal defect,1,4,15,40,Postinfarction ventricular septal defect associated with long-term steroid therapy.,9105126_0,-1,-1,-1,17062,-1,0.0025107278,0.9974892
17064,ventricular septal rupture,4,7,28,54,Two cases of postinfarction ventricular septal rupture in patients on long-term steroid therapy are presented and the favourable outcome in both cases described.,9105126_1,-1,-1,-1,17064,-1,0.0023133613,0.9976866
17067,septal rupture,9,11,77,91,A possible association between steroid therapy and subsequent postinfarction septal rupture is discussed.,9105126_2,-1,-1,-1,17067,-1,0.002136519,0.9978635
17070,status epilepticus,11,13,94,112,Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.,9121607_0,-1,-1,-1,17070,-1,0.0014554663,0.9985446
17072,deoxycorticosterone,12,13,96,115,"Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.",9121607_1,-1,-1,-1,17072,-1,0.9992078,0.00079225155
17075,5-H,9,10,60,63,"Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).",9121607_2,-1,-1,-1,17075,-1,0.99720556,0.002794446
17078,status epilepticus,31,33,209,227,"Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).",9121607_2,-1,-1,-1,17078,-1,0.0014221586,0.99857783
17080,benzodiazepine clonazepam,10,12,73,98,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,-1,-1,-1,17080,-1,0.9991124,0.00088755204
17081,pilocarpine seizures,15,17,121,141,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,-1,-1,-1,17081,-1,0.66849977,0.3315002
17083,motor impairment,34,36,250,266,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,-1,-1,-1,17083,-1,0.0016591254,0.99834085
17085,clonazepam,44,45,312,322,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,-1,-1,-1,17085,-1,0.99921465,0.00078527554
17090,kainic acid,23,25,148,159,"Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.",9121607_5,-1,-1,-1,17090,-1,0.99932265,0.0006773623
17094,status epilepticus,27,29,156,174,"However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and status epilepticus was obtained.",9121607_6,-1,-1,-1,17094,-1,0.0013992864,0.99860066
17096,NMDA,8,9,51,55,"The steroids also caused a dose-dependent delay in NMDA (257 mg/kg, s.c.)-induced lethality, but did not completely protect against NMDA seizures or lethality.",9121607_7,-1,-1,-1,17096,-1,0.9988439,0.0011560291
17097,NMDA seizures,22,24,132,145,"The steroids also caused a dose-dependent delay in NMDA (257 mg/kg, s.c.)-induced lethality, but did not completely protect against NMDA seizures or lethality.",9121607_7,-1,-1,-1,17097,-1,0.2450756,0.75492436
17100,status epilepticus,17,19,131,149,"We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.",9121607_8,-1,-1,-1,17100,-1,0.0013766965,0.9986234
17101,status epilepticus,34,36,215,233,"We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.",9121607_8,-1,-1,-1,17101,-1,0.0013502062,0.9986498
17102,nephrotic syndrome,10,12,76,94,Hepatic and extrahepatic angiotensinogen gene expression in rats with acute nephrotic syndrome.,9154656_0,-1,-1,-1,17102,-1,0.0013050033,0.9986951
17103,nephrotic syndrome,15,17,107,125,Plasma concentration and urine excretion of the renin-angiotensin system proteins are altered in rats with nephrotic syndrome (NS).,9154656_1,-1,-1,-1,17103,-1,0.0014494535,0.9985505
17104,NS,18,19,127,129,Plasma concentration and urine excretion of the renin-angiotensin system proteins are altered in rats with nephrotic syndrome (NS).,9154656_1,-1,-1,-1,17104,-1,0.0022880372,0.997712
17105,ribonucleic acid,5,7,27,43,"In this work the messenger ribonucleic acid (mRNA) levels of angiotensinogen (Ao) were analyzed with the slot-blot hybridization technique in liver and other extrahepatic tissues: kidney, heart, brain, and adrenal gland from control, nephrotic, and pair-fed (PF) rats.",9154656_2,-1,-1,-1,17105,-1,0.8814229,0.1185771
17107,NS,0,1,0,2,NS was induced by a single injection of puromycin amino-nucleoside (PAN).,9154656_3,-1,-1,-1,17107,-1,0.0024003591,0.99759966
17108,PAN,11,12,68,71,NS was induced by a single injection of puromycin amino-nucleoside (PAN).,9154656_3,-1,-1,-1,17108,-1,0.9980108,0.0019892468
17109,PAN,17,18,100,103,"Although a great urinary excretion and half-normal plasma levels of Ao were observed on day 6 after PAN injection, when NS was clearly established, hepatic Ao mRNA levels did not change.",9154656_4,-1,-1,-1,17109,-1,0.9975478,0.002452133
17110,NS,21,22,120,122,"Although a great urinary excretion and half-normal plasma levels of Ao were observed on day 6 after PAN injection, when NS was clearly established, hepatic Ao mRNA levels did not change.",9154656_4,-1,-1,-1,17110,-1,0.9944248,0.0055752154
17111,PAN,36,37,155,158,"Furthermore, the Ao mRNA levels did not change in any of the extrahepatic tissues studied on day 6, nor did its hepatic levels at days 1, 3, 5, or 7 after PAN injection.",9154656_5,-1,-1,-1,17111,-1,0.9974892,0.0025107851
17112,NS,19,20,118,120,These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute NS induced by PAN.,9154656_6,-1,-1,-1,17112,-1,0.0032209498,0.996779
17113,PAN,22,23,132,135,These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute NS induced by PAN.,9154656_6,-1,-1,-1,17113,-1,0.9944776,0.005522295
17114,Neuroleptic malignant syndrome,0,3,0,30,Neuroleptic malignant syndrome with risperidone.,9165568_0,-1,-1,-1,17114,-1,0.011895367,0.98810464
17116,Neuroleptic malignant syndrome,0,3,0,30,Neuroleptic malignant syndrome is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia.,9165568_1,-1,-1,-1,17116,-1,0.2914823,0.70851773
17119,benzisoxazole,3,4,15,28,"Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.",9165568_2,-1,-1,-1,17119,-1,0.99926585,0.0007341453
17120,serotonin 5-HT2,9,11,64,79,"Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.",9165568_2,-1,-1,-1,17120,-1,0.9981427,0.0018573101
17124,neuroleptic malignant syndrome,14,17,84,114,"With this low frequency of extrapyramidal symptoms, it was thought the frequency of neuroleptic malignant syndrome might also be lowered.",9165568_4,-1,-1,-1,17124,-1,0.14136626,0.85863376
17125,neuroleptic malignant syndrome,4,7,30,60,A 73-year-old woman developed neuroleptic malignant syndrome after monotherapy with risperidone.,9165568_5,-1,-1,-1,17125,-1,0.04326483,0.9567352
17128,dantrolene,10,11,82,92,The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine.,9165568_6,-1,-1,-1,17128,-1,0.9992355,0.000764465
17131,neuroleptic malignant syndrome,17,20,122,152,It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from neuroleptic malignant syndrome.,9165568_7,-1,-1,-1,17131,-1,0.08392374,0.91607624
17133,Atypical sensations,0,2,0,19,"Atypical sensations following the use of subcutaneous sumatriptan are common, but of uncertain origin.",9195768_1,-1,-1,-1,17133,-1,0.001728365,0.9982716
17135,tingling,5,6,32,40,Two patients are presented with tingling or burning sensations limited to areas of heat exposure or sunburn.,9195768_3,-1,-1,-1,17135,-1,0.0018367656,0.9981633
17136,burning sensations,7,9,44,62,Two patients are presented with tingling or burning sensations limited to areas of heat exposure or sunburn.,9195768_3,-1,-1,-1,17136,-1,0.0016208845,0.9983791
17137,sunburn,16,17,100,107,Two patients are presented with tingling or burning sensations limited to areas of heat exposure or sunburn.,9195768_3,-1,-1,-1,17137,-1,0.0034870526,0.99651295
17141,endophthalmitis,11,12,98,113,"BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery.",9199746_1,-1,-1,-1,17141,-1,0.0019446801,0.99805534
17143,amikacin retinal toxicity,8,11,39,64,METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.,9199746_2,-1,-1,-1,17143,-1,0.39931428,0.6006857
17146,streptococcal endophthalmitis,19,21,135,164,METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.,9199746_2,-1,-1,-1,17146,-1,0.0021137975,0.99788624
17147,Endophthalmitis,2,3,9,24,RESULTS: Endophthalmitis resolved with improvement in visual acuity to 6/24 at three months.,9199746_3,-1,-1,-1,17147,-1,0.0018356451,0.99816436
17149,telangiectasis,8,9,71,85,Fundus fluorescein angiography confirmed macular capillary closure and telangiectasis.,9199746_4,-1,-1,-1,17149,-1,0.0014708107,0.9985292
17150,retinal toxicity,9,11,75,91,CONCLUSIONS: Currently accepted intravitreal antibiotic regimens may cause retinal toxicity and macular ischaemia.,9199746_5,-1,-1,-1,17150,-1,0.0016058406,0.9983942
17151,ischaemia,13,14,104,113,CONCLUSIONS: Currently accepted intravitreal antibiotic regimens may cause retinal toxicity and macular ischaemia.,9199746_5,-1,-1,-1,17151,-1,0.0013794197,0.9986206
17152,retinal toxicity,5,7,39,55,Treatment strategies aimed at avoiding retinal toxicity are discussed.,9199746_6,-1,-1,-1,17152,-1,0.0015214911,0.9984785
17153,carteolol hydrochloride,4,6,26,49,"The attenuating effect of carteolol hydrochloride, a beta-adrenoceptor antagonist, on neuroleptic-induced catalepsy in rats.",9201797_0,-1,-1,-1,17153,-1,0.99920255,0.00079742225
17155,akathisia,12,13,81,90,"It is known that beta-adrenoceptor antagonists are effective in the treatment of akathisia, one of the extrapyramidal side effects that occur during neuroleptic treatment.",9201797_1,-1,-1,-1,17155,-1,0.0013138247,0.99868613
17156,neuroleptic,23,24,149,160,"It is known that beta-adrenoceptor antagonists are effective in the treatment of akathisia, one of the extrapyramidal side effects that occur during neuroleptic treatment.",9201797_1,-1,-1,-1,17156,-1,0.9989178,0.0010822244
17158,akathisia,20,21,161,170,"Neuroleptic-induced catalepsy, a model of neuroleptic-induced extrapyramidal side effects, was considered suitable as a model for predicting neuroleptic-induced akathisia in humans, although neuroleptic-induced catalepsy was not considered a specific test for neuroleptic-induced akathisia.",9201797_2,-1,-1,-1,17158,-1,0.0011440624,0.99885595
17160,akathisia,35,36,280,289,"Neuroleptic-induced catalepsy, a model of neuroleptic-induced extrapyramidal side effects, was considered suitable as a model for predicting neuroleptic-induced akathisia in humans, although neuroleptic-induced catalepsy was not considered a specific test for neuroleptic-induced akathisia.",9201797_2,-1,-1,-1,17160,-1,0.0011201854,0.99887985
17161,carteolol,5,6,26,35,"Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.",9201797_3,-1,-1,-1,17161,-1,0.9992488,0.00075115386
17164,biperiden,26,27,179,188,"Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.",9201797_3,-1,-1,-1,17164,-1,0.999081,0.0009189646
17165,Carteolol,0,1,0,9,"Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.",9201797_4,-1,-1,-1,17165,-1,0.9992078,0.00079223
17167,biperiden,7,8,38,47,"Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.",9201797_4,-1,-1,-1,17167,-1,0.9990982,0.0009018815
17169,carteolol,4,5,25,34,"The inhibitory effect of carteolol was almost comparable to that of propranolol, but was weaker than that of biperiden.",9201797_5,-1,-1,-1,17169,-1,0.99918777,0.0008122641
17171,biperiden,19,20,109,118,"The inhibitory effect of carteolol was almost comparable to that of propranolol, but was weaker than that of biperiden.",9201797_5,-1,-1,-1,17171,-1,0.99892706,0.001072884
17172,Carteolol,0,1,0,9,Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.,9201797_6,-1,-1,-1,17172,-1,0.99913365,0.0008663483
17174,Carteolol,0,1,0,9,Carteolol did not antagonize the inhibitory effects of haloperidol on apomorphine-induced stereotypy and locomotor activity in rats.,9201797_7,-1,-1,-1,17174,-1,0.9992347,0.0007653186
17176,carteolol,3,4,13,22,"In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5-hydroxytryptophan-induced head twitch in rats.",9201797_8,-1,-1,-1,17176,-1,0.99918526,0.0008147638
17177,head twitch,24,26,177,188,"In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5-hydroxytryptophan-induced head twitch in rats.",9201797_8,-1,-1,-1,17177,-1,0.0025144122,0.9974855
17178,carteolol,2,3,9,18,"Finally, carteolol did not inhibit physostigmine-induced lethality in rats.",9201797_9,-1,-1,-1,17178,-1,0.99915826,0.00084179646
17179,carteolol,5,6,36,45,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,-1,-1,-1,17179,-1,0.99926037,0.0007396114
17181,akathisia,24,25,185,194,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,-1,-1,-1,17181,-1,0.0017519061,0.9982481
17182,antipsychotic,28,29,235,248,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,-1,-1,-1,17182,-1,0.9988488,0.0011511769
17184,Granulosa cell tumor of the ovary,0,6,0,33,Granulosa cell tumor of the ovary associated with antecedent tamoxifen use.,9205462_0,-1,-1,-1,17184,-1,0.004161248,0.99583876
17192,aspartate transaminase,1,3,4,26,Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use.,9205462_4,-1,-1,-1,17192,-1,0.98876697,0.011233063
17193,alanine transaminase,4,6,31,51,Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use.,9205462_4,-1,-1,-1,17193,-1,0.9860774,0.013922533
17195,granulosa cell tumor of the ovary,19,25,104,137,"After an additional 17 months of elevated serum transaminases, the patient was found to have a stage Ic granulosa cell tumor of the ovary.",9205462_5,-1,-1,-1,17195,-1,0.006122599,0.9938775
17196,liver dysfunction,5,7,44,61,CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism.,9205462_6,-1,-1,-1,17196,-1,0.0013902937,0.99860966
17197,granulosa cell tumors,13,16,91,112,CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism.,9205462_6,-1,-1,-1,17197,-1,0.0031538308,0.99684614
17200,AZT,7,8,48,51,Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia.,9209318_0,-1,-1,-1,17200,-1,0.99874616,0.0012537952
17201,myelodysplasia,10,11,62,76,Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia.,9209318_0,-1,-1,-1,17201,-1,0.0011219607,0.99887806
17202,AZT,0,1,0,3,AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.,9209318_1,-1,-1,-1,17202,-1,0.99878365,0.0012163543
17203,macrocytic anemia,4,6,18,35,AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.,9209318_1,-1,-1,-1,17203,-1,0.0013548731,0.9986451
17204,AIDS,7,8,39,43,AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.,9209318_1,-1,-1,-1,17204,-1,0.0018607997,0.99813914
17205,AZT,12,13,66,69,AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.,9209318_1,-1,-1,-1,17205,-1,0.99877816,0.001221823
17206,AZT,13,14,75,78,It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.,9209318_2,-1,-1,-1,17206,-1,0.9990897,0.0009102503
17207,thymidine,20,21,106,115,It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.,9209318_2,-1,-1,-1,17207,-1,0.9990753,0.0009247335
17209,AZT,5,6,28,31,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,-1,17209,-1,0.99908936,0.00091059733
17210,H2O,8,9,43,46,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,-1,17210,-1,0.99801135,0.0019886086
17211,H2O,27,28,126,129,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,-1,17211,-1,0.9978594,0.00214062
17212,AZT,36,37,170,173,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,-1,17212,-1,0.9990243,0.0009757771
17213,mg,47,48,224,226,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,-1,17213,-1,0.9973144,0.0026855809
17214,mg,9,10,39,41,At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6).,9209318_4,-1,-1,-1,17214,-1,0.9952407,0.004759309
17216,myelodysplastic syndrome,14,16,99,123,Histological examination on 9 of 10 mice with such thrombocytopenia showed changes compatible with myelodysplastic syndrome (MDS).,9209318_5,-1,-1,-1,17216,-1,0.0011437044,0.9988563
17217,MDS,17,18,125,128,Histological examination on 9 of 10 mice with such thrombocytopenia showed changes compatible with myelodysplastic syndrome (MDS).,9209318_5,-1,-1,-1,17217,-1,0.0011327341,0.9988673
17218,hypocellular myelodysplasia,5,7,24,51,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17218,-1,0.001500812,0.99849916
17219,myelodysplastic granulocytosis,12,14,81,111,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17219,-1,0.0014794271,0.99852055
17220,hypercellular marrow,18,20,126,146,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17220,-1,0.0026101426,0.99738985
17221,megakaryocytic myelosis,30,32,209,232,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17221,-1,0.0017702103,0.9982298
17222,hyperplastic marrow,35,37,251,270,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17222,-1,0.0027347328,0.9972652
17223,dysmyelopoiesis,38,39,272,287,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17223,-1,0.001664684,0.9983353
17224,hypocellular marrow,41,43,294,313,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17224,-1,0.0030020657,0.99699795
17225,myelodysplasia,47,48,331,345,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17225,-1,0.0013637136,0.9986363
17226,dyserythropoiesis,49,50,351,368,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17226,-1,0.0014596609,0.9985404
17227,hemosiderosis,51,52,370,383,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17227,-1,0.0015022162,0.99849784
17228,hypocellular marrow,54,56,390,409,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17228,-1,0.0030107573,0.9969893
17229,AZT,2,3,16,19,"Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the myelodysplastic syndrome.",9209318_8,-1,-1,-1,17229,-1,0.99888307,0.0011169859
17230,myelodysplastic syndrome,26,28,167,191,"Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the myelodysplastic syndrome.",9209318_8,-1,-1,-1,17230,-1,0.0014030595,0.99859697
17234,mg,10,11,56,58,Injections of ketamine in doses from 100 microgram to 3 mg into the artery produced a depression of the SA nodal activity by a direct action.,921394_2,-1,-1,-1,17234,-1,0.98893213,0.011067843
17239,pituitary tumors,16,18,118,134,Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis.,9214597_0,-1,-1,-1,17239,-1,0.002934691,0.99706537
17241,Estrogens,0,1,0,9,"Estrogens, which have been associated with several types of human and animal cancers, can induce tumor angiogenesis in the pituitary of Fischer 344 rats.",9214597_1,-1,-1,-1,17241,-1,0.9982628,0.0017371915
17245,estrogen carcinogenesis,9,11,64,87,"The mechanistic details of tumor angiogenesis induction, during estrogen carcinogenesis, are still unknown.",9214597_2,-1,-1,-1,17245,-1,0.3801532,0.61984676
17248,VIII,28,29,162,166,"To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats, the density of blood vessels was analysed using factor VIII related antigen (FVIIIRAg) immunohistochemistry and the expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was examined by Western blot and immunohistochemical analysis.",9214597_3,-1,-1,-1,17248,-1,0.9948841,0.005115938
17249,E2,6,7,48,50,"The results demonstrated that 17beta-estradiol (E2) induces neovascularization, as well as the growth and enlargement of blood vessels after 7 days of exposure.",9214597_5,-1,-1,-1,17249,-1,0.9987313,0.0012686404
17251,E2,15,16,103,105,The high tumor angiogenic potential was associated with an elevated VEGF/VPF protein expression in the E2 exposed pituitary of ovariectomized (OVEX) rats.,9214597_6,-1,-1,-1,17251,-1,0.9985417,0.0014582548
17252,E2,4,5,17,19,"After 15 days of E2 exposure, VEGF/VPF protein expression, in the non-endothelial cell population, sharply declined and was restricted to the blood vessels.",9214597_8,-1,-1,-1,17252,-1,0.99892575,0.0010742643
17253,E2,26,27,181,183,"Furthermore, immunohistochemical studies demonstrated that VEGFR-2 (flk-1/KDR), expression was elevated significantly in the endothelial cells of microblood vessels after 7 days of E2 exposure.",9214597_10,-1,-1,-1,17253,-1,0.998708,0.0012919323
17256,nephrogenic diabetes insipidus,1,4,11,41,Persistent nephrogenic diabetes insipidus following lithium therapy.,9226773_0,-1,-1,-1,17256,-1,0.0014666512,0.99853337
17259,head injury,14,16,92,103,We report the case of a patient who developed severe hypernatraemic dehydration following a head injury.,9226773_1,-1,-1,-1,17259,-1,0.0016235991,0.99837637
17260,nephrogenic diabetes insipidus,10,13,67,97,"Ten years previously he had been diagnosed to have lithium-induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued.",9226773_2,-1,-1,-1,17260,-1,0.0016228488,0.9983771
17262,polyuric,4,5,24,32,"He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of nephrogenic diabetes insipidus.",9226773_3,-1,-1,-1,17262,-1,0.0020963487,0.9979037
17265,nephrogenic diabetes insipidus,28,31,191,221,"He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of nephrogenic diabetes insipidus.",9226773_3,-1,-1,-1,17265,-1,0.002259427,0.9977406
17267,nephrogenic diabetes insipidus,2,5,16,46,Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped.,9226773_4,-1,-1,-1,17267,-1,0.0014539355,0.9985461
17270,nephrogenic diabetes insipidus,15,18,110,140,We discuss the possible renal mechanisms and the implications for management of patients with lithium-induced nephrogenic diabetes insipidus.,9226773_5,-1,-1,-1,17270,-1,0.0016305534,0.9983695
17271,NIK-247,2,3,11,18,Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia.,9228650_0,-1,-1,-1,17271,-1,0.99887997,0.0011199772
17273,NIK-247,3,4,15,22,"The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.",9228650_1,-1,-1,-1,17273,-1,0.99913627,0.00086370157
17275,cholinesterase,21,22,151,165,"The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.",9228650_1,-1,-1,-1,17275,-1,0.99870574,0.0012942787
17276,tacrine,23,24,177,184,"The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.",9228650_1,-1,-1,-1,17276,-1,0.99922967,0.0007702895
17277,E-2020,25,26,189,195,"The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.",9228650_1,-1,-1,-1,17277,-1,0.99905413,0.0009459155
17278,NIK-247,0,1,0,7,"NIK-247, tacrine and E-2020 all strongly inhibited acetylcholinesterase (AChE) in human red blood cells (IC50s = 1.0 x 10(-6), 2.9 x 10(-7) and 3.7 x 10(-8) M, respectively).",9228650_2,-1,-1,-1,17278,-1,0.9988871,0.0011128999
17279,tacrine,2,3,9,16,"NIK-247, tacrine and E-2020 all strongly inhibited acetylcholinesterase (AChE) in human red blood cells (IC50s = 1.0 x 10(-6), 2.9 x 10(-7) and 3.7 x 10(-8) M, respectively).",9228650_2,-1,-1,-1,17279,-1,0.9989869,0.0010130646
17280,E-2020,4,5,21,27,"NIK-247, tacrine and E-2020 all strongly inhibited acetylcholinesterase (AChE) in human red blood cells (IC50s = 1.0 x 10(-6), 2.9 x 10(-7) and 3.7 x 10(-8) M, respectively).",9228650_2,-1,-1,-1,17280,-1,0.9985668,0.0014332517
17281,NIK-247,3,4,13,20,"In addition, NIK-247 and tacrine, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.",9228650_3,-1,-1,-1,17281,-1,0.9989427,0.0010573178
17282,tacrine,5,6,25,32,"In addition, NIK-247 and tacrine, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.",9228650_3,-1,-1,-1,17282,-1,0.999154,0.0008460807
17283,E-2020,9,10,42,48,"In addition, NIK-247 and tacrine, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.",9228650_3,-1,-1,-1,17283,-1,0.99883133,0.001168656
17284,NIK-247,6,7,35,42,"Moreover, the inhibitory effect of NIK-247 on AChE was reversible.",9228650_5,-1,-1,-1,17284,-1,0.9983973,0.0016026404
17287,NIK-247,4,5,28,35,These findings suggest that NIK-247 at a low dose (0.1-1 mg/kg p.o.) improves scopolamine-induced amnesia but does not affect spontaneous movement.,9228650_8,-1,-1,-1,17287,-1,0.9990125,0.0009875284
17289,NIK-247,4,5,26,33,The findings suggest that NIK-247 may be a useful drug for the treatment of Alzheimer's disease.,9228650_9,-1,-1,-1,17289,-1,0.9985434,0.0014565809
17290,Alzheimer's disease,14,17,76,95,The findings suggest that NIK-247 may be a useful drug for the treatment of Alzheimer's disease.,9228650_9,-1,-1,-1,17290,-1,0.002369766,0.99763024
17292,cardiovascular disease,6,8,40,62,The role of nicotine in smoking-related cardiovascular disease.,9245658_0,-1,-1,-1,17292,-1,0.0014027655,0.9985972
17294,cardiovascular disease,13,15,86,108,Nicotine activates the sympathetic nervous system and in this way could contribute to cardiovascular disease.,9245658_1,-1,-1,-1,17294,-1,0.0016952245,0.9983047
17299,carbon monoxide,39,41,261,276,"Almost certainly, nicotine via its hemodynamic effects contributes to acute cardiovascular events, although current evidence suggests that the effects of nicotine are much less important than are the prothrombotic effects of cigarette smoking or the effects of carbon monoxide.",9245658_3,-1,-1,-1,17299,-1,0.9991364,0.00086364447
17306,atrioventricular reentrant tachycardia,3,6,35,73,Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.,9249847_0,-1,-1,-1,17306,-1,0.0024556303,0.99754435
17308,idiopathic dilated cardiomyopathy,18,21,165,198,Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.,9249847_0,-1,-1,-1,17308,-1,0.0015388145,0.99846125
17309,WPW syndrome,4,6,18,30,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,-1,-1,-1,17309,-1,0.0016365383,0.99836344
17310,idiopathic dilated cardiomyopathy,7,10,35,68,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,-1,-1,-1,17310,-1,0.0014067106,0.9985933
17311,atrioventricular reentrant tachycardia,12,15,82,120,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,-1,-1,-1,17311,-1,0.0021347527,0.99786526
17312,AVRT,16,17,122,126,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,-1,-1,-1,17312,-1,0.0017739243,0.9982261
17314,AVRT,24,25,178,182,"QRS without preexcitation, caused by junctional escape beats after verapamil or unidirectional antegrade block of accessory pathway after catheter ablation, established frequent AVRT attack.",9249847_2,-1,-1,-1,17314,-1,0.0058906106,0.9941094
17316,A-86929,11,12,73,80,"Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.",9270571_0,-1,-1,-1,17316,-1,0.998706,0.0012940359
17319,DA,6,7,34,36,The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.,9270571_1,-1,-1,-1,17319,-1,0.9985195,0.0014805695
17320,Parkinson's disease,15,18,79,98,The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.,9270571_1,-1,-1,-1,17320,-1,0.0022353001,0.9977647
17321,PD,19,20,100,102,The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.,9270571_1,-1,-1,-1,17321,-1,0.0020314136,0.9979686
17322,DA,5,6,33,35,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17322,-1,0.9982712,0.0017287591
17323,SKF-82958,11,12,65,74,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17323,-1,0.9986072,0.0013927467
17324,"6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide",13,16,76,165,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17324,-1,0.9971942,0.0028058433
17325,A-77636,18,19,171,178,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17325,-1,0.998539,0.0014610243
17326,"[1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride",20,28,180,275,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17326,-1,0.99596953,0.0040304344
17327,SKF-82958,43,44,351,360,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17327,-1,0.9986927,0.0013073687
17328,A-77636,53,54,387,394,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17328,-1,0.99869317,0.0013069056
17329,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",10,11,69,113,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,-1,-1,-1,17329,-1,0.998543,0.0014570118
17331,dyskinetic,24,25,225,235,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,-1,-1,-1,17331,-1,0.0016893309,0.9983107
17332,A-86929,39,40,301,308,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,-1,-1,-1,17332,-1,0.9985424,0.0014575557
17333,"[-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+",41,42,310,369,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,-1,-1,-1,17333,-1,0.9866888,0.013311263
17334,DA,54,55,439,441,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,-1,-1,-1,17334,-1,0.99809474,0.0019052859
17336,DA,3,4,17,19,"Levodopa and the DA D2-like receptor agonist, LY-171555 ([4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo lo-3-4-quinoline hydrochloride) were also used for comparison.",9270571_4,-1,-1,-1,17336,-1,0.9987239,0.0012760041
17337,LY-171555,8,9,46,55,"Levodopa and the DA D2-like receptor agonist, LY-171555 ([4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo lo-3-4-quinoline hydrochloride) were also used for comparison.",9270571_4,-1,-1,-1,17337,-1,0.9986559,0.0013440056
17338,4-quinoline,13,14,122,133,"Levodopa and the DA D2-like receptor agonist, LY-171555 ([4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo lo-3-4-quinoline hydrochloride) were also used for comparison.",9270571_4,-1,-1,-1,17338,-1,0.9979512,0.002048779
17339,hydrochloride,14,15,134,147,"Levodopa and the DA D2-like receptor agonist, LY-171555 ([4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo lo-3-4-quinoline hydrochloride) were also used for comparison.",9270571_4,-1,-1,-1,17339,-1,0.99783283,0.0021671443
17340,A-86929,3,4,24,31,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,-1,-1,-1,17340,-1,0.99886763,0.0011323786
17343,LY-171555,14,15,108,117,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,-1,-1,-1,17343,-1,0.9989374,0.0010625245
17345,LY-171555,31,32,219,228,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,-1,-1,-1,17345,-1,0.9989409,0.0010590834
17347,DA,4,5,29,31,Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.,9270571_6,-1,-1,-1,17347,-1,0.99898785,0.0010120767
17349,DA,37,38,230,232,Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.,9270571_6,-1,-1,-1,17349,-1,0.99895954,0.0010403978
17350,DA,1,2,7,9,Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in PD and merit further attention.,9270571_7,-1,-1,-1,17350,-1,0.9982029,0.0017970402
17351,A-86929,13,14,79,86,Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in PD and merit further attention.,9270571_7,-1,-1,-1,17351,-1,0.99855465,0.0014453296
17352,PD,28,29,166,168,Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in PD and merit further attention.,9270571_7,-1,-1,-1,17352,-1,0.0024750214,0.99752504
17354,hydrochlorofluorocarbons,6,7,36,60,Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons.,9284778_0,-1,-1,-1,17354,-1,0.9989692,0.0010308346
17355,chlorofluorocarbons,12,13,98,117,Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons.,9284778_0,-1,-1,-1,17355,-1,0.9989506,0.0010493736
17356,Hydrochlorofluorocarbons,2,3,12,36,BACKGROUND: Hydrochlorofluorocarbons (HCFCs) are used increasingly in industry as substitutes for ozone-depleting chlorofluorocarbons (CFCs).,9284778_1,-1,-1,-1,17356,-1,0.99876165,0.0012383785
17357,HCFCs,4,5,38,43,BACKGROUND: Hydrochlorofluorocarbons (HCFCs) are used increasingly in industry as substitutes for ozone-depleting chlorofluorocarbons (CFCs).,9284778_1,-1,-1,-1,17357,-1,0.997866,0.0021340868
17358,chlorofluorocarbons,15,16,114,133,BACKGROUND: Hydrochlorofluorocarbons (HCFCs) are used increasingly in industry as substitutes for ozone-depleting chlorofluorocarbons (CFCs).,9284778_1,-1,-1,-1,17358,-1,0.99862516,0.0013748306
17359,CFCs,17,18,135,139,BACKGROUND: Hydrochlorofluorocarbons (HCFCs) are used increasingly in industry as substitutes for ozone-depleting chlorofluorocarbons (CFCs).,9284778_1,-1,-1,-1,17359,-1,0.9980202,0.0019797874
17363,HCFC 123,23,25,165,173,"We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,-1,-1,-1,17363,-1,0.9985324,0.0014675229
17365,HCFC 124,29,31,215,223,"We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,-1,-1,-1,17365,-1,0.9984767,0.0015232749
17368,trifluoroacetyl halide,16,18,118,140,"Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.",9284778_5,-1,-1,-1,17368,-1,0.99836224,0.0016377659
17371,HCFCs,5,6,25,30,We aimed to test whether HCFCs 123 and 124 can result in serious liver disease.,9284778_6,-1,-1,-1,17371,-1,0.9975938,0.0024061413
17373,trifluoroacetyl,16,17,109,124,METHODS: For one severely affected worker liver biopsy and immunohistochemical stainings for the presence of trifluoroacetyl protein adducts were done.,9284778_7,-1,-1,-1,17373,-1,0.9987036,0.0012963444
17374,hepatocellular necrosis,7,9,41,64,FINDINGS: The liver biopsy sample showed hepatocellular necrosis which was prominent in perivenular zone three and extended focally from portal tracts to portal tracts and centrilobular areas (bridging necrosis).,9284778_9,-1,-1,-1,17374,-1,0.0019932296,0.99800676
17376,halothane hepatitis,10,12,67,86,"Autoantibodies against P450 2E1 or P58, previously associated with halothane hepatitis, were detected in the serum of five affected workers.",9284778_11,-1,-1,-1,17376,-1,0.73294085,0.26705912
17377,HCFCs,8,9,53,58,INTERPRETATION: Repeated exposure of human beings to HCFCs 123 and 124 can result in serious liver injury in a large proportion of the exposed population.,9284778_12,-1,-1,-1,17377,-1,0.9986494,0.0013506475
17380,hamartoma,2,3,10,19,Bile duct hamartoma occurring in association with long-term treatment with danazol.,9293063_0,-1,-1,-1,17380,-1,0.0018513491,0.9981487
17382,hamartoma,7,8,30,39,We report a case of bile duct hamartoma which developed in a patient who had been on long-term danazol treatment.,9293063_1,-1,-1,-1,17382,-1,0.001753417,0.99824655
17387,TLE,23,24,145,148,Neuropeptide-Y (NPY) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy (TLE).,9305828_1,-1,-1,-1,17387,-1,0.0027075883,0.99729234
17389,PILO,3,4,17,21,The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.,9305828_3,-1,-1,-1,17389,-1,0.9980976,0.0019024406
17391,status epilepticus,15,17,80,98,The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.,9305828_3,-1,-1,-1,17391,-1,0.0013142439,0.9986858
17394,PILO,3,4,13,17,"In addition, PILO injected animals exhibited a reduction in the number of NPY-immunoreactive interneurons compared with controls.",9305828_7,-1,-1,-1,17394,-1,0.9986609,0.0013390534
17395,PILO,30,31,174,178,"The results demonstrate that changes in NPY expression, including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons, are present in the PILO model of TLE.",9305828_8,-1,-1,-1,17395,-1,0.99638283,0.0036171975
17396,TLE,33,34,188,191,"The results demonstrate that changes in NPY expression, including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons, are present in the PILO model of TLE.",9305828_8,-1,-1,-1,17396,-1,0.002466651,0.9975333
17397,Parkinson's disease,5,8,46,65,Posteroventral medial pallidotomy in advanced Parkinson's disease.,9321531_0,-1,-1,-1,17397,-1,0.002606002,0.99739397
17398,Parkinson's disease,13,16,112,131,"BACKGROUND: Posteroventral medial pallidotomy sometimes produces striking improvement in patients with advanced Parkinson's disease, but the studies to date have involved small numbers of patients and short-term follow-up.",9321531_1,-1,-1,-1,17398,-1,0.002363652,0.9976363
17399,Parkinson's disease,5,8,29,48,"METHODS: Forty patients with Parkinson's disease underwent serial, detailed assessments both after drug withdrawal (""off"" period) and while taking their optimal medical regimens (""on"" period).",9321531_2,-1,-1,-1,17399,-1,0.0024311452,0.9975688
17404,bradykinesia,13,14,96,108,"The improvements in dyskinesias and the total scores for off-period parkinsonism, contralateral bradykinesia, and rigidity were sustained in the 11 patients examined at two years.",9321531_5,-1,-1,-1,17404,-1,0.0011420579,0.998858
17407,Parkinson's disease,4,7,27,46,"CONCLUSIONS: In late-stage Parkinson's disease, pallidotomy significantly reduces levodopa-induced dyskinesias and off-period disability.",9321531_9,-1,-1,-1,17407,-1,0.0021529736,0.9978471
17409,disability,15,16,126,136,"CONCLUSIONS: In late-stage Parkinson's disease, pallidotomy significantly reduces levodopa-induced dyskinesias and off-period disability.",9321531_9,-1,-1,-1,17409,-1,0.0014142906,0.9985857
17411,Clarithromycin,0,1,0,14,Clarithromycin is a relatively new macrolide antibiotic that offers twice-daily dosing.,9326871_1,-1,-1,-1,17411,-1,0.9989654,0.0010346284
17412,macrolide,5,6,35,44,Clarithromycin is a relatively new macrolide antibiotic that offers twice-daily dosing.,9326871_1,-1,-1,-1,17412,-1,0.99824834,0.0017517306
17413,erythromycin,3,4,16,28,It differs from erythromycin only in the methylation of the hydroxyl group at position 6.,9326871_2,-1,-1,-1,17413,-1,0.99875677,0.0012432082
17414,erythromycin,5,6,36,48,"Although the side-effect profile of erythromycin is established, including gastroenteritis and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.",9326871_3,-1,-1,-1,17414,-1,0.9990526,0.0009474611
17415,gastroenteritis,10,11,75,90,"Although the side-effect profile of erythromycin is established, including gastroenteritis and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.",9326871_3,-1,-1,-1,17415,-1,0.0012975205,0.9987024
17416,macrolides,27,28,205,215,"Although the side-effect profile of erythromycin is established, including gastroenteritis and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.",9326871_3,-1,-1,-1,17416,-1,0.9986072,0.0013927679
17418,erythromycin,11,12,87,99,Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides.,9326871_4,-1,-1,-1,17418,-1,0.9990521,0.0009479012
17419,macrolides,20,21,143,153,Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides.,9326871_4,-1,-1,-1,17419,-1,0.9985644,0.0014355616
17420,ventricular dysrhythmias,5,7,20,44,We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of clarithromycin.,9326871_5,-1,-1,-1,17420,-1,0.0013361037,0.9986639
17421,clarithromycin,14,15,90,104,We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of clarithromycin.,9326871_5,-1,-1,-1,17421,-1,0.999198,0.00080200646
17422,dysrhythmias,1,2,4,16,The dysrhythmias resolved after discontinuation of the drug.,9326871_6,-1,-1,-1,17422,-1,0.0013860922,0.99861383
17423,erectile dysfunction,6,8,38,58,"Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy.",9334596_0,-1,-1,-1,17423,-1,0.0014186752,0.9985813
17425,erectile dysfunction,18,20,121,141,"PURPOSE: We reviewed the results of serum testosterone and prolactin determination in 1,022 patients referred because of erectile dysfunction and compared the data with history, results of physical examination, other etiological investigations and effects of endocrine therapy to refine the rules of cost-effective endocrine screening and to pinpoint actual responsibility for hormonal abnormalities.",9334596_1,-1,-1,-1,17425,-1,0.0014894081,0.99851054
17429,gynecomastia,20,21,115,127,"Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire, gynecomastia or testosterone less than 4 ng./ml.",9334596_3,-1,-1,-1,17429,-1,0.001533799,0.99846625
17431,erectile dysfunction,15,17,96,116,"Prolactin results were compared with those of a previous personal cohort of 1,340 patients with erectile dysfunction and systematic prolactin determination.",9334596_5,-1,-1,-1,17431,-1,0.0014733886,0.9985266
17433,small testes,14,16,100,112,"Main clinical criteria tested regarding efficiency in hormone determination were low sexual desire, small testes and gynecomastia.",9334596_6,-1,-1,-1,17433,-1,0.0023975654,0.9976024
17434,gynecomastia,17,18,117,129,"Main clinical criteria tested regarding efficiency in hormone determination were low sexual desire, small testes and gynecomastia.",9334596_6,-1,-1,-1,17434,-1,0.0015283885,0.99847156
17435,testosterone heptylate,4,6,31,53,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,-1,-1,-1,17435,-1,0.9991253,0.000874696
17436,human chorionic gonadotropin,7,10,57,85,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,-1,-1,-1,17436,-1,0.9985569,0.0014430424
17437,hypogonadism,11,12,90,102,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,-1,-1,-1,17437,-1,0.001655223,0.9983448
17442,pituitary tumors,1,3,4,20,Two pituitary tumors were discovered after testosterone determination.,9334596_11,-1,-1,-1,17442,-1,0.0026101663,0.99738985
17445,hypothalamic dysfunction,12,14,75,99,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,-1,-1,-1,17445,-1,0.0015617501,0.9984383
17446,luteinizing hormone,18,20,124,143,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,-1,-1,-1,17446,-1,0.9988537,0.0011463282
17447,erectile dysfunction,30,32,191,211,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,-1,-1,-1,17447,-1,0.0014636891,0.99853635
17448,androgen,45,46,263,271,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,-1,-1,-1,17448,-1,0.9990583,0.0009417592
17452,androgen,33,34,199,207,"Determining testosterone only in cases of low sexual desire or abnormal physical examination would have missed 40% of the cases with low testosterone, including 37% of those subsequently improved by androgen therapy.",9334596_13,-1,-1,-1,17452,-1,0.99891794,0.0010820987
17454,prolactinomas,7,8,28,41,"in 1.86% of 1,821 patients, prolactinomas in 7, 0.38%).",9334596_18,-1,-1,-1,17454,-1,0.008480013,0.99152
17458,erectile dysfunction,13,15,83,103,CONCLUSIONS: Low prevalences and effects of low testosterone and high prolactin in erectile dysfunction cannot justify their routine determination.,9334596_22,-1,-1,-1,17458,-1,0.00151262,0.99848735
17459,pituitary tumors,21,23,130,146,"However, cost-effective screening strategies recommended so far missed 40 to 50% of cases improved with endocrine therapy and the pituitary tumors.",9334596_23,-1,-1,-1,17459,-1,0.0024583414,0.99754167
17463,gynecomastia,12,13,67,79,"Prolactin should be determined only in cases of low sexual desire, gynecomastia and/or testosterone less than 4 ng./ml.",9334596_25,-1,-1,-1,17463,-1,0.0014885475,0.9985115
17469,serotonin 5-HT2,12,14,75,90,Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors.,9351491_1,-1,-1,-1,17469,-1,0.99793005,0.0020699906
17472,neuroleptics,33,34,241,253,Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics.,9351491_2,-1,-1,-1,17472,-1,0.99257964,0.007420403
17475,n,40,41,254,255,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,-1,-1,-1,17475,-1,0.11371464,0.8862854
17477,n,47,48,278,279,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,-1,-1,-1,17477,-1,0.08720305,0.912797
17488,5-FU,15,16,118,122,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,-1,-1,-1,17488,-1,0.9989924,0.0010076127
17489,leucovorin,17,18,127,137,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,-1,-1,-1,17489,-1,0.9991579,0.0008421507
17490,MFL,19,20,139,142,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,-1,-1,-1,17490,-1,0.9508013,0.049198747
17495,5-FU,8,9,70,74,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,-1,-1,-1,17495,-1,0.99873704,0.0012629529
17496,leucovorin,11,12,80,90,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,-1,-1,-1,17496,-1,0.9990965,0.0009034623
17497,MFL,13,14,92,95,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,-1,-1,-1,17497,-1,0.996786,0.0032140485
17500,5-FU,30,31,184,188,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,-1,-1,-1,17500,-1,0.99903846,0.00096156
17501,leucovorin,37,38,216,226,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,-1,-1,-1,17501,-1,0.9991326,0.00086744525
17502,h,44,45,246,247,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,-1,-1,-1,17502,-1,0.48121583,0.51878417
17503,lung metastasis,12,14,64,79,"Most of these patients had more than two metastatic sites, with lung metastasis predominant.",9390208_5,-1,-1,-1,17503,-1,0.0031329964,0.996867
17505,MFL,5,6,28,31,Median number of courses of MFL regimen given was six and the median cumulative dose of mitoxantrone was 68.35 mg/m2.,9390208_8,-1,-1,-1,17505,-1,0.49353367,0.5064663
17511,MFL,1,2,4,7,The MFL regimen achieves little palliative benefit and induces severe toxicity at a fairly high rate.,9390208_17,-1,-1,-1,17511,-1,0.9693318,0.030668175
17514,impaired heart function,17,20,110,133,Administration of this regimen to breast cancer patients who have been treated by chemotherapy and those with impaired heart function requires careful attention.,9390208_18,-1,-1,-1,17514,-1,0.0035975794,0.9964024
17517,Agranulocytosis,0,1,0,15,"Agranulocytosis occurred 3-20 weeks after initiation of ticlopidine, so frequent examination of white cell count during treatment is recommended.",9401499_5,-1,-1,-1,17517,-1,0.0017397206,0.9982603
17521,calcium channel blockers,11,14,58,82,"The fact that 5 of the 6 patients who received concurrent calcium channel blockers died, should alert clinicians to be more cautious when using these two drugs simultaneously.",9401499_8,-1,-1,-1,17521,-1,0.99875283,0.0012471975
17523,diabetes insipidus,16,18,119,137,Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium-induced diabetes insipidus rat.,9406968_0,-1,-1,-1,17523,-1,0.003406737,0.9965933
17524,arginine vasopressin,3,5,18,38,"The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.",9406968_1,-1,-1,-1,17524,-1,0.9991424,0.0008575169
17525,AVP,6,7,40,43,"The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.",9406968_1,-1,-1,-1,17525,-1,0.99894077,0.0010591852
17528,LiCl,9,10,53,57,The male Wistar rats consuming a diet that contained LiCl (60 mmol/kg) for 4 weeks developed marked polyuria.,9406968_2,-1,-1,-1,17528,-1,0.9990344,0.00096556457
17530,hypotonic,8,9,47,56,The Li-treated rats produced a large volume of hypotonic urine with low ionic concentrations.,9406968_3,-1,-1,-1,17530,-1,0.0021000647,0.9978999
17532,AVP,3,4,24,27,Plasma concentration of AVP and transcripts of AVP gene in the PVN and SON were significantly increased in the Li-treated rats compared with controls.,9406968_5,-1,-1,-1,17532,-1,0.9989303,0.0010696999
17533,AVP,7,8,47,50,Plasma concentration of AVP and transcripts of AVP gene in the PVN and SON were significantly increased in the Li-treated rats compared with controls.,9406968_5,-1,-1,-1,17533,-1,0.9988978,0.0011021704
17535,AVP,19,20,131,134,These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.,9406968_6,-1,-1,-1,17535,-1,0.9990025,0.0009974925
17536,AVP,24,25,159,162,These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.,9406968_6,-1,-1,-1,17536,-1,0.99902654,0.00097341294
17537,diabetes insipidus,36,38,220,238,These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.,9406968_6,-1,-1,-1,17537,-1,0.0035720754,0.99642795
17538,glyceryl trinitrate,2,4,10,29,Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine-morphine administration.,9431903_0,-1,-1,-1,17538,-1,0.9990507,0.0009492822
17540,glyceryl trinitrate,8,10,39,58,OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.,9431903_1,-1,-1,-1,17540,-1,0.99910164,0.00089838356
17544,mg prostigmine,13,15,88,102,METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.,9431903_2,-1,-1,-1,17544,-1,0.99846375,0.0015363146
17545,mg morphine,18,20,126,137,METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.,9431903_2,-1,-1,-1,17545,-1,0.9978114,0.0021886567
17546,glyceryl trinitrate,6,8,41,60,The entire procedure was repeated during glyceryl trinitrate infusion (Nitrolingual 1 microg/kg/min for 120 min).,9431903_3,-1,-1,-1,17546,-1,0.9990175,0.0009824571
17547,Nitrolingual,10,11,71,83,The entire procedure was repeated during glyceryl trinitrate infusion (Nitrolingual 1 microg/kg/min for 120 min).,9431903_3,-1,-1,-1,17547,-1,0.99865377,0.0013462527
17549,Glyceryl trinitrate,0,2,0,19,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,-1,-1,-1,17549,-1,0.9991161,0.000883811
17550,glyceryl trinitrate,79,81,382,401,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,-1,-1,-1,17550,-1,0.9991511,0.00084882486
17551,glyceryl trinitrate,12,14,77,96,CONCLUSION: These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine-induced sphincter of Oddi spasm in humans.,9431903_6,-1,-1,-1,17551,-1,0.999121,0.0008789959
17553,glyceryl trinitrate,1,3,6,25,"Since glyceryl trinitrate is able to overcome even the drastic effect of morphine, it might be of relevance in the treatment of sphincter of Oddi dyskinesia.",9431903_7,-1,-1,-1,17553,-1,0.9990752,0.0009247533
17556,mg,23,24,182,184,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,-1,-1,-1,17556,-1,0.98175585,0.018244166
17557,mg,31,32,202,204,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,-1,-1,-1,17557,-1,0.9762437,0.023756295
17558,mg,39,40,222,224,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,-1,-1,-1,17558,-1,0.98193765,0.018062294
17560,pirenzepine,17,18,137,148,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17560,-1,0.9992073,0.00079271704
17561,dicyclomine,19,20,153,164,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17561,-1,0.9992269,0.00077307294
17563,hemicholinium-3,24,25,196,211,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17563,-1,0.998887,0.0011129831
17565,quinpirole,49,50,403,413,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17565,-1,0.99931395,0.00068611
17567,2-methoxy-4-amino-5-chlorobenzoic,54,55,451,484,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17567,-1,0.9979955,0.0020045214
17568,2-methoxy-4-amino-5-chlorobenzoic acid,54,56,451,489,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17568,-1,0.9983552,0.0016448112
17569,2-(diethylamino)ethyl,56,57,490,511,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17569,-1,0.99797434,0.002025631
17570,2-(diethylamino)ethyl ester hydrochloride,56,59,490,531,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17570,-1,0.99797744,0.0020225672
17571,5-hydroxytryptamin1A,61,62,537,557,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17571,-1,0.99806505,0.0019349146
17578,1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide,63,65,569,638,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17578,-1,0.99842095,0.0015790649
17579,polyamines,67,68,647,657,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17579,-1,0.99835,0.001650036
17581,mg,5,6,18,20,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,-1,-1,-1,17581,-1,0.9907612,0.009238785
17584,mg,20,21,86,88,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,-1,-1,-1,17584,-1,0.9887764,0.011223554
17585,dicyclomine,26,27,104,115,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,-1,-1,-1,17585,-1,0.9992632,0.0007367595
17586,mg,29,30,119,121,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,-1,-1,-1,17586,-1,0.99064356,0.009356411
17588,glomerular disease,3,5,41,59,Immunopathology of penicillamine-induced glomerular disease.,950631_0,-1,-1,-1,17588,-1,0.0013128114,0.9986872
17591,membranous glomerulonephritis,8,10,44,73,"The findings were similar to those in early membranous glomerulonephritis, differences being observed however in the results of staining for the early-acting complement components C1q and C4.",950631_5,-1,-1,-1,17591,-1,0.0015303582,0.99846965
17594,migraine without aura,15,18,79,100,"Using a positron emission tomography (PET) study it was shown recently that in migraine without aura certain areas in the brain stem were activated during the headache state, but not in the headache free interval.",9514561_1,-1,-1,-1,17594,-1,0.0017720769,0.9982279
17602,painful sensation,16,18,101,118,A small amount of capsaicin was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve.,9514561_4,-1,-1,-1,17602,-1,0.0015914926,0.9984085
17608,cluster headache,42,44,236,252,"The increase of activation in the region of the cavernous sinus however, suggests that this structure is more likely to be involved in trigeminal transmitted pain as such, rather than in a specific type of headache as was suggested for cluster headache.",9514561_7,-1,-1,-1,17608,-1,0.0018171066,0.99818283
17609,hearing loss,7,9,46,58,The effect of different anaesthetic agents in hearing loss following spinal anaesthesia.,9522143_0,-1,-1,-1,17609,-1,0.0024999434,0.9975
17610,hearing loss,3,5,13,25,The cause of hearing loss after spinal anaesthesia is unknown.,9522143_1,-1,-1,-1,17610,-1,0.0025171754,0.99748284
17612,hearing loss,9,11,43,55,The aim of this study was to describe this hearing loss and to investigate other factors influencing the degree of hearing loss.,9522143_3,-1,-1,-1,17612,-1,0.0022441268,0.99775594
17613,hearing loss,20,22,115,127,The aim of this study was to describe this hearing loss and to investigate other factors influencing the degree of hearing loss.,9522143_3,-1,-1,-1,17613,-1,0.0025640004,0.997436
17617,hearing loss,8,10,54,66,Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).,9522143_5,-1,-1,-1,17617,-1,0.0021031138,0.9978969
17619,P,27,28,126,127,Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).,9522143_5,-1,-1,-1,17619,-1,0.32005,0.67994994
17620,hearing loss,2,4,12,24,The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine.,9522143_6,-1,-1,-1,17620,-1,0.004170635,0.9958294
17623,hearing loss,7,9,46,58,None of the patients complained of subjective hearing loss.,9522143_7,-1,-1,-1,17623,-1,0.0019374794,0.99806255
17624,neurological deficit,2,4,12,32,A transient neurological deficit following intrathecal injection of 1% hyperbaric bupivacaine for unilateral spinal anaesthesia.,9522152_0,-1,-1,-1,17624,-1,0.0012168358,0.9987832
17626,neurological deficit,6,8,32,52,We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1% hyperbaric bupivacaine slowly injected through a 25-gauge pencil-point spinal needle.,9522152_1,-1,-1,-1,17626,-1,0.0011190973,0.9988809
17627,mg,16,17,110,112,We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1% hyperbaric bupivacaine slowly injected through a 25-gauge pencil-point spinal needle.,9522152_1,-1,-1,-1,17627,-1,0.9930224,0.006977595
17629,hypoaesthesia,19,20,103,116,"The surgery and anaesthesia were uneventful, but 3 days after surgery, the patient reported an area of hypoaesthesia over L3-L4 dermatomes of the leg which had been operated on (loss of pinprick sensation) without reduction in muscular strength.",9522152_2,-1,-1,-1,17629,-1,0.0014119457,0.998588
17630,reduction,38,39,214,223,"The surgery and anaesthesia were uneventful, but 3 days after surgery, the patient reported an area of hypoaesthesia over L3-L4 dermatomes of the leg which had been operated on (loss of pinprick sensation) without reduction in muscular strength.",9522152_2,-1,-1,-1,17630,-1,0.002869061,0.99713093
17631,strength,41,42,236,244,"The surgery and anaesthesia were uneventful, but 3 days after surgery, the patient reported an area of hypoaesthesia over L3-L4 dermatomes of the leg which had been operated on (loss of pinprick sensation) without reduction in muscular strength.",9522152_2,-1,-1,-1,17631,-1,0.005513754,0.9944863
17632,lead,49,50,304,308,"However, we suggest that a low solution concentration should be preferred for unilateral spinal anaesthesia with a hyperbaric anaesthetic solution (if pencil-point needle and slow injection rate are employed), in order to minimize the risk of a localized high peak anaesthetic concentration, which might lead to a transient neurological deficit.",9522152_5,-1,-1,-1,17632,-1,0.008042791,0.9919572
17633,neurological deficit,53,55,324,344,"However, we suggest that a low solution concentration should be preferred for unilateral spinal anaesthesia with a hyperbaric anaesthetic solution (if pencil-point needle and slow injection rate are employed), in order to minimize the risk of a localized high peak anaesthetic concentration, which might lead to a transient neurological deficit.",9522152_5,-1,-1,-1,17633,-1,0.0014238376,0.99857616
17634,Transient neurologic symptoms,0,3,0,29,Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.,9523805_0,-1,-1,-1,17634,-1,0.0012405076,0.9987595
17638,transient neurologic symptoms,6,9,42,71,BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.,9523805_1,-1,-1,-1,17638,-1,0.001254261,0.9987457
17639,TNSs,10,11,73,77,BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.,9523805_1,-1,-1,-1,17639,-1,0.0015572188,0.9984428
17648,TNSs,24,25,164,168,"Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.",9523805_4,-1,-1,-1,17648,-1,0.0019935265,0.9980065
17655,TNSs,12,13,67,71,"In the evening of postoperative day 1, patients were evaluated for TNSs by a physician unaware of the drug administered and the details of the anesthetic procedure.",9523805_8,-1,-1,-1,17655,-1,0.002183718,0.9978163
17657,TNSs,9,10,61,65,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,-1,-1,-1,17657,-1,0.002128505,0.9978715
17659,P,18,19,106,107,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,-1,-1,-1,17659,-1,0.5960772,0.40392274
17661,TNSs,33,34,176,180,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,-1,-1,-1,17661,-1,0.0021284677,0.9978715
17665,P,37,38,190,191,"Times to ambulate and to void were similar after lidocaine and prilocaine (150 vs. 165 min and 238 vs. 253 min, respectively) but prolonged after bupivacaine (200 and 299 min, respectively; P < 0.05).",9523805_10,-1,-1,-1,17665,-1,0.49526668,0.5047334
17668,TNSs,25,26,154,158,CONCLUSIONS: Prilocaine may be preferable to lidocaine for short surgical procedures because it has a similar duration of action but a lower incidence of TNSs.,9523805_11,-1,-1,-1,17668,-1,0.0019748982,0.9980252
17670,iron dextran,16,18,120,132,Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.,9523850_0,-1,-1,-1,17670,-1,0.99870515,0.0012948045
17671,iron dextran,12,14,56,68,The safety and efficacy of total dose infusion (TDI) of iron dextran has been well documented.,9523850_1,-1,-1,-1,17671,-1,0.9986016,0.0013984225
17673,MP,23,24,148,150,"The purpose of this randomized, double-blind, prospective study was to investigate whether intravenous (i.v.) administration of methylprednisolone (MP) prevents this complication.",9523850_3,-1,-1,-1,17673,-1,0.9980191,0.0019809552
17674,mg,29,30,129,131,"Sixty-five patients, 34 women and 31 men, ages 36 to 80 years, received either normal saline before and after TDI (group 1), 125 mg i.v.",9523850_4,-1,-1,-1,17674,-1,0.9974038,0.0025962146
17675,MP,0,1,0,2,"MP before and saline after TDI (group 2), or 125 mg i.v.",9523850_5,-1,-1,-1,17675,-1,0.9985536,0.0014464258
17676,mg,13,14,49,51,"MP before and saline after TDI (group 2), or 125 mg i.v.",9523850_5,-1,-1,-1,17676,-1,0.9971232,0.0028767665
17677,MP,0,1,0,2,MP before and after TDI (group 3).,9523850_6,-1,-1,-1,17677,-1,0.9356773,0.06432272
17678,MP,6,7,46,48,These data demonstrate that administration of MP before and after TDI reduces the frequency and severity of the arthralgia-myalgia syndrome.,9523850_11,-1,-1,-1,17678,-1,0.9986784,0.0013216472
17679,mg,4,5,21,23,We conclude that 125 mg i.v.,9523850_12,-1,-1,-1,17679,-1,0.99541265,0.0045874272
17680,MP,0,1,0,2,MP should be given routinely before and after TDI of iron dextran.,9523850_13,-1,-1,-1,17680,-1,0.88654554,0.113454476
17681,iron dextran,10,12,53,65,MP should be given routinely before and after TDI of iron dextran.,9523850_13,-1,-1,-1,17681,-1,0.9986846,0.0013154662
17682,Prolongation of the QT interval,0,5,0,31,Prolongation of the QT interval related to cisapride-diltiazem interaction.,9545159_0,-1,-1,-1,17682,-1,0.0061710943,0.99382895
17684,gastrointestinal motility disorders,18,21,95,130,"Cisapride, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of gastrointestinal motility disorders.",9545159_1,-1,-1,-1,17684,-1,0.0015063012,0.9984937
17685,Prolongation of QT interval,0,4,0,27,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,-1,-1,-1,17685,-1,0.0054892665,0.99451077
17686,torsades de pointes,5,8,29,48,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,-1,-1,-1,17686,-1,0.0021040977,0.99789584
17687,sudden cardiac death,10,13,54,74,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,-1,-1,-1,17687,-1,0.0016120279,0.99838793
17688,erythromycin,20,21,132,144,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,-1,-1,-1,17688,-1,0.99917126,0.0008287876
17689,azole antifungal agents,22,25,148,171,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,-1,-1,-1,17689,-1,0.9988605,0.001139529
17691,gastroesophageal reflux disorder,14,17,89,121,"A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.",9545159_3,-1,-1,-1,17691,-1,0.0013102333,0.99868983
17695,QT-interval,8,9,40,51,The patient was in near syncope and had QT-interval prolongation.,9545159_4,-1,-1,-1,17695,-1,0.08295138,0.91704863
17696,prolongation,9,10,52,64,The patient was in near syncope and had QT-interval prolongation.,9545159_4,-1,-1,-1,17696,-1,0.0023638515,0.9976362
17704,n,47,48,288,289,"We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.",9549528_1,-1,-1,-1,17704,-1,0.021037271,0.9789627
17706,n,59,60,346,347,"We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.",9549528_1,-1,-1,-1,17706,-1,0.0164777,0.9835223
17707,dyskinetic parkinsonian,1,3,4,27,"The dyskinetic parkinsonian patients exhibited a pattern of response which was markedly different from those of the normal subjects and non-dyskinetic parkinsonian patients, with a significant overactivation in the supplementary motor area and the ipsi- and contralateral primary motor areas.",9549528_4,-1,-1,-1,17707,-1,0.0028207654,0.99717927
17709,hyperkinetic abnormal involuntary movement,9,13,57,99,"These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like L-dopa-induced peak dose dyskinesia, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop.",9549528_5,-1,-1,-1,17709,-1,0.0017290482,0.998271
17712,sinusitis,10,11,75,84,Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults.,9564988_0,-1,-1,-1,17712,-1,0.0011640309,0.998836
17714,mg,12,13,66,68,PURPOSE: To evaluate the efficacy and safety of levofloxacin (500 mg orally once daily for 10 to 14 days) in treating adult outpatients with acute bacterial sinusitis.,9564988_1,-1,-1,-1,17714,-1,0.9911795,0.008820535
17715,sinusitis,29,30,157,166,PURPOSE: To evaluate the efficacy and safety of levofloxacin (500 mg orally once daily for 10 to 14 days) in treating adult outpatients with acute bacterial sinusitis.,9564988_1,-1,-1,-1,17715,-1,0.0012272105,0.9987728
17716,signs and symptoms,8,11,47,65,Clinical response was assessed on the basis of signs and symptoms and sinus radiograph or computed tomography results.,9564988_4,-1,-1,-1,17716,-1,0.0034616566,0.9965384
17719,flatulence,9,10,59,69,"The most common drug-related adverse events were diarrhea, flatulence, and nausea; most adverse events were mild to moderate in severity.",9564988_13,-1,-1,-1,17719,-1,0.0013728144,0.9986272
17722,mg,11,12,69,71,CONCLUSION: The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial sinusitis.,9564988_14,-1,-1,-1,17722,-1,0.9953479,0.004652075
17723,sinusitis,23,24,138,147,CONCLUSION: The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial sinusitis.,9564988_14,-1,-1,-1,17723,-1,0.001317796,0.9986822
17724,endometrial carcinoma,3,5,20,41,Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study.,9579567_0,-1,-1,-1,17724,-1,0.00159936,0.9984006
17735,n,9,10,59,60,"Cases of endometrial cancer diagnosed after breast cancer (n = 135) and 467 controls matched for age, year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included.",9579567_3,-1,-1,-1,17735,-1,0.040044814,0.9599552
17739,p,26,27,152,153,"Women who had received tamoxifen were significantly more likely to have endometrial cancer diagnosed than those who had not (crude relative risk = 4.9, p = 0.0001).",9579567_4,-1,-1,-1,17739,-1,0.36946926,0.6305307
17740,p,15,16,94,95,"Univariate and adjusted analyses showed that the risk increased with the length of treatment (p = 0.0001) or the cumulative dose of tamoxifen received (p = 0.0001), irrespective of the daily dose.",9579567_5,-1,-1,-1,17740,-1,0.33590913,0.6640909
17742,p,27,28,152,153,"Univariate and adjusted analyses showed that the risk increased with the length of treatment (p = 0.0001) or the cumulative dose of tamoxifen received (p = 0.0001), irrespective of the daily dose.",9579567_5,-1,-1,-1,17742,-1,0.4075844,0.5924156
17743,p,18,19,95,96,"Women who had undergone pelvic radiotherapy also had a higher risk (crude relative risk = 7.8, p = 0.0001).",9579567_6,-1,-1,-1,17743,-1,0.35918677,0.64081323
17745,p,14,15,82,83,"After adjusting for confounding factors, the risk was higher for tamoxifen users (p = 0.0012), treatment for more than 3 years (all p < 0.03) and pelvic radiotherapy (p = 0.012).",9579567_7,-1,-1,-1,17745,-1,0.25992247,0.7400775
17746,p,27,28,132,133,"After adjusting for confounding factors, the risk was higher for tamoxifen users (p = 0.0012), treatment for more than 3 years (all p < 0.03) and pelvic radiotherapy (p = 0.012).",9579567_7,-1,-1,-1,17746,-1,0.31857634,0.68142366
17747,p,35,36,167,168,"After adjusting for confounding factors, the risk was higher for tamoxifen users (p = 0.0012), treatment for more than 3 years (all p < 0.03) and pelvic radiotherapy (p = 0.012).",9579567_7,-1,-1,-1,17747,-1,0.24988621,0.7501138
17755,Endometrial cancers,0,2,0,19,Endometrial cancers diagnosed in women treated with tamoxifen have poorer prognosis.,9579567_11,-1,-1,-1,17755,-1,0.0023533604,0.99764663
17765,hyperkalaemia,16,17,90,103,The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23-year-old Malawian woman.,9587734_1,-1,-1,-1,17765,-1,0.0014653458,0.9985347
17772,hyperkalaemia,30,31,167,180,"Apart from the reduction in the patient's level of consciousness, there were no signs of motor neurone damage or of any of the other known predisposing conditions for hyperkalaemia following the administration of suxamethonium.",9587734_6,-1,-1,-1,17772,-1,0.0018984373,0.99810153
17777,Acute hepatitis,0,2,0,15,"Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.",9625142_0,-1,-1,-1,17777,-1,0.0011183929,0.99888164
17779,erythroblastocytopenia,8,9,50,72,"Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.",9625142_0,-1,-1,-1,17779,-1,0.0011218496,0.9988782
17781,acute hepatitis,4,6,27,42,An 80-yr-old man developed acute hepatitis shortly after ingesting oral ceftriaxone.,9625142_1,-1,-1,-1,17781,-1,0.0012074106,0.9987925
17785,erythroblastocytopenia,35,36,240,262,"Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia.",9625142_2,-1,-1,-1,17785,-1,0.0011711232,0.9988288
17787,beta lactam,20,22,122,133,Despite the widespread use of these agents this triad of side effects has not previously been reported in connection with beta lactam antibiotics.,9625142_4,-1,-1,-1,17787,-1,0.9986639,0.0013360686
17789,NMDA,6,7,36,40,Contribution of the glycine site of NMDA receptors in rostral and intermediate-caudal parts of the striatum to the regulation of muscle tone in rats.,9630698_0,-1,-1,-1,17789,-1,0.9988632,0.0011367638
17791,NMDA,16,17,83,87,The aim of the present study was to assess the contribution of the glycine site of NMDA receptors in the striatum to the regulation of muscle tone.,9630698_1,-1,-1,-1,17791,-1,0.99894935,0.0010507171
17792,Muscle rigidity,0,2,0,15,Muscle rigidity was induced by haloperidol (2.5 mg/kg i.p.).,9630698_3,-1,-1,-1,17792,-1,0.002021929,0.99797803
17795,"5,7-DCKA",3,4,28,36,"5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).",9630698_4,-1,-1,-1,17795,-1,0.9982712,0.0017287995
17797,muscle rigidity,35,37,220,235,"5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).",9630698_4,-1,-1,-1,17797,-1,0.0019330869,0.99806696
17798,"5,7-DCKA",0,1,0,8,"5,7-DCKA injected bilaterally in a dose of 4.5 microg/0.5 microl into the intermediate-caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone.",9630698_5,-1,-1,-1,17798,-1,0.9985392,0.0014608024
17801,NMDA,11,12,65,69,The present results suggest that blockade of the glycine site of NMDA receptors in the rostral part of the striatum may be mainly responsible for the antiparkinsonian action of this drug.,9630698_6,-1,-1,-1,17801,-1,0.99902654,0.00097345933
17804,CBDCA,10,11,59,64,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,-1,-1,-1,17804,-1,0.99874794,0.0012519873
17806,CDDP,15,16,82,86,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,-1,-1,-1,17806,-1,0.99885464,0.0011453676
17808,CBDCA,5,6,20,25,"However, the use of CBDCA higher-intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage.",9636837_2,-1,-1,-1,17808,-1,0.998914,0.0010860303
17809,neurotoxic drugs,13,15,84,100,"However, the use of CBDCA higher-intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage.",9636837_2,-1,-1,-1,17809,-1,0.1580508,0.8419492
17810,peripheral nervous system damage,27,31,177,209,"However, the use of CBDCA higher-intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage.",9636837_2,-1,-1,-1,17810,-1,0.0019129025,0.99808717
17811,CBDCA,8,9,50,55,MATERIALS AND METHODS: Two different schedules of CBDCA administration (10 mg/kg and 15 mg/kg i.p. twice a week for nine times) were evaluated in Wistar rats.,9636837_3,-1,-1,-1,17811,-1,0.9991014,0.0008985705
17813,CBDCA,2,3,9,14,RESULTS: CBDCA administration induced dose-dependent peripheral neurotoxicity.,9636837_5,-1,-1,-1,17813,-1,0.99891245,0.0010875231
17814,peripheral neurotoxicity,6,8,53,77,RESULTS: CBDCA administration induced dose-dependent peripheral neurotoxicity.,9636837_5,-1,-1,-1,17814,-1,0.0014090724,0.9985909
17816,CDDP,23,24,125,129,"The dorsal root ganglia sensory neurons and, to a lesser extent, satellite cells showed the same changes as those induced by CDDP, mainly affecting the nucleus and nucleolus of ganglionic sensory neurons.",9636837_7,-1,-1,-1,17816,-1,0.99887925,0.0011207412
17817,platinum,5,6,33,41,"Moreover, significant amounts of platinum were detected in the dorsal root ganglia and kidney after CBDCA treatment.",9636837_8,-1,-1,-1,17817,-1,0.99858344,0.0014165422
17818,CBDCA,16,17,100,105,"Moreover, significant amounts of platinum were detected in the dorsal root ganglia and kidney after CBDCA treatment.",9636837_8,-1,-1,-1,17818,-1,0.99891317,0.001086877
17819,CBDCA,2,3,13,18,"CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.",9636837_9,-1,-1,-1,17819,-1,0.9989341,0.0010658812
17821,CDDP,25,26,137,141,"CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.",9636837_9,-1,-1,-1,17821,-1,0.9989698,0.0010301847
17823,CBDCA,17,18,89,94,This model can be used alone or in combination with other drugs to explore the effect of CBDCA on the peripheral nervous system.,9636837_10,-1,-1,-1,17823,-1,0.99911004,0.0008898798
17825,thyrotoxicosis,7,8,36,50,Thyroxine abuse: an unusual case of thyrotoxicosis in pregnancy.,9653867_0,-1,-1,-1,17825,-1,0.0019408467,0.9980591
17826,Eating disorders,0,2,0,16,Eating disorders and the associated behavioural problems and drug abuse are uncommon in pregnancy.,9653867_1,-1,-1,-1,17826,-1,0.0015705633,0.99842936
17828,eating disorders,14,16,81,97,"This case illustrates a number of problems that may be encountered in women with eating disorders in pregnancy, including prolonged and recurrent metabolic disturbances and diuretic abuse.",9653867_3,-1,-1,-1,17828,-1,0.0015589865,0.99844104
17829,metabolic disturbances,23,25,146,168,"This case illustrates a number of problems that may be encountered in women with eating disorders in pregnancy, including prolonged and recurrent metabolic disturbances and diuretic abuse.",9653867_3,-1,-1,-1,17829,-1,0.0015509687,0.99844897
17830,diuretic,26,27,173,181,"This case illustrates a number of problems that may be encountered in women with eating disorders in pregnancy, including prolonged and recurrent metabolic disturbances and diuretic abuse.",9653867_3,-1,-1,-1,17830,-1,0.99860007,0.0013999343
17831,eating disorders,14,16,94,110,"In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for thyrotoxicosis remains obscure, thyroxine abuse should be considered and explored.",9653867_4,-1,-1,-1,17831,-1,0.0016049303,0.998395
17832,thyrotoxicosis,24,25,148,162,"In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for thyrotoxicosis remains obscure, thyroxine abuse should be considered and explored.",9653867_4,-1,-1,-1,17832,-1,0.03534146,0.96465856
17834,trimipramine,1,2,9,21,Repeated trimipramine induces dopamine D2/D3 and alpha1-adrenergic up-regulation.,9660111_0,-1,-1,-1,17834,-1,0.99928313,0.00071691186
17836,Trimipramine,0,1,0,12,"Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and 5-hydroxytryptamine, nor does it induce beta-adrenergic down-regulation.",9660111_1,-1,-1,-1,17836,-1,0.99934334,0.0006567077
17837,TRI,2,3,14,17,"Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and 5-hydroxytryptamine, nor does it induce beta-adrenergic down-regulation.",9660111_1,-1,-1,-1,17837,-1,0.99863976,0.001360275
17839,imipramine,16,17,93,103,"Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and 5-hydroxytryptamine, nor does it induce beta-adrenergic down-regulation.",9660111_1,-1,-1,-1,17839,-1,0.99930894,0.00069109385
17843,TRI,11,12,53,56,"The aim of the present study was to find out whether TRI given repeatedly was able to induce adaptive changes in the dopaminergic and alpha1-adrenergic systems, demonstrated by us previously for various antidepressants.",9660111_3,-1,-1,-1,17843,-1,0.9989141,0.0010858332
17845,TRI,0,1,0,3,TRI was given to male Wistar rats and male Albino Swiss mice perorally twice daily for 14 days.,9660111_4,-1,-1,-1,17845,-1,0.9980205,0.001979497
17846,TRI,4,5,24,27,In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.,9660111_5,-1,-1,-1,17846,-1,0.99877506,0.0012249711
17847,reserpine hypothermia,14,16,65,86,In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.,9660111_5,-1,-1,-1,17847,-1,0.65760684,0.3423932
17848,5-hydroxytryptophan head twitches,23,26,123,156,In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.,9660111_5,-1,-1,-1,17848,-1,0.47745937,0.5225406
17849,TRI,0,1,0,3,"TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).",9660111_6,-1,-1,-1,17849,-1,0.99893206,0.0010679822
17851,quinpirole,13,14,93,103,"TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).",9660111_6,-1,-1,-1,17851,-1,0.9993525,0.0006475226
17854,TRI,11,12,80,83,The stereotypies induced by d-amphetamine or apomorphine are not potentiated by TRI.,9660111_7,-1,-1,-1,17854,-1,0.9985469,0.0014531008
17859,TRI,13,14,83,86,"It may be concluded that, like other tricyclic antidepressants studied previously, TRI given repeatedly increases the responsiveness of brain dopamine D2 and D3 (locomotor activity but not stereotypy) as well as alpha1-adrenergic receptors to their agonists.",9660111_9,-1,-1,-1,17859,-1,0.99877447,0.001225518
17864,irritable bowel syndrome,13,16,91,115,Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.,9669632_0,-1,-1,-1,17864,-1,0.001312039,0.9986879
17865,Irritable bowel syndrome,2,5,12,36,BACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility.,9669632_1,-1,-1,-1,17865,-1,0.0013557703,0.9986443
17866,abdominal pain,10,12,58,72,BACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility.,9669632_1,-1,-1,-1,17866,-1,0.0013380628,0.9986619
17867,disordered gastrointestinal motility,19,22,110,146,BACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility.,9669632_1,-1,-1,-1,17867,-1,0.001716461,0.9982836
17869,irritable bowel syndrome,25,28,146,170,"Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).",9669632_2,-1,-1,-1,17869,-1,0.0017421825,0.9982578
17870,IBS,29,30,172,175,"Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).",9669632_2,-1,-1,-1,17870,-1,0.001726528,0.9982735
17871,IBS,5,6,36,39,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17871,-1,0.0014793116,0.9985207
17872,n,9,10,67,68,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17872,-1,0.007488973,0.99251103
17873,n,15,16,98,99,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17873,-1,0.0063263495,0.9936737
17875,mg,35,36,201,203,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17875,-1,0.9938637,0.006136338
17876,n,40,41,223,224,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17876,-1,0.07133176,0.9286682
17877,n,47,48,243,244,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17877,-1,0.06301656,0.9369834
17879,mm Hg,20,22,128,133,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,-1,17879,-1,0.035130482,0.9648695
17881,P,27,28,161,162,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,-1,17881,-1,0.47958678,0.5204133
17882,mm Hg,38,40,200,205,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,-1,17882,-1,0.04252488,0.9574751
17884,P,63,64,308,309,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,-1,17884,-1,0.5192239,0.4807761
17886,P,99,100,462,463,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,-1,17886,-1,0.5111475,0.4888525
17887,IBS,11,12,90,93,No significant differences in jejunal motility were found in the constipation-predominant IBS group.,9669632_6,-1,-1,-1,17887,-1,0.0018715461,0.9981285
17889,IBS,13,14,113,116,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,-1,-1,-1,17889,-1,0.0015442447,0.99845576
17890,mm,27,28,160,162,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,-1,-1,-1,17890,-1,0.0070862486,0.9929137
17892,P,33,34,190,191,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,-1,-1,-1,17892,-1,0.33557492,0.664425
17893,mm,44,45,225,227,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,-1,-1,-1,17893,-1,0.007824613,0.9921754
17894,IBS,1,2,22,25,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,-1,-1,-1,17894,-1,0.0015655288,0.9984345
17897,mm,23,24,118,120,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,-1,-1,-1,17897,-1,0.007509394,0.9924906
17899,P,29,30,148,149,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,-1,-1,-1,17899,-1,0.33909184,0.6609081
17900,mm,40,41,183,185,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,-1,-1,-1,17900,-1,0.008156526,0.9918434
17902,IBS,11,12,87,90,CONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS.,9669632_10,-1,-1,-1,17902,-1,0.0018517475,0.9981483
17913,mg,7,8,46,48,"Women were randomised to receive tamoxifen 20 mg per day or placebo, both orally for 5 years.",9672273_5,-1,-1,-1,17913,-1,0.9958209,0.0041791396
17924,vascular events,13,15,77,92,"Compared with the placebo group, there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen.",9672273_15,-1,-1,-1,17924,-1,0.0014276603,0.99857235
17925,hypertriglyceridaemia,16,17,97,118,"Compared with the placebo group, there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen.",9672273_15,-1,-1,-1,17925,-1,0.0015112329,0.9984888
17935,postoperative pain,9,11,77,95,Pethidine-associated seizure in a healthy adolescent receiving pethidine for postoperative pain control.,9672936_0,-1,-1,-1,17935,-1,0.0036239712,0.996376
17937,analgesia,13,14,102,111,A healthy 17-year-old male received standard intermittent doses of pethidine via a patient-controlled analgesia (PCA) pump for management of postoperative pain control.,9672936_1,-1,-1,-1,17937,-1,0.008554104,0.9914459
17938,postoperative pain,21,23,141,159,A healthy 17-year-old male received standard intermittent doses of pethidine via a patient-controlled analgesia (PCA) pump for management of postoperative pain control.,9672936_1,-1,-1,-1,17938,-1,0.0028983708,0.9971016
17939,h,1,2,13,14,Twenty-three h postoperatively he developed a brief self-limited seizure.,9672936_2,-1,-1,-1,17939,-1,0.0863941,0.9136059
17942,norpethidine,4,5,26,38,Both plasma pethidine and norpethidine were elevated in the range associated with clinical manifestations of central nervous system excitation.,9672936_3,-1,-1,-1,17942,-1,0.99910754,0.00089239323
17943,CNS toxicity,5,7,26,38,No other risk factors for CNS toxicity were identified.,9672936_4,-1,-1,-1,17943,-1,0.001502855,0.9984971
17946,norpethidine,17,18,118,130,This method allowed frequent self-dosing of pethidine at short time intervals and rapid accumulation of pethidine and norpethidine.,9672936_5,-1,-1,-1,17946,-1,0.9991812,0.0008187903
17948,postoperative analgesia,11,13,54,77,The routine use of pethidine via PCA even for a brief postoperative analgesia should be reconsidered.,9672936_6,-1,-1,-1,17948,-1,0.0023249183,0.9976751
17949,mepivacaine,8,9,47,58,An unusual toxic reaction to axillary block by mepivacaine with adrenaline.,9698967_0,-1,-1,-1,17949,-1,0.99926037,0.00073961774
17951,increase in blood pressure,1,5,3,29,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17951,-1,0.027596083,0.97240394
17952,atrial fibrillation,8,10,46,65,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17952,-1,0.0014464436,0.9985536
17954,loss of consciousness,16,19,106,127,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17954,-1,0.003396622,0.99660337
17955,mepivacaine,43,44,267,278,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17955,-1,0.9993349,0.00066510367
17956,mg,45,46,283,285,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17956,-1,0.99451643,0.0054835007
17958,mg,49,50,314,316,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17958,-1,0.99420834,0.0057917153
17959,Dupuytren's contracture,54,57,336,359,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17959,-1,0.007576782,0.9924232
17963,atrial fibrillation,12,14,83,102,The block was successful and surgery was conducted as scheduled despite persisting atrial fibrillation.,9698967_3,-1,-1,-1,17963,-1,0.0016451197,0.99835485
17964,mepivacaine,18,19,115,126,Both the temporal relationship of events and the response to treatment suggest that a rapid systemic absorption of mepivacaine with adrenaline and/or interaction of these drugs with the patient's cardiovascular medications were responsible for the perioperative complications.,9698967_5,-1,-1,-1,17964,-1,0.9993469,0.0006531062
17966,vanishing bile duct,2,5,28,47,Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child.,9721172_0,-1,-1,-1,17966,-1,0.0029191705,0.99708086
17967,vanishing bile duct syndrome,1,5,6,34,"Acute vanishing bile duct syndrome is a rare but established cause of progressive cholestasis in adults, is most often drug or toxin related, and is of unknown pathogenesis.",9721172_1,-1,-1,-1,17967,-1,0.0020076777,0.9979923
17969,hypersensitivity reaction,7,9,70,95,"Stevens-Johnson syndrome is a well-recognized immune complex-mediated hypersensitivity reaction that affects all age groups, is drug or infection induced, and has classic systemic, mucosal, and dermatologic manifestations.",9721172_3,-1,-1,-1,17969,-1,0.0012323346,0.99876773
17970,vanishing bile duct syndrome,12,16,76,104,"A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use.",9721172_4,-1,-1,-1,17970,-1,0.0022077688,0.99779224
17972,ursodeoxycholic acid,3,5,21,41,"Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.",9721172_5,-1,-1,-1,17972,-1,0.9990055,0.0009944754
17975,cholestatic disease,13,15,80,99,"Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.",9721172_5,-1,-1,-1,17975,-1,0.0015818494,0.9984181
17977,vanishing bile duct syndrome,5,9,39,67,This case documents acute drug-related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens-Johnson syndrome and vanishing bile duct syndrome.,9721172_6,-1,-1,-1,17977,-1,0.00211115,0.99788886
17978,vanishing bile duct syndrome,27,31,190,218,This case documents acute drug-related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens-Johnson syndrome and vanishing bile duct syndrome.,9721172_6,-1,-1,-1,17978,-1,0.002360324,0.99763966
17982,appetite suppressant,20,22,122,142,"Primary pulmonary hypertension is a rare, progressive and incurable disease, which has been associated with the intake of appetite suppressant drugs.",9727773_1,-1,-1,-1,17982,-1,0.99660933,0.0033907567
17986,fenfluramines,11,12,80,93,"Twenty-three of the patients had previously taken appetite suppressants, mainly fenfluramines, as compared with only 5 of the controls (66 versus 6%, p<0.0001).",9727773_5,-1,-1,-1,17986,-1,0.9991248,0.00087521126
17987,p<0.0001,27,28,150,158,"Twenty-three of the patients had previously taken appetite suppressants, mainly fenfluramines, as compared with only 5 of the controls (66 versus 6%, p<0.0001).",9727773_5,-1,-1,-1,17987,-1,0.35751396,0.64248604
17993,lead,9,10,67,71,A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated primary pulmonary hypertension.,9727773_9,-1,-1,-1,17993,-1,0.018638635,0.9813613
17998,absence seizures,8,10,61,77,Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.,9746003_0,-1,-1,-1,17998,-1,0.0016474301,0.99835265
18001,absence seizures,7,9,60,76,Carbamazepine and vigabatrin are contraindicated in typical absence seizures.,9746003_1,-1,-1,-1,18001,-1,0.0016772895,0.99832267
18008,sodium valproate,8,10,50,66,"Optimal control of the absences was achieved with sodium valproate, lamotrigine, or ethosuximide alone or in combination.",9746003_6,-1,-1,-1,18008,-1,0.9993043,0.0006957064
18009,lamotrigine,11,12,68,79,"Optimal control of the absences was achieved with sodium valproate, lamotrigine, or ethosuximide alone or in combination.",9746003_6,-1,-1,-1,18009,-1,0.99932075,0.0006793254
18010,ethosuximide,14,15,84,96,"Optimal control of the absences was achieved with sodium valproate, lamotrigine, or ethosuximide alone or in combination.",9746003_6,-1,-1,-1,18010,-1,0.9992367,0.00076334324
18011,Choreoathetoid movements,0,2,0,24,Choreoathetoid movements associated with rapid adjustment to methadone.,9754849_0,-1,-1,-1,18011,-1,0.0027678986,0.99723214
18013,hyperkinesias,1,2,13,26,Choreatiform hyperkinesias are known to be occasional movement abnormalities during intoxications with cocaine but not opiates.,9754849_1,-1,-1,-1,18013,-1,0.0012273875,0.99877256
18014,movement abnormalities,7,9,54,76,Choreatiform hyperkinesias are known to be occasional movement abnormalities during intoxications with cocaine but not opiates.,9754849_1,-1,-1,-1,18014,-1,0.001587742,0.99841225
18016,euphoria,6,7,25,33,This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.,9754849_2,-1,-1,-1,18016,-1,0.0015858444,0.99841416
18017,choreoathetoid movements,8,10,38,62,This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.,9754849_2,-1,-1,-1,18017,-1,0.002691781,0.99730825
18019,heroine,28,29,197,204,This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.,9754849_2,-1,-1,-1,18019,-1,0.99916065,0.0008393272
18021,folic acid,3,5,26,36,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,-1,18021,-1,0.9992151,0.00078485446
18022,SLE,8,9,56,59,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,-1,18022,-1,0.0014648086,0.99853516
18023,folic acid,10,12,61,71,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,-1,18023,-1,0.9991704,0.0008296509
18024,epilepsy)OBJECTIVE,13,14,76,94,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,-1,18024,-1,0.006602826,0.9933971
18026,structural birth defects,38,41,251,275,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,-1,18026,-1,0.0014564174,0.9985436
18028,folic acid,8,10,53,63,"RESULTS: Of 60 epileptic women with periconceptional folic acid (0.8 mg)-containing multivitamin supplementation, no one developed epilepsy-related side effects during the periconception period.",9758264_2,-1,-1,-1,18028,-1,0.9992435,0.0007565266
18030,cleft lip and palate,7,11,45,65,One epileptic woman delivered a newborn with cleft lip and palate.,9758264_3,-1,-1,-1,18030,-1,0.0023609113,0.99763906
18034,folic acid,11,13,81,91,This 22-year-old epileptic woman was treated continuously by carbamazepine and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.,9758264_5,-1,-1,-1,18034,-1,0.9993222,0.0006778431
18035,status epilepticus,2,4,14,32,She developed status epilepticus and later symptoms of systemic lupus erythematodes.,9758264_6,-1,-1,-1,18035,-1,0.0014287682,0.99857116
18036,systemic lupus erythematodes,8,11,55,83,She developed status epilepticus and later symptoms of systemic lupus erythematodes.,9758264_6,-1,-1,-1,18036,-1,0.0015922331,0.9984078
18037,stillbirth,4,5,25,35,Her pregnancy ended with stillbirth.,9758264_7,-1,-1,-1,18037,-1,0.0028043746,0.9971956
18039,autoimmune disease,7,9,46,64,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,-1,-1,-1,18039,-1,0.001283407,0.9987166
18040,lupus,12,13,88,93,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,-1,-1,-1,18040,-1,0.00118156,0.99881846
18041,mg,29,30,173,175,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,-1,-1,-1,18041,-1,0.9940183,0.0059817364
18042,folic acid,32,34,180,190,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,-1,-1,-1,18042,-1,0.9992262,0.00077372586
18044,mg,5,6,23,25,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,-1,-1,-1,18044,-1,0.9880107,0.011989262
18045,folic acid,8,10,30,40,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,-1,-1,-1,18045,-1,0.99914896,0.00085101806
18047,autoimmune disease,21,23,97,115,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,-1,-1,-1,18047,-1,0.0014559348,0.9985441
18048,epileptic seizures,30,32,147,165,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,-1,-1,-1,18048,-1,0.0012758481,0.99872416
18049,antipsychotics,5,6,32,46,Adverse effects of the atypical antipsychotics.,9766615_0,-1,-1,-1,18049,-1,0.99524385,0.0047561345
18050,antipsychotics,3,4,19,33,Adverse effects of antipsychotics often lead to noncompliance.,9766615_2,-1,-1,-1,18050,-1,0.99711704,0.0028829556
18051,lead,5,6,40,44,Adverse effects of antipsychotics often lead to noncompliance.,9766615_2,-1,-1,-1,18051,-1,0.007945899,0.9920541
18052,antipsychotics,7,8,41,55,The side effect profiles of the atypical antipsychotics are more advantageous than those of the conventional neuroleptics.,9766615_4,-1,-1,-1,18052,-1,0.9979284,0.0020716668
18053,neuroleptics,16,17,109,121,The side effect profiles of the atypical antipsychotics are more advantageous than those of the conventional neuroleptics.,9766615_4,-1,-1,-1,18053,-1,0.9986559,0.0013440158
18055,EPS,15,16,116,119,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,-1,-1,18055,-1,0.0013114256,0.99868864
18056,tardive dyskinesia,18,20,122,140,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,-1,-1,18056,-1,0.0011086669,0.9988914
18059,weight gain,51,53,328,339,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,-1,-1,18059,-1,0.0031597293,0.99684024
18060,EPS,9,10,47,50,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,-1,-1,-1,18060,-1,0.0012089723,0.99879104
18061,weight gain,26,28,154,165,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,-1,-1,-1,18061,-1,0.0020808924,0.99791914
18065,agranulocytosis,44,45,257,272,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,-1,-1,-1,18065,-1,0.0015179573,0.99848205
18067,lead,27,28,175,179,"Since the incidence and severity of specific adverse effects differ among the various atypicals, the clinician should carefully consider which side effects are most likely to lead to the individual's dissatisfaction and noncompliance before choosing an antipsychotic for a particular patient.",9766615_7,-1,-1,-1,18067,-1,0.010183487,0.98981655
18068,antipsychotic,38,39,253,266,"Since the incidence and severity of specific adverse effects differ among the various atypicals, the clinician should carefully consider which side effects are most likely to lead to the individual's dissatisfaction and noncompliance before choosing an antipsychotic for a particular patient.",9766615_7,-1,-1,-1,18068,-1,0.99605066,0.003949374
18080,emergency department,25,27,143,163,"We attempted to identify all incident strokes in women ages 15-44 years during a 3-year period using hospital admission and discharge records, emergency department logs, and payment requests for out-of-plan hospitalizations.",9799166_4,-1,-1,-1,18080,-1,0.02083586,0.9791642
18091,psychosis,9,10,74,83,"A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.",9812111_0,-1,-1,-1,18091,-1,0.0011522719,0.9988477
18092,disruptive behaviors,11,13,88,108,"A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.",9812111_0,-1,-1,-1,18092,-1,0.0013116392,0.9986884
18093,Alzheimer's disease,14,17,112,131,"A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.",9812111_0,-1,-1,-1,18093,-1,0.0023609768,0.99763906
18095,psychosis,26,27,139,148,OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.,9812111_1,-1,-1,-1,18095,-1,0.0011910904,0.99880886
18096,disruptive behaviors,28,30,153,173,OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.,9812111_1,-1,-1,-1,18096,-1,0.0013645957,0.99863535
18097,Alzheimer's disease,33,36,191,210,OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.,9812111_1,-1,-1,-1,18097,-1,0.0024442656,0.99755573
18100,Alzheimer's disease,45,48,213,232,"METHOD: In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), haloperidol, 2-3 mg/day (standard dose), and haloperidol, 0.50-0.75 mg/day (low dose), were compared in 71 outpatients with Alzheimer's disease.",9812111_2,-1,-1,-1,18100,-1,0.0026875646,0.9973124
18106,psychosis,31,32,197,206,"RESULTS: For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.",9812111_4,-1,-1,-1,18106,-1,0.0015304784,0.99846953
18107,psychomotor agitation,35,37,221,242,"RESULTS: For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.",9812111_4,-1,-1,-1,18107,-1,0.0016028649,0.9983972
18108,extrapyramidal signs,17,19,84,104,"The advantage of standard dose over low dose was replicated in phase B. In phase A, extrapyramidal signs tended to be greater with the standard dose than in the other two conditions, primarily because of a subgroup (20%) who developed moderate to severe signs.",9812111_6,-1,-1,-1,18108,-1,0.0014317483,0.9985682
18111,extrapyramidal signs,26,28,156,176,"CONCLUSIONS: The results indicated a favorable therapeutic profile for haloperidol in doses of 2-3 mg/day, although a subgroup developed moderate to severe extrapyramidal signs.",9812111_8,-1,-1,-1,18111,-1,0.0014198283,0.9985802
18113,neuroleptics,12,13,80,92,The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.,9812111_10,-1,-1,-1,18113,-1,0.9991629,0.0008370584
18114,Alzheimer's disease,15,18,101,120,The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.,9812111_10,-1,-1,-1,18114,-1,0.002648327,0.99735165
18115,psychosis,20,21,135,144,The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.,9812111_10,-1,-1,-1,18115,-1,0.0012074744,0.9987925
18116,disruptive behaviors,22,24,149,169,The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.,9812111_10,-1,-1,-1,18116,-1,0.0014633824,0.9985366
18117,Acute renal failure,0,3,0,19,Acute renal failure subsequent to the administration of rifampicin.,982002_0,-1,-1,-1,18117,-1,0.0013996557,0.9986003
18118,rifampicin,8,9,56,66,Acute renal failure subsequent to the administration of rifampicin.,982002_0,-1,-1,-1,18118,-1,0.99906474,0.0009352379
18119,acute renal failure,16,19,72,91,A clinical presentation is made of a 2-3 year follow-up of six cases of acute renal failure that have been reported earlier.,982002_2,-1,-1,-1,18119,-1,0.0011328392,0.99886715
18120,renal failure,5,7,37,50,The patients had developed transient renal failure after the intermittent administration of rifampicin.,982002_3,-1,-1,-1,18120,-1,0.0015253338,0.99847466
18121,rifampicin,12,13,92,102,The patients had developed transient renal failure after the intermittent administration of rifampicin.,982002_3,-1,-1,-1,18121,-1,0.9991211,0.00087892433
18122,renal lesions,6,8,32,45,"Although in the acute stage the renal lesions histologically appeared toxic, evidence suggestive of an immunological mechanism cannot be excluded.",982002_11,-1,-1,-1,18122,-1,0.0018489998,0.998151
18131,radiocalcium,15,16,79,91,"Infusions of epinephrine (4 mug per kilogram per minute for 6 hours) increased radiocalcium uptakes into intact myocardium and each of its subcellular components with the mitochondrial fraction showing the most consistent changes when compared to saline-infused control animals (4,957 vs. 827 counts per minute per gram of dried tissue or fraction).",983936_2,-1,-1,-1,18131,-1,0.9988673,0.0011327941
18133,mg.per,11,12,80,86,Myocardial concentrations of calcium also increased significantly (12.0 vs. 5.0 mg.per 100 Gm. of fat-free dry weight).,983936_3,-1,-1,-1,18133,-1,0.8981706,0.101829454
18134,calcium chloride,2,4,13,29,Infusions of calcium chloride sufficient to raise serum calcium concentrations 2 mEq.,983936_4,-1,-1,-1,18134,-1,0.998601,0.0013989893
18137,radiocalcium,1,2,14,26,"Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion (2,682,2,803, and 3,424 counts per minute per gram of dried fraction, respectively).",983936_6,-1,-1,-1,18137,-1,0.99871373,0.0012862288
18143,mg,13,14,74,76,"Myocardial calcium concentrations also were decreased (11.2, 8.3, and 8.9 mg. per 100 Gm. of fat-free dry weight, respectively) in the three treatment groups, being significantly decreased only in the last two.",983936_7,-1,-1,-1,18143,-1,0.9454486,0.054551437
18148,SM-5887,9,10,63,70,Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.,9848575_0,-1,-1,-1,18148,-1,0.99877673,0.0012232175
18151,SM-5887,11,12,76,83,This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.,9848575_1,-1,-1,-1,18151,-1,0.9989901,0.0010098389
18152,SM-5887,18,19,123,130,This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.,9848575_1,-1,-1,-1,18152,-1,0.9990138,0.0009862267
18156,SM-5887,29,30,149,156,"In the chronic treatment, beagle dogs of each sex were given intravenously once every 3 weeks, either a sublethal dose of doxorubicin (1.5 mg/kg) or SM-5887 (2.5 mg/kg).",9848575_2,-1,-1,-1,18156,-1,0.9988626,0.0011374479
18159,SM-5887,33,34,238,245,"Animals which received over six courses of doxorubicin demonstrated the electrocardiogram (ECG) changes, decrease of blood pressure and high-grade histopathological cardiomyopathy, while animals which were terminally sacrificed after the SM-5887 administration did not show any changes in ECG, blood pressure and histopathological examinations.",9848575_4,-1,-1,-1,18159,-1,0.99883777,0.0011623014
18161,SM-5887,8,9,58,65,"To examine a possibly deteriorating cardiotoxic effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1.5 mg/kg).",9848575_5,-1,-1,-1,18161,-1,0.9988864,0.001113662
18165,SM-5887,18,19,98,105,"Nine weeks after pre-treatment, dogs were given four courses of either doxorubicin (1.5 mg/kg) or SM-5887 (2.5 mg/kg) once every 3 weeks.",9848575_6,-1,-1,-1,18165,-1,0.99895537,0.0010446451
18168,SM-5887,5,6,21,28,"On the contrary, the SM-5887 treatment did not progress the grade of cardiomyopathy.",9848575_8,-1,-1,-1,18168,-1,0.99795985,0.0020401992
18170,SM-5887,3,4,15,22,"In conclusion, SM-5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin-induced cardiotoxicity in dogs.",9848575_9,-1,-1,-1,18170,-1,0.9987872,0.0012127957
18174,FK506,11,12,86,91,Clinical and histopathologic examination of renal allografts treated with tacrolimus (FK506) for at least one year.,9855119_0,-1,-1,-1,18174,-1,0.9991436,0.00085640396
18176,FK506,19,20,131,136,BACKGROUND: We clinically and pathologically analyzed renal allografts from 1 9 renal transplant patients treated with tacrolimus (FK506) for more than 1 year.,9855119_1,-1,-1,-1,18176,-1,0.99912244,0.0008775552
18177,n,16,17,80,81,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18177,-1,0.009005991,0.99099404
18178,n=5,26,27,111,114,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18178,-1,0.017517615,0.98248243
18179,n,31,32,124,125,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18179,-1,0.009143433,0.99085665
18180,IgA nephropathy,37,39,141,156,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18180,-1,0.025357604,0.97464246
18181,n,40,41,158,159,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18181,-1,0.011163389,0.98883665
18182,n,48,49,182,183,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18182,-1,0.012542477,0.9874576
18183,FK506 nephropathy,55,57,210,227,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18183,-1,0.49611187,0.50388813
18184,n,58,59,229,230,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18184,-1,0.009305646,0.9906943
18185,FK506 nephropathy,65,67,251,268,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18185,-1,0.49804005,0.5019599
18186,n,68,69,270,271,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18186,-1,0.008747208,0.99125284
18187,FK506 nephropathy,14,16,87,104,"Of the nonepisode biopsies, 7 and 4 biopsies showed minimal-type and mild-type chronic FK506 nephropathy, respectively.",9855119_5,-1,-1,-1,18187,-1,0.5767115,0.42328852
18188,FK506 nephropathy,1,3,8,25,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,-1,-1,-1,18188,-1,0.5274812,0.47251886
18189,focal segmental glomerulosclerosis,27,30,163,197,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,-1,-1,-1,18189,-1,0.001668451,0.9983316
18190,interstitial fibrosis,39,41,235,256,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,-1,-1,-1,18190,-1,0.001456,0.998544
18192,FK506 nephropathy,10,12,65,82,"The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).",9855119_7,-1,-1,-1,18192,-1,0.6958022,0.30419785
18193,P,32,33,215,216,"The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).",9855119_7,-1,-1,-1,18193,-1,0.43309987,0.56690013
18194,FK506 nephropathy,7,9,50,67,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,-1,-1,-1,18194,-1,0.5322337,0.4677663
18195,FK506 nephropathy,27,29,202,219,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,-1,-1,-1,18195,-1,0.51863897,0.481361
18196,lead,34,35,245,249,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,-1,-1,-1,18196,-1,0.017031645,0.9829684
18197,of,37,38,267,269,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,-1,-1,-1,18197,-1,0.0054906383,0.9945094
18201,ethinyl estradiol,8,10,50,67,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,-1,-1,-1,18201,-1,0.99907255,0.00092746364
18202,EE,11,12,69,71,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,-1,-1,-1,18202,-1,0.9986953,0.0013046726
18204,contrast,1,2,3,11,"In contrast, 7H6 and ZO-1 immunostaining was more discontinuous, outlining the bile canaliculi after BDL.",9862868_8,-1,-1,-1,18204,-1,0.3275583,0.6724417
18205,EE,1,2,6,8,"After EE treatment, changes in immunostaining for 7H6 and ZO-1 were similar to those seen in periportal hepatocytes after BDL, but distributed more diffusely throughout the lobule.",9862868_10,-1,-1,-1,18205,-1,0.9983369,0.0016630619
18207,fenfluramine,8,9,47,59,Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.,9867728_0,-1,-1,-1,18207,-1,0.99922097,0.00077896286
18208,dexfenfluramine,10,11,64,79,Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.,9867728_0,-1,-1,-1,18208,-1,0.99918157,0.00081842794
18209,fenfluramine,18,19,103,115,"BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market.",9867728_1,-1,-1,-1,18209,-1,0.9992331,0.00076687435
18210,dexfenfluramine,20,21,120,135,"BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market.",9867728_1,-1,-1,-1,18210,-1,0.999206,0.00079400337
18211,valvular disease,22,24,140,156,"BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market.",9867728_1,-1,-1,-1,18211,-1,0.0019078829,0.9980921
18212,valvular abnormalities,10,12,54,76,OBJECTIVE: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.,9867728_2,-1,-1,-1,18212,-1,0.0020180813,0.9979819
18213,fenfluramine,15,16,92,104,OBJECTIVE: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.,9867728_2,-1,-1,-1,18213,-1,0.9992761,0.0007238718
18214,dexfenfluramine,17,18,108,123,OBJECTIVE: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.,9867728_2,-1,-1,-1,18214,-1,0.99923337,0.00076664926
18215,fenfluramine,6,7,31,43,PATIENTS: 46 patients who used fenfluramine or dexfenfluramine for 14 days or more and had echocardiograms obtained before therapy.,9867728_5,-1,-1,-1,18215,-1,0.9992042,0.00079579244
18216,dexfenfluramine,8,9,47,62,PATIENTS: 46 patients who used fenfluramine or dexfenfluramine for 14 days or more and had echocardiograms obtained before therapy.,9867728_5,-1,-1,-1,18216,-1,0.9991549,0.00084507104
18217,valvulopathy,7,8,41,53,"The primary outcome was new or worsening valvulopathy, defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U.S. Food and Drug Administration criteria (at least mild aortic regurgitation or moderate mitral regurgitation).",9867728_7,-1,-1,-1,18217,-1,0.0016951842,0.99830484
18219,aortic regurgitation,39,41,233,253,"The primary outcome was new or worsening valvulopathy, defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U.S. Food and Drug Administration criteria (at least mild aortic regurgitation or moderate mitral regurgitation).",9867728_7,-1,-1,-1,18219,-1,0.0024688554,0.9975311
18222,bicuspid aortic valve,3,6,17,38,One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation.,9867728_9,-1,-1,-1,18222,-1,0.0031939934,0.996806
18223,aortic regurgitation,8,10,48,68,One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation.,9867728_9,-1,-1,-1,18223,-1,0.0018485949,0.99815136
18224,aortic insufficiency,6,8,42,62,The second patient developed new moderate aortic insufficiency.,9867728_10,-1,-1,-1,18224,-1,0.0016727281,0.9983273
18226,nerve growth factor,6,9,50,69,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,-1,-1,-1,18226,-1,0.9983005,0.0016994972
18229,nerve growth factor,31,34,232,251,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,-1,-1,-1,18229,-1,0.99809784,0.00190216
18230,NGF,35,36,253,256,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,-1,-1,-1,18230,-1,0.9984724,0.0015276421
18231,PG-9,6,7,37,41,"In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.",9869257_1,-1,-1,-1,18231,-1,0.9990159,0.0009840732
18234,S-(-)-ET-126,40,41,228,240,"In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.",9869257_1,-1,-1,-1,18234,-1,0.9987915,0.001208544
18235,PG-9,6,7,37,41,"In the same experimental conditions, PG-9 (5-20 microg per mouse, i.c.v.) was also able to prevent antimuscarine-induced amnesia, demonstrating a central localization of the activity.",9869257_2,-1,-1,-1,18235,-1,0.99885154,0.0011483971
18237,PG-9,6,7,32,36,"At the highest effective doses, PG-9 did not produce any collateral symptoms as revealed by the Irwin test, and it did not modify spontaneous motility and inspection activity, as revealed by the hole-board test.",9869257_3,-1,-1,-1,18237,-1,0.9985833,0.0014166462
18238,PG-9,0,1,0,4,PG-9 was also able to increase the amount of NGF secreted in vitro by astrocytes in a dose-dependent manner.,9869257_4,-1,-1,-1,18238,-1,0.9982968,0.001703195
18239,NGF,9,10,45,48,PG-9 was also able to increase the amount of NGF secreted in vitro by astrocytes in a dose-dependent manner.,9869257_4,-1,-1,-1,18239,-1,0.99846965,0.0015303509
18240,NGF,2,3,12,15,The maximal NGF contents obtained by PG-9 were 17.6-fold of the control value.,9869257_5,-1,-1,-1,18240,-1,0.9976011,0.0023989596
18241,PG-9,6,7,37,41,The maximal NGF contents obtained by PG-9 were 17.6-fold of the control value.,9869257_5,-1,-1,-1,18241,-1,0.99776053,0.0022394538
18242,PG-9,12,13,83,87,"During culture, no morphological changes were found at effective concentrations of PG-9.",9869257_6,-1,-1,-1,18242,-1,0.9978383,0.0021617212
18243,PG-9,7,8,42,46,The current work indicates the ability of PG-9 to induce beneficial effects on cognitive processes and stimulate activity of NGF synthesis in astroglial cells.,9869257_7,-1,-1,-1,18243,-1,0.99866545,0.0013345667
18244,NGF,19,20,125,128,The current work indicates the ability of PG-9 to induce beneficial effects on cognitive processes and stimulate activity of NGF synthesis in astroglial cells.,9869257_7,-1,-1,-1,18244,-1,0.99873406,0.0012658975
18245,PG-9,2,3,11,15,"Therefore, PG-9 could represent a potential useful drug able to improve the function of impaired cognitive processes.",9869257_8,-1,-1,-1,18245,-1,0.997997,0.002002931
18246,impaired cognitive processes,15,18,88,116,"Therefore, PG-9 could represent a potential useful drug able to improve the function of impaired cognitive processes.",9869257_8,-1,-1,-1,18246,-1,0.0035327508,0.99646723
18248,tobramicyn,15,16,84,94,OBJECTIVE: To evaluate the effect of dosage regimen (once-daily vs. twice-daily) of tobramicyn on steady-state serum concentrations and toxicity.,9875685_1,-1,-1,-1,18248,-1,0.9977736,0.002226359
18251,n,3,4,10,11,Group OD (n = 22) received a once-daily dose of tobramycin and group TD (n = 21) received the same dose divided into two doses daily.,9875685_3,-1,-1,-1,18251,-1,0.16797133,0.8320287
18253,n,17,18,73,74,Group OD (n = 22) received a once-daily dose of tobramycin and group TD (n = 21) received the same dose divided into two doses daily.,9875685_3,-1,-1,-1,18253,-1,0.15701804,0.842982
18255,body weight,14,16,66,77,"RESULTS: The two groups were comparable with respect to sex, age, body weight and renal function.",9875685_6,-1,-1,-1,18255,-1,0.05620052,0.9437995
18256,renal function,17,19,82,96,"RESULTS: The two groups were comparable with respect to sex, age, body weight and renal function.",9875685_6,-1,-1,-1,18256,-1,0.0066810427,0.9933189
18257,TD,19,20,81,83,Peak concentrations were > 6 microg/ml in 100% of the OD group and in 67% of the TD group (P< 0.01).,9875685_9,-1,-1,-1,18257,-1,0.99470913,0.0052908035
18258,P,22,23,91,92,Peak concentrations were > 6 microg/ml in 100% of the OD group and in 67% of the TD group (P< 0.01).,9875685_9,-1,-1,-1,18258,-1,0.38094,0.61906
18259,TD,15,16,108,110,Mean peak concentrations were markedly different: 11.00+/-2.89 microg/ml in OD vs. 6.53+/-1.45 microg/ml in TD (P< 0.01).,9875685_10,-1,-1,-1,18259,-1,0.9906193,0.009380632
18260,P,17,18,112,113,Mean peak concentrations were markedly different: 11.00+/-2.89 microg/ml in OD vs. 6.53+/-1.45 microg/ml in TD (P< 0.01).,9875685_10,-1,-1,-1,18260,-1,0.3658937,0.63410634
18261,TD,14,15,84,86,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18261,-1,0.45193362,0.5480664
18262,h,21,22,108,109,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18262,-1,0.12898625,0.87101376
18263,h,26,27,132,133,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18263,-1,0.12495854,0.8750415
18264,TD,28,29,137,139,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18264,-1,0.35750598,0.6424941
18265,Vd,31,32,142,144,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18265,-1,0.5799443,0.42005566
18266,TD,41,42,193,195,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18266,-1,0.72479725,0.2752027
18267,Cl,44,45,198,200,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18267,-1,0.51983064,0.4801694
18268,TD,54,55,259,261,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18268,-1,0.5514274,0.44857264
18270,TD,18,19,91,93,"Increased serum creatinine was observed in 73% of patients in OD versus 57% of patients in TD, without evidence of nephrotoxicity.",9875685_12,-1,-1,-1,18270,-1,0.0039262385,0.9960737
18272,TD,1,2,3,5,"In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function.",9875685_13,-1,-1,-1,18272,-1,0.004402246,0.9955978
18273,decreased auditory function,7,10,38,65,"In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function.",9875685_13,-1,-1,-1,18273,-1,0.0040799896,0.99591994
18274,auditory loss,17,19,98,111,"In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function.",9875685_13,-1,-1,-1,18274,-1,0.0038021442,0.9961979
18275,decreased auditory function,32,35,174,201,"In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function.",9875685_13,-1,-1,-1,18275,-1,0.0043392866,0.9956607
18283,GABA,29,30,215,219,"High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).",9915601_1,-1,-1,-1,18283,-1,0.9988833,0.0011167396
18289,pindolol,7,8,65,73,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,-1,-1,-1,18289,-1,0.99919575,0.00080427673
18291,atenolol,11,12,89,97,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,-1,-1,-1,18291,-1,0.9992186,0.0007814458
18295,methylatropine,8,9,53,67,Enhancement was not observed in rats pretreated with methylatropine or previously vagotomised.,9915601_4,-1,-1,-1,18295,-1,0.999271,0.0007289793
18298,FK 506,9,11,66,72,"Mechanisms of FK 506-induced hypertension in the rat.-Tacrolimus (FK 506) is a powerful, widely used immunosuppressant.",9931093_0,-1,-1,-1,18298,-1,0.99906665,0.0009333392
18299,FK 506,4,6,24,30,The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity.,9931093_1,-1,-1,-1,18299,-1,0.9988225,0.0011774141
18303,FK 506,15,17,92,98,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,-1,-1,-1,18303,-1,0.9991466,0.0008534197
18304,nitric oxide,41,43,231,243,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,-1,-1,-1,18304,-1,0.9969247,0.0030753438
18305,FR 139317,13,15,78,87,"In addition, the effect of the specific endothelin type A receptor antagonist FR 139317 on FK 506-induced hypertension in rats was studied.",9931093_3,-1,-1,-1,18305,-1,0.99881566,0.0011843537
18307,FK,0,1,0,2,"FK 506, 5 mg.",9931093_4,-1,-1,-1,18307,-1,0.99871135,0.0012886777
18308,mg,4,5,10,12,"FK 506, 5 mg.",9931093_4,-1,-1,-1,18308,-1,0.9833845,0.016615516
18309,mm Hg,13,15,73,78,"d-1 given for 4 weeks, elevated blood pressure from 102+/-13 to 152+/-15 mm Hg and increased the synthesis of ET-1 and the levels of ET-1 mRNA in the mesenteric artery (240% and 230%, respectively).",9931093_6,-1,-1,-1,18309,-1,0.03526474,0.9647352
18310,FK 506,0,2,0,6,"FK 506 decreased eNOS activity and the levels of eNOS mRNA in the aorta (48% and 55%, respectively).",9931093_8,-1,-1,-1,18310,-1,0.9987274,0.0012726518
18311,FR 139317,3,5,22,31,The administration of FR 139317 (10 mg. kg-1.,9931093_9,-1,-1,-1,18311,-1,0.99842995,0.001570064
18312,mg,7,8,36,38,The administration of FR 139317 (10 mg. kg-1.,9931093_9,-1,-1,-1,18312,-1,0.9839643,0.0160357
18314,FK 506,4,6,28,34,These results indicate that FK 506 may increase blood pressure not only by increasing ET-1 production but also by decreasing NO synthesis in the vasculature.,9931093_11,-1,-1,-1,18314,-1,0.9986847,0.0013152518
18315,Structural and functional impairment of mitochondria,0,6,0,52,Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression.,9952311_0,-1,-1,-1,18315,-1,0.005741431,0.9942585
18317,c,15,16,125,126,Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression.,9952311_0,-1,-1,-1,18317,-1,0.9960735,0.003926477
18319,ADR,5,6,23,26,The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.,9952311_1,-1,-1,-1,18319,-1,0.997262,0.0027380511
18321,cardiovascular toxicity,17,19,90,113,The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.,9952311_1,-1,-1,-1,18321,-1,0.0015416553,0.9984584
18322,ADR,3,4,26,29,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,-1,-1,-1,18322,-1,0.9986864,0.0013136495
18323,c,8,9,70,71,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,-1,-1,-1,18323,-1,0.99196917,0.008030844
18324,ADR,22,23,143,146,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,-1,-1,-1,18324,-1,0.99877745,0.0012225594
18325,ADR,40,41,256,259,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,-1,-1,-1,18325,-1,0.9987476,0.0012524121
18326,heart tissue damage,17,20,121,140,"At various times during treatment, the animals were assessed for cardiovascular functions by electrocardiography and for heart tissue damage by electron microscopy.",9952311_3,-1,-1,-1,18326,-1,0.003539485,0.9964605
18327,ADR,10,11,53,56,"Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.",9952311_6,-1,-1,-1,18327,-1,0.010915643,0.9890843
18328,cardiovascular arrhythmias,12,14,64,90,"Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.",9952311_6,-1,-1,-1,18328,-1,0.0012307509,0.9987692
18330,body weight,39,41,229,240,"Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.",9952311_6,-1,-1,-1,18330,-1,0.94147015,0.058529906
18331,ADR,31,32,172,175,"Such abnormalities were not observed in the mitochondria of liver tissue; and 3) among the three genes of COX enzyme examined, only COXII gene expression was suppressed by ADR treatment, mainly after 8 weeks in both heart and liver.",9952311_7,-1,-1,-1,18331,-1,0.9988562,0.0011437719
18332,ADR,21,22,126,129,"Knowing that heart mitochondria represent almost 40% of heart muscle by weight, we conclude that the deteriorating effects of ADR on cardiovascular function involve mitochondrial structural and functional impairment.",9952311_8,-1,-1,-1,18332,-1,0.9684645,0.03153555
18333,mitochondrial structural and functional impairment,26,31,165,215,"Knowing that heart mitochondria represent almost 40% of heart muscle by weight, we conclude that the deteriorating effects of ADR on cardiovascular function involve mitochondrial structural and functional impairment.",9952311_8,-1,-1,-1,18333,-1,0.01084431,0.9891557
1690,lithium,24,25,122,129,"In contrast, mood switches were less frequent in patients receiving lithium (15%, 4/26) than in patients not treated with lithium (44%, 8/18; p = .04).",11379838_7,0,-1,0,1690,-1,0.99872416,0.001275864
3479,heparin,7,8,47,54,"In ICH induction using 0.014-unit collagenase, heparin enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.",12716030_5,0,-1,0,3479,-1,0.9988908,0.0011091807
13729,penicillamine,32,33,198,211,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,0,-1,0,13729,-1,0.9991466,0.0008534648
11093,morphine,26,27,129,137,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,0,-1,0,11093,-1,0.9989862,0.001013839
16734,serotonin,3,4,25,34,"Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.",8888541_1,0,-1,0,16734,-1,0.9986003,0.0013997571
15212,ouabain,26,27,172,179,No significant change in myocardial oxygen consumption occurred after ouabain administration but this may be related to a greater decrease in mean arterial pressure in the ouabain patients than in the control patients.,783197_9,0,-1,0,15212,-1,0.9992374,0.00076258567
15834,oral contraceptives,17,19,104,123,"Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.",839274_1,0,-1,0,15834,-1,0.998862,0.0011380321
4897,adriamycin,5,6,25,35,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,0,-1,0,4897,-1,0.99897754,0.0010225334
17367,halothane,11,12,90,99,"Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.",9284778_5,0,-1,0,17367,-1,0.9990778,0.0009221521
5403,steroid,4,5,30,37,Dose reduction or concomitant steroid therapy may have a role in selected patients.,1595783_6,0,-1,0,5403,-1,0.99856573,0.0014343222
7328,lipopolysaccharide,8,9,49,67,We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine neurotoxicity.,17608141_7,0,-1,0,7328,-1,0.9991543,0.0008456357
9866,argatroban,6,7,45,55,"RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with hepatic impairment]).",20003049_5,0,-1,0,9866,-1,0.99920374,0.00079632737
13582,propranolol,37,38,236,247,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,0,-1,0,13582,-1,0.9992524,0.00074760464
13247,nifedipine,19,20,131,141,"Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.",3952818_3,0,-1,0,13247,-1,0.9992847,0.0007153238
479,clozapine,2,3,12,21,"NRA0160 and clozapine antagonized MAP-induced stereotyped behavior in mice, although their effects did not exceed 50% inhibition, even at the highest dose given.",10579464_5,0,-1,0,479,-1,0.9993001,0.0006999173
11502,fentanyl,2,3,18,26,"Microinjection of fentanyl (2.5 micrograms/50 nl) directly into this pontine nucleus, on the other hand, elicited discernible electromyographic excitation.",2564649_5,0,-1,0,11502,-1,0.9992217,0.00077826326
10215,enalapril,6,7,37,46,"It was concluded that treatment with enalapril was well tolerated and it is, therefore, unreasonable to restrict the initiation of treatment with enalapril to inpatients.",2024540_7,0,-1,0,10215,-1,0.9992286,0.0007714282
10667,methamphetamine,3,4,16,31,The symptoms of methamphetamine (METH)-induced psychosis are similar to those of paranoid type schizophrenia.,20705401_5,0,-1,0,10667,-1,0.99895394,0.0010459949
10691,capecitabine,14,15,84,96,AREAS COVERED IN THIS REVIEW: This article reviews the pharmacology and efficacy of capecitabine with a special emphasis on its safety.,20722491_2,0,-1,0,10691,-1,0.99890184,0.0010981048
11962,diazepam,4,5,23,31,The data indicate that diazepam acts through the benzodiazepine-GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex bradycardia mediated through baroreceptor reflexes in response to an acute increase in arterial pressure.,2894433_6,0,-1,0,11962,-1,0.9991968,0.00080318307
16195,sertraline,5,6,29,39,There was no indication that sertraline exacerbated the impairment produced by haloperidol since an equivalent effect also occurred in the placebo group.,8617710_7,0,-1,0,16195,-1,0.9993192,0.00068083033
528,calcium,27,28,147,154,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,0,-1,0,528,-1,0.9984756,0.0015244322
13908,propranolol,25,26,108,119,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,0,-1,0,13908,-1,0.9993199,0.000680104
2436,5-azacytidine,6,7,39,52,"We observed the exencephaly induced by 5-azacytidine at embryonic day 13.5 (E13.5), let the embryos develop exo utero until E18.5, and re-observed the same embryos at E18.5.",11875660_3,0,-1,0,2436,-1,0.9986149,0.0013850365
5320,alcohol,11,12,60,67,"Thyroid disorders, illicit drug or stimulant use, and acute alcohol intoxication are among these causes.",15899738_3,0,-1,0,5320,-1,0.9984074,0.0015926523
8975,sulphasalazine,20,21,141,155,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,0,-1,0,8975,-1,0.99919146,0.0008085281
16283,paclitaxel,8,9,53,63,Results thus far suggest no dose-response effect for paclitaxel doses above 200 mg/m2.,8643971_19,0,-1,0,16283,-1,0.99890363,0.0010963347
1987,paracetamol,17,18,102,113,"Furthermore, we evaluated whether some factors have the potential to increase the risk of reaction to paracetamol and nimesulide.",11694026_3,0,-1,0,1987,-1,0.99927956,0.0007204799
17788,glycine,3,4,20,27,Contribution of the glycine site of NMDA receptors in rostral and intermediate-caudal parts of the striatum to the regulation of muscle tone in rats.,9630698_0,0,-1,0,17788,-1,0.99889284,0.0011071786
12104,lithium,21,22,128,135,We measured serum thyroxine and urine-concentrating ability (Umax) in response to desmopressin (DDAVP) in 85 patients receiving lithium.,3001299_2,0,-1,0,12104,-1,0.9992205,0.00077949016
17891,cisapride,29,30,164,173,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,0,-1,0,17891,-1,0.99922335,0.0007766193
6191,desipramine,4,5,36,47,Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine.,16725121_6,0,-1,0,6191,-1,0.9993222,0.00067788834
3456,Hydrocortisone acetate,0,2,0,22,Hydrocortisone acetate (50 mg) was given orally every 6 hours for 24 hours after a 5-day fixed-salt diet (150 mmol/d).,12707296_4,0,-1,0,3456,-1,0.9989786,0.0010213756
14705,halothane,17,18,121,130,This demonstrates the participation of the renin--angiotensin system in antagonizing the combined hypotensive effects of halothane and SNP.,7352670_8,0,-1,0,14705,-1,0.9993025,0.00069749815
7557,Heparin,0,1,0,7,Heparin was injected over 10 seconds on the right abdominal site and 30 seconds on the left abdominal site.,17931375_5,0,-1,0,7557,-1,0.9987123,0.0012876568
17052,diltiazem,12,13,78,87,"We studied three calcium channel blockers of different structure, nifedipine, diltiazem, and verapamil, along with the new agent.",9100294_3,0,-1,0,17052,-1,0.9992429,0.000757105
9978,bupropion,11,12,74,83,These results provide empirical support for conducting a further study of bupropion.,20067456_13,0,-1,0,9978,-1,0.9991597,0.00084025937
11504,fentanyl,10,11,60,68,It is speculated that the induction of muscular rigidity by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons.,2564649_6,0,-1,0,11504,-1,0.9992398,0.00076020433
12754,iron,18,19,134,138,Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.,3503576_1,0,-1,0,12754,-1,0.99900776,0.00099226
1606,acetaminophen,16,17,95,108,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,0,-1,0,1606,-1,0.999158,0.0008419545
5560,pentobarbital,15,16,86,99,"Dissociated learning of rats in the normal state and the state of amnesia produced by pentobarbital (15 mg/kg, ip) was carried out.",1616457_1,0,-1,0,5560,-1,0.99924505,0.00075497455
12696,sparteine,22,23,138,147,"Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine.",3437726_0,0,-1,0,12696,-1,0.99931955,0.0006804516
3355,docetaxel,11,12,64,73,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,0,-1,0,3355,-1,0.9988732,0.0011267618
10651,lidocaine,16,17,100,109,"The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine (2.7 +/- 1.9 vs. 3.8 +/- 2.2, P = 0.03).",2070391_4,0,-1,0,10651,-1,0.99814105,0.0018589337
6101,desipramine,2,3,12,23,"Relative to desipramine alone, mean AUC and C(max) of desipramine increased 3.6- and 1.8-fold when coadministered with cinacalcet.",16680561_6,0,-1,0,6101,-1,0.9993611,0.00063889025
14309,adriamycin,14,15,87,97,1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.,6769133_3,0,-1,0,14309,-1,0.9992261,0.0007739051
860,ketamine,14,15,75,83,The purpose of the present study was to examine the safety and efficacy of ketamine for sedation in the treatment of children's fractures in the emergency department.,10901305_2,0,-1,0,860,-1,0.9989826,0.001017358
8688,aldosterone,1,2,7,18,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice.,18768591_6,0,-1,0,8688,-1,0.9987319,0.0012681022
7023,smoking,12,13,69,76,The objective of this study was to determine the effects of maternal smoking on transient evoked otoacoustic emissions (TEOAEs) of healthy neonates.,17343925_2,0,-1,0,7023,-1,0.9984408,0.0015591676
10535,Suxamethonium,0,1,0,13,Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.,20633755_1,0,-1,0,10535,-1,0.9990638,0.0009361972
16360,acetaminophen,7,8,47,60,"These studies suggest that both phenacetin and acetaminophen may contribute to the burden of ESRD, with the risk of the latter being somewhat less than that of the former.",8669433_4,0,-1,0,16360,-1,0.99923766,0.0007623393
15772,losartan,37,38,250,258,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,0,-1,0,15772,-1,0.999281,0.0007190467
8335,metoprolol,10,11,88,98,Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.,1848636_0,0,-1,0,8335,-1,0.9993507,0.0006492216
3053,zonisamide,29,30,195,205,"Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.",12523465_2,0,-1,0,3053,-1,0.9992601,0.0007398493
7418,fluoxetine,3,4,21,31,Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat.,17702969_0,0,-1,0,7418,-1,0.99911445,0.00088552386
6918,clonidine,12,13,88,97,"Alpha2ABC-/- mice were completely unresponsive to the analgesic and hypnotic effects of clonidine; however, clonidine significantly lowered heart rate in alpha2ABC-/- mice by up to 150 bpm.",17261653_4,0,-1,0,6918,-1,0.999243,0.0007569657
7228,ribavirin,18,19,123,132,An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.,17511042_0,0,-1,0,7228,-1,0.99923074,0.0007692156
193,Magnesium,0,1,0,9,Magnesium levels in patients on lithium treatment were unchanged from baseline levels.,10354657_11,0,-1,0,193,-1,0.99873966,0.001260406
3777,methylphenidate,10,11,88,103,Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine.,12907924_2,0,-1,0,3777,-1,0.9993919,0.0006081174
15134,creatinine,7,8,46,56,"Laboratory variables of renal function [serum creatinine, blood urea nitrogen (BUN) and electrolytes] were evaluated before initiation of therapy and every 2 days, until termination of the study (a period of at least 6 days).",7791169_3,0,-1,0,15134,-1,0.99851483,0.0014851961
3988,amino acid,15,17,124,134,"Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.",1436384_0,0,-1,0,3988,-1,0.99855787,0.0014421688
16260,cisplatin,7,8,38,47,A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.,8643971_0,0,-1,0,16260,-1,0.99871266,0.0012873828
13225,amikacin,10,11,82,90,Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin.,3950060_0,0,-1,0,13225,-1,0.99932516,0.00067484175
12913,acetaminophen,32,33,151,164,"In Australia, the pediatric usage of aspirin has been extremely low for the past 25 years (less than 1% of total dosage units sold), with paracetamol (acetaminophen) dominating the pediatric analgesic and antipyretic market.",3670965_7,0,-1,0,12913,-1,0.9992084,0.0007916742
1170,paclitaxel,26,27,175,185,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,0,-1,0,1170,-1,0.9988432,0.0011567379
15865,cimetidine,7,8,40,50,The cerebrospinal fluid: serum ratio of cimetidine concentrations was 0.24:1 and indicates that cimetidine passes the blood-brain barrier; it also raises the possibility that M.S. changes are due to blockade of histamine H2-receptors in the central nervous system.,84204_4,0,-1,0,15865,-1,0.999345,0.0006550137
12767,deferoxamine,26,27,210,222,"Auditory deterioration and improvement, demonstrated serially in individual patients receiving and not receiving deferoxamine, respectively, provided convincing evidence for a cause-and-effect relation between deferoxamine administration and ototoxicity.",3503576_6,0,-1,0,12767,-1,0.9993788,0.0006212007
7018,smoking,8,9,49,56,Influence of smoking on developing cochlea. Does smoking during pregnancy affect the amplitudes of transient evoked otoacoustic emissions in newborns?OBJECTIVE: Maternal tobacco smoking has negative effects on fetal growth.,17343925_0,0,-1,0,7018,-1,0.99850637,0.0014936536
3762,dopamine,22,23,112,120,"A single MPEP (5 mg/kg ip) injection reduced the basal extracellular dopamine level in the striatum, as well as dopamine release stimulated either by methamphetamine (10 mg/kg sc) or by intrastriatally administered veratridine (100 microM).",12907309_4,0,-1,0,3762,-1,0.999084,0.0009159785
18125,hydrocortisone,8,9,51,65,"Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.",983936_0,0,-1,0,18125,-1,0.9992268,0.000773179
1983,paracetamol,8,9,59,70,"Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous, respiratory and anaphylactoid reactions induced by nonsteroidal anti-inflammatory drugs (NSAIDs).",11694026_1,0,-1,0,1983,-1,0.999253,0.00074695697
4494,estrogen,8,9,54,62,The present study investigated whether this effect of estrogen involves interaction with alpha2- and/or I1-receptors.,15145918_2,0,-1,0,4494,-1,0.99884015,0.0011598449
4961,spironolactone,11,12,72,86,"Because treatments for heart failure have changed since the benefits of spironolactone were reported, the prevalence of these complications may differ in current clinical practice.",15632880_2,0,-1,0,4961,-1,0.99921274,0.0007871906
8680,doxorubicin,4,5,13,24,"To this end, doxorubicin (15 mug/g body wt) was injected intravenously into gene-targeted mice lacking SGK1 (sgk1(-/-)) and their wild-type littermates (sgk1(+/+)).",18768591_4,0,-1,0,8680,-1,0.99878365,0.0012163486
196,calcium,4,5,25,32,"After lithium treatment, calcium levels were higher than either baseline levels or control levels.",10354657_12,0,-1,0,196,-1,0.9985025,0.0014974845
13707,mexiletine,9,10,60,70,The antiarrhythmic effects of the sustained release form of mexiletine (Mexitil-Perlongets) were evaluated in a double-blind placebo trial in 630 patients with recent documented myocardial infarction.,6209318_2,0,-1,0,13707,-1,0.9992791,0.0007209438
16372,ifosfamide,8,9,54,64,Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.,8677458_1,0,-1,0,16372,-1,0.9992156,0.00078438193
1158,Paclitaxel,0,1,0,10,"Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.",11135224_0,0,-1,0,1158,-1,0.9988206,0.0011793284
10625,ribavirin,14,15,110,119,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,0,-1,0,10625,-1,0.9992755,0.000724457
7392,Levofloxacin,0,1,0,12,"Levofloxacin, a fluoroquinolone, is one of the most commonly prescribed antibiotics in clinical practice and is effective against Gram-positive, Gram-negative, and atypical bacteria.",17639754_2,0,-1,0,7392,-1,0.99910885,0.00089115946
15269,5-fluorouracil,16,17,103,117,"Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected.",7858459_4,0,-1,0,15269,-1,0.9990258,0.00097417523
654,clonidine,14,15,97,106,"Given that sympathetic neural dominance exhibits a similar developmental pattern, and given that clonidine induces sympathetic withdrawal and bradycardia, we hypothesized that clonidine's developmental effects on cardiac rate and ultrasound production would mirror each other.",10737864_3,0,-1,0,654,-1,0.99924445,0.0007556033
11150,theophylline,11,12,107,119,Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.,2348231_3,0,-1,0,11150,-1,0.99935573,0.0006442705
5947,creatine,42,43,228,236,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,0,-1,0,5947,-1,0.99853873,0.0014612881
1888,Fentanyl,0,1,0,8,"Fentanyl, an opioid analgesic, is frequently used in the neonatal intensive care unit setting for these very purposes.",11581460_2,0,-1,0,1888,-1,0.99904627,0.0009536944
7276,iopamidol,23,24,160,169,"CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.",17562951_10,0,-1,0,7276,-1,0.9992415,0.0007585092
15925,cimetidine,6,7,43,53,"The arrhythmias were temporally related to cimetidine administration, disappeared after dechallenge, and did not recur during ranitidine treatment.",8437969_3,0,-1,0,15925,-1,0.9993069,0.0006931287
11213,phenobarbital,3,4,18,31,No enhancement by phenobarbital of the hepatocarcinogenicity of a choline-devoid diet in the rat.,2396046_0,0,-1,0,11213,-1,0.99906117,0.00093889766
9597,creatinine,12,13,73,83,"Patients were admitted to the hospital for measurement of lithium level, creatinine clearance, urine volume, and maximum osmolality.",1987816_3,0,-1,0,9597,-1,0.9987668,0.0012332258
1184,cisplatin,7,8,44,53,"CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.",11135224_14,0,-1,0,1184,-1,0.99872667,0.0012733041
7843,clonidine,12,13,75,84,"RESULTS: There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine (17.5% versus 3.4%; p =.02), but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes.",18182964_6,0,-1,0,7843,-1,0.9991273,0.00087270804
7911,heparin,31,32,213,220,OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration.,18208574_1,0,-1,0,7911,-1,0.9985703,0.0014296577
9540,olanzapine,10,11,56,66,"Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.",19759529_8,0,-1,0,9540,-1,0.9993204,0.0006795824
8353,metoprolol,3,4,8,18,"In PMs, metoprolol increased the terbutaline area under the plasma concentration vs. time curve (+67%).",1848636_9,0,-1,0,8353,-1,0.999323,0.0006770626
13123,morphine,16,17,78,86,"The results suggest that rigidity, which is assumed to be due to an action of morphine in the striatum, can be antagonized by another process leading to dopaminergic activation in the striatum.",3780846_9,0,-1,0,13123,-1,0.9990578,0.0009421168
15042,calcium,3,4,20,27,Monitoring of serum calcium and cis-RA levels is indicated in future trials.,7707116_15,0,-1,0,15042,-1,0.99870646,0.0012935442
17370,halothane,28,29,208,217,"Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.",9284778_5,0,-1,0,17370,-1,0.9990544,0.00094566145
13561,propranolol,6,7,51,62,Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.,6111982_2,0,-1,0,13561,-1,0.9992848,0.0007152297
10293,Cocaine,0,1,0,7,"Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.",20477932_0,0,-1,0,10293,-1,0.99922204,0.0007780001
7072,simvastatin,7,8,52,63,A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.,17344566_1,0,-1,0,7072,-1,0.999175,0.000825017
16327,steroid,10,11,77,84,Weights of respiratory and peripheral muscles were similarly decreased after steroid treatment.,8665051_6,0,-1,0,16327,-1,0.99886787,0.001132102
553,Dopamine,0,1,0,8,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,0,-1,0,553,-1,0.9987972,0.0012028223
11563,2-acetylaminofluorene,27,28,182,203,The initiated hepatocytes in the liver were assayed as the gamma-glutamyltransferase (gamma-GT) positive foci formed following a 2-week selection regimen consisting of dietary 0.02% 2-acetylaminofluorene coupled with a necrogenic dose of CCl4.,2578334_2,0,-1,0,11563,-1,0.99886227,0.0011377692
13429,methyldopa,6,7,38,48,Patterns of hepatic injury induced by methyldopa.,424937_0,0,-1,0,13429,-1,0.9991721,0.0008279952
4602,lidocaine,9,10,67,76,Treatment of tinnitus by intratympanic instillation of lignocaine (lidocaine) 2 per cent through ventilation tubes.,1527456_0,0,-1,0,4602,-1,0.99870133,0.0012985972
2195,creatinine,42,43,271,281,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,0,-1,0,2195,-1,0.9986512,0.001348768
18071,amphetamine,4,5,22,33,Stroke and cocaine or amphetamine use.,9799166_0,0,-1,0,18071,-1,0.9991499,0.0008500422
13808,caffeine,31,32,225,233,"A patient who allegedly consumed 100 tablets of an over-the-counter analgesic containing sodium acetylsalicylate, caffeine, and acetaminophen displayed no significant CNS stimulation despite the presence of 175 micrograms of caffeine per mL of serum.",6308277_1,0,-1,0,13808,-1,0.99919194,0.0008081203
6895,atropine,4,5,36,44,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,0,-1,0,6895,-1,0.9993543,0.00064566213
13547,scopolamine,9,10,54,65,"However, studies into the dose necessary to combating scopolamine intoxication are indicated.",603022_2,0,-1,0,13547,-1,0.9992986,0.0007013926
600,sodium,2,3,11,17,"Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.",10706004_0,0,-1,0,600,-1,0.998901,0.0010989592
11785,norepinephrine,9,10,67,81,Measurement of resting norepinephrine spillover rate to plasma and norepinephrine uptake indicated that overall resting sympathetic nervous system activity was not increased.,2722224_8,0,-1,0,11785,-1,0.9984723,0.0015276944
15111,verapamil,8,9,60,69,Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.,7785794_0,0,-1,0,15111,-1,0.9993125,0.000687513
8884,warfarin,22,23,129,137,"We propose that naturally occurring compounds such as flavonoids, which are present in fruit juices, may increase the potency of warfarin by competing for the enzymes that normally inactivate warfarin.",19058474_2,0,-1,0,8884,-1,0.9988668,0.0011332056
15789,vincristine,8,9,46,57,It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good.,8384253_12,0,-1,0,15789,-1,0.99933976,0.00066018564
14611,procainamide,6,7,33,45,"In the remaining three patients, procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter.",7234705_3,0,-1,0,14611,-1,0.99921346,0.00078651693
14136,amiodarone,6,7,45,55,Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.,6637851_0,0,-1,0,14136,-1,0.9993305,0.0006694956
3920,morphine,28,29,199,207,It is also suggested from collected evidence that the activity-increasing effects of morphine in mice are mediated by mechanisms different from those which mediate the activity-increasing effects of morphine in rats.,137340_8,0,-1,0,3920,-1,0.9991171,0.0008829659
673,ketamine,5,6,50,58,Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans.,10743446_0,0,-1,0,673,-1,0.99916124,0.0008387907
13426,paracetamol,12,13,67,78,A low yield of tumours at various other sites also arose following paracetamol feeding.,4090988_8,0,-1,0,13426,-1,0.99922633,0.0007736765
265,acetaminophen,15,16,68,81,Aggregation was lower (P < .05) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day.,10414674_7,0,-1,0,265,-1,0.99924517,0.00075483316
6503,mannitol,28,29,161,169,"Mannitol concentrations were measured in plasma and white matter by a modified version of the enzyme assay of Blonquist et al. RESULTS: In most glioma patients, mannitol concentrations in white matter were 2 to 6 times higher than in plasma (mean 3.5 times).",17019386_8,0,-1,0,6503,-1,0.9991128,0.0008871512
15617,clonidine,4,5,25,34,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,0,-1,0,15617,-1,0.99934286,0.0006570788
7108,terbutaline,4,5,24,35,Newborn rats were given terbutaline (10 mg/kg) daily on postnatal days (PN) 2 to 5 or PN 11 to 14 and examined 24 h after the last dose and at PN 30.,17400887_5,0,-1,0,7108,-1,0.99933136,0.0006686431
5485,cocaine,3,4,14,21,"Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.",1601297_2,0,-1,0,5485,-1,0.9988813,0.0011187504
13963,picrotoxin,26,27,159,169,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,0,-1,0,13963,-1,0.9992446,0.0007554798
18290,labetalol,9,10,75,84,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,0,-1,0,18290,-1,0.999243,0.0007569871
17926,tamoxifen,20,21,134,143,"Compared with the placebo group, there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen.",9672273_15,0,-1,0,17926,-1,0.998809,0.0011910452
2295,metoclopramide,5,6,30,44,Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.,11858397_0,0,-1,0,2295,-1,0.9991522,0.00084779307
16020,midazolam,14,15,108,117,We prospectively evaluated the incidence of venous complications after intravenous injection of diazepam or midazolam in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy.,8514073_2,0,-1,0,16020,-1,0.99932873,0.0006713172
11803,lidocaine,13,14,99,108,Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine.,2790457_0,0,-1,0,11803,-1,0.9991522,0.0008477911
165,sirolimus,6,7,39,48,"CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.",10328196_5,0,-1,0,165,-1,0.99846137,0.001538701
14169,adriamycin,2,3,15,25,Early adjuvant adriamycin in superficial bladder carcinoma.,6640832_0,0,-1,0,14169,-1,0.99898344,0.0010165434
5483,cocaine,8,9,83,90,Electrocardiographic evidence of myocardial injury in psychiatrically hospitalized cocaine abusers.,1601297_0,0,-1,0,5483,-1,0.99845886,0.0015411966
637,dopamine,27,28,167,175,"They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors.",10721819_10,0,-1,0,637,-1,0.9991968,0.0008031256
5913,serotonin,13,14,92,101,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,0,-1,0,5913,-1,0.99904865,0.0009513403
17898,cisapride,25,26,122,131,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,0,-1,0,17898,-1,0.99925965,0.00074034516
2289,bilirubin,15,16,92,101,The alanine aminotransferase was elevated to a peak concentration of 1533 U/L and the serum bilirubin reached a peak of 17.0 mg/dL. There was slow improvement over 4 months.,11847945_5,0,-1,0,2289,-1,0.99815995,0.0018400117
7130,dex,18,19,108,111,"3. Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.",17439425_3,0,-1,0,7130,-1,0.99888796,0.0011120929
2008,timolol,22,23,103,110,"DESIGN: This trial evaluated the effect of placebo, 0.5% aqueous timolol (timolol solution) and a 0.5% timolol suspension that forms a gel on application to the conjunctiva (timolol gellan) on the 24-hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate.",11704023_3,0,-1,0,2008,-1,0.9992461,0.00075392023
2100,amifostine,2,3,18,28,"Patients received amifostine, 910 mg/m2 intravenously over 15 minutes.",11745184_7,0,-1,0,2100,-1,0.99933857,0.0006614664
13361,amiodarone,9,10,72,82,Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy.,3997294_0,0,-1,0,13361,-1,0.9992686,0.00073137437
11376,amantadine,11,12,85,95,"Conversely, brain normetanephrine concentration was increased from saline control by amantadine in the BALB/C mice.",2484011_9,0,-1,0,11376,-1,0.9993131,0.0006869176
1321,cyclophosphamide,24,25,148,164,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,0,-1,0,1321,-1,0.9989428,0.0010572226
10892,azidothymidine,17,18,96,110,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,0,-1,0,10892,-1,0.9991561,0.0008439031
5327,creatine,18,19,98,106,"However, when the patient was questioned about use of herbal products and supplements, the use of creatine monohydrate was revealed.",15899738_7,0,-1,0,5327,-1,0.9989466,0.0010534645
15145,creatinine,6,7,28,38,"The mean increments in BUN, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups.",7791169_7,0,-1,0,15145,-1,0.9982665,0.001733518
3347,thalidomide,30,31,199,210,STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.,12627929_1,0,-1,0,3347,-1,0.99930143,0.00069854653
4064,levodopa,24,25,159,167,These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to levodopa and demonstrate the value of these models for further studying the pathophysiology of LIDs.,14568327_7,0,-1,0,4064,-1,0.9991271,0.00087291596
7656,paracetamol,27,28,163,174,We propose that the paracetamol dose should not exceed 2 g/day in such patients and that their liver function should be monitored closely while being treated with paracetamol.,18004067_6,0,-1,0,7656,-1,0.9992536,0.00074640947
2015,timolol,64,65,327,334,"METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).",11704023_4,0,-1,0,2015,-1,0.999159,0.00084099866
11660,Captopril,0,1,0,9,"Captopril may, by the same mechanism, reduce the increase in glomerular filtration that is known to occur after an injection of thrombin, thereby diminishing the aggregation of fibrin monomers in the glomeruli, with the result that less fibrin will be deposited and thus less kidney damage will be produced.",2670794_8,0,-1,0,11660,-1,0.9992834,0.0007166195
12130,6-hydroxydopamine,26,27,163,180,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,0,-1,0,12130,-1,0.9991084,0.00089156115
13036,potassium,26,27,191,200,"The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease, even minor falls in plasma potassium concentrations are probably best avoided in such patients.",3732088_7,0,-1,0,13036,-1,0.9989116,0.0010883367
3115,iodixanol,27,28,169,178,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,0,-1,0,3115,-1,0.9991565,0.0008435622
14739,tobramycin,16,17,89,99,"Thus, gentamicin was associated with renal failure more than three times as often as was tobramycin.",7420681_7,0,-1,0,14739,-1,0.9989195,0.0010805009
17364,"1-chloro-1,2,2,2-tetrafluoroethane",27,28,179,213,"We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,0,-1,0,17364,-1,0.9973737,0.0026263504
6986,doxorubicin,33,34,238,249,"To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.",1732369_2,0,-1,0,6986,-1,0.99904126,0.00095876533
6626,Dex,17,18,99,102,Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001).,17042910_13,0,-1,0,6626,-1,0.9989127,0.0010873283
8338,metoprolol,13,14,84,94,We investigated if the latter also applies to the beta-2 adrenoceptor antagonism by metoprolol.,1848636_3,0,-1,0,8338,-1,0.99931216,0.0006878682
7209,dobutamine,7,8,44,54,The increase in dP/dtejc during infusion of dobutamine in this group was severely impaired as compared to the non-ischemic group.,17491223_6,0,-1,0,7209,-1,0.99936706,0.0006329296
11980,potassium,1,2,8,17,Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.,28952_0,0,-1,0,11980,-1,0.9989392,0.0010608374
6854,cocaine,21,22,152,159,"Earlier studies have demonstrated that antagonism of sigma1 receptors attenuates the convulsive, lethal, locomotor stimulatory and rewarding actions of cocaine in mice.",17241657_1,0,-1,0,6854,-1,0.998982,0.0010179544
11627,cortisol,8,9,45,53,"In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy, yet continuous blood pressure monitoring demonstrated hypertension 31 (patient 1) and 52 weeks (patient 2) after treatment.",2632720_2,0,-1,0,11627,-1,0.9989157,0.0010843825
4234,aminophylline,7,8,32,45,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,0,-1,0,4234,-1,0.99926656,0.00073338306
17440,Testosterone,2,3,9,21,RESULTS: Testosterone was less than 3 ng./ml.,9334596_8,0,-1,0,17440,-1,0.9985323,0.0014676661
1977,prochlorperazine,3,4,16,32,"The efficacy of prochlorperazine in the treatment of headache and nausea likewise did not appear to be affected by the rate of administration, although no formal statistical comparisons were made.",11679859_15,0,-1,0,1977,-1,0.99922144,0.0007784935
17996,carbamazepine,3,4,21,34,Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.,9746003_0,0,-1,0,17996,-1,0.99930954,0.0006904724
4098,mesna,7,8,27,32,"One, two or three doses of mesna were replaced with dexamethasone alone or with dexamethasone plus mesna.",14633084_4,0,-1,0,4098,-1,0.9991166,0.00088334957
1848,terfenadine,10,11,49,60,"For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.",11569530_10,0,-1,0,1848,-1,0.9992999,0.00070014613
16825,Phenylephrine,0,1,0,13,"Phenylephrine infusion increased arterial pressure, arteriolar diameter and clearance of fluorescent dextran by a similar magnitude in both groups.",8955532_4,0,-1,0,16825,-1,0.9992532,0.00074681867
5564,pentobarbital,9,10,64,77,These findings show that the brain-dissociated state induced by pentobarbital is formed with the participation of the mechanisms of information perception.,1616457_7,0,-1,0,5564,-1,0.99909425,0.0009057442
11111,phenytoin,8,9,55,64,All seizures were controlled with therapeutic doses of phenytoin.,2343592_3,0,-1,0,11111,-1,0.9993012,0.00069873827
12825,sulindac,25,26,165,173,"As no other medications known to effect serum potassium had been given concomitantly, this course of events is suggestive of a cause-and-effect relationship between sulindac and hyperkalemia.",3560096_5,0,-1,0,12825,-1,0.9992537,0.00074625295
11939,glutamate,17,18,100,109,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,0,-1,0,11939,-1,0.99903286,0.0009671647
16598,antidepressants,10,11,79,94,Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants.,8766220_0,0,-1,0,16598,-1,0.99910825,0.0008917073
14254,kanamycin,7,8,39,48,"To quantify the effects of gentamicin, kanamycin and netilmicin on renal protein reabsorption and accumulation, these drugs were administered to rats intraperitoneally (30 mg/kg/day) for 7, 14 or 21 days.",6728084_1,0,-1,0,14254,-1,0.9991234,0.00087659125
15891,fluoxetine,5,6,39,49,Increase of Parkinson disability after fluoxetine medication.,8423889_0,0,-1,0,15891,-1,0.9990845,0.00091553136
9518,glycine,3,4,15,22,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",19759529_4,0,-1,0,9518,-1,0.9989122,0.0010877651
5757,scopolamine,2,3,9,20,"However, scopolamine and ritanserin co-administration resulted in a significant decrease in escape latencies and traveled distances as compared to the scopolamine-treated rats.",16364460_8,0,-1,0,5757,-1,0.999395,0.0006050089
10576,phenobarbitone,5,6,46,60,Pharmacokinetic interactions of curcumin with phenobarbitone and carbamazepine were also studied.,20667451_5,0,-1,0,10576,-1,0.9993419,0.00065805047
7300,glutamate,17,18,95,104,"Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2.",17600377_5,0,-1,0,7300,-1,0.9987645,0.0012355516
2164,capsaicin,22,23,168,177,"CONCLUSIONS: These results show selective inhibition by intrathecal adenosine of hypersensitivity, presumed to reflect central sensitization in humans after peripheral capsaicin injection.",11752998_6,0,-1,0,2164,-1,0.99927586,0.0007241478
8129,pentobarbital,40,41,227,240,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,0,-1,0,8129,-1,0.9992481,0.00075186713
2021,timolol,12,13,61,68,"During the night, the mean 12-hour heart rate on placebo and timolol gellan were both significantly less than on timolol solution; the difference between solution and gellan treatments was statistically significant (P = .01).",11704023_8,0,-1,0,2021,-1,0.9992004,0.00079962594
13604,benzodiazepines,2,3,7,22,"Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.",6118280_6,0,-1,0,13604,-1,0.9991043,0.00089569506
11082,bupivacaine,19,20,106,117,infusion of morphine (mean 73.6 mg) and five patients receiving a continuous extradural infusion of 0.25% bupivacaine (mean 192 mg) in the 24-h period following upper abdominal surgery.,2334618_3,0,-1,0,11082,-1,0.99929714,0.0007028355
11694,Nitroprusside,0,1,0,13,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,0,-1,0,11694,-1,0.9992975,0.0007024991
7383,pravastatin,12,13,75,86,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,0,-1,0,7383,-1,0.999116,0.0008839794
2633,risperidone,26,27,162,173,"Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.",12013711_1,0,-1,0,2633,-1,0.9992512,0.0007487669
16234,Paclitaxel,0,1,0,10,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.",8643966_1,0,-1,0,16234,-1,0.9989889,0.0010110147
6798,5-hydroxytryptamine,24,25,136,155,"The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats.",17194457_1,0,-1,0,6798,-1,0.9985746,0.0014253197
8987,sulphasalazine,4,5,24,38,This case suggests that sulphasalazine can induce PR3-ANCA-positive necrotizing glomerulonephritis.,19203554_7,0,-1,0,8987,-1,0.99907863,0.0009213103
2809,metoclopramide,8,9,53,67,We describe a patient where intravenous injection of metoclopramide was immediately followed by asystole repeatedly.,12139551_1,0,-1,0,2809,-1,0.99916506,0.0008349041
8586,Doxorubicin,0,1,0,11,Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.,18674790_6,0,-1,0,8586,-1,0.99897254,0.0010274666
6950,angiotensin,9,10,59,70,"The recognition of angiotensin-converting enzyme (ACE) and angiotensin receptor blocker (ARB) intestinal angioedema constitutes a challenge to primary care physicians, internists, emergency room personal and surgeons.",17285209_10,0,-1,0,6950,-1,0.99817705,0.0018229731
2101,amifostine,4,5,24,34,"After completion of the amifostine infusion, cisplatin 120 mg/m2 was administered over 30 minutes.",11745184_8,0,-1,0,2101,-1,0.999345,0.0006549387
2147,adenosine,46,47,293,302,"METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg.",11752998_3,0,-1,0,2147,-1,0.9990121,0.0009879105
4319,propranolol,6,7,51,62,"Methimazole-induced cholestasis was diagnosed, and propranolol therapy was resumed.",14982270_5,0,-1,0,4319,-1,0.99923825,0.0007617634
8724,isoproterenol,37,38,247,260,"Taking into account that the sarcolemmal integrity is stabilized by the dystrophin-glycoprotein complex (DGC) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins, this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins.",18808529_3,0,-1,0,8724,-1,0.999241,0.0007590063
10218,cocaine,8,9,56,63,Brainstem dysgenesis in an infant prenatally exposed to cocaine.,20304337_0,0,-1,0,10218,-1,0.9988788,0.0011212358
10793,succinylcholine,13,14,73,88,"CONCLUSION: eleven of 13 patients with a prolonged duration of action of succinylcholine had mutations in BCHE, indicating that this is the possible reason for a prolonged period of apnea.",21029050_11,0,-1,0,10793,-1,0.9992095,0.00079047936
16602,paroxetine,7,8,44,54,This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.,8766220_2,0,-1,0,16602,-1,0.9992384,0.00076159503
10763,haloperidol,17,18,141,152,Electrophysiological recordings showed that microinjection of neurotensin induced excitation of pallidal neurons in the presence of systemic haloperidol administration.,20882060_6,0,-1,0,10763,-1,0.9993512,0.0006487419
1117,metoprolol,8,9,44,54,"STUDY OBJECTIVE: To determine the effect of metoprolol on dobutamine stress testing with technetium-99m sestamibi single-photon emission computed tomography imaging and ST-segment monitoring, and to assess the impact of intravenous glucagon on metoprolol's effects.",11079278_1,0,-1,0,1117,-1,0.9993327,0.0006672203
17574,1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine,63,64,569,625,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0,-1,0,17574,-1,0.99841154,0.00158848
17051,nifedipine,10,11,66,76,"We studied three calcium channel blockers of different structure, nifedipine, diltiazem, and verapamil, along with the new agent.",9100294_3,0,-1,0,17051,-1,0.99937624,0.0006238374
11757,morphine,21,22,126,134,"Latency to the loss of righting reflex, rigidity and behavior on recovery, reflected the relative predominance of ketamine or morphine in each combination.",2716967_5,0,-1,0,11757,-1,0.99909735,0.00090265
10578,phenobarbitone,8,9,34,48,"At the end of study period, serum phenobarbitone and carbamazepine, whole brain malondialdehyde and reduced glutathione levels were estimated.",20667451_8,0,-1,0,10578,-1,0.9993561,0.0006439686
15116,metoprolol,24,25,183,193,A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.,7785794_2,0,-1,0,15116,-1,0.99936014,0.00063981576
10635,ribavirin,19,20,127,136,"In contrast with the literature, serum levels of angiogenesis factors did not change significantly by pegylated interferon and ribavirin therapy.",20698227_6,0,-1,0,10635,-1,0.99923515,0.0007648993
15959,lovastatin,9,10,50,60,OBJECTIVE: To evaluate the efficacy and safety of lovastatin in women with moderate hypercholesterolemia.,8480959_1,0,-1,0,15959,-1,0.9989791,0.0010209269
8838,lamivudine,18,19,124,134,The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (HBs Ag) positive patients with rheumatologic disease.,19037603_1,0,-1,0,8838,-1,0.99924195,0.0007581042
3340,docetaxel,9,10,70,79,Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.,12627929_0,0,-1,0,3340,-1,0.9990994,0.0009006895
5079,ceftriaxone,5,6,22,33,It is well known that ceftriaxone leads to pseudolithiasis in some patients.,15737522_1,0,-1,0,5079,-1,0.998938,0.0010619516
678,lidocaine,11,12,71,80,We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.,10743446_1,0,-1,0,678,-1,0.9991248,0.0008752179
11746,ketamine,17,18,135,143,"Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.",2716967_2,0,-1,0,11746,-1,0.99912375,0.00087630696
15324,cholesterol,21,22,120,131,"Chemical analysis of gall stones retrieved at cholecystectomy from two patients, showed that they contained 71% and 87% cholesterol by weight.",7890216_3,0,-1,0,15324,-1,0.9970112,0.002988852
6616,Dex,45,46,181,184,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,0,-1,0,6616,-1,0.9989511,0.0010488598
5904,ecstasy,2,3,17,24,"Fifteen polydrug ecstasy users and 15 polydrug non-ecstasy user controls completed a general drug use questionnaire, the Brixton Spatial Anticipation task (set shifting), Backward Digit Span procedure (memory updating), Inhibition of Return (inhibition), an emotional intelligence scale, the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire (DEX).",16574712_3,0,-1,0,5904,-1,0.9984363,0.0015637589
1327,doxorubicin,32,33,189,200,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,0,-1,0,1327,-1,0.9989027,0.001097353
8826,caffeine,1,2,12,20,Intravenous caffeine is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy.,18997632_2,0,-1,0,8826,-1,0.999044,0.0009559687
11017,ifosfamide,5,6,37,47,Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.,2320800_0,0,-1,0,11017,-1,0.99914205,0.00085788633
12301,alfentanil,5,6,34,44,Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone.,3115150_6,0,-1,0,12301,-1,0.99927205,0.0007279751
8271,histamine,6,7,36,45,"Moreover, a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats.",18442015_10,0,-1,0,8271,-1,0.99867165,0.0013284006
11368,amantadine,1,2,11,21,Subsequent amantadine treatments produced enhancement of motility from corresponding control in all mouse strains with the BALB/C mice being the least sensitive.,2484011_5,0,-1,0,11368,-1,0.9992873,0.0007127449
1530,Calcitonin,0,1,0,10,Calcitonin gene-related peptide levels during nitric oxide-induced headache in patients with chronic tension-type headache.,11284996_0,0,-1,0,1530,-1,0.99668425,0.0033156858
3628,phenobarbital,35,36,224,237,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,0,-1,0,3628,-1,0.9992336,0.00076640816
8355,metoprolol,5,6,26,36,"There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs (72 +/- 7 ng.ml-1) than EMs (42 +/- 8 ng.ml-1, P less than .001).(ABSTRACT TRUNCATED AT 250 WORDS)",1848636_11,0,-1,0,8355,-1,0.9992756,0.0007244419
626,isoproterenol,5,6,52,65,"Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v.",10721819_5,0,-1,0,626,-1,0.99928004,0.0007200231
6358,amphetamine,21,22,92,103,"Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively.",16867021_3,0,-1,0,6358,-1,0.9993729,0.00062716927
2009,timolol,34,35,174,181,"DESIGN: This trial evaluated the effect of placebo, 0.5% aqueous timolol (timolol solution) and a 0.5% timolol suspension that forms a gel on application to the conjunctiva (timolol gellan) on the 24-hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate.",11704023_3,0,-1,0,2009,-1,0.99920255,0.0007975135
8439,pergolide,11,12,73,82,Valvular heart disease in patients with Parkinson's disease treated with pergolide.,18560792_0,0,-1,0,8439,-1,0.9990771,0.00092285604
18250,tobramycin,10,11,63,73,MATERIALS AND METHODS: Patients undergoing treatment with i.v. tobramycin (4 mg/kg/day) were randomised to two groups.,9875685_2,0,-1,0,18250,-1,0.9990596,0.00094037654
7187,iron,18,19,106,110,"These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.",17490790_6,0,-1,0,7187,-1,0.99845314,0.0015467964
5709,gabapentin,6,7,18,28,"We found that (i) gabapentin reduced the activations in the bilateral operculoinsular cortex, independently of the presence of central sensitization; (ii) gabapentin reduced the activation in the brainstem, only during central sensitization; (iii) gabapentin suppressed stimulus-induced deactivations, only during central sensitization; this effect was more robust than the effect on brain activation.",16330766_7,0,-1,0,5709,-1,0.9991998,0.00080015487
14369,noradrenaline,3,4,23,36,Intrarenal infusion of noradrenaline caused hypertension at doses which did not do so when infused intravenously.,6861444_2,0,-1,0,14369,-1,0.99921477,0.00078517763
12182,Lovastatin,0,1,0,10,Lovastatin has been marketed in the United States for over 6 months.,3076126_4,0,-1,0,12182,-1,0.99899954,0.001000429
10575,curcumin,3,4,32,40,Pharmacokinetic interactions of curcumin with phenobarbitone and carbamazepine were also studied.,20667451_5,0,-1,0,10575,-1,0.99917185,0.00082814577
13415,prostaglandins,8,9,55,69,Our case supports the hypothesis that endogenous renal prostaglandins play a role in the maintenance of renal blood flow when circulating plasma volume is diminished.,4071154_3,0,-1,0,13415,-1,0.9981134,0.0018865679
8858,isoproterenol,37,38,217,230,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,0,-1,0,8858,-1,0.9992092,0.00079076446
18087,cocaine,3,4,11,18,"The use of cocaine and/or amphetamine is a strong risk factor for stroke in this socioeconomically heterogeneous, insured urban population.",9799166_10,0,-1,0,18087,-1,0.9990903,0.0009097102
16439,norepinephrine,8,9,51,65,"However, L-dopa restored the bradycardia caused by norepinephrine in addition to decreasing blood pressure and heart rate.",869641_6,0,-1,0,16439,-1,0.99905235,0.00094770076
11850,potassium,16,17,109,118,"In the 7-hour period after terbutaline administration, plasma samples were taken for determination of plasma potassium levels and drug concentrations.",2826064_4,0,-1,0,11850,-1,0.9990451,0.00095493643
11024,ifosfamide,28,29,174,184,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,0,-1,0,11024,-1,0.999193,0.0008069952
14814,carbimazole,14,15,101,112,Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.,7504976_0,0,-1,0,14814,-1,0.99935764,0.0006423049
17485,risperidone,13,14,79,90,"Based on these observations, it is concluded that 5-HT2 blockade obtained with risperidone at D2 occupancy rates of 60% and above does not appear to protect against the risk for extrapyramidal side effects.",9351491_7,0,-1,0,17485,-1,0.99928015,0.0007199175
16351,phenacetin,14,15,88,98,"Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.",8669433_1,0,-1,0,16351,-1,0.9993462,0.000653818
15232,rifampin,20,21,161,169,This report documents the unusual occurrence of rapidly progressive glomerulonephritis with crescents and fibrillar glomerulonephritis in a patient treated with rifampin.,7834920_5,0,-1,0,15232,-1,0.99901855,0.0009814309
8740,paclitaxel,7,8,48,58,Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.,18809400_4,0,-1,0,8740,-1,0.99901104,0.0009889237
833,naloxone,8,9,58,66,This effect was completely prevented by pretreatment with naloxone.,10840460_16,0,-1,0,833,-1,0.9991984,0.00080166076
17885,cisapride,95,96,436,445,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,0,-1,0,17885,-1,0.99908006,0.0009198775
16559,ethanol,42,43,225,232,"In these animals, only minor increases of serum transaminase activities were measured in the presence of AAP, and unlike the exacerbation caused by ethanol in mice on a standard diet, the liver damage was inhibited by 50% by ethanol.",8742498_5,0,-1,0,16559,-1,0.99905986,0.00094012707
7151,gentamicin,17,18,121,131,PURPOSE: To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space at the end of routine cataract surgery.,17466854_1,0,-1,0,7151,-1,0.99898237,0.0010175839
5960,glutathione,34,35,237,248,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,0,-1,0,5960,-1,0.9987305,0.0012694732
2276,risperidone,21,22,110,121,"The mean duration of therapy with cabergoline was 523.5 +/- 129.7 days, and the mean duration of therapy with risperidone was 788.5 +/- 162.5 days.",11838826_8,0,-1,0,2276,-1,0.9993088,0.00069121906
2360,steroids,15,16,111,119,These results identify a novel neuropharmacological site for the modulation of memory processes by neuroactive steroids.,11860495_11,0,-1,0,2360,-1,0.99875057,0.0012493684
7834,methylphenidate,25,26,123,138,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,0,-1,0,7834,-1,0.9993136,0.0006864295
2079,cisplatin,16,17,76,85,Older reports suggest an objective response rate of 8% when 60-120 mg/m2 of cisplatin is administered every 3-4 weeks.,11745184_1,0,-1,0,2079,-1,0.9989286,0.0010713919
7990,trihexyphenidyl,16,17,113,128,CONCLUSION: The epsilon4 allele in healthy elderly was associated with increased subjective mental slowing after trihexyphenidyl anticholinergic challenge.,18239197_9,0,-1,0,7990,-1,0.99905306,0.00094694254
15005,halothane,30,31,209,218,This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.,7647582_8,0,-1,0,15005,-1,0.99930894,0.0006910761
13211,vancomycin,15,16,82,92,Drugs were ceased in six patients because of adverse reactions; in three of these vancomycin was considered the likely cause.,3934126_3,0,-1,0,13211,-1,0.9984114,0.0015885404
198,calcium,9,10,60,67,"Thus, lithium treatment counteracted the decrease in plasma calcium levels associated with aging.",10354657_13,0,-1,0,198,-1,0.9984523,0.0015476568
11354,lindane,17,18,121,128,Is the treatment of scabies hazardous?Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.,2476560_0,0,-1,0,11354,-1,0.9989943,0.0010056851
3157,iodixanol,17,18,109,118,"CONCLUSIONS: Nephropathy induced by contrast medium may be less likely to develop in high-risk patients when iodixanol is used rather than a low-osmolar, nonionic contrast medium.",12571256_12,0,-1,0,3157,-1,0.9992404,0.0007596641
14799,potassium,42,43,267,276,"In all the experiments, the attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level.",7453952_6,0,-1,0,14799,-1,0.9990201,0.0009798845
5525,carboplatin,21,22,142,153,"For human glioblastoma recurrences, the feasibility, safety, and short-term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study.",16132524_4,0,-1,0,5525,-1,0.999193,0.0008070371
11847,terbutaline,11,12,62,73,Six healthy subjects were given a 0.5 mg subcutaneous dose of terbutaline on two occasions: 1 hour after oral administration of a placebo and 1 hour after 80 mg oxprenolol orally.,2826064_3,0,-1,0,11847,-1,0.99935716,0.00064284814
176,lithium,7,8,41,48,"OBJECTIVES: To assess changes induced by lithium maintenance therapy on the incidence of thyroid, parathyroid and ion alterations.",10354657_1,0,-1,0,176,-1,0.99901354,0.0009864264
14463,aspartate,27,28,170,179,"A correlation was found between serum acid protease activity and prothrombin time, and the increase in cathepsin D activity was sustained over several days compared with aspartate aminotransferase, which showed a sharp early peak and then a fall.",7007443_3,0,-1,0,14463,-1,0.9984036,0.001596422
3878,prazosin,20,21,124,132,Head-up tilts in these rats did not produce orthostatic hypotension when performed either prior to or after acute dosing of prazosin (0.1 mg kg-1 i.p.).,1355091_8,0,-1,0,3878,-1,0.99918085,0.00081907155
2498,morphine,14,15,111,119,"Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.",11900788_5,0,-1,0,2498,-1,0.999175,0.00082492566
17189,tamoxifen,9,10,58,67,CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive breast carcinoma.,9205462_3,0,-1,0,17189,-1,0.99886537,0.0011346752
14262,aminoglycosides,2,3,10,25,All three aminoglycosides decreased GFR and increased urinary excretion of sodium and potassium.,6728084_6,0,-1,0,14262,-1,0.9985305,0.0014694722
3358,thalidomide,29,30,154,165,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,0,-1,0,3358,-1,0.9992612,0.0007387625
8811,ifosfamide,5,6,37,47,The protracted infusion schedule for ifosfamide permits convenient outpatient administration without Mesna and reduces the drug cost of clinical usage of this agent by up to  890 per cycle.,1899352_11,0,-1,0,8811,-1,0.999212,0.0007879411
15240,dexamethasone,36,37,193,206,RESULTS: A significant increase in intraocular pressure developed in 13 of the 44 pairs of eyes perfused with dexamethasone with an average pressure rise of 17.5 +/- 3.8 mm Hg after 12 days of dexamethasone exposure.,7843916_7,0,-1,0,15240,-1,0.9990877,0.00091231643
7806,sulpiride,7,8,62,71,"Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.",18162529_4,0,-1,0,7806,-1,0.99931896,0.0006811003
4431,pyridoxine,12,13,61,71,"A placebo had no effect, but niacinamide was as effective as pyridoxine.",150790_4,0,-1,0,4431,-1,0.99916863,0.0008313812
8846,Lamivudine,0,1,0,10,Lamivudine therapy was started 3-7 days prior to immunosuppressive therapy in all patients.,19037603_5,0,-1,0,8846,-1,0.9992175,0.0007824879
4007,dopamine,2,3,13,21,Depletion of dopamine in the striatum was also antagonized when LY274614 was given after the injection of amphetamine; LY274614 protected when given up to 4 hr after but not when given 8 or 24 hr after amphetamine.,1436384_7,0,-1,0,4007,-1,0.999148,0.0008519182
16034,alcohol,17,18,103,110,"Smoking, nonsteroidal anti-inflammatory drug use, intravenous catheter site, dwell time of the needle, alcohol use, and pain during the injection had no effect on the incidence of venous complications.",8514073_7,0,-1,0,16034,-1,0.9985934,0.0014065693
12838,calcitonin,10,11,94,104,Regional localization of the antagonism of amphetamine-induced hyperactivity by intracerebral calcitonin injections.,3615541_0,0,-1,0,12838,-1,0.9992449,0.00075511204
14687,sodium nitroprusside,3,5,27,47,Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats.,7352670_0,0,-1,0,14687,-1,0.99913126,0.00086873973
10648,lidocaine,20,21,128,137,Twenty patients were asked to quantify the severity of pain after receiving standard lidocaine in one femoral area and buffered lidocaine in the opposite femoral area.,2070391_3,0,-1,0,10648,-1,0.99851376,0.0014862275
2601,reserpine,26,27,154,163,"MK-801 (0.1 mg/kg), administered 30 min before the observation test, prevented the vacuous chewing movements, tongue protrusions and catalepsy induced by reserpine.",11999899_5,0,-1,0,2601,-1,0.9993024,0.00069761946
4228,bicuculline,4,5,32,43,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,0,-1,0,4228,-1,0.9993099,0.0006901135
3186,tacrolimus,12,13,89,99,"Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.",12584269_0,0,-1,0,3186,-1,0.9992198,0.00078026386
15783,vincristine,35,36,193,204,Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.,8384253_1,0,-1,0,15783,-1,0.99931884,0.0006811217
17641,bupivacaine,21,22,149,160,BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.,9523805_1,0,-1,0,17641,-1,0.9992955,0.000704542
551,apomorphine,3,4,9,20,"In mice, apomorphine produced qualitatively different responses under novel conditions when compared to those behaviors elicited in the home test cage.",10683478_6,0,-1,0,551,-1,0.9992792,0.0007208632
16455,aspirin,20,21,126,133,"In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.",8701950_2,0,-1,0,16455,-1,0.99903476,0.0009652371
9807,phenylephrine,26,27,123,136,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,0,-1,0,9807,-1,0.9992493,0.00075069664
16772,oral contraceptives,16,18,76,95,A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking oral contraceptives.,891050_1,0,-1,0,16772,-1,0.99870193,0.0012980446
2103,mannitol,3,4,26,34,Intravenous hydration and mannitol was administered before and after cisplatin.,11745184_9,0,-1,0,2103,-1,0.9989575,0.0010424863
13501,azathioprine,9,10,60,72,Liver biopsies should be undertaken at regular intervals if azathioprine therapy is continued so that structural liver damage may be detected at an early and reversible stage.,4812392_4,0,-1,0,13501,-1,0.9990606,0.0009394166
11204,magnesium,2,3,10,19,"The serum magnesium concentration was 3.0 mEq/L, which is usually well tolerated.",2385256_2,0,-1,0,11204,-1,0.9985877,0.0014123404
15253,folinic acid,10,12,70,82,Acute confusion induced by a high-dose infusion of 5-fluorouracil and folinic acid.,7858459_0,0,-1,0,15253,-1,0.999106,0.0008939693
6930,clonidine,15,16,112,121,Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.,17263743_0,0,-1,0,6930,-1,0.9992836,0.00071635423
1953,prochlorperazine,15,16,96,112,STUDY OBJECTIVE: We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2-minute bolus or 15-minute infusion.,11679859_1,0,-1,0,1953,-1,0.99926454,0.0007353979
17672,methylprednisolone,21,22,128,146,"The purpose of this randomized, double-blind, prospective study was to investigate whether intravenous (i.v.) administration of methylprednisolone (MP) prevents this complication.",9523850_3,0,-1,0,17672,-1,0.99918693,0.0008130326
9223,scopolamine,9,10,64,75,Components of lemon essential oil attenuate dementia induced by scopolamine.,19356307_0,0,-1,0,9223,-1,0.99931645,0.0006834991
10302,cocaine,9,10,57,64,"NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.",20477932_4,0,-1,0,10302,-1,0.99916685,0.00083315844
1516,Diltiazem,0,1,0,9,"Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).",11282081_9,0,-1,0,1516,-1,0.99910766,0.00089230645
1177,cisplatin,25,26,112,121,"After 154 courses of therapy, the median dose intensity was 131 mg/m(2) for paclitaxel (97.3%), 117 mg/m(2) for cisplatin (97.3%), and 1378 mg/m(2) for gemcitabine (86.2%).",11135224_9,0,-1,0,1177,-1,0.998645,0.0013550584
17318,dopamine,4,5,24,32,The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.,9270571_1,0,-1,0,17318,-1,0.998841,0.0011590929
10331,cisplatin,8,9,56,65,"Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.",20510337_6,0,-1,0,10331,-1,0.99916935,0.00083061977
6989,Dobutamine,0,1,0,10,Dobutamine infusion at 10 micrograms/kg per min was discontinued after six studies secondary to a 50% incidence rate of adverse symptoms.,1732369_6,0,-1,0,6989,-1,0.99934846,0.0006515234
6741,sirolimus,6,7,32,41,"It has also been suggested that sirolimus directly causes increased glomerular permeability/injury, but evidence for this mechanism is currently inconclusive.",17147461_8,0,-1,0,6741,-1,0.99902225,0.0009777434
16005,ciprofloxacin,3,4,31,44,Nephrotoxicity associated with ciprofloxacin is uncommon.,8494478_1,0,-1,0,16005,-1,0.99833053,0.0016694965
11702,nitroprusside,8,9,55,68,It was concluded that labetalol offers advantages over nitroprusside.,2696505_6,0,-1,0,11702,-1,0.99929595,0.0007039845
1908,rapamycin,11,12,86,95,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,0,-1,0,1908,-1,0.99888676,0.0011132975
5268,succinylcholine,17,18,81,96,"Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.",15893386_3,0,-1,0,5268,-1,0.9991335,0.0008664969
10015,cocaine,18,19,140,147,"CONCLUSIONS: Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.",20080983_11,0,-1,0,10015,-1,0.99914074,0.0008592583
2841,carbachol,5,6,36,45,"Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of tremor and clonus were recorded and converted to threshold dose.",12198388_4,0,-1,0,2841,-1,0.99934787,0.0006521004
916,cyclosporine,13,14,79,91,The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.,11007689_1,0,-1,0,916,-1,0.99918765,0.00081230665
1345,cyclophosphamide,28,29,204,220,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,0,-1,0,1345,-1,0.99910384,0.0008961748
1454,tacrolimus,5,6,34,44,The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.,11263551_7,0,-1,0,1454,-1,0.9992636,0.0007364577
13412,indomethacin,24,25,136,148,"We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.",4071154_1,0,-1,0,13412,-1,0.99900526,0.0009947267
2672,morphine,10,11,73,81,"The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that metamizol did not potentiate morphine-induced constipation.",12063090_9,0,-1,0,2672,-1,0.99919623,0.0008037523
2619,reserpine,48,49,272,281,"Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.",11999899_10,0,-1,0,2619,-1,0.9992685,0.0007315703
1328,cyclophosphamide,44,45,241,257,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,0,-1,0,1328,-1,0.9989459,0.0010540807
10963,clonidine,6,7,49,58,Naloxone reverses the antihypertensive effect of clonidine.,227508_0,0,-1,0,10963,-1,0.9992982,0.00070182764
15821,didanosine,5,6,43,53,Adverse reactions possibly attributable to didanosine were common.,8387218_7,0,-1,0,15821,-1,0.99898094,0.001018977
11631,11-deoxycortisol,9,10,55,71,"In patient 1, plasma levels of deoxycorticosterone and 11-deoxycortisol were elevated.",2632720_3,0,-1,0,11631,-1,0.9983851,0.0016149008
9902,azidothymidine,8,9,66,80,Sensitivity of erythroid progenitor colonies to erythropoietin in azidothymidine treated immunodeficient mice.,2004015_0,0,-1,0,9902,-1,0.9991968,0.0008031835
7649,alcohol,27,28,157,164,CASE REPORT: We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3-5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol/day.,18004067_2,0,-1,0,7649,-1,0.9991308,0.00086928625
14644,Indomethacin,0,1,0,12,Indomethacin was first given four weeks prior to the onset of symptoms.,7263204_3,0,-1,0,14644,-1,0.9988556,0.0011444538
4196,oxygen,1,2,11,17,Hyperbaric oxygen therapy for control of intractable cyclophosphamide-induced hemorrhagic cystitis.,1468485_0,0,-1,0,4196,-1,0.9986339,0.0013661148
2786,heparin,1,2,21,28,Low-molecular-weight heparin for the treatment of patients with mechanical heart valves.,12109865_0,0,-1,0,2786,-1,0.99806184,0.0019382024
13925,MESNA,13,14,114,119,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,0,-1,0,13925,-1,0.9989785,0.0010215831
10590,curcumin,4,5,24,32,These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.,20667451_12,0,-1,0,10590,-1,0.9991309,0.00086914876
8305,lamivudine,23,24,150,160,Comparison of the mean ALT values revealed significantly higher mean alanine aminotransferase (ALT) values in the control group than the prophylactic lamivudine group; 154:64 (p < 0.32).,18464113_13,0,-1,0,8305,-1,0.9992237,0.0007762353
1194,serotonin,17,18,114,123,"In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.",11147747_4,0,-1,0,1194,-1,0.9988256,0.0011743528
14570,lidocaine,20,21,101,110,"The CD50 and LD50, respectively, were 57.7 and 58.7 mg/kg for bupivacaine, 111.0 and 133.1 mg/kg for lidocaine, and 243.4 and 266.5 mg/kg for chloroprocaine.",7189975_2,0,-1,0,14570,-1,0.9991365,0.0008635676
3168,dexamethasone,4,5,31,44,"Offspring of rats administered dexamethasone on days 15 and 16 gestation had a 20% reduction in glomerular number compared with control at 6 to 9 months of age (22 527+/-509 versus 28 050+/-561, P<0.05), which was comparable to the percent reduction in glomeruli measured at 3 weeks of age.",12574103_4,0,-1,0,3168,-1,0.9989718,0.0010281864
4437,pyridoxine,14,15,84,94,The patient has been followed for six years and has required pharmacologic doses of pyridoxine to control her behavior.,150790_8,0,-1,0,4437,-1,0.9992186,0.0007814239
2549,antidepressant,4,5,26,40,Bupropion is a monocyclic antidepressant structurally related to amphetamine.,11928786_1,0,-1,0,2549,-1,0.9983291,0.0016708648
7473,Estrogen,0,1,0,8,Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir.,17879945_0,0,-1,0,7473,-1,0.99899584,0.0010042001
9589,catecholamines,3,4,20,34,"Increasing doses of catecholamines, sedatives, and muscle relaxants administered through a central venous catheter were ineffective.",19843802_2,0,-1,0,9589,-1,0.99869883,0.0013011005
9363,ecstasy,19,20,136,143,These ecstasy-specific effects may be related to the vulnerability of isocortical and allocortical regions to the neurotoxic effects of ecstasy.,19631624_12,0,-1,0,9363,-1,0.99912506,0.00087495946
17032,fluoxetine,11,12,60,70,OBJECTIVE: The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis.,9098464_1,0,-1,0,17032,-1,0.999175,0.00082494895
3900,prazosin,18,19,131,139,"Furthermore, the bradycardia that accompanied the noradrenaline-induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47-71% reduction of the pressor effect in chronic alpha 1-receptor blocked SHR.(ABSTRACT TRUNCATED AT 400 WORDS)",1355091_13,0,-1,0,3900,-1,0.9992143,0.0007857124
5204,tacrolimus,7,8,49,59,"Other causes include drug-related (cyclosporine, tacrolimus) toxicity, procoagulant status, and antibody-mediated rejection.",15859940_11,0,-1,0,5204,-1,0.9990563,0.000943701
18293,hexamethonium,22,23,141,154,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,0,-1,0,18293,-1,0.99932027,0.0006797606
14934,simvastatin,3,4,21,32,"While lovastatin and simvastatin have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity.",7604176_8,0,-1,0,14934,-1,0.99915266,0.00084732554
13823,caffeine,4,5,18,26,"In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).",6308277_5,0,-1,0,13823,-1,0.9992781,0.00072186504
14560,haloperidol,10,11,60,71,The incidence of parkinsonism was higher at higher doses of haloperidol and in younger patients.,7161250_2,0,-1,0,14560,-1,0.9992719,0.0007280619
8112,amikacin,23,24,188,196,Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin.,18356633_4,0,-1,0,8112,-1,0.99933344,0.0006665893
3174,dexamethasone,5,6,33,46,"Male rats that received prenatal dexamethasone on days 15 and 16, 17 and 18, and 13 and 14 of gestation had elevated blood pressures at 6 months of age; the latter group did not have a reduction in glomerular number.",12574103_6,0,-1,0,3174,-1,0.9990451,0.000954885
1130,Metoprolol,0,1,0,10,Metoprolol plus glucagon also reduced the maximum heart rate 29% versus control.,11079278_9,0,-1,0,1130,-1,0.9992131,0.0007868457
13228,creatinine,11,12,61,71,"Variables evaluated included patient weight, age, sex, serum creatinine level, creatinine clearance, duration of therapy, total dose, mean daily dose, organism minimum inhibitory concentration (MIC), mean peak levels, mean trough levels, mean area under the serum concentration-time curve (AUC), total AUC, mean AUC greater than MIC, total AUC greater than MIC, mean Schumacher's intensity factor (IF), total IF, In (mean maximum concentration [Cmax]/MIC).",3950060_3,0,-1,0,13228,-1,0.9982529,0.001747069
9459,levofloxacin,17,18,103,115,"PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures.",19707748_1,0,-1,0,9459,-1,0.99921966,0.00078034675
13646,cimetidine,34,35,189,199,"However, ranitidine was threefold more potent than cimetidine both in acute inhibition studies and in the median maintenance dose needed (1.2 g per day for ranitidine and 3.6 g per day for cimetidine).",6150641_5,0,-1,0,13646,-1,0.99926883,0.0007312138
5197,tacrolimus,16,17,92,102,"Three cases were related to cyclosporine, and 1 case was secondary to both cyclosporine and tacrolimus.",15859940_8,0,-1,0,5197,-1,0.99906,0.0009399994
9493,pilocarpine,19,20,171,182,"Moreover, M(3)-muscarinic acetylcholine receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine.",19721134_5,0,-1,0,9493,-1,0.99938464,0.00061536045
13866,verapamil,11,12,66,75,Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept.,6323692_6,0,-1,0,13866,-1,0.99926,0.0007399917
13043,chloroquine,16,17,113,124,We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_1,0,-1,0,13043,-1,0.99933076,0.0006692337
7820,amphetamine,21,22,134,145,Reverse or inverted left ventricular apical ballooning syndrome (reverse Takotsubo cardiomyopathy) in a young woman in the setting of amphetamine use.,18177388_0,0,-1,0,7820,-1,0.999278,0.00072199444
7119,phenobarbital,8,9,62,75,Experiments with systemic administration of the Pgp substrate phenobarbital and the selective Pgp inhibitor tariquidar in TR(-) rats substantiated that Pgp is functional and compensates for the lack of MRP2 in the BBB.,17437408_11,0,-1,0,7119,-1,0.99927396,0.0007260702
3636,lindane,22,23,150,157,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,0,-1,0,3636,-1,0.99907875,0.00092125015
4100,dexamethasone,15,16,80,93,"One, two or three doses of mesna were replaced with dexamethasone alone or with dexamethasone plus mesna.",14633084_4,0,-1,0,4100,-1,0.9990024,0.0009976365
12333,alfentanil,7,8,58,68,"Following instrumentation, halothane was discontinued and alfentanil (125 mu/kg) administered iv during emergence from halothane anesthesia.",3125768_4,0,-1,0,12333,-1,0.9992397,0.0007603402
498,Warfarin,5,6,27,35,Treatment for 2 weeks with Warfarin caused massive focal calcification of the artery media in 20-day-old rats and less extensive focal calcification in 42-day-old rats.,10669626_2,0,-1,0,498,-1,0.9989046,0.0010954484
4731,serotonin,25,26,168,177,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,0,-1,0,4731,-1,0.9987993,0.0012007025
12299,alfentanil,36,37,214,224,"Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.",3115150_5,0,-1,0,12299,-1,0.999265,0.0007349422
8693,urea,8,9,47,51,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).",18768591_8,0,-1,0,8693,-1,0.9985775,0.0014225352
11402,nitroglycerin,7,8,45,58,Early onset migraine attacks were induced by nitroglycerin in seven out of 10 patients versus no patient in the placebo group.,2515254_1,0,-1,0,11402,-1,0.9991658,0.0008342138
3081,bupropion,6,7,31,40,He received a 10-day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation.,12549952_3,0,-1,0,3081,-1,0.9992719,0.00072812126
12230,ketoconazole,4,5,34,46,Hepatic reactions associated with ketoconazole in the United Kingdom.,3101906_0,0,-1,0,12230,-1,0.9991726,0.0008273279
9590,epinephrine,5,6,20,31,"However, a bolus of epinephrine injected through an alternative catheter provoked a hypertensive crisis.",19843802_3,0,-1,0,9590,-1,0.9987079,0.0012921201
6098,cinacalcet,46,47,266,276,"METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).",16680561_3,0,-1,0,6098,-1,0.9992274,0.00077255955
8369,methylprednisolone,17,18,105,123,"Symptoms persisted for three months despite TAC dose reduction, administration of IVIG and four doses of methylprednisolone pulse therapy.",18503483_6,0,-1,0,8369,-1,0.99917465,0.0008253177
3783,Ciprofloxacin,0,1,0,13,Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia.,12911170_1,0,-1,0,3783,-1,0.9986345,0.0013654754
11648,angiotensin,11,12,50,61,"Injection of Captopril (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both pulmonary and renal insufficiency in this rat model.",2670794_2,0,-1,0,11648,-1,0.9988587,0.0011413292
8406,sevoflurane,23,24,139,150,METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.,18544179_3,0,-1,0,8406,-1,0.9991798,0.00082015636
7155,methylprednisolone,19,20,66,84,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,0,-1,0,7155,-1,0.9992507,0.00074931764
9303,paclitaxel,10,11,90,100,Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.,19473225_0,0,-1,0,9303,-1,0.99862444,0.0013755274
10364,haloperidol,35,36,204,215,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,0,-1,0,10364,-1,0.99929905,0.000700956
2119,desogestrel,17,18,107,118,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,0,-1,0,2119,-1,0.9992576,0.00074237597
12500,sodium,9,10,69,75,Systolic pressure variation is greater during hemorrhage than during sodium nitroprusside-induced hypotension in ventilated dogs.,3341566_0,0,-1,0,12500,-1,0.99902105,0.0009789655
5838,acetylcholine,20,21,139,152,"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).",16428827_1,0,-1,0,5838,-1,0.9987458,0.0012541476
12821,sulindac,20,21,106,114,We describe 4 patients in whom hyperkalemia ranging from 6.1 to 6.9 mEq/l developed within 3 to 8 days of sulindac administration.,3560096_3,0,-1,0,12821,-1,0.99928683,0.0007131987
8436,sevoflurane,33,34,234,245,"CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.",18544179_11,0,-1,0,8436,-1,0.999127,0.0008730232
3776,methylphenidate,14,15,100,115,An 82-year-old man with treatment-resistant depression and early Alzheimer's disease was started on methylphenidate.,12907924_1,0,-1,0,3776,-1,0.9993443,0.0006556532
11756,ketamine,19,20,114,122,"Latency to the loss of righting reflex, rigidity and behavior on recovery, reflected the relative predominance of ketamine or morphine in each combination.",2716967_5,0,-1,0,11756,-1,0.99911124,0.00088879105
6178,norepinephrine,2,3,15,29,Alterations of norepinephrine transporter (NET) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice.,16725121_1,0,-1,0,6178,-1,0.99891186,0.0010882025
471,serotonin,17,18,90,99,"NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM).",10579464_3,0,-1,0,471,-1,0.9988739,0.0011260406
1166,cisplatin,22,23,116,125,"METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.",11135224_3,0,-1,0,1166,-1,0.99871004,0.001289924
2830,theophylline,9,10,58,70,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,0,-1,0,2830,-1,0.99928755,0.00071246433
12384,Verapamil,0,1,0,9,Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram.,3173179_0,0,-1,0,12384,-1,0.99932194,0.00067808025
6501,Mannitol,0,1,0,8,"Mannitol concentrations were measured in plasma and white matter by a modified version of the enzyme assay of Blonquist et al. RESULTS: In most glioma patients, mannitol concentrations in white matter were 2 to 6 times higher than in plasma (mean 3.5 times).",17019386_8,0,-1,0,6501,-1,0.99909353,0.0009064776
2477,Nicotine,0,1,0,8,Nicotine potentiation of morphine-induced catalepsy in mice.,11900788_0,0,-1,0,2477,-1,0.9989569,0.0010430723
13345,warfarin,10,11,52,60,We present the case of a 28-year-old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip.,3985451_1,0,-1,0,13345,-1,0.99897003,0.0010299294
18033,carbamazepine,8,9,61,74,This 22-year-old epileptic woman was treated continuously by carbamazepine and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.,9758264_5,0,-1,0,18033,-1,0.99934036,0.0006596004
14886,paramethasone,5,6,37,50,Two patients treated with parenteral paramethasone (Triniol) and dexamethasone (Sedionbel) are described.,7582165_1,0,-1,0,14886,-1,0.9984297,0.0015702853
6618,Dex,10,11,78,81,"Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).",17042910_12,0,-1,0,6618,-1,0.9989341,0.001065931
4942,ribavirin,9,10,48,57,"With respect to hemoglobin level at the time of ribavirin reduction, a rate of continuation of therapy in patients with > or =10 g/dl hemoglobin was higher than that in patients with <10 g/dl ( P = 0.036).",15580403_9,0,-1,0,4942,-1,0.9992625,0.0007374254
16813,Epinephrine,0,1,0,11,"Epinephrine has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution.",8953972_4,0,-1,0,16813,-1,0.9988257,0.0011742434
13900,amitriptyline,16,17,104,117,Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients.,6386793_6,0,-1,0,13900,-1,0.9993481,0.0006519147
11668,cocaine,2,3,16,23,"Stroke followed cocaine use by inhalation, intranasal, intravenous, and intramuscular routes.",2673163_3,0,-1,0,11668,-1,0.99888295,0.0011170236
1999,paracetamol,12,13,76,87,"Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.",11694026_8,0,-1,0,1999,-1,0.9992336,0.0007664005
9501,oxycodone,17,18,112,121,"Seventy-one participants completed 2 separate study days and were blind to medication condition (placebo, 10-mg oxycodone).",19729346_2,0,-1,0,9501,-1,0.9993011,0.0006989501
617,isoproterenol,31,32,180,193,"It has been shown that bromocriptine-induced tachycardia, which persisted after adrenalectomy, is (i) mediated by central dopamine D2 receptor activation and (ii) reduced by 5-day isoproterenol pretreatment, supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart.",10721819_1,0,-1,0,617,-1,0.99931335,0.000686665
15161,alprazolam,20,21,123,133,METHOD: In London and Toronto 154 patients who met DSM-III criteria for panic disorder with agoraphobia were randomised to alprazolam or placebo.,7802851_4,0,-1,0,15161,-1,0.9992291,0.00077087915
9662,tacrolimus,5,6,45,55,Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient: case report.,19917396_0,0,-1,0,9662,-1,0.9990753,0.0009247278
932,cyclosporine,5,6,31,43,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,0,-1,0,932,-1,0.99920124,0.0007987287
3383,ticlopidine,12,13,68,79,This complication will be observed even less often in the future as ticlopidine is being replaced by the newer antiplatelet agent clopidogrel.,12639165_12,0,-1,0,3383,-1,0.99915457,0.0008453775
12824,potassium,8,9,46,55,"As no other medications known to effect serum potassium had been given concomitantly, this course of events is suggestive of a cause-and-effect relationship between sulindac and hyperkalemia.",3560096_5,0,-1,0,12824,-1,0.99839157,0.0016084588
10392,etoposide,14,15,54,63,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,0,-1,0,10392,-1,0.9990497,0.0009502713
14253,gentamicin,5,6,27,37,"To quantify the effects of gentamicin, kanamycin and netilmicin on renal protein reabsorption and accumulation, these drugs were administered to rats intraperitoneally (30 mg/kg/day) for 7, 14 or 21 days.",6728084_1,0,-1,0,14253,-1,0.9991704,0.0008295987
13226,amikacin,6,7,35,43,Data from 60 patients treated with amikacin were analyzed for factors associated with nephrotoxicity.,3950060_1,0,-1,0,13226,-1,0.99933654,0.000663477
14198,aspirin,32,33,164,171,An autoradiographic study was performed on male F-344 rats fed diet containing FANFT at a level of 0.2% and/or aspirin at a level of 0.5% to evaluate the effect of aspirin on the increased cell proliferation induced by FANFT in the forestomach and bladder.,6692345_2,0,-1,0,14198,-1,0.9990397,0.00096030947
5570,calcium,11,12,71,78,Twenty-five women were given raloxifene hydrochloride (60 mg/day) plus calcium (500 mg/day).,16167916_2,0,-1,0,5570,-1,0.9990707,0.00092932343
14994,enflurane,8,9,63,72,This study was performed to determine cross-reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane.,7647582_4,0,-1,0,14994,-1,0.99917185,0.00082819123
9059,naloxone,3,4,22,30,The opioid antagonist naloxone has been shown to block or reverse the hypotensive actions of captopril.,1928887_2,0,-1,0,9059,-1,0.99933475,0.00066517334
18098,haloperidol,16,17,89,100,"METHOD: In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), haloperidol, 2-3 mg/day (standard dose), and haloperidol, 0.50-0.75 mg/day (low dose), were compared in 71 outpatients with Alzheimer's disease.",9812111_2,0,-1,0,18098,-1,0.99926084,0.0007391044
16344,steroid,48,49,279,286,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,0,-1,0,16344,-1,0.99854195,0.0014580993
3749,dopamine,20,21,150,158,"Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.",12907309_0,0,-1,0,3749,-1,0.9990416,0.0009583351
14792,amiloride,6,7,32,41,"6 h after the administration of amiloride, a reduction was observed in the lithium content of the renal medulla but not in the other organs studied.",7453952_3,0,-1,0,14792,-1,0.9993955,0.00060455356
14966,zidovudine,20,21,129,139,"A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression.",7628595_1,0,-1,0,14966,-1,0.9992518,0.00074823905
13658,ranitidine,8,9,33,43,"Both are safe at high doses, but ranitidine is threefold more potent and does not cause the antiandrogen side effects frequently seen with high doses of cimetidine.",6150641_9,0,-1,0,13658,-1,0.99931407,0.0006858795
7483,ritonavir,27,28,183,192,"In the present study, we have investigated the molecular mechanisms by which female hormones influence cholesterol metabolism in macrophages in response to the HIV protease inhibitor ritonavir.",17879945_5,0,-1,0,7483,-1,0.9992575,0.000742476
6161,diazepam,5,6,39,47,The patient received bromocriptine and diazepam to treat his symptoms.,16720068_6,0,-1,0,6161,-1,0.99923825,0.000761778
1058,creatinine,18,19,113,123,RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].,11063349_6,0,-1,0,1058,-1,0.99798954,0.0020104656
5686,nicotine,11,12,60,68,Patients were randomized in a 1:1 ratio to receive the 4-mg nicotine lozenge or 4-mg nicotine gum.,16330293_5,0,-1,0,5686,-1,0.99904984,0.0009502062
10249,yohimbine,12,13,85,94,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,0,-1,0,10249,-1,0.99927396,0.00072610966
17727,tamoxifen,14,15,76,85,"F  d  ration Nationale des Centres de Lutte Contre le Cancer (FNCLCC).Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be carefully examined.",9579567_1,0,-1,0,17727,-1,0.998868,0.0011320582
9041,dexamethasone,24,25,109,122,"Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1.",19274460_2,0,-1,0,9041,-1,0.999186,0.0008140094
1459,cyclosporine,16,17,91,103,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,0,-1,0,1459,-1,0.99923646,0.0007636019
17663,prilocaine,11,12,63,73,"Times to ambulate and to void were similar after lidocaine and prilocaine (150 vs. 165 min and 238 vs. 253 min, respectively) but prolonged after bupivacaine (200 and 299 min, respectively; P < 0.05).",9523805_10,0,-1,0,17663,-1,0.9992004,0.00079961226
5418,azithromycin,2,3,19,31,Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups.,15985056_4,0,-1,0,5418,-1,0.99911684,0.00088314764
17622,bupivacaine,17,18,97,108,The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine.,9522143_6,0,-1,0,17622,-1,0.9993074,0.00069260376
15860,cimetidine,36,37,205,215,"In order that this syndrome might be investigated changes in mental status (M.S.) were correlated with serum concentrations and renal and hepatic function in 36 patients, 30 patients had no M.S. change on cimetidine and 6 had moderate to severe changes.",84204_1,0,-1,0,15860,-1,0.9993075,0.0006924539
15785,vincristine,27,28,186,197,"Physical and quantitative sensory examination with determination of vibratory perception and thermal discrimination thresholds were performed, four to 77 months (median 34 months) after vincristine treatment.",8384253_3,0,-1,0,15785,-1,0.99930227,0.0006977601
535,Warfarin,20,21,118,126,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,0,-1,0,535,-1,0.99902236,0.0009775845
2351,scopolamine,12,13,57,68,Both PREGS and its (-) enantiomer blocked the effects of scopolamine.,11860495_8,0,-1,0,2351,-1,0.9993629,0.0006371126
6620,Dex,17,18,106,109,"Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).",17042910_12,0,-1,0,6620,-1,0.9989316,0.0010683831
9785,Sorafenib,0,1,0,9,Sorafenib is a multikinase inhibitor that targets signaling pathways necessary for cellular proliferation and survival.,19944333_10,0,-1,0,9785,-1,0.9988826,0.0011174015
15265,5-fluorouracil,11,12,65,79,"This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given.",7858459_3,0,-1,0,15265,-1,0.9989793,0.0010206997
18130,epinephrine,2,3,13,24,"Infusions of epinephrine (4 mug per kilogram per minute for 6 hours) increased radiocalcium uptakes into intact myocardium and each of its subcellular components with the mitochondrial fraction showing the most consistent changes when compared to saline-infused control animals (4,957 vs. 827 counts per minute per gram of dried tissue or fraction).",983936_2,0,-1,0,18130,-1,0.9991215,0.0008785266
17298,nicotine,22,23,154,162,"Almost certainly, nicotine via its hemodynamic effects contributes to acute cardiovascular events, although current evidence suggests that the effects of nicotine are much less important than are the prothrombotic effects of cigarette smoking or the effects of carbon monoxide.",9245658_3,0,-1,0,17298,-1,0.99914944,0.00085053407
10202,prazosin,11,12,65,73,Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure.,2024540_0,0,-1,0,10202,-1,0.9992555,0.0007444708
3319,urea,10,11,78,82,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,0,-1,0,3319,-1,0.9985493,0.0014506709
2252,warfarin,29,30,163,171,"Subsequent treatments included alternative anticoagulants (11 patients), thrombolytic drugs (3 patients), inferior vena cava filters (3 patients) and, eventually, warfarin (11 patients).",11827497_13,0,-1,0,2252,-1,0.9985238,0.0014762748
4101,mesna,17,18,99,104,"One, two or three doses of mesna were replaced with dexamethasone alone or with dexamethasone plus mesna.",14633084_4,0,-1,0,4101,-1,0.9991009,0.000899093
16180,caffeine,6,7,34,42,"We suspect that the potential for caffeine to stabilize high resistance states in susceptible persons suggests that its use may facilitate their disease progression, as well as hinder accurate diagnosis and treatment.",8607407_11,0,-1,0,16180,-1,0.9989936,0.0010064673
8647,simvastatin,30,31,222,233,"Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.",18752389_10,0,-1,0,8647,-1,0.9992901,0.00070982595
7195,apomorphine,3,4,21,32,"Acute treatment with apomorphine caused disruption of prepulse inhibition (PPI) in controls and in rats that had undergone either maternal deprivation or corticosterone treatment, but was surprisingly absent in rats that had undergone the combined early and late stress.",17490864_3,0,-1,0,7195,-1,0.9993007,0.0006993279
2494,atropine,3,4,37,45,"Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.",11900788_5,0,-1,0,2494,-1,0.9993656,0.00063439895
11952,diazepam,3,4,30,38,Intravenous administration of diazepam (1-30 mg kg-1) produced a dose-dependent decrease in both the mean arterial pressure and the heart rate.,2894433_2,0,-1,0,11952,-1,0.99926096,0.00073905726
1464,cyclophosphamide,5,6,44,60,Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy.,11271907_0,0,-1,0,1464,-1,0.9989548,0.0010451786
8023,morphine,10,11,71,79,Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats.,18308784_0,0,-1,0,8023,-1,0.9989662,0.0010338358
4111,Dexamethasone,2,3,12,25,CONCLUSION: Dexamethasone in combination with mesna was efficient in blocking IFS-induced HC.,14633084_9,0,-1,0,4111,-1,0.99906844,0.0009316201
11551,citalopram,10,11,77,87,"The results indicate that fluvoxamine given repeatedly acts differently than citalopram, another selective serotonin uptake inhibitor, and differs also from other antidepressant drugs.",2576810_6,0,-1,0,11551,-1,0.9993272,0.00067284034
3833,Furosemide,0,1,0,10,Furosemide may be deleterious in the prevention of radiocontrast nephropathy.,1300436_8,0,-1,0,3833,-1,0.9993006,0.00069935847
11230,methyldopa,9,10,68,78,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,0,-1,0,11230,-1,0.9992804,0.000719606
16095,clonidine,9,10,74,83,Infusion of the central nervous system alpha2-adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.,8586822_6,0,-1,0,16095,-1,0.9992812,0.0007187524
17480,haloperidol,10,11,75,86,There was no significant difference between occupancy levels obtained with haloperidol or risperidone.,9351491_5,0,-1,0,17480,-1,0.99930024,0.0006997779
4747,cyclophosphamide,27,28,173,189,"In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis.",1545575_3,0,-1,0,4747,-1,0.99914646,0.0008535104
14643,indomethacin,16,17,90,102,A case of fatal aplastic anemia is described in which no drugs other than allopurinol and indomethacin were given.,7263204_2,0,-1,0,14643,-1,0.99913377,0.00086630124
7515,alcohol,3,4,10,17,"No toxin, alcohol, or other drugs were reported.",17919553_6,0,-1,0,7515,-1,0.99725527,0.0027447126
13485,metoclopramide,9,10,64,78,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,0,-1,0,13485,-1,0.9992442,0.0007557844
681,capsaicin,26,27,165,174,We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.,10743446_1,0,-1,0,681,-1,0.9992798,0.00072016375
16204,corticosteroids,11,12,73,88,Persistent paralysis after prolonged use of atracurium in the absence of corticosteroids.,8638206_0,0,-1,0,16204,-1,0.9989335,0.0010664642
10949,morphine,6,7,45,53,Facilitation of memory retrieval by pre-test morphine and its state dependency in the step-through type passive avoidance learning test in mice.,2273650_0,0,-1,0,10949,-1,0.9989317,0.0010682782
2104,cisplatin,9,10,69,78,Intravenous hydration and mannitol was administered before and after cisplatin.,11745184_9,0,-1,0,2104,-1,0.9987864,0.0012136381
17183,dopamine,34,35,281,289,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,0,-1,0,17183,-1,0.9988746,0.0011253549
1524,diltiazem,3,4,22,31,Neither verapamil nor diltiazem affected atrial conduction in the presence of autonomic blockade.,11282081_11,0,-1,0,1524,-1,0.9990669,0.00093313516
5563,pentobarbital,10,11,65,78,Differences in the parameters of training under the influence of pentobarbital between Groups 1 and 2 were revealed.,1616457_6,0,-1,0,5563,-1,0.99909246,0.0009075449
3159,dexamethasone,1,2,9,22,Prenatal dexamethasone programs hypertension and renal injury in the rat.,12574103_0,0,-1,0,3159,-1,0.9990338,0.0009662281
11369,amantadine,27,28,172,182,"The locomotor activity was decreased from corresponding controls in all strains studied, except for the ICR mice, during an overnight drug-free period following the fourth amantadine treatment.",2484011_6,0,-1,0,11369,-1,0.9993036,0.00069644273
6906,carbachol,3,4,22,31,"While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response, isoprenaline-induced relaxations were smaller in inflamed strips.",17244258_10,0,-1,0,6906,-1,0.9993413,0.00065861613
705,tacrolimus,2,3,17,27,"We characterized tacrolimus side effects that warranted discontinuation of the drug, and outcomes after conversion.",10743694_2,0,-1,0,705,-1,0.9990495,0.00095046463
5663,chloroquine,15,16,106,117,The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation.,1628552_3,0,-1,0,5663,-1,0.99929965,0.00070035603
5363,propofol,20,21,127,135,"OBJECTIVES: To assess patients' ability to repeat and recall words presented to them while undergoing procedural sedation with propofol, and correlate their recall with their level of awareness as measured by bispectral index (BIS) monitoring.",15930398_1,0,-1,0,5363,-1,0.998611,0.0013889425
7257,iodixanol,18,19,110,119,"METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.",17562951_2,0,-1,0,7257,-1,0.99927336,0.0007266988
3324,creatinine,13,14,96,106,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,0,-1,0,3324,-1,0.99879056,0.001209452
5731,oxygen,10,11,65,71,"There were no significant differences in renal sodium excretion, oxygen consumption, or urinary flow rates in kidneys perfused with suprofen compared with the drug-free control groups.",1636026_3,0,-1,0,5731,-1,0.9983443,0.0016557139
2406,spironolactone,23,24,144,158,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,0,-1,0,2406,-1,0.999183,0.0008169424
3991,glutamate,22,23,178,187,"LY274614, 3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3- carboxylic acid, has been described as a potent antagonist of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor.",1436384_1,0,-1,0,3991,-1,0.99836415,0.0016359092
4535,isoproterenol,16,17,94,107,The results show that pretreatment with TCR may be useful in preventing the damage induced by isoproterenol in rat heart.,15233872_6,0,-1,0,4535,-1,0.99927074,0.0007293021
4116,dexamethasone,19,20,95,108,"However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC.",14633084_10,0,-1,0,4116,-1,0.99907315,0.00092685147
17974,tacrolimus,10,11,64,74,"Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.",9721172_5,0,-1,0,17974,-1,0.99927586,0.0007242051
10263,tacrolimus,5,6,47,57,Rosaceiform dermatitis associated with topical tacrolimus treatment.,20466178_0,0,-1,0,10263,-1,0.9990356,0.0009644759
9021,Pain,0,1,0,4,"Pain rating was performed using a computerized visual analogue scale (0-100) digitized at 1/s, either immediately online or one hour or one day after injection.",19269743_4,-1,1,1,9021,-1,0.0028335168,0.99716645
7033,Syncope,0,1,0,7,Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.,17344330_0,-1,1,1,7033,-1,0.0012469178,0.9987531
147,neurotoxicity,7,8,29,42,"In the other 3 cases, direct neurotoxicity was also probable, but unfortunately radiological investigations were not done to definitely exclude a compressive aetiology.",10225068_5,-1,1,1,147,-1,0.0015737833,0.9984262
17515,aplastic anemia,1,3,20,35,Ticlopidine-induced aplastic anemia: report of three Chinese patients and review of the literature.,9401499_0,-1,1,1,17515,-1,0.0010618728,0.99893814
4637,convulsive,1,2,4,14,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,-1,1,1,4637,-1,0.001590851,0.9984092
1473,cardiotoxicity,25,26,159,173,We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.,11279304_3,-1,1,1,1473,-1,0.0010487684,0.9989512
3363,prostate cancer,12,14,73,88,CONCLUSION: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE.,12627929_8,-1,1,1,3363,-1,0.0018147134,0.9981852
8013,proteinuria,23,24,134,145,"Patients without proteinuria had increased renal function (median 42.5 vs. 64.1, p = 0.25), whereas patients who developed high-grade proteinuria showed decreased renal function at the end of follow-up (median 39.6 vs. 29.2, p = 0.125).",18261172_9,-1,1,1,8013,-1,0.0016193613,0.99838066
1668,manic,4,5,27,32,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,1,1,1668,-1,0.0026476837,0.99735236
10790,apnea,17,18,103,108,"We determined the BChE activity and the BCHE genotype using molecular genetic methods, the duration of apnea, time to sufficient spontaneous ventilation and whether neuromuscular monitoring was used.",21029050_5,-1,1,1,10790,-1,0.0014952774,0.99850476
3632,convulsions,63,64,384,395,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,-1,1,1,3632,-1,0.0013766387,0.9986234
7266,diabetes,3,4,17,25,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,-1,1,1,7266,-1,0.0021901627,0.9978098
12449,locomotor hyperactivity,8,10,65,88,"These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.",3220106_8,-1,1,1,12449,-1,0.0021826199,0.9978174
12963,coma,8,9,51,55,"Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.",3703509_3,-1,1,1,12963,-1,0.0013366174,0.9986634
13761,milk fever,31,33,173,183,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,1,1,13761,-1,0.0024781595,0.9975218
15079,proteinuria,6,7,28,39,Free NP did not provoke any proteinuria.,7724492_4,-1,1,1,15079,-1,0.001567117,0.9984328
15390,acidosis,3,4,24,32,Hepatic dysfunction and acidosis are contributing risk factors.,7910951_9,-1,1,1,15390,-1,0.0013951561,0.99860483
13410,ascites,18,19,103,110,"We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.",4071154_1,-1,1,1,13410,-1,0.001289165,0.9987109
13763,milk fever,46,48,252,262,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,1,1,13763,-1,0.0027479304,0.99725205
2435,exencephaly,3,4,16,27,"We observed the exencephaly induced by 5-azacytidine at embryonic day 13.5 (E13.5), let the embryos develop exo utero until E18.5, and re-observed the same embryos at E18.5.",11875660_3,-1,1,1,2435,-1,0.0021361469,0.9978638
7999,proteinuria,7,8,45,56,"In cardiac transplantation, the incidence of proteinuria associated with Srl is unknown.",18261172_3,-1,1,1,7999,-1,0.0013682527,0.9986318
14855,Nephrotoxicity,0,1,0,14,Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.,7542793_0,-1,1,1,14855,-1,0.0014326362,0.99856734
15809,toxicity,3,4,12,20,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,-1,1,1,15809,-1,0.0018106849,0.9981893
11911,prolactinoma,20,21,148,160,"Electron microscopy disclosed many secretory granules, slightly distorted rough endoplasmic reticulum, and partially dilated Golgi cisternae in the prolactinoma cells.",2887062_3,-1,1,1,11911,-1,0.21754926,0.78245074
9453,hypotension,22,23,156,167,Sodium nitroprusside is a non-selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced hypotension.,1969772_8,-1,1,1,9453,-1,0.0012043127,0.9987956
15591,hypotension,24,25,174,185,"Nitroglycerin has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse nitroglycerin-induced hypotension.",809711_1,-1,1,1,15591,-1,0.0011150546,0.998885
2430,exencephaly,3,4,27,38,Sequential observations of exencephaly and subsequent morphological changes by mouse exo utero development system: analysis of the mechanism of transformation from exencephaly to anencephaly.,11875660_0,-1,1,1,2430,-1,0.0019960513,0.9980039
14370,hypertension,5,6,44,56,Intrarenal infusion of noradrenaline caused hypertension at doses which did not do so when infused intravenously.,6861444_2,-1,1,1,14370,-1,0.0012950907,0.9987049
14786,polyuria,8,9,58,66,"The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.",7453952_1,-1,1,1,14786,-1,0.0014092964,0.99859065
2318,seizures,15,16,94,102,Excitotoxicity leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level.,11860278_2,-1,1,1,2318,-1,0.001221836,0.99877816
9871,coagulopathy,32,33,230,242,CONCLUSIONS: Correlation of plasma argatroban concentration versus the patient's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient's extended coagulopathy.,20003049_6,-1,1,1,9871,-1,0.0012405963,0.9987594
13474,fasciculation,18,19,88,101,Fasciculations in six areas of the body were scored from 0 to 3 and summated as a total fasciculation score.,435349_6,-1,1,1,13474,-1,0.0033799745,0.99662006
14351,amnesia,92,93,537,544,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,1,1,14351,-1,0.0017384628,0.9982615
3028,toxicity,17,18,100,108,"Generally, carboplatin is said to have milder side effects than cisplatin, whose ocular and orbital toxicity are well known.",12483326_4,-1,1,1,3028,-1,0.0013895194,0.9986105
2554,overdose,11,12,52,60,"In the initial 6 months since it's introduction, 12 overdose cases have been reported to The National Poisons Information Centre.",11928786_3,-1,1,1,2554,-1,0.0025991474,0.9974009
3903,hyperactivity,2,3,21,34,The morphine-induced hyperactivity was potentiated by scopolamine and attenuated by physostigmine.,137340_3,-1,1,1,3903,-1,0.0014073411,0.9985927
9195,proteinuria,2,3,23,34,Clinically significant proteinuria following the administration of sirolimus to renal transplant recipients.,19356053_0,-1,1,1,9195,-1,0.0013506705,0.9986493
10342,cholestasis,22,23,151,162,"A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.",2051906_2,-1,1,1,10342,-1,0.0011225053,0.99887747
8064,hyperactivity,8,9,64,77,"Pretreatment with the D2 agonist PHNO enhanced nicotine-induced hyperactivity, whereas the D1 agonist SKF 38393 had no effect.",1833784_8,-1,1,1,8064,-1,0.0014238022,0.99857616
12386,hypertensive,11,12,71,83,Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram.,3173179_0,-1,1,1,12386,-1,0.0024222063,0.99757785
8638,hepatotoxicity,19,20,119,133,The patient's lipid panel had been maintained with simvastatin for 18 months before the conversion without evidence of hepatotoxicity.,18752389_4,-1,1,1,8638,-1,0.0013339327,0.99866605
14155,ataxia,9,10,61,67,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,1,1,14155,-1,0.0012347986,0.99876523
11023,anuria,20,21,139,145,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,-1,1,1,11023,-1,0.0014204996,0.9985795
11167,death,2,3,10,15,"Causes of death, with special reference to cerebral haemorrhage, among 240 patients with pathologically verified Parkinson's disease were investigated using the Annuals of the Pathological Autopsy Cases in Japan from 1981 to 1985.",2355241_1,-1,1,1,11167,-1,0.0019715098,0.99802846
9004,dyskinesias,56,57,262,273,"Ten consecutive patients (mean age, 58.4 +/- 6.8 years; 7 men, 3 women) with similar characteristics at the duration of disease (mean disease time, 8.4 +/- 3.5 years), disabling motor fluctuations (Hoehn _ Yahr stage 3-5 in off-drug phases) and levodopa-induced dyskinesias were selected.",19234905_2,-1,1,1,9004,-1,0.0010805624,0.9989195
13663,seizures,15,16,103,111,"In one patient, enflurane administered during a donor nephrectomy resulted in unexpected partial motor seizures.",6153967_2,-1,1,1,13663,-1,0.0013376296,0.99866235
8299,hepatitis,17,18,65,74,"Of our control group (n= 50), 21 patients (42%) were established hepatitis.",18464113_10,-1,1,1,8299,-1,0.0015734243,0.99842656
13691,cardiac hypertrophy,3,5,19,38,The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).,6203632_1,-1,1,1,13691,-1,0.0021614134,0.99783856
12312,amnesia,18,19,97,104,"The patient's subjective assessment of mood rating, an objective test of performance, a test for amnesia, and vital signs were recorded for up to 300 min after administration of the trial drug.",3120485_5,-1,1,1,12312,-1,0.0015335763,0.9984665
17555,dyskinesia,26,27,146,156,"Since glyceryl trinitrate is able to overcome even the drastic effect of morphine, it might be of relevance in the treatment of sphincter of Oddi dyskinesia.",9431903_7,-1,1,1,17555,-1,0.0012882113,0.9987118
3790,interstitial nephritis,3,5,21,43,"Unfortunately, acute interstitial nephritis was irreversible and the patient developed end-stage renal disease.",12911170_5,-1,1,1,3790,-1,0.001085177,0.99891484
14513,nephrotic,12,13,78,87,"In the pre-nephrotic stage lipoproteinuria was negligible, while in the early nephrotic stage the urinary loss of plasma lipoproteins consisted mainly of HDL.",7066357_10,-1,1,1,14513,-1,0.0023553162,0.9976447
189,hypothyroidism,13,14,96,110,All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).,10354657_9,-1,1,1,189,-1,0.0012351472,0.9987649
6668,hypertension,6,7,40,52,"Past medical history was remarkable for hypertension, hyperlipidemia, and depression.",17111419_3,-1,1,1,6668,-1,0.0012931617,0.9987068
2808,cardiac arrest,18,20,128,142,Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.,12139551_0,-1,1,1,2808,-1,0.0012938239,0.9987062
2448,exencephalic,35,36,227,239,"Microscopic observation showed the configuration of exencephaly at E13.5, frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15.5, and multiple modes of reduction in the exencephalic tissue at E18.5.",11875660_8,-1,1,1,2448,-1,0.0053425967,0.99465734
13349,hematoma,5,6,43,51,"Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment, resulting in a femoral nerve palsy and partial loss of quadriceps functions.",3985451_2,-1,1,1,13349,-1,0.001425695,0.99857426
15655,nephrolithiasis,5,6,40,55,Carbonic anhydrase inhibitors can cause nephrolithiasis.,8170551_1,-1,1,1,15655,-1,0.001404266,0.9985958
12037,seizures,29,30,160,168,"In the course of developing this model, a common vehicle, propylene glycol, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited weight gain.",2924746_4,-1,1,1,12037,-1,0.0013081915,0.99869186
4774,endometrial cancer,48,50,172,190,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,-1,1,1,4774,-1,0.0021928072,0.9978072
17769,bradycardia,7,8,48,59,"Forty seconds after injection of suxamethonium, bradycardia and cardiac arrest occurred.",9587734_3,-1,1,1,17769,-1,0.0011569981,0.99884295
2246,thrombocytopenia,19,20,110,126,"RESULTS: Patients went home after hospitalizations that had included heparin exposure--in most cases, with no thrombocytopenia recognized--only to return to the hospital (median, day 14) with thromboembolic complications.",11827497_8,-1,1,1,2246,-1,0.0011868344,0.99881315
6271,hypertension,5,6,58,70,Atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.,16820346_0,-1,1,1,6271,-1,0.0012101718,0.99878985
17471,psychotic symptoms,16,18,124,142,Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics.,9351491_2,-1,1,1,17471,-1,0.0012910697,0.99870896
693,pain,17,18,131,135,Ketamine reduced both the area of brush-evoked and punctate-evoked hyperalgesia significantly and it tended to reduce brush-evoked pain.,10743446_7,-1,1,1,693,-1,0.0013967189,0.9986033
154,psoriasis,11,12,81,90,Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.,10328196_0,-1,1,1,154,-1,0.0014848801,0.99851507
16596,hallucinations,2,3,15,29,Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants.,8766220_0,-1,1,1,16596,-1,0.0014716036,0.99852836
17317,parkinsonian,17,18,100,112,"Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.",9270571_0,-1,1,1,17317,-1,0.0035966462,0.99640334
2241,thrombocytopenia,12,13,72,88,PATIENTS: 14 patients seen over a 3-year period in whom heparin-induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications.,11827497_6,-1,1,1,2241,-1,0.0010138719,0.99898607
4043,parkinsonian,5,6,47,59,Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.,14568327_0,-1,1,1,4043,-1,0.0017431481,0.99825686
362,depression,3,4,25,35,"Since cortical spreading depression has been shown to liberate NO in animals, this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura.",10524660_11,-1,1,1,362,-1,0.0021948155,0.9978052
11258,ventricular arrhythmias,10,12,78,101,"Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.",2435991_1,-1,1,1,11258,-1,0.0013737613,0.99862623
11110,seizures,1,2,4,12,All seizures were controlled with therapeutic doses of phenytoin.,2343592_3,-1,1,1,11110,-1,0.0014302174,0.9985697
4503,hypotension,3,4,30,41,The enhanced alpha-methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity.,15145918_8,-1,1,1,4503,-1,0.0013671428,0.99863285
5188,Thrombotic microangiopathy,2,4,12,38,OBJECTIVES: Thrombotic microangiopathy is a well-known problem in patients following renal transplantation.,15859940_1,-1,1,1,5188,-1,0.0011761059,0.9988238
13991,proteinuria,7,8,64,75,Effect of captopril on pre-existing and aminonucleoside-induced proteinuria in spontaneously hypertensive rats.,6454943_0,-1,1,1,13991,-1,0.0012916459,0.99870837
5121,headache,12,13,79,87,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,-1,1,1,5121,-1,0.0010891458,0.9989109
3353,toxicity,11,12,69,77,This 4-week cycle was repeated until there was evidence of excessive toxicity or disease progression.,12627929_6,-1,1,1,3353,-1,0.0014666289,0.99853337
7924,thrombosis,28,29,146,156,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,1,1,7924,-1,0.0013560079,0.99864405
9460,seizures,49,50,288,296,"PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures.",19707748_1,-1,1,1,9460,-1,0.0012119366,0.99878806
15909,hypotension,33,34,126,137,"The mean arterial pressure was 77 +/- 2 mmHg (10.3 +/- 0.3 kPa) before hypotension and 50 +/- 0 mmHg (6.7 +/- 0.0 kPa) during hypotension in the hypotensive group, and 86 +/- 2 mmHg (11.5 +/- 0.3 kPa) during anaesthesia in the control group.",8424298_4,-1,1,1,15909,-1,0.0018875297,0.99811244
15168,aggression,25,26,140,150,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,1,1,15168,-1,0.0012197909,0.9987802
4177,headache,10,11,70,78,"However, plasma CGRP concentrations failed to change during immediate headache and in the subjects with no migraine attack.",14659530_8,-1,1,1,4177,-1,0.0013935547,0.9986065
2453,exencephalic,29,30,212,224,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,-1,1,1,2453,-1,0.0041557723,0.9958442
4446,rigidity,5,6,47,55,"Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.",15096016_5,-1,1,1,4446,-1,0.0011540427,0.99884593
4626,seizures,35,36,196,204,"beta4 -/- mice were less sensitive to the effects of nicotine both at low doses, measured as decreased exploration in an open field, and at high doses, measured as sensitivity to nicotine-induced seizures.",15275829_5,-1,1,1,4626,-1,0.0014801485,0.99851984
10935,weakness,26,27,126,134,The study was designed to have a power of greater than 0.90 to detect a slowing to 25% of the expected rate of progression of weakness at P less than 0.05.,2266990_4,-1,1,1,10935,-1,0.001430914,0.998569
633,bradycardia,15,16,127,138,"These results show that 15-day isoproterenol pretreatment not only abolished but reversed bromocriptine-induced tachycardia to bradycardia, an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart.",10721819_9,-1,1,1,633,-1,0.0011440538,0.99885595
9015,Pain,0,1,0,4,Pain memory is thought to affect future pain sensitivity and thus contribute to clinical pain conditions.,19269743_1,-1,1,1,9015,-1,0.0021391555,0.99786085
9312,ovarian cancer,1,3,12,26,"Forty-three ovarian cancer patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P).",19473225_3,-1,1,1,9312,-1,0.0026128949,0.9973871
17513,breast cancer,5,7,34,47,Administration of this regimen to breast cancer patients who have been treated by chemotherapy and those with impaired heart function requires careful attention.,9390208_18,-1,1,1,17513,-1,0.0035164892,0.99648345
10278,peripheral neuropathy,10,12,84,105,"Exclusion criteria included CNS leukemic infiltration at diagnosis, therapy-related peripheral neuropathy, late-onset encephalopathy, or long-term neurocognitive defects.",20470218_4,-1,1,1,10278,-1,0.0011549345,0.9988451
15137,pain,13,14,79,83,Response to treatment was estimated by the visual analog scale for severity of pain.,7791169_4,-1,1,1,15137,-1,0.0023136442,0.9976864
1257,hypotension,16,17,114,125,Adults chronically treated with angiotensin converting enzyme inhibitors may have a limited ability to respond to hypotension when the sympathetic response is simultaneously blocked.,11198499_3,-1,1,1,1257,-1,0.0012788689,0.99872106
5180,necrosis,27,28,173,181,"Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.",15858223_8,-1,1,1,5180,-1,0.0015764994,0.99842346
7065,syncope,12,13,82,89,CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.,17344330_14,-1,1,1,7065,-1,0.0012279116,0.9987721
7682,pain,7,8,40,44,"However, both incidence and severity of pain were not different between Groups R4 and R6.",18006530_9,-1,1,1,7682,-1,0.0016930294,0.998307
6656,seizures,11,12,65,73,"In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.",17074608_2,-1,1,1,6656,-1,0.0011030382,0.99889696
11184,hypotensive,20,21,115,126,The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.,2355241_4,-1,1,1,11184,-1,0.0017817935,0.99821824
11428,fatigue,19,20,89,96,"Symptomatic adverse effects were present in 96% of subjects, most commonly nausea (64%), fatigue (55%) and headache (49%).",2528969_5,-1,1,1,11428,-1,0.0014067275,0.9985933
2657,constipation,6,7,55,67,Metamizol potentiates morphine antinociception but not constipation after chronic treatment.,12063090_0,-1,1,1,2657,-1,0.001410317,0.9985897
1887,pain,13,14,74,78,"Sedation has been commonly used in the neonate to decrease the stress and pain from the noxious stimuli and invasive procedures in the neonatal intensive care unit, as well as to facilitate synchrony between ventilator and spontaneous breaths.",11581460_1,-1,1,1,1887,-1,0.0016473008,0.99835277
2233,convulsive,6,7,44,54,INTERPRETATION: Tranexamic acid retains its convulsive action within FS.,11807648_12,-1,1,1,2233,-1,0.0018859081,0.9981141
13772,neuropathy,23,24,148,158,Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.,6287825_5,-1,1,1,13772,-1,0.001252956,0.998747
5474,hypercalcemia,11,12,70,83,CONCLUSION: Milk-alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons.,16006300_9,-1,1,1,5474,-1,0.0015786026,0.99842143
13687,anemia,34,35,211,217,"Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.",6203452_5,-1,1,1,13687,-1,0.0011641419,0.99883586
9419,polyuria,7,8,54,62,Mice lacking mPGES-1 are resistant to lithium-induced polyuria.,19692487_0,-1,1,1,9419,-1,0.0012342882,0.9987657
9441,hypotension,9,10,55,66,The hypothesis that fenoldopam could be used to induce hypotension and preserve blood flow to the kidney was tested.,1969772_4,-1,1,1,9441,-1,0.0013914661,0.9986085
14834,hepatotoxicity,2,3,10,24,"Moreover, hepatotoxicity may not be restricted to one class of antithyroid agents.",7504976_10,-1,1,1,14834,-1,0.0013670997,0.99863285
10498,proteinuria,15,16,98,109,"CONCLUSIONS: PAN glomeruli already showed significant pathology by day 4, despite relatively mild proteinuria.",20588063_12,-1,1,1,10498,-1,0.0014395,0.9985605
8109,infections,18,19,140,150,Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.,18356633_1,-1,1,1,8109,-1,0.0013219026,0.998678
11729,renal dysfunction,28,30,125,142,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,-1,1,1,11729,-1,0.0017462175,0.99825376
16237,breast carcinoma,25,27,168,184,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.",8643966_1,-1,1,1,16237,-1,0.002689874,0.99731016
7874,acidosis,19,20,120,128,"Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse.",18186898_6,-1,1,1,7874,-1,0.0012562769,0.9987437
16988,hepatotoxic,27,28,132,143,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,1,1,16988,-1,0.0020354737,0.9979645
2775,bradycardia,6,7,50,61,"The patient remained unresponsive with junctional bradycardia, unrecordable blood pressure, and then became asystolic.",12101159_4,-1,1,1,2775,-1,0.001208802,0.9987913
11742,catalepsy,11,12,84,93,Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat.,2716967_1,-1,1,1,11742,-1,0.0013507201,0.9986493
2843,tremor,21,22,122,128,"Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of tremor and clonus were recorded and converted to threshold dose.",12198388_4,-1,1,1,2843,-1,0.0012381832,0.9987618
6686,hypertension,3,4,23,35,Delayed institution of hypertension during focal cerebral ischemia: effect on brain edema.,1711760_0,-1,1,1,6686,-1,0.0012729677,0.998727
4945,interstitial nephritis,2,4,16,38,Recurrent acute interstitial nephritis induced by azithromycin.,15602202_0,-1,1,1,4945,-1,0.0011430156,0.998857
8386,nephrosis,19,20,135,144,"We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.",18541230_1,-1,1,1,8386,-1,0.0011888613,0.9988111
16862,deaths,5,6,27,33,"We describe an outbreak of deaths from cocaine-induced excited delirium (EDDs) in Dade County, Florida between 1979 and 1990.",8988571_1,-1,1,1,16862,-1,0.0014778732,0.9985221
4764,gallbladder disease,7,9,53,72,"Outcomes included venous thromboembolism, cataracts, gallbladder disease, and endometrial hyperplasia or cancer.",15458908_4,-1,1,1,4764,-1,0.001818943,0.9981811
4490,hypotension,9,10,94,105,Differential modulation by estrogen of alpha2-adrenergic and I1-imidazoline receptor-mediated hypotension in female rats.,15145918_0,-1,1,1,4490,-1,0.0011456393,0.9988544
2239,thrombocytopenia,6,7,53,69,Delayed recognition and treatment of heparin-induced thrombocytopenia contribute to poor patient outcomes.,11827497_2,-1,1,1,2239,-1,0.0009875734,0.99901235
5868,myoclonus,3,4,34,43,Remifentanil pretreatment reduces myoclonus after etomidate.,16563323_0,-1,1,1,5868,-1,0.0014416635,0.99855834
29,hypercalcemia,7,8,46,59,These effects were accompanied by episodes of hypercalcemia and hyperphosphatemia.,10027919_12,-1,1,1,29,-1,0.0020454018,0.9979546
5213,toxicity,10,11,60,68,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,-1,1,1,5213,-1,0.0022842141,0.99771583
9025,pain,3,4,19,23,The strong burning pain decayed exponentially within a few minutes.,19269743_7,-1,1,1,9025,-1,0.0021173751,0.99788254
7906,thrombosis,8,9,52,62,Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia.,18208574_0,-1,1,1,7906,-1,0.0010832165,0.99891675
14618,arrhythmia,5,6,21,31,"In two patients, the arrhythmia degenerated into irreversible ventricular fibrillation and both patients died.",7234705_6,-1,1,1,14618,-1,0.0013278504,0.9986721
4186,migraine,25,26,171,179,Platelet serotonin content decreased significantly (P<0.01) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with migraine attack.,14659530_10,-1,1,1,4186,-1,0.001616907,0.99838305
13213,rash,10,11,57,61,"Reactions included thrombophlebitis (20 of 54 patients), rash (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).",3934126_4,-1,1,1,13213,-1,0.0012436197,0.9987564
1904,nephrotoxicity,22,23,126,140,"Acute nephrotoxicity, which occurs in the early period after transplantation, leads to a higher rate of dialysis, and chronic nephrotoxicity may eventually result in graft loss.",11583940_3,-1,1,1,1904,-1,0.0012775784,0.9987224
2478,catalepsy,4,5,42,51,Nicotine potentiation of morphine-induced catalepsy in mice.,11900788_0,-1,1,1,2478,-1,0.0014364655,0.9985636
17037,hyperprolactinemia,20,21,107,125,"DESIGN: Fluoxetine, a serotonin reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce hyperprolactinemia.",9098464_2,-1,1,1,17037,-1,0.001637355,0.9983626
8519,cardiotoxic,13,14,70,81,"Clinical use of the anthracycline doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.",18627295_1,-1,1,1,8519,-1,0.0015829351,0.998417
9591,hypertensive,13,14,84,96,"However, a bolus of epinephrine injected through an alternative catheter provoked a hypertensive crisis.",19843802_3,-1,1,1,9591,-1,0.0012828319,0.9987172
14989,hepatic injury,14,16,98,112,"Two halogenated anesthetics, enflurane and isoflurane, have been associated with an allergic-type hepatic injury both alone and following previous exposure to halothane.",7647582_1,-1,1,1,14989,-1,0.0014134928,0.99858654
17761,cardiac arrest,1,3,22,36,Suxamethonium-induced cardiac arrest and death following 5 days of immobilization.,9587734_0,-1,1,1,17761,-1,0.0012818236,0.99871814
807,death,51,52,232,237,"Patients with a DBP reduction of > or =20% in the high-dose group had a significantly increased adjusted OR for the compound outcome variable death or dependency (Barthel Index <60) (n/N=25/26, OR 10. 16, 95% CI 1.02 to 101.74) and death alone (n/N=9/26, OR 4.336, 95% CI 1.131 16.619) compared with all placebo patients (n/N=62/92 and 14/92, respectively).",10835440_8,-1,1,1,807,-1,0.0022237485,0.9977762
6663,encephalopathy,25,26,168,182,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,1,1,6663,-1,0.001116478,0.99888355
14109,hemorrhagic,5,6,18,29,"The 20 deaths, 52 hemorrhagic and thromboembolic complications, and 21 surgical procedures to manage the complications confirm the seriousness of the disorder.",6615052_5,-1,1,1,14109,-1,0.0016585633,0.99834144
3303,acne,19,20,107,111,"CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.",12615818_7,-1,1,1,3303,-1,0.0012836845,0.99871635
18005,myoclonic jerks,15,17,103,118,"Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine.",9746003_4,-1,1,1,18005,-1,0.0015183166,0.9984817
15049,ischemia,33,34,152,160,"Peripheral venous blood samples were withdrawn from the femoral vein four times (once every 5 min) before ischemia (0 time) and 5, 15, and 30 min after ischemia.",7710775_2,-1,1,1,15049,-1,0.005252372,0.9947476
5112,aneurysm,20,21,137,145,Angiography and intracoronary ultrasound demonstrated lack of contact between stent and vessel wall in a 15-mm long segment with maximal aneurysm diameter of 6.0 mm.,15804801_4,-1,1,1,5112,-1,0.004386416,0.9956136
14516,aplastic anemia,1,3,6,21,Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol.,7072798_0,-1,1,1,14516,-1,0.0012372585,0.9987627
1932,hepatitis,13,14,87,96,"A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.",11672959_1,-1,1,1,1932,-1,0.0011708868,0.99882907
4298,hypoxia,34,35,233,240,"In this report we describe the case of a 37-year-old white woman with Ebstein's anomaly, who developed a rare syndrome called platypnea-orthodeoxia, characterized by massive right-to-left interatrial shunting with transient profound hypoxia and cyanosis.",14976857_1,-1,1,1,4298,-1,0.0013008589,0.99869907
3235,cardiomyopathy,22,23,137,151,"We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.",12589964_2,-1,1,1,3235,-1,0.0010836181,0.9989164
9173,hemorrhagic,6,7,46,57,"Twenty-four hours after hemorrhage induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay.",19319147_8,-1,1,1,9173,-1,0.0016111165,0.9983889
6110,nausea,29,30,175,181,"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.",16680561_9,-1,1,1,6110,-1,0.0014962351,0.9985038
17087,toxicity,55,56,390,398,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,-1,1,1,17087,-1,0.0018934833,0.9981065
2849,convulsion,5,6,32,42,"RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.",12198388_8,-1,1,1,2849,-1,0.0013371558,0.9986628
6751,Proteinuria,0,1,0,11,Proteinuria after conversion to sirolimus in renal transplant recipients.,17175308_0,-1,1,1,6751,-1,0.0013492042,0.99865085
7907,thrombocytopenia,13,14,96,112,Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia.,18208574_0,-1,1,1,7907,-1,0.0010238942,0.9989761
10927,weakness,13,14,75,83,There is evidence that growth hormone may be related to the progression of weakness in Duchenne dystrophy.,2266990_1,-1,1,1,10927,-1,0.0013537587,0.9986462
10490,catalepsy,16,17,127,136,These findings suggest that glutamate-mediated mechanisms in the neural circuits at the IC level influence haloperidol-induced catalepsy and participate in the regulation of motor activity.,20558148_8,-1,1,1,10490,-1,0.0018145913,0.99818534
9995,epileptic,15,16,124,133,"At hippocampal Schaeffer collateral-CA1 synapses, long-term potentiation was preserved in BMC-transplanted rats compared to epileptic controls.",20080419_7,-1,1,1,9995,-1,0.01148173,0.9885183
1925,major depression,14,16,86,102,We report a favorable response to treatment with citalopram by a 15-year-old boy with major depression who exhibited palpebral twitching during his first 2 weeks of treatment.,11642480_2,-1,1,1,1925,-1,0.0018127408,0.99818724
11208,paralysis,1,2,9,18,"Although paralysis after magnesium administration has been described in patients with known myasthenia gravis, it has not previously been reported to be the initial or only manifestation of the disease.",2385256_7,-1,1,1,11208,-1,0.0011765687,0.99882346
10123,nephropathy,7,8,62,73,"Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.",20195852_1,-1,1,1,10123,-1,0.001372553,0.9986274
11186,hypotensive,26,27,152,163,The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.,2355241_4,-1,1,1,11186,-1,0.001783488,0.99821645
15275,cancers,13,14,105,112,High-dose 5-fluorouracil/folinic acid infusion therapy has recently become a popular regimen for various cancers.,7858459_6,-1,1,1,15275,-1,0.0024321645,0.99756783
2078,breast carcinoma,38,40,253,269,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,-1,1,1,2078,-1,0.0017745863,0.9982254
18203,cholestasis,16,17,100,111,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,-1,1,1,18203,-1,0.0013725699,0.9986274
13343,hemorrhage,2,3,27,37,Warfarin-induced iliopsoas hemorrhage with subsequent femoral nerve palsy.,3985451_0,-1,1,1,13343,-1,0.0012276513,0.9987723
6347,bleeding,29,30,135,143,A warfarin-drug interaction could have contributed to the haemorrhage in 24 (41%) of the warfarin patients and in 7 of these (12%) the bleeding complication was considered being possible to avoid.,16858720_7,-1,1,1,6347,-1,0.0016641136,0.9983359
1469,cardiotoxicity,11,12,90,104,"Anthracyclines are effective antineoplastic drugs, but they frequently cause dose-related cardiotoxicity.",11279304_1,-1,1,1,1469,-1,0.0011886117,0.99881136
4190,migraine,26,27,166,174,"In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.",14659530_11,-1,1,1,4190,-1,0.0014970781,0.99850297
9111,cancer,16,17,113,119,"In our patient, both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS.",19300240_13,-1,1,1,9111,-1,0.0052455626,0.99475443
1597,deaths,11,12,72,78,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,-1,1,1,1597,-1,0.001412352,0.9985877
4021,hemolytic anemia,2,4,25,41,Cefotetan-induced immune hemolytic anemia.,1445986_0,-1,1,1,4021,-1,0.0010909728,0.998909
15850,seizures,34,35,215,223,In situ hybridization methods were used to determine if glutamic acid decarboxylase (GAD) mRNA-containing neurons within the hilus of the dentate gyrus are vulnerable to seizure-induced damage in a model of chronic seizures.,8410199_1,-1,1,1,15850,-1,0.0013346723,0.99866533
10708,schizophrenia,14,15,101,114,The glutamatergic N-methyl-D-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia.,20727411_1,-1,1,1,10708,-1,0.0018301177,0.9981699
8887,seizures,9,10,87,95,Effect of increasing intraperitoneal infusion rates on bupropion hydrochloride-induced seizures in mice.,19105845_0,-1,1,1,8887,-1,0.0012316599,0.99876827
2603,tremor,9,10,61,67,"However, MK-801 injection produced a significant increase of tremor in reserpine-treated mice.",11999899_6,-1,1,1,2603,-1,0.0011791921,0.99882084
4537,thrombotic,15,16,136,146,Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.,15266215_0,-1,1,1,4537,-1,0.0014829519,0.9985171
14935,myopathy,9,10,65,73,"While lovastatin and simvastatin have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity.",7604176_8,-1,1,1,14935,-1,0.0011519087,0.9988481
10828,renal toxicity,1,3,10,24,"Potential renal toxicity and elevated alanine transaminase (ALT) concentration were reported in 12.2% and 48.8% of dogs, respectively.",21418164_6,-1,1,1,10828,-1,0.0016232909,0.9983767
4669,toxicity,7,8,50,58,"In high doses, its nonhematological dose-limiting toxicity is cardiomyopathy.",15325671_2,-1,1,1,4669,-1,0.0013624796,0.9986375
9850,seizures,26,27,180,188,CONCLUSION: Our results suggest that use of high-dose TXA in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical seizures in susceptible patients.,19996135_11,-1,1,1,9850,-1,0.0011166141,0.9988834
2224,seizures,4,5,20,28,The degree of these seizures increased with increasing concentration of tAMCA.,11807648_9,-1,1,1,2224,-1,0.0014651825,0.9985348
11031,nephrotoxic,4,5,22,33,Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies.,2320800_5,-1,1,1,11031,-1,0.0016071085,0.9983929
17758,breast cancer,5,7,32,45,Women who receive tamoxifen for breast cancer should be offered gynaecological surveillance during and after treatment.,9579567_12,-1,1,1,17758,-1,0.002230355,0.9977697
11485,albuminuria,57,58,243,254,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,1,1,11485,-1,0.170627,0.829373
4985,hyperkalemia,3,4,36,48,CONCLUSIONS: Spironolactone-induced hyperkalemia and renal insufficiency are more common in our clinical experience than reported previously.,15632880_10,-1,1,1,4985,-1,0.001071719,0.99892825
712,nephrotoxicity,22,23,108,122,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,1,1,712,-1,0.0014043783,0.99859565
769,cocaine abuse,18,20,103,116,This group was compared with a control group of 135 patients with ruptured aneurysms and no history of cocaine abuse.,10807237_4,-1,1,1,769,-1,0.79357135,0.20642868
975,pain,21,22,127,131,"Providing pain management for known opioid abusers is a challenging clinical task, in part because little is known about their pain experience and analgesic requirements.",11027904_1,-1,1,1,975,-1,0.0020220503,0.9979779
12247,hepatitis,25,26,153,162,In two of the three deaths probably associated with ketoconazole treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis.,3101906_13,-1,1,1,12247,-1,0.0012449916,0.998755
8509,death,4,5,37,42,CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin.,18619688_10,-1,1,1,8509,-1,0.0020215465,0.9979785
12739,Jaundice,0,1,0,8,Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia.,3496378_2,-1,1,1,12739,-1,0.0011788674,0.9988211
5505,seizures,2,3,26,34,Cocaine-induced brainstem seizures and behavior.,1610717_0,-1,1,1,5505,-1,0.0013105902,0.9986895
10230,hyperprolactinemia,12,13,88,106,Serum testosterone concentration increased with pubertal status but was not affected by hyperprolactinemia.,20331935_7,-1,1,1,10230,-1,0.002510386,0.9974896
4312,hyperthyroidism,28,29,145,160,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,-1,1,1,4312,-1,0.0013212287,0.99867874
17726,Cancer,12,13,54,60,"F  d  ration Nationale des Centres de Lutte Contre le Cancer (FNCLCC).Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be carefully examined.",9579567_1,-1,1,1,17726,-1,0.0034115124,0.99658847
8431,hypotension,16,17,126,137,"Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.",18544179_10,-1,1,1,8431,-1,0.0012815149,0.9987185
7723,weakness,4,5,21,29,Her vocal change and weakness began to improve spontaneously about 3 weeks after transfer.,18023325_11,-1,1,1,7723,-1,0.0016175322,0.99838245
16403,pain,10,11,35,39,"Five of the 13 patients (38%) with pain and seven of the 41 patients (17%) without pain admitted to a high alcohol intake, which might be a contributing factor.",8686832_4,-1,1,1,16403,-1,0.0016263067,0.9983736
17994,primary pulmonary hypertension,16,19,106,136,A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated primary pulmonary hypertension.,9727773_9,-1,1,1,17994,-1,0.0015283687,0.99847156
6246,amnesia,5,6,30,37,"Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.).",16755009_8,-1,1,1,6246,-1,0.0016137789,0.99838626
5401,malignancy,17,18,92,102,"The diagnosis depends on exclusion of other entities, such as heart failure, infection, and malignancy.",1595783_4,-1,1,1,5401,-1,0.0016840799,0.99831593
17603,migraine,11,12,67,75,Using the same stereotactic space limits as in the above mentioned migraine study no brain stem activation was found in the acute pain state compared to the pain free state.,9514561_6,-1,1,1,17603,-1,0.0022713006,0.99772877
12339,rigidity,4,5,32,40,"These observations suggest that rigidity should be prevented when alfentanil, and, presumably, other opiates, are used in the anesthetic management of patients with ICP problems.",3125768_8,-1,1,1,12339,-1,0.0012262014,0.99877375
1996,angioedema,24,25,147,157,"Furthermore, 18.28% of patients with a history of chronic urticaria and 11.8% of subjects with an history of NSAID-induced urticaria/angioedema or angioedema alone (with or without chronic urticaria) resulted to be intolerant to alternative drugs.",11694026_7,-1,1,1,1996,-1,0.0011938212,0.99880624
16725,seizure,10,11,68,75,"Using linear regression we found that no correlation exists between seizure duration, elevation of phenytoin serum levels and cerebellar volume.",8864707_8,-1,1,1,16725,-1,0.0015298314,0.9984701
10919,epilepsy,1,2,7,15,Serial epilepsy caused by levodopa/carbidopa administration in two patients on hemodialysis.,2265898_0,-1,1,1,10919,-1,0.0012888163,0.9987112
5803,vasculitis,1,2,15,25,PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.,16418614_0,-1,1,1,5803,-1,0.0010843741,0.9989157
17600,migraine,26,27,149,157,"To test this hypothesis we performed an experimental pain study in seven healthy volunteers, using the same positioning in the PET scanner as in the migraine patients.",9514561_3,-1,1,1,17600,-1,0.0028264055,0.99717355
17539,spasm,9,10,55,60,Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine-morphine administration.,9431903_0,-1,1,1,17539,-1,0.0014313816,0.99856853
13995,hypertensive,9,10,55,67,Proteinuria is a side effect of captopril treatment in hypertensive patients.,6454943_1,-1,1,1,13995,-1,0.0021488562,0.99785113
6884,seizures,25,26,136,144,We report QTLs identified using a B6 (host) x A/J (donor) CSS panel to localize genes involved in susceptibility to pilocarpine-induced seizures.,17242861_4,-1,1,1,6884,-1,0.0013557592,0.9986443
7903,diarrhea,8,9,43,51,"The incidences of headache, dizziness, and diarrhea were similar between the 2 groups.",18201582_11,-1,1,1,7903,-1,0.0014923881,0.99850756
8263,ulcer,18,19,137,142,"Gastric acid back-diffusion, mucosal LPO generation, histamine concentration, microvascular permeability, luminal hemoglobin content and ulcer areas were determined.",18442015_7,-1,1,1,8263,-1,0.0021622274,0.99783784
4954,hyperkalemia,4,5,47,59,Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.,15632880_0,-1,1,1,4954,-1,0.0011624598,0.99883753
13335,rheumatoid arthritis,37,39,233,253,"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.",3970039_9,-1,1,1,13335,-1,0.0013301077,0.99866986
4848,stroke,27,28,116,122,"Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).",15531665_5,-1,1,1,4848,-1,0.0017346421,0.9982653
169,psoriasis,4,5,29,38,"Because patients with severe psoriasis may develop capillary leak from various systemic therapies, clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators.",10328196_7,-1,1,1,169,-1,0.0014252334,0.99857473
14785,polydipsia,6,7,43,53,"The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.",7453952_1,-1,1,1,14785,-1,0.0014245048,0.99857545
6716,hypertension,5,6,45,57,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,1,1,6716,-1,0.0011962046,0.99880373
9455,hypotension,31,32,191,202,Fenoldopam is a selective dopamine-1 (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension.,1969772_9,-1,1,1,9455,-1,0.0011820197,0.998818
7996,nephrotoxic,12,13,59,70,"The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.",18261172_2,-1,1,1,7996,-1,0.0015609368,0.998439
572,hemolytic anemia,20,22,135,151,"This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms.",10704919_2,-1,1,1,572,-1,0.0010953513,0.9989046
9396,tachycardia,12,13,80,91,"Five hours after exposure, he developed disulfiram-like syndrome with flushing, tachycardia, and arterial hypotension after consuming three glasses of wine.",19657887_8,-1,1,1,9396,-1,0.001237905,0.99876213
7966,hyperalgesia,5,6,24,36,"To this end, persistent hyperalgesia was induced by administration of capsaicin in the tail of gonadally intact F344 rats, following which the tail was immersed in a mildly noxious thermal stimulus, and tail-withdrawal latencies measured.",18221780_3,-1,1,1,7966,-1,0.0013530222,0.99864703
9274,pain,8,9,34,38,"However, it is not known that how pain intensity ratings are affected by attention in capsaicin-induced secondary hyperalgesia.",19387625_2,-1,1,1,9274,-1,0.0017867738,0.9982133
6152,fever,4,5,18,23,"The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.",16720068_4,-1,1,1,6152,-1,0.001364154,0.9986358
4178,migraine,17,18,107,115,"However, plasma CGRP concentrations failed to change during immediate headache and in the subjects with no migraine attack.",14659530_8,-1,1,1,4178,-1,0.0014728564,0.99852717
15402,myocarditis,12,13,94,105,Medications were discontinued when erythema multiforme and congestive heart failure caused by myocarditis occurred.,7919560_3,-1,1,1,15402,-1,0.0011424093,0.9988576
6443,atherosclerosis,1,2,7,22,"Aortic atherosclerosis was diagnosed by radiographic detection of calcified deposits in the abdominal aorta, which have been shown to reflect intima atherosclerosis.",16938416_3,-1,1,1,6443,-1,0.0015984921,0.99840146
16152,ventricular arrhythmias,27,29,142,165,"Eighteen of 31 (58%) patients showed cardiac toxicity, defined as having one or more of the following abnormalities: late potentials, complex ventricular arrhythmias, left ventricular dilation, decreased shortening fraction, or decreased ejection fraction.",8600333_5,-1,1,1,16152,-1,0.0015438552,0.9984561
2438,anencephaly,9,10,65,76,We confirmed several cases of transformation from exencephaly to anencephaly.,11875660_4,-1,1,1,2438,-1,0.0019458485,0.99805415
14646,aplastic anemia,19,21,134,149,A positive lymphocyte transformation test with indomethacin in vitro further substantiates the potential role of this drug in causing aplastic anemia in a susceptible patient.,7263204_4,-1,1,1,14646,-1,0.0010912103,0.99890876
2441,exencephalic,16,17,95,107,"To analyze the transformation patterns, we classified the exencephaly by size and shape of the exencephalic tissue into several types at E13.5 and E18.5.",11875660_6,-1,1,1,2441,-1,0.0047745695,0.9952254
2010,glaucoma,48,49,256,264,"DESIGN: This trial evaluated the effect of placebo, 0.5% aqueous timolol (timolol solution) and a 0.5% timolol suspension that forms a gel on application to the conjunctiva (timolol gellan) on the 24-hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate.",11704023_3,-1,1,1,2010,-1,0.0024217637,0.9975782
5748,amnesia,14,15,103,110,The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.,16364460_1,-1,1,1,5748,-1,0.001774479,0.9982255
9747,hemolytic anemia,9,11,55,71,"The mechanism by which omeprazole caused the patient's hemolytic anemia is uncertain, but physicians should be alerted to this possible adverse effect.",1992636_8,-1,1,1,9747,-1,0.0011179365,0.9988821
17827,drug abuse,8,10,61,71,Eating disorders and the associated behavioural problems and drug abuse are uncommon in pregnancy.,9653867_1,-1,1,1,17827,-1,0.19098479,0.8090153
2378,cardiac dysfunction,6,8,45,64,Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals.,11861791_8,-1,1,1,2378,-1,0.0017884185,0.9982116
2971,headache,3,4,17,25,"Faster relief of headache was the most important reason for preference, cited by 67.3% of patients preferring rizatriptan and 54.2% of patients who preferred ergotamine/caffeine.",12464714_4,-1,1,1,2971,-1,0.0014872935,0.9985127
145,neurotoxicity,10,11,53,66,Three of the cases were most likely caused by direct neurotoxicity of hyperbaric 5% lignocaine.,10225068_4,-1,1,1,145,-1,0.001270776,0.99872917
356,headache,5,6,25,33,At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society.,10524660_9,-1,1,1,356,-1,0.0012413391,0.9987587
14850,bradycardia,1,2,15,26,"Dose-dependent bradycardia induced by verapamil was potentiated by LNa, LCa, and HCa.",7516729_7,-1,1,1,14850,-1,0.0011671331,0.9988329
9273,pain,1,2,10,14,Perceived pain intensity is modulated by attention.,19387625_1,-1,1,1,9273,-1,0.0030882969,0.9969117
496,calcification,41,42,287,300,"Warfarin-induced artery calcification is accelerated by growth and vitamin D.The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.",10669626_0,-1,1,1,496,-1,0.00621491,0.99378514
7964,pain,13,14,79,83,"The purpose of this investigation was to extend these findings to a persistent pain model which could be distinguished from acute pain models on the basis of the nociceptive fibers activated, neurochemical substrates, and duration of the nociceptive stimulus.",18221780_2,-1,1,1,7964,-1,0.0016725232,0.99832743
2260,hyperprolactinemia,20,21,123,141,"BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children.",11838826_1,-1,1,1,2260,-1,0.001474395,0.9985257
18075,ischemic stroke,10,12,68,83,The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series.,9799166_1,-1,1,1,18075,-1,0.0013719465,0.998628
9790,seizures,10,11,78,86,"Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.",19944736_2,-1,1,1,9790,-1,0.0012088474,0.99879116
4634,convulsions,6,7,48,59,The effects of sevoflurane on lidocaine-induced convulsions.,15278670_0,-1,1,1,4634,-1,0.0012699466,0.99873
9456,Seizures,0,1,0,8,Seizures associated with levofloxacin: case presentation and literature review.,19707748_0,-1,1,1,9456,-1,0.0014628321,0.9985372
15230,glomerulonephritis,9,10,68,86,This report documents the unusual occurrence of rapidly progressive glomerulonephritis with crescents and fibrillar glomerulonephritis in a patient treated with rifampin.,7834920_5,-1,1,1,15230,-1,0.001409912,0.99859005
12676,Hepatotoxicity,0,1,0,14,Hepatotoxicity and malaise are again the most frequent side effects.,3431591_9,-1,1,1,12676,-1,0.0014234863,0.9985765
7877,myopathy,6,7,29,37,"Fanconi syndrome, as well as myopathy, is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA.",18186898_8,-1,1,1,7877,-1,0.0011931867,0.99880683
11727,glycosuria,10,11,44,54,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,-1,1,1,11727,-1,0.0015613962,0.99843866
993,Pain,0,1,0,4,Pain not responsive to morphine is often problematic.,11027905_1,-1,1,1,993,-1,0.0017909451,0.9982091
9944,delirium,9,10,34,42,The mean +/- SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group (0.5+/-1.5 days vs 1.4+/-4.0 days; P=.01).,20042557_7,-1,1,1,9944,-1,0.0012545342,0.99874544
16346,atrophy,58,59,324,331,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,-1,1,1,16346,-1,0.0013319326,0.9986681
10190,hypotension,4,5,33,44,The effect of isoflurane-induced hypotension on glomerular function and renal blood flow was investigated in 20 human subjects.,2021202_1,-1,1,1,10190,-1,0.0012912897,0.9987087
2081,toxicities,12,13,84,94,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,-1,1,1,2081,-1,0.0015939759,0.998406
11602,depression,3,4,27,37,Antihypertensive drugs and depression: a reappraisal.,26094_0,-1,1,1,11602,-1,0.001971664,0.99802834
5655,dizziness,23,24,156,165,"A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.",1628552_1,-1,1,1,5655,-1,0.001337585,0.99866235
11429,headache,25,26,107,115,"Symptomatic adverse effects were present in 96% of subjects, most commonly nausea (64%), fatigue (55%) and headache (49%).",2528969_5,-1,1,1,11429,-1,0.0013570187,0.998643
14926,hypertension,13,14,91,103,"The patient, a 69-year-old man was affected by non-insulin-dependent diabetes mellitus and hypertension.",7604176_3,-1,1,1,14926,-1,0.0013595141,0.9986405
14403,convulsions,46,47,268,279,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,-1,1,1,14403,-1,0.0014680387,0.99853194
16058,tumors,7,8,56,62,"Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.",85485_2,-1,1,1,16058,-1,0.0028839288,0.9971161
10852,nausea,9,10,63,69,"Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis.",2224762_8,-1,1,1,10852,-1,0.0013200407,0.99867994
12770,toxicity,2,3,10,18,"With mild toxicity, a reduction to 30 or 40 mg/kg per dose should result in a reversal of the abnormal results to normal within four weeks.",3503576_9,-1,1,1,12770,-1,0.0013790112,0.998621
2285,hepatitis,13,14,68,77,"There was no evidence for viral, autoimmune, or metabolic causes of hepatitis.",11847945_3,-1,1,1,2285,-1,0.0013315642,0.99866843
2674,constipation,25,26,181,193,"The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that metamizol did not potentiate morphine-induced constipation.",12063090_9,-1,1,1,2674,-1,0.0013007313,0.9986992
16311,dyskinesia,13,14,79,89,Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.,8649546_1,-1,1,1,16311,-1,0.0010749691,0.99892503
17296,atherosclerosis,14,15,96,111,"Animal studies and mechanistic studies indicate that nicotine could play a role in accelerating atherosclerosis, but evidence among humans is too inadequate to be definitive about such an effect.",9245658_2,-1,1,1,17296,-1,0.0017974116,0.99820256
13219,ototoxicity,11,12,93,104,Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.,3934126_5,-1,1,1,13219,-1,0.0013072417,0.9986928
13854,depressed,13,14,108,117,Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.,6323692_3,-1,1,1,13854,-1,0.007565901,0.99243414
9049,neuropathy,13,14,95,105,The most frequent adverse events were hematological and gastrointestinal toxicities as well as neuropathy.,19274460_7,-1,1,1,9049,-1,0.0014019035,0.99859804
9063,hypotension,13,14,76,87,"We report a case of an intentional captopril overdose, manifested by marked hypotension, that resolved promptly with the administration of naloxone.",1928887_3,-1,1,1,9063,-1,0.0011956955,0.99880433
1973,headache,21,22,120,128,The difference between the bolus and infusion groups in the percentage of participants who saw a 50% reduction in their headache intensity within 30 minutes was 11.8% (95% CI -9.6% to 33.3%).,11679859_12,-1,1,1,1973,-1,0.0016748919,0.99832505
16441,bradycardia,17,18,86,97,5-HTP (5 mg/kg i.v.) decreased blood pressure and heart rate and decreased the reflex bradycardia to norepinephrine.,869641_7,-1,1,1,16441,-1,0.0013712138,0.99862885
7403,leukoencephalopathy,1,2,8,27,Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients.,17682013_0,-1,1,1,7403,-1,0.0011203293,0.9988796
158,psoriasis,4,5,25,34,After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.,10328196_2,-1,1,1,158,-1,0.00139385,0.99860615
2961,migraine,13,14,100,108,Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.,12464714_0,-1,1,1,2961,-1,0.0015516978,0.99844825
3594,anemia,3,4,35,41,Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.,12820454_0,-1,1,1,3594,-1,0.0011344115,0.9988656
12948,depressed,12,13,73,82,Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman.,3693336_1,-1,1,1,12948,-1,0.0026275634,0.9973724
2033,hemolytic anemia,12,14,96,112,Combination therapy is associated with a clinically important adverse effect: ribavirin-induced hemolytic anemia (RIHA).,11705128_2,-1,1,1,2033,-1,0.0010832811,0.99891675
1891,hypotension,12,13,86,97,"Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.",11581460_3,-1,1,1,1891,-1,0.0012269516,0.99877304
17369,hepatotoxicity,26,27,190,204,"Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.",9284778_5,-1,1,1,17369,-1,0.001640893,0.99835914
2236,thrombocytopenia,3,4,28,44,"BACKGROUND: Heparin-induced thrombocytopenia presents 5 to 12 days after heparin exposure, with or without arterial or venous thromboemboli.",11827497_1,-1,1,1,2236,-1,0.0010706837,0.9989293
17461,low sexual desire,15,18,85,102,We now advocate that before age 50 years testosterone be determined only in cases of low sexual desire and abnormal physical examination but that it be measured in all men older than 50 years.,9334596_24,-1,1,1,17461,-1,0.0030137543,0.9969862
2154,pain,7,8,41,45,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,1,1,2154,-1,0.0014526746,0.99854726
16986,toxicity,49,50,319,327,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,1,1,16986,-1,0.0016152982,0.9983847
10189,hypotension,7,8,68,79,Renal function and hemodynamics during prolonged isoflurane-induced hypotension in humans.,2021202_0,-1,1,1,10189,-1,0.0011980119,0.99880195
4401,liver injury,28,30,216,228,"CONCLUSIONS: The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo-prepared dilevalol antigens, suggesting the involvement of an immunologic mechanism in dilevalol-induced liver injury.",1504402_8,-1,1,1,4401,-1,0.0014340968,0.998566
17188,tumors,12,13,86,92,Review of the literature reveals an association between tamoxifen use and gynecologic tumors.,9205462_2,-1,1,1,17188,-1,0.0017816671,0.99821836
14567,convulsions,4,5,37,48,Deaths from local anesthetic-induced convulsions in mice.,7189975_0,-1,1,1,14567,-1,0.0012901747,0.9987098
5836,amnesia,10,11,89,96,Daidzein activates choline acetyltransferase from MC-IXC cells and improves drug-induced amnesia.,16428827_0,-1,1,1,5836,-1,0.0014816095,0.9985184
4670,cardiomyopathy,9,10,62,76,"In high doses, its nonhematological dose-limiting toxicity is cardiomyopathy.",15325671_2,-1,1,1,4670,-1,0.0012057682,0.9987942
11177,Cerebral haemorrhage,0,2,0,20,"Cerebral haemorrhage was the 11th most frequent cause of death, accounting for only 0.8% of deaths among the patients, whereas it was the 5th most common cause of death among the Japanese general population in 1985.",2355241_3,-1,1,1,11177,-1,0.0015441346,0.9984559
13953,seizures,5,6,22,30,The child in whom the seizures persisted was later found to have ceroid lipofuscinosis.,6415512_3,-1,1,1,13953,-1,0.0014493444,0.9985506
1387,vasculitis,5,6,95,105,Propylthiouracil-induced perinuclear-staining antineutrophil cytoplasmic autoantibody-positive vasculitis in conjunction with pericarditis.,11250767_0,-1,1,1,1387,-1,0.0011107854,0.99888927
1349,convulsions,27,28,166,177,"The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions.",11243580_1,-1,1,1,1349,-1,0.0013514406,0.9986486
7198,locomotor hyperactivity,1,3,20,43,Amphetamine-induced locomotor hyperactivity was similar in all groups.,17490864_6,-1,1,1,7198,-1,0.0014996892,0.99850035
4714,tremor,3,4,24,30,"DISCUSSION: Quantifying tremor by using an inexpensive laser pointer is, with the exception of children (<12 years) a sensitive and reproducible method.",15338796_18,-1,1,1,4714,-1,0.0014476446,0.9985524
3796,seizures,4,5,30,38,They offer protection against seizures in a range of models and seem to inhibit certain stages of drug dependence in preclinical assessments.,12921865_2,-1,1,1,3796,-1,0.0012902584,0.9987098
2268,hyperprolactinemia,13,14,92,110,METHODS: We undertook a retrospective case review of four children with risperidone-induced hyperprolactinemia treated with cabergoline.,11838826_5,-1,1,1,2268,-1,0.0018271515,0.9981729
4029,hemolytic anemia,18,20,134,150,"These observations, in conjunction with clinical and laboratory evidence of extravascular hemolysis, are consistent with drug-induced hemolytic anemia, possibly involving both drug-adsorption and autoantibody formation mechanisms.",1445986_5,-1,1,1,4029,-1,0.0010170208,0.99898297
1974,nausea,14,15,75,81,The difference in the percentage of patients with a 50% reduction in their nausea was 12.6% (95% CI -4.6% to 29.8%).,11679859_13,-1,1,1,1974,-1,0.0015425708,0.99845743
9739,hemolytic anemia,17,19,94,110,We report the first case of a serious short-term adverse reaction with the use of omeprazole: hemolytic anemia.,1992636_4,-1,1,1,9739,-1,0.0011988969,0.9988011
6714,hypertensive,21,22,110,122,"The area of histochemical injury (as a percent of the cross-sectional area of the hemisphere) was less in the hypertensive group (33 +/- 3% vs 21 +/- 2%, P less than 0.05).",1711760_11,-1,1,1,6714,-1,0.0074866405,0.99251336
14638,aplastic anemia,1,3,6,21,Fatal aplastic anemia due to indomethacin--lymphocyte transformation tests in vitro.,7263204_0,-1,1,1,14638,-1,0.001145,0.998855
4977,diabetes,11,12,71,79,"Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134).",15632880_8,-1,1,1,4977,-1,0.0013872762,0.99861276
8242,atherosclerotic,10,11,71,86,Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats.,18442015_0,-1,1,1,8242,-1,0.0024988095,0.9975012
4593,Myocarditis,0,1,0,11,Myocarditis is rare and eosinophilic myocarditis is rarer.,15266362_5,-1,1,1,4593,-1,0.0014012028,0.99859875
2976,pain,5,6,36,40,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,-1,1,1,2976,-1,0.002278576,0.9977214
16267,toxicity,11,12,62,70,We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.,8643971_3,-1,1,1,16267,-1,0.0016186993,0.99838126
3938,proteinuria,19,20,113,124,"The results indicate that Li-induced nephropathy, even when the GFR is only modestly reduced, is associated with proteinuria and arterial systolic hypertension.",1378968_10,-1,1,1,3938,-1,0.0012187185,0.99878126
1203,seizures,2,3,22,30,Acute cocaine-induced seizures: differential sensitivity of six inbred mouse strains.,11166519_0,-1,1,1,1203,-1,0.0013014487,0.9986985
6747,proteinuria,38,39,234,245,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,-1,1,1,6747,-1,0.0014365119,0.99856347
1930,fever,9,10,60,65,"A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.",11672959_1,-1,1,1,1930,-1,0.0011849215,0.99881506
3118,diabetes,6,7,37,45,The study involved 129 patients with diabetes with serum creatinine concentrations of 1.5 to 3.5 mg per deciliter who underwent coronary or aortofemoral angiography.,12571256_4,-1,1,1,3118,-1,0.0019221223,0.99807787
11510,rigidity,5,6,46,54,"Although the neurochemistry of opiate-induced rigidity has yet to be fully elucidated, recent work suggests a role for a central adrenergic mechanism.",2569282_3,-1,1,1,11510,-1,0.001236478,0.99876356
5703,hyperalgesia,12,13,83,95,Abnormal brain responses to somatosensory stimuli have been found in patients with hyperalgesia as well as in normal subjects during experimental central sensitization.,16330766_3,-1,1,1,5703,-1,0.0013577692,0.99864227
16751,tremors,13,14,73,80,"Within 2 h he became confused with jerking movements of his extremities, tremors and rigidity.",8888541_6,-1,1,1,16751,-1,0.0016283257,0.99837166
13841,hypotension,7,8,67,78,"Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.",6308526_3,-1,1,1,13841,-1,0.0011460584,0.9988539
4261,sexual dysfunction,12,14,87,105,"A randomized, placebo-controlled, crossover study of ephedrine for SSRI-induced female sexual dysfunction.",14742097_0,-1,1,1,4261,-1,0.0014234403,0.9985765
8156,hepatotoxicity,5,6,32,46,The likely frequency of serious hepatotoxicity with sulfasalazine was estimated at 0.4% of treated patients.,18405372_14,-1,1,1,8156,-1,0.0012947478,0.99870527
17344,dyskinesias,24,25,173,184,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,-1,1,1,17344,-1,0.001115036,0.998885
11318,anemia,2,3,13,19,A reversible anemia was the only adverse effect observed.,2445283_4,-1,1,1,11318,-1,0.0013279219,0.9986721
3853,hypertensive,24,25,189,201,Studies were performed to evaluate whether chronic prazosin treatment alters the alpha 2-adrenoceptor function for orthostatic control of arterial blood pressure in conscious spontaneously hypertensive rats (SHR).,1355091_1,-1,1,1,3853,-1,0.00351154,0.99648845
17268,polyuria,15,16,106,114,Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped.,9226773_4,-1,1,1,17268,-1,0.0012088456,0.99879116
6213,hypotension,14,15,87,98,"RESULTS: Minutes after oral administration, the patient developed nausea, sweating and hypotension, and finally collapsed.",16740173_7,-1,1,1,6213,-1,0.0014018253,0.99859816
10435,thrombocytopenia,9,10,53,69,"Acute normal tissue toxicities (i.e., leukopenia and thrombocytopenia) and late normal tissue toxicities (i.e., myocardial and kidney injury) were evaluated by functional/physiological assays and by morphological techniques.",2054792_3,-1,1,1,10435,-1,0.0013672326,0.9986327
1379,anemia,4,5,19,25,"In the group where anemia was prevented by rHuEPO treatment, growth delay was comparable with that of nonanemic controls (13.3 days).",11245434_9,-1,1,1,1379,-1,0.0013187138,0.99868125
1193,incontinence,12,13,74,86,"In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.",11147747_4,-1,1,1,1193,-1,0.0012939267,0.9987061
7709,peripheral neuropathy,1,3,6,27,Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy.,18023325_1,-1,1,1,7709,-1,0.001359307,0.9986407
17142,infarction,14,15,123,133,"BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery.",9199746_1,-1,1,1,17142,-1,0.0015286382,0.9984713
18076,stroke,7,8,47,53,The limited number of epidemiologic studies of stroke and use of cocaine and/or amphetamine have been done in settings that serve mostly the poor and/or minorities.,9799166_2,-1,1,1,18076,-1,0.0017076763,0.99829227
12612,cancers,22,23,136,143,"By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.",3412544_2,-1,1,1,12612,-1,0.0019053919,0.9980946
14621,ventricular tachycardia,20,22,135,158,"In the seventh patient, a permanent ventricular pacemaker was inserted and, despite continuation of procainamide therapy, polymorphous ventricular tachycardia did not reoccur.",7234705_7,-1,1,1,14621,-1,0.0013756913,0.9986243
4405,edema,10,11,76,81,Nephrotic syndrome is often accompanied by sodium retention and generalized edema.,15075188_1,-1,1,1,4405,-1,0.0011836519,0.9988164
587,Hemolysis,0,1,0,9,"Hemolysis caused by TAM was not preceded by the leakage of K(+) from the cells, also excluding a colloid-osmotic type mechanism of hemolysis, according to the effects on osmotic fragility curves.",10704919_9,-1,1,1,587,-1,0.001123862,0.99887615
543,calcification,31,32,217,230,"These observations indicate that although the gamma-carboxyglutamate residues of matrix Gla protein are apparently required for its function as a calcification inhibitor, they are not required for its accumulation at calcification sites.",10669626_15,-1,1,1,543,-1,0.00308587,0.99691415
7223,thrombotic,8,9,40,50,"Finally, the contribution of a primary, thrombotic effect of cocaine has not been excluded.",1749407_9,-1,1,1,7223,-1,0.0021381602,0.9978618
13008,cirrhosis,24,25,170,179,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,-1,1,1,13008,-1,0.0013441388,0.9986558
10445,arrhythmia,1,2,4,14,"The arrhythmia resolved after therapy with atenolol, but recurred a year later.",20552622_3,-1,1,1,10445,-1,0.0014406986,0.9985593
1661,bipolar,3,4,32,39,Antidepressant-induced mania in bipolar patients: identification of risk factors.,11379838_0,-1,1,1,1661,-1,0.002228377,0.99777156
14602,paralysis,21,22,120,129,"None of the animals that received bupivacaine, normal saline, or normal saline titrated to a pH 3.0 developed hind-limb paralysis.",7199841_5,-1,1,1,14602,-1,0.0014603997,0.99853957
4840,diabetes,42,43,273,281,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,1,1,4840,-1,0.0024811197,0.9975189
13740,nephrolithiasis,9,10,54,69,One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.,625456_1,-1,1,1,13740,-1,0.0011954848,0.99880457
3807,seizures,1,2,8,16,Kindled seizures were induced by daily administration of 60 mg/kg cocaine for 5 days.,12921865_5,-1,1,1,3807,-1,0.0015527797,0.99844724
6321,neurotoxicity,31,32,163,176,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,-1,1,1,6321,-1,0.0012410932,0.9987589
6296,hypertension,7,8,64,76,"Thus, atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.",16820346_7,-1,1,1,6296,-1,0.0012033262,0.9987967
13843,bradycardia,14,15,132,143,"Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.",6308526_3,-1,1,1,13843,-1,0.001111961,0.9988881
10033,hypoxia,1,2,5,12,Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.,20084309_9,-1,1,1,10033,-1,0.0013879945,0.9986119
16438,bradycardia,5,6,29,40,"However, L-dopa restored the bradycardia caused by norepinephrine in addition to decreasing blood pressure and heart rate.",869641_6,-1,1,1,16438,-1,0.0013462233,0.99865377
12826,hyperkalemia,27,28,178,190,"As no other medications known to effect serum potassium had been given concomitantly, this course of events is suggestive of a cause-and-effect relationship between sulindac and hyperkalemia.",3560096_5,-1,1,1,12826,-1,0.0019433532,0.9980566
5336,arrhythmia,10,11,70,80,Previous anecdotal reports have linked creatine to the development of arrhythmia.,15899738_12,-1,1,1,5336,-1,0.0013434069,0.99865663
6330,hyperthermia,6,7,43,55,alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.,16844102_6,-1,1,1,6330,-1,0.0012325365,0.9987675
4280,breast cancer,20,22,135,148,The results showed specific impairments in processing speed and verbal memory in women receiving hormonal therapy for the treatment of breast cancer.,14745746_6,-1,1,1,4280,-1,0.0025126082,0.9974874
12872,renal damage,4,6,29,41,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,1,1,12872,-1,0.0015517503,0.99844825
12675,renal toxicity,22,24,131,145,Preliminary results at 400 and 500 mg/m2 suggest that a reduction in nephrotoxicity may have been achieved with only 1 instance of renal toxicity in 10 patients.,3431591_8,-1,1,1,12675,-1,0.0013938096,0.99860626
17589,rheumatoid arthritis,3,5,19,39,Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D-penicillamine.,950631_1,-1,1,1,17589,-1,0.0014914491,0.9985085
13457,overdose,10,11,57,65,"Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.",430165_2,-1,1,1,13457,-1,0.0018225427,0.9981774
10170,acute liver failure,3,6,42,61,Antituberculosis therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia.,20196116_1,-1,1,1,10170,-1,0.0012180529,0.998782
9950,sexual dysfunction,8,10,48,66,The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.,20067456_0,-1,1,1,9950,-1,0.001514547,0.9984855
18198,cholestasis,15,16,117,128,Different lobular distributions of altered hepatocyte tight junctions in rat models of intrahepatic and extrahepatic cholestasis.,9862868_0,-1,1,1,18198,-1,0.001407278,0.9985927
17700,parkinsonian,4,5,33,45,Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia.,9549528_0,-1,1,1,17700,-1,0.001660268,0.9983398
11074,proteinuria,10,11,77,88,D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.,2334179_8,-1,1,1,11074,-1,0.0011407326,0.9988593
5460,hypercalcemia,16,17,92,105,METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome.,16006300_2,-1,1,1,5460,-1,0.001877982,0.99812204
11684,stroke,65,66,368,374,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,1,1,11684,-1,0.0011385758,0.99886143
15467,thrombosis,10,11,73,83,"Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.",8012887_2,-1,1,1,15467,-1,0.0011123577,0.9988876
5883,apnea,7,8,43,48,"None of the patients experienced sedation, apnea, nausea, or pruritus after injection of both drugs.",16563323_9,-1,1,1,5883,-1,0.0012834803,0.9987166
3909,hyperactivity,21,22,120,133,"In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.",137340_4,-1,1,1,3909,-1,0.0015605786,0.9984394
12282,thrombocytopenia,21,22,137,153,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,-1,1,1,12282,-1,0.0011063383,0.9988937
15652,nephrolithiasis,1,2,22,37,Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders.,8170551_0,-1,1,1,15652,-1,0.0011402229,0.99885976
10441,toxicity,13,14,97,105,"Thus, while whole body hyperthermia enhances Adriamycin-mediated antitumor effect, normal tissue toxicity is also increased, and the potential therapeutic gain of the combined modality treatment is eroded.",2054792_7,-1,1,1,10441,-1,0.001321783,0.99867815
13249,cardiotoxicity,11,12,59,73,"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.",3952818_4,-1,1,1,13249,-1,0.0010803126,0.9989197
719,hepatotoxicity,68,69,285,299,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,1,1,719,-1,0.0014151871,0.99858487
7340,Myocarditis,2,3,13,24,CONCLUSIONS: Myocarditis is an increasingly recognized complication associated with the use of clozapine.,17612891_7,-1,1,1,7340,-1,0.0011618453,0.9988381
4616,seizures,12,13,98,106,The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice.,15275829_0,-1,1,1,4616,-1,0.0011940087,0.998806
15288,extrapyramidal symptoms,26,28,127,150,This change resulted within 2-4 weeks in the 50-200% increase in the plasma levels of these neuroleptics and the appearance of extrapyramidal symptoms.,7862923_3,-1,1,1,15288,-1,0.001496072,0.9985039
700,hyperalgesia,11,12,73,85,The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology.,10743446_10,-1,1,1,700,-1,0.0011559548,0.998844
15013,Seizure,0,1,0,7,Seizure after flumazenil administration in a pediatric patient.,7651879_0,-1,1,1,15013,-1,0.0014550084,0.99854505
497,artery calcification,14,16,83,103,The first series of experiments examined the influence of age and growth status on artery calcification in Warfarin-treated rats.,10669626_1,-1,1,1,497,-1,0.002306336,0.9976936
3083,acute liver failure,2,5,13,32,He developed acute liver failure with rapid deterioration of renal function.,12549952_4,-1,1,1,3083,-1,0.0014240552,0.9985759
2171,nephrotoxic,13,14,88,99,BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic.,11773892_1,-1,1,1,2171,-1,0.0018626428,0.99813735
15712,hyperalgesia,4,5,34,46,Five patients developed universal hyperalgesia and hyperesthesia which in 2 cases were accompanied by myoclonus.,8278214_3,-1,1,1,15712,-1,0.0012633337,0.9987367
6806,aggression,4,5,24,34,"Animals were tested for aggression in their home cage, both with and without physical provocation (mild tail pinch).",17194457_5,-1,1,1,6806,-1,0.0017353971,0.9982646
14641,aplastic anemia,4,6,16,31,A case of fatal aplastic anemia is described in which no drugs other than allopurinol and indomethacin were given.,7263204_2,-1,1,1,14641,-1,0.0011389018,0.9988611
